PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	PG	WC	SC	GA	UT	PM
J	Tomoda, K; Yoshikawa, M; Osaki, S; Kimura, H				Tomoda, K.; Yoshikawa, M.; Osaki, S.; Kimura, H.			THE RELATIONSHIP BETWEEN COLLAGEN FIBRE ORIENTATION AND ANISOTROPY IN MECHANICAL PROPERTY ON THE HUMAN LUNG	RESPIROLOGY			English	Meeting Abstract									[Tomoda, K.; Yoshikawa, M.; Kimura, H.] Nara Med Univ, Dept Internal Med 2, Kashihara, Nara, Japan; [Osaki, S.] Nara Med Univ, Dept Dermatol, Kashihara, Nara, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	O-P-004	54	54				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300157		
J	Onuki, T; Nakayama, M; Sata, M; Mato, N; Nakaya, T; Yamasawa, H; Bando, M; Sugiyama, Y				Onuki, T.; Nakayama, M.; Sata, M.; Mato, N.; Nakaya, T.; Yamasawa, H.; Bando, M.; Sugiyama, Y.			COMPARISON OF CHARACTERISTICS OF PATIENTS WITH TUBERCULOSIS DIAGNOSED AND NOT DIAGNOSED BY FIBRE OPTIC BRONCHOSCOPY	RESPIROLOGY			English	Meeting Abstract									[Onuki, T.; Nakayama, M.; Sata, M.; Mato, N.; Nakaya, T.; Yamasawa, H.; Bando, M.; Sugiyama, Y.] Jichi Med Univ Hosp, Dept Med, Div Pulm Med, Shimotsuke, Tochigi, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	O-Q-007	55	55				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300163		
J	Takasaki, J; Kanno, Y; Kobayashi, N				Takasaki, J.; Kanno, Y.; Kobayashi, N.			CHARACTERISTICS AND PROBLEMS OF FOREIGN TUBERCULOSIS TREATED IN OUR HOSPITAL	RESPIROLOGY			English	Meeting Abstract									[Takasaki, J.; Kanno, Y.; Kobayashi, N.] Natl Ctr Global Hlth & Med, Dept Resp Med, Tokyo, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	O-Q-015	58	58				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300171		
J	Hara, K; Ueno, M; Isobe, Z; Maeno, T; Kurabayashi, M; Kita, H				Hara, Kenichiro; Ueno, Manabu; Isobe, Zen; Maeno, Toshitaka; Kurabayashi, Masahiko; Kita, Hirohito			AIRWAY EXPOSURE TO STAPHYLOCOCCUS AUREUS PARTICLES PROMOTES DEVELOPMENT OF ANTIGEN-SPECIFIC TH2-TYPE IMMUNITY TO INHALED ANTIGENS THROUGH PRODUCTION OF THYMIC STROMAL LYMPHOPOIETIN (TSLP)	RESPIROLOGY			English	Meeting Abstract									[Hara, Kenichiro; Ueno, Manabu; Isobe, Zen; Maeno, Toshitaka; Kurabayashi, Masahiko] Gunma Univ, Grad Sch Med, Dept Med & Biol Sci, Maebashi, Gumma, Japan; [Kita, Hirohito] Mayo Clin, Allerg Dis Res Lab, Rochester, MN USA								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-A-001	63	63				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300181		
J	Takeyama, K; Kamata, M; Hanawa, T; Akaba, T; Arimura, K; Isono, K; Kondo, M; Tamaoki, J				Takeyama, K.; Kamata, M.; Hanawa, T.; Akaba, T.; Arimura, K.; Isono, K.; Kondo, M.; Tamaoki, J.			ROLE OF EPIDERMAL GROWTH FACTOR RECEPTOR IN METHACHOLINE-INDUCED AIRWAY HYPERRESPONSIVENESS IN RATS IN VIVO	RESPIROLOGY			English	Meeting Abstract									[Takeyama, K.; Kamata, M.; Hanawa, T.; Akaba, T.; Arimura, K.; Isono, K.; Kondo, M.; Tamaoki, J.] Tokyo Womens Med Univ, Sch Med, Dept Med 1, Tokyo, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-A-002	63	63				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300182		
J	Mori, A; Kouyama, S; Yamaguchi, M; Iijima, Y; Abe, A; Ohtomo, T; Fukuhara, M; Itoh, J; Hiroaki, H; Takafumi, M; Kentaro, W; Mitsui, C; Oshikata, C; Tanimoto, H; Fukutomi, Y; Sekiya, K; Takahiro, T; Taniguchi, M; Maeda, Y; Ohtomo, M; Hasegawa, M; Akiyama, K; Kaminuma, O				Mori, Akio; Kouyama, Satoshi; Yamaguchi, Miyako; Iijima, Yo; Abe, Akemi; Ohtomo, Takayuki; Fukuhara, Masanori; Itoh, Jun; Hiroaki, Hayashi; Takafumi, Minami; Kentaro, Watarai; Mitsui, Chihiro; Oshikata, Chiyako; Tanimoto, Hidenori; Fukutomi, Yuma; Sekiya, Kiyoshi; Takahiro, Tsuburai; Taniguchi, Masami; Maeda, Yuji; Ohtomo, Mamoru; Hasegawa, Maki; Akiyama, Kazuo; Kaminuma, Osamu			ANALYSIS OF T CELL-DEPENDENT BRONCHOCONSTRICTION	RESPIROLOGY			English	Meeting Abstract									[Mori, Akio; Kouyama, Satoshi; Yamaguchi, Miyako; Iijima, Yo; Abe, Akemi; Ohtomo, Takayuki; Fukuhara, Masanori; Itoh, Jun; Hiroaki, Hayashi; Takafumi, Minami; Kentaro, Watarai; Mitsui, Chihiro; Oshikata, Chiyako; Tanimoto, Hidenori; Fukutomi, Yuma; Sekiya, Kiyoshi; Takahiro, Tsuburai; Taniguchi, Masami; Maeda, Yuji; Ohtomo, Mamoru; Hasegawa, Maki; Akiyama, Kazuo] Natl Hosp Org, Sagamihara Natl Hosp, Clin Res Ctr, Sagamihara, Kanagawa, Japan; [Kaminuma, Osamu] Tokyo Metropolitan Inst Med Sci, Tokyo 113, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-A-005	64	64				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300185		
J	Horie, M; Mikami, Y; Noguchi, S; Matsuzaki, H; Tarui, M; Narumoto, O; Hirota, N; Mitani, A; Saito, A; Jo, T; Sakamoto, M; Takami, K; Kohyama, T; Takizawa, H; Nagase, T; Yamauchi, Y				Horie, M.; Mikami, Y.; Noguchi, S.; Matsuzaki, H.; Tarui, M.; Narumoto, O.; Hirota, N.; Mitani, A.; Saito, A.; Jo, T.; Sakamoto, M.; Takami, K.; Kohyama, T.; Takizawa, H.; Nagase, T.; Yamauchi, Y.			TRANSFORMING GROWTH FACTOR-BETA INDUCES THE PRODUCTION OF NEUROTROPHINS IN LUNG FIBROBLASTS VIA SMAD PATHWAY	RESPIROLOGY			English	Meeting Abstract									[Horie, M.; Mikami, Y.; Noguchi, S.; Matsuzaki, H.; Tarui, M.; Narumoto, O.; Hirota, N.; Mitani, A.; Saito, A.; Jo, T.; Sakamoto, M.; Takami, K.; Kohyama, T.; Takizawa, H.; Nagase, T.; Yamauchi, Y.] Tokyo Univ Hosp, Tokyo, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-A-008	65	65				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300188		
J	Ichinose, M; Ohta, K; Tohda, Y; Engel, M; Moroni-Zentgraf, P; Kunimitsu, S; Sakamoto, W; Adachi, M				Ichinose, M.; Ohta, K.; Tohda, Y.; Engel, M.; Moroni-Zentgraf, P.; Kunimitsu, S.; Sakamoto, W.; Adachi, M.			ONCE-DAILY TIOTROPIUM RESPIMAT (R) IS WELL TOLERATED AND EFFICACIOUS OVER 52 WEEKS IN JAPANESE PATIENTS WITH SYMPTOMATIC ASTHMA RECEIVING INHALED CORTICOSTEROIDS (ICS) +/- LONG-ACTING B2-AGONIST (LABA): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY	RESPIROLOGY			English	Meeting Abstract									[Ichinose, M.] Tohoku Univ, Dept Resp Med, Grad Sch Med, Sendai, Miyagi 980, Japan; [Ohta, K.] Tokyo Natl Hosp, Natl Hosp Org, Tokyo, Japan; [Tohda, Y.] Kinki Univ, Dept Resp Med & Allergol, Sch Med, Higashiosaka, Osaka 577, Japan; [Engel, M.; Moroni-Zentgraf, P.] Boehringer Ingelheim Pharma GmbH & Co KG, TA Resp Dis, Biberach, Germany; [Kunimitsu, S.] Nippon Boehringer Ingelheim Co Ltd, Clin Trial Management, Tokyo, Japan; [Sakamoto, W.] Nippon Boehringer Ingelheim Co Ltd, Med Data Serv Dept, Ingelheim, Germany; [Adachi, M.] Int Univ Hlth & Welf, Sanno Hosp, Dept Clin Res, Otawara, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-A-009	65	65				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300189		
J	Inui, T; Wada, H; Nakamoto, K; Sada, M; Tsuji, S; Nakamura, M; Honda, K; Tanaka, Y; Koide, T; Takata, S; Yokoyama, T; Kurai, D; Saraya, T; Ishii, H; Koyama, H; Kogane, T; Horie, M; Mikami, Y; Noguchi, S; Matsuzaki, H; Yamauchi, Y; Kohyama, T; Goto, H; Takizawa, H				Inui, T.; Wada, H.; Nakamoto, K.; Sada, M.; Tsuji, S.; Nakamura, M.; Honda, K.; Tanaka, Y.; Koide, T.; Takata, S.; Yokoyama, T.; Kurai, D.; Saraya, T.; Ishii, H.; Koyama, H.; Kogane, T.; Horie, M.; Mikami, Y.; Noguchi, S.; Matsuzaki, H.; Yamauchi, Y.; Kohyama, T.; Goto, H.; Takizawa, H.			INFLUENCE OF GENE POLYMORPHISM ON AIR POLLUTANTS-INDUCED AIRWAY OXIDATIVE STRESS AMONG ASTHMATIC PATIENTS	RESPIROLOGY			English	Meeting Abstract									[Inui, T.; Wada, H.; Nakamoto, K.; Sada, M.; Tsuji, S.; Nakamura, M.; Honda, K.; Tanaka, Y.; Koide, T.; Takata, S.; Yokoyama, T.; Kurai, D.; Saraya, T.; Ishii, H.; Goto, H.; Takizawa, H.] Kyorin Univ, Sch Med, Dept Resp Med, Tokyo, Japan; [Koyama, H.; Kogane, T.; Kohyama, T.] Teikyo Univ, Sch Med, Univ Hosp, Dept Internal Med 4, Kawasaki, Kanagawa, Japan; [Horie, M.; Mikami, Y.; Noguchi, S.; Matsuzaki, H.; Yamauchi, Y.] Univ Tokyo, Grad Sch Med, Dept Resp Med, Tokyo, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-A-012	67	67				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300192		
J	Ro, S; Hojo, M; Miyoshi, S; Takasaki, J; Sugiyama, H				Ro, S.; Hojo, M.; Miyoshi, S.; Takasaki, J.; Sugiyama, H.			EVALUATION OF THE RELATIONSHIP BETWEEN FRACTION OF EXHALED NITRIC OXIDE (FENO) AND ADHERENCE TO MEDICATION IN ASTHMA PATIENTS USING ADHERENCE STARTS WITH KNOWLEDGE-20 (ASK-20)	RESPIROLOGY			English	Meeting Abstract									[Ro, S.; Hojo, M.; Miyoshi, S.; Takasaki, J.; Sugiyama, H.] Natl Ctr Global Hlth & Med Japan, Tokyo, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-A-013	67	67				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300193		
J	Horio, Y; Fujii, K; Tsumura, S; Hirosako, S; Nakamura, K; Hirayama, S; Kohrogi, H				Horio, Y.; Fujii, K.; Tsumura, S.; Hirosako, S.; Nakamura, K.; Hirayama, S.; Kohrogi, H.		Kumamoto Asthma Res Grp	LOW DOSE OF COMBINED BUDESONIDE/FORMOTEROL (BUD/FM) IS BETTER THAN MEDIUM DOSE OF BUD MONOTHERAPY IN STEPPING DOWN FROM MEDIUM DOSE OF BUD/FM IN CONTROLLED ASTHMATIC PATIENTS	RESPIROLOGY			English	Meeting Abstract									[Horio, Y.; Fujii, K.; Tsumura, S.; Hirosako, S.; Nakamura, K.; Hirayama, S.; Kohrogi, H.; Kumamoto Asthma Res Grp] Kumamoto Univ, Dept Resp Med, Kumamoto Univ Hosp, Fac Life Sci, Kumamoto, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-A-014	68	68				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300194		
J	Kohyama, K; Kohyama, A; Abe, S; Morioka, J; Kodaira, K; Nakano, K; Souma, R; Satoh, H; Sugiyama, K; Fukushima, Y				Kohyama, K.; Kohyama, A.; Abe, S.; Morioka, J.; Kodaira, K.; Nakano, K.; Souma, R.; Satoh, H.; Sugiyama, K.; Fukushima, Y.			POLYMORPHISMS OF ALOX15 GENE IN JAPANESE PATIENTS WITH ASPIRIN-EXACERBATED RESPIRATORY DISEASE (AERD)	RESPIROLOGY			English	Meeting Abstract									[Kohyama, K.; Kohyama, A.; Abe, S.; Nakano, K.; Souma, R.; Satoh, H.; Sugiyama, K.; Fukushima, Y.] Dokkyo Med Univ, Dept Resp Med, Koshigaya Hosp Japan, Mibu, Tochigi, Japan; [Morioka, J.; Kodaira, K.] Ora Hosp Japan, Yokosuka, Kanagawa, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-A-024	71	71				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300204		
J	Souma, R; Sugiyama, K; Fujimatsu, T; Yoshida, N; Tokita, S; Tatewaki, M; Masuda, H; Fukushima, F; Hirata, H; Fukuda, T; Fukushima, Y				Souma, R.; Sugiyama, K.; Fujimatsu, T.; Yoshida, N.; Tokita, S.; Tatewaki, M.; Masuda, H.; Fukushima, F.; Hirata, H.; Fukuda, T.; Fukushima, Y.			EFFECT OF ADJUSTING THE COMBINATION OF BUDESONIDE/FORMOTEROL	RESPIROLOGY			English	Meeting Abstract									[Souma, R.; Sugiyama, K.; Fujimatsu, T.; Yoshida, N.; Tokita, S.; Tatewaki, M.; Masuda, H.; Fukushima, Y.] Dokkyo Med Univ, Koshigaya Hosp, Dept Resp Med, Koshigaya, Saitama, Japan; [Fukushima, F.; Hirata, H.; Fukuda, T.] Dokkyo Med Univ, Dept Pulm Med & Clin Immunol, Mibu, Tochigi, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-A-036	76	76				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300215		
J	Yatera, K; Yamasaki, K; Nishida, C; Noguchi, S; Oda, K; Akata, K; Kawanami, Y; Kawanami, T; Ishimoto, H; Mukae, H				Yatera, Kazuhiro; Yamasaki, Kei; Nishida, Chinatsu; Noguchi, Shingo; Oda, Keishi; Akata, Kentarou; Kawanami, Yukiko; Kawanami, Toshinori; Ishimoto, Hiroshi; Mukae, Hiroshi			REAL-WORLD SWITCHING EFFECTS OF DIFFERENT INHALED CORTICOSTEROID/LONG-ACTING BETA-AGONIST COMBINED INHALERS IN THE TREATMENT OF ASTHMA	RESPIROLOGY			English	Meeting Abstract									[Yatera, Kazuhiro; Yamasaki, Kei; Nishida, Chinatsu; Noguchi, Shingo; Oda, Keishi; Akata, Kentarou; Kawanami, Yukiko; Kawanami, Toshinori; Ishimoto, Hiroshi; Mukae, Hiroshi] Univ Occupat & Environm Hlth, Dept Resp Med, Kitakyushu, Fukuoka, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-A-035	76	76				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300214		
J	Nakamoto, K; Wada, H; Tsuji, S; Sada, M; Inui, T; Nakamura, M; Honda, K; Tanaka, Y; Koide, T; Takata, S; Yokoyama, T; Saraya, T; Kurai, D; Ishii, H; Goto, H; Takizawa, H				Nakamoto, Keitaro; Wada, Hiroo; Tsuji, Shingo; Sada, Mitsuru; Inui, Toshiya; Nakamura, Masuo; Honda, Kojiro; Tanaka, Yasutaka; Koide, Takashi; Takata, Saori; Yokoyama, Takuma; Saraya, Takeshi; Kurai, Daisuke; Ishii, Haruyuki; Goto, Hajime; Takizawa, Hajime			CLINICAL FEATURES AND ASSOCIATION WITH AIR POLLUTION IN PATIENTS WITH SEVERE ASTHMA	RESPIROLOGY			English	Meeting Abstract									[Nakamoto, Keitaro; Wada, Hiroo; Tsuji, Shingo; Sada, Mitsuru; Inui, Toshiya; Nakamura, Masuo; Honda, Kojiro; Tanaka, Yasutaka; Koide, Takashi; Takata, Saori; Yokoyama, Takuma; Saraya, Takeshi; Kurai, Daisuke; Ishii, Haruyuki; Goto, Hajime; Takizawa, Hajime] Kyorin Univ, Sch Med, Dept Resp Med, Tokyo, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-A-042	78	78				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300221		
J	Hayama, M; Izumo, T; Matsumoto, Y; Chavez, C; Tsuchida, T; Sasada, S				Hayama, Manabu; Izumo, Takehiro; Matsumoto, Yuji; Chavez, Christine; Tsuchida, Takaaki; Sasada, Shinji			TBNA THROUGH A GUIDE SHEATH (GS-TBNA) FOR PERIPHERAL PULMONARY LESIONS THAT CANNOT BE PRECISELY DETECTED BY RADIAL EBUS	RESPIROLOGY			English	Meeting Abstract									[Hayama, Manabu; Izumo, Takehiro; Matsumoto, Yuji; Chavez, Christine; Tsuchida, Takaaki; Sasada, Shinji] Natl Canc Ctr Hosp, Resp Endoscopy Div, Dept Endoscopy, Kashiwa, Chiba, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-B-001	80	80				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300225		
J	Okafuji, K; Kitamura, A; Nishimura, N; Baba, H; Nakaoka, H; Tomishima, Y; Jinta, T; Chonabayashi, N				Okafuji, Kohei; Kitamura, Atsushi; Nishimura, Naoki; Baba, Hiroyuki; Nakaoka, Hiroshi; Tomishima, Yutaka; Jinta, Torahiko; Chonabayashi, Naohiko			A NEW TECHNIQUE OF ENDOBRONCHIAL ULTRASONOGRAPHY WITH A GUIDE SHEATH (EBUS-GS) GUIDED TRANSBRONCHIAL NEEDLE ASPIRATION (TBNA), A PRELIMINARY REPORT	RESPIROLOGY			English	Meeting Abstract									[Okafuji, Kohei; Kitamura, Atsushi; Nishimura, Naoki; Baba, Hiroyuki; Nakaoka, Hiroshi; Tomishima, Yutaka; Jinta, Torahiko; Chonabayashi, Naohiko] St Lukes Int Hosp, Div Pulm Med, Tokyo, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-B-003	80	80				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300227		
J	Sasada, S; Izumo, T; Matsumoto, Y; Hayama, M; Chavez, C; Tsuchida, T				Sasada, Shinji; Izumo, Takehiro; Matsumoto, Yuji; Hayama, Manabu; Chavez, Christine; Tsuchida, Takaaki			A NEW MIDDLE-RANGE DIAMETER BRONCHOSCOPE WITH LARGE CHANNEL FOR TRANSBRONCHIAL SAMPLING OF PERIPHERAL PULMONARY LESIONS	RESPIROLOGY			English	Meeting Abstract									[Sasada, Shinji; Izumo, Takehiro; Matsumoto, Yuji; Hayama, Manabu; Chavez, Christine; Tsuchida, Takaaki] Natl Canc Ctr, Resp Endoscopy Div, Dept Endoscopy, Chuo Ku, Tokyo 1040054, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-B-002	80	80				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300226		
J	Hiroki, E; Kurihara, M; Otsuji, M; Katsutoshi, A; Kuniaki, S; Kazuhisa, T				Hiroki, Ebana; Kurihara, Masatoshi; Otsuji, Mizuto; Katsutoshi, Ando; Kuniaki, Seyama; Kazuhisa, Takahashi			EFFICACY AND ACCURACY OF FLUOROSCOPIC THORACOGRAPHY ON THE IDENTIFICATION OF LEAKAGE SITE ON THE LUNG IN PATIENTS WITH SPONTANEOUS PNEUMOTHORAX WHO HAVE CONTINUOUS AIR LEAKAGE	RESPIROLOGY			English	Meeting Abstract									[Hiroki, Ebana; Katsutoshi, Ando; Kuniaki, Seyama; Kazuhisa, Takahashi] Juntendo Univ, Fac Med, Div Resp Med, Tokyo, Japan; [Hiroki, Ebana; Katsutoshi, Ando; Kuniaki, Seyama; Kazuhisa, Takahashi] Grad Sch Med, Tokyo, Japan; [Hiroki, Ebana; Kurihara, Masatoshi] Nissan Tamagawa Hosp, Pneumothorax Res Ctr, Tokyo, Japan; [Hiroki, Ebana; Kurihara, Masatoshi] Nissan Tamagawa Hosp, Div Thorac Surg, Tokyo, Japan; [Hiroki, Ebana; Otsuji, Mizuto] Tokyo Metropolitan Bokutoh Hosp, Dept Thorac & Cardiovasc Surg, Tokyo, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-B-004	81	81				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300228		
J	Hanawa, T; Arimura, K; Sekine, Y; Sato, A; Hata, A; Yanagisawa, A; Hasegawa, M; Hiroshima, K; Katsura, H; Tagaya, E; Takeyama, K; Kondo, M; Tamaoki, J				Hanawa, Tomohide; Arimura, Ken; Sekine, Yasuo; Sato, Akitoshi; Hata, Atsushi; Yanagisawa, Asako; Hasegawa, Mizue; Hiroshima, Kenzo; Katsura, Hideki; Tagaya, Etsuko; Takeyama, Kiyoshi; Kondo, Mitsuko; Tamaoki, Jun			THE STUDY OF RAPID ON-SITE EVALUATION (ROSE) DURING ENDOBRONCHIAL ULTRASOUND-GUIDED TRANSBRONCHIAL NEEDLE ASPIRATION (EBUS-TBNA)	RESPIROLOGY			English	Meeting Abstract									[Hanawa, Tomohide; Arimura, Ken] Tokyo Womens Med Univ, Dept Med 1, Tokyo, Japan; [Arimura, Ken; Tagaya, Etsuko; Takeyama, Kiyoshi; Kondo, Mitsuko; Tamaoki, Jun] Tokyo Womens Med Univ, Grad Sch Med Sci, Div Pulm, Tokyo, Japan; [Arimura, Ken; Sato, Akitoshi; Hasegawa, Mizue; Katsura, Hideki] Tokyo Womens Med Univ, Dept Pulm Med, Yachiyo Med Ctr, Tokyo, Japan; [Sekine, Yasuo; Hata, Atsushi] Tokyo Womens Med Univ, Dept Thorac Surg, Yachiyo Med Ctr, Tokyo, Japan; [Yanagisawa, Asako] Tokyo Womens Med Univ, Dept Emergency Med, Yachiyo Med Ctr, Tokyo, Japan; [Hiroshima, Kenzo] Tokyo Womens Med Univ, Yachiyo Med Ctr, Dept Pathol, Tokyo, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-B-008	83	83				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300232		
J	Kida, H; Muraoka, H; Okamoto, M; Inoue, T; Furuya, N; Nishine, H; Inoue, T; Mineshita, M; Kurimoto, N; Miyazawa, T				Kida, Hirotaka; Muraoka, Hiromi; Okamoto, Mariko; Inoue, Teppei; Furuya, Naoki; Nishine, Hiroki; Inoue, Takeo; Mineshita, Masamichi; Kurimoto, Noriaki; Miyazawa, Teruomi			NEW PLUGGING TECHNIQUE FOR ENDOBRONCHIAL WATANABE SPIGOT (EWS): SIDE GRASPING METHOD	RESPIROLOGY			English	Meeting Abstract									[Kida, Hirotaka; Muraoka, Hiromi; Okamoto, Mariko; Inoue, Teppei; Furuya, Naoki; Nishine, Hiroki; Inoue, Takeo; Mineshita, Masamichi; Kurimoto, Noriaki; Miyazawa, Teruomi] St Marianna Univ, Sch Med, Dept Internal Med & Resp Surg, Div Resp & Infect Dis, Kawasaki, Kanagawa, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-B-010	83	83				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300234		
J	Katsuhiko, M; Seishi, N; Yuka, I; Masaki, M; Noriaki, K				Katsuhiko, Morita; Seishi, Nosaka; Yuka, Imoto; Masaki, Murayama; Noriaki, Kurimoto			DIAGNOSTIC YIELDS FOR PERIPHERAL LUNG NODULES WITH SUSPICIOUS MALIGNANCY THROUGH THE ENDOBRONCHIAL ULTRASONOGRAPHY WITH A GUIDE SHEATH (EBUS-GS)	RESPIROLOGY			English	Meeting Abstract									[Katsuhiko, Morita; Seishi, Nosaka] Iwakuni Minami Hosp, Dept Chest Surg, Iwakuni, Japan; [Yuka, Imoto; Masaki, Murayama] Iwakuni Minami Hosp, Dept Pulm Med, Iwakuni, Japan; [Noriaki, Kurimoto] St Marianna Univ Hosp, Dept Chest Surg, Kawasaki, Kanagawa, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-B-015	85	85				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300239		
J	Azagami, S; Okamoto, M; Handa, H; Nishine, H; Nobuyama, S; Inoue, T; Mineshita, M; Miyazawa, T				Azagami, Shinya; Okamoto, Mariko; Handa, Hiroshi; Nishine, Hiroki; Nobuyama, Seiichi; Inoue, Takeo; Mineshita, Masamichi; Miyazawa, Teruomi			TWO CASES OF ENDOBRONCHIAL SCHWANNOMA TREATED WITH INTERVENTINAL BRONCHOSCOPY	RESPIROLOGY			English	Meeting Abstract									[Azagami, Shinya; Okamoto, Mariko; Handa, Hiroshi; Nishine, Hiroki; Nobuyama, Seiichi; Inoue, Takeo; Mineshita, Masamichi; Miyazawa, Teruomi] St Marianna Univ, Sch Med, Dept Internal Med, Div Resp & Infect Dis, Kawasaki, Kanagawa, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-B-019	87	87				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300243		
J	Pratomo, IP; Isbaniyah, F; Yamaoka, E; Morihara, N; Fukuba, I; Hiyama, E				Pratomo, I. P.; Isbaniyah, F.; Yamaoka, E.; Morihara, N.; Fukuba, I; Hiyama, E.			NEXT GENERATION SEQUENCING: GENOMIC CHARACTERISTICS AND ANTIMICROBIAL PROFILES OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS COLLECTED FROM INPATIENTS IN INTENSIVE CARE UNIT OF HIROSHIMA UNIVERSITY HOSPITAL, HIROSHIMA, JAPAN	RESPIROLOGY			English	Meeting Abstract									[Pratomo, I. P.] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Hiroshima, Japan; [Pratomo, I. P.; Yamaoka, E.; Morihara, N.; Fukuba, I; Hiyama, E.] Hiroshima Univ, Nat Sci Ctr Basic Res & Dev, Hiroshima, Japan; [Isbaniyah, F.] Univ Indonesia, Dept Pulmonol & Resp Med, Jakarta, Indonesia; [Hiyama, E.] Hiroshima Univ Hosp, Dept Pediat Surg, Hiroshima, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-C-001	91	91				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300254		
J	Pulsiripunya, C; Fujimura, M				Pulsiripunya, C.; Fujimura, M.			IMPORTANCE OF RECOGNITION OF SINOBRONCHIAL SYNDROME (SBS) BECAUSE OF EXCELLENT EFFECT OF LOW DOSE ERYTHROMYCIN (LDEM) THERAPY IN THAILAND	RESPIROLOGY			English	Meeting Abstract									[Pulsiripunya, C.] Chest Dis Inst Thailand, Nonthaburi, Thailand; [Fujimura, M.] Nanao Hosp Natl Hosp Org, Nanao, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-E-014	99	99				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300276		
J	Fujimoto, K; Yamazaki, H; Ura, M				Fujimoto, Keisaku; Yamazaki, Haruna; Ura, Midori			EFFICACY OF MONO-THERAPY WITH TIOTROPIUM OR INDACATEROL OR THE COMBINATION OF THE TWO DRUGS ON DYNAMIC LUNG HYPERINFLATION AND EXERCISE TOLERANCE IN COPD	RESPIROLOGY			English	Meeting Abstract									[Fujimoto, Keisaku; Yamazaki, Haruna; Ura, Midori] Shinshu Univ Sch Hlth Sci, Dept Clin Lab Sci, Nagano, Japan								0	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-F-003	101	101				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300279		
J	Uno, T				Uno, Tomoyasu			RESEARCH OF SMOKING AND COPD (CHRONIC OBSTRUCTIVE PULMONALY DISEASE) AWARENESS IN UNIVERSITY STUDENTS	RESPIROLOGY			English	Meeting Abstract									[Uno, Tomoyasu] Fukushima Univ, Hlth Care Ctr, Fukushima, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-F-014	103	103				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300289		
J	Mochizuki, T; Ueda, R; Inoue, Y; Umeda, A; Sato, T				Mochizuki, Taichi; Ueda, Ryuta; Inoue, Yasushi; Umeda, Akira; Sato, Tetsuo			CLINICAL STUDY OF COPD, BRONCHIAL ASTHMA OR OSAS PATIENTS WHO UNDERWENT A HOME SLEEP TEST	RESPIROLOGY			English	Meeting Abstract									[Mochizuki, Taichi; Umeda, Akira] Int Univ Hlth & Welf Shioya Hosp, Dept Internal Med, Otawara, Tochigi, Japan; [Mochizuki, Taichi; Ueda, Ryuta; Inoue, Yasushi; Sato, Tetsuo] Int Univ Hlth & Welf Mita Hosp, Resp Dis Ctr, Tokyo, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-F-015	104	104				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300290		
J	Terui, Y; Shioya, T; Hasegawa, K; Suto, E; Kawagoshi, A; Satake, M; Sawamura, S; Sakata, S				Terui, Yoshino; Shioya, Takanobu; Hasegawa, Koichi; Suto, Eriko; Kawagoshi, Atsuyoshi; Satake, Masahiro; Sawamura, Sachie; Sakata, Shunichi			MEASUREMENT OF THE WHEELCHAIR-OPERATING TIME IN DAILY LIVING USING A NEW TRIAXIAL ACCELEROMETER SYSTEM	RESPIROLOGY			English	Meeting Abstract									[Terui, Yoshino; Shioya, Takanobu; Satake, Masahiro] Akita Univ Grad Sch Hlth Sci, Dept Phys Therapy, Akita, Japan; [Terui, Yoshino; Hasegawa, Koichi; Suto, Eriko] Akita Prefectural Ctr Rehabil & Psychiat Med, Dept Funct Training, Akita, Japan; [Kawagoshi, Atsuyoshi] Akita City Gen Hosp, Dept Rehabil, Akita, Japan; [Sawamura, Sachie] Brain & Blood Vessels Akita, Dept Funct Training, Akita, Japan; [Sakata, Shunichi] Kumamoto Technol & Ind Fdn, Nagoya, Aichi, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-F-018	105	105				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300293		
J	Shioya, T; Sugawara, K; Takahashi, H; Kasai, C; Kiyokawa, N; Watanabe, T; Fujii, S; Kashiwagura, T; Homma, M; Satake, M				Shioya, T.; Sugawara, K.; Takahashi, H.; Kasai, C.; Kiyokawa, N.; Watanabe, T.; Fujii, S.; Kashiwagura, T.; Homma, M.; Satake, M.			EFFECT OF ANTI-INFLAMMATORY SUPPLEMENTATION WITH WHEY PEPTIDE AND EXERCISE THERAPY IN PATIENTS WITH COPD	RESPIROLOGY			English	Meeting Abstract									[Shioya, T.; Sugawara, K.; Takahashi, H.; Kasai, C.; Kiyokawa, N.; Watanabe, T.; Fujii, S.; Kashiwagura, T.; Homma, M.; Satake, M.] Akita Univ Grad Sch Hlth Sci, Akita City Gen Hosp, Dept Rehabil, Dept Hlth Sci, Akita, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-F-021	106	106				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300296		
J	Uno, T				Uno, Tomoyasu			COMPARATIVE STUDY ON SMOKING AND CHRONIC OBSTRUCTIVE PULMONALY DISEASE (COPD) AWARENESS	RESPIROLOGY			English	Meeting Abstract									[Uno, Tomoyasu] Fukushima Univ, Hlth Care Ctr, Fukushima, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-F-023	107	107				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300298		
J	Kume, H; Imbe, S; Nishiyama, O; Iwanaga, T; Higashimoto, Y; Tohda, Y				Kume, H.; Imbe, S.; Nishiyama, O.; Iwanaga, T.; Higashimoto, Y.; Tohda, Y.			ROLE OF L-TYPE CA2+CHANNEL/KCA CHANNEL LINKAGE IN THE SYNERGISTIC RESPONSE BETWEEN ANTICHOLINERGIC AGENTS AND BETA2-ADRENOCEPTOR AGONISTS IN AIRWAY SMOOTH MUSCLE	RESPIROLOGY			English	Meeting Abstract									[Kume, H.; Imbe, S.; Nishiyama, O.; Iwanaga, T.; Higashimoto, Y.; Tohda, Y.] Kinki Univ, Fac Med, Dept Resp Med & Allergol, Osakasayama City, Osaka 5898851, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-F-027	108	108				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300302		
J	Hirano, R; Ishii, H; Igata, F; Matsumoto, T; Fujita, M; Watanabe, K				Hirano, R.; Ishii, H.; Igata, F.; Matsumoto, T.; Fujita, M.; Watanabe, K.			RISK FACTORS FOR THE DEVELOPMENT OF PNEUMONIA IN PATIENTS TREATED WITH INHALED CORTICOSTEROIDS	RESPIROLOGY			English	Meeting Abstract									[Hirano, R.; Ishii, H.; Igata, F.; Matsumoto, T.; Fujita, M.; Watanabe, K.] Fukuoka Univ, Sch Med, Dept Resp Med, Fukuoka, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-F-029	109	109				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300304		
J	Hino, M; Tanaka, Y; Onda, N; Takoi, H; Kosaihira, S; Motohashi, N				Hino, M.; Tanaka, Y.; Onda, N.; Takoi, H.; Kosaihira, S.; Motohashi, N.			COULD COPD PATIENTS WITH SEVERE AIR FLOW LIMITATION INHALE TURBUHALER (R) EFFECTIVELY?	RESPIROLOGY			English	Meeting Abstract									[Hino, M.; Tanaka, Y.; Onda, N.; Takoi, H.; Kosaihira, S.; Motohashi, N.] Nippon Med Sch, INBAHITEC Med Ctr, Dept Resp Med, Chiba, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-F-044	113	113				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300317		
J	Ijiri, N; Kanazawa, H; Yoshikawa, T; Shirai, A; Takeda, N; Watanabe, T; Kamoi, H; Hirata, K				Ijiri, N.; Kanazawa, H.; Yoshikawa, T.; Shirai, A.; Takeda, N.; Watanabe, T.; Kamoi, H.; Hirata, K.			A NEW INTEGRATED INDEX OF 6-MIN WALK TEST FOCUSED ON AN IMPACT OF OXYGEN DESATURATION - APPLICATION TO COPD	RESPIROLOGY			English	Meeting Abstract									[Ijiri, N.; Kanazawa, H.; Yoshikawa, T.; Shirai, A.; Takeda, N.; Watanabe, T.; Kamoi, H.; Hirata, K.] Osaka City Univ, Grad Sch Med, Dept Resp Med, Osaka, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-F-047	114	114				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300320		
J	Ueno, M; Maeno, T; Hara, K; Masubuchi, H; Suga, T; Motegi, M; Shimizu, Y; Kurabayashi, M				Ueno, Manabu; Maeno, Toshitaka; Hara, Kenichiro; Masubuchi, Hiroaki; Suga, Tatsuo; Motegi, Mitsuru; Shimizu, Yuzi; Kurabayashi, Masahiko			ANALYSIS OF COPD EXACERBATION MECHANISM USING CIGARETTE SMOKE COMBINED LPS MOUSE MODEL	RESPIROLOGY			English	Meeting Abstract									Takasaki Gen Media Ctr, Natl Hosp Org, Dept Resp Med, Takasaki, Gumma, Japan; Gunma Univ Hosp, Dept Allergy & Resp Med, Maebashi, Gumma, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-F-048	114	114				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300321		
J	Seto, R; Ogawa, E; Ryujin, Y; Goto, K; Higami, Y; Kanda, R; Nakagawa, H; Fukunaga, K; Uchida, Y; Van Tho, N; Wada, H; Yamaguchi, M; Nagao, T; Nakano, Y				Seto, Ruriko; Ogawa, Emiko; Ryujin, Yasushi; Goto, Kenichi; Higami, Yuichi; Kanda, Rie; Nakagawa, Hiroaki; Fukunaga, Kentaro; Uchida, Yasuki; Van Tho, Nguyen; Wada, Hiroshi; Yamaguchi, Masafumi; Nagao, Taishi; Nakano, Yasutaka			FORCED OSCILLATION TECHNIQUE MEASUREMENTS WITH AND WITHOUT CHEEK SUPPORT IN COPD	RESPIROLOGY			English	Meeting Abstract									[Seto, Ruriko; Ogawa, Emiko; Ryujin, Yasushi; Goto, Kenichi; Higami, Yuichi; Kanda, Rie; Nakagawa, Hiroaki; Fukunaga, Kentaro; Uchida, Yasuki; Van Tho, Nguyen; Wada, Hiroshi; Yamaguchi, Masafumi; Nagao, Taishi; Nakano, Yasutaka] Shiga Univ Med Sci, Dept Internal Med, Div Resp Med, Shiga, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-F-053	115	115				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300326		
J	Matsumura, T; Takarada, K; Oki, Y; Fujimoto, Y; Kaneko, H; Ohira, M; Ishikawa, A				Matsumura, Takuro; Takarada, Kana; Oki, Yutaro; Fujimoto, Yukari; Kaneko, Hiromi; Ohira, Mineko; Ishikawa, Akira			LONG-TERM EFFECT OF HOME NURSING INTERVENTION ON COST AND HEALTHCARE UTILIZATION FOR PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE	RESPIROLOGY			English	Meeting Abstract									[Matsumura, Takuro; Oki, Yutaro; Fujimoto, Yukari; Ishikawa, Akira] Kobe Univ, Grad Sch Hlth Sci, Dept Community Hlth Sci, Kobe, Hyogo, Japan; [Takarada, Kana] Seihoukai Oyama Hosp, Dept Rehabil, Seihoukai, Japan; [Kaneko, Hiromi] Home Visit Nursing Stn Wakakusa, Kyoto, Japan; [Ohira, Mineko] Natl Hosp Org, Higashi Nagano Hosp, Tokyo, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-F-058	117	117				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300331		
J	Fujimoto, Y; Oki, Y; Sakai, H; Misu, S; Kaneko, M; Kawashima, T; Nishio, M; Matsumura, T; Mitani, Y; Yamaguchi, T; Takahashi, K; Ishikawa, A				Fujimoto, Yukari; Oki, Yutaro; Sakai, Hideki; Misu, Shogo; Kaneko, Masahiro; Kawashima, Tsunehiro; Nishio, Masato; Matsumura, Takuro; Mitani, Yuji; Yamaguchi, Takumi; Takahashi, Kazuki; Ishikawa, Akira			RELATIONSHIP BETWEEN LUNG FUNCTION AND THE 6-MINUTE WALK TEST IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE	RESPIROLOGY			English	Meeting Abstract									[Fujimoto, Yukari; Oki, Yutaro; Sakai, Hideki; Misu, Shogo; Kaneko, Masahiro; Kawashima, Tsunehiro; Nishio, Masato; Matsumura, Takuro; Mitani, Yuji; Yamaguchi, Takumi; Takahashi, Kazuki; Ishikawa, Akira] Kobe Univ, Grad Sch Hlth Sci, Kobe City Hosp Org, Kobe City Med Ctr,West Hosp,Obihiro Resp Med Hosp, Kobe, Hyogo, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-F-061	118	118				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300334		
J	Oki, Y; Fujimoto, Y; Sakai, H; Misu, S; Matsumura, T; Mitani, Y; Yamaguchi, T; Kaneko, M; Ishikawa, A				Oki, Yutaro; Fujimoto, Yukari; Sakai, Hideki; Misu, Shogo; Matsumura, Takuro; Mitani, Yuji; Yamaguchi, Takumi; Kaneko, Masahiro; Ishikawa, Akira			RELATIONSHIP BETWEEN EXERCISE-INDUCED DESATURATION AND DYSPNEOA DURING THE 6-MINUTE WALKING TEST IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE	RESPIROLOGY			English	Meeting Abstract									[Oki, Yutaro; Fujimoto, Yukari; Misu, Shogo; Matsumura, Takuro; Mitani, Yuji; Yamaguchi, Takumi; Ishikawa, Akira] Kobe Univ, Grad Sch Hlth Sci, Kobe, Hyogo, Japan; [Oki, Yutaro; Sakai, Hideki; Misu, Shogo; Kaneko, Masahiro] Kobe City Hosp Org, Kobe City Med Ctr, West Hosp, Kobe, Hyogo, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-F-059	118	118				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300332		
J	Satake, M; Shioya, T; Takahashi, H; Sugawara, K; Kasai, C; Kiyokawa, N; Watanabe, T; Sato, S; Kawagoshi, A				Satake, Masahiro; Shioya, Takanobu; Takahashi, Hitomi; Sugawara, Keiyu; Kasai, Chikage; Kiyokawa, Noritaka; Watanabe, Toru; Sato, Sayaka; Kawagoshi, Atsuyoshi			RECOVERY PROCESS AFTER 6-MINUTE WALK TEST IN STABLE COPD PATIENTS	RESPIROLOGY			English	Meeting Abstract									[Satake, Masahiro; Shioya, Takanobu] Akita Univ, Grad Sch Hlth Sci, Dept Phys Therapy, Akita 010, Japan; [Takahashi, Hitomi; Sugawara, Keiyu; Kasai, Chikage; Kiyokawa, Noritaka; Watanabe, Toru; Sato, Sayaka; Kawagoshi, Atsuyoshi] Akita City Hosp, Dept Rehabil, Akita, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-F-060	118	118				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300333		
J	Ohbayashi, H				Ohbayashi, H.			COMPARISON OF THE EFFECTS OF SINGLE INHALATIONS OF FORMOTEROL AND TIOTROPIUM BROMIDE ON EARLY-PHASE PULMONARY FUNCTION AND SYMPTOMS IN A RANDOMIZED CROSSOVER STUDY	RESPIROLOGY			English	Meeting Abstract									[Ohbayashi, H.] Tohno Chuo Clin, Dept Allergy & Resp Med, Mizunami, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-F-066	120	120				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300339		
J	Motohashi, N; Onda, N; Takoi, H; Kosaihira, S; Tanaka, Y; Hino, M; Gemma, A				Motohashi, Norihisa; Onda, Naomi; Takoi, Hiroyuki; Kosaihira, Seiji; Tanaka, Yosuke; Hino, Mitsunori; Gemma, Akihiko			EVALUATION OF THE PULMONARY FUNCTION TESTS OF THE PATIENTS WHO WERE REFERRAL FROM PRIMARY CARE DOCTORS FOR THE CHRONIC COUGH	RESPIROLOGY			English	Meeting Abstract									[Motohashi, Norihisa; Onda, Naomi; Takoi, Hiroyuki; Kosaihira, Seiji; Tanaka, Yosuke; Hino, Mitsunori; Gemma, Akihiko] Chiba Hokusoh Hosp, Resp Dis Ctr, Nippon Med Sch, Chiba, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-F-070	121	121				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300343		
J	Yosuke, T; Mitsunori, H; Naomi, O; Hiroyuki, T; Seiji, K; Norihisa, M; Akihiko, G				Yosuke, Tanaka; Mitsunori, Hino; Naomi, Onda; Hiroyuki, Takoi; Seiji, Kosaihira; Norihisa, Motohashi; Akihiko, Gemma			COMPARISON OF MONOTHERAPY WITH A LONG-ACTING MUSCARINIC ANTAGONIST VERSUS COMBINATION THERAPY WITH A LONG-ACTING MUSCARINIC ANTAGONIST PLUS A LONG-ACTING BETA2-AGONIST IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE	RESPIROLOGY			English	Meeting Abstract									[Yosuke, Tanaka; Mitsunori, Hino; Naomi, Onda; Hiroyuki, Takoi; Seiji, Kosaihira; Norihisa, Motohashi; Akihiko, Gemma] Chiba Hokusoh Hosp, Resp Dis Ctr, Nippon Med Sch, Chiba, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-F-073	122	122				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300346		
J	Nakamura, H; Miyagi, A; Tateyama, M; Tasato, D; Haranaga, S; Higa, F; Fujita, J				Nakamura, Hideta; Miyagi, Ayane; Tateyama, Masao; Tasato, Daisuke; Haranaga, Shusaku; Higa, Futoshi; Fujita, Jiro			THE PREVALENCE OF AIRWAY OBSTRUCTION AMONG JAPANESE HIV-POSITIVE MALE PATIENTS COMPARED WITH GENERAL POPULATION: A CASE-COONTROL STUDY OF SINGLE CENTER ANALYSIS	RESPIROLOGY			English	Meeting Abstract									[Nakamura, Hideta; Miyagi, Ayane; Tateyama, Masao; Tasato, Daisuke; Haranaga, Shusaku; Higa, Futoshi; Fujita, Jiro] Univ Ryukyus, Fac Med, Dept Infect Resp & Digest Med, Nishihara, Okinawa 90301, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-F-076	123	123				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300349		
J	Makita, H; Nagai, K; Suzuki, M; Shimizu, K; Konno, S; Ito, YM; Nishimura, M				Makita, H.; Nagai, K.; Suzuki, M.; Shimizu, K.; Konno, S.; Ito, Y. M.; Nishimura, M.		Hokkaido Copd Cohort Study	DIFFERENTIAL CHANGES OF COMPONENTS IN QUALITY OF LIFE OVER 5 YEARS IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE PATIENTS	RESPIROLOGY			English	Meeting Abstract									[Makita, H.; Nagai, K.; Suzuki, M.; Shimizu, K.; Konno, S.; Nishimura, M.] Hokkaido Univ, Dept Med 1, Sch Med, Sapporo, Hokkaido 060, Japan; [Ito, Y. M.] Hokkaido Univ, Dept Biostat, Grad Sch Med, Sapporo, Hokkaido 060, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-F-084	126	126				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300357		
J	Miyoshi, S; Suzuki, M; Shiozawa, A; Ro, S; Masaki, H; Koike, T; Fujitani, J; Takeda, Y; Hojo, M; Sugiyama, H				Miyoshi, Shion; Suzuki, Manabu; Shiozawa, Ayako; Ro, Shoki; Masaki, Haruna; Koike, Tomokazu; Fujitani, Junko; Takeda, Yuichiro; Hojo, Masayuki; Sugiyama, Haruhito			THE EFFICACY OF PHYSIOTHERAPY USING RTX RESPIRATOR AGAINST PATIENTS WITH PNEUMONIA	RESPIROLOGY			English	Meeting Abstract									[Miyoshi, Shion; Suzuki, Manabu; Shiozawa, Ayako; Ro, Shoki; Masaki, Haruna; Takeda, Yuichiro; Hojo, Masayuki; Sugiyama, Haruhito] Natl Ctr Global Hlth & Med, Dept Resp Med, Tokyo, Japan; [Koike, Tomokazu; Fujitani, Junko] Natl Ctr Global Hlth & Med, Dept Phys Med & Rehabil, Tokyo, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-G-027	137	137				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300388		
J	Isobe, Z; Isobe, I; Maeno, T; Kurabayashi, M				Isobe, Z.; Isobe, I.; Maeno, T.; Kurabayashi, M.			FACTORS AFFECTING SUCCESS IN SMOKING-CESSATION THERAPIES USING NICOTINE PATCHES AND VARENICLINE	RESPIROLOGY			English	Meeting Abstract									[Isobe, Z.; Isobe, I.] Isobe Clin, Kaizuka, Japan; [Maeno, T.; Kurabayashi, M.] Gunma Univ, Dept Resp Med, Sch Med, Maebashi, Gumma, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-H-003	139	139				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300395		
J	Manriquez, MEV; Iglesias, ALH; Manabe, T; Flores, MDG; Morales, MSL; Camargo, AS; Morales, MEP; Ramos, LA; Valadez, JG; Takasaki, J; Kudo, K				Vazquez Manriquez, M. E.; Higuera Iglesias, A. L.; Manabe, T.; Garcia Flores, De Los Angeles M.; Lule Morales, M. S.; Stanford Camargo, A.; Palomar Morales, M. E.; Alfaro Ramos, L.; Gonzalez Valadez, J.; Takasaki, J.; Kudo, K.			SOCIOECONOMIC AND EDUCATION CONCERNING AWARENESS AND BEHAVIOURS RELATING TO INFLUENZA IN MEXICO	RESPIROLOGY			English	Meeting Abstract									[Vazquez Manriquez, M. E.; Higuera Iglesias, A. L.; Garcia Flores, De Los Angeles M.; Lule Morales, M. S.; Palomar Morales, M. E.; Alfaro Ramos, L.] Natl Inst Resp Dis, Mexico City, DF, Mexico; [Manabe, T.] Univ Tsukuba, Fac Med, Tsukuba, Ibaraki 305, Japan; [Stanford Camargo, A.] SSA DGPS, Mexico City, DF, Mexico; [Gonzalez Valadez, J.] Univ Autonoma Metropolitana, Mexico City, DF, Mexico; [Takasaki, J.] Natl Ctr Global Hlth & Med, Tokyo, Japan; [Kudo, K.] Waseda Univ, Tokyo, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-H-023	145	145				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300413		
J	Hirose, M; Matsumuro, A; Arai, T; Sugimoto, C; Inoue, Y				Hirose, Masaki; Matsumuro, Akiko; Arai, Toru; Sugimoto, Chikatoshi; Inoue, Yoshikazu			SERUM B CELL ACTIVATING FACTOR BELONGING TO THE TUMOUR NECROSIS FACTOR FAMILY (BAFF) IN AUTOIMMUNE PULMONARY ALVEOLAR PROTEINOSIS	RESPIROLOGY			English	Meeting Abstract									[Hirose, Masaki; Matsumuro, Akiko; Arai, Toru; Sugimoto, Chikatoshi; Inoue, Yoshikazu] Natl Hosp Org Kinki Chuo Chest Med Ctr, Clin Res Ctr, Sakai, Osaka, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-I-002	146	146				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300415		
J	Noguchi, S; Yatera, K; Wang, KY; Oda, K; Akata, K; Yamasaki, K; Kawanami, T; Ishimoto, H; Toyohira, Y; Shimokawa, H; Yanagihara, N; Tsutsui, M; Mukae, H				Noguchi, Shingo; Yatera, Kazuhiro; Wang, Ke-Yong; Oda, Keishi; Akata, Kentarou; Yamasaki, Kei; Kawanami, Toshinori; Ishimoto, Hiroshi; Toyohira, Yumiko; Shimokawa, Hiroaki; Yanagihara, Nobuyuki; Tsutsui, Masato; Mukae, Hiroshi			NITRIC OXIDE EXERTS PROTECTIVE EFFECTS AGAINST BLEOMYCIN-INDUCED PULMONARY FIBROSIS IN MICE	RESPIROLOGY			English	Meeting Abstract									[Noguchi, Shingo; Yatera, Kazuhiro; Oda, Keishi; Akata, Kentarou; Yamasaki, Kei; Kawanami, Toshinori; Ishimoto, Hiroshi; Mukae, Hiroshi] Univ Occupat & Environm Hlth, Dept Resp Med, Fukuoka, Japan; [Wang, Ke-Yong] Univ Occupat & Environm Hlth, Shared Use Res Ctr, Fukuoka, Japan; [Toyohira, Yumiko; Yanagihara, Nobuyuki] Univ Occupat & Environm Hlth, Sch Med, Dept Pharmacol, Fukuoka, Japan; [Shimokawa, Hiroaki] Tohoku Univ, Grad Sch Med, Dept Cardiovasc Med, Sendai, Miyagi 980, Japan; [Tsutsui, Masato] Univ Ryukyus, Grad Sch Med, Dept Pharmacol, Nishihara, Okinawa 90301, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-I-003	146	146				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300416		
J	Hiroyuki, T; Yosuke, T; Naomi, O; Seiji, K; Norihisa, M; Mitsunori, H; Kenji, H; Akihiko, G				Hiroyuki, Takoi; Yosuke, Tanaka; Naomi, Onda; Seiji, Kosaihira; Norihisa, Motohashi; Mitsunori, Hino; Kenji, Hayashihara; Akihiko, Gemma			CLINICAL FEATURES OF PATIENTS WITH PLEUROPARENCHYMAL FIBROELASTOSIS (PPFE): OUR EXPERIENCE	RESPIROLOGY			English	Meeting Abstract									[Hiroyuki, Takoi; Yosuke, Tanaka; Naomi, Onda; Seiji, Kosaihira; Norihisa, Motohashi; Mitsunori, Hino] Nippon Med Sch, Chiba Hokusoh Hosp, Resp Dis Ctr, Chiba, Japan; [Kenji, Hayashihara] Ibaraki Higashi Natl Hosp, Dept Resp Med, Ibaraki, Japan; [Akihiko, Gemma] Nippon Med Sch, Dept Internal Med, Div Pulm Med, Tokyo 113, Japan; [Akihiko, Gemma] Nippon Med Sch, Dept Internal Med, Div Infect Dis, Tokyo 113, Japan; [Akihiko, Gemma] Nippon Med Sch, Dept Internal Med, Div Oncol, Tokyo 113, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-I-005	147	147				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300418		
J	Ichimuray; Tsushima, K; Matsumura, T; Yokota, A; Terada, J; Iesato, K; Sakao, S; Tada, Y; Tanabe, N; Tatsumi, K				Ichimuray; Tsushima, K.; Matsumura, T.; Yokota, A.; Terada, J.; Iesato, K.; Sakao, S.; Tada, Y.; Tanabe, N.; Tatsumi, K.			THE PREDICTIVE FACTORS FOR THE EFFECT OF PIRFENIDONE IN IDIOPATHIC PULMONARY FIBROSIS	RESPIROLOGY			English	Meeting Abstract									[Ichimuray; Tsushima, K.; Matsumura, T.; Yokota, A.; Terada, J.; Iesato, K.; Sakao, S.; Tada, Y.; Tanabe, N.; Tatsumi, K.] Chiba Univ Hosp, Dept Respirol, Chiba, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-I-008	148	148				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300421		
J	Morimoto, C; Hamao, N; Inao, T; Yasuda, Y; Yasuda, I; Tsuji, T; Okamori, S; Kaji, Y; Yasuda, T; Hashimoto, S; Hajiro, T; Tanaka, E; Taguchi, Y; Honjo, G; Kobashi, Y; Noma, S; Iioka, H; Maesako, Y; Akasaka, T; Ono, H				Morimoto, Chie; Hamao, Nobuyoshi; Inao, Takashi; Yasuda, Yuto; Yasuda, Ikkoh; Tsuji, Takahiro; Okamori, Satoshi; Kaji, Yusuke; Yasuda, Takehiro; Hashimoto, Seishu; Hajiro, Takashi; Tanaka, Eisaku; Taguchi, Yoshio; Honjo, Gen; Kobashi, Yoichiro; Noma, Satoshi; Iioka, Hutoshi; Maesako, Yoshitomo; Akasaka, Takashi; Ono, Hitoshi			IS PULMONARY UPPER LOBE FIBROSIS ONE OF LATE-ONSET NONINFECTIOUS PULMONARY COMPLICATIONS AFTER BONE MARROW TRANSPLANTATION?	RESPIROLOGY			English	Meeting Abstract									[Morimoto, Chie; Hamao, Nobuyoshi; Inao, Takashi; Yasuda, Yuto; Yasuda, Ikkoh; Tsuji, Takahiro; Okamori, Satoshi; Kaji, Yusuke; Yasuda, Takehiro; Hashimoto, Seishu; Hajiro, Takashi; Tanaka, Eisaku; Taguchi, Yoshio] Tenri Hosp, Dept Resp Med, Tenri, Nara, Japan; [Honjo, Gen; Kobashi, Yoichiro] Tenri Hosp, Dept Pathol, Tenri, Nara, Japan; [Noma, Satoshi] Tenri Hosp, Dept Radiol, Tenri, Nara, Japan; [Iioka, Hutoshi; Maesako, Yoshitomo; Akasaka, Takashi; Ono, Hitoshi] Tenri Hosp, Dept Hematol, Tenri, Nara, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-I-009	148	148				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300422		
J	Yasuda, T; Taguchi, Y; Tanaka, E; Hajiro, T; Hashimoto, S; Kaji, Y; Morimoto, C; Inao, T; Yasuda, Y; Hamao, N; Noma, S				Yasuda, Takehiro; Taguchi, Yoshio; Tanaka, Eisaku; Hajiro, Takashi; Hashimoto, Seishu; Kaji, Yusuke; Morimoto, Chie; Inao, Takashi; Yasuda, Yuto; Hamao, Nobuyoshi; Noma, Stoshi			PREVALENCE OF AMRUBICIN INDUCED LUNG INJURY IN OUR HOSPITAL	RESPIROLOGY			English	Meeting Abstract									[Yasuda, Takehiro; Taguchi, Yoshio; Tanaka, Eisaku; Hajiro, Takashi; Hashimoto, Seishu; Kaji, Yusuke; Morimoto, Chie; Inao, Takashi; Yasuda, Yuto; Hamao, Nobuyoshi] Tenri Hosp, Dept Resp Med, Nara, Japan; [Noma, Stoshi] Tenri Hosp, Div Diagnost Radiol, Dept Radiol, Nara, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-I-006	148	148				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300419		
J	Bando, M; Sugiyama, Y; Azuma, A; Ebina, M; Taniguchi, H; Taguchi, Y; Takahashi, H; Homma, S; Nukiwa, T; Kudoh, S				Bando, Masashi; Sugiyama, Yukihiko; Azuma, Arata; Ebina, Masahito; Taniguchi, Hiroyuki; Taguchi, Yoshio; Takahashi, Hiroki; Homma, Sakae; Nukiwa, Toshihiro; Kudoh, Shoji		Minist Hlth Labour Welfare	A PROSPECTIVE SURVEY BY WEB REGISTRATION ON IDIOPATHIC PULMONARY FIBROSIS IN JAPAN	RESPIROLOGY			English	Meeting Abstract									[Bando, Masashi; Sugiyama, Yukihiko] Jichi Med Univ, Dept Med, Div Pulm Med, Shimotsuke, Tochigi, Japan; [Azuma, Arata] Nippon Med Sch, Div Pulm Med Infect & Oncol, Tokyo 113, Japan; [Ebina, Masahito] Tohoku Pharmaceut Univ Hosp, Dept Resp Med, Sendai, Miyagi, Japan; [Taniguchi, Hiroyuki] Tosei Gen Hosp, Dept Resp Med & Allergy, Seto, Aichi, Japan; [Taguchi, Yoshio] Tenri Hosp, Dept Resp Med, Tenri, Nara 632, Japan; [Takahashi, Hiroki] Sapporo Med Univ Hosp, Dept Internal Med 3, Sapporo, Hokkaido, Japan; [Homma, Sakae] Toho Univ, Omori Med Ctr, Dept Resp Med, Tokyo, Japan; [Nukiwa, Toshihiro] South Miyagi Med Ctr, Sendai, Miyagi, Japan; [Kudoh, Shoji] Double Barred Cross Hosp, Resp Dis Ctr, Tokyo, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-I-011	149	149				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300424		
J	Ishii, H; Igata, F; Hirano, R; Fujita, M; Watanabe, K				Ishii, Hiroshi; Igata, Fumiyasu; Hirano, Ryosuke; Fujita, Masaki; Watanabe, Kentaro			CLINICAL AND PATHOLOGICAL EVALUATION OF THE 23 AUTOPSY PATIENTS WITH INTERSTITIAL PNEUMONIAS	RESPIROLOGY			English	Meeting Abstract									[Ishii, Hiroshi; Igata, Fumiyasu; Hirano, Ryosuke; Fujita, Masaki; Watanabe, Kentaro] Fukuoka Univ, Sch Med, Dept Resp Med, Fukuoka, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-I-010	149	149				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300423		
J	Aono, Y; Amano, Y; Kamiya, Y; Yoshimura, K; Uto, T; Sagiska, S; Sato, Z; Imokawa, S; Yasuda, K				Aono, Yuya; Amano, Yusuke; Kamiya, Yousuke; Yoshimura, Kathuhiro; Uto, Tomohiro; Sagiska, Shinya; Sato, Zyun; Imokawa, Shiro; Yasuda, Kazumasa			CLINICOPATHOLOGICAL STUDY OF INTERSTITIAL PNEUMONIA WITH ANTI-AMINOACYL TRNA SYNTHETASE (ANTI-ARS) SYNDROME	RESPIROLOGY			English	Meeting Abstract									[Aono, Yuya; Amano, Yusuke; Kamiya, Yousuke; Yoshimura, Kathuhiro; Uto, Tomohiro; Sagiska, Shinya; Sato, Zyun; Imokawa, Shiro; Yasuda, Kazumasa] Iwata City Hosp, Dept Resp Med, Iwata, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-I-012	150	150				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300425		
J	Kitamura, A; Nishimura, N; Nakaoka, H; Okafuji, K; Tomishima, Y; Jinta, T; Chohnabayashi, N				Kitamura, Atsushi; Nishimura, Naoki; Nakaoka, Hiroshi; Okafuji, Kouhei; Tomishima, Yutaka; Jinta, Torahiko; Chohnabayashi, Naohiko			HIGH-RESOLUTION CT FINDINGS AND INTER-OBSERVER CONCORDANCE FOR ACUTE HYPERSENSITIVITY PNEUMONITIS ASSOCIATED WITH HOME ULTRASONIC HUMIDIFIERS	RESPIROLOGY			English	Meeting Abstract									[Kitamura, Atsushi; Nishimura, Naoki; Nakaoka, Hiroshi; Okafuji, Kouhei; Tomishima, Yutaka; Jinta, Torahiko; Chohnabayashi, Naohiko] St Lukes Int Hosp, Div Pulm Med, Tokyo, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-I-013	150	150				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300426		
J	Miyamura, T; Hara, S; Ishimatsu, Y; Obase, Y; Sakamoto, N; Kakugawa, T; Hara, A; Nakashima, S; Harada, T; Tomonaga, M; Kohno, S				Miyamura, Takuto; Hara, Shintaro; Ishimatsu, Yuji; Obase, Yasushi; Sakamoto, Noriho; Kakugawa, Tomoyuki; Hara, Atsuko; Nakashima, Shota; Harada, Tatsuhiko; Tomonaga, Masaomi; Kohno, Shigeru			SERUM SOLUBLE INTERLEUKIN-2 RECEPTOR LEVEL COULD DIFFERENTIATE BETWEEN PNEUMOCYSTIS JIROVECII PNEUMONIA AND METHOTREXATE-INDUCED PNEUMONITIS IN PATIENTS WITH RHEUMATOID ARTHRITIS UNDER METHOTREXATE THERAPY	RESPIROLOGY			English	Meeting Abstract									[Miyamura, Takuto; Hara, Shintaro; Ishimatsu, Yuji; Obase, Yasushi; Sakamoto, Noriho; Kakugawa, Tomoyuki; Hara, Atsuko; Nakashima, Shota; Harada, Tatsuhiko; Tomonaga, Masaomi; Kohno, Shigeru] Nagasaki Univ Sch Med, Dept Internal Med 2, Nagasaki, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-I-014	150	150				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300427		
J	Igata, F; Ishii, H; Hirano, R; Fujita, M; Watanabe, K				Igata, Fumiyasu; Ishii, Hiroshi; Hirano, Ryosuke; Fujita, Masaki; Watanabe, Kentaro			PEMETREXED-INDUCED PNEUMONITIS IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER	RESPIROLOGY			English	Meeting Abstract									[Igata, Fumiyasu; Ishii, Hiroshi; Hirano, Ryosuke; Fujita, Masaki; Watanabe, Kentaro] Fukuoka Univ Sch Med, Dept Resp Med, Fukuoka, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-I-015	151	151				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300428		
J	Yamauchi, H; Bando, M; Ogura, T; Suda, T; Taniguchi, H; Mukae, H; Kishi, K; Sugiyama, Y				Yamauchi, Hiroyoshi; Bando, Masashi; Ogura, Takashi; Suda, Takafumi; Taniguchi, Hiroyuki; Mukae, Hiroshi; Kishi, Kazuma; Sugiyama, Yukihiko			A NEW METHOD TO EVALUATE THE CLINICAL EFFICACY OF PIRFENIDONE FOR PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS BY USING PERSONAL FORCED VITAL CAPACITY CHANGE	RESPIROLOGY			English	Meeting Abstract									[Yamauchi, Hiroyoshi; Bando, Masashi; Sugiyama, Yukihiko] Jichi Med Univ, Dept Med, Div Pulm Med, Shimotsuke, Tochigi, Japan; [Bando, Masashi; Ogura, Takashi; Suda, Takafumi; Taniguchi, Hiroyuki; Mukae, Hiroshi; Kishi, Kazuma; Sugiyama, Yukihiko] Minist Hlth Labour & Welf, Tokyo, Japan; [Ogura, Takashi] Kanagawa Cardiovasc & Resp Ctr, Dept Resp Med, Yokohama, Kanagawa, Japan; [Suda, Takafumi] Hamamatsu Univ Sch Med, Dept Resp Med, Shizuoka, Japan; [Taniguchi, Hiroyuki] Tosei Gen Hosp, Dept Resp Med & Allergy, Seto, Aichi, Japan; [Mukae, Hiroshi] Univ Occupat & Environm Hlth, Dept Resp Med, Fukuoka, Japan; [Kishi, Kazuma] Toranomon Gen Hosp, Dept Resp Med, Tokyo, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-I-016	151	151				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300429		
J	Ikeo, S; Ikeda, S; Arita, M; Ishida, T				Ikeo, Satoshi; Ikeda, Satoshi; Arita, Machiko; Ishida, Tadashi			INTERSTITIAL LUNG DISEASE INDUCED BY BOFU-TSUSHO-SAN: A REPORT OF 4 CASES	RESPIROLOGY			English	Meeting Abstract									[Ikeo, Satoshi; Ikeda, Satoshi; Arita, Machiko; Ishida, Tadashi] Kurashiki Cent Hosp, Dept Resp Med, Kurashiki, Okayama, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-I-018	152	152				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300431		
J	Naomi, O; Yosuke, T; Hiroyuki, T; Seiji, K; Norihisa, M; Mitsunori, H; Akihiko, G				Naomi, Onda; Yosuke, Tanaka; Hiroyuki, Takoi; Seiji, Kosaihira; Norihisa, Motohashi; Mitsunori, Hino; Akihiko, Gemma			CLINICAL FEATURES OF PATIENTS WITH COMBINED PULMONARY FIBROSIS AND EMPHYSEMA (CPFE) FOCUSING ON PULMONARY HYPERTENSION: OUR EXPERIENCE	RESPIROLOGY			English	Meeting Abstract									[Naomi, Onda; Yosuke, Tanaka; Hiroyuki, Takoi; Seiji, Kosaihira; Norihisa, Motohashi; Mitsunori, Hino; Akihiko, Gemma] Nippon Med Sch, Chiba Hokusoh Hosp, Resp Dis Ctr, Tokyo, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-I-019	152	152				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300432		
J	Okimoto, N; Kawai, Y; Kato, T; Kurihara, T; Miyashita, N				Okimoto, Niro; Kawai, Yasuhiro; Kato, Tadashi; Kurihara, Takeyuki; Miyashita, Naoyuki			CHANGES IN SERUM KL-6 AFTER INTRAVENOUS FOSFOMYCIN ADMINISTRATION IN IDIOPATHIC INTERSTITIAL PNEUMONIA	RESPIROLOGY			English	Meeting Abstract									[Okimoto, Niro; Kawai, Yasuhiro; Kato, Tadashi; Kurihara, Takeyuki; Miyashita, Naoyuki] Kawasaki Hosp, Kawasaki Med Sch, Dept Gen Internal Med 1, Kawasaki, Kanagawa, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-I-022	153	153				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300435		
J	Okamoto, M; Handa, H; Azagami, S; Kakinuma, K; Muraoka, H; Usuba, A; Inoue, T; Morikawa, K; Furuya, N; Kida, H; Fujiwara, M; Nishine, H; Nobuyama, S; Inoue, T; Mineshita, M; Miyazawa, T				Okamoto, M.; Handa, H.; Azagami, S.; Kakinuma, K.; Muraoka, H.; Usuba, A.; Inoue, T.; Morikawa, K.; Furuya, N.; Kida, H.; Fujiwara, M.; Nishine, H.; Nobuyama, S.; Inoue, T.; Mineshita, M.; Miyazawa, T.			BREATH ANALYSIS USING ION MOBILITY SPECTROMETRY IN PATIENTS WITH LUNG CANCER BEFORE AND AFTER TUMOUR RESECTION	RESPIROLOGY			English	Meeting Abstract									[Okamoto, M.; Handa, H.; Azagami, S.; Kakinuma, K.; Muraoka, H.; Usuba, A.; Inoue, T.; Morikawa, K.; Furuya, N.; Kida, H.; Fujiwara, M.; Nishine, H.; Nobuyama, S.; Inoue, T.; Mineshita, M.; Miyazawa, T.] St Marianna Univ Sch Med, Div Resp & Infect Dis, Kawasaki, Kanagawa, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-J-003	154	154				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300439		
J	Tode, N; Kikuchi, T; Hirano, T; Santoso, A; Kanehira, M; Ichinose, M				Tode, Naoki; Kikuchi, Toshiaki; Hirano, Taizou; Santoso, Arif; Kanehira, Masahiko; Ichinose, Masakazu			WHOLE-EXOME SEQUENCE BY PERIPHERAL BLOOD DNA FROM FAMILIAL EGFR-MUTANT LUNG CANCER PATIENTS	RESPIROLOGY			English	Meeting Abstract									[Tode, Naoki; Kikuchi, Toshiaki; Hirano, Taizou; Santoso, Arif; Kanehira, Masahiko; Ichinose, Masakazu] Tohoku Univ Grad Sch Med, Dept Resp Med, Sendai, Miyagi, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-J-001	154	154				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300437		
J	Kinoshita, A; Tomonaga, N; Saijo, T; Ikeda, T; Fukuda, M; Nakamura, Y; Senju, H; Nakano, H; Kitazaki, T; Ogawara, D; Taniguchi, H; Motoshima, K; Yamaguchi, H; Nakatomi, K; Shimada, M; Nagashima, S; Tsukamoto, K; Kohno, S				Kinoshita, Akitoshi; Tomonaga, Nanae; Saijo, Tomoyuki; Ikeda, Takaya; Fukuda, Minoru; Nakamura, Yoichi; Senju, Hiroaki; Nakano, Hirofumi; Kitazaki, Takeshi; Ogawara, Daiki; Taniguchi, Hirokazu; Motoshima, Kohei; Yamaguchi, Hiroyuki; Nakatomi, Katsumi; Shimada, Midori; Nagashima, Seiji; Tsukamoto, Kazuhiro; Kohno, Shigeru			A PHASE II STUDY OF AMRUBICIN AND CARBOPLATIN FOR PREVIOUSLY UNTREATED PATIENTS WITH EXTENSIVE-DISEASE SMALL CELL LUNG CANCER	RESPIROLOGY			English	Meeting Abstract									[Kinoshita, Akitoshi; Tomonaga, Nanae; Saijo, Tomoyuki] Nagasaki Prefecture Shimabara Hosp, Nagasaki, Japan; [Kinoshita, Akitoshi; Tomonaga, Nanae; Ikeda, Takaya; Fukuda, Minoru; Nakamura, Yoichi; Senju, Hiroaki; Nakano, Hirofumi; Kitazaki, Takeshi; Ogawara, Daiki; Taniguchi, Hirokazu; Motoshima, Kohei; Yamaguchi, Hiroyuki; Nakatomi, Katsumi; Shimada, Midori; Nagashima, Seiji; Tsukamoto, Kazuhiro; Kohno, Shigeru] Nagasaki Thorac Oncol Grp, Nagasaki, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-J-007	155	155				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300443		
J	Kobayashi, I; Takahashi, F; Nurwidya, F; Murakami, A; Kato, M; Shimada, N; Suina, K; Kanemaru, R; Yagishita, S; Ko, R; Asao, T; Ohashi, R; Muraki, K; Yoshioka, Y; Takahashi, M; Takahashi, K				Kobayashi, Isao; Takahashi, Fumiyuki; Nurwidya, Fariz; Murakami, Akiko; Kato, Motoyasu; Shimada, Naoko; Suina, Kentaro; Kanemaru, Ryota; Yagishita, Shigehiro; Ko, Ryo; Asao, Tetsuhiko; Ohashi, Rina; Muraki, Keiko; Yoshioka, Yasuko; Takahashi, Motomi; Takahashi, Kazuhisa			OCT4 PLAYS A KEY ROLE IN THE PERSISTENCE OF GEFITINIB-RESISTANT LUNG CANCER STEM CELLS	RESPIROLOGY			English	Meeting Abstract									[Kobayashi, Isao; Takahashi, Fumiyuki; Nurwidya, Fariz; Murakami, Akiko; Kato, Motoyasu; Shimada, Naoko; Suina, Kentaro; Kanemaru, Ryota; Yagishita, Shigehiro; Ko, Ryo; Asao, Tetsuhiko; Ohashi, Rina; Muraki, Keiko; Yoshioka, Yasuko; Takahashi, Motomi; Takahashi, Kazuhisa] Juntendo Univ Grad Sch Med, Dept Resp Med, Tokyo, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-J-004	155	155				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300440		
J	Sawata, T; Bando, M; Sata, M; Nakayama, M; Mato, N; Nakaya, T; Yamasawa, H; Takahashi, M; Okamoto, H; Sugiyama, Y				Sawata, Tetsuro; Bando, Masashi; Sata, Masafumi; Nakayama, Masayuki; Mato, Naoko; Nakaya, Takakiyo; Yamasawa, Hideaki; Takahashi, Masaharu; Okamoto, Hiroaki; Sugiyama, Yukihiko			ASSOCIATION OF TORQUE TENO VIRUS DNA TITER WITH THE GROWTH OF PRIMARY LUNG CANCER	RESPIROLOGY			English	Meeting Abstract									[Sawata, Tetsuro; Bando, Masashi; Sata, Masafumi; Nakayama, Masayuki; Mato, Naoko; Nakaya, Takakiyo; Yamasawa, Hideaki; Sugiyama, Yukihiko] Jichi Med Univ, Div Pulm Med, Dept Med, Shimotsuke, Tochigi, Japan; [Takahashi, Masaharu; Okamoto, Hiroaki] Jichi Med Univ, Div Virol, Dept Infect & Immun, Shimotsuke, Tochigi, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-J-009	156	156				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300445		
J	Matsuo, A; Wada, Y; Makino, M; Kawaguchi, K; Kanemoto, R; Shionoya, R; Nakamura, E				Matsuo, Akemi; Wada, Yousuke; Makino, Mutsuki; Kawaguchi, Kenji; Kanemoto, Ryoko; Shionoya, Rie; Nakamura, Emiko			THE CONTRIBUTION OF THE CELL BLOCKS OBTAINED FROM BRONCHIAL BRUSHING SPECIMENS IN THE DIAGNOSIS OF LUNG CANCER	RESPIROLOGY			English	Meeting Abstract									[Matsuo, Akemi; Wada, Yousuke] Shinonoi Gen Hosp, Dept Resp Med, Nagano, Japan; [Makino, Mutsuki; Kawaguchi, Kenji] Shinonoi Gen Hosp, Dept Resp Med, Nagano, Japan; [Kanemoto, Ryoko; Shionoya, Rie; Nakamura, Emiko] Shinonoi Gen Hosp, Dept Clin Lab, Nagano, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-J-026	161	161				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300462		
J	Asai, N; Katsuta, E; Numanami, H; Haniuda, M; Yamaguchi, E; Kubo, A				Asai, Nobuhiro; Katsuta, Eisuke; Numanami, Hiroki; Haniuda, Masayuki; Yamaguchi, Etsuro; Kubo, Akihito			THE CLASSIFICATION OF INTERSTITIAL PNEUMONIA BY THE OFFICIAL ATS/ERS/JRS/ALAT STATEMENT COULD PREDICT ACUTE EXACERBATION OF INTERSTITIAL LUNG DISEASE IN ADVANCED NON-SMALL CELL LUNG CANCER PATIENTS WITH PRE-EXISTING INTERSTITIAL LUNG DISEASE	RESPIROLOGY			English	Meeting Abstract									[Asai, Nobuhiro; Yamaguchi, Etsuro; Kubo, Akihito] Aichi Med Univ, Sch Med, Div Resp Med & Allergol, Dept Internal Med, Nagakute, Aichi, Japan; [Katsuta, Eisuke; Numanami, Hiroki; Haniuda, Masayuki] Aichi Med Univ, Sch Med, Nagakute, Aichi, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-J-036	163	163				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300471		
J	Kobayashi, K; Inaoka, H; Kokubo, K; Kobayashi, H				Kobayashi, Kozue; Inaoka, Hidenori; Kokubo, Kenichi; Kobayashi, Hirosuke			EFFECTS OF PEEP-LIKE CYCLIC STRETCHING ON THE IL-6 GENE AND PROTEIN PRODUCTION IN NORMAL HUMAN PULMONARY ARTERY ENDOTHELIAL CELLS IN VITRO	RESPIROLOGY			English	Meeting Abstract									[Kobayashi, Kozue; Inaoka, Hidenori; Kokubo, Kenichi; Kobayashi, Hirosuke] Kitasato Univ, Sch Allied Hlth Sci, Tokyo, Japan; [Kobayashi, Kozue; Inaoka, Hidenori; Kokubo, Kenichi; Kobayashi, Hirosuke] Kitasato Univ, Grad Sch Med Sci, Tokyo, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-K-004	173	173				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300506		
J	Shioya, T; Satake, M; Kagawagoshi, A; Sato, K; Sano, M; Hashimoto, M; Ito, H				Shioya, T.; Satake, M.; Kagawagoshi, A.; Sato, K.; Sano, M.; Hashimoto, M.; Ito, H.			GENETIC EPIDEMIOLOGY OF HEREDITARY HAEMORRHAGIC TELANGIECTASIA ASSOCIATED WITH PULMONARY ARTERIOVENOUS MALFORMATION	RESPIROLOGY			English	Meeting Abstract									[Shioya, T.; Satake, M.; Kagawagoshi, A.; Sato, K.; Sano, M.; Hashimoto, M.; Ito, H.] Akita Univ, Grad Sch Hlth Sci, Dept Phys Therapy, Dept Pulm Med, Akita 010, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-K-001	173	173				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300504		
J	Hoshi, S; Yokomizo, I; Okuda, M; Suzuki, K				Hoshi, Sakuo; Yokomizo, Ichiro; Okuda, Mikihisa; Suzuki, Kouichi			RELATION BETWEEN SLEEP APNEOA SYNDROME AND DEPRESSION - EFFECTIVENESS OF A SELF-RELATING DEPRESSION SCALE QUESTIONNAIRE	RESPIROLOGY			English	Meeting Abstract									[Hoshi, Sakuo] Yurin Hosp, Dept Resp Med, Tokyo, Japan; [Yokomizo, Ichiro] Yurin Hosp, Dept Dent & Oral Surg, Tokyo, Japan; [Okuda, Mikihisa] Yurin Hosp, Dept Lab Examinat, Tokyo, Japan; [Suzuki, Kouichi] Yurin Hosp, Dept Gastroenterol Med, Tokyo, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-K-007	175	175				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300509		
J	Kinjo, T; Yamazato, S; Yamamoto, T; Ikemiyagi, N; Taira, H; Miyagi, A; Nishiyama, N; Fujita, A; Uehara, A; Nabeya, D; Karimata, Y; Haranaga, S; Fujita, J				Kinjo, Takeshi; Yamazato, Shoshin; Yamamoto, Tomoko; Ikemiyagi, Nanae; Taira, Hirona; Miyagi, Ayane; Nishiyama, Naoya; Fujita, Akane; Uehara, Ayako; Nabeya, Daijiro; Karimata, Yosuke; Haranaga, Shusaku; Fujita, Jiro			THE EFFECT OF MEDICAL EDUCATION PROJECT TO IMPROVE THE SKILLS IN READING CHEST X-RAY	RESPIROLOGY			English	Meeting Abstract									[Kinjo, Takeshi; Yamazato, Shoshin; Yamamoto, Tomoko; Ikemiyagi, Nanae; Taira, Hirona; Miyagi, Ayane; Nishiyama, Naoya; Fujita, Akane; Uehara, Ayako; Nabeya, Daijiro; Karimata, Yosuke; Haranaga, Shusaku; Fujita, Jiro] Univ Ryukyus, Dept Internal Med 1, Fac Med, Dept Infect Resp & Digest Med Control & Prevent I, Nishihara, Okinawa 90301, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-K-008	175	175				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300510		
J	Asaji, M; Tobino, K; Nishizawa, S; Yoshimine, K; Ko, Y; Yamaji, Y; Yasuda, Y; Tsuruno, K; Miyajima, H; Mukasa, Y; Ebi, N				Asaji, Mina; Tobino, Kazunori; Nishizawa, Saori; Yoshimine, Kohei; Ko, Yuki; Yamaji, Yoshikazu; Yasuda, Yuichro; Tsuruno, Kosuke; Miyajima, Hiroyuki; Mukasa, Yosuke; Ebi, Noriyuki			CHEST COMPUTED TOMOGRAPHIC FINDINGS IN RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS	RESPIROLOGY			English	Meeting Abstract									[Asaji, Mina; Tobino, Kazunori; Nishizawa, Saori; Yoshimine, Kohei; Ko, Yuki; Yamaji, Yoshikazu; Yasuda, Yuichro; Tsuruno, Kosuke; Miyajima, Hiroyuki; Mukasa, Yosuke; Ebi, Noriyuki] Iizuka Hosp, Dept Resp Med, Iizuka, Fukuoka, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-K-012	176	176				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300514		
J	Nishimuta, H; Kiribayasi, T; Hagiwara, O; Ishii, T; Kusachi, S				Nishimuta, Hironobu; Kiribayasi, Takaharu; Hagiwara, Osahiko; Ishii, Tomotaka; Kusachi, Shinya			3 CASES OF YOUNG PATIENT WITH PULMONARY ARTERIOVENOUS FISTULA, TREATED BY VIDEO ASSISTED THORACOSCOPIC SURGERY	RESPIROLOGY			English	Meeting Abstract									[Nishimuta, Hironobu; Kiribayasi, Takaharu; Hagiwara, Osahiko; Ishii, Tomotaka; Kusachi, Shinya] Toho Univ, Med Ctr, Ohashi Hosp, Dept Surg, Tokyo, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-K-015	177	177				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300517		
J	Inoue, T; Handa, H; Inoue, T; Mineshita, M; Maddula, S; Baumbach, JI; Miyazawa, T				Inoue, Teppei; Handa, Hiroshi; Inoue, Takeo; Mineshita, Masamichi; Maddula, S.; Baumbach, J. I.; Miyazawa, Teruomi			VOLATILE ORGANIC COMPOUNDS FROM TRACHEOBRONCHIAL STENT-RELATED BIOFILM FORMATION DETECTED BY ION MOBILITY SPECTROMETRY	RESPIROLOGY			English	Meeting Abstract									[Inoue, Teppei; Handa, Hiroshi; Inoue, Takeo; Mineshita, Masamichi; Miyazawa, Teruomi] St Marianna Univ, Sch Med, Dept Internal Med, Div Resp & Infect Dis,Miyamae Ku, Kawasaki, Kanagawa 2168511, Japan; [Maddula, S.; Baumbach, J. I.] Reutlingen Univ, Fac Appl Chem, D-72762 Reutlingen, Germany								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-K-017	178	178				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300519		
J	Kiribayashi, T; Saida, Y; Nagao, J; Watanabe, M; Okamoto, Y; Nakamura, Y; Asai, K; Enomoto, T; Nishimuta, H; Hagiwara, O; Ishii, T; Kusachi, S				Kiribayashi, Takaharu; Saida, Yoshihisa; Nagao, Jiro; Watanabe, Manabu; Okamoto, Yasushi; Nakamura, Yoichi; Asai, Koji; Enomoto, Toshiyuki; Nishimuta, Hironobu; Hagiwara, Osahiko; Ishii, Tomotaka; Kusachi, Shinya			EVALUATION OF TOTAL THORACOSCOPIC EXTENDED THYMECTOMY FOR MYASTHENIA GRAVIS	RESPIROLOGY			English	Meeting Abstract									[Kiribayashi, Takaharu; Saida, Yoshihisa; Nagao, Jiro; Watanabe, Manabu; Okamoto, Yasushi; Nakamura, Yoichi; Asai, Koji; Enomoto, Toshiyuki; Nishimuta, Hironobu; Hagiwara, Osahiko; Ishii, Tomotaka; Kusachi, Shinya] Toho Univ, Ohashi Med Ctr, Dept Surg, Tokyo, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-K-016	178	178				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300518		
J	Nishikawa, Y; Kokubo, K; Kobayashi, K; Hataishi, R; Shinbo, T; Hirose, M; Kobayashi, H				Nishikawa, Yuki; Kokubo, Kenichi; Kobayashi, Kozue; Hataishi, Ryuji; Shinbo, Toshihiro; Hirose, Minoru; Kobayashi, Hirosuke			HYDROGEN GAS INHALATION AMELIORATES DIRECT LUNG INJURY AND INDIRECT CONTRALATERAL LUNG INJURY IN A MURINE ASPIRATION PNEUMONIA MODEL	RESPIROLOGY			English	Meeting Abstract									[Nishikawa, Yuki; Kokubo, Kenichi; Kobayashi, Kozue; Shinbo, Toshihiro; Hirose, Minoru; Kobayashi, Hirosuke] Kitasato Univ, Sch Allied Hlth Sci, Tokyo, Japan; [Nishikawa, Yuki] Tokyo Med Ctr, Tokyo, Japan; [Hataishi, Ryuji] Kitasato Univ, Sch Med, Tokyo, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-K-019	179	179				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300521		
J	Kokubo, K; Aoki, M; Kobayashi, K; Shimouchi, A; Kobayashi, H				Kokubo, Kenichi; Aoki, Mirei; Kobayashi, Kozue; Shimouchi, Akito; Kobayashi, Hirosuke			HYDROGEN CONCENTRATION IN EXPIRATORY GAS AFTER TAKING INDIGESTIBLE SUGARS	RESPIROLOGY			English	Meeting Abstract									[Kokubo, Kenichi; Aoki, Mirei; Kobayashi, Kozue; Kobayashi, Hirosuke] Kitasato Univ, Sch Allied Hlth Sci, Tokyo, Japan; [Shimouchi, Akito] Natl Cerebral & Cardiovasc Ctr, Suita, Osaka, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-K-023	180	180				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300525		
J	Kato, T				Kato, Tadashi			TWO CASES OF MALIGNANT PLEURAL MESOTHELIOMA WAS DIAGNOSED BY BRONCHOSCOPY	RESPIROLOGY			English	Meeting Abstract									[Kato, Tadashi] Kawasaki Med Sch Univ Kawasaki Hosp Gen Internal, Kawasaki, Kanagawa, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-K-033	184	184				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300535		
J	Hagiwara, O; Kiribayashi, T; Nishimuta, H; Kusachi, S; Yokouchi, Y				Hagiwara, Osahiko; Kiribayashi, Takaharu; Nishimuta, Hironobu; Kusachi, Shinya; Yokouchi, Yuki			RESECTABLE INTRALOBER PULMONARY SEQUESTRATION ACCOMPANIED REPEATED FEVER	RESPIROLOGY			English	Meeting Abstract									[Hagiwara, Osahiko; Kiribayashi, Takaharu; Nishimuta, Hironobu; Kusachi, Shinya] Toho Univ Med Ctr Ohashi Hosp, Dept Surg, Tokyo, Japan; [Yokouchi, Yuki] Toho Univ Ohashi Hosp, Dept Diagnost Pathol, Tokyo, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-K-037	185	185				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300539		
J	Matsushima, S; Bottoli, I; Skerjanec, A; Groenewegen, A; Lowe, PJ; Maahs, S; Arm, JP				Matsushima, Soichiro; Bottoli, Ivan; Skerjanec, Andrej; Groenewegen, Andrea; Lowe, Phillip J.; Maahs, Suzanne; Arm, Jonathan P.			SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF QGE031, A HIGH AFFINITY ANTI-IGE ANTIBODY IN CAUCASIAN AND JAPANESE ATOPIC SUBJECTS	RESPIROLOGY			English	Meeting Abstract									[Matsushima, Soichiro] Integrated Hosp Care Novartis Pharma KK, Tokyo, Japan; [Bottoli, Ivan] Novartis Pharma AG, Primary Care, Basel, Switzerland; [Skerjanec, Andrej; Arm, Jonathan P.] Novartis Inst Biomed Res, Basel, Switzerland; [Groenewegen, Andrea] Novartis Pharma AG, Biomarker Dev, Basel, Switzerland; [Lowe, Phillip J.] Novartis Pharma AG, Adv Quantitat Sci, Basel, Switzerland; [Maahs, Suzanne] Novartis Inst Biomed Res, E Hanover, NJ USA								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-K-048	188	188				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300550		
J	Oki, M; Saka, H; Kitagawa, C; Kogure, Y; Ryuge, M; Oka, S; Tsuboi, R; Nakahata, M; Hori, K; Murakami, Y; Ise, Y; Tokojima, M				Oki, Masahide; Saka, Hideo; Kitagawa, Chiyoe; Kogure, Yoshihito; Ryuge, Misaki; Oka, Saori; Tsuboi, Rie; Nakahata, Masashi; Hori, Kazumi; Murakami, Yasushi; Ise, Yuko; Tokojima, Masatoshi			AIRWAY STENTING IN PATIENTS WHO REQUIRE INTUBATION DUE TO MALIGNANT AIRWAY STENOSIS	RESPIROLOGY			English	Meeting Abstract									[Oki, Masahide; Saka, Hideo; Kitagawa, Chiyoe; Kogure, Yoshihito; Ryuge, Misaki; Oka, Saori; Tsuboi, Rie; Nakahata, Masashi; Hori, Kazumi; Murakami, Yasushi; Ise, Yuko; Tokojima, Masatoshi] Nagoya Med Ctr, Dept Resp Med, Nagoya, Aichi, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-K-050	188	188				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300552		
J	Nishitsuji, M; Uo, M; Tani, M; Okazaki, A; Okura, N; Nishi, K				Nishitsuji, Masaru; Uo, Mayuka; Tani, Mayuko; Okazaki, Akihito; Okura, Noriyuki; Nishi, Koichi			THE SEASONAL CHANGE OF THE SELF ASSESSMENT OF ALLERGIC RHINITIS AND ASTHMA QUESTIONNAIRE (SACRA) IN JAPAN	RESPIROLOGY			English	Meeting Abstract									[Nishitsuji, Masaru; Uo, Mayuka; Tani, Mayuko; Okazaki, Akihito; Okura, Noriyuki; Nishi, Koichi] Ishikawa Prefectural Cent Hosp, Kanazawa, Ishikawa, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-K-052	189	189				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300554		
J	Shinke, H; Hori, S; Hazeki, N; Otera, H; Kobayashi, K; Funada, Y; Fukabori, T; Nishimura, Y				Shinke, Haruko; Hori, Suya; Hazeki, Nobuko; Otera, Hiroshi; Kobayashi, Kazuyuki; Funada, Yasuhiro; Fukabori, Takashi; Nishimura, Yoshihiro			BRONCHIAL ASTHMA IN NURSING HOMES FOR ELDERLY IN JAPAN: QUESTIONNAIRE SURVEY	RESPIROLOGY			English	Meeting Abstract									[Shinke, Haruko; Hori, Suya; Hazeki, Nobuko; Otera, Hiroshi; Kobayashi, Kazuyuki; Funada, Yasuhiro; Nishimura, Yoshihiro] Kobe Univ, Grad Sch Med, Dept Internal Med, Div Resp Med, Kobe, Hyogo, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-K-058	191	191				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300560		
J	Hazeki, N; Funada, Y; Nakata, K; Shinke, H; Hori, S; Otera, H; Kobayashi, K; Ishihara, K; Kajiyama, M; Ishida, A; Nakatani, Y; Oka, K; Kanaoka, M; Kishimoto, N; Kurosaka, F; Tanaka, A; Nishian, T; Mochizuki, Y; Yagi, K; Yamada, M; Usuki, H; Omoto, A; Fukabori, T; Yamamoto, H; Terada, T; Nishimura, Y				Hazeki, Nobuko; Funada, Yasuhiro; Nakata, Kyousuke; Shinke, Haruko; Hori, Suya; Otera, Hiroshi; Kobayashi, Kazuyuki; Ishihara, Kyousuke; Kajiyama, Mizutaka; Ishida, Akihito; Nakatani, Yuji; Oka, Kastumi; Kanaoka, Masaki; Kishimoto, Nobuyasu; Kurosaka, Fumitake; Tanaka, Akira; Nishian, Toshihiko; Mochizuki, Yoshirou; Yagi, Kazuyuki; Yamada, Mistuhiro; Usuki, Hiroaki; Omoto, Akiyoshi; Fukabori, Takashi; Yamamoto, Hiroyuki; Terada, Tadayuki; Nishimura, Yoshihiro			INVESTIGATION OF CHILDREN'S FOLLOW-UP CONSULTATIONS AFTER EMERGENCY DEPARTMENT VISITS FOR ASTHMA ATTACKS IN LARGE AND MEDIUM SIZED CITIES	RESPIROLOGY			English	Meeting Abstract									[Hazeki, Nobuko; Funada, Yasuhiro; Nakata, Kyousuke; Shinke, Haruko; Hori, Suya; Otera, Hiroshi; Kobayashi, Kazuyuki; Nishimura, Yoshihiro] Kobe Univ, Grad Sch Med, Div Resp Med, Kobe, Hyogo, Japan; [Ishihara, Kyousuke] Kobe City Med Ctr West Hosp, Kobe City Hosp Org, Kobe, Hyogo, Japan; [Kajiyama, Mizutaka; Ishida, Akihito] Kobe Childrens Primary Emergency Med Ctr, Kobe, Hyogo, Japan; [Ishihara, Kyousuke; Nakatani, Yuji; Oka, Kastumi; Kanaoka, Masaki; Kishimoto, Nobuyasu; Kurosaka, Fumitake; Tanaka, Akira; Nishian, Toshihiko; Mochizuki, Yoshirou; Yagi, Kazuyuki; Yamada, Mistuhiro; Usuki, Hiroaki; Omoto, Akiyoshi; Fukabori, Takashi; Yamamoto, Hiroyuki; Terada, Tadayuki; Nishimura, Yoshihiro] Facilitator Zero Asthma Death Comm Hyogo, Kobe, Hyogo, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-K-063	193	193				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300565		
J	Pulsiripunya, C; Fujimura, M				Pulsiripunya, C.; Fujimura, M.			SINOBRONCHIAL SYNDROME (SBS) NOT TO BE MISTAKEN FOR UPPER AIRWAY COUGH SYNDROME (UACS): CLINICAL EXPERIENCE WITH LOW DOSE ERYTHROMYCIN (LDEM) THERAPY IN THAILAND	RESPIROLOGY			English	Meeting Abstract									[Pulsiripunya, C.] Chest Dis Inst Thailand, Nothanburi, Thailand; [Fujimura, M.] Natl Hosp Org, Nanao Hosp, Gifu, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-K-071	195	195				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300571		
J	Nishida, C; Yatera, K; Ogoshi, T; Yamasaki, K; Orihashi, T; Kawanami, Y; Kido, T; Ishimoto, H; Takenaka, K; Shibuya, R; Kasai, T; Tanaka, F; Furuya, M; Mukae, H				Nishida, Chinatsu; Yatera, Kazuhiro; Ogoshi, Takaaki; Yamasaki, Kei; Orihashi, Takeshi; Kawanami, Yukiko; Kido, Takashi; Ishimoto, Hiroshi; Takenaka, Ken; Shibuya, Ryo; Kasai, Takahiko; Tanaka, Fumihiro; Furuya, Mitsuko; Mukae, Hiroshi			BIRT-HOGG-DUBE SYNDROME COMPLICATED WITH LUNG CANCER; A POSSIBLE LINK OF THESE TWO DISEASE ENTITIES	RESPIROLOGY			English	Meeting Abstract									[Nishida, Chinatsu; Yatera, Kazuhiro; Ogoshi, Takaaki; Yamasaki, Kei; Orihashi, Takeshi; Kawanami, Yukiko; Kido, Takashi; Ishimoto, Hiroshi; Mukae, Hiroshi] Univ Occupat & Environm Hlth, Dept Resp Med, Kitakyushu, Fukuoka, Japan; [Takenaka, Ken; Tanaka, Fumihiro] Univ Occupat & Environm Hlth, Dept Surg 2, Kitakyushu, Fukuoka, Japan; [Shibuya, Ryo; Kasai, Takahiko] Univ Occupat & Environm Hlth, Dept Pathol & Oncol 1, Kitakyushu, Fukuoka, Japan; [Furuya, Mitsuko] Yokohama City Univ, Grad Sch Med, Dept Mol Pathol, Yokohama, Kanagawa, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-K-073	196	196				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300573		
J	Yasuda, Y; Tobino, K; Ko, Y; Asaji, M; Yamaji, Y; Tsuruno, K; Miyajima, H; Mukasa, Y; Ebi, N				Yasuda, Yuichiro; Tobino, Kazunori; Ko, Yuki; Asaji, Mina; Yamaji, Yoshikazu; Tsuruno, Kosuke; Miyajima, Hiroyuki; Mukasa, Yosuke; Ebi, Noriyuki			PREDICTION OF THE CLINICAL COURSE OF PNEUMOTHORAX USING CHEST X-RAY	RESPIROLOGY			English	Meeting Abstract									[Yasuda, Yuichiro; Tobino, Kazunori; Ko, Yuki; Asaji, Mina; Yamaji, Yoshikazu; Tsuruno, Kosuke; Miyajima, Hiroyuki; Mukasa, Yosuke; Ebi, Noriyuki] Iizuka Hosp, Dept Resp Med, Iizuka, Fukuoka 8200018, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-K-078	197	197				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300578		
J	Takeda, N; Asai, K; Ijiri, N; Shirai, A; Watanabe, T; Konishi, K; Kamoi, H; Kanazawa, H; Hirata, K				Takeda, N.; Asai, K.; Ijiri, N.; Shirai, A.; Watanabe, T.; Konishi, K.; Kamoi, H.; Kanazawa, H.; Hirata, K.			THE IMPACT OF PARTICULATE MATTER WITH THEIR DIAMETERS LESS THAN 2.5.MM (PM2.5) LEVELS ON EMERGENCY DEPARTMENT VISITS WITH RESPIRATORY COMPLICATIONS IN OSAKA	RESPIROLOGY			English	Meeting Abstract									[Takeda, N.; Asai, K.; Ijiri, N.; Shirai, A.; Watanabe, T.; Konishi, K.; Kamoi, H.; Kanazawa, H.; Hirata, K.] Osaka City Univ, Grad Sch Med, Dept Resp Med, Osaka 558, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-K-085	200	200				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300585		
J	Fujioka, T; Tokunaga, K; Hirooka, S; Masunaga, A; Kojima, K; Hirosako, S; Okamoto, S; Ichiyasu, H; Fujii, K; Ikeda, O; Yamashita, Y; Kohrogi, H				Fujioka, T.; Tokunaga, K.; Hirooka, S.; Masunaga, A.; Kojima, K.; Hirosako, S.; Okamoto, S.; Ichiyasu, H.; Fujii, K.; Ikeda, O.; Yamashita, Y.; Kohrogi, H.			SEVERE PULMONARY FAILURE WITH PULMONARY ARTERIO-VENOUS FISTULA DUE TO HEREDITARY HAEMORRHAGIC TELANGIECTASIA SUCCESSFULLY TREATED WITH COIL EMBOLIZATION IN A WOMAN JUST AFTER DELIVERY AND HER FATHER WITH IGG4-RELATED DISEASE	RESPIROLOGY			English	Meeting Abstract									[Fujioka, T.; Tokunaga, K.; Hirooka, S.; Masunaga, A.; Kojima, K.; Hirosako, S.; Okamoto, S.; Ichiyasu, H.; Fujii, K.; Ikeda, O.; Yamashita, Y.; Kohrogi, H.] Kumamoto Univ Hosp, Dept Resp Med, Kumamoto, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-M-007	207	207				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300610		
J	Kushima, H; Ishii, H; Sato, T; Tokimatsu, I; Kadota, J				Kushima, H.; Ishii, H.; Sato, T.; Tokimatsu, I; Kadota, J.			PROPHYLACTIC ADMINISTRATION OF SULFAMETHOXAZOLE-TRIMETHOPRIM ELIMINATES AIRWAY COLONIZATION OF PNEUMOCYSTIS JIROVE	RESPIROLOGY			English	Meeting Abstract									[Kushima, H.; Ishii, H.; Sato, T.; Tokimatsu, I; Kadota, J.] Oita Univ Hosp, Dept Resp Med, Oita, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-N-007	209	209				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300618		
J	Yamazato, S; Yamamoto, T; Ikemiyagi, N; Taira, H; Miyagi, A; Kurihara, K; Kokuba, T; Nishiyama, N; Fujita, A; Uehara, A; Nabeya, D; Karimata, Y; Kinjo, T; Haranaga, S; Fujita, J				Yamazato, Shoshin; Yamamoto, Tomoko; Ikemiyagi, Nanae; Taira, Hirona; Miyagi, Ayane; Kurihara, Kazuhiro; Kokuba, Tsukasa; Nishiyama, Naoya; Fujita, Akane; Uehara, Ayako; Nabeya, Daijiro; Karimata, Yosuke; Kinjo, Takeshi; Haranaga, Shusaku; Fujita, Jiro			CLINICAL UTILITY OF A RAPID ANTIGEN TEST FOR DETECTING HUMAN METAPNEUMOVIRUS: USAGE EXPERIENCE DURING AN OUTBREAK IN A LONG-TERM CARE FACILITY IN OKINAWA, JAPAN	RESPIROLOGY			English	Meeting Abstract									[Yamazato, Shoshin; Yamamoto, Tomoko; Ikemiyagi, Nanae; Taira, Hirona; Miyagi, Ayane; Kurihara, Kazuhiro; Kokuba, Tsukasa; Nishiyama, Naoya; Fujita, Akane; Uehara, Ayako; Nabeya, Daijiro; Karimata, Yosuke; Kinjo, Takeshi; Haranaga, Shusaku; Fujita, Jiro] Univ Ryukyus, Fac Med, Dept Infect Resp & Digest Med Control & Prevent I, Dept Internal Med 1, Okinawa, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-N-008	210	210				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300619		
J	Sato, M; Abe, S; Abe, Y; Sato, K; Nemoto, T; Nunomiya, K; Kimura, T; Yamauchi, K; Igarashi, A; Inoue, S; Shibata, Y; Kubota, I				Sato, Masamichi; Abe, Shuichi; Abe, Yuki; Sato, Kento; Nemoto, Takako; Nunomiya, Keiko; Kimura, Tomomi; Yamauchi, Keiko; Igarashi, Akira; Inoue, Sumito; Shibata, Yoko; Kubota, Isao			EVALUATION OF CHEMOTHERAPY FOR PULMONARY NON-TUBERCULOUS MYCOBACTERIAL DISEASE	RESPIROLOGY			English	Meeting Abstract									[Sato, Masamichi; Abe, Yuki; Sato, Kento; Nemoto, Takako; Nunomiya, Keiko; Kimura, Tomomi; Yamauchi, Keiko; Igarashi, Akira; Inoue, Sumito; Shibata, Yoko; Kubota, Isao] Yamagata Univ, Fac Med, Dept Cardiol Pulmonol & Nephrol, Yamagata 990, Japan; [Abe, Shuichi] Yamagata Univ Hosp, Clin Lab, Yamagata, Japan; [Abe, Shuichi] Yamagata Univ Hosp, Yamagata, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-N-015	212	212				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300626		
J	Furuie, H; Toyama, K; Koyama, K; Ogura, Y; Ishizuka, H				Furuie, H.; Toyama, K.; Koyama, K.; Ogura, Y.; Ishizuka, H.			PHARMACOKINETICS OF LANINAMIVIR OCTANOATE, A LONG-ACTING NEURAMINIDASE INHIBITOR, IN ALVEOLAR MACROPHAGES AND THE CONTRIBUTION OF ACYL-PROTEIN THIOESTERASE 1 TO FORM AN ACTIVE METABOLITE, LANINAMIVIR	RESPIROLOGY			English	Meeting Abstract									[Furuie, H.] Osaka Pharmacol Clin Res Hosp, Osaka, Japan; [Toyama, K.; Koyama, K.; Ishizuka, H.] Daiichi Sankyo Co Ltd, Tokyo, Japan; [Ogura, Y.] Daiichi Sankyo RD Novare Co Ltd, Tokyo, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-N-025	216	216				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300635		
J	Hama, M; Atsuhito, U; Yasuo, M; Yamamoto, H; Hanaoka, M				Hama, Mineyuki; Atsuhito, Ushiki; Yasuo, Masanori; Yamamoto, Hiroshi; Hanaoka, Masayuki			VALIDITY OF THE ST. GEORGE'S RESPIRATORY QUESTIONNAIRE AND COPD ASSESSMENT TEST IN ASSESSING HEALTH STATUS IN PULMONARY INFECTION WITH NONTUBERCULOUS MYCOBACTERIUM	RESPIROLOGY			English	Meeting Abstract									[Hama, Mineyuki; Atsuhito, Ushiki; Yasuo, Masanori; Yamamoto, Hiroshi; Hanaoka, Masayuki] Shinshu Univ, Sch Med, Dept Internal Med 1, Matsumoto, Nagano, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-N-029	217	217				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300639		
J	Kitamura, T; Hayama, M; Inoue, H; Kataoka, Y; Sawaiv, S; Mio, T				Kitamura, Tomotaka; Hayama, Manabu; Inoue, Hideki; Kataoka, Youko; Sawaiv, Satoru; Mio, Tadashi			ASPERGILLUS EMPYEMA WITH ASPERGILLUS-RELATED EOSINOPHILIC PNEUMONIA: A CASE REPORT AND REVIEW OF THE LITERATURE	RESPIROLOGY			English	Meeting Abstract									[Kitamura, Tomotaka] Hoshigaoka Med Ctr, Dept Resp Med, Hirakata, Osaka 5738511, Japan; [Hayama, Manabu; Inoue, Hideki; Mio, Tadashi] Kyoto Med Ctr, Dept Resp Med, Fushimi Ku, Kyoto 6128555, Japan; [Kataoka, Youko] Kyoto Med Ctr, Dept Thorac Surg, Fushimi Ku, Kyoto 6128555, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-N-028	217	217				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300638		
J	Yamamoto, T; Ikemiyagi, N; Taira, H; Miyagi, A; Yamazato, S; Kurihara, K; Kokuba, T; Nishiyama, N; Fujita, A; Uehara, A; Nabeya, D; Karimata, Y; Kinjo, T; Haranaga, S; Fujita, J				Yamamoto, Tomoko; Ikemiyagi, Nanae; Taira, Hirona; Miyagi, Ayane; Yamazato, Shoshin; Kurihara, Kazuhiro; Kokuba, Tsukasa; Nishiyama, Naoya; Fujita, Akane; Uehara, Ayako; Nabeya, Daijiro; Karimata, Yosuke; Kinjo, Takeshi; Haranaga, Shusaku; Fujita, Jiro			AETIOLOGY OF VIRAL PATHOGENS IN PATIENTS WITH INFLUENZA-LIKE ILLNESS DURING AN INFLUENZA SEASON AT THE UNIVERSITY HOSPITAL IN OKINAWA, JAPAN	RESPIROLOGY			English	Meeting Abstract									[Yamamoto, Tomoko; Ikemiyagi, Nanae; Taira, Hirona; Miyagi, Ayane; Yamazato, Shoshin; Kurihara, Kazuhiro; Kokuba, Tsukasa; Nishiyama, Naoya; Fujita, Akane; Uehara, Ayako; Nabeya, Daijiro; Karimata, Yosuke; Kinjo, Takeshi; Haranaga, Shusaku; Fujita, Jiro] Univ Ryukyus, Fac Med, Dept Infect Resp & Digest Med Control & Prevent I, Dept Internal Med 1, Nishihara, Okinawa 90301, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-N-027	217	217				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300637		
J	Kasamatsu, Y; Shirano, M; Goto, T				Kasamatsu, Yu; Shirano, Michinori; Goto, Tetsushi			A USEFUL COMPOSITE SCALE OF PCR AND THE (1 -> 3)-B-D-GLUCAN ASSAY FOR DIAGNOSING PNEUMOCYSTIS PNEUMONIA IN IMMUNOCOMPROMISED PATIENTS WITH ACUTE LUNG DISEASE	RESPIROLOGY			English	Meeting Abstract									[Kasamatsu, Yu; Shirano, Michinori; Goto, Tetsushi] Osaka City Gen Hosp, Dept Infect Dis, Osaka, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-N-032	218	218				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300642		
J	Ito, Y; Takeda, K; Takazono, T; Tashiro, M; Kosai, K; Morinaga, Y; Nakamura, S; Imamura, Y; Kurihara, S; Tsukamoto, M; Miyazaki, T; Izumikawa, K; Yanagihara, K; Tashiro, T; Kohno, S				Ito, Yuya; Takeda, Kazuaki; Takazono, Takahiro; Tashiro, Masato; Kosai, Kosuke; Morinaga, Yoshitomo; Nakamura, Shigeki; Imamura, Yoshifumi; Kurihara, Shintaro; Tsukamoto, Misuzu; Miyazaki, Taiga; Izumikawa, Koichi; Yanagihara, Katsunori; Tashiro, Takayoshi; Kohno, Shigeru			COMPARISON OF CLINICAL CHARACTERISTIC AND PROGNOSIS IN EACH ENTITY OF CHRONIC PULMONARY ASPERGILLOSIS	RESPIROLOGY			English	Meeting Abstract									[Ito, Yuya; Takeda, Kazuaki; Takazono, Takahiro; Tashiro, Masato; Kosai, Kosuke; Morinaga, Yoshitomo; Nakamura, Shigeki; Imamura, Yoshifumi; Kurihara, Shintaro; Tsukamoto, Misuzu; Miyazaki, Taiga; Tashiro, Takayoshi; Kohno, Shigeru] Nagasaki Univ, Grad Sch Biomed Sci, Dept Mol Microbiol & Immunol, Nagasaki 852, Japan; [Takeda, Kazuaki; Kosai, Kosuke; Morinaga, Yoshitomo; Yanagihara, Katsunori] Nagasaki Univ Hosp, Dept Lab Med, Nagasaki, Japan; [Tashiro, Masato; Kurihara, Shintaro; Tsukamoto, Misuzu; Izumikawa, Koichi] Nagasaki Univ, Grad Sch Biomed Sci, Dept Infect Dis, Nagasaki, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-N-037	220	220				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300647		
J	Tanaka, K; Ogasawara, T; Aoshima, Y; Yano, T; Kasamatsu, N				Tanaka, Kazuki; Ogasawara, Takashi; Aoshima, Youichirou; Yano, Toshiaki; Kasamatsu, Norio			PROCALCITONIN-GUIDED ALGORITHM IN NURSING AND HEALTHCARE-ASSOCIATED PNEUMONIA	RESPIROLOGY			English	Meeting Abstract									[Tanaka, Kazuki; Ogasawara, Takashi; Aoshima, Youichirou; Yano, Toshiaki; Kasamatsu, Norio] Hamamatsu Med Ctr, Dept Resp Med, Hamamatsu, Shizuoka 4328580, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-N-036	220	220				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300646		
J	Suzuki, F; Katsurada, N; Aoshima, M; Yamawaki, S; Otsuki, A; Watanabe, J; Takai, M; Katsurada, M; Nakashima, K; Misawa, M; Kaneko, N; Ishifuji, T; Morimoto, K; Ariyoshi, K				Suzuki, Fumi; Katsurada, Naoko; Aoshima, Masahiro; Yamawaki, Satoshi; Otsuki, Ayumu; Watanabe, Junko; Takai, Motohisa; Katsurada, Masahiro; Nakashima, Kei; Misawa, Masafumi; Kaneko, Norihiro; Ishifuji, Tomoko; Morimoto, Kounosuke; Ariyoshi, Koya			VIRAL INFECTION IN PATIENTS WITH NURSING AND HEALTHCARE-ASSOCIATED PNEUMONIA (NHCAP)	RESPIROLOGY			English	Meeting Abstract									[Suzuki, Fumi; Katsurada, Naoko; Aoshima, Masahiro; Yamawaki, Satoshi; Otsuki, Ayumu; Watanabe, Junko; Takai, Motohisa; Katsurada, Masahiro; Nakashima, Kei; Misawa, Masafumi; Kaneko, Norihiro] Kameda Med Ctr, Tokyo, Japan; [Ishifuji, Tomoko; Morimoto, Kounosuke; Ariyoshi, Koya] Nagasaki Univ, Inst Trop Med, Nagasaki, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-N-039	221	221				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300649		
J	Tsuruno, K; Tobino, K; Ko, Y; Yamaji, Y; Asaji, M; Yasuda, Y; Miyajima, H; Mukasa, Y; Ebi, N				Tsuruno, Kosuke; Tobino, Kazunori; Ko, Yuki; Yamaji, Yoshikazu; Asaji, Mina; Yasuda, Yuichiro; Miyajima, Hiroyuki; Mukasa, Yosuke; Ebi, Noriyuki			THE USEFULNESS OF LOCAL ANAESTHETIC THORACOSCOPY FOR PARAPNEUMONIC PLEURAL EFFUSIONS	RESPIROLOGY			English	Meeting Abstract									[Tsuruno, Kosuke; Tobino, Kazunori; Ko, Yuki; Yamaji, Yoshikazu; Asaji, Mina; Yasuda, Yuichiro; Miyajima, Hiroyuki; Mukasa, Yosuke; Ebi, Noriyuki] Iizuka Hosp, Dept Resp Med, Iizuka, Fukuoka, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-N-040	221	221				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300650		
J	Abe, Y; Abe, S; Wada, T; Iwabuchi, K; Shibata, Y; Kubota, I				Abe, Yuki; Abe, Shuichi; Wada, Toshihiro; Iwabuchi, Katsuyoshi; Shibata, Yoko; Kubota, Isao			CLINICAL EVALUATION OF ASPIRATION PNEUMONIA IN A COMMUNITY HOSPITAL IN JAPAN	RESPIROLOGY			English	Meeting Abstract									[Abe, Yuki; Wada, Toshihiro; Iwabuchi, Katsuyoshi] Yamagata City Hosp Saiseikan, Yamagata, Japan; [Abe, Shuichi] Yamagata Univ Hosp, Yamagata, Japan; [Abe, Yuki; Shibata, Yoko; Kubota, Isao] Yamagata Univ, Fac Med, Dept Cardiol Pulmonol & Nephrol, Yamagata 990, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-N-041	222	222				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300651		
J	Aoshima, M; Otsuki, A; Watanabe, J; Takai, M; Katsurada, M; Nakashima, K; Katsurada, N; Misawa, M; Otsuka, Y				Aoshima, Masahiro; Otsuki, Ayumu; Watanabe, Junko; Takai, Motohisa; Katsurada, Masahiro; Nakashima, Kei; Katsurada, Naoko; Misawa, Masafumi; Otsuka, Yoshihito			INTRAVENOUS AZITHROMYCIN MONOTHERAPY FOR NON-SEVERE COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA - A PROSPECTIVE, OPEN LABELLED, NON-COMPARATIVE STUDY	RESPIROLOGY			English	Meeting Abstract									[Aoshima, Masahiro; Otsuki, Ayumu; Watanabe, Junko; Takai, Motohisa; Katsurada, Masahiro; Nakashima, Kei; Katsurada, Naoko; Misawa, Masafumi] Kameda Med Ctr, Dept Pulm Med, Chiba, Japan; [Otsuka, Yoshihito] Kameda Med Ctr, Dept Lab Med, Chiba, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-N-044	223	223				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300654		
J	Ikemiyagi, N; Yamamoto, T; Taira, H; Miyagi, A; Yamazato, S; Kurihara, K; Kokuba, T; Nishiyama, N; Fujita, A; Uehara, A; Nabeya, D; Karimata, Y; Kinjo, T; Haranaga, S; Higa, F; Fujita, J				Ikemiyagi, Nanae; Yamamoto, Tomoko; Taira, Hirona; Miyagi, Ayane; Yamazato, Shoshin; Kurihara, Kazuhiro; Kokuba, Tsukasa; Nishiyama, Naoya; Fujita, Akane; Uehara, Ayako; Nabeya, Daijiro; Karimata, Yosuke; Kinjo, Takeshi; Haranaga, Shusaku; Higa, Futoshi; Fujita, Jiro			CLINICAL UTILITY OF MULTIPLEX PCR TO DIAGNOSE RESPIRATORY VIRAL PNEUMONIA	RESPIROLOGY			English	Meeting Abstract									[Ikemiyagi, Nanae; Yamamoto, Tomoko; Taira, Hirona; Miyagi, Ayane; Yamazato, Shoshin; Kurihara, Kazuhiro; Kokuba, Tsukasa; Nishiyama, Naoya; Fujita, Akane; Uehara, Ayako; Nabeya, Daijiro; Karimata, Yosuke; Kinjo, Takeshi; Haranaga, Shusaku; Higa, Futoshi; Fujita, Jiro] Univ Ryukyus, Dept Infect Resp & Digest Med, Dept Internal Med 1, Fac Med, Nishihara, Okinawa 90301, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-N-046	223	223				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300656		
J	Nakamura, S; Iwanaga, N; Takazono, T; Miyazaki, T; Izumikawa, K; Yanagihara, K; Kohno, S				Nakamura, S.; Iwanaga, N.; Takazono, T.; Miyazaki, T.; Izumikawa, K.; Yanagihara, K.; Kohno, S.			THE ASSOCIATION BETWEEN THE SEVERITY OF SWALLOWING IMPAIRMENT AND OUTCOMES OF ASPIRATION PNEUMONIA: A RETROSPECTIVE STUDY OF 321 CASES	RESPIROLOGY			English	Meeting Abstract									[Nakamura, S.; Iwanaga, N.; Takazono, T.; Miyazaki, T.; Kohno, S.] Dept Resp Dis, Unit Translat Med, Tokyo, Japan; [Nakamura, S.; Miyazaki, T.; Izumikawa, K.] Nagasaki Univ, Dept Infect Dis, Unit Mol Microbiol & Immunol, Grad Sch Biomed Sci, Nagasaki, Japan; [Yanagihara, K.] Nagasaki Univ Hosp, Dept Lab Med, Nagasaki, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-N-048	224	224				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300658		
J	Suyama, T; Hirayama, T; Hourai, Y; Tashiro, M; Takazono, T; Kosai, K; Morinaga, Y; Kurihara, S; Nakamura, S; Miyazaki, T; Tsukamoto, M; Izumikawa, K; Yanagihara, K; Kawakami, A; Tashiro, T; Kohno, S				Suyama, Takayuki; Hirayama, Tatsuro; Hourai, Yoshiro; Tashiro, Masato; Takazono, Takahiro; Kosai, Kosuke; Morinaga, Yoshitomo; Kurihara, Shintaro; Nakamura, Shigeki; Miyazaki, Taiga; Tsukamoto, Misuzu; Izumikawa, Koichi; Yanagihara, Katsunori; Kawakami, Atsushi; Tashiro, Takayoshi; Kohno, Shigeru			A CASE REPORT OF PULMONARY NOCARDIOSIS CAUSED BY N. CONCAVA, AND REVIEW OF THE LITERATURES	RESPIROLOGY			English	Meeting Abstract									[Suyama, Takayuki] Isahaya Gen Hosp, Dept Internal Med, Isahaya, Japan; [Suyama, Takayuki; Hirayama, Tatsuro; Takazono, Takahiro; Kurihara, Shintaro; Nakamura, Shigeki; Miyazaki, Taiga; Tashiro, Takayoshi; Kohno, Shigeru] Nagasaki Univ Hosp, Dept Internal Med 2, Nagasaki, Japan; [Hourai, Yoshiro; Kawakami, Atsushi] Nagasaki Univ Hosp, Dept Internal Med 1, Nagasaki, Japan; [Tashiro, Masato; Tsukamoto, Misuzu; Izumikawa, Koichi] Nagasaki Univ Hosp, Infect Control & Educ Ctr, Nagasaki, Japan; [Kosai, Kosuke; Morinaga, Yoshitomo; Yanagihara, Katsunori] Nagasaki Univ Hosp, Dept Lab Med, Nagasaki, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-N-047	224	224				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300657		
J	Takayasu, H; Iwasaki, T; Inoue, D; Kakiuchi, Y; Funaki, T; Yamazaki, Y; Tateno, H; Katou, E; Wakabayashi, A; Hayashi, M; Takeda, N; Matsukura, S; Kokubu, F				Takayasu, Hiromi; Iwasaki, Takuya; Inoue, Daisuke; Kakiuchi, Yuusuke; Funaki, Toshitaka; Yamazaki, Youhei; Tateno, Hidetsugu; Katou, Eisuke; Wakabayashi, Aya; Hayashi, Makoto; Takeda, Norikazu; Matsukura, Satoshi; Kokubu, Fumio			CLINICAL FEATURES OF COMMUNITY-ACQUIRED PNEUMONIA(CAP) AND NURSING AND HEALTHCARE-ASSOCIATED PNEUMONIA(NHCAP) IN OUR HOSPITAL	RESPIROLOGY			English	Meeting Abstract									[Takayasu, Hiromi; Iwasaki, Takuya; Inoue, Daisuke; Kakiuchi, Yuusuke; Funaki, Toshitaka; Yamazaki, Youhei; Tateno, Hidetsugu; Katou, Eisuke; Wakabayashi, Aya; Hayashi, Makoto; Takeda, Norikazu; Matsukura, Satoshi; Kokubu, Fumio] Showa Univ, Fujigaoka Hosp, Dept Resp Med, Yokohama, Kanagawa 227, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-N-050	225	225				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300660		
J	Koyama, N; Fujita, Y; Yamamoto, Y; Yamauchi, M; Tomoda, K; Yoshikawa, M; Kimura, H				Koyama, Noriko; Fujita, Yukio; Yamamoto, Yoshifumi; Yamauchi, Motoo; Tomoda, Koichi; Yoshikawa, Masanori; Kimura, Hiroshi			SERUM LEVELS OF SOLUBLE FORM OF RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEOA	RESPIROLOGY			English	Meeting Abstract									[Koyama, Noriko; Fujita, Yukio; Yamamoto, Yoshifumi; Yamauchi, Motoo; Tomoda, Koichi; Yoshikawa, Masanori; Kimura, Hiroshi] Nara Med Univ, Dept Internal Med & Resp Med 2, Nara, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-O-005	228	228				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300670		
J	Ohkura, K; Kawagoshi, A; Sugawara, K; Takahashi, H; Satake, M; Shioya, T				Ohkura, K.; Kawagoshi, A.; Sugawara, K.; Takahashi, H.; Satake, M.; Shioya, T.			RELATIONSHIP BETWEEN NOCTURNAL OXYGEN SATURATION AND FUNCTION OF DIAPHRAGM ASSESSED BY ULTRASONOGRAPHY IN COPD	RESPIROLOGY			English	Meeting Abstract									Akita City Hosp, Dept Rehabil, Akita, Japan; Akita Univ, Dept Phys Therapy, Grad Sch Med, Akita 010, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-O-007	229	229				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300672		
J	Ota, H; Tamaki, S; Yamauchi, M; Tomoda, K; Yoshikawa, M; Kimura, H; Itaya-Hironaka, A; Sakuramoto-Tsuchid, S; Yamauchi, A; Takasawa, S				Ota, Hiroyo; Tamaki, Shinji; Yamauchi, Motoo; Tomoda, Koichi; Yoshikawa, Masanori; Kimura, Hiroshi; Itaya-Hironaka, Asako; Sakuramoto-Tsuchid, Sumiyo; Yamauchi, Akiyo; Takasawa, Shin			INTERMITTENT HYPOXIA INDUCED PANCREATIC BETA-CELL PROLIFERATION VIA UP-REGULATION OF REG FAMILY GENES AND HGF GENE	RESPIROLOGY			English	Meeting Abstract									[Ota, Hiroyo; Tamaki, Shinji; Yamauchi, Motoo; Tomoda, Koichi; Yoshikawa, Masanori; Kimura, Hiroshi] Nara Med Univ, Dept Internal Med 2, Nara, Japan; [Itaya-Hironaka, Asako; Sakuramoto-Tsuchid, Sumiyo; Yamauchi, Akiyo; Takasawa, Shin] Nara Med Univ, Dept Biochem, Nara, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-O-006	229	229				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300671		
J	Yoshimine, H; Narui, K; Hara, M; Inoue, K; Ozawa, H				Yoshimine, Hiroyuki; Narui, Koji; Hara, Minoru; Inoue, Kenichiro; Ozawa, Hiroki			SLEEP-DISORDERED BREATHING FOR JAPANESE EXPATRIATES LIVED IN CHINA AND INDONESIA	RESPIROLOGY			English	Meeting Abstract									[Yoshimine, Hiroyuki; Inoue, Kenichiro] Inoue Hosp, Kyoto, Japan; [Narui, Koji] Toranomon Gen Hosp, Sleep Ctr, Tokyo, Japan; [Hara, Minoru] Kyoai Hosp, Jakarta Japan Clin, Tokyo, Japan; [Ozawa, Hiroki] Nagasaki Univ, Dept Psychiat, Nagasaki, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-O-011	230	230				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300676		
J	Hino, M; Tanaka, Y; Onda, N; Takoi, H; Kosaihira, S; Motohashi, N; Takahashi, N; Ookubo, T				Hino, M.; Tanaka, Y.; Onda, N.; Takoi, H.; Kosaihira, S.; Motohashi, N.; Takahashi, N.; Ookubo, T.			CLINICAL ANALYSIS OF SLEEP-DISORDERED BREATHING IN END-STAGE RENAL DISEASE WITH HAEMODIALYSIS	RESPIROLOGY			English	Meeting Abstract									[Hino, M.; Tanaka, Y.; Onda, N.; Takoi, H.; Kosaihira, S.; Motohashi, N.] Nippon Med Sch, Dept Resp Med, INBAHITEC Med Ctr, Chiba 2701694, Japan; [Takahashi, N.; Ookubo, T.] Ookubo Hosp, Dept Urol, Mito, Ibaraki, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-O-017	231	231				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300680		
J	Saito, M; Niitsuma, K				Saito, Miwako; Niitsuma, Katsunao			RAPID IDENTIFICATION OF MYCOBACTERIA BY MATRIX-ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY	RESPIROLOGY			English	Meeting Abstract									[Saito, Miwako; Niitsuma, Katsunao] Fukushima Med Univ, Dept Infect Dis & Pulm Med, Aizu Med Ctr, Fukushima, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-Q-008	237	237				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300696		
J	Tanaka, G; Ngoc, PTM; Hang, NTL; Lien, LT; Thuong, PH; Cuong, VC; Keicho, N				Tanaka, Goh; Phan Thi Minh Ngoc; Nguyen Thi Le Hang; Luu Thi Lien; Pham Huu Thuong; Vu Cao Cuong; Keicho, Naoto			A RETROSPECTIVE ANALYSIS OF PATIENT DATA FOR THE MANAGEMENT OF TUBERCULOSIS IN HANOI	RESPIROLOGY			English	Meeting Abstract									[Tanaka, Goh] Tokyo Univ Hosp, Dept Resp Med, Tokyo, Japan; [Phan Thi Minh Ngoc; Nguyen Thi Le Hang] NCGM BMH Med Collaborat Ctr, Hanoi, Vietnam; [Luu Thi Lien] Hanoi Dept Hlth, Hanoi, Vietnam; [Pham Huu Thuong; Vu Cao Cuong] Hanoi Lung Hosp, Hanoi, Vietnam; [Keicho, Naoto] Natl Ctr Global Hlth & Med, Tokyo, Japan; [Keicho, Naoto] Res Inst TB JATA, Dept Pathophysiol & Host Def, Kiyose, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-Q-026	242	242				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300712		
J	Tam, DB; Matsushita, I; Hang, NTL; Hong, LT; Lien, LT; Thuong, PH; Cuong, VC; Hijikata, M; Kobayashi, N; Sakurada, S; Higuchi, K; Harada, N; Keicho, N				Do Bang Tam; Matsushita, Ikumi; Nguyen Thi Le Hang; Le Thi Hong; Luu Thi Lien; Pham Huu Thuong; Vu Cao Cuong; Hijikata, Minako; Kobayashi, Nobuyuki; Sakurada, Shinsaku; Higuchi, Kazue; Harada, Nobuyuki; Keicho, Naoto			NEGATIVE INTERFERON-GAMMA RESPONSE WITH AND WITHOUT POSITIVE CONVERSION DURING TREATMENT IN PATIENTS WITH ACTIVE TUBERCULOSIS	RESPIROLOGY			English	Meeting Abstract									[Do Bang Tam; Le Thi Hong] Hanoi Lung Hosp, Dept Biochem Hematol & Blood Transfus, Hanoi, Vietnam; [Matsushita, Ikumi; Hijikata, Minako; Keicho, Naoto] Res Inst TB JATA, Dept Pathophysiol & Host Def, Kiyose, Japan; [Nguyen Thi Le Hang] NCGM BMH Med Collaborat Ctr, Hanoi, Vietnam; [Luu Thi Lien] Hanoi Dept Hlth, Hanoi, Vietnam; [Pham Huu Thuong; Vu Cao Cuong] Hanoi Lung Hosp, Hanoi, Vietnam; [Hijikata, Minako; Keicho, Naoto] Natl Ctr Global Hlth & Med, Kiyose, Japan; [Kobayashi, Nobuyuki] NHO Tokyo Natl Hosp, Tokyo, Japan; [Sakurada, Shinsaku] Natl Ctr Global Hlth & Med, Bur Int Med Cooperat, Kiyose, Japan								0	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1323-7799	1440-1843		RESPIROLOGY	Respirology	NOV	2014	19			3	SI	P-Q-029	243	243				1	Respiratory System	Respiratory System	AS8YQ	WOS:000344531300715		
J	Inoue, M; Arakawa, A; Yamane, S; Kadonosono, K				Inoue, Maiko; Arakawa, Akira; Yamane, Shin; Kadonosono, Kazuaki			SHORT-TERM EFFICACY OF INTRAVITREAL AFLIBERCEPT IN TREATMENT-NAIVE PATIENTS WITH POLYPOIDAL CHOROIDAL VASCULOPATHY	RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES			English	Article							ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; PHOTODYNAMIC THERAPY; MACULAR DEGENERATION; CLINICOPATHOLOGICAL CORRELATION; FOLLOW-UP; RANIBIZUMAB; BEVACIZUMAB; VERTEPORFIN; PENETRATION	Purpose: To evaluate the functional and morphologic outcomes of patients with polypoidal choroidal vasculopathy who underwent intravitreal aflibercept treatment. Methods: We prospectively studied all the treatment-naive patients with polypoidal choroidal vasculopathy who were scheduled to undergo intravitreal aflibercept between February 2013 and July 2013. The best-corrected visual acuity was compared before treatment and at 6 months after the initial treatment. Changes in the central foveal thickness, choroidal thickness, presence/absence of subretinal fluid, fibrin, pigment epithelial detachment, and subretinal hemorrhage were also evaluated. The regression of the polyps was assessed using indocyanine green angiography. Results: A total of 16 patients were included in this study. A significantly better best-corrected visual acuity at 6 months was seen, compared with that at baseline (P = 0.041). The mean central foveal thickness significantly decreased from 417 +/- 127 mu m to 187 +/- 50 mu m (P < 0.001). The mean choroidal thickness also significantly decreased from 250 +/- 63 mu m to 217 +/- 64 mu m (P = 0.011). Overall, a complete resolution was obtained in 93.3% (14/15) of the cases with subretinal fluid, 75.0% (3/4) of the cases with fibrin, and 88.9% (8/9) of the cases with subretinal hemorrhage. Fifty-six percent (5/9) of the cases with pigment epithelial detachment obtained a complete improvement, whereas 33.3%(3/9) exhibited a partial decrease. The rate of polyp regression was 75.0% (12/16). Conclusion: Intravitreal aflibercept was well tolerated and had improved the vision of treatment-naive patients with polypoidal choroidal vasculopathy when it was evaluated at short-term follow-up examinations. Intravitreal aflibercept might be associated with a high possibility of achieving involution of polyps and reducing exudative findings.	[Inoue, Maiko; Arakawa, Akira; Yamane, Shin; Kadonosono, Kazuaki] Yokohama City Univ, Dept Ophthalmol, Med Ctr, Yokohama, Kanagawa 232, Japan	Inoue, M (reprint author), Dept Ophthalmol, Minami Ku, 4-57 Urafune Cho, Yokohama, Kanagawa 2320024, Japan.	maicoo@urahp.yokohama-cu.ac.jp					Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x; Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017; Rosa RH, 2002, ARCH OPHTHALMOL-CHIC, V120, P502; Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478; Yuzawa M, 2005, BRIT J OPHTHALMOL, V89, P602, DOI 10.1136/bjo.2004.049296; Lafaut BA, 2000, RETINA-J RET VIT DIS, V20, P650, DOI 10.1097/00006982-200011000-00010; Koh AHC, 2013, RETINA-J RET VIT DIS, V33, P686, DOI 10.1097/IAE.0b013e3182852446; Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009; Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030; Nakashizuka H, 2008, INVEST OPHTH VIS SCI, V49, P4729, DOI 10.1167/iovs.08-2134; Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012; Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025; Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029; Chan WM, 2004, OPHTHALMOLOGY, V111, P1576, DOI 10.1016/j.ophta.2003.12.056; Gomi F, 2008, OPHTHALMOLOGY, V115, P141, DOI 10.1016/j.ophtha.2007.02.031; Spaide RF, 2002, RETINA-J RET VIT DIS, V22, P529, DOI 10.1097/00006982-200210000-00001; Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006; Akaza E, 2007, JPN J OPHTHALMOL, V51, P270, DOI 10.1007/s10384-007-0452-3; Terasaki H, 2002, BRIT J OPHTHALMOL, V86, P321, DOI 10.1136/bjo.86.3.321; Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481; Yuzawa Mitsuko, 2012, Nippon Ganka Gakkai Zasshi, V116, P200; Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466; Okubo A, 2002, BRIT J OPHTHALMOL, V86, P1093, DOI 10.1136/bjo.86.10.1093; Cho H, 2013, BRIT J OPHTHALMOL, V97, P1032, DOI 10.1136/bjophthalmol-2013-303344; Rouvas AA, 2011, RETINA-J RET VIT DIS, V31, P464, DOI 10.1097/IAE.0b013e3181f274ec; Heiduschka P, 2007, INVEST OPHTH VIS SCI, V48, P2814, DOI 10.1167/iovs.06-1171; Hikichi T, 2012, AM J OPHTHALMOL; Koh A, 2012, RETINA; Kuroiwa S, 2004, CLIN EXP OPHTHALMOL, V32, P297, DOI 10.1111/j.1442-9071.2004.00827.x; Leal S, 2010, RETINA-J RET VIT DIS, V30, P1197, DOI 10.1097/IAE.0b013e3181d37486; Lee SC, 2004, OPHTHALMOLOGICA, V218, P193, DOI 10.1159/000076844; Lee WK, 2012, AM J OPHTHALMOL; Shahar J, 2006, RETINA-J RET VIT DIS, V26, P262, DOI 10.1097/00006982-200603000-00002; YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001	34	6	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0275-004X	1539-2864		RETINA-J RET VIT DIS	Retin.-J. Retin. Vitr. Dis.	NOV	2014	34	11					2178	2184				7	Ophthalmology	Ophthalmology	AT0DK	WOS:000344607100010		
J	Saito, M; Kano, M; Itagaki, K; Oguchi, Y; Sekiryu, T				Saito, Masaaki; Kano, Mariko; Itagaki, Kanako; Oguchi, Yasuharu; Sekiryu, Tetsuju			SWITCHING TO INTRAVITREAL AFLIBERCEPT INJECTION FOR POLYPOIDAL CHOROIDAL VASCULOPATHY REFRACTORY TO RANIBIZUMAB	RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES			English	Article							ENDOTHELIAL GROWTH-FACTOR; EPITHELIUM-DERIVED FACTOR; MACULAR DEGENERATION; PHOTODYNAMIC THERAPY; VEGF TRAP; NEOVASCULAR MEMBRANES; VERTEPORFIN; BEVACIZUMAB; TACHYPHYLAXIS; EXPRESSION	Purpose: To clarify the efficacy of switching to intravitreal aflibercept injection to treat polypoidal choroidal vasculopathy refractory to ranibizumab. Methods: In this retrospective study, 43 eyes of 42 patients (mean age, 76.5 years) with polypoidal choroidal vasculopathy treated with aflibercept (2 mg/0.05 mL) were reviewed. A treatment history of 3 consecutive monthly intravitreal injections of ranibizumab as an induction phase followed by a pro re nata maintenance phase over 12 months was seen for all patients. All patients who were refractory to ranibizumab (defined as having persist subretinal or intraretinal fluid by optical coherence tomography and unchanged or decreased visual acuity compared with the time of the first ranibizumab injection, despite receiving the last 3 consecutive monthly intravitreal ranibizumab injections after 12 months). Results: The mean logarithm of the minimum angle of resolution best-corrected visual acuity levels (Snellen equivalent) improved significantly (P = 0.0074) from 0.38 (20/48) at baseline to 0.34 (20/43) 3 months after switching to aflibercept (Month 3) (mean best-corrected visual acuity improvement, 0.47 line). The central retinal thickness decreased significantly (P < 0.0001) from 245 mu m at baseline to 131 mu m at Month 3. Of 30 eyes with polypoidal lesions at baseline, the polypoidal lesions regressed completely in 15 eyes (50%) at Month 3. Conclusion: Administering intravitreal aflibercept injection for patients with polypoidal choroidal vasculopathy refractory to ranibizumab maintained or improved visual acuity and reduced or eliminated exudative lesions and occluding polypoidal lesions without adverse events with short-term follow-up.	[Saito, Masaaki; Kano, Mariko; Itagaki, Kanako; Oguchi, Yasuharu; Sekiryu, Tetsuju] Fukushima Med Univ, Sch Med, Dept Ophthalmol, Fukushima 9601295, Japan	Saito, M (reprint author), Fukushima Med Univ, Sch Med, Dept Ophthalmol, 1 Hikariga Oka, Fukushima 9601295, Japan.	smasaaki@fmu.ac.jp					Akaza E, 2011, JPN J OPHTHALMOL, V55, P39, DOI 10.1007/s10384-010-0886-x; Bakall B, 2013, AM J OPHTHALMOL, V156, P15, DOI 10.1016/j.ajo.2013.02.017; Yannuzzi LA, 1997, ARCH OPHTHALMOL-CHIC, V115, P478; Saito M, 2012, RETINA-J RET VIT DIS, V32, P1250, DOI 10.1097/IAE.0b013e318236e503; Maruko I, 2007, AM J OPHTHALMOL, V144, P15, DOI 10.1016/j.ajo.2007.03.047; Kvanta A, 1996, INVEST OPHTH VIS SCI, V37, P1929; Ho VY, 2013, AM J OPHTHALMOL, V156, P23, DOI 10.1016/j.ajo.2013.02.009; Gasperini JL, 2012, BRIT J OPHTHALMOL, V96, P14, DOI 10.1136/bjo.2011.204685; Yonekawa Y, 2013, AM J OPHTHALMOL, V156, P29, DOI 10.1016/j.ajo.2013.03.030; Mitchell P, 2010, BRIT J OPHTHALMOL, V94, P2, DOI 10.1136/bjo.2009.159160; Tong JP, 2006, AM J OPHTHALMOL, V141, P456, DOI 10.1016/j.ajo.2005.10.012; Koh A, 2012, RETINA-J RET VIT DIS, V32, P1453, DOI 10.1097/IAE.0b013e31824f91e8; Kurashige Y, 2008, AM J OPHTHALMOL, V146, P513, DOI 10.1016/j.ajo.2008.05.025; Kokame GT, 2010, BRIT J OPHTHALMOL, V94, P297, DOI 10.1136/bjo.2008.150029; Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6; Imamura Y, 2010, SURV OPHTHALMOL, V55, P501, DOI 10.1016/j.survophthal.2010.03.004; Oh H, 1999, INVEST OPHTH VIS SCI, V40, P1891; Heier JS, 2012, OPHTHALMOLOGY, V119, P2537, DOI 10.1016/j.ophtha.2012.09.006; Gomi F, 2008, BRIT J OPHTHALMOL, V92, P70, DOI 10.1136/bjo.2007.122283; Saito M, 2011, RETINA-J RET VIT DIS, V31, P1589, DOI 10.1097/IAE.0b013e31820f4b21; Lafaut BA, 2000, GRAEF ARCH CLIN EXP, V238, P752, DOI 10.1007/s004170000180; Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481; Akaza E, 2008, RETINA-J RET VIT DIS, V28, P717, DOI 10.1097/IAE.0b013e31816577cb; Stewart MW, 2008, BRIT J OPHTHALMOL, V92, P667, DOI 10.1136/bjo.2007.134874; Brown DM, 2006, NEW ENGL J MED, V355, P1432, DOI 10.1056/NEJMoa062655; SPAIDE RF, 1995, RETINA-J RET VIT DIS, V15, P100, DOI 10.1097/00006982-199515020-00003; Matsuoka M, 2004, BRIT J OPHTHALMOL, V88, P809, DOI 10.1136/bjo.2003.032466; Byeon SH, 2008, JPN J OPHTHALMOL, V52, P57, DOI 10.1007/s10384-007-0498-2; Eghoj MS, 2012, BRIT J OPHTHALMOL, V96, P21, DOI 10.1136/bjo.2011.203893; Tano Yasuo, 2009, Nippon Ganka Gakkai Zasshi, V113, P1098; Lalwani Geeta A, 2009, Am J Ophthalmol, V148, P43, DOI 10.1016/j.ajo.2009.01.024; Uyama M, 2002, AM J OPHTHALMOL, V133, P639, DOI 10.1016/S0002-9394(02)01404-6; Ladas ID, 2004, EYE, V18, P455, DOI 10.1038/sj.eye.6700706; Barnard Keith, 2006, Circulation, V114, pf173; Hikichi T, 2010, AM J OPHTHALMOL, V150, P674, DOI 10.1016/j.ajo.2010.05.026; Kliffen M, 1997, BRIT J OPHTHALMOL, V81, P154, DOI 10.1136/bjo.81.2.154; Otsuji Tsuyoshi, 2013, Clin Ophthalmol, V7, P1487, DOI 10.2147/OPTH.S46317; Saito M, 2008, BRIT J OPHTHALMOL, V92, P1642, DOI 10.1136/bjo.2007.137075; Saito M, 2013, GRAEFES ARCH CLIN EX; Saito Masaaki, 2009, Nippon Ganka Gakkai Zasshi, V113, P792; Scassellati-Sforzolini B, 2001, RETINA-J RET VIT DIS, V21, P121, DOI 10.1097/00006982-200104000-00004; Tano Y, 2008, OPHTHALMOLOGY, V115, P585, DOI 10.1016/j.ophtha.2007.10.018; YANNUZZI LA, 1990, RETINA-J RET VIT DIS, V10, P1, DOI 10.1097/00006982-199001010-00001	43	5	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0275-004X	1539-2864		RETINA-J RET VIT DIS	Retin.-J. Retin. Vitr. Dis.	NOV	2014	34	11					2192	2201				10	Ophthalmology	Ophthalmology	AT0DK	WOS:000344607100012		
J	Miyauchi, S; Umekita, K; Hidaka, T; Umeki, K; Aratake, Y; Takahashi, N; Sawaguchi, A; Nakatake, A; Morinaga, I; Morishita, K; Okayama, A				Miyauchi, Shunichi; Umekita, Kunihiko; Hidaka, Toshihiko; Umeki, Kazumi; Aratake, Yatsuki; Takahashi, Nobuyasu; Sawaguchi, Akira; Nakatake, Ayako; Morinaga, Itsuki; Morishita, Kazuhiro; Okayama, Akihiko			Increased plasma lactoferrin levels in leucocytapheresis therapy in patients with rheumatoid arthritis	RHEUMATOLOGY			English	Article						rheumatoid arthritis; neutrophils; inflammation; cytokines and inflammatory mediators; proteomics	FILTRATION LEUKOCYTAPHERESIS THERAPY; BOVINE LACTOFERRIN; CONTROLLED-TRIAL; PROTEIN; COUNTS; VALIDATION; CRITERIA; CELLS	Objective. The aim of this study was to clarify the mechanism of leucocytapheresis (LCAP) in patients with RA. Methods. Protein profiles of blood samples from two patients with RA obtained via LCAP column inlet and outlet lines were analysed by two-dimensional fluorescence difference gel electrophoresis and mass spectrometry. The lactoferrin (LTF) levels of peripheral and circulating blood samples from seven patients obtained via the LCAP column blood circuit were then determined by ELISA. Peripheral blood samples from 14 patients with RA were exposed to unwoven polyester fibre filters and the LTF level was determined. In addition, morphological changes in neutrophils after exposure to the filter were examined by optical microscopy, electronic microscopy and LTF immunostaining. Results. LTF levels were increased in both samples from the LCAP column outlet and peripheral blood at the end of LCAP treatment. Furthermore, peripheral blood samples exposed to the filter revealed a decreased number of neutrophils and an increased level of LTF. Morphological analysis of the exposed neutrophils showed vacuolization of the cytoplasm and degranulation of LTF-positive granules. These data suggest that LTF stored in the granules of neutrophils is released from the neutrophils caught in the LCAP column. Conclusion. Because LTF has been reported to have multiple anti-inflammatory properties, increased levels of LTF may contribute to the clinical effect of LCAP in patients with RA.	[Miyauchi, Shunichi; Umekita, Kunihiko; Umeki, Kazumi; Aratake, Yatsuki; Okayama, Akihiko] Miyazaki Univ, Fac Med, Dept Rheumatol Infect Dis & Lab Med, Kiyotake, Miyazaki 8891692, Japan; [Hidaka, Toshihiko] Zenjinkai Shimin No Mori Hosp, Inst Rheumatol, Miyazaki, Japan; [Takahashi, Nobuyasu; Sawaguchi, Akira] Miyazaki Univ, Fac Med, Dept Anat, Kiyotake, Miyazaki 8891692, Japan; [Nakatake, Ayako; Morinaga, Itsuki; Morishita, Kazuhiro] Miyazaki Univ, HTLV ATL Res Facil 1, Kiyotake, Miyazaki 8891692, Japan	Okayama, A (reprint author), Miyazaki Univ, Fac Med, Dept Rheumatol Infect Dis & Lab Med, Kiyotake, Miyazaki 8891692, Japan.	okayama@med.miyazaki-u.ac.jp					Aletaha D, 2005, ARTHRITIS RES THER, V7, P796; Lipsky PE, 2000, NEW ENGL J MED, V343, P1594, DOI 10.1056/NEJM200011303432202; Smolen JS, 2003, RHEUMATOLOGY, V42, P244, DOI 10.1093/rheumatology/keg072; PREVOO MLL, 1995, ARTHRITIS RHEUM, V38, P44, DOI 10.1002/art.1780380107; Haversen L, 2002, CELL IMMUNOL, V220, P83, DOI 10.1016/S0008-8749(03)00006-6; Annane D, 2005, LANCET, V365, P63, DOI 10.1016/S0140-6736(04)17667-8; Elass-Rochard E, 1998, INFECT IMMUN, V66, P486; Nishimoto N, 2007, ANN RHEUM DIS, V66, P1162, DOI 10.1136/ard.2006.068064; Yamauchi K, 2006, BIOCHEM CELL BIOL, V84, P291, DOI 10.1139/006-54; HENZEL WJ, 1993, P NATL ACAD SCI USA, V90, P5011, DOI 10.1073/pnas.90.11.5011; van Gestel AM, 1998, ARTHRITIS RHEUM, V41, P1845, DOI 10.1002/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K; Brennan FM, 2008, J CLIN INVEST, V118, P3537, DOI 10.1172/JCI36389; Unlu M, 1997, ELECTROPHORESIS, V18, P2071, DOI 10.1002/elps.1150181133; Faurschou M, 2003, MICROBES INFECT, V5, P1317, DOI 10.1016/j.micinf.2003.09.008; Shimamura M, 2004, INT J CANCER, V111, P111, DOI 10.1002/ijc.20187; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BAYNES RD, 1986, SCAND J HAEMATOL, V36, P79; Cumberbatch M, 2003, CLIN EXP IMMUNOL, V132, P352, DOI 10.1046/j.1365-2249.2003.02146.x; Eguchi Katsumi, 2007, Mod Rheumatol, V17, P481, DOI 10.1007/s10165-007-0630-7; Elass E, 2002, INFECT IMMUN, V70, P1860, DOI 10.1128/IAI.70.4.1860-1866.2002; Hidaka T, 2001, J CLIN APHERESIS, V16, P74, DOI 10.1002/jca.1016; Hidaka T, 1999, ARTHRITIS RHEUM, V42, P431, DOI 10.1002/1529-0131(199904)42:3<431::AID-ANR6>3.0.CO;2-2; KLOCK JC, 1976, BLOOD, V48, P149; Noguchi M, 1998, Ther Apher, V2, P109, DOI 10.1111/j.1744-9987.1998.tb00086.x; ORAM JD, 1968, BIOCHIM BIOPHYS ACTA, V170, P351, DOI 10.1016/0304-4165(68)90015-9; Ueki Y, 2007, CLIN EXP RHEUMATOL, V25, P810; Umekita K, 2009, MOD RHEUMATOL, V19, P265, DOI 10.1007/s10165-009-0164-2; Yamaji K, 2006, THER APHER DIAL, V10, P396, DOI 10.1111/j.1744-9987.2006.00402.x; Yamasaki S, 2002, ARTIF ORGANS, V26, P378, DOI 10.1046/j.1525-1594.2002.06834.x; YUO A, 1990, BIOCHEM BIOPH RES CO, V171, P491, DOI 10.1016/0006-291X(90)91420-W; Zimecki Michal, 1996, Archivum Immunologiae et Therapiae Experimentalis, V44, P51	31	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1462-0324	1462-0332		RHEUMATOLOGY	RHEUMATOLOGY	NOV	2014	53	11					1966	1972		10.1093/rheumatology/keu219		7	Rheumatology	Rheumatology	AT0SI	WOS:000344644800008		
J	Takagi, Y; Sumi, M; Nakamura, H; Iwamoto, N; Horai, Y; Kawakami, A; Nakamura, T				Takagi, Yukinori; Sumi, Misa; Nakamura, Hideki; Iwamoto, Naoki; Horai, Yoshiro; Kawakami, Atsushi; Nakamura, Takashi			Ultrasonography as an additional item in the American College of Rheumatology classification of Sjogren's syndrome	RHEUMATOLOGY			English	Article						Sjogren's syndrome; diagnosis; classification; criteria; ultrasonography; imaging	SALIVARY-GLAND ULTRASONOGRAPHY; DIAGNOSTIC-VALUE; SCORING SYSTEM; PAROTID-GLAND; CRITERIA; SIALOGRAPHY; SONOGRAPHY	Objective. In this study we evaluated US as an additional classification item in the ACR classification of SS. Methods. Of 581 patients classified as either SS (n = 364) or non-SS (n = 217) based on the minimum requirements of the American-European Consensus Group (AECG) classification, 184 patients (102 SS and 82 non-SS) who had scored two or more positive or two or more negative results according to the ACR criteria were selected. The AECG classification was used as the gold standard. A parotid and/or submandibular gland that was assigned a score >= G1 was designated as SS positive. We evaluated US alone or with varying combinations of the ACR classification items in the diagnosis of SS. Results. The ACR criteria diagnosed the 184 patients with 91% sensitivity, 90% specificity and 91% accuracy. US alone diagnosed the 184 ACR patients with 79% sensitivity, 90% specificity and 83% accuracy, which was comparable to the results of US diagnosis in the AECG cohort (81%, 86% and 83%, respectively). Incorporating the US criteria as an alternative to one of the three ACR classification items achieved 89-91% sensitivity, 87-96% specificity and 89% or 92% accuracy, which was comparable to that of the original ACR classification. Furthermore, kappa analysis indicated that the results of the original ACR and US-replaced ACR classifications matched completely (kappa = 0.960-0.974). Conclusion. These results suggest that US can be used as an alternative to any of the three ACR classification items.	[Takagi, Yukinori; Sumi, Misa; Nakamura, Takashi] Nagasaki Univ, Sch Dent, Dept Radiol & Canc Biol, Nagasaki 8528588, Japan; [Nakamura, Hideki; Iwamoto, Naoki; Horai, Yoshiro; Kawakami, Atsushi] Nagasaki Univ, Grad Sch Biomed Sci, Dept Immunol & Rheumatol, Unit Translat Med, Nagasaki 8528588, Japan	Nakamura, T (reprint author), Nagasaki Univ, Sch Dent, Dept Radiol & Canc Biol, 1-7-1 Sakamoto, Nagasaki 8528588, Japan.	taku@nagasaki-u.ac.jp					Daniels TE, 2009, ARTHRIT RHEUM-ARTHR, V61, P711, DOI 10.1002/art.24397; Baldini C, 2012, J AUTOIMMUN, V39, P9, DOI 10.1016/j.jaut.2011.12.006; Ramos-Casals M, 2010, JAMA-J AM MED ASSOC, V304, P452, DOI 10.1001/jama.2010.1014; Vitali C, 2013, ANN RHEUM DIS, V72, P476, DOI 10.1136/annrheumdis-2012-202565; Milic VD, 2010, SCAND J RHEUMATOL, V39, P160, DOI 10.3109/03009740903270623; Vitali C, 2002, ANN RHEUM DIS, V61, P554, DOI 10.1136/ard.61.6.554; Hocevar A, 2005, RHEUMATOLOGY, V44, P768, DOI 10.1093/rheumatology/keh588; Vitali C, 2013, ARTHRITIS RHEUM-US, V65, P1950, DOI 10.1002/art.37945; Tzioufas AG, 2008, NAT CLIN PRACT RHEUM, V4, P454, DOI 10.1038/ncprheum0864; Bowman SJ, 2014, ANN RHEUM DIS, V73, P1, DOI 10.1136/annrheumdis-2013-203953; Shiboski SC, 2012, ARTHRIT CARE RES, V64, P475, DOI 10.1002/acr.21591; Milic VD, 2009, J RHEUMATOL, V36, P1495, DOI 10.3899/jrheum.081267; Takagi Y, 2010, ANN RHEUM DIS, V69, P1321, DOI 10.1136/ard.2009.123836; Cornec D, 2013, ARTHRITIS RHEUM-US, V65, P216, DOI 10.1002/art.37698; Ariji Y, 1996, AM J ROENTGENOL, V166, P935; Bootsma H, 2013, ARTHRITIS RHEUM-US, V65, P21, DOI 10.1002/art.37701; Howlett DC, 2004, CLIN RADIOL, V59, P1070, DOI 10.1016/j.crad.2004.06.025; Izumi M, 1998, ANN RHEUM DIS, V57, P464, DOI 10.1136/ard.57.8.464; KAWAMURA H, 1990, ARTHRITIS RHEUM, V33, P505, DOI 10.1002/art.1780330407; Kimura Y, 2011, ORAL RADIOL, V27, P73, DOI 10.1007/s11282-011-0062-0; Takagi Y, 2013, CLIN EXP RHEUMATOL, V31, P773; Yonetsu K, 2002, ANN RHEUM DIS, V61, P276, DOI 10.1136/ard.61.3.276	22	6	6	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1462-0324	1462-0332		RHEUMATOLOGY	RHEUMATOLOGY	NOV	2014	53	11					1977	1983		10.1093/rheumatology/keu238		7	Rheumatology	Rheumatology	AT0SI	WOS:000344644800010		
J	Shimizu, M; Ueno, K; Ishikawa, S; Tokuhisa, Y; Inoue, N; Yachie, A				Shimizu, Masaki; Ueno, Kazuyuki; Ishikawa, Sayaka; Tokuhisa, Yuko; Inoue, Natsumi; Yachie, Akihiro			Treatment of refractory polyarticular juvenile idiopathic arthritis with tacrolimus	RHEUMATOLOGY			English	Letter							RHEUMATOID-ARTHRITIS; REMISSION; SAFETY		[Shimizu, Masaki; Ueno, Kazuyuki; Ishikawa, Sayaka; Tokuhisa, Yuko; Inoue, Natsumi; Yachie, Akihiro] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Dept Pediat, Sch Med, Kanazawa, Ishikawa 9208641, Japan	Shimizu, M (reprint author), Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Dept Pediat, Sch Med, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan.	shimizum@staff.kanazawa-u.ac.jp	Yachie, Akihiro/C-4660-2015				Aihara Y, 2001, PEDIATR INT, V43, P95, DOI 10.1046/j.1442-200x.2001.01322.x; Magari K, 2004, INFLAMM RES, V53, P544, DOI 10.1007/s00011-004-1294-9; Hinks A, 2005, ARTHRITIS RHEUM, V52, P1694, DOI 10.1002/art.21049; Ruperto N, 2010, ARTHRITIS RHEUM-US, V62, P1792, DOI 10.1002/art.27431; Kamphuis S, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2088; Saulsbury FT, 1999, J RHEUMATOL, V26, P1606; Takeuchi T, 2014, MOD RHEUMATOL, V24, P8, DOI 10.3109/14397595.2013.854074; Tanaka H, 2007, EUR J PEDIATR, V166, P1053, DOI 10.1007/s00431-006-0380-0	8	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1462-0324	1462-0332		RHEUMATOLOGY	RHEUMATOLOGY	NOV	2014	53	11					2120	2122		10.1093/rheumatology/keu297		4	Rheumatology	Rheumatology	AT0SI	WOS:000344644800033		
J	Kobayashi, H; Isohanni, M; Jaaskelainen, E; Miettunen, J; Veijola, J; Haapea, M; Jarvelin, MR; Jones, PB; Murray, GK				Kobayashi, Hiroyuki; Isohanni, Matti; Jaaskelainen, Erika; Miettunen, Jouko; Veijola, Juha; Haapea, Marianne; Jarvelin, Marjo-Riitta; Jones, Peter B.; Murray, Graham K.			Linking the Developmental and Degenerative Theories of Schizophrenia: Association Between Infant Development and Adult Cognitive Decline	SCHIZOPHRENIA BULLETIN			English	Article						schizophrenia; cognition; executive function; memory; neurodevelopment	1966 BIRTH COHORT; PROGRESSIVE BRAIN CHANGES; 31-YEAR FOLLOW-UP; MOTOR DEVELOPMENT; CHILDHOOD; METAANALYSIS; PERFORMANCE; MILESTONES; DISORDER; RISK	Neurodevelopmental and neurodegenerative theories may be viewed as incompatible accounts that compete to explain the pathogenesis of schizophrenia. However, it is possible that neurodevelopmental and neurodegenerative processes could both reflect common underlying causal mechanisms. We hypothesized that cognitive dysfunction would gradually deteriorate over time in schizophrenia and the degree of this deterioration in adulthood would be predicted by an infant measure of neurodevelopment. We aimed to examine the association between age of learning to stand in infancy and deterioration of cognitive function in adulthood. Participants were nonpsychotic control subjects (n = 76) and participants with schizophrenia (n = 36) drawn from the Northern Finland 1966 Birth Cohort study. The schizophrenia group showed greater deterioration in abstraction with memory than controls, but there were no differences between schizophrenia and controls in rate of change of other cognitive measures. Age of learning to stand in infancy significantly inversely predicted later deterioration of abstraction with memory in adult schizophrenia (later infant development linked to greater subsequent cognitive deterioration during adulthood), possibly suggesting a link between abnormal neurodevelopmental and neurodegenerative processes in schizophrenia.	[Kobayashi, Hiroyuki; Jones, Peter B.; Murray, Graham K.] Univ Cambridge, Dept Psychiat, Cambridge CB2 2QQ, England; [Kobayashi, Hiroyuki] Toho Univ, Sch Med, Dept Neuropsychiat, Tokyo, Japan; [Isohanni, Matti; Jaaskelainen, Erika; Miettunen, Jouko; Veijola, Juha; Haapea, Marianne] Univ Oulu, Dept Psychiat, Oulu, Finland; [Isohanni, Matti; Jaaskelainen, Erika; Miettunen, Jouko; Veijola, Juha; Haapea, Marianne] Oulu Univ Hosp, Oulu, Finland; [Jarvelin, Marjo-Riitta] Univ London Imperial Coll Sci Technol & Med, Dept Epidemiol & Biostat, MRC HPA Ctr Environm & Hlth, London, England; [Jarvelin, Marjo-Riitta] Univ Oulu, Inst Hlth Sci, Oulu, Finland; [Jarvelin, Marjo-Riitta] Bioctr Oulu, Oulu, Finland; [Jarvelin, Marjo-Riitta] Natl Inst Hlth & Welf, Dept Life Course & Serv, Oulu, Finland; [Murray, Graham K.] Univ Cambridge, Behav & Clin Neurosci Inst, Cambridge CB2 2QQ, England	Murray, GK (reprint author), Univ Cambridge, Dept Psychiat, Box 189,Level 4,Addenbrookes Hosp Hills Rd, Cambridge CB2 2QQ, England.	gm285@cam.ac.uk		Jones, Peter/0000-0002-0387-880X; Miettunen, Jouko/0000-0003-0575-2669	UK Medical Research Council [G0701911]; Academy of Finland; Sigrid Juselius Foundation; Stanley Foundation; Brain and Behavior Research Fund; Medical Research Council [G1000183, 093875/Z/10/Z]; Wellcome Trust [G1000183, 093875/Z/10/Z]	The study was supported by the UK Medical Research Council (G0701911), the Academy of Finland, the Sigrid Juselius Foundation, the Stanley Foundation, and the Brain and Behavior Research Fund, and was conducted in part within the University of Cambridge Behavioural and Clinical Neuroscience Institute, supported by a joint award by the Medical Research Council and Wellcome Trust (G1000183 and 093875/Z/10/Z). The funding bodies did not participate in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or the preparation, review, or approval of the manuscript.	Glahn DC, 2000, BIOL PSYCHIAT, V47, P34, DOI 10.1016/S0006-3223(99)00187-0; Pol HEH, 2008, SCHIZOPHRENIA BULL, V34, P354, DOI 10.1093/schbul/sbm168; Kempton MJ, 2010, SCHIZOPHR RES, V120, P54, DOI 10.1016/j.schres.2010.03.036; Glahn DC, 1997, NEUROPSYCHOLOGY, V11, P602, DOI 10.1037/0894-4105.11.4.602; Kurtz MM, 2005, SCHIZOPHR RES, V74, P15, DOI 10.1016/j.schres.2004.07.005; Ridler K, 2006, P NATL ACAD SCI USA, V103, P15651, DOI 10.1073/pnas.0602639103; Caspi A, 2003, SCHIZOPHR RES, V65, P87, DOI 10.1016/S0920-9964(03)00056-2; Harrison PJ, 1999, BRAIN, V122, P593, DOI 10.1093/brain/122.4.593; Szoke A, 2008, BRIT J PSYCHIAT, V192, P248, DOI 10.1192/bjp.bp.106.029009; DeLisi LE, 2004, PSYCHIAT RES-NEUROIM, V130, P57, DOI 10.1016/j.pscychresns.2003.08.004; Kremen WS, 2010, SCHIZOPHR RES, V118, P1, DOI 10.1016/j.schres.2010.01.009; Isohanni M, 2001, SCHIZOPHR RES, V52, P1, DOI 10.1016/S0920-9964(00)00179-1; Murray GK, 2006, J CHILD PSYCHOL PSYC, V47, P25, DOI 10.1111/j.1469-7610.2005.01450.x; JONES P, 1994, LANCET, V344, P1398, DOI 10.1016/S0140-6736(94)90569-X; Andreasen NC, 2010, BIOL PSYCHIAT, V67, P255, DOI 10.1016/j.biopsych.2009.08.040; Sorensen HJ, 2010, SCHIZOPHR RES, V118, P41, DOI 10.1016/j.schres.2010.01.029; Moilanen K, 2003, SOC PSYCH PSYCH EPID, V38, P305, DOI 10.1007/s00127-003-0638-z; Isohanni M, 1997, SOC PSYCH PSYCH EPID, V32, P303, DOI 10.1007/BF00789044; Lieberman JA, 1999, BIOL PSYCHIAT, V46, P729, DOI 10.1016/S0006-3223(99)00147-X; Olabi B, 2011, BIOL PSYCHIAT, V70, P88, DOI 10.1016/j.biopsych.2011.01.032; Hedman AM, 2013, SCHIZOPHR RES, V146, P201, DOI 10.1016/j.schres.2013.01.027; Cannon M, 2006, BRIT J PSYCHIAT, V189, P463, DOI 10.1192/bjp.bp.105.020552; Delis DC, 1987, CALIFORNIA VERBAL LE; Haapea M, 2011, PSYCHIAT RES-NEUROIM, V194, P326, DOI 10.1016/j.pscychresns.2011.06.002; Haapea M, 2008, SCAND J PUBLIC HEALT, V36, P728, DOI 10.1177/1403494808092250; Isohanni M, 2004, SCHIZOPHR RES, V71, P213, DOI 10.1016/j.schres.2004.03.008; Malaspina Dolores, 2006, J Clin Psychiatry, V67, pe07; Murray GK, 2006, SCHIZOPHR RES, V81, P65, DOI 10.1016/j.schres.2005.08.016; MURRAY RM, 1987, BRIT MED J, V295, P681; Neumann CS, 1996, ADV CLIN CHILD PSYCH, V18, P173; RANTAKALLIO P, 1969, ACTA PAEDIAT SCAND S, V0193; RANTAKALLIO P, 1985, EARLY HUM DEV, V11, P141, DOI 10.1016/0378-3782(85)90101-X; Rosso IM, 2000, SCHIZOPHRENIA BULL, V26, P367; Taanila A, 2005, DEV MED CHILD NEUROL, V47, P581, DOI 10.1017/S0012162205001155; Walker EF, 1996, SCHIZOPHR RES, V22, P93, DOI 10.1016/S0920-9964(96)00070-9; WEINBERGER DR, 1987, ARCH GEN PSYCHIAT, V44, P660	36	3	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0586-7614	1745-1701		SCHIZOPHRENIA BULL	Schizophr. Bull.	NOV	2014	40	6					1319	1327		10.1093/schbul/sbu010		9	Psychiatry	Psychiatry	AT0FF	WOS:000344611900016		
J	Katsuta, N; Ohnuma, T; Maeshima, H; Takebayashi, Y; Higa, M; Takeda, M; Nakamura, T; Nishimon, S; Sannohe, T; Hotta, Y; Hanzawa, R; Higashiyama, R; Shibata, N; Arai, H				Katsuta, Narimasa; Ohnuma, Tohru; Maeshima, Hitoshi; Takebayashi, Yuto; Higa, Motoyuki; Takeda, Mayu; Nakamura, Toru; Nishimon, Shohei; Sannohe, Takahiro; Hotta, Yuri; Hanzawa, Ryo; Higashiyama, Ryoko; Shibata, Nobuto; Arai, Heii			Significance of Measurements of Peripheral Carbonyl Stress Markers in a Cross-sectional and Longitudinal Study in Patients With Acute-stage Schizophrenia	SCHIZOPHRENIA BULLETIN			English	Article						clinical course; pentosidine; pyridoxal; vitamin B6	OXIDATIVE STRESS; PROJECTS JUSP; PRODUCTS	Altered peripheral carbonyl stress markers, high levels of serum pentosidine, which accumulates following carbonyl stress, and low levels of pyridoxal (vitamin B6), which detoxifies reactive carbonyl compounds, have been reported in a cross-sectional study of chronic schizophrenia. However, changes in the levels of these compounds in patients with schizophrenia have not been investigated in a longitudinal study. To clarify whether these markers may be biological markers that reflect the clinical course of the disease, the serum levels of these compounds were investigated in a cross-sectional and a longitudinal study. One hundred and thirty-seven acute-stage Japanese patients were enrolled. Among these, 53 patients were followed from the acute stage to remission. A portion of patients in the acute stage (14 cases, 10.2%) showed extremely high pentosidine levels. These levels were not associated with the severity of symptoms but were associated with antipsychotic dose amounts. Pyridoxal levels were lower in schizophrenia and increased according to the clinical course of the illness. Furthermore, 18 patients with decreased pyridoxal levels according to the clinical course showed that the greater the decrease in pyridoxal levels, the lesser the improvement in symptoms. Thus, extremely high pentosidine levels in a portion of patients may be caused by higher daily antipsychotic doses, whereas pyridoxal levels were lower in schizophrenia and increased according to the clinical course. Patients with decreasing pyridoxal levels during the clinical course showed less improvement in symptoms. Carbonyl stress markers may also be therapeutic biological markers in some patients with schizophrenia.	[Katsuta, Narimasa; Ohnuma, Tohru; Maeshima, Hitoshi; Takebayashi, Yuto; Higa, Motoyuki; Takeda, Mayu; Nakamura, Toru; Nishimon, Shohei; Sannohe, Takahiro; Hotta, Yuri; Hanzawa, Ryo; Higashiyama, Ryoko; Shibata, Nobuto; Arai, Heii] Juntendo Univ, Sch Med, Dept Psychiat, Tokyo 1138421, Japan	Ohnuma, T (reprint author), Juntendo Univ, Sch Med, Dept Psychiat, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	tohru.oonuma@nifty.ne.jp			Juntendo Institute of Mental Health [201109, 201209]	Juntendo Institute of Mental Health (201109, 201209).	Ohnuma T, 2008, PROG NEURO-PSYCHOPH, V32, P1905, DOI 10.1016/j.pnpbp.2008.07.022; Toyosima M, 2011, BRIT J PSYCHIAT, V199, P245, DOI 10.1192/bjp.bp.111.093849; Arai M, 2010, ARCH GEN PSYCHIAT, V67, P589, DOI 10.1001/archgenpsychiatry.2010.62; Flatow J, 2013, BIOL PSYCHIAT, V74, P400, DOI 10.1016/j.biopsych.2013.03.018; OVERALL JE, 1962, PSYCHOL REP, V10, P799; Jaisson S, 2010, CLIN CHEM, V56, P1401, DOI 10.1373/clinchem.2010.145201; Jinno M, 2011, HUM REPROD, V26, P604, DOI 10.1093/humrep/deq388; Marchbanks RM, 2003, SCHIZOPHR RES, V65, P33, DOI 10.1016/S0920-9964(03)00011-2; Yao JK, 2001, CNS DRUGS, V15, P287, DOI 10.2165/00023210-200115040-00004; Maeshima H, 2007, PROG NEURO-PSYCHOPH, V31, P1410, DOI 10.1016/j.pnpbp.2007.06.009; Prabakaran S, 2004, MOL PSYCHIATR, V9, P684, DOI 10.1038/sj.mp.4001511; Sanaka T, 2002, NEPHRON, V91, P64, DOI 10.1159/000057606; Arai M, 2011, PSYCHIAT CLIN NEUROS, V65, P606, DOI 10.1111/j.1440-1819.2011.02261.x; Bech P, 1986, Acta Psychiatr Scand Suppl, V326, P1; Hatano T, 2010, PSYCHIAT RES, V177, P27, DOI 10.1016/j.psychres.2010.02.014; Lerner V, 2002, J CLIN PSYCHIAT, V63, P54; Miyashita M, 2014, SCHIZOPHRENIA BULL, V40, P1040, DOI 10.1093/schbul/sbt129; Monnier VM, 2003, CRITICAL REV OXIDATI, V2, P414	18	6	6	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0586-7614	1745-1701		SCHIZOPHRENIA BULL	Schizophr. Bull.	NOV	2014	40	6					1366	1373		10.1093/schbul/sbt234		8	Psychiatry	Psychiatry	AT0FF	WOS:000344611900021		
J	Mizuno, Y; Suzuki, T; Nakagawa, A; Yoshida, K; Mimura, M; Fleischhacker, WW; Uchida, H				Mizuno, Yuya; Suzuki, Takefumi; Nakagawa, Atsuo; Yoshida, Kazunari; Mimura, Masaru; Fleischhacker, Walter Wolfgang; Uchida, Hiroyuki			Pharmacological Strategies to Counteract Antipsychotic-Induced Weight Gain and Metabolic Adverse Effects in Schizophrenia: A Systematic Review and Meta-analysis	SCHIZOPHRENIA BULLETIN			English	Article						antipsychotic; meta-analysis; metabolic; concomitant; PRISMA; schizophrenia	PLACEBO-CONTROLLED TRIAL; CLOZAPINE-TREATED PATIENTS; CONTROLLED CLINICAL-TRIAL; DOUBLE-BLIND; 1ST-EPISODE SCHIZOPHRENIA; BODY-WEIGHT; ADJUNCTIVE TREATMENT; MENTAL-ILLNESS; LIFE-STYLE; OLANZAPINE	Background: Antipsychotic-induced metabolic adversities are often difficult to manage. Using concomitant medications to counteract these adversities may be a rational option. Objective: To systematically determine the effectiveness of medications to counteract antipsychotic-induced metabolic adversities in patients with schizophrenia. Data Sources: Published articles until November 2013 were searched using 5 electronic databases. Clinical trial registries were searched for unpublished trials. Study Selection: Double-blind randomized placebo-controlled trials focusing on patients with schizophrenia were included if they evaluated the effects of concomitant medications on antipsychotic-induced metabolic adversities as a primary outcome. Data Extraction: Variables relating to participants, interventions, comparisons, outcomes, and study design were extracted. The primary outcome was change in body weight. Secondary outcomes included clinically relevant weight change, fasting glucose, hemoglobin A1c, fasting insulin, insulin resistance, cholesterol, and triglycerides. Data Synthesis: Forty trials representing 19 unique interventions were included in this meta-analysis. Metformin was the most extensively studied drug in regard to body weight, the mean difference amounting to -3.17 kg (95% CI: -4.44 to -1.90 kg) compared to placebo. Pooled effects for topiramate, sibutramine, aripiprazole, and reboxetine were also different from placebo. Furthermore, metformin and rosiglitazone improved insulin resistance, while aripiprazole, metformin, and sibutramine decreased blood lipids. Conclusion: When nonpharmacological strategies alone are insufficient, and switching antipsychotics to relatively weight-neutral agents is not feasible, the literature supports the use of concomitant metformin as first choice among pharmacological interventions to counteract antipsychotic-induced weight gain and other metabolic adversities in schizophrenia.	[Mizuno, Yuya; Suzuki, Takefumi; Nakagawa, Atsuo; Yoshida, Kazunari; Mimura, Masaru; Uchida, Hiroyuki] Keio Univ, Sch Med, Dept Neuropsychiat, Tokyo 1608582, Japan; [Suzuki, Takefumi] Inokashira Hosp, Dept Psychiat, Tokyo, Japan; [Nakagawa, Atsuo] Keio Univ, Sch Med, Ctr Clin Res, Tokyo 1608582, Japan; [Fleischhacker, Walter Wolfgang] Med Univ Innsbruck, Dept Psychiat & Psychotherapy, A-6020 Innsbruck, Austria; [Uchida, Hiroyuki] Ctr Addict & Mental Hlth, Geriatr Mental Hlth Program, Toronto, ON, Canada	Uchida, H (reprint author), Keio Univ, Sch Med, Dept Neuropsychiat, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	hiroyuki.uchida.hu@gmail.com	Uchida, Hiroyuki/I-4867-2015	Uchida, Hiroyuki/0000-0002-0628-7036	Astellas; Dainippon Sumitomo Pharma; Eli Lilly; Elsevier Japan; Meiji Seika Pharma; Novartis Pharma; Otsuka Pharmaceutical; Wiley Japan; Meiji Seika; Asahi Kasei Pharma; Astellas, DaiichiSankyo; Eisai; GlaxoSmithKline; Janssen Pharmaceutical; Mochida Pharmaceutical; MSD; Pfizer; Shionogi; Takeda; Mitsubishi Tanabe Pharma; Yoshitomiyakuhin; ReckittBenckiser; Abbvie	Y.M. has received manuscript fees or speaker's honoraria from Dainippon Sumitomo Pharma, Eli Lilly, and Wiley Japan within the past 3 years.; T. S. has received manuscript or speaker's fees from Astellas, Dainippon Sumitomo Pharma, Eli Lilly, Elsevier Japan, Meiji Seika Pharma, Novartis Pharma, Otsuka Pharmaceutical, and Wiley Japan within the past 3 years.; A. N. has received speaker's honoraria from Eli Lilly, Pfizer, Mochida Pharmaceutical, Yoshitomiyakuhin, Otsuka Pharmaceutical, Dainippon Sumitomo Pharma, and Mitsubishi Tanabe Pharma and textbook royalties from Igaku-shoin within the past 3 years.; K. Y. has received manuscript fees or speaker's honoraria from Dainippon Sumitomo Pharma, Meiji Seika, and Wiley Japan within the past 3 years.; M. M. has received grants and/or speaker's honoraria from Asahi Kasei Pharma, Astellas, DaiichiSankyo, Dainippon Sumitomo Pharma, Eisai, Eli Lilly, GlaxoSmithKline, Janssen Pharmaceutical, Meiji Seika Pharma, Mochida Pharmaceutical, MSD, Novartis Pharma, Otsuka Pharmaceutical, Pfizer, Shionogi, Takeda, Mitsubishi Tanabe Pharma, and Yoshitomiyakuhin within the past 3 years. W. W. F. has received research grants from Otsuka Pharmaceutical, Pfizer, Janssen Pharmaceutical, and ReckittBenckiser, as well as consulting honoraria from Lundbeck, Roche, Bristol-Myers Squibb, Otsuka Pharmaceutical, Janssen Pharmaceutical, Pfizer, MedAvante, and Merck.; He has received speaker honoraria from Lundbeck, Janssen Pharmaceutical, Otsuka Pharmaceutical, and Roche, as well as holds stock from MedAvante. H. U. has received grants from Pfizer, Astellas, Eisai, Otsuka Pharmaceutical, GlaxoSmithKline, Shionogi, Dainippon Sumitomo Pharma, Eli Lilly, Mochida Pharmaceutical, Meiji Seika Pharma, Janssen Pharmaceutical, and Yoshitomiyakuhin and speaker's honoraria from Otsuka Pharmaceutical, Eli Lilly, Shionogi, GlaxoSmithKline, Yoshitomiyakuhin, Dainippon Sumitomo Pharma, Meiji Seika Pharma, Abbvie, and Janssen Pharmaceutical within the past 3 years.	Afshar H, 2009, J PSYCHOPHARMACOL, V23, P157, DOI 10.1177/0269881108089816; American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity, 2004, DIABETES CARE, V27, P596; Henderson DC, 2005, AM J PSYCHIAT, V162, P954, DOI 10.1176/appi.ajp.162.5.954; Graham KA, 2005, AM J PSYCHIAT, V162, P1744, DOI 10.1176/appi.ajp.162.9.1744; Fernandez E, 2010, SCHIZOPHR RES, V121, P213, DOI 10.1016/j.schres.2010.06.001; Poyurovsky M, 2004, EUR NEUROPSYCHOPHARM, V14, P332; Arman S, 2008, SAUDI MED J, V29, P1130; Lieberman JA, 2005, NEW ENGL J MED, V353, P1209, DOI 10.1056/NEJMoa051688; Fleischhacker WW, 2014, INT J NEUROPSYCHOPH, V17, P1083, DOI 10.1017/S1461145712000399; Maayan L, 2010, NEUROPSYCHOPHARMACOL, V35, P1520, DOI 10.1038/npp.2010.21; [Anonymous], 2010, MED LETT DRUGS THER, V52, P88; Wu RR, 2012, AM J PSYCHIAT, V169, P813, DOI 10.1176/appi.ajp.2012.11091432; Fan X, 2013, ACTA PSYCHIAT SCAND, V127, P217, DOI 10.1111/acps.12009; Henderson DC, 2007, ACTA PSYCHIAT SCAND, V115, P101, DOI 10.1111/j.1600-0447.2006.00855.x; Deberdt W, 2005, EUR NEUROPSYCHOPHARM, V15, P13, DOI 10.1016/j.euroneuro.2004.03.005; Higgins JPT, 2003, BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557; Fleischhacker WW, 2008, J CLIN PSYCHIAT, V69, P514; Fleischhacker WW, 2010, INT J NEUROPSYCHOPH, V13, P1115, DOI 10.1017/S1461145710000490; Baptista T, 2009, PHARMACOPSYCHIATRY, V42, P14, DOI 10.1055/s-0028-1085438; Joffe G, 2008, J CLIN PSYCHIAT, V69, P706; Bresee LC, 2010, SCHIZOPHR RES, V117, P75, DOI 10.1016/j.schres.2009.12.016; Poyurovsky M, 2007, PSYCHOPHARMACOLOGY, V192, P441, DOI 10.1007/s00213-007-0731-1; Carney CP, 2006, J GEN INTERN MED, V21, P1133, DOI 10.1111/j.1525-1497.2006.00563.x; Jarskog LF, 2013, AM J PSYCHIAT, V170, P1032, DOI 10.1176/appi.ajp.2013.12010127; Poyurovsky M, 2003, AM J PSYCHIAT, V160, P297, DOI 10.1176/appi.ajp.160.2.297; Cavazzoni P, 2003, EUR NEUROPSYCHOPHARM, V13, P81, DOI 10.1016/S0924-977X(02)00127-X; Egger M, 1997, BRIT MED J, V315, P629; Poyurovsky M, 2013, PSYCHOPHARMACOLOGY, V226, P615, DOI 10.1007/s00213-012-2935-2; Tuomilehto J, 2001, NEW ENGL J MED, V344, P1343, DOI 10.1056/NEJM200105033441801; Atmaca M, 2003, HUM PSYCHOPHARM CLIN, V18, P457, DOI 10.1002/hup.514; Atmaca M, 2004, HUM PSYCHOPHARM CLIN, V19, P37, DOI 10.1002/hup.477; Baptista T, 2006, CAN J PSYCHIAT, V51, P192; Carrizo E, 2009, SCHIZOPHR RES, V113, P19, DOI 10.1016/j.schres.2009.05.007; Coodin S, 2001, CAN J PSYCHIAT, V46, P549; James WPT, 2010, NEW ENGL J MED, V363, P905, DOI 10.1056/NEJMoa1003114; Stevens VJ, 2001, ANN INTERN MED, V134, P1; Narula PK, 2010, SCHIZOPHR RES, V118, P218, DOI 10.1016/j.schres.2010.02.001; Wang M, 2012, SCHIZOPHR RES, V138, P54, DOI 10.1016/j.schres.2012.02.021; Fernandez E, 2012, SCHIZOPHR RES, V137, P262, DOI 10.1016/j.schres.2012.02.005; McEvoy JP, 2005, SCHIZOPHR RES, V80, P19, DOI 10.1016/j.schres.2005.07.014; Ko YH, 2005, CLIN NEUROPHARMACOL, V28, P169, DOI 10.1097/01.wnf.0000172994.56028.c3; Wu RR, 2008, AM J PSYCHIAT, V165, P352, DOI 10.1176/appi.ajp.2007.07010079; Henderson DC, 2009, ACTA PSYCHIAT SCAND, V119, P457, DOI 10.1111/j.1600-0447.2008.01325.x; Baptista T, 2008, PSYCHIAT RES, V159, P250, DOI 10.1016/j.psychres.2008.01.011; Dickerson FB, 2006, ACTA PSYCHIAT SCAND, V113, P306, DOI 10.1111/j.1600-0447.2005.00637.x; Daumit GL, 2003, J NERV MENT DIS, V191, P799, DOI 10.1097/01.nmd.0000100923.20188.2d; Baptista T, 2007, SCHIZOPHR RES, V93, P99, DOI 10.1016/j.schres.2007.03.029; Maayan L, 2011, J CHILD ADOL PSYCHOP, V21, P517, DOI 10.1089/cap.2011.0015; Poyurovsky M, 2002, AM J PSYCHIAT, V159, P1058, DOI 10.1176/appi.ajp.159.6.1058; Assuncao SSM, 2006, REV BRAS PSIQUIATR, V28, P270, DOI 10.1590/S1516-44462006000700005; Ball M Patricia, 2011, Clin Schizophr Relat Psychoses, V5, P17, DOI 10.3371/CSRP.5.1.3; Biedermann F, 2013, INT CLIN PSYCHOPHARM; Borovicka MC, 2002, J CLIN PSYCHIAT, V63, P345; Bustillo JR, 2003, NEUROPSYCHOPHARMACOL, V28, P527, DOI 10.1038/sj.npp.1300089; Chen CH, 2013, J CLIN PSYCHIAT, V74, pE424, DOI 10.4088/JCP.12m08186; Faulkner G, 2007, COCHRANE DB SYST REV, V1; Fiedorowicz JG, 2012, CURR PSYCHIAT REV, V8, P25; Ghanizadeh A, 2013, SCHIZOPHR RES, V147, P110, DOI 10.1016/j.schres.2013.03.021; GOODALL E, 1988, BRIT J PSYCHIAT, V153, P208, DOI 10.1192/bjp.153.2.208; Henderson DC, 2009, J CLIN PSYCHOPHARM, V29, P165, DOI 10.1097/JCP.0b013e31819a8dbe; Higgins JPT, 2011, COCHRANE HDB SYSTEMA; Li J, 2013, SCHIZOPHR RES, V146, P40, DOI 10.1016/j.schres.2013.01.034; MODELL W, 1965, J AMER MED ASSOC, V193, P275; Moher D, 2009, BMJ-BRIT MED J, V339, DOI 10.1136/bmj.b2535; Straus SE, 2010, EVIDENCE BASED MED P, V4th; Sudhakar TP, 2008, INDIAN J PSYCHOL MED, V30, P24; Wu RR, 2008, JAMA-J AM MED ASSOC, V299, P185, DOI 10.1001/jama.2007.56-b	67	10	10	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0586-7614	1745-1701		SCHIZOPHRENIA BULL	Schizophr. Bull.	NOV	2014	40	6					1385	1403		10.1093/schbul/sbu030		19	Psychiatry	Psychiatry	AT0FF	WOS:000344611900023		
J	Nishida, A; Xu, KM; Croudace, T; Jones, PB; Barnett, J; Richards, M				Nishida, Atsushi; Xu, Kate Man; Croudace, Tim; Jones, Peter B.; Barnett, Jenifer; Richards, Marcus			Adolescent Self-control Predicts Midlife Hallucinatory Experiences: 40-Year Follow-up of a National Birth Cohort	SCHIZOPHRENIA BULLETIN			English	Article						self-control; adolescent; psychotic-like-experiences; longitudinal; conduct problems	ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; ORBITOFRONTAL CORTEX; PSYCHOTIC SYMPTOMS; ADULT PSYCHOPATHOLOGY; CORTICAL THICKNESS; MENTAL-HEALTH; CHILDHOOD; SCHIZOPHRENIA; OUTCOMES; POPULATION	Background: Associations between self-control in adolescence and adult mental health are unclear in the general population; to our knowledge, no study has investigated self-control in relation to psychotic-like symptoms. Aims: To investigate the relationship between adolescent self-control and the midlife mental health outcomes of anxiety and depression symptoms and psychotic-like experiences (PLEs), controlling for the effect of adolescent conduct and emotional problems and for parental occupational social class and childhood cognition. Methods: A population-based sample, the MRC National Survey of Health and Development (the British 1946 birth cohort) was contacted 23 times between ages 6 weeks and 53 years. Teachers completed rating scales to assess emotional adjustment and behaviors, from which factors measuring self-control, behavioral, and emotional problems were extracted. At age 53 years, PLEs were self-reported by 2918 participants using 4 items from the Psychosis Screening Questionnaire; symptoms of anxiety and depression were assessed using the scaled version of the General Health Questionnaire (GHQ-28). Results: After adjustment for the above covariates, poor adolescent self-control was associated with the presence of PLEs in adulthood, specifically hallucinatory experiences at age 53 years, even after adjustment for GHQ-28 scores. Conclusions: Lower self-control in adolescence is a risk factor for hallucinatory experiences in adulthood.	[Nishida, Atsushi] Tokyo Metropolitan Inst Med Sci, Dept Psychiat & Behav Sci, Tokyo 113, Japan; [Nishida, Atsushi; Richards, Marcus] UCL, MRC Unit Lifelong Hlth & Ageing, London, England; [Xu, Kate Man; Jones, Peter B.; Barnett, Jenifer] Univ Cambridge, Dept Psychiat, Cambridge, England; [Croudace, Tim] Univ York, Dept Hlth Sci, York YO10 5DD, N Yorkshire, England; [Croudace, Tim] Univ York, Hull York Med Sch, York YO10 5DD, N Yorkshire, England; [Jones, Peter B.] Cambridgeshire & Peterborough NHS Fdn Trust, CAMEO, Cambridge, England; [Barnett, Jenifer] Cambridge Cognit Ltd, Cambridge, England	Nishida, A (reprint author), UCL, MRC Unit Lifelong Hlth & Aging, 33 Bedford Pl, London WC1B 5JU, England.	nishida-at@igakuken.or.jp		Jones, Peter/0000-0002-0387-880X; Croudace, Tim/0000-0001-8346-7463	Medical Research Council; Wellcome Trust [088869/Z/09/Z]; Ministry of Education, Culture, Sports, Science and Technology of Japan Scientific Research Grant on Innovative Area [23118004]; Japanese Society for the Promotion of Scientific Research Grant	Funding for the National Survey of Health and Development is provided by the Medical Research Council. This work was supported by the Medical Research Council (to M. R.), Wellcome Trust grant (088869/Z/09/Z), the Ministry of Education, Culture, Sports, Science and Technology of Japan Scientific Research Grant on Innovative Area (to A.N., 23118004; Adolescent Mind & Self-Regulation), and the Japanese Society for the Promotion of Scientific Research Grant (to A.N., Strategic Young Researcher Overseas Visits Program for Accelerating Brain Circulation).	Richards M, 2003, J CLIN EXP NEUROPSYC, V25, P614, DOI 10.1076/jcen.25.5.614.14581; Kaymaz N, 2012, PSYCHOL MED, V42, P2239, DOI 10.1017/S0033291711002911; Wadsworth M, 2006, INT J EPIDEMIOL, V35, P49, DOI 10.1093/ije/dyi201; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139; Kelleher I, 2012, PSYCHOL MED, V42, P1857, DOI 10.1017/S0033291711002960; Fan J, 2007, J NEUROSCI, V27, P2272, DOI 10.1523/JNEUROSCI.3470-06.2007; Fornito A, 2008, HUM BRAIN MAPP, V29, P222, DOI 10.1002/hbm.20381; Ochsner KN, 2004, NEUROIMAGE, V23, P483, DOI 10.1016/j.neuroimage.2004.06.030; Borgwardt SJ, 2008, SCHIZOPHR RES, V106, P108, DOI 10.1016/j.schres.2008.08.007; Elander J, 1996, INT J METHOD PSYCH, V6, P63, DOI 10.1002/(SICI)1234-988X(199607)6:2<63::AID-MPR151>3.3.CO;2-M; Yucel M, 2002, BIOL PSYCHIAT, V52, P15, DOI 10.1016/S0006-3223(02)01312-4; Clark C, 2007, ARCH GEN PSYCHIAT, V64, P668, DOI 10.1001/archpsyc.64.6.668; Larquet M, 2010, SCHIZOPHR RES, V116, P266, DOI 10.1016/j.schres.2009.11.010; Moffitt TE, 2011, P NATL ACAD SCI USA, V108, P2693, DOI 10.1073/pnas.1010076108; Hatch SL, 2007, SOC SCI MED, V64, P2285, DOI 10.1016/j.socscimed.2007.02.027; Blair C, 2008, DEV PSYCHOPATHOL, V20, P899, DOI 10.1017/S0954579408000436; Makris N, 2007, CEREB CORTEX, V17, P1364, DOI 10.1093/cercor/bhl047; Johns LC, 2004, BRIT J PSYCHIAT, V185, P298, DOI 10.1192/bjp.185.4.298; Fusar-Poli P, 2007, NEUROSCI BIOBEHAV R, V31, P465, DOI 10.1016/j.neubiorev.2006.11.006; Sevy S, 2007, SCHIZOPHR RES, V92, P74, DOI 10.1016/j.schres.2007.01.005; Dickson H, 2014, J PSYCHIATR RES, V50, P92, DOI 10.1016/j.jpsychires.2013.12.003; Deary IJ, 2000, INTELLIGENCE, V28, P49, DOI 10.1016/S0160-2896(99)00031-8; Rutter M, 2006, J CHILD PSYCHOL PSYC, V47, P276, DOI 10.1111/j.1469-7610.2006.01614.x; GirgiS RR, 2007, PROG NEURO-PSYCHOPH, V31, P41, DOI 10.1016/j.pnpbp.2006.06.007; Copeland WE, 2009, ARCH GEN PSYCHIAT, V66, P764, DOI 10.1001/archgenpsychiatry.2009.85; Pantelis C, 2003, LANCET, V361, P281, DOI 10.1016/S0140-6736(03)12323-9; Fergusson DM, 2013, J AM ACAD CHILD PSY, V52, P709, DOI 10.1016/j.jaac.2013.04.008; Murray EA, 2007, J NEUROSCI, V27, P8166, DOI 10.1523/JNEUROSCI.1556-07.2007; Fergusson DM, 2005, ARCH GEN PSYCHIAT, V62, P66, DOI 10.1001/archpsyc.62.1.66; Barnett JH, 2012, BRIT J PSYCHIAT, V201, P124, DOI 10.1192/bjp.bp.111.102053; Nakamura M, 2008, BRAIN, V131, P180, DOI 10.1093/brain/awm265; Franklin TR, 2002, BIOL PSYCHIAT, V51, P134, DOI 10.1016/S0006-3223(01)01269-0; JONES P, 1994, LANCET, V344, P1398, DOI 10.1016/S0140-6736(94)90569-X; Kelleher I, 2012, BRIT J PSYCHIAT, V201, P26, DOI 10.1192/bjp.bp.111.101543; Takayanagi Y, 2010, SCHIZOPHR RES, V121, P55, DOI 10.1016/j.schres.2010.05.006; Parellada E, 2008, NUCL MED COMMUN, V29, P894, DOI 10.1097/MNM.0b013e328302cd10; Kelleher I, 2013, SCHIZOPHRENIA BULL, V39, P1018, DOI 10.1093/schbul/sbs086; PLASSMAN BL, 1995, NEUROLOGY, V45, P1446; Shaw P, 2006, ARCH GEN PSYCHIAT, V63, P540, DOI 10.1001/archpsyc.63.5.540; Rolls ET, 2008, PROG NEUROBIOL, V86, P216, DOI 10.1016/j.pneurobio.2008.09.001; van Os J, 2009, PSYCHOL MED, V39, P179, DOI 10.1017/S0033291708003814; Moffitt TE, 2007, ARCH GEN PSYCHIAT, V64, P651, DOI 10.1001/archpsyc.64.6.651; Kringelbach ML, 2005, NAT REV NEUROSCI, V6, P691, DOI 10.1038/nrn1747; Bauer I. M., 2011, HDB SELF REGULATION, P64; Bruggemann JM, 2013, INT J PSYCHOPHYSIOL, V89, P374, DOI 10.1016/j.ijpsycho.2013.05.008; Colman I, 2007, AM J PSYCHIAT, V164, P126, DOI 10.1176/appi.ajp.164.1.126; Colman I, 2009, BRIT MED J, V338, DOI 10.1136/bmj.a2981; Eisenberg N., 2011, HDB SELF REGULATION, P263; Haas L F, 2001, J Neurol Neurosurg Psychiatry, V71, P761, DOI 10.1136/jnnp.71.6.761; Jenkins R, 2008, MENTAL HEALTH FUTURE; Kuh Diana, 2011, Int J Epidemiol, V40, pe1, DOI 10.1093/ije/dyq231; Murray RM, 2008, EUR NEUROPSYCHOPHARM, V18, P21; Muthen LK, 2010, MPLUS USERS GUIDE; Olino TM, 2010, J ABNORM CHILD PSYCH, V38, P1139, DOI 10.1007/s10802-010-9427-9; Pigeon DA, 1964, TESTS USED IN THE 19; Rutter M, 1970, EDUCATION HEALTH AND; Soosay I, 2012, BMC PSYCHIATRY, V12, P12; Stafford M, 2013, EUR J AGEING, V10, P145, DOI 10.1007/s10433-013-0258-8; van Os J, 2014, PSYCHOL MED, V44, P17; Whittle S, 2008, J AM ACAD CHILD PSY, V47, P682, DOI 10.1097/CHI.0b013e31816bffca; Xu MK, 2013, PSYCHOL AGING, V28, P958, DOI 10.1037/a0033787	61	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0586-7614	1745-1701		SCHIZOPHRENIA BULL	Schizophr. Bull.	NOV	2014	40	6					1543	1551		10.1093/schbul/sbu050		9	Psychiatry	Psychiatry	AT0FF	WOS:000344611900039		
J	Fee, D; Yokoo, A; Johnson, JB				Fee, David; Yokoo, Akihiko; Johnson, Jeffrey B.			Introduction to an Open Community Infrasound Dataset from the Actively Erupting Sakurajima Volcano, Japan	SEISMOLOGICAL RESEARCH LETTERS			English	Editorial Material							VULCANIAN ERUPTION; EXPLOSIVE ERUPTIONS; ALASKA; WAVE		[Fee, David] Univ Alaska Fairbanks, Inst Geophys, Alaska Volcano Observ, Wilson Infrasound Observ, Fairbanks, AK 99775 USA; [Yokoo, Akihiko] Kyoto Univ, Inst Geothermal Sci, Aso Volcanol Lab, Kumamoto, Japan; [Johnson, Jeffrey B.] Boise State Univ, Dept Geosci, Boise, ID 83725 USA	Fee, D (reprint author), Univ Alaska Fairbanks, Inst Geophys, Alaska Volcano Observ, Wilson Infrasound Observ, Fairbanks, AK 99775 USA.	dfee@gi.alaska.edu					Lopez T, 2013, GEOCHEM GEOPHY GEOSY, V14, P5106, DOI 10.1002/2013GC004817; Johnson JB, 2011, J VOLCANOL GEOTH RES, V206, P61, DOI 10.1016/j.jvolgeores.2011.06.006; Iguchi M, 2008, J VOLCANOL GEOTH RES, V178, P1, DOI 10.1016/j.jvolgeores.2007.10.010; Matoza RS, 2009, J GEOPHYS RES-SOL EA, V114, DOI 10.1029/2008JB006128; Matoza RS, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2008GL036486; Fee D, 2013, J VOLCANOL GEOTH RES, V249, P123, DOI 10.1016/j.jvolgeores.2012.09.002; Ichihara M, 2012, GEOPHYS RES LETT, V39, DOI 10.1029/2011GL050542; Arrowsmith SJ, 2010, REV GEOPHYS, V48, DOI 10.1029/2010RG000335; Fee D., 2010, J GEOPHYS RES, V115; Garces M, 1999, GEOPHYS RES LETT, V26, P2537; Goto A, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2011GL046858; Iguchi M., 2013, B VOLCANOL SOC JAPAN, V58, P113; Iguchi M., 1990, ANN DISASTER PREVE B, P1; ISHIHARA K, 1985, J GEODYN, V3, P327, DOI 10.1016/0264-3707(85)90041-9; Ishihara K., 1990, MAGMA TRANSPORT STOR, P335; Johnson J, 2008, J VOLCANOL GEOTH RES, V177, P673, DOI 10.1016/j.jvolgeores.2008.06.028; Johnson JB, 2012, J GEOPHYS RES-ATMOS, V117, DOI 10.1029/2012JD017694; Johnson JB, 2014, SEISMOL RES LETT, V85, P1163, DOI 10.1785/0220140058; Kamo K., 1994, VOLCANIC ASH AVIATIO, P357; Kim K, 2012, GEOPHYS J INT, V191, P1192, DOI 10.1111/j.1365-246X.2012.05696.x; Kim K, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2010GL046615; Kim K, 2014, SEISMOL RES LETT, V85, P1177, DOI 10.1785/0220140029; Lacanna G, 2013, J VOLCANOL GEOTH RES, V250, P9, DOI 10.1016/j.jvolgeores.2012.10.005; Lacanna G, 2014, J GEOPHYS RES-SOL EA, V119, P2988, DOI 10.1002/2013JB010827; Marcillo O, 2012, J ATMOS OCEAN TECH, V29, P1275, DOI 10.1175/JTECH-D-11-00101.1; Matoza RS, 2014, SEISMOL RES LETT, V85, P1187, DOI 10.1785/0220140110; Matoza RS, 2014, GEOPHYS RES LETT, V41, P1964, DOI 10.1002/2014GL059301; Matsumoto A., 2013, B VOLCANOL SOC JAPAN, V58, P191; Mckee K, 2014, SEISMOL RES LETT, V85, P1200, DOI 10.1785/0220140119; McNutt SR, 2013, J VOLCANOL GEOTH RES, V259, P63, DOI 10.1016/j.jvolgeores.2013.03.016; Morrissey M, 2008, J VOLCANOL GEOTH RES, V175, P315, DOI 10.1016/j.jvolgeores.2008.03.008; Petersen T, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2006GL026491; Pierce A.D., 1981, ACOUSTICS INTRO ITS; Shimano T., 2013, B VOLCANOL, V75, P1; TAHIRA M, 1982, J METEOROL SOC JPN, V60, P896; Tameguri T, 2002, B VOLCANOL SOC JPN, V47, P197; UHIRA K, 1994, J GEOPHYS RES-SOL EA, V99, P17775, DOI 10.1029/94JB00990; Yokoo A, 2014, SEISMOL RES LETT, V85, P1212, DOI 10.1785/0220140047; Yokoo A, 2009, B VOLCANOL, V71, P619, DOI 10.1007/s00445-008-0247-5; Yokoo A., 2013, B VOLCANOLOGICAL SOC, V58, P163; Yokoo A, 2007, EARTH PLANETS SPACE, V59, P177	41	4	4	SEISMOLOGICAL SOC AMER	ALBANY	400 EVELYN AVE, SUITE 201, ALBANY, CA 94706-1375 USA	0895-0695			SEISMOL RES LETT	Seismol. Res. Lett.	NOV-DEC	2014	85	6					1151	1162		10.1785/0220140051		12	Geochemistry & Geophysics	Geochemistry & Geophysics	AS8QD	WOS:000344512500003		
J	Mckee, K; Fee, D; Rowell, C; Yokoo, A				Mckee, Kathleen; Fee, David; Rowell, Colin; Yokoo, Akihiko			Network-Based Evaluation of the Infrasonic Source Location at Sakurajima Volcano, Japan	SEISMOLOGICAL RESEARCH LETTERS			English	Article							RADIAL SEMBLANCE; ERUPTION		[Mckee, Kathleen; Fee, David; Rowell, Colin] Univ Alaska Fairbanks, Inst Geophys, Alaska Volcano Observ, Wilson Infrasound Observ, Fairbanks, AK 99775 USA; [Yokoo, Akihiko] Kyoto Univ, Grad Sch Sci, Inst Geothermal Sci, Aso Volcanol Lab, Kumamoto 8691404, Japan	Mckee, K (reprint author), Univ Alaska Fairbanks, Inst Geophys, Alaska Volcano Observ, Wilson Infrasound Observ, Fairbanks, AK 99775 USA.	dfee@gi.alaska.edu			National Science Foundation [EAR-1113294]; Geophysical Institute	We would like to thank the Sakurajima Volcano Research Center, Mie Ichihara, and Yuki Abe for assistance with data collection and planning, as well as Jeff Johnson, Philippa Demonte, Brian Terbush, and Robin Matoza. Funding was provided by National Science Foundation Grant EAR-1113294 and the Geophysical Institute. The manuscript was significantly improved by two helpful reviews.	NEIDELL NS, 1971, GEOPHYSICS, V36, P482, DOI 10.1190/1.1440186; Iguchi M, 2008, J VOLCANOL GEOTH RES, V178, P1, DOI 10.1016/j.jvolgeores.2007.10.010; Almendros J, 2003, B SEISMOL SOC AM, V93, P1890, DOI 10.1785/0120020143; Cannata A, 2011, GEOPHYS J INT, V185, P253, DOI 10.1111/j.1365-246X.2011.04951.x; Dawson P, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL021163; Fee D, 2014, SEISMOL RES LETT, V85, P1151, DOI 10.1785/0220140051; HADDEN WJ, 1981, J ACOUST SOC AM, V69, P1266, DOI 10.1121/1.385809; Johnson JB, 2013, J VOLCANOL GEOTH RES, V256, P105, DOI 10.1016/j.jvolgeores.2013.02.016; Johnson JB, 2011, J VOLCANOL GEOTH RES, V199, P1, DOI 10.1016/j.jvolgeores.2010.08.005; Johnson JB, 2003, J VOLCANOL GEOTH RES, V121, P15, DOI 10.1016/S0377-0273(02)00409-2; Jones KR, 2008, J VOLCANOL GEOTH RES, V177, P661, DOI 10.1016/j.jvolgeores.2008.02.001; Jones KR, 2011, J VOLCANOL GEOTH RES, V199, P15, DOI 10.1016/j.jvolgeores.2010.08.006; Kawakatsu H, 2000, J VOLCANOL GEOTH RES, V101, P129, DOI 10.1016/S0377-0273(00)00166-9; KIM K, 2011, GEOPHYS RES LETT, V38, DOI DOI 10.1029/2010G1046615; Kim K, 2014, SEISMOL RES LETT, V85, P1177, DOI 10.1785/0220140029; Lacanna G, 2013, J VOLCANOL GEOTH RES, V250, P9, DOI 10.1016/j.jvolgeores.2012.10.005; Matoza RS, 2011, J VOLCANOL GEOTH RES, V200, P35, DOI 10.1016/j.jvolgeores.2010.11.022; Modrak RT, 2010, GEOPHYS J INT, V181, P399, DOI 10.1111/j.1365-246X.2010.04499.x; Montalto P, 2010, PURE APPL GEOPHYS, V167, P1215, DOI 10.1007/s00024-010-0051-y; Pierce A.D., 1981, ACOUSTICS INTRO ITS; Ripepe M, 2009, J VOLCANOL GEOTH RES, V182, P131, DOI 10.1016/j.jvolgeores.2009.02.011; RIPEPE M, 2002, GEOPHYS RES LETT, V29, DOI DOI 10.1029/2002GL015452; Ripepe M, 2007, J GEOPHYS RES-SOL EA, V112, DOI 10.1029/2006JB004613; Rowell CR, 2014, J VOLCANOL GEOTH RES, V283, P101, DOI 10.1016/j.jvolgeores.2014.06.015; Yokoo A, 2014, SEISMOL RES LETT, V85, P1212, DOI 10.1785/0220140047; Yokoo A, 2009, B VOLCANOL, V71, P619, DOI 10.1007/s00445-008-0247-5; Yokoo A., 2013, B VOLCANOLOGICAL SOC, V58, P163	27	1	1	SEISMOLOGICAL SOC AMER	ALBANY	400 EVELYN AVE, SUITE 201, ALBANY, CA 94706-1375 USA	0895-0695			SEISMOL RES LETT	Seismol. Res. Lett.	NOV-DEC	2014	85	6					1200	1211		10.1785/0220140119		12	Geochemistry & Geophysics	Geochemistry & Geophysics	AS8QD	WOS:000344512500007		
J	Yokoo, A; Suzuki, YJ; Iguchi, M				Yokoo, Akihiko; Suzuki, Yujiro J.; Iguchi, Masato			Dual Infrasound Sources from a Vulcanian Eruption of Sakurajima Volcano Inferred from Cross-Array Observation	SEISMOLOGICAL RESEARCH LETTERS			English	Article							WAVE-FIELD; JAPAN		[Yokoo, Akihiko] Kyoto Univ, Grad Sch Sci, Inst Geothermal Sci, Aso Volcanol Lab, Kumamoto 8691404, Japan; [Suzuki, Yujiro J.] Univ Tokyo, Earthquake Res Inst, Tokyo 1130032, Japan; [Iguchi, Masato] Kyoto Univ, Sakurajima Volcano Res Ctr, Disaster Prevent Res Inst, Kagoshima 8911419, Japan	Yokoo, A (reprint author), Kyoto Univ, Grad Sch Sci, Inst Geothermal Sci, Aso Volcanol Lab, 5280 Kawayo, Kumamoto 8691404, Japan.	yokoo@aso.vgs.kyoto-u.ac.jp			Kyoto University [23H-01]; University of Tokyo [2011-G-03, 2012-G-06]; Japan Society for the Promotion of Science (JSPS) [23654157]	This study was supported by Kyoto University (23H-01), the University of Tokyo (2011-G-03 and 2012-G-06), and Japan Society for the Promotion of Science (JSPS) (23654157). We thank E. Swanson, J. B. Johnson, and two anonymous reviewers for improving the manuscript.	Almendros J, 2002, B SEISMOL SOC AM, V92, P2333, DOI 10.1785/0120020037; Johnson JB, 2011, J VOLCANOL GEOTH RES, V206, P61, DOI 10.1016/j.jvolgeores.2011.06.006; Fee D, 2010, J VOLCANOL GEOTH RES, V193, P67, DOI 10.1016/j.jvolgeores.2010.03.006; Ripepe M, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL015452; Rost S, 2002, REV GEOPHYS, V40, DOI 10.1029/2000RG000100; Matoza RS, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2008GL036486; Yamasato H, 1997, J PHYS EARTH, V45, P397; Fee D, 2013, J VOLCANOL GEOTH RES, V249, P123, DOI 10.1016/j.jvolgeores.2012.09.002; Cannata A, 2011, J VOLCANOL GEOTH RES, V208, P1, DOI 10.1016/j.jvolgeores.2011.09.003; Arechiga RO, 2011, J GEOPHYS RES-ATMOS, V116, DOI 10.1029/2010JD015248; Cannata A, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2008GL036738; Chirsties D. R., 2010, INFRASOUND MONITORIN, P29; Edwards WN, 2012, GEOPHYS J INT, V190, P335, DOI 10.1111/j.1365-246X.2012.05465.x; Fee D, 2011, GEOPHYS RES LETT, V38, DOI 10.1029/2010GL046422; Iguchi M., 2013, B VOLCANOL SOC JAPAN, V58, P115; Johnson JB, 2013, J VOLCANOL GEOTH RES, V256, P105, DOI 10.1016/j.jvolgeores.2013.02.016; Jones KR, 2011, J VOLCANOL GEOTH RES, V199, P15, DOI 10.1016/j.jvolgeores.2010.08.006; KEEN CG, 1965, J I ELECTRON RAD ENG, V30, P297; Kim K., 2014, SEISMOL RES LETT, V86, P1177; Lacanna G, 2013, J VOLCANOL GEOTH RES, V250, P9, DOI 10.1016/j.jvolgeores.2012.10.005; Medici EF, 2014, GEOPHYS RES LETT, V41, P414, DOI 10.1002/2013GL058340; Ripepe M, 2009, EOS T AGU, V90, P229, DOI DOI 10.1029/2009E0270001; Rowell CR, 2014, J VOLCANOL GEOTH RES, V283, P101, DOI 10.1016/j.jvolgeores.2014.06.015; Sakai T., 2000, Q J SEISMOL, V63, P1; Suwa H, 2014, EARTH PLANET SC LETT, V385, P154, DOI 10.1016/j.epsl.2013.10.032; Tam C.K.W., 1996, 961716 AIAA; Yokoo A, 2009, EARTH PLANETS SPACE, V61, P1345; Yokoo A, 2009, B VOLCANOL, V71, P619, DOI 10.1007/s00445-008-0247-5; Yokoo A., 2013, B VOLCANOLOGICAL SOC, V58, P163	29	3	3	SEISMOLOGICAL SOC AMER	ALBANY	400 EVELYN AVE, SUITE 201, ALBANY, CA 94706-1375 USA	0895-0695			SEISMOL RES LETT	Seismol. Res. Lett.	NOV-DEC	2014	85	6					1212	1222		10.1785/0220140047		11	Geochemistry & Geophysics	Geochemistry & Geophysics	AS8QD	WOS:000344512500008		
J	Borgese, L; Bilo, F; Tsuji, K; Fernandez-Ruiz, R; Margui, E; Streli, C; Pepponi, G; Stosnach, H; Yamada, T; Vandenabeele, P; Maina, DM; Gatari, M; Shepherd, KD; Towett, EK; Bennun, L; Custo, G; Vasquez, C; Depero, LE				Borgese, Laura; Bilo, Fabjola; Tsuji, Kouichi; Fernandez-Ruiz, Ramon; Margui, Eva; Streli, Christina; Pepponi, Giancarlo; Stosnach, Hagen; Yamada, Takashi; Vandenabeele, Peter; Maina, David M.; Gatari, Michael; Shepherd, Keith D.; Towett, Erick K.; Bennun, Leonardo; Custo, Graciela; Vasquez, Cristina; Depero, Laura E.			First Total Reflection X-Ray Fluorescence round-robin test of water samples: Preliminary results	SPECTROCHIMICA ACTA PART B-ATOMIC SPECTROSCOPY			English	Article; Proceedings Paper	15th International Conference on Total Reflection X-Ray Fluorescence Analysis and Related Methods / 49th Annual Conference on X-Ray Chemical Analysis (TXRF)	SEP 23-27, 2013	Osaka, JAPAN			TXRF; Elemental chemical analysis; Water; Interlaboratory study; Round robin test	DRINKING-WATER; SPECTROMETRY; CARRIERS; ELEMENTS	Total Reflection X-Ray Fluorescence (TXRF) is a mature technique to evaluate quantitatively the elemental composition of liquid samples deposited on clean and well polished reflectors. In this paper the results of the first worldwide TXRF round-robin test of water samples, involving 18 laboratories in 10 countries are presented and discussed. The test was performed within the framework of the VAMAS project, interlaboratory comparison of TXRF spectroscopy for environmental analysis, whose aim is to develop guidelines and a standard methodology for biological and environmental analysis by means of the TXRF analytical technique. (C) 2014 Elsevier B.V. All rights reserved.	[Borgese, Laura; Bilo, Fabjola; Depero, Laura E.] Univ Brescia, Chem Technol Lab, Brescia, Italy; [Tsuji, Kouichi] Osaka City Univ, Grad Sch Engn, Osaka 558, Japan; [Fernandez-Ruiz, Ramon] Univ Autonoma Madrid, Lab TXRF, Serv Interdept Invest SIdI, Madrid, Spain; [Margui, Eva] Univ Girona, Dept Chem, Girona, Spain; [Streli, Christina] TU Wien, Vienna, Austria; [Pepponi, Giancarlo] Fdn Bruno Kessler, Trento, Italy; [Stosnach, Hagen] Bruiser Nano GmbH, Berlin, Germany; [Yamada, Takashi] Rigaku Corp, Takatsuki, Osaka, Japan; [Vandenabeele, Peter] Univ Ghent, Dept Archaeol, B-9000 Ghent, Belgium; [Maina, David M.; Gatari, Michael] Univ Nairobi, Inst Nucl Sci & Technol, Nairobi, Kenya; [Shepherd, Keith D.; Towett, Erick K.] World Agroforesby Ctr ICRAF, Nairobi, Kenya; [Bennun, Leonardo] Univ Concepcion, Dept Fis, Lab Fis Aplicada, Concepcion, Chile; [Custo, Graciela; Vasquez, Cristina] Ctr Atamico Constituyentes, Lab B025, San Martin, Argentina	Depero, LE (reprint author), Univ Brescia, Chem Technol Lab, Brescia, Italy.	laura.depero@unibs.it	Fernandez-Ruiz, R/B-5218-2008; Muchoki Macharia, Benson/G-1700-2015; Depero, Laura Eleonora/A-3176-2009; 	Muchoki Macharia, Benson/0000-0002-5779-6789; Depero, Laura Eleonora/0000-0001-7818-3212; borgese, laura/0000-0003-3486-2656; Margui, Eva/0000-0003-4630-1530			Moreira S, 2008, SPECTROCHIM ACTA B, V63, P1432, DOI 10.1016/j.sab.2008.10.022; Fernandez-Ruiz R, 2008, ANAL CHEM, V80, P8372, DOI 10.1021/ac800780x; [Anonymous], 2000, 14706 ISO; Margui E, 2010, CHEMOSPHERE, V80, P263, DOI 10.1016/j.chemosphere.2010.04.027; Richardson SD, 2011, ANAL CHEM, V83, P4614, DOI 10.1021/ac200915r; Cataldo F, 2012, J RADIOANAL NUCL CH, V293, P119, DOI 10.1007/s10967-012-1777-z; Karjou J, 2007, SPECTROCHIM ACTA B, V62, P177, DOI 10.1016/j.sab.2007.02.003; PRANGE A, 1993, SPECTROCHIM ACTA B, V48, P153, DOI 10.1016/0584-8547(93)80019-Q; Pashkova GV, 2013, X-RAY SPECTROM, V42, P524, DOI 10.1002/xrs.2513; Stosnach H, 2005, ANAL SCI, V21, P873, DOI 10.2116/analsci.21.873; Azoulay A, 2001, J GEN INTERN MED, V16, P168, DOI 10.1111/j.1525-1497.2001.04189.x; [Anonymous], 2004, 17331 ISO; Creed J. T., 1994, 2008 US EPA CINC ENV; deBoer JLM, 1996, WATER RES, V30, P190, DOI 10.1016/0043-1354(95)00120-A; Esaka F, 2003, SPECTROCHIM ACTA B, V58, P2145, DOI 10.1016/S0584-8547(03)00189-7; Espinoza-Quinones F. R., 2011, WATER SCI TECHNOL, V63; Gleick P. H., 2009, BIENNIAL REPORT FRES; GULSON BL, 1994, SCI TOTAL ENVIRON, V144, P279, DOI 10.1016/0048-9697(94)90447-2; Kim J. H., 2006, COBALT INORGANIC COB, V69, P8; Klockenkamper R., 1997, TOTAL REFLECTION XRA; Landsberger S, 2000, J RADIOANAL NUCL CH, V244, P35, DOI 10.1023/A:1006750301058; Montero Alvarez A., 2007, Journal of Radioanalytical and Nuclear Chemistry, V273, P427, DOI 10.1007/s10967-007-6895-7; Moreira S, 2006, INSTRUM SCI TECHNOL, V34, P567, DOI 10.1080/10739140600811682; Moya-Riffo A, 2013, X-RAY SPECTROM, V42, P93, DOI 10.1002/xrs.2439; PRANGE A, 1989, SPECTROCHIM ACTA B, V44, P437, DOI 10.1016/0584-8547(89)80049-7; Sullivan P. J., 2005, ENV SCI DRINKING WAT; Tavares GA, 2011, J RADIOANAL NUCL CH, V287, P377, DOI 10.1007/s10967-010-0885-x; Torres EL, 1998, X-RAY SPECTROM, V27, P161, DOI 10.1002/(SICI)1097-4539(199805/06)27:3<161::AID-XRS260>3.3.CO;2-4; United Nations, 2013, MILL DEV GOALS REP 2	29	6	6	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0584-8547			SPECTROCHIM ACTA B	Spectroc. Acta Pt. B-Atom. Spectr.	NOV 1	2014	101						6	14		10.1016/j.sab.2014.06.024		9	Spectroscopy	Spectroscopy	AS7MO	WOS:000344440300002		
J	Ashida, T; Tsuji, K				Ashida, Takafumi; Tsuji, Kouichi			Development of a compact grazing exit X-ray fluorescence spectrometer for fast trace elemental analysis	SPECTROCHIMICA ACTA PART B-ATOMIC SPECTROSCOPY			English	Article; Proceedings Paper	15th International Conference on Total Reflection X-Ray Fluorescence Analysis and Related Methods / 49th Annual Conference on X-Ray Chemical Analysis (TXRF)	SEP 23-27, 2013	Osaka, JAPAN			Grazing-exit; X-ray fluorescence; Trace elemental analysis; Energy dispersive spectrometry	ELECTRON-PROBE MICROANALYSIS; EMISSION; SURFACE	A compact grazing exit X-ray fluorescence (GE-XRF) spectrometer was developed in the laboratory. An Al cylindrical collimator for the primary X-rays was placed just above the sample stage. This collimator also played the role of an exit slit to detect fluorescent X-rays at small grazing exit angles. Therefore, no additional exit slit was used in this setup, leading to a compact design. The entire size of the analysis equipment was 80 mm x 200 mm x 170 mm (horizontal x vertical x height). The maximum exit angle was adjusted to the height of the sample stage. The background was drastically reduced at grazing exit angles, enabling trace elemental analysis. A calibration curve was obtained using 10 mu L Ga solutions. Accordingly, the detection limit for Ga was evaluated to be 20 ppb. (C) 2014 Elsevier B.V. All rights reserved.	[Ashida, Takafumi; Tsuji, Kouichi] Osaka City Univ, Grad Sch Engn, Dept Appl Chem & Bioengn, Sumiyoshi Ku, Osaka 5588585, Japan	Ashida, T (reprint author), Osaka City Univ, Grad Sch Engn, Dept Appl Chem & Bioengn, Sumiyoshi Ku, 3-3-138 Sugimoto, Osaka 5588585, Japan.	ashidatakafumi@gmail.com					PARRATT LG, 1954, PHYS REV, V95, P359, DOI 10.1103/PhysRev.95.359; Emoto T, 2004, SPECTROCHIM ACTA B, V59, P1291, DOI 10.1016/j.sab.2004.05.016; Margui E, 2010, ANAL CHEM, V82, P7744, DOI 10.1021/ac101615w; Sakurai K, 2002, ANAL CHEM, V74, P4532, DOI 10.1021/ac025720y; Noma T, 1999, X-RAY SPECTROM, V28, P433, DOI 10.1002/(SICI)1097-4539(199911/12)28:6<433::AID-XRS386>3.0.CO;2-C; YONEDA Y, 1971, REV SCI INSTRUM, V42, P1069, DOI 10.1063/1.1685282; Tsuji K, 1999, ANAL CHEM, V71, P2497, DOI 10.1021/ac990075p; Kayser Y, 2012, X-RAY SPECTROM, V41, P98, DOI 10.1002/xrs.2372; BECKER RS, 1983, PHYS REV LETT, V50, P153, DOI 10.1103/PhysRevLett.50.153; Awane T, 2009, ANAL CHEM, V81, P3356, DOI 10.1021/ac802599x; Awane T, 2003, ANAL CHEM, V75, P3831, DOI 10.1021/ac020740I; Awane T, 2004, SPECTROCHIM ACTA B, V59, P1235, DOI 10.1016/j.sab.2004.04.011; Bohlen A. V., 1987, ANAL CHEM, V59, P2551; de Bola P. K., 1998, SILICON MAT SCI TECH, P1511; Klockenkamper R., 1997, TOTAL REFLECTION XRA; Kunimura S, 2007, ANAL CHEM, V79, P2593, DOI 10.1021/ac062279t; Potts PJ, 2008, PORTABLE X-RAY FLUORESCENCE SPECTROMETRY: CAPABILITIES FOR IN SITU ANALYSIS, P1, DOI 10.1039/9781847558640; STOESSEL R-P, 1985, Analytical Chemistry, V57, P2880, DOI 10.1021/ac00291a031; Tetsuoka T., 2006, XRAY SPECTROM, V35, P89; Tsuji K., 2004, XRAY SPECTROMETRY RE, P293; Tsuji K, 1999, ANAL CHEM, V71, P5033, DOI 10.1021/ac990568u; Tsuji K, 1999, SPECTROCHIM ACTA B, V54, P1243, DOI 10.1016/S0584-8547(99)00073-7; Van Grieken R. E., 2002, HDB XRAY SPECTROMETR, P354	23	3	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0584-8547			SPECTROCHIM ACTA B	Spectroc. Acta Pt. B-Atom. Spectr.	NOV 1	2014	101						200	203		10.1016/j.sab.2014.08.033		4	Spectroscopy	Spectroscopy	AS7MO	WOS:000344440300028		
J	Eto, SZ; Matsuo, T; Matsumura, T; Fujii, T; Tanaka, MY				Eto, Shuzo; Matsuo, Toyofumi; Matsumura, Takuro; Fujii, Takashi; Tanaka, Masayoshi Y.			Quantitative estimation of carbonation and chloride penetration in reinforced concrete by laser-induced breakdown spectroscopy	SPECTROCHIMICA ACTA PART B-ATOMIC SPECTROSCOPY			English	Article						Laser-induced breakdown spectroscopy; Two-dimensional profile; Concrete; Chloride-induced damage; Carbonation	PLASMA	The penetration profile of chlorine in a reinforced concrete (RC) specimen was determined by laser-induced breakdown spectroscopy (LIBS). The concrete core was prepared from RC beams with cracking damage induced by bending load and salt water spraying. LIBS was performed using a specimen that was obtained by splitting the concrete core, and the line scan of laser pulses gave the two-dimensional emission intensity profiles of 100 x 80 mm(2) within one hour. The two-dimensional profile of the emission intensity suggests that the presence of the crack had less effect on the emission intensity when the measurement interval was larger than the crack width. The chlorine emission spectrum was measured without using the buffer gas, which is usually used for chlorine measurement, by collinear double-pulse LIBS. The apparent diffusion coefficient, Which is one of the most important parameters for chloride penetration in concrete, was estimated using the depth profile of chlorine emission intensity and Fick's law. The carbonation depth was estimated on the basis of the relationship between carbon and calcium emission intensities. When the carbon emission intensity was statistically higher than the calcium emission intensity at the measurement point, we determined that the point was carbonated. The estimation results were consistent with the spraying test results using phenolphthalein solution. These results suggest that the quantitative estimation by LIBS of carbonation depth and chloride penetration can be performed simultaneously. (C) 2014 Elsevier B.V. All rights reserved.	[Eto, Shuzo; Matsuo, Toyofumi; Matsumura, Takuro; Fujii, Takashi] Cent Res Inst Elect Power Ind, Yokosuka, Kanagawa 2400196, Japan; [Tanaka, Masayoshi Y.] Kyushu Univ, Interdisciplinary Grad Sch Engn Sci, Yokosuka, Kanagawa 2400196, Japan	Eto, SZ (reprint author), Cent Res Inst Elect Power Ind, 2-6-1 Nagasaka, Yokosuka, Kanagawa 2400196, Japan.	eto@criepi.denken.or.jp					Wilsch G, 2005, CONSTR BUILD MATER, V19, P724, DOI 10.1016/j.conbuildmat.2005.06.001; [Anonymous], JSCE GUIDELINES CONC, P62; Labutin TA, 2013, J APPL SPECTROSC+, V80, P315, DOI 10.1007/s10812-013-9766-8; Gehlen CD, 2009, SPECTROCHIM ACTA B, V64, P1135, DOI 10.1016/j.sab.2009.07.021; Aguilera JA, 1998, APPL SURF SCI, V127, P309, DOI 10.1016/S0169-4332(97)00648-X; Weritz F, 2006, ANAL BIOANAL CHEM, V385, P248, DOI 10.1007/s00216-006-0362-0; Burakov V. S., 2007, Journal of Applied Spectroscopy, V74, DOI 10.1007/s10812-007-0052-5; Eto S, 2013, SPECTROCHIM ACTA B, V87, P74, DOI 10.1016/j.sab.2013.05.005; Eto S., 2012, H11012 CRIEPI; Gondal MA, 2011, APPL OPTICS, V50, P3488, DOI 10.1364/AO.50.003488; GOTO S, 1981, CEMENT CONCRETE RES, V11, P751, DOI 10.1016/0008-8846(81)90033-8; Kagawa K, 2004, APPL SPECTROSC, V58, P887, DOI 10.1366/0003702041655458; Kobayashi K., 1990, CONCRETE RES TECHNOL, V1, P69; Matsuo T., 2011, N11007 CRIEPI; Sugiyama K, 2010, APPL OPTICS, V49, pC181, DOI 10.1364/AO.49.00C181; Wiggenhauser H, 1998, NDT&E INT, V31, P307, DOI 10.1016/S0963-8695(98)00008-5	16	3	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0584-8547			SPECTROCHIM ACTA B	Spectroc. Acta Pt. B-Atom. Spectr.	NOV 1	2014	101						245	253		10.1016/j.sab.2014.09.004		9	Spectroscopy	Spectroscopy	AS7MO	WOS:000344440300035		
J	Nakanishi, K; Tanaka, N; Kamei, N; Hiramatsu, T; Ujigo, S; Sumiyoshi, N; Rikita, T; Takazawa, A; Ochi, M				Nakanishi, K.; Tanaka, N.; Kamei, N.; Hiramatsu, T.; Ujigo, S.; Sumiyoshi, N.; Rikita, T.; Takazawa, A.; Ochi, M.			Resection of spinous processes can cause spinal cord injury in patient with ossification of the posterior longitudinal ligament in the thoracic spine	SPINAL CORD			English	Editorial Material								Study design: Case report. Objective: To report intraoperative spinal cord injury by resection of spinous processes in a 73-year-old man with ossification of the posterior longitudinal ligament (OPLL) in the thoracic spine. Methods: A 73-year-old man presented with cervicothoracic OPLL with bilateral numbness and clumsiness of his hand weakness of his lower extremities and severe gait disturbance. His Japanese Orthopaedic Association (JOA) score was 7.5 out of 17. Cervical laminoplasty (C2-6) cervicothoracic laminectomy (C7-T10) and posterior fusion (C7-T10) were performed in the prone position with electrophysiologic monitoring of the spinal cord-evoked potentials (SCEPs). Results: The spinal processes with supra-and interspinous ligaments between C7 and T10 were resected. After resection the amplitude of SCEP waveforms decreased rapidly to o10% of control levels. Laminectomy was performed and after 80 min of SCEP deterioration an instrumented fusion with correction for kyphosis was completed. The SCEP amplitude recovered gradually. Immediately after surgery the patient suffered severe motor loss in both lower limbs. His neurological recovery progressed gradually from 2 days after surgery and he was able to walk at 3 months after surgery. At 6 years after surgery the JOA score was 11. Conclusion: Our results suggest that intraoperative spinal cord injury can occur before posterior decompression by resection of spinal processes with supra-and interspinous ligaments. The timing of the instrumented stabilization using a temporary rod is important and should be considered immediately after posterior exposure of the spine.	[Nakanishi, K.; Tanaka, N.; Kamei, N.; Hiramatsu, T.; Ujigo, S.; Sumiyoshi, N.; Rikita, T.; Takazawa, A.; Ochi, M.] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Orthoped Surg, Hiroshima 7348551, Japan	Nakanishi, K (reprint author), Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Dept Orthoped Surg, Minami Ku, Kasumi 1-2-3, Hiroshima 7348551, Japan.	kazn@hiroshima-u.ac.jp			Japan Society for the Promotion of Science, Ministry of Health, Labour and Welfare [24592198]	This work was supported by the Grants-in-Aid for Scientific Research (Scientific Research C, Research Project Number: 24592198) from Japan Society for the Promotion of Science, Ministry of Health, Labour and Welfare.	Matsumoto M, 2008, SPINE, V33, P1034, DOI 10.1097/BRS.0b013e31816c913b; Matsuyama Y, 2005, J SPINAL DISORD TECH, V18, P492, DOI 10.1097/01.bsd.0000155033.63557.9c; Matsuyama Y, 2009, EUR SPINE J, V18, P943, DOI 10.1007/s00586-009-0956-2; Yamazaki M, 2010, EUR SPINE J, V19, P691, DOI 10.1007/s00586-009-1266-4; Ito Z, 2012, J FUNCT DIAG SPINAL, V34, P175; Kobayashi S, 2014, J NEUROSURG-SPINE, V20, P102, DOI 10.3171/2013.10.SPINE12944; Nakanishi K, 2005, SPINE, V30, pE382, DOI 10.1097/01.brs.0000167825.53097.56; TAMAKI T, 1984, CLIN ORTHOP RELAT R, P58; Yamazaki M, 2006, SPINAL CORD, V44, P130, DOI 10.1038/sj.sc.3101807	9	1	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1362-4393	1476-5624		SPINAL CORD	Spinal Cord	NOV	2014	52			3			S19	S21		10.1038/sc.2014.151		3	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AT7FZ	WOS:000345103500008		
J	Sato, M; Sugiyama, K; Kondo, T; Izumi, SI				Sato, M.; Sugiyama, K.; Kondo, T.; Izumi, S-I			Rehabilitation for paraplegia caused by neuromyelitis optica: a case report	SPINAL CORD			English	Editorial Material							MULTIPLE-SCLEROSIS	Study design: Single case report. Objective: We present a case of paraplegia due to neuromyelitis optica (NMO) with poor rehabilitation outcome. Setting: University hospital, Japan. Case report: A 27-year-old woman with NMO presented with T5 paraplegia of ASIA impairment scale grade A. Spinal cord magnetic resonance imaging revealed a lesion spanning C3 to L1 level. After acute phase treatment, flaccid paraplegia below T5 and a T2-weighted hyperintense lesion from T6 to T10 level remained. Rehabilitation aimed at independence of activities of daily living with wheelchair assistance, including transfer activity, was provided for 19 months. However, flaccid paralysis of the trunk and limbs persisted, and safe independent transfer was not achieved. Conclusion: Spinal lesions spanning many vertebral segments, a characteristic of NMO, can cause extensive flaccid paralysis of the trunk and limbs. Rehabilitation may achieve poorer functional recovery than that for spinal cord injury.	[Sato, M.; Sugiyama, K.; Kondo, T.; Izumi, S-I] Tohoku Univ, Grad Sch Med, Dept Phys Med & Rehabil, Sendai, Miyagi 9808575, Japan	Sato, M (reprint author), Tohoku Univ, Grad Sch Med, Aoba Ku, 2-1 Seiryocho, Sendai, Miyagi 9808575, Japan.	manzyuudaifuku@gmail.com					Wingerchuk DM, 2007, LANCET NEUROL, V6, P805, DOI 10.1016/S1474-4422(07)70216-8; Misu T, 2007, BRAIN, V130, P1224, DOI 10.1093/brain/awm047; Wingerchuk DM, 2006, NEUROLOGY, V66, P1485, DOI 10.1212/01.wnl.0000216139.44259.74; Oh J., 2012, NEUROL RES INT, V2012, DOI DOI 10.1155/2012/460825.PUBMED:22363840; Pessoa FMC, 2012, EUR J RADIOL, V81, P2697, DOI 10.1016/j.ejrad.2011.11.026	5	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1362-4393	1476-5624		SPINAL CORD	Spinal Cord	NOV	2014	52			3			S14	S15		10.1038/sc.2014.139		2	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	AT7FZ	WOS:000345103500006		
J	Ishibe, T; Senzoku, F; Ikeda, N; Kamba, Y; Mikawa, Y				Ishibe, Tatsuya; Senzoku, Fukuji; Ikeda, Noboru; Kamba, Yusuke; Mikawa, Yoshihiro			Detection of the Communicating Hole(s) of Spinal Extradural Arachnoid Cysts Using Time-Spatial Labeling Inversion Pulse Magnetic Resonance Imaging	SPINE			English	Article						spinal extradural arachnoid cyst; spinal extradural meningeal cyst; adult; thoracic spinal cord; thoracolumbar spine; communicating hole; ostium; communicating site; time-spatial labeling inversion pulse magnetic resonance imaging; T-SLIP; time-SLIP; MRI; myelography; myelocomputed tomography	CEREBROSPINAL-FLUID; CLINICAL ARTICLE; MENINGEAL CYSTS	Study Design. Report of 2 cases. Objective. To report the usefulness of time-spatial labeling inversion pulse magnetic resonance imaging (T-SLIP MRI) for detection of the communicating hole(s) of spinal extradural arachnoid cysts (SEACs). Summary of Background Data. SEACs normally communicate with the subarachnoid space via small communicating hole(s) in the dura. It is necessary to identify the accurate locations of these communicating hole(s) before attempting to close them through limited laminotomy/laminectomy. Myelocomputed tomography or conventional MRI may fail to detect the locations of the hole(s) because they comprise small dural defects. Methods. Case 1: A 33-year-old female presented with an SEAC at the T11-L2 vertebral level. Case 2: An 82-year-old female presented with an SEAC at T12-L4 vertebral level. Results. Case 1: T-SLIP MR image of the left parasagittal plane (not the midsagittal or right parasagittal plane) revealed cerebrospinal fluid flow from the subarachnoid space into the cyst at L1. After limited laminotomy at T12-L1 and partial cyst resection, we identified 2 contiguous dural holes immediately medial to the left L1 pedicle; this corroborated the preoperative T-SLIP MRI findings. The holes were sutured. Postoperative conventional MR image confirmed significant cyst shrinkage. Case 2: T-SLIP MR image revealed a curved line at the L1 pedicle in the right parasagittal plane. After L1 laminectomy and partial cyst resection, a dural hole was identified immediately medial to the right L1 pedicle, which was in agreement with the preoperative T-SLIP MRI findings. After surgery, the lower extremity pain disappeared. Postoperative conventional MR image revealed significant cyst shrinkage. Conclusion. T-SLIP MRI is useful for detection of the communicating hole(s) of SEACs.	[Ishibe, Tatsuya; Senzoku, Fukuji; Ikeda, Noboru; Kamba, Yusuke; Mikawa, Yoshihiro] Japan Community Hlth Care Org, Tamatsukuri Hosp, Ctr Spine Surg, Matsue, Shimane 6990293, Japan	Ishibe, T (reprint author), Japan Community Hlth Care Org, Tamatsukuri Hosp, Ctr Spine Surg, 1-2 Yumachi,Tamayu Cho, Matsue, Shimane 6990293, Japan.	tishibe@tamahosp.jp					NABORS MW, 1988, J NEUROSURG, V68, P366, DOI 10.3171/jns.1988.68.3.0366; Yabuki S, 2007, SPINE, V32, pE585; Yamada S, 2008, RADIOLOGY, V249, P644, DOI 10.1148/radiol.2492071985; Watanabe K, 2011, J NEUROSURG-SPINE, V14, P51, DOI 10.3171/2010.9.SPINE09933; Shimada K, 2009, AM J ROENTGENOL, V193, P106, DOI 10.2214/AJR.08.1626; Bond AE, 2012, J NEUROSURG-PEDIATR, V9, P432, DOI 10.3171/2012.1.PEDS11391; Bunck AC, 2011, EUR RADIOL, V21, P1788, DOI 10.1007/s00330-011-2105-7; Wheaton AJ, 2012, J MAGN RESON IMAGING, V36, P286, DOI 10.1002/jmri.23641; Funao H, 2012, NEUROSURGERY, V71, P278, DOI 10.1227/NEU.0b013e318257bf74; Furtado SV, 2011, J NEUROSURG-SPINE, V15, P107, DOI 10.3171/2011.3.SPINE10672; Ido K, 2002, J CLIN NEUROSCI, V9, P694, DOI 10.1054/jocn.2002.1138; Ishibe T, 2014, J SPINE RES, V5, P106; Ito K, 2002, AM J ROENTGENOL, V178, P343; Lee CH, 2012, ACTA NEUROCHIR, V154, P1219, DOI 10.1007/s00701-012-1356-7; Neo M, 2004, SPINE, V29, pE426, DOI 10.1097/01.brs.0000141189.41705.70; Samura K, 2007, J NEUROSURG, V107, P297, DOI 10.3171/PED-07/10/297	16	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0362-2436	1528-1159		SPINE	SPINE	NOV 1	2014	39	23					E1394	E1397		10.1097/BRS.0000000000000591		4	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	AT0DB	WOS:000344606100008		
J	Sekiguchi, M; Wakita, T; Otani, K; Onishi, Y; Fukuhara, S; Kikuchi, S; Konno, S				Sekiguchi, Miho; Wakita, Takafumi; Otani, Koji; Onishi, Yoshihiro; Fukuhara, Shunichi; Kikuchi, Shin-ichi; Konno, Shin-ichi			Lumbar Spinal Stenosis-Specific Symptom Scale Validity and Responsiveness	SPINE			English	Article						lumbar spinal stenosis; symptom scale; self-administered questionnaire; criterion validity; responsiveness; conservative therapies; ROC analysis; Guyatt responsiveness index; lumbar extension test; walking stress test	LOW-BACK-PAIN; OSWESTRY DISABILITY INDEX; HEALTH SURVEY SF-36; PERFORMANCE; QUALITY; HISTORY; TIME	Study Design. Cross-sectional study. Objectives. To test the validity and responsiveness of the lumbar spinal stenosis (LSS)-specific symptom scale (FLS-25 [Fukushima LSS Scale 25]). Summary of Background Data. The FLS-25, a self-administered questionnaire designed to comprehensively cover various symptoms of LSS, has been developed to address the need to measure symptoms specific to this disorder. Methods. One hundred sixty-seven patients with confirmed LSS who required conservative therapy were asked to complete a questionnaire including questions regarding walking capacity and the FLS-25. These patients also underwent a lumbar extension test and a walking stress test, which are stress tests designed to objectively evaluate LSS symptoms, to measure standing time, walking distance, and walking time. Relationship between the FLS-25 scores and these external standards was analyzed to evaluate the criterion validity of the FLS-25. The patients underwent the same evaluations after 8 weeks of conservative therapy. The relationship between changes from baseline to week 8 in FLS-25 scores and changes in the 3 external standards was analyzed to evaluate the responsiveness of the FLS-25. Results. The distribution of FLS-25 scores among patients was symmetric, and there were no ceiling or floor effects. FLS-25 scores increased as self-reported walking capacity decreased (P = 0.006). The mean standing time in the lumbar extension test was 165 (SD = 109) seconds, and FLS-25 scores increased as standing time decreased (P = 0.003). In the walking stress test, mean walking distance and mean walking time were 213 (SD = 154) m and 236 (SD = 114) seconds. FLS-25 scores increased as walking distance (P = 0.002) and walking time (P = 0.054) decreased. Changes from baseline to week 8 in FLS-25 scores correlated with changes in the stress test standing time (P = 0.014), walking distance (P < 0.001), and walking time (P < 0.001). Conclusion. The criterion validity and responsiveness of the FLS-25 were confirmed. The use of FLS-25 in clinical and investigational settings is warranted to monitor patients and evaluate therapeutic efficacy.	[Sekiguchi, Miho; Otani, Koji; Kikuchi, Shin-ichi; Konno, Shin-ichi] Fukushima Med Univ, Sch Med, Dept Orthoped Surg, Fukushima 9601295, Japan; [Wakita, Takafumi] Kansai Univ, Dept Sociol, Osaka, Japan; [Wakita, Takafumi; Onishi, Yoshihiro] iHope Int, Inst Hlth Outcomes & Proc Evaluat Res, Kyoto, Japan; [Fukuhara, Shunichi] Kyoto Univ, Dept Healthcare Epidemiol, Kyoto, Japan; [Fukuhara, Shunichi] Fukushima Med Univ, Ctr Innovat Res Communities & Clin Excellence, Fukushima 9601295, Japan	Sekiguchi, M (reprint author), Fukushima Med Univ, Sch Med, Dept Orthoped Surg, Fukushima 9601295, Japan.	miho-s@fmu.ac.jp					GUYATT G, 1987, J CHRON DIS, V40, P171, DOI 10.1016/0021-9681(87)90069-5; KATZ JN, 1995, ARTHRITIS RHEUM, V38, P1236, DOI 10.1002/art.1780380910; Stucki G, 1996, SPINE, V21, P796, DOI 10.1097/00007632-199604010-00004; Geisser ME, 2007, CLIN J PAIN, V23, P780; Jansson KA, 2009, J BONE JOINT SURG BR, V91B, P210, DOI 10.1302/0301-620X.91B2.21119; Resnick DK, 2005, J NEUROSURG-SPINE, V2, P639, DOI 10.3171/spi.2005.2.6.0639; Sirvanci M, 2008, EUR SPINE J, V17, P679, DOI 10.1007/s00586-008-0646-5; Ostelo RWJG, 2008, SPINE, V33, P90, DOI 10.1097/BRS.0b013e31815e3a10; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Roland M, 2000, SPINE, V25, P3115, DOI 10.1097/00007632-200012150-00006; DEYO RA, 1986, J CHRON DIS, V39, P897, DOI 10.1016/0021-9681(86)90038-X; Beattie PF, 2000, SPINE, V25, P819, DOI 10.1097/00007632-200004010-00010; Fairbank J C, 1980, Physiotherapy, V66, P271; KIKUCHI S, 1988, SPINE, V13, P1327, DOI 10.1097/00007632-198811000-00020; Konno S, 2007, BMC MUSCLOSKELET DIS, V102, P1; MCHORNEY CA, 1994, MED CARE, V32, P40, DOI 10.1097/00005650-199401000-00004; Otani K, 2013, SCI WORLD J, DOI 10.1155/2013/590652; ROLAND M, 1983, SPINE, V8, P141, DOI 10.1097/00007632-198303000-00004; Sato K, 1997, SPINE, V22, P898; Sekiguchi M, 2012, SPINE, V37, P232, DOI 10.1097/BRS.0b013e318216afb4; STRATFORD PW, 1994, PHYS THER, V74, P528; STUCKI G, 1995, J CLIN EPIDEMIOL, V48, P1369, DOI 10.1016/0895-4356(95)00054-2; Takahashi N, 2011, RINSYOSEIKEI, V46, P333; Takayama B, 2010, RINSYOSEIKEI, V45, P587; The EuroQol Group, 1990, HLTH POLICY, V16, P199, DOI DOI 10.1016/0168-8510(90)90421-9; Walsh TL, 2003, SPINE, V28, P607, DOI 10.1097/00007632-200303150-00017; Zeigang F, 2008, BMC MUSCULOSKEL DIS, V9, P89	27	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0362-2436	1528-1159		SPINE	SPINE	NOV 1	2014	39	23					E1388	E1393		10.1097/BRS.0000000000000583		6	Clinical Neurology; Orthopedics	Neurosciences & Neurology; Orthopedics	AT0DB	WOS:000344606100007		
J	Jia, LJ; Ge, HB; Suzuki, T				Jia, Liang-Jiu; Ge, Hanbin; Suzuki, Toshimitsu			Effect of post weld treatment on cracking behaviors of beam-column connections in steel bridge piers	STEEL AND COMPOSITE STRUCTURES			English	Article						ductile fracture; post weld treatment; burr grinding; R-finish; beam-column connection; steel bridge pier	DUCTILE CRACK; MOMENT CONNECTIONS; BRITTLE-FRACTURE; CYCLE FATIGUE; PERFORMANCE; EARTHQUAKE; INITIATION; JOINTS; DAMAGE; CLASSIFICATION	A great number of moment-resisting steel structures collapsed due to ductile crack initiation at welded beam-column connections, followed by explosive brittle fracture in the Kobe (Hyogoken-Nanbu) earthquake in 1995. A series of experimental and numerical studies on cracking behaviors of beam-column connections in steel bridge piers were carried out by the authors' team. This paper aims to study the effect of post weld treatment on cracking behaviors of the connections during a strong earthquake event. Experiments of three specimens with different weld finishes, i.e., as-welded, R-finish, and burr grinding, were conducted. The experimental results indicate that the instants of ductile crack initiation are greatly delayed for the specimens with R-finish and burr grinding finishes compared with the as-welded one. The strain concentration effect in the connection is also greatly reduced in the specimens with post weld treatment compared with the as-welded one, which was also verified in the tests.	[Jia, Liang-Jiu] Meijo Univ, Adv Res Ctr Nat Disaster Risk Reduct, Tenpaku Ku, Nagoya, Aichi 4688502, Japan; [Ge, Hanbin] Meijo Univ, Dept Civil Engn, Tenpaku Ku, Nagoya, Aichi 4688502, Japan; [Suzuki, Toshimitsu] Mitubishi Heavy Ind Ltd, Hiroshima Machinery Works, Naka Ku, Hiroshima 7308642, Japan	Ge, HB (reprint author), Meijo Univ, Dept Civil Engn, Tenpaku Ku, 1-501 Shiogamaguchi, Nagoya, Aichi 4688502, Japan.	LJ_JIA@hotmail.com; gehanbin@meijo-u.ac.jp; toshimitsu_suzuki@mbe.mhi.co.jp			JSPS [24560588]; Natural Disaster Risk Reduction, Meijo University; Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan	The study is supported in part by grants from the JSPS Grants-in-Aid for Scientific Research (C) (No. 24560588), and the Advanced Research Center for Natural Disaster Risk Reduction, Meijo University, which is supported by Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan.	American Welding Society D1.1, 1996, STRUCT WELD COD STEE; Ricles JM, 2002, J STRUCT ENG-ASCE, V128, P429, DOI 10.1061/(ASCE)0733-9445(2002)128:4(429); Iwashita T, 2012, J STRUCT ENG, V138, P744, DOI 10.1061/(ASCE)ST.1943-541X.0000507; Pedersen MM, 2010, WELD WORLD, V54, pR208; Mahin SA, 1998, ENG STRUCT, V20, P261, DOI 10.1016/S0141-0296(97)00032-1; Kuwamura H, 1997, J STRUCT ENG-ASCE, V123, P729, DOI 10.1061/(ASCE)0733-9445(1997)123:6(729); Nakashima M, 1998, ENG STRUCT, V20, P271, DOI 10.1016/S0141-0296(97)00019-9; Mao CS, 2001, J STRUCT ENG-ASCE, V127, P1036, DOI 10.1061/(ASCE)0733-9445(2001)127:9(1036); Kuwamura H, 1997, J STRUCT ENG-ASCE, V123, P864, DOI 10.1061/(ASCE)0733-9445(1997)123:7(864); Architectural Institute of Japan (AIJ), 1995, FRACT STEEL STRUCT D; Bruneau M, 1996, CAN J CIVIL ENG, V23, P678; Building Center of Japan, 2003, GUID PREV BRITTL FRA; EI-Tawil S., 2000, J STRUCT ENG-ASCE, V126, P79; FEMA (Federal Emergency Management Agency), 2000, FEMA350; Ge HB, 2013, J BRIDGE ENG, V18, P858, DOI 10.1061/(ASCE)BE.1943-5592.0000429; Ge HB, 2012, J EARTHQ ENG, V16, P623, DOI 10.1080/13632469.2012.676231; Ge H.B., 2011, J EARTHQ TSUNAMI, V5, P1; Haagensen P.J., 2001, 13181500 IIW; Jia L.J., 2013, J STRUCT ENG-ASCE, V140, DOI 10.1061/(ASCE)ST.1943-541X.0000944; Jia L.J., 2013, J STRUCT ENG-ASCE, V140, DOI 10.1061/(ASCE)ST.1943-541X.0000848; Kang L, 2013, J EARTHQ ENG, V17, P323, DOI 10.1080/13632469.2012.746211; Kirkhope KJ, 1999, MAR STRUCT, V12, P447, DOI 10.1016/S0951-8339(99)00013-1; Kuwamura H, 2003, J STRUCT ENG-ASCE, V129, P1475, DOI 10.1061/(ASCE)0733-9445(2003)129:11(1475); Kuwamura H, 2003, ENG STRUCT, V25, P547, DOI 10.1016/S0141-0296(02)00166-9; Kuwamura Laboratory, 1995, FIELD SURV REP STRUC; Luo XQ, 2012, STEEL COMPOS STRUCT, V13, P383; Mashiri FR, 2001, THIN WALL STRUCT, V39, P261, DOI 10.1016/S0263-8231(00)00061-6; Metropolitan Expressway Company Limited, 2008, REC DES CONSTR BRIDG; Miki Chitoshi, 2005, International Journal of STEEL STRUCTURES, V5, P133; Nagoya Expressway Public Corporation, 2004, STAND ATL STEEL STRU; O'Sullivan D., 1998, J PERFORM CONSTR FAC, V12, P213, DOI 10.1061/(ASCE)0887-3828(1998)12:4(213); Qian XD, 2013, J CONSTR STEEL RES, V90, P49, DOI 10.1016/j.jcsr.2013.07.016; Qian XD, 2005, J STRUCT ENG-ASCE, V131, P768, DOI 10.1061/(ASCE)0733-9445(2005)131:5(768); Roeder Charles W., 2005, International Journal of STEEL STRUCTURES, V5, P141; Schafer BW, 2000, J STRUCT ENG-ASCE, V126, P1131, DOI 10.1061/(ASCE)0733-9445(2000)126:10(1131); Stojadinovic B, 2000, J STRUCT ENG-ASCE, V126, P40; Usami T, 2009, J EARTHQ TSUNAMI, V3, P175, DOI 10.1142/S179343110900055X	37	0	0	TECHNO-PRESS	DAEJEON	PO BOX 33, YUSEONG, DAEJEON 305-600, SOUTH KOREA	1229-9367	1598-6233		STEEL COMPOS STRUCT	Steel Compos. Struct.	NOV	2014	17	5					685	702				18	Construction & Building Technology; Engineering, Civil; Materials Science, Composites	Construction & Building Technology; Engineering; Materials Science	AT5IB	WOS:000344976000007		
J	Taniguchi, T; Hirose, D; Hashimoto, T				Taniguchi, Tsuyoshi; Hirose, Daisuke; Hashimoto, Takuma			A New Method for the Synthesis of 1,4-Diols: C(sp(3))-H Hydroxylation Induced by Iron-Catalyzed Redox Hydration of Alkenes	SYNLETT			English	Article						alkenes; hydroxylation; iron; oxygen; radicals	C-H BONDS; OXIDATION-REDUCTION HYDRATION; MOLECULAR-OXYGEN; PHOTOCHEMICAL REACTION; UNACTIVATED ALKENES; FUNCTIONALIZATION; OLEFINS; COMPLEXES; ALCOHOLS; CONVERSION	A novel method for the synthesis of 1,4-diols from alkenes is presented. The reaction is the basis of iron-catalyzed redox hydration of alkenes. The second hydroxyl group is introduced by hydroxylation of an inert C-H bond. The mechanism includes a radical 1,5-hydrogen-transfer process of an intermediary alkoxy radical. In this paper, we describe how this new method has been discovered and developed.	[Taniguchi, Tsuyoshi; Hashimoto, Takuma] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Sch Pharmaceut Sci, Kanazawa, Ishikawa 9201192, Japan; [Hirose, Daisuke] Kanazawa Univ, Grad Sch Nat Sci & Technol, Kanazawa, Ishikawa 9201192, Japan	Taniguchi, T (reprint author), Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Sch Pharmaceut Sci, Kakuma Machi, Kanazawa, Ishikawa 9201192, Japan.	tsuyoshi@p.kanazawa-u.ac.jp	Taniguchi, Tsuyoshi/D-8414-2015		MEXT/JSPS KAKENHI [23790008, 25460011]	We are grateful to MEXT/JSPS KAKENHI Grant No. 23790008 and 25460011.	Nam W, 2002, INORG CHEM, V41, P3647, DOI 10.1021/ic011145p; Waser J, 2006, J AM CHEM SOC, V128, P11693, DOI 10.1021/ja062355+; Piera J, 2008, ANGEW CHEM INT EDIT, V47, P3506, DOI 10.1002/anie.200700604; Doyle MP, 2010, CHEM REV, V110, P704, DOI 10.1021/cr900239n; Chiba S, 2014, ORG BIOMOL CHEM, V12, P4051, DOI 10.1039/c4ob00469h; Campbell AN, 2012, ACCOUNTS CHEM RES, V45, P851, DOI 10.1021/ar2002045; Prateeptongkum S, 2009, CHEM COMMUN, P1990, DOI 10.1039/b900326f; Barker TJ, 2012, J AM CHEM SOC, V134, P13588, DOI 10.1021/ja3063716; Recupero F, 2007, CHEM REV, V107, P3800, DOI 10.1021/cr040170k; Gormisky PE, 2013, J AM CHEM SOC, V135, P14052, DOI 10.1021/ja407388y; KATO K, 1990, B CHEM SOC JPN, V63, P179, DOI 10.1246/bcsj.63.179; White MC, 2012, SCIENCE, V335, P807, DOI 10.1126/science.1207661; Ghavtadze N, 2014, NAT CHEM, V6, P122, DOI [10.1038/nchem.1841, 10.1038/NCHEM.1841]; Ackermann L, 2011, CHEM REV, V111, P1315, DOI 10.1021/cr100412j; Lyons TW, 2010, CHEM REV, V110, P1147, DOI 10.1021/cr900184e; Gomez L, 2013, J ORG CHEM, V78, P1421, DOI 10.1021/jo302196q; Dong GB, 2011, SCIENCE, V333, P1609, DOI 10.1126/science.1208685; Moteki SA, 2013, ANGEW CHEM INT EDIT, V52, P8657, DOI 10.1002/anie.201304359; Zhu YF, 2014, CHEM SCI, V5, P2379, DOI 10.1039/c4sc00093e; Newhouse T, 2011, ANGEW CHEM INT EDIT, V50, P3362, DOI 10.1002/anie.201006368; Punniyamurthy T, 2005, CHEM REV, V105, P2329, DOI 10.1021/cr050523v; Hashimoto T, 2014, ANGEW CHEM INT EDIT, V53, P2730, DOI 10.1002/anie.201308675; Chen K, 2008, J AM CHEM SOC, V130, P7247, DOI 10.1021/ja802491q; Adams AM, 2014, CHEM SCI, V5, P656, DOI 10.1039/c3sc52649f; Godula K, 2006, SCIENCE, V312, P67, DOI 10.1126/science.1114731; BARTON DHR, 1960, J AM CHEM SOC, V82, P2640, DOI 10.1021/ja01495a061; Lo JC, 2014, J AM CHEM SOC, V136, P1304, DOI 10.1021/ja4117632; Cekovic Z, 2003, TETRAHEDRON, V59, P8073, DOI 10.1016/S0040-4020(03)01202-X; Leggans EK, 2012, ORG LETT, V14, P1428, DOI 10.1021/ol300173v; Robinson A, 2012, ORG BIOMOL CHEM, V10, P1795, DOI 10.1039/c2ob06975j; Simmons EM, 2012, NATURE, V483, P70, DOI 10.1038/nature10785; OKAMOTO T, 1984, J ORG CHEM, V49, P1589, DOI 10.1021/jo00183a020; Chen X, 2009, ANGEW CHEM INT EDIT, V48, P5094, DOI 10.1002/anie.200806273; Hu XR, 2014, J AM CHEM SOC, V136, P5287, DOI 10.1021/ja502208z; Taniguchi T, 2010, ORG LETT, V12, P112, DOI 10.1021/ol902562j; Yamaguchi J, 2012, ANGEW CHEM INT EDIT, V51, P8960, DOI 10.1002/anie.201201666; Gaspar B, 2007, ANGEW CHEM INT EDIT, V46, P4519, DOI 10.1002/anie.200700575; Baran P. S., 2010, SYNLETT, P1733; BARTON DH, 1961, J AM CHEM SOC, V83, P4076, DOI 10.1021/ja01480a030; de la Pradilla RF, 2011, ORG LETT, V13, P2468, DOI 10.1021/ol200718y; Fenghua Z. L., 2014, ORG LETT, V16, P3396; Hamilton D. S., 2013, J AM CHEM SOC, V134, P18577; Katritzky A. R., 2005, COMPREHENSIVE ORGANI, V2; Li L, 2012, J AM CHEM SOC, V134, P17376, DOI 10.1021/ja307145e; Molinari R, 2010, ASIA-PAC J CHEM ENG, V5, P191, DOI 10.1002/apj.369; MUKAIYAMA T, 1989, CHEM LETT, P449, DOI 10.1246/cl.1989.449; Nam W, 2000, ANGEW CHEM INT EDIT, V39, P3646, DOI 10.1002/1521-3773(20001016)39:20<3646::AID-ANIE3646>3.0.CO;2-Q; Nam W, 2000, INORG CHEM, V39, P5572, DOI 10.1021/ic000502d; Smith M. B., 2001, MARCHS ADV ORGANIC C; Sugimori T, 1998, INORG CHIM ACTA, V283, P275, DOI 10.1016/S0020-1693(98)00090-5; Taniguchi T., 2010, ORG LETT, V12, P5084; Too PC, 2013, BEILSTEIN J ORG CHEM, V9, DOI 10.3762/bjoc.9.138; Tortosa M, 2011, ANGEW CHEM INT EDIT, V50, P3950, DOI 10.1002/anie.201100613; WOLFF ME, 1963, CHEM REV, V63, P55, DOI 10.1021/cr60221a004	54	0	0	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0936-5214	1437-2096		SYNLETT	Synlett	NOV	2014	25	18					2531	2535		10.1055/s-0034-1379214		5	Chemistry, Organic	Chemistry	AS8FJ	WOS:000344485100003		
J	Matsui, K; Ishigami, T; Yamaguchi, T; Yamaguchi, E; Tada, N; Miura, T; Itoh, A				Matsui, Keita; Ishigami, Takafumi; Yamaguchi, Tomoaki; Yamaguchi, Eiji; Tada, Norihiro; Miura, Tsuyoshi; Itoh, Akichika			Aerobic Photooxidative Synthesis of Phenols from Arylboronic Acids Using 2-Propanol as Solvent	SYNLETT			English	Article						aerobic; boronic acid; phenol; photooxidation; visible light	VISIBLE-LIGHT IRRADIATION; PALLADIUM-CATALYZED HYDROXYLATION; HIGHLY EFFICIENT CONVERSION; BASE-FREE CONDITIONS; ARYL HALIDES; OXIDATIVE HYDROXYLATION; MOLECULAR-OXYGEN; BORONIC ACIDS; PHOTOREDOX CATALYSIS; IPSO-HYDROXYLATION	We report a useful method for the synthesis of phenols from arylboronic acids with hydrogen peroxide generated in situ by aerobic photooxidation. This reaction uses visible-light irradiation and easily handled 2-chloroanthraquinone as an organocatalyst under mild conditions, that is, an air atmosphere and ambient pressure and temperature. Because of this method's metal- and base-free conditions, it represents an environmentally benign approach to the synthesis of phenols from arylboronic acids.	[Matsui, Keita; Ishigami, Takafumi; Yamaguchi, Tomoaki; Yamaguchi, Eiji; Tada, Norihiro; Itoh, Akichika] Gifu Pharmaceut Univ, Gifu 5011196, Japan; [Miura, Tsuyoshi] Tokyo Univ Pharm & Life Sci, Hachioji, Tokyo 1920392, Japan	Itoh, A (reprint author), Gifu Pharmaceut Univ, 1-25-4 Daigaku Nishi, Gifu 5011196, Japan.	itoha@gifu-pu.ac.jp			Japan Society for the Promotion of Science (JSPS) [24790015]	This work was supported by Grant-in-Aid for Young Scientists (B)(No. 24790015) from the Japan Society for the Promotion of Science (JSPS).	Xu JM, 2010, ORG LETT, V12, P1964, DOI 10.1021/ol1003884; Gogoi A, 2013, TETRAHEDRON LETT, V54, P1821, DOI 10.1016/j.tetlet.2013.01.079; Molander GA, 2011, J ORG CHEM, V76, P623, DOI 10.1021/jo102208d; Sergeev AG, 2009, ANGEW CHEM INT EDIT, V48, P7595, DOI 10.1002/anie.200902148; Yang HJ, 2011, CHEM-EUR J, V17, P5652, DOI 10.1002/chem.201003711; Sawant SD, 2014, TETRAHEDRON LETT, V55, P811, DOI 10.1016/j.tetlet.2013.12.003; Tlili A, 2009, ANGEW CHEM INT EDIT, V48, P8725, DOI 10.1002/anie.200903639; Nobuta T, 2012, TETRAHEDRON LETT, V53, P5306, DOI 10.1016/j.tetlet.2012.07.091; Zou YQ, 2012, ANGEW CHEM INT EDIT, V51, P784, DOI 10.1002/anie.201107028; Chen DS, 2013, SYNLETT, V24, P499, DOI 10.1055/s-0032-1318197; Jiang H, 2012, CHEM COMMUN, V48, P7203, DOI 10.1039/c2cc32711b; Wang L, 2012, CHEM COMMUN, V48, P5476, DOI 10.1039/c2cc31115a; WEBB KS, 1995, TETRAHEDRON LETT, V36, P5117; Anderson KW, 2006, J AM CHEM SOC, V128, P10694, DOI 10.1021/ja0639719; Zhao DB, 2009, ANGEW CHEM INT EDIT, V48, P8729, DOI 10.1002/anie.200903923; Chen G, 2007, TETRAHEDRON LETT, V48, P473, DOI 10.1016/j.tetlet.2006.11.036; Willis MC, 2007, ANGEW CHEM INT EDIT, V46, P3402, DOI 10.1002/anie.200605071; Kariya A, 2014, RSC ADV, V4, P13191, DOI 10.1039/c3ra47863g; Hirashima S, 2010, ORG LETT, V12, P3645, DOI 10.1021/ol1014575; Zhu C, 2012, ORG LETT, V14, P3494, DOI 10.1021/ol301463c; Mulakayala N, 2012, TETRAHEDRON LETT, V53, P6004, DOI 10.1016/j.tetlet.2012.08.087; Cammidge AN, 2011, ORG LETT, V13, P6034, DOI 10.1021/ol202500z; Pitre SP, 2013, J AM CHEM SOC, V135, P13286, DOI 10.1021/ja406311g; Guo SM, 2013, SYNLETT, V24, P1712, DOI 10.1055/s-0033-1339303; Prakash GKS, 2009, ADV SYNTH CATAL, V351, P1567, DOI 10.1002/adsc.200900071; Inamoto K, 2011, CHEM COMMUN, V47, P11775, DOI 10.1039/c1cc14974a; Tada N, 2012, GREEN CHEM, V14, P3007, DOI 10.1039/c2gc36238d; Gallon BJ, 2007, ANGEW CHEM INT EDIT, V46, P7251, DOI 10.1002/anie.200701389; Simon J, 2001, J ORG CHEM, V66, P633, DOI 10.1021/jo0015873; Schulz T, 2009, ANGEW CHEM INT EDIT, V48, P918, DOI 10.1002/anie.200804898; Maleczka RE, 2003, J AM CHEM SOC, V125, P7792, DOI 10.1021/ja0349857; Nobuta T, 2013, RSC ADV, V3, P10189, DOI 10.1039/c3ra41850b; Gohain M, 2014, TETRAHEDRON LETT, V55, P2082, DOI 10.1016/j.tetlet.2014.02.048; Kianmehr E, 2007, TETRAHEDRON LETT, V48, P2713, DOI 10.1016/j.tetlet.2007.02.069; Hosoi K, 2010, CHEM COMMUN, V46, P1284, DOI 10.1039/b914093j; Cui L, 2013, TETRAHEDRON LETT, V54, P162, DOI 10.1016/j.tetlet.2012.10.119; Chowdhury AD, 2011, EUR J INORG CHEM, P3232, DOI 10.1002/ejic.201100240; Cui L, 2011, GREEN CHEM, V13, P2347, DOI 10.1039/c1gc15437k; Gogoi A, 2012, SYNLETT, P1079, DOI 10.1055/s-0031-1290654; Hanson P, 2002, J CHEM SOC PERK T 2, P1135, DOI 10.1039/b200748g; Kaboudin B, 2011, EUR J ORG CHEM, P6656, DOI 10.1002/ejoc.201100994; Kanai N, 2010, ORG LETT, V12, P1948, DOI 10.1021/ol1003675; Larock R. C., 1999, COMPREHENSIVE ORGANI, P959; Matsusaki Y, 2012, SYNLETT, P2059, DOI 10.1055/s-0032-1316585; Mehmood A., 2012, CATAL COMMUN, V12, P64; Nobuta T, 2012, SYNLETT, P2975, DOI 10.1055/s-0032-1317508; Nobuta T, 2011, ORG LETT, V13, P2576, DOI 10.1021/ol200681k; Qu H.-L., 2013, J ORG CHEM, V78, P7482; Rappoport Z., 2003, CHEM PHENOLS; Shimada Y, 2013, SYNTHESIS-STUTTGART, V45, P2684, DOI 10.1055/s-0033-1338420; Tada N, 2011, TETRAHEDRON LETT, V52, P3821, DOI 10.1016/j.tetlet.2011.05.077; Tada N, 2011, GREEN CHEM, V13, P1669, DOI 10.1039/c1gc15154a; Thakur KG, 2011, CHEM COMMUN, V47, P6692, DOI 10.1039/c1cc10782h; Travis BR, 2002, EUR J ORG CHEM, P3429; Tyman J. H. P., 1996, SYNTHETIC NATURAL PH; Wang L, 2014, J FLUORINE CHEM, V158, P44, DOI 10.1016/j.jfluchem.2013.12.006; Yang DS, 2014, TETRAHEDRON, V70, P3630, DOI 10.1016/j.tet.2014.03.076; Zheng J, 2012, CHEM COMMUN, V48, P6235, DOI 10.1039/c2cc31948a	58	1	1	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0936-5214	1437-2096		SYNLETT	Synlett	NOV	2014	25	18					2613	2616		10.1055/s-0034-1379099		4	Chemistry, Organic	Chemistry	AS8FJ	WOS:000344485100014		
J	Tandiary, MA; Masui, Y; Onaka, M				Tandiary, Michael Andreas; Masui, Yoichi; Onaka, Makoto			Chlorination of Benzylic and Allylic Alcohols with Trimethylsilyl Chloride Enhanced by Natural Sodium Montmorillonite	SYNLETT			English	Article						hydrous sodium montmorillonite; chlorination; benzylic alcohols; allylic alcohols; trimethylsilyl chloride	ION-EXCHANGED MONTMORILLONITE; ALPHA-ARYL ALCOHOLS; CONVENIENT; ESTERS	A new and practical method for the efficient chlorination of tertiary, secondary, and primary benzylic and allylic alcohols is described. The method is characterized by the formation of hydrogen chloride from trimethylsilyl chloride and trace water, the formation of a carbenium ion through the protonation of an alcohol and subsequent dehydration, and the chlorination of the carbenium ion. During the process, sodium ion-exchanged montmorillonite plays a crucial role in capturing the generated hydrogen chloride, stabilizing the carbenium intermediate as well as promoting the chlorination.	[Tandiary, Michael Andreas] Univ Tokyo, Grad Sch Sci, Dept Chem, Bunkyo Ku, Tokyo 1130033, Japan; [Masui, Yoichi; Onaka, Makoto] Univ Tokyo, Grad Sch Arts & Sci, Meguro Ku, Tokyo 1538902, Japan	Onaka, M (reprint author), Univ Tokyo, Grad Sch Arts & Sci, Meguro Ku, Komaba 3-8-1, Tokyo 1538902, Japan.	conaka@mail.ecc.u-tokyo.ac.jp					Tandiary MA, 2014, TETRAHEDRON LETT, V55, P4160, DOI 10.1016/j.tetlet.2014.05.042; Arnaiz FJ, 1995, J CHEM EDUC, V72, P1139; Denegri B, 2006, CHEM-EUR J, V12, P1648, DOI 10.1002/chem.200500845; Larock R. C., 1999, COMPREHENSIVE ORGANI, P689; Le Roux C., 1994, SYNLETT, P723; LEE JG, 1988, J ORG CHEM, V53, P3634, DOI 10.1021/jo00250a048; LEROUX C, 1994, J ORG CHEM, V59, P2238, DOI 10.1021/jo00087a048; Maurya M. R., 1990, J CHEM EDUC, V67, P974; Pizey J. S., 1974, SYNTHETIC REAGENTS, V1, P321; Rule HG, 1930, J CHEM SOC, P1894, DOI 10.1039/jr9300001894; Salomaa P., 1971, CHEM HYDROXYL GROU 1, P595; Synder D. C., 1995, J ORG CHEM, V60, P2638; Wang JC, 2010, SYNLETT, P2493, DOI 10.1055/s-0030-1258567; Wang JC, 2010, TETRAHEDRON LETT, V51, P3300, DOI 10.1016/j.tetlet.2010.04.074; Wang JC, 2011, ACS CATAL, V1, P446, DOI 10.1021/cs1000812	15	1	1	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0936-5214	1437-2096		SYNLETT	Synlett	NOV	2014	25	18					2639	2643		10.1055/s-0034-1379226		5	Chemistry, Organic	Chemistry	AS8FJ	WOS:000344485100019		
J	Ghosh, S; Chandar, NB; Sarkar, D; Ghosh, MK; Ganguly, B; Chakraborty, I				Ghosh, Subrata; Chandar, Nellore Bhanu; Sarkar, Debayan; Ghosh, Manoj Kumar; Ganguly, Bishwajit; Chakraborty, Indrajit			Unprecedented C-Methylation at the 2-Position of 2-Carboxy-4-Chromanones - A Case Study with the Corey-Chaykovsky Reagent	SYNLETT			English	Article						4-chromanone-2-carboxylate; C-methylation; regioselectivity; dimethylsulfoxonium methylide; theoretical calculations	POLARIZABLE CONTINUUM MODEL; DIMETHYLOXOSULFONIUM METHYLIDE; ORGANIC-SYNTHESIS; CHROMANONES; ACIDS; ANTAGONISTS; FLAVONOIDS; ALDEHYDES; CYCLOPROPANATION; 4-CHROMANONES	An unprecedented C-methylation at the 2-position of 4-chromanone-2-carboxylates was achieved in good yield on treatment with dimethylsulfoxonium methylide. The reaction was performed with excellent chemo- as well as regioselectivity. It is the first synthetic report of alkylation at the 2-position of the chromanone framework through a very mild and simple approach. Such an uncommon behavioral pattern of the Corey-Chaykovsky reagent is justified by theoretical potential energy surface calculations.	[Ghosh, Subrata] Natl Inst Mat Sci, Adv Key Technol Div, Nano Characterizat Unit, Tsukuba, Ibaraki 3050047, Japan; [Chandar, Nellore Bhanu; Ganguly, Bishwajit] Cent Salt & Marine Chem Res Inst, Analyt Discipline & Centralized Instrument Facil, Computat & Simulat Unit, Bhavnagar 3624002, Gujarat, India; [Sarkar, Debayan; Ghosh, Manoj Kumar] Natl Inst Technol, Dept Chem, Rourkela 769008, Odissa, India; [Chakraborty, Indrajit] KIIT Univ, Dept Chem, Bhubaneswar 751024, Odissa, India; [Chandar, Nellore Bhanu; Ganguly, Bishwajit] CSIR CSMCRI, Acad Sci & Innovat Res, Bhavnagar 364002, Gujarat, India	Ganguly, B (reprint author), Cent Salt & Marine Chem Res Inst, Analyt Discipline & Centralized Instrument Facil, Computat & Simulat Unit, GB Marg, Bhavnagar 3624002, Gujarat, India.	ganguly@csmcri.org; indraji2001@gmail.com			CSIR, New Delhi	I.C. is grateful to KIIT University, Bhubaneswar and BG is grateful to the Central Salt and Marine Chemicals Research Institute (CSIR), Gujarat, for providing research facilities during this program. S. G. thanks Dr. A. Bandyopadhyay (NIMS) & MEXT for full support of laboratory facilities. We are also grateful to Dr. T. K. Paine and Dr. S. Ghosh of IACS, Kolkata for providing us with specific laboratory facilities. N. B. C. is grateful to the CSIR, New Delhi, for the award of a Fellowship and also thankful to AcSIR for enrolment into a PhD program. We thank the anonymous reviewers for their valuable comments/suggestions that have helped us to improve this manuscript.	Aggarwal VK, 2006, CHEM-EUR J, V12, P568, DOI 10.1002/chem.200500693; Aggarwal VK, 2002, J AM CHEM SOC, V124, P5747, DOI 10.1021/ja025633n; YE T, 1994, CHEM REV, V94, P1091, DOI 10.1021/cr00028a010; GONZALEZ C, 1991, J CHEM PHYS, V95, P5853, DOI 10.1063/1.461606; Timar T, 2000, J HETEROCYCLIC CHEM, V37, P1389; Li AH, 1997, CHEM REV, V97, P2341, DOI 10.1021/cr960411r; COREY EJ, 1965, J AM CHEM SOC, V87, P1353, DOI 10.1021/ja01084a034; Patonay T, 2001, TETRAHEDRON LETT, V42, P1403, DOI 10.1016/S0040-4039(00)02264-4; Harborne JB, 2001, NAT PROD REP, V18, P310, DOI 10.1039/b006257j; Cui HF, 2009, J ORG CHEM, V74, P1400, DOI 10.1021/jo8023818; Mahapatra T, 2008, TETRAHEDRON-ASYMMETR, V19, P1224, DOI 10.1016/j.tetasy.2008.04.024; Barone V, 1998, J COMPUT CHEM, V19, P404, DOI 10.1002/(SICI)1096-987X(199803)19:4<404::AID-JCC3>3.0.CO;2-W; Mennucci B, 1997, J CHEM PHYS, V106, P5151, DOI 10.1063/1.473558; Cances E, 1997, J CHEM PHYS, V107, P3032, DOI 10.1063/1.474659; Biddle MM, 2007, J AM CHEM SOC, V129, P3830, DOI 10.1021/ja070394v; FRANZEN V, 1961, CHEM BER-RECL, V94, P2942, DOI 10.1002/cber.19610941117; GOLOLOBOV YG, 1987, TETRAHEDRON, V43, P2609, DOI 10.1016/S0040-4020(01)86869-1; Tomasi J, 1999, J MOL STRUC-THEOCHEM, V464, P211, DOI 10.1016/S0166-1280(98)00553-3; Barone V, 1997, J CHEM PHYS, V107, P3210, DOI 10.1063/1.474671; Koyama H, 2004, J MED CHEM, V47, P3255, DOI 10.1021/jm030621d; IWASAKI H, 1987, TETRAHEDRON LETT, V28, P6355, DOI 10.1016/S0040-4039(01)91372-3; Annoura H, 1996, BIOORG MED CHEM LETT, V6, P763, DOI 10.1016/0960-894X(96)00104-7; Aggarwal VK, 2005, ANGEW CHEM INT EDIT, V44, P5468, DOI 10.1002/anie.200501526; WITTIG G, 1953, LIEBIGS ANN CHEM, V580, P44; Bernardy F., 1985, ORGANIC SULFUR CHEM; Bianco A, 2003, TETRAHEDRON LETT, V44, P9107, DOI 10.1016/j.tetlet.2003.10.060; Bianco A, 2004, EUR J ORG CHEM, P2894, DOI 10.1002/ejoc.200400032; Cao SG, 2004, J NAT PROD, V67, P454, DOI 10.1021/np0303815; Chang L. C., 2001, BIOACTIVE COMPOUNDS; CLARKE PD, 1986, TETRAHEDRON LETT, V27, P91, DOI 10.1016/S0040-4039(00)83949-0; COHEN N, 1989, J MED CHEM, V32, P1842, DOI 10.1021/jm00128a028; COUTTS SJ, 1994, TETRAHEDRON, V50, P11755, DOI 10.1016/S0040-4020(01)85668-4; COX B, 1989, SYNTHESIS-STUTTGART, P709; Dean F. A., 1963, NATURALLY OCCURRING; FRANZEN V, 1963, CHEM BER-RECL, V96, P1881, DOI 10.1002/cber.19630960722; Friden-Saxin M, 2009, J ORG CHEM, V74, P2755, DOI 10.1021/jo802783z; Frisch M J, 2010, GAUSSIAN 09 REVISION; GONZALEZ C, 1990, J PHYS CHEM-US, V94, P5523, DOI 10.1021/j100377a021; Harborne J. B, 1994, FLAVONOIDS; Johnson A. W., 1966, YLIDE CHEM; KABBE HJ, 1982, ANGEW CHEM INT EDIT, V21, P247, DOI 10.1002/anie.198202471; KELLY SE, 1991, J ORG CHEM, V56, P1325, DOI 10.1021/jo00003a081; Meng LG, 2010, TETRAHEDRON LETT, V51, P1748, DOI 10.1016/j.tetlet.2010.01.093; PAGNI RM, 1974, J CHEM SOC CHEM COMM, P224, DOI 10.1039/c39740000224; Park JY, 2008, EUR J ORG CHEM, P5461, DOI 10.1002/ejoc.200800782; Patil S. G., 2011, J CHEM PHARM RES, V3, P457; Sarges R, 1996, J MED CHEM, V39, P4783, DOI 10.1021/jm950364f; TRAYNELI.VJ, 1966, J ORG CHEM, V31, P243, DOI 10.1021/jo01339a055; Trost B. M., 1975, SULFUR YLIDES EMERGI, V31; VEDEJS E, 1984, ACCOUNTS CHEM RES, V17, P358, DOI 10.1021/ar00106a003; Wallen EAA, 2007, ORG LETT, V9, P389, DOI 10.1021/ol062478z; WITIAK DT, 1971, J MED CHEM, V14, P758, DOI 10.1021/jm00290a021; YAMAUCHI K, 1978, J ORG CHEM, V43, P1593, DOI 10.1021/jo00402a027	53	2	2	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0936-5214	1437-2096		SYNLETT	Synlett	NOV	2014	25	18					2649	2653		10.1055/s-0034-1379203		5	Chemistry, Organic	Chemistry	AS8FJ	WOS:000344485100021		
J	Takemoto, Y; Yoshida, H; Takaki, K				Takemoto, Yuki; Yoshida, Hiroto; Takaki, Ken			Facile Access to vic-Borylstannylalkanes via Copper-Catalyzed Three-Component Borylstannylation of Alkenes	SYNTHESIS-STUTTGART			English	Article						alkene; borylstannylation; borylstannylalkane; copper	INTRAMOLECULAR BIS-SILYLATION; REGIOSELECTIVE FORMAL HYDROBORATION; STEREOSELECTIVE-SYNTHESIS; ROOM-TEMPERATURE; COPPER(I)-CATALYZED REACTION; ALKYNES; DIBORON; ADDITIONS; BORYLATION; REACTIVITY	A copper complex has been found to catalyze the borylstannylation of alkenes through three-component coupling with a diboron and a tin alkoxide, affording vic-borylstannylalkanes of structural diversity in a regio- and stereoselective manner. The versatility of this borylstannylation has been also demonstrated by employing allenes, leading to the sole formation of borylstannylated products, which have alkenylborane and allylstannane units.	[Takemoto, Yuki; Yoshida, Hiroto; Takaki, Ken] Hiroshima Univ, Dept Appl Chem, Grad Sch Engn, Higashihiroshima 724, Japan; [Yoshida, Hiroto] ACT C, JST, Higashihiroshima 7398527, Japan	Takemoto, Y (reprint author), Hiroshima Univ, Dept Appl Chem, Grad Sch Engn, Higashihiroshima 724, Japan.	yhiroto@hiroshima-u.ac.jp	Yoshida, Hiroto/B-7954-2011	Yoshida, Hiroto/0000-0001-6890-4397			Kleeberg C, 2009, ANGEW CHEM INT EDIT, V48, P5350, DOI 10.1002/anie.200901879; Endo K, 2012, J ORG CHEM, V77, P7223, DOI 10.1021/jo3015165; Coombs JR, 2013, J AM CHEM SOC, V135, P11222, DOI 10.1021/ja4041016; Kliman LT, 2009, J AM CHEM SOC, V131, P13210, DOI 10.1021/ja9047762; Alfaro R, 2012, J AM CHEM SOC, V134, P15165, DOI 10.1021/ja307670k; Semba K, 2013, CHEM-EUR J, V19, P7125, DOI 10.1002/chem.201300443; Soderquist JA, 1998, TETRAHEDRON LETT, V39, P2511, DOI 10.1016/S0040-4039(98)00382-7; Matsuda N, 2013, J AM CHEM SOC, V135, P4934, DOI 10.1021/ja4007645; Yoshida H, 2012, ANGEW CHEM INT EDIT, V51, P235, DOI 10.1002/anie.201106706; Ito H, 2010, J AM CHEM SOC, V132, P5990, DOI 10.1021/ja101793a; Endo K, 2010, J AM CHEM SOC, V132, P11033, DOI 10.1021/ja105176v; Beletskaya I, 2006, CHEM REV, V106, P2320, DOI 10.1021/cr050530j; HUSSMANN G, 1983, J AM CHEM SOC, V105, P1263, DOI 10.1021/ja00343a031; Yoshida H, 2013, ORG LETT, V15, P952, DOI 10.1021/ol4001526; Ohmura T, 2006, J AM CHEM SOC, V128, P13366, DOI 10.1021/ja065588+; Endo K, 2010, J ORG CHEM, V75, P3469, DOI 10.1021/jo1003407; Endo K, 2012, J ORG CHEM, V77, P4826, DOI 10.1021/jo3004293; Bonet A, 2011, ANGEW CHEM INT EDIT, V50, P7158, DOI 10.1002/anie.201101941; Kliman LT, 2012, ANGEW CHEM INT EDIT, V51, P521, DOI 10.1002/anie.201105716; HAYASHI T, 1990, ORGANOMETALLICS, V9, P280, DOI 10.1021/om00115a043; Suginome M, 2000, CHEM REV, V100, P3221, DOI 10.1021/cr9902805; Wrackmeyer B, 2007, APPL ORGANOMET CHEM, V21, P531, DOI 10.1002/aoc.1263; Burks HE, 2007, J AM CHEM SOC, V129, P8766, DOI 10.1021/ja070572k; Lee Y, 2009, J AM CHEM SOC, V131, P18234, DOI 10.1021/ja9089928; SUGINOME M, 1995, J AM CHEM SOC, V117, P9608, DOI 10.1021/ja00142a047; Beletskaya I, 1999, CHEM REV, V99, P3435, DOI 10.1021/cr9902594; SODERQUIST JA, 1983, J ORG CHEM, V48, P1801, DOI 10.1021/jo00159a003; Le H, 2013, ORG LETT, V15, P1432, DOI 10.1021/ol400088g; Suginome M, 1997, ANGEW CHEM INT EDIT, V36, P2516, DOI 10.1002/anie.199725161; Takemoto Y, 2012, CHEM-EUR J, V18, P14841, DOI 10.1002/chem.201202435; Sakae R, 2014, ORG LETT, V16, P1228, DOI 10.1021/ol5001507; Mlynarski SN, 2014, NATURE, V505, P386, DOI 10.1038/nature12781; Luzung MR, 2004, J AM CHEM SOC, V126, P10858, DOI 10.1021/ja046248w; Rubina M, 2002, J AM CHEM SOC, V124, P11566, DOI 10.1021/ja027095k; Meng FK, 2013, CHEM-EUR J, V19, P3204, DOI 10.1002/chem.201203803; Endo K, 2011, ORG LETT, V13, P3368, DOI 10.1021/ol201115k; Lee YM, 2009, J AM CHEM SOC, V131, P3160, DOI 10.1021/ja809382c; Yoshida H, 2014, ORG LETT, V16, P3512, DOI 10.1021/ol501465x; Mamane V, 2004, J AM CHEM SOC, V126, P8654, DOI 10.1021/ja048094q; Tobisu M, 2010, J ORG CHEM, V75, P4841, DOI 10.1021/jo101024f; Ito H, 2008, ANGEW CHEM INT EDIT, V47, P7424, DOI 10.1002/anie.200802342; Yang CT, 2012, ANGEW CHEM INT EDIT, V51, P528, DOI 10.1002/anie.201106299; Zhong CM, 2010, J AM CHEM SOC, V132, P11440, DOI 10.1021/ja103783p; Burks H. E., 2007, CHEM COMMUN, P4725; COYLE TD, 1968, J ORGANOMET CHEM, V12, P269, DOI 10.1016/S0022-328X(00)93848-8; Endo K, 2011, CHEM LETT, V40, P1440, DOI 10.1246/cl.2011.1440; Endo K, 2009, SYNLETT, P1331, DOI 10.1055/s-0028-1088131; Endo K, 2013, CHEM LETT, V42, P1363, DOI 10.1246/cl.130643; Ferris GE, 2013, J AM CHEM SOC, V135, P2501, DOI 10.1021/ja400506j; FISH RH, 1972, J ORGANOMET CHEM, V42, P345, DOI 10.1016/S0022-328X(00)90084-6; HAMMOND B, 1971, J INORG NUCL CHEM, V33, P1017, DOI 10.1016/0022-1902(71)80169-0; HOGENBIRK M, 1989, TETRAHEDRON LETT, V30, P6195, DOI 10.1016/S0040-4039(01)93340-4; ISHIYAMA T, 1991, SYNLETT, P687; Ito H., 2011, CHEM COMMUN, V47, P6698; Kageyuki I, 2014, SYNTHESIS-STUTTGART, V46, P1924, DOI 10.1055/s-0033-1341267; KILLING H, 1984, ORGANOMETALLICS, V3, P1917, DOI 10.1021/om00090a025; Kumada M., 1964, J ORGANOMET CHEM, V1, P411, DOI 10.1016/S0022-328X(00)80032-7; Lautens M., 1995, ANGEW CHEM INT EDIT, V33, P2448, DOI 10.1002/anie.199424481; Lautens M, 1996, TETRAHEDRON, V52, P7221, DOI 10.1016/0040-4020(96)00247-5; Lee J. H., 2011, ANGEW CHEM INT EDIT, V50, P12075; Mitchell T. N., 1994, J ORGANOMET CHEM, V437, P127; MURAKAMI M, 1991, J AM CHEM SOC, V113, P3987, DOI 10.1021/ja00010a049; MURAKAMI M, 1993, J AM CHEM SOC, V115, P6487, DOI 10.1021/ja00068a003; Nakagawa M, 2005, TETRAHEDRON LETT, V46, P5257, DOI 10.1016/j.tetlet.2005.06.035; Onozawa S, 1996, ORGANOMETALLICS, V15, P5450, DOI 10.1021/om9607199; Shimizu M, 2006, CHEM LETT, V35, P1222, DOI 10.1246/cl.2006.1222; Shimizu M, 2001, ANGEW CHEM INT EDIT, V40, P4283, DOI 10.1002/1521-3773(20011119)40:22<4283::AID-ANIE4283>3.3.CO;2-V; Shimizu M, 2003, J ORGANOMET CHEM, V686, P286, DOI 10.1016/S0022-328X(03)00561-8; Singidi RR, 2010, ORG LETT, V12, P2622, DOI 10.1021/ol100824f; Stewart PS, 2011, ORG LETT, V13, P1478, DOI 10.1021/ol2001599; Suginome M, 2005, CHEM-EUR J, V11, P2954, DOI 10.1002/chem.200401031; Trofimov A, 2007, J ORG CHEM, V72, P8910, DOI 10.1021/jo701855c; Walton JC, 2000, J AM CHEM SOC, V122, P5455, DOI 10.1021/ja9944812; WATANABE H, 1982, J ORGANOMET CHEM, V225, P343, DOI 10.1016/S0022-328X(00)86834-5; Weber L, 2000, ORGANOMETALLICS, V19, P2891, DOI 10.1021/om000042w; Wrackmeyer B, 2001, CHEM-EUR J, V7, P775, DOI 10.1002/1521-3765(20010216)7:4<775::AID-CHEM775>3.3.CO;2-M; WRACKMEYER B, 1989, TETRAHEDRON, V45, P1119, DOI 10.1016/0040-4020(89)80021-3; Wrackmeyer B., 2009, J ORGANOMET CHEM, V694, P3793; Yoshida H, 2013, CHEM COMMUN, V49, P11671, DOI 10.1039/c3cc47173j; Yoshida H, 2014, CHEM COMMUN, V50, P8299, DOI 10.1039/c4cc01757a	80	3	3	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0039-7881	1437-210X		SYNTHESIS-STUTTGART	Synthesis	NOV	2014	46	22					3024	3032		10.1055/s-0034-1379385		9	Chemistry, Organic	Chemistry	AT0XD	WOS:000344655700003		
J	Kiura, T; Bosch, OJH; Nguyen, NC; Shirasaka, S; Maeno, T				Kiura, Toshiro; Bosch, Ockie J. H.; Nguyen, Nam C.; Shirasaka, Seiko; Maeno, Takashi			Creating a New Business Through Applying the Systems-Based Evolutionary Learning Laboratory Approach	SYSTEMS RESEARCH AND BEHAVIORAL SCIENCE			English	Article						creating a new business model; continuous learning cycle; systems thinking; Evolutionary Learning Laboratory; mental models	THINKING APPROACH; MANAGEMENT	The mission of business enterprises is to use their resources to create new values. It is believed that the learning from implementation through a cyclical process that continually explores the needs of customers is effective in terms of spending less resources under the unreliable conditions, which businesses operate. However, the sequence of implementation and adaption or turnabout (pivot) through the feedback of customers is only a process of trial and error and focusses strongly on linear thinking. The purpose of this study is to propose and validate the use of a systems-based methodology for creating a business model that includes a more effective learning cycle. For this, the well-proven systems-based Evolutionary Learning Laboratory is utilised and proposed as a methodology for creating a business model. The systems thinking based learning cycle has been found to be the most useful in creating a new systems-based business model. It was possible to identify the seed ideas for creating the concepts of a new business model. A systemic view and structure of the issue under consideration assisted the entrepreneurs to develop a shared understanding of the mental models of the multistakeholders, including the target customers. The systems model (integration of the mental models) serves as a 'thinking map' in the continuous learning cycle. The business ideas and strategies are identified through exploring the relationships between the different components of the model. This is followed by their validation and verification through implementation and reflection on the outcomes. The results of applying this methodology created a new business model that is based on the backgrounds and knowledge of customers and all other relevant stakeholders. The methodology does not only allow entrepreneurs to make decisions systemically but also enable them to trace the effects of the decisions after they have been implemented and to adapt where necessary in an ongoing cycle of refinement (continuous improvement). The effectiveness of the methodology in dealing with complex issues (such as developing a new business) has shown positive outcomes during an evaluation workshop. The methodology can contribute significantly to the tools that entrepreneurs are currently using. Copyright (c) 2014 John Wiley & Sons, Ltd.	[Kiura, Toshiro; Shirasaka, Seiko; Maeno, Takashi] Keio Univ, Grad Sch Syst Design & Management, Hiyoshi, Japan; [Bosch, Ockie J. H.; Nguyen, Nam C.] Univ Adelaide, Syst Design & Complex Management Alliance, Sch Business, Adelaide, SA 5005, Australia	Kiura, T (reprint author), Keio Univ, Grad Sch Syst Design & Management, Hiyoshi, Japan.	toshiro.kiura@gmail.com					Nguyen NC, 2013, SYST RES BEHAV SCI, V30, P104, DOI 10.1002/sres.2145; Donaldson KM, 2006, RES ENG DES, V16, P174, DOI 10.1007/s00163-006-0012-8; Bosch OJH, 2007, SYST RES BEHAV SCI, V24, P217, DOI 10.1002/sres.818; Cabrera D, 2008, EVAL PROGRAM PLANN, V31, P299, DOI 10.1016/j.evalprogplan.2007.12.001; Bosch OJH, 2013, SYST RES BEHAV SCI, V30, P116, DOI 10.1002/sres.2171; Nguyen NC, 2011, SYST RES BEHAV SCI, V28, P51, DOI 10.1002/sres.1044; Blank S., 2013, HARVARD BUS REV, V91, P2; Bosch OJH, 2007, P C IMPR TRIPL BOTT; Bosch OJH, 2011, WORKING PAPER; Cabinet Office, 2012, WHIT PAP CHILDR YOUN; Donaldson K, 2004, ENG TECHN C SEPT 200; IBM, 2006, EXP INN HOR IBM GLOB; IBM, 2010, CAP COMPL IBM GLOB C; Isaksen SG, 1998, CREATIVITY RES UNIT; Ishii K, 2009, ICED 09 - THE 17TH INTERNATIONAL CONFERENCE ON ENGINEERING DESIGN, VOL 10: DESIGN EDUCATION AND LIFELONG LEARNING, P57; Ishii K, 2004, VALUE ENG VALUE IDEN; Ishii K, 2010, PROCEEDINGS OF THE ASME INTERNATIONAL DESIGN ENGINEERING TECHNICAL CONFERENCES AND COMPUTERS AND INFORMATION IN ENGINEERING CONFERENCE, VOL 8, PTS A AND B, P135; Ishii K., 2001, CUSTOMER VALUE CHAIN; Maani K., 2007, SYSTEMS THINKING SYS; Nguyen NC, 2009, P INT SOC SYST SCI 2; Nguyen NC, 2012, SYST RES BEHAV SCI, V29, P14, DOI 10.1002/sres.1097; Osborn A. F., 1953, APPL IMAGINATION PRI; Pohle G, 2006, BUSINESS MODEL INNOV; Ries E., 2011, LEAN STARTUP TODAYS; Sherk J., 2010, TECHNOLOGY EXPLAINS; Smith C, 2007, SYST RES BEHAV SCI, V24, P567, DOI 10.1002/sres.835; The Statistics Bureau and the Director-General for Policy Planning of Japan, 2013, 2012 EMPL STAT SURV	27	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1092-7026	1099-1743		SYST RES BEHAV SCI	Syst. Res. Behav. Sci.	NOV-DEC	2014	31	6					696	707		10.1002/sres.2319		12	Management; Social Sciences, Interdisciplinary	Business & Economics; Social Sciences - Other Topics	AT2RU	WOS:000344783500004		
J	Hara, A; Sato, D; Sahara, Y				Hara, Akinori; Sato, Daisaku; Sahara, Yasuyuki			New Governmental Regulatory System for Stem Cell-Based Therapies in Japan	THERAPEUTIC INNOVATION & REGULATORY SCIENCE			English	Article						regenerative medicine; innovation; regulation; stem cells; specific processed cells; regenerative medical products	FDA	Regenerative medicine using stem cells is expected to provide tools for the replacement or repair of damaged tissues, opening up the possibility of treating many diseases that cannot otherwise be effectively treated. To promote the development of and access to regenerative medicine, it is important to take a balance of expedited provision of innovative therapies and appropriate steps to ensure safety and efficacy. While most developed countries have various regulatory frameworks for clinical trials and medical treatments involving stem cells, the Act on the Safety of Regenerative Medicine and the Revised Pharmaceutical Affairs Law have recently been simultaneously passed by the Japanese Diet. According to the former act, these medical technologies are categorized into 3 classes depending on their anticipated potential risk to human health, and the specific procedures falling into each class are determined. In addition, the act enables medical institutions to commission cell processing by business facilities outside the institution (even foreign facilities) that fulfill the requirements set out by the Ministry of Health, Labour and Welfare, with the aim to promote collaboration between academia and industry from an early stage. According to the latter law, a therapeutic product for regenerative medicine is defined as a product distinct from pharmaceuticals and medical devices, enabling regenerative medical products to be given a conditional, time-limited marketing authorization much earlier than that under the previous system. The new legal framework of regenerative medicine is expected to achieve the aim to develop and promote regenerative medicine, aiming at timely provision of safe and effective therapies and products.	[Hara, Akinori] Minist Hlth Labour & Welf, Hlth Policy Bur, Div Res & Dev, Off Promot Regenerat Med, Tokyo 1008916, Japan; [Sato, Daisaku] Pharmaceut & Med Devices Agcy, Tokyo, Japan; [Sahara, Yasuyuki] Minist Hlth Labour & Welf, Hlth Policy Bur, Tokyo 1008916, Japan	Hara, A (reprint author), Minist Hlth Labour & Welf, Hlth Policy Bur, Div Res & Dev, Off Promot Regenerat Med,Chiyoda Ku, 1-2-2 Kasumigaseki, Tokyo 1008916, Japan.	hara-akinori@mhlw.go.jp					Cyranoski D, 2013, NATURE, V494, P413, DOI 10.1038/494413a; Halme DG, 2006, NEW ENGL J MED, V355, P1730, DOI 10.1056/NEJMhpr063086; Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019; Cyranoski D, 2010, NATURE, V468, P485, DOI 10.1038/468485a; [Anonymous], 2013, NATURE, V494, P5; European Medicines Agency, EMEA1499952008; Food and Drug Administration, 97N0068 FOOD DRUG AD; Hamburg MA, 2010, NEW ENGL J MED, V363, P2228, DOI 10.1056/NEJMsa1007467; Office for Human Research Protections, IRBS ASS; Pharmaceuticals and Medical Devices Agency, REL SERV ADV HLTH EF; World Medical Association, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI [10.1001/jama.2013.281053, DOI 10.1001/JAMA.2013.281053]	11	6	6	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2168-4790	2168-4804		THER INNOV REGUL SCI	Ther. Innov. Regul. Sci.	NOV	2014	48	6					681	688		10.1177/2168479014526877		8	Medical Informatics; Pharmacology & Pharmacy	Medical Informatics; Pharmacology & Pharmacy	AS9KU	WOS:000344562500008		
J	Tominaga, T				Tominaga, Toshiyoshi			Competitive Strategies for Japanese Clinical Trial Sites: A New Approach to Quality	THERAPEUTIC INNOVATION & REGULATORY SCIENCE			English	Article						clinical trial; quality; risk based; Japan; Asia		In Japan and other major East Asian countries in the global drug development scene, trial sites play a major role in conducting clinical trials by intervening between sponsors and investigators. The recent globalization of clinical development has been intensifying competition among the regions, trial sites, and investigators in terms of cost, speed, and quality. The quality of clinical trialsthe key factor for competitivenessis now being defined with a risk-based approach. Within this backdrop, Japanese trial sites now assume a new role in attaining the necessary amount of quality with increased efficiency. The author proposes strategies for Japanese trial sites to explore the potential to survive the competition. These strategies include further differentiation among trial sites and building in-house quality systems in hospitals. The strategies should be viable in other Asian countries with similar institution-based systems of conducting clinical trials.	[Tominaga, Toshiyoshi] Osaka City Univ Hosp, Food & Drug Evaluat Ctr, Osaka 5450051, Japan	Tominaga, T (reprint author), Osaka City Univ Hosp, Food & Drug Evaluat Ctr, Abeno Ku, Asahi Machi 1-2-7, Osaka 5450051, Japan.	tominaga-t@med.osaka-cu.ac.jp					Asano K, 2013, CLIN PHARMACOL THER, V94, P195, DOI 10.1038/clpt.2013.106; [Anonymous], 1996, GUID GOOD CLIN PRACT; Ave C, 2013, C CRCS FUNCT CLIN RE; Desai PB, 2012, DRUG INF J, V46, P455, DOI 10.1177/0092861512446807; European Federation of Pharmaceutical Industries and Associations, 2011, EFPIAS EFF PROM CLIN; Evaluation and Licensing Division Pharmaceutical and Food Safety Bureau Ministry of Health Labor and Welfare, 2013, BAS PRINC RISK BAS A; FDA, 2007, GUID IND COMP SYST U; FDA, 2013, GUID IND OV CLIN INV; International Conference on Harmonisation of Technical Require-ments for Registration of Pharmaceuticals for Human Use, 1998, ETHN FACT ACC FOR CL; Japan Pharmaceuticals Manufacturers Association, 2012, RES SURV PHARM CO CU; Japan Pharmaceuticals Manufacturers Association, 2011, QUAL CONTR MED I EFF; Kanmuri K, 2013, THER INNOV REGUL SCI, V47, P430, DOI 10.1177/2168479013488584; Maeda H, 2013, 10 DIA JAP ANN M; Ministry of Health Labor and Welfare Ministry of Education Culture Sports Science and Technology, 2012, 5 YEAR CLIN TRIALS V; Miyazaki K, 2013, J CLIN THER MED, V29, P1029; Miyazaki S., 2014, 2 DIA CLIN OP MON WO; Osawa T, 2013, 12 KIT HARV S; Prime Minister of Japan and His Cabinet, 2013, JAP REV STRAT JAP IS; Shibata Y, 2012, 9 DIA JAP ANN M; Teshirogi I, 2011, 11 KIT U HARV SCH PU; Uden S, 2011, 11 KIT U HARV SCH PU	21	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2168-4790	2168-4804		THER INNOV REGUL SCI	Ther. Innov. Regul. Sci.	NOV	2014	48	6					702	708		10.1177/2168479014529573		7	Medical Informatics; Pharmacology & Pharmacy	Medical Informatics; Pharmacology & Pharmacy	AS9KU	WOS:000344562500011		
J	Tanaka, S; Fukinbara, S; Tsuchiya, S; Suganami, H; Ito, YM				Tanaka, Shiro; Fukinbara, Satoru; Tsuchiya, Satoru; Suganami, Hideki; Ito, Yoichi M.			Current Practice in Japan for the Prevention and Treatment of Missing Data in Confirmatory Clinical Trials: A Survey of Japanese and Foreign Pharmaceutical Manufacturers	THERAPEUTIC INNOVATION & REGULATORY SCIENCE			English	Article						missing data analysis; pharmaceutical manufacturers; current practice; last observation carried forward; mixed-effect models for repeated measures		This study aims to survey the current practice in Japan for the prevention and treatment of missing data in clinical trials since the publication of regulatory guidelines on missing data issues. A web-based questionnaire was conducted among 65 member companies of the Japan Pharmaceutical Manufacturers Association in 2013. Responses were obtained on 187 clinical trials from 55 companies, including 42 based in Japan and 13 based in other countries. Missing data were most frequent in trials involving the central nervous system (65.2% had 10% missing data). Overall, last observation carried forward (LOCF) was the most popular method for handling missing data (45.0%), followed by mixed-effect models for repeated measures (15.5%), although this was used as frequently as LOCF imputation in central nervous system trials. Even after the publication of regulatory guidelines discouraging use of LOCF, LOCF imputation remains the most popular method for treating missing data among pharmaceutical manufacturers in Japan.	[Tanaka, Shiro] Kyoto Univ, Grad Sch Med & Publ Hlth, Dept Pharmacoepidemiol, Kyoto, Japan; [Fukinbara, Satoru] Ono Pharmaceut Co Ltd, Data Sci Dev Headquarters, Osaka, Japan; [Fukinbara, Satoru; Tsuchiya, Satoru; Suganami, Hideki] Japan Pharmaceut Mfg Assoc, Data Sci Expert Comm, Tokyo, Japan; [Tsuchiya, Satoru] Dainippon Sumitomo Pharmaceut Co Ltd, Biostat, Data Sci, Tokyo, Japan; [Suganami, Hideki] Kowa Co Ltd, Clin Data Sci Dept, Tokyo, Japan; [Ito, Yoichi M.] Hokkaido Univ, Grad Sch Med, Dept Biostat, Sapporo, Hokkaido 0608638, Japan	Ito, YM (reprint author), Hokkaido Univ, Grad Sch Med, Dept Biostat, Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido 0608638, Japan.	ito-ym@med.hokudai.ac.jp			Hokkaido University, Sapporo, Japan	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The authors received financial support for editing of this article from Hokkaido University, Sapporo, Japan.	Little RJ, 2012, NEW ENGL J MED, V367, P1355, DOI 10.1056/NEJMsr1203730; O'Neill RT, 2012, CLIN PHARMACOL THER, V91, P550, DOI 10.1038/clpt.2011.340; European Medicines Agency, GUID MISS DAT CONF C; Molnar FJ, 2009, OPEN MED, V3, P31; National Research Council, 2010, PREV TREATM MISS DAT; Wood Angela M, 2004, Clin Trials, V1, P368, DOI 10.1191/1740774504cn032oa	6	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2168-4790	2168-4804		THER INNOV REGUL SCI	Ther. Innov. Regul. Sci.	NOV	2014	48	6					717	723		10.1177/2168479014530974		7	Medical Informatics; Pharmacology & Pharmacy	Medical Informatics; Pharmacology & Pharmacy	AS9KU	WOS:000344562500013		
J	Narimatsu, H; Sugawara, Y; Morita, T; Hayashi, E; Kami, M				Narimatsu, Hiroto; Sugawara, Yuya; Morita, Tomohiro; Hayashi, Emiko; Kami, Masahiro			The Impact of the Great East Japan Earthquake on Research Activity in a Disaster-Stricken Area	THERAPEUTIC INNOVATION & REGULATORY SCIENCE			English	Letter									[Narimatsu, Hiroto] Yamagata Univ, Grad Sch Med, Dept Publ Hlth, Yamagata 9909585, Japan; [Sugawara, Yuya] Yamagata Univ, Fac Med, Inst Promot Med Sci Res, Yamagata 9909585, Japan; [Morita, Tomohiro; Kami, Masahiro] Univ Tokyo, Inst Med Sci, Div Social Commun Syst Adv Clin Res, Tokyo, Japan; [Hayashi, Emiko] Tokai Univ, Inst Innovat Sci & Technol, Isehara, Kanagawa, Japan	Narimatsu, H (reprint author), Yamagata Univ, Grad Sch Med, Dept Publ Hlth, 2-2-2 Iida Nishi, Yamagata 9909585, Japan.	hiroto-narimatsu@umin.org					NISTEP, SCI TECHN IND 2013	1	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2168-4790	2168-4804		THER INNOV REGUL SCI	Ther. Innov. Regul. Sci.	NOV	2014	48	6					NP28	NP29		10.1177/2168479014555914		2	Medical Informatics; Pharmacology & Pharmacy	Medical Informatics; Pharmacology & Pharmacy	AS9KU	WOS:000344562500005		
J	Raskob, GE; Angchaisuksiri, P; Blanco, AN; Buller, H; Gallus, A; Hunt, BJ; Hylek, EM; Kakkar, A; Konstantinides, SV; McCumber, M; Ozaki, Y; Wendelboe, A; Weitz, JI				Raskob, G. E.; Angchaisuksiri, P.; Blanco, A. N.; Buller, H.; Gallus, A.; Hunt, B. J.; Hylek, E. M.; Kakkar, A.; Konstantinides, S. V.; McCumber, M.; Ozaki, Y.; Wendelboe, A.; Weitz, J. I.		ISTH Steering Comm World	Thrombosis: A major contributor to global disease burden ISTH Steering Committee for World Thrombosis Day	THROMBOSIS AND HAEMOSTASIS			English	Article						Thrombosis; venous thromboembolism; stroke; ischaemic heart disease	DEEP-VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM RISK; FEDERAL STATISTICAL OFFICE; NURSING-HOME RESIDENTS; QUALITY-OF-LIFE; PULMONARY-EMBOLISM; UNITED-STATES; POSTTHROMBOTIC SYNDROME; SYSTEMATIC ANALYSIS; MATERNAL MORTALITY	Thrombosis is a common pathology underlying ischaemic heart disease, ischaemic stroke, and venous thromboembolism (VTE). The Global Burden of Disease Study 2010 (GBD 2010) documented that ischaemic heart disease and stroke collectively caused one in four deaths worldwide. GBD 2010 did not report data for VTE as a cause of death and disability. We performed a systematic review of the literature on the global disease burden due to VTE in low, middle and high income countries. Studies from Western Europe, North America, Australia, and Southern Latin America (Argentina) yielded consistent results with annual incidences ranging from 0.75 to 2.69 per 1,000 individuals in the population. The incidence increased to between 2 and 7 per 1,000 among those 70 years of age or more. Although the incidence is lower in individuals of Chinese and Korean ethnicity, their disease burden is not low because of population aging. VTE associated with hospitalisation was the leading cause of disability-adjusted-life-years (DALYs) lost in low and middle income countries, and second in high income countries, responsible for more DALYs lost than nosocomial pneumonia, catheter-related blood stream infections, and adverse drug events. VTE causes a major burden of disease across low, middle, and high income countries. More detailed data on the global burden of VTE should be obtained to inform policy and resource allocation in health systems, and to evaluate if improved utilisation of preventive measures will reduce the burden.	[Raskob, G. E.; McCumber, M.; Wendelboe, A.] Univ Oklahoma, Hlth Sci Ctr, Coll Publ Hlth, Oklahoma City, OK 73104 USA; [Angchaisuksiri, P.] Mahidol Univ, Ramathibodi Hosp, Fac Med, Bangkok 10400, Thailand; [Blanco, A. N.] Acad Nacl Med Buenos Aires, Div Hemostasia, Buenos Aires, DF, Argentina; [Buller, H.] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands; [Gallus, A.] Flinders Med Ctr, SA Pathol Dept Hematol, Adelaide, SA, Australia; [Hunt, B. J.] Guys & St Thomas NHS Fdn Trust, Thrombosis & Thrombophilia Ctr, London, England; [Hylek, E. M.] Boston Univ, Sch Med, Boston, MA 02118 USA; [Kakkar, A.] Thrombosis Res Inst, London SW3 6LR, England; [Konstantinides, S. V.] Johannes Gutenberg Univ Mainz, Ctr Thrombosis & Hemostasis, Mainz, Germany; [Ozaki, Y.] Univ Yamanashi, Dept Lab Med, Kofu, Yamanashi, Japan; [Weitz, J. I.] McMaster Univ, Hamilton, ON, Canada; [Weitz, J. I.] Thrombosis & Atherosclerosis Res Inst, Hamilton, ON, Canada	Raskob, GE (reprint author), Univ Oklahoma, Hlth Sci Ctr, Coll Publ Hlth, 801 NE13th St, Oklahoma City, OK 73104 USA.	Gary-Raskob@ouhsc.edu					Sultan AA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070310; Access Economics Party Limited, 2008, AUSTR NZ WORK PART M; Aranaz-Andres JM, 2011, BMJ QUAL SAF, V20, P1043, DOI 10.1136/bmjqs.2011.051284; Yusuf Hussain R., 2012, Morbidity and Mortality Weekly Report, V61, P401; ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; Janke RM, 2000, J CLIN EPIDEMIOL, V53, P103, DOI 10.1016/S0895-4356(99)00147-X; Jha AK, 2013, BMJ QUAL SAF, V22, P809, DOI 10.1136/bmjqs-2012-001748; Cushman M, 2004, AM J MED, V117, P19, DOI 10.1016/j.amjmed.2004.01.018; Cohen AT, 2008, LANCET, V371, P387, DOI 10.1016/S0140-6736(08)60202-0; Virkus RA, 2011, THROMB HAEMOSTASIS, V106, P304, DOI 10.1160/TH10-12-0823; KNIFFIN WD, 1994, ARCH INTERN MED, V154, P861; Schmidt M, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002698; Lee CH, 2010, J THROMB HAEMOST, V8, P1515, DOI 10.1111/j.1538-7836.2010.03873.x; NORDSTROM M, 1992, J INTERN MED, V232, P155; Gaborit FS, 2013, THROMB HAEMOSTASIS, V110, P39, DOI 10.1160/TH12-10-0790; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Naess IA, 2007, J THROMB HAEMOST, V5, P692; Wells PS, 2014, JAMA-J AM MED ASSOC, V311, P717, DOI 10.1001/jama.2014.65; Wen SW, 2005, CAN MED ASSOC J, V173, P759, DOI 10.1503/cmaj.045156; Stein PD, 2004, AM J MED, V116, P435, DOI 10.1016/j.amjmed.2003.11.020; WOO KS, 1988, INT J CARDIOL, V20, P373, DOI 10.1016/0167-5273(88)90291-4; Holst AG, 2010, CIRCULATION, V121, P1896, DOI 10.1161/CIRCULATIONAHA.109.921460; Deitelzweig SB, 2011, AM J HEMATOL, V86, P217, DOI 10.1002/ajh.21917; Kane EV, 2013, EUR J OBSTET GYN R B, V169, P223, DOI 10.1016/j.ejogrb.2013.03.024; Sweetland S, 2012, J THROMB HAEMOST, V10, P2277, DOI 10.1111/j.1538-7836.2012.04919.x; Feigin VL, 2014, LANCET, V383, P245, DOI 10.1016/S0140-6736(13)61953-4; Petrauskiene V, 2005, DIABETOLOGIA, V48, P1017, DOI 10.1007/s00125-005-1715-5; Klatsky AL, 2000, AM J CARDIOL, V85, P1334, DOI 10.1016/S0002-9149(00)00766-9; Severinsen MT, 2010, EUR J INTERN MED, V21, P268, DOI 10.1016/j.ejim.2010.03.013; Jang MJ, 2011, J THROMB HAEMOST, V9, P85, DOI 10.1111/j.1538-7836.2010.04108.x; Kachroo S, 2012, AM J HEALTH-SYST PH, V69, P567, DOI 10.2146/ajhp110241; Heit JA, 2001, J VASC SURG, V33, P1022, DOI 10.1067/mva.2001.113308; Jamison DT, 2013, LANCET, V382, P1898, DOI 10.1016/S0140-6736(13)62105-4; Huerta C, 2007, ARCH INTERN MED, V167, P935, DOI 10.1001/archinte.167.9.935; Lindqvist P, 1999, OBSTET GYNECOL, V94, P595, DOI 10.1016/S0029-7844(99)00308-7; Deitelzweig SB, 2011, J THROMB THROMBOLYS, V31, P133, DOI 10.1007/s11239-010-0503-3; Pengo V, 2004, NEW ENGL J MED, V350, P2257, DOI 10.1056/NEJMoa032274; Engbers MJ, 2010, J THROMB HAEMOST, V8, P2105, DOI 10.1111/j.1538-7836.2010.03986.x; Horton R, 2012, LANCET, V380, P2053, DOI 10.1016/S0140-6736(12)62133-3; Goldhaber SZ, 2011, NEW ENGL J MED, V365, P2167, DOI 10.1056/NEJMoa1110899; Cohen AT, 2013, NEW ENGL J MED, V368, P513, DOI 10.1056/NEJMoa1111096; Oger E, 2000, THROMB HAEMOSTASIS, V83, P657; Wiener RS, 2011, ARCH INTERN MED, V171, P831, DOI 10.1001/archinternmed.2011.178; Raskob GE, 2012, J BONE JOINT SURG BR, V94B, P257, DOI 10.1302/0301-620X.94B2.27850; Murray CJL, 2012, LANCET, V380, P2063, DOI 10.1016/S0140-6736(12)61899-6; Heit JA, 2005, ANN INTERN MED, V143, P697; Silverstein MD, 1998, ARCH INTERN MED, V158, P585, DOI 10.1001/archinte.158.6.585; Berg CJ, 2010, OBSTET GYNECOL, V116, P1302, DOI 10.1097/AOG.0b013e3181fdfb11; Angchaisuksiri P, 2011, THROMB HAEMOSTASIS, V106, P585, DOI 10.1160/TH11-03-0184; Kroger K, 2010, J THROMB THROMBOLYS, V29, P349, DOI 10.1007/s11239-009-0396-1; Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4; White RH, 1998, ANN INTERN MED, V128, P737; Cohen AT, 2007, THROMB HAEMOSTASIS, V98, P756, DOI 10.1160/TH07-03-0212; Ho WK, 2008, MED J AUSTRALIA, V189, P144; Kahn SR, 2002, ARCH INTERN MED, V162, P1144, DOI 10.1001/archinte.162.10.1144; Stein PD, 2008, AM J CARDIOL, V102, P927, DOI 10.1016/j.amjcard.2008.05.046; Beemath A, 2006, AM J CARDIOL, V98, P1073, DOI 10.1016/j.amjcard.2006.05.030; Catterick D, 2014, BLOOD COAGUL FIBRINO; Cheuk BLY, 2004, BRIT J SURG, V91, P424, DOI 10.1002/bjs.4454; Falck-Yitter Y, 2012, CHEST S, V141, pe2785; Fawcus SR, 2005, BJOG-INT J OBSTET GY, V112, P1257, DOI 10.1111/j.1471-0528.2005.00601.x; Gomes JP, 2003, J GEN INTERN MED, V18, P934, DOI 10.1046/j.1525-1497.2003.21133.x; Gould MK, 2012, CHEST, V141, pe227S, DOI DOI 10.1378/CHEST.11-2297; Guijarro Ricardo, 2005, Eur J Intern Med, V16, P279, DOI 10.1016/j.ejim.2005.02.007; Hald EM, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000483; Heit JA, 2005, BLOOD, V106, p267A; Heit JA., 2008, ARTERIOSCLER THROMB, V28, P3702; Heyl PS, 2013, MATERN CHILD HLTH J, V17, P1230, DOI 10.1007/s10995-012-1117-5; Hunter DJ, 2014, NEW ENGL J MED, V370, P1753, DOI 10.1056/NEJMe1404077; Ikai H, 2012, WORLD J SURG, V36, P278; Kahn SR, 2012, CHEST, V141, pe195S; KIERKEGAARD A, 1980, ACTA CHIR SCAND, V146, P267; Kunisawa S, 2012, WORLD J SURG, V36, P280, DOI 10.1007/s00268-011-1229-x; Lester W, 2013, HEART, V99, P1734, DOI 10.1136/heartjnl-2013-304479; Lutsey PL, 2010, AM J PUBLIC HEALTH, V100, P1506, DOI 10.2105/AJPH.2008.157776; Mellemkjaer L, 1999, BRIT MED J, V319, P820; Moretti A M, 2010, Monaldi Arch Chest Dis, V73, P18; Moysidis T, 2010, BLOOD COAGUL FIBRIN, V21, P511, DOI 10.1097/MBC.0b013e328339cc49; Nicolaides A N, 2013, Int Angiol, V32, P111; Noble S, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004561; Reardon G, 2013, J AM MED DIR ASSOC, V14, P578, DOI 10.1016/j.jamda.2013.02.003; Samuelsson E, 2004, ACTA OBSTET GYN SCAN, V83, P674, DOI 10.1111/j.0001-6349.2004.00574.x; Samuelsson E, 2007, ACTA OBSTET GYN SCAN, V86, P435, DOI 10.1080/00016340701207500; Santosa F, 2014, HAMOSTASEOLOGIE, V34, P88, DOI 10.5482/HAMO-13-05-0028; Sharma S, 2008, AUST NZ J OBSTET GYN, V48, P44, DOI 10.1111/j.1479-828X.2007.00799.x; Shiraev TP, 2013, THROMB RES, V132, P19, DOI 10.1016/j.thromres.2013.04.032; Spannagl Michael, 2005, Thromb J, V3, P8, DOI 10.1186/1477-9560-3-8; Sullivan EA, 2004, AUST NZ J OBSTET GYN, V44, P452, DOI 10.1111/j.1479-828X.2004.00313.x; Tagalakis V, 2013, AM J MED, V126; Vázquez Fernando Javier, 2013, Thromb J, V11, P16, DOI 10.1186/1477-9560-11-16; White RH, 2006, THROMB HAEMOSTASIS, V96, P267, DOI 10.1160/TH06-07-0365; Wilson RM, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e832	92	4	4	SCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTEN	STUTTGART	HOLDERLINSTRASSE 3, D-70174 STUTTGART, GERMANY	0340-6245			THROMB HAEMOSTASIS	Thromb. Haemost.	NOV	2014	112	5					843	852		10.1160/TH14-08-0671		10	Hematology; Peripheral Vascular Disease	Hematology; Cardiovascular System & Cardiology	AT0NX	WOS:000344633700001		
J	Raskob, GE; Angchaisuksiri, P; Blanco, AN; Buller, H; Gallus, A; Hunt, BJ; Hylek, EM; Kakkar, A; Konstantinides, SV; McCumber, M; Ozaki, Y; Wendelboe, A; Weitz, JI				Raskob, G. E.; Angchaisuksiri, P.; Blanco, A. N.; Buller, H.; Gallus, A.; Hunt, B. J.; Hylek, E. M.; Kakkar, A.; Konstantinides, S. V.; McCumber, M.; Ozaki, Y.; Wendelboe, A.; Weitz, J. I.			Thrombosis: A major contributor to global disease burden	THROMBOSIS RESEARCH			English	Reprint							DEEP-VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM RISK; FEDERAL STATISTICAL OFFICE; NURSING-HOME RESIDENTS; QUALITY-OF-LIFE; PULMONARY-EMBOLISM; UNITED-STATES; POSTTHROMBOTIC SYNDROME; SYSTEMATIC ANALYSIS; MATERNAL MORTALITY	Thrombosis is a common pathology underlying ischemic heart disease, ischemic stroke, and venous thromboembolism (VTE). The Global Burden of Disease Study 2010 (GBD 2010) documented that ischemic heart disease and stroke collectively caused one in four deaths worldwide. GBD 2010 did not report data for VTE as a cause of death and disability. We performed a systematic review of the literature on the global disease burden due to VTE in low, middle and high income countries. Studies from Western Europe, North America, Australia, and Southern Latin America (Argentina) yielded consistent results with annual incidences ranging from 0.75 to 2.69 per 1,000 individuals in the population. The incidence increased to between 2 and 7 per 1,000 among those 70 years of age or more. Although the incidence is lower in individuals of Chinese and Korean ethnicity, their disease burden is not low because of population aging. VTE associated with hospitalization was the leading cause of disabilityad justed-life-years (DALYs) lost in low and middle income countries, and second in high income countries, responsible for more DALYs lost than nosocomial pneumonia, catheter-related blood stream infections, and adverse drug events. VTE causes a major burden of disease across low, middle, and high income countries. More detailed data on the global burden of VTE should be obtained to inform policy and resource allocation in health systems, and to evaluate if improved utilization of preventive measures will reduce the burden. (C) 2014 The Authors. Published by Elsevier Ltd.	[Raskob, G. E.; McCumber, M.; Wendelboe, A.] Univ Oklahoma, Hlth Sci Ctr, Coll Publ Hlth, Oklahoma City, OK 73104 USA; [Angchaisuksiri, P.] Mahidol Univ, Ramathibodi Hosp, Fac Med, Bangkok 10400, Thailand; [Blanco, A. N.] Acad Nacl Med Buenos Aires, Div Hemostasia, Buenos Aires, DF, Argentina; [Buller, H.] Acad Med Ctr, Dept Vasc Med, NL-1105 Amsterdam, Netherlands; [Gallus, A.] Flinders Med Ctr, SA Pathol, Dept Hematol, Bedford Pk, SA 5042, Australia; [Hunt, B. J.] NHS Fdn Trust, Thrombosis & Thrombophilia Ctr, London, England; [Hylek, E. M.] Boston Univ, Sch Med, Boston, MA 02118 USA; [Kakkar, A.] Thrombosis Res Inst, London SW3 6LR, England; [Konstantinides, S. V.] Johannes Gutenberg Univ Mainz, Ctr Thrombosis & Hemostasis, D-55131 Mainz, Germany; [Ozaki, Y.] Univ Yamanashi, Dept Lab Med, Chuo Ku, Yamanashi 4093898, Japan; [Weitz, J. I.] McMaster Univ, Hamilton, ON L8L 2X2, Canada; [Weitz, J. I.] Thrombosis & Atherosclerosis Res Inst, Hamilton, ON L8L 2X2, Canada	Raskob, GE (reprint author), Univ Oklahoma, Hlth Sci Ctr, Coll Publ Hlth, 801 NE 13th St, Oklahoma City, OK 73104 USA.	Gary-Raskob@ouhsc.edu					Sultan AA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070310; Access Economics Pty Limited, 2008, BURD VEN THROMB AUST; Aranaz-Andres JM, 2011, BMJ QUAL SAF, V20, P1043, DOI 10.1136/bmjqs.2011.051284; Yusuf Hussain R., 2012, Morbidity and Mortality Weekly Report, V61, P401; ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; Janke RM, 2000, J CLIN EPIDEMIOL, V53, P103, DOI 10.1016/S0895-4356(99)00147-X; Heit JA, 2008, ARTERIOSCL THROM VAS, V28, P370, DOI 10.1161/ATVBAHA.108.162545; Jha AK, 2013, BMJ QUAL SAF, V22, P809, DOI 10.1136/bmjqs-2012-001748; Cushman M, 2004, AM J MED, V117, P19, DOI 10.1016/j.amjmed.2004.01.018; Cohen AT, 2008, LANCET, V371, P387, DOI 10.1016/S0140-6736(08)60202-0; Virkus RA, 2011, THROMB HAEMOSTASIS, V106, P304, DOI 10.1160/TH10-12-0823; Schmidt M, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-002698; Lee CH, 2010, J THROMB HAEMOST, V8, P1515, DOI 10.1111/j.1538-7836.2010.03873.x; NORDSTROM M, 1992, J INTERN MED, V232, P155; Gaborit FS, 2013, THROMB HAEMOSTASIS, V110, P39, DOI 10.1160/TH12-10-0790; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Naess IA, 2007, J THROMB HAEMOST, V5, P692; Wells PS, 2014, JAMA-J AM MED ASSOC, V311, P717, DOI 10.1001/jama.2014.65; Wen SW, 2005, CAN MED ASSOC J, V173, P759, DOI 10.1503/cmaj.045156; Stein PD, 2004, AM J MED, V116, P435, DOI 10.1016/j.amjmed.2003.11.020; WOO KS, 1988, INT J CARDIOL, V20, P373, DOI 10.1016/0167-5273(88)90291-4; Holst AG, 2010, CIRCULATION, V121, P1896, DOI 10.1161/CIRCULATIONAHA.109.921460; Deitelzweig SB, 2011, AM J HEMATOL, V86, P217, DOI 10.1002/ajh.21917; Kane EV, 2013, EUR J OBSTET GYN R B, V169, P223, DOI 10.1016/j.ejogrb.2013.03.024; Sweetland S, 2012, J THROMB HAEMOST, V10, P2277, DOI 10.1111/j.1538-7836.2012.04919.x; Feigin VL, 2014, LANCET, V383, P245, DOI 10.1016/S0140-6736(13)61953-4; Petrauskiene V, 2005, DIABETOLOGIA, V48, P1017, DOI 10.1007/s00125-005-1715-5; Klatsky AL, 2000, AM J CARDIOL, V85, P1334, DOI 10.1016/S0002-9149(00)00766-9; Severinsen MT, 2010, EUR J INTERN MED, V21, P268, DOI 10.1016/j.ejim.2010.03.013; Jang MJ, 2011, J THROMB HAEMOST, V9, P85, DOI 10.1111/j.1538-7836.2010.04108.x; Kachroo S, 2012, AM J HEALTH-SYST PH, V69, P567, DOI 10.2146/ajhp110241; Heit JA, 2001, J VASC SURG, V33, P1022, DOI 10.1067/mva.2001.113308; Jamison DT, 2013, LANCET, V382, P1898, DOI 10.1016/S0140-6736(13)62105-4; Huerta C, 2007, ARCH INTERN MED, V167, P935, DOI 10.1001/archinte.167.9.935; Lindqvist P, 1999, OBSTET GYNECOL, V94, P595, DOI 10.1016/S0029-7844(99)00308-7; Deitelzweig SB, 2011, J THROMB THROMBOLYS, V31, P133, DOI 10.1007/s11239-010-0503-3; Pengo V, 2004, NEW ENGL J MED, V350, P2257, DOI 10.1056/NEJMoa032274; Horton R, 2012, LANCET, V380, P2053, DOI 10.1016/S0140-6736(12)62133-3; Goldhaber SZ, 2011, NEW ENGL J MED, V365, P2167, DOI 10.1056/NEJMoa1110899; Cohen AT, 2013, NEW ENGL J MED, V368, P513, DOI 10.1056/NEJMoa1111096; Oger E, 2000, THROMB HAEMOSTASIS, V83, P657; Wiener RS, 2011, ARCH INTERN MED, V171, P831, DOI 10.1001/archinternmed.2011.178; Raskob GE, 2012, J BONE JOINT SURG BR, V94B, P257, DOI 10.1302/0301-620X.94B2.27850; Catterick D, 2014, BLOOD COAGUL FIBRIN, V25, P571, DOI 10.1097/MBC.0000000000000100; Murray CJL, 2012, LANCET, V380, P2063, DOI 10.1016/S0140-6736(12)61899-6; Heit JA, 2005, ANN INTERN MED, V143, P697; Silverstein MD, 1998, ARCH INTERN MED, V158, P585, DOI 10.1001/archinte.158.6.585; Berg CJ, 2010, OBSTET GYNECOL, V116, P1302, DOI 10.1097/AOG.0b013e3181fdfb11; Angchaisuksiri P, 2011, THROMB HAEMOSTASIS, V106, P585, DOI 10.1160/TH11-03-0184; Kroger K, 2010, J THROMB THROMBOLYS, V29, P349, DOI 10.1007/s11239-009-0396-1; Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4; White RH, 1998, ANN INTERN MED, V128, P737; Cohen AT, 2007, THROMB HAEMOSTASIS, V98, P756, DOI 10.1160/TH07-03-0212; Ho WK, 2008, MED J AUSTRALIA, V189, P144; Kahn SR, 2002, ARCH INTERN MED, V162, P1144, DOI 10.1001/archinte.162.10.1144; Stein PD, 2008, AM J CARDIOL, V102, P927, DOI 10.1016/j.amjcard.2008.05.046; Beemath A, 2006, AM J CARDIOL, V98, P1073, DOI 10.1016/j.amjcard.2006.05.030; Cheuk BLY, 2004, BRIT J SURG, V91, P424, DOI 10.1002/bjs.4454; Cohen AT, 2008, LANCET, V371, P1914; Engers MJ, 2010, J THROMB HAEMOST, V8, P2105; Falck-Ytter Y, 2012, CHEST S, V141, pe278S; Fawcus SR, 2005, BJOG-INT J OBSTET GY, V112, P1257, DOI 10.1111/j.1471-0528.2005.00601.x; Gomes JP, 2003, J GEN INTERN MED, V18, P934, DOI 10.1046/j.1525-1497.2003.21133.x; Gould MK, 2012, CHEST S, V141, pe227S; Guijarro Ricardo, 2005, Eur J Intern Med, V16, P279, DOI 10.1016/j.ejim.2005.02.007; Hald EM, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000483; Heit JA, 2005, BLOOD, V106, p267A; Heyl PS, 2013, MATERN CHILD HLTH J, V17, P1230, DOI 10.1007/s10995-012-1117-5; Hunter DJ, 2014, NEW ENGL J MED, V370, P1753, DOI 10.1056/NEJMe1404077; Ikai H, 2012, WORLD J SURG, V36, P278; Kahn SR, 2012, CHEST S, V141, pe195S; KIERKEGAARD A, 1980, ACTA CHIR SCAND, V146, P267; Kniffin W. D. Jr., 1994, Archives of Internal Medicine, V154, P861, DOI 10.1001/archinte.154.8.861; Kunisawa S, 2012, WORLD J SURG, V36, P280, DOI 10.1007/s00268-011-1229-x; Lester W, 2013, HEART, V99, P1734, DOI 10.1136/heartjnl-2013-304479; Lutsey PL, 2010, AM J PUBLIC HEALTH, V100, P1506, DOI 10.2105/AJPH.2008.157776; Mellemkjaer L, 1999, BRIT MED J, V319, P820; Moretti A M, 2010, Monaldi Arch Chest Dis, V73, P18; Moysidis T, 2010, BLOOD COAGUL FIBRIN, V21, P511, DOI 10.1097/MBC.0b013e328339cc49; Nicolaides A N, 2013, Int Angiol, V32, P111; Noble S, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004561; Reardon G, 2013, J AM MED DIR ASSOC, V14, P578, DOI 10.1016/j.jamda.2013.02.003; Samuelsson E, 2004, ACTA OBSTET GYN SCAN, V83, P674, DOI 10.1111/j.0001-6349.2004.00574.x; Samuelsson E, 2007, ACTA OBSTET GYN SCAN, V86, P435, DOI 10.1080/00016340701207500; Santosa F, 2014, HAMOSTASEOLOGIE, V34, P88, DOI 10.5482/HAMO-13-05-0028; Sharma S, 2008, AUST NZ J OBSTET GYN, V48, P44, DOI 10.1111/j.1479-828X.2007.00799.x; Shiraev TP, 2013, THROMB RES, V132, P19, DOI 10.1016/j.thromres.2013.04.032; Sixty-sixth World Health Assembly, 2013, FOLL POL DECL HIGH L; Spannagl Michael, 2005, Thromb J, V3, P8, DOI 10.1186/1477-9560-3-8; Sullivan EA, 2004, AUST NZ J OBSTET GYN, V44, P452, DOI 10.1111/j.1479-828X.2004.00313.x; Tagalakis V, 2013, AM J MED, V126; Vázquez Fernando Javier, 2013, Thromb J, V11, P16, DOI 10.1186/1477-9560-11-16; White RH, 2006, THROMB HAEMOSTASIS, V96, P267, DOI 10.1160/TH06-07-0365; Wilson RM, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e832	94	2	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0049-3848			THROMB RES	Thromb. Res.	NOV	2014	134	5					931	938		10.1016/j.thromres.2014.08.014		8	Hematology; Peripheral Vascular Disease	Hematology; Cardiovascular System & Cardiology	AS8ED	WOS:000344482000001		
J	Tabata, N; Hokimoto, S; Akasaka, T; Arima, Y; Kaikita, K; Kumagae, N; Morita, K; Miyazaki, H; Oniki, K; Nakagawa, K; Matsui, K; Ogawa, H				Tabata, Noriaki; Hokimoto, Seiji; Akasaka, Tomonori; Arima, Yuichiro; Kaikita, Koichi; Kumagae, Naoki; Morita, Kazunori; Miyazaki, Hiroko; Oniki, Kentaro; Nakagawa, Kazuko; Matsui, Kunihiko; Ogawa, Hisao			Chronic kidney disease status modifies the association of CYP2C19 polymorphism in predicting clinical outcomes following coronary stent implantation	THROMBOSIS RESEARCH			English	Article						coronary disease; stents; pharmacology; genetics; kidney	ELEVATION MYOCARDIAL-INFARCTION; ST-SEGMENT ELEVATION; RESIDUAL PLATELET-AGGREGATION; CLOPIDOGREL METABOLISM; CARDIOVASCULAR EVENTS; PRACTICE GUIDELINES; ADVERSE OUTCOMES; FOCUSED UPDATE; TASK-FORCE; INTERVENTION	Introduction: There is some controversy regarding the effect of CYP2C19 polymorphism on clinical outcome in patients with dual antiplatelet therapy. Chronic kidney disease (CKD) is associated with increased risk of cardiovascular event, but the association between the possession of CYP2C19 loss-of-function (LOF) alleles and clinical outcome according to the presence of CKD is poorly understood. The aim of this study was to investigate whether CKD status modifies the association of CYP2C19 polymorphism in predicting outcomes in a prospective cohort study. Material and Methods: We enrolled 331 patients following coronary stent implantation. Patients were divided into two groups: CKD (n = 154) and non-CKD (n = 177). Platelet reactivity and CYP2C19 polymorphism were examined. The subjects were further divided into two groups according to the possession of CYP2C19 LOF alleles: carriers and non-carriers. Patients were followed up and clinical events were evaluated according to CKD and carrier status. Results: The proportion of high platelet reactivity was significantly higher in carriers than in non-carriers in both CKD (42.4% versus 21.7%; P = 0.016) and non-CKD groups (34.3% versus 3.7%; P < 0.001). In the non-CKD group alone, the incidence of cardiovascular events was significantly higher in carriers than in non-carriers (13.7% versus 1.7%; P = 0.013). Kaplan-Meier analysis demonstrated a significantly higher probability of cardiovascular events in carriers than in non-carriers in the non-CKD group (log-rank test: P = 0.013) and there was no significant difference in the CKD group (log-rank test: P = 0.591). Multivariate analysis identified carriers as an independent predictor of cardiovascular events only in the non-CKD group alone (hazard ratio: 8.048; 95% confidence interval: 1.066 to 60.757; P = 0.043). Conclusions: CYP2C19 polymorphism significantly correlates with clinical outcome in non-CKD patients, and CKD status modifies the association of CYP2C19 polymorphism in predicting clinical outcomes following coronary stent implantation. (C) 2014 Elsevier Ltd. All rights reserved.	[Tabata, Noriaki; Hokimoto, Seiji; Akasaka, Tomonori; Arima, Yuichiro; Kaikita, Koichi; Matsui, Kunihiko; Ogawa, Hisao] Kumamoto Univ, Grad Sch Med Sci, Dept Cardiovasc Med, Kumamoto 8608556, Japan; [Kumagae, Naoki; Morita, Kazunori; Miyazaki, Hiroko; Oniki, Kentaro; Nakagawa, Kazuko] Kumamoto Univ, Grad Sch Med & Pharmaceut Sci, Div Pharmacol & Therapeut, Kumamoto 8608556, Japan	Hokimoto, S (reprint author), Kumamoto Univ, Grad Sch Med Sci, Dept Cardiovasc Med, Chuo Ku, 1-1-1 Honjo, Kumamoto 8608556, Japan.	shokimot@kumamoto-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology, Japan	This work was supported in part by Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan.	Wright RS, 2011, J AM COLL CARDIOL, V57, P1920, DOI 10.1016/j.jacc.2011.02.009; Kubota T, 1996, CLIN PHARMACOL THER, V60, P661, DOI 10.1016/S0009-9236(96)90214-3; Man M, 2010, J CLIN PHARMACOL, V50, P929, DOI 10.1177/0091270009355161; McEntegart MB, 2012, J AM COLL CARDIOL, V59, P1745, DOI 10.1016/j.jacc.2012.02.019; Stone GW, 2012, J AM COLL CARDIOL, V60, P1975, DOI 10.1016/j.jacc.2012.09.004; Hokimoto S, 2014, THROMB RES, V133, P599, DOI 10.1016/j.thromres.2014.01.003; Tantry US, 2013, J AM COLL CARDIOL, V62, P2261, DOI 10.1016/j.jacc.2013.07.101; Geisler T, 2008, J THROMB HAEMOST, V6, P54; Thygesen K, 2012, CIRCULATION, V126, P2020, DOI 10.1161/CIR.0b013e31826e1058; Ang L, 2008, J AM COLL CARDIOL, V52, P1052, DOI 10.1016/j.jacc.2008.05.054; Yamamoto K, 2011, J CARDIOL, V57, P194, DOI 10.1016/j.jjcc.2010.10.007; Gremmel T, 2013, NEPHROL DIAL TRANSPL, V28, P2116, DOI 10.1093/ndt/gft103; Trenk D, 2008, J AM COLL CARDIOL, V51, P1925, DOI 10.1016/j.jacc.2007.12.056; Chen ZM, 2005, LANCET, V366, P1607; Serebruany V, 2009, AM HEART J, V158, P925, DOI 10.1016/j.ahj.2009.10.012; RICHARDS B, 1993, HUM MOL GENET, V2, P159, DOI 10.1093/hmg/2.2.159; Simon T, 2009, NEW ENGL J MED, V360, P363, DOI 10.1056/NEJMoa0808227; Kushner FG, 2009, J AM COLL CARDIOL, V54, P2205, DOI 10.1016/j.jacc.2009.10.015; Ono T, 2011, THROMB RES, V128, pE130, DOI 10.1016/j.thromres.2011.07.028; Geisler T, 2010, EUR HEART J, V31, P59, DOI 10.1093/eurheartj/ehp402; Collet JP, 2009, LANCET, V373, P309, DOI 10.1016/S0140-6736(08)61845-0; Attallah N, 2005, CLIN NEPHROL, V64, P412; DEMORAIS SMF, 1994, MOL PHARMACOL, V46, P594; Fischer MJ, 2013, BMC NEPHROL, V14, DOI 10.1186/1471-2369-14-107; Holmes MV, 2011, JAMA-J AM MED ASSOC, V306, P2704, DOI 10.1001/jama.2011.1880; King Spencer B 3rd, 2008, J Am Coll Cardiol, V51, P172, DOI 10.1016/j.jacc.2007.10.002; Mao Liu, 2013, Arch Cardiovasc Dis, V106, P517, DOI 10.1016/j.acvd.2013.06.055; Meadows TA, 2011, MAYO CLIN PROC, V86, P960, DOI 10.4065/mcp.2011.0010; Mega JL, 2009, NEW ENGL J MED, V360, P354, DOI 10.1056/NEJMoa0809171; Miao Yu, 2012, Catheter Cardiovasc Interv, V80, P361, DOI 10.1002/ccd.23464; Sabatine MS, 2005, NEW ENGL J MED, V352, P1179, DOI 10.1056/NEJMoa050522; Samara WM, 2005, THROMB RES, V115, P89, DOI 10.1016/j.thromres.2004.07.002	32	1	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0049-3848			THROMB RES	Thromb. Res.	NOV	2014	134	5					939	944		10.1016/j.thromres.2014.07.039		6	Hematology; Peripheral Vascular Disease	Hematology; Cardiovascular System & Cardiology	AS8ED	WOS:000344482000002		
J	Kobayashi, H; Reid, G; Hadfield, M				Kobayashi, Hisaaki; Reid, Gregory; Hadfield, Marie			Effects of vaginal delivery, cesarean section and exposure to labor on endothelial function of pregnant women	THROMBOSIS RESEARCH			English	Article						Cesarean section; Endothelial function; Flow-mediated vasodilatation; Post-term pregnancy; Vaginal delivery	FLOW-MEDIATED VASODILATION; OXIDATIVE STRESS; DYSFUNCTION; CORONARY; PREECLAMPSIA; PATHOGENESIS; RISK	Introduction: This study was undertaken to assess the influence of labor and cesarean section on endothelial function. Materials and Methods: Flow-mediated vasodilatation (FMD) was measured before and after delivery for an assessment of endothelial function in three groups: (1) the Vaginal delivery group (with spontaneous labor or induction of labor, n = 48), (2) the Elective C/S group (with a cesarean planned, n = 20), and (3) the C/S after FP group (scheduled for vaginal delivery but required to have an emergency cesarean section because of failure in progress, n = 11). Results: There were statistically significant changes between the antepartum and postpartum FMD values in the Vaginal delivery group and the Elective C/S group but not in the C/S after FP group (P < 0.001, P = 0.023 and P = 0.22 respectively). Conclusions: These observations suggest that labor may enhance endothelial function and that cesarean section may impair endothelial function. (C) 2014 Elsevier Ltd. All rights reserved.	[Kobayashi, Hisaaki] Nishisaitama Chuo Natl Hosp, Dept Obstet, Tokorozawa, Saitama 3591151, Japan; [Kobayashi, Hisaaki] Nishisaitama Chuo Natl Hosp, Dept Gynecol, Tokorozawa, Saitama 3591151, Japan; [Reid, Gregory; Hadfield, Marie] Univ Manitoba, Hlth Sci Ctr, Dept Obstet, Winnipeg, MB, Canada; [Reid, Gregory] Univ Manitoba, Hlth Sci Ctr, Dept Gynecol & Reprod Sci, Winnipeg, MB, Canada	Kobayashi, H (reprint author), Nishisaitama Chuo Natl Hosp, Dept Obstet & Gynecol, 2-1671 Wakasa, Tokorozawa, Saitama 3591151, Japan.	koba9akira@hotmail.com					Roberts JM, 2002, PLACENTA, V23, P359, DOI 10.1053/plac.2002.0819; ANDERSON TJ, 1995, J AM COLL CARDIOL, V26, P1235, DOI 10.1016/0735-1097(95)00327-4; Landmesser U, 2002, CIRCULATION, V106, P3073, DOI 10.1161/01.CIR.0000041431.57222.AF; [Anonymous], 2001, THROMBOSIS THROMBOEM, P49; Kroegel C, 2003, RESPIRATION, V70, P7, DOI 10.1159/000068427; Pechanova O, 2007, PHYSIOL RES, V56, pS7; Hansen AK, 2008, BRIT MED J, V336, P85, DOI 10.1136/bmj.39405.539282.BE; Stuhlinger MC, 2003, CIRCULATION, V108, P933, DOI 10.1161/01.CIR.0000085067.55901.89; Vanhoutte PM, 2009, CIRC J, V73, P595; Calles-Escandon J, 2001, ENDOCR REV, V22, P36, DOI 10.1210/er.22.1.36; Bechara C, 2007, AM J PHYSIOL-HEART C, V293, pH3088, DOI 10.1152/ajpheart.00473.2007; Buhimschi IA, 2003, AM J OBSTET GYNECOL, V189, P181, DOI 10.1067/mob.2003.357; Dalaker K, 1998, TROMBOEMOLISKE KOMPL, P72; Harris Andrea, 2002, Curr Atheroscler Rep, V4, P373, DOI 10.1007/s11883-002-0075-6; Hollis B, 2002, CURR OPIN OBSTET GYN, V14, P203, DOI 10.1097/00001703-200204000-00015; Kobayashi H, 1996, LANCET, V347, P1336, DOI 10.1016/S0140-6736(96)90986-1; Lee R, 2003, HEMATOL ONCOL CLIN N, V17, P85, DOI 10.1016/S0889-8588(02)00090-4; Moens AL, 2005, CHEST, V127, P2254, DOI 10.1378/chest.127.6.2254; Yoshida A, 2000, HYPERTENSION, V36, P400; Zanardo V, 2003, THROMB RES, V112, P33, DOI 10.1016/j.thromres.2003.11.004	20	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0049-3848			THROMB RES	Thromb. Res.	NOV	2014	134	5					1004	1007		10.1016/j.thromres.2014.08.029		4	Hematology; Peripheral Vascular Disease	Hematology; Cardiovascular System & Cardiology	AS8ED	WOS:000344482000013		
J	Al-Sharabi, N; Xue, Y; Fujio, M; Ueda, M; Gjerde, C; Mustafa, K; Fristad, I				Al-Sharabi, Niyaz; Xue, Ying; Fujio, Masahito; Ueda, Minoru; Gjerde, Cecilie; Mustafa, Kamal; Fristad, Inge			Bone Marrow Stromal Cell Paracrine Factors Direct Osteo/Odontogenic Differentiation of Dental Pulp Cells	TISSUE ENGINEERING PART A			English	Article							MESENCHYMAL STEM-CELLS; MIDBRAIN DOPAMINERGIC-NEURONS; RECOMBINANT HUMAN GROWTH; GROWTH/DIFFERENTIATION FACTOR-5; CONDITIONED MEDIUM; IN-VITRO; AUGMENTATION; ANGIOGENESIS; GDF-5	Growth factors play an important role in osteo/odontogenic differentiation of human dental pulp cells (hDPCs). The aim of this in vitro study was to compare the biological effects of recombinant human growth differentiation factor 5 (rhGDF-5) alone and a cocktail of soluble growth factors (conditioned medium) released from human bone marrow mesenchymal stem cells (hBMMSCs) on the morphology, proliferation and osteo/odontogenic differentiation potential of hDPCs. Passage 4 hDPCs were harvested for culture in four different media: (a) DMEM with 10% FBS, (b) odontogenic induction medium (OM), (c) OM plus 500 ng/mL rhGDF-5, and (d) OM plus conditioned medium (CM). Morphological changes at 48 and 120 h were determined by crystal violet staining. The proliferation rates at 3, 24, 48, and 120 h were assayed by MTT. Using real-time reverse transcription-polymerase chain reaction (RT-PCR), the mRNA levels of dentin sialophosphoprotein (DSPP), dentin matrix protein 1 (DMP1), collagen type I (Col 1), Runt-related transcription factor 2 (Cbfa1/Runx2), alkaline phosphatase (ALP), osteocalcin (OC), beta 3 tubulin (TUBB3), glial cell-derived neurotrophic factor (GDNF), angiopoietin-1 (Ang1), and vascular endothelial growth factor A (VEGFA), were determined at 2, 5, and 9 days. Protein expression of dental sialoprotein (DSP), DMP1, OC, and TUBB3 was recorded at 5 days, using western blot and immunocytochemistry. The effect of the different culture media on mineralization was determined by ALP staining at day 5 and Alizarin red S staining at days 7 and 14. In response to the different culture media, the shape of the hDPCs varied from spindled to polygonal and cuboidal. CM inhibited the cellular proliferation rate, while rhGDF-5 had no effect at early time points, but promoted cellular proliferation at 120 h of culture. In the CM group, the mRNA levels of Cbfa1/Runx2, Col 1, ALP, VEGFA, Ang1, and TUBB3 decreased and the levels of GDNF and OC increased. The mRNA levels of DSPP and DMP1 were inconsistent at the time points evaluated. The staining assays also demonstrated that compared with the other groups, the CM group exhibited lower expression of ALP and higher mineralization levels. Protein expression of DSP, DMP1, OC, and TUBB3 was pronounced by the CM-treated cells. It is concluded that under these in vitro conditions, CM released from hBMMSCs have a greater osteo/odontogenic inductive effect on hDPCs than rhGDF-5.	[Al-Sharabi, Niyaz; Xue, Ying; Fujio, Masahito; Gjerde, Cecilie; Mustafa, Kamal; Fristad, Inge] Univ Bergen, Dept Clin Dent, Ctr Clin Dent Res, N-5009 Bergen, Norway; [Fujio, Masahito; Ueda, Minoru] Nagoya Univ, Dept Oral & Maxillofacial Surg, Nagoya, Aichi 4648601, Japan	Fristad, I (reprint author), Univ Bergen, Dept Clin Dent, Ctr Clin Dent Res, Arstadveien 19, N-5009 Bergen, Norway.	inge.fristad@iko.uib.no			University of Bergen; quota program	The authors are indebted to the staff of the Department of Oral and Maxillofacial Surgery for providing the tooth samples. The authors would also like to thank Rita Greiner-Simonsen, Siren Hammer Ostvold, Kaia Berstad, Randi Sundfjord, and Dr. Melanie Liesenfeld (Center for Clinical Dental Research) for their excellent technical assistance. The flow cytometric analyses were performed at MIC. The study was funded by the University of Bergen and quota program.	Javazon EH, 2004, EXP HEMATOL, V32, P414, DOI 10.1016/j.exphem.2004.02.004; Gruber RM, 2009, CLIN ORAL IMPLAN RES, V20, P175, DOI 10.1111/j.1600-0501.2008.01628.x; Emanueli C, 2003, BRIT J PHARMACOL, V140, P614, DOI 10.1038/sj.bjp.0705458; Buxton P, 2001, J BONE JOINT SURG AM, V83A, pS23; Hegarty SV, 2013, MOL CELL NEUROSCI, V56, P263, DOI 10.1016/j.mcn.2013.06.006; Koch FP, 2010, CLIN ORAL IMPLAN RES, V21, P1301, DOI 10.1111/j.1600-0501.2010.01949.x; van Koppen A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038746; Zeng Q, 2007, BONE, V40, P374, DOI 10.1016/j.bone.2006.09.022; Osugi M, 2012, TISSUE ENG PT A, V18, P1479, DOI [10.1089/ten.TEA.2011.0325, 10.1089/ten.tea.2011.0325]; Nakamura K, 1999, EXP CELL RES, V250, P351, DOI 10.1006/excr.1999.4535; O'Keeffe GW, 2004, J NEUROCYTOL, V33, P479, DOI 10.1007/s11068-004-0511-y; Tripuwabhrut P, 2012, EUR J ORAL SCI, V120, P311, DOI 10.1111/j.1600-0722.2012.00980.x; Chang MC, 2013, J ENDODONT, V39, P1272, DOI 10.1016/j.joen.2013.06.003; Paula-Silva FWG, 2009, J DENT RES, V88, P339, DOI 10.1177/0022034509334070; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Gilboa L, 2000, MOL BIOL CELL, V11, P1023; Yu JH, 2006, TISSUE ENG, V12, P3097, DOI 10.1089/ten.2006.12.3097; Nakano N, 2010, NEUROSCI LETT, V483, P57, DOI 10.1016/j.neulet.2010.07.062; Chen LW, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001886; Suchanek J, 2009, BIOMED PAP, V153, P31; Thesleff I, 2003, J CELL SCI, V116, P1647, DOI 10.1242/jcs.00410; Takamizawa S, 2004, CELL BIOL INT, V28, P255, DOI 10.1016/j.cellbi.2004.01.010; Sun J, 2012, CELLS TISSUES ORGANS, V196, P510, DOI 10.1159/000339245; Baba O, 2004, EUR J ORAL SCI, V112, P163, DOI 10.1111/j.0909-8836.2004.00110.x; Bakopoulou A, 2011, CALCIFIED TISSUE INT, V88, P130, DOI 10.1007/s00223-010-9438-0; Bao Yongxia, 2006, Zhongguo Fei Ai Za Zhi, V9, P143, DOI 10.3779/j.issn.1009-3419.2006.02.09; Baume L. J., 1980, BIOL PULP DENTINE HI; Gronthos S, 2002, J DENT RES, V81, P531; Guo LJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062332; Hatakeyama Y., 2012, INTERNET J DENT SCI, V10, DOI [10.5580/2b1a, DOI 10.5580/2B1A]; Janebodin K, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027526; Lian J B, 1995, Iowa Orthop J, V15, P118; Liu J, 2007, IN VITRO CELL DEV-AN, V43, P120, DOI 10.1007/s11626-007-9022-8; Miyazono Kohei, 2002, Sci STKE, V2002, ppe40, DOI 10.1126/stke.2002.151.pe40; Peng HR, 2005, J BONE MINER RES, V20, P2017, DOI 10.1359/JBMR.050708; Sonoyama W, 2007, CULTURE HUMAN STEM C, P187, DOI 10.1002/9780470167526.ch8; Sreenath TL, 1999, INT J DEV BIOL, V43, P509; Sumita Y, 2010, GROWTH FACTORS, V28, P56, DOI 10.3109/08977190903373380; Yamashita H, 1997, EXP CELL RES, V235, P218, DOI 10.1006/excr.1997.3664	39	2	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1937-3341	1937-335X		TISSUE ENG PT A	Tissue Eng. Part A	NOV 1	2014	20	21-22					3063	3072		10.1089/ten.tea.2013.0718		10	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology	Cell Biology; Biotechnology & Applied Microbiology	AS9XU	WOS:000344592600024		
J	Uchinaka, A; Kawaguchi, N; Mori, S; Hamada, Y; Miyagawa, S; Saito, A; Sawa, Y; Matsuura, N				Uchinaka, Ayako; Kawaguchi, Naomasa; Mori, Seiji; Hamada, Yoshinosuke; Miyagawa, Shigeru; Saito, Atsuhiro; Sawa, Yoshiki; Matsuura, Nariaki			Tissue Inhibitor of Metalloproteinase-1 and -3 Improves Cardiac Function in an Ischemic Cardiomyopathy Model Rat	TISSUE ENGINEERING PART A			English	Article							FOCAL ADHESION KINASE; II TYPE-2 RECEPTOR; MYOCARDIAL-INFARCTION; MATRIX METALLOPROTEINASES; DILATED CARDIOMYOPATHY; CONTRACTILE ACTIVITY; HEART-FAILURE; EXPRESSION; TIMP-3; MICE	Matrix metalloproteinases (MMPs) and a family of tissue inhibitors of metalloproteinases (TIMPs) may contribute to myocardial remodeling in heart failure. TIMPs are the main inhibitors of MMPs and have other MMP-independent functions. Because little is known of the role of TIMPs in the heart, we examined the effects of TIMPs on cardiac fibroblasts (CFs) and cardiomyocytes. In vitro, TIMP-1-4 enhanced smooth muscle actin (SMA) expression in CFs, and TIMP-1 and TIMP-3 enhanced the expression of phosphorylated Smad-3 and phosphorylated transforming growth factor (TGF)-beta type 1 receptor in CFs; this effect was inhibited by TGF-beta receptor blocker SB-505124. TIMPs-1, -3, and -4 also inhibited the FAK, AKT, and ERK pathways that induce cardiac hypertrophy. TIMP-1 and TIMP-2 suppressed apoptosis in cardiomyocytes; in contrast, TIMP-4 induced apoptosis in CFs. TIMP-2 stimulated collagen synthesis. Collagen gels containing TIMP-1 or TIMP-3, which exhibit cardioprotective effects in vitro, were transplanted to the left ventricular anterior wall of a rat heart model of myocardial infarction. Gel-released TIMP-1 and TIMP-3 significantly improved cardiac function and myocardial remodeling and enhanced SMA expression in the infarcted area in ischemic cardiomyopathy model rats. Further, the transplantation of TIMP-1 or TIMP-3 gels inhibited apoptosis in the ischemic myocardium and reduced MMP-2 activity. TIMPs may be an ideal target of cardiac regeneration therapy.	[Uchinaka, Ayako; Kawaguchi, Naomasa; Mori, Seiji; Hamada, Yoshinosuke; Matsuura, Nariaki] Osaka Univ, Grad Sch Med, Dept Mol Pathol, Div Hlth Sci, Suita, Osaka 5650871, Japan; [Kawaguchi, Naomasa] Osaka Univ, Grad Sch Med, Dept Cardiovasc Pathol, Div Hlth Sci, Suita, Osaka 5650871, Japan; [Miyagawa, Shigeru; Sawa, Yoshiki] Osaka Univ, Grad Sch Med, Dept Cardiovasc Surg, Suita, Osaka 5650871, Japan; [Saito, Atsuhiro] Osaka Univ, Grad Sch Med, Osaka Univ Hosp, Med Ctr Translat Res, Suita, Osaka 5650871, Japan	Kawaguchi, N (reprint author), Osaka Univ, Grad Sch Med, Dept Mol Pathol, Div Hlth Sci, 1-7 Yamada Oka, Suita, Osaka 5650871, Japan.	kawaguch@sahs.med.osaka-u.ac.jp					Hammoud L, 2007, CARDIOVASC RES, V75, P359, DOI 10.1016/j.cardiores.2007.05.006; Hinz B, 2001, MOL BIOL CELL, V12, P2730; Dobaczewski M, 2010, CIRC RES, V107, P418, DOI 10.1161/CIRCRESAHA.109.216101; Heymans S, 2005, AM J PATHOL, V166, P15, DOI 10.1016/S0002-9440(10)62228-6; Widdop RE, 2003, BRIT J PHARMACOL, V140, P809, DOI 10.1038/sj.bjp.0705448; Baba HA, 2003, CARDIOVASC RES, V59, P390, DOI 10.1016/S0008-6363(03)00393-6; Takatani T, 2004, AM J PHYSIOL-CELL PH, V287, pC949, DOI 10.1152/ajpcell.00042.2004; Hinz B, 2001, AM J PATHOL, V159, P1009, DOI 10.1016/S0002-9440(10)61776-2; Uchinaka A, 2012, MOL CELL BIOCHEM, V368, P203, DOI 10.1007/s11010-012-1361-4; Nadruz W, 2005, CARDIOVASC RES, V68, P87, DOI 10.1016/j.cardiores.2005.05.011; Torsoni AS, 2003, CIRC RES, V93, P140, DOI 10.1161/01.RES.0000081595.25297.1B; Yamamoto M, 2003, BIOMATERIALS, V24, P4375, DOI 10.1016/S0142-9612(03)00337-5; Lovelock JD, 2005, AM J PHYSIOL-HEART C, V288, pH461, DOI 10.1152/ajpheart.00402.2004; Matsumura S, 2005, J CLIN INVEST, V115, P599, DOI 10.1172/JCI200522304; Kang KH, 2008, CARDIOVASC RES, V79, P150, DOI 10.1093/cvr/cvn072; Heymans S, 1999, NAT MED, V5, P1135; Brew K, 2000, BBA-PROTEIN STRUCT M, V1477, P267, DOI 10.1016/S0167-4838(99)00279-4; Hammoud L, 2009, AM J PHYSIOL-CELL PH, V296, pC735, DOI 10.1152/ajpcell.00246.2008; Tabata Y, 1999, TISSUE ENG, V5, P127, DOI 10.1089/ten.1999.5.127; Creemers EEJM, 2003, AM J PHYSIOL-HEART C, V284, pH364, DOI 10.1152/ajpheart.00511.2002; Woessner JF, 2001, J CLIN INVEST, V108, P799, DOI 10.1172/JCI13709; Senbonmatsu T, 2003, EMBO J, V22, P6471, DOI 10.1093/emboj/cdg637; Baranek T, 2007, J IMMUNOL, V179, P6184; Boulday G, 2004, ANN NY ACAD SCI, V1030, P28, DOI 10.1196/annals.1329.004; Fedak PWM, 2004, CIRCULATION, V110, P2401, DOI 10.1161/01.CIR.0000134959.83967.2D; Fedak PWM, 2003, AM J PHYSIOL-HEART C, V284, pH626, DOI 10.1152/ajpheart.00684.2002; Glass C, 2012, CELL TRANSPLANT, V21, P1931, DOI 10.3727/096368911X627561; Heymans S, 2006, CIRCULATION, V114, P565, DOI 10.1161/CIRCULATIONAHA.105.591032; Kothapalli CR, 2010, ACTA BIOMATER, V6, P170, DOI 10.1016/j.actbio.2009.06.006; Satoh M, 1999, CIRCULATION, V99, P3260; Wisniewska M, 2008, J MOL BIOL, V381, P1307, DOI 10.1016/j.jmb.2008.06.088	31	7	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1937-3341	1937-335X		TISSUE ENG PT A	Tissue Eng. Part A	NOV 1	2014	20	21-22					3073	3084		10.1089/ten.tea.2013.0763		12	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology	Cell Biology; Biotechnology & Applied Microbiology	AS9XU	WOS:000344592600025		
J	Abe, H; Ogawa, T; Wang, LY; Kimura, M; Tanaka, T; Morita, R; Yoshida, T; Shibutani, M				Abe, Hajime; Ogawa, Takashi; Wang, Liyun; Kimura, Masayuki; Tanaka, Takeshi; Morita, Reiko; Yoshida, Toshinori; Shibutani, Makoto			Promoter-region hypermethylation and expression downregulation of Yy1 (Yin yang 1) in preneoplastic liver lesions in a thioacetamide rat hepatocarcinogenesis model	TOXICOLOGY AND APPLIED PHARMACOLOGY			English	Article						CpG island hypermethylation; Glutathione S-transferase placental form (GST-P); Liver tumor promotion; Rat; Thioacetamide (TAA); Yy1	TUMOR-PROMOTION; HUMAN CANCER; C-MYC; ABERRANT ACTIVATION; CELL-PROLIFERATION; EARLY-STAGE; PROTEINS; DNA; PHASE; P53	Thioacetamide (TAA) has been used to develop a rodent model for hepatocarcinogenesis. To determine the genes with epigenetic modifications in early hepatocarcinogenesis, we did a genome-wide scan for hypermethylated promoter regions using CpG island microarrays in TAA-promoted rat liver tissue. Eight genes were selected based on the microarray profile; of these, Yy1 and Wdr45b were confirmed to be hypermethylated by methylation-specific polymerase chain reaction (PCR) and pyrosequencing and downregulated by real-time reverse transcription PCR. Non-neoplastic liver cells had nuclear Yy1 immunoreactivity, while preneoplastic foci with glutathione S-transferase placental form (GST-P) immunoreactivity had decreased Yy1 immunoreactivity. The incidence of these foci was proportional to the dose of TAA administered. Co-expression analysis of gene products downstream of Yy1 revealed increased nuclear phospho-c-Myc(+) foci as well as nuclear and cytoplasmic p21(Cip1+) foci in Yy1(-) or GST-P+ foci in response to TAA-promotion dose. Although the absolute number of cells was low, the incidence of death receptor 5(-) foci was increased in Yy1(-) foci in proportion to the TAA dose. Yy1(-)/GST-P+ foci revealed a higher number of proliferating cell nuclear antigen (PCNA)-immunoreactive cells than Yy1(+)/GST-P+ foci, while cleaved caspase-3(+) cells were unchanged between Yy1(-)/GST-P+ and Yy1(+)/GST-P+ foci. In the case of Wdr45b, most GST-P+ foci were Wdr45b(-) and were not increased by TAA promotion. These results suggest involvement of Yy1 in the epigenetic gene regulation at the early stages of TAA promoted cell proliferation and concomitant cell cycle arrest in preneoplastic lesions. (C) 2014 Elsevier Inc. All rights reserved.	[Abe, Hajime; Ogawa, Takashi; Wang, Liyun; Kimura, Masayuki; Tanaka, Takeshi; Morita, Reiko; Yoshida, Toshinori; Shibutani, Makoto] Tokyo Univ Agr & Technol, Lab Vet Pathol, Fuchu, Tokyo 1838509, Japan; [Abe, Hajime; Kimura, Masayuki; Tanaka, Takeshi; Morita, Reiko] Gifu Univ, United Grad Sch Vet Sci, Gifu 5011193, Japan	Shibutani, M (reprint author), Tokyo Univ Agr & Technol, Lab Vet Pathol, 3-5-8 Saiwai Cho, Fuchu, Tokyo 1838509, Japan.	mshibuta@cc.tuat.ac.jp	Yoshida, Toshinori/B-7255-2015; Shibutani, Makoto/C-2510-2013		Ministry of Education, Culture, Sports, Science and Technology of Japan [22380163]	This work was supported by a Grant-in-Aid for Scientific Research (B) from the Ministry of Education, Culture, Sports, Science and Technology of Japan (Grant no. 22380163).	Jones PL, 1998, NAT GENET, V19, P187, DOI 10.1038/561; Supic G, 2013, NUTR CANCER, V65, P781, DOI 10.1080/01635581.2013.805794; Stirnimann CU, 2010, TRENDS BIOCHEM SCI, V35, P565, DOI 10.1016/j.tibs.2010.04.003; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; GERVASI PG, 1989, J CANCER RES CLIN, V115, P29, DOI 10.1007/BF00391596; Wang CC, 2007, CANCER RES, V67, P4816, DOI 10.1158/0008-5472.CAN-07-0504; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Li D, 2001, CELL MOL LIFE SCI, V58, P2085, DOI 10.1007/PL00000838; Yafune A, 2014, EXP TOXICOL PATHOL, V66, P1, DOI 10.1016/j.etp.2013.07.001; Yafune A, 2013, TOXICOL LETT, V219, P203, DOI 10.1016/j.toxlet.2013.03.012; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; Kawate S, 1999, ONCOLOGY-BASEL, V57, P157, DOI 10.1159/000012024; Proikas-Cezanne T, 2004, ONCOGENE, V23, P9314, DOI 10.1038/sj.onc.1208331; Pilarsky C, 2004, NEOPLASIA, V6, P744, DOI 10.1593/neo.04277; Feinberg AP, 2006, NAT REV GENET, V7, P21, DOI 10.1038/nrg1748; Taniai E, 2012, J TOXICOL SCI, V37, P1093; Atchison Michael, 2011, Critical Reviews in Oncogenesis, V16, P143; Austen M, 1998, ONCOGENE, V17, P511, DOI 10.1038/sj.onc.1201968; Fujii Y, 2013, TOXICOLOGY, V305, P30, DOI 10.1016/j.tox.2013.01.002; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Ichimura R, 2010, TOXICOL APPL PHARM, V246, P128, DOI 10.1016/j.taap.2010.04.016; Ishii H, 2012, INT J ONCOL, V40, P1575, DOI 10.3892/ijo.2012.1362; KURODA K, 1987, J NATL CANCER I, V79, P1047; Lee MH, 2012, ONCOGENE, V31, P116, DOI 10.1038/onc.2011.217; Lin YW, 2011, CANCER INVEST, V29, P187, DOI 10.3109/07357907.2010.512605; Mangipudy R S, 1995, Environ Health Perspect, V103, P260, DOI 10.2307/3432546; Mizukami S, 2010, ARCH TOXICOL, V84, P319, DOI 10.1007/s00204-009-0496-x; Nicholson Sarah, 2011, Critical Reviews in Oncogenesis, V16, P245; Osman I, 1999, CLIN CANCER RES, V5, P2082; Peng Shian-Yang, 1993, Journal of the Formosan Medical Association, V92, P866; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487; Shirai T, 1997, TOXICOL PATHOL, V25, P453; Taniai E, 2009, CANCER SCI, V100, P813, DOI 10.1111/j.1349-7006.2009.01120.x; Tsuchiya T, 2012, TOXICOLOGY, V299, P146, DOI 10.1016/j.tox.2012.05.018; Uskokovic-Markovic S, 2007, J PHARM PHARM SCI, V10, P340; van Hoesel AQ, 2013, BRIT J CANCER, V108, P2033, DOI 10.1038/bjc.2013.136; Xie XD, 2007, MOL CELL BIOCHEM, V301, P115, DOI 10.1007/s11010-006-9402-5; Yafune A, 2013, TOXICOL LETT, V222, P295, DOI 10.1016/j.toxlet.2013.08.006; Yeh PY, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-53; Zaravinos A, 2010, CELL CYCLE, V9, P512; Zhang Qiang, 2011, Critical Reviews in Oncogenesis, V16, P163	42	1	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0041-008X	1096-0333		TOXICOL APPL PHARM	Toxicol. Appl. Pharmacol.	NOV 1	2014	280	3					467	474		10.1016/j.taap.2014.08.013		8	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	AT5JU	WOS:000344980400008		
J	Hayashi, S				Hayashi, Shuhei			A C-2 GENERIC TRICHOTOMY FOR DIFFEOMORPHISMS: HYPERBOLICITY OR ZERO LYAPUNOV EXPONENTS OR THE C-1 CREATION OF HOMOCLINIC BIFURCATIONS	TRANSACTIONS OF THE AMERICAN MATHEMATICAL SOCIETY			English	Article						Axiom A with no cycles; heterodimensional cycles; homoclinic tangencies; Lyapunov exponents; hyperbolic measures; Pesin theory; C-2 generic properties	ERGODIC CLOSING LEMMA; HETERODIMENSIONAL CYCLES; GLOBAL PERSPECTIVE; DYNAMICS; TANGENCIES; DENSITY; CONJECTURE; STABILITY; SYSTEMS; SETS	Palis conjectured that densely in Diff(r)(M), r >= 1, diffeomorphisms are either hyperbolic or exhibit homoclinic bifurcations. We prove a generic trichotomy for C-2 diffeomorphisms: an Axiom A diffeomorphism with no cycles or Kupka-Smale ones admitting zero Lyapunov exponents or the C-1 creation of homoclinic bifurcations (i.e., the creation of homoclinic tangencies or heterodimensional cycles by some C-1 small perturbations).	Univ Tokyo, Grad Sch Math Sci, Tokyo, Japan	Hayashi, S (reprint author), Univ Tokyo, Grad Sch Math Sci, 3-8-1 Komaba, Tokyo, Japan.	shuhei@ms.u-tokyo.ac.jp					Abdenur F, 2003, ANN SCI ECOLE NORM S, V36, P213, DOI 10.1016/S0012-9593(03)00008-9; Abraham R., 1970, P S PURE MATH, VXIV, P5; Pujals ER, 2009, ANN MATH, V169, P675; Palis J, 2005, ANN I H POINCARE-AN, V22, P485, DOI 10.1016/j.anijhpc.2005.01.001; Cao YL, 2006, DISCRETE CONT DYN S, V15, P61; Hayashi S, 1997, ANN MATH, V145, P81, DOI 10.2307/2951824; HIRSCH M, 1970, INVENT MATH, V9, P121, DOI 10.1007/BF01404552; Bonatti C, 2004, INVENT MATH, V158, P33, DOI 10.1007/s00222-004-0368-1; MANE R, 1982, ANN MATH, V116, P503, DOI 10.2307/2007021; Palis J, 2000, ASTERISQUE, P335; Pujals ER, 2000, ANN MATH, V151, P961, DOI 10.2307/121127; Crovisier S, 2010, ANN MATH, V172, P1641; Crovisier S, 2011, ADV MATH, V226, P673, DOI 10.1016/j.aim.2010.07.013; Barreira Luis, 2003, UNIVERSITY LECTURE S, V23; Bonatti C., 2005, ENCYCL MATH SCI, V102; Cao YL, 2003, NONLINEARITY, V16, P1473, DOI 10.1088/0951-7715/16/4/316; Crovisier S., PREPRINT ARXIV 1011; Diaz LJ, 2009, ERGOD THEOR DYN SYST, V29, P1479, DOI 10.1017/S0143385708000849; Hayashi S, 2010, ERGOD THEOR DYN SYST, V30, P773, DOI 10.1017/S0143385709000273; Hayashi S, 2000, BOL SOC BRAS MAT, V31, P337, DOI 10.1007/BF01241633; Hayashi S, 2010, P AM MATH SOC, V138, P1371; Hayashi S, 2007, B BRAZ MATH SOC, V38, P203, DOI 10.1007/s00574-007-0044-3; Hirsch M., 1977, LECT NOTES MATH, V583; Katok A., 1980, I HAUTES ETUDES SCI, V51, P137; MANE R, 1988, PUBL MATH-PARIS, P139; Mane Ricardo, 1988, I HAUTES ETUDES SCI, V66, P161; Matie R., 1987, ERGEBNISSE DER MATHE, V8; Newhouse S, 1979, PUBL MATH-PARIS, V50, P101, DOI DOI 10.1007/BF02684771; Newhouse S., 1970, P AMS S PURE MATH, V14, P191; Newhouse S., 1974, TOPOLOGY, V13, P9, DOI 10.1016/0040-9383(74)90034-2; Palis J, 2008, NONLINEARITY, V21, pT37, DOI 10.1088/0951-7715/21/4/T01; Palis J, 1982, GEOMETRIC THEORY DYN; Palis Jacob, 2001, ASTERISQUE, V261, pxiii; Pliss V., 1972, DIFF URAVENYIA, V8, P268; Pollicott Mark, 1993, LONDON MATHEMATICAL, V180; PUGH CC, 1967, AM J MATH, V89, P1010, DOI 10.2307/2373414; Pugh Charles C., 1983, ERGOD THEOR DYN SYST, V3, P261, DOI [10.1017/S0143385700001978, DOI 10.1017/S0143385700001978]; Pujals ER, 2008, NONLINEARITY, V21, pT233, DOI 10.1088/0951-7715/21/11/T02; Pujals ER, 2008, DISCRETE CONT DYN S, V20, P335; Pujals ER, 2009, ANN I H POINCARE-AN, V26, P1971, DOI 10.1016/j.anihpc.2009.04.003; Pujals ER, 2006, DISCRETE CONT DYN S, V16, P179; Shub Michael, 1987, GLOBAL STABILITY DYN; Tsujii M, 2005, ACTA MATH-DJURSHOLM, V194, P37, DOI 10.1007/BF02392516; Wen L, 2002, NONLINEARITY, V15, P1445, DOI 10.1088/0951-7715/15/5/306; Wen L, 2004, B BRAZ MATH SOC, V35, P419, DOI 10.1007/s00574-004-0023-x	45	0	0	AMER MATHEMATICAL SOC	PROVIDENCE	201 CHARLES ST, PROVIDENCE, RI 02940-2213 USA	0002-9947	1088-6850		T AM MATH SOC	Trans. Am. Math. Soc.	NOV	2014	366	11					5613	5651	PII S0002-9947(2014)06425-8			39	Mathematics	Mathematics	AT3HK	WOS:000344826200001		
J	Ibrahim, S; Masmoudi, N; Nakanishi, K				Ibrahim, Slim; Masmoudi, Nader; Nakanishi, Kenji			THRESHOLD SOLUTIONS IN THE CASE OF MASS-SHIFT FOR THE CRITICAL KLEIN-GORDON EQUATION	TRANSACTIONS OF THE AMERICAN MATHEMATICAL SOCIETY			English	Article							CRITICAL WAVE-EQUATION; GLOBAL WELL-POSEDNESS; BLOW-UP; SCATTERING	We study global dynamics for the focusing nonlinear Klein-Gordon equation with the energy-critical nonlinearity in two or higher dimensions when the energy equals the threshold given by the ground state of a mass-shifted equation, and prove that the solutions are divided into scattering and blowup. In short, the Kenig-Merle scattering/blowup dichotomy extends to the threshold energy in the case of mass-shift for the critical nonlinear Klein-Gordon equation.	[Ibrahim, Slim] Univ Victoria, Dept Math & Stat, Victoria, BC V8P 5C3, Canada; [Masmoudi, Nader] NYU, Courant Inst Math Sci, New York, NY 10012 USA; [Nakanishi, Kenji] Kyoto Univ, Dept Math, Kyoto 6068502, Japan	Ibrahim, S (reprint author), Univ Victoria, Dept Math & Stat, POB 3060 STN CSC, Victoria, BC V8P 5C3, Canada.	ibrahim@math.uvic.ca; masmoudi@courant.nyu.edu; n-kenji@math.kyoto-u.ac.jp			NSERC [371637-2009]; University of Victoria; NSF [DMS-0703145]	The first author was partially supported by NSERC# 371637-2009 grant and a start up fund from the University of Victoria.; The second author was partially supported by an NSF Grant DMS-0703145.	Ibrahim S, 2011, ANAL PDE, V4, P405, DOI 10.2140/apde.2011.4.405; Kenig CE, 2006, INVENT MATH, V166, P645, DOI 10.1007/s00222-006-0011-4; GINIBRE J, 1989, COMMUN MATH PHYS, V123, P535, DOI 10.1007/BF01218585; PAYNE LE, 1975, ISRAEL J MATH, V22, P273, DOI 10.1007/BF02761595; Duyckaerts T, 2012, J EUR MATH SOC, V14, P1389, DOI 10.4171/JEMS/336; Duyckaerts T, 2009, GEOM FUNCT ANAL, V18, P1787, DOI 10.1007/s00039-009-0707-x; Duyckaerts T, 2008, INT MATH RES PAP, DOI 10.1093/imrp/rpn002; Ibrahim S., TRUDINGER MOSE UNPUB; Ibrahim S, 2009, DUKE MATH J, V150, P287, DOI 10.1215/00127094-2009-053; Ibrahim S, 2006, COMMUN PUR APPL MATH, V59, P1639, DOI 10.1002/cpa.20127; Ibrahim S, 2011, ANAL PDE, V4, P341, DOI 10.2140/apde.2011.4.341; Kenig C, 2008, ACTA MATH-DJURSHOLM, V201, P147, DOI 10.1007/s11511-008-0031-6	12	2	2	AMER MATHEMATICAL SOC	PROVIDENCE	201 CHARLES ST, PROVIDENCE, RI 02940-2213 USA	0002-9947	1088-6850		T AM MATH SOC	Trans. Am. Math. Soc.	NOV	2014	366	11					5653	5669	PII S0002-9947(2014)05852-2			17	Mathematics	Mathematics	AT3HK	WOS:000344826200002		
J	Sunada, S; Hayakawa, M				Sunada, Shigeru; Hayakawa, Masafumi			Passive Damping of a Flapping Wing	TRANSACTIONS OF THE JAPAN SOCIETY FOR AERONAUTICAL AND SPACE SCIENCES			English	Article						Flapping Wing; Damping; Quasi-Steady Analysis; UAV	FLIGHT DYNAMICS; STABILITY; TIME	Yaw and roll damping measurements of a flapping-wing aircraft during hover are taken with a load cell. Yaw damping is also estimated by analyzing the vibration of the suspended flapping-wing aircraft. The damping values obtained using the two methods increase with the increase of angular frequencies of yaw and rolling motions. They are also calculated using quasi-steady analysis. Furthermore, yaw damping is also estimated using the equation proposed by Hedrick et al. for flying animals. When the angular frequencies of yawing and rolling motions are smaller than 10% of the frequency of flapping motion, the theoretical values from the quasi-steady analysis and the equation of Hedrick et al. agree well with the experimental values.	[Sunada, Shigeru; Hayakawa, Masafumi] Osaka Prefecture Univ, Sakai, Osaka 591, Japan	Sunada, S (reprint author), Osaka Prefecture Univ, Sakai, Osaka 591, Japan.						Gao N, 2011, J THEOR BIOL, V270, P98, DOI 10.1016/j.jtbi.2010.11.022; Hedrick TL, 2009, SCIENCE, V324, P252, DOI 10.1126/science.1168431; Sunada S, 2010, AIAA J, V48, P1261, DOI 10.2514/1.J050098; Orlowski CT, 2012, PROG AEROSP SCI, V51, P18, DOI 10.1016/j.paerosci.2012.01.001; Taylor GK, 2005, J ROY SOC INTERFACE, V2, P197, DOI 10.1098/rsif.2005.0036; Gao N., 2009, J BIOMECH SCI ENG, V4, P105, DOI DOI 10.1299/JBSE.4.105; Keennon M., 2012, 50 AIAA AER SCI M NA	7	0	0	JAPAN SOC AERONAUT SPACE SCI	TOKYO	KOKUKAIKAN-BUNKAN 1-18-2 SHINBASHI MINATO-KU, TOKYO, JAPAN	0549-3811			T JPN SOC AERONAUT S	Trans. Jpn. Soc. Aeronaut. Space Sci.	NOV	2014	57	6					325	330				6	Engineering, Aerospace	Engineering	AT3MQ	WOS:000344839300003		
J	Nakamura, Y; Takeichi, N; Kageyama, K				Nakamura, Yoichi; Takeichi, Noboru; Kageyama, Kota			A Self-separation Algorithm using Relative Speed for a High-density Air Corridor	TRANSACTIONS OF THE JAPAN SOCIETY FOR AERONAUTICAL AND SPACE SCIENCES			English	Article						Air Traffic Management; Traffic Flow; Air Corridor; Self-separation		This paper discusses algorithms for the self-separation of aircraft operating in a high-density air corridor. An air corridor is a tube or band-shaped piece of airspace that connects congested airports, high-demand city areas, etc. Aircraft in the corridor all fly in the same direction, and only aircraft capable of self-separation may operate in the corridor. An appropriate self-separation algorithm is indispensable for realizing high traffic throughput while maintaining safety. In this paper, we augment a previously developed basic self-separation function with a new algorithm that determines heading changes based on the relative speed of other traffic. The basic self-separation function uses the relative lateral positions of other aircraft to determine heading changes for conflict avoidance assuming that all aircraft intend to fly along the corridor. Numerical traffic simulations show that the new algorithm, based on relative speed, leads to the formation of groups of aircraft with similar speed. It is clarified that the introduction of a simple common rule concerning turn direction achieves a drastic improvement in the degree of control while maintaining safety. It is also found that the control amount is equalized regardless of the flight speed and its variability.	[Nakamura, Yoichi; Kageyama, Kota] Elect Nav Res Inst, Dept Air Traff Management, Tokyo, Japan; [Takeichi, Noboru] Nagoya Univ, Dept Aerosp Engn, Nagoya, Aichi 4648601, Japan	Nakamura, Y (reprint author), Elect Nav Res Inst, Dept Air Traff Management, Tokyo, Japan.						International Civil Aviation Organization, 2009, 9905 INT CIV AV ORG; Japan Civil Aviation Bureau, LONG TERM VIS FUT AI; Joint Planning & Development Office, 2010, CONC OP NEXT GEN AIR; Nakamura Y., 2012, J JPN SOC AERONAUT S, V60, P17; Nakamura Y., 2011, J JPN SOC AERONAUT S, V59, P76; RTCA, 2002, DO42A RTCA; Takeichi N, 2014, T JPN SOC AERONAUT S, V57, P179; Takeichi N., 2012, 28 INT C AER SCI; Xue M., 2009, AIAA GUID NAV CONTR; Yousefi A., 2010, IEEE AIAA 29 DIG AV; Yousefi A., 2010, 10 AIAA ATIO C 4 WOR	11	0	0	JAPAN SOC AERONAUT SPACE SCI	TOKYO	KOKUKAIKAN-BUNKAN 1-18-2 SHINBASHI MINATO-KU, TOKYO, JAPAN	0549-3811			T JPN SOC AERONAUT S	Trans. Jpn. Soc. Aeronaut. Space Sci.	NOV	2014	57	6					336	342				7	Engineering, Aerospace	Engineering	AT3MQ	WOS:000344839300005		
J	Yokoyama, N				Yokoyama, Nobuhiro			Model Predictive Control for Parallel Planning of Conflict-free Trajectories for Multiple Aircraft	TRANSACTIONS OF THE JAPAN SOCIETY FOR AERONAUTICAL AND SPACE SCIENCES			English	Article						Model Predictive Control; Trajectory Planning; Compatibility Constraint; Recursive Feasibility	RESOLUTION; SYSTEMS; OPTIMIZATION; STRATEGIES; SCHEME	This paper proposes a parallel model predictive control (MPC) scheme for planning conflict-free trajectories for multiple aircraft, in which each aircraft's computer synchronously solves mixed-integer quadratically constrained quadratic programming (MIQCQP) problems. The main contribution of this paper is the formulation of compatibility constraints for the separation of aircraft, which guarantees recursive feasibility and enables synchronous calculations. Moreover, the constraints on the velocity and acceleration, which are often overly simplified in existing studies, are tightly formulated in the framework of mixed-integer linear constraints. Through numerical simulations, the effectiveness of the scheme is confirmed in terms of the scalability, the recursive feasibility, and the validity of the trajectories.	Natl Def Acad, Dept Aerosp Engn, Yokosuka, Kanagawa 239, Japan	Yokoyama, N (reprint author), Natl Def Acad, Dept Aerosp Engn, Yokosuka, Kanagawa 239, Japan.						Menon PK, 1999, J GUID CONTROL DYNAM, V22, P202, DOI 10.2514/2.4384; Bemporad A, 1999, AUTOMATICA, V35, P407, DOI 10.1016/S0005-1098(98)00178-2; Frazzoli E, 2001, J GUID CONTROL DYNAM, V24, P79, DOI 10.2514/2.4678; Borrelli F, 2004, IEEE DECIS CONTR P, P1099, DOI 10.1109/CDC.2004.1428839; Chen H, 1998, AUTOMATICA, V34, P1205, DOI 10.1016/S0005-1098(98)00073-9; Samad T, 2007, P IEEE, V95, P92, DOI 10.1109/JPROC.2006.887327; Kuwata Y, 2007, IEEE T CONTR SYST T, V15, P627, DOI 10.1109/TCST.2007.899152; Dimarogonas DV, 2006, AUTOMATICA, V42, P229, DOI 10.1016/j.automatica.2005.09.019; Raghunathan AU, 2004, J GUID CONTROL DYNAM, V27, P586, DOI 10.2514/1.11168; Tomlin C, 1998, IEEE T AUTOMAT CONTR, V43, P509, DOI 10.1109/9.664154; Bicchi A., 2000, IEEE Transactions on Intelligent Transportation Systems, V1, DOI 10.1109/6979.898228; Dumbar W. B., 2006, AUTOMATICA, V42, P549; Eby M. S., 1994, Lincoln Laboratory Journal, V7; Frazzoli E., 2005, P AIAA GUID NAV CONT; Inalhan G, 2002, IEEE DECIS CONTR P, P1147; Maciejowski J. M., 2002, PREDICTIVE CONTROL C; Schouwenaars T., 2004, P AIAA GUID NAV CONT; Wang P., 2012, P 31 CHIN CONTR C 20, P6327; Yokoyama N., 2008, J JPN SOC AERONAUT S, V56, P262, DOI 10.2322/jjsass.56.262	19	0	0	JAPAN SOC AERONAUT SPACE SCI	TOKYO	KOKUKAIKAN-BUNKAN 1-18-2 SHINBASHI MINATO-KU, TOKYO, JAPAN	0549-3811			T JPN SOC AERONAUT S	Trans. Jpn. Soc. Aeronaut. Space Sci.	NOV	2014	57	6					352	360				9	Engineering, Aerospace	Engineering	AT3MQ	WOS:000344839300007		
J	Kono, M; Saigo, K; Takagi, Y; Takahashi, T; Kawauchi, S; Wada, A; Hashimoto, M; Minami, Y; Imoto, S; Takenokuchi, M; Morikawa, T; Funakoshi, K				Kono, Mari; Saigo, Katsuyasu; Takagi, Yuri; Takahashi, Takayuki; Kawauchi, Sawako; Wada, Atsushi; Hashimoto, Makoto; Minami, Yosuke; Imoto, Shion; Takenokuchi, Mariko; Morikawa, Takashi; Funakoshi, Kunihiro			Heme-related molecules induce rapid production of neutrophil extracellular traps	TRANSFUSION			English	Article							ACUTE LUNG INJURY; PRESTORAGE LEUKOREDUCTION; BLOOD; ACTIVATION; FAILURE; PLASMA; TRALI; DEFEROXAMINE; INFLAMMATION; IRRADIATION	BackgroundPulmonary endothelial cell damages caused by neutrophil overactivation could result in acute lung injuries including transfusion-related acute lung injury (TRALI). We previously reported that heme-related molecules derived from hemolysis induced the production of reactive oxygen species from neutrophils. Recently, neutrophil extracellular traps (NETs) have been demonstrated to associate with the onset of TRALI. Study Design and MethodsIn this study, neutrophils' morphologic changes induced by the heme-related molecule hemin were confirmed to be NETs via confocal laser scanning microscopy and electron microscopy (EM). Additionally, concentrations of hemin in red blood cell (RBC) components were measured via enzyme-linked immunosorbent assay and possible contribution of these molecules to the onset of TRALI was discussed. ResultsSYTOX green staining observation via confocal laser scanning microscopy revealed that neutrophil morphology changed rapidly upon addition of hemin. The nuclei began to be enlarged and become segmented after 5 minutes, and NET-like structures were released from neutrophils after 15 minutes. In EM observation, NET-like structures appeared after 10 minutes and the nucleoplasm was partially separated from the nuclear membrane, which were consistent with the features of NET formation. These structures stained positively for both myeloperoxidase and histone H3 antibodies. ConclusionThus, our results suggest that hemin induced NETs in 15 minutes, a quicker reaction than NET induction by phorbol myristate acetate requiring 3 hours. Moreover, since RBC components, especially those with long-term storage, contained sufficient hemin concentration to induce NETs, special attention to hemolysis of stored RBC components is important.	[Kono, Mari; Takagi, Yuri; Kawauchi, Sawako; Wada, Atsushi; Morikawa, Takashi; Funakoshi, Kunihiro] Sysmex Corp, Cell Anal Ctr, Sci Affairs, Kobe, Hyogo, Japan; [Saigo, Katsuyasu; Takenokuchi, Mariko] Himeji Dokkyo Univ, Fac Pharmacol Sci, Himeji, Hyogo, Japan; [Takahashi, Takayuki] Shinko Hosp, Dept Hematol, Kobe, Hyogo, Japan; [Hashimoto, Makoto; Minami, Yosuke] Kobe Univ Hosp, Div Blood Transfus, Kobe, Hyogo, Japan; [Imoto, Shion] Kobe Tokiwa Univ, Dept Hlth Sci, Kobe, Hyogo, Japan	Kono, M (reprint author), 1-3-2 Murotani,Nishi Ku, Kobe, Hyogo 6512241, Japan.	Kono.Mari@sysmex.co.jp					Almyroudis NG, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00045; Khan SY, 2006, BLOOD, V108, P2455, DOI 10.1182/blood-2006-04-017251; Singh NRP, 2012, EUR J CLIN INVEST, V42, P1342, DOI 10.1111/j.1365-2362.2012.02720.x; Silliman CC, 2003, TRANSFUSION, V43, P633, DOI 10.1046/j.1537-2995.2003.00385.x; Zimmermann R, 2009, TRANSFUSION, V49, P75, DOI 10.1111/j.1537-2995.2008.01920.x; Villar J, 2011, INTENS CARE MED, V37, P1932, DOI 10.1007/s00134-011-2380-4; Ghosh S, 2013, J CLIN INVEST, V123, P4809, DOI 10.1172/JCI64578; Walter PB, 2008, HAEMATOL-HEMATOL J, V93, P817, DOI 10.3324/haematol.11755; Zimmerman JL, 2013, CHEST, V144, P1058, DOI 10.1378/chest.12-2016; Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818; Hishizawa M, 2009, INTERNAL MED, V48, P1979, DOI 10.2169/internalmedicine.48.2569; Silliman CC, 2005, BLOOD, V105, P2266, DOI 10.1182/blood-2004-07-2929; Pilsczek FH, 2010, J IMMUNOL, V185, P7413, DOI 10.4049/jimmunol.1000675; Gardiner EE, 2012, BLOOD REV, V26, P255, DOI 10.1016/j.blre.2012.09.001; Brinkmann V, 2007, NAT REV MICROBIOL, V5, P577, DOI 10.1038/nrmicro1710; Kostopanagiotou GG, 2009, EUR RESPIR J, V33, P1429, DOI 10.1183/09031936.00123108; Caudrillier A, 2012, J CLIN INVEST, V122, P2661, DOI 10.1172/JCI61303; Thomas GM, 2012, BLOOD, V119, P6335, DOI 10.1182/blood-2012-01-405183; Sachs UJH, 2006, BLOOD, V107, P1217, DOI 10.1182/blood-2005-04-1744; Graca-Souza AV, 2002, BLOOD, V99, P4160, DOI 10.1182/blood.V99.11.4160; Bux J, 2011, VOX SANG, V100, P122, DOI 10.1111/j.1423-0410.2010.01392.x; Vlahakos D, 2012, ARTIF ORGANS, V36, P400, DOI 10.1111/j.1525-1594.2011.01385.x; Marcos V, 2010, NAT MED, V16, P1018, DOI 10.1038/nm.2209; Porto BN, 2007, J BIOL CHEM, V282, P24430, DOI 10.1074/jbc.M703570200; Holness L, 2004, TRANSFUS MED REV, V18, P184, DOI 10.1016/j.tmrv.2004.03.004; Fuchs TA, 2007, J CELL BIOL, V176, P231, DOI 10.1083/jcb.200606027; Luhr OR, 1999, AM J RESP CRIT CARE, V159, P1849; Triulzi DJ, 2009, ANESTH ANALG, V108, P770, DOI 10.1213/ane.0b013e31819029b2; Chaudhary R, 2012, BLOOD TRANSFUS-ITALY, V10, P59, DOI 10.2450/2011.0107-10; Djalali AG, 2005, RESUSCITATION, V66, P225, DOI 10.1016/j.resuscitation.2005.02.004; Eder AF, 2007, TRANSFUSION, V47, P599, DOI 10.1111/j.1537-2995.2007.01102.x; Gandhi MJ, 2007, TRANSFUS APHER SCI, V36, P17, DOI 10.1016/j.transci.2006.09.007; Hirayama J, 2005, BIOL PHARM BULL, V28, P1318, DOI 10.1248/bpb.28.1318; Irish Critical Care Trials Group, 2008, CRIT CARE, V12, pR30; Kono M, 2013, BLOOD TRANSFUS-ITALY, V11, P53, DOI 10.2450/2012.0141-11; Lombardo ME, 2005, ANAL BIOCHEM, V341, P199, DOI 10.1016/j.ab.2004.11.002; Nakamura A, 2011, TRANSFUSION MED, V21, P365, DOI 10.1111/j.1365-3148.2011.01093.x; Orino K, 2013, BIOMETALS, V26, P789, DOI 10.1007/s10534-013-9657-8; Saigo Katsuyasu, 2008, Rinsho Byori, V56, P967; Saigo Katsuyasu, 2013, J Clin Med Res, V5, P57, DOI 10.4021/jocmr1180w; Shaz BH, 2011, BLOOD, V117, P1463, DOI 10.1182/blood-2010-04-278135; Zarogiannis SG, 2011, AM J RESP CELL MOL, V45, P386, DOI 10.1165/rcmb.2010-0432OC; Zunszain Patricia A, 2003, BMC Struct Biol, V3, P6, DOI 10.1186/1472-6807-3-6	45	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0041-1132	1537-2995		TRANSFUSION	Transfusion	NOV	2014	54	11					2811	2819		10.1111/trf.12700		9	Hematology	Hematology	AT1FQ	WOS:000344679200006		
J	Owada, T; Kaneko, M; Matsumoto, C; Sobata, R; Igarashi, M; Suzuki, K; Matsubayashi, K; Mio, K; Uchida, S; Satake, M; Tadokoro, K				Owada, Takashi; Kaneko, Moe; Matsumoto, Chieko; Sobata, Rieko; Igarashi, Masashi; Suzuki, Ko; Matsubayashi, Keiji; Mio, Kazuhiro; Uchida, Shigeharu; Satake, Masahiro; Tadokoro, Kenji			Establishment of culture systems for Genotypes 3 and 4 hepatitis E virus (HEV) obtained from human blood and application of HEV inactivation using a pathogen reduction technology system	TRANSFUSION			English	Article							FULMINANT-HEPATITIS; SPORADIC ACUTE; TRANSFUSION; PLASMA	BackgroundIt has been demonstrated that the hepatitis E virus (HEV) can be transmitted via blood transfusion, and the risk of HEV transmission via transfusion has become a major global concern. An HEV culture system for blood-derived HEV has been sought to obtain valuable knowledge of the virus and the risk of HEV infection through blood products. Study Design and MethodsWe endeavored to establish an HEV culture system using RNA-positive blood specimens for Genotypes (G) 3 and 4 and applied this system to evaluate tissue culture infectious dose (TCID). We applied this method to investigate the potential of the Mirasol pathogen reduction technology (PRT) system (Terumo BCT) to inactivate live HEV in contaminated platelet samples (PLTs). PLTs were spiked with cultured HEV G3 or G4 and then treated with the Mirasol PRT system. PLTs were examined before and after the treatment for HEV load using TCID titration. ResultsWe successfully established two strains for HEV production: the JRC-HE3 strain for G3 and the UA1 strain for G4. The Mirasol PRT system expressed more than 3log inactivation for JRC-HE3 and more than 2log inactivation for UA1. ConclusionThe Mirasol PRT system inactivated greater than 2 to 3 logs of live HEV in PLTs and can potentially be used to lower the possibility of blood-borne HEV transmission. The G3 and G4 HEV inocula identified in this study and the hepatoma cell culture system provide a new means to assess HEV infectious titer and to evaluate other pathogen reduction strategies.	[Owada, Takashi; Kaneko, Moe; Matsumoto, Chieko; Sobata, Rieko; Igarashi, Masashi; Uchida, Shigeharu; Satake, Masahiro; Tadokoro, Kenji] Japanese Red Cross Soc, Cent Blood Inst, Blood Serv Headquarters, Tokyo 1358521, Japan; [Suzuki, Ko] Japanese Red Cross, Tohoku Block Blood Ctr, Shibuya, Miyagi, Japan; [Matsubayashi, Keiji] Japanese Red Cross, Hokkaido Block Blood Ctr, Shibuya, Hokkaido, Japan; [Mio, Kazuhiro] Natl Inst Adv Ind Sci & Technol, Biomed Informat Res Ctr, Tokyo, Japan	Owada, T (reprint author), Japanese Red Cross Soc, Cent Blood Inst, Blood Serv Headquarters, Tokyo 1358521, Japan.	owada@hokkaido.bc.jrc.or.jp					Tanaka T, 2007, J GEN VIROL, V88, P903, DOI 10.1099/vir.0.82535-0; Takahashi M, 2007, J CLIN MICROBIOL, V45, P3671, DOI 10.1128/JCM.01086-07; Takahashi M, 2010, J CLIN MICROBIOL, V48, P1112, DOI 10.1128/JCM.02002-09; Prowse CV, 2013, VOX SANG, V104, P183, DOI 10.1111/j.1423-0410.2012.01662.x; Hauser L, 2014, BLOOD, V123, P796, DOI 10.1182/blood-2013-09-524348; Kaufmann A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021150; Okamoto H, 2007, VIRUS RES, V127, P216, DOI 10.1016/j.virusres.2007.02.002; Sakata H, 2008, TRANSFUSION, V48, P2568, DOI 10.1111/j.1537-2995.2008.01910.x; Matsubayashi K, 2008, TRANSFUSION, V48, P1368, DOI 10.1111/j.1537-2995.2008.01722.x; Vanlandingham DL, 2013, TRANSFUSION, V53, P284, DOI 10.1111/j.1537-2995.2012.03717.x; Bajpai M, 2011, INDIAN J MED MICROBI, V29, P353, DOI 10.4103/0255-0857.90158; Centers for Disease Control and Prevention, 1993, MMWR-MORBID MORTAL W, V42, P1; NANDA SK, 1994, J MED VIROL, V42, P133, DOI 10.1002/jmv.1890420207; Takahashi K, 2003, INTERVIROLOGY, V46, P308, DOI 10.1159/000073210; Urayama T., 2010, Open Veterinary Science Journal, V4, P11; Wichmann Ole, 2008, J Infect Dis, V198, P1732, DOI 10.1086/593211	16	4	4	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0041-1132	1537-2995		TRANSFUSION	Transfusion	NOV	2014	54	11					2820	2827		10.1111/trf.12686		8	Hematology	Hematology	AT1FQ	WOS:000344679200007		
J	Tadokoro, C; Nihira, T; Nakano, K				Tadokoro, Chiharu; Nihira, Takahiro; Nakano, Ken			Minimization of Friction at Various Speeds Using Autonomous Viscosity Control of Nematic Liquid Crystal	TRIBOLOGY LETTERS			English	Article						Lubrication; Liquid crystal; Carboxylic acid; Molecular orientation; Viscosity; Flow alignment; Surface anchoring	TRIBOLOGICAL PROPERTIES; LUBRICATING PROPERTIES; BOUNDARY FILMS; ADDITIVES; CONFINEMENT; MIXTURES; SHEAR; OILS	To demonstrate the concept of the smart lubrication system using liquid crystal (LC) lubricant proposed by Nakano (Tribol Lett 14:17-24, 2003), the following three types of tests were performed:(1) film thickness measurements in pure rolling contacts, (2) friction coefficient measurements in rolling-sliding contacts, and (3) molecular orientation measurements in stationary cells. In all of these types of tests, a nematic LC [4-pentyl-4'-cyanobiphenyl (5CB)] and a carboxylic acid [hexadecanoic acid (HDA)] were used as the base fluid and the additive, respectively. The results of these tests confirm the following mechanism. First, surface films of the HDA additive that spontaneously adsorb onto contact surfaces induce surface anchoring, which has the effect of making 5CB molecules align themselves perpendicular to the surfaces, competing with the flow alignment of 5CB molecules and inducing an increase in the apparent viscosity of 5CB with decreasing entrainment speed. This increase in the apparent viscosity generates a constant friction coefficient region in the Stribeck curve on the left side of the minimum friction coefficient point, resulting in the minimization of friction at various speeds.	[Tadokoro, Chiharu] Tokyo Univ Sci, Dept Mech Engn, Tokyo 1258585, Japan; [Nihira, Takahiro; Nakano, Ken] Yokohama Natl Univ, Fac Environm & Informat Sci, Yokohama, Kanagawa 2408501, Japan	Nakano, K (reprint author), Yokohama Natl Univ, Fac Environm & Informat Sci, 79-7 Tokiwadai, Yokohama, Kanagawa 2408501, Japan.	nakano@ynu.ac.jp	Nakano, Ken/N-1907-2014	Nakano, Ken/0000-0001-7437-7984	Ministry of Education, Culture, Sports, Science, and Technology (MEXT) in Japan	This work was carried out as a part of the "Green Tribology Innovation Network" Project in the area of Advanced Environment Materials of the Green Network of Excellence (GRENE) program funded by the Ministry of Education, Culture, Sports, Science, and Technology (MEXT) in Japan.	Wazynska B, 2006, TRIBOL LETT, V24, P1, DOI 10.1007/s11249-006-9049-0; FISCHER TE, 1988, TRIBOL T, V31, P442, DOI 10.1080/10402008808981846; Janik J, 2001, LANGMUIR, V17, P5476, DOI 10.1021/la001392q; Mori S, 1996, TRIBOL INT, V29, P35, DOI 10.1016/0301-679X(95)00032-Y; Artsyukhovich A, 1999, LANGMUIR, V15, P2217, DOI 10.1021/la980415m; KIMURA Y, 1994, WEAR, V175, P143, DOI 10.1016/0043-1648(94)90177-5; Ruths M, 1996, LANGMUIR, V12, P6637, DOI 10.1021/la960412e; Li JW, 1999, LANGMUIR, V15, P7662, DOI 10.1021/la981750d; Carrion FJ, 2009, INT J MOL SCI, V10, P4102, DOI 10.3390/ijms10094102; BARCHAN GP, 1988, CHEM TECH FUELS OIL+, V24, P550, DOI 10.1007/BF00726118; Zhang XJ, 2012, LIQ CRYST, V39, P1305, DOI 10.1080/02678292.2012.715686; Nakano K, 2003, TRIBOL LETT, V14, P17, DOI 10.1023/A:1021710131040; Bermudez MD, 1997, WEAR, V212, P188, DOI 10.1016/S0043-1648(97)00152-X; Cui M., 1999, MOL CRYST LIQ CRYST, V331, P49, DOI 10.1080/10587259908047499; de Gennes P. G., 1993, PHYS LIQUID CRYSTALS; GRIBAILO AP, 1983, CHEM TECH FUELS OIL+, V19, P342, DOI 10.1007/BF00731562; Hamrock BJ, 1981, BALL BEARING LUBRICA; JOHNSTON GJ, 1991, TRIBOL T, V34, P187, DOI 10.1080/10402009108982026; Latyshev VN, 2009, J FRICT WEAR+, V30, P411, DOI 10.3103/S1068366609060063; Moksin V., 2011, ACAD J MANUF ENG, V9, P89; Moksin V., 2011, MECHANICS, V17, P570; Nakano Ken, 2012, Tribology Online, V7, DOI 10.2474/trol.7.1; Novikov VV, 2011, J FRICT WEAR+, V32, P452, DOI 10.3103/S1068366611060109; Shen MW, 2001, CHINESE SCI BULL, V46, P1227, DOI 10.1007/BF02900609; Vekteris V, 2008, MATER SCI+, V44, P730, DOI 10.1007/s11003-009-9125-3; WU ST, 1993, OPT ENG, V32, P1775, DOI 10.1117/12.143988	26	2	2	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1023-8883	1573-2711		TRIBOL LETT	Tribol. Lett.	NOV	2014	56	2					239	247		10.1007/s11249-014-0404-2		9	Engineering, Chemical; Engineering, Mechanical	Engineering	AT0FP	WOS:000344612900007		
J	Sekido, N; Kida, J; Wakamatsu, D; Okada, H; Matsuya, H				Sekido, Noritoshi s; Kida, Jun; Wakamatsu, Daisuke; Okada, Hiroki; Matsuya, Hidekazu			Effects of alpha 1 Antagonist and Cholinesterase Inhibitor on Cystometric Parameters in Lumbar Canal Stenosis Rats With Underactive Bladder	UROLOGY			English	Article							URINARY-TRACT SYMPTOMS; OUTLET OBSTRUCTION; ACETYLCHOLINESTERASE INHIBITOR; DETRUSOR OVERACTIVITY; PRESSURE; CONTRACTILITY; SUPPRESSION; DYSFUNCTION; TAMSULOSIN; DISTIGMINE	OBJECTIVE To examine the lower urinary tract function of a rat lumbar canal stenosis (LCS) model by in vivo cystometry before and after alpha 1 adrenoceptor antagonist or cholinesterase inhibitor administration. MATERIALS AND METHODS One small hole was drilled at the fifth lumbar vertebral arch, and a rectangular piece of silicone rubber was inserted into the L5-L6 epidural space. Two weeks after the surgery, awake cystometry was performed before and after the oral administration of the vehicle, tamsulosin (TAM, 0.03 and 0.1 mg/kg), or distigmine (DIS, 0.3 and 1 mg/kg). We compared the awake cystometry parameters before and after drug administration. RESULTS The LCS rats showed a large maximum cystometric capacity (MCC) and a high residual urine rate with a lower maximum bladder pressure during micturition (Pmax). TAM and DIS significantly decreased the pressure at the onset of voiding contraction, MCC, and postvoid residual urine volume. Residual urine rate was also significantly decreased by DIS at 0.3 and 1.0 mg/kg, and TAM at 0.03 mg/kg. DIS significantly increased the frequency of nonvoiding contractions per minute. Pmax was not significantly different even after administration of DIS. CONCLUSION The LCS rats had salient characteristics of severe infra-sacral neuropathic bladder dysfunction. TAM and DIS decreased postvoid residual urine volume, but this decrease was not accompanied by an increased Pmax or increased voided volume. Rather, decreased MCC was a possible contributing factor. Moreover, increased nonvoiding contractions after administration of DIS might participate in the decreased MCC. This novel model will be useful in studying the pharmacotherapy of the underactive bladder. (C) 2014 Elsevier Inc.	Toho Univ, Ohashi Hosp, Fac Med, Med Ctr,Dept Urol,Meguro Ku, Tokyo 1538515, Japan	Sekido, N (reprint author), Toho Univ, Ohashi Hosp, Fac Med, Med Ctr,Sch Med,Dept Urol,Meguro Ku, 2-17-6 Ohashi, Tokyo 1538515, Japan.	nsekido@med.toho-u.ac.jp			Ono Pharmaceutical Co, Ltd, Japan	This study was funded by Ono Pharmaceutical Co, Ltd, Japan.	Barendrecht MM, 2007, BJU INT, V99, P749, DOI 10.1111/j.1464-410X.2006.06742.x; Sekido N, 2012, INT J UROL, V19, P216, DOI 10.1111/j.1442-2042.2011.02947.x; Smith PP, 2010, NEUROUROL URODYNAM, V29, P408, DOI 10.1002/nau.20765; Yokoyama O, 2007, J UROLOGY, V177, P771, DOI 10.1016/j.juro.2006.09.076; Abarbanel J, 2007, UROLOGY, V69, P436, DOI 10.1016/j.urology.2006.11.019; Nomiya M, 2014, J UROLOGY, V191, P1462, DOI 10.1016/j.juro.2013.10.097; Yoshida M, 2006, UROLOGY, V67, P425, DOI 10.1016/j.urology.2005.08.014; Cellek S, 2014, NAT REV UROL, V11, P231, DOI 10.1038/nrurol.2014.53; Streng T, 2006, BJU INT, V97, P1094, DOI 10.1111/j.1464-410X.2006.06137.x; Kalichman L, 2009, SPINE J, V9, P545, DOI 10.1016/j.spinee.2009.03.005; Bae JH, 2005, BJU INT, V96, P1131, DOI 10.1111/j.1464-410X.2005.05812.x; Cong ML, 2010, J INT MED RES, V38, P1149; Daneshgari F, 2009, J UROLOGY, V182, pS18, DOI 10.1016/j.juro.2009.08.070; ELSALMY S, 1985, J UROLOGY, V134, P1011; Harada T, 2010, BIOL PHARM BULL, V33, P653; Hashimoto T, 2005, J UROLOGY, V174, P1137, DOI 10.1097/01.ju.0000168616.71956.a4; Nagabukuro H, 2004, EUR J PHARMACOL, V494, P225, DOI 10.1016/j.ejphar.2004.05.007; Nakai K, 2002, ANESTH ANALG, V94, P1537; Nishiguchi J, 2007, BJU INT, V99, P680, DOI 10.1111/j.1464-410X.2006.06643.x; Nishijima S, 2007, BIOMED RES-TOKYO, V28, P275, DOI 10.2220/biomedres.28.275; Ohtake A, 2006, EUR J PHARMACOL, V545, P185, DOI 10.1016/j.ejphar.2006.06.054; Perner A, 1997, SPINE, V22, P2693, DOI 10.1097/00007632-199711150-00019; Sakakibara R, 2005, J NEUROL, V252, P953, DOI 10.1007/s00415-005-0790-3; Sekido N, 2012, NEUROUROL URODYNAM, V31, P1190, DOI 10.1002/nau.21255; Sone A, 1994, Nihon Hinyokika Gakkai Zasshi, V85, P611; Sugaya K, 2012, INT J UROL, V19, P480, DOI 10.1111/j.1442-2042.2011.02953.x; Tatemichi S, 2012, UROLOGY, V80, p486e9; Tsai CH, 2010, SPINE, V35, pE849, DOI 10.1097/BRS.0b013e3181d55ad8; Yamanishi T, 2004, INT J UROL, V11, P88, DOI 10.1111/j.1442-2042.2004.00753.x; Yamanishi T, 1998, EUR UROL, V34, P360, DOI 10.1159/000019756	30	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0090-4295	1527-9995		UROLOGY	Urology	NOV	2014	84	5							1248.e9	10.1016/j.urology.2014.07.036		7	Urology & Nephrology	Urology & Nephrology	AS8CU	WOS:000344478700076		
J	Sasaki, M; Ishidoya, S; Ito, A; Saito, H; Yamada, S; Mitsuzuka, K; Kaiho, Y; Shibuya, D; Yamaguchi, T; Arai, Y				Sasaki, Mitsuharu; Ishidoya, Shigeto; Ito, Akihiro; Saito, Hideo; Yamada, Shigeyuki; Mitsuzuka, Koji; Kaiho, Yasuhiro; Shibuya, Daisuke; Yamaguchi, Takuhiro; Arai, Yoichi			Low Percentage of Free Prostate-specific Antigen (PSA) Is a Strong Predictor of Later Detection of Prostate Cancer Among Japanese Men With Serum Levels of Total PSA of 4.0 ng/mL or Less	UROLOGY			English	Article							DIGITAL RECTAL EXAMINATION; FREE/TOTAL PSA; POPULATION; RISK	OBJECTIVE To investigate the effect of the percentage of free prostate-specific antigen (%fPSA) on future prostate cancer risk. MATERIALS AND METHODS We examined serum total PSA (tPSA) and %fPSA annually in a prostate cancer-screening cohort between July 2001 and June 2011. Men with tPSA >4.0 ng/mL or tPSA of 2.0-4.0 ng/mL with %fPSA <= 12% were screened as positive and were recommended to undergo a biopsy. The study population consisted of 6368 men, aged 40-79 years, who had tPSA <= 4.0 ng/mL at initial screening and who subsequently underwent 1 or more screenings. We calculated the cumulative risk and hazard ratio of prostate cancer stratified by the initial %fPSA groups as quartiles of prostate cancer patients. RESULTS During a median follow-up of 36 months, 119 men were diagnosed with prostate cancer. The lowest quartile of %fPSA (<13.3%) was associated with a 21.2-fold higher risk of having prostate cancer compared with the highest quartile (>22.2%). For the subset with an initial tPSA <= 1.0 ng/mL, all men diagnosed with cancer had an initial %fPSA <= 33.3% (median). For the subset with tPSA >1.0 ng/mL, men with %fPSA >23.0% (median) had significantly higher risk for cancer than those with %fPSA > 23.0% (P < .0001). Of the 114 men with prostate cancer in whom pathologic findings were available, 79 (69.3%) had a Gleason score >= 3 + 4 = 7. CONCLUSION A low %fPSA is a strong predictor of a subsequent diagnosis of prostate cancer among men with tPSA levels <= 4.0 ng/mL. Measurement of %fPSA might enhance the detection of high-grade cancer that warrants aggressive treatment. (C) 2014 Elsevier Inc.	[Sasaki, Mitsuharu] Tohoku Univ, Grad Sch Med, Dept Urol, Aoba Ku, Sendai, Miyagi 9808574, Japan; Sendai City Hosp, Dept Urol, Sendai, Miyagi, Japan; Miyagi Canc Soc, Sendai, Miyagi, Japan; Tohoku Univ, Grad Sch Med, Div Biostat, Sendai, Miyagi 9808574, Japan	Sasaki, M (reprint author), Tohoku Univ, Grad Sch Med, Dept Urol, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.	mitsuharu@uro.med.tohoku.ac.jp			Daiwa Securities Health Foundation, Japan	This work was partly supported by a Grant-in-Aid from the Daiwa Securities Health Foundation, Japan.	Thompson IM, 2004, NEW ENGL J MED, V350, P2239, DOI 10.1056/NEJMoa031918; Catalona WJ, 1999, UROLOGY, V54, P220, DOI 10.1016/S0090-4295(99)00185-5; Catalona WJ, 1997, JAMA-J AM MED ASSOC, V277, P1452, DOI 10.1001/jama.277.18.1452; Raaijmakers R, 2004, J UROLOGY, V171, P2245, DOI 10.1097/01.ju.0000127731.56103.50; Southwick PC, 1999, J UROLOGY, V162, P1346, DOI 10.1016/S0022-5347(05)68282-1; Djavan B, 1999, UROLOGY, V54, P517, DOI 10.1016/S0090-4295(99)00153-3; Arcangeli CG, 1998, UROLOGY, V51, P558, DOI 10.1016/S0090-4295(98)00035-1; Carter HB, 2004, NEW ENGL J MED, V350, P2292, DOI 10.1056/NEJMe048003; CATALONA WJ, 1991, NEW ENGL J MED, V324, P1156, DOI 10.1056/NEJM199104253241702; COONER WH, 1990, J UROLOGY, V143, P1146; Finne P, 2008, EUR UROL, V54, P362, DOI 10.1016/j.eururo.2007.10.056; Ishidoya S, 2008, JPN J CLIN ONCOL, V38, P844, DOI 10.1093/jjco/hyn107; Orikasa K, 2008, INT J UROL, V15, P900, DOI 10.1111/j.1442-2042.2008.02106.x; Vickers AJ, 2010, BRIT MED J, V341, DOI 10.1136/bmj.c4521; Weight CJ, 2013, UROLOGY, V82, P1211, DOI 10.1016/j.urology.2013.06.074	15	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0090-4295	1527-9995		UROLOGY	Urology	NOV	2014	84	5					1163	1167		10.1016/j.urology.2014.04.055		5	Urology & Nephrology	Urology & Nephrology	AS8CU	WOS:000344478700050		
J	Kashima, S; Inoue, T; Chiba, M; Komine, N; Ito, R; Numakura, K; Tsuruta, H; Saito, M; Akihama, S; Narita, S; Tsuchiya, N; Satoh, S; Onishi, H; Habuchi, T				Kashima, Soki; Inoue, Takamitsu; Chiba, Mitsuru; Komine, Naoki; Ito, Ryuichi; Numakura, Kazuyuki; Tsuruta, Hiroshi; Saito, Mitsuru; Akihama, Susumu; Narita, Shintaro; Tsuchiya, Norihiko; Satoh, Shigeru; Onishi, Hirohide; Habuchi, Tomonori			Renal Subcapsular Fluid Collection Caused by Penetration of a Pancreatic Pseudocyst	UROLOGY			English	Editorial Material							KIDNEY; CT	A 63-year-old man presented with left flank pain and spiked fever. Computed tomography revealed a pancreatic cyst and left renal subcapsular fluid collection that appeared to be connected to the cyst. High levels of amylase and lipase were observed in a test puncture of renal fluid collection. The cause of the fluid collection was diagnosed as penetration of the pancreatic pseudocyst. Endoscopic nasobiliary drainage was used to drain the pancreatic pseudocyst and renal subcapsular fluid collection. The present case demonstrated that renal subcapsular fluid collection may be caused by penetration of a pancreatic pseudocyst. (C) 2014 Elsevier Inc.	[Inoue, Takamitsu] Akita Univ, Sch Med, Dept Urol, Akita 0108543, Japan; Akita Univ, Sch Med, Dept Gastroenterol, Akita 0108543, Japan	Inoue, T (reprint author), Akita Univ, Sch Med, Dept Urol, 1-1-1 Hondo, Akita 0108543, Japan.	takmitz@gmail.com					BAKER MK, 1983, AM J ROENTGENOL, V140, P729; FELDBERG MAM, 1987, GASTROINTEST RADIOL, V12, P121, DOI 10.1007/BF01885120; Kimura Hiroko, 2012, Hinyokika Kiyo, V58, P421; LO J, 1995, J COMPUT ASSIST TOMO, V19, P823, DOI 10.1097/00004728-199509000-00027; Mortele KJ, 2000, ABDOM IMAGING, V25, P272, DOI 10.1007/s002610000032; RAUCH RF, 1983, J COMPUT ASSIST TOMO, V7, P536, DOI 10.1097/00004728-198306000-00032	6	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0090-4295	1527-9995		UROLOGY	Urology	NOV	2014	84	5					E23	E24		10.1016/j.urology.2014.07.048		2	Urology & Nephrology	Urology & Nephrology	AS8CU	WOS:000344478700005		
J	Yoshimura, H; Nakahira, R; Kishimoto, TE; Michishita, M; Ohkusu-Tsukada, K; Takahashi, K				Yoshimura, H.; Nakahira, R.; Kishimoto, T. E.; Michishita, M.; Ohkusu-Tsukada, K.; Takahashi, K.			Differences in Indicators of Malignancy Between Luminal Epithelial Cell Type and Myoepithelial Cell Type of Simple Solid Carcinoma in the Canine Mammary Gland	VETERINARY PATHOLOGY			English	Article						dog; immunohistochemistry; mammary tumor; myoepithelial cell; p63; simple solid carcinoma	TUMORS	Routinely diagnosed simple solid carcinoma (SSC) of the canine mammary gland comprises a heterogeneous group of tumors. Seventy-two cases that had been diagnosed as SSC based on hematoxylin and eosin-stained tissue sections were reclassified immunohistochemically on the basis of myoepithelial markers p63 and -smooth muscle actin, as well as a luminal epithelial marker cytokeratin 8. Only 23 cases (32%) were true SSC, composed only of luminal epithelial cells, whereas 11 cases (15%) were malignant myoepithelioma (MM), composed predominantly of myoepithelial cells, and 38 cases (53%) were biphasic carcinoma (BC), characterized by biphasic proliferation of luminal epithelial and basal/myoepithelial components. As the pathological parameters were compared between the reclassified tumor types, infiltrative potential, vascular/lymphatic invasion, lymph node metastasis, and Ki-67 labeling index were higher in true SSC compared with MM and BC, suggesting that the former may exhibit a poorer prognosis compared with the latter two.	[Yoshimura, H.; Nakahira, R.; Kishimoto, T. E.; Michishita, M.; Ohkusu-Tsukada, K.; Takahashi, K.] Nippon Vet & Life Sci Univ NVLU, Dept Vet Pathol, Musashino, Tokyo 1808602, Japan	Takahashi, K (reprint author), Nippon Vet & Life Sci Univ NVLU, Dept Vet Pathol, 1-7-1 Kyonan Cho, Musashino, Tokyo 1808602, Japan.	kimimasa@nvlu.ac.jp					Pena LL, 1998, J VET DIAGN INVEST, V10, P237; Pena L, 2013, VET PATHOL, V50, P94, DOI 10.1177/0300985812447830; Sorenmo KU, 2011, VET PATHOL, V48, P85, DOI 10.1177/0300985810389480; Savera AT, 2000, AM J SURG PATHOL, V24, P761, DOI 10.1097/00000478-200006000-00001; Goldschmidt M, 2011, VET PATHOL, V48, P117, DOI 10.1177/0300985810393258; Barnes L, 2005, WHO CLASSIFICATION T, P209; Gama A, 2003, VET PATHOL, V40, P412, DOI 10.1354/vp.40-4-412; Martin de las Mulas J, 2004, VET COMP ONCOL, V2, P24, DOI 10.1111/j.1476-5810.2004.00036.x; Misdorp W., 2002, Tumors in domestic animals, P575, DOI 10.1002/9780470376928.ch12; Misdorp W, 1999, HISTOLOGICAL CLASSIF, P11; Yoshimura H, 2011, VET PATHOL, V48, P313, DOI 10.1177/0300985810369901; Zarbo RJ, 2002, MODERN PATHOL, V15, P298, DOI 10.1038/modpathol.3880525	12	3	3	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	NOV	2014	51	6					1090	1095		10.1177/0300985813516637		6	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	AT1GQ	WOS:000344681800005		
J	Park, ES; Uchida, K; Nakayama, H				Park, E. -S.; Uchida, K.; Nakayama, H.			Establishment of a Rat Model for Canine Necrotizing Meningoencephalitis (NME)	VETERINARY PATHOLOGY			English	Article						autoantibody; animal model; experimental autoimmune encephalitis (EAE); dog; necrotizing meningoencephalitis (NME)	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FELINE INFECTIOUS PERITONITIS; CENTRAL-NERVOUS-SYSTEM; PUG DOGS; GRANULOMATOUS MENINGOENCEPHALOMYELITIS; CELLS; EXPRESSION; MICROGLIA; NECROSIS; BRAIN	The pathogenesis of necrotizing meningoencephalitis (NME), necrotizing leukoencephalitis (NLE), and granulomatous meningoencephalomyelitis (GME) is still uncertain, although they are considered immune-mediated diseases. The purpose of the present study is to generate a rodent model(s) of these diseases. Rats were injected with rat cerebral or cerebellar homogenate. Rats injected with cerebral homogenate (Cbr) exhibited vacuolar or malacic changes mainly in the cerebral cortex. CD3-positive T cells and Iba-1-positive and CD163-negative microglia infiltrated and activated around the lesions. IgG deposited in the glial fibrillary acid protein (GFAP)-positive glia limitans from the early phase, and CD3-positive T cells attached to GFAP-positive astrocytes. Autoantibodies against GFAP were detected in the sera. These pathological features of Cbr rats were consistent with those of canine NME. In contrast, rats injected with cerebral homogenate (Cbe) exhibited demyelinating lesions with inflammatory reactions in the cerebellum, brainstem, and spinal cord. The presence of demyelination and autoantibodies against myelin proteins in Cbe rats was similar to murine experimental autoimmune encephalitis and differed from NME, NLE, and GME. All the present findings indicate that autoantibodies together with microglia and T cells may play a major role in the pathogenesis of idiopathic canine meningoencephalomyelitis.	[Park, E. -S.; Uchida, K.; Nakayama, H.] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Vet Pathol, Tokyo 1138657, Japan	Uchida, K (reprint author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Vet Pathol, Tokyo 1138657, Japan.	auchidak@mail.ecc.u-tokyo.ac.jp					Aloisi F, 2000, IMMUNOL TODAY, V21, P141, DOI 10.1016/S0167-5699(99)01512-1; Talarico LR, 2010, J SMALL ANIM PRACT, V51, P138, DOI 10.1111/j.1748-5827.2009.00823.x; Lassmann H, 2007, REV NEUROL-FRANCE, V163, P651, DOI 10.1016/S0035-3787(07)90474-9; Schatzberg SJ, 2005, J VET INTERN MED, V19, P553, DOI 10.1892/0891-6640(2005)19[553:PCRSFD]2.0.CO;2; Fabriek BO, 2005, IMMUNOBIOLOGY, V210, P153, DOI 10.1016/j.imbio.2005.05.010; Spitzbarth I, 2010, J COMP PATHOL, V142, P235, DOI 10.1016/j.jcpa.2009.08.158; Henning EC, 2009, J CEREBR BLOOD F MET, V29, P1229, DOI 10.1038/jcbfm.2009.48; BANIK NL, 1992, CRIT REV NEUROBIOL, V6, P257; Higgins RJ, 2008, VET PATHOL, V45, P336, DOI 10.1354/vp.45-3-336; Mayer MC, 2012, THER ADV NEUROL DISO, V5, P147, DOI 10.1177/1756285611433772; CORDY DR, 1989, VET PATHOL, V26, P191; Rappert A, 2004, J NEUROSCI, V24, P8500, DOI 10.1523/JNEUROSCI.2451-04.2004; Ducote JM, 1999, VET RADIOL ULTRASOUN, V40, P617, DOI 10.1111/j.1740-8261.1999.tb00888.x; Biber K, 2002, NEUROSCIENCE, V112, P487, DOI 10.1016/S0306-4522(02)00114-8; Suzuki M, 2003, J VET MED SCI, V65, P1233, DOI 10.1292/jvms.65.1233; BRADLEY GA, 1991, VET PATHOL, V28, P91; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; Kipar A, 1998, VET PATHOL, V35, P43; Aranami Toshimasa, 2008, Allergol Int, V57, P115, DOI 10.2332/allergolint.R-07-159; Berg AL, 2005, VET MICROBIOL, V111, P15, DOI 10.1016/j.vetmic.2005.07.017; Foley JE, 2003, J FELINE MED SURG, V5, P313, DOI 10.1016/S1098-612X(03)00048-2; KOBAYASHI Y, 1994, J COMP PATHOL, V110, P129, DOI 10.1016/S0021-9975(08)80184-3; KURODA Y, 1991, J NEUROIMMUNOL, V34, P159, DOI 10.1016/0165-5728(91)90125-Q; Levine JM, 2008, J VET INTERN MED, V22, P961, DOI 10.1111/j.1939-1676.2008.0137.x; Matsuki N, 2004, J VET MED SCI, V66, P295, DOI 10.1292/jvms.66.295; Mohindru M, 2004, J NEUROIMMUNOL, V155, P127, DOI 10.1016/j.jneuroim.2004.06.012; Park ES, 2013, VET PATHOL, V50, P1127, DOI 10.1177/0300985813488957; Park ES, 2012, VET PATHOL, V49, P682, DOI 10.1177/0300985811429311; Rezaie Payam, 2003, Neuroembryology, V2, P130, DOI 10.1159/000074192; SELMAJ K, 1995, J NEUROIMMUNOL, V56, P135, DOI 10.1016/0165-5728(94)00139-F; Suzuki M, 2003, J VET MED SCI, V65, P1319, DOI 10.1292/jvms.65.1319; Uchida K, 1999, VET PATHOL, V36, P301, DOI 10.1354/vp.36-4-301; Weissenbock H, 1998, J CLIN MICROBIOL, V36, P2127	33	1	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0300-9858	1544-2217		VET PATHOL	Vet. Pathol.	NOV	2014	51	6					1151	1164		10.1177/0300985813519115		14	Pathology; Veterinary Sciences	Pathology; Veterinary Sciences	AT1GQ	WOS:000344681800012		
J	Iwai, D; Nagase, M; Sato, K				Iwai, Daisuke; Nagase, Momoyo; Sato, Kosuke			Shadow removal of projected imagery by occluder shape measurement in a multiple overlapping projection system	VIRTUAL REALITY			English	Article						Shadow removal; Multiple overlapping projection; Synthetic aperture capturing; Visual hull	LIGHT SUPPRESSION; DISPLAYS; ELIMINATION	This paper presents a shadow removal technique for a multiple overlapping projection system. In particular, this paper deals with situations where cameras cannot be placed between the occluder and projection surface. We apply a synthetic aperture capturing technique to estimate the appearance of the projection surface, and a visual hull reconstruction technique to measure the shape of the occluder. Once the shape is acquired, shadow regions on the surface can be estimated. The proposed shadow removal technique allows users to balance between the following two criteria: the likelihood of new shadow emergence and the spatial resolution of the projected results. Through a real projection experiment, we evaluate the proposed shadow removal technique.	[Iwai, Daisuke; Nagase, Momoyo; Sato, Kosuke] Osaka Univ, Grad Sch Engn Sci, Toyonaka, Osaka 5608531, Japan	Iwai, D (reprint author), Osaka Univ, Grad Sch Engn Sci, 1-3 Machikaneyama, Toyonaka, Osaka 5608531, Japan.	daisuke.iwai@sys.es.osaka-u.ac.jp					Abdel-Aziz Y. I., 1971, P ASP UI S CLOS RANG, P1; Raskar R, 2001, SPRING EUROGRAP, P89; Nagase M, 2011, VIRTUAL REAL-LONDON, V15, P119, DOI 10.1007/s10055-010-0168-4; Bimber O, 2006, IEEE T VIS COMPUT GR, V12, P658, DOI 10.1109/TVCG.2006.75; Bimber O, 2008, COMPUT GRAPH FORUM, V27, P2219, DOI 10.1111/j.1467-8659.2008.01175.x; LAURENTINI A, 1994, IEEE T PATTERN ANAL, V16, P150, DOI 10.1109/34.273735; Bandyopadhyay D, 2001, IEEE AND ACM INTERNATIONAL SYMPOSIUM ON AUGMENTED REALITY, PROCEEDINGS, P207; Jaynes C, 2001, IEEE VISUAL, P175; Audet S, 2007, P IEEE C COMP VIS PA, P1; Bimber O., 2005, Proceedings. International Symposium on Mixed and Augmented Reality; Cham TJ, 2003, PROC CVPR IEEE, P513; Jaynes C, 2004, IEEE T VIS COMPUT GR, V10, P290, DOI 10.1109/TVCG.2004.1272728; Jones B.R., 2010, P 9 IEEE INT S MIX A, P165; Ladikos A, 2008, P IEEE WORKSH VIS CO; Low KL, 2001, P ACM S VIRT REAL SO, P93, DOI DOI 10.1145/505008.505026; Sato K., 1987, Proceedings of the First International Conference on Computer Vision (Cat. No.87CH2465-3); Sugaya Y, 2010, P INT WORKSH PROJ CA, P13; Sukthankar R, 2001, PROC CVPR IEEE, P151; Summet J, 2007, IEEE T VIS COMPUT GR, V13, P508, DOI [10.1109/TVCG.2007.1007, 10.1107/TVCG.2007.1007]; Vaish V., 2006, P 2006 IEEE COMP SOC, V2, P2331; Wang Z, 2004, IEEE T IMAGE PROCESS, V13, P600, DOI 10.1109/TIP.2003.819861; Yoshida T., 2003, P INT C VIRT SYST MU, P161	22	1	1	SPRINGER LONDON LTD	LONDON	236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND	1359-4338	1434-9957		VIRTUAL REAL-LONDON	Virtual Real.	NOV	2014	18	4					245	254		10.1007/s10055-014-0250-4		10	Computer Science, Interdisciplinary Applications; Computer Science, Software Engineering; Imaging Science & Photographic Technology	Computer Science; Imaging Science & Photographic Technology	AT0AZ	WOS:000344600500002		
J	Okura, F; Kanbara, M; Yokoya, N				Okura, Fumio; Kanbara, Masayuki; Yokoya, Naokazu			Aerial full spherical HDR imaging and display	VIRTUAL REALITY			English	Article						Omnidirectional camera; High dynamic range image; Immersive panorama; Image-based lighting; Tone-mapping	TELEPRESENCE; VIDEO	This paper describes a framework for aerial imaging of high dynamic range (HDR) scenes for use in virtual reality applications, such as immersive panorama applications and photorealistic superimposition of virtual objects using image-based lighting. We propose a complete and practical system to acquire full spherical HDR images from the sky, using two omnidirectional cameras mounted above and below an unmanned aircraft. The HDR images are generated by combining multiple omnidirectional images captured with different exposures controlled automatically. Our system consists of methods for image completion, alignment, and color correction, as well as a novel approach for automatic exposure control, which selects optimal exposure so as to avoid banding artifacts. Experimental results indicated that our system generated better spherical images compared to an ordinary spherical image completion system in terms of naturalness and accuracy. In addition to proposing an imaging method, we have carried out an experiment about display methods for aerial HDR immersive panoramas utilizing spherical images acquired by the proposed system. The experiment demonstrated HDR imaging is beneficial to immersive panorama using an HMD, in addition to ordinary uses of HDR images.	[Okura, Fumio; Kanbara, Masayuki; Yokoya, Naokazu] Nara Inst Sci & Technol NAIST, Grad Sch Informat Sci, Nara 89165, Japan	Okura, F (reprint author), Nara Inst Sci & Technol NAIST, Grad Sch Informat Sci, Takayama Cho, Nara 89165, Japan.	fumio-o@is.naist.jp; kanbara@is.naist.jp; yokoya@is.naist.jp			Japan Society for the Promotion of Science (JSPS) [23240024, 25-7448]; "Ambient Intelligence'' project - Ministry of Education, Culture, Sports, Science and Technology (MEXT)	This research was supported by the Japan Society for the Promotion of Science (JSPS) Grant-in-Aid for Scientific Research (A), No. 23240024, Grant-in-Aid for JSPS Fellows No. 25-7448, and by the "Ambient Intelligence'' project funded by Ministry of Education, Culture, Sports, Science and Technology (MEXT).	Goodrich MA, 2008, J FIELD ROBOT, V25, P89, DOI 10.1002/rob.20226; Reinhard E, 2002, ACM T GRAPHIC, V21, P267; Kang SB, 2003, ACM T GRAPHIC, V22, P319, DOI 10.1145/882262.882270; Hasinoff SW, 2010, PROC CVPR IEEE, P553, DOI 10.1109/CVPR.2010.5540167; Kawai N, 2009, LECT NOTES COMPUT SC, V5414, P271; Igawa N, 2004, SOL ENERGY, V77, P137, DOI 10.1016/j.solener.2004.04.016; Onoe Y, 1998, COMPUT VIS IMAGE UND, V71, P154, DOI 10.1006/cviu.1998.0705; Herwitz SR, 2004, COMPUT ELECTRON AGR, V44, P49, DOI 10.1016/j.compag.2004.02.006; Zomet A, 2003, IEEE T PATTERN ANAL, V25, P741, DOI 10.1109/TPAMI.2003.1201823; SHI JB, 1994, 1994 IEEE COMPUTER SOCIETY CONFERENCE ON COMPUTER VISION AND PATTERN RECOGNITION, PROCEEDINGS, P593; Rother C, 2004, ACM T GRAPHIC, V23, P309, DOI 10.1145/1015706.1015720; Anguelov D, 2010, COMPUTER, V43, P32, DOI 10.1109/MC.2010.170; Chen S. E., 1995, P SIGGRAPH 95, P29, DOI DOI 10.1145/218380.218395; Debevec P., 1998, P SIGGRAPH 98, P189, DOI DOI 10.1145/1401132.1401175; Debevec P. E., 1997, P ACM SIGGRAPH, P369, DOI DOI 10.1145/258734.258884; Debevec P.E., 1996, P SIGGRAPH 96, P11, DOI 10.1145/237170.237191; Goodnight N., 2003, P 14 EUR WORKSH REND, P26; Grossberg MD, 2003, P IEEE WORKSH COL PH, P1; Ikeda S, 2003, PROCEEDINGS OF THE IEEE INTERNATIONAL CONFERENCE ON MULTISENSOR FUSION AND INTEGRATION FOR INTELLIGENT SYSTEMS, P155, DOI 10.1109/MFI-2003.2003.1232649; Kawai Norihiko, 2010, IPSJ Transactions on Computer Vision and Applications, V2, DOI 10.2197/ipsjtcva.2.200; Kitaura M, 2012, PROC SPIE, V8292, DOI 10.1117/12.908265; Kopf J, 2010, CM T GRAPH P ACM SIG, V29; Moezzi S, 1997, IEEE MULTIMEDIA, V4, P17, DOI 10.1109/MMUL.1997.580996; Okura Fumio, 2011, P ACM SIGGRAPH 11, P78; Reinhard E., 2002, Journal of Graphics Tools, V7; Reinhard E., 2010, HIGH DYNAMIC RANGE I; Sato T, 2004, LECT NOTES COMPUT SC, V3022, P326; Shum HY, 2003, IEEE T CIRC SYST VID, V13, P1020, DOI 10.1109/TCSVT.2003.817360; Stumpfel J., 2004, P 3 INT C COMP GRAPH, P145, DOI 10.1145/1029949.1029977; Ward G., 2003, Journal of Graphics Tools, V8	30	1	1	SPRINGER LONDON LTD	LONDON	236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND	1359-4338	1434-9957		VIRTUAL REAL-LONDON	Virtual Real.	NOV	2014	18	4					255	269		10.1007/s10055-014-0249-x		15	Computer Science, Interdisciplinary Applications; Computer Science, Software Engineering; Imaging Science & Photographic Technology	Computer Science; Imaging Science & Photographic Technology	AT0AZ	WOS:000344600500003		
J	Endo, M; Kimura, K; Kuwayama, T; Monji, Y; Iwata, H				Endo, M.; Kimura, K.; Kuwayama, T.; Monji, Y.; Iwata, H.			Effect of estradiol during culture of bovine oocyte-granulosa cell complexes on the mitochondrial DNA copies of oocytes and telomere length of granulosa cells	ZYGOTE			English	Article						Early antral follicle; Estradiol; Mitochondrial number; Telomere length	ESTROGEN-RECEPTOR-BETA; IN-VITRO GROWTH; OVARIAN-FOLLICLES; COPY NUMBER; MATURATION; APOPTOSIS; PIG; 17-BETA-ESTRADIOL; IDENTIFICATION; TRANSCRIPTION	During the development of oocytes from early antral follicles (EAFs) to antral follicles (AFs), the mitochondrial DNA copy number (Mt DNA number) increases, and granulosa cells markedly proliferate. This study examined the effect of supplementation of culture medium with estradiol-17 beta(E-2) on the in vitro growth of oocytes, and increases in the Mt DNA number, and telomere length during the in vitro culture of oocytes derived from EAFs (0.4-0.7 mm in diameter). The E-2 supplementation improved antrum formation and the ratio of oocytes reaching the metaphase II (MII) stage, and there was a significant difference in these values between addition E-2 concentrations of 10 mu g/ml and 0.1 mu g/ml. When the oocytes were cultured in the medium containing 10 mu g/ml E-2, the Mt DNA number determined by real-time polymerase chain reaction (PCR) significantly increased, and the ratio of the Mt DNA number at the end of culture to the Mt DNA number at the beginning of the culture was greatly different among cows, and could be predicted by the degree of the difference between the Mt DNA number of oocytes derived from EAFs and that of oocytes derived from AFs (3-6 mm in diameter). When oocytes were cultured for 16 days in a medium containing 10 mu g/ml E-2 or 0.1 mu g/ml E-2, the Mt DNA number of oocytes grown in vitro did not differ, but the telomere length of the granulosa cells was significantly greater in the 10 mu g/ml E-2 group than in the 0.1 mu g/ml group. In conclusion, E-2 supplementation in culture medium improved the growth of oocytes derived from EAFs, and a high E-2 concentration increased the telomere length of the granulosa cells.	[Endo, M.; Kuwayama, T.; Monji, Y.; Iwata, H.] Tokyo Univ Agr, Dept Anim Sci, Atsugi, Kanagawa 2430034, Japan; [Kimura, K.] Natl Inst Livestock & Grassland Sci, Tsukuba, Tochigi 3292793, Japan	Iwata, H (reprint author), Tokyo Univ Agr, Dept Anim Sci, Funako 1737, Atsugi, Kanagawa 2430034, Japan.	h1iwata@nodai.ac.jp					El Shourbagy SH, 2006, REPRODUCTION, V131, P233, DOI 10.1530/rep.1.00551; Liu JP, 2010, REPRODUCTION, V140, P215, DOI 10.1530/REP-10-0008; Iwata H, 2011, REPROD FERT DEVELOP, V23, P424, DOI 10.1071/RD10133; Xu M, 2006, BIOL REPROD, V75, P916, DOI 10.1095/biolreprod.106.054833; Wang LY, 2009, J ZHEJIANG UNIV-SC B, V10, P483, DOI 10.1631/jzus.B0820379; Chiaratti MR, 2010, BIOL REPROD, V82, P76, DOI 10.1095/biolreprod.109.077776; Sastre-Serra J, 2012, CELL PHYSIOL BIOCHEM, V29, P261, DOI 10.1159/000337607; Yamagata Y, 2002, ENDOCR J, V49, P589, DOI 10.1507/endocrj.49.589; Wai T, 2010, BIOL REPROD, V83, P52, DOI 10.1095/biolreprod.109.080887; Mattingly KA, 2008, MOL ENDOCRINOL, V22, P609, DOI 10.1210/me.2007-0029; Chen JQ, 2009, BBA-MOL CELL RES, V1793, P1540, DOI 10.1016/j.bbamcr.2009.06.001; Reynier P, 2001, MOL HUM REPROD, V7, P425, DOI 10.1093/molehr/7.5.425; Misiti S, 2000, MOL CELL BIOL, V20, P3764, DOI 10.1128/MCB.20.11.3764-3771.2000; West-Farrell ER, 2009, BIOL REPROD, V80, P432, DOI 10.1095/biolreprod.108.071142; Weber TA, 2010, EXP GERONTOL, V45, P503, DOI 10.1016/j.exger.2010.03.018; Emmen JMA, 2005, ENDOCRINOLOGY, V146, P2817, DOI 10.1210/en.2004-1108; Evans ACO, 2004, BIOL REPROD, V70, P1475, DOI 10.1095/biolreprod.103.025114; Santos TA, 2006, FERTIL STERIL, V85, P584, DOI 10.1016/j.fertnstert.2005.09.017; Bayne S, 2011, PROTEIN CELL, V2, P333, DOI 10.1007/s13238-011-1033-2; Beker-van Woudenberg AR, 2004, BIOL REPROD, V70, P1465, DOI 10.1095/biolreprod.103.025684; Couse JF, 2005, ENDOCRINOLOGY, V146, P3247, DOI 10.1210/en.2005-0213; Hattori M, 2004, MOL CELL BIOCHEM, V260, P13, DOI 10.1023/B:MCBI.0000026046.32875.70; Hirao Y, 2004, BIOL REPROD, V70, P83, DOI 10.1095/biolreprod.103.021238; Huynh K, 2004, BIOL REPROD, V70, P1263, DOI 10.1095/biolreprod.103.022111; Iwata H., 2006, ZYGOTE, V13, P303, DOI 10.1017/S0967199405003412; Kondoh K, 2007, EXP CELL RES, V313, P3486, DOI 10.1016/j.yexcr.2007.06.028; Lavranos TC, 1999, BIOL REPROD, V61, P358, DOI 10.1095/biolreprod61.2.358; Ling SH, 2006, STEROIDS, V71, P799, DOI 10.1016/j.steroids.2006.05.010; Mastromonaco G. F., 2006, BMC DEV BIOL, V9, P6; Russo V, 2006, J HISTOCHEM CYTOCHEM, V54, P443, DOI 10.1369/jhc.4A6603.2006; Sakamoto A, 2006, J REPROD DEVELOP, V52, P669, DOI 10.1262/jrd.17112	31	1	1	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0967-1994	1469-8730		ZYGOTE	Zygote	NOV	2014	22	4					431	439		10.1017/S0967199412000603		9	Cell Biology; Developmental Biology; Reproductive Biology	Cell Biology; Developmental Biology; Reproductive Biology	AT3CK	WOS:000344813100001		
J	Hara, H; Yamane, I; Noto, I; Kagawa, N; Kuwayama, M; Hirabayashi, M; Hochi, S				Hara, H.; Yamane, I.; Noto, I.; Kagawa, N.; Kuwayama, M.; Hirabayashi, M.; Hochi, S.			Microtubule assembly and in vitro development of bovine oocytes with increased intracellular glutathione level prior to vitrification and in vitro fertilization	ZYGOTE			English	Article						Bovine oocytes; Intracellular glutathione; beta-Mercaptoethanol; Multiple asters; Vitrification	MATURED PORCINE OOCYTES; CYSTEAMINE SUPPLEMENTATION; BLASTOCYST DEVELOPMENT; BETA-MERCAPTOETHANOL; EMBRYO DEVELOPMENT; MIXED DISULFIDE; THIOL COMPOUNDS; MALE PRONUCLEUS; MOUSE OOCYTES; PIG OOCYTES	Although vitrification is a useful technique for preservation of bovine oocytes, the yield of blastocysts derived from the vitrified oocytes is still low. We have recently reported a new type of cryoinjury, multiple aster formation, by which pronuclear migration and development of vitrified-warmed and in vitro-fertilized bovine oocytes are impaired. The aim of the present study was to investigate the effect of glutathione (GSH) content of vitrified bovine oocytes on multiple aster formation and subsequent in vitro development. Treatment of bovine cumulus-oocyte complexes with beta-mercaptoethanol (beta ME) and L-cysteine (Cys) during in vitro maturation resulted in 2.5-fold higher GSH content not only in fresh control but also in vitrified-warmed oocytes. The percentage of normally fertilized zygotes exhibiting sperm aster(s) was >95% in all four groups (with or without beta ME/Cys x fresh control or vitrified). The frequency of multiple aster formation in vitrified oocytes (three-fold higher than that in fresh control oocytes) was not affected by the increased level of intracellular GSH with beta ME/Cys. Consequently, the migration and development of pronuclei as well as the yield of blastocysts from vitrified-warmed oocytes (17 versus 41%) were not improved. In addition, there was no effect of increased GSH level on the yield of blastocysts in fresh control groups.	[Hara, H.; Hochi, S.] Shinshu Univ, Interdisciplinary Grad Sch Sci & Technol, Ueda, Nagano 3868567, Japan; [Yamane, I.; Noto, I.; Hochi, S.] Shinshu Univ, Grad Sch Sci & Technol, Ueda, Nagano 3868567, Japan; [Kagawa, N.] Kato Ladies Clin, Shinjuku Ku, Tokyo, Japan; [Kuwayama, M.] Reprosupport Med Res Ctr, Shinjuku Ku, Tokyo, Japan; [Hirabayashi, M.] Natl Inst Physiol Sci, Okazaki, Aichi 4448787, Japan; [Hirabayashi, M.] Grad Univ Adv Studies, Okazaki, Aichi 4448787, Japan; [Hochi, S.] Shinshu Univ, Fac Text Sci & Technol, Ueda, Nagano 3868567, Japan	Hochi, S (reprint author), Shinshu Univ, Interdisciplinary Grad Sch Sci & Technol, Ueda, Nagano 3868567, Japan.	shochi@shinshu-u.ac.jp			Japan Society for the Promotion of Sciences [24580407]	This work was supported in part by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Sciences (no. 24580407).	Abeydeera LR, 1998, THERIOGENOLOGY, V50, P747, DOI 10.1016/S0093-691X(98)00180-0; Hara H, 2012, THERIOGENOLOGY, V77, P908, DOI 10.1016/j.theriogenology.2011.09.018; Holm P, 1999, THERIOGENOLOGY, V52, P683, DOI 10.1016/S0093-691X(99)00162-4; Brad AM, 2003, MOL REPROD DEV, V64, P492, DOI 10.1002/mrd.10254; Chian RC, 2004, J REPROD DEVELOP, V50, P685, DOI 10.1262/jrd.50.685; Larman MG, 2006, REPRODUCTION, V131, P53, DOI 10.1530/rep.1.00878; Shimizu H, 2009, J CELL SCI, V122, P3145, DOI 10.1242/jcs.052795; SCHATTEN G, 1994, DEV BIOL, V165, P299, DOI 10.1006/dbio.1994.1256; TAKAHASHI M, 1993, BIOL REPROD, V49, P228, DOI 10.1095/biolreprod49.2.228; PERREAULT SD, 1988, DEV BIOL, V125, P181, DOI 10.1016/0012-1606(88)90070-X; Shi WQ, 2006, REPRODUCTION, V131, P795, DOI 10.1530/rep.1.00899; Hara H, 2011, J REPROD DEVELOP, V57, P428, DOI 10.1262/jrd.10-167N; MEISTER A, 1983, SCIENCE, V220, P472, DOI 10.1126/science.6836290; DEMATOS DG, 1995, MOL REPROD DEV, V42, P432, DOI 10.1002/mrd.1080420409; Sutovsky P, 1997, BIOL REPROD, V56, P1503, DOI 10.1095/biolreprod56.6.1503; Furnus CC, 1999, THERIOGENOLOGY, V51, P373, DOI 10.1016/S0093-691X(99)91932-5; OHMORI H, 1983, CELL IMMUNOL, V79, P173, DOI 10.1016/0008-8749(83)90060-6; deMatos DG, 1996, MOL REPROD DEV, V45, P451, DOI 10.1002/(SICI)1098-2795(199612)45:4<451::AID-MRD7>3.3.CO;2-Q; Balasubramanian S, 2007, ANIM REPROD SCI, V98, P282, DOI 10.1016/j.anireprosci.2006.03.011; YOSHIDA M, 1993, BIOL REPROD, V49, P89, DOI 10.1095/biolreprod49.1.89; Gupta MK, 2010, FERTIL STERIL, V93, P2602, DOI 10.1016/j.fertnstert.2010.01.043; Choe C, 2010, J REPROD DEVELOP, V56, P575, DOI 10.1262/jrd.09-214H; de Matos DG, 2002, MOL REPROD DEV, V62, P203, DOI 10.1002/mrd.10087; FUKU E, 1992, CRYOBIOLOGY, V29, P485, DOI 10.1016/0011-2240(92)90051-3; Ge L, 2008, FERTIL STERIL, V90, P2376, DOI 10.1016/j.fertnstert.2007.10.054; ISHII T, 1981, J BIOL CHEM, V256, P2387; Kim MK, 2007, J VET MED SCI, V69, P627, DOI 10.1292/jvms.69.627; Leibo S. P., 1981, New technologies in animal breeding, P127; Mizushima S, 2001, THERIOGENOLOGY, V55, P1431, DOI 10.1016/S0093-691X(01)00492-7; Rodriguez-Gonzalez E, 2003, MOL REPROD DEV, V65, P446, DOI 10.1002/mrd.10316; Tamas S, 2007, CRYOBIOLOGY, V55, P115, DOI 10.1016/j.cryobiol.2007.06.008	31	1	1	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0967-1994	1469-8730		ZYGOTE	Zygote	NOV	2014	22	4					476	482		10.1017/S0967199413000105		7	Cell Biology; Developmental Biology; Reproductive Biology	Cell Biology; Developmental Biology; Reproductive Biology	AT3CK	WOS:000344813100007		
J	Briggs, RJ; Nicholson, R; Vazvaei, F; Busch, J; Mabuchi, M; Mahesh, KS; Brudny-Kloeppel, M; Weng, N; Galvinas, PAR; Duchene, P; Hu, P; Abbott, RW				Briggs, R. J.; Nicholson, R.; Vazvaei, F.; Busch, J.; Mabuchi, M.; Mahesh, K. S.; Brudny-Kloeppel, M.; Weng, N.; Galvinas, P. A. R.; Duchene, P.; Hu, Pei; Abbott, R. W.			Method Transfer, Partial Validation, and Cross Validation: Recommendations for Best Practices and Harmonization from the Global Bioanalysis Consortium Harmonization Team	AAPS JOURNAL			English	Article						bioanalytical method validation; cross validation; method transfer; partial validation		This paper presents the recommendations of the Global Bioanalytical Consortium Harmonization Team on method transfer, partial validation, and cross validation. These aspects of bioanalytical method validation, while important, have received little detailed attention in recent years. The team has attempted to define, separate, and describe these related activities, and present practical guidance in how to apply these techniques.	[Briggs, R. J.] Eurofins, Abingdon, Oxon, England; [Nicholson, R.] PPD, Richmond, VA USA; [Vazvaei, F.] Roche Innovat Ctr, New York, NY USA; [Busch, J.] Pfizer Inc, Groton, CT 06340 USA; [Mabuchi, M.] Mitsubishi Tanabe Pharmaceutical Corp, Osaka, Japan; [Mahesh, K. S.] Clinigene Int Ltd, Bangalore, Karnataka, India; [Brudny-Kloeppel, M.] Bayer, Berlin, Germany; [Weng, N.] Janssen Pharmaceut R&D LLC, Spring House, PA USA; [Galvinas, P. A. R.] Magabi Pesquisas Clin & Farmaceut LTDA, Sau Paulo, Brazil; [Duchene, P.] Eurofins, Vergeze, France; [Hu, Pei] Beijing Union Med Coll Hosp, Beijing, Peoples R China; [Abbott, R. W.] Shire, Basingstoke, Hants, England	Briggs, RJ (reprint author), Eurofins, Abingdon, Oxon, England.	ray.briggs@merckgroup.com					DeSilva B, 2012, BIOANALYSIS, V4, P2213, DOI [10.4155/bio.12.205, 10.4155/BIO.12.205]; [Anonymous], 2013, MHLW GUIDELINE BIOAN; DeSilva B, 2003, PHARM RES, V20; European Medicines Agency, EMEACHMPEWP192217200; Fast Douglas M, 2009, AAPS J, V11, P238, DOI 10.1208/s12248-009-9100-9; Lowes S, 2012, BIOANALYSIS, V4, P2117, DOI 10.4155/BIO.12.192; Senbro CJ, 2012, BIOANALYSIS, V3, P2393; Timmerman P, 2010, BIOANALYSIS, V2, P683, DOI [10.4155/bio.10.34, 10.4155/BIO.10.34]; U.S. Department of Health and Human Services, 2001, GUID IND BIOAN METH; van Amsterdam P, 2010, BIOANALYSIS, V2, P1801, DOI [10.4155/bio.10.146, 10.4155/BIO.10.146]; van Amsterdam P, 2010, BIOANALYSIS, V2, P689, DOI [10.4155/bio.10.37, 10.4155/BIO.10.37]; Viswanathan CT, 2007, AAPS J, V9, pE30, DOI 10.1208/aapsj0901004	12	8	8	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1550-7416			AAPS J	AAPS J.	NOV	2014	16	6					1143	1148		10.1208/s12248-014-9650-3		6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AS5ZN	WOS:000344345000001		
J	Timmerman, P; Arnold, M; DeSilva, B; Garofolo, F; Golob, M; van Amsterdam, P; Kudoh, S; Singhal, P; Tang, D; Riccio, MF; Barrientos, R; Savale, S; Kurokawa, T				Timmerman, Philip; Arnold, Mark; DeSilva, Binodh; Garofolo, Fabio; Golob, Michaela; van Amsterdam, Peter; Kudoh, Shinobu; Singhal, Puran; Tang, Daniel; Riccio, Maria Francesca; Barrientos, Rafael; Savale, Shrinivas; Kurokawa, Tatsuo			Introduction to the Proposals from the Global Bioanalysis Consortium Harmonization Team	AAPS JOURNAL			English	Editorial Material							METHOD VALIDATION; WHITE PAPER; RECOMMENDATIONS; GUIDANCE		[Timmerman, Philip] Janssen Res & Dev, B-2340 Beerse, Belgium; [Arnold, Mark; DeSilva, Binodh] Bristol Myers Squibb Co, Princeton, NJ 08543 USA; [Garofolo, Fabio] Algorithme Pharma, Laval, PQ, Canada; [Golob, Michaela] Merck Serono, D-85567 Grafing, Germany; [van Amsterdam, Peter] Abbott Healthcare Prod, NL-1381 CP Weesp, Netherlands; [Kudoh, Shinobu] Shimadzu Shimadzu Techno Res, Nakagyo Ku, Kyoto 6048436, Japan; [Singhal, Puran] Alkem Labs Ltd, Taloja 410208, Navi Mumbai, India; [Tang, Daniel] Chong Hing Finance Ctr, ICON Lab Serv, Shanghai 200003, Peoples R China; [Riccio, Maria Francesca] CAEP Ctr Avancado Estudos & Pesquisas LTDA, Campinas, SP, Brazil; [Barrientos, Rafael] Eurofarma Lab SA, Itapevi, SP, Brazil; [Savale, Shrinivas] Torrent Pharmaceut Ltd, Gandhinagar 382428, Gujarat, India; [Kurokawa, Tatsuo] Keio Univ, Fac Pharm, Tokyo 108, Japan	Timmerman, P (reprint author), Janssen Res & Dev, Turnhoutseweg 30, B-2340 Beerse, Belgium.	ptimmerm@its.jnj.com					Ahene A, 2013, AAPS J, V16, P164; SHAH VP, 1992, PHARMACEUT RES, V9, P588, DOI 10.1023/A:1015829422034; Findlay JWA, 2000, J PHARMACEUT BIOMED, V21, P1249, DOI 10.1016/S0731-7085(99)00244-7; Savoie N, 2010, BIOANALYSIS, V2, P1945, DOI [10.4155/bio.10.164, 10.4155/BIO.10.164]; Sailstad JM, 2014, AAPS J, V16, P488, DOI 10.1208/s12248-014-9582-y; Bansal SK, 2010, BIOANALYSIS, V2, P685, DOI [10.4155/bio.10.39, 10.4155/BIO.10.39]; Bower JF, 2014, AAPS J, V16, P352, DOI 10.1208/s12248-014-9566-y; Briggs RJ, 2014, AAPS J, V16, P1143, DOI 10.1208/s12248-014-9650-3; DeSilva B, 2003, RECOMMENDATIONS BIOA, V20; Dudal S, 2014, AAPS J, V16; Fast Douglas M, 2009, AAPS J, V11, P238, DOI 10.1208/s12248-009-9100-9; Fluhler E, 2014, AAPS J, V16; Kelley M, 2014, AAPS J, V16, P221, DOI 10.1208/s12248-013-9553-8; King LE, 2014, AAPS J, V16; Kudoh S, 2012, PHARM TECH JAPAN, V28, P489; Shah V P, 2000, Pharm Res, V17, P1551, DOI 10.1023/A:1007669411738; Stevenson L, 2013, AAPS J, V16, P83; Timmerman P, 2010, BIOANALYSIS, V2, P683, DOI [10.4155/bio.10.34, 10.4155/BIO.10.34]; U.S. Department of Health and Human Services, 2001, GUID IND BIOAN METH; van de Merbel N, 2014, AAPSJ, V16; van Amsterdam P, 2010, BIOANALYSIS, V2, P1801, DOI [10.4155/bio.10.146, 10.4155/BIO.10.146]; van Amsterdam P, 2010, BIOANALYSIS, V2, P689, DOI [10.4155/bio.10.37, 10.4155/BIO.10.37]; Verhaeghe T, 2014, AAPS J, V16, P240, DOI 10.1208/s12248-013-9556-5; Viswanathan CT, 2007, AAPS J, V9, pE117; Woolf E, 2014, AAPS J, V16; Young GC, 2014, AAPS J, V16	26	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1550-7416			AAPS J	AAPS J.	NOV	2014	16	6					1159	1161		10.1208/s12248-014-9609-4		3	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AS5ZN	WOS:000344345000003		
J	Yoneyama, T; Kudo, T; Jinno, F; Schmidt, ER; Kondo, T				Yoneyama, Tomoki; Kudo, Takashi; Jinno, Fumihiro; Schmidt, Eric R.; Kondo, Takahiro			Retrospective Data Analysis and Proposal of a Practical Acceptance Criterion for Inter-laboratory Cross-validation of Bioanalytical Methods Using Liquid Chromatography/Tandem Mass Spectrometry	AAPS JOURNAL			English	Article						acceptance criterion; cross-validation; Guideline on bioanalytical method validation (BMV); inter-laboratory reliability; regulated bioanalysis	ASSAYS	The purpose of this study is to conduct a retrospective data analysis for inter-laboratory cross-validation studies to set a reasonable and practical acceptance criterion based on a number of cross-validation results. From the results of cross-validation studies for 16 compounds and their metabolites, analytical bias and variation were evaluated. The accuracy of cross-validation samples was compared with that of quality control (QC) samples with statistical comparison of the analytical variation. An acceptance criterion was derived with a confidential interval approach. As the results, while a larger bias was observed for the cross-validation samples, the bias was not fully caused by analytical variation or bias attributable to the analytical methods. The direction of the deviation between the cross-validation samples and QC samples was random and not concentration-dependent, suggesting that inter-laboratory variability such as preparation errors could be a source of bias. A derived acceptance criterion corresponds to one prescribed in the Guideline on bioanalytical method validation from the Ministry of Health, Labour and Welfare in Japan and is a little wider than one in the European Medical Agency. In conclusion, thorough retrospective data analysis revealed potential causes of larger analytical bias in inter-laboratory cross-validation studies. A derived acceptance criterion would be practical and reasonable for the inter-laboratory cross-validation study.	[Yoneyama, Tomoki; Kudo, Takashi; Jinno, Fumihiro; Kondo, Takahiro] Takeda Pharmaceut Co Ltd, Div Pharmaceut Res, Drug Metab & Pharmacokinet Res Labs, Fujisawa, Kanagawa 2518555, Japan; [Schmidt, Eric R.] Takeda Dev Ctr Amer Inc, Clin Pharmacol, Clin Sci, Deerfield, IL USA	Yoneyama, T (reprint author), Takeda Pharmaceut Co Ltd, Div Pharmaceut Res, Drug Metab & Pharmacokinet Res Labs, 26-1,Muraoka Higashi 2 Chome, Fujisawa, Kanagawa 2518555, Japan.	tomoki.yoneyama@takeda.com					Gansser D, 2002, CHROMATOGRAPHIA, V55, pS71, DOI 10.1007/BF02493356; [Anonymous], 2011, GUID BIOAN METH VAL; KARNES HT, 1991, PHARMACEUT RES, V8, P421, DOI 10.1023/A:1015882607690; GILBERT MT, 1995, J PHARMACEUT BIOMED, V13, P385, DOI 10.1016/0731-7085(95)01310-H; Trufelli H, 2011, MASS SPECTROM REV, V30, P491, DOI 10.1002/mas.20298; Viswanathan CT, 2007, PHARM RES, V24, P1962, DOI 10.1007/s11095-007-9291-7; SHAH VP, 1991, EUR J DRUG METAB PH, V16, P249; Food and Drug Administration, 2001, GUID IND BIOAN METH; Food and Drug administration, 2013, GUID IND BI IN PRESS; Lin ZJ, 2011, BIOANALYSIS, V3, P57, DOI [10.4155/bio.10.168, 10.4155/BIO.10.168]; Ministry of Health Labour and Welfare, 2013, GUID BIOAN METH VAL; Muirhead DC, 2000, CHROMATOGRAPHIA, V52, pS72, DOI 10.1007/BF02493128; Shah V P, 2000, Pharm Res, V17, P1551, DOI 10.1023/A:1007669411738; Xu XH, 2013, BIOANALYSIS, V5, P83, DOI [10.4155/bio.12.291, 10.4155/BIO.12.291]; Yoneyama T, 2012, PHARM MED DEVICE REG, V43, P750	15	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1550-7416			AAPS J	AAPS J.	NOV	2014	16	6					1226	1236		10.1208/s12248-014-9653-0		11	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AS5ZN	WOS:000344345000011		
J	Motoyama, K; Mitsuyasu, R; Akao, C; Tanaka, T; Ohyama, A; Sato, N; Higashi, T; Arima, H				Motoyama, Keiichi; Mitsuyasu, Ryosuke; Akao, Chiho; Tanaka, Takahiro; Ohyama, Ayumu; Sato, Nana; Higashi, Taishi; Arima, Hidetoshi			Design and Evaluation of Thioalkylated Mannose-Modified Dendrimer (G3)/alpha-Cyclodextrin Conjugates as Antigen-Presenting Cell-Selective siRNA Carriers	AAPS JOURNAL			English	Article						antigen-presenting cells; cyclodextrin; dendrimer; mannose; siRNA carrier	MEDIATED GENE DELIVERY; SITE-SPECIFIC DELIVERY; POLYAMIDOAMINE DENDRIMER; CYCLODEXTRIN CONJUGATE; LIPID NANOPARTICLES; BETA-CYCLODEXTRINS; ALPHA-CYCLODEXTRIN; RECEPTOR; EXPRESSION; DRUG	To design and evaluate the potential use of thioalkylated mannose-modified dendrimer (generation 3; G3) conjugates with alpha-cyclodextrin (Man-S-alpha-CDE (G3)) as novel antigen-presenting cell (APC)-selective siRNA carriers, we investigated the RNAi effects of siRNA complexes with Man-S-alpha-CDEs (G3). Man-S-alpha-CDE (G3, average degree of substitution of mannose (DSM) 4)/siRNA complex had the potent RNAi effects in both NR8383 cells, a rat alveolar macrophage cell line, and JAWSII cells, a mouse dendritic cell line, through adequate physicochemical properties, mannose receptor (MR)-mediated cellular uptake, and efficient phagosomal escape of the siRNA complex. In addition, cytotoxic activities of the siRNA complexes with alpha-CDE (G3, DS2) and Man-S-alpha-CDE (G3, DSM4) were almost negligible up to a charge ratio of 100 (carrier/siRNA). Taken together, these results suggest that Man-S-alpha-CDE (G3, DSM4) has the potential for a novel APC-selective siRNA carrier.	[Motoyama, Keiichi; Mitsuyasu, Ryosuke; Akao, Chiho; Tanaka, Takahiro; Ohyama, Ayumu; Sato, Nana; Higashi, Taishi; Arima, Hidetoshi] Kumamoto Univ, Dept Phys Pharmaceut, Grad Sch Pharmaceut Sci, Chuo Ku, Kumamoto 8620973, Japan; [Ohyama, Ayumu; Arima, Hidetoshi] Kumamoto Univ, Program Leading Grad Sch, HIGO Hlth life Sci Interdisciplinary & Glocal Ori, Kumamoto 8620973, Japan	Arima, H (reprint author), Kumamoto Univ, Dept Phys Pharmaceut, Grad Sch Pharmaceut Sci, Chuo Ku, 5-1 Oe Honmachi, Kumamoto 8620973, Japan.	arimah@gpo.kumamoto-u.ac.jp			Japan Society for the Promotion of Science [23590045]	This work was partially supported by Grant-in-Aid for Scientific Research (C) from Japan Society for the Promotion of Science (23590045).	Abdou S, 1997, ARCH VIROL, V142, P1585, DOI 10.1007/s007050050182; Song EW, 2003, NAT MED, V9, P347, DOI 10.1038/nm828; Wada K, 2005, J CONTROL RELEASE, V104, P397, DOI 10.1016/j.jconrel.2005.02.016; Arima H, 2011, EUR J PHARM SCI, V44, P375, DOI 10.1016/j.ejps.2011.08.019; Chiu YL, 2004, CHEM BIOL, V11, P1165, DOI 10.1016/j.chembiol.2004.06.006; Jiang HL, 2008, BIOMATERIALS, V29, P1931, DOI 10.1016/j.biomaterials.2007.12.025; Tsutsumi T, 2007, J CONTROL RELEASE, V119, P349, DOI 10.1016/j.jconrel.2007.03.013; East L, 2002, BBA-GEN SUBJECTS, V1572, P364, DOI 10.1016/S0304-4165(02)00319-7; Kihara F, 2003, BIOCONJUGATE CHEM, V14, P342, DOI 10.1021/bc025613a; Xiao B, 2013, J BIOMED MATER RES A, V101, P1888, DOI 10.1002/jbm.a.34493; Kedmi R, 2010, BIOMATERIALS, V31, P6867, DOI 10.1016/j.biomaterials.2010.05.027; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Jain SK, 2008, NANOMED-NANOTECHNOL, V4, P41, DOI 10.1016/j.nano.2007.11.004; Diaz-Moscoso A, 2011, BIOMATERIALS, V32, P7263, DOI 10.1016/j.biomaterials.2011.06.025; Croyle MA, 1998, PHARMACEUT RES, V15, P1348, DOI 10.1023/A:1011985101580; Hillaireau H, 2009, CELL MOL LIFE SCI, V66, P2873, DOI 10.1007/s00018-009-0053-z; Kim N, 2012, INT J PHARMACEUT, V427, P123, DOI 10.1016/j.ijpharm.2011.08.014; Oh YK, 2009, ADV DRUG DELIVER REV, V61, P850, DOI 10.1016/j.addr.2009.04.018; Jain A, 2010, J CONTROL RELEASE, V148, P359, DOI [10.1016/j.jconrel.2010.09.003, 10.1016/j.conrel.2010.09.003]; Hayashi Y, 2012, MOL PHARMACEUT, V9, P1645, DOI 10.1021/mp200654g; Whitehead KA, 2009, NAT REV DRUG DISCOV, V8, P129, DOI 10.1038/nrd2742; Sahay G, 2010, J CONTROL RELEASE, V145, P182, DOI 10.1016/j.jconrel.2010.01.036; Boskovic J, 2006, J BIOL CHEM, V281, P8780, DOI 10.1074/jbc.M513277200; UEKAMA K, 1987, CRIT REV THER DRUG, V3, P1; Arima H, 2001, BIOCONJUGATE CHEM, V12, P476, DOI 10.1021/bc000111n; Pack DW, 2005, NAT REV DRUG DISCOV, V4, P581, DOI 10.1038/nrd1775; Bird L, 2004, NAT REV IMMUNOL, V4, P494, DOI 10.1038/nri1408; Diebold Sandra S., 2002, Somatic Cell and Molecular Genetics, V27, P65, DOI 10.1023/A:1022975705406; Freeman DJ, 1996, PHARMACEUT RES, V13, P202, DOI 10.1023/A:1016078728202; Galustian C, 2004, INT IMMUNOL, V16, P853, DOI 10.1093/intimm/dxh089; Kelly C, 2010, P 7 BRIT SOC GEN THE; Kihara F, 2002, BIOCONJUGATE CHEM, V13, P1211, DOI 10.1021/bc025557d; SATO Y, 1993, J CLIN INVEST, V91, P1909, DOI 10.1172/JCI116409; Watts JK, 2010, BIOORG MED CHEM LETT, V20, P3203, DOI 10.1016/j.bmcl.2010.03.109; Xiao W, 2010, J MICROENCAPSUL, V27, P447, DOI 10.3109/02652040903471090; Zhou Jiehua, 2010, Silence, V1, P4, DOI 10.1186/1758-907X-1-4	36	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1550-7416			AAPS J	AAPS J.	NOV	2014	16	6					1298	1308		10.1208/s12248-014-9665-9		11	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AS5ZN	WOS:000344345000018		
J	Hong, D; Yarnada, Y; Sheehan, M; Shikano, S; Kuo, CH; Tian, M; Tsung, CK; Fukuzumi, S				Hong, Dachao; Yarnada, Yusuke; Sheehan, Margaret; Shikano, Shinya; Kuo, Chun-Hong; Tian, Ming; Tsung, Chia-Kuang; Fukuzumi, Shunichi			Mesoporous Nickel Ferrites with Spinel Structure Prepared by an Aerosol Spray Pyrolysis Method for Photocatalytic Hydrogen Evolution	ACS SUSTAINABLE CHEMISTRY & ENGINEERING			English	Article						Nickel ferrite; Hydrogen evolution; Photocatalysis; Metal oxide sphere; Crystallinilty; Surface area; Ramp rate	METAL-OXIDE CATALYSTS; VISIBLE-LIGHT-DRIVEN; WATER OXIDATION; SURFACE-AREA; NANOPARTICLES; NIFE2O4; ROUTE; MICROSPHERES; NANOCRYSTALS; FRAMEWORKS	Submicron-sized mesoporous nickel ferrite (NiFe2O4) spheres were prepared by an aerosol spray pyrolysis method using Pluronic F127 as a structure-directing agent, and their photocatalytic performance for hydrogen (H-2) evolution was examined in an aqueous MeOH solution by visible light irradiation (lambda > 420 nm). The structure of the spherical mesoporous nickel ferrites was studied by transmission electron microscopy, powder X-ray diffraction, and N-2 adsorption desorption-desorption isotherm measurements. Mesoporous NiFe2O4 spheres of high specific surface area (278 m(2) g(-1)) with a highly crystalline framework were prepared by adjusting the amount of structure-directing agent and the calcining condition. High photocatalytic activity of mesoporous NiFe2O4 for H-2 evolution from water with methanol was achieved due to the combination of high surface area and high crystallinity of the nickel ferrites.	[Hong, Dachao; Yarnada, Yusuke; Shikano, Shinya; Fukuzumi, Shunichi] Osaka Univ, Japan Sci & Technol Agcy, ALCA, Grad Sch Engn,Dept Mat & Life Sci, Suita, Osaka 5650871, Japan; [Sheehan, Margaret; Kuo, Chun-Hong; Tian, Ming; Tsung, Chia-Kuang] Boston Coll, Merkert Chem Ctr, Dept Chem, Chestnut Hill, MA 02467 USA	Tsung, CK (reprint author), Boston Coll, Merkert Chem Ctr, Dept Chem, 2609 Beacon St, Chestnut Hill, MA 02467 USA.	frank.tsung@bc.edu; fukuzumi@chem.eng.osaka-u.ac.jp	Fukuzumi, Shunichi /E-4728-2010; Kuo, Chun-Hong/D-8902-2015	Kuo, Chun-Hong/0000-0001-6633-8985	MEXT (Japan) [24350069, 25600025]; ALCA project from JST; NRF/MEST (Korea) through GRL [2010-00353]; JSPS	This work was partially supported by a Grant-in-Aid (24350069 and 25600025) from the MEXT (Japan), an ALCA project from JST, and by NRF/MEST (Korea) through GRL (2010-00353) Programs. D.H. gratefully acknowledges support from JSPS by Grant-in-Aid for JSPS Fellowship for Young Scientists. We acknowledge the Research Centre for Ultra-Precision Science & Technology in Osaka University for TEM measurements.	Tsung CK, 2008, ANGEW CHEM INT EDIT, V47, P8682, DOI 10.1002/anie.200802487; Navarro RM, 2010, ENERG ENVIRON SCI, V3, P1865, DOI 10.1039/c001123a; Maeda K, 2007, J PHYS CHEM C, V111, P7851, DOI 10.1021/jp070911w; Boissiere C, 2011, ADV MATER, V23, P599, DOI 10.1002/adma.201001410; Deng H, 2007, MATER CHEM PHYS, V101, P509, DOI 10.1016/j.matchemphys.2006.10.002; Casbeer E, 2012, SEP PURIF TECHNOL, V87, P1, DOI 10.1016/j.seppur.2011.11.034; Gokon N, 2009, SOL ENERGY, V83, P527, DOI 10.1016/j.solener.2008.10.003; Santos PTA, 2010, MATER SCI FORUM, V660-661, P771, DOI 10.4028/www.scientific.net/MSF.660-661.771; Abbaspour A, 2013, FUEL, V104, P575, DOI 10.1016/j.fuel.2012.07.016; Ostomel TA, 2006, SMALL, V2, P1261, DOI 10.1002/smll.200600177; Cheng Y, 2005, J SOLID STATE CHEM, V178, P2394, DOI 10.1016/j.jssc.2005.05.006; Sun QC, 2012, PHYS REV B, V86, DOI 10.1103/PhysRevB.86.205106; Hong DC, 2013, PHYS CHEM CHEM PHYS, V15, P19125, DOI 10.1039/c3cp53518e; Lv HJ, 2010, J MATER CHEM, V20, P3665, DOI 10.1039/b919897k; Shankar K, 2009, J PHYS CHEM C, V113, P6327, DOI 10.1021/jp809385x; Kuai L, 2014, ANGEW CHEM INT EDIT, V53, P7547, DOI 10.1002/anie.201404208; Xu SH, 2007, APPL CATAL B-ENVIRON, V71, P177, DOI 10.1016/j.apcatb.2006.09.004; Yamada Y, 2012, PHYS CHEM CHEM PHYS, V14, P5753, DOI 10.1039/c2cp00022a; Goncalves RH, 2011, J AM CHEM SOC, V133, P6012, DOI 10.1021/ja111454f; Fresno F, 2010, INT J HYDROGEN ENERG, V35, P8503, DOI 10.1016/j.ijhydene.2010.05.032; Osterloh FE, 2013, CHEM SOC REV, V42, P2294, DOI 10.1039/c2cs35266d; Chen XB, 2010, CHEM REV, V110, P6503, DOI 10.1021/cr1001645; Yang PD, 1998, NATURE, V396, P152; Hong DC, 2012, J AM CHEM SOC, V134, P19572, DOI 10.1021/ja309771h; Kudo A, 2009, CHEM SOC REV, V38, P253, DOI 10.1039/b800489g; Lu YF, 1999, NATURE, V398, P223; Maeda K, 2006, PURE APPL CHEM, V78, P2267, DOI 10.1351/pac200678122267; Ginosar DM, 2009, INT J HYDROGEN ENERG, V34, P4065, DOI 10.1016/j.ijhydene.2008.09.064; Fukuzumi S, 2013, J PHYS CHEM LETT, V4, P3458, DOI 10.1021/jz401560x; Abe R, 2013, J AM CHEM SOC, V135, P16872, DOI 10.1021/ja4048637; Peng TY, 2012, CATAL COMMUN, V28, P116, DOI 10.1016/j.catcom.2012.08.031; Bao NZ, 2007, J AM CHEM SOC, V129, P12374, DOI 10.1021/ja074458d; SING KSW, 1985, PURE APPL CHEM, V57, P603, DOI 10.1351/pac198557040603; Liu SH, 2012, CHEMCATCHEM, V4, P1462, DOI 10.1002/cctc.201200264; Areva S, 2004, CHEM COMMUN, P1630, DOI 10.1039/b405690f; Banerjee AM, 2011, INT J HYDROGEN ENERG, V36, P4768, DOI 10.1016/j.ijhydene.2011.01.073; Gao Z, 2010, MICROPOR MESOPOR MAT, V132, P188, DOI 10.1016/j.micromeso.2010.02.019; Gokon N, 2011, INT J HYDROGEN ENERG, V36, P2014, DOI 10.1016/j.ijhydene.2010.11.034; Larumbe S, 2012, J APPL PHYS, V111, DOI 10.1063/1.4720079; Li L, 2008, ADV MATER, V20, P903, DOI 10.1002/adma.200701507; Lubberhuizen WH, 2000, J POROUS MAT, V7, P147, DOI 10.1023/A:1009617105840; Mann AKP, 2011, CHEM MATER, V23, P1017, DOI 10.1021/cm103007v; Markus M., 2014, J PHYS CONDENS MATT, V26; Taguchi A, 2005, MICROPOR MESOPOR MAT, V77, P1, DOI 10.1016/j.micromeso.2004.06.030; Yaiiez-Vilar S., 2009, J SOLID STATE CHEM, V182, P2685	45	4	4	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	2168-0485			ACS SUSTAIN CHEM ENG	ACS Sustain. Chem. Eng.	NOV	2014	2	11					2588	2594		10.1021/sc500484b		7	Chemistry, Multidisciplinary; Engineering, Chemical	Chemistry; Engineering	AS5LE	WOS:000344311600013		
J	Fu, FY; Yang, QL; Zhou, JP; Hu, HZ; Jia, BQ; Zhang, L				Fu, Feiya; Yang, Quanling; Zhou, Jinping; Hu, Haoze; Jia, Baoquan; Zhang, Lina			Structure and Properties of Regenerated Cellulose Filaments Prepared from Cellulose Carbamate-NaOH/ZnO Aqueous Solution	ACS SUSTAINABLE CHEMISTRY & ENGINEERING			English	Article						Cellulose filaments; Cellulose carbamate; Orientation; Mechanical properties; Dye properties	IONIC LIQUIDS; 1-ALLYL-3-METHYLIMIDAZOLIUM CHLORIDE; SILK FIBERS; DISSOLUTION; SOLVENT; SYSTEM; SPUN; PULP; FILM	In this work, regenerated cellulose (RC) filaments were successfully spun from cellulose carbamate in a NaOH/ZnO aqueous solution on a pilot scale. The structure and properties of the RC filaments were characterized using SEM, FT-IR, elemental analysis, C-13 NMR, XRD, 2D WAXD, tensile testing, and dye testing. The nitrogen-free and sulfur-free RC filaments exhibited a bright surface and circular cross section. The filaments demonstrated a typical cellulose II crystal structure and a relatively high degree of orientation. Improved tenacity and structure were obtained in the RC fibers due to improved post-processing spinning steps and an increased drawing ratio. The tenacity of the fibers was determined in the range of 1.69-2.36 cN/dtex, which was comparable with that of commercial viscose rayon. Furthermore, the RC filaments showed improved dye properties compared with viscose rayon. The described carbamate pathway provided a simple and environmentally friendly method, offering an alternate to the environmental drawbacks of the viscose process.	[Fu, Feiya; Zhou, Jinping; Hu, Haoze; Jia, Baoquan; Zhang, Lina] Wuhan Univ, Dept Chem, Wuhan 430072, Peoples R China; [Fu, Feiya; Zhou, Jinping; Hu, Haoze; Jia, Baoquan; Zhang, Lina] Wuhan Univ, Key Lab Biomed Polymers, Minist Educ, Wuhan 430072, Peoples R China; [Yang, Quanling] Univ Tokyo, Grad Sch Agr & Life Sci, Bunkyo Ku, Tokyo 1138657, Japan	Zhou, JP (reprint author), Wuhan Univ, Dept Chem, Wuhan 430072, Peoples R China.	zhoujp325@whu.edu.cn	Yang, Quanling/J-8420-2014		National Natural Science Foundation of China [51273151]; Program for New Century Excellent Talents in University [NCET-11-0415]; Natural Science Foundation of Hubei Province [2009CDA040]	This work was financially supported by the National Natural Science Foundation of China (51273151), Program for New Century Excellent Talents in University (NCET-11-0415), and Natural Science Foundation of Hubei Province (2009CDA040).	Gao QY, 2011, CARBOHYD POLYM, V83, P1253, DOI 10.1016/j.carbpol.2010.09.029; Cai J, 2007, ADV MATER, V19, P821, DOI 10.1002/adma.200601521; Chen MJ, 2014, ACS SUSTAIN CHEM ENG, V2, P1164, DOI 10.1021/sc400555v; Yin CY, 2007, EUR POLYM J, V43, P2111, DOI 10.1016/j.europolymj.2007.01.041; Zhang H, 2007, ADV MATER, V19, P698, DOI 10.1002/adma.200600442; Fink HP, 2001, PROG POLYM SCI, V26, P1473, DOI 10.1016/S0079-6700(01)00025-9; Zhang LN, 2002, J POLYM SCI POL PHYS, V40, P1521, DOI 10.1002/polb.10215; Li R, 2010, IND ENG CHEM RES, V49, P11380, DOI 10.1021/ie101144h; Sehaqui H, 2012, ACS APPL MATER INTER, V4, P1043, DOI 10.1021/am2016766; Cai T, 2010, J APPL POLYM SCI, V115, P1047, DOI 10.1002/app.31081; Casas A, 2013, CARBOHYD POLYM, V92, P1946, DOI 10.1016/j.carbpol.2012.11.057; Nada AMA, 2000, POLYM DEGRAD STABIL, V67, P111, DOI 10.1016/S0141-3910(99)00100-7; Fink HP, 2014, CELLULOSE, V21, P31, DOI 10.1007/s10570-013-0137-7; Mormann W, 2002, CARBOHYD POLYM, V50, P201, DOI 10.1016/S0144-8617(02)00016-4; Guo Y, 2010, CELLULOSE, V17, P1115, DOI 10.1007/s10570-010-9446-2; Rose M, 2011, MACROMOL RAPID COMM, V32, P1299, DOI 10.1002/marc.201100230; ALTENA FW, 1982, MACROMOLECULES, V15, P1491, DOI 10.1021/ma00234a008; Swatloski RP, 2002, J AM CHEM SOC, V124, P4974, DOI 10.1021/ja025790m; Zhang H, 2005, MACROMOLECULES, V38, P8272, DOI 10.1021/ma0505676; Reddy N, 2010, J MATER SCI, V45, P6617, DOI 10.1007/s10853-010-4752-5; Cai J, 2005, MACROMOL BIOSCI, V5, P539, DOI 10.1002/mabi.200400222; Guo Y, 2009, MACROMOL RAPID COMM, V30, P1504, DOI 10.1002/marc.200900238; Sen S, 2013, ACS SUSTAIN CHEM ENG, V1, P858, DOI 10.1021/sc400085a; Guo BQ, 2013, ACS SUSTAIN CHEM ENG, V1, P1474, DOI 10.1021/sc400252e; [Anonymous], 2005, GBT137582008; Yu LB, 2014, J MATER CHEM A, V2, P6402, DOI 10.1039/c4ta00004h; Yan LF, 2014, ACS SUSTAIN CHEM ENG, V2, P897, DOI 10.1021/sc400507s; Klemm D, 2005, ANGEW CHEM INT EDIT, V44, P3358, DOI 10.1002/anie.200460587; Qi HS, 2013, J MATER CHEM A, V1, P2161, DOI 10.1039/c2ta00882c; Cai J, 2004, MACROMOL RAPID COMM, V25, P1558, DOI 10.1002/marc.2004000172; Kosan B, 2008, CELLULOSE, V15, P59, DOI 10.1007/s10570-007-9160-x; Chen XM, 2006, POLYMER, V47, P2839, DOI 10.1016/j.polymer.2006.02.044; Brown W., 1965, EUR POLYM J, V1, P1, DOI DOI 10.1016/0014-3057(65)90041-8; Carrillo F., 2004, EUR POLYM J, V40, P2229, DOI DOI 10.1016/J.EURP0LYMJ.2004.05.003; CUCULO JA, 1994, J POLYM SCI POL CHEM, V32, P229, DOI 10.1002/pola.1994.080320203; Fu FY, 2014, ACS SUSTAIN CHEM ENG, V2, P2363, DOI 10.1021/sc5003787; Fu F., 2014, CELLULOSE, V212, P819; Guo Y, 2011, BIOMACROMOLECULES, V12, P1927, DOI 10.1021/bm200331g; Hakansson KMO, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5018; Jiang GS, 2012, CARBOHYD POLYM, V87, P2012, DOI 10.1016/j.carbpol.2011.10.022; Labafzadeh SR, 2014, RSC ADV, V4, P22434, DOI 10.1039/c4ra02316a; Maji TK, 2002, J APPL POLYM SCI, V84, P969, DOI 10.1002/app.10202; Ruan D, 2006, MACROMOL RAPID COMM, V27, P1495, DOI 10.1002/marc.200600232; Wang K., 2008, China Patent, Patent No. [CN101760632 (A), 101760632]; Woodings C, 2001, REGENERATED CELLULOS; Woodings CR, 1995, INT J BIOL MACROMOL, V17, P305, DOI 10.1016/0141-8130(96)81836-8	46	3	3	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	2168-0485			ACS SUSTAIN CHEM ENG	ACS Sustain. Chem. Eng.	NOV	2014	2	11					2604	2612		10.1021/sc500559g		9	Chemistry, Multidisciplinary; Engineering, Chemical	Chemistry; Engineering	AS5LE	WOS:000344311600015		
J	Gopal, A; Saeki, A; Ide, M; Seki, S				Gopal, Anesh; Saeki, Akinori; Ide, Marina; Seki, Shu			Fluorination of Benzothiadiazole-Benzobisthiazole Copolymer Leads to Additive-Free Processing with Meliorated Solar Cell Performance	ACS SUSTAINABLE CHEMISTRY & ENGINEERING			English	Article						Organic photovoltaic cell; 1,8-Diiodooctane (DIO); Time-resolved microwave conductivity (TRMC); Low bandgap polymer; X-ray diffraction	POWER-CONVERSION EFFICIENCY; RESOLVED MICROWAVE CONDUCTIVITY; OPEN-CIRCUIT VOLTAGE; D-A POLYMERS; PHOTOVOLTAIC PERFORMANCE; CONJUGATED POLYMERS; MOLECULAR-ORIENTATION; ORGANIC PHOTOVOLTAICS; SOLVENT ADDITIVES; MATERIALS DESIGN	Processing solvents and conditions have unique importance in the performance of bulk heterojunction organic solar cells. In the present work, we have investigated the role of a primary solvent and solvent additive in the device performance of two benzobisthiazole (BBTz)-based push-pull type polymers. In an inverted cell structure, the BBTz-co-fluorinated benzothiadiazole polymer (PBBTzFT) with a PC71BM acceptor showed additive-free enhanced performance with a power conversion efficiency (PCE) of 6.4% from a 1,2-dichlorobenzene solvent, while the BBTz-co-pyridylthiadiazole polymer (PBBTzPT) showed maximum performance from a chlorobenzene (CB) solution with a 1,8-diiodooctane (DIO) additive (PCE = 2.3%). The detailed investigation by atomic force microscopy and two-dimensional grazing incidence X-ray diffraction corroborates that the fluorination of benzothiadiazole brought about optimal morphology without a solvent additive, the PCE of which is comparable with the previous nonfluorinated analogue (PCE = 6.5%) processed from CB with DIO.	Osaka Univ, Grad Sch Engn, Dept Appl Chem, Suita, Osaka 5650871, Japan		saeki@chem.eng.osaka-u.ac.jp; seki@chem.eng.osaka-u.ac.jp	Saeki, Akinori/B-7756-2011; Seki, Shu/E-5346-2010; Gopal, Anesh/F-8538-2010	Seki, Shu/0000-0001-7851-4405; Gopal, Anesh/0000-0001-6161-1751	Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan; Toyota Physical & Chemical Research Institute Scholars, Japan	This work was supported by a KAKENHI grant from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan, and a research grant from Toyota Physical & Chemical Research Institute Scholars, Japan. The authors thank Dr. Tomoyuki Koganezawa at Japan Synchrotron Radiation Research Institute, Japan, and Dr. Itaru Osaka at RIKEN, Japan, for the 2D-GIXRD experiments (Proposals 2013B1719 and 2014A1530).	Osaka I, 2010, ADV MATER, V22, P4993, DOI 10.1002/adma.201002117; Aguirre JC, 2014, ADV FUNCT MATER, V24, P784, DOI 10.1002/adfm.201301757; Price SC, 2011, J AM CHEM SOC, V133, P4625, DOI 10.1021/ja1112595; Po R, 2014, ENERG ENVIRON SCI, V7, P925, DOI 10.1039/c3ee43460e; Graetzel M, 2012, NATURE, V488, P304, DOI 10.1038/nature11476; Mei JG, 2014, CHEM MATER, V26, P604, DOI 10.1021/cm4020805; Nguyen TL, 2014, ENERG ENVIRON SCI, V7, P3040, DOI 10.1039/c4ee01529k; Scharber MC, 2006, ADV MATER, V18, P789, DOI 10.1002/adma.200501717; Li G, 2012, NAT PHOTONICS, V6, P153, DOI 10.1038/NPHOTON.2012.11; Rolczynski BS, 2012, J AM CHEM SOC, V134, P4142, DOI 10.1021/ja209003y; Lee JK, 2008, J AM CHEM SOC, V130, P3619, DOI 10.1021/ja710079w; Blouin N, 2008, J AM CHEM SOC, V130, P732, DOI 10.1021/ja0771989; Stuart AC, 2013, J AM CHEM SOC, V135, P1806, DOI 10.1021/ja309289u; Dou LT, 2013, ADV MATER, V25, P6642, DOI 10.1002/adma.201302563; Tumbleston JR, 2014, NAT PHOTONICS, V8, P385, DOI 10.1038/nphoton.2014.55; Osaka I, 2014, ADV MATER, V26, P331, DOI 10.1002/adma.201303059; Treat ND, 2011, ADV ENERGY MATER, V1, P82, DOI 10.1002/aenm.201000023; Woo S, 2014, ADV ENERGY MATER, V4, DOI 10.1002/aenm.201301692; Grozema FC, 2011, J PHYS CHEM LETT, V2, P2951, DOI 10.1021/jz201229a; Wang N, 2013, J AM CHEM SOC, V135, P17060, DOI 10.1021/ja409881g; Tumbleston JR, 2013, ADV FUNCT MATER, V23, P3463, DOI 10.1002/adfm.201300093; He ZC, 2012, NAT PHOTONICS, V6, P591, DOI 10.1038/NPHOTON.2012.190; Park HY, 2013, J MATER CHEM A, V1, P6327, DOI 10.1039/c3ta10637c; Rogers JT, 2011, ADV MATER, V23, P2284, DOI 10.1002/adma.201003690; Zhang MJ, 2013, ADV MATER, V25, P4944, DOI 10.1002/adma.201301494; Jo J, 2009, ADV FUNCT MATER, V19, P866, DOI 10.1002/adfm.200800968; Zhou HX, 2011, ANGEW CHEM INT EDIT, V50, P2995, DOI 10.1002/anie.201005451; Guo X, 2012, ENERG ENVIRON SCI, V5, P7943, DOI 10.1039/c2ee21481d; Chen HC, 2012, CHEM MATER, V24, P4766, DOI 10.1021/cm302861s; Li K, 2013, J AM CHEM SOC, V135, P13549, DOI 10.1021/ja406220a; Babel A, 2003, J AM CHEM SOC, V125, P13656, DOI 10.1021/ja0371810; Chen LM, 2009, ADV MATER, V21, P1434, DOI 10.1002/adma.200802854; Jo J, 2012, ADV ENERGY MATER, V2, P1397, DOI 10.1002/aenm.201200350; Ma W, 2013, ADV ENERGY MATER, V3, P864, DOI 10.1002/aenm.201200912; Chen HY, 2009, NAT PHOTONICS, V3, P649, DOI 10.1038/NPHOTON.2009.192; Sondergaard R, 2012, MATER TODAY, V15, P36; Tsuji M, 2014, ADV FUNCT MATER, V24, P28, DOI 10.1002/adfm.201301371; Boudreault PLT, 2011, CHEM MATER, V23, P456, DOI 10.1021/cm1021855; Huang Y, 2014, CHEM REV, V114, P7006, DOI 10.1021/cr400353v; Chao YH, 2014, ADV MATER, V26, P5205, DOI 10.1002/adma.201401345; Albrecht S, 2012, J AM CHEM SOC, V134, P14932, DOI 10.1021/ja305039j; Saeki A, 2012, J AM CHEM SOC, V134, P19035, DOI 10.1021/ja309524f; Ahmed E, 2011, MACROMOLECULES, V44, P7207, DOI 10.1021/ma201128x; Schmidt K, 2014, ADV MATER, V26, P300, DOI 10.1002/adma.201303622; Li WW, 2013, J AM CHEM SOC, V135, P5529, DOI 10.1021/ja401434x; Wang Y, 2013, MACROMOLECULES, V46, P9587, DOI 10.1021/ma401709r; Qin TS, 2014, J AM CHEM SOC, V136, P6049, DOI 10.1021/ja500935d; Peet J, 2011, APPL PHYS LETT, V98, DOI 10.1063/1.3544940; Cheng YJ, 2009, CHEM REV, V109, P5868, DOI 10.1021/cr900182s; Rivnay J, 2012, CHEM REV, V112, P5488, DOI 10.1021/cr3001109; You JB, 2013, ADV MATER, V25, P3973, DOI 10.1002/adma.201300964; Graham KR, 2012, ADV FUNCT MATER, V22, P4801, DOI 10.1002/adfm.201102456; Saeki A, 2011, ADV ENERGY MATER, V1, P661, DOI 10.1002/aenm.201100143; Saeki A, 2014, J MATER CHEM A, V2, P6075, DOI 10.1039/c3ta14109h; OSAHENI JA, 1995, J AM CHEM SOC, V117, P7389, DOI 10.1021/ja00133a012; Rance WL, 2011, ACS NANO, V5, P5635, DOI 10.1021/nn201251v; Thompson BC, 2008, ANGEW CHEM INT EDIT, V47, P58, DOI 10.1002/anie.200702506; Yau CP, 2014, ADV FUNCT MATER, V24, P678, DOI 10.1002/adfm.201302270; You JB, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2411	59	5	5	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	2168-0485			ACS SUSTAIN CHEM ENG	ACS Sustain. Chem. Eng.	NOV	2014	2	11					2613	2622		10.1021/sc50056171		10	Chemistry, Multidisciplinary; Engineering, Chemical	Chemistry; Engineering	AS5LE	WOS:000344311600016		
J	Edalati, K; Daio, T; Lee, S; Horita, Z; Nishizaki, T; Akune, T; Nojima, T; Sasaki, T				Edalati, Kaveh; Daio, Takeshi; Lee, Seungwon; Horita, Zenji; Nishizaki, Terukazu; Akune, Tadahiro; Nojima, Tsutomu; Sasaki, Takahiko			High strength and superconductivity in nanostructured niobium-titanium alloy by high-pressure torsion and annealing: Significance of elemental decomposition and supersaturation	ACTA MATERIALIA			English	Article						Severe plastic deformation (SPD); Ultrafine-grained (UFG) materials; Electrical properties; Magnetic properties; Critical temperature of superconductivity	SEVERE PLASTIC-DEFORMATION; VACANCY FORMATION ENERGIES; CRITICAL CURRENT-DENSITY; REDUCING GRAIN-BOUNDARY; NB-TI SUPERCONDUCTORS; ROLL-BONDING ARB; THERMAL-STABILITY; AL-MG; PHASE-TRANSFORMATIONS; SOLUTE SEGREGATION	A powder mixture of Nb-47 wt.% Ti (a well-known composition for superconducting magnets) was subjected to severe plastic deformation using high-pressure torsion (HPT) and subsequently annealed at 573 K. Ti gradually dissolved in Nb with increasing shear strain, with a fast kinetics comparable to lattice diffusion at 700-1200 K. At large strains, a complete transition to a nanostructured p phase occurred at room temperature, which is far below the equilibrium temperature of 690 K. Nanoclusters of Ti with a body-centered cubic structure were also detected at large strains. Subsequent annealing led to elemental decomposition, formation of a nanoscale lamellar structure and segregation of Nb at grain boundaries. Superconductivity occurred at temperatures below 9 K, while the transition temperature decreased with increasing shear strain because of supersaturation of Ti in Nb and increased with annealing because of elemental decomposition. The Nb-Ti alloy after HPT exhibited hardness/strength peaks followed by softening at large strains, while hardening occurred after annealing. The maximum hardness, tensile and bending strengths were 4, 1.7 and 2.7 GPa, respectively. (C) 2014 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.	[Edalati, Kaveh; Lee, Seungwon; Horita, Zenji] Kyushu Univ, Int Inst Carbon Neutral Energy Res WPI I2CNER, WPI, Fukuoka 8190395, Japan; [Edalati, Kaveh; Lee, Seungwon; Horita, Zenji] Kyushu Univ, Fac Engn, Dept Mat Sci & Engn, Fukuoka 8190395, Japan; [Daio, Takeshi] Kyushu Univ, Int Res Ctr Hydrogen Energy, Fukuoka 8190395, Japan; [Nishizaki, Terukazu; Akune, Tadahiro] Kyushu Sangyo Univ, Dept Elect Engn & Informat Technol, Fukuoka 8138503, Japan; [Nojima, Tsutomu; Sasaki, Takahiko] Tohoku Univ, Inst Mat Res, Sendai, Miyagi 9808577, Japan	Edalati, K (reprint author), Kyushu Univ, Fac Engn, Dept Mat Sci & Engn, Fukuoka 8190395, Japan.	kaveh.edalati@zaiko6.zaiko.kyushu-u.ac.jp; terukazu@ip.kyusan-u.ac.jp	Nojima, Tsutomu/C-6539-2009; Sasaki, Takahiko/F-1231-2010; 	Sasaki, Takahiko/0000-0002-0767-5428; Edalati, Kaveh/0000-0003-3885-2121; lee, seungwon/0000-0003-0344-0717	Japan Society for Promotion of Science (JSPS) [25889043]; Light Metals Educational Foundation of Japan; MEXT, Japan [22102004]	K.E. thanks the Japan Society for Promotion of Science (JSPS) for a Grant-in-Aid for Research Activity (No. 25889043). This work was supported in part by the Light Metals Educational Foundation of Japan and in part by a Grant-in-Aid for Scientific Research from the MEXT, Japan, in Innovative Areas "Bulk Nanostructured Metals" (No. 22102004).	Kawasaki M, 2011, ACTA MATER, V59, P308, DOI 10.1016/j.actamat.2010.09.034; Figueiredo RB, 2012, ACTA MATER, V60, P3190, DOI 10.1016/j.actamat.2012.02.027; Zhilyaev AP, 2008, PROG MATER SCI, V53, P893, DOI 10.1016/j.pmatsci.2008.03.002; Valiev RZ, 2010, J MATER SCI, V45, P4718, DOI 10.1007/s10853-010-4588-z; Pippan R, 2010, ANNU REV MATER RES, V40, P319, DOI 10.1146/annurev-matsci-070909-104445; Todaka Y, 2008, SCRIPTA MATER, V59, P615, DOI 10.1016/j.scriptamat.2008.05.015; Valiev RZ, 2006, PROG MATER SCI, V51, P881, DOI 10.1016/j.pmatsci.2006.02.003; Sauvage X, 2014, ACTA MATER, V72, P125, DOI 10.1016/j.actamat.2014.03.033; Straumal BB, 2012, MATER TRANS, V53, P63, DOI 10.2320/matertrans.MD201111; Zhilyaev AP, 2011, MAT SCI ENG A-STRUCT, V528, P3496, DOI 10.1016/j.msea.2011.01.062; Edalati K, 2009, MAT SCI ENG A-STRUCT, V523, P277, DOI 10.1016/j.msea.2009.07.029; Straumal BB, 2004, ACTA MATER, V52, P4469, DOI 10.1016/j.actamat.2004.06.006; Kirchheim R, 2007, ACTA MATER, V55, P5129, DOI 10.1016/j.actamat.2007.05.047; Valiev RZ, 2006, JOM-US, V58, P33, DOI 10.1007/s11837-006-0213-7; Bridgman PW, 1935, PHYS REV, V48, P825, DOI 10.1103/PhysRev.48.825; Edalati K, 2013, APPL PHYS LETT, V102, DOI 10.1063/1.4804273; Kirchheim R, 2007, ACTA MATER, V55, P5139, DOI 10.1016/j.actamat.2007.05.033; Edalati K, 2014, ACTA MATER, V68, P207, DOI 10.1016/j.actamat.2014.01.037; Edalati K, 2011, MAT SCI ENG A-STRUCT, V528, P7301, DOI 10.1016/j.msea.2011.06.031; Valiev RZ, 2000, PROG MATER SCI, V45, P103, DOI 10.1016/S0079-6425(99)00007-9; Bachmaier A, 2012, ACTA MATER, V60, P860, DOI 10.1016/j.actamat.2011.10.044; Xu C, 2007, ACTA MATER, V55, P203, DOI 10.1016/j.actamat.2006.07.029; Popov VV, 2011, MAT SCI ENG A-STRUCT, V528, P1491, DOI 10.1016/j.msea.2010.10.052; Edalati K, 2011, SCRIPTA MATER, V64, P880, DOI 10.1016/j.scriptamat.2011.01.023; Ikoma Y, 2012, APPL PHYS LETT, V101, DOI 10.1063/1.4754574; Divinski SV, 2009, ACTA MATER, V57, P5706, DOI 10.1016/j.actamat.2009.07.066; Lee DJ, 2012, SCRIPTA MATER, V67, P384, DOI 10.1016/j.scriptamat.2012.05.024; Srinivasarao B, 2013, MAT SCI ENG A-STRUCT, V562, P196, DOI 10.1016/j.msea.2012.11.027; Popova EN, 2006, PHYS MET METALLOGR+, V101, P52, DOI 10.1134/S0031918X06010078; Saito Y, 1999, ACTA MATER, V47, P579, DOI 10.1016/S1359-6454(98)00365-6; Tian YZ, 2012, ACTA MATER, V60, P269, DOI 10.1016/j.actamat.2011.09.058; MOFFAT DL, 1988, METALL TRANS A, V19, P2389, DOI 10.1007/BF02645466; Schweigert VA, 1998, PHYS REV LETT, V81, P2783, DOI 10.1103/PhysRevLett.81.2783; Cubero-Sesin JM, 2013, J MATER SCI, V48, P4713, DOI 10.1007/s10853-012-6935-8; Oh-ishi K, 2013, ACTA MATER, V61, P3482, DOI 10.1016/j.actamat.2013.02.042; Edalati K, 2014, ACTA MATER, V69, P68, DOI 10.1016/j.actamat.2014.01.036; Bachmaier A, 2014, PHIL MAG LETT, V94, P9, DOI 10.1080/09500839.2013.852284; Balachandran S, 2009, IEEE T APPL SUPERCON, V19, P2606, DOI 10.1109/TASC.2009.2018153; Baro M. D., 2001, Reviews on Advanced Materials Science, V2; Beloshenko VA, 2013, PHYS MET METALLOGR+, V114, P992, DOI 10.1134/S0031918X13090032; Bhattacharjee PP, 2011, INT J MATER RES, V102, P173, DOI 10.3139/146.110465; COOLEY LD, 1991, APPL PHYS LETT, V58, P2984, DOI 10.1063/1.104689; Croitoru MD, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.024511; Edalati K, 2010, METALL MATER TRANS A, V41A, P3308, DOI 10.1007/s11661-010-0400-6; Edalati K, 2013, APPL PHYS LETT, V103, DOI 10.1063/1.4816082; Edalati K, 2011, MAT SCI ENG A-STRUCT, V528, P7514, DOI 10.1016/j.msea.2011.06.080; Fujita T, 2004, MAT SCI ENG A-STRUCT, V371, P241, DOI 10.1016/j.msea.2003.12.042; HEUSSNER RW, 1995, IEEE T APPL SUPERCON, V5, P1705, DOI 10.1109/77.402905; Kilmametov AR, 2007, Z KRISTALLOGR, P339; Lee S, 2012, MATER TRANS, V53, P38, DOI 10.2320/matertrans.MD2011311; Liddicoat PV, 2010, NAT COMMUN, V1, DOI 10.1038/ncomms1062; Mathaudhu SN, 2007, IEEE T APPL SUPERCON, V17, P2660, DOI 10.1109/TASC.2007.899413; Mathaudhu SN, 2005, IEEE T APPL SUPERCON, V15, P3438, DOI 10.1109/TASC.2005.849044; Mehrer H., 1990, NUMERICAL DATA FUNCT, V26; MEINGAST C, 1989, J APPL PHYS, V66, P5971, DOI 10.1063/1.343625; Murray J., 1981, B ALLOY PHASE DIAGRA, V2, P55; Nishizaki T, 2013, PHYSICA C, V493, P132, DOI 10.1016/j.physc.2013.03.046; Oberdorfer B, 2010, SCRIPTA MATER, V63, P452, DOI 10.1016/j.scriptamat.2010.05.007; Oh-ishi K, 1999, J MATER RES, V14, P4200, DOI 10.1557/JMR.1999.0569; Pearson PW, 1958, HDB LATTICE SPACINGS; Perez-Prado MT, 2008, SCRIPTA MATER, V58, P219, DOI 10.1016/j.scriptamat.2007.09.043; Poole C., 2007, SUPERCONDUCTIVITY; Sakai G, 2005, MAT SCI ENG A-STRUCT, V393, P344, DOI 10.1016/j.msea.2004.11.007; Sandim MJR, 2006, SUPERCOND SCI TECH, V19, P1233, DOI 10.1088/0953-2048/19/12/002; Sauvage X, 2008, SCRIPTA MATER, V58, P1125, DOI 10.1016/j.scriptamat.2008.02.010; Sauvage X, 2005, ACTA MATER, V53, P2127, DOI 10.1016/j.actamat.2005.01.024; Savitzkii EM, 1973, SUPERCONDUCTING MAT; SEGAL VM, 1981, RUSS METALL+, P99; Sort J, 2003, ACTA MATER, V51, P6385, DOI 10.1016/j.actamat.2003.08.006; Starink MJ, 2013, ACTA MATER, V61, P183, DOI 10.1016/j.actamat.2012.09.048; Suematsu H, 2009, J PHYS CONF SER, V150, DOI 10.1088/1742-6596/150/5/052250	71	1	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1359-6454	1873-2453		ACTA MATER	Acta Mater.	NOV	2014	80						149	158		10.1016/j.actamat.2014.07.065		10	Materials Science, Multidisciplinary; Metallurgy & Metallurgical Engineering	Materials Science; Metallurgy & Metallurgical Engineering	AS3XK	WOS:000344208300014		
J	Yilmazer, H; Niinomi, M; Cho, K; Nakai, M; Hieda, J; Sato, S; Todaka, Y				Yilmazer, H.; Niinomi, M.; Cho, K.; Nakai, M.; Hieda, J.; Sato, S.; Todaka, Y.			Microstructural evolution of precipitation-hardened beta-type titanium alloy through high-pressure torsion	ACTA MATERIALIA			English	Article						Titanium alloys; Precipitation; Nanostructured materials; Dislocation structure; High-pressure torsion	SEVERE PLASTIC-DEFORMATION; RESOLUTION ELECTRON-MICROSCOPY; GRAIN-BOUNDARY STRUCTURE; MECHANICAL-PROPERTIES; AL-MG; PROFILE ANALYSIS; DUPLEX STRUCTURE; CONTRAST FACTORS; FE ALLOY; DISLOCATION	In order to elucidate the microstructural refinement mechanism and the effect of secondary phase on the microstructural evolution of beta-type titanium alloy, severe plastic deformation was conducted on samples of a precipitation-hardened Ti-29Nb-13Ta-4.6Zr (TNTZ). Specifically, TNTZ that was precipitation-hardened through an aging treatment (TNTZAT) was subjected to high-pressure torsion (HPT) processing (TNTZ(AHPT)). The microstructure of TNTZ(AHPT), which has been evaluated as a function of the torsional rotation number, N, exhibits ultrafine elongated beta grains. The needle-like alpha precipitates in TNTZ(AT), which exhibit a diameter of approximately 12 nm, are homogeneously distributed within the beta grains. The dislocation density and subgrain diameter, estimated by X-ray line profile analysis, saturate at approximately 4.2 x 10(16) m(-2) and 12.2 nm, respectively, at N >= 10. The beta grains contain nanostructured subgrains having non-uniform morphologies surrounded by blurred and wavy boundaries. A saturated hardness distribution at approximately 450 HV indicates that microstructural homogeneity has been achieved at N >= 10. The alpha precipitates enhance the beta grain refinement and microstructural homogeneity is achieved in TNTZ(AHPT) at N >= 10, whereas this occurs at later stages (N > 20) in TNTZ which is solution-treated and therefore does not contain any alpha precipitates. (C) 2014 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.	[Yilmazer, H.; Niinomi, M.; Cho, K.; Nakai, M.; Hieda, J.] Tohoku Univ, Inst Mat Res, Sendai, Miyagi 9808577, Japan; [Sato, S.] Ibaraki Univ, Grad Sch Sci & Engn, Hitachi, Ibaraki 3168511, Japan; [Todaka, Y.] Toyohashi Univ Technol, Dept Mech Engn, Toyohashi, Aichi 4418580, Japan	Yilmazer, H (reprint author), Tohoku Univ, Inst Mat Res, Sendai, Miyagi 9808577, Japan.	hakan@imr.tohoku.ac.jp	Todaka, Yoshikazu/D-3809-2015; Nakai, Masaaki/C-1919-2009; Niinomi, Mitsuo/B-5965-2011		New Energy and Industrial Technology Development Organization (NEDO); Japan Society for the Promotion of Science (JSPS); Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan	This work was performed in part on commission from New Energy and Industrial Technology Development Organization (NEDO), and supported in part by Grants-in-Aid for Scientific Research (A), Young Scientists (A), Challenging Exploratory Research from the Japan Society for the Promotion of Science (JSPS) and Inter-University Cooperative Research Program "Innovation Research for Biosis-Abiosis Intelligent Interface" from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan.	Dalla Torre F, 2004, ACTA MATER, V52, P4819, DOI 10.1016/j.actamat.2004.06.040; WILKENS M, 1975, J APPL CRYSTALLOGR, V8, P191, DOI 10.1107/S0021889875010060; Banerjee R, 2004, BIOMATERIALS, V25, P3413, DOI 10.1016/j.biomaterials.2003.10.041; Zhilyaev AP, 2008, PROG MATER SCI, V53, P893, DOI 10.1016/j.pmatsci.2008.03.002; Todaka Y, 2008, SCRIPTA MATER, V59, P615, DOI 10.1016/j.scriptamat.2008.05.015; Valiev RZ, 2006, PROG MATER SCI, V51, P881, DOI 10.1016/j.pmatsci.2006.02.003; Fischer FD, 2011, ACTA MATER, V59, P3463, DOI 10.1016/j.actamat.2011.02.020; Valiev RZ, 2002, J MATER RES, V17, P5, DOI 10.1557/JMR.2002.0002; NAZAROV AA, 1993, ACTA METALL MATER, V41, P1033, DOI 10.1016/0956-7151(93)90152-I; Niinomi M, 2003, BIOMATERIALS, V24, P2673, DOI 10.1016/S0142-9612(03)00069-3; Divinski SV, 2011, ACTA MATER, V59, P1974, DOI 10.1016/j.actamat.2010.11.063; Sakai G, 2005, MAT SCI ENG A-STRUCT, V406, P268, DOI 10.1016/j.msea.2005.06.049; Lee S, 2002, ACTA MATER, V50, P553, DOI 10.1016/S1359-6454(01)00368-8; Hughes DA, 2000, ACTA MATER, V48, P2985, DOI 10.1016/S1359-6454(00)00082-3; Gubicza J, 2004, J ALLOY COMPD, V378, P248, DOI 10.1016/j.jallcom.2003.11.162; Ungar T, 1999, J APPL CRYSTALLOGR, V32, P992, DOI 10.1107/S0021889899009334; Dragomir IC, 2002, J APPL CRYSTALLOGR, V35, P556, DOI 10.1107/S0021889802009536; Wei Q, 2006, ACTA MATER, V54, P4079, DOI 10.1016/j.actamat.2006.05.005; Ungar T, 2001, J APPL CRYSTALLOGR, V34, P298, DOI 10.1107/S0021889801003715; Tirry W, 2005, ACTA MATER, V53, P1041, DOI 10.1016/j.actamat.2004.10.049; Qiao XG, 2012, PHILOS MAG, V92, P446, DOI 10.1080/14786435.2011.616865; Banerjee D, 2013, ACTA MATER, V61, P844, DOI 10.1016/j.actamat.2012.10.043; Ivasishin OM, 2008, J ALLOY COMPD, V457, P296, DOI 10.1016/j.jallcom.2007.03.070; Kolobov YR, 2003, INT J REFRACT MET H, V21, P69, DOI 10.1016/S0263-4368(03)00002-7; Ito Y, 2009, MAT SCI ENG A-STRUCT, V503, P32, DOI 10.1016/j.msea.2008.03.055; Edalati K, 2014, ACTA MATER, V68, P207, DOI 10.1016/j.actamat.2014.01.037; Tsuji N, 2002, SCRIPTA MATER, V46, P305, DOI 10.1016/S1359-6462(01)01243-X; Ungar T, 1999, PHYS STATUS SOLIDI A, V171, P425, DOI 10.1002/(SICI)1521-396X(199902)171:2<425::AID-PSSA425>3.0.CO;2-W; Zhilyaev AP, 2005, MAT SCI ENG A-STRUCT, V410, P277, DOI 10.1016/j.msea.2005.08.044; Ho WF, 1999, BIOMATERIALS, V20, P2115, DOI 10.1016/S0142-9612(99)00114-3; Ribarik G, 2001, J APPL CRYSTALLOGR, V34, P669, DOI 10.1107/S0021889801011451; Park CH, 2013, SCRIPTA MATER, V68, P996, DOI 10.1016/j.scriptamat.2013.02.055; Languillaume J, 1997, ACTA MATER, V45, P1201, DOI 10.1016/S1359-6454(96)00216-9; Valiev RZ, 1996, ACTA MATER, V44, P4705, DOI 10.1016/S1359-6454(96)00156-5; HUGHES DA, 1993, ACTA METALL MATER, V41, P1421, DOI 10.1016/0956-7151(93)90251-M; Weiss I, 1998, MAT SCI ENG A-STRUCT, V243, P46, DOI 10.1016/S0921-5093(97)00783-1; Groma I, 1998, PHYS REV B, V57, P7535, DOI 10.1103/PhysRevB.57.7535; Xu W, 2009, SCRIPTA MATER, V60, P1012, DOI 10.1016/j.scriptamat.2009.02.043; Tane M, 2011, ACTA MATER, V59, P6975, DOI 10.1016/j.actamat.2011.07.050; Horita Z, 1996, J MATER RES, V11, P1880, DOI 10.1557/JMR.1996.0239; Bonarski BJ, 2008, J MATER SCI, V43, P7513, DOI 10.1007/s10853-008-2794-8; Cepeda-Jimenez CM, 2011, J ALLOY COMPD, V509, P636, DOI 10.1016/j.jallcom.2010.09.122; EMBURY JD, 1966, ACTA METALL MATER, V14, P147, DOI 10.1016/0001-6160(66)90296-3; Furuhara T, 2001, J MATER PROCESS TECH, V117, P318, DOI 10.1016/S0924-0136(01)00790-7; Gubicza J, 2004, MAT SCI ENG A-STRUCT, V387, P55, DOI 10.1016/j.msea.2004.03.076; Horita Z, 1998, J MATER RES, V13, P446, DOI 10.1557/JMR.1998.0057; Kim J.H., 2010, METALL MATER TRANS A, V42A, P1805; KUHLMANWILSDORF D, 1991, SCRIPTA METALL MATER, V25, P1557, DOI 10.1016/0956-716X(91)90451-6; Li L, 2009, SCRIPTA MATER, V60, P317, DOI 10.1016/j.scriptamat.2008.10.031; LOUCHET F, 1975, ACTA METALL MATER, V23, P17, DOI 10.1016/0001-6160(75)90064-4; Nakai M, 2012, METALL MATER TRANS A, V43A, P294, DOI 10.1007/s11661-011-0860-3; Oh-ishi K, 2001, J MATER RES, V16, P583, DOI 10.1557/JMR.2001.0084; Purcek G, 2008, MAT SCI ENG A-STRUCT, V490, P403, DOI 10.1016/j.msea.2008.01.080; Rajinikanth V, 2011, MAT SCI ENG A-STRUCT, V528, P1702, DOI 10.1016/j.msea.2010.10.102; Schafler E, 2011, SCRIPTA MATER, V64, P130, DOI 10.1016/j.scriptamat.2010.09.026; Senkov ON, 1998, NANOSTRUCT MATER, V10, P691, DOI 10.1016/S0965-9773(98)00107-X; Ungar T, 2009, BULK NANOSTRUCTURED; Ungar T, 2004, SCRIPTA MATER, V51, P777, DOI 10.1016/j.scriptamat.2004.05.007; Ungar T, 2005, POWDER DIFFR, V20, P366, DOI 10.1154/1.2135313; Ungar T, 2001, MAT SCI ENG A-STRUCT, V14219, P1; Valiev RZ, 2004, NATURE MAT      0803, P511; Wadsack R, 2003, FUSION ENG DES, V66-68, P265, DOI 10.1016/S0920-3796(03)00136-4; WILKENS M, 1969, ACTA METALL MATER, V17, P1155, DOI 10.1016/0001-6160(69)90092-3; Wilkens M, 1969, FUNDAMENTAL ASPECTS, V317; Xu W, 2012, ACTA MATER, V60, P5067, DOI 10.1016/j.actamat.2012.05.042; Xu W, 2013, SCRIPTA MATER, V68, P67, DOI 10.1016/j.scriptamat.2012.09.023; Yilmazer H, 2013, MAT SCI ENG C-MATER, V33, P2499, DOI 10.1016/j.msec.2013.01.056; Yilmazer H, 2012, J MECH BEHAV BIOMED, V10, P235, DOI 10.1016/j.jmbbm.2012.02.022; Zhilyaev AP, 2001, SCRIPTA MATER, V44, P2753, DOI 10.1016/S1359-6462(01)00955-1	69	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1359-6454	1873-2453		ACTA MATER	Acta Mater.	NOV	2014	80						172	182		10.1016/j.actamat.2014.07.041		11	Materials Science, Multidisciplinary; Metallurgy & Metallurgical Engineering	Materials Science; Metallurgy & Metallurgical Engineering	AS3XK	WOS:000344208300016		
J	Tahara, M; Kanaya, T; Kim, HY; Inamura, T; Hosoda, H; Miyazaki, S				Tahara, Masaki; Kanaya, Takafumi; Kim, Hee Young; Inamura, Tomonari; Hosoda, Hideki; Miyazaki, Shuichi			Heating-induced martensitic transformation and time-dependent shape memory behavior of Ti-Nb-O alloy	ACTA MATERIALIA			English	Article						Martensitic transformation; Nanodomain; Titanium alloys; Shape memory effect; Lattice modulation	TRANSMISSION ELECTRON-MICROSCOPY; LOW YOUNGS MODULUS; GUM METAL; BIOMEDICAL ALLOYS; SUPERELASTIC PROPERTIES; MECHANICAL-PROPERTIES; DEFORMATION-BEHAVIOR; NITROGEN ADDITION; TINBSN ALLOYS; OXYGEN	The temperature dependence of nano-sized lattice modulation (nanodomains) introduced by oxygen atoms and martensitic transformation behavior of the (Ti-23Nb)-1.0O alloy were systematically investigated. Nanodomains in the beta phase became unstable at higher temperatures and disappeared >373 K, where time-dependent heating-induced forward transformation (HIFT) was confirmed in the (Ti-23Nb)-1.0O alloy. The thermally activated process of HIFT in the (Ti-23Nb)-1.0O alloy was the diffusion of oxygen atoms in nanodomains. Anomalous temperature dependence of shape memory behavior was also confirmed in the (Ti-23Nb)-1.0O alloy, and its mechanism was successfully explained by the diffusion of oxygen atoms during tensile deformation. (C) 2014 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.	[Tahara, Masaki; Inamura, Tomonari; Hosoda, Hideki] Tokyo Inst Technol, Precis & Intelligence Lab, Yokohama, Kanagawa 2268503, Japan; [Tahara, Masaki; Kanaya, Takafumi; Kim, Hee Young; Miyazaki, Shuichi] Univ Tsukuba, Div Mat Sci, Tsukuba, Ibaraki 3058573, Japan; [Miyazaki, Shuichi] King Abdulaziz Univ, Ctr Excellence Adv Mat Res, Jeddah 21589, Saudi Arabia	Kim, HY (reprint author), Univ Tsukuba, Div Mat Sci, Tsukuba, Ibaraki 3058573, Japan.	heeykim@ims.tsukuba.ac.jp; miyazaki@ims.tsukuba.ac.jp	Miyazaki, Shuichi/A-3113-2012; Kim, Hee Young/F-6065-2011	Miyazaki, Shuichi/0000-0003-3849-4176; Kim, Hee Young/0000-0003-1981-6678	JSPS KAKENHI [22-409, 26249104, 23860021, 24686077, 25289247, 26870194, 26220907]; Funding Program for Next Generation World-Leading Researchers from JSPS [LR015]; Advanced Low Carbon Technology Research and Development Program of the Japan Science and Technology Agency [JY240121]	This work was partially supported by JSPS KAKENHI Grant Numbers 22-409, 26249104, 23860021, 24686077, 25289247, 26870194, 26220907 and the Funding Program for Next Generation World-Leading Researchers (LR015) from JSPS and the Advanced Low Carbon Technology Research and Development Program (JY240121) of the Japan Science and Technology Agency.	Inamura T, 2004, MATER TRANS, V45, P1083, DOI 10.2320/matertrans.45.1083; Ito W, 2008, APPL PHYS LETT, V92, DOI 10.1063/1.2833699; Takahashi E, 2002, MATER TRANS, V43, P2978, DOI 10.2320/matertrans.43.2978; Al-Zain Y, 2010, ACTA MATER, V58, P4212, DOI 10.1016/j.actamat.2010.04.013; Obbard EG, 2011, ACTA MATER, V59, P112, DOI 10.1016/j.actamat.2010.09.015; Withey EA, 2010, ACTA MATER, V58, P2652, DOI 10.1016/j.actamat.2009.12.052; Kim HY, 2006, ACTA MATER, V54, P423, DOI 10.1016/j.actamat.2005.09.014; Masumoto K, 2006, MAT SCI ENG A-STRUCT, V438, P835, DOI 10.1016/j.msea.2006.02.060; Kim HY, 2006, MAT SCI ENG A-STRUCT, V438, P839, DOI 10.1016/j.msea.2006.02.136; Tahara M, 2011, ACTA MATER, V59, P6208, DOI 10.1016/j.actamat.2011.06.015; Kim HY, 2006, ACTA MATER, V54, P2419, DOI 10.1016/j.actamat.2006.01.019; Kim JI, 2005, MATER TRANS, V46, P852, DOI 10.2320/matertrans.46.852; Besse M, 2011, ACTA MATER, V59, P5982, DOI 10.1016/j.actamat.2011.06.006; Tane M, 2010, ACTA MATER, V58, P6790, DOI 10.1016/j.actamat.2010.09.007; Furuhara T, 2006, MAT SCI ENG A-STRUCT, V438, P825, DOI 10.1016/j.msea.2006.02.084; Matsumoto H, 2005, MATER TRANS, V46, P1070, DOI 10.2320/matertrans.46.1070; Tahara M, 2009, FUNCT MATER LETT, V2, P79, DOI 10.1142/S1793604709000600; Yano T, 2010, SCRIPTA MATER, V63, P536, DOI 10.1016/j.scriptamat.2010.05.025; Tahara M, 2010, MAT SCI ENG A-STRUCT, V527, P6844, DOI 10.1016/j.msea.2010.07.052; Kim HY, 2013, ACTA MATER, V61, P4874, DOI 10.1016/j.actamat.2013.04.060; Saito T, 2003, SCIENCE, V300, P464, DOI 10.1126/science.1081957; Ren XB, 2010, PHILOS MAG, V90, P141, DOI 10.1080/14786430903074771; Kim HY, 2004, MATER TRANS, V45, P2443, DOI 10.2320/matertrans.45.2443; Tahara M, 2013, J ALLOY COMPD, V577, pS404, DOI 10.1016/j.jallcom.2011.12.113; Obbard EG, 2010, ACTA MATER, V58, P3557, DOI 10.1016/j.actamat.2010.02.010; Kuramoto S, 2006, MAT SCI ENG A-STRUCT, V442, P454, DOI 10.1016/j.msea.2005.12.089; Ping DH, 2005, SCRIPTA MATER, V52, P1287, DOI 10.1016/j.scriptamat.2005.02.029; Yin FX, 2006, ADV MATER, V18, P1541, DOI 10.1002/adma.200600128; Kim JI, 2005, MAT SCI ENG A-STRUCT, V403, P334, DOI 10.1016/j.msea.2005.05.050; Yano T, 2009, ACTA MATER, V57, P628, DOI 10.1016/j.actamat.2008.10.002; Collings E.W., 1984, PHYS METALLURGY TITA; Horiuchi Y, 2007, MATER TRANS, V48, P414, DOI 10.2320/matertrans.48.414; Horiuchi Y, 2006, MAT SCI ENG A-STRUCT, V438, P830, DOI 10.1016/j.msea.2006.02.058; Horiuchi Y, 2006, MATER TRANS, V47, P1209, DOI 10.2320/matertrans.47.1209; Horiuchi Y, 2007, MATER TRANS, V48, P407, DOI 10.2320/matertrans.48.407; Hosoda H, 2006, MAT SCI ENG A-STRUCT, V438, P870, DOI 10.1016/j.msea.2006.02.151; Kim HY, 2006, MAT SCI ENG A-STRUCT, V417, P120, DOI 10.1016/j.msea.2005.10.065; Kim HY, 2007, MATER TRANS, V48, P400, DOI 10.2320/matertrans.48.400; Kim J.I., 2006, MAT T, V47, P505, DOI 10.2320/matertrans.47.505; Nii Y, 2010, PHYS REV B, V82, DOI 10.1103/PhysRevB.82.214104; Niitsu K, 2013, APPL PHYS LETT, V102, DOI 10.1063/1.4809935; Otsuka K, 1999, SHAPE MEMORY MAT; Sharma VK, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.140401; Tahara M, 2009, MATER TRANS, V50, P2726, DOI 10.2320/matertrans.MA200907; Tailing RJ, 2009, ACTA MAT, V57, P1188; Wang Y, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.132201; Yu LM, 2007, J MATER SCI, V42, P7819, DOI 10.1007/s10853-007-1619-5	47	4	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	1359-6454	1873-2453		ACTA MATER	Acta Mater.	NOV	2014	80						317	326		10.1016/j.actamat.2014.07.012		10	Materials Science, Multidisciplinary; Metallurgy & Metallurgical Engineering	Materials Science; Metallurgy & Metallurgical Engineering	AS3XK	WOS:000344208300028		
J	Matsuo, A; Hamada, H; Kaise, H; Chikazu, D; Yamada, K; Kohno, N				Matsuo, Akira; Hamada, Hayato; Kaise, Hiroshi; Chikazu, Daichi; Yamada, Kimito; Kohno, Norio			Characteristics of the early stages of intravenous bisphosphonate-related osteonecrosis of the jaw in patients with breast cancer	ACTA ODONTOLOGICA SCANDINAVICA			English	Article						bisphosphonate; osteonecrosis; breast cancer; oral hygiene	RISK-FACTORS; MULTIPLE-MYELOMA; ZOLEDRONIC ACID; PREVENTIVE MEASURES; SURGICAL RESECTION; METASTASES; IMPLEMENTATION; EXPERIENCE; MANAGEMENT; FREQUENCY	Objective. The clinical features of the early stages of bisphosphonate-related osteonecrosis of the jaw (BRONJ) in patients with breast cancer remain unclear. A retrospective cohort study was conducted of patients with breast cancer who received intravenous bisphosphonate (BP) treatment in a single center in order to clarify the status of the early stages of BRONJ. Materials and methods. A BRONJ oral monitoring program was established in 247 breast cancer patients given intravenous BP treatment at the institution. The differences in age, BP treatment period, number of remaining teeth, oral hygiene status, presence of regular oral monitoring and the existence of suspected BRONJ (stage 0) among eight BRONJ and 36 non-BRONJ subjects who completed oral examinations were then compared. Results. BRONJ was observed in 0.4% of subjects on the first visit to the oral surgery clinic and in 3.2% of subjects during the follow-up period. Logistic regression analysis revealed that the odds ratio for identifying patients with BRONJ during follow-up by the presence of stage 0 at first visit was 24.0 (95% confidence interval [CI] = 3.6-161.7). The area under the receiver operating characteristic curve for identifying subjects with BRONJ by the presence of stage 0 was 0.82 (95% CI = 0.63-1.00). Conclusion. The results suggest that patients with stage 0 BRONJ on the first visit may progress to advanced BRONJ during the follow-up period. The oral monitoring program may contribute to the early detection of BRONJ.	[Matsuo, Akira; Hamada, Hayato; Chikazu, Daichi] Tokyo Med Univ, Dept Oral & Maxillofacial Surg, Shinjuku Ku, Tokyo, Japan; [Kaise, Hiroshi; Yamada, Kimito; Kohno, Norio] Tokyo Med Univ, Dept Breast Oncol, Shinjuku Ku, Tokyo, Japan	Matsuo, A (reprint author), Tokyo Med Univ, Dept Oral & Maxillofacial Surg, Shinjuku Ku, Tokyo, Japan.						Abu-Id MH, 2008, J CRANIO MAXILL SURG, V36, P95, DOI 10.1016/j.jcms.2007.06.008; American Association of Oral and Maxillofacial Surgeons, 2007, J ORAL MAXILLOFAC SU, V65, P369, DOI DOI 10.1016/J.JOMS.2006.11.003; Dimopoulos MA, 2009, ANN ONCOL, V20, P117, DOI 10.1093/annonc/mdn554; Khan AA, 2008, J RHEUMATOL, V35, P1391; Badros A, 2006, J CLIN ONCOL, V24, P945, DOI 10.1200/JCO.2005.04.2465; Yoneda T, 2010, J BONE MINER METAB, V28, P365, DOI 10.1007/s00774-010-0162-7; Williamson RA, 2010, INT J ORAL MAX SURG, V39, P251, DOI 10.1016/j.ijom.2009.11.014; Ripamonti CI, 2009, ANN ONCOL, V20, P137, DOI 10.1093/annonc/mdn526; Junquera L, 2008, J ORAL MAXIL SURG, V66, P1516, DOI 10.1016/j.joms.2008.02.012; Coleman RE, 1997, CANCER, V80, P1588, DOI 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.3.CO;2-Z; Saia G, 2010, J ORAL MAXIL SURG, V68, P797, DOI 10.1016/j.joms.2009.10.026; Bedogni A, 2008, ORAL SURG ORAL MED O, V105, P358, DOI 10.1016/j.tripleo.2007.08.040; Ficarra G, 2005, J CLIN PERIODONTOL, V32, P1123, DOI 10.1111/j.1600-051X.2005.00842; Hutchinson M, 2010, J ORAL MAXIL SURG, V68, P2232, DOI 10.1016/j.joms.2010.05.003; Ruggiero SL, 2004, J ORAL MAXIL SURG, V62, P527, DOI 10.1016/j.joms.2004.02.004; Aghaloo TL, 2011, J BONE MINER RES, V26, P1871, DOI 10.1002/jbmr.379; Van den Wyngaert T, 2009, ANN ONCOL, V20, P331, DOI 10.1093/annonc/mdn630; Mawardi H, 2009, J ORAL MAXIL SURG, V67, P593, DOI 10.1016/j.joms.2008.09.031; Ruggiero SL, 2009, J ORAL MAXIL SURG, V67, P2, DOI 10.1016/j.joms.2009.01.009; Hoff AO, 2008, J BONE MINER RES, V23, P826, DOI [10.1359/jbmr.080205, 10.1359/JBMR.080205]; Mavrokokki T, 2007, J ORAL MAXIL SURG, V65, P415, DOI 10.1016/j.joms.2006.10.061; Bedogni A, 2011, ORAL ONCOL, V47, P420, DOI 10.1016/j.oraloncology.2011.02.024; Silverman SL, 2009, AM J MED, V122, P33, DOI 10.1016/j.amjmed.2008.12.005; Wang EP, 2007, J ORAL MAXIL SURG, V65, P1328, DOI 10.1016/j.joms.2007.03.006; Durie BGM, 2005, NEW ENGL J MED, V353, P99; Bamias A, 2005, J CLIN ONCOL, V23, P8580, DOI 10.1200/JCO.2005.02.8670; OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014; Vahtsevanos K, 2009, J CLIN ONCOL, V27, P5356, DOI 10.1200/JCO.2009.21.9584; Berenson JR, 2001, CANCER, V91, P1191, DOI 10.1002/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0; Carlson ER, 2009, J ORAL MAXIL SURG, V67, P85, DOI 10.1016/j.joms.2009.01.006; Bilezikian JP, 2006, NEW ENGL J MED, V355, P2278, DOI 10.1056/NEJMp068157; Bagan JV, 2009, ORAL ONCOL, V45, P645, DOI 10.1016/j.oraloncology.2008.05.011; Bianch SD, 2007, ORAL SURG ORAL MED O, V104, P249, DOI 10.1016/j.tripleo.2007.01.040; Bujanda DA, 2007, ANN ONCOL, V18, P556, DOI 10.1093/annonc/mdl408; Fedele S, 2011, AM J MED, V123, P1060; Hess LM, 2008, AM J MED, V121, P475, DOI 10.1016/j.amjmed.2008.01.047; Ibrahim T, 2008, ONCOLOGIST, V13, P330, DOI 10.1634/theoncologist.2007-0159; Khosla S, 2007, J BONE MINER RES, V22, P1479, DOI 10.1359/JBMR.0707ONJ; Komatsubara S, 2003, J BONE MINER RES, V18, P512, DOI 10.1359/jbmr.2003.18.3.512; Quispe D, 2011, BREAST J, V17, P510, DOI 10.1111/j.1524-4741.2011.01119.x; Sanna G, 2006, ANN ONCOL, V17, P1512, DOI 10.1093/annonc/mdl163; Shahnazari M, 2010, BONE, V46, P1267, DOI 10.1016/j.bone.2009.11.019; Trister N, 2009, ORAL DIS, V15, P88; Vescovi P, 2011, ORAL ONCOL, V47, P191, DOI 10.1016/j.oraloncology.2010.11.007; Walter C, 2009, CANCER, V115, P1631, DOI 10.1002/cncr.24119; Watts NB, 1998, ENDOCRIN METAB CLIN, V27, P419, DOI 10.1016/S0889-8529(05)70014-1	46	0	0	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0001-6357	1502-3850		ACTA ODONTOL SCAND	Acta Odontol. Scand.	NOV	2014	72	8					656	663		10.3109/00016357.2014.887772		8	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	AS5SR	WOS:000344330400014		
J	Matsuura, T; Sasaki, M; Katafuchi, M; Tokutomi, K; Mizumachi, E; Makino, M; Naito, T; Sato, H				Matsuura, Takashi; Sasaki, Michiko; Katafuchi, Michitsuna; Tokutomi, Kentaro; Mizumachi, Emiri; Makino, Michiko; Naito, Toru; Sato, Hironobu			Characterization of the bone matrix and its contribution to tooth loss in human cadaveric mandibles	ACTA ODONTOLOGICA SCANDINAVICA			English	Article						age; collagen; lysine hydroxylation; mineral; sex	COLLAGEN CROSS-LINKS; AGE-RELATED-CHANGES; I COLLAGEN; OSTEOGENESIS IMPERFECTA; FORMALIN FIXATION; CORTICAL BONE; FEMORAL-HEAD; MINERALIZATION; HYDROXYLYSINE; FIBRILLOGENESIS	Objective. It is uncertain as to what extent the major bone matrix constituents, mineral and collagen, show inter-individual variation and dependence on age and sex in jawbones. The purpose of this study was to clarify this uncertainty using cadaveric mandibles and investigate the association of bone matrix with the number of existing teeth. Materials and methods. Cortical bone samples (1 x 1 cm) collected from the mental of 48 cadaveric mandibles (27 men and 21 women; age range = 56-93 years and 63-103 years, respectively) were used to quantify three bone matrix indices: mineral content, collagen content and extent of lysine hydroxylation of collagen. Associations with age and comparisons by sex were evaluated based on bone matrix indices and the numbers of existing teeth. The numbers of existing teeth were compared between the groups showing low and high bone matrix index values. Results. A great amount of inter-individual variation was seen in all bone matrix indices. No bone matrix indices were associated with age, while the number of existing teeth was negatively associated with age. The bone matrix indices and number of existing teeth did not differ by sex. The number of existing teeth was nearly twice as high in the group showing high collagen content as in the low collagen group; however, an analysis of covariance showed a significant inter-group difference not from bone matrix indices, but rather from age. Interestingly, in comparison to femoral collagen, mandibular collagen showed lower lysine hydroxylation, which can represent an aspect of bone quality. Conclusions. Mandibular bone matrix shows great inter-individual variation and is independent of age and sex, but did not show as strong a relationship with tooth loss as age. Even so, mandibular collagen may represent a unique characteristic of bone matrix and deserves to be further investigated.	[Matsuura, Takashi; Sasaki, Michiko; Katafuchi, Michitsuna; Tokutomi, Kentaro; Mizumachi, Emiri; Sato, Hironobu] Fukuoka Dent Coll, Dept Oral Rehabil, Sect Fixed Prosthodont, Fukuoka 8140193, Japan; [Makino, Michiko; Naito, Toru] Fukuoka Dent Coll, Dept Gen Dent, Sect Geriatr Dent, Fukuoka 8140193, Japan	Matsuura, T (reprint author), Fukuoka Dent Coll, Dept Oral Rehabil, Sect Fixed Prosthodont, Sawara Ku, 15-1 Tamura 2 Chome, Fukuoka 8140193, Japan.	matsuurt@college.fdcnet.ac.jp			 [24592945]	This study was supported by Grant-in-Aid 24592945 for Scientific Research (C), Japan. The authors thank Dr Mitsuo Yamauchi, the director of the Laboratory of Collagen Biochemistry at the Dental Research Center, University of North Carolina, Chapel Hill, NC, USA, for his informative suggestions.	Abe M, 2003, ANAL BIOCHEM, V318, P118, DOI 10.1016/S0003-2697(03)00194-5; AERSSENS J, 1993, CALCIFIED TISSUE INT, V53, P269, DOI 10.1007/BF01320913; ANDREASSEN TT, 1995, J BONE MINER RES, V10, P1057; Burr DB, 2002, BONE, V31, P8, DOI 10.1016/S8756-3282(02)00815-3; NIYIBIZI C, 1989, CONNECT TISSUE RES, V20, P247, DOI 10.3109/03008208909023894; Pornprasertsuk S, 2005, J BONE MINER RES, V20, P81, DOI 10.1359/JBMR.041026; YAMAUCHI M, 1986, BIOCHEMISTRY-US, V25, P4907, DOI 10.1021/bi00365a027; Boskey AL, 2010, J DENT RES, V89, P1333, DOI 10.1177/0022034510377791; Fishbein KW, 2007, MAGN RESON MED, V57, P1000, DOI 10.1002/mrm.21215; Notbohm H, 1999, J BIOL CHEM, V274, P8988, DOI 10.1074/jbc.274.13.8988; VOGT W, 1995, FREE RADICAL BIO MED, V18, P93, DOI 10.1016/0891-5849(94)00158-G; Sricholpech M, 2011, J BIOL CHEM, V286, P8846, DOI 10.1074/jbc.M110.178509; Tokutomi K, 2008, CONNECT TISSUE RES, V49, P361, DOI 10.1080/03008200802325292; Sricholpech M, 2012, J BIOL CHEM, V287, P22998, DOI 10.1074/jbc.M112.343954; Saito M, 2010, OSTEOPOROSIS INT, V21, P195, DOI 10.1007/s00198-009-1066-z; Fratzl P, 2004, J MATER CHEM, V14, P2115, DOI 10.1039/b402005g; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; MCCALDEN RW, 1993, J BONE JOINT SURG AM, V75A, P1193; Bailey AJ, 1999, EXP GERONTOL, V34, P337, DOI 10.1016/S0531-5565(99)00016-9; BAILEY AJ, 1992, BIOCHEM BIOPH RES CO, V185, P801, DOI 10.1016/0006-291X(92)91697-O; BARNES MJ, 1973, BIOCHIM BIOPHYS ACTA, V328, P373, DOI 10.1016/0005-2795(73)90271-7; BARNES MJ, 1973, BIOCHEM J, V132, P113; BOSKEY AL, 1982, CALCIFIED TISSUE INT, V34, P328, DOI 10.1007/BF02411262; Civitelli R, 2013, PRIMER METABOLIC BON, P948; Ding M, 2012, BONE, V51, P953, DOI 10.1016/j.bone.2012.07.018; EASTOE JE, 1973, CALC TISS RES, V12, P91, DOI 10.1007/BF02013724; Hickey SD, 1979, CONNECT TISSUE RES, V6, P223; IBRAHIM J, 1989, BIOCHIM BIOPHYS ACTA, V992, P9, DOI 10.1016/0304-4165(89)90044-5; KIRSCH E, 1981, EUR J CLIN INVEST, V11, P39, DOI 10.1111/j.1365-2362.1981.tb01763.x; KIVIRIKKO KI, 1985, ANN NY ACAD SCI, V460, P187, DOI 10.1111/j.1749-6632.1985.tb51167.x; PLESHKO NL, 1992, CALCIFIED TISSUE INT, V51, P72, DOI 10.1007/BF00296221; Saito M, 2006, OSTEOPOROSIS INT, V17, P986, DOI 10.1007/s00198-006-0087-0; Shiiba M, 2002, J BONE MINER RES, V17, P1639, DOI 10.1359/jbmr.2002.17.9.1639; SHIKATA H, 1985, ARCH ORAL BIOL, V30, P451, DOI 10.1016/0003-9969(85)90075-5; Silva MJ, 2006, J BONE MINER RES, V21, P78, DOI 10.1359/JBMR.050909; STRAWICH E, 1983, J BIOL CHEM, V258, P555; Wojtowicz A, 1999, CALCIFIED TISSUE INT, V64, P370, DOI 10.1007/PL00005816; WONG SYP, 1985, J BONE JOINT SURG AM, V67A, P274; Yamauchi M, 1996, CALCIUM PHOSPHORUS H, P127; YAMAUCHI M, 1982, P NATL ACAD SCI-BIOL, V79, P7684, DOI 10.1073/pnas.79.24.7684	40	0	0	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0001-6357	1502-3850		ACTA ODONTOL SCAND	Acta Odontol. Scand.	NOV	2014	72	8					753	761		10.3109/00016357.2014.903517		9	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	AS5SR	WOS:000344330400027		
J	Han, JM; Hong, G; Dilinuer, M; Lin, H; Zheng, G; Wang, XZ; Sasaki, K				Han, Jian-Min; Hong, Guang; Dilinuer, Maimaitishawuti; Lin, Hong; Zheng, Gang; Wang, Xin-Zhi; Sasaki, Keiichi			The adhesive strength and initial viscosity of denture adhesives	ACTA ODONTOLOGICA SCANDINAVICA			English	Article						denture adhesive; viscosity; adhesive strength	RETENTION	Objective. To examine the initial viscosity and adhesive strength of modern denture adhesives in vitro. Materials and methods. Three cream-type denture adhesives (Poligrip S, Corect Cream, Liodent Cream; PGS, CRC, LDC) and three powder-type denture adhesives (Poligrip Powder, New Faston, Zanfton; PGP, FSN, ZFN) were used in this study. The initial viscosity was measured using a controlled-stress rheometer. The adhesive strength was measured according to ISO-10873 recommended procedures. All data were analyzed independently by one-way analysis of variance combined with a Student-Newman-Keuls multiple comparison test at a 5% level of significance. Results. The initial viscosity of all the cream-type denture adhesives was lower than the powder-type adhesives. Before immersion in water, all the powder-type adhesives exhibited higher adhesive strength than the cream-type adhesives. However, the adhesive strength of cream-type denture adhesives increased significantly and exceeded the powder-type denture adhesives after immersion in water. For powder-type adhesives, the adhesive strength significantly decreased after immersion in water for 60 min, while the adhesive strength of the cream-type adhesives significantly decreased after immersion in water for 180 min. Conclusion. Cream-type denture adhesives have lower initial viscosity and higher adhesive strength than powder type adhesives, which may offer better manipulation properties and greater efficacy during application.	[Han, Jian-Min; Lin, Hong; Zheng, Gang] Peking Univ, Natl Engn Lab Digital & Mat Technol Stomatol, Dental Mat Lab, Beijing 100871, Peoples R China; [Han, Jian-Min; Lin, Hong; Zheng, Gang; Wang, Xin-Zhi] Sch & Hosp Stomatol, Beijing, Peoples R China; [Han, Jian-Min; Hong, Guang] Tohoku Univ, Liaison Ctr Innovat Dent, Grad Sch Dent, Sendai, Miyagi 9808575, Japan; [Dilinuer, Maimaitishawuti; Sasaki, Keiichi] Tohoku Univ, Grad Sch Dent, Div Adv Prosthet Dent, Sendai, Miyagi 9808575, Japan; [Wang, Xin-Zhi] Peking Univ, Dept Prosthodont, Beijing 100871, Peoples R China	Hong, G (reprint author), Tohoku Univ, Liaison Ctr Innovat Dent, Grad Sch Dent, Aoba Ku, 4-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.	hong@m.tohoku.ac.jp			Ministry of Education, Culture, Sports, Science and Technology, Japan [21791899, 24792052]	This research was supported by Grant-in-Aid (No. 21791899 and No. 24792052) for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan.	ADISMAN IK, 1989, J PROSTHET DENT, V62, P711; Uysal H, 1998, J ORAL REHABIL, V25, P209; Aziz EA, 2010, J AM SCI, V6, P556; CHEW CL, 1990, J ORAL REHABIL, V17, P425, DOI 10.1111/j.1365-2842.1990.tb01414.x; ELLIS B, 1980, J DENT, V8, P109, DOI 10.1016/0300-5712(80)90025-1; Grasso Joseph E, 2004, Dent Clin North Am, V48, P721, DOI 10.1016/j.cden.2004.04.002; Grasso JE, 1996, J AM DENT ASSOC, V127, P90; GRASSO JE, 1994, J PROSTHET DENT, V72, P399, DOI 10.1016/0022-3913(94)90560-6; Han JM, 2013, DENT MATER J, V33, P98; Hong G, 2011, ASIAN PAC J DENT, V11, P45; International Organization for Standardization, 2010, DENT DENT ADH, P3; Kalra P, 2012, J ADV PROSTHODONT, V4, P97, DOI 10.4047/jap.2012.4.2.97; KAPUR KK, 1967, J PROSTHET DENT, V18, P550, DOI 10.1016/0022-3913(67)90221-1; Koronis S, 2012, GERODONTOLOGY, V29, pE161, DOI 10.1111/j.1741-2358.2010.436.x; Kulak Yasemin, 2005, J Prosthodont, V14, P248, DOI 10.1111/j.1532-849X.2005.00049.x; LAMB DJ, 1980, J DENT, V8, P35, DOI 10.1016/S0300-5712(80)80043-1; LOVE WB, 1991, J PROSTHET DENT, V66, P356, DOI 10.1016/0022-3913(91)90263-V; MEANS CR, 1964, J PROSTHET DENT, V14, P1086, DOI 10.1016/0022-3913(64)90177-5; Munoz CA, 2012, J PROSTHODONT, V21, P123, DOI 10.1111/j.1532-849X.2011.00795.x; Ozcan Mutlu, 2005, J Prosthodont, V14, P122, DOI 10.1111/j.1532-849X.2005.00020.x; PANAGIOTOUNI E, 1995, J PROSTHET DENT, V73, P578, DOI 10.1016/S0022-3913(05)80120-9; Polyzois G, 2011, ODONTOLOGY, V99, P155, DOI 10.1007/s10266-011-0003-8; Psillakis Jason J, 2004, J Prosthodont, V13, P244; Sato Y, 2008, J JPN PROSTHODONT SO, V52, P175; SHAY K, 1991, J AM DENT ASSOC, V122, P70; Stafford G D, 1970, Dent Pract Dent Rec, V21, P17; STROBEL S, 1986, FOOD ADDIT CONTAM, V3, P47; TARBET WJ, 1980, J PROSTHET DENT, V44, P374, DOI 10.1016/0022-3913(80)90092-X; Tarib NA, 2010, HONG KONG DENT J, V7, P67; Tezvergil-Mutluay A, 2010, J PROSTHET DENT, V103, P380, DOI 10.1016/S0022-3913(10)60081-9; Weidner-Strahl S K, 1984, Quintessenz, V35, P1547; Wilson MJ, 1990, J DENT RES, V69, P970; WOELFEL JB, 1962, J AM DENT ASSOC, V64, P763	33	0	0	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0001-6357	1502-3850		ACTA ODONTOL SCAND	Acta Odontol. Scand.	NOV	2014	72	8					839	845		10.3109/00016357.2014.913309		7	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	AS5SR	WOS:000344330400040		
J	Hamanaka, I; Iwamoto, M; Lassila, L; Vallittu, P; Shimizu, H; Takahashi, Y				Hamanaka, Ippei; Iwamoto, Misa; Lassila, Lippo; Vallittu, Pekka; Shimizu, Hiroshi; Takahashi, Yutaka			Influence of water sorption on mechanical properties of injection-molded thermoplastic denture base resins	ACTA ODONTOLOGICA SCANDINAVICA			English	Article						injection-molded thermoplastic denture base resin; polyamide; polyethylene terephthalate copolymer; polycarbonate; water sorption	FIBER-REINFORCED COMPOSITES; FLEXURAL PROPERTIES; STREPTOCOCCUS-MUTANS; E-GLASS; RELINE MATERIALS; STRENGTH; IMMERSION; NYLON; ADHESION; POLYMER	Objective. This study investigated the influence of water sorption on certain mechanical properties of injection-molded thermoplastic denture base resins. Materials and methods. Six thermoplastic resins (two polyamides, two polyesters, one polycarbonate, one polymethylmethacrylate) and a polymethylmethacrylate (PMMA) conventional heat-polymerized denture-based polymer, selected as a control, were tested. Specimens of each denture base material were fabricated according to ISO 1567 specifications and were either dry or water-immersed for 30 days (n = 10). The ultimate flexural strength, the flexural strength at the proportional limit and the elastic modulus of the denture base materials were calculated. Results. Water sorption significantly decreased the ultimate flexural strength, the flexural strength at the proportional limit and the elastic modulus of one of the polyamides and the PMMAs. It also significantly increased the ultimate flexural strength of the polycarbonate. Conclusion. The mechanical properties of some injection-molded thermoplastic denture base resins changed after water sorption.	[Hamanaka, Ippei; Iwamoto, Misa; Shimizu, Hiroshi; Takahashi, Yutaka] Fukuoka Dent Coll, Div Removable Prosthodont, Fukuoka 8140193, Japan; [Hamanaka, Ippei; Iwamoto, Misa; Lassila, Lippo; Vallittu, Pekka] Univ Turku, Inst Dent, Dept Biomat Sci, Turku, Finland; [Hamanaka, Ippei; Iwamoto, Misa; Lassila, Lippo; Vallittu, Pekka] Univ Turku, Inst Dent, TCBC, Turku, Finland	Hamanaka, I (reprint author), Fukuoka Dent Coll, Sawara Ku, 2-15-1 Tamura, Fukuoka 8140193, Japan.	hamanaka@college.fdcnet.ac.jp					Yunus N, 2005, J ORAL REHABIL, V32, P65, DOI 10.1111/j.1365-2842.2004.01370.x; Takahashi Y, 2012, ACTA ODONTOL SCAND, V70, P297, DOI 10.3109/00016357.2011.600719; Katsumata Y, 2009, DENT MATER J, V28, P409; Takabayashi Y, 2010, DENT MATER J, V29, P353, DOI 10.4012/dmj.2009-114; Tanner J, 2005, CLIN ORAL INVEST, V9, P154, DOI 10.1007/s00784-005-0317-4; Tanner J, 2003, J BIOMED MATER RES B, V66B, P391, DOI 10.1002/jbm.b.10012; Anusavice KJ, 2013, PHILLIPS SCI DENT MA, P474; Anusavis KJ, 2013, PHILLIPS SCIENCE OF, V12th, P48; Chai J, 1998, INT J PROSTHODONT, V11, P121; GARDNER RJ, 1979, J APPL POLYM SCI, V24, P1269, DOI 10.1002/app.1979.070240512; Goiato Marcelo Coelho, 2008, Dent Today, V27, P116; Goiato MC, 2008, DENT TODAY, V27, P116; Hamanaka I, 2013, ACTA ODONTOL SCAND, V71, P1250, DOI 10.3109/00016357.2012.757645; Hamanaka I, 2011, ACTA ODONTOL SCAND, V69, P75, DOI 10.3109/00016357.2010.517557; Hamanaka I, 2014, ACTA ODONTOL SCAND, V72, P139, DOI 10.3109/00016357.2013.814803; International Standard, 1999, ISO 1567 FOR DENTIST; International Standard, 2003, ISO 1567 AMENDMENT 1; Ito M, 2013, J PROSTHET DENT, V109, P5, DOI 10.1016/S0022-3913(13)60002-5; Kaplan P, 2008, DENT TODAY, V27, P122; Kaplan Paul, 2008, Dent Today, V27, P122; Osada H, 2013, DENT MATER J, V32, P381, DOI 10.4012/dmj.2012-284; Powers JM, 2006, CRAIGS RESTORATIVE D, P51; Takahashi Y, 2013, ACTA ODONTOL SCAND, V71, P716, DOI 10.3109/00016357.2012.715196; Takahashi Y, 1998, INT J PROSTHODONT, V11, P49; Takahashi Y, 1997, INT J PROSTHODONT, V10, P508; Takahashi Y, 1999, INT J PROSTHODONT, V12, P348; Takahashi Y, 2000, INT J PROSTHODONT, V13, P205; Tanner J, 2001, BIOMATERIALS, V22, P1613, DOI 10.1016/S0142-9612(00)00314-8; Tanner J, 2000, J BIOMED MATER RES, V49, P250, DOI 10.1002/(SICI)1097-4636(200002)49:2<250::AID-JBM14>3.0.CO;2-F; Vallittu P K, 1996, J Prosthodont, V5, P186, DOI 10.1111/j.1532-849X.1996.tb00295.x; Vallittu PK, 1998, INT J PROSTHODONT, V11, P340; Vallittu PK, 2007, INT J PROSTHODONT, V20, P43; VALLITTU PK, 1993, ACTA ODONTOL SCAND, V51, P363, DOI 10.3109/00016359309040587; VALLITTU PK, 1995, J PROSTHET DENT, V74, P412, DOI 10.1016/S0022-3913(05)80384-1	34	1	1	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0001-6357	1502-3850		ACTA ODONTOL SCAND	Acta Odontol. Scand.	NOV	2014	72	8					859	865		10.3109/00016357.2014.919662		7	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	AS5SR	WOS:000344330400043		
J	Hsu, JC; Watari, I; Ono, R; Privatananupunt, J; Mizumachi-Kubono, M; Honda, K; Ishida, Y; Ono, T				Hsu, Jui-Chin; Watari, Ippei; Ono, Rieko; Privatananupunt, Jutiporn; Mizumachi-Kubono, Mariko; Honda, Koji; Ishida, Yuji; Ono, Takashi			Degeneration of fungiform and circumvallate papillae following molar extraction in rats	ACTA ODONTOLOGICA SCANDINAVICA			English	Article						cytokeratin 8; immunohistochemistry; taste	CHORDA-LINGUAL NERVE; TASTE-BUDS; GUSTATORY NEURONS; PAROTID SECRETION; SOLITARY TRACT; SALIVARY FLOW; CELLS; TRANSECTION; MASTICATION; MORPHOLOGY	Objective. Proper occlusion facilitates food intake and gustatory function is indispensable for the enjoyment of food. Although an interaction between dentoalveolar and gustatory afferent neurons has been suggested by previous studies, the relationship between occlusion and gustation remains unclear. This study investigated the effect of upper molar extraction which diminished occlusal support on peripheral gustatory receptors in rats. Materials and methods. Thirty-six 7-week-old male Wistar rats were randomly assigned to either the experimental or the control group. All maxillary molars were extracted from rats in the experimental group under anesthesia, while a sham operation was conducted in the control group. The rats were euthanized 7, 14 or 28 days after the procedure. The morphology of the circumvallate papillae and taste buds using immunohistochemical methods and the fungiform papillae were visualized with 1% methylene blue. Results. Defects in the gustatory epithelium were observed after maxillary molar extraction. Rats in the experimental group had significantly fewer fungiform papillae, narrower circumvallate papillae, shallower trench depth, smaller trench area, smaller taste bud area, lower ratios of taste bud area to trench area and fewer taste buds than those in the control group. Conclusions. The findings indicate that molar extraction would affect peripheral gustatory receptors. This is the first study to characterize changes in rat fungiform and circumvallate papillae after maxillary molar extraction. This study suggests a possible synergic relationship between dentoalveolar perception and gustatory function, which has clinical implications that occlusion is closely correlated with gustatory perception.	[Hsu, Jui-Chin; Watari, Ippei; Ono, Rieko; Privatananupunt, Jutiporn; Mizumachi-Kubono, Mariko; Honda, Koji; Ishida, Yuji; Ono, Takashi] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Orthodont Sci, Tokyo 1138549, Japan	Hsu, JC (reprint author), Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Div Oral Hlth Sci, Dept Orofacial Dev & Funct,Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138549, Japan.	sumire.orts@tmd.ac.jp			Japanese Ministry of Education, Culture, Sports, Science and Technology [23792421]	This study was supported in part by Grants-in-Aid for Scientific Research (No. 23792421) from the Japanese Ministry of Education, Culture, Sports, Science and Technology. The experimental procedures described here were approved by the Institutional Animal Care and Use Committee (No. 0130060A) and performed in accordance with the Animal Care Standards of Tokyo Medical and Dental University.	Chaudhari N, 2010, J CELL BIOL, V190, P285, DOI 10.1083/jcb.201003144; Braud A, 2012, J DENT RES, V91, P215, DOI 10.1177/0022034511429569; Sollars SI, 2002, J NEUROBIOL, V51, P223, DOI 10.1002/neu.10055; Asano-Miyoshi M, 2008, J MOL HISTOL, V39, P193, DOI 10.1007/s10735-007-9151-0; BEIDLER LM, 1965, J CELL BIOL, V27, P263, DOI 10.1083/jcb.27.2.263; Naftel JP, 1999, ANAT REC, V256, P433, DOI 10.1002/(SICI)1097-0185(19991201)256:4<433::AID-AR10>3.0.CO;2-R; ANDERSON DJ, 1985, J PHYSIOL-LONDON, V364, P19; BARTOSHUK LM, 1994, PHYSIOL BEHAV, V56, P1165, DOI 10.1016/0031-9384(94)90361-1; Huang Q, 2002, J DENT RES, V81, P209; Morris-Wiman J, 2000, CHEM SENSES, V25, P9, DOI 10.1093/chemse/25.1.9; Boucher Y, 2003, BRAIN RES, V973, P265, DOI 10.1016/S0006-8993(03)02526-5; Pedersen AM, 2002, ORAL DIS, V8, P117, DOI 10.1034/j.1601-0825.2002.02851.x; HECTOR MP, 1987, Q J EXP PHYSIOL CMS, V72, P285; Oakley B, 2004, J NEUROCYTOL, V33, P631, DOI 10.1007/s11068-005-3332-0; Drewnowski A, 1997, ANNU REV NUTR, V17, P237, DOI 10.1146/annurev.nutr.17.1.237; Devlin H, 2000, CELLS TISSUES ORGANS, V167, P33, DOI 10.1159/000016764; DONG C, 1995, ARCH ORAL BIOL, V40, P585, DOI 10.1016/0003-9969(95)00012-E; Farbman AI, 2003, J COMP NEUROL, V459, P9, DOI 10.1002/cne.10588; Faurion A, 2006, PHYSIOL BEHAV, V89, P44, DOI 10.1016/j.physbeh.2006.05.008; Guagliardo NA, 2007, J COMP NEUROL, V504, P206, DOI 10.1002/cne.21436; Huang YJ, 1996, J ANAT, V189, P315; KNAPP L, 1995, DIFFERENTIATION, V58, P341, DOI 10.1046/j.1432-0436.1995.5850341.x; MACKIE DA, 1990, PHYSIOL BEHAV, V47, P593, DOI 10.1016/0031-9384(90)90131-M; Mistretta CM, 1999, J COMP NEUROL, V409, P13; Mizumachi-Kubono M, 2012, ARCH ORAL BIOL, V57, P877, DOI 10.1016/j.archoralbio.2012.02.006; Nosrat IV, 2012, J BIOL CHEM, V287, P16791, DOI 10.1074/jbc.M111.328476; Oakley B, 1998, ANN NY ACAD SCI, V855, P50, DOI 10.1111/j.1749-6632.1998.tb10545.x; OAKLEY B, 1993, MICROSC RES TECHNIQ, V26, P187, DOI 10.1002/jemt.1070260302; Ohara K, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-139; Shafer DM, 1999, ORAL SURG ORAL MED O, V87, P419, DOI 10.1016/S1079-2104(99)70240-4; Shires CB, 2011, OTOLARYNG HEAD NECK, V144, P915, DOI 10.1177/0194599811399722; Sollars SI, 2005, J NEUROBIOL, V64, P310, DOI 10.1002/neu.20140; Witt M., 2003, Handbook of olfaction and gustation, P651	33	0	0	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0001-6357	1502-3850		ACTA ODONTOL SCAND	Acta Odontol. Scand.	NOV	2014	72	8					880	886		10.3109/00016357.2014.920105		7	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	AS5SR	WOS:000344330400046		
J	Mehta, D; Gowda, VS; Santosh, A; Finger, WJ; Sasaki, K				Mehta, Deepak; Gowda, Vishwas S.; Santosh, Ashwini; Finger, Werner J.; Sasaki, Keiichi			Randomized controlled clinical trial on the efficacy of dentin desensitizing agents	ACTA ODONTOLOGICA SCANDINAVICA			English	Article						clinical trial; dentin hypersensitivity; calcium-phosphate desensitizer	IN-VITRO EVALUATION; TOOTH HYPERSENSITIVITY; HYDRAULIC CONDUCTANCE; CERVICAL DENTIN; PREVALENCE; MANAGEMENT; TUBULES; SALIVA	Objective. To investigate the effects of four dentin desensitizers on pain reduction in hypersensitive cervical dentin lesions. Materials and methods. The trial was designed as a randomized, controlled, four-arm, single-masked study. Fifty subjects with at least one hypersensitive lesion in each of the four quadrants were allocated. The requested pre-operative pain, determined as a response to 2-s air-blast (AB) and probe scratching (PS), was >= 5 on a VAS scale, 0 = no through to 10 = worst pain. Randomly each subject received each of the four treatments: MS Coat One F (MSC, Sun Medical, Japan), Nanoseal (NAN, Nishin, Japan), Teethmate Desensitizer (TMD, Kuraray Noritake, Japan) and Gluma Desensitizer PowerGel (GLU, HeraeusKulzer, Germany). The investigator assessed blindly the pain response using the two stimuli and recorded the patients' VAS scores before and immediately after application, after 1 week and after 1, 3 and 6 months. Statistical data treatment. ANOVA and post-hoc testing (p <= 0.05). Results. Forty-nine subjects completed the trial. Pre-operative dentin hypersensitivity (DH) for the groups was not significantly different. All desensitizers reduced DH significantly throughout the 6-months observation. ANOVA revealed significant differences among VAS scores, obtained with the desensitizing agents (p < 0.001). Ranking by post-hoc testing was: MSC > NAN > TMD > GLU (p < 0.05). Upon PS NAN and TMD showed slight but significant regain of sensitivity after 6 months. For GLU PS scores immediately after application and after 6 months were not significantly different, whereas recalls after 1 week, 1 month and 3 months revealed significantly lower scores. Conclusion. The calcium phosphate-based TMD and GLU proved highly effective in reducing sensitivity.	[Mehta, Deepak; Gowda, Vishwas S.; Santosh, Ashwini] VokkaligaraSangha Dent Coll & Hosp, Dept Conservat Dent & Endodont, Bangalore 560004, Karnataka, India; [Finger, Werner J.] Tohoku Univ, Grad Sch Dent, Liaison Ctr Innovat Dent, Sendai, Miyagi 980, Japan; [Sasaki, Keiichi] Tohoku Univ, Grad Sch Dent, Liaison Ctr Innovat Dent, Dept Oral Funct & Morphol, Sendai, Miyagi 980, Japan; [Sasaki, Keiichi] Tohoku Univ, Grad Sch Dent, Div Adv Prosthet Dent, Sendai, Miyagi 980, Japan	Mehta, D (reprint author), VS Dent Coll & Hosp, Dept Conservat Dent & Endodont, Room 6,KR Rd, Bangalore 560004, Karnataka, India.	drdeemehta@gmail.com					ABSI EG, 1987, J CLIN PERIODONTOL, V14, P280, DOI 10.1111/j.1600-051X.1987.tb01533.x; Addy M, 2007, Int J Dent Hyg, V5, P53, DOI 10.1111/j.1601-5037.2007.00228.x; Splieth CH, 2013, CLIN ORAL INVEST, V17, pS3, DOI 10.1007/s00784-012-0889-8; Chow LC, 2009, DENT MATER J, V28, P1; Vora J, 2012, AM J DENT, V25, P293; CIUCCHI B, 1995, J ENDODONT, V21, P191, DOI 10.1016/S0099-2399(06)80564-9; GREENHILL JD, 1981, J DENT RES, V60, P686, DOI 10.1177/00220345810600030401; TROWBRIDGE HO, 1990, DENT CLIN N AM, V34, P561; Morris MF, 1999, AM J DENT, V12, P72; Qin CY, 2006, EUR J ORAL SCI, V114, P354; Suge T, 1995, J DENT RES, V74, P1709; Holland GR, 1997, J CLIN PERIODONTOL, V24, P808, DOI 10.1111/j.1600-051X.1997.tb01194.x; Thanatvarakorn O, 2013, DENT MATER J, V32, P615, DOI 10.4012/dmj.2013-073; Larsen MJ, 2003, ARCH ORAL BIOL, V48, P317, DOI 10.1016/S0003-9969(03)00007-4; BERMAN LH, 1985, J PERIODONTOL, V56, P216; Bowen WE, 1983, J DENT RES, V62, P672; Brannstrom M., 1963, SENSORY MECH DENTINE, P73; Canadian Advisory Board on Dentin Hypersensitivity, 2003, J CAN DENT ASSOC, V69, P221; Chabanski MB, 1997, J ORAL REHABIL, V24, P15, DOI 10.1046/j.1365-2842.1997.00471.x; Cunha-Cruz J, 2011, J DENT RES, V90, P304, DOI 10.1177/0022034510389179; Duran I, 2004, J ORAL REHABIL, V31, P341; FELTON D A, 1991, International Journal of Prosthodontics, V4, P292; Gernhardt CR, 2013, CLIN ORAL INVEST, V17, pS31, DOI 10.1007/s00784-012-0891-1; Gillam DG, 2010, DENT PRACT, V48, P34; Gillam DG, 2002, J ORAL REHABIL, V29, P226, DOI 10.1046/j.1365-2842.2002.00813.x; Imai Y, 1990, Dent Mater J, V9, P167; Ishihata H, 2009, AM J DENT, V22, P143; Lin PY, 2013, J CLIN PERIODONTOL, V40, P53, DOI 10.1111/jcpe.12011; Schmidlin PR, 2013, CLIN ORAL INVEST, V17, pS55, DOI 10.1007/s00784-012-0912-0; Schupbach P, 1997, EUR J ORAL SCI, V105, P414; Shetty S, 2010, J PERIODONTOL, V81, P1781, DOI 10.1902/jop.2010.100172; Thanatvarakorn O, 2013, J BIOMED MATER RES B, V101B, P303, DOI 10.1002/jbm.b.32840; Wanachantararak S., 2000, TOOTH WEAR SENSITIVI, P39	33	1	1	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0001-6357	1502-3850		ACTA ODONTOL SCAND	Acta Odontol. Scand.	NOV	2014	72	8					936	941		10.3109/00016357.2014.923112		6	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	AS5SR	WOS:000344330400053		
J	Ueno, M; Takeuchi, S; Takehara, S; Kawaguchi, Y				Ueno, Masayuki; Takeuchi, Susumu; Takehara, Sachiko; Kawaguchi, Yoko			Saliva viscosity as a potential risk factor for oral malodor	ACTA ODONTOLOGICA SCANDINAVICA			English	Article						oral malodor; organoleptic test; saliva viscosity; viscometer	WHOLE SALIVA	Objectives. The objective of this study was to assess whether saliva viscosity, measured by a viscometer, was a predictor of oral malodor. Materials and methods. The subjects were 617 patients who visited an oral malodor clinic. The organoleptic test (OT) was used for diagnosis of oral malodor. An oral examination assessed the numbers of teeth present and decayed teeth as well as the presence or absence of dentures. Further, periodontal pocket depths (PD), gingival bleeding, dental plaque and tongue coating were investigated. Unstimulated saliva were collected for 5 min. Saliva viscosity was measured with a viscometer. Logistic regression analysis with oral malodor status by OT as a dependent variable was performed. Possible confounders including age, gender, number of teeth present, number of decayed teeth, number of teeth with PD >= 4 mm, number of teeth with bleeding on probing, presence or absence of dentures, plaque index, area of tongue coating, saliva flow rate, saliva pH and saliva viscosity were used as independent variables. Results. Saliva viscosity (p = 0.047) along with the number of teeth with PD >= 4 mm(p = 0.001), plaque index (p = 0.037) and area of tongue coating (p < 0.001) were significant variables for oral malodor. Subjects with a higher number of teeth with PD >= 4mm(OR = 1.32), plaque index (OR = 2.13), area of tongue coating (OR = 3.17) and saliva viscosity (OR = 1.10) were more likely to have oral malodor compared to those with lower values. Conclusions. The results suggested that high saliva viscosity could be a potential risk factor for oral malodor.	[Ueno, Masayuki; Takehara, Sachiko; Kawaguchi, Yoko] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Oral Hlth Promot, Tokyo 1138549, Japan; [Takeuchi, Susumu] Tsurumi Univ, Sch Dent Med, Dept Community Dent, Kanagawa, Japan	Ueno, M (reprint author), Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Oral Hlth Promot, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138549, Japan.	ueno.ohp@tmd.ac.jp					Park MS, 2007, ORAL DIS, V13, P181, DOI 10.1111/j.1601-0825.2006.01263.x; Van Tornout M, 2013, J CLIN PERIODONTOL, V40, P180, DOI 10.1111/jcpe.12031; Helmerhorst EJ, 2007, J DENT RES, V86, P680; TONZETICH J, 1978, INT DENT J, V28, P309; Schipper RG, 2007, ARCH ORAL BIOL, V52, P1114, DOI 10.1016/j.archoralbio.2007.06.009; YAEGAKI K, 1992, J PERIODONTAL RES, V27, P233, DOI 10.1111/j.1600-0765.1992.tb01673.x; Amerongen AV, 2007, ANN NY ACAD SCI, V1098, P1, DOI 10.1196/annals.1384.033; BIESBROCK AR, 1992, CARIES RES, V26, P117; BRIEDIS D, 1980, RHEOL ACTA, V19, P365, DOI 10.1007/BF01543149; Casemiro LA, 2008, J APPL ORAL SCI, V16, P271, DOI 10.1590/S1678-77572008000400008; Hirotomi T, 2006, J DENT, V34, P692, DOI 10.1016/j.jdent.2006.01.001; Inoue H., 2008, J ORAL BIOSCI, V50, P134, DOI 10.2330/joralbiosci.50.134; Kawamoto M, 2002, ORL J OTO-RHINO-LARY, V64, P16, DOI 10.1159/000049081; Kitada K, 2012, GERODONTOLOGY, V29, pE981, DOI 10.1111/j.1741-2358.2011.00595.x; Kobayashi T, 2004, HIGASHI NIPPON DENT, V23, P83; Ministry of Health Labour and Welfare, 1999, SURV TRENDS HLTH WEL; Murineanu R, 2011, ROM J ORAL REHABIL, V3, P43; Nalcaci R, 2008, ORAL SURG ORAL MED O, V105, pE5, DOI 10.1016/j.tripleo.2008.02.016; Oho T, 2001, ORAL SURG ORAL MED O, V91, P531, DOI 10.1067/moe.2001.112543; Pham Thuy AV, 2010, International Journal of Clinical Preventive Dentistry, V6, P63; Pham Thuy A V, 2012, J Investig Clin Dent, V3, P284, DOI 10.1111/j.2041-1626.2012.00155.x; Rantonen PJF, 1998, ACTA ODONTOL SCAND, V56, P210; ROSENBERG M, 1991, J DENT RES, V70, P1436, DOI 10.1177/00220345910700110801; SILNESS J, 1964, Acta Odontol Scand, V22, P121, DOI 10.3109/00016356408993968; Suzuki N, 2008, J DENT HLTH, V58, P2; Ueno Masayuki, 2007, Journal of Medical and Dental Sciences, V54, P159; Zussman E, 2007, J DENT RES, V86, P281	27	0	0	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0001-6357	1502-3850		ACTA ODONTOL SCAND	Acta Odontol. Scand.	NOV	2014	72	8					1005	1009		10.3109/00016357.2014.938115		5	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	AS5SR	WOS:000344330400063		
J	Chong, PP; Tung, CH; Rahman, NABA; Yajima, M; Chin, FW; Yeng, CLS; Go, ES; Chan, CML; Yawata, N; Yamamoto, N				Chong, Pei Pei; Tung, Chee Hong; Rahman, Nurul Asyikin Bt Abdul; Yajima, Misako; Chin, Fee Wai; Yeng, Crystale Lim Siew; Go, Eng Soon; Chan, Cordelia M. L.; Yawata, Nobuyo; Yamamoto, Naoki			Prevalence and viral load of oncogenic human papillomavirus (HPV) in pterygia in multi-ethnic patients in the Malay Peninsula	ACTA OPHTHALMOLOGICA			English	Article						human papillomavirus; multi-ethnic; PCR detection; pterygia	SURFACE SQUAMOUS NEOPLASIA; CERVICAL CELL SPECIMENS; REAL-TIME PCR; OPHTHALMIC PTERYGIUM; HIGH-RISK; NORMAL CONJUNCTIVA; GENE-EXPRESSION; P53 GENE; PATHOGENESIS; DNA	PurposeThe aim of the study was to determine the prevalence of human papillomavirus (HPV) in primary and recurrent pterygia samples collected from different ethnic groups in the equatorial Malay Peninsula. MethodsDNA was extracted from 45 specimens of freshly obtained primary and recurrent pterygia from patients and from 11 normal conjunctival swabs from volunteers with no ocular surface lesion as control. The presence of HPV DNA was detected by nested PCR. PCR-positive samples were subjected to DNA sequencing to determine the HPV genotypes. Real-time PCR with HPV16 and HPV18 type-specific TaqMan probes was employed to determine the viral DNA copy number. ResultsOf 45 pterygia samples with acceptable DNA quality, 29 (64.4%) were positive for HPV DNA, whereas all the normal conjunctiva swabs were HPV negative. Type 18 was the most prevalent (41.4% of positive samples) genotype followed by type 16 (27.6%). There was one case each of the less common HPV58 and HPV59. Seven of the samples harboured mixed infections of both HPV16 and HPV18. All the four known recurrent pterygia samples were HPV-positive, whereas the sole early-stage pterygium sample in the study was HPV-negative. There was no significant association between HPV-positive status with gender or age. A high proportion of patients from the Indian ethnic group (five of six) were HPV-positive, whereas the Malay patients were found to have higher HPV positivity than the Chinese. The viral load of HPV18 samples ranged between 2 x 10(2) and 3 x 10(4) copies per g, whereas the viral load of HPV16 specimen was 4 x 10(1) to 10(2) copies per g. ConclusionThis report describes for the first time the quantitative measurement of HPV viral DNA for pterygium samples. The high prevalence of oncogenic HPVs in our samples suggests a possible role for HPV in the pathogenesis of pterygia. Moreover, the relatively low HPV viral load is concordant with the premalignant nature of this ocular condition.	[Chong, Pei Pei; Tung, Chee Hong; Rahman, Nurul Asyikin Bt Abdul; Chin, Fee Wai] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Biomed Sci, Serdang 43400, Selangor, Malaysia; [Chong, Pei Pei] Univ Putra Malaysia, Inst Biosci, Serdang 43400, Selangor, Malaysia; [Chong, Pei Pei; Yajima, Misako; Yamamoto, Naoki] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Microbiol, Translat Infect Dis Lab,Ctr Translat Med, Singapore 117595, Singapore; [Yajima, Misako] Toyama Univ, Dept Virol, Toyama 930, Japan; [Yeng, Crystale Lim Siew] Univ Coll Sedaya Int, Fac Allied Sci, Kuala Lumpur, Malaysia; [Go, Eng Soon] Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Surg, Opthalmol Unit, Serdang 43400, Selangor, Malaysia; [Chan, Cordelia M. L.] Singapore Natl Eye Ctr, Singapore, Singapore; [Yawata, Nobuyo] Agcy Sci Res & Technol, Singapore Inst Clin Sci, Infect & Immun Programme, Singapore, Singapore; [Yawata, Nobuyo] Singapore Eye Res Inst, Singapore, Singapore; [Yawata, Nobuyo] Duke Nus Grad Med Sch, Singapore, Singapore	Chong, PP (reprint author), Univ Putra Malaysia, Fac Med & Hlth Sci, Dept Biomed Sci, Serdang 43400, Selangor, Malaysia.	cpp@upm.edu.my			UPM Fundamental Research Grant; NUS SoM Start-up Grant [R-182-000-160-733, R-182-000-160-133]	Part of this work was presented as a poster in the 2nd University of Science Malaysia Ophthalmic Symposium, 2005. The study was funded for the work on nested PCR HPV detection by the UPM Fundamental Research Grant, and for the real-time PCR viral load quantification by the NUS SoM Start-up Grant (R-182-000-160-733, R-182-000-160-133).	Akgul B, 2005, ARCH VIROL, V150, P145, DOI 10.1007/s00705-004-0398-4; Beskow AH, 2002, INT J CANCER, V101, P526, DOI 10.1002/ijc.90010; CORONEO MT, 1993, BRIT J OPHTHALMOL, V77, P734, DOI 10.1136/bjo.77.11.734; Detorakis ET, 2001, CORNEA, V20, P164, DOI 10.1097/00003226-200103000-00010; FOSTER SA, 1994, J VIROL, V68, P5698; Husnjak K, 2000, J VIROL METHODS, V88, P125, DOI 10.1016/S0166-0934(00)00194-4; MACKENZIE FD, 1992, OPHTHALMOLOGY, V99, P1056; Shiroma H, 2009, AM J OPHTHALMOL, V148, P766, DOI 10.1016/j.ajo.2009.06.006; Chui J, 2011, AM J PATHOL, V178, P817, DOI 10.1016/j.ajpath.2010.10.037; Hirst LW, 2009, ARCH OPHTHALMOL-CHIC, V127, P31, DOI 10.1001/archophthalmol.2008.531; Fontaine V, 2007, J CLIN MICROBIOL, V45, P928, DOI 10.1128/JCM.02098-06; Liang K, 2011, MOL VIS, V17, P1687; Scott IU, 2002, OPHTHALMOLOGY, V109, P542, DOI 10.1016/S0161-6420(01)00991-5; Dushku N, 1999, ARCH OPHTHALMOL-CHIC, V117, P1593; Kjaer SK, 2002, BRIT MED J, V325, P572, DOI 10.1136/bmj.325.7364.572; ZIEGLER A, 1993, P NATL ACAD SCI USA, V90, P4216, DOI 10.1073/pnas.90.9.4216; Dong QF, 2011, INVEST OPHTH VIS SCI, V52, P5408, DOI 10.1167/iovs.10-6939; Ang M, 2012, OPHTHALMOLOGY, V119, P1509, DOI 10.1016/j.ophtha.2012.02.009; Chalkia AK, 2013, INT J MOL MED, V32, P539, DOI 10.3892/ijmm.2013.1438; Di Girolamo N, 2012, EYE, V26, P202, DOI 10.1038/eye.2011.312; Sherwin JC, 2013, ACTA OPHTHALMOL, V91, P363, DOI 10.1111/j.1755-3768.2011.02314.x; Detorakis ET, 2000, INT J MOL MED, V6, P35; Swan DC, 1999, J CLIN MICROBIOL, V37, P1030; Tornesello ML, 2006, BRIT J CANCER, V94, P446, DOI 10.1038/sj.bjc.6602921; Baleriola C, 2008, J CLIN VIROL, V42, P22, DOI 10.1016/j.jcv.2007.12.008; Broccolo F, 2013, J MED VIROL, V85, P472, DOI 10.1002/jmv.23487; CHEN JK, 1994, IN VITRO CELL DEV-AN, V30A, P243; Chen KH, 2003, BRIT J OPHTHALMOL, V87, P1046, DOI 10.1136/bjo.87.8.1046; COUTLEE F, 1995, J CLIN MICROBIOL, V33, P1973; DEGRASSI M, 1993, OPTOMETRY VISION SCI, V70, P1058, DOI 10.1097/00006324-199312000-00012; Di Girolamo N, 2004, PROG RETIN EYE RES, V23, P195, DOI 10.1016/j.preteyers.2004.02.002; Dolmetsch A. M., 1996, Investigative Ophthalmology and Visual Science, V37, pS43; Dushku N, 2001, ARCH OPHTHALMOL-CHIC, V119, P695; Elliott R, 1966, Trans Ophthalmol Soc Aust, V25, P71; Gallagher MJ, 2001, BRIT J OPHTHALMOL, V85, P782, DOI 10.1136/bjo.85.7.782; Gravitt PE, 2003, J VIROL METHODS, V112, P23, DOI 10.1016/S0166-0934(03)00186-1; Hrushesky WJM, 2005, CANCER EPIDEM BIOMAR, V14, P1940, DOI 10.1158/1055-9965.EPI-04-0940; Hsiao CH, 2010, CORNEA, V29, P123, DOI 10.1097/ICO.0b013e3181afdb06; Karcioglu ZA, 1997, BRIT J OPHTHALMOL, V81, P595, DOI 10.1136/bjo.81.7.595; Mcnairn AJ, 2011, EUR J DERMATOL, V21, P21, DOI 10.1684/ejd.2011.1267; Okuno T, 2011, CORNEA, V30, P204, DOI 10.1097/ICO.0b013e3181e2e9be; Paula JS, 2006, EYE, V20, P533, DOI 10.1038/sj.eye.6701917; Perra MT, 2002, HISTOL HISTOPATHOL, V17, P139; Piecyk-Sidor M, 2009, ACTA OPHTHALMOL, V87, P890, DOI 10.1111/j.1755-3768.2008.01372.x; PINKERTON OD, 1984, AM J OPHTHALMOL, V98, P225; Piras F, 2003, BRIT J OPHTHALMOL, V87, P864, DOI 10.1136/bjo.87.7.864; Purdie KJ, 1999, EMBO J, V18, P5359, DOI 10.1093/emboj/18.19.5359; Reid TW, 2003, BRIT J OPHTHALMOL, V87, P806, DOI 10.1136/bjo.87.7.806; Rodrigues FW, 2008, GENET MOL RES, V7, P1251; Rodriguez-Cabrera L, 2004, INVEST OPHTHALMOL VI, V43; Schellini Silvana Artioli, 2006, Arq Bras Oftalmol, V69, P519, DOI 10.1590/S0004-27492006000400012; Seaman WT, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-194; Sjo NC, 2007, BRIT J OPHTHALMOL, V91, P1014, DOI 10.1136/bjo.2006.108811; Tabrizi SN, 1997, AUST NZ J OPHTHALMOL, V25, P211, DOI 10.1111/j.1442-9071.1997.tb01394.x; Tan DTH, 2000, BRIT J OPHTHALMOL, V84, P212, DOI 10.1136/bjo.84.2.212; Tano T, 2013, ACTA OPHTHALMOL, V91, P232; Threlfall TJ, 1999, AM J OPHTHALMOL, V128, P280, DOI 10.1016/S0002-9394(99)00161-0; Tsai YY, 2009, MOL VIS, V15, P1092; Tsai YY, 2005, MOL VIS, V11, P50; Weinstein O, 2002, EYE, V16, P619, DOI 10.1038/sj.eye.6700150; WONG WW, 1978, ANN OPHTHALMOL, V10, P303	61	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1755-375X	1755-3768		ACTA OPHTHALMOL	Acta Ophthalmol.	NOV	2014	92	7					e569	e579		10.1111/aos.12427		11	Ophthalmology	Ophthalmology	AS3FN	WOS:000344162700010		
J	Hashimoto, Y; Saito, W; Saito, M; Hirooka, K; Yoshizawa, C; Noda, K; Ishida, S				Hashimoto, Yuki; Saito, Wataru; Saito, Michiyuki; Hirooka, Kiriko; Yoshizawa, Chikako; Noda, Kousuke; Ishida, Susumu			Retinal outer layer thickness increases with regression of multiple evanescent white dot syndrome and visual improvement positively correlates with photoreceptor outer segment length	ACTA OPHTHALMOLOGICA			English	Letter									[Hashimoto, Yuki; Saito, Wataru; Saito, Michiyuki; Hirooka, Kiriko; Yoshizawa, Chikako; Noda, Kousuke; Ishida, Susumu] Hokkaido Univ, Grad Sch Med, Dept Ophthalmol, Sapporo, Hokkaido 0608638, Japan; [Saito, Wataru; Noda, Kousuke; Ishida, Susumu] Hokkaido Univ, Grad Sch Med, Dept Ocular Circulat & Metab, Sapporo, Hokkaido 0608638, Japan	Saito, W (reprint author), Hokkaido Univ, Grad Sch Med, Dept Ocular Circulat & Metab, Kita Ku, Nishi 7,Kita 15, Sapporo, Hokkaido 0608638, Japan.	wsaito@med.hokudai.ac.jp					Li DJ, 2009, OPHTHALMOLOGY, V116, P762, DOI 10.1016/j.ophtha.2008.12.060; JAMPOL LM, 1984, ARCH OPHTHALMOL-CHIC, V102, P671; Hashimoto Y, 2014, GRAEF ARCH CLIN EXP, V252, P219, DOI 10.1007/s00417-013-2432-2; HORIGUCHI M, 1993, BRIT J OPHTHALMOL, V77, P452, DOI 10.1136/bjo.77.7.452	4	2	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1755-375X	1755-3768		ACTA OPHTHALMOL	Acta Ophthalmol.	NOV	2014	92	7					e591	e592		10.1111/aos.12413		2	Ophthalmology	Ophthalmology	AS3FN	WOS:000344162700019		
J	Shiraya, T; Kato, S; Shigeeda, T; Yamaguchi, T; Kaiya, T				Shiraya, Tomoyasu; Kato, Satoshi; Shigeeda, Takashi; Yamaguchi, Takuhiro; Kaiya, Tadayoshi			Comparison of burn size after retinal photocoagulation by conventional and high-power short-duration methods	ACTA OPHTHALMOLOGICA			English	Letter									[Shiraya, Tomoyasu; Kato, Satoshi; Shigeeda, Takashi] Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Tokyo 1138655, Japan; [Yamaguchi, Takuhiro] Tohoku Univ, Grad Sch Med, Div Biostat, Sendai, Miyagi 980, Japan; [Kaiya, Tadayoshi] Kaiya Eye Clin, Hamamatsu, Shizuoka, Japan	Kato, S (reprint author), Univ Tokyo, Grad Sch Med, Dept Ophthalmol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	katou-s@ka2.so-net.ne.jp					Maeshima K, 2004, RETINA-J RET VIT DIS, V24, P507, DOI 10.1097/00006982-200408000-00002; Muqit MMK, 2010, ARCH OPHTHALMOL-CHIC, V128, P448, DOI 10.1001/archophthalmol.2010.36	2	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1755-375X	1755-3768		ACTA OPHTHALMOL	Acta Ophthalmol.	NOV	2014	92	7					e585	e586		10.1111/aos.12393		2	Ophthalmology	Ophthalmology	AS3FN	WOS:000344162700015		
J	Yamamoto-Fukuda, T; Akiyama, N; Shibata, Y; Takahashi, H; Ikeda, T; Kohno, M; Koji, T				Yamamoto-Fukuda, Tomomi; Akiyama, Naotaro; Shibata, Yasuaki; Takahashi, Haruo; Ikeda, Tohru; Kohno, Michiaki; Koji, Takehiko			KGFR as a possible therapeutic target in middle ear cholesteatoma	ACTA OTO-LARYNGOLOGICA			English	Article						Keratinocyte growth factor; KGF; KGF receptor inhibitor; in vivo model; electroporation	KERATINOCYTE GROWTH-FACTOR; SIGNAL-REGULATED KINASE; CELL-PROLIFERATION; TUMOR-CELLS; RECEPTOR; PATHWAY; EXPRESSION; BLOCKADE	Conclusion: We demonstrated that repression of keratinocyte growth factor (KGF) receptor (KGFR) could be a potentially useful strategy in the conservative treatment of middle ear cholesteatoma. Objectives: Recently, the use of a selective inhibitor of the KGFR, SU5402, in an in vitro experiment resulted in the inhibition of the differentiation and proliferation of epithelial cells through KGF secretion by fibroblasts isolated from the cholesteatoma. In this study, we investigated the effects of the KGFR inhibitor during middle ear cholesteatoma formation in vivo. Methods: Based on the role of KGF in the development of cholesteatoma, Flag-hKGF cDNA driven by CMV14 promoter was transfected through electroporation into the external auditory canal of rats five times on every fourth day. Ears transfected with empty vector were used as controls. KGFR selective inhibitor (SU5402) or MEK inhibitor (PD0325901) was administered in the right ear of five rats after vector transfection. In the control, 2% DMSO in PBS was administered in the other ears after vector transfection. Results: The use of a selective KGFR inhibitor, SU5402, completely prevented middle ear cholesteatoma formation in the rats.	[Yamamoto-Fukuda, Tomomi; Koji, Takehiko] Nagasaki Univ, Grad Sch Biomed Sci, Dept Histol & Cell Biol, Nagasaki 8528523, Japan; [Yamamoto-Fukuda, Tomomi; Akiyama, Naotaro; Takahashi, Haruo] Nagasaki Univ, Grad Sch Biomed Sci, Dept Otolaryngol Head & Neck Surg, Dept Translat Med Sci, Nagasaki 8528523, Japan; [Shibata, Yasuaki; Ikeda, Tohru] Nagasaki Univ, Grad Sch Biomed Sci, Dept Oral Pathol & Bone Metab, Nagasaki 8528523, Japan; [Kohno, Michiaki] Nagasaki Univ, Grad Sch Biomed Sci, Dept Histol & Cell Biol, Lab Cell Regulat, Nagasaki 8528523, Japan	Yamamoto-Fukuda, T (reprint author), Nagasaki Univ, Grad Sch Biomed Sci, Dept Histol & Cell Biol, 1-12-4 Sakamoto, Nagasaki 8528523, Japan.	tomomiyf@nagasaki-u.ac.jp			Japanese Ministry of Education, Science, Sports, and Culture [23791906]; Naito Foundation	The authors thank Dr. Jeffrey S. Rubin from the National Cancer Institute/CCR/LCMB, for providing the human KGF cDNA construct. The study was supported by a Grant-in-Aid for Scientific Research from the Japanese Ministry of Education, Science, Sports, and Culture (no. 23791906 to T.Y-F.) and by a grant from the Naito Foundation (to T.Y-F.).	RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; Sharma GD, 2003, J BIOL CHEM, V278, P21989, DOI 10.1074/jbc.M302650200; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; KOJI T, 1994, J CELL BIOL, V125, P393, DOI 10.1083/jcb.125.2.393; Kohno M, 2006, ANN MED, V38, P200, DOI 10.1080/07853890600551037; Mohammadi M, 1997, SCIENCE, V276, P955, DOI 10.1126/science.276.5314.955; Hoshino R, 2001, J BIOL CHEM, V276, P2686, DOI 10.1074/jbc.M006132200; Gibney GT, 2013, NAT REV CLIN ONCOL, V10, P390, DOI 10.1038/nrclinonc.2013.83; Choijookhuu N, 2012, HISTOCHEM CELL BIOL, V137, P575, DOI 10.1007/s00418-012-0935-2; Davis GL, 2001, DIAGNOSTIC SURG PATH, P681; EDELSTEIN DR, 1989, OTOLARYNG CLIN N AM, V22, P1029; Matsumoto K, 2009, J THORAC CARDIOV SUR, V137, P1499, DOI 10.1016/j.jtcvs.2008.11.037; MCGINN MD, 1982, ACTA OTO-LARYNGOL, V93, P61, DOI 10.3109/00016488209130853; Portnoy J, 2004, AM J RESP CELL MOL, V30, P901, DOI 10.1165/rcmb.2003-0406OC; Raffa S, 2012, HISTOCHEM CELL BIOL, V138, P251, DOI 10.1007/s00418-012-0947-y; Tanimura S, 2003, BIOCHEM BIOPH RES CO, V304, P801, DOI 10.1016/S0006-291X(03)00670-3; Tos M, 1988, Adv Otorhinolaryngol, V40, P110; WOLFMAN DE, 1986, ANN OTO RHINOL LARYN, V95, P639; Yamamoto-Fukuda T, 2000, HISTOCHEM J, V32, P697, DOI 10.1023/A:1004171517639; Yamamoto-Fukuda T, 2003, LAB INVEST, V83, P123, DOI 10.1097/01.LAB.0000050763.64145.CB	20	0	0	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0001-6489	1651-2251		ACTA OTO-LARYNGOL	Acta Oto-Laryngol.	NOV	2014	134	11					1121	1127		10.3109/00016489.2014.907501		7	Otorhinolaryngology	Otorhinolaryngology	AS0PH	WOS:000343979400004		
J	Taura, A; Funabiki, K; Ohgita, H; Ogino, E; Torii, H; Matsunaga, M; Ito, J				Taura, Akiko; Funabiki, Kazuo; Ohgita, Hideaki; Ogino, Eriko; Torii, Hiroko; Matsunaga, Mami; Ito, Juichi			One-third of vertiginous episodes during the follow-up period are caused by benign paroxysmal positional vertigo in patients with Meniere's disease	ACTA OTO-LARYNGOLOGICA			English	Article						Vertigo attack; Meniere's disease; Kyoto University Hospital		Conclusion: In the present study, about one-third of patients with Meniere's disease developed benign paroxysmal positional vertigo (BPPV)-like attacks. Additionally, more than one-third of all vertigo attacks were BPPV-like attacks. Thus, vertigo attacks in patients with Meniere's disease must be carefully treated because the therapy for such vertigo attacks is totally different from the therapy for BPPV. Objective: Physicians sometimes encounter patients with previously diagnosed Meniere's disease who develop BPPV attacks during the course of clinical follow-up. In this study, we explored the frequency with which BPPV was involved in all vertiginous episodes among patients with Meniere's disease. Methods: This retrospective study involved 296 patients with Meniere's disease who visited Kyoto University Hospital. The diagnosis of Meniere's disease was based on the guidelines for the diagnosis of Meniere's disease proposed by the Committee on Hearing and Equilibrium. We judged the cause of vertigo as one of the following five types: (1) definite Meniere's disease attack, (2) suspicious Meniere's disease attack, (3) definite BPPV attack, (4) suspicious BPPV attack, or (5) unknown. Results: In all, 96 patients (32.8%) developed BPPV-like attacks, and 187 vertiginous episodes (37.9%) were caused by BPPV. The lateral semicircular canal was the most frequently involved canal.	[Taura, Akiko; Ohgita, Hideaki; Ogino, Eriko; Torii, Hiroko; Matsunaga, Mami; Ito, Juichi] Kyoto Univ, Grad Sch Med, Dept Otolaryngol Head & Neck Surg, Kyoto 6068507, Japan; [Funabiki, Kazuo] Osaka Biosci Inst, Osaka, Japan	Taura, A (reprint author), Kyoto Univ, Grad Sch Med, Dept Otolaryngol Head & Neck Surg, Sakyo Ku, 54 Kawaharacho, Kyoto 6068507, Japan.	taura@ent.kuhp.kyoto-u.ac.jp			Ministry of Health, Labour and Welfare, Japan	This study was supported by a Health and Labor Science Research Grant for Research on Specific Disease (Vestibular Disorders) from the Ministry of Health, Labour and Welfare, Japan (2014).	Buckingham RA, 1999, LARYNGOSCOPE, V109, P717, DOI 10.1097/00005537-199905000-00008; PARNES LS, 1993, ANN OTO RHINOL LARYN, V102, P325; Lee NH, 2010, OTOLARYNG HEAD NECK, V143, P413, DOI 10.1016/j.otohns.2010.06.905; FROEHLING DA, 1991, MAYO CLIN PROC, V66, P596; Balatsouras DG, 2012, ANN OTO RHINOL LARYN, V121, P682; Del Rio M, 2004, OTOLARYNG HEAD NECK, V130, P426, DOI 10.1016/j.otohns.2003.12.015; MONSELL EM, 1995, OTOLARYNG HEAD NECK, V113, P181; Bhattacharyya N, 2008, OTOLARYNGOL HEAD NEC, V139, P47; Ganança Cristina Freitas, 2007, Braz J Otorhinolaryngol, V73, P506; Gross EM, 2000, LARYNGOSCOPE, V110, P655, DOI 10.1097/00005537-200004000-00022; Hughes CA, 1997, LARYNGOSCOPE, V107, P607, DOI 10.1097/00005537-199705000-00010; Inagaki T, 2008, EQUILIBRIUM RES, V67, P18, DOI 10.3757/jser.67.18; Karlberg M, 2000, ACTA OTO-LARYNGOL, V120, P380; Korres S, 2002, OTOL NEUROTOL, V23, P926, DOI 10.1097/00129492-200211000-00019; Paparella M M, 1991, Acta Otolaryngol Suppl, V485, P26; Perez N, 2002, LARYNGOSCOPE, V112, P1104, DOI 10.1097/00005537-200206000-00031; Sekine Kazunori, 2005, Nihon Jibiinkoka Gakkai Kaiho, V108, P842; Takeda N, 1997, Nihon Jibiinkoka Gakkai Kaiho, V100, P449; Taura A, 2010, ACTA OTO-LARYNGOL, V130, P29, DOI 10.3109/00016489.2010.486800; Yamane H, 2010, ACTA OTO-LARYNGOL, V130, P233, DOI 10.3109/00016480903096648	20	2	2	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0001-6489	1651-2251		ACTA OTO-LARYNGOL	Acta Oto-Laryngol.	NOV	2014	134	11					1140	1145		10.3109/00016489.2014.936624		6	Otorhinolaryngology	Otorhinolaryngology	AS0PH	WOS:000343979400007		
J	Yoshida, T; Ikemiyagi, F; Ikemiyagi, Y; Tanaka, T; Yamamoto, M; Suzuki, M				Yoshida, Tomoe; Ikemiyagi, Fuyuko; Ikemiyagi, Yoshihiro; Tanaka, Tositake; Yamamoto, Masahiko; Suzuki, Mitsuya			The dominant foot affects the postural control mechanism: examination by body tracking test	ACTA OTO-LARYNGOLOGICA			English	Article						Dynamic body balance test; moving visual target; axis; spatial perception	HAND POSITION SIGNALS; BALANCE CONTROL; INTEGRATION; FOOTEDNESS; ADULTS; TARGET	Conclusion: The antero-posterior (AP) body tracking test (BTT) showed that the dominant foot could affect the tilt angle of the sway movement, delineated by primary component analysis. Differences associated with the dominant foot could represent the difference in space perception of each person. Objectives: To examine whether the dominant foot could affect the postural control mechanism using the BTT. Methods: Ninety-seven healthy participants enrolled in the study were classified into rightfoot and left-foot dominance groups, and their performances were compared. For the BTT, each participant stood on a stabilometer and caught the movement of a visual target moving vertically (anterior-posterior) or horizontally by the center of pressure movement, displayed on a 14-inch screen monitor at 100 cm in front of the subject. The mean displacement angle of the obtained stabilogram was evaluated by principal component analysis. Results: The AP BTT in the right-foot dominance group showed a clockwise tilt with a mean displacement angle of 3.022 +/- 3.761 degrees, whereas the group with left-foot dominance had a modest counter-clockwise tilt with a mean displacement angle of -0.694 +/- 4.497 degrees. This difference was found to be significant by the independent t test (p < 0.0001). In the lateral BTT, the mean displacement angles were not significant.	[Yoshida, Tomoe; Ikemiyagi, Fuyuko; Ikemiyagi, Yoshihiro; Tanaka, Tositake; Yamamoto, Masahiko; Suzuki, Mitsuya] Toho Univ, Dept Otorhinolaryngol, Sakura, Chiba 2858741, Japan	Yoshida, T (reprint author), Toho Univ, Med Ctr, Sakura Hosp, Dept Otorhinolaryngol, Shimoshizu 564-1, Sakura, Chiba 2858741, Japan.	tomoe@med.toho-u.ac.jp					Angunsri N, 2011, AURIS NASUS LARYNX, V38, P462, DOI 10.1016/j.anl.2011.01.016; Koslucher F, 2012, GAIT POSTURE, V36, P605, DOI 10.1016/j.gaitpost.2012.05.027; Wall C, 2009, GAIT POSTURE, V30, P16, DOI 10.1016/j.gaitpost.2009.02.019; Laurens J, 2010, GAIT POSTURE, V31, P37, DOI 10.1016/j.gaitpost.2009.08.241; Schneiders AG, 2010, PM&R, V2, P835, DOI 10.1016/j.pmrj.2010.06.004; Vesia M, 2008, J NEUROPHYSIOL, V100, P2005, DOI 10.1152/jn.90519.2008; Aoki H, 2012, ADV AGING RES, V1, P72; Balaguer Garcia R, 2012, ACTA OTORRINOLARINGO, V63, P332; Black FO, 2001, CURR OPIN OTOLARYNGO, V9, P314, DOI 10.1097/00020840-200110000-00011; Bobrova EV, 2007, BIOFIZIKA+, V52, P355; Boonstra TA, 2013, J NEUROENG REHABIL, V10, DOI 10.1186/1743-0003-10-23; Buneo CA, 2012, J NEUROPHYSIOL, V108, P187, DOI 10.1152/jn.00137.2011; De Agostini M, 2001, DEV NEUROPSYCHOL, V20, P429, DOI 10.1207/S15326942DN2001_7; Greffou S, 2008, J VISION, V8, DOI 10.1167/8.11.15; Ishikawa K, 2004, ACTA OTO-LARYNGOL, V124, P486, DOI 10.1080/00016480310000566; Kobori S, 1990, IEICE T, VE73, P1824; LEDIN T, 1991, ACTA OTO-LARYNGOL, V111, P813, DOI 10.3109/00016489109138416; Wang Z, 2013, LATERALITY, V18, P303, DOI 10.1080/1357650X.2012.672423; Yoshida T, 2010, EQUILIBRIUM RES, V69, P147; Yoshida Tomoe, 2013, Nihon Jibiinkoka Gakkai Kaiho, V116, P1308	20	0	0	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0001-6489	1651-2251		ACTA OTO-LARYNGOL	Acta Oto-Laryngol.	NOV	2014	134	11					1146	1150		10.3109/00016489.2014.940556		5	Otorhinolaryngology	Otorhinolaryngology	AS0PH	WOS:000343979400008		
J	Nakashima, T; Sato, H; Gyo, K; Hato, N; Yoshida, T; Shimono, M; Teranishi, M; Sone, M; Fukunaga, Y; Kobashi, G; Takahashi, K; Matsui, S; Ogawa, K				Nakashima, Tsutomu; Sato, Hiroaki; Gyo, Kiyofumi; Hato, Naohito; Yoshida, Tadao; Shimono, Mariko; Teranishi, Masaaki; Sone, Michihiko; Fukunaga, Yukari; Kobashi, Gen; Takahashi, Kunihiko; Matsui, Shigeyuki; Ogawa, Kaoru			Idiopathic sudden sensorineural hearing loss in Japan	ACTA OTO-LARYNGOLOGICA			English	Article						Sudden deafness; incidence; season; ENT doctors; epidemiology; acute low-tone sensorineural hearing loss; hospitals; private clinics; earthquake; population	NATIONWIDE EPIDEMIOLOGIC SURVEYS; DEAFNESS	Conclusion: An epidemiological survey of hospitals and private clinics in Japan regarding idiopathic sudden sensorineural hearing loss (SSNHL) revealed that the incidence of SSNHL was 60.9 per 100 000 population. There were more females than males in the younger generation. Objective: The incidence of SSNHL varies largely by country. Because the Japanese criteria for diagnosing SSNHL have changed in accordance with those widely used in other parts of the world, a clinicoepidemiological study was undertaken using the new criteria. Methods: Ehime, Aichi, and Iwate Prefectures were selected from the western, central, and northeastern regions of Japan, respectively. The subjects for this study were patients who suffered SSNHL between April 1, 2012 and March 31, 2013. Questionnaires were mailed to all hospitals and private clinics in which ENT doctors were working. Initial and final audiograms were requested for 10% of the patients. Results: In all, 78 of 90 hospitals (87%) and 303 of 407 private clinics (74%) responded. It was reported that 1663 patients visited hospitals and 3090 patients visited only private clinics. It was estimated that 6205 SSNHL patients visited hospitals or private clinics in 1 year from a population of 10 145 000. Also, 23% of patients suffered acute low-tone SNHL (female to male ratio; 3: 1 in definite cases).	[Nakashima, Tsutomu; Yoshida, Tadao; Shimono, Mariko; Teranishi, Masaaki; Sone, Michihiko; Fukunaga, Yukari] Nagoya Univ, Grad Sch Med, Dept Otorhinolaryngol, Nagoya, Aichi 466, Japan; [Sato, Hiroaki] Iwate Med Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Morioka, Iwate, Japan; [Gyo, Kiyofumi; Hato, Naohito] Ehime Univ, Sch Med, Dept Otolaryngol, Ehime, Japan; [Kobashi, Gen] Natl Inst Radiol Sci, Chiba 260, Japan; [Takahashi, Kunihiko; Matsui, Shigeyuki] Nagoya Univ, Grad Sch Med, Dept Biostat, Nagoya, Aichi 466, Japan; [Ogawa, Kaoru] Keio Univ, Sch Med, Dept Otolaryngol, Tokyo 160, Japan	Nakashima, T (reprint author), Nagoya Univ, Grad Sch Med, Dept Otorhinolaryngol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 466, Japan.	tsutomun@med.nagoya-u.ac.jp	Nakashima, Tsutomu/B-8259-2012; Takahashi, Kunihiko/I-7104-2014; Yoshida, Tadao/I-1619-2012	Nakashima, Tsutomu/0000-0003-3930-9120; 	Acute Profound Deafness Research Committee of Ministry of Health, Labour and Welfare in Japan	We thank all otolaryngologists who cooperated by answering the questionnaires. This work was supported by the Acute Profound Deafness Research Committee of the Ministry of Health, Labour and Welfare in Japan. We also thank Dr Yasuyo Takayanagi who encouraged and supported our study of SSNHL.	Furuhashi A, 2002, CLIN OTOLARYNGOL, V27, P458, DOI 10.1046/j.1365-2273.2002.00612.x; Suckfull M, 2009, DTSCH ARZTEBL INT, V106, P669, DOI 10.3238/arztebl.2009.0669; Klemm E, 2009, LARYNGO RHINO OTOL, V88, P524, DOI 10.1055/s-0028-1128133; Alexander TH, 2013, OTOL NEUROTOL, V34, P1586, DOI 10.1097/MAO.0000000000000222; Labatut T, 2013, EUR ARCH OTO-RHINO-L, V270, P2823, DOI 10.1007/s00405-012-2306-y; Teranishi M, 2007, ACTA OTO-LARYNGOL, V127, P1259, DOI 10.1080/00016480701242410; Chen X, 2012, LARYNGOSCOPE, V122, P2265, DOI 10.1002/lary.23452; Filipo R, 2013, ACTA OTO-LARYNGOL, V133, P900, DOI 10.3109/00016489.2013.788791; Kanzaki J, 1988, Acta Otolaryngol Suppl, V456, P31; Matsuda K, 2002, AUDIOL JPN, V45, P197; Nakashima T, 2000, OTOLARYNG HEAD NECK, V123, P593, DOI 10.1067/mhn.2000.109486; Nakashima T, 2000, AUDIOL JPN, V43, P98; Nakashima T, 2004, AUDIOL JPN, V47, P109; NAKASHIMA T, 1994, ACTA OTO-LARYNGOL, P14; NOMURA Y, 1988, ACTA OTO-LARYNGOL, P7; Nomura Y, 2014, MORPHOLOGICAL ASPECT; Shimono M, 2013, OTOL NEUROTOL, V34, P1241, DOI 10.1097/MAO.0b013e3182990e81; SIEGEL LG, 1975, OTOLARYNG CLIN N AM, V8, P467; Teranishi M, 2007, OTOL JPN, V17, P621; Wu CS, 2006, AUDIOL NEURO-OTOL, V11, P151, DOI 10.1159/000091198	20	0	0	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0001-6489	1651-2251		ACTA OTO-LARYNGOL	Acta Oto-Laryngol.	NOV	2014	134	11					1158	1163		10.3109/00016489.2014.919406		6	Otorhinolaryngology	Otorhinolaryngology	AS0PH	WOS:000343979400010		
J	Nishimoto, K; Kumai, Y; Yumoto, E				Nishimoto, Kohei; Kumai, Yoshihiko; Yumoto, Eiji			Paradoxical movement of rat vocal folds following recurrent laryngeal nerve injury	ACTA OTO-LARYNGOLOGICA			English	Article						Synkinesis; electromyography; animal model	PARALYZED CANINE LARYNX; IMPLANTABLE STIMULATOR; REINNERVATION; REGENERATION; SYNKINESIS; TRANSECTION; MUSCLE	Objective: To establish a rat model with paradoxical vocal fold movement to understand the detailed etiology and physiology of laryngeal synkinesis by evaluating vocal fold movement and by electromyography. Methods: Adult Wistar rats were used. The recurrent laryngeal nerve was transected, anastomosed, and the anastomotic portion was placed in a silicone tube. At 2, 4, and 10 weeks after the treatment (n = 30), we performed laryngoscopy and electromyography. The vocal fold movement was recorded, the hemiglottal area was measured, and the Darea was calculated by subtracting the area during expiration from that during inhalation. We evaluated the ratio of the Darea on the treated side to that of the normal side. After laryngoscopy, electromyography of the thyroarytenoid and posterior cricoarytenoid muscles was performed. Results: The mean Dareas were 1.5 +/- 3.4%, 2.3 +/- 21.5%, and 0.7 +/- 31.8% at 2, 4, and 10 weeks after anastomosis, respectively. Eighteen of 18 rats indicated synkinetic reinnervation at 4 and 10 weeks. Regarding vocal fold mobility, 8 of 18 animals showed paradoxical movement, and 5 of 18 exhibited impaired mobility. Conclusion: We have established an animal model of paradoxical movement following recurrent laryngeal nerve injury. This model may be useful in studying laryngeal synkinesis.	[Nishimoto, Kohei; Kumai, Yoshihiko; Yumoto, Eiji] Kumamoto Univ, Grad Sch Med, Dept Otolaryngol Head & Neck Surg, Kumamoto 8608556, Japan	Nishimoto, K (reprint author), Kumamoto Univ, Grad Sch Med, Dept Otolaryngol Head & Neck Surg, 1-1-1 Honjo, Kumamoto 8608556, Japan.	koheihei@gmail.com					Eller RL, 2009, J VOICE, V23, P229, DOI 10.1016/j.jvoice.2007.01.007; WOODSON GE, 1993, LARYNGOSCOPE, V103, P1235; Zealear DL, 2009, LARYNGOSCOPE, V119, P1737, DOI 10.1002/lary.20587; MU LC, 1991, LARYNGOSCOPE, V101, P699; Shiotani A, 2001, LARYNGOSCOPE, V111, P472, DOI 10.1097/00005537-200103000-00017; Crumley RL, 2000, ANN OTO RHINOL LARYN, V109, P365; ASHUR H, 1987, EXP NEUROL, V97, P365, DOI 10.1016/0014-4886(87)90096-3; Gacek R R, 1977, Ann Otol Rhinol Laryngol, V86, P771; KIRCHNER JA, 1966, LARYNGOSCOPE, V76, P1753; Kumai Y, 2013, ANN OTO RHINOL LARYN, V122, P49; Maronian NC, 2004, ANN OTO RHINOL LARYN, V113, P877; Motoyoshi K, 2004, LARYNGOSCOPE, V114, P1247, DOI 10.1097/00005537-200407000-00020; Nomura K, 2010, LARYNGOSCOPE, V120, P2399, DOI 10.1002/lary.21065; Paniello RC, 2000, ANN OTO RHINOL LARYN, V109, P447; Pitman MJ, 2011, LARYNGOSCOPE, V121, P320, DOI 10.1002/lary.21290; SIRIBODHI CHIRA, 1963, LARYNGOSCOPE, V73, P148; Tessema B, 2009, LARYNGOSCOPE, V119, P1644, DOI 10.1002/lary.20293; TONNAER JADM, 1992, EUR J PHARMACOL, V214, P33, DOI 10.1016/0014-2999(92)90092-I; vanLithBijl JT, 1996, ARCH OTOLARYNGOL, V122, P393; Yumoto E, 2004, ARCH OTOLARYNGOL, V130, P967, DOI 10.1001/archotol.130.8.967	20	0	0	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0001-6489	1651-2251		ACTA OTO-LARYNGOL	Acta Oto-Laryngol.	NOV	2014	134	11					1164	1171		10.3109/00016489.2014.936625		8	Otorhinolaryngology	Otorhinolaryngology	AS0PH	WOS:000343979400011		
J	Ichihara, T; Kawata, R; Higashino, M; Terada, T; Haginomori, SI				Ichihara, Takahiro; Kawata, Ryo; Higashino, Masaaki; Terada, Tetsuya; Haginomori, Shin-Ichi			A more appropriate clinical classification of benign parotid tumors: investigation of 425 cases	ACTA OTO-LARYNGOLOGICA			English	Article						Lower pole tumor; facial nerve paralysis; pleomorphic adenoma; Warthin's tumor	SUPERFICIAL PAROTIDECTOMY; PLEOMORPHIC ADENOMA; EXTRACAPSULAR DISSECTION; GLAND; SURGERY; MANAGEMENT; DEEP	Conclusions: It is appropriate to clinically classify benign parotid tumors into three groups, i.e. superficial tumors, deep tumors, and lower pole tumors. Objective: It is important to classify benign parotid tumors based on location when deciding the surgical strategy and conducting clinical research. In this study, we examined a classification of benign parotid tumors that was useful for clinical practice. Methods: We studied 425 patients with benign parotid tumors who underwent surgery at our hospital. Their age, gender, tumor histopathology, maximum tumor diameter, postoperative facial nerve paresis, operating time, and blood loss were investigated after classifying the tumors as superficial tumors, deep tumors, or lower pole tumors. We also investigated the same parameters after dividing the lower pole tumors into superficial and deep types. Results: Lower pole tumors had distinct characteristics from superficial and deep tumors. The incidence of facial nerve paresis was significantly higher and the operating time was significantly longer for deep tumors than for either superficial or lower pole tumors, while there were no significant differences between superficial and lower pole tumors. In addition, there were no significant differences in any of the parameters between the superficial and deep types of lower pole tumor.	[Ichihara, Takahiro; Kawata, Ryo; Higashino, Masaaki; Terada, Tetsuya; Haginomori, Shin-Ichi] Osaka Med Coll, Dept Otolaryngol Head & Neck Surg, Takatsuki, Osaka 5698686, Japan	Ichihara, T (reprint author), Osaka Med Coll, Dept Otolaryngol Head & Neck Surg, 2-7 Daigaku Machi, Takatsuki, Osaka 5698686, Japan.	oto073@poh.osaka-med.ac.jp					Albergotti WG, 2012, LARYNGOSCOPE, V122, P1954, DOI 10.1002/lary.23396; Orabona GD, 2013, J ORAL MAXIL SURG, V71, P410, DOI 10.1016/j.joms.2012.05.003; Bron LP, 1997, ARCH OTOLARYNGOL, V123, P1091; Witt RL, 2002, LARYNGOSCOPE, V112, P2141, DOI 10.1097/00005537-200212000-00004; Emodi O, 2010, J ORAL MAXIL SURG, V68, P2092, DOI 10.1016/j.joms.2009.09.075; Gaillard C, 2005, LARYNGOSCOPE, V115, P287, DOI 10.1097/01.mlg.0000154735.61775.cd; Harney MS, 2003, HEAD NECK-J SCI SPEC, V25, P649, DOI 10.1002/hed.10281; Higashino M, 2013, HEAD NECK-J SCI SPEC, V35, P1153, DOI 10.1002/hed.23103; Imaizumi A, 2009, ACTA RADIOL, V50, P806, DOI 10.1080/02841850903049358; Kawata R, 2007, ACTA OTO-LARYNGOL, V127, P966, DOI 10.1080/00016480601089432; O'Brien CJ, 2003, HEAD NECK-J SCI SPEC, V25, P946, DOI 10.1002/hed.10312; Przewoźny Tomasz, 2004, Otolaryngol Pol, V58, P583; Witt Robert L, 2009, Del Med J, V81, P119; YAMASHITA T, 1993, ACTA OTO-LARYNGOL, P113; Zbaren P, 2013, AM J SURG, V205, P109, DOI 10.1016/j.amjsurg.2012.05.026	15	0	0	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0001-6489	1651-2251		ACTA OTO-LARYNGOL	Acta Oto-Laryngol.	NOV	2014	134	11					1185	1191		10.3109/00016489.2014.914246		7	Otorhinolaryngology	Otorhinolaryngology	AS0PH	WOS:000343979400014		
J	Furusaka, T; Tanaka, A; Matsuda, H; Hasegawa, H; Asakawa, T; Shigihara, S				Furusaka, Tohru; Tanaka, Akane; Matsuda, Hiroshi; Hasegawa, Hisashi; Asakawa, Takeshi; Shigihara, Shuntaro			Cervical branch of the facial nerve approach for retrograde parotidectomy compared with anterograde parotidectomy	ACTA OTO-LARYNGOLOGICA			English	Article						New approach for parotidectomy; facial nerve paralysis; new surgical technique; nerve stimulator; surgical time	DUCT	Conclusion: The cervical branch of the facial nerve approach for parotidectomy is an excellent surgical technique that can reduce the incidence of facial nerve paralysis, surgical time, and surgical blood loss. Objective: To develop and evaluate a surgical technique for parotidectomy that can reduce the incidence of facial nerve paralysis. Methods: Retrograde parotidectomy following identification of the cervical branch of the facial nerve in 90 subjects was compared with standard anterograde parotidectomy in 100 subjects. Results: Retrograde parotidectomy with a cervical branch approach was associated with significant decreases in the incidence of facial nerve paralysis, surgical time, and surgical blood loss, compared with anterograde parotidectomy.	[Furusaka, Tohru; Hasegawa, Hisashi; Asakawa, Takeshi; Shigihara, Shuntaro] Nihon Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Tokyo 1738610, Japan; [Furusaka, Tohru; Tanaka, Akane; Matsuda, Hiroshi] Tokyo Univ Agr & Technol, Inst Symbiot Sci & Technol, Grad Sch, Lab Vet Mol Pathol & Therapeut,Div Anim Life Sci, Tokyo, Japan	Furusaka, T (reprint author), Nihon Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Itabashi Ku, 30-1 Ohyaguchi Kami Cho, Tokyo 1738610, Japan.	furusaka.tohru@nihon-u.ac.jp	Matsuda, Hiroshi/C-8358-2013	Matsuda, Hiroshi/0000-0003-3189-6842			ALKAYAT A, 1979, BRIT J ORAL SURG, V17, P91, DOI 10.1016/S0007-117X(79)80036-0; Emodi O, 2010, J ORAL MAXIL SURG, V68, P2092, DOI 10.1016/j.joms.2009.09.075; Bhatracharyya N, 2004, OTOLARYNG HEAD NECK, V131, P392, DOI 10.1016/j.otohns.2004.03.012; Helmus C, 1997, LARYNGOSCOPE, V107, P1024, DOI 10.1097/00005537-199708000-00003; KAWAKAMI S, 1994, ANN PLAS SURG, V32, P295, DOI 10.1097/00000637-199403000-00012; Oiki H, 1994, PRACT OTORHINOLARYNG, V87, P1389; Okumoto K, 1998, PRACTOTORHINOLARYNGO, ps117; Pogrel MA, 1996, J ORAL MAXIL SURG, V54, P71, DOI 10.1016/S0278-2391(96)90309-2; Richards AT, 2004, CLIN ANAT, V17, P463, DOI 10.1002/ca.20011; Sakuma N, 1991, OTOLARYNGOL HEAD NEC, V63, P909; Sarashina N, 1992, PRACT OTORHINOLARYNG, ps172; Tanaka O, 1990, PRACT OTORHINOLARYNG, ps286; Yamashita T., 1997, PRACT OTORHINOLARYNG, V90, P853; Yokoshima K, 2008, OTOLARYNGOL HEAD NEC, V80, P209; Yoshihashi H, 1999, PRACT OTORHINOLARYNG, V92, P1331	15	0	0	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0001-6489	1651-2251		ACTA OTO-LARYNGOL	Acta Oto-Laryngol.	NOV	2014	134	11					1192	1197		10.3109/00016489.2014.900701		6	Otorhinolaryngology	Otorhinolaryngology	AS0PH	WOS:000343979400015		
J	Tsukahara, K; Nakamura, K; Motohashi, R; Sato, H; Endo, M; Katsube, Y; Ueda, Y; Suzuki, M				Tsukahara, Kiyoaki; Nakamura, Kazuhiro; Motohashi, Ray; Sato, Hiroki; Endo, Minoru; Katsube, Yasuaki; Ueda, Yuri; Suzuki, Mamoru			Antiemetic therapy of fosaprepitant, palonosetron, and dexamethasone combined with cisplatin-based chemotherapy for head and neck carcinomas	ACTA OTO-LARYNGOLOGICA			English	Article						Chemotherapy-induced nausea and vomiting; CINV; aprepitant; rescue therapy; food intake	NEUROKININ-1 ANTAGONIST APREPITANT; PLACEBO-CONTROLLED TRIAL; SQUAMOUS-CELL CARCINOMA; HIGH-DOSE CISPLATIN; INDUCED NAUSEA; DOUBLE-BLIND; EMETOGENIC CHEMOTHERAPY; RECEPTOR ANTAGONIST; DELAYED EMESIS; PREVENTION	Conclusion: Concomitant antiemetic therapy comprising fosaprepitant, palonosetron, and dexamethasone is effective for head and neck carcinoma. Objective: A patient diary was constructed to determine the effectiveness of concomitant antiemetic therapy with a neurokinin-1 receptor antagonist (fosaprepitant), 5-hydroxytryptamine receptor antagonist (palonosetron), and dexamethasone in accordance with guidelines. Methods: Subjects comprised 41 patients who received 71 courses of chemotherapy, along with fosaprepitant, palonosetron, and dexamethasone. A patient diary was compiled concerning the presence/absence of vomiting, vomiting episodes, presence/absence of rescue therapy, food intake, presence/absence of nausea, and general condition. Results: The frequency of the primary end point of complete response in the overall phase was 69.0%. The proportion of patients with no vomiting in the overall phase was 90.1%. In the acute phase, the proportion of no nausea and slight nausea together was 91.5%, no change in and slightly reduced food intake together was 87.3%, and the proportion of good general condition and relatively good general condition was 85.9%. In the delayed phase, the proportion of no nausea and slight nausea together was 56.3%, no change in and slightly reduced food intake together was 43.7%, and the proportion of good general condition and relatively good general condition together was 53.5%.	[Tsukahara, Kiyoaki; Nakamura, Kazuhiro; Motohashi, Ray; Sato, Hiroki; Endo, Minoru; Katsube, Yasuaki; Ueda, Yuri] Tokyo Med Univ, Med Ctr, Dept Otolaryngol Head & Neck Surg, Hachioji, Tokyo 1930998, Japan; [Suzuki, Mamoru] Tokyo Med Univ, Dept Otolaryngol, Hachioji, Tokyo 1930998, Japan	Tsukahara, K (reprint author), Tokyo Med Univ, Med Ctr, 1163 Tatemachi, Hachioji, Tokyo 1930998, Japan.	tsuka@tokyo-med.ac.jp					Poli-Bigelli S, 2003, CANCER, V97, P3090, DOI 10.1002/cncr.11433; [Anonymous], 2007, NCCN CLIN PRACTICE G; Grunberg S, 2011, J CLIN ONCOL, V29, P1495, DOI 10.1200/JCO.2010.31.7859; Hesketh PJ, 2003, J CLIN ONCOL, V21, P4112, DOI 10.1200/JCO.2003.01.095; Roila F, 2006, ANN ONCOL, V17, P20, DOI 10.1093/annonc/mdj078; Lasseter KC, 2007, J CLIN PHARMACOL, V47, P834, DOI 10.1177/0091270007301800; Albany C, 2012, J CLIN ONCOL, V30, P3998, DOI 10.1200/JCO.2011.39.5558; Navari RM, 2013, SUPPORT CARE CANCER, V21, P1655, DOI 10.1007/s00520-012-1710-6; Chawla SP, 2003, CANCER, V97, P2290, DOI 10.1002/cncr.11320; Basch E, 2011, J CLIN ONCOL, V29, P4189, DOI 10.1200/JCO.2010.34.4614; Tavorath R, 1996, DRUGS, V52, P639; Kris MG, 1996, CANCER, V78, P2193, DOI 10.1002/(SICI)1097-0142(19961115)78:10<2193::AID-CNCR22>3.0.CO;2-T; Warr DG, 2005, J CLIN ONCOL, V23, P2822; Bender Catherine M, 2002, Clin J Oncol Nurs, V6, P94, DOI 10.1188/02.CJON.94-102; Gralla RJ, 1996, ONCOLOGY, V53, P86; Katori H, 2007, CANCER CHEMOTH PHARM, V60, P399, DOI 10.1007/s00280-006-0370-y; Mori M, 2011, CANCER CHEMOTH PHARM, V68, P855, DOI 10.1007/s00280-010-1551-2; Takahashi T, 2010, CANCER SCI, V101, P2455, DOI 10.1111/j.1349-7006.2010.01689.x; Tsukahara K, 2008, EUR ARCH OTO-RHINO-L, V265, P565, DOI 10.1007/s00405-007-0523-6; Tsukuda M, 2010, CANCER CHEMOTH PHARM, V66, P729, DOI 10.1007/s00280-009-1217-0	20	0	0	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0001-6489	1651-2251		ACTA OTO-LARYNGOL	Acta Oto-Laryngol.	NOV	2014	134	11					1198	1204		10.3109/00016489.2014.913314		7	Otorhinolaryngology	Otorhinolaryngology	AS0PH	WOS:000343979400016		
J	Motomura, H; Iguchi, H; Hatano, T; Kobayashi, R; Sakahara, D; Fujii, N; Mineo, M				Motomura, Hisashi; Iguchi, Hiroyoshi; Hatano, Takaharu; Kobayashi, Rie; Sakahara, Daisuke; Fujii, Naho; Mineo, Mari			Dynamic eye socket reconstruction after extensive resection of midfacial malignancies: preliminary results using temporalis transfer	ACTA OTO-LARYNGOLOGICA			English	Article						dynamic reconstruction; eyelid; maxillectomy; maxillary reconstruction; orbital exenteration		The functional and esthetic results of reconstructive surgery after extended total maxillectomy or extended orbital exenteration greatly depend on the quality of the orbital reconstruction. We developed dynamic eye socket reconstruction using temporalis transfer to achieve good orbital reconstruction, and examined the usefulness of our technique. Five patients (three men and two women, aged 44-72 years) who underwent extensive resection of midfacial malignancies were treated with dynamic eye socket reconstruction using temporalis transfer. In most cases, eye socket reconstruction was performed approximately 1 year after the initial surgery, and temporalis transfer was used after maturation of the eye socket. The follow-up period ranged from 16 to 120 months (average 63.8 months). Movement of the upper and lower eyelids was achieved in all cases, and definite creases at the lateral canthus were observed in two patients. A good shape in the reconstructed medial and lateral canthal areas was maintained in all patients. Our reconstruction technique is extremely effective in creating natural creases ('crow's feet') at the lateral canthus during smiling, enabling movement of the upper and lower eyelids, and maintaining a sharp palpebral morphology.	[Motomura, Hisashi; Hatano, Takaharu; Kobayashi, Rie; Sakahara, Daisuke; Fujii, Naho; Mineo, Mari] Osaka City Univ, Grad Sch Med, Dept Plast & Reconstruct Surg, Osaka 5458585, Japan; [Iguchi, Hiroyoshi] Osaka City Univ, Grad Sch Med, Dept Otolaryngol Head & Neck Surg, Osaka 5458585, Japan	Motomura, H (reprint author), Osaka City Univ, Grad Sch Med, Dept Plast & Reconstruct Surg, Abeno Ku, 1-4-3 Asahi Machi, Osaka 5458585, Japan.	motomurally@gmail.com					ANDERSEN J G, 1961, Br J Plast Surg, V14, P339, DOI 10.1016/S0007-1226(61)80057-X; KLIGMAN AM, 1985, BRIT J DERMATOL, V113, P37, DOI 10.1111/j.1365-2133.1985.tb02042.x; Hashikawa K, 2007, PLAST RECONSTR SURG, V119, P2182, DOI 10.1097/01.prs.0000260706.07368.f1; Cordeiro PG, 2012, PLAST RECONSTR SURG, V129, P139, DOI 10.1097/PRS.0b013e318221dc60; Fogli A, 1992, Ann Chir Plast Esthet, V37, P510; Hashikawa K, 2007, PLAST RECONSTR SURG, V119, P2189; Motomura H, 2012, ACTA OTO-LARYNGOL, V132, P887, DOI 10.3109/00016489.2012.658968; Motomura H, 2014, J PLAST RECONSTR AES, V67, pE78, DOI 10.1016/j.bjps.2013.08.021	8	0	0	INFORMA HEALTHCARE	LONDON	TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND	0001-6489	1651-2251		ACTA OTO-LARYNGOL	Acta Oto-Laryngol.	NOV	2014	134	11					1205	1210		10.3109/00016489.2014.940555		6	Otorhinolaryngology	Otorhinolaryngology	AS0PH	WOS:000343979400017		
J	Takenouchi, T; Sakamoto, Y; Miwa, T; Torii, C; Kosaki, R; Kishi, K; Takahashi, T; Kosaki, K				Takenouchi, Toshiki; Sakamoto, Yoshiaki; Miwa, Tomoru; Torii, Chiharu; Kosaki, Rika; Kishi, Kazuo; Takahashi, Takao; Kosaki, Kenjiro			Severe Craniosynostosis With Noonan Syndrome Phenotype Associated With SHOC2 Mutation: Clinical Evidence of Crosslink Between FGFR and RAS Signaling Pathways	AMERICAN JOURNAL OF MEDICAL GENETICS PART A			English	Article						craniosynostosis; RAS; FGFR; SHOC2	SAETHRE-CHOTZEN-SYNDROME; GERMLINE KRAS MUTATIONS; LOOSE ANAGEN HAIR; TWIST; OSTEOBLASTS; ACTIVATOR; GENE	Dysregulation in the RAS signaling cascade results in a family of malformation syndromes called RASopathies. Meanwhile, alterations in FGFR signaling cascade are responsible for various syndromic forms of craniosynostosis. In general, the phenotypic spectra of RASopathies and craniosynostosis syndromes do not overlap. Recently, however, mutations in ERF, a downstream molecule of the RAS signaling cascade, have been identified as a cause of complex craniosynostosis, suggesting that the RAS and FGFR signaling pathways can interact in the pathogenesis of malformation syndromes. Here, we document a boy with short stature, developmental delay, and severe craniosynostosis involving right coronal, bilateral lambdoid, and sagittal sutures with a de novo mutation in exon1 of SHOC2 (c.4A>G p.Ser2Gly). This observation further supports the existence of a crosslink between the RAS signaling cascade and craniosynostosis. In retrospect, the propositus had physical features suggestive of a dysregulated RAS signaling cascade, such as fetal pleural effusion, fetal hydrops, and atrial tachycardia. In addition to an abnormal cranial shape, which has been reported for this specific mutation, craniosynostosis might be a novel associated phenotype. In conclusion, the phenotypic combination of severe craniosynostosis and RASopathy features observed in the propositus suggests an interaction between the RAS and FGFR signaling cascades. Patients with craniosynostosis in combination with any RASopathy feature may require mutation screening for molecules in the FGFR-RAS signaling cascade. (c) 2014 Wiley Periodicals, Inc.	[Takenouchi, Toshiki; Takahashi, Takao] Keio Univ, Sch Med, Dept Pediat, Tokyo 1608582, Japan; [Sakamoto, Yoshiaki; Kishi, Kazuo] Keio Univ, Sch Med, Dept Plast & Reconstruct Surg, Tokyo 1608582, Japan; [Miwa, Tomoru] Keio Univ, Sch Med, Dept Neurosurg, Tokyo 1608582, Japan; [Torii, Chiharu; Kosaki, Kenjiro] Keio Univ, Sch Med, Ctr Med Genet, Tokyo 1608582, Japan; [Kosaki, Rika] Natl Ctr Child Hlth & Dev, Div Med Genet, Tokyo, Japan	Kosaki, K (reprint author), Keio Univ, Sch Med, Ctr Med Genet, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	kkosaki@z3.keio.jp			Research on Applying Health Technology from the Ministry of Health, Labour and Welfare, Japan [H23-013]	Grant sponsor: Research on Applying Health Technology from the Ministry of Health, Labour and Welfare, Japan; Grant number: H23-013.	Agochukwu NB, 2012, CHILD NERV SYST, V28, P1447, DOI 10.1007/s00381-012-1756-2; Schubbert S, 2006, NAT GENET, V38, P331, DOI 10.1038/ng1748; Brasil AS, 2012, AM J MED GENET A, V158A, P1178, DOI 10.1002/ajmg.a.35270; Kim HJ, 2003, DEV DYNAM, V227, P335, DOI 10.1002/dvdy.10319; Guenou H, 2005, HUM MOL GENET, V14, P1429, DOI 10.1093/hmg/ddi152; Cordeddu V, 2009, NAT GENET, V41, P1022, DOI 10.1038/ng.425; Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324; Gripp KW, 2013, AM J MED GENET A, V161, P2420, DOI 10.1002/ajmg.a.36098; Howard TD, 1997, NAT GENET, V15, P36, DOI 10.1038/ng0197-36; Shukla V, 2007, NAT GENET, V39, P1145, DOI 10.1038/ng2096; Sharma VP, 2013, NAT GENET, V45, P304, DOI 10.1038/ng.2531; ElGhouzzi V, 1997, NAT GENET, V15, P42; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Twigg SRF, 2013, NAT GENET, V45, P308, DOI 10.1038/ng.2539; McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110; Kratz CP, 2009, AM J MED GENET A, V149A, P1036, DOI 10.1002/ajmg.a.32786; Cohen Jr MM, 2000, CRANIOSYNOSTOSIS DIA, P1; Hing AV, 2009, AM J MED GENET A, V149A, P1024, DOI 10.1002/ajmg.a.32782; Jones KL, 2006, SMITHS RECOGNIZABLE, P1; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Takenouchi T, 2013, AM J MED GENET A, V161, P3057, DOI 10.1002/ajmg.a.36157; Takenouchi T, 2014, AM J MED GENET A, V164, P392, DOI 10.1002/ajmg.a.36288; Viskochil DH, 2011, AM J MED GENET C, V157C, P79, DOI 10.1002/ajmg.c.30301; Yousfi M, 2002, BIOCHEM BIOPH RES CO, V297, P641, DOI 10.1016/S0006-291X(02)02260-X	24	3	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1552-4825	1552-4833		AM J MED GENET A	Am. J. Med. Genet. A	NOV	2014	164	11					2869	2872		10.1002/ajmg.a.36705		4	Genetics & Heredity	Genetics & Heredity	AS3OB	WOS:000344187200026		
J	Kuroda, Y; Ohashi, I; Saito, T; Nagai, JI; Ida, K; Naruto, T; Wada, T; Kurosawa, K				Kuroda, Yukiko; Ohashi, Ikuko; Saito, Toshiyuki; Nagai, Jun-Ichi; Ida, Kazumi; Naruto, Takuya; Wada, Takahito; Kurosawa, Kenji			Deletion of UBE3A in Brothers With Angelman Syndrome at the Breakpoint With an Inversion at 15q11.2	AMERICAN JOURNAL OF MEDICAL GENETICS PART A			English	Article						Angelman syndrome; UBE3A deletion; familial cases; 15q inversion; chromosomal rearrangement	PRADER-WILLI-SYNDROME; GENE; PHENOTYPES; EPILEPSY; HBII-52	Angelman syndrome (AS) is characterized by severe intellectual disability with ataxia, epilepsy, and behavioral uniqueness. The underlining molecular deficit is the absence of the maternal copy of the imprinted UBE3A gene due to maternal deletions, which is observed in 70-75% of cases, and can be detected using fluorescent in situ hybridization (FISH) of the UBE3A region. Only a few familial AS cases have been reported with a complete deletion of UBE3A. Here, we report on siblings with AS caused by a microdeletion of 15q11.2-q12 encompassing UBE3A at the breakpoint of an inversion at 15q11.2 and 15q26.1. Karyotyping revealed an inversion of 15q, and FISH revealed the deletion of the UBE3A region. Array comparative genomic hybridization (CGH) demonstrated a 467kb deletion at 15q11.2-q12, encompassing only UBE3A, SNORD115, and PAR1, and a 53kb deletion at 15q26.1, encompassing a part of SLCO3A1. Their mother had a normal karyotype and array CGH detected no deletion of 15q11.2-q12, so we assumed gonadal mosaicism. This report describes a rare type of familial AS detected using the D15S10 FISH test. (c) 2014 Wiley Periodicals, Inc.	[Kuroda, Yukiko; Ohashi, Ikuko; Ida, Kazumi; Naruto, Takuya; Kurosawa, Kenji] Kanagawa Childrens Med Ctr, Div Med Genet, Yokohama, Kanagawa 2328555, Japan; [Saito, Toshiyuki; Nagai, Jun-Ichi] Kanagawa Childrens Med Ctr, Dept Clin Lab, Yokohama, Kanagawa 2328555, Japan; [Wada, Takahito] Kanagawa Childrens Med Ctr, Div Pediat Neurol, Yokohama, Kanagawa 2328555, Japan	Kurosawa, K (reprint author), Kanagawa Childrens Med Ctr, Div Med Genet, Minami Ku, 2-138-4 Mutsukawa, Yokohama, Kanagawa 2328555, Japan.	kkurosawa@kcmc.jp			The Ministry of Health, Labor and Welfare of Japan	Grant sponsor: The Ministry of Health, Labor and Welfare of Japan.	Tanaka M, 2008, AM J HUM GENET, V82, P1249, DOI 10.1016/j.ajhg.2008.04.020; Procter M, 2006, CLIN CHEM, V52, P1276, DOI 10.1373/clinchem.2006.067603; Minassian BA, 1998, ANN NEUROL, V43, P485, DOI 10.1002/ana.410430412; Runte M, 2005, HUM GENET, V116, P228, DOI 10.1007/s00439-004-1219-2; Kishore S, 2006, SCIENCE, V311, P230, DOI 10.1126/science.1118265; Lossie AC, 2001, J MED GENET, V38, P834, DOI 10.1136/jmg.38.12.834; Varela MC, 2004, EUR J HUM GENET, V12, P987, DOI 10.1038/sj.ejhg.5201264; Williams CA, 2006, AM J MED GENET A, V140A, P413, DOI 10.1002/ajmg.a.31074; Boyes L, 2006, EUR J MED GENET, V49, P472, DOI 10.1016/j.ejmg.2006.04.004; Burger J, 2002, AM J MED GENET, V111, P233, DOI 10.1002/ajmg.10498; Camprubi C, 2010, EUR J HUM GENET, V18, P154, DOI 10.1038/ejhg.2009.170; Kurosawa K, 2012, CONGENIT ANOM, V52, P106, DOI 10.1111/j.1741-4520.2011.00326.x; Piard J, 2011, AM J MED GENET A, V155A, P3170, DOI 10.1002/ajmg.a.34334; SAITOH S, 1992, LANCET, V339, P366, DOI 10.1016/0140-6736(92)91686-3; Sato K, 2007, AM J MED GENET A, V143A, P98, DOI 10.1002/ajmg.a.31550; SUGIMOTO T, 1992, EPILEPSIA, V33, P1078, DOI 10.1111/j.1528-1157.1992.tb01762.x; Wirth J, 2001, HUM MOL GENET, V10, P201, DOI 10.1093/hmg/10.3.201	17	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1552-4825	1552-4833		AM J MED GENET A	Am. J. Med. Genet. A	NOV	2014	164	11					2873	2878		10.1002/ajmg.a.36704		6	Genetics & Heredity	Genetics & Heredity	AS3OB	WOS:000344187200027		
J	Odonkor, CA; Hurst, P; Kondo, N; Makary, MA; Pronovost, PJ				Odonkor, Charles A.; Hurst, Pia; Kondo, Naoki; Makary, Martin A.; Pronovost, Peter J.			Halting the Revolving Door: How a Focus on Patient- and Community-Level Risks May Help Curb Readmissions After Surgery	AMERICAN JOURNAL OF MEDICAL QUALITY			English	Editorial Material									[Odonkor, Charles A.] Johns Hopkins Med Inst, Baltimore, MD 21287 USA; [Hurst, Pia] North Shore Long Isl Jewish Hlth Syst, Manhasset, NY USA; [Kondo, Naoki] Univ Tokyo, Sch Publ Hlth, Tokyo, Japan; [Makary, Martin A.; Pronovost, Peter J.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA	Odonkor, CA (reprint author), Johns Hopkins Med Inst, Phipps 160,600 North Wolfe St, Baltimore, MD 21287 USA.	codonko2@jhmi.edu					Friedman B, 2004, MED CARE RES REV, V61, P225, DOI 10.1177/1077558704263799; NEHI, PREV HOSP READM 25 B; PricewaterhouseCooper's Health Research Institute, 2013, PRIC EXC ID WAST HEA	3	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1062-8606	1555-824X		AM J MED QUAL	Am. J. Med. Qual.	NOV-DEC	2014	29	6					557	557		10.1177/1062860614546614		1	Health Care Sciences & Services	Health Care Sciences & Services	AS5MD	WOS:000344314000014		
J	Nagahama, Y; Sone, M; Chen, X; Okada, Y; Yamamoto, M; Xin, B; Matsuo, Y; Komatsu, M; Suzuki, A; Enomoto, K; Nishikawa, Y				Nagahama, Yasuharu; Sone, Masayuki; Chen, Xi; Okada, Yoko; Yamamoto, Masahiro; Xin, Bing; Matsuo, Yasuhiro; Komatsu, Mikiko; Suzuki, Akira; Enomoto, Katsuhiko; Nishikawa, Yuji			Contributions of Hepatocytes and Bile Ductular Cells in Ductular Reactions and Remodeling of the Biliary System after Chronic Liver Injury	AMERICAN JOURNAL OF PATHOLOGY			English	Article							MATURE RAT HEPATOCYTES; COLLAGEN GEL MATRIX; IN-VITRO; REGENERATION; TRANSDIFFERENTIATION	Mature hepatocytes are suggested to possess a capacity for bile ductular transdifferentiation, but whether and how hepatocytes contribute to ductular reaction in chronic liver diseases has not been elucidated. We examined whether mouse hepatocytes can transdifferentiate into bile ductular cells in vitro, using a three-dimensional collagen gel culture method, and in vivo, using a liver repopulation model in which beta-galactosidase-positive hepatocytes from Alb-Cre x ROSA26R mice were transplanted into the liver of wild-type mice. We further examined the relative contribution of intrinsic hepatocytes in ductular reaction in a hepatocyte lineage-tracing model using Mx1-Cre x ROSA26R mice treated with polyinosinic-polycytidylic acid. Within collagen gels, hepatocytes exhibited branching morphogenesis associated with the emergence of bile duct-like phenotype. In the Liver repopulation model, many beta-galactosidase- positive, hepatocyte-derived bile ductular structures were identified; these markedly increased after liver injury. In Mx1-Cre x ROSA26R mice, relatively minor but significant contributions of hepatocyte-derived bile ductules were observed in both periportal and centrilobular ductular reaction. As the centrilobular ductular reaction progressed, the portal ducts or ductules migrated toward the injured area and joined with hepatocyte-derived ductules, Leaving the portal tract without biliary structures. We conclude that hepatocytes and bite ducts or ductules are important sources of ductular reaction and that the intrahepatic biliary system undergoes remarkable remodeling in response to chronic liver injury.	[Nagahama, Yasuharu; Chen, Xi; Okada, Yoko; Yamamoto, Masahiro; Xin, Bing; Matsuo, Yasuhiro; Komatsu, Mikiko; Nishikawa, Yuji] Asahikawa Med Univ, Dept Pathol, Div Tumor Pathol, Asahikawa, Hokkaido 0788510, Japan; [Nagahama, Yasuharu; Sone, Masayuki] Otsuka Pharmaceut Co Ltd, Fujii Mem Res Inst, Otsu, Shiga, Japan; [Suzuki, Akira] Kyushu Univ, Med Inst Bioregulat, Div Embryon & Genet Engn, Fukuoka 812, Japan; [Enomoto, Katsuhiko] Akita Red Cross Hosp, Dept Pathol, Akita, Japan	Nishikawa, Y (reprint author), Asahikawa Med Univ, Dept Pathol, Div Tumor Pathol, Higashi 2-1-11, Asahikawa, Hokkaido 0788510, Japan.	nishikwa@asahikawa-med.ac.jp			Ministry of Education, Culture, Sports, Science, and Technology of Japan [18590362, 21590426, 24390092]	Supported by Ministry of Education, Culture, Sports, Science, and Technology of Japan grants 18590362, 21590426, and 24390092 (Y.N.).	DESMET V, 1995, PATHOL RES PRACT, V191, P513; Yanger K, 2011, DEV DYNAM, V240, P521, DOI 10.1002/dvdy.22561; Malato Y, 2011, J CLIN INVEST, V121, P4850, DOI 10.1172/JCI59261; Limaye PB, 2008, HEPATOLOGY, V47, P1702, DOI 10.1002/hep.22221; Ziol M, 2010, GASTROENTEROLOGY, V139, P335, DOI 10.1053/j.gastro.2010.04.012; Shiojiri N, 1997, MICROSC RES TECHNIQ, V39, P328, DOI 10.1002/(SICI)1097-0029(19971115)39:4<328::AID-JEMT3>3.0.CO;2-D; Beaussier M, 2005, J HEPATOL, V42, P257, DOI 10.1016/j.jhep.2004.10.025; Sekiya S, 2012, J CLIN INVEST, V122, P3914, DOI 10.1172/JCI63065; Lowes KN, 2003, J GASTROEN HEPATOL, V18, P4, DOI 10.1046/j.1440-1746.2003.02906.x; Yanger K, 2013, GENE DEV, V27, P719, DOI 10.1101/gad.207803.112; Yamaji S, 2010, P NATL ACAD SCI USA, V107, P22237, DOI 10.1073/pnas.1015793108; Clouston AD, 2005, HEPATOLOGY, V41, P809, DOI 10.1002/hep.20650; Alvaro D, 2007, GASTROENTEROLOGY, V132, P415, DOI 10.1053/j.gastro.2006.07.023; Tanimizu N, 2014, J BIOL CHEM, V289, P7589, DOI 10.1074/jbc.M113.517243; Meng FY, 2012, HEPATOLOGY, V55, P209, DOI 10.1002/hep.24673; Tanaka M, 1998, HEPATOLOGY, V27, P488, DOI 10.1002/hep.510270224; Michalopoulos GK, 2005, HEPATOLOGY, V41, P535, DOI 10.1002/hep.20600; Nishikawa Y, 2005, AM J PATHOL, V166, P1077, DOI 10.1016/S0002-9440(10)62328-0; Michalopoulos GK, 2011, INT J BIOCHEM CELL B, V43, P173, DOI 10.1016/j.biocel.2009.09.014; Gouw ASH, 2011, HEPATOLOGY, V54, P1853, DOI 10.1002/hep.24613; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Wang X, 2003, P NATL ACAD SCI USA, V100, P11881, DOI 10.1073/pnas.1734199100; Duncan AW, 2009, GASTROENTEROLOGY, V137, P466, DOI 10.1053/j.gastro.2009.05.044; Desmet VJ, 2011, VIRCHOWS ARCH, V458, P251, DOI 10.1007/s00428-011-1048-3; Gill RM, 2011, AM J SURG PATHOL, V35, P1400, DOI 10.1097/PAS.0b013e3182254283; Guo Danqing, 2002, Transplantation (Baltimore), V73, P1818, DOI 10.1097/00007890-200206150-00020; KUHN R, 1995, SCIENCE, V269, P1427, DOI 10.1126/science.7660125; Lefkowitch JH, 2010, SCHEUERS LIVER BIOPS, P93; LINDROS KO, 1985, BIOCHEM J, V228, P757; National Research Council, 2011, GUIDE CARE USE LAB A; Nishikawa Y, 2013, J CELL BIOCHEM, V114, P831, DOI 10.1002/jcb.24424; Nishikawa Y, 2012, METHODS MOL BIOL, V826, P153, DOI 10.1007/978-1-61779-468-1_13; Nishikawa Y, 1996, EXP CELL RES, V223, P357, DOI 10.1006/excr.1996.0091; Sone M, 2012, AM J PATHOL, V181, P2094, DOI 10.1016/j.ajpath.2012.08.034; Tarrats N, 2011, HEPATOLOGY, V54, P319, DOI 10.1002/hep.24388; VANEYKEN P, 1988, HISTOPATHOLOGY, V13, P605	36	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	NOV	2014	184	11					3001	3012		10.1016/j.ajpath.2014.07.005		12	Pathology	Pathology	AS0LS	WOS:000343969200014		
J	Hara, Y; Yanatori, I; Ikeda, M; Kiyokage, E; Nishina, S; Tomiyama, Y; Toida, K; Kishi, F; Kato, N; Imamura, M; Chayama, K; Hino, K				Hara, Yuichi; Yanatori, Izumi; Ikeda, Masanori; Kiyokage, Emi; Nishina, Sohji; Tomiyama, Yasuyuki; Toida, Kazunori; Kishi, Fumio; Kato, Nobuyuki; Imamura, Michio; Chayama, Kazuaki; Hino, Keisuke			Hepatitis C Virus Core Protein Suppresses Mitophagy by Interacting with Parkin in the Context of Mitochondrial Depolarization	AMERICAN JOURNAL OF PATHOLOGY			English	Article							OXIDATIVE STRESS; HEPATOCELLULAR-CARCINOMA; ELECTRON-TRANSPORT; AUTOPHAGY; MICE; REPLICATION; LIVER; P62/SQSTM1; INDUCTION; PERMEABILITY	Hepatitis C virus (HCV) causes mitochondrial injury and oxidative stress, and impaired mitochondria are selectively eliminated through autophagy-dependent degradation (mitophagy). We investigated whether HCV affects mitophagy in terms of mitochondrial quality control. The effect of HCV on mitophagy was examined using HCV-Japanese fulminant hepatitis-1-infected cells and the uncoupling reagent carbonyl cyanide m-chlorophenylhydrazone as a mitophagy inducer. In addition, liver cells from transgenic mice expressing the HCV polyprotein and human hepatocyte chimeric mice were examined for mitophagy. Translocation of the E3 ubiquitin ligase Parkin to the mitochondria was impaired without a reduction of pentaerythritol tetranitrate induced kinase 1 activity in the presence of HCV infection both in vitro and in vivo. Coimmunoprecipitation assays revealed that Parkin associated with the HCV core protein. Furthermore, a Yeast Two-Hybrid assay identified a specific interaction between the HCV core protein and an N-terminal Parkin fragment. Silencing Parkin suppressed HCV core protein expression, suggesting a functional role for the interaction between the HCV core protein and Parkin in HCV propagation. The suppressed Parkin transtocation to the mitochondria inhibited mitochondrial ubiquitination, decreased the number of mitochondria sequestered in isolation membranes, and reduced autophagic degradation activity. Through a direct interaction with Parkin, the HCV core protein suppressed mitophagy by inhibiting Parkin translocation to the mitochondria. This inhibition may amplify and sustain HCV-induced mitochondrial injury.	[Hara, Yuichi; Nishina, Sohji; Tomiyama, Yasuyuki; Hino, Keisuke] Kawasaki Med Univ, Dept Hepatol & Pancreatol, Kurashiki, Okayama 7010192, Japan; [Yanatori, Izumi; Kishi, Fumio] Kawasaki Med Univ, Dept Mol Genet, Kurashiki, Okayama 7010192, Japan; [Kiyokage, Emi; Toida, Kazunori] Kawasaki Med Univ, Dept Anat, Kurashiki, Okayama 7010192, Japan; [Ikeda, Masanori; Kato, Nobuyuki] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Tumor Virol, Okayama, Japan; [Imamura, Michio; Chayama, Kazuaki] Hiroshima Univ, Inst Biomed & Hlth Sci, Dept Gastroenterol & Metab, Hiroshima, Japan	Hino, K (reprint author), Kawasaki Med Univ, Dept Hepatol & Pancreatol, 577 Matsushima, Kurashiki, Okayama 7010192, Japan.	khino@med.kawasaki-m.ac.jp			Japan Society for the Promotion of Science [23390201, 25670374]; Ministry of Health, Labor and Welfare of Japan Health and Labor [25200601]; Kawasaki Medical School Research [P2]	Supported by Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research (B) 23390201 and Grant-in-Aid for Exploratory Research 25670374; Ministry of Health, Labor and Welfare of Japan Health and Labor Sciences Research grant 25200601 for research on hepatitis; and Kawasaki Medical School Research Project grant P2.	Ando M, 2008, LIVER INT, V28, P1158, DOI 10.1111/j.1478-3231.2008.01720.x; FARINATI F, 1995, J HEPATOL, V22, P449, DOI 10.1016/0168-8278(95)80108-1; Gegg ME, 2010, HUM MOL GENET, V19, P4861, DOI 10.1093/hmg/ddq419; Wang YQ, 2012, AUTOPHAGY, V8, P1462, DOI 10.4161/auto.21211; Furutani T, 2006, GASTROENTEROLOGY, V130, P2087, DOI 10.1053/j.gastro.2006.02.060; Kim I, 2007, ARCH BIOCHEM BIOPHYS, V462, P245, DOI 10.1016/j.abb.2007.03.034; Valgimigli M, 2002, FREE RADICAL RES, V36, P939, DOI 10.1080/107156021000006653; Okuda M, 2002, GASTROENTEROLOGY, V122, P366, DOI 10.1053/gast.2002.30983; Kurihara Y, 2012, J BIOL CHEM, V287, P3265, DOI 10.1074/jbc.M111.280156; Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268; Moriya K, 2001, CANCER RES, V61, P4365; Ikeda M, 1998, VIRUS RES, V56, P157, DOI 10.1016/S0168-1702(98)00063-X; Okatsu K, 2010, GENES CELLS, V15, P887, DOI 10.1111/j.1365-2443.2010.01426.x; Vives-Bauza C, 2010, P NATL ACAD SCI USA, V107, P378, DOI 10.1073/pnas.0911187107; Li K, 2002, HEPATOLOGY, V35, P1237, DOI 10.1053/jhep.2002.32968; Dreux M, 2009, P NATL ACAD SCI USA, V106, P14046, DOI 10.1073/pnas.0907344106; Hristova VA, 2009, J BIOL CHEM, V284, P14978, DOI 10.1074/jbc.M808700200; Korenaga M, 2005, J BIOL CHEM, V280, P37481, DOI 10.1074/jbc.M506412200; Ke PY, 2011, J CLIN INVEST, V121, P37, DOI 10.1172/JCI41474; Sir D, 2012, J BIOL CHEM, V287, P18036, DOI 10.1074/jbc.M111.320085; Shrivastava S, 2012, J VIROL, V86, P8705, DOI 10.1128/JVI.00616-12; Chan NC, 2011, HUM MOL GENET, V20, P1726, DOI 10.1093/hmg/ddr048; Sir D, 2008, HEPATOLOGY, V48, P1054, DOI 10.1002/hep.22464; Munafo DB, 2001, J CELL SCI, V114, P3619; Narendra D, 2008, J CELL BIOL, V183, P795, DOI 10.1083/jcb.200809125; Venditti P, 2013, MITOCHONDRION, V13, P71, DOI 10.1016/j.mito.2013.01.008; Matsuda N, 2010, J CELL BIOL, V189, P211, DOI 10.1083/jcb.200910140; Elmore SP, 2001, FASEB J, V15, P2286; Barbaro G, 1999, AM J GASTROENTEROL, V94, P2198; Chen D, 2010, J BIOL CHEM, V285, P38214, DOI 10.1074/jbc.M110.101469; Nishikawa M, 2001, CANCER RES, V61, P1843; Itakura E, 2012, J CELL SCI, V125, P1488, DOI 10.1242/jcs.094110; Geisler S, 2010, NAT CELL BIOL, V12, P119, DOI 10.1038/ncb2012; Lerat H, 2002, GASTROENTEROLOGY, V122, P352, DOI 10.1053/gast.2002.31001; Narendra DP, 2010, AUTOPHAGY, V6, P1090, DOI 10.4161/auto.6.8.13426; Tateno C, 2004, AM J PATHOL, V165, P901, DOI 10.1016/S0002-9440(10)63352-4; Nishina S, 2008, GASTROENTEROLOGY, V134, P226, DOI 10.1053/j.gastro.2007.10.011; Kim SJ, 2013, PLOS PATHOG, V9, DOI 10.1371/journal.ppat.1003285; Kimura T, 2008, J GEN VIROL, V89, P2108, DOI 10.1099/vir.0.83658-0; Narendra DP, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000298; SHARPE MA, 1995, BIOCHEM BIOPH RES CO, V216, P931, DOI 10.1006/bbrc.1995.2710; Toida K, 2000, NEUROSCIENCE, V101, P11, DOI 10.1016/S0306-4522(00)00356-0; Zhang GJ, 2000, J MEMBRANE BIOL, V175, P53, DOI 10.1007/s002320001054	43	2	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	NOV	2014	184	11					3026	3039		10.1016/j.ajpoth.2014.07.024		14	Pathology	Pathology	AS0LS	WOS:000343969200016		
J	Williams, DW; Lee, C; Kim, T; Yagita, H; Wu, HK; Park, S; Yang, P; Liu, HG; Shi, ST; Shin, KH; Kang, MK; Park, NH; Kim, RH				Williams, Drake W.; Lee, Cindy; Kim, Terresa; Yagita, Hideo; Wu, Hongkun; Park, Sil; Yang, Paul; Liu, Honghu; Shi, Songtao; Shin, Ki-Hyuk; Kang, Mo K.; Park, No-Hee; Kim, Reuben H.			Impaired Bone Resorption and Woven Bone Formation Are Associated with Development of Osteonecrosis of the Jaw-Like Lesions by Bisphosphonate and Anti-Receptor Activator of NF-kappa B Ligand Antibody in Mice	AMERICAN JOURNAL OF PATHOLOGY			English	Article							ZOLEDRONIC ACID; INDUCE OSTEONECROSIS; MONOCLONAL-ANTIBODY; DENOSUMAB; DISEASE; RANKL; OSTEOPOROSIS; RATS	Drug-induced osteonecrosis of the jaw (ONJ) is a detrimental intraoral lesion that often occurs after dental-related interventions in patients undergoing treatment with bisphosphonates or denosumab, the neutralizing human anti receptor activator of NF-kappa B Ligand (RANKL) antibody (Ab). The cause of ONJ by these drugs has been speculated to their direct effects on osteoclasts. However, the extent to which osteoclasts contribute to ONJ pathogenesis remains controversial. Herein, by using a tooth-extraction mouse model with i.v. administration of mouse anti-RANKL Ab or the bisphosphonate zoledronate (ZOL), we show that unresorbed bone due to impaired formation or suppressed functions of osteoclasts, respectively, is associated with ONJ development. After tooth extraction, ONJ-like lesions developed 50% in the anti-RANKL Ab-treated mice and 30% in the ZOL-treated mice. Nonviable and unresorbed bone was found more in anti-RANKL Ab-treated mice compared with mice receiving ZOL. All mice receiving anti-RANKL Ab had an undetectable tartrate-resistant acid phosphatase (TRAP) level in the serum and no TRAP-positive osteoclasts at the extracted sockets, whereas ZOL-treated mice had a decreased TRAP level without altering the numbers of TRAP-positive osteoclasts. Interestingly, the absence of newly formed woven bone in the extracted sockets was evident in ONJ-like lesions from both anti-RANKL Ab- and ZOL-treated mice. Our study suggests that the lack of osteoclasts' bone-resorptive functions by these drugs and suppression of woven bone formation after dental trauma may be associated with ONJ development.	[Williams, Drake W.; Lee, Cindy; Kim, Terresa; Park, Sil; Yang, Paul; Liu, Honghu; Shin, Ki-Hyuk; Kang, Mo K.; Park, No-Hee; Kim, Reuben H.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90095 USA; [Liu, Honghu; Park, No-Hee] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Liu, Honghu] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA 90095 USA; [Shin, Ki-Hyuk; Kang, Mo K.; Park, No-Hee; Kim, Reuben H.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA; [Yagita, Hideo] Juntendo Univ, Sch Med, Dept Immunol, Tokyo 113, Japan; [Wu, Hongkun] Sichuan Univ, West China Hosp Stomatol, State Key Lab Oral Dis, Chengdu 610064, Peoples R China; [Shi, Songtao] Univ Calif Los Angeles, Sch Dent, Ctr Craniofacial Mol Biol, Los Angeles, CA 90095 USA; [Park, No-Hee] Kyung Hee Univ, Seoul, South Korea	Kim, RH (reprint author), Univ Calif Los Angeles, Sch Dent, Ctr Hlth Sci, 10833 Le Conte Ave,Room 43-091, Los Angeles, CA 90095 USA.	rkim@dentistry.ucla.edu		Williams, Drake/0000-0002-7718-2098	National Institute of Dental and Craniofacial Research/NIH [R03DE021114, R0IDE023348]	Supported in part by National Institute of Dental and Craniofacial Research/NIH grants R03DE021114 and R0IDE023348 (R.H.K.), Dean's Faculty Research Seed grant (R.H.K.), and Chancellor's grant (N.-H.P.).	Henry DH, 2011, J CLIN ONCOL, V29, P1125, DOI 10.1200/JCO.2010.31.3304; Naylor K, 2012, NAT REV RHEUMATOL, V8, P379, DOI 10.1038/nrrheum.2012.86; Bi YM, 2010, AM J PATHOL, V177, P280, DOI 10.2353/ajpath.2010.090592; Aghaloo TL, 2010, J ORAL MAXIL SURG, V68, P959, DOI 10.1016/j.joms.2009.10.010; Aghaloo TL, 2011, J BONE MINER RES, V26, P1871, DOI 10.1002/jbmr.379; Kikuiri T, 2010, J BONE MINER RES, V25, P1668, DOI 10.1002/jbmr.37; Ruggiero SL, 2009, J ORAL MAXIL SURG, V67, P2, DOI 10.1016/j.joms.2009.01.009; Berglundh T, 2003, CLIN ORAL IMPLAN RES, V14, P251, DOI 10.1034/j.1600-0501.2003.00972.x; Bone HG, 2013, J CLIN ENDOCR METAB, V98, P4483, DOI 10.1210/jc.2013-1597; Feng X, 2011, ANNU REV PATHOL-MECH, V6, P121, DOI 10.1146/annurev-pathol-011110-130203; Baron R, 2011, BONE, V48, P677, DOI 10.1016/j.bone.2010.11.020; Stopeck AT, 2010, J CLIN ONCOL, V28, P5132, DOI 10.1200/JCO.2010.29.7101; Kostenuik PJ, 2009, J BONE MINER RES, V24, P182, DOI [10.1359/jbmr.081112, 10.1359/JBMR.081112]; Bouxsein ML, 2010, J BONE MINER RES, V25, P1468, DOI 10.1002/jbmr.141; Zhao C, 2006, CELL METAB, V4, P111, DOI 10.1016/j.cmet.2006.05.012; Diz P, 2012, J AM DENT ASSOC, V143, P981; Hokugo A, 2010, J BONE MINER RES, V25, P1337, DOI 10.1002/jbmr.23; Aghaloo TL, 2014, J BONE MINER RES, V29, P843, DOI 10.1002/jbmr.2097; Aguirre JI, 2012, J BONE MINER RES, V27, P2130, DOI 10.1002/jbmr.1669; Kuroshima S, 2012, ENDOCRINOLOGY, V153, P17, DOI 10.1210/en.2011-1439; Mawardi H, 2011, J DENT RES, V90, P1339, DOI 10.1177/0022034511420430; Bogado Cesar E, 2011, Curr Osteoporos Rep, V9, P12, DOI 10.1007/s11914-010-0040-1; Boyce Brendan F, 2007, Ann N Y Acad Sci, V1116, P245, DOI 10.1196/annals.1402.084; Del Fattore Andrea, 2012, Front Biosci (Elite Ed), V4, P2302; Gorski JP, 1998, CRIT REV ORAL BIOL M, V9, P201; Kamijo S, 2006, BIOCHEM BIOPH RES CO, V347, P124, DOI 10.1016/j.bbrc.2006.06.098; Kumar Satish K S, 2010, Curr Osteoporos Rep, V8, P40, DOI 10.1007/s11914-010-0008-1; Li D, 2010, ANN NY ACAD SCI, V1192, P84, DOI 10.1111/j.1749-6632.2009.05210.x; Pichardo SEC, 2013, J CRANIO MAXILL SURG, V41, pE65, DOI 10.1016/j.jcms.2012.10.014; Reid IR, 2011, NAT REV RHEUMATOL, V8, P90; Rizzoli René, 2011, Expert Rev Clin Pharmacol, V4, P593; Shimizu E, 2012, J DENT RES, V91, P268, DOI 10.1177/0022034511432170	32	3	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	NOV	2014	184	11					3084	3093		10.1016/j.ajpath.2014.07.010		10	Pathology	Pathology	AS0LS	WOS:000343969200020		
J	Wada, E; Yoshida, M; Kojima, Y; Nonaka, I; Ohashi, K; Nagata, Y; Shiozuka, M; Date, M; Higashi, T; Nishino, I; Matsuda, R				Wada, Eiji; Yoshida, Mizuko; Kojima, Yoriko; Nonaka, Ikuya; Ohashi, Kazuya; Nagata, Yosuke; Shiozuka, Masataka; Date, Munehiro; Higashi, Tetsuo; Nishino, Ichizo; Matsuda, Ryoichi			Dietary Phosphorus Overload Aggravates the Phenotype of the Dystrophin-Deficient mdx Mouse	AMERICAN JOURNAL OF PATHOLOGY			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; SKELETAL-MUSCLE DEGENERATION; LOW BONE-DENSITY; MICE; BLUE	Duchenne muscular dystrophy is a lethal X-linked disease with no effective treatment. Progressive muscle degeneration, increased macrophage infiltration, and ectopic calcification are characteristic features of the mdx mouse, a murine model of Duchenne muscular dystrophy. Because dietary phosphorus/phosphate consumption is increasing and adverse effects of phosphate overloading have been reported in several disease conditions, we examined the effects of dietary phosphorus intake in mdx mice phenotypes. On weaning, control and mdx mice were fed diets containing 0.7, 1.0, or 2.0 g phosphorus per 100 g until they were 90 days old. Dystrophic phenotypes were evaluated in cryosections of quadriceps and tibialis anterior muscles, and maximal forces and voluntary activity were measured. Ectopic calcification was analyzed by electron microscopy to determine the cells initially responsible for calcium deposition in skeletal muscle. Dietary phosphorus overload dramatically exacerbated the dystrophic phenotypes of mdx mice by increasing inflammation associated with infiltration of M1 macrophages. In contrast, minimal muscle necrosis and inflammation were observed in exercised mdx mice fed a low-phosphorus diet, suggesting potential beneficial therapeutic effects of lowering dietary phosphorus intake on disease progression. To our knowledge, this is the first report showing that dietary phosphorus intake directly affects muscle pathological characteristics of mdx mice. Dietary phosphorus overloading promoted dystrophic disease progression in mdx mice, whereas restricting dietary phosphorus intake improved muscle pathological characteristics and function.	[Wada, Eiji; Yoshida, Mizuko; Ohashi, Kazuya; Nagata, Yosuke; Shiozuka, Masataka; Matsuda, Ryoichi] Univ Tokyo, Grad Sch Arts & Sci, Tokyo 1538902, Japan; [Kojima, Yoriko; Nishino, Ichizo] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Neuromuscular Res, Tokyo, Japan; [Date, Munehiro] Kobayashi Inst Phys Res, Tokyo, Japan; [Higashi, Tetsuo] Hitachi Aloka Med Ltd, Tokyo, Japan	Matsuda, R (reprint author), Univ Tokyo, Grad Sch Arts & Sci, Meguro Ku, 15-309A,3-8-1 Komaba, Tokyo 1538902, Japan.	cmatsuda@mail.ecc.u-tokyo.ac.jp			Health and Labour Sciences Research grant for Comprehensive Research on Disability Health and Welfare [H22-016]; National Center of Neurology and Psychiatry Intramural Research grant [23-5]; Ministry of Education, Culture, Sports, Science, and Technology Japan; Ichiro Kanehara Foundation [25-3]; Fugaku Foundation [H23]; Japan Science Society Sasakawa Scientific Research [13-209]	Supported in part by a Health and Labour Sciences Research grant for Comprehensive Research on Disability Health and Welfare grant-in-aid H22-016, National Center of Neurology and Psychiatry Intramural Research grant 23-5 for Neurological and Psychiatric Disorder, Ministry of Education, Culture, Sports, Science, and Technology Japan grant-in aid 25650106, Ichiro Kanehara Foundation grant 25-3, Fugaku Foundation grant H23, and The Japan Science Society Sasakawa Scientific Research grant 13-209.	BULFIELD G, 1984, P NATL ACAD SCI-BIOL, V81, P1189, DOI 10.1073/pnas.81.4.1189; Bianchi ML, 2011, OSTEOPOROSIS INT, V22, P529, DOI 10.1007/s00198-010-1275-5; Buetler TM, 2002, AM J CLIN NUTR, V75, P749; SICINSKI P, 1989, SCIENCE, V244, P1578, DOI 10.1126/science.2662404; WATKINS SC, 1988, NATURE, V333, P863, DOI 10.1038/333863a0; COULTON GR, 1988, NEUROPATH APPL NEURO, V14, P53, DOI 10.1111/j.1365-2990.1988.tb00866.x; Zanotti S, 2011, HISTOPATHOLOGY, V59, P1215, DOI 10.1111/j.1365-2559.2011.04051.x; Villalta SA, 2011, J IMMUNOL, V187, P5419, DOI 10.4049/jimmunol.1101267; MOSER H, 1984, HUM GENET, V66, P17, DOI 10.1007/BF00275183; Passaquin AC, 2002, NEUROMUSCULAR DISORD, V12, P174, DOI 10.1016/S0960-8966(01)00273-5; DINGERKUS G, 1977, STAIN TECHNOL, V52, P229; Barton ER, 2005, MUSCLE NERVE, V32, P751, DOI 10.1002/mus.20425; Ruffell D, 2009, P NATL ACAD SCI USA, V106, P17475, DOI 10.1073/pnas.0908641106; Rufo A, 2011, J BONE MINER RES, V26, P1891, DOI 10.1002/jbmr.410; Razzaque MS, 2011, CLIN SCI, V120, P91, DOI 10.1042/CS20100377; BONUCCI E, 1973, AM J PATHOL, V71, P167; Carvalho Samara Camaçari de, 2013, J Neuroimmunol, V264, P41, DOI 10.1016/j.jneuroim.2013.09.007; CLAPTON WK, 1992, PATHOLOGY, V24, P311; Dorchies O, 2006, AM J PHYSIOL-CELL PH, V290, P616; Kikkawa M, 2009, CELL STRUCT FUNCT, V34, P77; SHIAU SYL, 1976, J PHARMACOL EXP THER, V196, P758; MATSUDA R, 1995, J BIOCHEM-TOKYO, V118, P959; McLeod M, 1980, TERATOLOGY, V22, P229, DOI DOI 10.1002/TERA.1420220306; *NAT RES COUNC, 1995, NUTR REQ LAB AN; Payne ET, 2006, MUSCLE NERVE, V33, P66, DOI 10.1002/mus.20436; QUINLAN JG, 1992, MUSCLE NERVE, V15, P837, DOI 10.1002/mus.880150713; Vercherat C, 2009, HUM MOL GENET, V18, P4304, DOI 10.1093/hmg/ddp383; Webb G, 1994, BIOTECH HISTOCHEM, V64, p181 ; Yoshida M, 2006, AM J PHYSIOL-REG I, V290, P449; ZDANOWICZ MM, 1995, J NUTR, V125, P1150	30	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	NOV	2014	184	11					3094	3104		10.1016/j.ajpath.2014.07.007		11	Pathology	Pathology	AS0LS	WOS:000343969200021		
J	Kobayashi, T; Hamaguchi, Y; Hasegawa, M; Fujimoto, M; Takehara, K; Matsushita, T				Kobayashi, Tadahiro; Hamaguchi, Yasuhito; Hasegawa, Minoru; Fujimoto, Manabu; Takehara, Kazuhiko; Matsushita, Takashi			B Cells Promote Tumor Immunity against B16F10 Melanoma	AMERICAN JOURNAL OF PATHOLOGY			English	Article							ANTIGEN-PRESENTING CELLS; REGULATORY T-CELLS; INFILTRATING LYMPHOCYTES; IN-VIVO; AUTOIMMUNE-DISEASES; DEFICIENT MICE; OVARIAN-CANCER; BREAST-CANCER; RESPONSES; ACTIVATION	B cells are known to be critical mediators of tumor immunity; however, the mechanisms through which they exert this function remain unclear. B-cell linker protein (BLNK) is an essential component of the B-cell antigen receptor signaling machinery and is required for B-cell development, as evidenced by BLNK-deficient (BLNK-/-) mice, in which the development and function of B cells are severely impaired. Herein, we evaluated the role of B cells in the development of tumor immunity against B16F10 melanoma using BLNK-/- mice. B16F10 melanoma grew more aggressively in BLNK-/- mice, resulting in a twofold increase in tumor volume compared with wild-type mice. As predicted, tumor-infiltrating B-cell numbers were decreased in BLNK-/- mice. Paradoxically, tumor-infiltrating 1-cell numbers were decreased in BLNK-/- mice, although inguinal lymph node 1-cell numbers were increased. Adoptive transfer of B cells from wild-type mice into BLNK-/- mice attenuated B16F10 melanoma growth, with increasing numbers of B and T cells infiltrating into tumors. In addition, percentages of interferon-gamma-and tumor necrosis factor-alpha producing tumor-infiltrating T cells were restored. Taken together, our study supports the concept that B cells enhance tumor immunity against B16F10 melanoma by promoting 1-cell infiltration into tumors and cytokine production within the tumor microenvironment.	[Kobayashi, Tadahiro; Hamaguchi, Yasuhito; Takehara, Kazuhiko; Matsushita, Takashi] Kanazawa Univ, Fac Med, Inst Med Pharmaceut & Hlth Sci, Dept Dermatol, Kanazawa, Ishikawa 9208641, Japan; [Hasegawa, Minoru] Univ Fukui, Dept Dermatol, Fukui 910, Japan; [Fujimoto, Manabu] Univ Tsukuba, Fac Med, Dept Dermatol, Tsukuba, Ibaraki, Japan	Matsushita, T (reprint author), Kanazawa Univ, Fac Med, Inst Med Pharmaceut & Hlth Sci, Dept Dermatol, 13-1 Takaramachi, Kanazawa, Ishikawa 9208641, Japan.	t-matsushita@med.kanazawa-u.ac.jp	Matsushita, Takashi /C-4750-2015	Matsushita, Takashi /0000-0002-1617-086X	Ministry of Education, Culture, Sports, Science, and Technology of Japan; Ministry of Health, Labor, and Welfare of Japan	Supported by Ministry of Education, Culture, Sports, Science, and Technology of Japan grants-in-aid and Ministry of Health, Labor, and Welfare of Japan grants-in-aid.	Dieckmann D, 2001, J EXP MED, V193, P1303, DOI 10.1084/jem.193.11.1303; KAWAKAMI Y, 1994, J EXP MED, V180, P347, DOI 10.1084/jem.180.1.347; Hansen MH, 2001, P NATL ACAD SCI USA, V98, P12659, DOI 10.1073/pnas.171460798; Rivera A, 2001, INT IMMUNOL, V13, P1583, DOI 10.1093/intimm/13.12.1583; Shevach EM, 2002, NAT REV IMMUNOL, V2, P389, DOI 10.1038/nri821; Nelson BH, 2010, J IMMUNOL, V185, P4977, DOI 10.4049/jimmunol.1001323; Bouaziz JD, 2007, P NATL ACAD SCI USA, V104, P20878, DOI 10.1073/pnas.0709205105; DiLillo DJ, 2010, J IMMUNOL, V184, P4006, DOI 10.4049/jimmunol.0903009; Joao C, 2004, J IMMUNOL, V172, P4709; Inoue S, 2006, CANCER RES, V66, P7741, DOI 10.1158/0008-5472.CAN-05-3766; Wieckowski E, 2002, CANCER RES, V62, P4884; Lindner S, 2013, CANCER RES, V73, P2468, DOI 10.1158/0008-5472.CAN-12-3450; Jumaa H, 1999, IMMUNITY, V11, P547, DOI 10.1016/S1074-7613(00)80130-2; Kobayashi N, 2007, CLIN CANCER RES, V13, P902, DOI 10.1158/1078-0432.CCR-06-2363; Nielsen JS, 2012, CLIN CANCER RES, V18, P3281, DOI 10.1158/1078-0432.CCR-12-0234; Kotlan B, 2005, J IMMUNOL, V175, P2278; Crawford A, 2006, J IMMUNOL, V176, P3498; Rodriguez-Pinto D, 2005, CELL IMMUNOL, V238, P67, DOI 10.1016/j.cellimm.2006.02.005; Watt V, 2007, J IMMUNOTHER, V30, P323, DOI 10.1097/CJI.0b013e31802bd9c8; Sakaguchi S, 2000, CELL, V101, P455, DOI 10.1016/S0092-8674(00)80856-9; BAKKER ABH, 1994, J EXP MED, V179, P1005, DOI 10.1084/jem.179.3.1005; Mauri C, 2003, J EXP MED, V197, P489, DOI 10.1084/jem.20021293; Minegishi Y, 1999, SCIENCE, V286, P1954, DOI 10.1126/science.286.5446.1954; Jin GH, 2013, J ALLERGY CLIN IMMUN, V131, P1674, DOI 10.1016/j.jaci.2013.01.044; Moulin V, 2000, J EXP MED, V192, P475, DOI 10.1084/jem.192.4.475; Batista FD, 1998, IMMUNITY, V8, P751, DOI 10.1016/S1074-7613(00)80580-4; Xiu Y, 2008, J IMMUNOL, V180, P2863; Shah S, 2005, INT J CANCER, V117, P574, DOI 10.1002/ijc.21177; Bouaziz JD, 2008, IMMUNOL REV, V224, P201, DOI 10.1111/j.1600-065X.2008.00661.x; Dong HP, 2006, AM J CLIN PATHOL, V125, P451, DOI 10.1309/15B66DQMFYYM78CJ; Qin ZH, 1998, NAT MED, V4, P627, DOI 10.1038/nm0598-627; Yasuda M, 2006, ANTICANCER RES, V26, P3607; Lampropoulou V, 2010, IMMUNOL REV, V233, P146, DOI 10.1111/j.0105-2896.2009.00855.x; Coronella-Wood JA, 2003, CANCER IMMUNOL IMMUN, V52, P715, DOI 10.1007/s00262-003-0409-4; Asano MS, 1996, J EXP MED, V183, P2165, DOI 10.1084/jem.183.5.2165; Hayashi K, 2000, P NATL ACAD SCI USA, V97, P2755, DOI 10.1073/pnas.040575697; Le Huu Doanh, 2012, J Invest Dermatol, V132, P2752, DOI 10.1038/jid.2012.226; Milne K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006412; Moutai T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092732; Pappu R, 1999, SCIENCE, V286, P1949, DOI 10.1126/science.286.5446.1949; Ritchie DS, 2004, SCAND J IMMUNOL, V60, P543, DOI 10.1111/j.0300-9475.2004.01517.x	41	1	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0002-9440	1525-2191		AM J PATHOL	Am. J. Pathol.	NOV	2014	184	11					3120	3129		10.1016/j.ajpath.2014.07.003		10	Pathology	Pathology	AS0LS	WOS:000343969200023		
J	Koyama, Y; Ota, Y; Sakaizumi, K; Simoda, N; Kodama, M; Toyokura, M; Masakado, Y				Koyama, Yuji; Ota, Yoshihide; Sakaizumi, Kazuo; Simoda, Naoshi; Kodama, Mitsuhiko; Toyokura, Minoru; Masakado, Yoshihisa			Swallowing Appliance: Intraoral Reshaping Prosthesis for Dysphagia Secondary to Oral Floor Cancer A Pilot Study	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						Dysphagia; Reshaping Prosthesis; Palatal Augmentation Prosthesis; Oral Floor Cancer	SPEECH	Patients with oral floor cancer often have difficulty swallowing solid foods. The aim of this study was to improve the propulsion of solid foods using a swallowing appliance (SW-A). Subjects comprised three patients with oral floor cancer who had undergone curative surgery. Each participant was asked to swallow gelatin under three conditions: without an SW-A, with a maxillary SW-A, and with both maxillary and mandibular SW-As. This procedure was repeated thrice with three volumes of gelatin (2.5, 5, and 7.5 ml), with videofluorographic swallowing study. Swallowing was assessed on the basis of whether the participant could propel the gelatin from the oral cavity to the pharynx. No subject could propel 2.5 ml of gelatin to the pharynx without an SW-A or with only a maxillary SW-A in place. When both SW-As were used, all subjects could propel all three volumes of gelatin. The mandibular SW-A complemented the compensatory effects of the maxillary SW-A.	[Koyama, Yuji; Simoda, Naoshi; Kodama, Mitsuhiko; Toyokura, Minoru; Masakado, Yoshihisa] Tokai Univ Oiso Hosp, Dept Rehabil Med, Sch Med, Oiso, Kanagawa 2590198, Japan; [Ota, Yoshihide; Sakaizumi, Kazuo] Tokai Univ Oiso Hosp, Dept Maxillofacial Surg, Sch Med, Oiso, Kanagawa 2590198, Japan	Koyama, Y (reprint author), Tokai Univ Oiso Hosp, Dept Rehabil Med, 21-2 Gakkyo, Oiso, Kanagawa 2590198, Japan.				MEXT KAKENHI [25350625]	Supported by MEXT KAKENHI grant number 25350625.	KAHRILAS PJ, 1993, GASTROENTEROLOGY, V104, P152; Hind JA, 2001, ARCH PHYS MED REHAB, V82, P1661, DOI 10.1053/apmr.2001.28006; CANTOR R, 1969, J PROSTHET DENT, V22, P253, DOI 10.1016/0022-3913(69)90254-6; DAVIS JW, 1987, J PROSTHET DENT, V57, P715, DOI 10.1016/0022-3913(87)90370-2; Koyama Y, 1998, JPN J REHABIL MED, V35, P245; LANG BR, 1969, PLAST RECONSTR SURG, V43, P467, DOI 10.1097/00006534-196905000-00003; Logemann JA, 1998, MANAGEMENT PATIENT O, P191; WHEELER RL, 1980, J PROSTHET DENT, V43, P313, DOI 10.1016/0022-3913(80)90408-4	8	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	NOV	2014	93	11					1008	1013		10.1097/PHM.0000000000000168		6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	AS6CT	WOS:000344353100011		
J	Maznev, AA; Wright, OB				Maznev, A. A.; Wright, O. B.			Demystifying umklapp vs normal scattering in lattice thermal conductivity	AMERICAN JOURNAL OF PHYSICS			English	Article								We discuss the textbook presentation of the concept of umklapp vs normal phonon-phonon scattering processes in the context of lattice thermal conductivity. A simplistic picture, in which the "momentum conservation" in a normal process leads to the conservation of the heat flux, is only valid within the single-velocity Debye model of phonon dispersion. Outside this model, the simple "momentum conservation" argument is demonstrably inaccurate and leads to conceptual confusion. Whether or not an individual scattering event changes the direction of the energy flow is determined by the phonon group velocity, which, unlike the quasimomentum, is a uniquely defined quantity independent of the choice of the primitive cell in reciprocal space. Furthermore, the statement that normal processes do not lead to a finite thermal conductivity when umklapp processes are absent is a statistical statement that applies to a phonon distribution rather than to individual scattering events. It is also important to understand that once umklapp processes are present, both normal and umklapp processes contribute to thermal resistance. A nuanced explanation of the subject would help avoid confusion of the student and establish a connection with cutting edge research. (C) 2014 American Association of Physics Teachers.	[Maznev, A. A.] MIT, Dept Chem, Cambridge, MA 02139 USA; [Wright, O. B.] Hokkaido Univ, Div Appl Phys, Fac Engn, Sapporo, Hokkaido 0608628, Japan	Maznev, AA (reprint author), MIT, Dept Chem, Cambridge, MA 02139 USA.				U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences [DE-SC0001299]	The authors greatly appreciate stimulating discussions with A. G. Every and comments on the manuscript by J. K. Eliason. The contribution by A. A. M. was supported as part of the S<SUP>3</SUP>TEC Energy Frontier Research Center funded by the U.S. Department of Energy, Office of Science, Office of Basic Energy Sciences under Award No. DE-SC0001299.	Ward A, 2010, PHYS REV B, V81, DOI 10.1103/PhysRevB.81.085205; HAMILTON RA, 1969, PHYS REV, V178, P1284, DOI 10.1103/PhysRev.178.1284; CALLAWAY J, 1959, PHYS REV, V113, P1046, DOI 10.1103/PhysRev.113.1046; Ward A, 2009, PHYS REV B, V80, DOI 10.1103/PhysRevB.80.125203; Ashcroft N W, 1976, SOLID STATE PHYSICS; Berman R., 1976, HERMAL CONDUCTION IN; Blakemore J. S., 1985, SOLID STATE PHYSICS; Broido D. A., 2007, APPL PHYS LETT, V91; Chen G., 2005, NANOSCALE ENERGY TRA; Debye P., 1914, VORTRAGE KINETISCHE, P17; Esfarjani K, 2011, PHYS REV B, V84, DOI 10.1103/PhysRevB.84.085204; HALL HE, 1974, SOLID STATE PHYSICS; Kittel C, 2005, INTRODUCTION TO SOLI; Lou L. F., 2003, INTRODUCTION TO PHON; Peierls R., 1955, QUANTUM THEORY OF SO; Peierls R, 1929, ANN PHYS-BERLIN, V3, P1055; Sirdeshmukh DB, 2011, SPRINGER SER MATER S, V147, P1, DOI 10.1007/978-3-642-19971-4; Srivastava G. P., 2006, ELEMENTS OF SOLID ST; Taylor P L, 2002, QUANTUM APPROACH CON; Zhang Z. M., 2007, NANO MICROSCALE HEAT; Ziman J. M., 1960, ELECTRONS AND PHONON	21	1	1	AMER ASSOC PHYSICS TEACHERS AMER INST PHYSICS	MELVILLE	STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA	0002-9505	1943-2909		AM J PHYS	Am. J. Phys.	NOV	2014	82	11					1062	1066		10.1119/1.4892612		5	Education, Scientific Disciplines; Physics, Multidisciplinary	Education & Educational Research; Physics	AS6HB	WOS:000344363800008		
J	Ruhr, IM; Bodinier, C; Mager, EM; Esbaugh, AJ; Williams, C; Takei, Y; Grosell, M				Ruhr, Ilan M.; Bodinier, Charlotte; Mager, Edward M.; Esbaugh, Andrew J.; Williams, Cameron; Takei, Yoshio; Grosell, Martin			Guanylin peptides regulate electrolyte and fluid transport in the Gulf toadfish (Opsanus beta) posterior intestine	AMERICAN JOURNAL OF PHYSIOLOGY-REGULATORY INTEGRATIVE AND COMPARATIVE PHYSIOLOGY			English	Article						guanylin; uroguanylin; HCO3-; CFTR; osmoregulation; fluid secretion	MARINE TELEOST FISH; HEAT-STABLE ENTEROTOXIN; EEL ANGUILLA-ANGUILLA; DUODENAL HCO3-SECRETION; CFTR CHLORIDE CHANNEL; BICARBONATE SECRETION; FUNDULUS-HETEROCLITUS; OSMOREGULATORY HORMONES; DICENTRARCHUS-LABRAX; FLOUNDER INTESTINE	The physiological effects of guanylin (GN) and uroguanylin (UGN) on fluid and electrolyte transport in the teleost fish intestine have yet to be thoroughly investigated. In the present study, the effects of GN, UGN, and renoguanylin (RGN; a GN and UGN homolog) on short-circuit current (Isc) and the transport of Cl- , Na-, bicarbonate (HCO3-), and fluid in the Gulf toadfish (Opsanus beta) intestine were determined using Ussing chambers, pH-stat titration, and intestinal sac experiments. GN, UGN, and RGN reversed the I-sc of the posterior intestine (absorptive-to-secretory), but not of the anterior intestine. RGN decreased baseline HCO3- secretion, but increased Cl- and fluid secretion in the posterior intestine. The secretory response of the posterior intestine coincides with the presence of basolateral NKCC1 and apical cystic fibrosis transmembrane conductance regulator (CFTR), the latter of which is lacking in the anterior intestine and is not permeable to HCO3- in the posterior intestine. However, the response to RGN by the posterior intestine is counterintuitive given the known role of the marine teleost intestine as a salt-and watera-bsorbing organ. These data demonstrate that marine teleosts possess a tissue-specific secretory response, apparently associated with sea-water adaptation, the exact role of which remains to be determined.	[Ruhr, Ilan M.; Bodinier, Charlotte; Mager, Edward M.; Esbaugh, Andrew J.; Williams, Cameron; Grosell, Martin] Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, Miami, FL 33149 USA; [Takei, Yoshio] Univ Tokyo, Ocean Res Inst, Tokyo 164, Japan	Ruhr, IM (reprint author), Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, 4600 Rickenbacker Causeway, Miami, FL 33149 USA.	iruhr@rsmas.miami.edu			National Science Foundation [IOS 1146695]	M. Grosell is Maytag Professor of Ichthyology and is supported by National Science Foundation Grant IOS 1146695.	Akiba Y, 2005, AM J PHYSIOL-GASTR L, V289, pG753, DOI 10.1152/ajpgi.00130.2005; CURRIE MG, 1992, P NATL ACAD SCI USA, V89, P947, DOI 10.1073/pnas.89.3.947; Wilson RW, 2009, SCIENCE, V323, P359, DOI 10.1126/science.1157972; Singer TD, 1998, AM J PHYSIOL-CELL PH, V274, pC715; Hiroi J, 2008, J EXP BIOL, V211, P2584, DOI 10.1242/jeb.018663; Smith HW, 1930, AM J PHYSIOL, V93, P480; Joo NS, 1998, AM J PHYSIOL-GASTR L, V274, pG633; Ishiguro H, 2009, J GEN PHYSIOL, V133, P315, DOI 10.1085/jgp.200810122; Seidler U, 1997, J PHYSIOL-LONDON, V505, P411, DOI 10.1111/j.1469-7793.1997.411bb.x; Allen A, 2005, AM J PHYSIOL-CELL PH, V288, pC1, DOI 10.1152/ajpcell.00102.2004; Guba M, 1996, GASTROENTEROLOGY, V111, P1558, DOI 10.1016/S0016-5085(96)70018-5; Toriano R, 2011, CELL PHYSIOL BIOCHEM, V28, P733, DOI 10.1159/000335767; Cutler CP, 2002, BBA-BIOMEMBRANES, V1566, P92, DOI 10.1016/S0005-2736(02)00596-5; Grosell M, 2006, J EXP BIOL, V209, P2813, DOI 10.1242/jeb.02345; Kopeikin Z, 2010, J GEN PHYSIOL, V136, P659, DOI 10.1085/jgp.201010518; SCHULZ S, 1992, J BIOL CHEM, V267, P16019; Hamra FK, 1997, P NATL ACAD SCI USA, V94, P2705, DOI 10.1073/pnas.94.6.2705; Bodinier C, 2009, COMP BIOCHEM PHYS A, V153, P345, DOI 10.1016/j.cbpa.2009.03.011; HALLBACK DA, 1991, ACTA PHYSIOL SCAND, V143, P271, DOI 10.1111/j.1748-1716.1991.tb09232.x; Forte LR, 1999, REGUL PEPTIDES, V81, P25, DOI 10.1016/S0167-0115(99)00033-6; Li ZP, 1996, GASTROENTEROLOGY, V111, P1714, DOI 10.1016/S0016-5085(96)70037-9; DESAUVAGE FJ, 1992, P NATL ACAD SCI USA, V89, P9089; CHAO AC, 1994, EMBO J, V13, P1065; Arshad N, 2013, WILEY INTERDISCIPLIN; Arshad N, 2012, FEBS LETT, V586, P2835, DOI 10.1016/j.febslet.2012.07.028; Bengtsson MW, 2007, ACTA PHYSIOL, V191, P309, DOI 10.1111/j.1748-1716.2007.01759.x; Bodinier C, 2009, J ANAT, V214, P318, DOI 10.1111/j.1469-7580.2009.01050.x; Carrithers SL, 2002, REGUL PEPTIDES, V107, P87, DOI 10.1016/S0167-0115(02)00069-1; Comrie MM, 2001, BIOCHEM BIOPH RES CO, V281, P1078, DOI 10.1006/bbrc.2001.4485; Comrie MR, 2001, COMP BIOCHEM PHYS B, V129, P575, DOI 10.1016/S1096-4959(01)00367-0; Cramb G, 2005, ANN NY ACAD SCI, V1040, P277, DOI 10.1196/annals.1327.042; DIAZ M, 1988, COMP BIOCHEM PHYS A, V91, P71, DOI 10.1016/0300-9629(88)91594-0; FRIZZELL RA, 1979, J MEMBRANE BIOL, V46, P27, DOI 10.1007/BF01959973; Genz J, 2011, COMP BIOCHEM PHYS A, V160, P156, DOI 10.1016/j.cbpa.2011.05.027; Gregorio SF, 2013, J EXP BIOL, V216, P470, DOI 10.1242/jeb.073742; Grosell M, 2011, ACTA PHYSIOL, V202, P421, DOI 10.1111/j.1748-1716.2010.02241.x; Grosell M, 2005, AM J PHYSIOL-REG I, V288, pR936, DOI 10.1152/ajpregu.00684.2003; Grosell M, 2010, FISH PHYSIOL, V30, P135; Grosell M, 2007, COMP BIOCHEM PHYS A, V148, P14, DOI 10.1016/j.cbpa.2006.10.017; Grosell M, 2009, J EXP BIOL, V212, P1684, DOI 10.1242/jeb.027730; Grosell M, 2006, AM J PHYSIOL-REG I, V291, pR1145, DOI 10.1152/ajpregu.00818.2005; Grosell M, 2001, FISH PHYSIOL BIOCHEM, V24, P81, DOI 10.1023/A:1011994129743; Grosell M, 2009, J EXP BIOL, V212, P1940, DOI 10.1242/jeb.026856; Guffey S, 2011, AM J PHYSIOL-REG I, V301, pR1682, DOI 10.1152/ajpregu.00059.2011; HALM DR, 1985, J GEN PHYSIOL, V85, P865, DOI 10.1085/jgp.85.6.865; Iio K, 2005, COMP BIOCHEM PHYS B, V140, P569, DOI 10.1016/j.cbpc.2004.12.006; Kalujnaia S, 2009, GEN COMP ENDOCR, V161, P103, DOI 10.1016/j.ygcen.2008.11.005; Kita T, 1999, AM J PHYSIOL-GASTR L, V277, pG960; KUHN M, 1994, J PHYSIOL-LONDON, V479, P433; Kurita Y, 2008, AM J PHYSIOL-REG I, V294, pR1402, DOI 10.1152/ajpregu.00759.2007; Kusakabe T, 2000, ZOOL SCI, V17, P131, DOI 10.2108/zsj.17.131; Li ZJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087591; Marshall W, 2006, PHYSL FISHES, V3, P177; Marshall WS, 2002, J EXP BIOL, V205, P745; McDonald MD, 2003, COMP BIOCHEM PHYS A, V134, P763, DOI 10.1016/S1095-6433(03)00010-2; Muller T, 2012, KIDNEY INT, V82, P1253; Rozenfeld J, 2012, AM J PHYSIOL-RENAL, V302, pF614, DOI 10.1152/ajprenal.00189.2011; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; Spiegel S, 2003, AM J PHYSIOL-GASTR L, V285, pG887, DOI 10.1152/ajpgi.00083.2003; Takei Y, 2007, GEN COMP ENDOCR, V152, P339, DOI 10.1016/j.ygcen.2007.05.005; Takei Y, 2006, J EXP ZOOL PART A, V305A, P787, DOI 10.1002/jez.a.309; Taylor JR, 2010, J EXP BIOL, V213, P459, DOI 10.1242/jeb.029363; Tresguerres M, 2010, AM J PHYSIOL-REG I, V299, pR62, DOI 10.1152/ajpregu.00761.2009; Wilson RW, 2002, BBA-BIOMEMBRANES, V1566, P182, DOI 10.1016/S0005-2736(02)00600-4; Wilson RW, 1996, J EXP BIOL, V199, P2331; Wilson RW, 2003, BBA-BIOMEMBRANES, V1618, P163, DOI 10.1016/j.bbamem.2003.09.014; Yuge S, 2003, J BIOL CHEM, V278, P22726, DOI 10.1074/jbc.M303111200; Yuge S, 2006, GEN COMP ENDOCR, V149, P10, DOI 10.1016/j.ygcen.2006.04.012; Yuge S, 2007, ZOOL SCI, V24, P1222, DOI 10.2108/zsj.24.1222	69	3	3	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0363-6119	1522-1490		AM J PHYSIOL-REG I	Am. J. Physiol.-Regul. Integr. Comp. Physiol.	NOV 1	2014	307	9					R1167	R1179		10.1152/ajpregu.00188.2014		13	Physiology	Physiology	AS2BW	WOS:000344084900010		
J	Granier, N; Hambuckers, A; Matsuzawa, T; Huynen, MC				Granier, Nicolas; Hambuckers, Alain; Matsuzawa, Tetsuro; Huynen, Marie-Claude			Density Estimates and Nesting-Site Selection in Chimpanzees of the Nimba Mountains, Cote d'Ivoire, and Guinea	AMERICAN JOURNAL OF PRIMATOLOGY			English	Article						chimpanzee; nest count; nesting-site selection; behavioral ecology; conservation	PAN-TROGLODYTES-VERUS; KALINZU FOREST; NATIONAL-PARK; CENSUS; BEHAVIOR; ECOLOGY; UGANDA; POPULATIONS; PATTERNS; COUNTS	We investigated nesting behavior of non habituated chimpanzees populating the Nimba Mountains to document their abundance and their criterions of nesting-site selection. During a 19-month study we walked 80km of transects and recces each month, and recorded 764 nests (mean group size=2.23 nests) along with characteristics of vegetation structure and composition, topography, and seasonality. Population density estimated with two nest count methods ranged between 0.14 and 0.65chimpanzee/km(2). These values are lower than previous estimates, emphasizing the necessity of protecting remaining wild ape populations. Chimpanzees built nests in 108 tree species out of 437 identified, but 2.3% of total species comprised 52% of nests. Despite they preferred nesting in trees of 25-29cm DBH and at a mean height of 8.02m, we recorded an important proportion of terrestrial nests (8.2%) that may reflect a cultural trait of Nimba chimpanzees. A logistic model of nest presence formulated as a function of 12 habitat variables revealed preference for gallery and mountain forests rather than lowland forest, and old-growth forest rather than secondary forests. They nested more frequently in the study area during the dry season (December-April). The highest probability of observing nests was at 770m altitude, particularly in steep locations (mean ground declivity=15.54%). Several of the reported nest characteristics combined with the existence of two geographically separated clusters of nest, suggest that the study area constitutes the non-overlapping peripheral areas of two distinct communities. This nest-based study led us to findings on the behavioral ecology of Nimba chimpanzees, which constitute crucial knowledge to implement efficient and purpose-built conservation. Am. J. Primatol. 76:999-1010, 2014. (c) 2014 Wiley Periodicals, Inc.	[Granier, Nicolas; Hambuckers, Alain; Huynen, Marie-Claude] Univ Liege, Liege, Belgium; [Matsuzawa, Tetsuro] Kyoto Univ, Primate Res Inst, Inuyama, Aichi 484, Japan	Granier, N (reprint author), Behav Biol Unit, Quai Van Beneden 22, B-4020 Liege, Belgium.	nicogranier@yahoo.fr			Ministry of Education, Culture, Sports, Science and Technology - Japan [16002001, 20002001, 24000001]; JSPS-ITP-HOPE	Contract grant sponsor: Ministry of Education, Culture, Sports, Science and Technology - Japan; contract grant numbers: 16002001, 20002001, 24000001; contract grant sponsor: JSPS-ITP-HOPE	Agresti A, 2002, WILEY SERIES PROBABI, P721; ANDERSON JR, 1984, ADV STUD BEHAV, V14, P165; Bolker BM, 2009, TRENDS ECOL EVOL, V24, P127, DOI 10.1016/j.tree.2008.10.008; Lehmann J, 2004, BEHAV ECOL SOCIOBIOL, V56, P207, DOI 10.1007/s00265-004-0781-x; Samson DR, 2013, PRIMATES, V54, P73, DOI 10.1007/s10329-012-0329-z; HASHIMOTO C, 1995, PRIMATES, V36, P477, DOI 10.1007/BF02382870; TUTIN CEG, 1984, AM J PRIMATOL, V6, P313, DOI 10.1002/ajp.1350060403; Plumptre AJ, 1996, INT J PRIMATOL, V17, P85, DOI 10.1007/BF02696160; Furuichi T, 2004, INT J PRIMATOL, V25, P755, DOI 10.1023/B:IJOP.0000029121.25284.7f; Schmidt CO, 2008, INT J PUBLIC HEALTH, V53, P165, DOI 10.1007/s00011-007-7068-3; Furuichi T, 2001, INT J PRIMATOL, V22, P913, DOI 10.1023/A:1012057403512; Ancrenaz M, 2004, INT J PRIMATOL, V25, P983, DOI 10.1023/B:IJOP.0000043347.84757.9a; Dormann CF, 2007, ECOGRAPHY, V30, P609, DOI 10.1111/j.2007.0906-7590.05171.x; Buckland ST, 2010, INT J PRIMATOL, V31, P833, DOI 10.1007/s10764-010-9431-5; Basabose AK, 2002, INT J PRIMATOL, V23, P263, DOI 10.1023/A:1013879427335; Stewart FA, 2013, AM J PRIMATOL, V75, P593, DOI 10.1002/ajp.22138; Buckland S.T., 1993, DISTANCE SAMPLING ES, P446; Doran D, 1997, INT J PRIMATOL, V18, P183, DOI 10.1023/A:1026368518431; Duvall CS, 2008, LANDSCAPE ECOL, V23, P699, DOI 10.1007/s10980-008-9231-x; Ghiglieri M. P., 1984, CHIMPANZEES KIBALE F, P226; Granier N, 2011, CHIMPANZEES BOSSOU N, P465; Hernandez-Aguilar RA, 2013, AM J PRIMATOL, V75, P979, DOI 10.1002/ajp.22163; Hoppe-Dominik B, 1991, PRIM REP, V31, P45; Hosmer DW, 2000, APPL LOGISTIC REGRES, P392; Humle T, 2001, FOLIA PRIMATOL, V72, P57, DOI 10.1159/000049924; Kleinbaum DG, 2010, LOGISTIC REGRESSION, P701; Koops K, 2012, INT J PRIMATOL, V33, P356, DOI 10.1007/s10764-012-9585-4; Kormos R, 2003, W AFRICAN CHIMPANZEE, P229; Kouakou CY, 2009, AM J PRIMATOL, V71, P447, DOI 10.1002/ajp.20673; Lamotte M, 1942, MAMMALIA, V6, P114; MARCHESI P, 1995, PRIMATES, V36, P591, DOI 10.1007/BF02382880; Matsuzawa Tetsuro, 1996, P211; McGrew WC, 2004, CULTURED CHIMPANZEE, P248; Plumptre AJ, 1997, INT J PRIMATOL, V18, P475, DOI 10.1023/A:1026302920674; ROY R., 2003, MEMOIRES MUSEUM NATL; Schroeder B, 2006, ROC AUC EVALUATING P; Shimada MK, 2000, PAN AFRICA NEWS, V7, P7; Sokal R.R., 1995, BIOMETRY PRINCIPLES, P887; Stanford CB, 2008, AM J PRIMATOL, V70, P642, DOI 10.1002/ajp.20539; Stewart FA, 2007, AM J PRIMATOL, V69, P930, DOI 10.1002/ajp.20432; Venables W. N., 2002, MODERN APPL STAT S, Vfourth, P497	41	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0275-2565	1098-2345		AM J PRIMATOL	Am. J. Primatol.	NOV	2014	76	11					999	1010		10.1002/ajp.22278		12	Zoology	Zoology	AR9XA	WOS:000343928900001		
J	Shimada, M; Sueur, C				Shimada, Masaki; Sueur, Cedric			The Importance of Social Play Network for Infant or Juvenile Wild Chimpanzees at Mahale Mountains National Park, Tanzania	AMERICAN JOURNAL OF PRIMATOLOGY			English	Article						social network analysis; network stability; play network; association network; chimpanzee	TENSION-REDUCTION MECHANISM; MACAQUES MACACA-FUSCATA; BONOBOS PAN-PANISCUS; SEX-DIFFERENCES; BEHAVIOR; TROGLODYTES; PATTERNS; COOPERATION; DYNAMICS; LIFE	Along with social grooming and food sharing, social play is considered to be an affiliative interaction among wild chimpanzees. However, infant, juvenile, and adolescent animals engage in social play more frequently than adult animals, while other affiliative interactions occur more commonly between adults. We studied the social play of well-habituated and individually identified wild chimpanzees of the M group in Mahale Mountains National Park, Tanzania over two research periods in 2010 and 2011 (21 and 17 observation days, respectively). In both periods, most members of the M group, including adolescents and adults, took part in social play at least once. The degree centralities of the play network in infants, juveniles, and adolescents were significantly higher than those seen in adults. There was a significant and positive correlation between the total number of participations in social play and the degree centrality of play networks. Partial play networks and partial association networks consisting of individuals in same-age categories were significantly and positively correlated in infants and juveniles, although they were not correlated in adolescents or adults. These results suggest that infants, juveniles and adolescents who played frequently were more central in the group, whilst the adults who played infrequently were more peripheral. In addition, the overall structure of the social play network was stable over time. The frequency of participation in social play positively contributed to the development of affiliative social relationships within the chimpanzee group during the infant or juvenile period, but did not have the same effect during the adolescent and adult period. The social play network may allow individuals to develop the social techniques necessary to acquire a central position in a society and enable them to develop affiliative relationships during the infant or juvenile period. Am. J. Primatol. 76:1025-1036, 2014. (c) 2014 Wiley Periodicals, Inc.	[Shimada, Masaki] Teikyo Univ Sci, Dept Anim Sci, Uenohara, Yamanashi 4090193, Japan; [Sueur, Cedric] Univ Strasbourg, Inst Pluridisciplinaire Hubert Curien, Strasbourg, France; [Sueur, Cedric] CNRS, Dept Ecol Physiol & Ethol, Strasbourg, France	Shimada, M (reprint author), Teikyo Univ Sci, Dept Anim Sci, 2525 Yatsusawa, Uenohara, Yamanashi 4090193, Japan.	masakishimada@japan.email.ne.jp	Sueur, Cedric/A-4020-2011	Sueur, Cedric/0000-0001-8206-2739	MEXT [21820064, 24720399, 19255008]; University of Strasbourg Institute for Advanced Study (USIAS); Fyssen Foundation	Contract grant sponsor: MEXT Grant-in-Aid (KAKENHI); contract grant numbers: 21820064, 24720399, 19255008; contract grant sponsor: University of Strasbourg Institute for Advanced Study (USIAS); contract grant sponsor: Fyssen Foundation	Flack JC, 2006, NATURE, V439, P426, DOI 10.1038/nature04326; Palagi E, 2004, ETHOLOGY, V110, P949, DOI 10.1111/j.1439-0310.2004.01035.x; Heider F, 1946, J PSYCHOL, V21, P107, DOI 10.1080/00223980.1946.9917275; Clark FE, 2011, AM J PRIMATOL, V73, P748, DOI 10.1002/ajp.20903; Lehmann J, 2009, ANIM BEHAV, V77, P377, DOI 10.1016/j.anbehav.2008.09.038; Itoh N, 2007, PRIMATES, V48, P87, DOI 10.1007/s10329-006-0031-0; Shimada M, 2006, PRIMATES, V47, P342, DOI 10.1007/s10329-006-0187-7; Maestripieri D, 2004, AM J PHYS ANTHROPOL, V123, P52, DOI 10.1002/ajpa.10295; Palagi E, 2006, AM J PHYS ANTHROPOL, V129, P418, DOI 10.1002/ajpa.20289; Palagi E, 2007, AM J PHYS ANTHROPOL, V134, P219, DOI 10.1002/ajpa.20657; Sueur C, 2011, ANIM BEHAV, V82, P845, DOI 10.1016/j.anbehav.2011.07.020; Kasper C, 2009, PRIMATES, V50, P343, DOI 10.1007/s10329-009-0153-2; Zamma K, 2011, PRIMATES, V52, P323, DOI 10.1007/s10329-011-0267-1; ALTMANN J, 1974, BEHAVIOUR, V49, P227, DOI 10.1163/156853974X00534; Wey T, 2008, ANIM BEHAV, V75, P333, DOI 10.1016/j.anbehav.2007.06.020; Aureli F, 2008, CURR ANTHROPOL, V49, P627, DOI 10.1086/586708; TERRY RL, 1970, J PSYCHOL, V76, P129; Nishida T, 2003, AM J PRIMATOL, V59, P99, DOI 10.1002/ajp.10068; Gilby IC, 2008, BEHAV ECOL SOCIOBIOL, V62, P1831, DOI 10.1007/s00265-008-0612-6; Vigilant L, 2001, P NATL ACAD SCI USA, V98, P12890, DOI 10.1073/pnas.231320498; Bateson P., 2007, MEASURING BEHAV INTR; Bekoff M., 1998, ANIMAL PLAY EVOLUTIO; Bjorklund D. E., 2002, ORIGINS HUMAN NATURE; Borgatti S. P., 2002, UCINET WINDOWS SOFTW; BROWN SG, 1988, PRIMATES, V29, P219, DOI 10.1007/BF02381123; Burghardt GM, 2005, GENESIS OF ANIMAL PLAY: TESTING THE LIMITS, P1; CAIRNS SJ, 1987, ANIM BEHAV, V35, P1454, DOI 10.1016/S0003-3472(87)80018-0; Cordoni G, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027344; Croft DP, 2008, EXPLORING ANIMAL SOCIAL NETWORKS, P1; de Nooy W., 2011, EXPLORATORY SOCIAL N; de Waal Frans, 2007, CHIMPANZEE POLITICS; EATON GG, 1986, PRIMATES, V27, P141, DOI 10.1007/BF02382594; Fagen R. A., 1981, ANIMAL PLAY BEHAV; Goodall J., 1986, CHIMPANZEES GOMBE; HAYAKI H, 1985, Primates, V26, P343, DOI 10.1007/BF02382452; HAYAKI H, 1988, PRIMATES, V29, P147, DOI 10.1007/BF02381119; HEMELRIJK CK, 1990, J THEOR BIOL, V143, P405, DOI 10.1016/S0022-5193(05)80036-0; Kanngiesser P, 2011, AM J PRIMATOL, V73, P758, DOI 10.1002/ajp.20914; Lewis Kerrie P., 2005, P27; MARKUS N, 1995, PRIMATES, V36, P213, DOI 10.1007/BF02381347; MERRICK N J, 1977, Primates, V18, P215, DOI 10.1007/BF02382960; Mitani JC, 2002, ANIM BEHAV, V64, P727, DOI 10.1006/anbe.2002.4014; Mitani JC, 2000, ANIM BEHAV, V59, P885, DOI 10.1006/anbe.1999.1389; Nakamura M, 2013, PRIMATES, V54, P171, DOI 10.1007/s10329-012-0337-z; Nishida T, 1990, CHIMPANZEES MAHALE M; Nishida T., 1968, Primates, V9, P167, DOI 10.1007/BF01730971; Nishida T, 1979, GREAT APES, P72; Nishida T, 2012, CHIMPANZEES LAKESHOR; Nishida T., 2010, CHIMPANZEE BEHAV WIL; Plooij F. X., 1984, BEHAV DEV FREE LIVIN; SCHINO G, 1988, AM J PRIMATOL, V16, P43, DOI 10.1002/ajp.1350160106; Shimada M, 2013, PRIMATES, V54, P245, DOI 10.1007/s10329-013-0348-4; Smith JE, 2013, ANIM BEHAV, V85, P715, DOI 10.1016/j.anbehav.2013.01.008; Spijkerman RP, 1997, INT J PRIMATOL, V18, P439, DOI 10.1023/A:1026342602018; Sueur C, 2011, AM J PRIMATOL, V73, P703, DOI 10.1002/ajp.20915; Symons D., 1978, PLAY AGGRESSION STUD; THIERRY B, 1985, BEHAV PROCESS, V11, P89, DOI 10.1016/0376-6357(85)90105-6; Thierry B., 2004, MACAQUE SOC MODEL ST; van Lawick-Goodall J., 1968, Animal Behaviour Monographs, V1, P161; Wasserman S., 1994, SOCIAL NETWORK ANAL; Watts David P., 1993, P148; Whitehead H., 2008, ANAL ANIMAL SOC QUAN; Wrangham R.W., 1992, P81	63	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0275-2565	1098-2345		AM J PRIMATOL	Am. J. Primatol.	NOV	2014	76	11					1025	1036		10.1002/ajp.22289		12	Zoology	Zoology	AR9XA	WOS:000343928900003		
J	Takeshita, RSC; Bercovitch, FB; Huffman, MA; Mouri, K; Garcia, C; Rigaill, L; Shimizu, K				Takeshita, Rafaela S. C.; Bercovitch, Fred B.; Huffman, Michael A.; Mouri, Keiko; Garcia, Cecile; Rigaill, Lucie; Shimizu, Keiko			Environmental, Biological, and Social Factors Influencing Fecal Adrenal Steroid Concentrations in Female Japanese Macaques (Macaca fuscata)	AMERICAN JOURNAL OF PRIMATOLOGY			English	Article						glucocorticoids; dehydroepiandrosterone-sulfate; seasonality; stress; Macaca fuscata	DEHYDROEPIANDROSTERONE-SULFATE DHEAS; PAN-TROGLODYTES-SCHWEINFURTHII; NONHUMAN-PRIMATES; CORTISOL-LEVELS; RHESUS-MONKEYS; SERUM DEHYDROEPIANDROSTERONE; TESTOSTERONE LEVELS; SEASONAL-VARIATION; PLASMA-CORTISOL; STRESS	The ability to determine hormonal profiles of primate populations using non-invasive techniques can help to monitor physical fitness, stress, and physiological responses to environmental changes. We investigated fecal glucocorticoids (fGC) and DHEAS concentrations in captive Japanese macaques (Macaca fuscata) in relation to environmental, biological, and social factors. The subjects were female Japanese monkeys from 4 months to 31 years old housed in captivity (27 in social groups and 12 in single cages). Fecal samples were collected from all females, and behavioral data from the social groups during the mating season and the following birth season. Hormonal concentrations were analyzed by enzyme immunoassay. Our results revealed that both fGC and fecal DHEAS concentrations are higher in females housed indoors in single cages than in those living outdoors in social groups. We also found that fGC concentrations were higher in the cycling females during the mating (winter) season than the lactating females in the birth (spring) season. Age was negatively associated to both fGC and fecal DHEAS levels, but the relationship between age and fecal DHEAS was more evident in females housed indoors in single cages than in females housed in outdoor social groups. We did not observe any association of dominance rank with either fecal DHEAS or fGC. This study showed that measurement of fecal DHEAS and fGC can be a good method to assess stress in Japanese macaques. These findings provide insights about the physiology of these two adrenal hormones in female Japanese macaques, which can be applied to wild populations and is fundamental for captive management and conservation biology. Am. J. Primatol. 76:1084-1093, 2014. (c) 2014 Wiley Periodicals, Inc.	[Takeshita, Rafaela S. C.; Bercovitch, Fred B.; Huffman, Michael A.; Mouri, Keiko; Rigaill, Lucie] Kyoto Univ, Primate Res Inst, Dept Ecol & Social Behav, Inuyama, Aichi 4848506, Japan; [Garcia, Cecile] CNRS, UPR 2147, Lab Dynam Evolut Humaine, Paris, France; [Shimizu, Keiko] Okayama Univ Sci, Dept Zool, Fac Sci, Okayama, Japan	Takeshita, RSC (reprint author), Kyoto Univ, Primate Res Inst, Dept Ecol & Social Behav, 41-2 Kanrin, Inuyama, Aichi 4848506, Japan.	rafaela.takeshita.32c@st.kyoto-u.ac.jp			Nippon Zaidan; Primate Research Institute, Kyoto University	Contract grant sponsor: Nippon Zaidan; contract grant sponsor: Primate Research Institute, Kyoto University	Leys C, 2013, J EXP SOC PSYCHOL, V49, P764, DOI 10.1016/j.jesp.2013.03.013; Baulieu EE, 1996, J CLIN ENDOCR METAB, V81, P3147, DOI 10.1210/jc.81.9.3147; Stalder T, 2012, BIOL PSYCHOL, V90, P218, DOI 10.1016/j.biopsycho.2012.03.010; Ostner J, 2002, BEHAV ECOL SOCIOBIOL, V52, P485, DOI 10.1007/s00265-002-0532-9; Kondo M, 2003, ZOO BIOL, V22, P65, DOI 10.1002/zoo.10073; Abbott DH, 2003, HORM BEHAV, V43, P67, DOI 10.1016/S0018-506X(02)00037-5; Cavigelli SA, 1999, ANIM BEHAV, V57, P935, DOI 10.1006/anbe.1998.1054; Sapolsky RM, 1997, ARCH GEN PSYCHIAT, V54, P1137; Weingrill T, 2004, HORM BEHAV, V45, P259, DOI 10.1016/j.yhbeh.2003.12.004; Muroyama Y, 2007, AM J PRIMATOL, V69, P603, DOI 10.1002/ajp.20366; Muller MN, 2004, BEHAV ECOL SOCIOBIOL, V55, P332, DOI 10.1007/s00265-003-0713-1; Vega SR, 2006, BRAIN RES, V1121, P59, DOI 10.1016/j.brainres.2006.08.105; Honess PE, 2006, NEUROSCI BIOBEHAV R, V30, P390, DOI 10.1016/j.neubiorev.2005.04.003; Whitten PL, 1998, YEARB PHYS ANTHROPOL, V41, P1; Epel ES, 2000, PSYCHOSOM MED, V62, P623; Fujita S, 2004, AM J PRIMATOL, V64, P367, DOI 10.1002/ajp.20086; Lane MA, 1997, J CLIN ENDOCR METAB, V82, P2093, DOI 10.1210/jc.82.7.2093; Maestripieri D, 2008, HORM BEHAV, V53, P170, DOI 10.1016/j.yhbeh.2007.09.013; Goodyer IM, 2000, BRIT J PSYCHIAT, V176, P142, DOI 10.1192/bjp.176.2.142; Girard-Buttoz C, 2009, PHYSIOL BEHAV, V98, P168, DOI 10.1016/j.physbeh.2009.05.005; Khorram O, 1997, J GERONTOL A-BIOL, V52, pM1; Huber S, 2003, GEN COMP ENDOCR, V130, P48, DOI 10.1016/S0016-6480(02)00535-X; DEVRIES H, 1995, ANIM BEHAV, V50, P1375, DOI 10.1016/0003-3472(95)80053-0; Vallee M, 2001, BRAIN RES REV, V37, P301, DOI 10.1016/S0165-0173(01)00135-7; Barrett GM, 2002, HORM BEHAV, V42, P85, DOI 10.1006/hbeh.2002.1804; Beehner JC, 2008, PHYSIOL BEHAV, V95, P508, DOI 10.1016/j.physbeh.2008.07.022; Boudarene M, 2002, ENCEPHALE, V28, P139; SHIVELY CA, 1989, ATHEROSCLEROSIS, V77, P69, DOI 10.1016/0021-9150(89)90011-7; Bardi M, 2003, AM J PHYS ANTHROPOL, V120, P298, DOI 10.1002/ajpa.10150; Bayazit V, 2009, AUST J BASIC APPL SC, V3, P1022; Beehner JC, 2005, ANIM BEHAV, V69, P1211, DOI 10.1016/j.anbehav.2004.08.014; Burnham K. P., 2002, MODEL SELECTION MULT; COELHO AM, 1991, AM J PRIMATOL, V23, P257, DOI 10.1002/ajp.1350230406; Cruess DG, 1999, PSYCHONEUROENDOCRINO, V24, P537, DOI 10.1016/S0306-4530(99)00010-4; Downs JL, 2008, NEUROBIOL AGING, V29, P1412, DOI 10.1016/j.neurobiolaging.2007.03.01; Du Chung-Li, 2011, Saf Health Work, V2, P169, DOI 10.5491/SHAW.2011.2.2.169; Erwin JM, 2004, J GERONTOL A-BIOL, V59, P424; FLOOD JF, 1988, BRAIN RES, V448, P178, DOI 10.1016/0006-8993(88)91116-X; Garcia C, 2009, AM J PRIMATOL, V71, P868, DOI 10.1002/ajp.20717; Girard I, 2002, J APPL PHYSIOL, V92, P1553, DOI 10.1152/japplphysiol.00465.2001; Goncharova ND, 2010, AGING-US, V2, P854; Goncharova ND, 2012, B EXP BIOL MED+, V153, P750, DOI 10.1007/s10517-012-1817-2; GUST DA, 1993, HORM BEHAV, V27, P318, DOI 10.1006/hbeh.1993.1024; Hoffman CL, 2010, AM J PRIMATOL, V72, P559, DOI 10.1002/ajp.20793; Hu Y, 2000, BIOCHEM PHARMACOL, V59, P753, DOI 10.1016/S0006-2952(99)00385-8; Kemnitz JW, 2000, J MED PRIMATOL, V29, P330, DOI 10.1034/j.1600-0684.2000.290504.x; MacIntosh AJJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051144; Maninger N, 2010, PSYCHONEUROENDOCRINO, V35, P1055, DOI 10.1016/j.psyneuen.2010.01.006; Martin P, 1993, MEASURING BEHAV INTR, V2nd, P84; Muehlenbein MP, 2003, EXP GERONTOL, V38, P1077, DOI 10.1016/j.exger.2003.07.001; Mustoe AC, 2012, GEN COMP ENDOCR, V175, P519, DOI 10.1016/j.ygcen.2011.12.020; Norikoshi K, 1975, P S 5 C INT PRIM SOC, P43; Perret M, 2005, EXP GERONTOL, V40, P582, DOI 10.1016/j.exger.2005.05.002; Poisbleau M, 2009, BEHAV PROCESS, V80, P99, DOI 10.1016/j.beproc.2008.08.002; RAWLINS RG, 1985, AM J PRIMATOL, V9, P87, DOI 10.1002/ajp.1350090203; Ritsner M, 2004, EUR NEUROPSYCHOPHARM, V14, P267; Sapolsky R.M., 2002, BEHAV ENDOCRINOLOGY, P409; SCHAPIRO SJ, 1993, APPL ANIM BEHAV SCI, V37, P251, DOI 10.1016/0168-1591(93)90115-6; Selye H., 1976, PSYCHOPATHOLOGY HUMA; Seraphin SB, 2008, AM J PRIMATOL, V70, P661, DOI 10.1002/ajp.20541; Shimizu K, 2005, J REPROD DEVELOP, V51, P1, DOI 10.1262/jrd.51.1; STEINMETZ HW, 2006, J MED PRIMATOL, V35, P3; Sugiyama Y., 1976, ADV STUD BEHAV, V7, P255; Takeshita RSC, 2013, GEN COMP ENDOCR, V191, P39, DOI 10.1016/j.ygcen.2013.05.019; Virgin CE, 1997, AM J PRIMATOL, V42, P25, DOI 10.1002/(SICI)1098-2345(1997)42:1<25::AID-AJP2>3.0.CO;2-0; WIEBE RH, 1988, AM J PRIMATOL, V14, P285, DOI 10.1002/ajp.1350140309; Yoshida T, 2001, PRIMATES, V42, P367, DOI 10.1007/BF02629627	67	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0275-2565	1098-2345		AM J PRIMATOL	Am. J. Primatol.	NOV	2014	76	11					1084	1093		10.1002/ajp.22295		10	Zoology	Zoology	AR9XA	WOS:000343928900008		
J	Balamurugan, AN; Naziruddin, B; Lockridge, A; Tiwari, M; Loganathan, G; Takita, M; Matsumoto, S; Papas, K; Trieger, M; Rainis, H; Kin, T; Kay, TW; Wease, S; Messinger, S; Ricordi, C; Alejandro, R; Markmann, J; Kerr-Conti, J; Rickels, MR; Liu, C; Zhang, X; Witkowski, P; Posselt, A; Maffi, P; Secchi, A; Berney, T; O'Connell, PJ; Hering, BJ; Barton, FB				Balamurugan, A. N.; Naziruddin, B.; Lockridge, A.; Tiwari, M.; Loganathan, G.; Takita, M.; Matsumoto, S.; Papas, K.; Trieger, M.; Rainis, H.; Kin, T.; Kay, T. W.; Wease, S.; Messinger, S.; Ricordi, C.; Alejandro, R.; Markmann, J.; Kerr-Conti, J.; Rickels, M. R.; Liu, C.; Zhang, X.; Witkowski, P.; Posselt, A.; Maffi, P.; Secchi, A.; Berney, T.; O'Connell, P. J.; Hering, B. J.; Barton, F. B.			Islet Product Characteristics and Factors Related to Successful Human Islet Transplantation From the Collaborative Islet Transplant Registry (CITR) 1999-2010	AMERICAN JOURNAL OF TRANSPLANTATION			English	Article						Clinical research; practice; diabetes: type 1; endocrinology; diabetology; health services and outcomes research; islet isolation; islet transplantation; Organ Procurement and Transplantation Network (OPTN); pancreas; simultaneous pancreas-kidney transplantation; registry; registry analysis	HISTIDINE-TRYPTOPHAN-KETOGLUTARATE; OF-WISCONSIN SOLUTION; ISOLATION-RELATED VARIABLES; PANCREAS PRESERVATION; ISOLATION OUTCOMES; 2-LAYER METHOD; CLINICAL TRANSPLANTATION; COLLAGENASE NB1; GRAFT-SURVIVAL; CULTURE	The Collaborative Islet Transplant Registry (CITR) collects data on clinical islet isolations and transplants. This retrospective report analyzed 1017 islet isolation procedures performed for 537 recipients of allogeneic clinical islet transplantation in 1999-2010. This study describes changes in donor and islet isolation variables by era and factors associated with quantity and quality of final islet products. Donor body weight and BMI increased significantly over the period (p<0.001). Islet yield measures have improved with time including islet equivalent (IEQ)/particle ratio and IEQs infused. The average dose of islets infused significantly increased in the era of 2007-2010 when compared to 1999-2002 (445.4156.8 vs. 421.3 +/- 155.4x10(3) IEQ; p<0.05). Islet purity and total number of cells significantly improved over the study period (p<0.01 and <0.05, respectively). Otherwise, the quality of clinical islets has remained consistently very high through this period, and differs substantially from nonclinical islets. In multivariate analysis of all recipient, donor and islet factors, and medical management factors, the only islet product characteristic that correlated with clinical outcomes was total IEQs infused. This analysis shows improvements in both quantity and some quality criteria of clinical islets produced over 1999-2010, and these parallel improvements in clinical outcomes over the same period. Product criteria from clinical grade allogeneic human islets exhibit consistently superior-quality characteristics and significantly increasing islet equivalent yield, paralleling improving success rates of islet transplantation for type I diabetes.	[Balamurugan, A. N.; Lockridge, A.; Tiwari, M.; Loganathan, G.; Hering, B. J.] Univ Minnesota, Dept Surg, Schulze Diabet Inst, Minneapolis, MN 55455 USA; [Naziruddin, B.; Takita, M.] Baylor Annette C & Harold C Simmons Transplant In, Dallas, TX USA; [Matsumoto, S.] Otsuka Pharmaceut Factory Inc, Ctr Res & Dev, Tokushima, Japan; [Papas, K.] Univ Arizona, Inst Cellular Transplantat, Tucson, AZ USA; [Trieger, M.; Rainis, H.; Wease, S.; Barton, F. B.] EMMES Corp, Rockville, MD USA; [Kin, T.] Univ Alberta, Clin Islet Lab, Edmonton, AB, Canada; [Kay, T. W.] St Vincents Hosp, Melbourne, Vic, Australia; [Messinger, S.] Univ Miami, Dept Publ Hlth Serv, Miami, FL USA; [Ricordi, C.; Alejandro, R.] Univ Miami, Diabet Res Inst, Miami, FL USA; [Markmann, J.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA; [Kerr-Conti, J.] Lille Univ Hosp, Lille, France; [Rickels, M. R.] Univ Penn, Dept Med, Philadelphia, PA 19104 USA; [Liu, C.] Univ Penn, Dept Surg, Philadelphia, PA 19104 USA; [Zhang, X.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA; [Witkowski, P.] Univ Chicago, Dept Surg, Chicago, IL 60637 USA; [Posselt, A.] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA; [Maffi, P.; Secchi, A.] San Raffaele Univ, Vita Salute, Milan, Italy; [Berney, T.] Univ Hosp Geneva, Dept Surg, Geneva, Switzerland; [O'Connell, P. J.] Univ Sydney, Westmead Hosp, Natl Pancreas Transplant Unit, Sydney, NSW 2006, Australia	Balamurugan, AN (reprint author), Univ Louisville, Dept Surg, Cardiovasc Innovat Inst, Islet Cell Lab, Louisville, KY 40292 USA.	isletologist@hotmail.com; fbarton@emmes.com	Loganathan, Gopalakrishnan/D-8762-2014		NIDDK; National Institutes of Health; JDRF International	The CITR is funded by the NIDDK, National Institutes of Health and by a supplemental grant from the JDRF International. Additional data were made available through cooperative agreements with the U. S. United Network for Organ Sharing (UNOS), Alexandria, Virginia, the Administrative and Bioinformatics Coordinating Center of the City of Hope, Duarte, California (1999-2009) and the NIDDK-sponsored CIT (www.citisletstudy.org), coordinated by the University of Iowa Clinical Trials and Data Management Center (2008-present).	Ponte GM, 2007, CELL TRANSPLANT, V16, P595; LAFFERTY KJ, 1983, ANNU REV IMMUNOL, V1, P143, DOI 10.1146/annurev.iy.01.040183.001043; Gaber AO, 2001, TRANSPLANTATION, V72, P1730, DOI 10.1097/00007890-200112150-00005; Niclauss N, 2011, TRANSPLANTATION, V91, P360, DOI 10.1097/TP.0b013e31820385e6; Sabek OM, 2008, CELL TRANSPLANT, V17, P785, DOI 10.3727/096368908786516747; Kitamura T, 2002, J CLIN INVEST, V110, P1839, DOI 10.1172/JCI200216857; KEDINGER M, 1977, NATURE, V270, P736, DOI 10.1038/270736a0; Lakey JRT, 1996, TRANSPLANTATION, V61, P1047, DOI 10.1097/00007890-199604150-00010; Fraker CA, 2013, CELL TRANSPLANT, V22, P1723, DOI 10.3727/096368912X657873; Barton FB, 2012, DIABETES CARE, V35, P1436, DOI 10.2337/dc12-0063; Nano R, 2005, DIABETOLOGIA, V48, P906, DOI 10.1007/s00125-005-1725-3; Movassat J, 1997, DIABETES, V46, P1445, DOI 10.2337/diabetes.46.9.1445; Balamurugan AN, 2010, TRANSPLANTATION, V89, P954, DOI 10.1097/TP.0b013e3181d21e9a; Balamurugan AN, 2012, TRANSPLANTATION, V93, P693, DOI 10.1097/TP.0b013e318247281b; Balamurugan AN, 2005, AM J TRANSPLANT, V5, P2671, DOI 10.1111/j.1600-6143.2005.01078.x; Brandhorst H, 1995, EXP CLIN ENDOCR DIAB, V103, P23; Brandhorst H, 2010, CELL TRANSPLANT, V19, P3, DOI 10.3727/096368909X477507; BRENDEL MD, 1994, CELL TRANSPLANT, V3, P427; Bucher P, 2004, TRANSPLANT P, V36, P1143, DOI 10.1016/j.transproceed.2004.04.023; Caballero-Corbalan J, 2007, TRANSPLANTATION, V84, P864, DOI 10.1097/01.tp.0000284584.60600.ab; Center CC, 2011, 7 CTR CC; Cosimi S, 1995, TRANSPLANT P, V27, P3355; Friberg AS, 2013, TRANSPLANTATION, V95, pE36, DOI 10.1097/TP.0b013e318283a859; Goto M, 2005, TRANSPLANT P, V37, P1315, DOI 10.1016/j.transproceed.2004.11.042; Hilling DE, 2014, CELL TRANSPLANT, V23, P921, DOI 10.3727/096368913X666412; Iglesias I, 2012, CELL TRANSPLANT, V21, P649, DOI 10.3727/096368911X623826; Itoh T, 2012, CELL TRANSPLANT, V21, P1371, DOI 10.3727/096368912X640592; Kaddis JS, 2009, JAMA-J AM MED ASSOC, V301, P1580, DOI 10.1001/jama.2009.482; Kaddis JS, 2010, AM J TRANSPLANT, V10, P646, DOI 10.1111/j.1600-6143.2009.02962.x; Kim SC, 2005, TRANSPL P, V37, P3402, DOI 10.1016/j.transproceed.2005.09.055; Kin T, 2008, TRANSPL INT, V21, P1029, DOI 10.1111/j.1432-2277.2008.00719.x; Kin T, 2006, TRANSPLANTATION, V82, P1286, DOI 10.1097/01.tp.0000244347.61060.af; Koh A, 2008, TRANSPLANTATION, V86, P1622, DOI 10.1097/TP.0b013e31818c2559; KORBUTT GS, 1994, CELL TRANSPLANT, V3, P291; KURODA Y, 1988, TRANSPLANTATION, V46, P457; LACY PE, 1979, SCIENCE, V204, P312, DOI 10.1126/science.107588; Liu XL, 2008, CELL TRANSPLANT, V17, P649, DOI 10.3727/096368908786092711; MARKMANN JF, 1990, TRANSPLANTATION, V49, P272, DOI 10.1097/00007890-199002000-00009; Matsumoto S, 2002, CELL TRANSPLANT, V11, P769; Matsumoto S, 2009, CELL TRANSPLANT, V18, P549; Niclauss N, 2008, TRANSPLANTATION, V86, P1603, DOI 10.1097/TP.0b013e31818f671a; Noguchi H, 2007, TRANSPLANTATION, V84, P655, DOI 10.1097/01.tp.0000277625.42147.62; Noguchi H, 2012, CELL TRANSPLANT, V21, P517, DOI 10.3727/096368911X605439; O'Gorman D, 2013, ISLETS, V5, P111, DOI 10.4161/isl.25222; O'Gorman D, 2005, TRANSPLANTATION, V80, P801, DOI 10.1097/01.tp.0000172216.47547.d5; Papas KK, 2007, AM J TRANSPLANT, V7, P707, DOI 10.1111/j.1600-6143.2006.01655.x; Qin HY, 2011, CELL TRANSPLANT, V20, P1127, DOI 10.3727/096368910X544942; Ricordi C, 2003, DIABETES, V52, P1595, DOI 10.2337/diabetes.52.7.1595; ROBERTSON GSM, 1993, ACTA DIABETOL, V30, P93; Salehi P, 2006, TRANSPLANTATION, V82, P983, DOI 10.1097/01.tp.0000232310.49237.06; Shimoda M, 2012, ISLETS, V4, P130, DOI 10.4161/isl.19255; SOCCI C, 1993, TRANSPLANTATION, V55, P661; Stahle M, 2013, TRANSPLANTATION, V96, pE91, DOI [10.1097/01.TP.0000437562.31212.d5, 10.1097/01.tp.0000437562.31212.d5]; Stewart ZA, 2009, AM J TRANSPLANT, V9, P217, DOI 10.1111/j.1600-6143.2008.02449.x; Tanioka Y, 1997, SURGERY, V122, P435, DOI 10.1016/S0039-6060(97)90037-4; Wang Y, 2013, CELL TRANSPLANT, V22, P2323, DOI 10.3727/096368912X662417; Webb MA, 2012, BIOTECHNOL GENET ENG, V28, P101, DOI 10.5661/bger-28-101; Wei Guo-hong, 2007, Nan Fang Yi Ke Da Xue Xue Bao, V27, P1352	58	6	6	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1600-6135	1600-6143		AM J TRANSPLANT	Am. J. Transplant.	NOV	2014	14	11					2595	2606		10.1111/ajt.12872		12	Surgery; Transplantation	Surgery; Transplantation	AS3LH	WOS:000344178800020		
J	Goto, Y; Omachi, S; Sanjoba, C; Matsumoto, Y				Goto, Yasuyuki; Omachi, Satoko; Sanjoba, Chizu; Matsumoto, Yoshitsugu			Short Report: Elevation of Serum B-Cell Activating Factor Levels During Visceral Leishmaniasis	AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE			English	Article							SYSTEMIC-LUPUS-ERYTHEMATOSUS; TANDEM REPEAT PROTEINS; INDIAN KALA-AZAR; LYMPHOCYTE STIMULATOR; BAFF; DISORDERS; INFECTION; MALARIA	Elevation of serum B-cell activating factor (BAFF) is one of the characteristics of immunological disorders, including autoimmunity, but the levels of BAFF in infectious diseases have not been studied well. Here, we showed the elevation of serum BAFF in patients with visceral leishmaniasis (VL). The mean serum BAFF value in VL patients (4.65 ng/mL) was 4.3 times higher than that of healthy controls (1.08 ng/mL), and 90% of VL patients showed serum BAFF above the cutoff that was calculated as the mean + 3 SDs of the controls. This report is the first on elevation of serum BAFF during VL.	[Goto, Yasuyuki; Omachi, Satoko; Sanjoba, Chizu; Matsumoto, Yoshitsugu] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Anim Resource Sci, Lab Mol Immunol, Tokyo 1138657, Japan	Goto, Y (reprint author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Anim Resource Sci, Lab Mol Immunol,Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	aygoto@mail.ecc.u-tokyo.ac.jp; satoko.bbk@gmail.com; asanjoba@mail.ecc.u-tokyo.ac.jp; aysmatsu@mail.ecc.u-tokyo.ac.jp	Goto, Yasuyuki/E-9028-2011	Goto, Yasuyuki/0000-0002-8654-7888	Japan Society for the Promotion of Science [23689024, 23256001]; Japan Science and Technology Agency/the Japan International Cooperation Agency, SATREPS	This study was supported by KAKENHI Grants 23689024 and 23256001 from the Japan Society for the Promotion of Science and a grant from the Japan Science and Technology Agency/the Japan International Cooperation Agency, SATREPS.	CARVALHO EM, 1985, J CLIN INVEST, V76, P2066, DOI 10.1172/JCI112209; GHALIB HW, 1993, J CLIN INVEST, V92, P324, DOI 10.1172/JCI116570; Tangye SG, 2006, SEMIN IMMUNOL, V18, P305, DOI 10.1016/j.smim.2006.04.004; Miles SA, 2005, J EXP MED, V201, P747, DOI 10.1084/jem.20041470; Doreau A, 2009, NAT IMMUNOL, V10, P778, DOI 10.1038/ni.1741; Groom J, 2002, J CLIN INVEST, V109, P59, DOI 10.1172/JCI200214121; Matsushita T, 2006, ARTHRITIS RHEUM, V54, P192, DOI 10.1002/art.21526; Goto Y, 2008, INFECT IMMUN, V76, P3967, DOI 10.1128/IAI.00604-08; Mackay F, 1999, J EXP MED, V190, P1697, DOI 10.1084/jem.190.11.1697; Goto Y, 2006, INFECT IMMUN, V74, P3939, DOI 10.1128/IAI.00101-06; Zhang J, 2001, J IMMUNOL, V166, P6; Bermejo DA, 2010, PLOS NEGLECT TROP D, V4, DOI 10.1371/journal.pntd.0000679; Briones J, 2002, EXP HEMATOL, V30, P135, DOI 10.1016/S0301-472X(01)00774-3; Elsawa SF, 2006, BLOOD, V107, P2882, DOI 10.1182/blood-2005-09-3552; GHOSE AC, 1980, CLIN EXP IMMUNOL, V40, P318; HALDAR JP, 1983, INFECT IMMUN, V42, P702; Nduati E, 2011, J INFECT DIS, V204, P962, DOI 10.1093/infdis/jir438; Scholzen A, 2014, J IMMUNOL, V192, P3719, DOI 10.4049/jimmunol.1302960	18	0	0	AMER SOC TROP MED & HYGIENE	MCLEAN	8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA	0002-9637	1476-1645		AM J TROP MED HYG	Am. J. Trop. Med. Hyg.	NOV	2014	91	5					912	914		10.4269/ajtmh.14-0260		3	Public, Environmental & Occupational Health; Tropical Medicine	Public, Environmental & Occupational Health; Tropical Medicine	AS7PO	WOS:000344447800011		
J	Ingram, T; Kai, Y				Ingram, Travis; Kai, Yoshiaki			The Geography of Morphological Convergence in the Radiations of Pacific Sebastes Rockfishes	AMERICAN NATURALIST			English	Article						adaptive radiation; clade-wide convergence; Hansen model; Ornstein-Uhlenbeck model; replicated radiation; SURFACE	ADAPTIVE RADIATION; ECOLOGICAL OPPORTUNITY; STABILIZING SELECTION; DEEP-SEA; EVOLUTION; SCORPAENIFORMES; FISHES; DIVERSIFICATION; TELEOSTEI; SIZE	The evolution of convergent phenotypes in lineages subject to similar selective pressures is a common feature of adaptive radiation. In geographically replicated radiations, repeated convergence occurs between clades occupying distinct regions or islands. Alternatively, a clade may repeatedly reach the same adaptive peaks in broadscale sympatry, resulting in extensive convergence within a region. Rockfish (Sebastes sp.) have radiated in both the northeast and northwest Pacific, allowing tests of the extent and geographic pattern of convergence in a marine environment. We used a suite of phylogenetically informed methods to test for morphological convergence in rockfish. We examined patterns of faunal similarity using nearest neighbor distances in morphospace and the frequency of morphologically similar yet distantly related species pairs. The extent of convergence both between regions and within the northeast Pacific exceeds the expectation under a Brownian motion null model, although constraints on trait space could account for the similarity. We then used a recently developed method (SURFACE) to identify adaptive peak shifts in Sebastes evolutionary history. We found that the majority of convergent peak shifts occur within the northeast Pacific rather than between regions and that the signal of peak shifts is strongest for traits related to trophic morphology. Pacific rockfish thus demonstrate a tendency toward morphological convergence within one of the two broad geographic regions in which they have diversified.	[Ingram, Travis] Univ Otago, Dept Zool, Dunedin 9054, New Zealand; [Kai, Yoshiaki] Kyoto Univ, Field Sci Educ & Res Ctr, Maizuru Fisheries Res Stn, Maizuru, Kyoto 6250086, Japan	Ingram, T (reprint author), Univ Otago, Dept Zool, Dunedin 9054, New Zealand.	travis.ingram@otago.ac.nz			National Science and Engineering Research Council of Canada	T.I. was funded by postgraduate and postdoctoral awards from the National Science and Engineering Research Council of Canada. We thank H. Imamura, T. Kawai, M. Love, K. Maslenikov, M. McCrea, K. Sakai, H. J. Walker, M. Yabe, and K. L. Yamanaka for arranging access to rockfish specimens and J. B. Losos, D. L. Mahler, and two reviewers for helpful comments that improved the manuscript.	Algar A. C., 2012, GLOBAL ECOL BIOGEOGR, V22, P391; Lanfear R, 2012, MOL BIOL EVOL, V29, P1695, DOI 10.1093/molbev/mss020; Kai Y, 2003, ICHTHYOL RES, V50, P239, DOI 10.1007/s10228-003-0163-9; Kane EA, 2012, ZOOLOGY, V115, P223, DOI 10.1016/j.zool.2012.03.002; Wiens JJ, 2011, PHILOS T R SOC B, V366, P2336, DOI 10.1098/rstb.2011.0059; Alfaro ME, 2009, P NATL ACAD SCI USA, V106, P13410, DOI 10.1073/pnas.0811087106; Drummond AJ, 2012, MOL BIOL EVOL, V29, P1969, DOI 10.1093/molbev/mss075; KOCHER TD, 1993, MOL PHYLOGENET EVOL, V2, P158, DOI 10.1006/mpev.1993.1016; Harmon LJ, 2008, BIOINFORMATICS, V24, P129, DOI 10.1093/bioinformatics/btm538; Ingram T, 2011, P ROY SOC B-BIOL SCI, V278, P613, DOI 10.1098/rspb.2010.1127; Gillespie R, 2004, SCIENCE, V303, P356, DOI 10.1126/science.1091875; Hendry CR, 2014, J EVOLUTION BIOL, V27, P760, DOI 10.1111/jeb.12349; Hyde JR, 2007, MOL PHYLOGENET EVOL, V44, P790, DOI 10.1016/j.ympev.2006.12.026; Harmon LJ, 2010, EVOLUTION, V64, P2385, DOI 10.1111/j.1558-5646.2010.01025.x; Chiba S, 2004, J EVOLUTION BIOL, V17, P131, DOI 10.1046/j.1420-9101.2004.00639.x; Losos JB, 1998, SCIENCE, V279, P2115, DOI 10.1126/science.279.5359.2115; Stephens PR, 2009, EVOLUTION, V63, P910, DOI 10.1111/j.1558-5646.2008.00597.x; Revell LJ, 2009, EVOLUTION, V63, P3258, DOI 10.1111/j.1558-5646.2009.00804.x; Hansen TF, 2012, ADAPTIVE LANDSCAPE IN EVOLUTIONARY BIOLOGY, P205; Near TJ, 2012, P NATL ACAD SCI USA, V109, P13698, DOI 10.1073/pnas.1206625109; Losos JB, 2010, AM NAT, V175, P623, DOI 10.1086/652433; Valentin A, 2002, J FISH BIOL, V60, P857, DOI 10.1006/jfbi.2002.1889; Scheffer M, 2006, P NATL ACAD SCI USA, V103, P6230, DOI 10.1073/pnas.0508024103; Frederich B, 2013, AM NAT, V181, P94, DOI 10.1086/668599; Orr JW, 2004, FISH B-NOAA, V102, P328; Rutschmann S, 2011, MOL ECOL, V20, P4707, DOI 10.1111/j.1365-294X.2011.05279.x; Bartoszek K, 2012, J THEOR BIOL, V314, P204, DOI 10.1016/j.jtbi.2012.08.005; Ingram T, 2013, METHODS ECOL EVOL, V4, P416, DOI 10.1111/2041-210X.12034; WRIGHT DI, 1983, T AM FISH SOC, V112, P638, DOI 10.1577/1548-8659(1983)112<638:ANEOZR>2.0.CO;2; Muto N, 2013, J EVOLUTION BIOL, V26, P1750, DOI 10.1111/jeb.12175; Butler MA, 2004, AM NAT, V164, P683, DOI 10.1086/426002; Hertz PE, 2013, EVOLUTION, V67, P2101, DOI 10.1111/evo.12072; CODY ML, 1978, ANNU REV ECOL SYST, V9, P265, DOI 10.1146/annurev.es.09.110178.001405; Ingram T, 2009, ECOLOGY, V90, P2444, DOI 10.1890/08-1841.1; WAINWRIGHT PC, 1995, ENVIRON BIOL FISH, V44, P97, DOI 10.1007/BF00005909; Orr JW, 2008, FISH B-NOAA, V106, P111; Mahler DL, 2010, EVOLUTION, V64, P2731, DOI 10.1111/j.1558-5646.2010.01026.x; Hyde JR, 2008, MOL ECOL, V17, P1122, DOI 10.1111/j.1365-294X.2007.03653.x; Thomas GH, 2012, METHODS ECOL EVOL, V3, P145, DOI 10.1111/j.2041-210X.2011.00132.x; Warrant EJ, 2004, BIOL REV, V79, P671, DOI 10.1017/S1464793103006420; [Anonymous], 2012, ARCH REV, V10, P3; Muschick M, 2012, CURR BIOL, V22, P2362, DOI 10.1016/j.cub.2012.10.048; Mahler DL, 2013, SCIENCE, V341, P292, DOI 10.1126/science.1232392; Stayton CT, 2008, J THEOR BIOL, V252, P1, DOI 10.1016/j.jtbi.2008.01.008; Hansen TF, 1997, EVOLUTION, V51, P1341, DOI 10.2307/2411186; Springer MS, 2004, TRENDS ECOL EVOL, V19, P430, DOI 10.1016/j.tree.2004.05.006; Huelsenbeck JP, 2003, SYST BIOL, V52, P131, DOI 10.1080/10635150390192780; Carroll AM, 2004, J EXP BIOL, V207, P3873, DOI 10.1242/jeb.01227; Muto N, 2011, FISH B-NOAA, V109, P429; Beaulieu JM, 2012, EVOLUTION, V66, P2369, DOI 10.1111/j.1558-5646.2012.01619.x; Barsukov V. V., 1981, J ICHTHYOL, V21, P1; Burnham K. P., 2002, MODEL SELECTION MULT; CHEN L-C, 1985, Journal of Taiwan Museum, V38, P23; LEA RN, 1972, COPEIA, P423; FROESE R., 2013, FISHBASE; Goatley CHR, 2009, CORAL REEFS, V28, P449, DOI 10.1007/s00338-009-0477-9; Ingram T., 2014, AM NATURALIST; Jordan D. S., 1920, FOSSIL FISHES DIATOM; Kai Y, 2008, ICHTHYOL RES, V55, P238, DOI 10.1007/s10228-007-0029-7; Kai Y., 2013, ZOOTAXA, V3637, P546; KENDALL Jr A, 2000, MAR FISH REV, V62, P1; Kozak K. H., 2009, EVOLUTION, V63, P1679; Love MS, 2002, ROCKFISHES NE PACIFI; Mahler D. L., 2014, MODERN PHYLOGENETIC, P425; Matsubara K., 1943, STUDIES SCORPAENOID, VI; Matsubara K., 1943, STUDIES SCORPAENOID, VII; Nakabo T., 2013, FISHES JAPAN PICTORI, P565; Neat FC, 2013, J FISH BIOL, V83, P1576, DOI 10.1111/jfb.12266; RICKLEFS RE, 1980, AUK, V97, P321; Schluter D., 2000, ECOLOGY ADAPTIVE RAD; SCHLUTER D, 1990, AM NAT, V136, P560, DOI 10.1086/285115; Simpson G.G, 1953, MAJOR FEATURES EVOLU; Venerus LA, 2013, NATURWISSENSCHAFTEN, V100, P645, DOI 10.1007/s00114-013-1061-2; Walker JA, 2002, J EXP BIOL, V205, P177	74	3	3	UNIV CHICAGO PRESS	CHICAGO	1427 E 60TH ST, CHICAGO, IL 60637-2954 USA	0003-0147	1537-5323		AM NAT	Am. Nat.	NOV	2014	184	5					E115	E131		10.1086/678053		17	Ecology; Evolutionary Biology	Environmental Sciences & Ecology; Evolutionary Biology	AS2LB	WOS:000344110400002		
J	Otake, T; Yarita, T; Aoyagi, Y; Numata, M; Takatsu, A				Otake, Takamitsu; Yarita, Takashi; Aoyagi, Yoshie; Numata, Masahiko; Takatsu, Akiko			Evaluation of the performance of 57 Japanese participating laboratories by two types of z-scores in proficiency test for the quantification of pesticide residues in brown rice	ANALYTICAL AND BIOANALYTICAL CHEMISTRY			English	Article						Proficiency test; Quality assurance/quality control; Pesticide residues; Brown rice	SUPERCRITICAL-FLUID EXTRACTION; MASS-SPECTROMETRIC DETECTION; MULTIRESIDUE METHOD; GAS-CHROMATOGRAPHY; ORGANOPHOSPHORUS; HOMOGENEITY; STABILITY	A proficiency test for the analysis of pesticide residues in brown rice was carried out to support upgrading in analytical skills of participant laboratories. Brown rice containing three target pesticides (etofenprox, fenitrothion, and isoprothiolane) was used as the test samples. The test samples were distributed to the 57 participants and analyzed by appropriate analytical methods chosen by each participant. It was shown that there was no significant difference among the reported values obtained by different types of analytical method. The analytical results obtained by National Metrology Institute of Japan (NMIJ) were 3 % to 10 % greater than those obtained by participants. The results reported by the participant were evaluated by using two types of z-scores, that is, one was the score based on the consensus values calculated from the analytical results of participants, and the other one was the score based on the reference values obtained by NMIJ with high reliability. Acceptable z-scores based on the consensus values and NMIJ reference values were achieved by 87 % to 89 % and 79 % to 94 % of the participants, respectively.	[Otake, Takamitsu; Yarita, Takashi; Aoyagi, Yoshie; Numata, Masahiko; Takatsu, Akiko] Natl Inst Adv Ind Sci & Technol, NMIJ, Tsukuba, Ibaraki 3058563, Japan	Otake, T (reprint author), Natl Inst Adv Ind Sci & Technol, NMIJ, 1-1-1 Umezono, Tsukuba, Ibaraki 3058563, Japan.	t-ootake@aist.go.jp					De Bievre P, 1997, FRESEN J ANAL CHEM, V359, P523, DOI 10.1007/s002160050625; [Anonymous], 2010, 17043 ISOIEC; Paya P, 2007, ANAL BIOANAL CHEM, V389, P1697, DOI 10.1007/s00216-007-1610-7; Thompson M, 2006, PURE APPL CHEM, V78, P145, DOI 10.1351/pac200678010145; Linsinger TPJ, 2001, ACCREDIT QUAL ASSUR, V6, P20, DOI 10.1007/s007690000261; Zhang LJ, 2012, CENT EUR J CHEM, V10, P900, DOI 10.2478/s11532-012-0034-1; Milton MJT, 2001, METROLOGIA, V38, P289, DOI 10.1088/0026-1394/38/4/1; Anastassiades M, 2003, J AOAC INT, V86, P412; Binici B, 2013, TALANTA, V116, P417, DOI 10.1016/j.talanta.2013.05.076; Lehotay SJ, 2005, J AOAC INT, V88, P615; Quinn TJ, 1997, METROLOGIA, V34, P61, DOI 10.1088/0026-1394/34/1/9; Thompson M, 2000, ANALYST, V125, P385, DOI 10.1039/b000282h; Araujo P, 2006, ANAL CHIM ACTA, V555, P348, DOI 10.1016/j.aca.2005.09.024; Codex Alimentarius Commission, 1997, 271997 CACGL; Hiramatsu S., 2013, REP PUB HLTH KOCHI, V59, P47; International Organization for Standardization, 2005, 17025 ISOIEC; International Organization for Standardization, 2006, GUID 35 REF MAT GEN; Judprasong K, 2013, FOOD CHEM, V140, P598, DOI 10.1016/j.foodchem.2012.11.127; Ministry of Agriculture Forestry and Fisheries Japan, 2013, SUMM EXP IMP AGR MAR; Ministry of Health Labor and Welfare Japan, 2006, AN METH RES COMP SUB; National Institute of Advanced Industrial Science and Technology National Metrology Institute of Japan, 2009, 7504A NMIJ CRM NAT I; National Statistics Center Japan, 2012, TABL FOOD SUPPL DEM; Norman KNT, 2001, J CHROMATOGR A, V907, P247, DOI 10.1016/S0021-9673(00)01081-5; Ono Y, 2006, ANAL SCI, V22, P1473, DOI 10.2116/analsci.22.1473; Otake T, 2009, J AGR FOOD CHEM, V57, P8208, DOI 10.1021/jf901758n; Otake T, 2008, J ENVIRON SCI HEAL B, V43, P390, DOI 10.1080/10934520701795608; Otake T, 2013, FOOD CHEM, V138, P1243, DOI 10.1016/j.foodchem.2012.11.125; Poole CF, 2007, J CHROMATOGR A, V1158, P241, DOI 10.1016/j.chroma.2007.01.018; Richter W, 1997, ACCREDIT QUAL ASSUR, V2, P354, DOI 10.1007/s007690050165; Saldanha H, 2012, FOOD CHEM, V132, P567, DOI 10.1016/j.foodchem.2011.10.071; Unites States Environmental Protection Agency, 2007, 6800 US EPA; Zhu YB, 2012, TRAC-TREND ANAL CHEM, V34, P152, DOI 10.1016/j.trac.2011.10.012	32	1	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1618-2642	1618-2650		ANAL BIOANAL CHEM	Anal. Bioanal. Chem.	NOV	2014	406	28					7337	7344		10.1007/s00216-014-8160-6		8	Biochemical Research Methods; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	AS5OQ	WOS:000344320300026		
J	He, Q; Takizawa, Y; Hayasaka, T; Masaki, N; Kusama, Y; Su, JP; Mineta, H; Setou, M				He, Qian; Takizawa, Yoshinori; Hayasaka, Takahiro; Masaki, Noritaka; Kusama, Yukiko; Su, Jiping; Mineta, Hiroyuki; Setou, Mitsutoshi			Increased phosphatidylcholine (16:0/16:0) in the folliculus lymphaticus of Warthin tumor (vol 406, pg 5815, 2014)	ANALYTICAL AND BIOANALYTICAL CHEMISTRY			English	Correction									[He, Qian; Su, Jiping] Guangxi Med Univ, Affiliated Hosp 1, Dept Otolaryngol Head & Neck Surg, Nanning 530021, Peoples R China; [He, Qian; Takizawa, Yoshinori; Mineta, Hiroyuki] Hamamatsu Univ Sch Med, Dept Otorhinolaryngol Head Neck Surg, Higashi Ku, Hamamatsu, Shizuoka 4313192, Japan; [He, Qian; Hayasaka, Takahiro; Masaki, Noritaka; Setou, Mitsutoshi] Hamamatsu Univ Sch Med, Dept Cell Biol & Anat, Higashi Ku, Hamamatsu, Shizuoka 4313192, Japan; [Kusama, Yukiko] Hamamatsu Univ Sch Med, Dept Diagnost Pathol, Higashi Ku, Hamamatsu, Shizuoka 4313192, Japan	Su, JP (reprint author), Guangxi Med Univ, Affiliated Hosp 1, Dept Otolaryngol Head & Neck Surg, 6 Shuangyong Rd, Nanning 530021, Peoples R China.	ymsu2@126.com; setou@hama-med.ac.jp					He Q, 2014, ANAL BIOANAL CHEM, V406, P5815, DOI 10.1007/s00216-014-7890-9	1	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1618-2642	1618-2650		ANAL BIOANAL CHEM	Anal. Bioanal. Chem.	NOV	2014	406	28					7409	7410		10.1007/s00216-014-8113-0		2	Biochemical Research Methods; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	AS5OQ	WOS:000344320300035		
J	Sasaki, N; Meyer, MJ; Malviya, SA; Stanislaus, AB; MacDonald, T; Doran, ME; Igumenshcheva, A; Hoang, AH; Eikermann, M				Sasaki, Nobuo; Meyer, Matthew J.; Malviya, Sanjana A.; Stanislaus, Anne B.; MacDonald, Teresa; Doran, Mary E.; Igumenshcheva, Arina; Hoang, Alan H.; Eikermann, Matthias			Effects of Neostigmine Reversal of Nondepolarizing Neuromuscular Blocking Agents on Postoperative Respiratory Outcomes A Prospective Study	ANESTHESIOLOGY			English	Article							NEGATIVE PHARYNGEAL PRESSURE; GENIOGLOSSUS MUSCLE-ACTIVITY; PARTIALLY PARALYZED HUMANS; POSTANESTHESIA CARE-UNIT; ACETYLCHOLINE-RECEPTOR; AIRWAY COLLAPSIBILITY; BLOCKADE; COMPLICATIONS; EDROPHONIUM; ATRACURIUM	Background: We tested the hypothesis that neostigmine reversal of neuromuscular blockade reduced the incidence of signs and symptoms of postoperative respiratory failure. Methods: We enrolled 3,000 patients in this prospective, observer-blinded, observational study. We documented the intraoperative use of neuromuscular blocking agents and neostigmine. At postanesthesia care unit admission, we measured train-of-four ratio and documented the ratio of peripheral oxygen saturation to fraction of inspired oxygen (S/F). The primary outcome was oxygenation at postanesthesia care unit admission (S/F). Secondary outcomes included the incidence of postoperative atelectasis and postoperative hospital length of stay. Post hoc, we defined high-dose neostigmine as more than 60 g/kg and unwarranted use of neostigmine as neostigmine administration in the absence of appropriate neuromuscular transmission monitoring. Results: Neostigmine reversal did not improve S/F at postanesthesia care unit admission (164 [95% CI, 162 to 164] vs. 164 [161 to 164]) and was associated with an increased incidence of atelectasis (8.8% vs. 4.5%; odds ratio, 1.67 [1.07 to 2.59]). High-dose neostigmine was associated with longer time to postanesthesia care unit discharge readiness (176 min [165 to 188] vs. 157 min [153 to 160]) and longer postoperative hospital length of stay (2.9 days [2.7 to 3.2] vs. 2.8 days [2.8 to 2.9]). Unwarranted use of neostigmine (n = 492) was an independent predictor of pulmonary edema (odds ratio, 1.91 [1.21 to 3.00]) and reintubation (odds ratio, 3.68 [1.10 to 12.4]). Conclusions: Neostigmine reversal did not affect oxygenation but was associated with increased atelectasis. High-dose neostigmine or unwarranted use of neostigmine may translate to increased postoperative respiratory morbidity.	[Sasaki, Nobuo] Showa Gen Hosp, Dept Emergency & Crit Care Med, Tokyo, Japan; [Meyer, Matthew J.; Eikermann, Matthias] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA USA; [Malviya, Sanjana A.; Stanislaus, Anne B.; Igumenshcheva, Arina; Hoang, Alan H.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02115 USA; [Igumenshcheva, Arina] Massachusetts Gen Hosp, MGH Anesthesia Res Grants, BWH Dept Prevent Med, Boston, MA 02115 USA; [MacDonald, Teresa; Doran, Mary E.] Massachusetts Gen Hosp, Boston, MA 02115 USA; [Eikermann, Matthias] Univ Klinikum Essen, Klin Anaesthesie & Intens Med, Essen, Germany	Meyer, MJ (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, 55 Fruit St, Boston, MA 02115 USA.	mjmeyer@mgh.harvard.edu			Schering-Plough Research Institute, Kenilworth, New Jersey, a Division of Schering Corporation [39442]	An investigator-initiated grant (IISP# 39442) was provided by Schering-Plough Research Institute, Kenilworth, New Jersey, a Division of Schering Corporation, to the Massachusetts General Hospital.	ALI HH, 1971, BRIT J ANAESTH, V43, P478, DOI 10.1093/bja/43.5.478; Khuri SF, 2005, ANN SURG, V242, P326, DOI 10.1097/01.sla.0000179621.33268.83; Butterly A, 2010, BRIT J ANAESTH, V105, P304, DOI 10.1093/bja/aeq157; Fuchs-Buder T, 2007, ACTA ANAESTH SCAND, V51, P789, DOI 10.1111/j.1399-6576.2007.01352.x; Brull SJ, 2010, ANESTH ANALG, V111, P129, DOI 10.1213/ANE.0b013e3181da8312; BEVAN DR, 1992, ANESTHESIOLOGY, V77, P785, DOI 10.1097/00000542-199210000-00025; CALDWELL JE, 1995, ANESTH ANALG, V80, P1168, DOI 10.1097/00000539-199506000-00018; Herbstreit F, 2010, ANESTHESIOLOGY, V113, P1280, DOI 10.1097/ALN.0b013e3181f70f3d; Eikermann M, 2007, ANESTHESIOLOGY, V107, P621; Jones RK, 2008, ANESTHESIOLOGY, V109, P816, DOI 10.1097/ALN.0b013e31818a3fee; Arbous MS, 2005, ANESTHESIOLOGY, V102, P257, DOI 10.1097/00000542-200502000-00005; Dimick JB, 2004, J AM COLL SURGEONS, V199, P531, DOI 10.1016/j.jamcollsurg.2004.05.276; Brueckmann B, 2013, ANESTHESIOLOGY, V118, P1276, DOI 10.1097/ALN.0b013e318293065c; Kopman AF, 2009, ANAESTHESIA, V64, P22, DOI 10.1111/j.1365-2044.2008.05867.x; Videira RLR, 2011, ANESTH ANALG, V113, P1192, DOI 10.1213/ANE.0b013e31822c986e; Sundman E, 2000, ANESTHESIOLOGY, V92, P977, DOI 10.1097/00000542-200004000-00014; Eriksson LI, 1997, ANESTHESIOLOGY, V87, P1035, DOI 10.1097/00000542-199711000-00005; Herbstreit F, 2009, ANESTHESIOLOGY, V110, P1253, DOI 10.1097/ALN.0b013e31819faa71; Kopman AF, 1997, ANESTHESIOLOGY, V86, P765, DOI 10.1097/00000542-199704000-00005; PAYNE JP, 1980, BRIT J ANAESTH, V52, P69, DOI 10.1093/bja/52.1.69; Kim KS, 2004, ANESTH ANALG, V99, P1080, DOI 10.1213/01.ane.0000130616.57678.80; Murphy GS, 2008, ANESTHESIOLOGY, V109, P389, DOI 10.1097/ALN.0b013e318182af3b; Murphy GS, 2008, ANESTH ANALG, V107, P130, DOI 10.1213/ane.0b013e31816d1268; Capron F, 2006, ANESTH ANALG, V102, P1578, DOI 10.1213/01.ane.0000204288.24395.38; Rice TW, 2007, CHEST, V132, P410, DOI 10.1378/chest.07-0617; Arndt GA, 1997, CAN J ANAESTH, V44, P321; BARROW MEH, 1966, BRIT J ANAESTH, V38, P420, DOI 10.1093/bja/38.6.420; BRULL SJ, 1990, ANESTHESIOLOGY, V72, P629, DOI 10.1097/00000542-199004000-00009; CATTERAL.M, 1967, LANCET, V1, P415; Coveler LA, 1997, CAN J ANAESTH, V44, P1127; DONATI F, 1989, ANESTH ANALG, V68, P13; ENGBOEK J, 1990, ANESTHESIOLOGY, V72, P803, DOI 10.1097/00000542-199005000-00005; FIEKERS JF, 1985, J PHARMACOL EXP THER, V234, P539; Grosse-Sundrup M, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e6329; Khuri SF, 2005, ANN SURG, V242, P341; Kopman AF, 2005, J CLIN ANESTH, V17, P30, DOI 10.1016/j.jclinane.2004.03.009; Krodel DJ, 2010, ANESTHESIOLOGY, V113, P200, DOI 10.1097/ALN.0b013e3181e32e68; Legendre P, 2000, J NEUROSCI, V20, P140; Meyer MJ, 2013, BMJ-BRIT MED J, V346, DOI 10.1136/bmj.f1460; Naguib M, 2005, PHARMACOLOGY MUSCLE, P481; YOST CS, 1994, ANESTH ANALG, V78, P520	41	8	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	NOV	2014	121	5					959	968		10.1097/ALN.0000000000000440		10	Anesthesiology	Anesthesiology	AS6JA	WOS:000344368700011		
J	Ishida, K; Kawamata, T; Tanaka, S; Shindo, T; Kawamata, M				Ishida, Kumiko; Kawamata, Tomoyuki; Tanaka, Satoshi; Shindo, Takayuki; Kawamata, Mikito			Calcitonin Gene-related Peptide Is Involved in Inflammatory Pain but Not in Postoperative Pain	ANESTHESIOLOGY			English	Article							SPINAL DORSAL-HORN; PRIMARY SENSORY NEURONS; ROOT GANGLION NEURONS; UNILATERAL INFLAMMATION; TACTILE ALLODYNIA; PLANTAR INCISION; RAT; RECEPTOR; MICE; IMMUNOREACTIVITY	Background: The aim of this study was to clarify the roles of calcitonin gene-related peptide (CGRP) in postoperative pain and inflammatory pain. Methods: CGRP knockout mice that the authors have developed and wild-type mice were used. Pain behaviors were assessed after incision and complete Freund's adjuvant (CFA) injection. Changes in CGRP and c-Fos expression in the dorsal horn were also examined. Results: Guarding pain scores in CGRP knockout mice were lower than those in wild-type mice at 24 h (3.8 1.6 vs. 6.8 +/- 1.5, P = 0.044) and 48 h (1.8 +/- 1.7 vs. 6.0 +/- 1.5, P = 0.001) after CFA injection (n = 8 to 9). Withdrawal latencies to heat stimulation in CGRP knockout mice were higher than those in wild-type mice at 24 to 72 h after CFA injection (4.9 +/- 1.0 vs. 3.4 +/- 0.8 at 24 h, P = 0.04; 5.1 +/- 0.3 vs. 3.2 +/- 0.9 at 48 h, P = 0.047; and 5.4 +/- 1.6 vs. 3.5 +/- 0.5 s at 72 h, P = 0.045) (n = 11 to 13), but withdrawal thresholds to mechanical stimulation were comparable. CGRP expression was increased at 24 h after CFA injection in wild-type mice, and the c-Fos-positive profile was increased at 4 h after CFA injection (ipsilateral vs. contralateral: 12.3 +/- 4.6 vs. 1.3 +/- 1.9, P < 0.0001) and maintained at 24 h (10.0 +/- 4.1 vs. 0.8 +/- 1.3, P < 0.0001) (n = 4 to 6). Conclusion: These results suggest that contribution of the CGRP system depends on the modality of pain and the stage of inflammation.	[Ishida, Kumiko; Kawamata, Tomoyuki; Tanaka, Satoshi; Kawamata, Mikito] Shinshu Univ, Sch Med, Dept Anesthesiol & Resuscitol, Matsumoto, Nagano 3908621, Japan; [Shindo, Takayuki] Shinshu Univ, Grad Sch Med, Dept Cardiovasc Med, Matsumoto, Nagano 3908621, Japan	Kawamata, M (reprint author), Shinshu Univ, Sch Med, Dept Anesthesiol & Resuscitol, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.	kawamata@shinshu-u.ac.jp			Japan Society for the Promotion of Science, Tokyo, Japan [21390432, 23791698]	Supported by grants-in-aid (grant no. 21390432 to Dr. Mikito Kawamata and grant no. 23791698 to Dr. Ishida) from the Japan Society for the Promotion of Science, Tokyo, Japan.	Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Fairbanks CA, 2003, ADV DRUG DELIVER REV, V55, P1007, DOI 10.1016/S0169-409X(03)00101-7; McCoy ES, 2013, NEURON, V78, P138, DOI 10.1016/j.neuron.2013.01.030; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Neumann S, 2008, J NEUROSCI, V28, P7936, DOI 10.1523/JNEUROSCI.1259-08.2008; Banik RK, 2006, ANESTHESIOLOGY, V105, P1246, DOI 10.1097/00000542-200612000-00025; Milligan ED, 2009, NAT REV NEUROSCI, V10, P23, DOI 10.1038/nrn2533; Cavanaugh DJ, 2009, P NATL ACAD SCI USA, V106, P9075, DOI 10.1073/pnas.0901507106; Oh-hashi Y, 2001, CIRC RES, V89, P983, DOI 10.1161/hh2301.100812; Zhang LP, 2001, PAIN, V89, P265, DOI 10.1016/S0304-3959(00)00378-X; Xu P, 2005, J NEUROSCI, V25, P9227, DOI 10.1523/JNEUROSCI.3051-05.2005; Xu J, 2009, PAIN, V144, P329, DOI 10.1016/j.pain.2009.05.019; Lawson SN, 2002, J PHYSIOL-LONDON, V540, P989, DOI 10.1113/jphysiol.2001.013086; Marvizon JCG, 1997, J NEUROSCI, V17, P8129; Zhu CZ, 2006, EUR J PHARMACOL, V531, P108, DOI 10.1016/j.ejphar.2005.12.019; Toda M, 2008, BIOMED PHARMACOTHER, V62, P352, DOI 10.1016/j.biopha.2008.02.003; Brennan TJ, 2011, PAIN, V152, pS33, DOI 10.1016/j.pain.2010.11.005; REN K, 1992, PAIN, V50, P331, DOI 10.1016/0304-3959(92)90039-E; Xu J, 2010, ANESTHESIOLOGY, V112, P153, DOI 10.1097/ALN.0b013e3181c2952e; MCCARTHY PW, 1990, NEUROSCIENCE, V34, P623, DOI 10.1016/0306-4522(90)90169-5; Niiyama Y, 2007, NEUROSCIENCE, V148, P560, DOI 10.1016/j.neuroscience.2007.05.049; Bennett AD, 2000, PAIN, V86, P163, DOI 10.1016/S0304-3959(00)00242-6; Bird GC, 2006, MOL PAIN, V2, DOI 10.1186/1744-8069-2-31; Boettger MK, 2007, EUR J PAIN, V11, P810, DOI 10.1016/j.ejpain.2006.12.008; KANGRGA I, 1990, J NEUROSCI, V10, P2026; KAWAMURA M, 1989, BRAIN RES, V497, P199, DOI 10.1016/0006-8993(89)90990-6; Lawson JJ, 2008, J PAIN, V9, P298, DOI 10.1016/j.jpain.2007.12.001; Leonard PA, 2004, ANESTH ANALG, V99, P1166, DOI 10.1213/01.ANE.0000130348.85587.BE; Marvizon JCG, 2007, NEUROSCIENCE, V148, P250, DOI 10.1016/j.neuroscience.2007.05.036; Okun A, 2011, MOL PAIN, V7, DOI 10.1186/1744-8069-7-4; Pogatzki EM, 2000, ANESTHESIOLOGY, V93, P489, DOI 10.1097/00000542-200008000-00029; Samsam M, 2000, PAIN, V84, P389, DOI 10.1016/S0304-3959(99)00240-7; Schadrack J, 1998, J NEUROSCI RES, V53, P203, DOI 10.1002/(SICI)1097-4547(19980715)53:2<203::AID-JNR9>3.3.CO;2-T; TUCHSCHERER MM, 1989, J NEUROSCI, V9, P195; Yu LC, 2009, NEUROSCI BIOBEHAV R, V33, P1185, DOI 10.1016/j.neubiorev.2009.03.009; YU LC, 1994, BRAIN RES, V653, P223, DOI 10.1016/0006-8993(94)90393-X; Yu LC, 1996, BRIT J PHARMACOL, V117, P43	37	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0003-3022	1528-1175		ANESTHESIOLOGY	Anesthesiology	NOV	2014	121	5					1068	1079		10.1097/ALN.0000000000000364		12	Anesthesiology	Anesthesiology	AS6JA	WOS:000344368700023		
J	Kusuoka, S; Marinelli, C				Kusuoka, Seiichiro; Marinelli, Carlo			On smoothing properties of transition semigroups associated to a class of SDEs with jumps	ANNALES DE L INSTITUT HENRI POINCARE-PROBABILITES ET STATISTIQUES			English	Article						Levy processes; Subordination; Transition semigroups; Non-local operators; Malliavin calculus	MALLIAVIN CALCULUS; EQUATIONS; OPERATORS	We prove smoothing properties of nonlocal transition semigroups associated to a class of stochastic differential equations (SDE) in R-d driven by additive pure-jump Levy noise. In particular, we assume that the Levy process driving the SDE is the sum of a subordinated Wiener process Y (i.e. Y = W o T, where T is an increasing pure-jump Levy process starting at zero and independent of the Wiener process W) and of an arbitrary Levy process independent of Y, that the drift coefficient is continuous (but not necessarily Lipschitz continuous) and grows not faster than a polynomial, and that the SDE admits a Feller weak solution. By a combination of probabilistic and analytic methods, we provide sufficient conditions for the Markovian semigroup associated to the SDE to be strong Feller and to map L-p(R-d) to continuous bounded functions. A key intermediate step is the study of regularizing properties of the transition semigroup associated to Y in terms of negative moments of the subordinator T.	[Kusuoka, Seiichiro] Tohoku Univ, Grad Sch Sci, Aoba Ku, Sendai, Miyagi 9808578, Japan; [Marinelli, Carlo] UCL, Dept Math, London WC1E 6BT, England	Kusuoka, S (reprint author), Tohoku Univ, Grad Sch Sci, Aoba Ku, 6-3 Aramaki Aza Aoba, Sendai, Miyagi 9808578, Japan.	kusuoka@math.tohoku.ac.jp; c.marinelli@ucl.ac.uk			Japan Society for the Promotion of Science	Part of the work for this paper was carried out when both authors where visiting the Institute for Applied Mathematics of the University of Bonn. We are particularly grateful to our hosts Sergio Albeverio and Andreas Eberle. The first-named author also gratefully acknowledges the support of the Japan Society for the Promotion of Science through the Excellent Young Researcher Overseas Visit Program.	Schilling RL, 2012, INFIN DIMENS ANAL QU, V15, DOI 10.1142/S0219025712500105; Marinelli C, 2010, J FUNCT ANAL, V258, P616, DOI 10.1016/j.jfa.2009.04.015; Marinelli C, 2010, ELECTRON J PROBAB, V15, P1528; Gordina M, 2011, POTENTIAL ANAL, V34, P293, DOI 10.1007/s11118-010-9198-5; Bally V, 2011, PROBAB THEORY REL, V151, P613, DOI 10.1007/s00440-010-0310-y; Bertoin J., 1996, LEVY PROCESSES; BISMUT JM, 1983, Z WAHRSCHEINLICHKEIT, V63, P147, DOI 10.1007/BF00538963; Bogachev V. I., 1998, GAUSSIAN MEASURES MA, V62; Bogdan K., 1980, POTENTIAL ANAL STABL, DOI Springer; Brainerd B., 1966, J AUSTR MATH SOC, V6, P289; Caffarelli L, 2011, J AM MATH SOC, V24, P849; Gyongy I., 1980, Stochastics, V4, DOI 10.1080/03610918008833154; Hartman P, 1942, AM J MATH, V64, P273, DOI 10.2307/2371683; HAWKES J, 1979, P LOND MATH SOC, V38, P335; Ishikawa Y, 2006, STOCH PROC APPL, V116, P1743, DOI 10.1016/j.spa.2006.04.013; Jacod J., 1980, Stochastics, V4, DOI 10.1080/17442508008833155; Knopova V., FORUM MATH, V25, P125; Kunita H, 2009, ASTERISQUE, P69; Kusuoka S, 2010, KYOTO J MATH, V50, P491, DOI 10.1215/0023608X-2010-003; Kusuoka S., 1985, J FS U TOKYO SC IA, V32, P1; Leandre R., 1988, LECT NOTES MATH, V1321, P414; LEPELTIER JP, 1976, ANN I H POINCARE B, V12, P43; Metivier M., 1982, SEMIMARTINGALES; Mikulevicius R., 1992, LIET MAT RINK, V32, P299; Pazy A., 1983, SEMIGROUPS LINEAR OP; Priola E, 2011, PROBAB THEORY REL, V149, P97, DOI 10.1007/s00440-009-0243-5; Priola E, 2004, J FUNCT ANAL, V216, P455, DOI 10.1016/j.jfa.2004.04.001; Samorodnitsky G., 1994, STABLE NONGAUSSIAN R; Triebel H., 1983, THEORY FUNCTION SPAC	29	0	0	INST MATHEMATICAL STATISTICS	CLEVELAND	3163 SOMERSET DR, CLEVELAND, OH 44122 USA	0246-0203			ANN I H POINCARE-PR	Ann. Inst. Henri Poincare-Probab. Stat.	NOV	2014	50	4					1347	1370		10.1214/13-AIHP559		24	Statistics & Probability	Mathematics	AS7NC	WOS:000344441600011		
J	Shrestha, R; Hui, SP; Sakurai, T; Yagi, A; Takahashi, Y; Takeda, S; Jin, S; Fuda, H; Chiba, H				Shrestha, Rojeet; Hui, Shu-Ping; Sakurai, Toshihiro; Yagi, Akiko; Takahashi, Yuji; Takeda, Seiji; Jin, Shigeki; Fuda, Hirotoshi; Chiba, Hitoshi			Identification of molecular species of cholesteryl ester hydroperoxides in very low-density and intermediate-density lipoproteins	ANNALS OF CLINICAL BIOCHEMISTRY			English	Article						Lipids; mass spectrometry; VLDL; IDL; fatty acid	PERFORMANCE LIQUID-CHROMATOGRAPHY; ORBITRAP MASS-SPECTROMETER; CORONARY-ARTERY-DISEASE; LIPID HYDROPEROXIDES; OXIDIZED LIPIDS; HUMAN PLASMA; PHOSPHOLIPID HYDROPEROXIDES; POSTCOLUMN DETECTION; OXIDATION; LDL	Background Oxidation of lipoproteins is thought to play a crucial role in atherogenesis. Role for triglyceride-rich lipoproteins in atherogenesis is unclear. Thus, we aimed to investigate whether cholesteryl ester hydroperoxides (CEOOH) are present in very low-density lipoproteins (VLDL) and intermediate-density lipoproteins (IDL) by using highly sensitive liquid chromatography/mass spectrometry. Methods Total lipids were extracted from the plasma of healthy donors (n=6) and their fractions of VLDL and IDL. Additional three plasma samples were analysed freshly for CEOOH. Detection and identification of CEOOH was conducted by liquid chromatography/LTQ ion trap mass spectrometry/Orbitrap high mass accuracy mass spectrometry. Authentic standards of CEOOH were used for unequivocal identification on the basis of their mass spectra. Results We identified six molecular CEOOH species overall, namely, Ch18:1-OOH, Ch18:2-OOH, Ch18:3-OOH, Ch20:4-OOH, Ch20:5-OOH and Ch22:6-OOH. Of them, Ch18:2-OOH, Ch20:5-OOH, Ch20:4-OOH and Ch22:6-OOH were detected in all IDL samples, while only Ch20:4-OOH was detected in all VLDL samples. All of CEOOH species except for Ch18:3-OOH were detected in plasma, with constant detection of Ch20:5-OOH, and Ch22:6-OOH in all plasma samples. Conclusion The presence of CEOOH species in VLDL and IDL was confirmed with the analytical sensitivity of 0.1pmol, showing the constant appearance of more CEOOH species in IDL than VLDL. This finding might add biochemical evidences of atherogenicity of these lipoproteins. Clinical utility of measuring CEOOH level in these lipoproteins need to be investigated for the risk assessment of the cardiovascular disease.	[Shrestha, Rojeet; Hui, Shu-Ping; Sakurai, Toshihiro; Yagi, Akiko; Takahashi, Yuji; Takeda, Seiji; Jin, Shigeki; Fuda, Hirotoshi; Chiba, Hitoshi] Hokkaido Univ, Fac Hlth Sci, Sapporo, Hokkaido 0600812, Japan	Hui, SP (reprint author), Hokkaido Univ, Fac Hlth Sci, Kita 12,Nishi 5, Sapporo, Hokkaido 0600812, Japan.	keino@hs.hokudai.ac.jp			The Ministry of Education, Culture, Sports, Sciences and Technology, Japan; Japan Society for Promotion of Sciences, Japan	This work was supported by Regional Innovation Strategy Support Program, Sapporo Health Innovation 'Smart-H', of The Ministry of Education, Culture, Sports, Sciences and Technology, Japan and partly by a Grant-in-Aid for scientific research from the Japan Society for Promotion of Sciences, Japan.	AKASAKA K, 1993, J CHROMATOGR-BIOMED, V622, P153, DOI 10.1016/0378-4347(93)80261-2; Sarwar N, 2007, CIRCULATION, V115, P450, DOI 10.1161/CIRCULATIONAHA.106.637793; Staprans I, 1996, J LIPID RES, V37, P420; YAMAMOTO Y, 1994, METHOD ENZYMOL, V233, P319; Hui SP, 2000, ANAL SCI, V16, P1023, DOI 10.2116/analsci.16.1023; Hui SP, 2012, ANAL BIOANAL CHEM, V403, P1831, DOI 10.1007/s00216-012-5833-x; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; Hui SP, 2012, ANAL BIOANAL CHEM, V404, P101, DOI 10.1007/s00216-012-6118-0; Staprans I, 1996, ARTERIOSCL THROM VAS, V16, P533; Hui SP, 2013, ANAL BIOANAL CHEM, V405, P4981, DOI 10.1007/s00216-013-6903-4; WALZEM RL, 1995, P NATL ACAD SCI USA, V92, P7460, DOI 10.1073/pnas.92.16.7460; Mack WJ, 1996, ARTERIOSCL THROM VAS, V16, P697; NOUROOZZADEH J, 1994, ANAL BIOCHEM, V220, P403, DOI 10.1006/abio.1994.1357; NAKAJIMA K, 1993, CLIN CHIM ACTA, V223, P53, DOI 10.1016/0009-8981(93)90062-9; AKASAKA K, 1993, J CHROMATOGR-BIOMED, V617, P205, DOI 10.1016/0378-4347(93)80489-Q; Arai H, 1996, FREE RADICAL BIO MED, V20, P365, DOI 10.1016/0891-5849(96)02062-X; Austin MA, 1998, AM J CARDIOL, V81, P7; CARPENTER KLH, 1993, BIOCHIM BIOPHYS ACTA, V1167, P121, DOI 10.1016/0005-2760(93)90151-X; Caslake MJ, 2000, HDB LIPOPROTEIN TEST, P625; Chiba H, 1997, J LIPID RES, V38, P1204; CRAMER GL, 1991, ANAL BIOCHEM, V193, P204, DOI 10.1016/0003-2697(91)90010-Q; Dio H, 2000, CIRCULATION, V102, P670; FREI B, 1988, ANAL BIOCHEM, V175, P120, DOI 10.1016/0003-2697(88)90369-7; HAMMER A, 1995, ARTERIOSCL THROM VAS, V15, P704; Harkewicz R, 2008, J BIOL CHEM, V283, P10241, DOI 10.1074/jbc.M709006200; Havel RJ, 2000, HDB LIPOPROTEIN TEST, P565; Herijgers N, 2000, J LIPID RES, V41, P1163; Hodis HN, 1997, CIRCULATION, V95, P2022; KORYTOWSKI W, 1993, ANAL BIOCHEM, V213, P111, DOI 10.1006/abio.1993.1393; KRAUSS RM, 1987, LANCET, V2, P62; Leitinger Norbert, 2003, Molecular Aspects of Medicine, V24, P239, DOI 10.1016/S0098-2997(03)00019-0; Nakajima K, 2008, ATHEROSCLEROSIS, V198, P237, DOI 10.1016/j.atherosclerosis.2007.09.016; Nakamura T, 2011, ATHEROSCLEROSIS, V218, P163, DOI 10.1016/j.atherosclerosis.2011.04.040; Takahashi Y, 1996, BIOCHEM BIOPH RES CO, V222, P453, DOI 10.1006/bbrc.1996.0765; Upston JM, 2002, AM J PATHOL, V160, P701, DOI 10.1016/S0002-9440(10)64890-0; Whitman SC, 1997, ARTERIOSCL THROM VAS, V17, P1707; YAMAMOTO Y, 1987, ANAL BIOCHEM, V160, P7, DOI 10.1016/0003-2697(87)90606-3; Yasuda M, 1997, J CHROMATOGR B, V693, P211, DOI 10.1016/S0378-4347(97)00034-0	38	1	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0004-5632	1758-1001		ANN CLIN BIOCHEM	Ann. Clin. Biochem.	NOV	2014	51	6					662	671		10.1177/0004563213516093		10	Medical Laboratory Technology	Medical Laboratory Technology	AS4MZ	WOS:000344251700004		
J	Koda, T; Morioka, I; Yokota, T; Kurokawa, D; Fujita, K; Nagasaka, M; Matsuo, K; Shibata, A; Sato, I; Kawano, S; Yamada, H; Nakamura, H; Iijima, K				Koda, Tsubasa; Morioka, Ichiro; Yokota, Tomoyuki; Kurokawa, Daisuke; Fujita, Kaori; Nagasaka, Miwako; Matsuo, Kiyomi; Shibata, Akio; Sato, Itsuko; Kawano, Seiji; Yamada, Hideto; Nakamura, Hajime; Iijima, Kazumoto			Postnatal serum concentrations of endogenous free fatty acids in newborns admitted to the neonatal intensive care unit: effects on unbound bilirubin	ANNALS OF CLINICAL BIOCHEMISTRY			English	Article						Clinical studies; bilirubin; analytes; lipids; analytes	BRAIN-STEM RESPONSES; PREMATURE-INFANTS; PEROXIDASE CONCENTRATION; ENZYMATIC METHOD; ALBUMIN; BINDING; GLUCOSE; HYPERBILIRUBINEMIA; PRETERM; SURGERY	Background Few studies have reported the characterization of postnatal serum concentrations of endogenous free fatty acids (FFAs) in high-risk newborns and their effects on unbound bilirubin (UB). Methods Serum concentrations of FFA, albumin (Alb), UB and total bilirubin (TB) were measured in 713 samples obtained within 5 days after birth from 439 newborns without intravenous lipid supplementation admitted to the neonatal intensive care unit (NICU). Serum FFA was reported as the day-specific percentile-based curve. Serum FFA and FFA/Alb ratios were compared in term and preterm patients. To assess the impact of FFA on UB, daily changes in FFA/Alb and UB/TB ratios were compared in term patients without receiving phototherapy or any drugs, and linear regression analysis was performed between FFA/Alb ratio and serum UB concentration or UB/TB ratio using 140 sera with hyperbilirubinemia of term and preterm patients. Results A percentile-based curve showed that serum FFA peaked at 1 day of age and progressively decreased. Serum FFA and the FFA/Alb ratio were significantly higher in term than in preterm patients at birth and 1 and 3 days of age. FFA/Alb ratio significantly changed over 5 days after birth, but UB/TB ratio remained constant. FFA/Alb ratio did not correlate with serum UB concentration or UB/TB ratio in sera with hyperbilirubinemia. Conclusions We assessed postnatal concentrations of serum FFA in a large number of high-risk newborns admitted to the NICU. The concentration of endogenous FFAs in newborns admitted to the NICU was not rising until it influenced UB.	[Koda, Tsubasa; Morioka, Ichiro; Yokota, Tomoyuki; Kurokawa, Daisuke; Fujita, Kaori; Nagasaka, Miwako; Matsuo, Kiyomi; Shibata, Akio; Nakamura, Hajime; Iijima, Kazumoto] Kobe Univ Hosp, Dept Pediat, Kobe, Hyogo 6500017, Japan; [Sato, Itsuko; Kawano, Seiji] Kobe Univ Hosp, Dept Clin Lab, Kobe, Hyogo 6500017, Japan; [Yamada, Hideto] Kobe Univ Hosp, Dept Obstet & Gynecol, Kobe, Hyogo 6500017, Japan	Morioka, I (reprint author), Kobe Univ Hosp, Dept Pediat, Chuo Ku, 7-5-2 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	ichim@med.kobe-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology in Japan	This work was supported by grants for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology in Japan (IM).	Ahlfors CE, 2007, CLIN BIOCHEM, V40, P261, DOI 10.1016/j.clinbiochem.2006.09.006; Amin SB, 2009, PEDIATRICS, V124, P211, DOI 10.1542/peds.2008-0846; Amin SB, 2010, JPEN-PARENTER ENTER, V34, P414, DOI 10.1177/0148607110362529; ANAGNOST.DE, 1971, PEDIATRICS, V47, P1000; Amin SB, 2004, SEMIN PERINATOL, V28, P340, DOI 10.1053/j.semperi.2004.09.005; FUNATO M, 1994, PEDIATRICS, V93, P50; Muramoto Y, 1999, CLIN CHIM ACTA, V289, P69, DOI 10.1016/S0009-8981(99)00158-8; Ahlfors CE, 2008, PEDIATRICS, V121, P976, DOI 10.1542/peds.2007-2297; BRANS YW, 1987, ARCH DIS CHILD, V62, P156; Brodersen R, 1978, INTENSIVE CARE NEWBO, P331; Calligaris SD, 2007, PEDIATR RES, V62, P576; ELPHICK MC, 1981, PEDIATR RES, V15, P313, DOI 10.1203/00006450-198104000-00005; HAMOSH M, 1987, BIOL NEONATE, V52, P50; Itabashi K, 2010, ACTA PEDIAT JPN, V114, P1271; Jakob SM, 2001, CURR OPIN CLIN NUTR, V4, P149, DOI 10.1097/00075197-200103000-00012; Kmiec Z, 2005, GERONTOLOGY, V51, P357, DOI 10.1159/000088698; Madan A, 2005, AVERYS DIS NEWBORN, P1226; Miwa A, 2011, NEONATOLOGY, V99, P202, DOI 10.1159/000314893; Miwa A, 2012, CLIN LAB, V58, P507; NAKAMURA H, 1977, CLIN CHIM ACTA, V79, P411; NAKAMURA H, 1985, PEDIATRICS, V75, P703; Nakamura Hajime, 1992, Acta Paediatrica Japonica, V34, P642; Ng PC, 2005, CLIN ENDOCRINOL, V63, P217, DOI 10.1111/j.1365-2265.2005.02328.x; ODELL GB, 1977, J LAB CLIN MED, V89, P295; OSTREA EM, 1983, J PEDIATR-US, V102, P426, DOI 10.1016/S0022-3476(83)80670-2; SHIMABUKU R, 1982, Kobe Journal of Medical Sciences, V28, P91; SPEAR ML, 1985, JPEN-PARENTER ENTER, V9, P144, DOI 10.1177/0148607185009002144; STARINSK.R, 1970, CLIN CHIM ACTA, V29, P311, DOI 10.1016/0009-8981(70)90052-5; SUGO S, 1990, CLIN CHEM, V36, P163; WHITINGTON PF, 1982, J PEDIATR GASTR NUTR, V1, P495, DOI 10.1097/00005176-198212000-00009; Yokota T, 2013, PEDIATR INT, V55, P54, DOI 10.1111/j.1442-200X.2012.03726.x; Yuvienco JMS, 2005, AM J PERINAT, V22, P429, DOI 10.1055/s-2005-916333; Zoban P, 1989, Czech Med, V12, P78	33	1	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0004-5632	1758-1001		ANN CLIN BIOCHEM	Ann. Clin. Biochem.	NOV	2014	51	6					680	687		10.1177/0004563214522771		8	Medical Laboratory Technology	Medical Laboratory Technology	AS4MZ	WOS:000344251700006		
J	Chiou, CS; Lauderdale, TL; Phung, DC; Watanabe, H; Kuo, JC; Wang, PJ; Liu, YY; Liang, SY; Chen, PC				Chiou, Chien-Shun; Lauderdale, Tsai-Ling; Dac Cam Phung; Watanabe, Haruo; Kuo, Jung-Che; Wang, Pei-Jen; Liu, Yen-Yi; Liang, Shiu-Yun; Chen, Pei-Chen			Antimicrobial Resistance in Salmonella enterica Serovar Typhi Isolates from Bangladesh, Indonesia, Taiwan, and Vietnam	ANTIMICROBIAL AGENTS AND CHEMOTHERAPY			English	Article							QUINOLONE RESISTANCE; SEROTYPE TYPHI; UNITED-STATES; EMERGENCE; FEVER; PLASMIDS; STRAINS; ASIA; HAPLOTYPES; MECHANISM	We characterized Salmonella enterica serovar Typhi isolates from Bangladesh, Indonesia, Taiwan, and Vietnam to investigate their genetic relatedness and antimicrobial resistance. The isolates from Bangladesh and Vietnam were genetically closely related but were distant from those from Indonesia and Taiwan. All but a few isolates from Indonesia and Taiwan were susceptible to all antimicrobials tested. The majority of isolates from Bangladesh and Vietnam were multidrug resistant (MDR) and belonged to the widespread haplotype H58 clone. IncHI1 plasmids were detected in all MDR S. Typhi isolates from Vietnam but in only 15% of MDR isolates from Bangladesh. Resistance genes in the majority of MDR S. Typhi isolates from Bangladesh should reside in the chromosome. Among the isolates from Bangladesh, 82% and 40% were resistant to various concentrations of nalidixic acid and ciprofloxacin, respectively. Several resistance mechanisms, including alterations in gyrase A, the presence of QnrS, and enhanced efflux pumps, were involved in the reduced susceptibility and resistance to fluoroquinolones. Intensive surveillance is necessary to monitor the spread of chromosome-mediated MDR and fluoroquinolone-resistant S. Typhi emerging in Bangladesh.	[Chiou, Chien-Shun; Kuo, Jung-Che; Wang, Pei-Jen; Liu, Yen-Yi; Liang, Shiu-Yun] Ctr Dis Control, Taichung, Taiwan; [Lauderdale, Tsai-Ling; Chen, Pei-Chen] Natl Hlth Res Inst, Zhunan, Taiwan; [Dac Cam Phung] Natl Inst Hyg & Epidemiol, Hanoi, Vietnam; [Watanabe, Haruo] Natl Inst Infect Dis, Tokyo, Japan	Chiou, CS (reprint author), Ctr Dis Control, Taichung, Taiwan.	nipmcsc@cdc.gov.tw	Lauderdale, Tsai-Ling/B-2660-2010		Centers for Disease Control, Department of Health, Taiwan [DOH98-DC-2021]; Ministry of Health and Welfare, Taiwan [MOHW103-CDC-C-315-000801]; National Health Research Institutes [IDPP03-014]; Ministry of Health, Labor and Welfare, Japan [H17 Shinkou Ippan 019]	This work was supported by a grant (DOH98-DC-2021) from the Centers for Disease Control, Department of Health, Taiwan, a grant (MOHW103-CDC-C-315-000801) from the Ministry of Health and Welfare, Taiwan, an intramural grant (IDPP03-014) from the National Health Research Institutes, and a grant (H17 Shinkou Ippan 019) from the Ministry of Health, Labor and Welfare, Japan.	Crump JA, 2004, B WORLD HEALTH ORGAN, V82, P346; Tran JH, 2002, P NATL ACAD SCI USA, V99, P5638, DOI 10.1073/pnas.082092899; Menezes GA, 2012, CLIN MICROBIOL INFEC, V18, P239, DOI 10.1111/j.1469-0691.2011.03546.x; Kariuki S, 2010, J CLIN MICROBIOL, V48, P2171, DOI 10.1128/JCM.01983-09; Tien YY, 2012, J MED MICROBIOL, V61, P223, DOI 10.1099/jmm.0.037291-0; Ribot EM, 2006, FOODBORNE PATHOG DIS, V3, P59, DOI 10.1089/fpd.2006.3.59; Baker S, 2008, J CLIN MICROBIOL, V46, P1741, DOI 10.1128/JCM.02249-07; Jacoby GA, 2005, CLIN INFECT DIS, V41, pS120, DOI 10.1086/428052; Connor BA, 2005, LANCET INFECT DIS, V5, P623, DOI 10.1016/S1473-3099(05)70239-5; Holt KE, 2008, NAT GENET, V40, P987, DOI 10.1038/ng.195; Saha SK, 2006, J CLIN MICROBIOL, V44, P3811, DOI 10.1128/JCM.01197-06; Eaves DJ, 2004, ANTIMICROB AGENTS CH, V48, P4012, DOI 10.1128/AAC.48.10.4012-4015.2004; Rowe B, 1997, CLIN INFECT DIS, V24, pS106; Tamang MD, 2007, INT J ANTIMICROB AG, V30, P330, DOI 10.1016/j.ijantimicag.2007.05.009; Lynch MF, 2009, JAMA-J AM MED ASSOC, V302, P859, DOI 10.1001/jama.2009.1229; KADO CI, 1981, J BACTERIOL, V145, P1365; Chau TT, 2007, ANTIMICROB AGENTS CH, V51, P4315, DOI 10.1128/AAC.00294-07; Roumagnac P, 2006, SCIENCE, V314, P1301, DOI 10.1126/science.1134933; Kanematsu E, 1998, ANTIMICROB AGENTS CH, V42, P433; Benacer D, 2010, J MICROBIOL BIOTECHN, V20, P1042, DOI 10.4014/jmb.0910.10028; Chiou CS, 2013, J CLIN MICROBIOL, V51, P669, DOI 10.1128/JCM.02726-12; Clinical and Laboratory Standards Institute (CLSI), 2013, M100S23 CLSI; Holt KE, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0001245; Holt KE, 2007, J BACTERIOL, V189, P4257, DOI 10.1128/JB.00232-07; Holt KE, 2011, PLOS NEGLECT TROP D, V5, DOI 10.1371/journal.pntd.0000929; Holt KE, 2010, BMC INFECT DIS, V10, DOI 10.1186/1471-2334-10-144; Kariuki S, 2004, J CLIN MICROBIOL, V42, P1477, DOI 10.1128/JCM.42.4.1477-1482.2004; Keddy KH, 2010, EMERG INFECT DIS, V16, P879, DOI 10.3201/eid1605.091917; Kim KY, 2011, INT J FOOD MICROBIOL, V146, P52, DOI 10.1016/j.ijfoodmicro.2011.01.037; Lamers RP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060666; Le TAH, 2007, J CLIN MICROBIOL, V45, P3485, DOI 10.1128/JCM.00948-07; Lee CJ, 2013, J MICROBIOL IMMUNOL, V46, P469, DOI 10.1016/j.jmii.2013.01.002; Medalla F, 2011, EMERG INFECT DIS, V17, P1095, DOI [10.3201/eid/1706.100594, 10.3201/eid1706.100594]; Mirza S, 2000, J CLIN MICROBIOL, V38, P1449; Nobthai P, 2010, SE ASIAN J TROP MED, V41, P1416; Smith AM, 2010, EPIDEMIOL INFECT, V138, P86, DOI 10.1017/S0950268809990331; Wain J, 2003, ANTIMICROB AGENTS CH, V47, P2732, DOI 10.1128/AAC.47.9.2732-2739.2003; Wu L-J, 2011, TAIWAN EPIDEMIOL B, V27, P67; Yanagi D, 2009, DIAGN MICR INFEC DIS, V64, P422, DOI 10.1016/j.diagmicrobio.2009.04.006	39	5	5	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0066-4804	1098-6596		ANTIMICROB AGENTS CH	Antimicrob. Agents Chemother.	NOV	2014	58	11					6501	6507		10.1128/AAC.03608-14		7	Microbiology; Pharmacology & Pharmacy	Microbiology; Pharmacology & Pharmacy	AS3EF	WOS:000344158600021		
J	Kemp, MW; Miura, Y; Payne, MS; Jobe, AH; Kallapur, SG; Saito, M; Stock, SJ; Spiller, OB; Ireland, DJ; Yaegashi, N; Clarke, M; Hahne, D; Rodger, J; Keelan, JA; Newnham, JP				Kemp, Matthew W.; Miura, Yuichiro; Payne, Matthew S.; Jobe, Alan H.; Kallapur, Suhas G.; Saito, Masatoshi; Stock, Sarah J.; Spiller, O. Brad; Ireland, Demelza J.; Yaegashi, Nobuo; Clarke, Michael; Hahne, Dorothee; Rodger, Jennifer; Keelan, Jeffrey A.; Newnham, John P.			Maternal Intravenous Administration of Azithromycin Results in Significant Fetal Uptake in a Sheep Model of Second Trimester Pregnancy	ANTIMICROBIAL AGENTS AND CHEMOTHERAPY			English	Article							BROAD-SPECTRUM ANTIBIOTICS; PRETERM BIRTH; P-GLYCOPROTEIN; TRANSPLACENTAL TRANSFER; RANDOMIZED TRIAL; HUMAN PLACENTA; PHARMACOKINETICS; INFECTION; ERYTHROMYCIN; EXPRESSION	Treatment of intrauterine infection is likely key to preventing a significant proportion of preterm deliveries before 32 weeks of gestation. Azithromycin (AZ) may be an effective antimicrobial in pregnancy; however, few gestation age-approriate data are available to inform the design of AZ-based treatment regimens in early pregnancy. We aimed to determine whether a single intra-amniotic AZ dose or repeated maternal intravenous (i.v.) AZ doses would safely yield therapeutic levels of AZ in an 80-day-gestation (term is 150 days) ovine fetus. Fifty sheep carrying single pregnancies at 80 days gestation were randomized to receive either: (i) a single intra-amniotic AZ administration or (ii) maternal intravenous AZ administration every 12 h. Amniotic fluid, maternal plasma, and fetal AZ concentrations were determined over a 5-day treatment regimen. Markers of liver injury and amniotic fluid inflammation were measured to assess fetal injury in response to drug exposure. A single intra-amniotic administration yielded significant AZ accumulation in the amniotic fluid and fetal lung. In contrast, repeated maternal intravenous administrations achieved high levels of AZ accumulation in the fetal lung and liver and a statistically significant increase in the fetal plasma drug concentration at 120 h. There was no evidence of fetal injury in response to drug exposure. These data suggest that (i) repeated maternal i. v. AZ dosing yields substantial fetal tissue uptake, although fetal plasma drug levels remain low; (ii) transfer of AZ from the amniotic fluid is less than transplacental transfer; and (iii) exposure to high concentrations of AZ did not elicit overt changes in fetal white blood cell counts, amniotic fluid monocyte chemoattractant protein 1 concentrations, or hepatotoxicity, all consistent with an absence of fetal injury.	[Kemp, Matthew W.; Miura, Yuichiro; Payne, Matthew S.; Jobe, Alan H.; Kallapur, Suhas G.; Saito, Masatoshi; Ireland, Demelza J.; Keelan, Jeffrey A.; Newnham, John P.] Univ Western Australia, Sch Womens & Infants Hlth, Perth, WA 6009, Australia; [Jobe, Alan H.; Kallapur, Suhas G.] Univ Cincinnati, Sch Med, Cincinnati Childrens Hosp Med Ctr, Div Pulm Biol, Cincinnati, OH USA; [Saito, Masatoshi; Yaegashi, Nobuo] Tohoku Univ Hosp, Div Perinatal Med, Sendai, Miyagi, Japan; [Stock, Sarah J.] Univ Edinburgh, MRC, Ctr Reprod Hlth, Edinburgh, Midlothian, Scotland; [Spiller, O. Brad] Cardiff Univ, Sch Med, Dept Child Hlth, Cardiff CF10 3AX, S Glam, Wales; [Clarke, Michael; Hahne, Dorothee] Univ Western Australia, Ctr Metabol, Perth, WA 6009, Australia; [Rodger, Jennifer] Univ Western Australia, Sch Anim Biol, Perth, WA 6009, Australia	Kemp, MW (reprint author), Univ Western Australia, Sch Womens & Infants Hlth, Perth, WA 6009, Australia.	matthew.kemp@uwa.edu.au	Keelan, Jeffrey/G-2170-2011	Ireland, Demelza/0000-0002-8763-3542; Keelan, Jeffrey/0000-0002-5403-6266	National Health and Medical Research Council [APP1049148]; international exchange Royal Society Grant [IE130066]; Microbiology and Infection Translational Research Group (MITReG); Children and Young People's Research Network (CYPRN) as part of the Welsh Government initiative; Women and Infants Research Foundation (Perth, Western Australia); National Collaborative Research Infrastructure Strategy (NCRIS); WA State Government ICP funding program	This work was supported by National Health and Medical Research Council project grant APP1049148 (M. W. K.). Bilateral travel between Australian and United Kingdom laboratories was funded by an international exchange Royal Society Grant (IE130066 to O.B.S. and M. W. K.). O.B.S. is supported by the Microbiology and Infection Translational Research Group (MITReG) and the Children and Young People's Research Network (CYPRN) as part of the Welsh Government initiative to support research. Y.M., J.A.K., and M. W. K. are supported by the Women and Infants Research Foundation (Perth, Western Australia). The UWA Centre for Metabolomics is funded by the National Collaborative Research Infrastructure Strategy (NCRIS) and the WA State Government ICP funding program.	Althabe F, 2012, BORN TOO SOON GLOBAL; Burd EM, 2010, CLIN MICROBIOL REV, V23, P550, DOI 10.1128/CMR.00074-09; Lahra MM, 2004, AM J OBSTET GYNECOL, V190, P147, DOI 10.1016/j.ajog.2003.07.012; Kim YS, 2006, AM J TROP MED HYG, V75, P955; Zhang Y, 2010, COMPUT METH PROG BIO, V99, P306, DOI 10.1016/j.cmpb.2010.01.007; Ray WA, 2012, NEW ENGL J MED, V366, P1881, DOI 10.1056/NEJMoa1003833; Iams JD, 2008, LANCET, V371, P164, DOI 10.1016/S0140-6736(08)60108-7; Sun M, 2006, PLACENTA, V27, P602, DOI 10.1016/j.placenta.2005.05.007; Mathias AA, 2005, AM J PHYSIOL-REG I, V289, pR963, DOI 10.1152/ajpregu.00173.2005; Waites KB, 2005, CLIN MICROBIOL REV, V18, P757, DOI 10.1128/CMR.18.4.757-789.2005; Amsden GW, 1996, CLIN THER, V18, P56, DOI 10.1016/S0149-2918(96)80179-2; Heikkinen T, 2000, BRIT J OBSTET GYNAEC, V107, P770, DOI 10.1111/j.1471-0528.2000.tb13339.x; Romero R, 2007, SEMIN REPROD MED, V25, P21, DOI 10.1055/s-2006-956773; Kenyon SL, 2001, LANCET, V357, P989, DOI 10.1016/S0140-6736(00)04234-3; Andrade SE, 2004, AM J OBSTET GYNECOL, V191, P398, DOI 10.1016/j.ajog.2004.04.025; Viscardi RM, 2010, CLIN PERINATOL, V37, P393, DOI 10.1016/j.clp.2009.12.003; Salman S, 2010, ANTIMICROB AGENTS CH, V54, P360, DOI 10.1128/AAC.00771-09; Kenyon SL, 2001, LANCET, V357, P979, DOI 10.1016/S0140-6736(00)04233-1; Goldenberg RL, 2008, LANCET, V371, P75, DOI 10.1016/S0140-6736(08)60074-4; Schwabedissen HEMZ, 2005, DRUG METAB DISPOS, V33, P896, DOI 10.1124/dmd.104.003335; DiGiulio DB, 2010, AM J REPROD IMMUNOL, V64, P38, DOI 10.1111/j.1600-0897.2010.00830.x; Novy MJ, 2009, REPROD SCI, V16, P56, DOI 10.1177/1933719108325508; Ramsey PS, 2003, AM J OBSTET GYNECOL, V188, P714, DOI 10.1067/mob.2003.141; LUDDEN TM, 1994, J PHARMACOKINET BIOP, V22, P431, DOI 10.1007/BF02353864; Mouton JW, 2008, J ANTIMICROB CHEMOTH, V61, P235, DOI 10.1093/jac/dkm476; Vahakangas K, 2009, BRIT J PHARMACOL, V158, P665, DOI 10.1111/j.1476-5381.2009.00336.x; Goldenberg RL, 2006, AM J OBSTET GYNECOL, V195, P1533, DOI 10.1016/j.ajog.2006.05.023; Romoren M, 2012, BRIT J CLIN PHARMACO, V74, P1053, DOI 10.1111/j.1365-2125.2012.04286.x; Acosta EP, 2014, J INFECT DIS, V209, P898, DOI 10.1093/infdis/jit578; Carter AM, 2007, PLACENTA, V28, pS41, DOI 10.1016/j.placenta.2006.11.002; Tita ATN, 2010, CLIN PERINATOL, V37, P339, DOI 10.1016/j.clp.2010.02.003; Svanstrom H, 2013, NEW ENGL J MED, V368, P1704, DOI 10.1056/NEJMoa1300799; LEWIT EM, 1995, FUTURE CHILD, V5, P35, DOI 10.2307/1602506; Brocklehurst P, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD000262.pub4; Carceles CM, 2007, VET J, V174, P154, DOI 10.1016/j.tvjl.2006.05.022; Carceles CM, 2005, J VET PHARMACOL THER, V28, P475, DOI 10.1111/j.1365-2885.2005.00680.x; Cerar D, 2009, WIEN KLIN WOCHENSCHR, V121, P469, DOI 10.1007/s00508-009-1180-0; Chandra RS, 2013, MALARIA J, V12, DOI 10.1186/1475-2875-12-122; DAVILA D, 1991, BIOPHARM DRUG DISPOS, V12, P505, DOI 10.1002/bdd.2510120704; Escudero E, 2006, RES VET SCI, V81, P366, DOI 10.1016/j.rvsc.2006.01.006; Fischer JH, 2012, ANTIMICROB AGENTS CH, V56, P715, DOI 10.1128/AAC.00717-11; FOULDS G, 1990, J ANTIMICROB CHEMOTH, V25, P73; GIRARD AE, 1990, J ANTIMICROB CHEMOTH, V25, P61; Grigsby PL, 2012, AM J OBSTET GYNECOL, V207; HOLBROOK KA, 1975, J INVEST DERMATOL, V65, P16, DOI 10.1111/1523-1747.ep12598029; Hunter RP, 2003, J VET PHARMACOL THER, V26, P117, DOI 10.1046/j.1365-2885.2003.00464.x; Jones HE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008205; Keelan JA, 2011, AM J OBSTET GYNECOL, V204; KIM M, 2012, HOSP PHARM, V47, P946, DOI DOI 10.1310/hpj4712-946; Lin KJ, 2013, AM J OBSTET GYNECOL, V208; Mitchell AA, 2011, AM J OBSTET GYNECOL, V205, p51e1; NIH, 2007, PRETERM BIRTH CAUSES; Novotna M, 2004, REPROD TOXICOL, V18, P785, DOI 10.1016/j.reprotox.2004.04.014; Pitsouni E, 2007, INT J ANTIMICROB AG, V30, P213, DOI 10.1016/j.ijantimicag.2007.04.015; Romero Roberto, 2002, Semin Neonatol, V7, P259, DOI 10.1016/S1084-2756(02)90121-1; STAMLER DA, 1994, ANTIMICROB AGENTS CH, V38, P217; Viscardi Rose Marie, 2014, Arch Dis Child Fetal Neonatal Ed, V99, pF87, DOI 10.1136/archdischild-2012-303351	57	0	0	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0066-4804	1098-6596		ANTIMICROB AGENTS CH	Antimicrob. Agents Chemother.	NOV	2014	58	11					6581	6591		10.1128/AAC.03721-14		11	Microbiology; Pharmacology & Pharmacy	Microbiology; Pharmacology & Pharmacy	AS3EF	WOS:000344158600030		
J	Song, I; Borland, J; Chen, SG; Peppercorn, A; Wajima, T; Piscitelli, SC				Song, Ivy; Borland, Julie; Chen, Shuguang; Peppercorn, Amanda; Wajima, Toshihiro; Piscitelli, Stephen C.			Effect of Fosamprenavir-Ritonavir on the Pharmacokinetics of Dolutegravir in Healthy Subjects	ANTIMICROBIAL AGENTS AND CHEMOTHERAPY			English	Article							HIV INTEGRASE INHIBITOR; DRUG-INTERACTIONS; S/GSK1349572; RALTEGRAVIR; VOLUNTEERS; ADULTS	Dolutegravir (DTG) is an HIV integrase inhibitor (INI) with demonstrated activity in INI-naive and INI-resistant patients. The objective of this open-label, 2-period, single-sequence study was to evaluate the effect of fosamprenavir-ritonavir (FPV-RTV) on the steady-state plasma pharmacokinetics of DTG. Twelve healthy subjects received 50 mg DTG once daily for 5 days (period 1), followed by 10 days of 50 mg DTG once daily in combination with 700/100 mg FPV-RTV every 12 h (period 2). All doses were administered in the fasting state. Serial pharmacokinetic samples for DTG and amprenavir and safety assessments were obtained throughout the study. Noncompartmental pharmacokinetic analysis was performed, and geometric least-squares mean ratios and 90% confidence intervals were generated for within-subject treatment comparison. Fosamprenavir-ritonavir decreased the DTG area under the concentration-time curve, maximum concentration in plasma, and concentration in plasma at the end of the dosing interval by 35%, 24%, and 49%, respectively. Both DTG and DTG with FPV-RTV were well tolerated; no subject withdrew because of adverse events. The most frequently reported drug-related adverse events were rash, abnormal dreams, and nasopharyngitis. The modest decrease in DTG exposure when it was coadministered with FPV-RTV is not considered clinically significant, and DTG dose adjustment is not required with coadministration of FPV-RTV in INI-naive patient populations on the basis of established "no-effect" boundaries of DTG. In the INI-resistant population, as a cautionary measure, alternative combinations that do not include FPV-RTV should be considered.	[Song, Ivy; Borland, Julie; Chen, Shuguang; Peppercorn, Amanda; Piscitelli, Stephen C.] GlaxoSmithKline, Res Triangle Pk, NC 27709 USA; [Wajima, Toshihiro] Shionogi & Co Ltd, Osaka, Japan	Song, I (reprint author), GlaxoSmithKline, Res Triangle Pk, NC 27709 USA.	ivy.h.song@gsk.com			ViiV Healthcare	Funding for this work was provided by ViiV Healthcare.	Cahn P, 2013, LANCET, V382, P700, DOI 10.1016/S0140-6736(13)61221-0; Patel P, 2011, J ANTIMICROB CHEMOTH, V66, P1567, DOI 10.1093/jac/dkr139; Arribas JR, 2013, CURR OPIN HIV AIDS, V8, P341, DOI 10.1097/COH.0b013e328361fabd; Song I, 2011, J CLIN PHARMACOL, V51, P237, DOI 10.1177/0091270010371113; Underwood MR, 2012, JAIDS-J ACQ IMM DEF, V61, P297, DOI 10.1097/QAI.0b013e31826bfd02; Reese MJ, 2013, DRUG METAB DISPOS, V41, P353, DOI 10.1124/dmd.112.048918; Foisy MM, 2008, ANN PHARMACOTHER, V42, P1048, DOI 10.1345/aph.1K615; Min S, 2010, ANTIMICROB AGENTS CH, V54, P254, DOI 10.1128/AAC.00842-09; Castellino S, 2013, ANTIMICROB AGENTS CH, V57, P3536, DOI 10.1128/AAC.00292-13; Bruggemann RJM, 2010, J ANTIMICROB CHEMOTH, V65, P2188, DOI 10.1093/jac/dkq280; Song I, 2011, BRIT J CLIN PHARMACO, V72, P103, DOI 10.1111/j.1365-2125.2011.03947.x; EMA, 2012, CPMPEWP56095REV1 EMA; Ford SL, 2008, ANTIMICROB AGENTS CH, V52, P534, DOI 10.1128/AAC.00724-07; Luber A, 2009, 49 INT C ANT AG CHEM; Nichols G, 2012, J INT AIDS SOC S4, V15, P18112; SAS Institute Inc, 2002, NLP PROC 2005 SAS ON; Song I, 2011, 12 INT WORKSH CLIN P; Song I, 2003, 53 INT C ANT AG CHEM; ViiV Healthcare, 2013, TIV SUMM PROD CHAR E; ViiV Healthcare, 2013, TIV PRESCR INF US; ViiV Healthcare, 2013, LEX PROD INF; Wire MB, 2007, ANTIMICROB AGENTS CH, V51, P2982, DOI 10.1128/AAC.00008-07	22	3	3	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0066-4804	1098-6596		ANTIMICROB AGENTS CH	Antimicrob. Agents Chemother.	NOV	2014	58	11					6696	6700		10.1128/AAC.03282-14		5	Microbiology; Pharmacology & Pharmacy	Microbiology; Pharmacology & Pharmacy	AS3EF	WOS:000344158600042		
J	Horita, Y; Maeda, S; Kazumi, Y; Doi, N				Horita, Yasuhiro; Maeda, Shinji; Kazumi, Yuko; Doi, Norio			In Vitro Susceptibility of Mycobacterium tuberculosis Isolates to an Oral Carbapenem Alone or in Combination with beta-Lactamase Inhibitors	ANTIMICROBIAL AGENTS AND CHEMOTHERAPY			English	Article							DRUG-RESISTANT TUBERCULOSIS; HEALTHY MALE-VOLUNTEERS; MEROPENEM-CLAVULANATE; TEBIPENEM PIVOXIL; EFFICACY; SAFETY; ACID; AMOXICILLIN/CLAVULANATE; PHARMACOKINETICS; PEPTIDOGLYCAN	We evaluated the antituberculosis (anti-TB) activity of five beta-lactams alone or in combination with beta-lactamase inhibitors against 41 clinical isolates of Mycobacterium tuberculosis, including multidrug-resistant and extensively drug-resistant strains. Of those, tebipenem, an oral carbapenem, showed the most potent anti-TB activity against clinical isolates, with a MIC range of 0.125 to 8 mu g/ml, which is achievable in the human blood. More importantly, in the presence of clavulanate, MIC values of tebipenem declined to 2 mu g/ml or less.	[Horita, Yasuhiro; Doi, Norio] Japan AntiTB Assoc, Res Inst TB, Dept Pathophysiol & Host Def, Kiyose, Tokyo, Japan; [Maeda, Shinji; Kazumi, Yuko] Japan AntiTB Assoc, Res Inst TB, Dept Mycobacterium Reference & Res, Kiyose, Tokyo, Japan	Doi, N (reprint author), Japan AntiTB Assoc, Res Inst TB, Dept Pathophysiol & Host Def, Kiyose, Tokyo, Japan.	ndoi@jata.or.jp					Dooley KE, 2013, J INFECT DIS, V207, P1352, DOI 10.1093/infdis/jis460; Gumbo T, 2010, ANTIMICROB AGENTS CH, V54, P1484, DOI 10.1128/AAC.01474-09; Abate G, 1998, J ANTIMICROB CHEMOTH, V42, P735, DOI 10.1093/jac/42.6.735; Lavollay M, 2008, J BACTERIOL, V190, P4360, DOI 10.1128/JB.00239-08; Gonzalo X, 2013, J ANTIMICROB CHEMOTH, V68, P366, DOI 10.1093/jac/dks395; Hugonnet JE, 2009, SCIENCE, V323, P1215, DOI 10.1126/science.1167498; Cordillot M, 2013, ANTIMICROB AGENTS CH, V57, P5940, DOI 10.1128/AAC.01663-13; Chambers HF, 2005, ANTIMICROB AGENTS CH, V49, P2816, DOI 10.1128/AAC.49.7.2816-2821.2005; Payen MC, 2012, INT J TUBERC LUNG D, V16, P558, DOI 10.5588/ijtld.11.0414; Scorpio A, 1996, NAT MED, V2, P662, DOI 10.1038/nm0696-662; White AR, 2004, J ANTIMICROB CHEMOTH, V53, pI3, DOI 10.1093/jac/dkh050; CHAMBERS HF, 1995, ANTIMICROB AGENTS CH, V39, P2620; Velayati AA, 2009, CHEST, V136, P420, DOI 10.1378/chest.08-2427; De Lorenzo S, 2013, EUR RESPIR J, V41, P1386, DOI 10.1183/09031936.00124312; Velayati AA, 2013, INT J CLIN EXP MED, V6, P307; Solapure S, 2013, ANTIMICROB AGENTS CH, V57, P2506, DOI 10.1128/AAC.00023-13; Dubee V, 2012, ANTIMICROB AGENTS CH, V56, P4189, DOI 10.1128/AAC.00665-12; VANEMBDEN JDA, 1993, J CLIN MICROBIOL, V31, P406; Wada T, 2004, J CLIN MICROBIOL, V42, P5277, DOI 10.1128/JCM.42.11.5277-5285.2004; Hugonnet JE, 2007, BIOCHEMISTRY-US, V46, P11998, DOI 10.1021/bi701506h; Baba Shunkichi, 2009, Jpn J Antibiot, V62, P155; BALL AP, 1980, LANCET, V1, P620; EUCAST, 2013, EUCAST CLINICAL BREA; Hazra S, 2014, BIOCHEMISTRY-US, V53, P3671, DOI 10.1021/bi500339j; Kijima Koji, 2009, Jpn J Antibiot, V62, P214; Mori H, 2007, J HEALTH SCI, V53, P302, DOI 10.1248/jhs.53.302; NADLER JP, 1991, CHEST, V99, P1025, DOI 10.1378/chest.99.4.1025; NAKASHIMA M, 2009, JPN J CHEMOTHER S1, V57, P82; NAKASHIMA M, 2009, JPN J CHEMOTHER S1, V57, P90; Sloan DJ, 2013, CURR RESP MED REV, V9, P200, DOI DOI 10.HTTP://DX.D0I.0RG/10.2174/1573398X113099990017; SUGANO T, 2009, JPN J CHEMOTHER S1, V57, P38; WHO, 2012, GLOBAL TUBERCULOSIS REPORT 2012, P1; Yamane N, 1999, Rinsho Byori, V47, P754	33	2	2	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0066-4804	1098-6596		ANTIMICROB AGENTS CH	Antimicrob. Agents Chemother.	NOV	2014	58	11					7010	7014		10.1128/AAC.03539-14		5	Microbiology; Pharmacology & Pharmacy	Microbiology; Pharmacology & Pharmacy	AS3EF	WOS:000344158600090		
J	Komori, K; Akahoshi, K; Kubokawa, M; Motomura, Y; Oya, M; Ihara, E; Nakamura, K				Komori, Keishi; Akahoshi, Kazuya; Kubokawa, Masaru; Motomura, Yasuaki; Oya, Masafumi; Ihara, Eikichi; Nakamura, Kazuhiko			Endoscopic submucosal dissection for rectal carcinoid tumour using the Clutch Cutter	ANZ JOURNAL OF SURGERY			English	Article						carcinoid tumour; Clutch Cutter; endoscopic submucosal dissection; endoscopic surgery; subepithelial lesion	GASTROINTESTINAL-TRACT; MUCOSAL RESECTION; SCISSORS FORCEPS; ASPIRATION METHOD; SNARE RESECTION; LIGATION DEVICE; LESIONS	BackgroundTo reduce the risk of complications related to endoscopic submucosal dissection (ESD) using knives, we developed the Clutch Cutter (CC), which can grasp and incise the target tissue similarly to biopsy techniques using an electrosurgical current. The aim of this study was to evaluate the efficacy and safety of ESD using the CC for removal of rectal carcinoid tumours. MethodsBetween December 2009 and December 2011, we prospectively enrolled seven patients (seven lesions) on 7 different days. Patients were endoscopically diagnosed with rectal subepithelial lesions (upper rectum, n = 3; lower rectum, n = 4) within the level 3 layer and without lymph node involvement, with the diagnosis confirmed by preliminary endoscopy, endoscopic ultrasound and endoscopic biopsies. ESD using the CC was performed in all cases, and the therapeutic efficacy, safety and tumour recurrence were assessed. ResultsAll lesions were treated easily and safely, and there were no inadvertent incisions. En bloc resection was obtained in all cases, and histologic tumour-free lateral/basal margins were obtained in six of the seven patients. No delayed haemorrhage, perforation or tumour recurrence occurred. ConclusionESD using the CC appears to be an easy, safe and technically efficient method for resecting rectal carcinoid tumour.	[Komori, Keishi; Akahoshi, Kazuya; Kubokawa, Masaru; Motomura, Yasuaki] Aso Iizuka Hosp, Dept Gastroenterol, Iizuka, Fukuoka 8208505, Japan; [Oya, Masafumi] Aso Iizuka Hosp, Dept Pathol, Iizuka, Fukuoka 8208505, Japan; [Ihara, Eikichi; Nakamura, Kazuhiko] Kyushu Univ, Grad Sch Med Sci, Dept Med & Bioregulatory Sci, Fukuoka 812, Japan	Akahoshi, K (reprint author), Aso Iizuka Hosp, Dept Gastroenterol, 3-83 Yoshio, Iizuka, Fukuoka 8208505, Japan.	kakahoshi2@aol.com					Akahoshi K, 2001, ENDOSCOPY, V33, P471, DOI 10.1055/s-2001-14270; Akahoshi K, 2010, ENDOSCOPY, V42, P419, DOI 10.1055/s-0029-1243973; Lee DS, 2010, ENDOSCOPY, V42, P647, DOI 10.1055/s-0030-1255591; GODWIN JD, 1975, CANCER, V36, P560, DOI 10.1002/1097-0142(197508)36:2<560::AID-CNCR2820360235>3.0.CO;2-4; Akahoshi K, 2007, ENDOSCOPY, V39, P1103, DOI 10.1055/s-2007-966842; Ono A, 2003, GASTROINTEST ENDOSC, V57, P583, DOI 10.1067/mge.2003.142; MATSUI K, 1993, AM J GASTROENTEROL, V88, P1949; Probst A, 2009, CLIN GASTROENTEROL H, V7, P149, DOI 10.1016/j.cgh.2008.09.005; Hopper AD, 2009, J GASTROEN HEPATOL, V24, P1516, DOI 10.1111/j.1440-1746.2009.05909.x; Akahoshi K, 2008, GASTROINTEST ENDOSC, V67, P1128, DOI 10.1016/j.gie.2007.12.007; Soga J, 2005, CANCER-AM CANCER SOC, V103, P1587, DOI 10.1002/cncr.20939; Modlin IM, 1997, CANCER, V79, P813, DOI 10.1002/(SICI)1097-0142(19970215)79:4<813::AID-CNCR19>3.0.CO;2-2; Akahoshi K, 2013, ENDOSCOPY, V45, P1035, DOI 10.1055/s-0033-1344863; Scherubl H, 2009, ENDOSCOPY, V41, P162, DOI 10.1055/s-0028-1119456; Park HW, 2010, GASTROINTEST ENDOSC, V72, P143, DOI 10.1016/j.gie.2010.01.040; Modlin IM, 2005, GASTROENTEROLOGY, V128, P1717, DOI 10.1053/j.gastro.2005.03.038; Ono H, 2001, GUT, V48, P225, DOI 10.1136/gut.48.2.225; Son HJ, 2013, INT J COLORECTAL DIS, V28, P57, DOI 10.1007/s00384-012-1538-z; Ichikawa J, 2003, ENDOSCOPY, V35, P203, DOI 10.1055/s-2003-37256; Ohkuwa M, 2001, ENDOSCOPY, V33, P221, DOI 10.1055/s-2001-12805; Mashimo Y, 2008, J GASTROEN HEPATOL, V23, P218, DOI 10.1111/j.1440-1746.2008.05313.x; HAJDU SI, 1974, AM J CLIN PATHOL, V61, P521; Berkelhammer C, 1999, GASTROINTEST ENDOSC, V50, P582, DOI 10.1016/S0016-5107(99)70092-1; Bialek A, 2013, WORLD J GASTROENTERO, V19, P1953, DOI 10.3748/wjg.v19.i12.1953; Hoteya S, 2009, DIGEST ENDOSC, V21, P266, DOI 10.1111/j.1443-1661.2009.00905.x; Iishi H, 1996, DIS COLON RECTUM, V39, P1438, DOI 10.1007/BF02054536; ImadaShirakata Y, 1997, ENDOSCOPY, V29, P34, DOI 10.1055/s-2007-1024058; Kawamoto K, 1997, GASTROINTEST ENDOSC, V46, P311, DOI 10.1016/S0016-5107(97)70116-0; Nagai T, 2004, ENDOSCOPY, V36, P202, DOI 10.1055/s-2004-814248; Neuhaus H, 2006, ENDOSCOPY, V38, P1016, DOI 10.1055/s-2006-944830; Onozato Y, 2007, ENDOSCOPY, V39, P423, DOI 10.1055/s-2007-966237; Oshitani N, 2000, J INT MED RES, V28, P241; SHIROUZU K, 1990, AM J SURG, V160, P262, DOI 10.1016/S0002-9610(06)80019-X; Soga J, 1997, SURG TODAY, V27, P112; YAMASHITA Y, 1995, SURG LAPAROSC ENDOSC, V5, P38; Zhou PH, 2010, SURG ENDOSC, V24, P2607, DOI 10.1007/s00464-010-1016-z	36	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1445-1433	1445-2197		ANZ J SURG	ANZ J. Surg.	NOV	2014	84	11					847	851		10.1111/ans.12643		5	Surgery	Surgery	AS6WS	WOS:000344400700018		
J	Ishibashi, N; Himeno, K; Masuda, Y; Perez, RH; Iwatani, S; Zendo, T; Wilaipun, P; Leelawatcharamas, V; Nakayama, J; Sonomoto, K				Ishibashi, Naoki; Himeno, Kohei; Masuda, Yoshimitsu; Perez, Rodney Honrada; Iwatani, Shun; Zendo, Takeshi; Wilaipun, Pongtep; Leelawatcharamas, Vichien; Nakayama, Jiro; Sonomoto, Kenji			Gene Cluster Responsible for Secretion of and Immunity to Multiple Bacteriocins, the NKR-5-3 Enterocins	APPLIED AND ENVIRONMENTAL MICROBIOLOGY			English	Article							LACTIC-ACID BACTERIA; ENTEROCOCCUS-FAECIUM NKR-5-3; GRAM-POSITIVE BACTERIA; CLASS-II BACTERIOCINS; MALT ISOLATE LACTOBACILLUS-SAKEI-5; HETEROLOGOUS EXPRESSION; BROCHOTHRIX-CAMPESTRIS; LISTERIA-MONOCYTOGENES; DIVERCIN V41; BROCHOCIN-C	Enterococcus faecium NKR-5-3, isolated from Thai fermented fish, is characterized by the unique ability to produce five bacteriocins, namely, enterocins NKR-5-3A, -B, -C, -D, and -Z (Ent53A, Ent53B, Ent53C, Ent53D, and Ent53Z). Genetic analysis with a genome library revealed that the bacteriocin structural genes (enkA [ent53A], enkC [ent53C], enkD [ent53D], and enkZ [ent53Z]) that encode these peptides (except for Ent53B) are located in close proximity to each other. This NKR-5-3ACDZ (Ent53ACDZ) enterocin gene cluster (approximately 13 kb long) includes certain bacteriocin biosynthetic genes such as an ABC transporter gene (enkT), two immunity genes (enkIaz and enkIc), a response regulator (enkR), and a histidine protein kinase (enkK). Heterologous-expression studies of enkT and Delta enkT mutant strains showed that enkT is responsible for the secretion of Ent53A, Ent53C, Ent53D, and Ent53Z, suggesting that EnkT is a wide-range ABC transporter that contributes to the effective production of these bacteriocins. In addition, EnkIaz and EnkIc were found to confer self-immunity to the respective bacteriocins. Furthermore, bacteriocin induction assays performed with the Delta enkRK mutant strain showed that EnkR and EnkK are regulatory proteins responsible for bacteriocin production and that, together with Ent53D, they constitute a three-component regulatory system. Thus, the Ent53ACDZ gene cluster is essential for the biosynthesis and regulation of NKR-5-3 enterocins, and this is, to our knowledge, the first report that demonstrates the secretion of multiple bacteriocins by an ABC transporter.	[Ishibashi, Naoki; Himeno, Kohei; Masuda, Yoshimitsu; Perez, Rodney Honrada; Iwatani, Shun; Zendo, Takeshi; Nakayama, Jiro; Sonomoto, Kenji] Kyushu Univ, Fac Agr, Grad Sch, Dept Biosci & Biotechnol, Fukuoka 812, Japan; [Wilaipun, Pongtep] Kasetsart Univ, Fac Fisheries, Dept Fishery Prod, Bangkok, Thailand; [Leelawatcharamas, Vichien] Kasetsart Univ, Fac Agroind, Dept Biotechnol, Bangkok, Thailand; [Sonomoto, Kenji] Kyushu Univ, Bioarchitecture Ctr, Dept Funct Metab Design, Fukuoka 812, Japan	Zendo, T (reprint author), Kyushu Univ, Fac Agr, Grad Sch, Dept Biosci & Biotechnol, Fukuoka 812, Japan.	zendo@agr.kyushu-u.ac.jp			Japan Society for the Promotion of Science (JSPS) [242491]; JSPS KAKENHI [24380051]; JSPS-NRCT (National Research Council of Thailand) Core University Program on Development of Thermotolerant Microbial Resources and Their Applications; Research Grant for Young Investigators of the Faculty of Agriculture, Kyushu University; Kato Memorial Bioscience Foundation	This work was partially supported by Research Fellow of the Japan Society for the Promotion of Science (JSPS) grant 242491, JSPS KAKENHI grant 24380051, the JSPS-NRCT (National Research Council of Thailand) Core University Program on Development of Thermotolerant Microbial Resources and Their Applications, the Research Grant for Young Investigators of the Faculty of Agriculture, Kyushu University, and the Kato Memorial Bioscience Foundation.	Ishibashi N, 2012, BIOSCI BIOTECH BIOCH, V76, P947, DOI 10.1271/bbb.110972; Kuipers OP, 1998, J BIOTECHNOL, V64, P15, DOI 10.1016/S0168-1656(98)00100-X; Masuda Y, 2012, BENEF MICROBES, V3, P3, DOI 10.3920/BM2011.0047; Maguin E, 1996, J BACTERIOL, V178, P931; JACOB AE, 1974, J BACTERIOL, V117, P360; Fujita K, 2007, APPL ENVIRON MICROB, V73, P2871, DOI 10.1128/AEM.02286-06; VANDEGUCHTE M, 1989, APPL ENVIRON MICROB, V55, P224; Ramnath M, 2000, APPL ENVIRON MICROB, V66, P3098, DOI 10.1128/AEM.66.7.3098-3101.2000; Nes IF, 1996, ANTON LEEUW INT J G, V70, P113, DOI 10.1007/BF00395929; Gobbetti M, 2007, INT J FOOD MICROBIOL, V120, P34, DOI 10.1016/j.ijfoodmicro.2007.06.012; McCormick JK, 1998, APPL ENVIRON MICROB, V64, P4757; Fimland G, 2002, MICROBIOL-SGM, V148, P3661; Vaughan A, 2003, APPL ENVIRON MICROB, V69, P7194, DOI 10.1128/AEM.69.12.7194-7203.2003; Oppegard C, 2010, APPL ENVIRON MICROB, V76, P1267, DOI 10.1128/AEM.02600-09; Himeno K, 2012, BIOSCI BIOTECH BIOCH, V76, P1245, DOI 10.1271/bbb.120089; Drider D, 2006, MICROBIOL MOL BIOL R, V70, P564, DOI 10.1128/MMBR.00016-05; Asaduzzaman SM, 2009, J BIOSCI BIOENG, V107, P475, DOI 10.1016/j.jbiosc.2009.01.003; Cotter PD, 2005, NAT REV MICROBIOL, V3, P777, DOI 10.1038/nrmicro1240; Diep DB, 1995, MOL MICROBIOL, V18, P631, DOI 10.1111/j.1365-2958.1995.mmi_18040631.x; Nallapareddy SR, 2006, APPL ENVIRON MICROB, V72, P334, DOI 10.1128/AEM.72.1.334-345.2006; Nissen-Meyer J, 2009, CURR PHARM BIOTECHNO, V10, P19; PARENTE E, 1992, J APPL BACTERIOL, V73, P290, DOI 10.1111/j.1365-2672.1992.tb04980.x; Rihakova J, 2009, LETT APPL MICROBIOL, V48, P1, DOI 10.1111/j.1472-765X.2008.02490.x; Ennahar S, 2000, FEMS MICROBIOL REV, V24, P85, DOI 10.1016/S0168-6445(99)00031-5; NISSENMEYER J, 1992, J BACTERIOL, V174, P5686; Oppegard C, 2007, J MOL MICROB BIOTECH, V13, P210, DOI 10.1159/000104750; Cintas LM, 2000, J BACTERIOL, V182, P6806, DOI 10.1128/JB.182.23.6806-6814.2000; Ennahar S, 2001, INT J FOOD MICROBIOL, V70, P291, DOI 10.1016/S0168-1605(01)00565-7; AXELSSON L, 1995, J BACTERIOL, V177, P2125; Metivier A, 1998, MICROBIOL-UK, V144, P2837; KLAENHAMMER TR, 1993, FEMS MICROBIOL REV, V12, P39, DOI 10.1111/j.1574-6976.1993.tb00012.x; Zendo T, 2006, APPL ENVIRON MICROB, V72, P3383, DOI 10.1128/AEM.72.5.3383-3389.2006; Diep DB, 2009, PEPTIDES, V30, P1562, DOI 10.1016/j.peptides.2009.05.014; VANBELKUM MJ, 1995, APPL ENVIRON MICROB, V61, P3573; Diep DB, 2007, P NATL ACAD SCI USA, V104, P2384, DOI 10.1073/pnas.0608775104; Dalet K, 2001, MICROBIOL-SGM, V147, P3263; Aymerich MT, 2002, INT DAIRY J, V12, P239, DOI 10.1016/S0958-6946(01)00143-1; Izquierdo E, 2008, ANTIMICROB AGENTS CH, V52, P1917, DOI 10.1128/AAC.01409-07; Izumi K, 2007, PEDIATR RES, V61, P660, DOI 10.1203/pdr.0b013e318053423a; O'Keeffe T, 1999, APPL ENVIRON MICROB, V65, P1506; Papathanasopoulos MA, 1997, CURR MICROBIOL, V35, P331, DOI 10.1007/s002849900264; Park SH, 2003, J APPL MICROBIOL, V95, P294, DOI 10.1046/j.1365-2672.2003.01975.x; Perez RH, 2012, J BIOSCI BIOENG, V114, P490, DOI 10.1016/j.jbiosc.2012.06.003; Sambrook J, 2001, MOL CLONING LAB MANU; Sarantinopoulos P, 2002, INT J FOOD MICROBIOL, V72, P125, DOI 10.1016/S0168-1605(01)00633-X; Sawa N, 2010, J APPL MICROBIOL, V109, P282, DOI 10.1111/j.1365-2672.2009.04653.x; SIRAGUSA GR, 1993, APPL ENVIRON MICROB, V59, P2326; Swetwiwathana A, 2007, FLEISCHWIRTSCHAFT IN, V22, P46; Vaughan A, 2004, FEMS MICROBIOL LETT, V235, P377, DOI 10.1016/j.femsle.2004.05.011	49	3	3	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0099-2240	1098-5336		APPL ENVIRON MICROB	Appl. Environ. Microbiol.	NOV	2014	80	21					6647	6655		10.1128/AEM.02312-14		9	Biotechnology & Applied Microbiology; Microbiology	Biotechnology & Applied Microbiology; Microbiology	AS3FA	WOS:000344160900009		
J	Miki, Y; Asano, Y				Miki, Yuta; Asano, Yasuhisa			Biosynthetic Pathway for the Cyanide-Free Production of Phenylacetonitrile in Escherichia coli by Utilizing Plant Cytochrome P450 79A2 and Bacterial Aldoxime Dehydratase	APPLIED AND ENVIRONMENTAL MICROBIOLOGY			English	Article							CYANOGENIC GLUCOSIDE DHURRIN; HEME-CONTAINING LYASE; SP STRAIN OXB-1; PHENYLACETALDOXIME DEHYDRATASE; BACILLUS SP; HETEROLOGOUS EXPRESSION; L-PHENYLALANINE; PURIFICATION; NITRILES; ENZYMES	The biosynthetic pathway for the production of phenylacetonitrile (PAN), which has a wide variety of uses in chemical and pharmaceutical industries, was constructed in Escherichia coli utilizing enzymes from the plant glucosinolate-biosynthetic and bacterial aldoxime-nitrile pathways. First, the single-step reaction to produce E,Z-phenylacetaldoxime (PAOx) from L-Phe was constructed in E. coli by introducing the genes encoding cytochrome P450 (CYP) 79A2 and CYP reductase from Arabidopsis thaliana, yielding the E,Z-PAOx-producing transformant. Second, this step was expanded to the production of PAN by further introducing the aldoxime dehydratase (Oxd) gene from Bacillus sp. strain OxB-1, yielding the PAN-producing transformant. The E,Z-PAOx-producing transformant also produced phenethyl alcohol and PAN as by-products, which were suggested to be the metabolites of E,Z-PAOx produced by E. coli enzymes, while the PAN-producing transformant accumulated only PAN in the culture broth, which suggested that the CYP79A2 reaction (the conversion of L-Phe to E,Z-PAOx) was a potential bottleneck in the PAN production pathway. Expression of active CYP79A2 and concentration of biomass were improved by the combination of the autoinduction method, coexpression of groE, encoding the heat shock protein GroEL/GroES, N-terminal truncation of CYP79A2, and optimization of the culture conditions, yielding a >60-fold concentration of E,Z-PAOx (up to 2.9 mM). The concentration of PAN was 4.9 mM under the optimized conditions. These achievements show the potential of this bioprocess to produce nitriles and nitrile derivatives in the absence of toxic chemicals.	[Asano, Yasuhisa] Toyama Prefectural Univ, Biotechnol Res Ctr, Imizu, Toyama, Japan; Toyama Prefectural Univ, Dept Biotechnol, Imizu, Toyama, Japan; JST, ERATO, Asano Act Enzyme Mol Project, Imizu, Toyama, Japan	Asano, Y (reprint author), Toyama Prefectural Univ, Biotechnol Res Ctr, Imizu, Toyama, Japan.	asano@pu-toyama.ac.jp					Adams R, 1922, ORG SYNTH, V2, P9; Ozaki T, 2013, J BIOL CHEM, V288, P9946, DOI 10.1074/jbc.M112.436451; Chemler JA, 2008, CURR OPIN BIOTECH, V19, P597, DOI 10.1016/j.copbio.2008.10.011; Julsing MK, 2008, CURR OPIN CHEM BIOL, V12, P177, DOI 10.1016/j.cbpa.2008.01.029; Noge K, 2013, FEBS LETT, V587, P1811, DOI 10.1016/j.febslet.2013.04.038; Kahn RA, 1999, ARCH BIOCHEM BIOPHYS, V363, P9, DOI 10.1006/abbi.1998.1068; Thiel V, 2010, ORG BIOMOL CHEM, V8, P234, DOI 10.1039/b909133e; OMURA T, 1964, J BIOL CHEM, V239, P2379; Kato Y, 2000, APPL ENVIRON MICROB, V66, P2290, DOI 10.1128/AEM.66.6.2290-2296.2000; Kato Y, 2000, BIOCHEMISTRY-US, V39, P800, DOI 10.1021/bi991598u; Wittstock U, 2000, J BIOL CHEM, V275, P14659, DOI 10.1074/jbc.275.19.14659; LOOMAN AC, 1987, EMBO J, V6, P2489; Naur P, 2003, PLANT PHYSIOL, V133, P63, DOI 10.1104/pp.102.019240; Irmisch S, 2013, PLANT CELL, V25, P4737, DOI 10.1105/tpc.113.118265; Ichinose H, 2012, ARCH BIOCHEM BIOPHYS, V518, P8, DOI 10.1016/j.abb.2011.12.010; BOUCHER JL, 1994, BIOCHEMISTRY-US, V33, P7811, DOI 10.1021/bi00191a008; Wagner S, 2007, MOL CELL PROTEOMICS, V6, P1527, DOI 10.1074/mcp.M600431-MCP200; Sonderby IE, 2010, TRENDS PLANT SCI, V15, P283, DOI 10.1016/j.tplants.2010.02.005; Ichinose H, 2013, BIOCHEM BIOPH RES CO, V438, P289, DOI 10.1016/j.bbrc.2013.07.057; Hamel J, 2011, CRIT CARE NURSE, V31, P72, DOI 10.4037/ccn2011799; Studier FW, 2005, PROTEIN EXPRES PURIF, V41, P207, DOI 10.1016/j.pep.2005.01.016; Kahn RA, 1997, PLANT PHYSIOL, V115, P1661, DOI 10.1104/pp.115.4.1661; Asano Y, 2010, MANUAL OF INDUSTRIAL MICROBIOLOGY AND BIOTECHNOLOGY, THIRD EDITION, P441; Asano Y, 1998, FEMS MICROBIOL LETT, V158, P185, DOI 10.1111/j.1574-6968.1998.tb12818.x; BARNES HJ, 1991, P NATL ACAD SCI USA, V88, P5597, DOI 10.1073/pnas.88.13.5597; BOTTEGHI C, 1982, SYNTHETIC COMMUN, V12, P25, DOI 10.1080/00397918208080062; FENSELAU AH, 1970, J ORG CHEM, V35, P3546, DOI 10.1021/jo00835a080; Ferreira-Silva B, 2010, TETRAHEDRON, V66, P3410, DOI 10.1016/j.tet.2010.03.050; FOLEY HG, 1973, J CHEM SOC CHEM COMM, P628, DOI 10.1039/c39730000628; Goder V, 2003, EMBO J, V22, P3645, DOI 10.1093/emboj/cdg361; GUO ZY, 1994, ARCH BIOCHEM BIOPHYS, V312, P436, DOI 10.1006/abbi.1994.1330; Hull AK, 2000, PROTEIN EXPRES PURIF, V18, P310, DOI 10.1006/prep.1999.1195; Kato Y, 1998, ARCH MICROBIOL, V170, P85, DOI 10.1007/s002030050618; Kato Y, 2003, PROTEIN EXPRES PURIF, V28, P131, DOI 10.1016/S1046-5928(02)00638-1; LEGRAS JL, 1990, WORLD J MICROB BIOT, V6, P83, DOI 10.1007/BF01200927; Maruoka K., 1991, COMPREHENSIVE ORGANI, V6, P763; Mitsuda M, 2006, PROTEIN EXPRES PURIF, V46, P401, DOI 10.1016/j.pep.2005.10.017; OXLEY P, 1946, J CHEM SOC, P763, DOI 10.1039/jr9460000763; Pollak P, 2000, ULLMANNS ENCY IND CH, P363; Seigler D.S., 1991, P35; Uchida E, 2004, BIOCHEM BIOPH RES CO, V323, P505, DOI 10.1016/j.bbrc.2004.08.110; Wu ZL, 2009, BIOTECHNOL LETT, V31, P1589, DOI 10.1007/s10529-009-0059-5; Xie SX, 2001, BIOSCI BIOTECH BIOCH, V65, P2666, DOI 10.1271/bbb.65.2666; Yamaguchi T, 2014, PLANT MOL BIOL, V86, P215, DOI 10.1007/s11103-014-0225-6	44	1	1	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0099-2240	1098-5336		APPL ENVIRON MICROB	Appl. Environ. Microbiol.	NOV	2014	80	21					6828	6836		10.1128/AEM.01623-14		9	Biotechnology & Applied Microbiology; Microbiology	Biotechnology & Applied Microbiology; Microbiology	AS3FA	WOS:000344160900027		
J	Ochiai, S; Yasumoto, S; Morohoshi, T; Ikeda, T				Ochiai, Seiji; Yasumoto, Sera; Morohoshi, Tomohiro; Ikeda, Tsukasa			AmiE, a Novel N-Acylhomoserine Lactone Acylase Belonging to the Amidase Family, from the Activated-Sludge Isolate Acinetobacter sp. Strain Ooi24	APPLIED AND ENVIRONMENTAL MICROBIOLOGY			English	Article							PSEUDOMONAS-AERUGINOSA PAO1; CHROMOBACTERIUM-VIOLACEUM; QUORUM; IDENTIFICATION; BACTERIA; COMMUNICATION; GENETICS; SEQUENCE	Many Gram-negative bacteria use N-acyl-L-homoserine lactones (AHLs) as quorum-sensing signal molecules. We have reported that Acinetobacter strains isolated from activated sludge have AHL-degrading activity. In this study, we cloned the amiE gene as an AHL-degradative gene from the genomic library of Acinetobacter sp. strain Ooi24. High-performance liquid chromatography analysis revealed that AmiE functions as an AHL acylase, which hydrolyzes the amide bond of AHL. AmiE showed a high level of degrading activity against AHLs with long acyl chains but no activity against AHLs with acyl chains shorter than eight carbons. AmiE showed homology with a member of the amidases (EC 3.5.1.4) but not with any known AHL acylase enzymes. An amino acid sequence of AmiE from Ooi24 showed greater than 99% identities with uncharacterized proteins from Acinetobacter ursingii CIP 107286 and Acinetobacter sp. strain CIP 102129, but it was not found in the draft or complete genome sequences of other Acinetobacter strains. The presence of transposase-like genes around the amiE genes of these three Acinetobacter strains suggests that amiE is transferred by a putative transposon. Furthermore, the expression of AmiE in Pseudomonas aeruginosa PAO1 reduced AHL accumulation and elastase activity, which were regulated by AHL-mediated quorum sensing.	[Ochiai, Seiji; Yasumoto, Sera; Morohoshi, Tomohiro; Ikeda, Tsukasa] Utsunomiya Univ, Grad Sch Engn, Dept Mat & Environm Chem, Utsunomiya, Tochigi, Japan; [Ochiai, Seiji; Yasumoto, Sera; Morohoshi, Tomohiro; Ikeda, Tsukasa] CREST, JST, Kawaguchi, Saitama, Japan	Morohoshi, T (reprint author), Utsunomiya Univ, Grad Sch Engn, Dept Mat & Environm Chem, Utsunomiya, Tochigi, Japan.	morohosi@cc.utsunomiya-u.ac.jp			Core Research for Evolutional Science and Technology (CREST) from the Japan Science and Technology Agency (JST)	This work was supported by Core Research for Evolutional Science and Technology (CREST) from the Japan Science and Technology Agency (JST).	de Kievit TR, 2000, INFECT IMMUN, V68, P4839, DOI 10.1128/IAI.68.9.4839-4849.2000; Chhabra SR, 2003, J MED CHEM, V46, P97, DOI 10.1021/jm020909n; Valle A, 2004, ENVIRON MICROBIOL, V6, P424, DOI 10.1111/j.1462-2920.2004.00581.x; HOLLOWAY BW, 1979, MICROBIOL REV, V43, P73; Wang WZ, 2010, APPL ENVIRON MICROB, V76, P2524, DOI 10.1128/AEM.02738-09; McClean KH, 1997, MICROBIOL-UK, V143, P3703; Lade H, 2014, INT J BIOL SCI, V10, P547, DOI 10.7150/ijbs.9028; Morohoshi T, 2008, BIOSCI BIOTECH BIOCH, V72, P1887, DOI 10.1271/bbb.80139; Rumbaugh KP, 1999, INFECT IMMUN, V67, P5854; Morohoshi T, 2012, J BIOSCI BIOENG, V113, P20, DOI 10.1016/j.jbiosc.2011.09.006; Uroz S, 2009, CHEMBIOCHEM, V10, P205, DOI 10.1002/cbic.200800521; Park SY, 2005, APPL ENVIRON MICROB, V71, P2632, DOI 10.1128/AEM.71.5.2632-2641.2005; Huang JJ, 2003, APPL ENVIRON MICROB, V69, P5941, DOI 10.1128/AEM.69.10.5941-5949.2003; Tamura K, 2013, MOL BIOL EVOL, V30, P2725, DOI 10.1093/molbev/mst197; Huang JJ, 2006, APPL ENVIRON MICROB, V72, P1190, DOI 10.1128/AEM.72.2.1190-1197.2006; Wahjudi M, 2011, MICROBIOL-SGM, V157, P2042, DOI 10.1099/mic.0.043935-0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Romero M, 2008, FEMS MICROBIOL LETT, V280, P73, DOI 10.1111/j.1574-6968.2007.01046.x; Waters CM, 2005, ANNU REV CELL DEV BI, V21, P319, DOI 10.1146/annurev.cellbio.21.012704.131001; Parsek MR, 2000, P NATL ACAD SCI USA, V97, P8789, DOI 10.1073/pnas.97.16.8789; Lin YH, 2003, MOL MICROBIOL, V47, P849, DOI 10.1046/j.1365-2958.2003.03351.x; Morohoshi T, 2008, FEMS MICROBIOL LETT, V279, P124, DOI 10.1111/j.1574-6968.2007.01016.x; KOVACH ME, 1995, GENE, V166, P175, DOI 10.1016/0378-1119(95)00584-1; Chong G, 2012, MICROB BIOTECHNOL, V5, P621, DOI 10.1111/j.1751-7915.2012.00348.x; Imura J, 2010, PHILOS T R SOC A, V368, P4977, DOI 10.1098/rsta.2010.0176; Lee B, 2014, BIOMACROMOLECULES, V15, P1153, DOI 10.1021/bm401595q; Chan KG, 2011, BMC MICROBIOL, V11, DOI 10.1186/1471-2180-11-51; Morohoshi T, 2005, MICROB ENV, V20, P264, DOI 10.1264/jsme2.20.264; Morohoshi T, 2009, BIOSCI BIOTECH BIOCH, V73, P2124, DOI 10.1271/bbb.90283; Ochiai S, 2013, BIOSCI BIOTECH BIOCH, V77, P2436, DOI 10.1271/bbb.130553; Sambrook J, 2001, MOL CLONING LAB MANU; Sanin F. D., 2011, SLUDGE ENG TREATMENT; Skouloubris S, 2001, MOL MICROBIOL, V40, P596, DOI 10.1046/j.1365-2958.2001.02400.x; SMITH AW, 1989, NUCLEIC ACIDS RES, V17, P10509, DOI 10.1093/nar/17.24.10509; Steindler L, 2009, APPL ENVIRON MICROB, V75, P5131, DOI 10.1128/AEM.02914-08; Yeon KM, 2009, ENVIRON SCI TECHNOL, V43, P380, DOI 10.1021/es8019275	36	0	0	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0099-2240	1098-5336		APPL ENVIRON MICROB	Appl. Environ. Microbiol.	NOV	2014	80	22					6919	6925		10.1128/AEM.02190-14		7	Biotechnology & Applied Microbiology; Microbiology	Biotechnology & Applied Microbiology; Microbiology	AS3FH	WOS:000344161700008		
J	Saito, M; Miyahara, S; Villanueva, SYAM; Aramaki, N; Ikejiri, M; Kobayashi, Y; Guevarra, JP; Masuzawa, T; Gloriani, NG; Yanagihara, Y; Yoshida, S				Saito, Mitsumasa; Miyahara, Satoshi; Villanueva, Sharon Y. A. M.; Aramaki, Natsumi; Ikejiri, Mami; Kobayashi, Yoshie; Guevarra, Jonathan P.; Masuzawa, Toshiyuki; Gloriani, Nina G.; Yanagihara, Yasutake; Yoshida, Shin-Ichi			PCR and Culture Identification of Pathogenic Leptospira spp. from Coastal Soil in Leyte, Philippines, after a Storm Surge during Super Typhoon Haiyan (Yolanda)	APPLIED AND ENVIRONMENTAL MICROBIOLOGY			English	Article							JAPAN; WATER; SURVIVAL; SEROVAR; PH	Leptospirosis is a zoonosis caused by pathogenic Leptospira spp. Most of the outbreaks of leptospirosis occur after floods caused by heavy rain in countries where Leptospira spp. are endemic. It has been believed that the overflow of seawater rarely causes outbreaks of leptospirosis because the leptospires are killed by salt water. On 8 November 2013, a storm surge caused by Super Typhoon Haiyan (Yolanda) inundated the entire coastal areas of Tacloban and Palo in Leyte, Philippines. The present study was carried out in order to determine whether the environmental leptospires in soil were able to survive after the storm surge in the affected areas. We collected 23 wet soil samples along the coastal areas of Tacloban and Palo 2 months after the storm surge. The samples were suspended in HEPES buffer, and the supernatants were cultured in liquid or semisolid Korthof's medium supplemented with five antimicrobial agents to inhibit the growth of contaminants. Leptospires were isolated from primary cultures of 22 out of 23 samples. The DNA of pathogenic Leptospira species was detected in 11 samples (47.8%) by analysis of flaB by nested PCR. Eventually, two pathogenic Leptospira strains were isolated and showed the highest 16S rRNA gene sequence similarity to Leptospira kmetyi. When these isolates were experimentally mixed with soil, they were found to survive in seawater for 4 days. These results show the possibility that leptospires living in soil survived after the storm surge. Our findings may serve as a warning that when seawater inundates the land during a storm surge or a tsunami, an outbreak of leptospirosis could occur in the disaster-stricken area.	[Saito, Mitsumasa; Miyahara, Satoshi; Villanueva, Sharon Y. A. M.; Aramaki, Natsumi; Ikejiri, Mami; Yoshida, Shin-Ichi] Kyushu Univ, Grad Sch Med Sci, Dept Bacteriol, Fukuoka 812, Japan; [Kobayashi, Yoshie] Univ Philippines, Coll Publ Hlth, LEPCON Project Off, Manila, Philippines; [Guevarra, Jonathan P.] Univ Philippines, Coll Publ Hlth, Dept Hlth Promot & Educ, Manila, Philippines; [Gloriani, Nina G.; Yanagihara, Yasutake] Univ Philippines, Coll Publ Hlth, Dept Med Microbiol, Manila, Philippines; [Masuzawa, Toshiyuki; Yanagihara, Yasutake] Chiba Inst Sci, Fac Pharmaceut Sci, Lab Microbiol & Immunol, Choshi, Chiba, Japan	Saito, M (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Bacteriol, Fukuoka 812, Japan.	msaito@bact.med.kyushu-u.ac.jp			Japan Science and Technology Agency (JST); Japan International Cooperation Agency (JICA); Japan Society for the Promotion of Science (JSPS) [25460536]	This study was supported by a grant in a scheme of the Science and Technology Research Partnership for Sustainable Development (SATREPS) Program from the Japan Science and Technology Agency (JST) and the Japan International Cooperation Agency (JICA) and by a Grant-in-Aid for Scientific Research (C) (grant no. 25460536) from the Japan Society for the Promotion of Science (JSPS).	Adler B, 2010, VET MICROBIOL, V140, P287, DOI 10.1016/j.vetmic.2009.03.012; Trueba G, 2004, INT MICROBIOL, V7, P35; Bharti AR, 2003, LANCET INFECT DIS, V3, P757, DOI 10.1016/S1473-3099(03)00830-2; Koizumi N, 2013, J MED MICROBIOL, V62, P630, DOI 10.1099/jmm.0.050039-0; Bourhy P, 2013, PLOS NEGLECT TROP D, V7, DOI 10.1371/journal.pntd.0002114; Chakraborty A, 2011, MICROBIOL IMMUNOL, V55, P494, DOI 10.1111/j.1348-0421.2011.00347.x; Woo THS, 1997, J CLIN MICROBIOL, V35, P3140; Saito M, 2013, APPL ENVIRON MICROB, V79, P601, DOI 10.1128/AEM.02728-12; Page RDM, 1996, COMPUT APPL BIOSCI, V12, P357; Levett PN, 2001, CLIN MICROBIOL REV, V14, P296, DOI 10.1128/CMR.14.2.296-326.2001; Asoh T, 2014, CAN J MICROBIOL, V60, P383, DOI 10.1139/cjm-2014-0016; CARLETON O, 1979, J BACTERIOL, V137, P1413; CHANG SL, 1948, J INFECT DIS, V82, P256; Goyet C., 1994, HDB METHODS ANAL VAR; Parker J, 2011, VET MICROBIOL, V152, P146, DOI 10.1016/j.vetmic.2011.04.028; Slack AT, 2009, INT J SYST EVOL MICR, V59, P705, DOI 10.1099/ijs.0.002766-0; SMITH CE, 1961, B WORLD HEALTH ORGAN, V24, P35; SMITH D. J. W., 1955, JOUR HYG, V53, P436; Tajima Y, 2013, COAST ENG J, V56; World Health Organisation W, 1999, WKLY EPIDEMIOL REC, V74, P237; World Health Organization, 2013, WEEKL SUMM REP EARL; Yanagihara Y, 2007, COMP IMMUNOL MICROB, V30, P399, DOI 10.1016/j.cimid.2007.05.003	22	4	4	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0099-2240	1098-5336		APPL ENVIRON MICROB	Appl. Environ. Microbiol.	NOV	2014	80	22					6926	6932		10.1128/AEM.02568-14		7	Biotechnology & Applied Microbiology; Microbiology	Biotechnology & Applied Microbiology; Microbiology	AS3FH	WOS:000344161700009		
J	Kenri, T; Sekizuka, T; Yamamoto, A; Iwaki, M; Komiya, T; Hatakeyama, T; Nakajima, H; Takahashi, M; Kuroda, M; Shibayama, K				Kenri, Tsuyoshi; Sekizuka, Tsuyoshi; Yamamoto, Akihiko; Iwaki, Masaaki; Komiya, Takako; Hatakeyama, Takashi; Nakajima, Hiroshi; Takahashi, Motohide; Kuroda, Makoto; Shibayama, Keigo			Genetic Characterization and Comparison of Clostridium botulinum Isolates from Botulism Cases in Japan between 2006 and 2011	APPLIED AND ENVIRONMENTAL MICROBIOLOGY			English	Article							SEROTYPE-A SUBTYPES; INFANT BOTULISM; NEUROTOXIN GENES; GENOME SEQUENCE; STRAINS; TOXIN; DIVERSITY; CLUSTERS; INTERRELATIONSHIPS; ORGANISMS	Genetic characterization was performed for 10 group I Clostridium botulinum strains isolated from botulism cases in Japan between 2006 and 2011. Of these, 1 was type A, 2 were type B, and 7 were type A(B) {carrying a silent bont/B [bont/(B)] gene} serotype strains, based on botulinum neurotoxin (BoNT) production. The type A strain harbored the subtype A1 BoNT gene (bont/ A1), which is associated with the ha gene cluster. The type B strains carried bont/B5 or bont/B6 subtype genes. The type A(B) strains carried bont/A1 identical to that of type A(B) strain NCTC2916. However, bont/(B) genes in these strains showed single-nucleotide polymorphisms (SNPs) among strains. SNPs at 2 nucleotide positions of bont/(B) enabled classification of the type A(B) strains into 3 groups. Pulsed-field gel electrophoresis (PFGE) and multiple-locus variable-number tandem-repeat analysis (MLVA) also provided consistent separation results. In addition, the type A(B) strains were separated into 2 lineages based on their plasmid profiles. One lineage carried a small plasmid (5.9 kb), and another harbored 21-kb plasmids. To obtain more detailed genetic information about the 10 strains, we sequenced their genomes and compared them with 13 group I C. botulinum genomes in a database using whole-genome SNP analysis. This analysis provided high-resolution strain discrimination and enabled us to generate a refined phylogenetic tree that provides effective traceability of botulism cases, as well as bioterrorism materials. In the phylogenetic tree, the subtype B6 strains, Okayama2011 and Osaka05, were distantly separated from the other strains, indicating genomic divergence of subtype B6 strains among group I strains.	[Kenri, Tsuyoshi; Yamamoto, Akihiko; Iwaki, Masaaki; Komiya, Takako; Takahashi, Motohide; Shibayama, Keigo] Natl Inst Infect Dis, Dept Bacteriol 2, Tokyo, Japan; [Sekizuka, Tsuyoshi; Kuroda, Makoto] Natl Inst Infect Dis, Lab Bacterial Gen, Pathogen Genom Ctr, Tokyo, Japan; Natl Inst Infect Dis, Lab Bacterial Gen, Pathogen Genom Ctr, Tokyo, Japan; [Hatakeyama, Takashi] Miyagi Prefectural Inst Publ Hlth & Environm, Sendai, Miyagi, Japan; [Nakajima, Hiroshi] Okayama Prefectural Inst Environm Sci & Publ Hlth, Okayama, Japan	Kenri, T (reprint author), Natl Inst Infect Dis, Dept Bacteriol 2, Tokyo, Japan.	kenri@niid.go.jp			Grant for Research on Emerging and Reemerging Infectious Diseases from the Ministry of Health, Labor and Welfare of Japan [H23 Shinko-Ippan-007]; Ministry of Education, Culture, Sports, Science and Technology of Japan [25117530]	This work was supported in part by a Grant for Research on Emerging and Reemerging Infectious Diseases (grant H23 Shinko-Ippan-007) from the Ministry of Health, Labor and Welfare of Japan and a Grant-in Aid for Scientific Research on Innovative Areas (grant 25117530) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698; FRANCIOSA G, 1994, J CLIN MICROBIOL, V32, P1911; Hutson RA, 1996, J BIOL CHEM, V271, P10786, DOI 10.1074/jbc.271.18.10786; Raphael BH, 2008, APPL ENVIRON MICROB, V74, P4390, DOI 10.1128/AEM.00260-08; Hill KK, 2007, J BACTERIOL, V189, P818, DOI 10.1128/JB.01180-06; Koboldt DC, 2009, BIOINFORMATICS, V25, P2283, DOI 10.1093/bioinformatics/btp373; Macdonald TE, 2008, APPL ENVIRON MICROB, V74, P875, DOI 10.1128/AEM.01539-07; Li H, 2008, GENOME RES, V18, P1851, DOI 10.1101/gr.078212.108; Raphael BH, 2010, APPL ENVIRON MICROB, V76, P4805, DOI 10.1128/AEM.03109-09; Jacobson MJ, 2008, APPL ENVIRON MICROB, V74, P2778, DOI 10.1128/AEM.02828-07; Stamatakis A, 2006, BIOINFORMATICS, V22, P2688, DOI 10.1093/bioinformatics/btl446; Sebaihia M, 2007, GENOME RES, V17, P1082, DOI 10.1101/gr.6282807; Whitemarsh RCM, 2013, INFECT IMMUN, V81, P3894, DOI 10.1128/IAI.00536-13; Li H, 2011, BIOINFORMATICS, V27, P2987, DOI 10.1093/bioinformatics/btr509; Umeda K, 2009, J CLIN MICROBIOL, V47, P2720, DOI 10.1128/JCM.00077-09; Lindstrom M, 2001, APPL ENVIRON MICROB, V67, P5694, DOI 10.1128/AEM.67.12.5694-5699.2001; Peck MW, 2009, ADV MICROB PHYSIOL, V55, P183, DOI 10.1016/S0065-2911(09)05503-9; Sobel J, 2005, CLIN INFECT DIS, V41, P1167, DOI 10.1086/444507; Arnon SS, 2001, JAMA-J AM MED ASSOC, V285, P1059, DOI 10.1001/jama.285.8.1059; Lindstrom M, 2006, CLIN MICROBIOL REV, V19, P298, DOI 10.1128/CMR.19.2.298-314.2006; Horowitz BZ, 2010, CLIN TOXICOL, V48, P880, DOI 10.3109/15563650.2010.526943; Hill KK, 2013, CURR TOP MICROBIOL, V364, P1, DOI 10.1007/978-3-642-33570-9_1; Barash JR, 2010, J PEDIATR-US, V156, P402, DOI 10.1016/j.jpeds.2009.09.072; Takeshi K, 1996, MICROBIOL IMMUNOL, V40, P5; Luquez C, 2012, APPL ENVIRON MICROB, V78, P8712, DOI 10.1128/AEM.02428-12; Koepke R, 2008, PEDIATRICS, V122, pE73, DOI 10.1542/peds.2007-1827; Luquez C, 2009, APPL ENVIRON MICROB, V75, P6094, DOI 10.1128/AEM.01009-09; Barash JR, 2014, J INFECT DIS, V209, P183, DOI 10.1093/infdis/jit449; Cawthorne A, 2005, EMERG INFECT DIS, V11, P781; Chertow DS, 2006, JAMA-J AM MED ASSOC, V296, P2476, DOI 10.1001/jama.296.20.2476; Dineen SS, 2000, APPL ENVIRON MICROB, V66, P5480, DOI 10.1128/AEM.66.12.5480-5483.2000; Dover N, 2014, J INFECT DIS, V209, P192, DOI 10.1093/infdis/jit450; Dover N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061205; Franciosa G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004829; Ghasemi M, 2012, CLIN NEUROPHARMACOL, V35, P254, DOI 10.1097/WNF.0b013e31826248b8; Hill KK, 2009, BMC BIOL, V7, DOI 10.1186/1741-7007-7-66; HUTSON RA, 1993, FEMS MICROBIOL LETT, V108, P103, DOI 10.1016/0378-1097(93)90495-N; HUTSON RA, 1993, ANTON LEEUW INT J G, V64, P273; Johnson EA, 2005, J CLIN MICROBIOL, V43, P2602, DOI 10.1128/JCM.43.6.2602-2607.2005; Kobayashi T, 2014, J PEDIATR-US, V164, P931, DOI 10.1016/j.jpeds.2013.11.044; Marshall KM, 2007, BIOCHEM BIOPH RES CO, V361, P49, DOI 10.1016/j.bbrc.2007.06.166; MOMOSE Y, 2012, INT J INFECT DIS, V24, P20; Nishiura H, 2007, EPIDEMIOL INFECT, V135, P126, DOI 10.1017/S0950268806006169; Rainey GJA, 2004, NAT REV MICROBIOL, V2, P721, DOI 10.1038/nrmicro977; SAKAGUCHI Y, 2014, GENOME ANNOUNC, V2; SMITH JK, 2010, BMJ CASE REP, V2010; Smith TJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001271; STROM MS, 1984, APPL ENVIRON MICROB, V48, P956; TAKAHASHI M, 1988, JPN J MED SCI BIOL, V41, P21; Tian RM, 2011, GENOME, V54, P546, DOI 10.1139/G11-019; Tritt A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042304; Zhang JC, 2010, CLIN TOXICOL, V48, P867, DOI 10.3109/15563650.2010.535003	52	2	2	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	0099-2240	1098-5336		APPL ENVIRON MICROB	Appl. Environ. Microbiol.	NOV	2014	80	22					6954	6964		10.1128/AEM.02134-14		11	Biotechnology & Applied Microbiology; Microbiology	Biotechnology & Applied Microbiology; Microbiology	AS3FH	WOS:000344161700012		
J	Hayata, K; Asada, S; Fujii, T; Inoue, H; Ishikawa, K; Sawayama, S				Hayata, Koutarou; Asada, Seiya; Fujii, Tatsuya; Inoue, Hiroyuki; Ishikawa, Kazuhiko; Sawayama, Shigeki			Gene Targeting by RNAi-Mediated Knockdown of Potent DNA Ligase IV Homologue in the Cellulase-Producing Fungus Talaromyces cellulolyticus	APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY			English	Article						Homologous recombination; DNA ligase IV; RNAi; Acremonium cellulolyticus; Cellulase	TRICHODERMA-REESEI; ACREMONIUM-CELLULOLYTICUS; TRANSFORMATION SYSTEM; ASPERGILLUS-ORYZAE; HYPOCREA-JECORINA; INTERFERENCE; NEUROSPORA; INTEGRATION; EXPRESSION; CULTURE	The genome of the cellulase-producing fungus Talaromyces cellulolyticus (formerly Acremonium cellulolyticus) was screened for a potent DNA ligase IV gene (ligD homologue). Homologous recombination efficiency in T. cellulolyticus is very low. Therefore, suppression of a non-homologous end-joining system was attempted to enable specific gene knockouts for molecular breeding. The transcript levels of ligD homologue were 0.037 of those of the parental YP-4 strain in the Li20 transformant carrying the RNAi construct targeting the ligD homologue. Transformation of the hairpin-type RNAi vector into T. cellulolyticus could be useful in fungal gene knockdown experiments. Cellulase production and protein secretion were similar in the parental YP-4 strain and the Li20 transformant. Knockout transformation of ligD homologue using the Li20 transformant led to 23.1 % double crossover gene targeting. Our results suggest that the potent DNA ligase IV gene of T. cellulolyticus is related to non-homologous end joining and that the knockdown of the ligD homologue is useful in gene targeting.	[Hayata, Koutarou; Asada, Seiya; Sawayama, Shigeki] Kyoto Univ, Grad Sch Agr, Div Appl Biosci, Sakyo Ku, Kyoto 6068502, Japan; [Fujii, Tatsuya; Inoue, Hiroyuki; Ishikawa, Kazuhiko] Natl Inst Adv Ind Sci & Technol, Biomass Refinery Res Ctr, Hiroshima 7390046, Japan	Sawayama, S (reprint author), Kyoto Univ, Grad Sch Agr, Div Appl Biosci, Sakyo Ku, Oiwake Cho, Kyoto 6068502, Japan.	sawayama@kais.kyoto-u.ac.jp			New Energy and Industrial Technology Development Organization (NEDO), Japan	This study was supported by the New Energy and Industrial Technology Development Organization (NEDO), Japan.	Guangtao Z, 2009, J BIOTECHNOL, V139, P146, DOI 10.1016/j.jbiotec.2008.10.007; ROMANO N, 1992, MOL MICROBIOL, V6, P3343, DOI 10.1111/j.1365-2958.1992.tb02202.x; Fujii T, 2012, BIOSCI BIOTECH BIOCH, V76, P245, DOI 10.1271/bbb.110498; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Steiger MG, 2011, APPL ENVIRON MICROB, V77, P114, DOI 10.1128/AEM.02100-10; Maruyama JI, 2008, BIOTECHNOL LETT, V30, P1811, DOI 10.1007/s10529-008-9763-9; Rappleye CA, 2004, MOL MICROBIOL, V53, P153, DOI 10.1111/j.1365-2958.2004.04131.x; Ninomiya Y, 2004, P NATL ACAD SCI USA, V101, P12248, DOI 10.1073/pnas.0402780101; Kubicek CP, 2013, J BIOTECHNOL, V163, P133, DOI 10.1016/j.jbiotec.2012.05.020; Martinez D, 2008, NAT BIOTECHNOL, V26, P553, DOI 10.1038/nbt1403; Nakayashiki H, 2008, CURR OPIN MICROBIOL, V11, P494, DOI 10.1016/j.mib.2008.10.001; Asada S, 2014, APPL BIOCHEM BIOTECH, V172, P3009, DOI 10.1007/s12010-014-0728-2; Fang X, 2009, J BIOSCI BIOENG, V107, P256, DOI 10.1016/j.jbiosc.2008.11.022; Fujii T., 2013, AMB EXPRESS, V3, P1; Fujii T, 2010, BIOSCI BIOTECH BIOCH, V74, P419, DOI 10.1271/bbb.90655; Fujii T, 2009, BIOTECHNOL BIOFUELS, V2, P1; GHOSE TK, 1979, BIOTECHNOL BIOENG, V21, P283, DOI 10.1002/bit.260210213; Imamura K, 2012, APPL ENVIRON MICROB, V78, P6996, DOI 10.1128/AEM.01770-12; Inoue H, 2013, J IND MICROBIOL BIOT, V40, P823, DOI 10.1007/s10295-013-1286-2; Ishibashi K, 2006, P NATL ACAD SCI USA, V103, P14871, DOI 10.1073/pnas.0604477103; Janus D, 2007, APPL ENVIRON MICROB, V73, P962, DOI 10.1128/AEM.02127-06; Kanna M., 2011, AMB EXPRESS, V1, P1; KISTLER HC, 1992, GENE, V117, P81, DOI 10.1016/0378-1119(92)90493-9; Rahman M., 2008, BIOTECHNOL ADV, V26, P202; Seidl V., 2010, BIOFUELS, V1, P343, DOI 10.4155/bfs.10.1; YAMANOBE T, 1987, AGR BIOL CHEM TOKYO, V51, P65; Yuen K, 2003, ARCH MICROBIOL, V179, P339, DOI [10.1007/s00203-003-0533-8, 10.1007/s00203-003-0598-4]	27	0	0	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0273-2289	1559-0291		APPL BIOCHEM BIOTECH	Appl. Biochem. Biotechnol.	NOV	2014	174	5					1697	1704		10.1007/s12010-014-1142-5		8	Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology	Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology	AS5XK	WOS:000344339700001		
J	Abe, K; Ishiwatari, T; Wakamatsu, M; Aburai, N				Abe, Katsuya; Ishiwatari, Takehiro; Wakamatsu, Michihiro; Aburai, Nobuhiro			Fatty Acid Content and Profile of the Aerial Microalga Coccomyxa sp. Isolated from Dry Environments	APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY			English	Article						Aerial microalga; Coccomyxa; Lipid; Fatty acid; Nitrogen deprivation	STRIOLATA VAR. MULTISTRIATA; LIPID PRODUCTION; NANNOCHLOROPSIS-OCULATA; BOTRYOCOCCUS-BRAUNII; BIODIESEL PRODUCTION; CHLORELLA-VULGARIS; LIGHT-INTENSITY; OIL PRODUCTION; ACCUMULATION; GROWTH	Aerial algae are considered to be highly tolerant of and adaptable to severe conditions including radiation, desiccation, high temperatures, and nutrient deficiency, compared with those from aquatic habitats. There are considerable variations in the fatty acid (FA) composition of aerial microalgae from dry environments. A new species with a high lipid level was found on concrete surfaces and was identified as Coccomyxa sp. KGU-D001 (Trebouxiophyceae). This study characterized its FA content and profile in a bath culture. The alga showed a constant specific growth rate (0.26 day(-1)) ranging in light intensity from 20 to 80 mu mol photons m(-2) s(-1). The algal cells started to form oil bodies in the early stationary phase of growth, and oil bodies occupied most of the cells during the late stationary phase when the cells accumulated 27 % total fatty acids (TFA). The process of lipid body formation accumulating large amounts of triacylglycerols (TAG) appeared to be very unusual in response to stress conditions persisting for a relatively long culture time (50 days). This study could indicate that aerial microalgae will be a candidate for biodiesel production when a new cultivation method is developed using extreme stresses such as nutritional deficiency and/or desiccation.	[Abe, Katsuya; Ishiwatari, Takehiro; Wakamatsu, Michihiro; Aburai, Nobuhiro] Kogakuin Univ, Dept Appl Chem, Fac Engn, Hachioji, Tokyo 1920015, Japan	Abe, K (reprint author), Kogakuin Univ, Dept Appl Chem, Fac Engn, 2665-1 Nakano Machi, Hachioji, Tokyo 1920015, Japan.	bt10335@ns.kogakuin.ac.jp			Strategic Research Foundation from the Ministry of Education, Culture, Sport, Science, and Technology, Japan (MEXT) [S1411005]	The authors would like to thank Prof. Hideaki Miyashita and Dr Satoshi Ohkubo (Department of Interdisciplinary Environment, Graduate School of Human and Environmental Studies, Kyoto University) for their scientific support in identification of the isolated strain. This study was supported in part by a grant from the Strategic Research Foundation Grant-aided Project for Private Universities from the Ministry of Education, Culture, Sport, Science, and Technology, Japan (MEXT), 2014-2018 (S1411005).	Abe K, 1998, J MAR BIOTECHNOL, V6, P53; Abe K, 2004, J BIOSCI BIOENG, V98, P34, DOI 10.1016/S1389-1723(04)70239-X; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Ratledge C, 2004, BIOCHIMIE, V86, P807, DOI 10.1016/j.biochi.2004.09.017; Liu JH, 2012, APPL BIOCHEM BIOTECH, V166, P2127, DOI 10.1007/s12010-012-9639-2; Rao AR, 2007, BIORESOURCE TECHNOL, V98, P560, DOI 10.1016/j.biortech.2006.02.007; Hu CW, 2013, FOOD CHEM, V138, P2071, DOI 10.1016/j.foodchem.2012.11.133; [Anonymous], 2004, 14214 EN; Zhekisheva M, 2002, J PHYCOL, V38, P325, DOI 10.1046/j.1529-8817.2002.01107.x; Abe K, 2007, FOOD CHEM, V100, P656, DOI 10.1016/j.foodchem.2005.10.026; Converti A, 2009, CHEM ENG PROCESS, V48, P1146, DOI 10.1016/j.cep.2009.03.006; Yeesang C, 2011, BIORESOURCE TECHNOL, V102, P3034, DOI 10.1016/j.biortech.2010.10.013; MEDLIN L, 1988, GENE, V71, P491, DOI 10.1016/0378-1119(88)90066-2; Takagi M, 2000, APPL MICROBIOL BIOT, V54, P112; Gouveia L, 2009, J IND MICROBIOL BIOT, V36, P269, DOI 10.1007/s10295-008-0495-6; Mansour MP, 2005, J APPL PHYCOL, V17, P287, DOI 10.1007/s10811-005-6625-x; MacKinney G, 1941, J BIOL CHEM, V140, P315; McGinnis KM, 1997, J APPL PHYCOL, V9, P19, DOI 10.1023/A:1007972214462; Feng DN, 2011, BIORESOURCE TECHNOL, V102, P6710, DOI 10.1016/j.biortech.2011.04.006; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Mata TM, 2010, RENEW SUST ENERG REV, V14, P217, DOI 10.1016/j.rser.2009.07.020; Ruangsomboon S, 2012, BIORESOURCE TECHNOL, V109, P261, DOI 10.1016/j.biortech.2011.07.025; GREENSPAN P, 1985, J CELL BIOL, V100, P965, DOI 10.1083/jcb.100.3.965; Makarova VV, 2007, PHOTOSYNTH RES, V94, P79, DOI 10.1007/s11120-007-9219-4; Pribyl P, 2012, APPL MICROBIOL BIOT, V94, P549, DOI 10.1007/s00253-012-3915-5; Msanne J, 2012, PHYTOCHEMISTRY, V75, P50, DOI 10.1016/j.phytochem.2011.12.007; Davidi L, 2012, PLANTA, V236, P19, DOI 10.1007/s00425-011-1585-7; Ahmad AL, 2011, RENEW SUST ENERG REV, V15, P584, DOI 10.1016/j.rser.2010.09.018; Sharma YC, 2008, FUEL, V87, P2355, DOI 10.1016/j.fuel.2008.01.014; Parida AK, 2007, PLANT BIOTECHNOL REP, V1, P37, DOI 10.1007/s11816-006-0004-1; BENAMOTZ A, 1985, J PHYCOL, V21, P72; Chaffin JD, 2012, J APPL PHYCOL, V24, P1045, DOI 10.1007/s10811-011-9732-x; Chiu SY, 2009, BIORESOURCE TECHNOL, V100, P833, DOI 10.1016/j.biortech.2008.06.061; Guarnieri M. T., 2011, PLOS ONE, V6, P1, DOI DOI 10.1371/JOURNAL.PONE.0025851; Gustavs L, 2010, PROTOPLASMA, V243, P3, DOI 10.1007/s00709-009-0060-9; Guzman HM, 2011, J APPL PHYCOL, V23, P7, DOI 10.1007/s10811-010-9526-6; Hamby R. K., 1988, PLANT MOL BIOL REP, V6, P175; Matsunaga T, 2009, BIOTECHNOL LETT, V31, P1367, DOI 10.1007/s10529-009-0029-y; Satoh A, 2013, BIORESOURCE TECHNOL, V137, P132, DOI [10.1016/j.biortech.2013.03.087, 10.1016/j.biortech.2]; Shiratake T., 2013, PLOS ONE, V8, P1; Siaut M, 2011, BMC BIOTECHNOL, V11, DOI 10.1186/1472-6750-11-7; Su CH, 2011, J APPL PHYCOL, V23, P903, DOI 10.1007/s10811-010-9609-4	42	0	0	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0273-2289	1559-0291		APPL BIOCHEM BIOTECH	Appl. Biochem. Biotechnol.	NOV	2014	174	5					1724	1735		10.1007/s12010-014-1181-y		12	Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology	Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology	AS5XK	WOS:000344339700003		
J	Tsuruya, M; Niwano, Y; Nakamura, K; Kanno, T; Nakashima, T; Egusa, H; Sasaki, K				Tsuruya, Makoto; Niwano, Yoshimi; Nakamura, Keisuke; Kanno, Taro; Nakashima, Takuji; Egusa, Hiroshi; Sasaki, Keiichi			Acceleration of Proliferative Response of Mouse Fibroblasts by Short-Time Pretreatment with Polyphenols	APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY			English	Article						Polyphenol; Proanthocyanidin; Fibroblast proliferation	SYSTEM UTILIZING PHOTOLYSIS; RAPID COLORIMETRIC ASSAY; HYDROGEN-PEROXIDE; IN-VITRO; ANTIOXIDANT ACTIVITY; BACTERICIDAL ACTION; RATS; CYTOTOXICITY; SURVIVAL; GROWTH	Under the hypothesis that photo-irradiated proanthocyanidin could accelerate wound healing through reactive oxygen species (ROS) formation, we examined the effect of proanthocyanidin on 3T3-L1 mouse fibroblasts with or without photo-irradiation. As a result, irrespective of presence or absence of photo-irradiation, only 1 min exposure of the cells to proanthocyanidin resulted in accelerated proliferation of the cells in a concentration-dependent manner. Similarly to proanthocyanidin, 1 min pretreatment with catechin, caffeic acid, and chlorogenic acid accelerated the proliferative response, but gallic acid, epicatechin gallate, epigallocatechin, and epigallocatechin gallate failed. If incorporated active ingredient such as proanthocyanidin for such a short time as 1 min accelerates the proliferation response, a bioassay was conducted by utilizing antioxidant potential of proanthocyanidin. That is, intracellular oxidation of 2',7'-dichlorodihydrofluorescin induced by H2O2 was significantly inhibited when the cells were pretreated with proanthocyanidin for 1 min, suggesting that incorporated proanthocyanidin into the cells exerted antioxidant effect. This was also supported by a liquid chromatography/mass spectrometry analysis in which incorporation of proanthocyanidin components such as catechin monomers and dimers into the cells within 1 min was confirmed. These results suggest that active polyphenolic compounds such as proanthocyanidin, catechin, caffeic acid, and chlorogenic acid incorporated into the cells in such a short time as 1 min could accelerate the proliferative response of the cells.	[Tsuruya, Makoto; Niwano, Yoshimi; Nakamura, Keisuke; Kanno, Taro; Egusa, Hiroshi; Sasaki, Keiichi] Tohoku Univ, Grad Sch Dent, Aoba Ku, Sendai, Miyagi 9808575, Japan; [Nakashima, Takuji] Kitasato Univ, Kiasato Inst Life Sci, Minato Ku, Tokyo 1088691, Japan	Niwano, Y (reprint author), Tohoku Univ, Grad Sch Dent, Aoba Ku, 4-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.	niwano@m.tohoku.ac.jp			Ministry of Education, Science, Sports and Culture, Japan [25893019, 26460116]; All Japan Coffee Association	This research was supported by the Ministry of Education, Science, Sports and Culture, Japan, Grant-in-Aid for Research Activity start-up, 25893019, 2013, and for Scientific Research (C), 26460116, 2014, and by the grant of All Japan Coffee Association, 2014.	BORENFREUND E, 1985, TOXICOL LETT, V24, P119, DOI 10.1016/0378-4274(85)90046-3; Borges A, 2014, BIOFOULING, V30, P183, DOI 10.1080/08927014.2013.852542; PRIEUR C, 1994, PHYTOCHEMISTRY, V36, P781, DOI 10.1016/S0031-9422(00)89817-9; Singh D, 2014, EVID-BASED COMPL ALT, DOI 10.1155/2014/701656; Soobrattee MA, 2005, MUTAT RES-FUND MOL M, V579, P200, DOI 10.1016/j.mrfmmm.2005.03.023; Nakamura K, 2012, J AGR FOOD CHEM, V60, P10048, DOI 10.1021/jf303177p; Kilic I, 2014, SPECTROCHIM ACTA A, V130, P447, DOI 10.1016/j.saa.2014.04.052; Arakawa H, 2004, BIOL PHARM BULL, V27, P277, DOI 10.1248/bpb.27.277; Eligini S, 2009, FREE RADICAL BIO MED, V46, P1428, DOI 10.1016/j.freeradbiomed.2009.02.026; Akagawa M, 2003, BIOSCI BIOTECH BIOCH, V67, P2632, DOI 10.1271/bbb.67.2632; Hayashi E, 2012, J BIOSCI BIOENG, V114, P193, DOI 10.1016/j.jbiosc.2012.03.020; RiceEvans CA, 1996, FREE RADICAL BIO MED, V20, P933, DOI 10.1016/0891-5849(95)02227-9; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; Atrux-Tallau N, 2011, EUR J DERMATOL, V21, P52, DOI 10.1684/ejd.2011.1270; Fu XJ, 2014, J PHOTOCH PHOTOBIO B, V136, P72, DOI 10.1016/j.jphotobiol.2014.04.016; Kumarappan CT, 2012, SAUDI J BIOL SCI, V19, DOI 10.1016/j.sjbs.2012.04.004; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Nadour M, 2012, APPL BIOCHEM BIOTECH, V167, P1802, DOI 10.1007/s12010-012-9633-8; Nakamura K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060053; Niwano Y, 1996, ARZNEIMITTEL-FORSCH, V46, P450; Niwano Y, 1996, ARZNEIMITTEL-FORSCH, V46, P218; Pan Q, 2011, INVEST OPHTH VIS SCI, V52, P1723, DOI 10.1167/iovs.10-5866; Schreml S, 2011, EXP DERMATOL, V20, P229, DOI 10.1111/j.1600-0625.2010.01195.x; Sugisawa A, 2004, BIOL PHARM BULL, V27, P1459, DOI 10.1248/bpb.27.1459; Yamada Y, 2012, J TOXICOL SCI, V37, P329; ZHANG SZ, 1990, CELL BIOL TOXICOL, V6, P219	26	3	3	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0273-2289	1559-0291		APPL BIOCHEM BIOTECH	Appl. Biochem. Biotechnol.	NOV	2014	174	6					2223	2235		10.1007/s12010-014-1124-7		13	Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology	Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology	AS5XO	WOS:000344340100017		
J	Yu, GC; Yano, S; Inoue, H; Inoue, S; Wang, JL; Endo, T				Yu, Guoce; Yano, Shinichi; Inoue, Hiroyuki; Inoue, Seiichi; Wang, Jianlong; Endo, Takashi			Structural Insights into Rice Straw Pretreated by Hot-Compressed Water in Relation to Enzymatic Hydrolysis	APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY			English	Article						Structural feature; Rice straw; Hot-compressed water; Pretreatment; Enzymatic hydrolysis	BIOETHANOL PRODUCTION PROCESS; CELLULOSE ACCESSIBILITY; LIGNOCELLULOSIC BIOMASS; CORN STOVER; DILUTE-ACID; CRYSTALLINITY INDEX; BIOREFINERY CONCEPT; DIGESTIBILITY; RECALCITRANCE; LIGNIN	Pretreatment-induced structural alteration is critical in influencing the rate and extent of enzymatic saccharification of lignocellulosic biomass. The present work has investigated structural features of rice straw pretreated by hot-compressed water (HCW) from 140 to 240 A degrees C for 10 or 30 min and enzymatic hydrolysis profiles of pretreated rice straw. Compositional profiles of pretreated rice straw were examined to offer the basis for structural changes. The wide-angle X-ray diffraction analysis revealed possible modification in crystalline microstructure of cellulose and the severity-dependent variation of crystallinity. The specific surface area (SSA) of pretreated samples was able to achieve more than 10-fold of that of the raw material and was in linear relationship with the removal of acetyl groups and xylan. The glucose yield by enzymatic hydrolysis of pretreated materials correlated linearly with the SSA increase and the dissolution of acetyl and xylan. A quantitatively intrinsic relationship was suggested to exist between enzymatic hydrolysis and the extraction of hemicellulose components in hydrothermally treated rice straw, and SSA was considered one important structural parameter signaling the efficiency of enzymatic digestibility in HCW-treated materials in which hemicellulose removal and lignin redistribution happened.	[Yu, Guoce; Yano, Shinichi; Inoue, Hiroyuki; Inoue, Seiichi; Endo, Takashi] Natl Inst Adv Ind Sci & Technol, Biomass Refinery Res Ctr, Higashihiroshima 7390046, Japan; [Yu, Guoce; Wang, Jianlong] Tsinghua Univ, Inst Nucl & New Energy Technol, Beijing 100084, Peoples R China	Yu, GC (reprint author), Natl Inst Adv Ind Sci & Technol, Biomass Refinery Res Ctr, 3-11-32 Kagamiyama, Higashihiroshima 7390046, Japan.	yugc@tsinghua.edu.cn; s-yano@aist.go.jp			Japan International Cooperation Agency in the "Research on Biomass Technology" program; Beijing Natural Science Foundation [5133035]	We thank Dr. Yoshikuni Teramoto and Ms Noriko Tanaka for their help in the WAXD measurement and Dr. Shinji Fujimoto for his assistance in using the surface area analyzer. We acknowledge Dr. Tsuyoshi Sakaki for his comments on the experimental results. This work was partly supported by Japan International Cooperation Agency in the "Research on Biomass Technology" program and Beijing Natural Science Foundation (5133035).	Zhang YHP, 2004, BIOTECHNOL BIOENG, V88, P797, DOI 10.1002/bit.20282; OSullivan AC, 1997, CELLULOSE, V4, P173, DOI 10.1023/A:1018431705579; Hong J, 2007, LANGMUIR, V23, P12535, DOI 10.1021/la7025686; Donohoe BS, 2008, BIOTECHNOL BIOENG, V101, P913, DOI 10.1002/bit.21959; Mosier N, 2005, BIORESOURCE TECHNOL, V96, P673, DOI 10.1016/j.biortech.2004.06.025; Zeng MJ, 2007, BIOTECHNOL BIOENG, V97, P265, DOI 10.1002/bit.21298; Zhao XB, 2012, BIOFUEL BIOPROD BIOR, V6, P561, DOI 10.1002/bbb.1350; French AD, 2013, CELLULOSE, V20, P583, DOI 10.1007/s10570-012-9833-y; SINITSYN AP, 1991, APPL BIOCHEM BIOTECH, V30, P43, DOI 10.1007/BF02922023; Yu Y, 2008, ENERG FUEL, V22, P46, DOI 10.1021/ef700292p; Alvira P, 2010, BIORESOURCE TECHNOL, V101, P4851, DOI 10.1016/j.biortech.2009.11.093; Hall M, 2010, FEBS J, V277, P1571, DOI 10.1111/j.1742-4658.2010.07585.x; Yoshida M, 2008, BIOSCI BIOTECH BIOCH, V72, P805, DOI 10.1271/bbb.70689; Xiao LP, 2011, BIORESOURCES, V6, P1576; Nitsos CK, 2013, CHEMSUSCHEM, V6, P110, DOI 10.1002/cssc.201200546; Kumar R, 2009, BIORESOURCE TECHNOL, V100, P3948, DOI 10.1016/j.biortech.2009.01.075; Zhao XB, 2012, BIOFUEL BIOPROD BIOR, V6, P465, DOI 10.1002/bbb.1331; Hu F, 2012, BIOENERG RES, V5, P1043, DOI 10.1007/s12155-012-9208-0; Himmel ME, 2007, SCIENCE, V315, P804, DOI 10.1126/science.1137016; Larsson PT, 1999, SOLID STATE NUCL MAG, V15, P31, DOI 10.1016/S0926-2040(99)00044-2; Mansfield SD, 1999, BIOTECHNOL PROGR, V15, P804, DOI 10.1021/bp9900864; Zhu ZG, 2009, BIOTECHNOL BIOENG, V103, P715, DOI 10.1002/bit.22307; Zhu L, 2008, BIORESOURCE TECHNOL, V99, P3817, DOI 10.1016/j.biortech.2007.07.033; Binod P, 2010, BIORESOURCE TECHNOL, V101, P4767, DOI 10.1016/j.biortech.2009.10.079; Yang B, 2008, BIOFUEL BIOPROD BIOR, V2, P26, DOI 10.1002/bbb.49; Xiao LP, 2013, BIORESOURCE TECHNOL, V135, P73, DOI 10.1016/j.biortech.2012.08.143; Kim S, 2004, BIOMASS BIOENERG, V26, P361, DOI 10.1016/j.biombioe.2003.08.002; Rollin JA, 2011, BIOTECHNOL BIOENG, V108, P22, DOI 10.1002/bit.22919; Ding SY, 2012, SCIENCE, V338, P1055, DOI 10.1126/science.1227491; Sasaki M, 2004, AICHE J, V50, P192, DOI 10.1002/aic.10018; Ruiz HA, 2013, RENEW SUST ENERG REV, V21, P35, DOI 10.1016/j.rser.2012.11.069; Zeng MJ, 2012, BIOTECHNOL BIOENG, V109, P398, DOI 10.1002/bit.23335; Chandra RP, 2007, ADV BIOCHEM ENG BIOT, V108, P67, DOI 10.1007/10_2007_064; Larsson PT, 1997, CARBOHYD RES, V302, P19, DOI 10.1016/S0008-6215(97)00130-4; Jeoh T, 2007, BIOTECHNOL BIOENG, V98, P112, DOI 10.1002/bit.21408; Yu G, 2010, APPL BIOCHEM BIOTECH, V160, P539, DOI 10.1007/s12010-008-8420-z; Hendriks ATWM, 2009, BIORESOURCE TECHNOL, V100, P10, DOI 10.1016/j.biortech.2008.05.027; Hsu TC, 2010, BIORESOURCE TECHNOL, V101, P4907, DOI 10.1016/j.biortech.2009.10.009; Ioelovich M, 2011, BIORESOURCES, V6, P2818; Arantes V, 2010, BIOTECHNOL BIOFUELS, V3, DOI 10.1186/1754-6834-3-4; Arantes V, 2011, BIOTECHNOL BIOFUELS, V4, DOI 10.1186/1754-6834-4-3; Brodeur G., 2011, ENZYME RES, V17, DOI DOI 10.4061/2011/787532; Chandel AK, 2014, BIOTECHNOL BIOFUELS, V7, DOI 10.1186/1754-6834-7-63; Chandra RP, 2008, CHARACTERIZATION LIG, P60, DOI 10.1002/9781444305425.ch4; Chundawat S. P. S., 2011, ANNU REV CHEM BIOMOL, V2; Hansen MAT, 2011, BIORESOURCE TECHNOL, V102, P2804, DOI 10.1016/j.biortech.2010.10.030; Ibbett R, 2013, BIOTECHNOL BIOFUELS, V6, DOI 10.1186/1754-6834-6-33; Kristensen JB, 2008, BIOTECHNOL BIOFUELS, V1, DOI 10.1186/1754-6834-1-5; Mittal A, 2011, BIOTECHNOL BIOFUELS, V4, DOI 10.1186/1754-6834-4-41; Park S, 2010, BIOTECHNOL BIOFUELS, V3, DOI 10.1186/1754-6834-3-10; Pu YQ, 2013, BIOTECHNOL BIOFUELS, V6, DOI 10.1186/1754-6834-6-15; PURI VP, 1984, BIOTECHNOL BIOENG, V26, P1219, DOI 10.1002/bit.260261010; Segal L., 1959, TEXT RES J, V29, P786, DOI [10.1177/004051755902901003, DOI 10.1177/004051755902901003]; Sluiter A., 2005, DETERMINATION SUGARS; Sluiter A., 2006, DETERMINATION STRUCT; THOMPSON DN, 1992, BIORESOURCE TECHNOL, V39, P155, DOI 10.1016/0960-8524(92)90135-K; Zeng MJ, 2012, BIOTECHNOL BIOENG, V109, P390, DOI 10.1002/bit.23337	57	0	0	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0273-2289	1559-0291		APPL BIOCHEM BIOTECH	Appl. Biochem. Biotechnol.	NOV	2014	174	6					2278	2294		10.1007/s12010-014-1199-1		17	Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology	Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology	AS5XO	WOS:000344340100022		
J	Takahashi, S; Okada, H; Abe, K; Kera, Y				Takahashi, S.; Okada, H.; Abe, K.; Kera, Y.			Genetic Transformation of the Yeast Rhodotorula gracilis ATCC 26217 by Electroporation	APPLIED BIOCHEMISTRY AND MICROBIOLOGY			English	Article							AMINO-ACID OXIDASE; HIGH-EFFICIENCY TRANSFORMATION; MOLECULAR CHARACTERIZATION; RHODOSPORIDIUM-TORULOIDES; SACCHAROMYCES-CEREVISIAE; PHLEOMYCIN RESISTANCE; D-ALANINE; D-SERINE; INDUCTION; MARKER	We examined the genetic transformation of the biotechnologically relevant yeast Rhodotorula gracilis ATCC 26217 by electroporation. To evaluate the yeast transformation, we created a genomic integration cassette that was targeted to the yeast orotidine-5'-phosphate decarboxylase gene (URA3 gene) locus and composed of the zeocin-resistant gene (Sh ble gene) with the URA3 promoter and terminator of the yeast. The yeast was unable to grow on medium containing 2.0 mu g/mL zeocin, even with the inoculation of a large number of cells (approximately 1.0 x 10(8) cells/plate). Using the integrative cassette and zeocin-containing medium, we successfully obtained yeast transformants by electroporation, and the highest transformation efficiency of approximately 40 colony-forming units/mu g DNA was obtained with a 0.6-kV electrical pulse. No homologous integration of the cassette at the URA3 gene locus was detected by the analyses of uracil auxotrophy and genomic PCR of transformants, suggesting that this method is a useful tool for randomly mutating the yeast genome.	[Takahashi, S.; Okada, H.; Abe, K.; Kera, Y.] Nagaoka Univ Technol, Dept Environm Syst Engn, Nagaoka, Niigata 9402188, Japan	Takahashi, S (reprint author), Nagaoka Univ Technol, Dept Environm Syst Engn, Nagaoka, Niigata 9402188, Japan.	shoutaka@vos.nagaokaut.ac.jp					TULLY M, 1985, GENE, V36, P235, DOI 10.1016/0378-1119(85)90178-7; Frengova GI, 2009, J IND MICROBIOL BIOT, V36, P163, DOI 10.1007/s10295-008-0492-9; Sasabe J, 2012, P NATL ACAD SCI USA, V109, P627, DOI 10.1073/pnas.1114639109; Mothet JP, 2000, P NATL ACAD SCI USA, V97, P4926, DOI 10.1073/pnas.97.9.4926; Pollegioni L, 2008, APPL MICROBIOL BIOT, V78, P1, DOI 10.1007/s00253-007-1282-4; Liu YB, 2013, APPL MICROBIOL BIOT, V97, P719, DOI 10.1007/s00253-012-4223-9; Khoronenkova SV, 2008, BIOCHEMISTRY-MOSCOW+, V73, P1511, DOI 10.1134/S0006297908130105; Ageitos JM, 2011, APPL MICROBIOL BIOT, V90, P1219, DOI 10.1007/s00253-011-3200-z; Molla G, 2003, YEAST, V20, P1061, DOI 10.1002/yea.1023; Tishkov VI, 2005, BIOCHEMISTRY-MOSCOW+, V70, P40, DOI 10.1007/s10541-005-0050-2; EDMAN JC, 1990, MOL CELL BIOL, V10, P4538; Lin XP, 2014, FEMS YEAST RES, V14, P547, DOI 10.1111/1567-1364.12140; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; Caldinelli L, 2013, BBA-MOL BASIS DIS, V1832, P400, DOI 10.1016/j.bbadis.2012.11.019; CALMELS T, 1991, CURR GENET, V20, P309, DOI 10.1007/BF00318520; GATIGNOL A, 1987, MOL GEN GENET, V207, P342, DOI 10.1007/BF00331599; Koh CMJ, 2014, BMC MICROBIOL, V14, DOI 10.1186/1471-2180-14-50; LYLE LR, 1968, J BACTERIOL, V96, P606; MANIVASAKAM P, 1993, NUCLEIC ACIDS RES, V21, P4414, DOI 10.1093/nar/21.18.4414; Nakamura H, 2012, EXP BIOL MED, V237, P703, DOI 10.1258/ebm.2012.011360; PRENTICE HL, 1992, NUCLEIC ACIDS RES, V20, P621, DOI 10.1093/nar/20.3.621; Sarower MG, 2003, ARCH BIOCHEM BIOPHYS, V420, P121, DOI 10.1016/j.abb.2003.09.035; Stegman LD, 1998, HUM GENE THER, V9, P185, DOI 10.1089/hum.1998.9.2-185; Takahashi S, 2011, APPL MICROBIOL BIOT, V89, P1213, DOI 10.1007/s00253-010-2985-5; Takahashi S, 2012, CURR MICROBIOL, V65, P764, DOI 10.1007/s00284-012-0227-z	25	1	1	MAIK NAUKA/INTERPERIODICA/SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013-1578 USA	0003-6838	1573-8183		APPL BIOCHEM MICRO+	Appl. Biochem. Microbiol.	NOV	2014	50	6					624	628		10.1134/S0003683814110040		5	Biotechnology & Applied Microbiology; Microbiology	Biotechnology & Applied Microbiology; Microbiology	AS3ER	WOS:000344159800011		
J	Arafiles, KHV; Iwasaka, H; Eramoto, Y; Okamura, Y; Tajima, T; Matsumura, Y; Nakashimada, Y; Aki, T				Arafiles, Kim Hazel V.; Iwasaka, Hiroaki; Eramoto, Yuri; Okamura, Yoshiko; Tajima, Takahisa; Matsumura, Yukihiko; Nakashimada, Yutaka; Aki, Tsunehiro			Value-added lipid production from brown seaweed biomass by two-stage fermentation using acetic acid bacterium and thraustochytrid	APPLIED MICROBIOLOGY AND BIOTECHNOLOGY			English	Article						Seaweed; Acetic acid bacteria; Thraustochytrid; Polyunsaturated fatty acids; Xanthophylls	POLYUNSATURATED FATTY-ACIDS; XANTHOPHYLLS; MANNITOL; POLYSACCHARIDES; CAROTENOIDS; HEALTH; ALGA	Thraustochytrid production of polyunsaturated fatty acids and xanthophylls have been generally sourced from crop-derived substrates, making the exploration of alternative feedstocks attractive since they promise increased sustainability and lower production costs. In this study, a distinct two-stage fermentation system was conceptualized for the first time, using the brown seaweed sugar mannitol as substrate for the intermediary biocatalyst Gluconobacter oxydans, an acetic acid bacterium, along with the marine thraustochytrid Aurantiochytrium sp. to produce the value-added lipids and xanthophylls. Jar fermenter culture resulted in seaweed mannitol conversion to fructose with an efficiency of 83 % by G. oxydans and, after bacteriostasis with sea salts, production of astaxanthin and docosahexaenoic acid by Aurantiochytrium sp. KH105. Astaxanthin productivity was high at 3.60 mg/L/day. This new system, therefore, widens possibilities of obtaining more varieties of industrially valuable products including foods, cosmetics, pharmaceuticals, and biofuel precursor lipids from seaweed fermentation upon the use of suitable thraustochytrid strains.	[Arafiles, Kim Hazel V.; Iwasaka, Hiroaki; Eramoto, Yuri; Okamura, Yoshiko; Tajima, Takahisa; Nakashimada, Yutaka; Aki, Tsunehiro] Hiroshima Univ, Grad Sch Adv Sci Matter, Higashihiroshima 7398530, Japan; [Matsumura, Yukihiko] Hiroshima Univ, Grad Sch Engn, Higashihiroshima 7398527, Japan; [Arafiles, Kim Hazel V.; Iwasaka, Hiroaki; Eramoto, Yuri; Okamura, Yoshiko; Tajima, Takahisa; Matsumura, Yukihiko; Nakashimada, Yutaka; Aki, Tsunehiro] Japan Sci & Technol Agcy JST, CREST, Tokyo, Japan	Aki, T (reprint author), Japan Sci & Technol Agcy JST, CREST, Tokyo, Japan.	aki@hiroshima-u.ac.jp	Aki, Tsunehiro/B-6719-2012; Matsumura, Yukihiko/D-5105-2011; Nakashimada, Yutaka/B-5493-2010	Aki, Tsunehiro/0000-0001-9753-2043; Matsumura, Yukihiko/0000-0002-1341-0493; Nakashimada, Yutaka/0000-0002-7452-7433	Core Research of Evolutional Science and Technology program (CREST) of the Japan Science and Technology Agency (JST)	This study was supported by the Core Research of Evolutional Science and Technology program (CREST) of the Japan Science and Technology Agency (JST).	Alexandratos N., 2012, WORLD AGR 2030 2050; Jiao GL, 2011, MAR DRUGS, V9, P196, DOI 10.3390/md9020196; Hussein G, 2006, J NAT PROD, V69, P443, DOI 10.1021/np050354+; Ratledge C, 2002, ADV APPL MICROBIOL, V51, P1, DOI 10.1016/S0065-2164(02)51000-5; Gupta A, 2012, BIOTECHNOL ADV, V30, P1733, DOI 10.1016/j.biotechadv.2012.02.014; Valentine J, 2012, GCB BIOENERGY, V4, P1, DOI 10.1111/j.1757-1707.2011.01111.x; Azam F, 2007, NAT REV MICROBIOL, V5, P782, DOI 10.1038/nrmicro1747; Schmidt I, 2011, APPL MICROBIOL BIOT, V89, P555, DOI 10.1007/s00253-010-2976-6; Innis SM, 2008, BRAIN RES, V1237, P35, DOI 10.1016/j.brainres.2008.08.078; Yamasaki T, 2006, J BIOSCI BIOENG, V102, P323, DOI 10.1263/jbb.102.323; Lopez MCGM, 2006, J BIOTECHNOL, V123, P329, DOI 10.1016/j.jbiotec.2005.11.010; Richhardt J, 2012, APPL ENVIRON MICROB, V78, P6975, DOI 10.1128/AEM.01166-12; Voutilainen S, 2006, AM J CLIN NUTR, V83, P1265; Aki T, 2003, J AM OIL CHEM SOC, V80, P789, DOI 10.1007/s11746-003-0773-2; Holdt SL, 2011, J APPL PHYCOL, V23, P543, DOI 10.1007/s10811-010-9632-5; Yaguchi T, 1997, J AM OIL CHEM SOC, V74, P1431, DOI 10.1007/s11746-997-0249-z; Iwasaka H, 2013, J OLEO SCI, V62, P729, DOI 10.5650/jos.62.729; Khomtimchenko SV, 1999, CHEM NAT PROD, V35, P17; Klein-Marcuschamer D, 2012, BIOTECHNOL BIOENG, V109, P1083, DOI 10.1002/bit.24370; MATEUS H, 1977, ECON BOT, V31, P24, DOI 10.1007/BF02860648; PERCIVAL E, 1979, BRIT PHYCOL J, V14, P103; PETERSON MH, 1956, APPL MICROBIOL, V4, P316; SHARMA S, 1994, J EXP MAR BIOL ECOL, V175, P227, DOI 10.1016/0022-0981(94)90028-0; Takaki Masatoshi, 2011, Journal of the Japan Society of Material Cycles and Waste Management, V22, DOI 10.3985/jjsmcwm.22.10; Yamasaki T, 2007, J BIOSCI BIOENG, V104, P200, DOI 10.1263/jbb.104.200	25	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0175-7598	1432-0614		APPL MICROBIOL BIOT	Appl. Microbiol. Biotechnol.	NOV	2014	98	22					9207	9216		10.1007/s00253-014-5980-4		10	Biotechnology & Applied Microbiology	Biotechnology & Applied Microbiology	AS5ZI	WOS:000344344500005		
J	Yazawa, H; Ogiso, M; Kumagai, H; Uemura, H				Yazawa, Hisashi; Ogiso, Masayo; Kumagai, Hiromichi; Uemura, Hiroshi			Suppression of ricinoleic acid toxicity by ptl2 overexpression in fission yeast Schizosaccharomyces pombe	APPLIED MICROBIOLOGY AND BIOTECHNOLOGY			English	Article						Schizosaccharomyces pombe; Yeast; Ricinoleic acid; FAH12; Fatty acid hydroxylase; Lipase	SACCHAROMYCES-CEREVISIAE; HETEROLOGOUS EXPRESSION; TRANSGENIC ARABIDOPSIS; OLEATE 12-HYDROXYLASE; PHOSPHOLIPASE A(2); GENES; HYDROXYLASE; INHIBITION; DESATURASE; SEEDS	We previously succeeded to obtain a high content of ricinoleic acid (RA), a hydroxylated fatty acid with great values as a petrochemical replacement, in fission yeast Schizosaccharomyces pombe by introducing Claviceps purpurea oleate Delta 12-hydroxylase gene (CpFAH12). Although the production was toxic to S. pombe cells, we identified plg7, encoding phospholipase A2, as a multicopy suppressor that restored the growth defect by removing RA from phospholipids and induced secretion of a part of the released free RA into culture media. In this study, we extended our analysis and examined the effect of triglyceride (TG) lipase overexpression on the tolerance to RA toxicity and RA productivity. S. pombe has three TG lipase genes, ptl1, ptl2, and ptl3, which have high protein sequence similarities to each other and to Saccharomyces cerevisiae counterparts TGL3, TGL4, and TGL5, but only ptl2 overexpression suppressed the growth defect induced by RA production, and the culture grown at 20 A degrees C secreted free RA into media like plg7 overexpression. Suppression by ptl2 was independent of plg7, and a large amount of free RA was accumulated in the cells concomitant with the decrease in RA moieties in phospholipids. Furthermore, the suppression by ptl2 was attenuated by bromoenol lactone (BEL), a phospholipase A2 specific inhibitor, suggesting that Ptl2p may have phospholipase activity. Simultaneous overexpression of ptl2 and plg7 in the FAH12 integrant increased secretion and intracellular accumulation of RA 1.2- and 1.3-fold, respectively, compared to those with single overexpression of plg7 on day 10 at 20 A degrees C.	[Yazawa, Hisashi; Ogiso, Masayo; Uemura, Hiroshi] Natl Inst Adv Ind Sci & Technol, Bioprod Res Inst, Tsukuba, Ibaraki 3058566, Japan; [Kumagai, Hiromichi] Asahi Glass Co Ltd, Yokohama, Kanagawa 2218755, Japan	Uemura, H (reprint author), Natl Inst Adv Ind Sci & Technol, Bioprod Res Inst, AIST Tsukuba Cent 6,Higashi 1-1-1, Tsukuba, Ibaraki 3058566, Japan.	hiroshi-uemura@aist.go.jp			Noda Institute for Scientific Research; New Energy and Industrial Technology Development Organization (NEDO)	Genomic DNA clones of S. pombe were provided by the National Bio-Resource Project (NBRP) of the MEXT, Japan. This work was partly supported by research grants from Noda Institute for Scientific Research and the New Energy and Industrial Technology Development Organization (NEDO) to HU.	Alfa C, 1993, EXPT FISSION YEAST L; Smith MA, 2003, PLANTA, V217, P507, DOI 10.1007/s00425-003-1015-6; HAZEN SL, 1991, J BIOL CHEM, V266, P7227; Lu CF, 2006, PLANT J, V45, P847, DOI 10.1111/j.1365-313X.2005.02636.x; Beopoulos A, 2014, APPL MICROBIOL BIOT, V98, P251, DOI 10.1007/s00253-013-5295-x; Matsuyama A, 2006, NAT BIOTECHNOL, V24, P841, DOI 10.1038/nbt1222; Kainou K, 2006, YEAST, V23, P605, DOI 10.1002/yea.1378; Yazawa H, 2012, APPL MICROBIOL BIOT, V96, P981, DOI 10.1007/s00253-012-4151-8; Rajakumari S, 2010, J BIOL CHEM, V285, P15769, DOI 10.1074/jbc.M109.076331; Broun P, 1997, PLANT PHYSIOL, V113, P933, DOI 10.1104/pp.113.3.933; Kumar R, 2006, PLANT J, V48, P920, DOI 10.1111/j.1365-313X.2006.02925.x; Meesapyodsuk D, 2008, PLANT PHYSIOL, V147, P1325, DOI 10.1104/pp.108.117168; Scharnewski M, 2008, FEBS J, V275, P2765, DOI 10.1111/j.1742-4658.2008.06417.x; Holic R, 2012, APPL MICROBIOL BIOT, V95, P179, DOI 10.1007/s00253-012-3959-6; Nakamura T, 2001, MOL BIOL CELL, V12, P3955; Broun P, 1998, PLANT J, V13, P201, DOI 10.1046/j.1365-313X.1998.00023.x; ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445; BALSINDE J, 1995, P NATL ACAD SCI USA, V92, P8527, DOI 10.1073/pnas.92.18.8527; VANDELOO FJ, 1995, P NATL ACAD SCI USA, V92, P6743, DOI 10.1073/pnas.92.15.6743; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; Evans C. T., 1989, YEAST, P367; Foulks Jason M, 2008, Free Radic Biol Med, V45, P434, DOI 10.1016/j.freeradbiomed.2008.04.034; GALLIARD T, 1966, J BIOL CHEM, V241, P5806; Idiris A, 2006, APPL MICROBIOL BIOT, V73, P404, DOI 10.1007/s00253-006-0489-0; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; Sambrook J, 2001, MOL CLONING LAB MANU; Tanaka K, 2000, MOL CELL BIOL, V20, P3459, DOI 10.1128/MCB.20.10.3459-3469.2000; Yazawa H, 2013, APPL MICROBIOL BIOT, V97, P8193, DOI 10.1007/s00253-013-4987-6; Yazawa H, 2013, APPL MICROBIOL BIOT, V97, P8663, DOI 10.1007/s00253-013-5060-1	29	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0175-7598	1432-0614		APPL MICROBIOL BIOT	Appl. Microbiol. Biotechnol.	NOV	2014	98	22					9325	9337		10.1007/s00253-014-6006-y		13	Biotechnology & Applied Microbiology	Biotechnology & Applied Microbiology	AS5ZI	WOS:000344344500015		
J	Rahmah, S; Kato, K; Yamamoto, S; Takii, K; Murata, O; Senoo, S				Rahmah, Sharifah; Kato, Keitaro; Yamamoto, Shinji; Takii, Kenji; Murata, Osamu; Senoo, Shigeharu			Improved survival and growth performances with stocking density manipulation and shelter availability in bagrid catfish Mystus nemurus (Cuvier & Valenciennes 1840) larvae	AQUACULTURE RESEARCH			English	Article						Mystus nemurus; growth; shelter; stocking density; survival	CLARIAS-GARIEPINUS BURCHELL; CHARR SALVELINUS-ALPINUS; JUVENILE ATLANTIC SALMON; AFRICAN CATFISH; BEHAVIOR; CANNIBALISM; LIGHT; PONDS; CLARIIDAE; CRAYFISH	Manipulation of stocking densities (10, 20, 30, 40 and 50 larvae L-1), each with or without the presence of shelter was conducted to determine the effects on survival, cannibalism and growth performances of larval bagrid catfish Mystus nemurus (Valenciennes 1840) from 2 to 14 days after hatching. This study revealed that stocking density significantly affected survival, cannibalism, total length, feed intake, specific growth rate and final weight of bagrid catfish larvae. Significantly higher survival was observed at moderate stocking density of more than 20 but less than 50 larvae L-1. Survival was significantly low beyond this threshold and was the lowest at 10 larvae L-1, coincides with the highest cannibalism. Total length, feed intake, specific growth rate and final weight were significantly higher at 10 larvae L-1. Shelter significantly improved total length and feed intake. No significant effects of stocking density and shelter were observed on the apparent feed conversion ratio and coefficient of variation. There was also no significant interaction between stocking density and shelter in all parameters. This study suggests that bagrid catfish larvae could be cultured at more than 20 but less than 50 larvae L-1 with the availability of shelter for optimal larviculture condition.	[Rahmah, Sharifah; Kato, Keitaro; Yamamoto, Shinji; Murata, Osamu] Kinki Univ, Fisheries Lab, Shirahama Expt Stn, Wakayama 6492211, Japan; [Takii, Kenji] Kinki Univ, Uragami Expt Stn, Fisheries Lab, Wakayama, Japan; [Senoo, Shigeharu] Univ Malaysia Sabah, Borneo Marine Res Inst, Kota Kinabalu, Malaysia	Rahmah, S (reprint author), Kinki Univ, Fisheries Lab, Shirahama Expt Stn, Shirahama Cho 3153, Wakayama 6492211, Japan.	sharifah186@gmail.com			global COE program (International Education and Research Center for Aquaculture Science of Bluefin Tuna and other Cultured Fish) from the Ministry of Education, Culture, Science, Sports and Technology, Japan; Kinki University, Japan; Universiti Malaysia Sabah, Malaysia	The authors would like to express gratitude to the global COE program (International Education and Research Center for Aquaculture Science of Bluefin Tuna and other Cultured Fish) from the Ministry of Education, Culture, Science, Sports and Technology, Japan, for the funding of this study with the collaboration of Kinki University, Japan and Universiti Malaysia Sabah, Malaysia.	Abidin MZ, 2006, AQUAC RES, V37, P416, DOI 10.1111/j.1365-2109.2005.01382.x; Al-Hafedh YS, 2004, J APPL ICHTHYOL, V20, P225, DOI 10.1111/j.1439-0426.2004.00544.x; ALMAZANRUEDA P, 2004, THESIS WAGENINGEN U; AMORNSAKUN T, SONGKLANAKARIN J SCI, V20, P373; HECHT T, 1988, J ZOOL, V214, P21; Almazan-Rueda P, 2004, AQUACULTURE, V231, P347, DOI 10.1016/j.aquaculture.2003.11.016; Rahmah S, 2014, AQUAC RES, V45, P501, DOI 10.1111/j.1365-2109.2012.03253.x; Valdimarsson SK, 1998, J FISH BIOL, V52, P42, DOI 10.1006/jfbi.1997.0557; Kestemont P, 2003, AQUACULTURE, V227, P333, DOI 10.1016/S0044-8486(03)00513-1; Valdimarsson SK, 1997, ANIM BEHAV, V54, P1405, DOI 10.1006/anbe.1997.0550; BRITZ PJ, 1992, J ZOOL, V227, P43; Hengsawat K, 1997, AQUACULTURE, V152, P67, DOI 10.1016/S0044-8486(97)00008-2; JORGENSEN EH, 1993, AQUACULTURE, V110, P191, DOI 10.1016/0044-8486(93)90272-Z; Jones CM, 1995, AQUACULTURE, V138, P239, DOI 10.1016/0044-8486(95)00069-0; Finstad AG, 2007, FRESHWATER BIOL, V52, P1710, DOI 10.1111/j.1365-2427.2007.01799.x; Baras E, 2003, AQUACULTURE, V219, P241, DOI 10.1016/S0044-8486(02)00349-6; Tantikitti C, 2001, AQUAC RES, V32, P135, DOI 10.1046/j.1355-557x.2001.00011.x; Hossain MAR, 1998, AQUACULTURE, V160, P251, DOI 10.1016/S0044-8486(97)00250-0; Gomes LC, 2000, AQUACULTURE, V183, P73, DOI 10.1016/S0044-8486(99)00288-4; APPLEBAUM S, 2000, AQUACULT ENG, V22, P260; Baskerville-Bridges B, 2000, AQUACULTURE, V181, P61, DOI 10.1016/S0044-8486(99)00220-3; Benhaim D, 2009, AQUACULTURE, V295, P38, DOI 10.1016/j.aquaculture.2009.06.024; Dou SZ, 2003, AQUACULTURE, V218, P309, DOI 10.1016/S0044-8486(02)00531-8; *FAO, 2010, FISHSTAT PLUS VER 2; HAYLOR G S, 1992, Aquaculture and Fisheries Management, V23, P303, DOI 10.1111/j.1365-2109.1992.tb00773.x; HECHT T, 1987, AQUACULTURE, V63, P195, DOI 10.1016/0044-8486(87)90071-8; Hecht Thomas, 1993, Journal of the World Aquaculture Society, V24, P246, DOI 10.1111/j.1749-7345.1993.tb00014.x; Hecht T, 1997, S AFR J SCI, V93, P537; Herbert BW, 2003, J WORLD AQUACULT SOC, V34, P433, DOI 10.1111/j.1749-7345.2003.tb00082.x; Johnston D, 2006, AQUACULTURE, V260, P114, DOI 10.1016/j.aquaculture.2006.05.057; KAISER H, 1995, J APPL ICHTHYOL, V11, P25, DOI 10.1111/j.1439-0426.1995.tb00003.x; Kaiser H., 1995, Aquaculture International, V3, P217, DOI 10.1007/BF00118103; KAMARUDIN MS, 2011, AFRICAN J BIOTECHNOL, V10, P44884; Khan M. S., 1994, Aquaculture and Fisheries Management, V25, P753, DOI 10.1111/j.1365-2109.1994.tb00739.x; Khan M.S., 1988, Indian Journal of Fisheries, V35, P78; Mesomya W., 2002, Kasetsart Journal, Natural Sciences, V36, P69; NAREJO NT, 2003, PAKISTAN J BIOL SCI, V6, P1753; Rahmah S., 2011, AQUACULTURE SCI, V59, P443; SAHOO SK, 2009, J APPL ICHTHYOL, V26, P609; SUTTLE KB, 2004, ECOL APPL, V14, P947; Toko I, 2007, AQUACULTURE, V262, P65, DOI 10.1016/j.aquaculture.2006.08.054; van de Nieuwegiessen PG, 2009, AQUACULTURE, V288, P69, DOI 10.1016/j.aquaculture.2008.11.009; Verhoef GD, 1999, AQUACULTURE, V170, P49, DOI 10.1016/S0044-8486(98)00395-0; Wocher H, 2011, AQUACULTURE, V315, P340, DOI 10.1016/j.aquaculture.2011.01.051; Zarski D, 2011, J APPL ICHTHYOL, V27, P1155, DOI 10.1111/j.1439-0426.2011.01769.x	45	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1355-557X	1365-2109		AQUAC RES	Aquac. Res.	NOV	2014	45	12					2000	2009		10.1111/are.12148		10	Fisheries	Fisheries	AS6JS	WOS:000344370600011		
J	Hasegawa, N; Sawaguchi, S; Tokuda, M; Unuma, T				Hasegawa, Natsuki; Sawaguchi, Sayumi; Tokuda, Masaharu; Unuma, Tatsuya			Fatty acid composition in sea cucumber Apostichopus japonicus fed with microbially degraded dietary sources	AQUACULTURE RESEARCH			English	Article						branched-chain fatty acid; biomarker; sea cucumber; Apostichopus japonicus; diet; microbes	CHROMATOGRAPHY-MASS-SPECTROMETRY; PSAMMECHINUS-MILIARIS; GROWTH; SEDIMENTS	Fatty acids (FAs) in the body walls of sea cucumber, Apostichopus japonicus, reared under diet-administered conditions were analysed to determine the accumulative status of dietary FAs. Four test diets different in diet source and microbial degradation, that is, a diet composed of powdered pennate diatoms (diet PD), one microbially degraded of diet PD (diet PDM), one composed of brown algae [tangle weed, Saccharina (Laminaria) longissima (Miyabe); diet BA], and one microbially degraded of diet BA (diet BAM), were fed to juvenile A. japonicus, respectively, for 2 months and the FA composition of the juvenile body wall was determined. FAs in body wall were influenced and changed by diet source and microbial degradation of diet. Degradation significantly promoted juvenile's growth and increased iso-15:0 in the body wall; however, iso15: 0 was not a growth factor. FA 20:4n6 and 20:5n3 were dominant in all groups despite being a minor dietary constituent, suggesting that these FAs can be readily accumulated or synthesized in the animal.	[Hasegawa, Natsuki; Sawaguchi, Sayumi; Unuma, Tatsuya] Fisheries Res Agcy, Hokkaido Natl Res Inst, Stock Enhancement & Fisheries Oceanog Div, Kushiro, Hokkaido, Japan; [Tokuda, Masaharu] Fisheries Res Agcy, Natl Res Inst Aquaculture, Aquaculture Syst Div, Watarai, Mie 5160108, Japan	Tokuda, M (reprint author), Fisheries Res Agcy, Natl Res Inst Aquaculture, Aquaculture Syst Div, Watarai, Mie 5160108, Japan.	masatoku@fra.affrc.go.jp			National Research Institute of Aquaculture, Fisheries Research Agency of Japan; Hokkaido Fisheries Research Institute, Fisheries Research Agency of Japan	The authors are grateful to Dr Yuichi Sakai, Mariculture Fisheries Research Institute of Hokkaido Research Organization, for his technical advice in experiments and providing the juvenile A. japonicus used in the study. This research was partly supported by annual research grants for "Research on Live Food Organisms Available in Aquaculture" provided by the National Research Institute of Aquaculture, Fisheries Research Agency of Japan, and "Research and Development of Food Sources for Juvenile Sea Cucumber in Ecological System" provided by Hokkaido Fisheries Research Institute, Fisheries Research Agency of Japan.	ALEXANDER LR, 1985, J CHROMATOGR, V342, P1, DOI 10.1016/S0378-4347(00)84484-9; Lane CE, 2006, J PHYCOL, V42, P493, DOI 10.1111/j.1529-8817.2006.00204.x; SARGENT JR, 1983, MAR BIOL, V76, P87, DOI 10.1007/BF00393059; Cook EJ, 2007, AQUACULTURE, V273, P586, DOI 10.1016/j.aquaculture.2007.10.032; Balzano S, 2011, MAR CHEM, V124, P2, DOI 10.1016/j.marchem.2010.11.001; Yamana Y, 2006, FISHERIES SCI, V72, P585, DOI 10.1111/j.1444-2906.2006.01187.x; Aly SM, 2008, AQUACULTURE, V277, P1, DOI 10.1016/j.aquaculture.2008.02.021; Kharlamenko VI, 2001, MAR ECOL PROG SER, V220, P103, DOI 10.3354/meps220103; Harel M, 2002, AQUACULTURE, V213, P347, DOI 10.1016/S0044-8486(02)00047-9; Liu Y, 2010, AQUAC RES, V41, pe881, DOI 10.1111/j.1365-2109.2010.02582.x; Cejas JR, 2004, COMP BIOCHEM PHYS B, V139, P209, DOI 10.1016/j.cbpc.2004.07.010; Camacho AP, 2007, AQUACULTURE, V266, P211, DOI 10.1016/j.aquaculture.2006.12.033; Choo P.-S., 2008, SEA CUCUMBERS GLOBAL, P81; Cook EJ, 1998, J SHELLFISH RES, V17, P1549; Esaki Y., 2004, B FUKUOKA FISHERIES, V14, P33; FAY L, 1991, J CHROMATOGR, V541, P89, DOI 10.1016/S0021-9673(01)95986-2; FOLCH J, 1957, J BIOL CHEM, V226, P497; Gordon N, 2006, AQUACULTURE, V252, P225, DOI 10.1016/j.aquaculture.2005.06.034; Hanson CE, 2010, AQUAT BOT, V93, P114, DOI 10.1016/j.aquabot.2010.04.004; Huiling S, 2004, ADV SEA CUCUMBER AQU, P327; KANENIWA M, 1986, COMP BIOCHEM PHYS B, V84, P451, DOI 10.1016/0305-0491(86)90105-7; Kasai T, 2003, FOOD SCI TECHNOL RES, V9, P45, DOI 10.3136/fstr.9.45; Ko SH, 2009, J WORLD AQUACULT SOC, V40, P659; LEO RF, 1966, SCIENCE, V152, P649, DOI 10.1126/science.152.3722.649; MIMURA T, 1981, J PHARMACOBIO-DYNAM, V4, P844; Oku H, 2003, BIOSCI BIOTECH BIOCH, V67, P2106, DOI 10.1271/bbb.67.2106; Rioux V, 2000, J NUTR BIOCH, V11, P298; Sonnichsen M, 1999, LIPIDS, V34, P1347, DOI 10.1007/s11745-999-0488-z; SVETASHEV VI, 1991, COMP BIOCHEM PHYS B, V98, P489, DOI 10.1016/0305-0491(91)90242-6; TAGIRI M, 1994, BIOSCI BIOTECH BIOCH, V58, P1093; Tokuda M, 2009, FISHERIES SCI, V75, P533, DOI 10.1007/s12562-008-0053-1	31	4	4	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1355-557X	1365-2109		AQUAC RES	Aquac. Res.	NOV	2014	45	12					2021	2031		10.1111/are.12149		11	Fisheries	Fisheries	AS6JS	WOS:000344370600013		
J	Higuchi, K; Horihata, Y				Higuchi, Kojiro; Horihata, Yoshihiro			Weak theories of concatenation and minimal essentially undecidable theories	ARCHIVE FOR MATHEMATICAL LOGIC			English	Article						Theory of concatenation; The monadic second-order theory of two successors; Minimal essentially undecidable theory; Interpretability	INTERPRETABILITY; DECIDABILITY	We consider weak theories of concatenation, that is, theories for strings or texts. We prove that the theory of concatenation , which is a weak subtheory of Grzegorczyk's theory , is a minimal essentially undecidable theory, that is, the theory is essentially undecidable and if one omits an axiom scheme from , then the resulting theory is no longer essentially undecidable. Moreover, we give a positive answer to Grzegorczyk and Zdanowski's conjecture that 'The theory is a minimal essentially undecidable theory'. For the alternative theories and which have the empty string, we also prove that the each theory without the neutrality of is to be such a theory too.	[Higuchi, Kojiro] Chiba Univ, Dept Math & Informat, Inage Ku, Chiba 2638522, Japan; [Horihata, Yoshihiro] Yonago Natl Coll Technol, Yonago, Tottori, Japan	Horihata, Y (reprint author), Yonago Natl Coll Technol, 4448 Hikona, Yonago, Tottori, Japan.	khiguchi@g.math.s.chiba-u.ac.jp; horihata@yonago-k.ac.jp					RABIN MO, 1969, T AM MATH SOC, V141, P1, DOI 10.2307/1995086; Svejdar V, 2009, NOTRE DAME J FORM L, V50, P87, DOI 10.1215/00294527-2008-029; Ganea M, 2009, J SYMBOLIC LOGIC, V74, P265, DOI 10.2178/jsl/1231082312; Friedman H., LECT NOTE 19 ANN TAR; Grzegorczyk A, 2004, ANN PURE APPL LOGIC, V126, P309, DOI 10.1016/j.apal.2003.11.029; Grzegorczyk A., 2005, Studia Logica, V79, DOI 10.1007/s11225-005-2976-1; Grzegorczyk A, 2008, ANDRZEJ MOSTOWSKI AND FOUNDATIONAL STUDIES, P72; Hilbert D., 2002, FDN MATH, P464; Horihata Y, 2012, NOTRE DAME J FORM L, V53, P203, DOI 10.1215/00294527-1715698; Jones J.P., 1983, ARCH MATH LOGIK GRUN, V23, P61, DOI 10.1007/BF02023013; Quine W. V. O., 1946, J SYMBOLIC LOGIC, V11, P105, DOI 10.2307/2268308; Sterken R., 2008, THESIS U AMSTERDAM; Svejdar V., 1978, COMMENTATIONES MATH, V19, P789; Svejdar V, 2008, LOGICA YB 2007 P LOG; Tarski A., LOGIC SEMANTICS META; Tarski A., 1934, CONCEPT TRUTH FORMAL, P152; Tarski Alfred, 1953, UNDECIDABLE THEORIES; van Heijenoort J., 2002, FREGE GODEL; Vaught R.L., 1962, LOGIC METHODOLOGY PH, P14; Visser A, 2009, NOTRE DAME J FORM L, V50, P61, DOI 10.1215/00294527-2008-028; Visser A, 1998, CSLI LECT N, P307; Visser A., 2009, LOGIC GROUP PREPRINT, V267; Yoshida O., 2012, THESIS TOHOKU U	23	0	0	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1432-0665			ARCH MATH LOGIC	Arch. Math. Log.	NOV	2014	53	7-8					835	853		10.1007/s00153-014-0391-x		19	Mathematics; Logic	Mathematics; Science & Technology - Other Topics	AS5PW	WOS:000344323300006		
J	Furue, M; Takahara, M; Nakahara, T; Uchi, H				Furue, Masutaka; Takahara, Masakazu; Nakahara, Takeshi; Uchi, Hiroshi			Role of AhR/ARNT system in skin homeostasis	ARCHIVES OF DERMATOLOGICAL RESEARCH			English	Review						Aryl hydrocarbon receptor; Aryl hydrocarbon receptor nuclear translocator; Dioxin; Malassezia; Melanogenesis; Th17; Treg; Ultraviolet	ARYL-HYDROCARBON RECEPTOR; YEAST MALASSEZIA-FURFUR; EPIDERMAL DIFFERENTIATION COMPLEX; REGULATORY T-CELLS; HUMAN KERATINOCYTES; DIOXIN RECEPTOR; BARRIER FUNCTION; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN ALTERS; MOLECULAR-MECHANISMS; CORNIFIED ENVELOPE	Aryl hydrocarbon receptor (AhR) is a ligand-dependent transcription factor that binds to structurally diverse synthetic and naturally occurring chemicals including dioxins, flavonoids, tryptophan photoproducts, and Malassezia metabolites. Upon binding to its ligands, cytoplasmic AhR translocates to the nucleus, heterodimerizes with aryl hydrocarbon receptor nuclear translocator (ARNT), and mediates numerous biological and toxicological effects by inducing the transcription of various AhR-responsive genes. AhR ligation controls oxidation/antioxidation, epidermal barrier function, photo-induced response, melanogenesis, and innate immunity. This review summarizes recent advances in the understanding of the regulatory mechanisms of skin homeostasis mediated by the AhR/ARNT system.	[Furue, Masutaka; Takahara, Masakazu; Nakahara, Takeshi; Uchi, Hiroshi] Kyushu Univ, Dept Dermatol, Higashi Ku, Fukuoka 8128582, Japan; [Furue, Masutaka; Uchi, Hiroshi] Kyushu Univ, Res & Clin Ctr Yusho & Dioxin, Fukuoka 8128582, Japan; [Furue, Masutaka; Nakahara, Takeshi] Kyushu Univ, Div Skin Surface Sensing, Fukuoka 8128582, Japan	Furue, M (reprint author), Kyushu Univ, Dept Dermatol, Higashi Ku, Maidashi 3-1-1, Fukuoka 8128582, Japan.	furue@dermatol.med.kyushu-u.ac.jp			Ministry of Health, Labour and Welfare; Ministry of Education, Culture, Sports, Science and Technology; Environment Technology Development Fund of the Ministry of the Environment, Japan	This work was partly supported by grants from The Ministry of Health, Labour and Welfare; The Ministry of Education, Culture, Sports, Science and Technology; and the Environment Technology Development Fund of the Ministry of the Environment, Japan.	Agostinis P, 2007, 403PE49 STKE, V403, ppe49; Akiyama Tomoko, 1995, Journal of Dermatology (Tokyo), V22, P930; Wei YD, 2000, ARCH BIOCHEM BIOPHYS, V383, P99, DOI 10.1006/abbi.2000.2037; Gaitanis G, 2008, J INVEST DERMATOL, V128, P1620, DOI 10.1038/sj.jid.5701252; Kadow S, 2011, J IMMUNOL, V187, P3104, DOI 10.4049/jimmunol.1100912; Yin YQ, 2013, TOXICOL APPL PHARM, V269, P89, DOI 10.1016/j.taap.2013.03.015; Ju QA, 2011, EXP DERMATOL, V20, P320, DOI 10.1111/j.1600-0625.2010.01204.x; Wang XW, 2012, BRIT J DERMATOL, V166, P1081, DOI 10.1111/j.1365-2133.2011.10798.x; Ray SS, 2003, TOXICOL APPL PHARM, V192, P131, DOI 10.1016/S0041-008X(03)00277-1; McLean WHI, 2013, J CLIN INVEST, V123, P551, DOI 10.1172/JCI67438; Jaiswal AK, 2004, FREE RADICAL BIO MED, V36, P1199, DOI 10.1016/j.freeradbiomed.2004.02.074; CAPUTO R, 1988, J AM ACAD DERMATOL, V19, P812, DOI 10.1016/S0190-9622(88)70238-8; Shimizu Y, 2000, P NATL ACAD SCI USA, V97, P779, DOI 10.1073/pnas.97.2.779; Vermeij WP, 2011, J INVEST DERMATOL, V131, P1435, DOI 10.1038/jid.2010.433; Quintana FJ, 2008, NATURE, V453, P65, DOI 10.1038/nature06880; Han SG, 2012, TOXICOL APPL PHARM, V261, P181, DOI 10.1016/j.taap.2012.03.024; Nguyen NT, 2010, P NATL ACAD SCI USA, V107, P19961, DOI 10.1073/pnas.1014465107; Niestroy J, 2011, TOXICOL IN VITRO, V25, P671, DOI 10.1016/j.tiv.2011.01.008; Matsumoto S, 2013, CHEMOSPHERE, V92, P772, DOI 10.1016/j.chemosphere.2013.04.005; Wakabayashi N, 2003, NAT GENET, V35, P238, DOI 10.1038/ng1248; Connor KT, 2008, J EXPO SCI ENV EPID, V18, P369, DOI 10.1038/sj.jes.7500607; Saurat JH, 2012, TOXICOL SCI, V125, P310, DOI 10.1093/toxsci/kfr223; Nebert DW, 2008, J BIOL CHEM, V283, P36061, DOI 10.1074/jbc.R800053200; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HIER SW, 1946, J BIOL CHEM, V166, P327; Panteleyev AA, 2006, EXP DERMATOL, V15, P705, DOI 10.1111/j.0906-6705.2006.00476.x; Li D, 2013, ONCOGENE, V32, P4950, DOI 10.1038/onc.2012.509; Schafer M, 2012, EMBO MOL MED, V4, P364, DOI 10.1002/emmm.201200219; Denison MS, 2011, TOXICOL SCI, V124, P1, DOI 10.1093/toxsci/kfr218; Gaitanis G, 2012, CLIN MICROBIOL REV, V25, P106, DOI [10.1128/​CMR.00021-11, 10.1128/CMR.00021-11]; Tigges J, 2014, J INVEST DERMATOL, V134, P556, DOI 10.1038/jid.2013.362; Fritsche E, 2007, P NATL ACAD SCI USA, V104, P8851, DOI 10.1073/pnas.0701764104; Sutter CH, 2011, TOXICOL SCI, V124, P128, DOI 10.1093/toxsci/kfr205; Quintana FJ, 2010, P NATL ACAD SCI USA, V107, P20768, DOI 10.1073/pnas.1009201107; Contador-Troca M, 2013, CARCINOGENESIS, V34, P2683, DOI 10.1093/carcin/bgt248; Soshilov A, 2008, J BIOL CHEM, V283, P32995, DOI 10.1074/jbc.M802414200; Chiba T, 2011, PULM PHARMACOL THER, V24, P133, DOI 10.1016/j.pupt.2010.08.002; Kennedy LH, 2013, TOXICOL SCI, V132, P235, DOI 10.1093/toxsci/kfs325; Geusau A, 2001, ENVIRON HEALTH PERSP, V109, P865, DOI 10.2307/3454832; Kypriotou M, 2012, EXP DERMATOL, V21, P643, DOI 10.1111/j.1600-0625.2012.01472.x; Luecke S, 2010, PIGM CELL MELANOMA R, V23, P828, DOI 10.1111/j.1755-148X.2010.00762.x; Funatake CJ, 2005, J IMMUNOL, V175, P4184; Geng SM, 2006, J CELL SCI, V119, P4901, DOI 10.1242/jcs.03282; Tauchi M, 2005, MOL CELL BIOL, V25, P9360, DOI 10.1128/MCB.25.21.9360-9368.2005; Sutter CH, 2009, P NATL ACAD SCI USA, V106, P4266, DOI 10.1073/pnas.0900874106; Hao N, 2013, BIOCHEM PHARMACOL, V86, P561, DOI 10.1016/j.bcp.2013.07.004; Oberg M, 2005, TOXICOL SCI, V85, P935, DOI 10.1093/toxsci/kfi154; Takagi S, 2003, J CLIN INVEST, V112, P1372, DOI 10.1172/JCI200318513; Kramer HJ, 2005, CHEMBIOCHEM, V6, P860, DOI 10.1002/cbic.200400247; Tsuji G, 2011, J DERMATOL SCI, V62, P42, DOI 10.1016/j.jdermsci.2010.10.017; Schallreuter KU, 2012, FASEB J, V26, P2471, DOI 10.1096/fj.11-201897; Wincent E, 2012, P NATL ACAD SCI USA, V109, P4479, DOI 10.1073/pnas.1118467109; Veldhoen M, 2008, NATURE, V453, P106, DOI 10.1038/nature06881; Costa C, 2010, TOXICOLOGY, V271, P83, DOI 10.1016/j.tox.2010.02.014; SUSKIND RR, 1985, SCAND J WORK ENV HEA, V11, P165; Magiatis P, 2013, J INVEST DERMATOL, V133, P2023, DOI 10.1038/jid.2013.92; Sorg O, 2009, LANCET, V374, P1179, DOI 10.1016/S0140-6736(09)60912-0; Kohda F, 2013, J DERMATOL SCI, V72, P75, DOI 10.1016/j.jdermsci.2013.05.008; Krutmann J, 2012, J INVEST DERMATOL, V132, P976, DOI 10.1038/jid.2011.394; Nguyen LP, 2008, CHEM RES TOXICOL, V21, P102, DOI 10.1021/tx7001965; Papaiahgari S, 2007, AM J RESP CELL MOL, V36, P304, DOI 10.1165/rcmb.2006-0131OC; Ikuta T, 2009, BIOCHEM PHARMACOL, V77, P588, DOI 10.1016/j.bcp.2008.10.003; Mayser P, 2002, ARCH DERMATOL RES, V294, P131, DOI 10.1007/s00403-002-0294-2; Jux B, 2009, J IMMUNOL, V182, P6709, DOI 10.4049/jimmunol.0713344; Marshall NB, 2008, J IMMUNOL, V181, P2382; van den Bogaard EH, 2013, J CLIN INVEST, V123, P917, DOI 10.1172/JCI65642; Diani-Moore S, 2006, TOXICOL SCI, V90, P96, DOI 10.1093/toxsci/kfj065; Mimura J, 1999, GENE DEV, V13, P20, DOI 10.1101/gad.13.1.20; Jux B, 2011, J INVEST DERMATOL, V131, P203, DOI 10.1038/jid.2010.269; Frauenstein K, 2013, CELL DEATH DIFFER, V20, P1425, DOI 10.1038/cdd.2013.102; Wincent E, 2009, J BIOL CHEM, V284, P2690, DOI 10.1074/jbc.M808321200; Nakamura M, 2013, EXP DERMATOL, V22, P556, DOI 10.1111/exd.12170; Loertscher JA, 2001, TOXICOL APPL PHARM, V175, P121, DOI 10.1006/taap.2001.9202; Loertscher JA, 2002, TOXICOL SCI, V68, P465, DOI 10.1093/toxsci/68.2.465; Fortes C, 2005, ARCH DERMATOL, V141, P1580, DOI 10.1001/archderm.141.12.1580; FURUE M, 2005, J DERMATOL SCI S, V1, pS3, DOI DOI 10.1016/J.DESCS.2005.03.002; Gaitanis G, 2011, MED HYPOTHESES, V77, P47, DOI 10.1016/j.mehy.2011.03.020; Haarmann-Stemmann T, 2012, J INVEST DERMATOL, V132, P7, DOI 10.1038/jid.2011.359; Iida T, 1999, CHEMOSPHERE, V38, P981, DOI 10.1016/S0045-6535(98)00360-9; Imamura Tomoaki, 2009, BMC Res Notes, V2, P27, DOI 10.1186/1756-0500-2-27; Kramer HJ, 2005, CHEMBIOCHEM, V6, P2290, DOI 10.1002/cbic.200500163; Lan CCE, 2013, PIGM CELL MELANOMA R, V26, P367, DOI 10.1111/pcmr.12077; Li Ying, 2011, Cell, V147, P629, DOI 10.1016/j.cell.2011.09.025; Mimura J, 2003, BBA-GEN SUBJECTS, V1619, P263, DOI 10.1016/S0304-4165(02)00485-3; Mohammadi-Bardbori A, 2012, CHEM RES TOXICOL, V25, P1878, DOI 10.1021/tx300169e; Nagayama J, 2010, CHEMOSPHERE, V80, P513, DOI 10.1016/j.chemosphere.2010.04.062; Navid F, 2013, J INVEST DERMATOL, V133, P2763, DOI 10.1038/jid.2013.221; Pastor MA, 2002, J CUTAN PATHOL, V29, P193, DOI 10.1034/j.1600-0560.2002.290401.x; Pot C, 2012, SWISS MED WKLY, V142, DOI 10.4414/smw.2012.13592; Schafer M., 2014, EMBO MOL MED; Schafer M, 2011, J INVEST DERMATOL, V131, P1409, DOI 10.1038/jid.2011.119; Tigges J, 2013, J INVEST DERMATOL, V133, P87, DOI 10.1038/jid.2012.259; Tsuji G, 2012, J INVEST DERMATOL, V132, P59, DOI 10.1038/jid.2011.194; Uchi H, 2012, EUR J DERMATOL, V22, P687, DOI 10.1684/ejd.2012.1805; Vermeij WP, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011957; Watabe Y, 2013, ARCH DERMATOL RES, V305, P755, DOI 10.1007/s00403-013-1403-0	96	9	11	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0340-3696	1432-069X		ARCH DERMATOL RES	Arch. Dermatol. Res.	NOV	2014	306	9					769	779		10.1007/s00403-014-1481-7		11	Dermatology	Dermatology	AS3HM	WOS:000344168300001		
J	Nishikori, Y; Shiota, N; Okunishi, H				Nishikori, Yoriko; Shiota, Naotaka; Okunishi, Hideki			The role of mast cells in cutaneous wound healing in streptozotocin-induced diabetic mice	ARCHIVES OF DERMATOLOGICAL RESEARCH			English	Article						Wound healing; Mast cells; Endothelial progenitor cells; Angiogenesis; Vascular regression	ENDOTHELIAL PROGENITOR CELLS; IN-VITRO ANGIOGENESIS; C-KIT; GENE-EXPRESSION; INVOLVEMENT; RECEPTOR; EXHIBIT; REPAIR; RATS; ACTIVATION	Mast cells (MCs) reside in cutaneous tissue, and an increment of MCs is suggested to induce vascular regression in the process of wound healing. To clarify participation of MCs in diabetic cutaneous wound healing, we created an excisional wound on diabetic mice 4 weeks after streptozotocin injections and subsequently investigated the healing processes for 49 days, comparing them with control mice. The rate of wound closure was not markedly different between the diabetic and control mice. In the proliferative phase at days 7 and 14, neovascularization in the wound was weaker in diabetic mice than in control mice. In the remodeling phase at day 21 and afterward, rapid vascular regression occurred in control mice; however, neovascularization was still observed in diabetic mice where the number of vessels in granulation tissues was relatively higher than in control mice. In the remodeling phase of the control mice, MCs within the wound began to increase rapidly and resulted in considerable accumulation, whereas the increment of MCs was delayed in diabetic mice. In addition, the number of fibroblast growth factor (FGF)- or vascular endothelial growth factor (VEGF)-immunopositive hypertrophic fibroblast-like spindle cells and c-Kit-positive/VEGFR2-positive/Fc epsilon RI alpha-negative endothelial progenitor cells (EPCs) were higher in diabetic wounds. In conclusion, neovascularization in the proliferative phase and vascular regression in the remodeling phase were impaired in diabetic mice. The delayed increment of MCs and sustained angiogenic stimuli by fibroblast-like spindle cells and EPCs may inhibit vascular regression in the remodeling phase and impair the wound-healing process in diabetic mice.	[Nishikori, Yoriko; Shiota, Naotaka; Okunishi, Hideki] Shimane Univ, Sch Med, Dept Pharmacol, Izumo, Shimane 6938501, Japan	Nishikori, Y (reprint author), Shimane Univ, Sch Med, Dept Pharmacol, 89-1 Enya Cho, Izumo, Shimane 6938501, Japan.	yakurign@med.shimane-u.ac.jp					Peplow PV, 2012, PHOTOMED LASER SURG, V30, P617, DOI 10.1089/pho.2012.3312; Noli C, 2001, VET DERMATOL, V12, P303, DOI 10.1046/j.0959-4493.2001.00272.x; Michaels J, 2007, WOUND REPAIR REGEN, V15, P665, DOI 10.1111/j.1524-475X.2007.00273.x; Cavalher-Machado SC, 2004, EUR RESPIR J, V24, P552, DOI 10.1183/09031936.04.00130803; Galli SJ, 2008, J DERMATOL SCI, V49, P7, DOI 10.1016/j.jdermsci.2007.09.009; Gurtner GC, 2008, NATURE, V453, P314, DOI 10.1038/nature07039; Yoder MC, 2007, BLOOD, V109, P1801, DOI 10.1182/blood-2006-08-043471; Singer AJ, 1999, NEW ENGL J MED, V341, P738; Fiorina P, 2010, CELL TRANSPLANT, V19, P1369, DOI 10.3727/096368910X514288; Trautmann A, 2000, J PATHOL, V190, P100, DOI 10.1002/(SICI)1096-9896(200001)190:1<100::AID-PATH496>3.0.CO;2-Q; Okayama Y, 2006, IMMUNOL RES, V34, P97, DOI 10.1385/IR:34:2:97; IruelaArispe ML, 1997, THROMB HAEMOSTASIS, V78, P672; Hur J, 2004, ARTERIOSCL THROM VAS, V24, P288, DOI 10.1161/01.ATV.0000114236.77009.06; Antsiferova M, 2013, J IMMUNOL, V191, P6147, DOI 10.4049/jimmunol.1301350; Mirza R, 2011, CYTOKINE, V56, P256, DOI 10.1016/j.cyto.2011.06.016; Wu LY, 2009, DEV CELL, V17, P35, DOI 10.1016/j.devcel.2009.05.010; Portero-Otin M, 2002, DIABETES, V51, P1535, DOI 10.2337/diabetes.51.5.1535; Trousdale RK, 2009, J SURG RES, V151, P100, DOI 10.1016/j.jss.2008.01.023; TSAI M, 1991, P NATL ACAD SCI USA, V88, P6382, DOI 10.1073/pnas.88.14.6382; Bevan D, 2004, J PATHOL, V203, P831, DOI 10.1002/path.1578; Kwon DS, 2008, INT WOUND J, V5, P453, DOI 10.1111/j.1742-481X.2007.00408.x; Martin A, 2003, MED RES REV, V23, P117, DOI 10.1002/med.10024; Ilan N, 1998, J CELL SCI, V111, P3621; Loomans CJM, 2004, DIABETES, V53, P195; Liu SH, 2013, J PATHOL, V230, P215, DOI 10.1002/path.4045; Maharlooei MK, 2011, DIABETES RES CLIN PR, V93, P228, DOI 10.1016/j.diabres.2011.04.018; Lindstedt KA, 2001, FASEB J, V15, P1377, DOI 10.1096/fj.00-0273com; Dentelli P, 2007, BLOOD, V109, P4264, DOI 10.1182/blood-2006-06-029603; Egozi EI, 2003, WOUND REPAIR REGEN, V11, P46, DOI 10.1046/j.1524-475X.2003.11108.x; Ashman LK, 1999, INT J BIOCHEM CELL B, V31, P1037, DOI 10.1016/S1357-2725(99)00076-X; Greenhalgh DG, 2003, METH MOLEC MED, V78, P181; STARKEY JR, 1988, INT J CANCER, V42, P48, DOI 10.1002/ijc.2910420110; Broadley K N, 1989, Biotechnol Ther, V1, P55; Dudeck A, 2010, EXP DERMATOL, V19, P424, DOI 10.1111/j.1600-0625.2010.01073.x; GALLI SJ, 1993, AM J PATHOL, V142, P965; Herdrich BJ, 2008, CYTOTHERAPY, V10, P543, DOI 10.1080/14653240802345820; Iba Y, 2004, INT IMMUNOPHARMACOL, V4, P1873, DOI 10.1016/j.intimp.2004.08.009; Karimi K, 1999, EXP HEMATOL, V27, P654, DOI 10.1016/S0301-472X(98)00083-6; Keswani SG, 2004, WOUND REPAIR REGEN, V12, P497, DOI 10.1111/j.1067-1927.2004.12501.x; Kim KL, 2011, CARDIOVASC RES, V92, P132, DOI 10.1093/cvr/cvr161; Lan CCE, 2009, BRIT J DERMATOL, V160, P1206, DOI 10.1111/j.1365-2133.2009.09089.x; Lee MJ, 2011, CYTOTHERAPY, V13, P165, DOI 10.3109/14653249.2010.512632; Lois Noemi, 2014, Front Endocrinol (Lausanne), V5, P44, DOI 10.3389/fendo.2014.00044; Nauta AC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059167; Nishikori Y, 1998, ARCH DERMATOL RES, V290, P553, DOI 10.1007/s004030050351; PEPPER MS, 1993, EXP CELL RES, V204, P356, DOI 10.1006/excr.1993.1043; Shiota N, 2010, INT ARCH ALLERGY IMM, V151, P80, DOI 10.1159/000232573; Tahergorabi Zoya, 2012, Int J Prev Med, V3, P827; Willenborg S, 2014, J INVEST DERMATOL, V134, P2005, DOI 10.1038/jid.2014.12; Zins SR, 2010, ANGIOGENESIS, V13, P293, DOI 10.1007/s10456-010-9186-9	50	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0340-3696	1432-069X		ARCH DERMATOL RES	Arch. Dermatol. Res.	NOV	2014	306	9					823	835		10.1007/s00403-014-1496-0		13	Dermatology	Dermatology	AS3HM	WOS:000344168300006		
J	Morimura, S; Sugaya, M; Suga, H; Miyagaki, T; Ohmatsu, H; Fujita, H; Asano, Y; Tada, Y; Kadono, T; Sato, S				Morimura, Sohshi; Sugaya, Makoto; Suga, Hiraku; Miyagaki, Tomomitsu; Ohmatsu, Hanako; Fujita, Hideki; Asano, Yoshihide; Tada, Yayoi; Kadono, Takafumi; Sato, Shinichi			TOX expression in different subtypes of cutaneous lymphoma	ARCHIVES OF DERMATOLOGICAL RESEARCH			English	Article						TOX; Cutaneous T cell lymphoma; CCR4; Mycosis fungoides	T-CELL LYMPHOMA; MYCOSIS-FUNGOIDES; SEZARY-SYNDROME; THYMOCYTE SELECTION; ABERRANT EXPRESSION; CLASSIFICATION; COMMITMENT; DISEASE; EORTC; CD8	Early cutaneous T cell lymphoma clinically and histologically resembles benign inflammatory skin diseases, which sometimes makes it difficult to reach a correct diagnosis. It is recently reported that thymocyte selection-associated high mobility group box factor (TOX) serves as a molecular marker for histological diagnosis of early-stage mycosis fungoides (MF). To examine whether TOX could be a marker of tumour cells in different types of cutaneous lymphoma, we investigated immunohistochemical staining for TOX with the lesional skin of patch, plaque, and tumour MF, S,zary syndrome (SS), lymphomatoid papulosis (LyP), primary cutaneous anaplastic large cell lymphoma (PCALCL), adult T cell leukemia/lymphoma (ATLL), peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS), atopic dermatitis (AD), and normal skin. TOX and CCR4 messenger RNA (mRNA) levels in lesional skin of MF/SS were also examined. Immunohistological staining showed that a high specific nuclear staining of TOX was observed at a high frequency in MF, SS, and PTCL, NOS. Tumour cells in LyP, PCALCL, and ATLL showed a slightly dim nuclear staining of TOX. TOX+ cells in MF and LyP expressed surface molecules characteristics of tumour cells in these diseases. Lesional skin of SS expressed higher levels of TOX mRNA, compared to normal skin or MF lesional skin. Moreover, TOX expression significantly correlated with CCR4 expression. TOX may be a specific marker for tumour cells in some types of cutaneous lymphoma.	[Morimura, Sohshi; Sugaya, Makoto; Suga, Hiraku; Miyagaki, Tomomitsu; Ohmatsu, Hanako; Fujita, Hideki; Asano, Yoshihide; Tada, Yayoi; Kadono, Takafumi; Sato, Shinichi] Univ Tokyo, Dept Dermatol, Fac Med, Bunkyo Ku, Tokyo 1138655, Japan	Sugaya, M (reprint author), Univ Tokyo, Dept Dermatol, Fac Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	sugayam-der@h.u-tokyo.ac.jp					Huang YS, 2014, ONCOTARGET, V5, P4418; Zhang YH, 2012, J INVEST DERMATOL, V132, P1698, DOI 10.1038/jid.2012.13; Willemze R, 2005, BLOOD, V105, P3768, DOI 10.1182/blood-2004-09-3502; He X, 2005, NATURE, V433, P826, DOI 10.1038/nature03338; van Doorn R, 2004, CANCER RES, V64, P5578, DOI 10.1158/0008-5472.CAN-04-1253; McGirt LY, 2014, J INVEST DERMATOL, V134, P1101, DOI 10.1038/jid.2013.461; Ishii T, 2010, CLIN CANCER RES, V16, P1520, DOI 10.1158/1078-0432.CCR-09-2697; Wilkinson B, 2002, NAT IMMUNOL, V3, P272, DOI 10.1038/ni767; Sugaya M, 2010, J DERMATOL SCI, V59, P81, DOI 10.1016/j.jdermsci.2010.05.005; Vega F, 2002, BLOOD, V100, P3369, DOI 10.1182/blood.V100.9.3369; Ferenczi K, 2002, J INVEST DERMATOL, V119, P1405, DOI 10.1046/j.1523-1747.2002.19610.x; Li JY, 2012, BREAST CANCER RES TR, V131, P837, DOI 10.1007/s10549-011-1502-6; Olsen E, 2007, BLOOD, V110, P1713, DOI 10.1182/blood-2007-03-055749; Kakinuma T, 2003, J AM ACAD DERMATOL, V48, P23, DOI 10.1067/mjd.2003.132; Litovinov IV, 2014, CLIN CANCER RES, V20, P3799; Miyagaki T, 2011, J DERMATOL SCI, V64, P1, DOI 10.1016/j.jdermsci.2011.07.007; Pare H, 2011, BLOOD, V118, P4853; Poszepczynska-Guigne E, 2004, J INVEST DERMATOL, V122, P820, DOI 10.1111/j.0022-202X.2004.22326.x; Sato T, 2005, IMMUNITY, V22, P317, DOI 10.1016/j.immuni.2005.01.012; Su MW, 2003, CANCER RES, V63, P7122; Swerdlow S, 2008, WHO CLASSIFICATION T, P296	21	3	3	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0340-3696	1432-069X		ARCH DERMATOL RES	Arch. Dermatol. Res.	NOV	2014	306	9					843	849		10.1007/s00403-014-1501-7		7	Dermatology	Dermatology	AS3HM	WOS:000344168300008		
J	Tada, A; Miura, H				Tada, Akio; Miura, Hiroko			Systematic review of the association of mastication with food and nutrient intake in the independent elderly	ARCHIVES OF GERONTOLOGY AND GERIATRICS			English	Review						Mastication; Prosthesis; Oral health; Food intake; Nutrient intake; Elderly	OLDER-ADULTS; EDENTULOUS SUBJECTS; NUTRITIONAL-STATUS; DIETARY ADEQUACY; CHEWING ABILITY; DENTAL STATUS; ORAL-HEALTH; TOOTH LOSS; VEGETABLE INTAKE; DENTITION STATUS	Substantial number of elderly people suffer from poor mastication, which is considered to have a detrimental effect on their dietary habits. However, the association between mastication and diet is far from conclusive. The objective of this systematic review was to assess the association of mastication with food and nutrient intake in the community dwelling elderly. We searched the PubMed, Web of Science, Cochrane Library, and Scirus databases to obtain information on the epidemiological studies in this research area. The included publications were analyzed for study design, main conclusions, and strength of evidence. A comprehensive quality assessment of all the included studies (28 cross-sectional and 7 intervention studies) was performed. In 22 of the 28 cross-sectional studies, elderly persons with better mastication and dentition reported significantly higher consumption of foods and intake of some nutrients than those with poorer oral health; however, the remaining studies showed no such differences. Five of the 7 intervention studies with an intervention involving the provision of new prostheses did not show significant improvement in food and/or nutrient intake. These discrepant findings suggest that masticatory ability explains only part of the variance in food and nutrient intake of the elderly. Two intervention studies with the combination of prosthetic treatment and dietary intervention produced changes in intake of foods such as fruits and vegetables. (C) 2014 Elsevier Ireland Ltd. All rights reserved.	[Tada, Akio] Univ Hyogo, Dept Hlth Sci, Kakogawa, Hyogo 6750195, Japan; [Miura, Hiroko] Natl Inst Publ Hlth, Dept Int Hlth & Collaborat, Wako, Saitama 3510197, Japan	Tada, A (reprint author), Univ Hyogo, Dept Hlth Sci, 2301 Shinzaike Hiraoka Cho, Kakogawa, Hyogo 6750195, Japan.	atada@hyogo-dai.ac.jp					Akpata E, 2011, COMMUNITY DENT ORAL, V39, P409, DOI 10.1111/j.1600-0528.2011.00612.x; WAYLER AH, 1984, J GERONTOL, V39, P284; Moynihan PJ, 2000, J DENT, V28, P557, DOI 10.1016/S0300-5712(00)00044-0; Liedberg B, 2007, GERODONTOLOGY, V24, P41, DOI 10.1111/j.1741-2358.2007.00150.x; Konttinen H, 2013, PUBLIC HEALTH NUTR, V16, P873, DOI 10.1017/S1368980012003540; Morais JA, 2003, J DENT RES, V82, P53; Marshall TA, 2002, J AM DENT ASSOC, V133, P1369; MANLY RS, 1950, J DENT RES, V29, P448, DOI 10.1177/00220345500290040701; Krall E, 1998, J AM DENT ASSOC, V129, P1261; Boylan S, 2011, PUBLIC HEALTH NUTR, V14, P678, DOI 10.1017/S1368980010002570; Feine JS, 2006, J ORAL REHABIL, V33, P301, DOI 10.1111/j.1365-2842.2006.01614.x; Awad MA, 2012, J DENT RES, V91, P39, DOI 10.1177/0022034511423396; BRODEUR JM, 1993, J PROSTHET DENT, V70, P468, DOI 10.1016/0022-3913(93)90087-5; BASIOTIS PP, 1987, J NUTR, V117, P1638; HARTSOOK EI, 1974, J PROSTHET DENT, V32, P32, DOI 10.1016/0022-3913(74)90096-1; Tucker KL, 2000, AM J CLIN NUTR, V71, P514; Kagawa R, 2012, INT J PROSTHODONT, V25, P368; Ervin RB, 2009, J PUBLIC HEALTH DENT, V69, P207, DOI 10.1111/j.1752-7325.2009.00124.x; Sahyoun NR, 2003, J AM DIET ASSOC, V103, P61, DOI 10.1053/jada.2003.50003; Lee JS, 2004, AM J CLIN NUTR, V79, P295; Tsai AC, 2011, J NUTR HEALTH AGING, V15, P265; Walls AWG, 2004, MECH AGEING DEV, V125, P853, DOI 10.1016/j.mad.2004.07.011; Sheiham A, 2001, J DENT RES, V80, P408; Joshipura KJ, 1996, J AM DENT ASSOC, V127, P459; Appollonio I, 1997, AGE AGEING, V26, P445, DOI 10.1093/ageing/26.6.445; Bartlett DW, 2013, J DENT, V41, P143, DOI 10.1016/j.jdent.2012.10.012; Bradbury J, 2006, J DENT RES, V85, P463; Bradbury J, 2008, J DENT RES, V87, P720; Brennan DS, 2010, AUST DENT J, V55, P143, DOI 10.1111/j.1834-7819.2010.01217.x; Chauncey H H, 1981, Spec Care Dentist, V1, P250, DOI 10.1111/j.1754-4505.1981.tb01266.x; de Andrade Fabiola Bof, 2009, Gerodontology, V26, P40, DOI 10.1111/j.1741-2358.2008.00220.x; De Marchi RJ, 2011, J ORAL REHABIL, V38, P533, DOI 10.1111/j.1365-2842.2010.02189.x; Ernest S L, 1993, Spec Care Dentist, V13, P102, DOI 10.1111/j.1754-4505.1993.tb01628.x; Fontijn-Tekamp F. A., 1996, European Journal of Clinical Nutrition, V50, pS117; Food and Nutrition Board National Research Council, 1989, REC DIET ALL; GREKSA LP, 1995, J PROSTHET DENT, V73, P142, DOI 10.1016/S0022-3913(05)80153-2; Gunji Atsuko, 2009, J Prosthodont Res, V53, P180, DOI 10.1016/j.jpor.2009.06.001; Hanson B S, 1987, Compr Gerontol B, V1, P62; Heneghan C, 2006, EVIDENCE BASED MED T; Hung HC, 2005, COMMUNITY DENT ORAL, V33, P167, DOI 10.1111/j.1600-0528.2005.00200.x; Hutton Brian, 2002, J Can Dent Assoc, V68, P182; Johansson L, 1999, BRIT J NUTR, V81, P211, DOI 10.1017/S0007114599000409; LACHAPELLE D, 1992, J CAN DIET ASSOC, V53, P145; Laurin D., 1994, J CAN DENT ASSOC, V60, P449; Laurin D, 1994, J Can Dent Assoc, V60, P443; Lin YC, 2010, INT J PROSTHODONT, V23, P127; Miura H, 1997, J ORAL REHABIL, V24, P457, DOI 10.1046/j.1365-2842.1997.00530.x; Miura K, 2012, PUBLIC HEALTH NUTR, V15, P218, DOI 10.1017/S136898001100139X; Moynihan PJ, 2012, J DENT, V40, P843, DOI 10.1016/j.jdent.2012.07.001; N'gom Papa Ibrahima, 2002, J Prosthet Dent, V87, P667, DOI 10.1067/mpr.2002.123229; Ochieng Bertha M N, 2006, Br J Community Nurs, V11, P78; Olivier M, 1995, J Can Dent Assoc, V61, P882; Osterberg T, 2002, Gerodontology, V19, P95, DOI 10.1111/j.1741-2358.2002.00095.x; Plan and Operation of the Third National Health and Nutrition Examination Survey, 1988, DHHS PHS PUBL, V94-1308; Sahyoun NR, 2003, J AM DIET ASSOC, V103, P1494, DOI 10.1016/S0002-8223(03)01231-8; SEBRING NG, 1995, J PROSTHET DENT, V74, P358, DOI 10.1016/S0022-3913(05)80374-9; Shinkai RSA, 2002, J PROSTHET DENT, V87, P490, DOI 10.1067/mpr.2002.124093; SLAGTER AP, 1992, J PROSTHET DENT, V68, P299, DOI 10.1016/0022-3913(92)90334-7; Tsuga K, 1998, J ORAL REHABIL, V25, P117; Walls AWG, 2000, J PUBLIC HEALTH DENT, V60, P304, DOI 10.1111/j.1752-7325.2000.tb03339.x; Willett W., 1998, NUTR EPIDEMIOLOGY, V2nd, P302; WITTER DJ, 1990, J DENT, V18, P185, DOI 10.1016/0300-5712(90)90107-P; Yoshida M, 2011, GERIATR GERONTOL INT, V11, P315, DOI 10.1111/j.1447-0594.2010.00688.x	63	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0167-4943	1872-6976		ARCH GERONTOL GERIAT	Arch. Gerontol. Geriatr.	NOV-DEC	2014	59	3					497	505		10.1016/j.archger.2014.08.005		9	Geriatrics & Gerontology	Geriatrics & Gerontology	AS3OG	WOS:000344187700001		
J	Sakurai, R; Fujiwara, Y; Sakuma, N; Suzuki, H; Ishihara, M; Higuchi, T; Imanaka, K				Sakurai, Ryota; Fujiwara, Yoshinori; Sakuma, Naoko; Suzuki, Hiroyuki; Ishihara, Masami; Higuchi, Takahiro; Imanaka, Kuniyasu			Influential factors affecting age-related self-overestimation of step-over ability: Focusing on frequency of going outdoors and executive function	ARCHIVES OF GERONTOLOGY AND GERIATRICS			English	Article						Aging; Self-estimation; Stepping-over; Overestimation; Going outdoors; Cognitive function	MINI-MENTAL-STATE; OLDER-ADULTS; CONSTRUCT-VALIDITY; POSTURAL LIMITS; WORKING-MEMORY; TRAIL; HOME; PREDICTORS; PEOPLE; HEALTH	Objective: Self-overestimation of step-over ability among older adults may result in a potential fall risk. However, the behavioral causal factor(s) of older adults' self-overestimation is unclear. We examined whether older adults' overestimation of step-over ability was mediated by an inactive lifestyle and/or poor executive function. Methods: A sample of 194 community-dwelling older adults was assigned to either a high (HG, once a day or more) or low (LG, every 2-3 days or less) frequency of going outdoors group. Executive function was determined by the Trail-Making Test (TMT). Both the HG and LG participants performed Step-Over Tests (SOT) in two ways: self-estimation of step-over ability and the actual step-over task. During the self-estimation task, participants observed the horizontal bar at a distance of 7 m and predicted the self-estimated maximum height (EH) of successful SOT trials. The motor task was then performed, determining the actual maximum height (AH) of successful trials. Results: A total of 36.1% of LG participants failed to successfully perform SOT trials at their EH (i.e., overestimation), whereas only 11.3% of HG participants failed. A multiple linear regression analysis showed that SOT overestimation was associated with an inactive lifestyle (low frequency of going outdoors) but not with executive function. Analyses of fall experience showed that both executive function and lifestyle significantly correlated with SOT overestimation among fallers, whereas only lifestyle was significantly correlated among non-fallers. Conclusion: Our results suggest that an inactive lifestyle is a possible correlate of SOT overestimation among older adults, while executive function further influenced overestimation only among fallers. (C) 2014 Elsevier Ireland Ltd. All rights reserved.	[Sakurai, Ryota; Higuchi, Takahiro; Imanaka, Kuniyasu] Tokyo Metropolitan Univ, Hachioji, Tokyo 1920397, Japan; [Sakurai, Ryota] Japan Soc Promot Sci, Chiyoda Ku, Tokyo 1020083, Japan; [Sakurai, Ryota; Fujiwara, Yoshinori; Suzuki, Hiroyuki] Tokyo Metropolitan Inst Gerontol, Res Team Social Participat & Community Hlth, Itabashi Ku, Tokyo 1730015, Japan; [Sakuma, Naoko] Tokyo Metropolitan Inst Gerontol, Res Team Promoting Independence Elderly, Itabashi Ku, Tokyo 1730015, Japan; [Ishihara, Masami] Tokyo Metropolitan Univ, Dept Human Sci, Hachioji, Tokyo 1920397, Japan	Sakurai, R (reprint author), Tokyo Metropolitan Inst Gerontol, Itabashi Ku, 35-2 Sakae Cho, Tokyo 1730015, Japan.	r_sakurai@hotmail.co.jp; imanaka@tmu.ac.jp			 [23-5365]	This study was supported by a Grant-in-Aid for JSPS (Japan Society for the Promotion of Science) fellows (23-5365). The authors acknowledge the continued efforts of the members of Unit 412 of the Tokyo Metropolitan Institute of Gerontology. We also thank Mr. Susumu Ogawa of Chuo University for his help in data collection.	Ahmed Mohamed S, 2005, Phys Med Rehabil Clin N Am, V16, P19, DOI 10.1016/j.pmr.2004.06.017; Sanchez-Cubillo I, 2009, J INT NEUROPSYCH SOC, V15, P438, DOI 10.1017/S1355617709090626; Hasegawa Y, 2005, CEREBROVASC DIS, V20, P325, DOI 10.1159/000087932; TOMBAUGH TN, 1992, J AM GERIATR SOC, V40, P922; Callisaya ML, 2008, J GERONTOL A-BIOL, V63, P165; Demakis GJ, 2004, J CLIN EXP NEUROPSYC, V26, P441, DOI 10.1080/13803390490510149; KOYANO W, 1991, ARCH GERONTOL GERIAT, V13, P103, DOI 10.1016/0167-4943(91)90053-S; Jabusch HC, 2009, HUM MOVEMENT SCI, V28, P74, DOI 10.1016/j.humov.2008.08.001; Fujita K, 2006, J EPIDEMIOL, V16, P261, DOI 10.2188/jea.16.261; Hirota C, 2010, GERIATR GERONTOL INT, V10, P40, DOI 10.1111/j.1447-0594.2009.00557.x; Shimada H, 2010, ARCH GERONTOL GERIAT, V50, P140, DOI 10.1016/j.archger.2009.02.015; Simonsick EM, 2005, J AM GERIATR SOC, V53, P198, DOI 10.1111/j.1532-5415.2005.53103.x; Diamond A, 2013, ANNU REV PSYCHOL, V64, P135, DOI 10.1146/annurev-psych-113011-143750; Jacobs JM, 2008, J AGING HEALTH, V20, P259, DOI 10.1177/0898264308315427; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; GAUDINO EA, 1995, J CLIN EXP NEUROPSYC, V17, P529, DOI 10.1080/01688639508405143; Ganguli M, 1996, J AM GERIATR SOC, V44, P363; Cohen-Mansfield J, 2012, ARCH GERONTOL GERIAT, V54, P55, DOI 10.1016/j.archger.2011.02.016; Gill TM, 2004, J GERONTOL A-BIOL, V59, P755; Butler AA, 2011, J GERONTOL A-BIOL, V66, P896, DOI 10.1093/gerona/glr071; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gabbard C, 2011, ARCH GERONTOL GERIAT, V53, P206, DOI 10.1016/j.archger.2010.10.006; GIBSON MJ, 1987, DAN MED BULL, V34, P1; Kono A, 2004, J GERONTOL A-BIOL, V59, P275; Kortte Kathleen Bechtold, 2002, Appl Neuropsychol, V9, P106, DOI 10.1207/S15324826AN0902_5; Liu-Ambrose T, 2008, ARCH PHYS MED REHAB, V89, P1335, DOI 10.1016/j.apmr.2007.11.052; Makizako H, 2013, ARCH GERONTOL GERIAT, V56, P118, DOI 10.1016/j.archger.2012.08.017; Nakamura Y, 2007, ARCH GERONTOL GERIAT, V44, P163, DOI 10.1016/j.archeger.2006.04.007; OBERG T, 1993, J REHABIL RES DEV, V30, P210; Robinovitch SN, 1999, J GERONTOL A-BIOL, V54, pB124, DOI 10.1093/gerona/54.3.B124; Sakurai R, 2013, BMC GERIATR, V13, DOI 10.1186/1471-2318-13-44	31	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0167-4943	1872-6976		ARCH GERONTOL GERIAT	Arch. Gerontol. Geriatr.	NOV-DEC	2014	59	3					577	583		10.1016/j.archger.2014.07.017		7	Geriatrics & Gerontology	Geriatrics & Gerontology	AS3OG	WOS:000344187700013		
J	Hagino, T; Ochiai, S; Watanabe, Y; Senga, S; Wako, M; Ando, T; Sato, E; Haro, H				Hagino, Tetsuo; Ochiai, Satoshi; Watanabe, Yoshiyuki; Senga, Shinya; Wako, Masanori; Ando, Takashi; Sato, Eiichi; Haro, Hirotaka			Complications after arthroscopic knee surgery	ARCHIVES OF ORTHOPAEDIC AND TRAUMA SURGERY			English	Article						Complication; Arthroscopy; Knee		Purpose To examine the complications of arthroscopic knee surgeries conducted in the Sports Medicine and Knee Center of our hospital. Subjects and methods In this prospective study, a total of 2,623 patients (1,396 men and 1,227 women) who underwent arthroscopic knee surgeries in our center between January 2006 and March 2013 (7 years and 3 months) were studied. The ages at surgery ranged 7-96 years (mean 33.5 years). Arthroscopy was conducted because of sports injuries in 1,653 patients (63.0 %). The main diagnoses included meniscal injury in 920 patients, discoid meniscus in 64 patients, anterior cruciate ligament injury in 580 knees, posterior cruciate ligament injury in 30 knees, loose body in 61 knees, and intraarticular fracture in 33 knees. Arthroscopic procedures included meniscectomy in 987 knees, meniscal suture repair in 262 knees, and anterior cruciate ligament reconstruction in 508 knees. Intraoperative and postoperative complications in these cases were investigated. Results The rate of complication was 7 in 2,623 cases (0.27 %). Intraoperative complications comprised three cases of intraarticular instrument breakage and one case of meniscal injury. Postoperative complications consisted of two cases of septic arthritis and one case of superficial infection, and reoperation was necessary in the two cases of septic arthritis. There were no neural, vascular and ligament injuries during surgery, and no complex regional pain syndrome, symptomatic deep vein thrombosis, and pulmonary embolism were observed. Conclusion Arthroscopic knee surgeries are considered to be minimally invasive, and are conducted relatively safe with low complication rates. In this series, however, seven cases of complications occurred, including two cases (0.08 %) of septic arthritis. Furthermore, symptomatic thromboembolism has been reported to occur also in arthroscopic surgery. The risk of severe complications has to be acknowledged.	[Hagino, Tetsuo; Ochiai, Satoshi; Watanabe, Yoshiyuki; Senga, Shinya] Kofu Natl Hosp, Sports Med & Knee Ctr, Kofu, Yamanashi 4008533, Japan; [Wako, Masanori; Ando, Takashi; Sato, Eiichi; Haro, Hirotaka] Univ Yamanashi, Fac Med, Dept Orthopaed Surg, Yamanashi, Japan	Hagino, T (reprint author), Kofu Natl Hosp, Sports Med & Knee Ctr, 11-35 Tenjin Cho, Kofu, Yamanashi 4008533, Japan.	tmhagino@amber.plala.or.jp					SMALL NC, 1990, CLIN SPORT MED, V9, P609; Jameson SS, 2011, J BONE JOINT SURG BR, V93B, P1327, DOI 10.1302/0301-620X.93B10.27078; SHERMAN OH, 1986, J BONE JOINT SURG AM, V68A, P256; Salzler MJ, 2014, AM J SPORT MED, V42, P292, DOI 10.1177/0363546513510677; Garrett WE, 2006, J BONE JOINT SURG AM, V88A, P660, DOI 10.2106/JBJS.E.01208; Bohensky MA, 2013, ARTHROSCOPY, V29, P716, DOI 10.1016/j.arthro.2012.11.020; Delee JC, 1985, ARTHROSCOPY, V1, P214, DOI 10.1016/S0749-8063(85)80086-4; Hagino Tetsuo, 2011, Sports Med Arthrosc Rehabil Ther Technol, V3, P21, DOI 10.1186/1758-2555-3-21; Hetsroni I, 2011, J BONE JOINT SURG BR, V93B, P47, DOI 10.1302/0301-620X.93B1.25498; Martin Christopher T, 2013, J Bone Joint Surg Am, V95, P1, DOI 10.2106/JBJS.L.01440; Reigstad O, 2006, KNEE SURG SPORT TR A, V14, P473, DOI 10.1007/s00167-005-0694-x; SMALL N C, 1988, Arthroscopy, V4, P215, DOI 10.1016/S0749-8063(88)80030-6; Small NC, 1986, ARTHROSCOPY, V2, P253, DOI 10.1016/S0749-8063(86)80080-9	13	1	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0936-8051	1434-3916		ARCH ORTHOP TRAUM SU	Arch. Orthop. Trauma Surg.	NOV	2014	134	11					1561	1564		10.1007/s00402-014-2054-0		4	Orthopedics; Surgery	Orthopedics; Surgery	AS1RY	WOS:000344059700009		
J	Watanabe, H; Tanaka, N; Inuta, T; Saitou, H; Yanagi, H				Watanabe, Hiroki; Tanaka, Naoki; Inuta, Tomonari; Saitou, Hideyuki; Yanagi, Hisako			Locomotion Improvement Using a Hybrid Assistive Limb in Recovery Phase Stroke Patients: A Randomized Controlled Pilot Study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Gait; Locomotion; Rehabilitation; Robotics; Stroke	BODY-WEIGHT SUPPORT; SUBACUTE STROKE; PHYSICAL PERFORMANCE; GAIT; WALKING; REHABILITATION; ROBOT; TRIAL; FEASIBILITY; RELIABILITY	Objective: To compare the efficacy of gait training using a single-leg version of the Hybrid Assistive Limb (HAL) on the paretic side with conventional gait training in individuals with subacute stroke. Design: Randomized open controlled pilot trial. Setting: Hospitalized care. Participants: Convenience sample of 44 patients who met the criteria; 12 patients refused. After randomization (N=32), 10 patients withdrew and a total of 22 poststroke participants (HAL group: n=11; conventional group: n=11) completed the randomized controlled trial. Interventions: All participants received twelve 20-minute sessions in 4 weeks of either HAL (wearing the single-leg version of the HAL on their paretic side) or conventional (performed by skilled and experienced physical therapists) gait training. Main Outcome Measures: Outcome measures were evaluated prior to training and after 12 sessions. Functional Ambulation Category (FAC) was the primary outcome measure, whereas secondary outcome measures included maximum walking speed, timed Up and Go test, 6-minute walk distance, Short Physical Performance Battery, Fugl-Meyer Assessment of Lower Extremity, and isometric muscle strength (hip flexion and extension, knee flexion and extension). Results: No participants withdrew because of adverse effects. Participants who received gait training with the HAL showed significantly more improvement in the FAC than those who received conventional gait training (95% confidence interval,.02.88; P=.04). Secondary measures did not differ between the 2 groups. Conclusions: The results obtained in this randomized controlled trial suggest that a gait training program with the HAL could improve independent walking more efficiently than conventional gait training. (C) 2014 by the American Congress of Rehabilitation Medicine	[Watanabe, Hiroki] Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Med Sci & Welf, Tsukuba, Ibaraki 3058577, Japan; [Watanabe, Hiroki; Tanaka, Naoki; Inuta, Tomonari; Saitou, Hideyuki] Tsukuba Mem Hosp, Dept Rehabil, Tsukuba, Ibaraki, Japan; [Yanagi, Hisako] Univ Tsukuba, Fac Med, Dept Med Sci & Welf, Tsukuba, Ibaraki 3058577, Japan	Yanagi, H (reprint author), Univ Tsukuba, Fac Med, Dept Med Sci & Welf, Tennodai 1-1-1, Tsukuba, Ibaraki 3058577, Japan.	hyanagi@md.tsukuba.ac.jp					Mehrholz J, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006185.pub3; Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111; Pohl M, 2007, CLIN REHABIL, V21, P17, DOI 10.1177/0269215506071281; Katz N, 1999, ARCH PHYS MED REHAB, V80, P379, DOI 10.1016/S0003-9993(99)90273-3; Suzuki K, 2007, ADV ROBOTICS, V21, P1441, DOI 10.1163/156855307781746061; Hesse S, 2000, ARCH PHYS MED REHAB, V81, P1158, DOI 10.1053/apmr.2000.6280; Shumway-Cook A, 2000, PHYS THER, V80, P896; JORGENSEN HS, 1995, ARCH PHYS MED REHAB, V76, P27, DOI 10.1016/S0003-9993(95)80038-7; Morone G, 2011, NEUROREHAB NEURAL RE, V25, P636, DOI 10.1177/1545968311401034; HOLDEN MK, 1986, PHYS THER, V66, P1530; Suzuki K, 1999, ARCH PHYS MED REHAB, V80, P179, DOI 10.1016/S0003-9993(99)90117-X; FINCH L, 1991, PHYS THER, V71, P842; Raphael C, 2007, HEART, V93, P476, DOI 10.1136/hrt.2006.089656; Chang WH, 2012, NEUROREHAB NEURAL RE, V26, P318, DOI 10.1177/1545968311408916; Freire AN, 2012, J AGING HEALTH, V24, P863, DOI 10.1177/0898264312438551; Kawamoto H, 2009, IEEE ENG MED BIO, P5038, DOI 10.1109/IEMBS.2009.5333698; Colombo G, 2001, SPINAL CORD, V39, P252, DOI 10.1038/sj.sc.3101154; Ada L, 2010, J PHYSIOTHER, V56, P153, DOI 10.1016/S1836-9553(10)70020-5; Iwata H, 2001, P IEEE VIRT REAL ANN, P131, DOI 10.1109/VR.2001.913779; Nilsson A, 2014, J NEUROENG REHABIL, V11, DOI 10.1186/1743-0003-11-92; Kawamoto H, 2005, ADV ROBOTICS, V19, P717, DOI 10.1163/1568553054455103; FUGLMEYER AR, 1975, SCAND J REHABIL MED, V7, P13; Kubota S, 2013, ARCH PHYS MED REHAB, V94, P1080, DOI 10.1016/j.apmr.2012.12.020; Dobkin BH, 2005, NEW ENGL J MED, V352, P1677, DOI 10.1056/NEJMcp043511; Bayona Nestor A, 2005, Top Stroke Rehabil, V12, P58; Beckerman H, 1996, ARCH PHYS MED REHAB, V77, P1144, DOI 10.1016/S0003-9993(96)90138-0; Bohannon R W, 1991, Int J Rehabil Res, V14, P246, DOI 10.1097/00004356-199109000-00010; Cohen J., 1988, STAT POWER ANAL BEHA; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; DICKSTEIN R, 1986, PHYS THER, V66, P1233; Guralnik JM, 1994, J GERONTOL, V49, P85; Hong SJ, 2012, ARCH PHYS MED REHAB, V93, P1065, DOI 10.1016/j.apmr.2011.12.022; Karnath HO, 2003, PHYS THER, V83, P1119; Kasaoka K., 2001, Proceedings 2001 IEEE/RSJ International Conference on Intelligent Robots and Systems. Expanding the Societal Role of Robotics in the the Next Millennium (Cat. No.01CH37180), DOI 10.1109/IROS.2001.977204; Kawamoto H, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-141; Kawamoto H, 2002, P INT C COMP HELP PE, P196; Lee S, 2005, ADV ROBOTICS, V19, P773, DOI 10.1163/1568553054455095; Lee S, 2002, P IEEE INT C SYST MA; Ohta T, 1974, No Shinkei Geka, V2, P623; Sankai Y, 2006, SICE ICASE INT JOINT, P18; Schwartz I, 2009, PM&R, V1, P516, DOI 10.1016/j.pmrj.2009.03.009; Tanaka N, 2012, CLIN REHABIL, V26, P686, DOI 10.1177/0269215511432356	42	3	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2014	95	11					2006	2012		10.1016/j.apmr.2014.07.002		7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	AS3XC	WOS:000344207500003		
J	Kitatani, R; Ohata, K; Takahashi, H; Shibuta, S; Hashiguchi, Y; Yamakami, N				Kitatani, Ryosuke; Ohata, Koji; Takahashi, Hideaki; Shibuta, Saori; Hashiguchi, Yu; Yamakami, Natsuki			Reduction in Energy Expenditure During Walking Using an Automated Stride Assistance Device in Healthy Young Adults	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Rehabilitation; Robotics; Walking	OXYGEN-CONSUMPTION; MULTICENTER TRIAL; MUSCULAR-ACTIVITY; CLINICAL GAIT; STROKE; SPEED; COST; REPRODUCIBILITY; NORMALIZATION; LOCOMOTION	Objective: To investigate the effects of an automated stride assistance device that assists hip joint flexion and extension movement in energy expenditure during walking in healthy young adults using an expired gas method. Design: Prospective, single-group design to compare the differences of energy expenditure between 2 assistive conditions. Setting: Laboratory. Participants: Healthy volunteers (N=10) aged 21 to 32 years. Interventions: Not applicable. Main Outcome Measures: Oxygen consumption per unit time ((V) over doto(2)) cost (ml.kg(-1).m(-1)), and heart rate (beats/min) were measured in 2 assistive conditions (with 3-Nm hip motion assistance and without assistance) and at 2 walking speeds (comfortable walking speed [CWS] and maximum walking speed [MWS]). Results: There were no significant differences in walking speed between the with- and without-assistance conditions at either the CWS or MWS. The (V) over doto(2) cost and heart rate were significantly reduced in the with-assistance condition compared with the without-assistance condition, at both the CWS and MWS. The reduction in the (V) over doto(2) cost during the with-assistance condition, relative to the without-assistance condition, was 7.06% at the CWS and 10.52% at the MWS. Conclusions: The automated stride assistance device is useful for reducing energy expenditure during walking in healthy adults. Further studies are warranted to investigate if this device provides substantial help to individuals with impaired mobility as a result of strength deficits. (C) 2014 by the American Congress of Rehabilitation Medicine	[Kitatani, Ryosuke; Ohata, Koji; Hashiguchi, Yu] Kyoto Univ, Grad Sch Med, Dept Phys Therapy Human Hlth Sci, Kyoto 6068507, Japan; [Kitatani, Ryosuke; Hashiguchi, Yu] Japan Soc Promot Sci, Tokyo, Japan; [Takahashi, Hideaki] Honda Res & Dev Co Ltd, Wako, Saitama, Japan; [Shibuta, Saori] Kyoto Univ Hosp, Kyoto 606, Japan; [Yamakami, Natsuki] Fujita Hlth Univ Hosp, Toyoake, Aichi, Japan	Kitatani, R (reprint author), Kyoto Univ, Grad Sch Med, Dept Phys Therapy Human Hlth Sci, Sakyo Ku, 53 Kawahara Cho, Kyoto 6068507, Japan.	kitatani.ryosuke.88x@st.kyoto-u.ac.jp					Husemann B, 2007, STROKE, V38, P349, DOI 10.1161/01.STR.0000254607.48765.cb; Brehm MA, 2008, GAIT POSTURE, V27, P196, DOI 10.1016/j.gaitpost.2007.03.012; Pohl M, 2007, CLIN REHABIL, V21, P17, DOI 10.1177/0269215506071281; Danielsson A, 2000, ARCH PHYS MED REHAB, V81, P953, DOI 10.1053/apmr.2000.6283; Hesse S, 2000, ARCH PHYS MED REHAB, V81, P1158, DOI 10.1053/apmr.2000.6280; Bohannon RW, 2011, PHYSIOTHERAPY, V97, P182, DOI 10.1016/j.physio.2010.12.004; Shimada H, 2009, GERIATR GERONTOL INT, V9, P372, DOI 10.1111/j.1447-0594.2009.00546.x; Schwartz MH, 2006, GAIT POSTURE, V24, P14, DOI 10.1016/j.gaitpost.2005.06.014; Wirz M, 2005, ARCH PHYS MED REHAB, V86, P672, DOI 10.1016/j.apmr.2004.08.004; Brehm MA, 2007, DEV MED CHILD NEUROL, V49, P45, DOI 10.1017/S0012162207000114; Baker R, 2001, GAIT POSTURE, V13, P202, DOI 10.1016/S0966-6362(00)00104-1; Schrack JA, 2013, AM J PHYS MED REHAB, V92, P28, DOI 10.1097/PHM.0b013e3182644165; Saibene F, 2003, EUR J APPL PHYSIOL, V88, P297, DOI 10.1007/s00421-002-0654-9; Colle F., 2006, Annales de Readaptation et de Medecine Physique, V49, P361, DOI 10.1016/j.annrmp.2006.04.010; Bohannon RW, 1997, AGE AGEING, V26, P15, DOI 10.1093/ageing/26.1.15; Bowen TR, 1998, J PEDIATR ORTHOPED, V18, P589, DOI 10.1097/00004694-199809000-00006; Colle F, 2006, Ann Readapt Med Phys, V49, P272, DOI 10.1016/j.annrmp.2006.04.009; David D, 2006, ARCH PHYS MED REHAB, V87, P482, DOI 10.1016/j.apmr.2005.11.034; Gottschall JS, 2005, J APPL PHYSIOL, V99, P23, DOI 10.1152/japplphysiol.01190.2004; Plasschaert F, 2009, GAIT POSTURE, V29, P311, DOI 10.1016/j.gaitpost.2008.09.015; Shimada H, 2007, IEEE T NEUR SYS REH, V15, P442, DOI 10.1109/TNSRE.2007.903978; Shimada H, 2008, BRIT J SPORT MED, V42, P922, DOI 10.1136/bjsm.2007.039453; Sutherland DH, 2005, GAIT POSTURE, V21, P447, DOI 10.1016/j.gaitpost.2004.07.008; Waters EL, 1999, GAIT POSTURE, V9, P207	24	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	NOV	2014	95	11					2128	2133		10.1016/j.apmr.2014.07.008		6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	AS3XC	WOS:000344207500018		
J	Onozato, H; Fukai, K; Kitano, R; Yamazoe, R; Morioka, K; Yamada, M; Ohashi, S; Yoshida, K; Kanno, T				Onozato, Hiroyuki; Fukai, Katsuhiko; Kitano, Rie; Yamazoe, Reiko; Morioka, Kazuki; Yamada, Manabu; Ohashi, Seiichi; Yoshida, Kazuo; Kanno, Toru			Experimental infection of cattle and goats with a foot-and-mouth disease virus isolate from the 2010 epidemic in Japan	ARCHIVES OF VIROLOGY			English	Article							PERSISTENCE; PIGS	In this study, we carried out experimental infections in cattle and goats using a foot-and-mouth disease virus (FMDV) isolate from the 2010 epidemic in Japan to analyze clinical manifestations, virus-shedding patterns and antibody responses in the animals. We found that the FMDV O/JPN/2010 isolate is virulent in cattle and goats, produces clinical signs, is spread efficiently by direct contact within the same species, and is persistently infectious in cattle. Quantitative analysis of levels of viral RNA in the tissues of cattle and goats infected with the isolate showed that the pharyngeal region is an important major target of the FMDV O/JPN/2010. Time course data of viral loads, excretion and transmission of the FMDV O/JPN/2010 in this study are key in providing quantitative data essential for epidemiological investigation and risk analysis in relation to disease controls.	[Onozato, Hiroyuki; Fukai, Katsuhiko; Kitano, Rie; Yamazoe, Reiko; Morioka, Kazuki; Yamada, Manabu; Ohashi, Seiichi; Yoshida, Kazuo; Kanno, Toru] Natl Agr & Food Res Org, Exot Dis Res Stn, Natl Inst Anim Hlth, Tokyo 1870022, Japan	Kanno, T (reprint author), Natl Agr & Food Res Org, Exot Dis Res Stn, Natl Inst Anim Hlth, 6-20-1 Josui Honcho, Tokyo 1870022, Japan.	kannot@affrc.go.jp			Foot-and-Mouth Disease Control Project of the Ministry of Agriculture, Forestry and Fisheries of Japan	We are grateful to Dr. Gerelmaa Ulziibat (State Central Veterinary Laboratory, Mongolia) and Dr. Akiko Tomiyasu (Animal Quarantine Service, Japan) for technical assistance. The authors would also like to thank Mr. Hiroki Kimura, Mr. Masayuki Kanda, Mr. Shinya Sato, Mr. Kenichi Ishii, Mr. Tatsuo Nakamura and Mr. Shigeo Mizumura for care of the animals. This study was supported by Grants-in-Aid for Scientific Research from the Foot-and-Mouth Disease Control Project of the Ministry of Agriculture, Forestry and Fisheries of Japan.	Alexandersen S, 2003, J COMP PATHOL, V129, P268, DOI 10.1016/S0021-9975(03)00045-8; Muroga N, 2012, J VET MED SCI, V74, P399, DOI 10.1292/jvms.11-0271; Zhang ZD, 2004, J GEN VIROL, V85, P2567, DOI 10.1099/vir.0.80011-0; Knowles NJ, 2012, EMERG INFECT DIS, V18, P499, DOI 10.3201/eid1803.110908; Alexandersen S, 2002, MICROBES INFECT, V4, P1099, DOI 10.1016/S1286-4579(02)01634-9; Alexandersen S, 2003, J COMP PATHOL, V129, P1, DOI 10.1016/S0021-9975(03)00041-0; Grubman MJ, 2004, CLIN MICROBIOL REV, V17, P465, DOI 10.1128/CMR.17.2.465-493.2004; Brehm KE, 2009, J CLIN MICROBIOL, V47, P3156, DOI [10.1128/JCM.00510-09, 10.1128/JCM.00510]; Donaldson D, 2004, FOOT MOUTH DIS CURRE, P93; Fukai K, 2011, J VET MED SCI, V73, P1207, DOI 10.1292/jvms.11-0063; Moniwa M, 2007, J VET DIAGN INVEST, V19, P9; REED L. J., 1938, AMER JOUR HYG, V27, P493; Sakamoto K, 2002, J VET MED SCI, V64, P91, DOI 10.1292/jvms.64.91; Sugiura K, 2001, REV SCI TECH OIE, V20, P701; World Organization for Animal Health, 2013, FOOT MOUTH DIS MAN D; Yamakawa M, 2002, TOP ANIM HLTH RES, V2, P49	16	1	1	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0304-8608	1432-8798		ARCH VIROL	Arch. Virol.	NOV	2014	159	11					2901	2908		10.1007/s00705-014-2135-y		8	Virology	Virology	AS0WF	WOS:000343995900007		
J	Ishibashi, M; Morita, N; Nomura-Kawaguchi, C; Shimizu, Y; Wakita, T; Esumi, M				Ishibashi, Mariko; Morita, Naoko; Nomura-Kawaguchi, Chisato; Shimizu, Yohko; Wakita, Takaji; Esumi, Mariko			CLEC4M-positive and CD81-negative Huh7 cells are not susceptible to JFH-1 HCVcc infection but mediate transinfection	ARCHIVES OF VIROLOGY			English	Article							HEPATITIS-C VIRUS; LECTINS DC-SIGN; ENDOTHELIAL-CELLS; HUMAN LIVER; ENTRY; NONINTEGRIN; EXPRESSION; PARTICLES; CD209L; TRANS	C-type lectin domain family 4, member M (CLEC4M), a trans-membrane protein specifically expressed in liver sinusoidal endothelial cells, is considered a candidate receptor for hepatotropism of hepatitis C virus (HCV). CLEC4M was previously reported to capture artificial HCVpp (pseudoparticle) and transmit it to hepatocytes (transinfection) via CLEC4M-positive cells. It is still not known whether CLEC4M acts as a receptor for HCVcc (cell-culture-produced HCV) transinfection or whether CLEC4M is an entry receptor for HCVcc. Initially, we established stably CLEC4M-positive and HCV-replication-permissive cell lines by introducing a CLEC4M expression vector into Huh7-25 cells (Huh7-25-CLEC4M) by transfection. Huh7-25 is a mutant cell line that is resistant to JFH-1 HCVcc due to the lack of expression of CD81 but permissive for replication of JFH1 HCV RNA. When Huh7-25-CLEC4M cells were infected with HCVcc and cultured for 6 days, none were positive for infection. Next, to examine whether CLEC4M functions as a receptor for transinfection, Huh7-25-CLEC4M cells were inoculated with HCVcc and thereafter co-cultured with Huh7-it cells, which are susceptible to HCV infection. The amount of HCV RNA was increased in Huh7-it cells co-cultured with Huh7-25-CLEC4M cells, and the transinfection was inhibited in the presence of anti-CLEC4M antibody during inoculation. Thus, CLEC4M cannot substitute for CD81 as an entry receptor for JFH-1 HCVcc. It just mediates transinfection without internalization of HCVcc. CD81 is still crucial for HCV entry into hepatocytes, and CLEC4M in liver sinusoidal endothelial cells may be responsible for hepatotropism of HCV infection by trapping circulating HCV to transmit it to adjacent hepatocytes.	[Ishibashi, Mariko; Morita, Naoko; Nomura-Kawaguchi, Chisato; Esumi, Mariko] Nihon Univ, Dept Pathol, Sch Med, Itabashi Ku, Tokyo 1738610, Japan; [Shimizu, Yohko] Nihon Univ, Open Res Ctr Genome & Infect Dis Control, Sch Med, Itabashi Ku, Tokyo 1738610, Japan; [Wakita, Takaji] Natl Inst Infect Dis, Dept Virol 2, Shinjuku Ku, Tokyo 1628640, Japan	Esumi, M (reprint author), Nihon Univ, Dept Pathol, Sch Med, Itabashi Ku, 30-1 Ohyaguchikami Cho, Tokyo 1738610, Japan.	esumi.mariko@nihon-u.ac.jp			MEXT [22590350]; Nihon University [06-023]; Nihon University School of Medicine 50th Anniversary Fund Research Grant	The authors thank Dr. M. Oshima, National Institute of Infection Diseases, Tokyo, Japan, for providing us with Huh7-it cells. This work was supported by a grant for "Open Research Center" Project for Private Universities: matching fund subsidy from MEXT (2005), Nihon University Joint Research Grant 06-023, Grant-in-Aid for Scientific Research (C) 22590350 from MEXT (2010), and "Strategic Research Base Development" Program for Private Universities subsidized by MEXT (2010). English editorial assistance was provided by NAI Inc. and funded by Nihon University School of Medicine 50th Anniversary Fund Research Grant (2012).	Agnello V, 1998, HEPATOLOGY, V28, P573, DOI 10.1002/hep.510280240; Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268; Fletcher NF, 2012, GASTROENTEROLOGY, V142, P634, DOI 10.1053/j.gastro.2011.11.028; Cormier EG, 2004, P NATL ACAD SCI USA, V101, P14067, DOI 10.1073/pnas.0405695101; Alvarez CP, 2002, J VIROL, V76, P6841, DOI 10.1128/JVI.76.13.6841-6844.2002; Zeisel MB, 2011, J HEPATOL, V54, P566, DOI 10.1016/j.jhep.2010.10.014; Appelmelk BJ, 2003, J IMMUNOL, V170, P1635; Bashirova AA, 2001, J EXP MED, V193, P671, DOI 10.1084/jem.193.6.671; Lai WK, 2006, AM J PATHOL, V169, P200, DOI 10.2353/ajpath.2006.051191; Lozach PY, 2004, J BIOL CHEM, V279, P32035, DOI 10.1074/jbc.M402296200; Chan VSF, 2006, NAT GENET, V38, P38, DOI 10.1038/ng1698; Akazawa D, 2007, J VIROL, V81, P5036, DOI 10.1128/JVI.01573-06; Breiner KM, 2001, HEPATOLOGY, V34, P803, DOI 10.1053/jhep.2001.27810; Burlone ME, 2009, J GEN VIROL, V90, P1055, DOI 10.1099/vir.0.008300-0; Wu L, 2006, NAT REV IMMUNOL, V6, P859, DOI 10.1038/nri1960; Ploss A, 2009, NATURE, V457, P882, DOI 10.1038/nature07684; Koppel EA, 2004, IMMUNOBIOLOGY, V209, P117, DOI 10.1016/j.imbio.2004.03.003; Pham TNQ, 2008, GASTROENTEROLOGY, V134, P812, DOI 10.1053/j.gastro.2007.12.011; Falkowska E, 2006, J GEN VIROL, V87, P2571, DOI 10.1099/vir.0.82034-0; Ishibashi M, 2010, BIOCHEM BIOPH RES CO, V392, P397, DOI 10.1016/j.bbrc.2010.01.034; Khoo US, 2008, J MOL MED-JMM, V86, P861, DOI 10.1007/s00109-008-0350-2; Ludwig IS, 2004, J VIROL, V78, P8322, DOI 10.1128/jvi.78.15.8322-8332.2004	22	0	0	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0304-8608	1432-8798		ARCH VIROL	Arch. Virol.	NOV	2014	159	11					2949	2955		10.1007/s00705-014-2150-z		7	Virology	Virology	AS0WF	WOS:000343995900012		
J	Tajima, S; Kotaki, A; Yagasaki, K; Taniwaki, T; Moi, ML; Nakayama, E; Saijo, M; Kurane, I; Takasaki, T				Tajima, Shigeru; Kotaki, Akira; Yagasaki, Kazumi; Taniwaki, Tae; Moi, Meng Ling; Nakayama, Eri; Saijo, Masayuki; Kurane, Ichiro; Takasaki, Tomohiko			Identification and amplification of Japanese encephalitis virus and Getah virus propagated from a single porcine serum sample: a case of coinfection	ARCHIVES OF VIROLOGY			English	Article							SAGIYAMA VIRUS; INFECTION; HORSES; ALPHAVIRUSES; RACEHORSES; GENOTYPE; SWINE	We detected two viruses, Japanese encephalitis virus (JEV)/Kochi/01/2005 and Getah virus (GETV)/Kochi/01/2005 in the same culture supernatant obtained by inoculation of Vero cells with a swine serum sample and subsequent passaging of the supernatant in Vero cells. Phylogenetic analysis using the nucleotide sequences of the complete genome and the E2 region of GETV indicated that GETV/Kochi/01/2005 is most similar to a Mongolian strain. In contrast, a partial sequence of the nsP1 protein coding region of GETV/Kochi/01/2005 showed that it was similar to Japanese strains isolated in the 1980s. Alignment of the nucleotide sequence of the E region of JEV showed that JEV/Kochi/01/2005 has the highest similarity to a Japanese strain. We also examined the changes in the amount of JEV/Kochi/01/2005 and GETV/Kochi/01/2005 present after passaging in Vero cells. The RNA copy number and infectious titer of JEV/Kochi/01/2005 decreased, whereas those of GETV/Kochi/01/2005 increased, following repeated passages in Vero cells. Our results provide evidence for coinfection with JEV and GETV in the Kochi/01/2005 pig. This is the first report of incidental confection with JEV and GETV in a domestic animal.	[Tajima, Shigeru; Kotaki, Akira; Yagasaki, Kazumi; Moi, Meng Ling; Nakayama, Eri; Saijo, Masayuki; Kurane, Ichiro; Takasaki, Tomohiko] Natl Inst Infect Dis, Dept Virol 1, Shinjuku Ku, Tokyo 1628640, Japan; [Taniwaki, Tae] Publ Hlth Inst Kochi Prefecture, Kochi 7800850, Japan	Tajima, S (reprint author), Natl Inst Infect Dis, Dept Virol 1, Shinjuku Ku, 1-23-1 Toyama, Tokyo 1628640, Japan.	stajima@nih.go.jp			Ministry of Health, Labor, and Welfare in Japan [H23-iyaku-ippan-003]; JSPS [25460577]	This work was supported in part by a Grant for Research on the Regulatory Science of Pharmaceuticals and Medical Devices from the Ministry of Health, Labor, and Welfare in Japan (H23-iyaku-ippan-003) and a Grant-in-Aid for Scientific Research (C) from the JSPS (25460577).	Campbell GL, 2011, B WORLD HEALTH ORGAN, V89, P766, DOI 10.2471/BLT.10.085233; Erlanger TE, 2009, EMERG INFECT DIS, V15, P1, DOI 10.3201/eid1501.080311; Arai S, 2008, JPN J INFECT DIS, V61, P333; Ma SP, 2003, AM J TROP MED HYG, V69, P151; Bryant JE, 2005, AM J TROP MED HYG, V73, P470; Solomon T, 2003, J VIROL, V77, P3091, DOI 10.1128/JVI.77.5.3091-3098.2003; Tajima S, 2010, VIROLOGY, V396, P298, DOI 10.1016/j.virol.2009.10.035; Pfeffer M, 1997, AM J TROP MED HYG, V57, P709; Uchil PD, 2001, AM J TROP MED HYG, V65, P242; Chang CY, 2006, J VET DIAGN INVEST, V18, P156; IGARASHI A, 1981, AM J TROP MED HYG, V30, P449; KAMADA M, 1980, AM J TROP MED HYG, V29, P984; KANAMITSU M, 1979, AM J TROP MED HYG, V28, P351; KONO Y, 1980, RES VET SCI, V29, P162; Kono Y., 1988, The arboviruses: epidemiology and ecology. Volume III., P21; KUMANOMIDO T, 1988, VET MICROBIOL, V16, P295, DOI 10.1016/0378-1135(88)90033-8; KUMANOMIDO T, 1988, VET MICROBIOL, V17, P367, DOI 10.1016/0378-1135(88)90050-8; Li Xue-Dong, 1992, Southeast Asian Journal of Tropical Medicine and Public Health, V23, P730; MARCHETTE N J, 1980, Southeast Asian Journal of Tropical Medicine and Public Health, V11, P14; MATSUYAMA T, 1967, Gunma Journal of Medical Science, V16, P131; Nerome R, 2007, J GEN VIROL, V88, P2762, DOI 10.1099/vir.0.82941-0; Pierson TC, 2013, FIELDS VIROLOGY, V2, P747; SCHERER WF, 1962, AM J TROP MED HYG, V11, P255; SENTSUI H, 1980, NATL I ANIM HEALTH Q, V20, P39; SENTSUI H, 1985, JPN J VET SCI, V47, P333; Seo HJ, 2012, ACTA VIROL, V56, P265, DOI 10.4149/av_2012_03_265; SHIBATA I, 1991, VET MICROBIOL, V27, P385, DOI 10.1016/0378-1135(91)90162-9; Shirako Y, 2000, J GEN VIROL, V81, P1353; Tsai Theodore F., 2000, Vaccine, V18, P1, DOI 10.1016/S0264-410X(00)00037-2; Turell MJ, 2003, J MED ENTOMOL, V40, P580, DOI 10.1603/0022-2585-40.4.580; Wang Huan-qin, 2006, Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi, V20, P52; Wekesa SN, 2001, VET MICROBIOL, V83, P137, DOI 10.1016/S0378-1135(01)00417-5; YAGO K, 1987, JPN J VET SCI, V49, P989; Yamaguchi Y, 2013, J GEN VIROL, V94, P90, DOI 10.1099/vir.0.044925-0; Zhai YG, 2008, J GEN VIROL, V89, P1446, DOI 10.1099/vir.0.83607-0	35	1	1	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0304-8608	1432-8798		ARCH VIROL	Arch. Virol.	NOV	2014	159	11					2969	2975		10.1007/s00705-014-2152-x		7	Virology	Virology	AS0WF	WOS:000343995900014		
J	Bui, VN; Mizutani, T; Nguyen, TH; Trinh, DQ; Awad, SSA; Minoungou, GL; Yamamoto, Y; Nakamura, K; Saito, K; Watanabe, Y; Runstadler, J; Huettmann, F; Ogawa, H; Imai, K				Vuong Nghia Bui; Mizutani, Tetsuya; Tung Hoang Nguyen; Dai Quang Trinh; Awad, Sanaa S. A.; Minoungou, Germaine L.; Yamamoto, Yu; Nakamura, Kikuyasu; Saito, Keisuke; Watanabe, Yukiko; Runstadler, Jonathan; Huettmann, Falk; Ogawa, Haruko; Imai, Kunitoshi			Characterization of a genetic and antigenic variant of avian paramyxovirus 6 isolated from a migratory wild bird, the red-necked stint (Calidris ruficollis)	ARCHIVES OF VIROLOGY			English	Article							COMPLETE GENOME SEQUENCE; RNA VIRUSES; INFECTIONS; SUBGROUPS; EXISTENCE; SEROTYPE	A hemagglutinating virus (8KS0813) was isolated from a red-necked stint. Hemagglutination inhibition and neutralization tests indicated that 8KS0813 was antigenically related to a prototype strain, APMV-6/duck/Hong Kong/18/199/77, but with an 8- and 16-fold difference, respectively, in their titers. The full genome sequence of 8KS0813 showed 98.6 % nucleotide sequence identity to that of APMV-6/duck/Italy/4524-2/07, which has been reported to belong to an APMV-6 subgroup, and showed less similarity to that of the prototype strain (70.6 % similarity). The growth of 8KS0813 and the prototype strain in four different cell cultures was greatly enhanced by adding trypsin. Interestingly, this virus induced syncytia only in Vero cells. 8KS0813 was identified as APMV-6/red-necked stint/Japan/8KS0813/08, but it is antigenically and genetically distinguishable from the prototype strain, suggesting that variant APMV-6 is circulating in migratory birds.	[Vuong Nghia Bui; Tung Hoang Nguyen; Dai Quang Trinh; Awad, Sanaa S. A.; Minoungou, Germaine L.; Ogawa, Haruko; Imai, Kunitoshi] Obihiro Univ Agr & Vet Med, Res Ctr Anim Hyg & Food Safety, Obihiro, Hokkaido 0808555, Japan; [Mizutani, Tetsuya] Natl Inst Infect Dis, Tokyo 2080011, Japan; [Yamamoto, Yu; Nakamura, Kikuyasu] Natl Inst Anim Hlth, Tsukuba, Ibaraki 3050856, Japan; [Saito, Keisuke; Watanabe, Yukiko] Inst Raptor Biomed, Kushiro, Hokkaido 0840922, Japan; [Runstadler, Jonathan; Huettmann, Falk] Univ Alaska Fairbanks, Inst Arctic Biol, Dept Biol & Wildlife, Fairbanks, AK 99775 USA	Imai, K (reprint author), Obihiro Univ Agr & Vet Med, Res Ctr Anim Hyg & Food Safety, 2-11 Inada, Obihiro, Hokkaido 0808555, Japan.	imaiku@obihiro.ac.jp	MIZUTANI, Tetsuya/G-1086-2013; 	MIZUTANI, Tetsuya/0000-0003-2570-0452; Trinh Quang, Dai/0000-0003-3435-0845	Program of Founding Research Centers for Emerging and Reemerging Infectious Diseases; Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan [19659115]; US National Institute of Allergy and Infectious Diseases (NIAID) [HHSN266200700009C, HHSN266200700007C]	We thank Dr. Shigeru Morikawa, National Institute of Infectious Disease, for invaluable suggestions in analysis of the sample. We are also grateful for the technical support of Sachiko Matsuda, Obihiro University of Agriculture and Veterinary Medicine, and Miho Nishimura, Fukuoka University. This work was partially supported by grants from the Program of Founding Research Centers for Emerging and Reemerging Infectious Diseases and by a Grant-in-Aid for Exploratory Research (19659115) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan. This work was also partially supported by the US National Institute of Allergy and Infectious Diseases (NIAID contracts HHSN266200700009C and HHSN266200700007C).	Alexander D.J., 2008, DIS POULTRY, P75; Miller PJ, 2010, J VIROL, V84, P11496, DOI 10.1128/JVI.00822-10; Runstadler JA, 2007, ARCH VIROL, V152, P1901, DOI 10.1007/s00705-007-0994-1; Hubalek Z, 2004, J WILDLIFE DIS, V40, P639; Kumar S, 2010, VIRUS RES, V149, P78, DOI 10.1016/j.virusres.2009.12.015; Briand FX, 2012, J VIROL, V86, P7710, DOI 10.1128/JVI.00946-12; Terregino C, 2013, ARCH VIROL, V158, P2233, DOI 10.1007/s00705-013-1735-2; Subbiah M, 2010, VIRUS RES, V152, P85, DOI 10.1016/j.virusres.2010.06.009; Xiao S, 2010, VIRUS RES, V150, P61, DOI 10.1016/j.virusres.2010.02.015; Chrysite LI, 1996, VIROLOGY METHOD MANU, P91; Creelan JL, 2002, AVIAN PATHOL, V31, P493, DOI 10.1080/0307945021000005860; Dimock NJ, 2007, INTRO MODERN VIROLOG; Imai K, 2012, ANTIVIR RES, V93, P225, DOI 10.1016/j.antiviral.2011.11.017; Lamb RA, 2007, FIELDS VIROLOGY, V2, P1449; Lindh E, 2008, VIROL J, V5, DOI 10.1186/1743-422X-5-35; Mizutani T, 2007, EMERG INFECT DIS, V13, P322; Sakai K, 2007, ARCH VIROL, V152, P1763, DOI 10.1007/s00705-007-0999-9; SHORTRIDGE KF, 1980, J GEN VIROL, V49, P255, DOI 10.1099/0022-1317-49-2-255; WHO manual, 2005, WHO MANUAL ANIMAL IN	19	0	0	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0304-8608	1432-8798		ARCH VIROL	Arch. Virol.	NOV	2014	159	11					3101	3105		10.1007/s00705-014-2162-8		5	Virology	Virology	AS0WF	WOS:000343995900031		
J	Yoshida, T; Kitazawa, Y; Komatsu, K; Neriya, Y; Ishikawa, K; Fujita, N; Hashimoto, M; Maejima, K; Yamaji, Y; Namba, S				Yoshida, Tetsuya; Kitazawa, Yugo; Komatsu, Ken; Neriya, Yutaro; Ishikawa, Kazuya; Fujita, Naoko; Hashimoto, Masayoshi; Maejima, Kensaku; Yamaji, Yasuyuki; Namba, Shigetou			Complete nucleotide sequence and genome structure of a Japanese isolate of hibiscus latent Fort Pierce virus, a unique tobamovirus that contains an internal poly(A) region in its 3' end	ARCHIVES OF VIROLOGY			English	Article							DEPENDENT RNA-POLYMERASE; TOBACCO; INFECTION; PROTEIN	In this study, we detected a Japanese isolate of hibiscus latent Fort Pierce virus (HLFPV-J), a member of the genus Tobamovirus, in a hibiscus plant in Japan and determined the complete sequence and organization of its genome. HLFPV-J has four open reading frames (ORFs), each of which shares more than 98 % nucleotide sequence identity with those of other HLFPV isolates. Moreover, HLFPV-J contains a unique internal poly(A) region of variable length, ranging from 44 to 78 nucleotides, in its 3'-untranslated region (UTR), as is the case with hibiscus latent Singapore virus (HLSV), another hibiscus-infecting tobamovirus. The length of the HLFPV-J genome was 6431 nucleotides, including the shortest internal poly(A) region. The sequence identities of ORFs 1, 2, 3 and 4 of HLFPV-J to other tobamoviruses were 46.6-68.7, 49.9-70.8, 31.0-70.8 and 39.4-70.1 %, respectively, at the nucleotide level and 39.8-75.0, 43.6-77.8, 19.2-70.4 and 31.2-74.2 %, respectively, at the amino acid level. The 5'- and 3'-UTRs of HLFPV-J showed 24.3-58.6 and 13.0-79.8 % identity, respectively, to other tobamoviruses. In particular, when compared to other tobamoviruses, each ORF and UTR of HLFPV-J showed the highest sequence identity to those of HLSV. Phylogenetic analysis showed that HLFPV-J, other HLFPV isolates and HLSV constitute a malvaceous-plant-infecting tobamovirus cluster. These results indicate that the genomic structure of HLFPV-J has unique features similar to those of HLSV. To our knowledge, this is the first report of the complete genome sequence of HLFPV.	[Yoshida, Tetsuya; Kitazawa, Yugo; Neriya, Yutaro; Ishikawa, Kazuya; Fujita, Naoko; Hashimoto, Masayoshi; Maejima, Kensaku; Yamaji, Yasuyuki; Namba, Shigetou] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Agr & Environm Biol, Bunkyo Ku, Tokyo 1138657, Japan; [Komatsu, Ken] Tokyo Univ Agr & Technol, Plant Pathol Lab, Fuchu, Tokyo 1838509, Japan	Namba, S (reprint author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Agr & Environm Biol, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	anamba@mail.ecc.u-tokyo.ac.jp	Komatsu, Ken/B-3244-2015	Komatsu, Ken/0000-0003-3323-7314	Japan Society for the Promotion of Science	This work was supported by Grants-in-Aids for Scientific Research from the Japan Society for the Promotion of Science.	Adkins S, 2006, ACTA HORTIC, P65; Allen JE, 2005, PLANT HLTH PROG, DOI [10.1094/PHP-2005-0105-01-HN, DOI 10.1094/PHP-2005-0105-01-HN]; Almeyda-Becerra C, 2007, PHYTOPATHOLOGY, V97, pS3; TAKAMATSU N, 1990, J VIROL, V64, P3686; Robaglia C, 2006, TRENDS PLANT SCI, V11, P40, DOI 10.1016/j.tplants.2005.11.004; Beauchemin C, 2007, J VIROL, V81, P10905, DOI 10.1128/JVI.01243-07; Adams MJ, 2009, ARCH VIROL, V154, P1967, DOI 10.1007/s00705-009-0506-6; Osman TAM, 2000, J VIROL, V74, P11671, DOI 10.1128/JVI.74.24.11671-11680.2000; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595; Adkins S, 2003, PLANT DIS, V87, P1190, DOI 10.1094/PDIS.2003.87.10.1190; DOI Y., 1969, Ann. phytopath. Soc., V35, P180; Hwang J, 2013, VIROLOGY, V439, P105, DOI 10.1016/j.virol.2013.02.004; Kashiwazaki S, 1982, ANN PHYTOPATHOL SOC, V48, P395; Kim NR, 2012, ARCH VIROL, V157, P185, DOI 10.1007/s00705-011-1142-5; Matsui Y, 2005, JPN J PHYTOPATHOL, V71, P232; Okano Y, 2010, ARCH VIROL, V155, P1367, DOI 10.1007/s00705-010-0708-y; Srinivasan KG, 2005, ARCH VIROL, V150, P153, DOI 10.1007/s00705-004-0404-x; Srinivasan KG, 2002, ARCH VIROL, V147, P1585, DOI 10.1007/s00705-002-0829-z; TAKAMATSU N, 1991, J VIROL, V65, P1619; Watanabe T, 1999, J VIROL, V73, P2633	20	2	2	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0304-8608	1432-8798		ARCH VIROL	Arch. Virol.	NOV	2014	159	11					3161	3165		10.1007/s00705-014-2175-3		5	Virology	Virology	AS0WF	WOS:000343995900043		
J	Shimokawa, H; Satoh, K				Shimokawa, Hiroaki; Satoh, Kimio			Vascular Function	ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY			English	Article						endothelial cells; muscle; smooth; vascular	SMOOTH-MUSCLE-CELLS; ENDOTHELIAL-CELLS; GROWTH-FACTOR; PULMONARY-HYPERTENSION; DOWN-REGULATION; BLOOD-PRESSURE; FABRY DISEASE; CRUCIAL ROLE; IN-VIVO; KINASE		[Shimokawa, Hiroaki; Satoh, Kimio] Tohoku Univ, Grad Sch Med, Dept Cardiovasc Med, Sendai, Miyagi 9808574, Japan	Shimokawa, H (reprint author), Tohoku Univ, Grad Sch Med, Dept Cardiovasc Med, Sendai, Miyagi 9808574, Japan.	shimo@cardio.med.tohoku.ac.jp			Ministry of Education, Culture, Sports, Science and Technology, Tokyo, Japan [21790698, 23659408, 24390193]; Ministry of Health, Labor, and Welfare, Tokyo, Japan [10102895]	This work was supported, in part, by the Grant-in-Aid for Tohoku University Global COE for Conquest of Signal Transduction Diseases with Network Medicine, the Grants-in-Aid for Scientific Research (21790698, 23659408, and 24390193) from the Ministry of Education, Culture, Sports, Science and Technology, Tokyo, Japan, and the Grants-in-Aid for Scientific Research (10102895) from the Ministry of Health, Labor, and Welfare, Tokyo, Japan.	Iso T, 2013, ARTERIOSCL THROM VAS, V33, P2549, DOI 10.1161/ATVBAHA.113.301588; Lin WL, 2013, ARTERIOSCL THROM VAS, V33, P2366, DOI 10.1161/ATVBAHA.113.301221; Satoh K, 2014, ARTERIOSCL THROM VAS, V34, P2, DOI 10.1161/ATVBAHA.113.302744; Tatematsu S, 2013, ARTERIOSCL THROM VAS, V33, P1788, DOI 10.1161/ATVBAHA.113.301300; Tedgui A, 2013, ARTERIOSCL THROM VAS, V33, P2697, DOI 10.1161/ATVBAHA.113.302607; Enkhjargal B, 2014, ARTERIOSCL THROM VAS, V34, P1505, DOI 10.1161/ATVBAHA.114.303735; Wood KC, 2013, ARTERIOSCL THROM VAS, V33, P1861, DOI 10.1161/ATVBAHA.112.301068; Ikeda S, 2014, ARTERIOSCL THROM VAS, V34, P1260, DOI 10.1161/ATVBAHA.114.303320; Xiao QZ, 2014, ARTERIOSCL THROM VAS, V34, P90, DOI 10.1161/ATVBAHA.113.301418; Dalvi P, 2013, ARTERIOSCL THROM VAS, V33, P2585, DOI 10.1161/ATVBAHA.113.302054; Shimizu T, 2013, ARTERIOSCL THROM VAS, V33, P2780, DOI 10.1161/ATVBAHA.113.301357; Song P, 2013, ARTERIOSCL THROM VAS, V33, P2800, DOI 10.1161/ATVBAHA.113.301869; Xiao YG, 2013, ARTERIOSCL THROM VAS, V33, P2733, DOI 10.1161/ATVBAHA.113.302062; Walshe TE, 2013, ARTERIOSCL THROM VAS, V33, P2608, DOI 10.1161/ATVBAHA.113.302161; Muratoglu SC, 2013, ARTERIOSCL THROM VAS, V33, P2137, DOI 10.1161/ATVBAHA.113.301893; Shiomi M, 2013, ARTERIOSCL THROM VAS, V33, P2518, DOI 10.1161/ATVBAHA.113.301303; Choi S, 2014, ARTERIOSCL THROM VAS, V34, P81, DOI 10.1161/ATVBAHA.113.302200; Zippel N, 2013, ARTERIOSCL THROM VAS, V33, P2792, DOI 10.1161/ATVBAHA.113.301848; Turlo KA, 2013, ARTERIOSCL THROM VAS, V33, P2325, DOI 10.1161/ATVBAHA.112.300648; Bhattacharya I, 2013, ARTERIOSCL THROM VAS, V33, P2105, DOI 10.1161/ATVBAHA.112.301001; Callegari A, 2013, ARTERIOSCL THROM VAS, V33, P2491, DOI 10.1161/ATVBAHA.113.301755; Ciccarelli M, 2013, ARTERIOSCL THROM VAS, V33, P2415, DOI 10.1161/ATVBAHA.113.302262; Doyon P, 2013, ARTERIOSCL THROM VAS, V33, P2850, DOI 10.1161/ATVBAHA.113.302487; Erbilgin A, 2013, ARTERIOSCL THROM VAS, V33, P2509, DOI 10.1161/ATVBAHA.113.301989; Karper JC, 2013, ARTERIOSCL THROM VAS, V33, P2810, DOI 10.1161/ATVBAHA.113.301882; Kröller-Schön Swenja, 2013, Arterioscler Thromb Vasc Biol, V33, P1928, DOI 10.1161/ATVBAHA.113.301717; Marinkovic G, 2013, ARTERIOSCL THROM VAS, V33, P2380, DOI 10.1161/ATVBAHA.113.301394; Parastatidis I, 2013, ARTERIOSCL THROM VAS, V33, P2389, DOI 10.1161/ATVBAHA.113.302175; Revuelta-Lopez E, 2013, ARTERIOSCL THROM VAS, V33, P2877, DOI 10.1161/ATVBAHA.113.302323; Soe NN, 2013, ARTERIOSCL THROM VAS, V33, P2147, DOI 10.1161/ATVBAHA.113.301894; Sutliff RL, 2013, ARTERIOSCL THROM VAS, V33, P2154, DOI 10.1161/ATVBAHA.113.301913; Wagner NM, 2013, ARTERIOSCL THROM VAS, V33, P1943, DOI 10.1161/ATVBAHA.113.301783	32	2	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-5642	1524-4636		ARTERIOSCL THROM VAS	Arterioscler. Thromb. Vasc. Biol.	NOV	2014	34	11					2359	2362		10.1161/ATVBAHA.114.304119		4	Hematology; Peripheral Vascular Disease	Hematology; Cardiovascular System & Cardiology	AS1QX	WOS:000344056400001		
J	Raskob, GE; Angchaisuksiri, P; Blanco, AN; Buller, H; Gallus, A; Hunt, BJ; Hylek, EM; Kakkar, A; Konstantinides, SV; McCumber, M; Ozaki, Y; Wendelboe, A; Weitz, JI				Raskob, G. E.; Angchaisuksiri, P.; Blanco, A. N.; Buller, H.; Gallus, A.; Hunt, B. J.; Hylek, E. M.; Kakkar, A.; Konstantinides, S. V.; McCumber, M.; Ozaki, Y.; Wendelboe, A.; Weitz, J. I.		ISTH Steering Comm World	Thrombosis A Major Contributor to Global Disease Burden	ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY			English	Article						pulmonary embolism; thrombosis; venous thromboembolism; venous thrombosis	DEEP-VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM RISK; FEDERAL STATISTICAL OFFICE; NURSING-HOME RESIDENTS; QUALITY-OF-LIFE; PULMONARY-EMBOLISM; UNITED-STATES; POSTTHROMBOTIC SYNDROME; SYSTEMATIC ANALYSIS; MATERNAL MORTALITY	Background Thrombosis is the common pathology underlying ischemic heart disease, ischemic stroke, and venous thromboembolism (VTE). The Global Burden of Disease Study 2010 (GBD 2010) documented that ischemic heart disease and stroke collectively caused 1 in 4 deaths worldwide. GBD 2010 did not report data for VTE as a cause of death and disability. Objective To review the literature on the global burden of disease caused by VTE. Approach and Results We performed a systematic review of the literature on the global disease burden because of VTE in low-, middle-, and high-income countries. Studies from Western Europe, North America, Australia, and Southern Latin America (Argentina) yielded consistent results with annual incidences ranging from 0.75 to 2.69 per 1000 individuals in the population. The incidence increased to between 2 and 7 per 1000 among those aged 70 years. Although the incidence is lower in individuals of Chinese and Korean ethnicity, their disease burden is not low because of population aging. VTE associated with hospitalization was the leading cause of disability-adjusted life-years lost in low- and middle-income countries, and second in high-income countries, responsible for more disability-adjusted life-years lost than nosocomial pneumonia, catheter-related blood stream infections, and adverse drug events. Conclusions VTE causes a major burden of disease across low-, middle-, and high-income countries. More detailed data on the global burden of VTE should be obtained to inform policy and resource allocation in health systems and to evaluate whether improved use of preventive measures will reduce the burden.	[Raskob, G. E.; McCumber, M.; Wendelboe, A.] Univ Oklahoma, Hlth Sci Ctr, Coll Publ Hlth, Oklahoma City, OK 73104 USA; [Angchaisuksiri, P.] Mahidol Univ, Ramathibodi Hosp, Fac Med, Bangkok 10400, Thailand; [Blanco, A. N.] Acad Nacl Med Buenos Aires, Div Hemostasia, Buenos Aires, DF, Argentina; [Buller, H.] Univ Amsterdam, Acad Med Ctr, Dept Vasc Med, NL-1105 AZ Amsterdam, Netherlands; [Gallus, A.] SA Pathol, Dept Hematol, Flinders Med Ctr, Adelaide, SA, Australia; [Hunt, B. J.] Guys & St Thomas NHS Fdn Trust, Thrombosis & Thrombophilia Ctr, London, England; [Hylek, E. M.] Boston Univ, Sch Med, Boston, MA 02215 USA; [Kakkar, A.] Thrombosis Res Inst, London SW3 6LR, England; [Konstantinides, S. V.] Johannes Gutenberg Univ Mainz, Ctr Thrombosis & Hemostasis, D-55122 Mainz, Germany; [Ozaki, Y.] Univ Yamanashi, Dept Lab Med, Tamaho, Yamanashi, Japan; [Weitz, J. I.] McMaster Univ, Hamilton, ON, Canada; [Weitz, J. I.] Thrombosis & Atherosclerosis Res Inst, Hamilton, ON, Canada	Raskob, GE (reprint author), Univ Oklahoma, Hlth Sci Ctr, Coll Publ Hlth, 801 NE13th St, Oklahoma City, OK 73104 USA.	Gary-Raskob@ouhsc.edu					Sultan AA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070310; Access Economics Pty Limited, 2008, BURD VEN THROMB AUST; Aranaz-Andres JM, 2011, BMJ QUAL SAF, V20, P1043, DOI 10.1136/bmjqs.2011.051284; Yusuf Hussain R., 2012, Morbidity and Mortality Weekly Report, V61, P401; ANDERSON FA, 1991, ARCH INTERN MED, V151, P933, DOI 10.1001/archinte.151.5.933; Janke RM, 2000, J CLIN EPIDEMIOL, V53, P103, DOI 10.1016/S0895-4356(99)00147-X; Heit JA, 2008, ARTERIOSCL THROM VAS, V28, P370, DOI 10.1161/ATVBAHA.108.162545; Jha AK, 2013, BMJ QUAL SAF, V22, P809, DOI 10.1136/bmjqs-2012-001748; Cushman M, 2004, AM J MED, V117, P19, DOI 10.1016/j.amjmed.2004.01.018; Cohen AT, 2008, LANCET, V371, P387, DOI 10.1016/S0140-6736(08)60202-0; Virkus RA, 2011, THROMB HAEMOSTASIS, V106, P304, DOI 10.1160/TH10-12-0823; Lee CH, 2010, J THROMB HAEMOST, V8, P1515, DOI 10.1111/j.1538-7836.2010.03873.x; NORDSTROM M, 1992, J INTERN MED, V232, P155; Gaborit FS, 2013, THROMB HAEMOSTASIS, V110, P39, DOI 10.1160/TH12-10-0790; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Naess IA, 2007, J THROMB HAEMOST, V5, P692; Wells PS, 2014, JAMA-J AM MED ASSOC, V311, P717, DOI 10.1001/jama.2014.65; Wen SW, 2005, CAN MED ASSOC J, V173, P759, DOI 10.1503/cmaj.045156; Stein PD, 2004, AM J MED, V116, P435, DOI 10.1016/j.amjmed.2003.11.020; WOO KS, 1988, INT J CARDIOL, V20, P373, DOI 10.1016/0167-5273(88)90291-4; Holst AG, 2010, CIRCULATION, V121, P1896, DOI 10.1161/CIRCULATIONAHA.109.921460; Deitelzweig SB, 2011, AM J HEMATOL, V86, P217, DOI 10.1002/ajh.21917; Kane EV, 2013, EUR J OBSTET GYN R B, V169, P223, DOI 10.1016/j.ejogrb.2013.03.024; Sweetland S, 2012, J THROMB HAEMOST, V10, P2277, DOI 10.1111/j.1538-7836.2012.04919.x; Feigin VL, 2014, LANCET, V383, P245, DOI 10.1016/S0140-6736(13)61953-4; Petrauskiene V, 2005, DIABETOLOGIA, V48, P1017, DOI 10.1007/s00125-005-1715-5; Klatsky AL, 2000, AM J CARDIOL, V85, P1334, DOI 10.1016/S0002-9149(00)00766-9; Severinsen MT, 2010, EUR J INTERN MED, V21, P268, DOI 10.1016/j.ejim.2010.03.013; Jang MJ, 2011, J THROMB HAEMOST, V9, P85, DOI 10.1111/j.1538-7836.2010.04108.x; Kachroo S, 2012, AM J HEALTH-SYST PH, V69, P567, DOI 10.2146/ajhp110241; Heit JA, 2001, J VASC SURG, V33, P1022, DOI 10.1067/mva.2001.113308; Jamison DT, 2013, LANCET, V382, P1898, DOI 10.1016/S0140-6736(13)62105-4; Huerta C, 2007, ARCH INTERN MED, V167, P935, DOI 10.1001/archinte.167.9.935; Lindqvist P, 1999, OBSTET GYNECOL, V94, P595, DOI 10.1016/S0029-7844(99)00308-7; Deitelzweig SB, 2011, J THROMB THROMBOLYS, V31, P133, DOI 10.1007/s11239-010-0503-3; Pengo V, 2004, NEW ENGL J MED, V350, P2257, DOI 10.1056/NEJMoa032274; Engbers MJ, 2010, J THROMB HAEMOST, V8, P2105, DOI 10.1111/j.1538-7836.2010.03986.x; Horton R, 2012, LANCET, V380, P2053, DOI 10.1016/S0140-6736(12)62133-3; Goldhaber SZ, 2011, NEW ENGL J MED, V365, P2167, DOI 10.1056/NEJMoa1110899; Cohen AT, 2013, NEW ENGL J MED, V368, P513, DOI 10.1056/NEJMoa1111096; Oger E, 2000, THROMB HAEMOSTASIS, V83, P657; Wiener RS, 2011, ARCH INTERN MED, V171, P831, DOI 10.1001/archinternmed.2011.178; Raskob GE, 2012, J BONE JOINT SURG BR, V94B, P257, DOI 10.1302/0301-620X.94B2.27850; Catterick D, 2014, BLOOD COAGUL FIBRIN, V25, P571, DOI 10.1097/MBC.0000000000000100; Murray CJL, 2012, LANCET, V380, P2063, DOI 10.1016/S0140-6736(12)61899-6; Heit JA, 2005, ANN INTERN MED, V143, P697; Silverstein MD, 1998, ARCH INTERN MED, V158, P585, DOI 10.1001/archinte.158.6.585; Berg CJ, 2010, OBSTET GYNECOL, V116, P1302, DOI 10.1097/AOG.0b013e3181fdfb11; Angchaisuksiri P, 2011, THROMB HAEMOSTASIS, V106, P585, DOI 10.1160/TH11-03-0184; Kroger K, 2010, J THROMB THROMBOLYS, V29, P349, DOI 10.1007/s11239-009-0396-1; Murray CJL, 2012, LANCET, V380, P2197, DOI 10.1016/S0140-6736(12)61689-4; White RH, 1998, ANN INTERN MED, V128, P737; Cohen AT, 2007, THROMB HAEMOSTASIS, V98, P756, DOI 10.1160/TH07-03-0212; Ho WK, 2008, MED J AUSTRALIA, V189, P144; Kahn SR, 2002, ARCH INTERN MED, V162, P1144, DOI 10.1001/archinte.162.10.1144; Stein PD, 2008, AM J CARDIOL, V102, P927, DOI 10.1016/j.amjcard.2008.05.046; Beemath A, 2006, AM J CARDIOL, V98, P1073, DOI 10.1016/j.amjcard.2006.05.030; Cheuk BLY, 2004, BRIT J SURG, V91, P424, DOI 10.1002/bjs.4454; Falck-Ytter Y, 2012, CHEST S, V141, pe278S; Fawcus SR, 2005, BJOG-INT J OBSTET GY, V112, P1257, DOI 10.1111/j.1471-0528.2005.00601.x; Gomes JP, 2003, J GEN INTERN MED, V18, P934, DOI 10.1046/j.1525-1497.2003.21133.x; Gould MK, 2012, CHEST, V141, pe227S, DOI DOI 10.1378/CHEST.11-2297; Guijarro Ricardo, 2005, Eur J Intern Med, V16, P279, DOI 10.1016/j.ejim.2005.02.007; Hald EM, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.113.000483; Heit JA, 2005, BLOOD, V106, p267A; Heyl PS, 2013, MATERN CHILD HLTH J, V17, P1230, DOI 10.1007/s10995-012-1117-5; Hunter DJ, 2014, NEW ENGL J MED, V370, P1753, DOI 10.1056/NEJMe1404077; Kahn SR, 2012, CHEST S2, V141, pe195; KIERKEGAARD A, 1980, ACTA CHIR SCAND, V146, P267; Kniffin W. D. Jr., 1994, Archives of Internal Medicine, V154, P861, DOI 10.1001/archinte.154.8.861; Kunisawa S, 2012, WORLD J SURG, V36, P280, DOI 10.1007/s00268-011-1229-x; Lester W, 2013, HEART, V99, P1734, DOI 10.1136/heartjnl-2013-304479; Lutsey PL, 2010, AM J PUBLIC HEALTH, V100, P1506, DOI 10.2105/AJPH.2008.157776; Mellemkjaer L, 1999, BRIT MED J, V319, P820; Moretti A M, 2010, Monaldi Arch Chest Dis, V73, P18; Moysidis T, 2010, BLOOD COAGUL FIBRIN, V21, P511, DOI 10.1097/MBC.0b013e328339cc49; Nicolaides A N, 2013, Int Angiol, V32, P111; Noble S, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004561; Reardon G, 2013, J AM MED DIR ASSOC, V14, P578, DOI 10.1016/j.jamda.2013.02.003; Samuelsson E, 2004, ACTA OBSTET GYN SCAN, V83, P674, DOI 10.1111/j.0001-6349.2004.00574.x; Samuelsson E, 2007, ACTA OBSTET GYN SCAN, V86, P435, DOI 10.1080/00016340701207500; Santosa F, 2014, HAMOSTASEOLOGIE, V34, P88, DOI 10.5482/HAMO-13-05-0028; Schmidt M, 2013, BMJ OPEN, P3; Sharma S, 2008, AUST NZ J OBSTET GYN, V48, P44, DOI 10.1111/j.1479-828X.2007.00799.x; Shiraev TP, 2013, THROMB RES, V132, P19, DOI 10.1016/j.thromres.2013.04.032; Sixty-Sixth World Health Assembly, 2013, FOLLOW UP POLITICAL; Spannagl Michael, 2005, Thromb J, V3, P8, DOI 10.1186/1477-9560-3-8; Sullivan EA, 2004, AUST NZ J OBSTET GYN, V44, P452, DOI 10.1111/j.1479-828X.2004.00313.x; Tagalakis V, 2013, AM J MED, V126; Vázquez Fernando Javier, 2013, Thromb J, V11, P16, DOI 10.1186/1477-9560-11-16; White RH, 2006, THROMB HAEMOSTASIS, V96, P267, DOI 10.1160/TH06-07-0365; Wilson RM, 2012, BRIT MED J, V344, DOI 10.1136/bmj.e832	92	8	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-5642	1524-4636		ARTERIOSCL THROM VAS	Arterioscler. Thromb. Vasc. Biol.	NOV	2014	34	11					2363	2371		10.1161/ATVBAHA.114.304488		9	Hematology; Peripheral Vascular Disease	Hematology; Cardiovascular System & Cardiology	AS1QX	WOS:000344056400002		
J	Kigawa, Y; Miyazaki, T; Lei, XF; Nakamachi, T; Oguchi, T; Kim-Kaneyama, J; Taniyama, M; Tsunawaki, S; Shioda, S; Miyazaki, A				Kigawa, Yasuyoshi; Miyazaki, Takuro; Lei, Xiao-Feng; Nakamachi, Tomoya; Oguchi, Tatsunori; Kim-Kaneyama, Joo-ri; Taniyama, Matsuo; Tsunawaki, Shohko; Shioda, Seiji; Miyazaki, Akira			NADPH Oxidase Deficiency Exacerbates Angiotensin II-Induced Abdominal Aortic Aneurysms in Mice	ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY			English	Article						aortic aneurysm; abdominal; cytokines; macrophages; NADPH oxidase; oxidative stress	CHRONIC GRANULOMATOUS-DISEASE; INFLAMMATORY RESPONSES; CARDIOVASCULAR HEALTH; IMMUNE-RESPONSES; IN-VIVO; ACTIVATION; CELLS; NOX2; MATRIX-METALLOPROTEINASE-9; DESTRUCTION	Objective Although nicotinamide adenine dinucleotide phosphate oxidase 2 (NOX2) is reportedly essential for phagocyte host defenses, it has been found to aggravate atherosclerosis in apolipoprotein E (Apoe)-null mice through excess production of superoxide. We therefore assessed the role of NOX2 in an experimental model of abdominal aortic aneurysm (AAA) and assessed the mechanism of NOX2 action in AAA. Approach and Results AAA was induced in low-density lipoprotein receptor-null (Ldlr(-/-)) mice by infusing angiotensin II. Nox2 expression was elevated in the abdominal aortae of these mice during infusion of angiotensin II, with enhanced Nox2 expression mainly because of the recruitment of NOX2-enriched macrophages into AAA lesions. Unexpectedly, systemic Nox2 deficiency promoted AAA development but reduced the level of reactive oxygen species in AAA lesions. Nox2 deficiency stimulated macrophage conversion toward the M1 subset, enhancing expression of interleukin (IL)-1 and matrix metalloproteinase-9/12 mRNA. Administration of neutralizing antibody against IL-1 abolished AAA development in Nox2-deficient mice. Bone marrow transplantation experiments revealed that AAA aggravation by Nox2 deficiency is because of bone marrow-derived cells. Isolated bone marrow-derived macrophages from Nox2-null mice could not generate reactive oxygen species. In contrast, IL-1 expression in peritoneal and bone marrow-derived macrophages, but not in peritoneal neutrophils, was substantially enhanced by Nox2 deficiency. Pharmacological inhibition of Janus kinase/signal transducers and activators of transcription signaling inhibited excess IL-1 expression in Nox2-deficient macrophages, whereas matrix metalloproteinase-9 secretion was constitutively stimulated via nuclear factor-B signals. ConclusionsNox2 deficiency enhances macrophage secretion of IL-1 and matrix metalloproteinase-9, disrupting tissue-remodeling functions in AAA lesions. These actions are unfavorable if NOX2 is to serve as a molecular target for AAA.	[Kigawa, Yasuyoshi; Miyazaki, Takuro; Lei, Xiao-Feng; Oguchi, Tatsunori; Kim-Kaneyama, Joo-ri; Tsunawaki, Shohko; Miyazaki, Akira] Showa Univ, Sch Med, Dept Biochem, Tokyo 1428555, Japan; [Nakamachi, Tomoya; Shioda, Seiji] Showa Univ, Sch Med, Dept Anat, Tokyo 1428555, Japan; [Nakamachi, Tomoya] Showa Univ, Ctr Biotechnol, Tokyo 1428555, Japan; [Kigawa, Yasuyoshi; Taniyama, Matsuo] Showa Univ, Fujigaoka Hosp, Div Endocrinol & Metab, Yokohama, Kanagawa 227, Japan; [Nakamachi, Tomoya] Toyama Univ, Grad Sch Sci & Engn, Lab Regulatory Biol, Toyama 930, Japan	Miyazaki, T (reprint author), Showa Univ, Sch Med, Dept Biochem, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.	taku@pharm.showa-u.ac.jp			Japan Society for the Promotion of Science [26461368, 24790784]; Takeda Science Foundation; Banyu Life Science Foundation International; Japan Heart Foundation	This study was supported in part by a Grant-in-Aid for Scientific Research (26461368 to A. Miyazaki) and a Showa University Research Grant for Young Researchers, a Grant-in-Aid for Young Scientists (24790784) from the Japan Society for the Promotion of Science, a research grant from Takeda Science Foundation, a research grant from Banyu Life Science Foundation International, and a Dr Hiroshi Irisawa and Dr Aya Irisawa Memorial Research Grant from Japan Heart Foundation (all to T. Miyazaki).	Anderson Robert N, 2002, Natl Vital Stat Rep, V50, P1; Heikkinen M, 2002, J VASC SURG, V36, P291, DOI 10.1067/mva.2002.125479; Deffert C, 2012, J PATHOL, V228, P341, DOI 10.1002/path.4061; Sokolovska A, 2013, NAT IMMUNOL, V14, P543, DOI 10.1038/ni.2595; Newman AB, 2001, ANN INTERN MED, V134, P182; Cave AC, 2006, ANTIOXID REDOX SIGN, V8, P691, DOI 10.1089/ars.2006.8.691; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Gavazzi G, 2007, HYPERTENSION, V50, P189, DOI 10.1161/HYPERTENSIONAHA.107.089706; Schroder K, 2012, CIRC RES, V110, P1217, DOI 10.1161/CIRCRESAHA.112.267054; Steinhubl SR, 2008, AM J CARDIOL, V101, p14D, DOI 10.1016/j.amjcard.2008.02.003; Judkins CP, 2010, AM J PHYSIOL-HEART C, V298, pH24, DOI 10.1152/ajpheart.00799.2009; Shi C, 2011, NAT REV IMMUNOL, V11, P762, DOI 10.1038/nri3070; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; Thomas M, 2006, CIRCULATION, V114, P404, DOI 10.1161/CIRCULATIONAHA.105.607168; Johnston WF, 2013, ARTERIOSCL THROM VAS, V33, P294, DOI 10.1161/ATVBAHA.112.300432; ROYERPOKORA B, 1986, NATURE, V322, P32, DOI 10.1038/322032a0; Shimizu K, 2004, J CLIN INVEST, V114, P300, DOI 10.1172/JCI200419855; Longo GM, 2002, J CLIN INVEST, V110, P625, DOI 10.1172/JCI200215334; Hu XY, 2009, IMMUNITY, V31, P539, DOI 10.1016/j.immuni.2009.09.002; van de Veerdonk FL, 2010, P NATL ACAD SCI USA, V107, P3030, DOI 10.1073/pnas.0914795107; Luttun A, 2004, CIRCULATION, V109, P1408, DOI 10.1161/01.CIR.0000121728.14930.DE; Yang CS, 2013, J IMMUNOL, V190, P6368, DOI 10.4049/jimmunol.1202574; Kim SY, 2010, IMMUNOL CELL BIOL, V88, P197, DOI 10.1038/icb.2009.87; Baril DT, 2007, NAT CLIN PRACT CARD, V4, P206, DOI 10.1038/ncpcardio0849; Hasan D, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-222; Lu RZ, 2012, PLOS PATHOG, V8, DOI 10.1371/journal.ppat.1002597; Nielsen M, 1997, P NATL ACAD SCI USA, V94, P6764, DOI 10.1073/pnas.94.13.6764; Segal BH, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009631; TEAHAN C, 1987, NATURE, V327, P720, DOI 10.1038/327720a0; TSUNAWAKI S, 1994, J EXP MED, V179, P291, DOI 10.1084/jem.179.1.291; van de Loo FAJ, 2003, AM J PATHOL, V163, P1525, DOI 10.1016/S0002-9440(10)63509-2; Whitmore LC, 2013, J INNATE IMMUN, V5, P565, DOI 10.1159/000347212; Zhang WJ, 2009, FREE RADICAL BIO MED, V46, P791, DOI 10.1016/j.freeradbiomed.2008.12.003	33	6	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-5642	1524-4636		ARTERIOSCL THROM VAS	Arterioscler. Thromb. Vasc. Biol.	NOV	2014	34	11					2413	2420		10.1161/ATVBAHA.114.303086		8	Hematology; Peripheral Vascular Disease	Hematology; Cardiovascular System & Cardiology	AS1QX	WOS:000344056400008		
J	Yaoita, N; Shirakawa, R; Fukumoto, Y; Sugimura, K; Miyata, S; Miura, Y; Nochioka, K; Miura, M; Tatebe, S; Aoki, T; Yamamoto, S; Satoh, K; Kimura, T; Shimokawa, H; Horiuchi, H				Yaoita, Nobuhiro; Shirakawa, Ryutaro; Fukumoto, Yoshihiro; Sugimura, Koichiro; Miyata, Satoshi; Miura, Yutaka; Nochioka, Kotaro; Miura, Masanobu; Tatebe, Shunsuke; Aoki, Tatsuo; Yamamoto, Saori; Satoh, Kimio; Kimura, Tomohiro; Shimokawa, Hiroaki; Horiuchi, Hisanori			Platelets Are Highly Activated in Patients of Chronic Thromboembolic Pulmonary Hypertension	ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY			English	Article						blood platelets; chronic thromboembolic pulmonary hypertension; GTP-binding proteins; pulmonary hypertension	INTEGRIN ALPHA(IIB)BETA(3); INFLAMMATORY CYTOKINES; ARTERIAL-HYPERTENSION; GRANULE SECRETION; AGGREGATION; COAGULATION; THROMBIN; EMBOLISM; REGISTRY; BLOOD	Objective Chronic thromboembolic pulmonary hypertension (CTEPH) is a fatal disease that is distinct from pulmonary arterial hypertension (PAH). Although CTEPH is characterized by obstruction of major pulmonary artery because of chronic thrombus, it remains unclear whether CTEPH is associated with prothrombotic condition. Approach and Results In addition to conventional markers, GTP-bound levels of Rap1, RhoA, RalA, Rac1, and Ras in platelets, which are implicated for platelet activation, were measured in patients without pulmonary hypertension (non-PH, n=15), patients with PAH (n=19), and patients with CTEPH (n=25). Furthermore, the responsiveness to ex vivo thrombin stimulation was also evaluated. The ratios of the P-selectin positive platelets in the non-PH patients, patients with PAH, and patients with CTEPH were 1.40% (median and interquartile range, 0.83-1.82), 2.40% (1.80-3.39), and 2.63% (1.90-8.22), respectively (non-PH versus CTEPH, P<0.01). The activated GPIIb/IIIa-positive platelets were 6.01% (1.34-7.87), 11.39% (5.69-20.86), and 9.74% (7.83-24.01), respectively (non-PH versus CTEPH, P=0.01). GTP-bound RhoA was 1.79% (0.94-2.83), 4.03% (2.01-5.14), and 2.01% (1.22-2.48), respectively (non-PH versus PAH, P=0.04), and GTP-bound RalA was 1.58% (1.08-2.11), 3.02% (2.03-3.54), and 2.64% (1.42-4.28), respectively (non-PH versus PAH, P=0.023; non-PH versus CTEPH, P=0.048). In contrast, Rac1, Rap1, or Ras was not activated in any groups. The platelets of patients with CTEPH exhibited hyperresponsiveness to ex vivo thrombin stimulation compared with those of non-PH patients when evaluated for the surface markers. Either D-dimer or fibrin degradation product level was not increased in patients with CTEPH. Conclusions These results provide the first direct evidence that platelets of patients with CTEPH are highly activated and exhibit hyperresponsiveness to thrombin stimulation.	[Yaoita, Nobuhiro; Fukumoto, Yoshihiro; Sugimura, Koichiro; Miyata, Satoshi; Miura, Yutaka; Nochioka, Kotaro; Miura, Masanobu; Tatebe, Shunsuke; Aoki, Tatsuo; Yamamoto, Saori; Satoh, Kimio; Shimokawa, Hiroaki] Tohoku Univ, Grad Sch Med, Dept Cardiovasc Med, Sendai, Miyagi 9808574, Japan; [Shirakawa, Ryutaro; Kimura, Tomohiro; Horiuchi, Hisanori] Tohoku Univ, Dept Mol & Cellular Biol, Inst Dev Aging & Canc, Sendai, Miyagi 9808574, Japan	Horiuchi, H (reprint author), Tohoku Univ, Dept Mol & Cellular Biol, Inst Dev Aging & Canc, Aoba Ku, 4-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.	horiuchi@idac.tohoku.ac.jp			MEXT; JSPS KAKENHI; Senshin Medical Research Foundation; Bayer Scholarship for Cardiovascular Research	This work was supported, in part, by the MEXT and JSPS KAKENHI grants (to H. Horiuchi and R. Shirakawa), grants from the Senshin Medical Research Foundation (to H. Horiuchi), and the Bayer Scholarship for Cardiovascular Research (to R. Shirakawa).	Kawato M, 2008, J BIOL CHEM, V283, P166, DOI 10.1074/jbc.M705340200; Diehl P, 2011, J THROMB THROMBOLYS, V31, P173, DOI 10.1007/s11239-010-0507-z; Bonderman D, 2007, CIRCULATION, V115, P2153, DOI 10.1161/CIRCULATIONAHA.106.661041; Saito R, 2013, ONCOGENE, V32, P894, DOI 10.1038/onc.2012.101; Shirakawa R, 2004, J BIOL CHEM, V279, P10730, DOI 10.1074/jbc.M309426200; Suzuki Y, 1999, BLOOD, V93, P3408; Adam SS, 2009, BLOOD, V113, P2878, DOI 10.1182/blood-2008-06-165845; Hoeper MM, 2006, CIRCULATION, V113, P2011, DOI 10.1161/CIRCULATIONAHA.105.602565; Pepke-Zaba J, 2011, CIRCULATION, V124, P1973, DOI 10.1161/CIRCULATIONAHA.110.015008; Aslan JE, 2011, BLOOD, V118, P3129, DOI 10.1182/blood-2011-02-331579; De Candia E, 2012, THROMB RES, V129, P250, DOI 10.1016/j.thromres.2011.11.001; Berger G, 2009, ISR MED ASSOC J, V11, P376; Pengo V, 2004, NEW ENGL J MED, V350, P2257, DOI 10.1056/NEJMoa032274; Simonneau G, 2009, J AM COLL CARDIOL, V54, pS43, DOI 10.1016/j.jacc.2009.04.012; Varol E, 2011, CLIN APPL THROMB-HEM, V17, pE171, DOI 10.1177/1076029610394438; Libby P, 2010, CIRC J, V74, P213, DOI 10.1253/circj.CJ-09-0706; Tripodi A, 1996, CLIN CHEM, V42, P664; Bertoni A, 2002, J BIOL CHEM, V277, P25715, DOI 10.1074/jbc.M202791200; Groth A, 2014, RESP RES, V15, DOI 10.1186/1465-9921-15-47; Kantake M, 2013, INT J CARDIOL, V165, P474, DOI 10.1016/j.ijcard.2011.08.851; MORII N, 1992, J BIOL CHEM, V267, P20921; Nakamura M, 2002, CIRC J, V66, P257, DOI 10.1253/circj.66.257; Nishioka H, 2001, BIOCHEM BIOPH RES CO, V280, P970, DOI 10.1006/bbrc.2001.4237; Galie N, 2009, EUR RESPIR J, V34, P1219, DOI 10.1183/09031936.00139009; Schoenwaelder SM, 2002, J BIOL CHEM, V277, P14738, DOI 10.1074/jbc.M200661200; Shirakawa R, 2009, J BIOL CHEM, V284, P21580, DOI 10.1074/jbc.M109.012112; Soon E, 2010, CIRCULATION, V122, P921, DOI 10.1161/CIRCULATIONAHA.109.933762; Tamburrelli C, 2011, THROMB RES, V128, P446, DOI 10.1016/j.thromres.2011.05.010; Wolf M, 2000, EUR RESPIR J, V15, P395, DOI 10.1034/j.1399-3003.2000.15b28.x; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486	30	2	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-5642	1524-4636		ARTERIOSCL THROM VAS	Arterioscler. Thromb. Vasc. Biol.	NOV	2014	34	11					2486	2494		10.1161/ATVBAHA.114.304404		9	Hematology; Peripheral Vascular Disease	Hematology; Cardiovascular System & Cardiology	AS1QX	WOS:000344056400017		
J	Imagawa, K; de Andres, MC; Hashimoto, K; Itoi, E; Otero, M; Roach, HI; Goldring, MB; Oreffo, ROC				Imagawa, Kei; de Andres, Maria C.; Hashimoto, Ko; Itoi, Eiji; Otero, Miguel; Roach, Helmtrud I.; Goldring, Mary B.; Oreffo, Richard O. C.			Association of Reduced Type IX Collagen Gene Expression in Human Osteoarthritic Chondrocytes With Epigenetic Silencing by DNA Hypermethylation	ARTHRITIS & RHEUMATOLOGY			English	Article							HUMAN ARTICULAR CHONDROCYTES; MATRIX-METALLOPROTEINASE 13; CPG SITES; HIP OSTEOARTHRITIS; DOWN-REGULATION; II COLLAGEN; PROFILING REVEALS; CANDIDATE GENES; POTENTIAL ROLE; CARTILAGE	Objective. To investigate whether the changes in collagen gene expression in osteoarthritic (OA) human chondrocytes are associated with changes in the DNA methylation status in the COL2A1 enhancer and COL9A1 promoter. Methods. Expression levels were determined using quantitative reverse transcription-polymerase chain reaction, and the percentage of DNA methylation was quantified by pyrosequencing. The effect of CpG methylation on COL9A1 promoter activity was determined using a CpG-free vector; cotransfections with expression vectors encoding SOX9, hypoxia-inducible factor 1 alpha (HIF-1 alpha), and HIF-2 alpha were carried out to analyze COL9A1 promoter activities in response to changes in the methylation status. Chromatin immunoprecipitation assays were carried out to validate SOX9 binding to the COL9A1 promoter and the influence of DNA methylation. Results. Although COL2A1 messenger RNA (mRNA) levels in OA chondrocytes were 19-fold higher than those in the controls, all of the CpG sites in the COL2A1 enhancer were totally demethylated in both samples. The levels of COL9A1 mRNA in OA chondrocytes were 6,000-fold lower than those in controls; 6 CpG sites of the COL9A1 promoter were significantly hypermethylated in OA patients as compared with controls. Treatment with 5-azadeoxycitidine enhanced COL9A1 gene expression and prevented culture-induced hypermethylation. In vitro methylation decreased COL9A1 promoter activity. Mutations in the 5 CpG sites proximal to the transcription start site decreased COL9A1 promoter activity. Cotransfection with SOX9 enhanced COL9A1 promoter activity; CpG methylation attenuated SOX9 binding to the COL9A1 promoter. Conclusion. This first demonstration that hypermethylation is associated with down-regulation of COL9A1 expression in OA cartilage highlights the pivotal role of epigenetics in OA, involving not only hypomethylation, but also hypermethylation, with important therapeutic implications for OA treatment.	[Imagawa, Kei; de Andres, Maria C.; Oreffo, Richard O. C.] Univ Southampton, Sch Med, Southampton SO16 6YD, Hants, England; [Imagawa, Kei; Hashimoto, Ko; Itoi, Eiji] Tohoku Univ, Grad Sch Med, Sendai, Miyagi 980, Japan; [Hashimoto, Ko] Hosp Special Surg, New York, NY 10021 USA; [Hashimoto, Ko] Weill Cornell Med Coll, New York, NY USA; [Otero, Miguel; Goldring, Mary B.] Hosp Special Surg, Weill Cornell Med Coll, New York, NY 10021 USA	Oreffo, ROC (reprint author), Univ Southampton, Sch Med, Inst Dev Sci, Bone & Joint Res Grp, MP 887,Tremona Rd, Southampton SO16 6YD, Hants, England.	roco@soton.ac.uk	Oreffo, Richard/A-4615-2011	Oreffo, Richard/0000-0001-5995-6726	NIH [R21-AR-054887, R01-AG-022021, RC4-AR-060546]; Wessex Medical Research [M19]; Biotechnology and Biological Sciences Research Council [G006970/1]	Supported by the NIH (grant R21-AR-054887 to Drs. Goldring and Roach and grants R01-AG-022021 and RC4-AR-060546 to Dr. Goldring), Wessex Medical Research (grant M19 to Drs. Roach and Oreffo), and the Biotechnology and Biological Sciences Research Council (grant G006970/1 to Dr. Oreffo).	Aigner T, 2003, MATRIX BIOL, V22, P363, DOI 10.1016/S0945-053X(03)00049-0; Alizadeh BZ, 2005, ARTHRITIS RHEUM, V52, P1437, DOI 10.1002/art.21020; Kim KI, 2013, J BONE MINER RES, V28, P1050, DOI 10.1002/jbmr.1843; Ijiri K, 2008, ARTHRITIS RHEUM, V58, P2075, DOI 10.1002/art.23504; Goldring MB, 2006, J CELL BIOCHEM, V97, P33, DOI 10.1002/jcb.20652; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Duval E, 2009, ARTHRITIS RHEUM, V60, P3038, DOI 10.1002/art.24851; Aigner T, 2006, ARTHRITIS RHEUM, V54, P3533, DOI 10.1002/art.22174; Loeser RF, 2009, OSTEOARTHR CARTILAGE, V17, P513, DOI 10.1016/j.joca.2008.08.003; da Silva MA, 2009, J ORTHOP RES, V27, P593, DOI 10.1002/jor.20799; Salminen H, 2001, ARTHRITIS RHEUM-US, V44, P947; Poschl E, 2005, ANN RHEUM DIS, V64, P477, DOI 10.1136/ard.2004.022509; Cheung KSC, 2009, RHEUMATOL INT, V29, P525, DOI 10.1007/s00296-008-0744-z; de Andres MC, 2013, ARTHRITIS RHEUM-US, V65, P732, DOI 10.1002/art.37806; Zimmermann P, 2008, ARTHRITIS RHEUM, V58, P2743, DOI 10.1002/art.23736; Schlichting N, 2014, MOL PHARMACEUT, V11, P2092, DOI 10.1021/mp5000554; Eyre D, 2002, ARTHRITIS RES, V4, P30, DOI 10.1186/ar380; Karlsson C, 2010, OSTEOARTHR CARTILAGE, V18, P581, DOI 10.1016/j.joca.2009.12.002; Imagawa K, 2011, BIOCHEM BIOPH RES CO, V405, P362, DOI 10.1016/j.bbrc.2011.01.007; Roach HI, 2005, ARTHRITIS RHEUM, V52, P3110, DOI 10.1002/art.21300; Hashimoto K, 2013, J BIOL CHEM, V288, P10061, DOI 10.1074/jbc.M112.421156; Schipani E, 2001, GENE DEV, V15, P2865; Lefebvre V, 1997, MOL CELL BIOL, V17, P2336; Klug M, 2006, EPIGENETICS, V1, P127; Sesselmann S, 2009, OSTEOARTHR CARTILAGE, V17, P507, DOI 10.1016/j.joca.2008.09.006; Kondo K, 2002, CANCER CELL, V1, P237, DOI 10.1016/S1535-6108(02)00043-0; Brena RM, 2006, NAT GENET, V38, P1359, DOI 10.1038/ng1206-1359; Bui C, 2012, FASEB J, V26, P3000, DOI 10.1096/fj.12-206367; Xu Y, 2012, OSTEOARTHR CARTILAGE, V20, P1029, DOI 10.1016/j.joca.2012.05.006; Hashimoto K, 2009, ARTHRITIS RHEUM-US, V60, P3303, DOI 10.1002/art.24882; Ma B, 2013, OSTEOARTHR CARTILAGE, V21, P599, DOI 10.1016/j.joca.2013.01.014; Moss TJ, 2007, MUTAT RES-FUND MOL M, V618, P163, DOI 10.1016/j.mrfmmm.2006.05.038; Hashimoto K, 2007, EPIGENETICS, V2, P86; Eyre DR, 2006, EUR CELLS MATER, V12, P57; HAAF T, 1995, PHARMACOL THERAPEUT, V65, P19, DOI 10.1016/0163-7258(94)00053-6; GOLDRING MB, 1994, J CLIN INVEST, V94, P2307, DOI 10.1172/JCI117595; Scott JL, 2010, ANN RHEUM DIS, V69, P1502, DOI 10.1136/ard.2009.119966; Lee JS, 2011, CONNECT TISSUE RES, V52, P496, DOI 10.3109/03008207.2011.585409; Reynard LN, 2011, HUM MOL GENET, V20, P3450, DOI 10.1093/hmg/ddr253; Yang S, 2010, NAT MED, V16, P687, DOI 10.1038/nm.2153; FASSLER R, 1994, P NATL ACAD SCI USA, V91, P5070, DOI 10.1073/pnas.91.11.5070; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; Brachvogel B, 2013, J BIOL CHEM, V288, P13481, DOI 10.1074/jbc.M112.444810; CHAN D, 1995, J BIOL CHEM, V270, P1747; Ghayor C, 2000, J BIOL CHEM, V275, P27421; Hagg R, 1997, J BIOL CHEM, V272, P20650, DOI 10.1074/jbc.272.33.20650; LEVINE A, 1992, P NATL ACAD SCI USA, V89, P10119, DOI 10.1073/pnas.89.21.10119; Loughlin J, 2002, EUR J HUM GENET, V10, P562, DOI 10.1038/sj.ejhg.5200848; Mustafa Z, 2000, RHEUMATOLOGY, V39, P299, DOI 10.1093/rheumatology/39.3.299; Zhang P, 2003, J BIOL CHEM, V278, P117, DOI 10.1074/jbc.M208049200	50	9	9	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2326-5191	2326-5205		ARTHRITIS RHEUMATOL	Arthritis Rheumatol.	NOV	2014	66	11					3040	3051		10.1002/art.38774		12	Rheumatology	Rheumatology	AS6BI	WOS:000344349500014		
J	Minoia, F; Davi, S; Horne, A; Demirkaya, E; Bovis, F; Li, CF; Lehmberg, K; Weitzman, S; Insalaco, A; Wouters, C; Shenoi, S; Espada, G; Ozen, S; Anton, J; Khubchandani, R; Russo, R; Pal, P; Kasapcopur, O; Miettunen, P; Maritsi, D; Merino, R; Shakoory, B; Alessio, M; Chasnyk, V; Sanner, H; Gao, YJ; Zeng, HS; Kitoh, T; Avcin, T; Fischbach, M; Frosch, M; Grom, A; Huber, A; Jelusic, M; Sawhney, S; Uziel, Y; Ruperto, N; Martini, A; Cron, RQ; Ravelli, A				Minoia, Francesca; Davi, Sergio; Horne, AnnaCarin; Demirkaya, Erkan; Bovis, Francesca; Li, Caifeng; Lehmberg, Kai; Weitzman, Sheila; Insalaco, Antonella; Wouters, Carine; Shenoi, Susan; Espada, Graciela; Ozen, Seza; Anton, Jordi; Khubchandani, Raju; Russo, Ricardo; Pal, Priyankar; Kasapcopur, Ozgur; Miettunen, Paivi; Maritsi, Despoina; Merino, Rosa; Shakoory, Bita; Alessio, Maria; Chasnyk, Vyacheslav; Sanner, Helga; Gao, Yi-Jin; Zeng Huasong; Kitoh, Toshiyuki; Avcin, Tadej; Fischbach, Michel; Frosch, Michael; Grom, Alexei; Huber, Adam; Jelusic, Marija; Sawhney, Sujata; Uziel, Yosef; Ruperto, Nicolino; Martini, Alberto; Cron, Randy Q.; Ravelli, Angelo		Pediat Rheumatology Int Trials Org; Childhood Arthrit Rheumatology Res; Pediat Rheumatology Collaborative; Histiocyte Soc	Clinical Features, Treatment, and Outcome of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis A Multinational, Multicenter Study of 362 Patients	ARTHRITIS & RHEUMATOLOGY			English	Article							HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; RHEUMATOID-ARTHRITIS; LUPUS-ERYTHEMATOSUS; ANAKINRA; CHILDREN; DISEASE; CYCLOSPORINE; GUIDELINES; DISORDERS; DIAGNOSIS	Objective. To describe the clinical, laboratory, and histopathologic features, current treatment, and outcome of patients with macrophage activation syndrome (MAS) complicating systemic juvenile idiopathic arthritis (JIA). Methods. In this multinational, multicenter study, pediatric rheumatologists and hemato-oncologists entered patient data collected retrospectively into a web-based database. Results. A total of 362 patients, 22% of whom had MAS at the onset of systemic JIA, were included in the study by 95 investigators from 33 countries. The most frequent clinical manifestations were fever (96%), hepatomegaly (70%), and splenomegaly (58%). Central nervous system dysfunction and hemorrhages were recorded in 35% and 20% of the patients, respectively. Platelet count and liver transaminase, ferritin, lactate dehydrogenase, triglyceride, and D-dimer levels were the sole laboratory biomarkers showing a percentage change of >50% between the pre-MAS visit and MAS onset. Evidence of macrophage hemophagocytosis was found in 60% of the patients who underwent bone marrow aspiration. MAS occurred most frequently in the setting of active underlying disease, in the absence of a specific trigger. Nearly all patients were given corticosteroids, and 61% received cyclosporine. Biologic medications and etoposide were given to 15% and 12% of the patients, respectively. Approximately one-third of the patients required admission to the intensive care unit (ICU), and the mortality rate was 8%. Conclusion. This study provides information on the clinical spectrum and current management of systemic JIA-associated MAS through the analysis of a very large patient sample. MAS remains a serious condition, as a sizeable proportion of patients required admission to the ICU or died.	[Minoia, Francesca; Davi, Sergio; Bovis, Francesca; Ruperto, Nicolino; Martini, Alberto; Ravelli, Angelo] Ist Giannina Gaslini, I-16147 Genoa, Italy; [Horne, AnnaCarin] Karolinska Univ Hosp Solna, Stockholm, Sweden; [Demirkaya, Erkan] Gulhane Mil Med Fac, Ankara, Turkey; [Li, Caifeng] Beijing Childrens Hosp, Beijing, Peoples R China; [Lehmberg, Kai] Univ Med Ctr, Hamburg, Germany; [Weitzman, Sheila] Hosp Sick Children, Toronto, ON M5G 1X8, Canada; [Insalaco, Antonella] Osped Pediat Bambino Gesu, Rome, Italy; [Wouters, Carine] Univ Hosp Gasthuisberg, Leuven, Belgium; [Shenoi, Susan] Seattle Childrens Hosp, Seattle, WA USA; [Espada, Graciela] Hosp Ninos Dr Ricardo Gutierrez, Buenos Aires, DF, Argentina; [Ozen, Seza] Hacettepe Univ, Ankara, Turkey; [Anton, Jordi] Hosp St Joan de Deu, Barcelona, Spain; [Khubchandani, Raju] Jaslok Hosp & Res Ctr, Mumbai, Maharashtra, India; [Russo, Ricardo] Hosp Pediat Juan P Garrahan, Buenos Aires, DF, Argentina; [Pal, Priyankar] Inst Child Hlth, Kolkata, India; [Kasapcopur, Ozgur] Istanbul Univ, Istanbul, Turkey; [Miettunen, Paivi] Univ Calgary, Calgary, AB, Canada; [Maritsi, Despoina] Athens Med Sch, Athens, Greece; [Merino, Rosa] Hosp Univ La Paz, Madrid, Spain; [Shakoory, Bita] Temple Univ, Philadelphia, PA 19122 USA; [Alessio, Maria] Univ Naples Federico II, Naples, Italy; [Chasnyk, Vyacheslav] St Petersburg State Pediat Med Acad, St Petersburg, Russia; [Sanner, Helga] Oslo Univ Hosp, Rigshosp, Oslo, Norway; [Gao, Yi-Jin] Fudan Univ, Childrens Hosp, Shanghai 200433, Peoples R China; [Zeng Huasong] Guangzhou Childrens Hosp, Guangzhou, Guangdong, Peoples R China; [Kitoh, Toshiyuki] Aichi Med Univ, Nagakute, Aichi 48011, Japan; [Avcin, Tadej] Univ Childrens Hosp, Ljubljana, Slovenia; [Fischbach, Michel] Hop Univ Hautepierre, Strasbourg, France; [Frosch, Michael] Univ Childrens Hosp Munster, Munster, Germany; [Grom, Alexei] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA; [Huber, Adam] IWK Hlth Ctr, Halifax, NS, Canada; [Jelusic, Marija] Univ Hosp Ctr Zagreb, Zagreb, Croatia; [Sawhney, Sujata] Sir Ganga Ram Hosp, New Delhi, India; [Uziel, Yosef] Meir Med Ctr, Kefar Sava, Israel; [Martini, Alberto; Ravelli, Angelo] Univ Genoa, Genoa, Italy; [Cron, Randy Q.] Univ Alabama Birmingham, Birmingham, AL USA	Ravelli, A (reprint author), Ist Giannina Gaslini, Largo G Gaslini 5, I-16147 Genoa, Italy.	angeloravelli@ospedale-gaslini.ge.it	Kitoh, Toshiyuki/F-8962-2010	Demirkaya, Erkan/0000-0003-4525-1789; Anton, Jordi/0000-0002-8792-4219; Kitoh, Toshiyuki/0000-0002-5519-8320	Novartis; Roche	Dr. Grom has received consulting fees, speaking fees, and/or honoraria from Novartis and Roche (less than $10,000 each).	Miettunen PM, 2011, RHEUMATOLOGY, V50, P417, DOI 10.1093/rheumatology/keq218; Arico M, 1996, LEUKEMIA, V10, P197; Ramanan AV, 2003, J RHEUMATOL, V30, P401; Ravelli A, 2012, GENES IMMUN, V13, P289, DOI 10.1038/gene.2012.3; Kelly A, 2007, CURR OPIN RHEUMATOL, V19, P477, DOI 10.1097/BOR.0b013e32825a6a79; Ruperto N, 2005, ARTHRITIS RHEUM, V52, P2854, DOI 10.1002/art.21230; Bennett TD, 2012, ARTHRITIS RHEUM-US, V64, P4135, DOI 10.1002/art.34661; Petty RE, 2004, J RHEUMATOL, V31, P390; Davi S, 2011, J RHEUMATOL, V38, P764, DOI 10.3899/jrheum.100996; Kimura Y, 2013, ARTHRIT CARE RES, V65, P745, DOI 10.1002/acr.21889; Gorelik M, 2013, J RHEUMATOL, V40, P1191, DOI 10.3899/jrheum.121131; Durand M, 2010, J RHEUMATOL, V37, P879, DOI 10.3899/jrheum.091046; Bleesing J, 2007, ARTHRITIS RHEUM, V56, P965, DOI 10.1002/art.22416; Grom AA, 2010, CURR OPIN RHEUMATOL, V22, P561, DOI 10.1097/01.bor.0000381996.69261.71; Ruperto N, 2012, NEW ENGL J MED, V367, P2396, DOI 10.1056/NEJMoa1205099; Behrens EM, 2008, J RHEUMATOL, V35, P343; Behrens EM, 2007, J RHEUMATOL, V34, P1133; Henter JI, 2002, BLOOD, V100, P2367, DOI 10.1182/blood-2002-01-0172; Sawhney S, 2001, ARCH DIS CHILD, V85, P421, DOI 10.1136/adc.85.5.421; Ravelli A, 2002, CURR OPIN RHEUMATOL, V14, P548, DOI 10.1097/01.BOR.0000020666.29529.57; Ravelli A, 2005, J PEDIATR-US, V146, P598, DOI 10.1016/j.jpeds.2004.12.016; Behrens EM, 2011, J CLIN INVEST, V121, P2264, DOI [10.1172/JCI43157, 10.1172/JC143157]; Henter JI, 2007, PEDIATR BLOOD CANCER, V48, P124, DOI 10.1002/pbc.21039; Athreya BH, 2002, CLIN EXP RHEUMATOL, V20, P121; Mouy R, 1996, J PEDIATR-US, V129, P750, DOI 10.1016/S0022-3476(96)70160-9; Nigrovic PA, 2011, ARTHRITIS RHEUM-US, V63, P545, DOI 10.1002/art.30128; Ravelli A, 1996, J PEDIATR-US, V128, P275, DOI 10.1016/S0022-3476(96)70408-0; Ramanan AV, 2003, J RHEUMATOL, V30, P2513; Kelly A, 2008, NAT CLIN PRACT RHEUM, V4, P615, DOI 10.1038/ncprheum0919; Stephan JL, 2001, RHEUMATOLOGY, V40, P1285, DOI 10.1093/rheumatology/40.11.1285; Bode SFN, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar3843; Buoncompagni A, 2005, PEDIAT RHEMATOL ONLI, V3, P70; Davi S, 2012, ANN PAEDIAT RHEUMATO, V1, P1; Davi S, 2014, ARTHRITIS RHEUMATOL; De Benedetti F, 2012, NEW ENGL J MED, V367, P2385, DOI 10.1056/NEJMoa1112802; Kahn PJ, 2013, J RHEUMATOL, V40, P743, DOI 10.3899/jrheum.121098; Laposata M, 1992, SI UNIT CONVERSION G; Lehmberg K, 2013, J PEDIATR-US, V162, P1245, DOI 10.1016/j.jpeds.2012.11.081; Lurati A, 2005, PEDIAT RHEUMATOL ONL, V3, P79; Ravelli A, 2008, HANDB SYST AUTOIMMUN, V6, P55, DOI 10.1016/S1571-5078(07)06008-4	40	16	16	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2326-5191	2326-5205		ARTHRITIS RHEUMATOL	Arthritis Rheumatol.	NOV	2014	66	11					3160	3169		10.1002/art.38802		10	Rheumatology	Rheumatology	AS6BI	WOS:000344349500026		
J	Muro, Y; Sugiura, K; Akiyama, M				Muro, Yoshinao; Sugiura, Kazumitsu; Akiyama, Masashi			Is the measurement of anti-PM-1 alpha antibodies at least as important as that of other systemic sclerosis-specific antibodies? Comment on the article by D'Aoust et al	ARTHRITIS & RHEUMATOLOGY			English	Letter									[Muro, Yoshinao; Sugiura, Kazumitsu; Akiyama, Masashi] Nagoya Univ, Grad Sch Med, Nagoya, Aichi 4648601, Japan	Muro, Y (reprint author), Nagoya Univ, Grad Sch Med, Nagoya, Aichi 4648601, Japan.		Sugiura, Kazumitsu /M-8913-2014; MURO, Yoshinao/M-8883-2014; 	Sugiura, Kazumitsu /0000-0002-5207-4592; Muro, Yoshinao/0000-0003-2329-8375			D'Aoust J, 2014, ARTHRITIS RHEUMATOL, V66, P1608, DOI 10.1002/art.38428; Mahler M, 2009, AUTOIMMUN REV, V8, P373, DOI 10.1016/j.autrev.2008.12.001; Muro Y, 2013, ARTHRITIS RES THER, V15, DOI 10.1186/ar4241	3	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	2326-5191	2326-5205		ARTHRITIS RHEUMATOL	Arthritis Rheumatol.	NOV	2014	66	11					3248	3248		10.1002/art.38803		1	Rheumatology	Rheumatology	AS6BI	WOS:000344349500040		
J	Kondo, M; Hirano, Y; Ikai, N; Kita, K; Jayanegara, A; Yokota, H				Kondo, Makoto; Hirano, Yoshiaki; Ikai, Noriyuki; Kita, Kazumi; Jayanegara, Anuraga; Yokota, Hiro-omi			Assessment of Anti-nutritive Activity of Tannins in Tea By-products Based on In vitro Rumen Fermentation	ASIAN-AUSTRALASIAN JOURNAL OF ANIMAL SCIENCES			English	Article						Tea By-product; In vitro Rumen Fermentation; Tannin; Tannin Binding Agent	GAS-PRODUCTION; GREEN TEA; POLYETHYLENE GLYCOLS; NUTRITIVE EVALUATION; METHANE PRODUCTION; ANIMAL NUTRITION; BROWSE; NITROGEN; DIGESTIBILITY; DEGRADATION	Nutritive values of green and black tea by-products and anti-nutritive activity of their tannins were evaluated in an in vitro rumen fermentation using various molecular weights of polyethylene glycols (PEG), polyvinyl pyrrolidone (PVP) and polyvinyl polypyrrolidone as tannin-binding agents. Significant improvement in gas production by addition of PEG4000, 6000 and 20000 and PVP was observed only from black tea by-product, but not from green tea by-product. All tannin binding agents increased NH3-N concentration from both green and black tea by-products in the fermentation medium, and the PEG6000 and 20000 showed relatively higher improvement in the NH3-N concentration. The PEG6000 and 20000 also improved in vitro organic matter digestibility and metabolizable energy contents of both tea by-products. It was concluded that high molecular PEG would be suitable to assess the suppressive activity of tannins in tea by-products by in vitro fermentation. Higher responses to gas production and NH3-N concentration from black tea by-product than green tea by-product due to PEG indicate that tannins in black tea by-product could suppress rumen fermentation more strongly than that in green tea by-product.	[Kondo, Makoto] Mie Univ, Grad Sch Bioresources, Tsu, Mie 5148507, Japan; [Kondo, Makoto; Hirano, Yoshiaki; Ikai, Noriyuki; Kita, Kazumi; Yokota, Hiro-omi] Nagoya Univ, Grad Sch Bioagri Sci, Nagoya, Aichi 4700151, Japan; [Hirano, Yoshiaki] Tokai Gakuen Univ, Nagoya, Aichi 4680014, Japan; [Kita, Kazumi] Iwate Univ, Sch Agr, Morioka, Iwate 0208550, Japan; [Jayanegara, Anuraga] Bogor Agr Univ, Fac Anim Sci, Bogor 16680, Indonesia	Kondo, M (reprint author), Mie Univ, Grad Sch Bioresources, Tsu, Mie 5148507, Japan.	makok@bio.mie-u.ac.jp					Al-Masri MR, 2012, BIORESOURCE TECHNOL, V103, P234, DOI 10.1016/j.biortech.2011.09.130; Rubanza CDK, 2005, ANIM FEED SCI TECH, V119, P129, DOI 10.1016/j,anifeedsci.2004.12.004; Mueller-Harvey I, 2006, J SCI FOOD AGR, V86, P2010, DOI 10.1002/jsfa.2577; MAKKAR HPS, 1995, BRIT J NUTR, V73, P897, DOI 10.1079/BJN19950095; Abarghuei MJ, 2010, LIVEST SCI, V132, P73, DOI 10.1016/j.livsci.2010.05.002; Jayanegara A, 2009, ANIM FEED SCI TECH, V150, P230, DOI 10.1016/j.anifeedsci.2008.10.011; Tolera A, 1997, ANIM FEED SCI TECH, V67, P181, DOI 10.1016/S0377-8401(96)01119-4; JONES DE, 1965, NATURE, V206, P299, DOI 10.1038/206299a0; Silanikove N, 2001, ANIM FEED SCI TECH, V91, P69, DOI 10.1016/S0377-8401(01)00234-6; Oh K, 2006, PEDOSPHERE, V16, P770, DOI 10.1016/S1002-0160(06)60113-6; Yang CS, 2000, J NUTR, V130, P2409; Licitra G, 1996, ANIM FEED SCI TECH, V57, P347, DOI 10.1016/0377-8401(95)00837-3; Singh B, 2005, ANIM FEED SCI TECH, V123, P351, DOI 10.1016/j.anifeedsci.2005.04.033; AOAC International, 2002, OFFICIAL METHODS ANA; Ben Salem H, 1999, ANIM SCI, V68, P809; Bhatta R, 2012, ASIAN AUSTRAL J ANIM, V25, P1389, DOI 10.5713/ajas.2012.12229; Getachew G, 2000, BRIT J NUTR, V84, P73; Kondo M, 2004, J SCI FOOD AGR, V84, P721, DOI 10.1002/jsfa.1718; Kondo M, 2004, J SCI FOOD AGR, V84, P728, DOI 10.1002/jsfa.1726; Kondo M, 2014, ASIAN AUSTRAL J ANIM, V27, P937, DOI 10.5713/ajas.2013.13387; Makkar H. P. S., 1996, QUANTIFICATION TANNI; Makkar H. P. S., 2004, FAO ANIMAL PRODUCTIO, V160, P55; Menke KH, 1988, ANIM RES DEV, V28, P7; Osuga IM, 2006, ANIM SCI J, V77, P414, DOI 10.1111/j.1740-0929.2006.00367.x; Osuga IM, 2007, J SCI FOOD AGR, V87, P1533, DOI 10.1002/jsfa.2883; VANSOEST PJ, 1991, J DAIRY SCI, V74, P3583; Wambui CC, 2012, GRASSL SCI, V58, P53, DOI 10.1111/j.1744-697X.2011.00236.x; WEATHERB.MW, 1967, ANAL CHEM, V39, P971, DOI 10.1021/ac60252a045; Yamamoto T, 1997, CHEM APPL GREEN TEA	29	0	0	ASIAN-AUSTRALASIAN ASSOC ANIMAL PRODUCTION SOC	SEOUL	ROOM 708 SAMMO SPOREX, 1638-32, SEOWON-DONG, GWANAK-GU, SEOUL 151-730, SOUTH KOREA	1011-2367	1976-5517		ASIAN AUSTRAL J ANIM	Asian Australas. J. Anim. Sci.	NOV	2014	27	11					1571	1576		10.5713/ajas.2014.14204		6	Agriculture, Dairy & Animal Science	Agriculture	AS4BX	WOS:000344219500008		
J	Araki, M; Niwayama, K; Tsukiyama, K				Araki, Mitsunori; Niwayama, Kei; Tsukiyama, Koichi			LABORATORY OPTICAL SPECTROSCOPY OF THE THIOPHENOXY RADICAL AND ITS PROFILE SIMULATION AS A DIFFUSE INTERSTELLAR BAND BASED ON ROTATIONAL DISTRIBUTION BY RADIATION AND COLLISIONS	ASTRONOMICAL JOURNAL			English	Article						astrochemistry; ISM: clouds; ISM: lines and bands; ISM: molecules	ELECTRONIC-SPECTRA; GAS-PHASE	The gas-phase optical absorption spectrum of the thiophenoxy radical (C6H5S), a diffuse interstellar band (DIB) candidate molecule, was observed in the discharge of thiophenol using a cavity ringdown spectrometer. The ground-state rotational constants of the thiophenoxy radical were theoretically calculated, and the excited-state rotational constants were determined from the observed rotational profile. The rotational profile of a near prolate molecule having C-2 nu symmetry was simulated on the basis of a rotational distribution model by radiation and collisions. Although the simulated profile did not agree with the observed DIBs, the upper limit of the column density for the thiophenoxy radical in the diffuse clouds toward HD 204827 was evaluated to be 2 x 10(13) cm(-2). The profile simulation indicates that rotational distribution by radiation and collisions is important to reproduce a rotational profile for a DIB candidate and that the near prolate C-2 nu molecule is a possible candidate for DIB with a band width variation dependent on the line of sight.	[Araki, Mitsunori; Niwayama, Kei; Tsukiyama, Koichi] Tokyo Univ Sci, Fac Sci Div 1, Dept Chem, Shinjuku Ku, Tokyo 1628601, Japan	Araki, M (reprint author), Tokyo Univ Sci, Fac Sci Div 1, Dept Chem, Shinjuku Ku, 1-3 Kagurazaka, Tokyo 1628601, Japan.	araki@rs.kagu.tus.ac.jp			Tokyo Ohka Foundation for the Promotion of Science and Technology; Research Foundation for Opto-Science and Technology; Sumitomo Foundation;  [25108002]	This study was funded by the Tokyo Ohka Foundation for the Promotion of Science and Technology, the Research Foundation for Opto-Science and Technology, the Sumitomo Foundation, and Grant-in-Aid for Scientific Research on Innovative Areas (grant No. 25108002).	PORTER G, 1955, T FARADAY SOC, V51, P1469, DOI 10.1039/tf9555101469; SHIBUYA K, 1988, CHEM PHYS, V121, P237, DOI 10.1016/0301-0104(88)90030-4; Hobbs LM, 2009, ASTROPHYS J, V705, P32, DOI 10.1088/0004-637X/705/1/32; Pan K, 2004, ASTROPHYS J SUPPL S, V151, P313, DOI 10.1086/381805; Oka T, 2004, ASTROPHYS J, V613, P349, DOI 10.1086/423030; Motylewski T, 2000, ASTROPHYS J, V531, P312, DOI 10.1086/308465; CHANG HM, 1975, J PHYS CHEM-US, V79, P1118, DOI 10.1021/j100578a017; Dahlstrom J, 2013, ASTROPHYS J, V773, DOI 10.1088/0004-637X/773/1/41; Frisch M. J., 2003, GAUSSIAN 03 REVISION; Heger M. L., 1922, LICK OBS B, V10, P141, DOI DOI 10.5479/ADS/BIB/1922LIC0B.10.141H; Hobbs L M, 2008, Astrophysical Journal, V680, DOI 10.1086/587930; Lim JS, 2006, ANGEW CHEM INT EDIT, V45, P6290, DOI 10.1002/anie.200601985; Oka T, 2013, ASTROPHYS J, V773, DOI 10.1088/0004-637X/773/1/42; Oka T, 2003, ASTROPHYS J, V582, P823, DOI 10.1086/344726; Oka T., 1974, ADAMP, V9, P127, DOI 10.1016/S0065-2199(08)60115-3; RUSSELL PG, 1975, J PHYS CHEM-US, V79, P1353, DOI 10.1021/j100581a005; Western C. M., PGOPHER PROGRAM SIMU	17	1	1	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0004-6256	1538-3881		ASTRON J	Astron. J.	NOV	2014	148	5							87	10.1088/0004-6256/148/5/87		5	Astronomy & Astrophysics	Astronomy & Astrophysics	AS2YB	WOS:000344141200013		
J	Kashima, I; Takahashi, M; Hashimoto, Y; Sakota, E; Nakamura, Y; Inada, T				Kashima, Isao; Takahashi, Masaki; Hashimoto, Yoshifumi; Sakota, Eri; Nakamura, Yoshikazu; Inada, Toshifumu			A functional involvement of ABCE1, eukaryotic ribosome recycling factor, in nonstop mRNA decay in Drosophila melanogaster cells	BIOCHIMIE			English	Article						mRNA surveillance; Protein surveillance; Nonstop decay (NSD); Translation termination; ABCE1	DEPENDENT TRANSLATION ARREST; QUALITY-CONTROL PATHWAYS; NO-GO DECAY; PROTEIN COMPLEX; TERMINATION CODON; STRUCTURAL BASIS; CONTROL SYSTEMS; POLY(A) TAIL; ELONGATION; YEAST	When ribosomes encounter mRNAs lacking stop codons, two quality-control machineries, NSD for nonstop mRNA decay and ribosome quality control (RQC) for co-translational degradation of the nonstop protein by the proteasome, are triggered to eliminate aberrant molecules. In yeast, it is known that Dom34 (a homolog of eRF1) and Ltn1 (an E3 ubiquitin ligase) play crucial roles in NSD and RQC, respectively, by triggering ribosome rescue at the 3' end of nonstop mRNAs and proteasome-dependent polypeptide degradation. Here we confirmed the essential role of Ltn1 in RQC for nonstop products in Drosophila cells, and further uncovered a functional role of ABCE1, a eukaryotic ribosome recycling factor, in NSD in Drosophila cells. (C) 2014 Elsevier B.V. and Societe francaise de biochimie et biologie Moleculaire (SFBBM). All rights reserved.	[Kashima, Isao; Takahashi, Masaki; Hashimoto, Yoshifumi; Sakota, Eri; Nakamura, Yoshikazu] Univ Tokyo, Inst Med Sci, Minato Ku, Tokyo 1088639, Japan; [Kashima, Isao; Inada, Toshifumu] Tohoku Univ, Grad Sch Pharmaceut Sci, Sendai, Miyagi 9808578, Japan	Nakamura, Y (reprint author), Univ Tokyo, Inst Med Sci, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	nak@ims.u-tokyo.ac.jp; tinada@m.tohoku.ac.jp			Ministry of Education, Sports, Culture, Science and Technology of Japan (MEXT); Uehara Memorial Foundation	We are grateful to Michiru Ozawa for excellent technical assistance, Kazushige Kuroha and Toshinobu Fujiwara for helpful discussions, and John Hershey for his reading and editing of the manuscript. This work was supported in part by grants from The Ministry of Education, Sports, Culture, Science and Technology of Japan (MEXT) to I.K., Y.N and T.I., and from the Uehara Memorial Foundation to I.K.	Gatfield D, 2003, EMBO J, V22, P3960, DOI 10.1093/emboj/cdg371; Tsuboi T, 2012, MOL CELL, V46, P518, DOI 10.1016/j.molcel.2012.03.013; Shoemaker CJ, 2011, P NATL ACAD SCI USA, V108, pE1392, DOI 10.1073/pnas.1113956108; Ito-Harashima S, 2007, GENE DEV, V21, P519, DOI 10.1101/gad.1490207; van Hoof A, 2002, SCIENCE, V295, P2262, DOI 10.1126/science.1067272; Popp MWL, 2013, ANNU REV GENET, V47, P139, DOI 10.1146/annurev-genet-111212-133424; Shoemaker CJ, 2012, NAT STRUCT MOL BIOL, V19, P594, DOI 10.1038/nsmb.2301; Meaux S, 2006, RNA, V12, P1323, DOI 10.1261/rna.46306; Dimitrova LN, 2009, J BIOL CHEM, V284, P10343, DOI 10.1074/jbc.M808840200; Pisareva VP, 2011, EMBO J, V30, P1804, DOI 10.1038/emboj.2011.93; Bengtson MH, 2010, NATURE, V467, P470, DOI 10.1038/nature09371; Brandman O, 2012, CELL, V151, P1042, DOI 10.1016/j.cell.2012.10.044; Lykke-Andersen J, 2014, J CELL BIOL, V204, P467, DOI 10.1083/jcb.201311103; Frischmeyer PA, 2002, SCIENCE, V295, P2258, DOI 10.1126/science.1067338; Nakamura Y, 2011, WIRES RNA, V2, P647, DOI 10.1002/wrna.81; Becker T, 2012, NATURE, V482, P501, DOI 10.1038/nature10829; Shoemaker CJ, 2010, SCIENCE, V330, P369, DOI 10.1126/science.1192430; Inada T, 2013, BBA-GENE REGUL MECH, V1829, P634, DOI 10.1016/j.bbagrm.2013.02.004; Pisarev AV, 2010, MOL CELL, V37, P196, DOI 10.1016/j.molcel.2009.12.034; Kervestin S, 2012, NAT REV MOL CELL BIO, V13, P700, DOI 10.1038/nrm3454; Inada T, 2005, EMBO J, V24, P1584, DOI 10.1038/sj.emboj.7600636; Defenouillere Q, 2013, P NATL ACAD SCI USA, V110, P5046, DOI 10.1073/pnas.1221724110; Orban TI, 2005, RNA, V11, P459, DOI 10.1261/rna.7231505; Doma MK, 2006, NATURE, V440, P561, DOI 10.1038/nature04530; Atkinson GC, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-290; Bebeacua C, 2012, P NATL ACAD SCI USA, V109, P1098, DOI 10.1073/pnas.1114341109; Carr-Schmid A, 2002, MOL CELL BIOL, V22, P2564, DOI 10.1128/MCB.22.8.2564-2574.2002; Chen LM, 2010, NAT STRUCT MOL BIOL, V17, P1233, DOI 10.1038/nsmb.1922; Franckenberg S, 2012, CURR OPIN STRUC BIOL, V22, P786, DOI 10.1016/j.sbi.2012.08.002; Izawa T, 2012, CELL REPORTS, V2, P447, DOI 10.1016/j.celrep.2012.08.010; Khoshnevis S, 2010, EMBO REP, V11, P214, DOI 10.1038/embor.2009.272; Kobayashi K, 2010, P NATL ACAD SCI USA, V107, P17575, DOI 10.1073/pnas.1009598107; Kuroha K, 2009, GENES CELLS, V14, P739, DOI 10.1111/j.1365-2443.2009.01304.x; Kuroha K, 2010, EMBO REP, V11, P956, DOI 10.1038/embor.2010.169; Livak K.J., 2001, METHODS, V25, P402; Matsuda R., 2013, GENES CELLS, V19, P1; Saito K, 2010, P NATL ACAD SCI USA, V107, P19242, DOI 10.1073/pnas.1009599107; Saito S, 2013, J BIOL CHEM, V288, P17832, DOI 10.1074/jbc.M112.448977; van den Elzen AMG, 2010, NAT STRUCT MOL BIOL, V17, P1446, DOI 10.1038/nsmb.1963	39	0	1	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	PARIS	23 RUE LINOIS, 75724 PARIS, FRANCE	0300-9084	1638-6183		BIOCHIMIE	Biochimie	NOV	2014	106						10	16		10.1016/j.biochi.2014.08.001		7	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	AS7KI	WOS:000344434700002		
J	Masuda, T; Mikami, B; Tani, F				Masuda, Tetsuya; Mikami, Bunzo; Tani, Fumito			Atomic structure of recombinant thaumatin II reveals flexible conformations in two residues critical for sweetness and three consecutive glycine residues	BIOCHIMIE			English	Article						Thaumatin; Sweet-tasting protein; Shelxl; Flexible conformations; Atomic resolution	YEAST PICHIA-PASTORIS; CYSTEINE-RICH DOMAIN; HIGH-YIELD SECRETION; TASTING PROTEIN; CRYSTAL-STRUCTURE; HUMAN T1R3; RECEPTORS; BRAZZEIN	Thaumatin, an intensely sweet-tasting protein used as a sweetener, elicits a sweet taste at 50 nM. Although two major variants designated thaumatin I and thaumatin II exist in plants, there have been few dedicated thaumatin II structural studies and, to date, data beyond atomic resolution had not been obtained. To identify the detailed structural properties explaining why thaumatin elicits a sweet taste, the structure of recombinant thaumatin II was determined at the resolution of 0.99 angstrom. Atomic resolution structural analysis with riding hydrogen atoms illustrated the differences in the direction of the side-chains more precisely and the electron density maps of the C-terminal regions were markedly improved. Though it had been suggested that the three consecutive glycine residues (G142-G143-G144) have highly flexible conformations, G143, the central glycine residue was successfully modelled in two conformations for the first time. Furthermore, the side chain r.m.s.d. values for two residues (R67 and R82) critical for sweetness exhibited substantially higher values, suggesting that these residues are highly disordered. These results demonstrated that the flexible conformations in two critical residues favoring their interaction with sweet taste receptors are prominent features of the intensely sweet taste of thaumatin. (C) 2014 Elsevier B.V. and Societe francaise de biochimie et biologie Moleculaire (SFBBM). All rights reserved.	[Masuda, Tetsuya; Tani, Fumito] Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Uji, Kyoto 6110011, Japan; [Mikami, Bunzo] Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Uji, Kyoto 6110011, Japan	Masuda, T (reprint author), Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Uji, Kyoto 6110011, Japan.	t2masuda@kais.kyoto-u.ac.jp			Japan Society for the Promotion of Science [19780074, 22580105, 25450167]; Japan Food Chemical Research Foundation	This work was supported by a Grant-in-Aid for Young Scientists (B) (T.M., no.19780074) and Scientific Research (C) (T.M., no. 22580105, 25450167) from The Japan Society for the Promotion of Science and by the Japan Food Chemical Research Foundation. The synchrotron radiation experiments were performed at BL26B1 in SPring-8 with the approval of the Japan Synchrotron Radiation Research Institute (JASRI) (proposal numbers 2010A6538, 2011A1417, 2011B1073, 2011B1404, 2012A1048, 2012B1067, 2012B1539).	Winn MD, 2011, ACTA CRYSTALLOGR D, V67, P235, DOI 10.1107/S0907444910045749; Cui M, 2006, CURR PHARM DESIGN, V12, P4591, DOI 10.2174/138161206779010350; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Assadi-Porter FM, 2010, J MOL BIOL, V398, P584, DOI 10.1016/j.jmb.2010.03.017; Cruickshank DWJ, 1999, ACTA CRYSTALLOGR D, V55, P583, DOI 10.1107/S0907444998012645; Asherie N, 2009, CRYST GROWTH DES, V9, P4189, DOI 10.1021/cg900465h; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Masuda T, 2011, BIOCHEM BIOPH RES CO, V410, P457, DOI 10.1016/j.bbrc.2011.05.158; Masuda T, 2011, ACTA CRYSTALLOGR F, V67, P652, DOI 10.1107/S174430911101373X; DeLano W. L., 2002, PYMOL MOL GRAPHICS S; Kim S.H., 1994, THAUMATIN, P135; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lovell S.C., PROTEINS, V50, P437; Masuda T, 2012, BIOCHEM BIOPH RES CO, V419, P72, DOI 10.1016/j.bbrc.2012.01.129; Masuda T, 2010, FOOD SCI TECHNOL RES, V16, P585, DOI 10.3136/fstr.16.585; Masuda T, 2013, BIOCHIMIE, V95, P1502, DOI 10.1016/j.biochi.2013.01.010; Masuda T, 2005, PROTEIN EXPRES PURIF, V39, P35, DOI 10.1016/j.pep.2004.09.009; Masuda T, 2004, BIOTECHNOL BIOENG, V85, P761, DOI 10.1002/bit.10786; Ohta K, 2008, FEBS J, V275, P3644, DOI 10.1111/j.1742-4658.2008.06509.x; Ohta K, 2011, BIOCHEM BIOPH RES CO, V413, P41, DOI 10.1016/j.bbrc.2011.08.033; Ohta K, 2011, BIOCHEM BIOPH RES CO, V406, P435, DOI 10.1016/j.bbrc.2011.02.063; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Sheldrick M., 1997, METHOD ENZYMOL, V277, P319; Shimizu-Ibuka A, 2006, J MOL BIOL, V359, P148, DOI 10.1016/j.jmb.2006.03.030; Teixeira SCM, 2010, ACTA CRYSTALLOGR D, V66, P1139, DOI 10.1107/S0907444910019785; Teixeira SCM, 2008, ACTA CRYSTALLOGR F, V64, P378, DOI 10.1107/S1744309108008294; Temussi PA, 2002, FEBS LETT, V526, P1, DOI 10.1016/S0014-5793(02)03155-1; Temussi PA, 2006, CELL MOL LIFE SCI, V63, P1876, DOI 10.1007/s00018-006-6077-8; VANDERWE.H, 1972, EUR J BIOCHEM, V31, P221; Walters DE, 2009, CHEM SENSES, V34, P679, DOI 10.1093/chemse/bjp048	30	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	PARIS	23 RUE LINOIS, 75724 PARIS, FRANCE	0300-9084	1638-6183		BIOCHIMIE	Biochimie	NOV	2014	106						33	38		10.1016/j.biochi.2014.07.016		6	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	AS7KI	WOS:000344434700005		
J	Iida, A; Tabata, Y; Baba, Y; Fujii, T; Watanabe, S				Iida, Atsumi; Tabata, Yoko; Baba, Yukihiro; Fujii, Tomoaki; Watanabe, Sumiko			Critical roles of DNase1l3l in lens nuclear degeneration in zebrafish	BIOCHIMIE			English	Article						DNase; Nuclear; Lens; Zebrafish	MOUSE EYE LENS; FIBER CELLS; DEOXYRIBONUCLEASE I; AMACRINE CELLS; OCULAR LENS; DIFFERENTIATION; EXPRESSION; GROWTH; HSF4; IDENTIFICATION	The vertebrate lens undergoes organelle and nuclear degradation during lens development, allowing the lens to become transparent. DNase2b is an enzyme responsible for nuclear degradation in the mouse lens; however, dnase2b expression in zebrafish showed a distribution pattern that differed from that in mice. No zebrafish dnase2b was detected by reverse-transcription polymerase chain reaction until around 120 h postfertilization (hpf), suggesting that dnase2b is not expressed in the critical period for lens nuclear degradation, which corresponds to 56-74 hpf. However, public database searches have indicated that dnase1l3l is strongly and specifically expressed in embryonic zebrafish lens. Whole mount in situ hybridization showed that dnase1l3l expression began around 36 hpf and was found exclusively in the lens until the adult stage. Morpholino (MO)-dependent downregulation of dnase1l3l expression during early development in zebrafish led to the failure of nuclear degradation in the lens. Immunostaining of lens sections showed that expression of Pax6, Prox1 and beta-catenin was comparable to the control in the early stage of development in dnase1l3l-MO injected embryos. However, downregulation of expression of these genes in lens was not observed in dnase1l3l-MO-treated zebrafish at 72 hpf, suggesting that the lens development was halted. Taken together, we showed that dnase1l3l plays major roles in nuclear degradation in zebrafish lens development. No homologous gene was found in other species in public databases, suggesting that dnase1l3l developed and acquired its function specifically in zebrafish. (C) 2014 Elsevier B.V. and Societe francaise de biochimie et biologie Moleculaire (SFBBM). All rights reserved.	[Iida, Atsumi; Tabata, Yoko; Baba, Yukihiro; Watanabe, Sumiko] Univ Tokyo, Inst Med Sci, Div Mol & Dev Biol, Tokyo 1088639, Japan; [Fujii, Tomoaki] Univ Tokyo, Inst Med Sci, Div Clin Genome Res, Adv Clin Res Ctr, Tokyo 1088639, Japan	Watanabe, S (reprint author), Univ Tokyo, Inst Med Sci, Div Mol & Dev Biol, Minato Ku, 4-6-1 Shirokanedai, Tokyo 1088639, Japan.	sumiko@ims.u-tokyo.ac.jp					Elshatory Y, 2007, J COMP NEUROL, V503, P182, DOI 10.1002/cne.21390; Swan CL, 2012, CELL STRESS CHAPERON, V17, P623, DOI 10.1007/s12192-012-0337-3; Girao H, 2005, INVEST OPHTH VIS SCI, V46, P1386, DOI 10.1167/iovs.04-0563; Ekstrom P, 2003, DEV BRAIN RES, V145, P1, DOI 10.1016/S0165-3806(03)00170-6; Napirei M, 2009, FEBS J, V276, P1059, DOI 10.1111/j.1742-4658.2008.06849.x; Lang RA, 2004, INT J DEV BIOL, V48, P783, DOI 10.1387/ijdb.041903rl; Rodriguez AM, 1997, GENOMICS, V42, P507, DOI 10.1006/geno.1997.4748; Muto A, 2006, DEV BIOL, V292, P90, DOI 10.1016/j.ydbio.2005.12.050; Link BA, 2000, DEVELOPMENT, V127, P2177; TREVARROW B, 1990, NEURON, V4, P669, DOI 10.1016/0896-6273(90)90194-K; Imai F, 2010, DEVELOPMENT, V137, P3257, DOI 10.1242/dev.053124; Nishimoto S, 2003, NATURE, V424, P1071, DOI 10.1038/nature01895; Fujimoto M, 2004, EMBO J, V23, P4297, DOI 10.1038/sj.emboj.7600435; Nakahara M, 2007, FEBS J, V274, P3055, DOI 10.1111/j.1742-4658.2007.05836.x; Min JN, 2004, GENESIS, V40, P205, DOI 10.1002/gene.20087; Lovicu FJ, 2005, DEV BIOL, V280, P1, DOI 10.1016/j.ydbio.2005.01.020; Cain S, 2008, DEV BIOL, V321, P420, DOI 10.1016/j.ydbio.2008.07.002; Ueki M, 2014, FEBS J, V281, P376, DOI 10.1111/febs.12608; Cui XK, 2013, BBA-MOL BASIS DIS, V1832, P1167, DOI 10.1016/j.bbadis.2013.03.007; Fashena D, 1999, J COMP NEUROL, V406, P415, DOI 10.1002/(SICI)1096-9861(19990412)406:3<415::AID-CNE9>3.0.CO;2-2; GalliResta L, 1997, J NEUROSCI, V17, P7831; Glass A.S., 2003, OPHTHALMIC RES, V36, P4; Greiling TMS, 2010, INVEST OPHTH VIS SCI, V51, P1540, DOI 10.1167/iovs.09-4388; Kurita R, 2003, DEV BIOL, V255, P113, DOI 10.1016/S0012-1606(02)00079-9; Matsui I., 2006, BIOCHEM BIOPH RES CO, V339, P485; Shiokawa D, 2003, BIOCHEM J, V376, P377, DOI 10.1042/BJ20030820; Thisse B., 2004, HIGH THROUGHPUT EXPR; Westerfield M., 1993, ZEBRAFISH BOOK; Yim J., 2012, INVEST OPHTH VIS SCI, V53, P4943	29	0	0	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	PARIS	23 RUE LINOIS, 75724 PARIS, FRANCE	0300-9084	1638-6183		BIOCHIMIE	Biochimie	NOV	2014	106						68	74		10.1016/j.biochi.2014.07.025		7	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	AS7KI	WOS:000344434700009		
J	Mohamed, A; Hancock, T; Nguyen, CH; Mamitsuka, H				Mohamed, Ahmed; Hancock, Timothy; Canh Hao Nguyen; Mamitsuka, Hiroshi			NetPathMiner: R/Bioconductor package for network path mining through gene expression	BIOINFORMATICS			English	Article								NetPathMiner is a general framework for mining, from genome-scale networks, paths that are related to specific experimental conditions. NetPathMiner interfaces with various input formats including KGML, SBML and BioPAX files and allows for manipulation of networks in three different forms: metabolic, reaction and gene representations. NetPathMiner ranks the obtained paths and applies Markov model-based clustering and classification methods to the ranked paths for easy interpretation. NetPathMiner also provides static and interactive visualizations of networks and paths to aid manual investigation.	[Mohamed, Ahmed; Hancock, Timothy; Canh Hao Nguyen; Mamitsuka, Hiroshi] Kyoto Univ, Bioinformat Ctr, Inst Chem Res, Uji, Kyoto, Japan; [Hancock, Timothy] Univ Melbourne, Dept Comp & Informat Syst, Melbourne, Vic 3010, Australia	Mohamed, A (reprint author), Kyoto Univ, Bioinformat Ctr, Inst Chem Res, Uji, Kyoto, Japan.				KAKENHI of MEXT, Japan [2430054]	This work is partially supported by KAKENHI (2430054) of MEXT, Japan.	Luo WJ, 2013, BIOINFORMATICS, V29, P1830, DOI 10.1093/bioinformatics/btt285; Kramer F, 2013, BIOINFORMATICS, V29, P520, DOI 10.1093/bioinformatics/bts710; Chechik G, 2008, NAT BIOTECHNOL, V26, P1251, DOI 10.1038/nbt.1499; Csardi G., 2006, INTERJOURNAL COMPLEX, P1695; Hancock T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031345; Hancock T, 2010, BIOINFORMATICS, V26, P2128, DOI 10.1093/bioinformatics/btq344; Shannon PT, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-217; van Iersel MP, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-5; Vert J., 2003, BIOINFORMATICS, V19, pii238	9	0	0	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1367-4803	1460-2059		BIOINFORMATICS	Bioinformatics	NOV 1	2014	30	21					3139	3141		10.1093/bioinformatics/btu501		3	Biochemical Research Methods; Biotechnology & Applied Microbiology; Computer Science, Interdisciplinary Applications; Mathematical & Computational Biology; Statistics & Probability	Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Computer Science; Mathematical & Computational Biology; Mathematics	AT0SG	WOS:000344644600026		
J	Lockley, MG; Xing, LD; Kim, JY; Matsukawa, M				Lockley, Martin G.; Xing, Lida; Kim, Jeong Yul; Matsukawa, Masaki			Tracking Lower Cretaceous Dinosaurs in China: a new database for comparison with ichnofaunal data from Korea, the Americas, Europe, Africa and Australia	BIOLOGICAL JOURNAL OF THE LINNEAN SOCIETY			English	Review						China; Cretaceous; dinosaurs; footprints; tetrapods	ISLE-OF-WIGHT; SOUTH-KOREA; PTEROSAUR TRACKS; SHANDONG PROVINCE; JINDONG FORMATION; HAMAN FORMATION; ICHNOSP NOV.; BIRD-TRACK; EAST-ASIA; DOMINATED ICHNOFAUNAS	Following the recent rapid increase in the reports of tetrapod tracksites in the Cretaceous, especially from the Lower Cretaceous, of China and other parts of East Asia, notably South Korea, a review of the ichnofaunal database from these regions is presented as the basis for comparisons with other Lower Cretaceous ichnofaunas that are abundant and reasonably well documented. These areas include parts of North and South America, especially the western USA, and parts of Europe, including the United Kingdom, Northern Germany, Spain, Italy and Croatia. The Chinese database presently includes about 70 Cretaceous sites, the majority of which are Early Cretaceous in age. Although abundant data are available from many regions, much of it has yet to be synthesized in detail or in standard formats. Moreover, ichnotaxonomy may be variable (provincial) between different regions. Thus, while comprehensive lists of sites are available for some regions (China and South America), in other regions such as South Korea and the western USA data have been compiled primarily on a formation by formation basis. The record for Europe is moderately good, but scattered in the primary literature and in need of further synthesis. The record for Australia and Africa is sparse and also in need of synthesis. The most notable regional differences between ichnofaunas appears to be in the relative abundance of distinctive bird and pterosaur track ichnotaxa in China and Korea in comparison with their scarcity or absence in other regions. The distinctive ichnogenus Minisauripus is also known only in China and Korea as are the majority of known dromaeosaurid track occurrences. Ornithopod-dominated and ornithopod-rich ichnofaunas are widespread and particularly abundant in the late Early Cretaceous Barremian to Albian, of some regions. Most well documented Early Cretaceous ichnofaunas are associated with siliciclastic facies and evidently differ from those associated with carbonate facies.(c) 2014 The Linnean Society of London, Biological Journal of the Linnean Society, 2014, 113, 770-789.	[Lockley, Martin G.] Univ Colorado Denver, Dinosaur Trackers Res Grp, Denver, CO 80217 USA; [Xing, Lida] China Univ Geosci, Sch Earth Sci & Resources, Beijing 100083, Peoples R China; [Kim, Jeong Yul] Korea Natl Univ Educ, Dept Earth Sci Educ, Cheongwon 363791, Chungbuk, South Korea; [Matsukawa, Masaki] Tokyo Gakugei Univ, Dept Environm Sci, Koganei, Tokyo 1848501, Japan	Lockley, MG (reprint author), Univ Colorado Denver, Dinosaur Trackers Res Grp, CB 172,POB 173364, Denver, CO 80217 USA.	martin.lockley@ucdenver.edu		Xing, Lida/0000-0003-3923-9206			Lockley MG, 2008, CRETACEOUS RES, V29, P115, DOI 10.1016/j.cretres.2007.04.003; Stanford Ray, 2007, Ichnos, V14, P155, DOI 10.1080/10420940601049404; Lockley MG, 2010, BIRDS-EVOL BEHAV ECO, P1; Matsukawa M, 2006, CRETACEOUS RES, V27, P3, DOI 10.1016/j.cretres.2005.10.009; Zhang JP, 2006, CRETACEOUS RES, V27, P44, DOI 10.1016/j.cretres.2005.10.006; CURRIE PJ, 1979, PALAEOGEOGR PALAEOCL, V28, P103, DOI 10.1016/0031-0182(79)90114-7; Xing LD, 2013, ACTA PALAEONTOL POL, V58, P723, DOI 10.4202/app.2011.0115; Xing Li-Da, 2012, Palaeoworld, V21, P50, DOI 10.1016/j.palwor.2012.02.004; Sacchi E, 2009, PALAEOGEOGR PALAEOCL, V271, P104, DOI 10.1016/j.palaeo.2008.09.018; Kim JY, 2012, ICHNOS, V19, P75, DOI 10.1080/10420940.2012.664054; Martin AJ, 2014, PALAEONTOLOGY, V57, P7, DOI 10.1111/pala.12082; Lockley MG, 2012, ICHNOS, V19, P105, DOI 10.1080/10420940.2011.625793; Xing LD, 2013, CRETACEOUS RES, V45, P114, DOI 10.1016/j.cretres.2013.07.009; Xing LD, 2013, CHINESE SCI BULL, V58, P2370, DOI 10.1007/s11434-013-5802-6; Haggart JW, 2006, CRETACEOUS RES, V27, P149, DOI 10.1016/j.cretres.2005.11.008; Lockley MG, 2012, ICHNOS, V19, P93, DOI 10.1080/10420940.2011.625726; Xing Lida, 2007, Dizhi Xuebao, V81, P1591; Moratalla JJ, 2010, PALAEOGEOGR PALAEOCL, V295, P116, DOI 10.1016/j.palaeo.2010.05.027; Kim JY, 2006, CRETACEOUS RES, V27, P56, DOI 10.1016/j.cretres.2005.10.005; Lockley MG, 2007, NATURWISSENSCHAFTEN, V94, P657, DOI 10.1007/s00114-007-0239-x; Hunt Adrian P., 2007, Ichnos, V14, P59, DOI 10.1080/10420940601006826; Lockley M, 2002, CRETACEOUS RES, V23, P363, DOI 10.1006/cres.2002.1005; Kim JY, 2008, PALAEOGEOGR PALAEOCL, V262, P72, DOI 10.1016/j.palaeo.2008.02.003; Lockley MG, 2012, ICHNOS, V19, P17, DOI 10.1080/10420940.2012.660409; LOCKLEY MG, 1992, PHILOS T ROY SOC B, V336, P113, DOI 10.1098/rstb.1992.0051; Xing LD, 2013, CRETACEOUS RES, V42, P55, DOI 10.1016/j.cretres.2013.01.006; Xing Li-Da, 2011, Palaeoworld, V20, P308, DOI 10.1016/j.palwor.2011.01.001; Xing LD, 2013, PALAEOWORLD, V22, P42, DOI 10.1016/j.palwor.2013.03.001; Lockley MG, 2006, CRETACEOUS RES, V27, P70, DOI 10.1016/j.cretres.2005.10.010; Paik IS, 2012, ICHNOS, V19, P6, DOI 10.1080/10420940.2012.660404; Xing LD, 2013, PALAEOGEOGR PALAEOCL, V392, P177, DOI 10.1016/j.palaeo.2013.09.003; Kim JY, 2009, CRETACEOUS RES, V30, P1387, DOI 10.1016/j.cretres.2009.08.003; Petti FM, 2010, CRETACEOUS RES, V31, P546, DOI 10.1016/j.cretres.2010.07.004; Romilio A, 2013, J VERTEBR PALEONTOL, V33, P102; He Q, 2013, ACTA GEOL SIN-ENGL, V87, P1477, DOI 10.1111/1755-6724.12151; Lucas Spencer G., 2007, Ichnos, V14, P5, DOI 10.1080/10420940601006792; Lockley Martin, 2007, Ichnos, V14, P39, DOI 10.1080/10420940601006818; Lockley MG, 2013, ACTA GEOL SIN-ENGL, V87, P1, DOI 10.1111/1755-6724.12026; Lockley MG, 2014, BIOL J LINN SOC, V113, P721, DOI 10.1111/bij.12294; Contessi M, 2012, PALAIOS, V27, P455, DOI 10.2110/palo.2011.p11-114r; BELLAIR P., 1948, BULL SOC HIST NAT AFRIQUE DU NORD, V39, P168; Belvedere M, 2013, PALAEOGEOGR PALAEOCL, V383, P52, DOI 10.1016/j.palaeo.2013.04.026; Bensalah M, 2005, SCI TECHNOLOGIE, V23, P107; Calvo JO, 2001, CRETACEOUS RES, V22, P585, DOI 10.1006/cres.2001.0276; Castanera D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081830; COLBERT E H, 1967, Journal of the Royal Society of Western Australia, V50, P21; CURRIE P J, 1981, Journal of Vertebrate Paleontology, V1, P257; Currie Philip J., 1995, P431; Dalla Vecchia Fabio M., 2008, Oryctos, V8, P89; Farlow J.O., 1989, P371; Farlow James O., 2001, P408; Gierlinski Gerard D., 2008, Oryctos, V8, P29; Houck KJ, 2006, CRETACEOUS RES, V27, P102, DOI 10.1016/j.cretres.2005.10.004; Huh M, 2012, ICHNOS, V19, P43, DOI 10.1080/10420940.2011.632297; Huh M, 2006, CRETACEOUS RES, V27, P114; Hwang KG, 2004, J GEOLOGICAL SOC KOR, V40, P145; Ibrahim N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090751; Jacobs L.L., 1989, P349; KIM B. K., 1969, J GEOLOGICAL SOC KOR, V5, P243; Kim JY, 2012, ICHNOS, V19, P50, DOI 10.1080/10420940.2011.625779; Kim JY, 2013, ICHNOS, V20, P72, DOI 10.1080/10420940.2013.787071; Kim JY, 2012, ICHNOS, V19, P84, DOI 10.1080/10420940.2012.664056; Kim KS, 2012, ICHNOS, V19, P66; Le Loeuff J, 2010, NEW MEXICO MUSEUM NA, V51, P99; Lee YN, 2000, SPECIAL PUBLICATION, V4, P1; Lee YN, 2008, CRETACEOUS RES, V29, P345, DOI 10.1016/j.cretres.2007.05.004; Leonardi G., 1989, P165; Leonardi G, 1994, ANNOTATED ATLAS S AM, P1; Leonardi G, 1984, ORME DINOSAURI, P163; Li J, 2009, MEMOIRS BEIJING MUSE, V61, P51; Li J, 2011, DINOSAUR TRACKS LOWE; Li Jian-Jun, 2006, Acta Palaeontologica Sinica, V45, P221; Li R, 2014, CRETACEOUS RES, V52, P83; Li R.H., 2007, NATURWISSENSCHAFTEN, V95, P185; Li RH, 2011, CRETACEOUS RES, V32, P422, DOI 10.1016/j.cretres.2010.10.006; Lim JD, 2000, NATURWISSENSCHAFTEN, V87, P256, DOI 10.1007/s001140050715; Lim Jong-Deock, 2002, P157; Lockley M, 2006, CRETACEOUS RES, V27, P33, DOI 10.1016/j.cretres.2005.10.007; Lockley Martin, 2006, Bulletin of the New Mexico Museum of Natural History and Science, P95; Lockley M, 2006, CRETACEOUS RES, V27, P139, DOI 10.1016/j.cretres.2005.10.002; Lockley M. G., 2012, 11 MES TERR EC AUG 1, P311; Lockley M. G., 2012, 11 MES TERR EC S AUG; Lockley M. G., 2012, 11 MES TERR EC AUG 1, P315; Lockley M. G., 2011, CRETACEOUS RES, V34, P84; Lockley M. G., 2014, NEW MEXICO MUSEUM NA, V62, P287; LOCKLEY M.G., 2014, NEW MEXICO MUSEUM NA, V62, P393; Lockley MG, 1994, REV GEOCIENCIAS MUSE, V10, P233; Lockley MG, 2009, LONDON GEOLOGICAL SO, V315, P251; Lockley MG, 1994, PALEOBIOLOGY TRACE F, P241; Lockley MG, 2010, NEW MEXICO MUSEUM NA, V51, P99; Lockley Martin G., 2004, Ichnos, V11, P261, DOI 10.1080/10420940490428805; Lockley Martin G., 2012, Journal of Stratigraphy, V36, P503; Lockley M.G., 2014, NEW MEXICO MUSEUM NA, V62, P279; Lockley MG, 2012, ICHNOS, V19, P1, DOI 10.1080/10420940.2012.660400; Lockley MG, 1997, SPECIAL PUBLICATION, V2, P17; LOCKLEY M.G., 2010, NEW MEX MUS NAT HIST, V51, P137; Lockley Martin, 2009, [Journal of the paleontological Society of Korea, 고생물학회지], V25, P17; Lockwood JAF, 2014, BIOL J LINN SOC, V113, P707, DOI 10.1111/bij.12349; Long J, 1998, DINOSAURS AUSTR NZ; Lucas S. G., 1989, GEOLOGICAL SOC AM SP, V238, P75, DOI DOI 10.1130/SPE238-P75; Martin AJ, 2012, ALCHERINGA, V36, P171, DOI 10.1080/03115518.2011.597564; Masrour Moussa, 2013, Geogaceta, V53, P33; Matsukawa Masaki, 2005, Ichnos, V12, P201, DOI 10.1080/10420940591009231; Matsukawa M, 2014, BIOL J LINN SOC, V113, P836, DOI 10.1111/bij.12368; McCrea R. T., 2014, NEW MEXICO MUSEUM NA, V62, P5; Mehl MG, 1931, AM J SCI, V21, P441; Meyer CA, 2004, ICHNOS, V10, P221; Nicosia U, 2000, GEOL ROMANA, V35, P237; Peng Bing-xia, 2004, Earth Science (Wuhan), V29, P21; Pittman J.G., 1989, P135; Pond S, 2014, BIOL J LINN SOC, V113, P737, DOI 10.1111/bij.12340; Romilio A, 2011, CRETACEOUS RES, V32, P135, DOI 10.1016/j.cretres.2010.11.003; Sarjeant William A.S., 1998, Ichnos, V6, P183; Sternberg CM, 1932, NATL MUSEUM CANADA A, P59; THULBORN R A, 1984, Memoirs of the Queensland Museum, V21, P413; Thulborn RA, 2013, ALCHERINGA, V37, P312, DOI 10.1080/03115518.2013.748482; Thulborn T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036208; Xing Li-da, 2009, Dizhi Tongbao, V28, P829; Xing Li-Da, 2011, Vertebrata Palasiatica, V49, P423; Xing Li-da, 2009, Acta Palaeontologica Sinica, V48, P662; Yabe H, 1940, P IMPERIAL ACAD JAPA, V16, P560; Yang Seong-Young, 1995, Ichnos, V4, P21; Yang SY, 1982, J GEOL SOC KOREA, V18, P138; YOUNG CHUNG-CHIEN, 1960, VERTEBR PALASIAT [CHINA], V4, P53; [张建平 Zhang JianPing], 2012, [科学通报, Chinese Science Bulletin], V57, P144; Zhen Shuonan, 1995, Memoirs of Beijing Natural History Museum, V54, P105; Zhen S., 1989, P187	127	4	4	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0024-4066	1095-8312		BIOL J LINN SOC	Biol. J. Linnean Soc.	NOV	2014	113	3			SI		770	789		10.1111/bij.12308		20	Evolutionary Biology	Evolutionary Biology	AS3NI	WOS:000344184500009		
J	Matsukawa, M; Shibata, K; Sato, K; Xing, X; Lockley, MG				Matsukawa, Masaki; Shibata, Kenichiro; Sato, Kenta; Xing, Xu; Lockley, Martin G.			The Early Cretaceous terrestrial ecosystems of the Jehol Biota based on food-web and energy-flow models	BIOLOGICAL JOURNAL OF THE LINNEAN SOCIETY			English	Article						ecological pyramids; energy intake; Konservat-lagerstatte; metabolic rates; net primary productivity; Yixian and Jiufotang formations	NORTHEAST CHINA; FEATHERED DINOSAURS; YIXIAN FORMATION; AGE; SIHETUN; STRATIGRAPHY; PERSPECTIVES; ASSEMBLAGES; NONMARINE	The ancient terrestrial ecosystems of the Lower Cretaceous Yixian Formation and the Jiufotang Formation, consecutive components of the Jehol Group in Northeast China were reconstructed using an energy-flow and food-web model. This model can be used to quantitatively estimate population densities for ancient terrestrial vertebrates based on food webs, net primary productivity, and three categories of energy-transfer efficiency. The results indicate that densities reached 866 individuals km(-2) and 4122 individuals km(-2) in two ecosystems, respectively. The main component of the vertebrate fauna of the Yixian Formation consisted of large herbivorous dinosaurs, while much smaller avians dominated the Jiufotang fauna. The model also indicates a temporal transition in the dinosaur fauna from the Yixian fauna to the Jiufotang fauna in which theropods decreased and ceratopsids became more abundant. We then compared these estimates of biodiversity with the Early Cretaceous Choyr fauna of Mongolia, and Tetori fauna of Japan using Simpson's diversity indices. Those indices, based on biomass, indicate that the biodiversities of the Jehol fauna lay between those of the Choyr and Tetori faunas. This range in biodiversity seems attributable to fundamental differences in vegetation and the environment.(c) 2014 The Linnean Society of London, Biological Journal of the Linnean Society, 2014, 113, 836-853.	[Matsukawa, Masaki; Sato, Kenta] Tokyo Gakugei Univ, Dept Environm Sci, Koganei, Tokyo 1848501, Japan; [Shibata, Kenichiro] Yokosuka City Museum, Yokosuka, Kanagawa 2380016, Japan; [Xing, Xu] Chinese Acad Sci, Inst Vertebrate Paleontol & Paleoanthropol, Key Lab Evolutionary Systemat Vertebrates, Beijing, Peoples R China; [Lockley, Martin G.] Univ Colorado, Dinosaur Trackers Res Grp, Denver, CO 80217 USA	Matsukawa, M (reprint author), Tokyo Gakugei Univ, Dept Environm Sci, Koganei, Tokyo 1848501, Japan.	matsukaw@u-gakugei.ac.jp			Japanese Ministry of Education, Science, Sports and Culture [11791012]; National Natural Science Foundation of China [41120124002]	We thank Gareth Dyke for his efforts to organize the Jehol-Wealden International Conference, held at Southampton University, England, in September 2013. We thank Prof. J. A. Allen and three anonymous reviewers for their helpful comments. MM's work is financially supported in part by fund of the Grant-in-Aid for university and Society Collaboration of the Japanese Ministry of Education, Science, Sports and Culture (Matsukawa, no. 11791012, 1999-2001). XX's work is supported by the National Natural Science Foundation of China (41120124002).	Jiang BY, 2007, CRETACEOUS RES, V28, P183, DOI 10.1016/j.cretres.2006.05.010; Sha JG, 2007, CRETACEOUS RES, V28, P146, DOI 10.1016/j.cretres.2006.12.002; Zhu RX, 2007, CRETACEOUS RES, V28, P171, DOI 10.1016/j.cretres.2006.06.003; Swisher CC, 2002, CHINESE SCI BULL, V47, P135; Chang SC, 2009, PALAEOGEOGR PALAEOCL, V280, P94, DOI 10.1016/j.palaeo.2009.06.021; Yang W, 2007, CRETACEOUS RES, V28, P177, DOI 10.1016/j.cretres.2006.05.011; He HY, 2006, GEOCHEM GEOPHY GEOSY, V7, DOI 10.1029/2005GC001083; Zhou ZH, 2010, SCI CHINA EARTH SCI, V53, P1894, DOI 10.1007/s11430-010-4094-9; BEHRENSMEYER AK, 1979, PALEOBIOLOGY, V5, P12; Swisher CC, 1999, NATURE, V400, P58, DOI 10.1038/21872; Zhang HC, 2010, SCI CHINA EARTH SCI, V53, P1908, DOI 10.1007/s11430-010-4098-5; Pan YH, 2013, CRETACEOUS RES, V44, P30, DOI 10.1016/j.cretres.2013.03.007; Zhou ZH, 2003, NATURE, V421, P807, DOI 10.1038/nature01420; Fursich FT, 2007, PALAEOGEOGR PALAEOCL, V253, P434, DOI 10.1016/j.palaco.2007.06.012; Barrett PM, 2001, NATL GEOGRAPHIC DINO; Barrett PM, 2006, INTEGR ZOOL, V1, P15, DOI 10.1111/j.1749-4877.2006.00006.x; Begon M, 1996, ECOLOGY INDIVIDUALS; Burnie D., 2001, ANIMA DEFINITIVE VIS; Chang M., 2003, JEHOL BIOTA EMERGENC; Dalsatt J, 2006, NATURWISSENSCHAFTEN, V93, P444, DOI 10.1007/s00114-006-0125-y; FARLOW JO, 1976, ECOLOGY, V57, P841, DOI 10.2307/1941052; Fowler M. E., 1978, ZOO WILD ANIMAL MED; Funaki Y, 2002, PICTURE BOOK SHOGAKU; Grabau A. W., 1923, B GEOLOGICAL SURVEY, V5, P183; Gu Z. -W., 1962, JURASSIC CRETACEOUS; He HY, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2005GL025274; He HY, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL019790; Heal OW, 1975, UNIFYING CONCEPTS EC, P89; Hethke M, 2013, J GEOL SOC LONDON, V170, P817, DOI 10.1144/jgs2012-102; Hidaka T, 1996, ENCY JAPANESE ANIMAL, V1; Hidaka T, 1996, ENCY JAPANESE ANIMAL, V3; Hidaka T, 1996, ENCY JAPANESE ANIMAL, V5; Hirano H, 2004, PICTURE BOOK SHOGAKU; Holtz Jr T. R., 2007, DINOSAURS MOST COMPL; Houston D. C., 1979, SERENGETI DYNAMICS E, P263; International Commission on Stratigraphy, 2013, INT CHRON CHART; Jiang BY, 2006, J ASIAN EARTH SCI, V28, P205, DOI 10.1016/j.jseaes.2005.07.006; Jiang BY, 2007, CRETACEOUS RES, V28, P199, DOI 10.1016/j.cretres.2006.05.013; Jin F, 2008, CHINESE SCI BULL, V53, P2820, DOI 10.1007/s11434-008-0209-5; Kimura T, 1987, B TOKYO GAKUGEI U 4, V39, P87; Kukihara Reiji, 2010, Bulletin of Tokyo Gakugei University Natural Sciences, V62, P79; Kukihara R, 2004, B TOKYO GAKUGEI U, V56, P153; Matsui M, 2004, PICTURE BOOK SHOGAKU; Matsukawa M, 2006, CRETACEOUS RES, V27, P285, DOI 10.1016/j.cretres.2005.11.010; Raup D.M., 1978, PRINCIPLES PALEONTOL; Saiki K, 2003, J ASIAN EARTH SCI, V21, P813, DOI 10.1016/S1367-9120(02)00107-4; Sha Jin-geng, 2012, Journal of Stratigraphy, V36, P357; Sha Jin Geng, 2007, Beringeria, V37, P189; Snerson D, 1986, SERENGETI NATL PARK; Wang X.-L., 2003, JEHOL BIOTA, P19; Wang XL, 2006, GEOL J, V41, P405, DOI 10.1002/gj.1046; Whittaker R.H., 1975, COMMUNITIES ECOSYSTE; Witton M. P., 2013, PTEROSAURS NATURAL H; Xing L, 2012, PLOS ONE, V7; Xu Xing, 2006, Geological Journal, V41, P419; Zhou Z. -H., 2010, MORPHOLOGY PHYLOGENY, P419; Zhou ZG, 2006, GEOL J, V41, P377, DOI 10.1002/gj.1045	57	2	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0024-4066	1095-8312		BIOL J LINN SOC	Biol. J. Linnean Soc.	NOV	2014	113	3			SI		836	853		10.1111/bij.12368		18	Evolutionary Biology	Evolutionary Biology	AS3NI	WOS:000344184500014		
J	Kitagawa, H				Kitagawa, Hiroshi			Using Sugar Remodeling to Study Chondroitin Sulfate Function	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Review						chondroitin sulfate; proteoglycan; glycobiology; sulfotransferase; glycosyltransferase	PROTEIN LINKAGE REGION; TRANSFERS N-ACETYLGALACTOSAMINE; SIMPLEX-VIRUS INFECTIVITY; E-DISACCHARIDE EXPRESSION; EMBRYONIC-CELL DIVISION; MOLECULAR-CLONING; CAENORHABDITIS-ELEGANS; GLYCOSAMINOGLYCAN BIOSYNTHESIS; OSTEOBLAST DIFFERENTIATION; POLYMERIZING FACTOR	Chondroitin sulfate (CS) chains constitute a class of glycosaminoglycans (GAGs). CS chains are distributed on the surfaces of virtually all cells and throughout most extracellular matrices; they are covalently attached to serine residues of core proteoglycan proteins. CS proteoglycans have been implicated as regulators of a variety of biological events, including cell-cell and cell-matrix adhesion, cell proliferation, morphogenesis, and neurite outgrowth. The functional diversity of CS proteoglycans is mainly attributed to the structural variability of the GAG chains, specifically the CS chains. Despite their relatively simple polysaccharide backbones, CS chains acquire remarkable structural variability via several types of enzymatic modifications, including sulfation. Moreover, the sulfation status of CS chains, chain length, number of CS chains per core protein, or combinations thereof can be finely tuned via CS biosynthetic machinery to specify the structure and function of CS proteoglycans. The term "sugar remodeling" refers to the experimental or therapeutic structural alteration of CS chains via perturbation of specific CS biosynthetic enzymes in cells or living organisms; sugar remodeling is a promising approach to the study of CS chain function. This review focuses on our recent findings regarding CS function which have resulted from studies involving sugar remodeling.	Kobe Pharmaceut Univ, Dept Biochem, Kobe, Hyogo 6588558, Japan	Kitagawa, H (reprint author), Kobe Pharmaceut Univ, Dept Biochem, Kobe, Hyogo 6588558, Japan.	kitagawa@kobepharma-u.ac.jp			Supported Program for the Strategic Research Foundation at Private Universities from the Ministry of Education, Culture, Sports, Science and Technology of Japan	This review of our recent findings commemorates my acceptance of the Pharmaceutical Society of Japan Award for Divisional Scientific Promotions. I would like to thank all collaborators, especially Drs. Satomi Nadanaka, Tadahisa Mikami, Tomomi Izumikawa, Shinji Miyata, and Toshiyasu Koike at the Department of Biochemistry, Kobe Pharmaceutical University, Japan, for major contributions to the results described in this review. This work was supported in part by Grants-in-Aid for Scientific Research (B), for Challenging Exploratory Research, and for Scientific Research on Innovative Areas and by the Supported Program for the Strategic Research Foundation at Private Universities from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Mikami T, 2009, J BIOL CHEM, V284, P4494, DOI 10.1074/jbc.M809227200; Uyama T, 2002, J BIOL CHEM, V277, P8841, DOI 10.1074/jbc.M111434200; Thiele H, 2004, P NATL ACAD SCI USA, V101, P10155, DOI 10.1073/pnas.0400334101; Rochlin K, 2010, DEV BIOL, V341, P66, DOI 10.1016/j.ydbio.2009.10.024; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Galtrey CM, 2007, BRAIN RES REV, V54, P1, DOI 10.1016/j.brainresrev.2006.09.006; Mikami T, 2013, BBA-GEN SUBJECTS, V1830, P4719, DOI 10.1016/j.bbagen.2013.06.006; Sato T, 2003, J BIOL CHEM, V278, P3063, DOI 10.1074/jbc.M208886200; Lewis DA, 2005, NAT REV NEUROSCI, V6, P312, DOI 10.1038/nrn1648; Bradbury EJ, 2002, NATURE, V416, P636, DOI 10.1038/416636a; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; Kitagawa H, 2001, J BIOL CHEM, V276, P38721, DOI 10.1074/jbc.M106871200; Saigoh K, 2011, J HUM GENET, V56, P143, DOI 10.1038/jhg.2010.148; Purushothaman A, 2007, J BIOL CHEM, V282, P19442, DOI 10.1074/jbc.M700630200; Kii I, 2004, J BONE MINER RES, V19, P1840, DOI 10.1359/JBMR.040812; Sugahara K, 2003, CURR OPIN STRUC BIOL, V13, P612, DOI 10.1016/j.sbi.2003.09.011; Nadanaka S, 2008, J BIOCHEM, V144, P7, DOI 10.1093/jb/mvn040; Gama CI, 2006, NAT CHEM BIOL, V2, P467, DOI 10.1038/nchembio810; Bergefall K, 2005, J BIOL CHEM, V280, P32193, DOI 10.1074/jbc.M503645200; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; Yada T, 2003, J BIOL CHEM, V278, P30235, DOI 10.1074/jbc.M303657200; Kitagawa H, 1997, J BIOL CHEM, V272, P31377, DOI 10.1074/jbc.272.50.31377; Cheng SL, 2000, J BONE MINER RES, V15, P2362, DOI 10.1359/jbmr.2000.15.12.2362; Mikami T, 2012, J BIOL CHEM, V287, P38531, DOI 10.1074/jbc.M111.336925; Izumikawa T, 2004, J BIOL CHEM, V279, P53755, DOI 10.1074/jbc.M409615200; Koike T, 2009, BIOCHEM J, V421, P157, DOI 10.1042/BJ20090474; Kitagawa H, 2003, J BIOL CHEM, V278, P23666, DOI 10.1074/jbc.M302493200; Hwang HY, 2003, NATURE, V423, P439, DOI 10.1038/nature01634; Sugiyama S, 2008, CELL, V134, P508, DOI 10.1016/j.cell.2008.05.054; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; Koike T, 2014, J BIOL CHEM, V289, P6695, DOI 10.1074/jbc.M113.520536; Uyama T, 2006, J BIOL CHEM, V281, P38668, DOI 10.1074/jbc.M609320200; Gotoh M, 2002, J BIOL CHEM, V277, P38189, DOI 10.1074/jbc.M203619200; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; Izumikawa T, 2007, BIOCHEM J, V403, P545, DOI 10.1042/BJ20061876; Nadanaka S, 2008, J BIOL CHEM, V283, P27333, DOI 10.1074/jbc.M802997200; Izumikawa T, 2008, J BIOL CHEM, V283, P11396, DOI 10.1074/jbc.M707549200; Kitagawa H, 2000, J BIOL CHEM, V275, P21075, DOI 10.1074/jbc.M002101200; Izumikawa T, 2010, J BIOL CHEM, V285, P12190, DOI 10.1074/jbc.M110.100941; Uyama T, 2003, J BIOL CHEM, V278, P3072, DOI 10.1074/jbc.M209446200; Mizuguchi S, 2003, NATURE, V423, P443, DOI 10.1038/nature01635; Nadanaka S, 2013, J BIOL CHEM, V288, P9321, DOI 10.1074/jbc.M112.416909; Izumikawa T, 2011, BIOCHEM J, V434, P321, DOI 10.1042/BJ20101456; Yada T, 2003, J BIOL CHEM, V278, P39711, DOI 10.1074/jbc.M304421200; Sato T, 2011, J BIOL CHEM, V286, P5803, DOI 10.1074/jbc.M110.159244; Gotoh M, 2002, J BIOL CHEM, V277, P38179, DOI 10.1074/jbc.M202601200; Miyazaki T, 2008, J CELL PHYSIOL, V217, P769, DOI 10.1002/jcp.21557; Kitagawa H, 1999, GLYCOBIOLOGY, V9, P697, DOI 10.1093/glycob/9.7.697; Watanabe Y, 2010, BIOCHEM J, V432, P47, DOI 10.1042/BJ20100847; Izumikawa T, 2013, BBA-GEN SUBJECTS, V1830, P4806, DOI 10.1016/j.bbagen.2013.06.017; Izumikawa T, 2012, BIOCHEM J, V441, P697, DOI 10.1042/BJ20111472; Izumikawa T, 2014, SCI REP-UK, V4, DOI 10.1038/srep03701; Kitagawa H, 1999, J BIOL CHEM, V274, P13933, DOI 10.1074/jbc.274.20.13933; Koike T, 2012, BIOCHEM BIOPH RES CO, V420, P523, DOI 10.1016/j.bbrc.2012.03.024; Nadanaka S, 2011, J BIOL CHEM, V286, P4199, DOI 10.1074/jbc.M110.155093; Nadanaka S, 1998, J BIOL CHEM, V273, P33728, DOI 10.1074/jbc.273.50.33728; Nadanaka S, 2013, BIOCHEM J, V454, P133, DOI 10.1042/BJ20130323; Nadanaka S, 2014, MATRIX BIOL, V35, P18, DOI 10.1016/j.matbio.2013.10.010; Ogawa H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043806; Pavlath GK, 2010, EXP CELL RES, V316, P3067, DOI 10.1016/j.yexcr.2010.05.025; Purnomo E, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000405; Wei G, 1999, J BIOL CHEM, V274, P7857, DOI 10.1074/jbc.274.12.7857; Wilson DG, 2012, DEV BIOL, V363, P413, DOI 10.1016/j.ydbio.2012.01.005; Yamada S, 1999, FEBS LETT, V459, P327, DOI 10.1016/S0014-5793(99)01286-7	64	2	2	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	NOV	2014	37	11					1705	1712				8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AS0JW	WOS:000343964500001		
J	Nakamura, T; Kushida, T; Okamoto, N; Oe, K; Ikeura, A; Li, M; Ikehara, S; Iide, H				Nakamura, Tomohisa; Kushida, Taketoshi; Okamoto, Naofumi; Oe, Kenichi; Ikeura, Atsushi; Li, Ming; Ikehara, Susumu; Iide, Hirokazu			Induction of Autoimmune Arthritis after Direct Injection of Bone Marrow Cells from Arthritis-Prone SKG/Jcl Mice into Bone Cavity of Normal Mice	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						autoimmune arthritis; SKG/Jcl mouse; bone marrow cell; lineage-negative immature cell; receptor activator of nuclear factor kappa-B ligand	DONOR LYMPHOCYTE INFUSION; RHEUMATOID-ARTHRITIS; SKG MICE; RECEPTOR ACTIVATOR; DENDRITIC CELLS; TRANSPLANTATION; DISEASES; PREVENTION; TUMOR; OSTEOCLASTOGENESIS	SKG/Jcl (SKG) mice spontaneously develop T cell-mediated autoimmune arthritis and may be an effective model for studying human rheumatoid arthritis. We sought to confirm that arthritis in SKG mice was caused by stem cell disorders. We induced systemic arthritis in normal C57/BL6 (B6) mice (H-2(b) type) by injecting lineage-negative (lin(-)) immature cells isolated from bone marrow cells (BMCs) of SKG mice (H-2(d) type) directly into bone cavities. Twenty weeks later, we analyzed arthritis scores, hematoxylin-eosin (H-E) staining and tartrate-resistant acid phosphatase (TRAP) staining in ankle joints, H-2 type of hematolymphoid and osteoblast-like cells, serum levels of tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) and percentages of CD4(+) T cells and osteoblast-like cells expressing receptor activator of nuclear factor kappa-B ligand (RANKL) in recipient mice. Donor-derived hematolymphoid cells and osteoblast-like cells had completely replaced donor-derived cells in the recipients (H-2(b) to H-2(d)). All recipients showed severe joint swelling with hyperemia and developed hypertrophic synovitis with lymphocytes accumulated around joints. All recipients also had higher TNF-alpha and IL-6 levels than untreated B6 controls. Furthermore, the percentages of CD4(+) T cells and osteoblast-like cells expressing RANKL and the number of TRAP(+) cells were greater in treated animals. Donor-derived hematolymphoid cells and osteoblast-like cells persisted in these recipients and promoted autoimmune arthritis and an increase in osteoclasts. Because autoimmune arthritis may be associated with abnormal lin(-) immature cells, patients with intractable autoimmune arthritis may be treated by replacing these cells with direct injection of lin(-) immature cells isolated from normal BMCs.	[Nakamura, Tomohisa; Kushida, Taketoshi; Okamoto, Naofumi; Oe, Kenichi; Ikeura, Atsushi; Iide, Hirokazu] Kansai Med Univ, Dept Orthopaed Surg, Osaka 5731191, Japan; [Li, Ming; Ikehara, Susumu] Kansai Med Univ, Dept Stem Cell Disorder, Osaka 5731191, Japan	Kushida, T (reprint author), Kansai Med Univ, Dept Orthopaed Surg, Osaka 5731191, Japan.	kushidat@hirakata.kmu.ac.jp			MEXT-Supported Program of the Strategic Research Foundation for private universities	This work was funded by a MEXT-Supported Program of the Strategic Research Foundation for private universities.	Charles JF, 2012, J CLIN INVEST, V122, P4592, DOI 10.1172/JCI60920; Kitaura H, 2005, J CLIN INVEST, V115, P3418, DOI 10.1172/JCI26132; Huber LC, 2006, RHEUMATOLOGY, V45, P669, DOI 10.1093/rheumatology/kel065; O'Brien CA, 1999, J BIOL CHEM, V274, P19301, DOI 10.1074/jbc.274.27.19301; Wilson NJ, 2007, NAT IMMUNOL, V8, P950, DOI 10.1038/ni1497; Azuma Y, 2000, J BIOL CHEM, V275, P4858, DOI 10.1074/jbc.275.7.4858; Ichioka N, 2002, STEM CELLS, V20, P542, DOI 10.1634/stemcells.20-6-542; Sakaguchi N, 2003, NATURE, V426, P454, DOI 10.1038/nature02119; Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661; MacGregor AJ, 2000, ARTHRITIS RHEUM, V43, P30, DOI 10.1002/1529-0131(200001)43:1<30::AID-ANR5>3.0.CO;2-B; Yoshitomi H, 2005, J EXP MED, V201, P949, DOI 10.1084/jem.20051758; Hata H, 2004, J CLIN INVEST, V114, P582, DOI 10.1172/JCI200421795; Wolfe F, 2001, J RHEUMATOL, V28, P1817; Takayanagi H, 2000, ARTHRITIS RHEUM, V43, P259, DOI 10.1002/1529-0131(200002)43:2<259::AID-ANR4>3.0.CO;2-W; IKEHARA S, 1985, P NATL ACAD SCI USA, V82, P2483, DOI 10.1073/pnas.82.8.2483; MCDONAGH J, 1994, BRIT J RHEUMATOL, V33, P118; HELIN HJ, 1995, ARTHRITIS RHEUM, V38, P242, DOI 10.1002/art.1780380213; Keane J, 2001, NEW ENGL J MED, V345, P1098, DOI 10.1056/NEJMoa011110; Kushida T, 2001, BLOOD, V97, P3292, DOI 10.1182/blood.V97.10.3292; Azuma K, 2012, INFLAMMATION, V35, P1462, DOI 10.1007/s10753-012-9459-0; BALDWIN JL, 1977, ARTHRITIS RHEUM, V20, P1043, DOI 10.1002/art.1780200502; Duarte J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010558; Feng W, 2007, TRANSPLANTATION, V84, P1459, DOI 10.1097/01.tp.0000288182.75398.74; HOLLAND FJ, 1991, J CLIN ENDOCR METAB, V72, P837; IKEHARA S, 1990, P NATL ACAD SCI USA, V87, P8341, DOI 10.1073/pnas.87.21.8341; Ikehara S, 1998, INT J MOL MED, V1, P5; JARVINEN P, 1994, SEMIN ARTHRITIS RHEU, V24, P19, DOI 10.1016/0049-0172(94)90096-5; Kobayashi K, 2006, INFLAMM RES, V55, P335, DOI 10.1007/s00011-006-5208-x; Krause Andreas, 1996, Current Opinion in Rheumatology, V8, P203, DOI 10.1097/00002281-199605000-00007; Kushida T, 2009, J AUTOIMMUN, V32, P216, DOI 10.1016/j.jaut.2009.02.015; LAMPETER EF, 1993, LANCET, V341, P1243, DOI 10.1016/0140-6736(93)91148-F; Li M, 2012, INT J BIOL SCI, V8, P1335, DOI 10.7150/ijbs.4654; LOWENTHAL RM, 1993, J RHEUMATOL, V20, P137; Lutzky V, 2007, ARTHRITIS RES THER, V9, DOI 10.1186/ar2200; MARMONT AM, 1994, STEM CELLS, V12, P125; MELMS A, 1992, BONE MARROW TRANSPL, V9, P78; Misaki K, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3339; Miyake T, 2009, IMMUNOLOGY, V126, P552, DOI 10.1111/j.1365-2567.2008.02920.x; Nagate T, 2009, J VET MED SCI, V71, P713, DOI 10.1292/jvms.71.713; NAKAGAWA T, 1993, ARTHRITIS RHEUM, V36, P263; Nakamura K, 2004, STEM CELLS, V22, P125, DOI 10.1634/stemcells.22-2-125; Nelson J L, 1997, J Rheumatol Suppl, V48, P23; Silman Alan J, 2002, Arthritis Res, V4 Suppl 3, pS265, DOI 10.1186/ar578; Suzuki Y, 2005, STEM CELLS, V23, P365, DOI 10.1634/stemcells.2004-0258; WEYAND CM, 1992, ANN INTERN MED, V117, P801; YIN JAL, 1992, BONE MARROW TRANSPL, V9, P31	46	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	NOV	2014	37	11					1719	1726				8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AS0JW	WOS:000343964500003		
J	Shimokawa, Y; Sasahara, K; Yoda, N; Mizuno, K; Umehara, K				Shimokawa, Yoshihiko; Sasahara, Katsunori; Yoda, Noriaki; Mizuno, Katsuhiko; Umehara, Ken			Delamanid Does Not Inhibit or Induce Cytochrome P450 Enzymes in Vitro	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						delamanid; OPC-67683; CYP; CYP inhibition; CYP induction; drug interaction	CULTURED RAT HEPATOCYTES; PULMONARY TUBERCULOSIS; RESISTANT TUBERCULOSIS; DRUG-INTERACTIONS; HIV; OPC-67683; MORTALITY; UPDATE	Delamanid is a new drug for the treatment of multidrug-resistant tuberculosis. Individuals who are co-infected with human immunodeficiency virus and Mycobacterium tuberculosis may require treatment with a number of medications that might interact significantly with the CYP enzyme system as inhibitors or inducers. It is therefore important to understand how drugs in development for the treatment of tuberculosis will affect CYP enzyme metabolism. The ability of delamanid to inhibit or induce CYP enzymes was investigated in vitro using human liver microsomes or human hepatocytes. Delamanid.(100 mu M). had little potential for mechanism-based inactivation on eight CYP isoforms (CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP3A4). Delamanid's metabolites were noted to inhibit the metabolism of some CYP isoforms, but these effects were observed only at metabolite concentrations that were well above those observed in human plasma during clinical trials. Delamanid (<= 10 mu M) did not induce CYP1A2, CYP2C9, and CYP3A4 activities in human hepatocytes, and there were no increases in CYP1A2, CYP2B6, CYP2C9, and CYP3A4 mRNA levels. Taken together, these data suggest that delamanid is unlikely to cause clinically relevant drug-drug interactions when co-administered with products that are metabolized by the CYP enzyme system.	[Shimokawa, Yoshihiko; Sasahara, Katsunori; Yoda, Noriaki; Mizuno, Katsuhiko; Umehara, Ken] Otsuka Pharmaceut Co Ltd, Tokushima Res Inst, Kawaguchi, Tokushima 7710192, Japan	Shimokawa, Y (reprint author), Otsuka Pharmaceut Co Ltd, Tokushima Res Inst, 463-10 Kagasuno, Kawaguchi, Tokushima 7710192, Japan.	Shimokawa.Yoshihiko@otsuka.jp					Guengerich FP, 2010, CURR DRUG METAB, V11, P1; Diacon AH, 2011, INT J TUBERC LUNG D, V15, P949, DOI 10.5588/ijtld.10.0616; Madan A, 2003, DRUG METAB DISPOS, V31, P421, DOI 10.1124/dmd.31.4.421; Wang RW, 2000, DRUG METAB DISPOS, V28, P360; Sasaki H, 2006, J MED CHEM, V49, P7854, DOI 10.1021/jm060957y; Robertson P, 2000, DRUG METAB DISPOS, V28, P664; Gengiah TN, 2011, EXPERT OPIN DRUG SAF, V10, P559, DOI 10.1517/14740338.2011.546783; Falzon D, 2011, EUR RESPIR J, V38, P516, DOI 10.1183/09031936.00073611; SHIMADA T, 1994, J PHARMACOL EXP THER, V270, P414; Reid A, 2006, LANCET INFECT DIS, V6, P483, DOI 10.1016/S1473-3099(06)70549-7; LeCluyse E L, 1996, Pharm Biotechnol, V8, P121; Skripconoka V, 2013, EUR RESPIR J, V41, P1393, DOI 10.1183/09031936.00125812; Obach RS, 2007, DRUG METAB DISPOS, V35, P246, DOI 10.1124/dmd.106.012633; Gler MT, 2012, NEW ENGL J MED, V366, P2151, DOI 10.1056/NEJMoa1112433; Gandhi NR, 2012, INT J TUBERC LUNG D, V16, P90, DOI 10.5588/ijtld.11.0153; Wienkers LC, 2005, NAT REV DRUG DISCOV, V4, P825, DOI 10.1038/nrd1851; Madan A, 1999, DRUG METAB DISPOS, V27, P327; Maggiolo F, 2009, J ANTIMICROB CHEMOTH, V64, P910, DOI 10.1093/jac/dkp334; European Medicines Agency, GUID INV DRUG INT; Flockhart DA, 2007, DRUG INTERACTIONS CY; Ikeda T, 2001, XENOBIO METABOL DISP, V16, P115; LECLUYSE EL, 1994, AM J PHYSIOL, V266, pC1764; Matsumoto M, 2006, PLOS MED, V3, P2131, DOI 10.1371/journal.pmed.0030466; Mudra DR, 2001, CURR PROTOC TOXICOL; Piscitelli SC, 2001, NEW ENGL J MED, V344, P984, DOI 10.1056/NEJM200103293441307; Quistorff B., 1990, METHODS MOL BIOL ANI, V5, P151; World Health Organization, 2011, WHOHTMTB20113; World Health Organization, WHO REP 2011 GLOB TU	28	6	6	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	NOV	2014	37	11					1727	1735				9	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AS0JW	WOS:000343964500004		
J	Katagiri, Y; Miyazaki, Y; Uchino, T; Kagawa, Y				Katagiri, Yukiko; Miyazaki, Yasunori; Uchino, Tomonobu; Kagawa, Yoshiyuki			Preparation of Goreisan Suppository and Pharmacokinetics of trans-Cinnamic Acid after Administration to Rabbits	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						goreisan; suppository; pharmacokinetics; trans-cinnamic acid (CA); enema; dissolution		Goreisan suppository is prepared as a hospital preparation, and successfully used for the treatment of diarrhea and vomiting in young children with common cold. While clinical efficacy of the suppository has been reported, few studies have been carried out to clarify the preparation procedure and pharmacokinetics of the suppository. In this study, trans-cinnamic acid (CA) was used as a representative substance of goreisan constituents, and assayed by HPLC-UV. We investigated the properties of goreisan suppositories prepared using various sizes of pulverized goreisan extract granules, in vitro dissolution profiles using the reciprocating dialysis tube method, and pharmacokinetics in rabbits compared with those for goreisan enema. Mass and content uniformity tests on the suppositories of three size fractions, 0-75, 75-150, and 150-300 mu m, showed good acceptance for all kinds of suppository. Storage stability at 4 degrees C was maintained until 4 months. In vitro dissolution of CA from the suppository was proportional to time until 45 mm, and slower than that from the enema. Finally, 80% of CA had dissolved at 60 min. Pharmacokinetic study in rabbits revealed that the area under the plasma concentration-time curve from 0 to 120 min (AUC(0-120min)) of the suppository was twice that of the enema. Moreover, from a study in rabbits using CA injection and CA suppository, we revealed that CA was rapidly and well absorbed from the rectum, showing 84% absolute bioavailability. Thus, we illustrated the defined preparation procedure of the suppository and the superiority of the suppository over the enema. This study will support evidence that the suppository is fast-acting and efficacious in clinical use.	[Katagiri, Yukiko; Miyazaki, Yasunori; Uchino, Tomonobu; Kagawa, Yoshiyuki] Univ Shizuoka, Sch Pharmaceut Sci, Dept Clin Pharmaceut, Suruga Ku, Shizuoka 4228526, Japan	Miyazaki, Y (reprint author), Univ Shizuoka, Sch Pharmaceut Sci, Dept Clin Pharmaceut, Suruga Ku, 52-1 Yada, Shizuoka 4228526, Japan.	miyaza@u-shizuoka-ken.ac.jp					[Anonymous], 2006, TSUMURA GOREISAN EXT; [Anonymous], 2007, KOTARO GOREISANRYO E; [Anonymous], 2007, TSUMURA GEREISAN EXT; DEBOER AG, 1982, CLIN PHARMACOKINET, V7, P285; Fukutomi O., 2005, EVOLV KAMPO, V1, P25; Fukutomi O., 2006, Journal of Traditional Medicines, V23, P151; Hashimoto H, 2001, SCI KAMPO MED, V25, P178; Ikehata M, 2008, PHYTOTHER RES, V22, P12, DOI 10.1002/ptr.2234; Itoh S, 2006, EUR J PHARM BIOPHARM, V64, P393, DOI 10.1016/j.ejpb.2006.06.004; Iwakoshi H, 2001, JPN J NURSING, V65, P488; Jingami S, 2005, J JPN SOC HOSP PHARM, V41, P1543; Li P, 2007, ANAL BIOANAL CHEM, V389, P2259, DOI 10.1007/s00216-007-1612-5; Li W, 2009, INT C COMP INT SOFTW, P1, DOI 10.1115/1.802908.paper34; Miyakawa S, 2007, JPN PEDIAT SOC ORIEN, V22, P41; Nishi K, 1998, J JPN SOC HOSP PHARM, V34, P1173; Nishimura N, 2009, YAKUGAKU ZASSHI, V129, P759, DOI 10.1248/yakushi.129.759; Suzuki H, 1987, EISEI SHIKENJO HOKOK, V105, P7; VENGPEDERSEN P, 1980, J PHARMACOKINET BIOP, V8, P463, DOI 10.1007/BF01059546; Yoshida M, 2000, JPN J ORIENT MED, V28, P36; Yoshida M., 2003, JPN PEDIAT SOC ORIEN, V19, P13	20	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	NOV	2014	37	11					1736	1741				6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AS0JW	WOS:000343964500005		
J	Ara, MN; Matsuda, T; Hyodo, M; Sakurai, Y; Ohga, N; Hida, K; Harashima, H				Ara, Mst Naznin; Matsuda, Takashi; Hyodo, Mamoru; Sakurai, Yu; Ohga, Noritaka; Hida, Kyoko; Harashima, Hideyoshi			Construction of an Aptamer Modified Liposomal System Targeted to Tumor Endothelial Cells	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						aptamer based liposome; targeted drug delivery; tumor endothelial cell; heat shock protein 70 (HSP70); cell-based systematic evolution of ligands by exponential enrichment	DRUG-DELIVERY; CANCER METASTASIS; HEAT-SHOCK-PROTEIN-70; ABNORMALITIES; ANGIOGENESIS; INFLAMMATION; LIGANDS; MODELS; HSP70	We describe herein the development of a high affinity and specific DNA aptamer as a new ligand for use in liposomal nanoparticles to target cultured mouse tumor endothelial cells (mTECs). Active targeted nanotechnology based drug delivery systems are currently of great interest, due to their potential for reducing side effects and facilitating the delivery of cytotoxic drugs or genes in a site specific manner. In this study, we report on a promising aptamer candidate AraHH036 that shows selective binding towards mTECs. The aptamer does not bind to normal cells, normal endothelial cells or tumor cells. Therefore, we synthesized an aptamer-polyethylene glycol (PEG) lipid conjugate and prepared aptamer based liposomes (ALPs) by the standard lipid hydration method. First, we quantified the higher capacity of ALPs to internalize into mTECs by incubating ALPs containing 1 mol%, 5 mol% and 10 mol% aptamer of total lipids and compared the results to those for unmodified PEGylated liposomes (PLPs). A confocal laser scanning microscope (CLSM) uptake study indicated that the ALPs were taken up more efficiently than PLPs. The measured K-d value of the ALPs was 142 nM. An intracellular trafficking study confirmed that most of the rhodamine labeled ALPs were taken up and co-localized with the green lysotracker, thus confirming that they were located in lysosomes. Finally, using an aptamer based proteomics approach, the molecular target protein of the aptamer was identified as heat shock protein 70 (HSP70). The results suggest that these ALPs offer promise as a new carrier molecule for delivering anti-angiogenesis drugs to tumor vasculature.	[Ara, Mst Naznin; Hyodo, Mamoru; Sakurai, Yu; Harashima, Hideyoshi] Hokkaido Univ, Fac Pharmaceut Sci, Lab Innovat Nanomed, Kita Ku, Sapporo, Hokkaido 0600812, Japan; [Matsuda, Takashi; Harashima, Hideyoshi] Hokkaido Univ, Fac Pharmaceut Sci, Lab Mol Design Pharmaceut, Kita Ku, Sapporo, Hokkaido 0600812, Japan; [Ohga, Noritaka; Hida, Kyoko] Hokkaido Univ, Grad Sch Dent Med, Div Vasc Biol, Kita Ku, Sapporo, Hokkaido 0600812, Japan	Harashima, H (reprint author), Hokkaido Univ, Fac Pharmaceut Sci, Lab Innovat Nanomed, Kita Ku, Kita 12,Nishi 6, Sapporo, Hokkaido 0600812, Japan.	harasima@pharm.hokudai.ac.jp	Hida, Kyoko/A-8444-2012		Special Education and Research Expenses of the Ministry of Education, Culture, Sports, Science and Technology of Japan; Ministry of Education, Culture, Sports, Science and Technology of Japan [11018330]	This study was supported by Grants from the Special Education and Research Expenses of the Ministry of Education, Culture, Sports, Science and Technology of Japan. This study was also supported by Grant-in-Aid for Young Scientists (B, 11018330) from the Ministry of Education, Culture, Sports, Science and Technology of Japan. The authors also thank Dr. Milton S. Feather for his advice in writing the English manuscript.	Akhter A, 2013, INT J PHARMACEUT, V456, P195, DOI 10.1016/j.ijpharm.2013.07.068; Zhang Y, 2011, CURR MED CHEM, V18, P4185; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Bayer C, 2014, INT J RADIAT ONCOL, V88, P694, DOI 10.1016/j.ijrobp.2013.11.008; Allen TM, 2013, ADV DRUG DELIVER REV, V65, P36, DOI 10.1016/j.addr.2012.09.037; Murphy ME, 2013, CARCINOGENESIS, V34, P1181, DOI 10.1093/carcin/bgt111; ELLINGTON AD, 1990, NATURE, V346, P818, DOI 10.1038/346818a0; Matsuda K, 2010, BIOCHEM BIOPH RES CO, V394, P947, DOI 10.1016/j.bbrc.2010.03.089; Tan WH, 2011, TRENDS BIOTECHNOL, V29, P634, DOI 10.1016/j.tibtech.2011.06.009; Hida K, 2005, CANCER RES, V65, P2507, DOI 10.1158/0008-5472.CAN-05-0002; Chang HI, 2012, INT J NANOMED, V7, P49, DOI 10.2147/IJN.S26766; Zhou JH, 2011, OLIGONUCLEOTIDES, V21, P1, DOI 10.1089/oli.2010.0264; WOODLE MC, 1992, BIOCHIM BIOPHYS ACTA, V1113, P171, DOI 10.1016/0304-4157(92)90038-C; Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483; Burdick MM, 2001, IEEE ENG MED BIOL, V20, P86, DOI 10.1109/51.932731; Weigelt B, 2005, NAT REV CANCER, V5, P591, DOI 10.1038/nrc1670; Shangguan D, 2006, P NATL ACAD SCI USA, V103, P11838, DOI 10.1073/pnas.0602615103; Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115; Siegel G, 1997, INT J MICROCIRC, V17, P257, DOI 10.1159/000179238; Akino T, 2009, AM J PATHOL, V175, P2657, DOI 10.2353/ajpath.2009.090202; Multhoff G, 2011, CELL STRESS CHAPERON, V16, P251, DOI 10.1007/s12192-010-0247-1; TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121; Suzuki Y, 2010, J CELL SCI, V123, P1684, DOI 10.1242/jcs.061556; Ara MN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050174; CULLEN BR, 1989, CELL, V58, P423, DOI 10.1016/0092-8674(89)90420-0; GABIZON A, 1988, P NATL ACAD SCI USA, V85, P6949, DOI 10.1073/pnas.85.18.6949; Gabizon A, 1997, DRUGS, V54, P15; Hida K, 2008, CANCER SCI, V99, P459, DOI 10.1111/j.1349-7006.2007.00704.x; Nallamothu R., 2006, AAPS PHARMSCITECH, V7, pE7, DOI 10.1208/pt070232; Reinemann CS, 2014, SWISS MED WEEKLY, V144, P1; Stangl S, 2011, P NATL ACAD SCI USA, V108, P733, DOI 10.1073/pnas.1016065108	31	1	2	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	NOV	2014	37	11					1742	1749				8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AS0JW	WOS:000343964500006		
J	Saito, M; Abe, M; Furukawa, T; Yagi, M; Koike, Y; Wakasugi, Y; Tabuchi, N; Uno, K				Saito, Mikio; Abe, Manabu; Furukawa, Tomoyasu; Yagi, Motohiro; Koike, Yoshihiro; Wakasugi, Yutaka; Tabuchi, Norihiko; Uno, Katsuji			Examination of Patients Suspected as Having Hypersensitivity to Iodinated Contrast Media with Leukocyte Migration Test	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						iodinated contrast media (ICM); leukocyte migration test (LMT); pseudoallergy; non-immediate hypersensitivity; allergic history	LATE ADVERSE-REACTIONS; BETA-LACTAM ANTIBIOTICS; RISK; ANAPHYLAXIS; PREVENTION; MANAGEMENT; DRUGS	In vivo tests may be used for the diagnosis of allergy to iodinated contrast media (ICM); however, the tests do not provide definitive diagnosis and are associated with risks for patients. Diagnoses based on in vitro tests are limited, and there are almost no relevant studies. Herein, the authors examined involvement of allergic reaction from a multilateral standpoint in 39 patients suspected of having ICM allergies using leukocyte migration test (LMT). The positive rate of LMT was 44%. A comparison with the positive rate of LMT in drugs other than ICM (74%) indicated 30% difference, which was significantly low value, suggesting that there is poor involvement of these drugs in the allergic reaction. In LMT positives, 76% of hypersensitivity reactions were skin rash mainly erythema, and 18% was anaphylactic reactions. Cases considered as non-immediate hypersensitivity accounted for about 4 times as many as immediate-type hypersensitivity. In examination of relevancy between a history of drugs or food allergies, the incidence of ICM allergies was 35%. There is a high possibility that these adverse reactions were caused by pseudoallergy to drug. It was suggested that most hypersensitivity reactions were skin rash related to non-immediate hypersensitivity, and approximately 20% of the reaction was immediate anaphylactic reaction. Therefore attention should be paid not only to immediate-type hypersensitivity but also delayed reactions. Moreover, it was considered that patients with past history of drug or food allergies have a high potential for manifestation of the reactions.	[Saito, Mikio; Abe, Manabu] Niigata Univ Pharm & Life Sci, Fac Pharmaceut Sci, Lab Clin Pharm, Akiha Ku, Niigata 9568603, Japan; [Furukawa, Tomoyasu] Niitsu Med Ctr Hosp, Dept Pharm, Akiha Ku, Niigata 9560025, Japan; [Yagi, Motohiro] Agano Hosp, Brain Dis Ctr, Dept Pharm, Niigata 9592221, Japan; [Koike, Yoshihiro] Toyoura Hosp, Dept Pharm, Shibata, Niigata 9592311, Japan; [Wakasugi, Yutaka] Suibarago Hosp, Dept Internal Med, Niigata 9592093, Japan; [Tabuchi, Norihiko; Uno, Katsuji] Fukuyama Univ, Fac Pharm & Pharmaceut Sci, Mol Microbiol Lab, Fukuyama, Hiroshima 7290292, Japan	Saito, M (reprint author), Niigata Univ Pharm & Life Sci, Fac Pharmaceut Sci, Lab Clin Pharm, Akiha Ku, 265-1 Higashizima, Niigata 9568603, Japan.	saitom@nupals.ac.jp					Abe M, 1998, JPN J ALLERGOL, V47, P1264; Abe Manabu, 2011, Allergology International, V60, P497, DOI 10.2332/allergolint.10-OA-0288; Akiyama M, 1990, Nihon Hifuka Gakkai Zasshi, V100, P1057; Almen T, 1994, INVEST RADIOL S1, V29, P37; Torres MJ, 2012, ALLERGY, V67, P929, DOI 10.1111/j.1398-9995.2012.02840.x; BUSH WH, 1991, AM J ROENTGENOL, V157, P1153; Prieto-Garcia A, 2013, J INVEST ALLERG CLIN, V23, P183; Webb JAW, 2003, EUR RADIOL, V13, P181, DOI 10.1007/s00330-002-1650-5; YOSHIKAWA H, 1992, RADIOLOGY, V183, P737; Thomsen HS, 1998, DRUG SAFETY, V19, P313, DOI 10.2165/00002018-199819040-00006; KATAYAMA H, 1990, RADIOLOGY, V175, P621; Morcos SK, 2005, BRIT J RADIOL, V78, P686, DOI 10.1259/bjr/26301414; Laroche D, 1999, ALLERGY, V54, P13; Kvedariene V, 2006, CLIN EXP ALLERGY, V36, P1072, DOI 10.1111/j.1365-2222.2006.02532.x; Brockow K, 2009, ALLERGY, V64, P234, DOI 10.1111/j.1398-9995.2008.01832.x; Broome DR, 2008, EUR J RADIOL, V66, P230, DOI 10.1016/j.ejrad.2008.02.011; Aoki Yoshio, 2002, Nihon Hoshasen Gijutsu Gakkai Zasshi, V58, P1245; Asano S, 1990, Rinsho Hoshasen, V35, P533; Ayabe M, 2004, J ENV DERMATOLOGY, V11, P21; BEYERENKE SA, 1992, RADIOLOGE, V32, P165; Furuichi M, 2005, SKIN RES, V4, P537; Grainger RG, 2001, MED IMAGING, P27; Hong SJ, 2002, ALLERGY ASTHMA PROC, V23, P347; KATAYAMA H, 1991, INVEST RADIOL, V26, pS33; Laporte JR, 2003, PHARMACOEPIDEM DR S, V12, P195, DOI 10.1002/pds.822; Lieberman PL, 1999, CLIN REV ALLERG IMMU, V17, P469, DOI 10.1007/BF02737651; Morcos SK, 2001, EUR RADIOL, V11, P1720, DOI 10.1007/s003300000778; Saito M, 2007, JPN J PHARM HLTH CAR, V33, P416; Saito M, 2009, JPN J PHARM HLTH CAR, V35, P103; Saito M, 2008, BIOL PHARM BULL, V31, P299, DOI 10.1248/bpb.31.299; Sano N, 1998, JPN J ALLERGOL, V47, P1198; Sidhu PS, 1999, CONSTAST MEDIA, P99; Siegle RL, 1999, ACAD RADIOL, V6, P307, DOI 10.1016/S1076-6332(99)80455-3; Takahashi S, 2001, J J CLIN DERMATOLOGY, V55, P766; Täuber U, 1989, Fortschr Geb Rontgenstrahlen Nuklearmed Erganzungsbd, V128, P215; Thong BYH, 2004, ANN ALLERG ASTHMA IM, V92, P619; Uno K., 2010, JPN J PHARM HLTH CAR, V36, P613; UNO K, 1989, J ANTIMICROB CHEMOTH, V24, P241, DOI 10.1093/jac/24.2.241; Uno K, 1987, J ANTIMICROB CHEMOTH, V35, P205; Uno Katsuji, 1993, Japanese Journal of Allergology, V42, P656; Watanabe H, 1999, DERMATOLOGY, V198, P291, DOI 10.1159/000018133; Yoshikawa H, 1996, SOGO RINSHO, V45, P1845	42	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	NOV	2014	37	11					1750	1757				8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AS0JW	WOS:000343964500007		
J	Ito, Y; Taniguchi, M; Hayashi, A; Anai, M; Morita, S; Ko, E; Yoshimoto, N; Yoshii, Y; Kobuchi, S; Sakaeda, T; Takade, K				Ito, Yukako; Taniguchi, Mayu; Hayashi, Asuka; Anai, Miku; Morita, Shinya; Ko, Emi; Yoshimoto, Naoko; Yoshii, Yasuhiro; Kobuchi, Shinji; Sakaeda, Toshiyuki; Takade, Kanji			Application of Dissolving Microneedles to Glucose Monitoring through Dermal Interstitial Fluid	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						glucose monitoring; dissolving microneedle; interstitial fluid; skin; rat	TRANSDERMAL DRUG-DELIVERY; PERCUTANEOUS-ABSORPTION; BLOOD-GLUCOSE; MICROPILES; INSULIN; SYSTEM; SKIN; RATS	Dissolving microneedles (DMs) were applied to glucose monitoring in the dermal interstitial fluid (ISF) of rats and their potential as an alternative blood glucose Monitoring device was evaluated. Sodium chondroitin sulfate was used to prepare DM array chips, which consisted of 300 DMs/cm(2). The mean length of the DMs was 475 +/- 18 mu m and the mean diameter of the basement was 278 +/- 8 mu m. After DMs were inserted into the skin of the hair-removed rat abdomen, a wet unwoven cloth containing 10-30 mu L of water was placed on the skin and ISF was extracted. By increasing the absorbed amount of water on the unwoven cloth from 10 to 30 mu L, the extracted amount of glucose increased from 1.66 +/- 0.35 mu g to 2.75 +/- 0.61 mu g. Increasing the adhesion time of the wet unwoven cloth to the skin from 0.1 to 5.0 mm, increased the amount of ISF glucose from 1.99 +/- 0.13 mu g to 5.04 +/- 0.38 mu g. The relation between the amount of glucose in ISF and blood glucose concentrations was examined. With increase in the adhesion time, the coefficient of determination, r(2), increased from 0.501 to 0.750. The number of DMs also affected the relationship and values of the coefficient of determinations, r(2) were: 0.340 (25 DMs), 0.758 (50 DMs), 0.763 (100 DMs), 0.774 (200 DMs), and 0.762 (300 DMs). These results indicate the usefulness of DMs as an alternative blood glucose monitoring device.	[Ito, Yukako; Taniguchi, Mayu; Hayashi, Asuka; Anai, Miku; Morita, Shinya; Ko, Emi; Yoshimoto, Naoko; Yoshii, Yasuhiro; Kobuchi, Shinji; Sakaeda, Toshiyuki] Kyoto Pharmaceut Univ, Dept Pharmacokinet, Yamashina Ku, Kyoto 6078412, Japan; [Takade, Kanji] BioSerenTach Inc, Shimogyo Ku, Kyoto 6008040, Japan	Ito, Y (reprint author), Kyoto Pharmaceut Univ, Dept Pharmacokinet, Yamashina Ku, Kyoto 6078412, Japan.	yukako@mb.kyoto-phu.ac.jp			Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan-Supported Program for the Strategic Research Foundation at Private Universities; MEXT	This study was supported by the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan-Supported Program for the Strategic Research Foundation at Private Universities, 2008-2013. This study was also supported by a Grant-in-Aid for Scientific Research provided by MEXT, 2010-2013.	Bariya SH, 2012, J PHARM PHARMACOL, V64, P11, DOI 10.1111/j.2042-7158.2011.01369.x; Prausnitz MR, 2004, ADV DRUG DELIVER REV, V56, P581, DOI 10.1016/j.addr.2003.10.023; Ito Y, 2006, J DRUG TARGET, V14, P255, DOI 10.1080/10611860600785080; Sieg A, 2004, CLIN CHEM, V50, P1383, DOI 10.1373/clinchem.2004.032862; Kim YC, 2012, ADV DRUG DELIVER REV, V64, P1547, DOI 10.1016/j.addr.2012.04.005; Coulman SA, 2009, INT J PHARM, V366, P190, DOI 10.1016/j.ijpharm.2008.08.040; Ito Y, 2006, EUR J PHARM SCI, V29, P82, DOI 10.1016/j.ejps.2006.05.011; Ito Y, 2008, J DRUG TARGET, V16, P243, DOI 10.1080/10611860801902575 ; Ito Y, 2008, BIOL PHARM BULL, V31, P1631, DOI 10.1248/bpb.31.1631; Ito Y, 2008, INT J PHARM, V349, P124, DOI 10.1016/j.ijpharm.2007.07.036; Ito Y, 2012, DIABETES TECHNOL THE, V14, P891, DOI 10.1089/dia.2012.0096; Ito Y, 2013, J DRUG DELIV SCI TEC, V23, P577; KAJIWARA K, 1992, MED PROG TECHNOL, V18, P181; Lee S, 2005, ULTRASOUND MED BIOL, V31, P971, DOI 10.1016/j.ultrasmedbio.2005.04.004; Ministry of Health and Welfare, MEAS LIF REL DIS HLT; Sato T, 2011, DIABETES TECHNOL THE, V13, P1194, DOI 10.1089/dia.2011.0089; Murthy S Srinivasa, 2008, J Diabetes Sci Technol, V2, P250; Stout P J, 2001, Diabetes Technol Ther, V3, P81, DOI 10.1089/152091501750220046; Takada K, 2008, Drug Discov Ther, V2, P140; Wang Ping M, 2005, Diabetes Technol Ther, V7, P131, DOI 10.1089/dia.2005.7.131; Yamakoshi K, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2360919	21	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	NOV	2014	37	11					1776	1781				6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AS0JW	WOS:000343964500010		
J	Kato, R; Shigemoto, K; Akiyama, H; Ieda, A; Ijiri, Y; Hayashi, T				Kato, Ryuji; Shigemoto, Kota; Akiyama, Hiromasa; Ieda, Asaka; Ijiri, Yoshio; Hayashi, Tetsuya			Human Hepatocarcinoma Functional Liver Cell-4 Cell Line Exhibits High Expression of Drug-Metabolizing Enzymes in Three-Dimensional Culture	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						CYP; uridine diphosphate-glucuronosyl transferase; expression; functional liver cell; three-dimensional culture	NUCLEAR FACTOR 4-ALPHA; PREGNANE-X-RECEPTOR; CONSTITUTIVE ANDROSTANE RECEPTOR; UDP-GLUCURONOSYLTRANSFERASE 1A1; DISTAL ENHANCER MODULE; HUMAN HEPATOCYTES; CYTOCHROME-P450 EXPRESSION; TRANSCRIPTIONAL REGULATION; EXTRACELLULAR-MATRIX; GENE-EXPRESSION	The expression levels of CYP and uridine diphosphate-glucuronosyl transferase (UGT) are lower in hepatocellular carcinoma cell lines than in human primary hepatocytes. However, a functional liver cell (FLC)-4 cell line that has a greater capacity to secrete liver-specific proteins than other hepatocellular carcinoma cells has recently been established. A three-dimensional culture using Engelbreth-Holm-Swan (EHS) gel induces the secretion of liver-specific proteins via the induction of hepatocyte nuclear factor-4 alpha (HNF-4 alpha). The aim of this study was to evaluate the mRNA expression of the enzymes CYP and UGT in FLC-4 and HepG2 cells in monolayer and three-dimensional cultures using EHS gel. The mRNA levels of HNF-4a, albumin, pregnane X receptor (PXR), constitutive androstane receptor (CAR), CYPs (1A2, 2E1, 2C8, 2C9, 2C19, 2D6, and 3A4) and UGTs (1A1, 1A6, 1A9, and 2B7) were determined using real-time reverse transcription (RT) PCR. In a monolayer culture, the mRNA expression levels of HNF-4 alpha, albumin, PXR, CAR, CYPs (2E1, 2C9, 2C19, 2D6, and 3A4) and UGTs (1A1, 1A6, and 1A9) were higher in FLC-4 cells than in HepG2 cells. In FLC-4 cells, the mRNA expression levels of HNF-4 alpha, albumin, PXR, CAR, CYPs (2E1, 2C8, 2C19, and 3A4) and UGTs (1A1, 1A6, 1A9, and 2B7) significantly increased in three-dimensional culture. FLC-4 cells cultured in EHS gel showed significantly increased expression levels of CYPs and UGTs. The results of this study suggest that human hepatocellular carcinoma FLC-4 cells cultured in EHS gel show potential for use in studying in vitro drug metabolism.	[Kato, Ryuji; Shigemoto, Kota; Akiyama, Hiromasa; Ieda, Asaka; Ijiri, Yoshio; Hayashi, Tetsuya] Osaka Univ Pharmaceut Sci, Lab Cardiovasc Pharmacotherapy & Toxicol, Takatsuki, Osaka 5691094, Japan	Kato, R (reprint author), Osaka Univ Pharmaceut Sci, Lab Cardiovasc Pharmacotherapy & Toxicol, 4-20-1 Nasahara, Takatsuki, Osaka 5691094, Japan.	rkato@gly.oups.ac.jp					Sugatani J, 2004, BIOCHEM PHARMACOL, V67, P989, DOI 10.1016/j.bcp.2003.11.002; Kamiyama Y, 2007, DRUG METAB PHARMACOK, V22, P287, DOI 10.2133/dmpk.22.287; Rana R, 2010, DRUG METAB DISPOS, V38, P591, DOI 10.1124/dmd.109.030387; Jover R, 2009, CURR DRUG METAB, V10, P508; Rodriguez-Antona C, 2002, XENOBIOTICA, V32, P505, DOI 10.1080/00498250210128675; Osabe M, 2008, DRUG METAB DISPOS, V36, P294, DOI 10.1124/dmd.107.017731; Aleksunes LM, 2012, DRUG METAB DISPOS, V40, P1366, DOI 10.1124/dmd.112.045112; Hamilton GA, 2001, CELL TISSUE RES, V306, P85; Oda H, 2008, BIOCHEM PHARMACOL, V75, P1209, DOI 10.1016/j.bcp.2007.11.003; Gong PF, 2006, HEPATOLOGY, V43, P144, DOI 10.1002/hep.21004; Iwazaki N, 2008, DRUG METAB PHARMACOK, V23, P59, DOI 10.2133/dmpk.23.59; Donato MT, 2008, CURR DRUG METAB, V9, P1; Goodwin B, 1999, MOL PHARMACOL, V56, P1329; Jover R, 2001, HEPATOLOGY, V33, P668, DOI 10.1053/jhep.2001.22176; Chen YP, 2004, J PHARMACOL EXP THER, V308, P495, DOI 10.1124/jpet.103.058818; Ramamoorthy A, 2012, DRUG METAB DISPOS, V40, P726, DOI 10.1124/dmd.111.040329; Ehmer U, 2010, DRUG METAB DISPOS, V38, P1246, DOI 10.1124/dmd.109.030403; Goodwin B, 2001, MOL PHARMACOL, V60, P427; Hasumura S, 1988, Hum Cell, V1, P98; HATA S, 1992, BIOCHIM BIOPHYS ACTA, V1131, P211, DOI 10.1016/0167-4781(92)90080-J; Kobayashi K, 2012, DRUG METAB PHARMACOK, V27, P478, DOI 10.2133/dmpk.DMPK-12-RG-016; Laurent T, 2012, J CELL PHYSIOL, V227, P2898, DOI 10.1002/jcp.23033; Richert L, 2009, TOXICOL APPL PHARM, V235, P86, DOI 10.1016/j.taap.2008.11.019; Yueh MF, 2011, MOL PHARMACOL, V79, P1053, DOI 10.1124/mol.110.070649	24	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	NOV	2014	37	11					1782	1787				6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AS0JW	WOS:000343964500011		
J	Kawaguchi, T; Azuma, K; Yamaguchi, T; Iwase, S; Matsunaga, T; Yamada, K; Miyamatsu, H; Takeuchi, H; Kohno, N; Akashi, T; Unezaki, S				Kawaguchi, Takashi; Azuma, Kanako; Yamaguchi, Takuhiro; Iwase, Satoru; Matsunaga, Tadaharu; Yamada, Kimito; Miyamatsu, Hironobu; Takeuchi, Hironori; Kohno, Norio; Akashi, Takao; Unezaki, Sakae			Preferences for Pharmacist Counselling in Patients with Breast Cancer: A Discrete Choice Experiment	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						pharmacist counselling; patients' preference; breast cancer; chemotherapy; discrete choice experiment; outpatient chemotherapy department	WILLINGNESS-TO-PAY; QUALITY-OF-LIFE; INFORMATION NEEDS; DECISION-MAKING; RECEIVING CHEMOTHERAPY; COMMUNITY PHARMACIES; FOLLOW-UP; CARE; SATISFACTION; COMMUNICATION	With the shift of a large proportion of cancer chemotherapy recipients to ambulatory care, the role of hospital pharmacists has changed, and their provision of information is essential care for cancer patients. There is little research on pharmacist-patient relations, particularly about pharmacist counselling, in Japan. To meet patients' needs, pharmacist counselling should be optimized. Here, breast cancer patients' preferences for pharmacist counselling were assessed using a discrete choice experiment. Bayesian nonlinear optimal methodology was employed to obtain six attributes (attitude of pharmacist, quality of information, explanation of side effects, frequency of pharmacist counselling before starting chemotherapy, cost of pharmacist counselling, and follow-up with the pharmacist after starting chemotherapy) of two to three levels each. The attributes and levels were used to create 12 hypothetical scenarios that were divided into two questionnaires of six choice sets each. Two hundred eighty participants were randomly assigned to complete one of these questionnaires (blocks). Attributes were analyzed by conditional logit model to determine significant predictors of patient preferences. The responses of 278 patients to 1667 scenarios were analyzed. Attitude of pharmacist, quality of information, cost of pharmacist counselling, and follow-up with the pharmacist after starting chemotherapy were significant predictors of patient preferences, with quality of information receiving the highest priority. Thus patients receiving pharmacist counselling before starting chemotherapy prefer to interact with a pharmacist with a friendly, interested attitude who provides individualized information. Further research is needed to elucidate the information that Japanese patients consider most important and to enhance pharmacist-patient communication.	[Kawaguchi, Takashi; Takeuchi, Hironori; Unezaki, Sakae] Tokyo Univ Pharm & Life Sci, Sch Pharm, Dept Pract Pharm, Hachioji, Tokyo 1920392, Japan; [Azuma, Kanako; Miyamatsu, Hironobu; Akashi, Takao] Tokyo Med Univ Hosp, Dept Pharm, Shinjuku Ku, Tokyo 1600023, Japan; [Yamada, Kimito; Kohno, Norio] Tokyo Med Univ Hosp, Dept Breast Oncol, Shinjuku Ku, Tokyo 1600023, Japan; [Yamaguchi, Takuhiro] Tohoku Univ, Grad Sch Med, Div Biostat, Aoba Ku, Sendai, Miyagi 9808574, Japan; [Iwase, Satoru] Univ Tokyo, Dept Palliat Med, Inst Med Sci, Minato Ku, Tokyo 1080071, Japan; [Matsunaga, Tadaharu] Nagumo Clin, Chiyoda Ku, Tokyo 1410032, Japan	Kawaguchi, T (reprint author), Tokyo Univ Pharm & Life Sci, Sch Pharm, Dept Pract Pharm, 1432-1 Horinouchi, Hachioji, Tokyo 1920392, Japan.	tkawa@toyaku.ac.jp					Harrison JD, 2009, SUPPORT CARE CANCER, V17, P1117, DOI 10.1007/s00520-009-0615-5; HENSHER DA, 1994, TRANSPORTATION, V21, P107, DOI 10.1007/BF01098788; McKee Megan, 2011, J Oncol Pharm Pract, V17, P387, DOI 10.1177/1078155210389217; Husson O, 2013, PSYCHO-ONCOLOGY, V22, P490, DOI 10.1002/pon.3042; Murad MS, 2014, RES SOC ADMIN PHARM, V10, P1, DOI 10.1016/j.sapharm.2013.03.002; Kamei M, 2001, YAKUGAKU ZASSHI, V121, P215, DOI 10.1248/yakushi.121.215; Doloresco F, 2009, AM J HEALTH-SYST PH, V66, pS13, DOI 10.2146/ajhp080674; Degner LF, 1997, JAMA-J AM MED ASSOC, V277, P1485, DOI 10.1001/jama.277.18.1485; Vogel BA, 2008, PATIENT EDUC COUNS, V71, P79, DOI 10.1016/j.pec.2007.11.023; Cavaco AM, 2010, PATIENT EDUC COUNS, V80, P377, DOI 10.1016/j.pec.2010.06.028; Kimman ML, 2010, ACTA ONCOL, V49, P328, DOI 10.3109/02841860903536002; Muhlbacher AC, 2011, EUR J HEALTH ECON, V12, P193, DOI 10.1007/s10198-010-0218-6; Tinelli M, 2007, ANN PHARMACOTHER, V41, P1962, DOI 10.1345/aph.1K242; Degner L F, 1998, J Nurs Meas, V6, P137; Lancsar E, 2008, PHARMACOECONOMICS, V26, P661, DOI 10.2165/00019053-200826080-00004; Liekweg A, 2004, SUPPORT CARE CANCER, V12, P73, DOI 10.1007/s00520-003-0539-4; Bridges JFP, 2011, VALUE HEALTH, V14, P403, DOI 10.1016/j.jval.2010.11.013; Gourdji I, 2003, J NURS CARE QUAL, V18, P43; Galloway S, 1997, J ADV NURS, V25, P1175, DOI 10.1046/j.1365-2648.1997.19970251175.x; Cox A, 2006, EUR J ONCOL NURS, V10, P263, DOI 10.1016/j.ejon.2005.10.007; Kessels R, 2011, APPL STOCH MODEL BUS, V27, P173, DOI 10.1002/asmb.906; Porteous T, 2006, BRIT J GEN PRACT, V56, P911; Davies NJ, 2008, PSYCHO-ONCOL, V17, P1048, DOI 10.1002/pon.1305; van Empel IWH, 2011, HUM REPROD, V26, P584, DOI 10.1093/humrep/deq389; Iconomou G, 2002, PALLIATIVE MED, V16, P315, DOI 10.1191/0239216302pm574oa; Mallinger JB, 2005, PATIENT EDUC COUNS, V57, P342, DOI 10.1016/j.pec.2004.09.009; Whitmer KM, 2006, J PALLIAT MED, V9, P628, DOI 10.1089/jpm.2006.9.628; Husson O, 2011, ANN ONCOL, V22, P761, DOI 10.1093/annonc/mdq413; Bakker DA, 2001, PATIENT EDUC COUNS, V43, P61, DOI 10.1016/S0738-3991(00)00147-6; Barner JC, 1999, CLIN THER, V21, P878, DOI 10.1016/S0149-2918(99)80009-5; Ben Akiva M., 1985, DISCRETE CHOICE ANAL; CASSILETH BR, 1980, INT J RADIAT ONCOL, V6, P493; Chuang E, 2012, J IMMIGR MINOR HEALT, V14, P754, DOI 10.1007/s10903-012-9577-7; GORE PR, 1994, J CLIN PHARM THER, V19, P17, DOI 10.1111/j.1365-2710.1994.tb00803.x; Iihara H, 2012, J EVAL CLIN PRACT, V18, P753, DOI 10.1111/j.1365-2753.2011.01665.x; Ikesue Hiroaki, 2008, Gan To Kagaku Ryoho, V35, P578; Kawaguchi T, 2013, BMC MED INFORM DECIS, V13, DOI 10.1186/1472-6947-13-50; Louviere J, 2000, STATED CHOICE METHOD; Matsuda A, 2013, JPN J CLIN ONCOL, V43, P328, DOI 10.1093/jjco/hys233; Naik-Panvelkar Pradnya, 2013, Int J Pharm Pract, V21, P3, DOI 10.1111/ijpp.12002; Papanikolaou P, 2007, HEALTH SOC CARE COMM, V15, P588, DOI 10.1111/j.1365-2524.2007.00728.x; PROPPER C, 1990, ECON J, V100, P193, DOI 10.2307/2234196; Rehnberg G, 2001, PATIENT EDUC COUNS, V42, P1, DOI 10.1016/S0738-3991(99)00118-4; Sleath B, 1995, AM J PHARM EDUC, V59, P374; Suh D C, 2000, J Am Pharm Assoc (Wash), V40, P818; Yamagishi A, 2009, J PAIN SYMPTOM MANAG, V37, P823, DOI 10.1016/j.jpainsymman.2008.04.015	46	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	NOV	2014	37	11					1795	1802				8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AS0JW	WOS:000343964500013		
J	Matsumoto, K; Kanazawa, N; Shigemi, A; Ikawa, K; Morikawa, N; Koriyama, T; Orita, M; Kawamura, H; Tokuda, K; Nishi, J; Takeda, Y				Matsumoto, Kazuaki; Kanazawa, Naoko; Shigemi, Akari; Ikawa, Kazuro; Morikawa, Norifumi; Koriyama, Toyoyasu; Orita, Michiyo; Kawamura, Hideki; Tokuda, Koichi; Nishi, Junichiro; Takeda, Yasuo			Factors Affecting Treatment and Recurrence of Clostridium difficile Infections	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						Clostridium difficile; antiinfective agent; gastric acid-suppressive agent; anticancer agent; steroid; recurrence	ANTIBIOTIC USE; RISK-FACTORS; DIARRHEA; DISEASE; EPIDEMIOLOGY; METAANALYSIS; COLITIS; TRANSPLANTATION; METRONIDAZOLE; CHEMOTHERAPY	The antimicrobial agents vancomycin and metronidazole have been used to treat Clostridium difficile infections (CDIs). However, it remains unclear why patients are at risk of treatment failure and recurrence. Therefore, this study retrospectively examined 98 patients with CDIs who were diagnosed based on the detection of toxin-positive C. difficile to determine the risk factors affecting drug treatment responses and the recurrence of CDI. No significant difference was observed in the cure rate or dosage between the vancomycin and metronidazole groups. The 90-d mortality rate and total number of drugs associated with CDIs, including antiinfective agents used within 2 months before the detection of toxin-positive C. difficile, were significantly lower in the treatment success group than in the failure group. The total number of antiinfective agents and gastric acid-suppressive agents used during CDI therapy was also significantly lower in the success group than in the failure group. The period from the completion of CDI therapy to restarting the administration of anticancer agents and steroids was significantly longer in patients without than in patients with recurrence. These results indicate that the total number of drugs associated with CDIs should be minimized to reduce the risk of CDIs, that not only antibiotics but also gastric acid-suppressive agents should be discontinued during CDI therapy to increase therapeutic efficacy, and that the use of anticancer agents and steroids should be delayed as long as possible after patients are cured by CDI therapy to prevent recurrence.	[Matsumoto, Kazuaki; Kanazawa, Naoko; Shigemi, Akari; Takeda, Yasuo] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Clin Pharm & Pharmacol, Kagoshima 8908520, Japan; [Matsumoto, Kazuaki; Kanazawa, Naoko; Shigemi, Akari; Koriyama, Toyoyasu; Orita, Michiyo; Kawamura, Hideki; Tokuda, Koichi; Nishi, Junichiro] Kagoshima Univ Hosp, Infect Control Team, Kagoshima 8908520, Japan; [Ikawa, Kazuro; Morikawa, Norifumi] Hiroshima Univ, Dept Clin Pharmacotherapy, Minami Ku, Hiroshima 7348551, Japan	Takeda, Y (reprint author), Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Clin Pharm & Pharmacol, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan.	takeda@m.kufm.kagoshima-u.ac.jp					Aldeyab MA, 2009, ANTIMICROB AGENTS CH, V53, P2082, DOI 10.1128/AAC.01214-08; McFarland LV, 2008, NAT CLIN PRACT GASTR, V5, P40, DOI 10.1038/ncpgasthep1029; Hookman P, 2009, WORLD J GASTROENTERO, V15, P1554, DOI 10.3748/wjg.15.1554; Janarthanan S, 2012, AM J GASTROENTEROL, V107, P1001, DOI 10.1038/ajg.2012.179; Blot E, 2003, J HOSP INFECT, V53, P187, DOI 10.1053/jhin.2002.1356; Drekonja DM, 2011, ANN INTERN MED, V155, P839, DOI [10.7326/0003-4819-155-12-201112200-00007, 10.1059/0003-4819-155-12-201112200-00007]; Deshpande A, 2013, J ANTIMICROB CHEMOTH, V68, P1951, DOI 10.1093/jac/dkt129; Johal SS, 2004, J CLIN PATHOL, V57, P973, DOI 10.1136/jcp.2003.015875; Zar FA, 2007, CLIN INFECT DIS, V45, P302, DOI 10.1086/519265; Cohen SH, 2010, INFECT CONT HOSP EP, V31, P431, DOI 10.1086/651706; Vernaz N, 2009, J ANTIMICROB CHEMOTH, V63, P1272, DOI 10.1093/jac/dkp128; Brown KA, 2013, ANTIMICROB AGENTS CH, V57, P2326, DOI 10.1128/AAC.02176-12; Kamboj M, 2011, CLIN INFECT DIS, V53, P1003, DOI 10.1093/cid/cir643; Kyne L, 2001, LANCET, V357, P189, DOI 10.1016/S0140-6736(00)03592-3; Leonard J, 2007, AM J GASTROENTEROL, V102, P2047, DOI 10.1111/j.1572-0241.2007.01275.x; Bilgrami S, 1999, BONE MARROW TRANSPL, V23, P1039, DOI 10.1038/sj.bmt.1701773; Monaghan T, 2008, GUT, V57, P850, DOI 10.1136/gut.2007.128157; FEKETY R, 1989, AM J MED, V86, P15, DOI 10.1016/0002-9343(89)90223-4; Pepin J, 2005, CLIN INFECT DIS, V41, P1254, DOI 10.1086/496986; Oka K, 2012, J CLIN MICROBIOL, V50, P915, DOI 10.1128/JCM.05588-11; Owens RC, 2008, CLIN INFECT DIS, V46, pS19, DOI 10.1086/521859; ANAND A, 1993, CLIN INFECT DIS, V17, P109; CUDMORE MA, 1982, ARCH INTERN MED, V142, P333, DOI 10.1001/archinte.142.2.333; Gorschluter M, 2001, CLIN INFECT DIS, V33, P786, DOI 10.1086/322616; Kunishima H, 2013, J INFECT CHEMOTHER, V19, P360, DOI 10.1007/s10156-013-0553-5; Mertz D, 2010, EUR J CLIN MICROBIOL, V29, P1575, DOI 10.1007/s10096-010-1022-z; Modena S, 2006, J CLIN GASTROENTEROL, V40, P49; Morales Chamorro R, 2005, CLIN TRANSL ONCOL, V7, P258, DOI 10.1007/BF02710173; Sharma AK, 1998, CLIN INFECT DIS, V27, P1540, DOI 10.1086/517744; Svenungsson B, 2003, J CLIN MICROBIOL, V41, P4031, DOI 10.1128/JCM.41.9.4031-4037.2003; Thomas C, 2003, J ANTIMICROB CHEMOTH, V51, P1339, DOI 10.1093/jac/dkg254	31	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	NOV	2014	37	11					1811	1815				5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AS0JW	WOS:000343964500015		
J	Fukasawa, H; Muratake, H; Nagae, M; Sugiyama, K; Shudo, K				Fukasawa, Hiroshi; Muratake, Hideaki; Nagae, Marina; Sugiyama, Kiyoshi; Shudo, Koichi			Transdermal Administration of Aqueous Pregabalin Solution as a Potential Treatment Option for Patients with Neuropathic Pain to Avoid Central Nervous System-Mediated Side Effects	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						neuropathic pain; pregabalin; transdermal administration	LIGATION; AGENTS; ACIDS; MODEL; RATS	Pregabalin, (S)-3-isobutyl-gamma-aminobutyric acid (GABA), is a widely used adjuvant therapy for patients with neuropathic pain, which is defined as chronic pain caused by lesions or diseases of the somatosensory nervous system. However, dizziness and somnolence (sleepiness) are common dose-limiting side effects, probably due to excessive sedative effects on higher centers of the central nervous system (CNS) which are involved in the anticonvulsant and analgesic actions of pregabalin. We speculated that transdermal delivery would minimize centrally mediated side effects. To test this idea, we evaluated the analgesic effects of pregabalin delivered through the transdermal route in animal models of neuropathic pain. Transdermally administered pregabalin increased the pain thresholds in response to mechanical stimuli in a partial sciatic nerve ligation model in rats and a spinal nerve ligation model in mice, and surprisingly also in normal animals. It is noteworthy that simple transdermal application of an aqueous solution of pregabalin is effective. This could be a useful treatment option to avoid or minimize the CNS-mediated side effects of orally administered pregabalin.	[Fukasawa, Hiroshi; Muratake, Hideaki; Shudo, Koichi] Res Fdn ITSUU Lab, Setagaya Ku, Tokyo 1580094, Japan; [Nagae, Marina; Sugiyama, Kiyoshi] Hoshi Univ, Dept Clin Pharmacokinet, Shinagawa Ku, Tokyo 1428501, Japan	Fukasawa, H (reprint author), Res Fdn ITSUU Lab, Setagaya Ku, 2-28-10 Tamagawa, Tokyo 1580094, Japan.	hfukasawa@itsuu.or.jp					Chen SR, 2001, ANESTHESIOLOGY, V95, P1473, DOI 10.1097/00000542-200112000-00029; Stahl SM, 2013, TRENDS PHARMACOL SCI, V34, P332, DOI 10.1016/j.tips.2013.04.001; Treede RD, 2008, NEUROLOGY, V70, P1630, DOI 10.1212/01.wnl.0000282763.29778.59; Zaccara G, 2011, EPILEPSIA, V52, P826, DOI 10.1111/j.1528-1167.2010.02966.x; Baron R, 2010, LANCET NEUROL, V9, P807, DOI 10.1016/S1474-4422(10)70143-5; SELTZER Z, 1990, PAIN, V43, P205, DOI 10.1016/0304-3959(90)91074-S; Field MJ, 2006, P NATL ACAD SCI USA, V103, P17537, DOI 10.1073/pnas.0409066103; Li Z, 2011, EUR J PHARMACOL, V667, P80, DOI 10.1016/j.ejphar.2011.05.054; KIM SH, 1992, PAIN, V50, P355; Jensen TS, 2011, PAIN, V152, P2204, DOI 10.1016/j.pain.2011.06.017; Tuchman M, 2010, J PAIN, V11, P1241, DOI 10.1016/j.jpain.2010.02.024; Bryans JS, 1999, MED RES REV, V19, P149, DOI 10.1002/(SICI)1098-1128(199903)19:2<149::AID-MED3>3.0.CO;2-B; SILVERMAN RB, 1991, J MED CHEM, V34, P2295, DOI 10.1021/jm00111a053; O'Connor AB, 2009, AM J MED, V122, pS22, DOI 10.1016/j.amjmed.2009.04.007; Dworkin RH, 2010, MAYO CLIN PROC, V85, pS3, DOI 10.4065/mcp.2009.0649; Fukasawa H, 2014, ACS CHEM NEUROSCI, V5, P525, DOI 10.1021/cn500053d; Muratake H, 2012, BIOORG MED CHEM LETT, V22, P7602, DOI 10.1016/j.bmcl.2012.10.001; Plaza-Villegas F, 2012, OR SURG OR MED OR PA, V114, P449, DOI 10.1016/j.oooo.2012.05.002; TAYLOR CP, 1993, EPILEPSY RES, V14, P11, DOI 10.1016/0920-1211(93)90070-N	19	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	NOV	2014	37	11					1816	1819				4	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AS0JW	WOS:000343964500016		
J	Aoyagi, R; Funakoshi-Tago, M; Fujiwara, Y; Tamura, H				Aoyagi, Ryohei; Funakoshi-Tago, Megumi; Fujiwara, Yosuke; Tamura, Hiroomi			Coffee Inhibits Adipocyte Differentiation via Inactivation of PPAR gamma	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						3T3-L1; adipocyte; coffee; differentiation; obesity; peroxisome proliferator-activated receptor gamma (PPAR gamma)	NF-KAPPA-B; GENE-EXPRESSION; 3T3-L1 ADIPOCYTES; ANTIOXIDANT; CONSUMPTION; METABOLISM; OBESITY; CELLS; NRF2; MICE	Recent epidemiological studies showed that coffee consumption is associated with a lower risk of type 2 diabetes, presumably due to suppression of excess fat accumulation in adipocytes. However, the mechanism underlying the effect of coffee on adipocyte differentiation has not been well documented. To elucidate the mechanism, we investigated the effect of coffee on the differentiation of mouse preadipocyte 3T3-L1 cells. Coffee reduced the accumulation of lipids during adipocytic differentiation of 3T3-L1 cells. At 5% coffee, the accumulation of lipids decreased to half that of the control. Coffee also inhibited the expression of the peroxisome proliferator-activated receptor gamma (PPAR gamma), a transcription factor controlling the differentiation of adipocytes. Furthermore, coffee reduced the expression of other differentiation marker genes, aP2, adiponectin, CCAAT-enhancer-binding protein alpha (C/EBP alpha), glucose transporter 4 (GLUT4), and lipoprotein lipase (LPL), during adipocyte differentiation. Major bioactive constituents in coffee extracts, such as caffeine, trigonelline, chlorogenic acid, and caffeic acid, showed no effect on PPAR gamma gene expression. The inhibitory activity was produced by the roasting of the coffee beans.	[Aoyagi, Ryohei; Funakoshi-Tago, Megumi; Fujiwara, Yosuke; Tamura, Hiroomi] Keio Univ, Grad Sch Pharmaceut Sci, Minato Ku, Tokyo 1058512, Japan	Tamura, H (reprint author), Keio Univ, Grad Sch Pharmaceut Sci, Minato Ku, 1-5-30 Shibakoen, Tokyo 1058512, Japan.	tamura-hr@pha.keio.ac.jp			Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan; MEXT-Supported Program for the Strategic Research Foundation at Private Universities	We are grateful to Dr. K. Oka for his encouragement. This work was supported in part by a Grant-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan, and by a Grant from the MEXT-Supported Program for the Strategic Research Foundation at Private Universities.	Greenberg JA, 2006, AM J CLIN NUTR, V84, P682; Daglia M, 2000, J AGR FOOD CHEM, V48, P1449, DOI 10.1021/jf990510g; Nicoli MC, 1997, CANCER LETT, V114, P71, DOI 10.1016/S0304-3835(97)04628-4; Paur I, 2010, FREE RADICAL BIO MED, V48, P1218, DOI 10.1016/j.freeradbiomed.2010.02.005; White UA, 2010, MOL CELL ENDOCRINOL, V318, P10, DOI 10.1016/j.mce.2009.08.023; Paur I, 2010, CANCER PREV RES, V3, P653, DOI 10.1158/1940-6207.CAPR-09-0089; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Zhan LJ, 2012, FREE RADICAL BIO MED, V53, P758, DOI 10.1016/j.freeradbiomed.2012.05.041; Huxley R, 2009, ARCH INTERN MED, V169, P2053, DOI 10.1001/archinternmed.2009.439; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; del Castillo MD, 2002, J AGR FOOD CHEM, V50, P3698, DOI 10.1021/jf011702q; Isshiki M, 2011, BIOL PHARM BULL, V34, P1624, DOI 10.1248/bpb.34.1624; Kershaw EE, 2004, J CLIN ENDOCR METAB, V89, P2548, DOI 10.1210/jc.2004-0395; Rosen ED, 2006, NAT REV MOL CELL BIO, V7, P885, DOI 10.1038/nrm2066; Masuzaki H, 2001, SCIENCE, V294, P2166, DOI 10.1126/science.1066285; Huang JS, 2010, AM J PHYSIOL-GASTR L, V299, pG1211, DOI 10.1152/ajpgi.00322.2010; van Dam RM, 2005, JAMA-J AM MED ASSOC, V294, P97, DOI 10.1001/jama.294.1.97; Higdon JV, 2006, CRIT REV FOOD SCI, V46, P101, DOI 10.1080/10408390500400009; Floyd ZE, 2012, BBA-MOL BASIS DIS, V1822, P1090, DOI 10.1016/j.bbadis.2012.03.014; Hemati N, 1997, J BIOL CHEM, V272, P25913, DOI 10.1074/jbc.272.41.25913; Nakabayashi H, 2008, BIOFACTORS, V34, P293, DOI 10.3233/BIO-2009-1083; Takahashi S, 2014, J FUNCT FOODS, V6, P157, DOI 10.1016/j.jff.2013.10.002; Wahli W, 2008, J INTERN MED, V263, P613, DOI 10.1111/j.1365-2796.2008.01951.x; Yamauchi R, 2010, J AGR FOOD CHEM, V58, P5597, DOI 10.1021/jf904062c	24	2	2	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	NOV	2014	37	11					1820	1825				6	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AS0JW	WOS:000343964500017		
J	Tanaka, H; Takahashi, Y; Hamaguchi, S; Iida-Tanaka, N; Oka, T; Nishio, M; Ohtsuki, A; Namekata, I				Tanaka, Hikaru; Takahashi, Yukiko; Hamaguchi, Shogo; Iida-Tanaka, Naoko; Oka, Takayuki; Nishio, Masato; Ohtsuki, Atsushi; Namekata, Iyuki			Effect of Terfenadine and Pentamidine on the hERG Channel and Its Intracellular Trafficking: Combined Analysis with Automated Voltage Clamp and Confocal Microscopy	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						human ether-a-go-go related gene (hERG); intracellular trafficking; arrhythmia; terfenadine; pentamidine	LONG QT SYNDROME; I-KR; CARDIAC-ARRHYTHMIA; POTASSIUM CHANNELS; MDCK CELLS; REPOLARIZATION; MYOCARDIUM; PROBUCOL; INTERVAL; VOLUME	The effects of terfenadine and pentamidine on the human ether-a-go-go related gene (hERG) channel current and its intracellular trafficking were evaluated. Green fluorescent protein (GFP)-linked hERG channels were expressed in HEK293 cells, and the membrane current was measured by an automated whole cell voltage clamp system. To evaluate drug effects on channel trafficking to the cell membrane, the fraction of channel present on the cell membrane was quantified by current measurement after drug washout and confocal microscopy. Terfenadine directly blocked the hERG channel current but had no effect on trafficking of hERG channels to the cell membrane after application in culture medium for 2 d. In contrast, pentamidine had no direct effect on the hERG channel current but reduced trafficking of hERG channels. The two drugs inhibited hERG channel function through different mechanisms: terfenadine through direct channel blockade and pentamidine through inhibition of channel trafficking to the cell membrane. Combined use of automated voltage clamp and confocal microscopic analyses would provide insights into the mechanisms of drug-induced QT-prolongation and arrhythmogenesis.	[Tanaka, Hikaru; Takahashi, Yukiko; Hamaguchi, Shogo; Oka, Takayuki; Nishio, Masato; Ohtsuki, Atsushi; Namekata, Iyuki] Toho Univ, Fac Pharmaceut Sci, Dept Pharmacol, Chiba 2748510, Japan; [Iida-Tanaka, Naoko] Otsuma Womens Univ, Dept Food Sci, Chiyoda Ku, Tokyo 1028357, Japan	Namekata, I (reprint author), Toho Univ, Fac Pharmaceut Sci, Dept Pharmacol, Chiba 2748510, Japan.	iyuki@phar.toho-u.ac.jp					Farkas AS, 2010, DRUGS, V70, P573, DOI 10.2165/11535230-000000000-00000; Wang L, 2007, J PHARMACOL EXP THER, V320, P525, DOI 10.1124/jpet.106.113043; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; van der Heyden MAG, 2008, BRIT J PHARMACOL, V153, P406, DOI 10.1038/sj.bjp.0707618; Dennis A, 2007, BIOCHEM SOC T, V35, P1060; Iida-Tanaka N, 2008, BIOL PHARM BULL, V31, P731, DOI 10.1248/bpb.31.731; Hamaguchi S, 2013, J PHARMACOL SCI, V123, P167, DOI 10.1254/jphs.13099FP; Cordes JS, 2005, BRIT J PHARMACOL, V145, P15, DOI 10.1038/sj.bjp.0706140; Kuryshev YA, 2005, J PHARMACOL EXP THER, V312, P316, DOI 10.1124/jpet.104.073692; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; BRAN S, 1995, ARCH INTERN MED, V155, P765, DOI 10.1001/archinte.155.7.765; Milligan CJ, 2009, NAT PROTOC, V4, P244, DOI 10.1038/nprot.2008.230; Tsuneoka Y, 2012, J PHARMACOL SCI, V119, P287, DOI 10.1254/jphs.12062SC; Classen S, 2008, J MEMBRANE BIOL, V222, P31; ELHARRAR V, 1979, PACE, V2, P435, DOI 10.1111/j.1540-8159.1979.tb05219.x; Fermini B, 2003, NAT REV DRUG DISCOV, V2, P439, DOI 10.1038/nrd1108; Guo J, 2007, J PHARMACOL EXP THER, V321, P911, DOI 10.1124/jpet.107.120931; Hashimoto K, 2007, J PHARMACOL SCI, V103, P333, DOI 10.1254/jphs.CRJ06013X; Iida-Tanaka N, 2007, J PHARMACOL SCI, V104, P397, DOI 10.1254/jphs.SC0070024; Ishii K, 2012, J PHARMACOL SCI, V120, P264, DOI 10.1254/jphs.12R12CP; Masumiya H, 2004, BIOL PHARM BULL, V27, P131, DOI 10.1248/bpb.27.131; SALATA JJ, 1995, CIRC RES, V76, P110; Takahara A, 2012, J PHARMACOL SCI, V120, P165, DOI 10.1254/jphs.12117FP; Tamargo J, 2000, JPN J PHARMACOL, V83, P1, DOI 10.1254/jjp.83.1; Witchel HJ, 2011, CARDIOVASC THER, V29, P251, DOI 10.1111/j.1755-5922.2010.00154.x; Yokoyama H, 2009, J PHARMACOL SCI, V110, P476, DOI 10.1254/jphs.09071FP; Zeng H, 2008, ASSAY DRUG DEV TECHN, V6, P235, DOI 10.1089/adt.2007.116	28	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	NOV	2014	37	11					1826	1830				5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AS0JW	WOS:000343964500018		
J	Okuno, T; Honda, E; Arakawa, T; Ogino, H; Ueno, H				Okuno, Tomofumi; Honda, Eri; Arakawa, Tomohiro; Ogino, Hirofumi; Ueno, Hitoshi			Glutathione-Dependent Cell Cycle G(1) Arrest and Apoptosis Induction in Human Lung Cancer A549 Cells Caused by Methylseleninic Acid: Comparison with Sodium Selenite	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						methylseleninic acid; cell cycle arrest; apoptosis; reduced glutathione; human lung cancer A549 cell	HUMAN PROSTATE-CANCER; DNA-DAMAGE; IN-VITRO; CHEMOPREVENTION; CARCINOGENESIS; INVOLVEMENT; INHIBITION; METABOLISM; MECHANISMS; PREVENTION	The aim of the present study was to clarify the mechanism underlying the inhibition of cell proliferation in human lung cancer A549 cells by selenium (Se) compounds. Methylseleninic acid (CH3SeO2H, abbreviated as MSA), a synthetic Se compound, is a direct precursor of active methylselenol (CH3SeH) and is considered to be one of beneficial agents for cancer prevention and therapy. Sodium selenite (Na2SeO3), an inorganic Se form, is utilized in clinical Se supplementation. MSA markedly inhibited the growth of A549 cells at a concentration of 2.5x10(-6)mol/L for 1 d. On Day 1, Na2SeO3 also inhibited A549 cell growth at the concentration of 7.5x10(-6)mol/L. These compounds induced cell cycle arrest at the G(1) phase and apoptosis under the inhibitory condition. Reduced glutathione (GSH) is critical to MSA or Na2SeO3 metabolism. The depletion of intracellular GSH suppressed Na2SeO3-induced G(1) arrest, but promoted Na2SeO3-induced apoptosis. Therefore, Na2SeO3 appears to have directly induced apoptosis. In contrast, the MSA-induced G(1) arrest was ameliorated by a marked decrease in GSH content. Additionally, the depletion of GSH slightly suppressed MSA-induced apoptosis. The difference in inhibitory effects between MSA and Na2SeO3 may be due to this variation in GSH-related metabolism. After exposure of A549 cells to MSA, the GSH content was significantly decreased. These results indicate that because MSA-induced G(1) arrest and apoptosis induction are enhanced by GSH, the maintenance of GSH is essential for the effective anticancer action of MSA in A549 cells.	[Okuno, Tomofumi; Honda, Eri; Arakawa, Tomohiro; Ogino, Hirofumi; Ueno, Hitoshi] Setsunan Univ, Fac Pharmaceut Sci, Dept Publ Hlth & Prevent Pharmacol, Hirakata, Osaka 5730101, Japan	Okuno, T (reprint author), Setsunan Univ, Fac Pharmaceut Sci, Dept Publ Hlth & Prevent Pharmacol, 45-1 Nagaotoge Cho, Hirakata, Osaka 5730101, Japan.	okuno@pharm.setsuna.ac.jp					Jiang C, 2002, MOL CANCER THER, V1, P1059; Ohta Y, 2008, TOXICOL APPL PHARM, V226, P169, DOI 10.1016/j.taap.2007.09.011; TOYOOKA T, 1983, J CHROMATOGR, V282, P495, DOI 10.1016/S0021-9673(00)91626-1; Wu GY, 2004, J NUTR, V134, P489; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107; Macip S, 2003, MOL CELL BIOL, V23, P8576, DOI 10.1128/MCB.23.23.8576-8585.2003; Rayman MP, 2005, P NUTR SOC, V64, P527, DOI 10.1079/PNS2005467; Ip C, 2000, CANCER RES, V60, P2882; Zhuo HJ, 2004, CANCER EPIDEM BIOMAR, V13, P771; Drake EN, 2006, MED HYPOTHESES, V67, P318, DOI 10.1016/j.mehy.2006.01.058; Combs GF, 1998, PHARMACOL THERAPEUT, V79, P179, DOI 10.1016/S0163-7258(98)00014-X; Brozmanova J, 2010, ARCH TOXICOL, V84, P919, DOI 10.1007/s00204-010-0595-8; Dong Y, 2002, CANCER RES, V62, P708; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Li GX, 2008, CARCINOGENESIS, V29, P1005, DOI 10.1093/carcin/bgn007; Park SH, 2012, TOXICOL LETT, V212, P252, DOI 10.1016/j.toxlet.2012.06.007; Wang L, 2009, CANCER PREV RES, V2, P484, DOI 10.1158/1940-6207.CAPR-08-0173; Homma S, 2009, CLIN CANCER RES, V15, P3423, DOI 10.1158/1078-0432.CCR-08-2822; Jiang C, 2001, CANCER RES, V61, P3062; Silvera SAN, 2007, CANCER CAUSE CONTROL, V18, P7, DOI 10.1007/s10552-006-0057-z; Rayman MP, 2008, BRIT J NUTR, V100, P238, DOI 10.1017/S0007114508922522; Zeng HW, 2009, J NUTR, V139, P1613, DOI 10.3945/jn.109.110320; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Valavanidis A, 2009, INT J ENV RES PUB HE, V6, P445, DOI 10.3390/ijerph6020445; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Knaapen AM, 2006, MUTAGENESIS, V21, P225, DOI 10.1093/mutage/gel032; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; Jiang C, 2004, MOL CANCER THER, V3, P877; Boudreau RTM, 2007, EXP MOL PATHOL, V83, P347, DOI 10.1016/j.yexmp.2007.09.003; Ganther H. E., 1986, J AM COLL TOXICOL, V5, P1; Gerald F., 2006, SELENIUM ITS MOL BIO, P249; Lui C, 2012, MOL CARCINOG, V51, P303; NOMURA A, 1987, J NATL CANCER I, V79, P103; PRYOR WA, 1985, CHEM-BIOL INTERACT, V54, P171, DOI 10.1016/S0009-2797(85)80161-7; Rikiishi H, 2007, J BIOENERG BIOMEMBR, V39, P91, DOI 10.1007/s10863-006-9005-7; Sakazaki H, 2001, J HEALTH SCI, V47, P258, DOI 10.1248/jhs.47.258; Sinha R, 2001, BIOCHEM PHARMACOL, V61, P311, DOI 10.1016/S0006-2952(00)00545-1; Tudek B, 2006, J PHYSIOL PHARMACOL, V57, P33	38	1	1	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	NOV	2014	37	11					1831	1837				7	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AS0JW	WOS:000343964500019		
J	Yagasaki, R; Nakahara, T; Ushikubo, H; Mori, A; Sakamoto, K; Ishii, K				Yagasaki, Rina; Nakahara, Tsutomu; Ushikubo, Hiroko; Mori, Asami; Sakamoto, Kenji; Ishii, Kunio			Anti-angiogenic Effects of Mammalian Target of Rapamycin Inhibitors in a Mouse Model of Oxygen-Induced Retinopathy	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						mammalian target of rapamycin; pathologic angiogenesis; retina; vascular endothelial growth factor	ENDOTHELIAL GROWTH-FACTOR; RETINAL VASCULAR DEVELOPMENT; INTRAVITREAL BEVACIZUMAB; MACULAR DEGENERATION; SURVIVAL FACTOR; EXPRESSION; NEOVASCULARIZATION; MICE; PREMATURITY; APELIN	Ocular pathologic angiogenesis is a causative factor for retinopathy of prematurity, diabetic retinopathy, and age-related macular degeneration. In the present study, we examined the effects of rapamycin and everolimus, inhibitors of mammalian target of rapamycin (mTOR), on retinal pathologic angiogenesis in mice with oxygen-induced retinopathy (OIR), an animal model of proliferative ischemic retinopathy. Mice were exposed to 80% oxygen from postnatal day (P) 7 to P10, and were then brought into room air and subcutaneously injected with rapamycin and everolimus. The neovascular tufts, the size of the central avascular zone, and the immunoreactivity for phosphorylated ribosomal protein S6 (pS6), a downstream indicator of mTOR activity, were evaluated in fiat-mounted retinas. Retinal neovascular tufts and vascular growth in the avascular zone were observed in P15 mice with OIR. In addition, intense immunoreactivity for pS6 was detected in the neovascular tufts and in endothelial cells located at the vascular-avascular border. Both rapamycin and everolimus reduced the extent of retinal neovascular tufts and pS6 immunoreactivity, but they also increased the size of the avascular zone. Thus, activation of the mTOR pathway in endothelial cells contributes to retinal pathologic angiogenesis, and mTOR inhibitors that target proliferating endothelial cells are promising candidates as anti-angiogenic agents for the treatment of vasoproliferative retinal diseases.	[Yagasaki, Rina; Nakahara, Tsutomu; Ushikubo, Hiroko; Mori, Asami; Sakamoto, Kenji; Ishii, Kunio] Kitasato Univ, Sch Pharmaceut Sci, Dept Mol Pharmacol, Minato Ku, Tokyo 1088641, Japan	Nakahara, T (reprint author), Kitasato Univ, Sch Pharmaceut Sci, Dept Mol Pharmacol, Minato Ku, 5-9-1 Shirokane, Tokyo 1088641, Japan.	nakaharat@pharm.kitasato-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [23122517, 25122712, 23590112]	This study was supported by Grants-in-Aid for Scientific Research on Innovative Areas (Nos. 23122517, 25122712, T.N.) and a Grant-in-Aid for Scientific Research (C) (No. 23590112, T.N.) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002; ALON T, 1995, NAT MED, V1, P1024, DOI 10.1038/nm1095-1024; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; Kasai A, 2010, ARTERIOSCL THROM VAS, V30, P2182, DOI 10.1161/ATVBAHA.110.209775; Nishijima K, 2007, AM J PATHOL, V171, P53, DOI 10.2353/ajpath.2007.061237; Saint-Geniez M, 2004, INT J DEV BIOL, V48, P1045, DOI 10.1387/ijdb.041895ms; Guba M, 2002, NAT MED, V8, P128, DOI 10.1038/nm0202-128; Finger RP, 2014, OPHTHALMOLOGY, V121, P1246, DOI 10.1016/j.ophtha.2013.12.032; Mintz-Hittner HA, 2011, NEW ENGL J MED, V364, P603, DOI 10.1056/NEJMoa1007374; Stahl A, 2008, FEBS LETT, V582, P3097, DOI 10.1016/j.febslet.2008.08.005; Moradian S, 2008, GRAEF ARCH CLIN EXP, V246, P1699, DOI 10.1007/s00417-008-0914-4; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; del Toro R, 2010, BLOOD, V116, P4025, DOI 10.1182/blood-2010-02-270819; Morita A, 2014, EXP EYE RES, V120, P127, DOI 10.1016/j.exer.2014.01.009; Xue Q, 2009, ARTERIOSCL THROM VAS, V29, P1172, DOI 10.1161/ATVBAHA.109.185918; Phung TL, 2006, CANCER CELL, V10, P159, DOI 10.1016/j.ccr.2006.07.003; Mayerhofer M, 2002, BLOOD, V100, P3767, DOI 10.1182/blood-2002-01-0109; Gragoudas ES, 2004, NEW ENGL J MED, V351, P2805, DOI 10.1056/NEJMoa042760; Kasai A, 2008, ARTERIOSCL THROM VAS, V28, P1717, DOI 10.1161/ATVBAHA.108.163402; Shi WY, 2006, INVEST OPHTH VIS SCI, V47, P3339, DOI 10.1167/iovs.05-1425; Dejneka NS, 2004, MOL VIS, V10, P964; Saint-Geniez M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003554	22	2	2	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	NOV	2014	37	11					1838	1842				5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AS0JW	WOS:000343964500020		
J	Kobayashi, H; Motoyoshi, N; Itagaki, T; Inokuchi, N				Kobayashi, Hiroko; Motoyoshi, Naomi; Itagaki, Tadashi; Inokuchi, Norio			Mutagenesis of the Novel Hericium erinaceus Ribonuclease, RNase He1, Reveals Critical Responsible Residues for Enzyme Stability and Activity	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						ribonuclease; primary structure; Hericium erinaceus; thermostability	AMINO-ACID-SEQUENCE; PLEUROTUS-OSTREATUS; ALPHA-SARCIN; PURIFICATION; HOMOLOGY; PROTEIN; LECTIN; EGGS; T1	Here, we determined the sequence of a cDNA encoding a guanylic acid-specific ribonuclease (RNase He1) from Hericium erinaceus that exhibits high sequence identity (59%) with RNase Po1, an enzyme with anticancer activity and which is found in Pleurotus ostreatus. RNase He1 and RNase Po1 have similar structures and heat stabilities; hence, RNase He1 may also have potential as an anti-cancer agent. Therefore, we initiated structure-function studies to further characterize the enzyme. Based on the RNase Po1 structure, RNase He1 is predicted to form 3 disulfide bonds involving Cys7-Cys98, Cys5-Cys83, and Cys47-Cys81 linkages. The Cys5A1a mutant exhibited no RNase activity, whereas the Cys81A1a mutant retained RNase activity, but had reduced heat stability. Therefore, the Cys5-Cys83 bond in RNase He1 is essential for the structure of the RNase active site region. Similarly, the Cys47-Cys81 bond helps maintain the conformational stability of the active site region, and may contribute to the greater heat stability of RNase He1.	[Kobayashi, Hiroko; Motoyoshi, Naomi; Itagaki, Tadashi; Inokuchi, Norio] Nihon Univ, Sch Pharm, Funabashi, Chiba 2748555, Japan	Kobayashi, H (reprint author), Nihon Univ, Sch Pharm, 7-7-1 Narashinodai, Funabashi, Chiba 2748555, Japan.	kobayashi.hiroko@nihon-u.ac.jp					Huang HC, 1998, J BIOL CHEM, V273, P6395, DOI 10.1074/jbc.273.11.6395; ENDO Y, 1983, J BIOL CHEM, V258, P2662; Fang EF, 2012, APOPTOSIS, V17, P377, DOI 10.1007/s10495-011-0684-z; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; ARDELT W, 1991, J BIOL CHEM, V266, P245; Arnold K, 2006, BIOINFORMATICS, V22, P195, DOI 10.1093/bioinformatics/bti770; IRIE M, 1967, J BIOCHEM-TOKYO, V62, P509; KAMIYA Y, 1990, J BIOCHEM-TOKYO, V108, P139; Kim SP, 2011, FOOD FUNCT, V2, P348, DOI 10.1039/c1fo10030k; Kobayashi H, 2014, BIOL PHARM BULL, V37, P968, DOI 10.1248/bpb.b13-00929; Kobayashi H, 2013, BIOSCI BIOTECH BIOCH, V77, P1486, DOI 10.1271/bbb.130133; NOMURA H, 1994, J BIOCHEM-TOKYO, V116, P26; OHGI K, 1993, J BIOCHEM-TOKYO, V113, P219; SACCO G, 1983, J BIOL CHEM, V258, P5811; TAKAHASH.K, 1965, J BIOL CHEM, V240, P4117; TITANI K, 1987, BIOCHEMISTRY-US, V26, P2189, DOI 10.1021/bi00382a018	17	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	NOV	2014	37	11					1843	1847				5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AS0JW	WOS:000343964500021		
J	Endo, S; Arai, Y; Matsunaga, T; Ikari, A; El-Kabbani, O; Hara, A; Kitade, Y				Endo, Satoshi; Arai, Yuki; Matsunaga, Toshiyuki; Ikari, Akira; El-Kabbani, Ossama; Hara, Akira; Kitade, Yukio			Probing AKR1C30 and AKR1C31 with Site-Directed Mutagenesis: Identifying the Roles of Residues 54 and 56 in the Binding of Substrates and Inhibitors	BIOLOGICAL & PHARMACEUTICAL BULLETIN			English	Article						aldo-keto reductase; carbenoxolone; drug ketone reductase; hydroxysteroid dehydrogenase; site-directed mutagenesis	ALDO-KETO REDUCTASES; HUMAN 20-ALPHA-HYDROXYSTEROID DEHYDROGENASE; XENOBIOTIC CARBONYL-COMPOUNDS; ALTERNATIVE BINDING; SPECIFICITY; IDENTIFICATION; SUPERFAMILY; FAMILY; SENSITIVITY; TISSUES	Five rabbit aldo-keto reductases (AKRs) that participate in the reduction of drug ketones and endogenous ketosteroids have recently been cloned and characterized. Among them, AKR1C30 and AKR1C31 show the highest amino acid sequence identity of 91%, but markedly differ in their substrate specificity and inhibitor sensitivity. AKR1C30 reduces two drugs (ketotifen and naloxone) and 17-keto-5 beta-androstanes, whereas AKR1C31 does not reduce the two drugs, but is active towards loxoprofen and various 3/17/20-ketosteroids. In addition, AKR1C30 is selectively inhibited by carbenoxolone, valproic acid and phenobarbital. Residues A54 and R56 are located adjacent to the catalytic residue Y55 of AKR1C30. To clarify the determinants for the substrate specificity and inhibitor sensitivity of AKR1C30, we performed the mutagenesis of A54 and R56 to the corresponding residues (L and Q) of AKR1C31. The A54L mutation produced an enzyme that had almost the same substrate specificity as AKR1C31 and decreased the sensitivity to the inhibitors except for carbenoxolone. The R56Q mutation decreased the affinity for only carbenoxolone among the substrates and inhibitors. Thus, the difference in the properties between the two enzymes can be attributed to their residue difference at positions 54 and 56.	[Endo, Satoshi; Arai, Yuki; Matsunaga, Toshiyuki; Ikari, Akira] Gifu Pharmaceut Univ, Biochem Lab, Gifu 5011196, Japan; [El-Kabbani, Ossama] Monash Univ, Dept Med Chem, Victorian Coll Pharm, Parkville, Vic 3052, Australia; [Hara, Akira; Kitade, Yukio] Gifu Univ, Fac Engn, Dept Biomol Sci, Gifu 5011193, Japan	Endo, S (reprint author), Gifu Pharmaceut Univ, Biochem Lab, Gifu 5011196, Japan.	sendo@gifu-pu.ac.jp	Endo, Satoshi/F-8059-2011	Endo, Satoshi/0000-0003-0578-9672			Ishikura S, 2006, J BIOCHEM, V139, P1053, DOI 10.1093/jb/mvj109; Qiu W, 2004, MOL ENDOCRINOL, V18, P1798, DOI 10.1210/me.2004-0032; Jin Y, 2007, ANNU REV PHARMACOL, V47, P263, DOI 10.1146/annurev.pharmtox.47.120505.105337; Endo S, 2013, BIOCHEM PHARMACOL, V86, P1366, DOI 10.1016/j.bcp.2013.08.024; Matsunaga T, 2006, DRUG METAB PHARMACOK, V21, P1, DOI 10.2133/dmpk.21.1; Faucher F, 2007, J MOL BIOL, V369, P525, DOI 10.1016/j.jmb.2007.03.058; Penning TM, 1999, J STEROID BIOCHEM, V69, P211, DOI 10.1016/S0960-0760(99)00038-2; Ishikura S, 2004, BIOL PHARM BULL, V27, P1939, DOI 10.1248/bpb.27.1939; Endo S, 2013, BIOL PHARM BULL, V36, P1514; Hoffmann F, 2007, DRUG METAB REV, V39, P87, DOI 10.1080/03602530600969440; Barski OA, 2008, DRUG METAB REV, V40, P553, DOI 10.1080/03602530802431439 ; Couture JF, 2003, J MOL BIOL, V331, P593, DOI 10.1016/S0022-2836(03)00762-9; Couture JF, 2004, J MOL BIOL, V339, P89, DOI 10.1016/j.jmb.2004.03.035; Matsuura K, 1997, BIOCHEM J, V323, P61; Arampatzis S, 2005, J MOL ENDOCRINOL, V35, P89, DOI 10.1677/jme.1.01736; Dhagat U, 2009, ACTA CRYSTALLOGR D, V65, P257, DOI 10.1107/S0907444908044028; Dhagat U, 2010, BIOORG MED CHEM LETT, V20, P5274, DOI 10.1016/j.bmcl.2010.06.137; El-Kabbani O, 2009, J MED CHEM, V52, P3259, DOI 10.1021/jm9001633; Endo S, 2007, ARCH BIOCHEM BIOPHYS, V465, P136, DOI 10.1016/j.abb.2007.05.008; Endo S, 2013, ARCH BIOCHEM BIOPHYS, V529, P131, DOI 10.1016/j.abb.2012.11.013; Endo S, 2007, ENZYMOLOGY MOL BIOL, V13, P273; Endo S, 2014, DRUG METAB DISPOS, V42, P803, DOI 10.1124/dmd.113.056044; Ishikura S, 2005, ENZYMOLOGY MOL BIOL, P341; Matsumoto K, 2006, BIOL PHARM BULL, V29, P539, DOI 10.1248/bpb.29.539; Zhang B, 2014, J STEROID BIOCHEM, V141, P135, DOI 10.1016/j.jsbmb.2014.01.003	25	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0918-6158			BIOL PHARM BULL	Biol. Pharm. Bull.	NOV	2014	37	11					1848	1852				5	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AS0JW	WOS:000343964500022		
J	Singla, A; Iwasa, H; Inubushi, K				Singla, Ankit; Iwasa, Hirokuni; Inubushi, Kazuyuki			Effect of biogas digested slurry based-biochar and digested liquid on N2O, CO2 flux and crop yield for three continuous cropping cycles of komatsuna (Brassica rapa var. perviridis)	BIOLOGY AND FERTILITY OF SOILS			English	Article						Agriculture; Biochar; CO2 flux; Crop yield; Digested liquid; N2O flux	GREENHOUSE-GAS EMISSIONS; NITROUS-OXIDE EMISSION; FAST-PYROLYSIS BIOCHAR; MICROBIAL BIOMASS; CARBON-DIOXIDE; SOIL; CHARCOAL; DYNAMICS; NITRIFICATION; FERTILIZER	Biogas production generates digested slurry, as a byproduct, which can be used as fertilizer after its conversion into digested liquid and biochar. A microcosm-based study was conducted to evaluate the effects of chemical fertilizer (CF), digested liquid (DL) and varying concentrations of biogas digested slurry based-biochar along with DL on N2O flux, CO2 flux, soil chemical properties and crop yield for three continuous cropping cycles of komatsuna (Brassica rapa var. perviridis) from April to July 2013. Analyses revealed that DL-treated soils released almost equal cumulative amounts of N2O and CO2 as soils treated with CF. The soil mineral-N contents were also similar for the DL- and CF-treated soils while DL application increased the soluble organic carbon (SOC) content of the soil compared to CF treatment. The application of slurry-based biochar increased N2O and CO2 flux, which, in turn, appeared to depend upon biochar concentration. The application of biochar probably increased the nitrification rate as biochar-treated soils had higher values of NO3 (-)-N and lower values of NH4 (+)-N compared to soils not treated with biochar at most of the observations. The SOC content was also the highest in biochar-treated soils. The overall crop yield for three cropping cycles was the highest in DL and biochar at low application rate (BL), and it was lower in CF, biochar at medium (BM) and high (BH) application rate. This study indicates that the application of DL could be an effective strategy to minimize the use of CF, without affecting N2O flux, CO2 flux, soil mineral N, and increasing crop productivity. The effects of slurry-based biochar on greenhouse gases flux and crop yield depends on the application rate of biochar.	[Singla, Ankit; Iwasa, Hirokuni; Inubushi, Kazuyuki] Chiba Univ, Grad Sch Hort, Matsudo, Chiba 2718510, Japan; [Iwasa, Hirokuni] Chiba Prefectural Agr & Forestry Res Ctr, Chiba 2660006, Japan; [Singla, Ankit] Arni Univ, Sch Basic Sci, Dept Microbiol, Kathgarh 176401, Himachal Pardes, India	Inubushi, K (reprint author), Chiba Univ, Grad Sch Hort, Matsudo, Chiba 2718510, Japan.	ankitsingla2607@yahoo.co.in; inubushi@faculty.chiba-u.jp			ICAR (Indian Council of Agricultural Research), India	The first author is thankful to ICAR (Indian Council of Agricultural Research), India to provide financial support under International Fellowship Scheme to carry out this study. We are also thankful to Dr. Masato Nakamura, National Agriculture and Food Research Organization, Japan to provide the biogas byproducts.	Alburquerque JA, 2011, AGR ECOSYST ENVIRON, V160, P15; Amkha S, 2009, SOIL SCI PLANT NUTR, V55, P772, DOI 10.1111/j.1747-0765.2009.00418.x; Anderson JM, 1989, HDB METHODS TROPICAL, P42; Velthof GL, 2002, NUTR CYCL AGROECOSYS, V62, P249, DOI 10.1023/A:1021259107244; Kammann C, 2012, J ENVIRON QUAL, V41, P1052, DOI 10.2134/jeq2011.0132; Steiner C, 2008, J PLANT NUTR SOIL SC, V171, P893, DOI 10.1002/jpln.200625199; Rajkovich S, 2012, BIOL FERT SOILS, V48, P271, DOI 10.1007/s00374-011-0624-7; Saarnio S, 2013, SOIL BIOL BIOCHEM, V58, P99, DOI 10.1016/j.soilbio.2012.10.035; Asai H, 2009, FIELD CROP RES, V111, P81, DOI 10.1016/j.fcr.2008.10.008; Bruun EW, 2012, SOIL BIOL BIOCHEM, V46, P73, DOI 10.1016/j.soilbio.2011.11.019; Jones DL, 2012, SOIL BIOL BIOCHEM, V45, P113, DOI 10.1016/j.soilbio.2011.10.012; Xie ZB, 2013, PLANT SOIL, V370, P527, DOI 10.1007/s11104-013-1636-x; Singla A, 2014, PADDY WATER ENVIRON, V12, P239, DOI 10.1007/s10333-013-0357-3; Lehmann J, 2007, NATURE, V447, P143, DOI 10.1038/447143a; Bruun EW, 2011, EUR J SOIL SCI, V62, P581, DOI 10.1111/j.1365-2389.2011.01377.x; Lehmann J, 2011, SOIL BIOL BIOCHEM, V43, P1812, DOI 10.1016/j.soilbio.2011.04.022; Jones DL, 2011, SOIL BIOL BIOCHEM, V43, P1723, DOI 10.1016/j.soilbio.2011.04.018; Kuzyakov Y, 2010, SOIL BIOL BIOCHEM, V42, P1363, DOI 10.1016/j.soilbio.2010.04.003; Win KT, 2009, SOIL SCI PLANT NUTR, V55, P190, DOI 10.1111/j.1747-0765.2008.00337.x; Hayakawa A, 2009, SOIL BIOL BIOCHEM, V41, P521, DOI 10.1016/j.soilbio.2008.12.011; Zimmerman AR, 2011, SOIL BIOL BIOCHEM, V43, P1169, DOI 10.1016/j.soilbio.2011.02.005; Singh BP, 2010, J ENVIRON QUAL, V39, P1224, DOI 10.2134/jeq2009.0138; Wardle DA, 2008, SCIENCE, V320, P629, DOI 10.1126/science.1154960; Wang JY, 2012, PLANT SOIL, V360, P287, DOI 10.1007/s11104-012-1250-3; Yanai Y, 2007, SOIL SCI PLANT NUTR, V53, P181, DOI 10.1111/j.1747-0765.2007.00123.x; Ebid A, 2008, PLANT SOIL, V304, P241, DOI 10.1007/s11104-008-9543-2; Bruun S, 2008, ORG GEOCHEM, V39, P839, DOI 10.1016/j.orggeochem.2008.04.020; Antil RS, 2009, NUTR CYCL AGROECOSYS, V85, P95, DOI 10.1007/s10705-009-9251-1; Alotaibi KD, 2013, BIOL FERT SOILS, V49, P129, DOI 10.1007/s00374-012-0704-3; Kolb SE, 2009, SOIL SCI SOC AM J, V73, P1173, DOI 10.2136/sssaj2008.0232; Bailey V.L., 2010, SOIL BIOL BIOCHEM, V43, P296, DOI [10.1016/j.soilbio.2010.10.014, DOI 10.1016/J.SOILBIO.2010.10.014]; CABRERA ML, 1994, PLANT SOIL, V163, P189, DOI 10.1007/BF00007967; Cannavo P, 2004, SOIL BIOL BIOCHEM, V36, P463, DOI 10.1016/j.soilbio.2003.10.023; Carole RS, 1971, MICROCHEM J, V16, P657; Inubushi K, 1996, BIOL FERT SOILS, V23, P292; IPCC, 2013, CLIM CHANG 2013 PHYS; Muller C, 2004, SOIL BIOL BIOCHEM, V36, P453, DOI 10.1016/j.soilbio.2003.08.027; Shanthi Prabhav, 2013, Annals of Environmental Science, V7, P17; Singla A, 2012, J BIOFUELS, V3, P39; Singla A, 2014, J INTEGR AGR, V13, P635, DOI 10.1016/S2095-3119(13)60721-2; Singla A, 2013, BIOL FERT SOILS, V49, P971, DOI 10.1007/s00374-013-0796-4; Singla A, 2013, INT J AGR ENV BIOTEC, V6, P233; Song YJ, 2014, BIOL FERT SOILS, V50, P321, DOI 10.1007/s00374-013-0857-8; VANCE ED, 1987, SOIL BIOL BIOCHEM, V19, P703, DOI 10.1016/0038-0717(87)90052-6; Zwieten LV, 2010, PLANT SOIL, V327, P235, DOI DOI 10.1007/S11104-009-0050-X	45	4	4	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0178-2762	1432-0789		BIOL FERT SOILS	Biol. Fertil. Soils	NOV	2014	50	8					1201	1209		10.1007/s00374-014-0950-7		9	Soil Science	Agriculture	AS3HN	WOS:000344168400004		
J	Lagos, LM; Navarrete, OU; Maruyama, F; Crowley, DE; Cid, FP; Mora, ML; Jorquera, MA				Lagos, Lorena M.; Navarrete, Oscar U.; Maruyama, Fumito; Crowley, David E.; Cid, Fernanda P.; Mora, Maria L.; Jorquera, Milko A.			Bacterial community structures in rhizosphere microsites of ryegrass (Lolium perenne var. Nui) as revealed by pyrosequencing	BIOLOGY AND FERTILITY OF SOILS			English	Article						Andisol; Bacterial community; Pyrosequencing; Rhizosphere microsites; Ryegrass	RIBOSOMAL-RNA GENES; MICROBIAL COMMUNITIES; SOIL TYPE; ROOT; GROWTH; PLANTS	Management of soils to facilitate plant beneficial microbial interactions requires basic knowledge of the species composition and microbial community structures in the plant rhizosphere. Here, we examined composition of bacterial communities associated with rhizosphere microsites located at the root tips and mature root zones of Lolium perenne when grown in Chilean ash-derived volcanic soils (Andisols: Freire and Piedras Negras soil series). Community structures were analyzed by pyrosequencing of 16S ribosomal RNA (rRNA) genes followed by in silico analysis for phylogenetic assignments (MOTHUR and Visualization tool for Taxonomic Compositions of Microbial Community (VITCOMIC)). Analysis of the community structure revealed significant differences in community structures in relation to the soil series, which differed particularly in the relative abundance of Cyanobacteria and Firmicutes. However, no significant differences were observed with respect to root microsite location in the same Andisol series. Predominant taxa included members of the Proteobacteria, Actinobacteria, and Acidobacteria. Analysis by VITCOMIC showed that dominant bacterial groups comprised only 5 to 10 % of the total bacterial community and the remaining majority of bacteria included low-abundant taxa (Fusobacteria, Thermotogae, Lentisphaerae, Tenericutes, Deferribacteres Spirochaetes, Planctomycetes, Thermotogae, and Deinococcus-Thermus), most of which have not been previously reported or associated with the plant rhizosphere according to GenBank database. The results indicate that most of bacteria in the Chilean Andisols have not been described to the rhizosphere plants and their functional traits are still largely unknown.	[Lagos, Lorena M.; Cid, Fernanda P.] Univ La Frontera, Programa Doctorado Ciencias Recursos Nat, Temuco 01145, Chile; [Navarrete, Oscar U.] Univ La Frontera, Programa Magister Ciencias Ingn Menc Biotecnol, Temuco 01145, Chile; [Maruyama, Fumito] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Bunkyo Ku, Tokyo 1138510, Japan; [Crowley, David E.] Univ Calif Riverside, Dept Environm Sci, Riverside, CA 92521 USA; [Mora, Maria L.; Jorquera, Milko A.] Univ La Frontera, Temuco 01145, Chile	Jorquera, MA (reprint author), Univ La Frontera, Ave Francisco Salazar, Temuco 01145, Chile.	milko.jorquera@ufrontera.cl			FONDECYT [1120505, 1141247]; supercomputing infrastructure of the NLHPC at Centro de Modelacion y Computacion Cientifica at Universidad de La Frontera (CMCC-UFRO) [ECM-02]; CONICYT [21120698]	This study was supported by FONDECYT Project no. 1120505 and 1141247. This research was partially supported by the supercomputing infrastructure of the NLHPC (ECM-02) (Responsible Dr. Andres Avila) at Centro de Modelacion y Computacion Cientifica at Universidad de La Frontera (CMCC-UFRO). L. Lagos thanks the CONICYT PhD Scholarships no. 21120698.	Marschner P, 2011, SOIL BIOL BIOCHEM, V43, P883, DOI 10.1016/j.soilbio.2011.01.005; Bertin C, 2003, PLANT SOIL, V256, P67, DOI 10.1023/A:1026290508166; Bastida F, 2009, EUR J SOIL SCI, V60, P845, DOI 10.1111/j.1365-2389.2009.01184.x; de Campos SB, 2013, MICROB ECOL, V65, P593, DOI 10.1007/s00248-012-0132-9; Dini-Andreote F, 2013, PLANT SOIL, V373, P1, DOI 10.1007/s11104-013-1687-z; Barret M, 2011, BIOL FERT SOILS, V47, P729, DOI 10.1007/s00374-011-0605-x; Hannula SE, 2014, BIOL FERT SOILS, V50, P433, DOI 10.1007/s00374-014-0895-x; Marschner P, 2004, PLANT SOIL, V261, P199, DOI 10.1023/B:PLSO.0000035569.80747.c5; Watt M, 2006, ANN BOT-LONDON, V97, P839, DOI 10.1093/aob/mc1028; Hayat R, 2010, ANN MICROBIOL, V60, P579, DOI 10.1007/s13213-010-0117-1; Yang CH, 2000, APPL ENVIRON MICROB, V66, P345; Chaer G, 2009, MICROB ECOL, V58, P414, DOI 10.1007/s00248-009-9508-x; Pruesse E, 2012, BIOINFORMATICS, V28, P1823, DOI 10.1093/bioinformatics/bts252; Jorquera MA, 2008, BIOL FERT SOILS, V44, P1025, DOI 10.1007/s00374-008-0288-0; Edgar RC, 2011, BIOINFORMATICS, V27, P2194, DOI 10.1093/bioinformatics/btr381; Hinsinger P, 2005, NEW PHYTOL, V168, P293, DOI 10.1111/j.1469-8137.2005.01512.x; Marschner P, 2001, SOIL BIOL BIOCHEM, V33, P1437, DOI 10.1016/S0038-0717(01)00052-9; Chaparro JM, 2012, BIOL FERT SOILS, V48, P489, DOI 10.1007/s00374-012-0691-4; DeAngelis KM, 2009, ISME J, V3, P168, DOI 10.1038/ismej.2008.103; Suzuki C, 2009, SOIL SCI PLANT NUTR, V55, P80, DOI 10.1111/j.1747-0765.2008.00344.x; Schloss PD, 2009, APPL ENVIRON MICROB, V75, P7537, DOI 10.1128/AEM.01541-09; Janssen PH, 2006, APPL ENVIRON MICROB, V72, P1719, DOI 10.1128/AEM.72.3.1719-1728.2006; Lombard N, 2011, FEMS MICROBIOL ECOL, V78, P31, DOI 10.1111/j.1574-6941.2011.01140.x; Nannipieri P., 2008, V15, P215; GOOD IJ, 1953, BIOMETRIKA, V40, P237, DOI 10.2307/2333344; Jaeger CH, 1999, APPL ENVIRON MICROB, V65, P2685; Arjun JK, 2011, BIOTECHNOL BIOINF BI, V1, P361; Bertsch PM, 1996, METHODS SOIL ANAL 3, P526; Garveba P, 2004, ANNU REV PHYTOPATHOL, V42, P243; He JZ, 2005, SOIL BIOL BIOCHEM, V37, P2337, DOI 10.1016/j.soilbio.2005.04.016; Jorquera MA, 2011, FEMS MICROBIOL ECOL, V75, P163, DOI 10.1111/j.1574-6941.2010.00995.x; Jorquera MA, 2010, EUR J SOIL BIOL, V46, P255, DOI 10.1016/j.ejsobi.2010.03.005; Lin YT, 2011, MICROB ECOL, V61, P429, DOI 10.1007/s00248-010-9748-9; Marschner P, 2001, MYCORRHIZA, V11, P297, DOI 10.1007/s00572-001-0136-7; Martinez OA, 2011, BIOL FERT SOILS, V47, P875, DOI 10.1007/s00374-011-0593-x; Mora ML, 1999, COMMUN SOIL SCI PLAN, V30, P427, DOI 10.1080/00103629909370214; Mori H, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-332; Murphy J., 1962, ANAL CHIM ACTA, V27, P31, DOI DOI 10.1016/S0003-2670(00)88444-5; Nannipieri P., 2008, V15, P339; Wang ZY, 2004, J ENVIRON QUAL, V33, P1387; Warncke D., 1998, N CENTRAL REG RES PU, V221, P31; Yang C, 2012, PLANT SOIL, V367, P493	42	5	5	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0178-2762	1432-0789		BIOL FERT SOILS	Biol. Fertil. Soils	NOV	2014	50	8					1253	1266		10.1007/s00374-014-0939-2		14	Soil Science	Agriculture	AS3HN	WOS:000344168400009		
J	Gosho, M; Maruo, K; Sato, Y				Gosho, Masahiko; Maruo, Kazushi; Sato, Yasunori			Effect of covariate omission in Weibull accelerated failure time model: A caution	BIOMETRICAL JOURNAL			English	Article						Asymptotic bias; Asymptotic variance; Type I error; Weibull distribution		The accelerated failure time model is presented as an alternative to the proportional hazard model in the analysis of survival data. We investigate the effect of covariates omission in the case of applying a Weibull accelerated failure time model. In an uncensored setting, the asymptotic bias of the treatment effect is theoretically zero when important covariates are omitted; however, the asymptotic variance estimator of the treatment effect could be biased and then the size of the Wald test for the treatment effect is likely to exceed the nominal level. In some cases, the test size could be more than twice the nominal level. In a simulation study, in both censored and uncensored settings, Type I error for the test of the treatment effect was likely inflated when the prognostic covariates are omitted. This work remarks the careless use of the accelerated failure time model. We recommend the use of the robust sandwich variance estimator in order to avoid the inflation of the Type I error in the accelerated failure time model, although the robust variance is not commonly used in the survival data analyses.	[Gosho, Masahiko] Aichi Med Univ, Unit Biostat, Adv Med Res Ctr, Nagakute, Aichi 4801195, Japan; [Maruo, Kazushi] Kowa Co Ltd, Clin Data Sci Dept, Chuo Ku, Tokyo 1038433, Japan; [Sato, Yasunori] Chiba Univ Hosp, Clin Res Ctr, Chuo Ku, Chiba 2608677, Japan	Gosho, M (reprint author), Aichi Med Univ, Unit Biostat, Adv Med Res Ctr, 1-1 Yazakokarimata, Nagakute, Aichi 4801195, Japan.	mgosho@aichi-med-u.ac.jp	Maruo, Kazushi/I-2538-2014	Maruo, Kazushi/0000-0002-3093-0386			WHITE H, 1980, ECONOMETRICA, V48, P817, DOI 10.2307/1912934; GAIL MH, 1984, BIOMETRIKA, V71, P431; Cox DR, 1961, P 4 BERK S MATH STAT, V1, P105; FORD I, 1995, STAT MED, V14, P735, DOI 10.1002/sim.4780140804; Hosmer D.W., 2008, APPL SURVIVAL ANAL; R Development Core Team, 2008, R LANG ENV STAT COMP; SAS Institute Inc, 2008, SAS STAT US GUID; Therneau T., 2013, PACKAGE SURVIVAL	8	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0323-3847	1521-4036		BIOMETRICAL J	Biom. J.	NOV	2014	56	6					991	1000		10.1002/bimj.201300006		10	Mathematical & Computational Biology; Statistics & Probability	Mathematical & Computational Biology; Mathematics	AS3LE	WOS:000344178400007		
J	Sasaki, D; Sasaki, K; Tsuge, Y; Morita, M; Kondo, A				Sasaki, Daisuke; Sasaki, Kengo; Tsuge, Yota; Morita, Masahiko; Kondo, Akihiko			Comparison of metabolomic profiles of microbial communities between stable and deteriorated methanogenic processes	BIORESOURCE TECHNOLOGY			English	Article						Metabolomic analysis; Intracellular metabolites; Central metabolism; Microbial community; Methanogenic process	CHROMATOGRAPHY-MASS SPECTROMETRY; ANAEROBIC-DIGESTION PROCESS; TRICARBOXYLIC-ACID CYCLE; CLOSTRIDIUM-ACETOBUTYLICUM; BIOGAS PRODUCTION; WASTE-WATER; SOLID-WASTE; PATHWAY; METABOLITES; MICROORGANISMS	Central metabolite profiles from glucose in microbial communities during methanogenic process were compared between a stable methanogenic reactor (MR) and a deteriorated reactor (DR). The concentrations of intracellular metabolites related to the Embden-Meyerhof and pentose phosphate pathways, with the exception of pyruvate, remained high in the MR, showing increased carbon flux in the glycolysis pathway during stable methanogenesis. Extracellular acetate temporarily accumulated in the MR, consistent with higher ATP level in the MR. Intracellular concentrations of the intermediates in the reductive branch of tricarboxylic acid cycle, malate, fumarate, and succinate were higher in the DR. Low NADH/NAD(+) ratio both in the MR and DR would suggest NADH consumption during acetate and lactate/succinate production in the MR and DR, respectively. Intracellular glutamate levels were higher in the MR, correlating with lower NADPH/NADP(+) ratio concentrations in the MR. These findings contribute to a better understanding of the metabolic state during stable methanogenesis. (C) 2014 Elsevier Ltd. All rights reserved.	[Sasaki, Daisuke; Kondo, Akihiko] Kobe Univ, Grad Sch Engn, Nada Ku, Kobe, Hyogo 6578501, Japan; [Sasaki, Kengo; Tsuge, Yota] Kobe Univ, Org Adv Sci & Technol, Nada Ku, Kobe, Hyogo 6578501, Japan; [Morita, Masahiko] Cent Res Inst Elect Power Ind, Environm Sci Res Lab, Bioengn Sect, Abiko, Chiba 2701194, Japan; [Kondo, Akihiko] RIKEN, Biomass Engn Program, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan	Kondo, A (reprint author), Kobe Univ, Grad Sch Engn, Nada Ku, 1-1 Rokkodai Cho, Kobe, Hyogo 6578501, Japan.	akondo@kobe-u.ac.jp	Kondo, Akihiko/A-2130-2015; SASAKI, Daisuke/F-9597-2015		New Energy and Industrial Technology Development Organization (NEDO), Japan	We are grateful to Yasuko Koura and Ayami Fujino for their analytical support with the experiments. This work was supported by the New Energy and Industrial Technology Development Organization (NEDO), Japan.	Zhang WW, 2010, MICROBIOL-SGM, V156, P287, DOI 10.1099/mic.0.034793-0; Hassan AN, 2012, J DAIRY SCI, V95, P6188, DOI 10.3168/jds.2012-5732; Bajad SU, 2006, J CHROMATOGR A, V1125, P76, DOI 10.1016/j.chroma.2006.05.019; Stams AJM, 2009, NAT REV MICROBIOL, V7, P568, DOI 10.1038/nrmicro2166; Lisec J, 2006, NAT PROTOC, V1, P387, DOI 10.1038/nprot.2006.59; Bennett BD, 2009, NAT CHEM BIOL, V5, P593, DOI 10.1038/nchembio.186; Tang YQ, 2004, WATER RES, V38, P2537, DOI 10.1016/j.watres.2004.03.012; Feng XY, 2009, APPL ENVIRON MICROB, V75, P5001, DOI 10.1128/AEM.00715-09; Fiehn O, 2000, NAT BIOTECHNOL, V18, P1157, DOI 10.1038/81137; Ariesyady HD, 2007, WATER RES, V41, P1554, DOI 10.1016/j.watres.2006.12.036; Putri SP, 2013, J BIOSCI BIOENG, V115, P579, DOI 10.1016/j.jbiosc.2012.12.007; Amador-Noguez D, 2010, J BACTERIOL, V192, P4452, DOI 10.1128/JB.00490-10; Rodriguez J, 2006, BIOTECHNOL BIOENG, V93, P592, DOI 10.1002/bit.20765; Toya Y, 2013, BIOTECHNOL ADV, V31, P818, DOI 10.1016/j.biotechadv.2013.05.002; Bennett BD, 2008, NAT PROTOC, V3, P1299, DOI 10.1038/nprot.2008.107; Berg IA, 2011, APPL ENVIRON MICROB, V77, P1925, DOI 10.1128/AEM.02473-10; Jahreis K, 2008, FEMS MICROBIOL REV, V32, P891, DOI 10.1111/j.1574-6976.2008.00125.x; Hori T, 2006, APPL ENVIRON MICROB, V72, P1623, DOI 10.1128/AEM.72.2.1623-1630.2006; Angelidaki I, 2003, ADV BIOCHEM ENG BIOT, V82, P1; Angelidaki I, 2011, METHOD ENZYMOL, V494, P327, DOI 10.1016/B978-0-12-385112-3.00016-0; Luo B, 2007, J CHROMATOGR A, V1147, P153, DOI 10.1016/j.chroma.2007.02.034; Ragsdale SW, 2008, BBA-PROTEINS PROTEOM, V1784, P1873, DOI 10.1016/j.bbapap.2008.08.012; Kopke M, 2010, P NATL ACAD SCI USA, V107, P13087, DOI 10.1073/pnas.1004716107; Risberg K, 2013, BIORESOURCE TECHNOL, V149, P232, DOI 10.1016/j.biortech.2013.09.054; Kato H, 2012, J BIOSCI BIOENG, V113, P665, DOI 10.1016/j.jbiosc.2011.12.013; Amador-Noguez D, 2011, APPL ENVIRON MICROB, V77, P7984, DOI 10.1128/AEM.05374-11; Weiland P, 2010, APPL MICROBIOL BIOT, V85, P849, DOI 10.1007/s00253-009-2246-7; Angenent LT, 2004, TRENDS BIOTECHNOL, V22, P477, DOI 10.1016/j.tibtech.2004.07.001; Date Y, 2012, J PROTEOME RES, V11, P5602, DOI 10.1021/pr3008682; Freguia S., 2008, ENVIRON SCI TECHNOL, V42, P7939; MOUNTFORT DO, 1978, APPL ENVIRON MICROB, V35, P648; Hasunuma T, 2011, MICROB CELL FACT, V10, DOI 10.1186/1475-2859-10-2; Sasaki D, 2011, J BIOSCI BIOENG, V111, P41, DOI 10.1016/j.jbiosc.2010.08.011; Sasaki K, 2010, APPL MICROBIOL BIOT, V86, P1573, DOI 10.1007/s00253-010-2469-7; Trotter EW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025501; Yang DW, 2014, BIOTECHNOL LETT, V36, P1461, DOI 10.1007/s10529-014-1508-3; Yuan J, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.60	37	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0960-8524	1873-2976		BIORESOURCE TECHNOL	Bioresour. Technol.	NOV	2014	172						83	90		10.1016/j.biortech.2014.08.054		8	Agricultural Engineering; Biotechnology & Applied Microbiology; Energy & Fuels	Agriculture; Biotechnology & Applied Microbiology; Energy & Fuels	AS2MG	WOS:000344113800011		
J	Koyama, Y; Zhao, R; Ike, M; Tokuyasu, K				Koyama, Yoshiyuki; Zhao, Rui; Ike, Masakazu; Tokuyasu, Ken			Candida utilis assimilates oligomeric sugars in rice straw hydrolysate via the Calcium-Capturing-by-Carbonation (CaCCO) process for glutathione- and cell-biomass production	BIORESOURCE TECHNOLOGY			English	Article						Candida utilis; Rice straw; Cell biomass; Glutathione; Oligosaccharides	ENZYMATIC SACCHARIFICATION; TRICHODERMA-REESEI; PRETREATMENT; FERMENTATION; CULTIVATION; CELLULASES; RESISTANT; ETHANOL; YEAST	Rice-straw hydrolysate (RSH) prepared via the CaCCO (Calcium Capturing by Carbonation) process contains not only monosaccharides but also significant amounts of oligosaccharides. In this study, a glutathione-producing yeast, Candida utilis NBRC 0626, was found to assimilate those oligosaccharides. The yields of reduced glutathione (GSH) and dry cell weight (DCW) per consumed sugars in a medium with RSH after 72 h incubation were 10.1 mg/g-sugars and 0.49 g/g-sugars, respectively. The yields were comparative to those in a medium containing a model monosaccharide mix, suggesting that the assimilated oligosaccharides contribute to additional GSH and DCW production. Glycosyl linkage analysis indicated that the yeast could cleave xylose-, galactose-, and arabinose residues as well as glucose residues at the non-reducing ends. After 72 h incubation, 99.1% of the total glucose residues and 84.2% of the total xylose residues in RSH were depleted. Thus the yeast could be applied for efficient utilization of lignocellulosic hydrolysates. (C) 2014 Elsevier Ltd. All rights reserved.	[Koyama, Yoshiyuki; Zhao, Rui; Ike, Masakazu; Tokuyasu, Ken] Natl Agr & Food Res Org, Natl Food Res Inst, Tsukuba, Ibaraki 3058642, Japan	Tokuyasu, K (reprint author), Natl Agr & Food Res Org, Natl Food Res Inst, 2-1-12 Kannondai, Tsukuba, Ibaraki 3058642, Japan.	tokuyasu@affrc.go.jp			Ministry of Agriculture, Forestry and Fisheries of Japan (Rural Biofuel Research Project)	We are grateful to M. Tabuse, H. Nakayama, K. Yamanaka, X. F. Lv, Y. Miyamoto, X. J. Geng, and Y. Nishiguchi for excellent technical assistant. This work was supported by a grant from the Ministry of Agriculture, Forestry and Fisheries of Japan (Rural Biofuel Research Project).	Zhou CH, 2011, CHEM SOC REV, V40, P5588, DOI 10.1039/c1cs15124j; Klinke HB, 2004, APPL MICROBIOL BIOT, V66, P10, DOI 10.1007/s00253-004-1642-2; Bowman MJ, 2012, BIORESOURCE TECHNOL, V110, P437, DOI 10.1016/j.biortech.2012.01.062; Sies H, 1999, FREE RADICAL BIO MED, V27, P916, DOI 10.1016/S0891-5849(99)00177-X; Ximenes E, 2011, ENZYME MICROB TECH, V48, P54, DOI 10.1016/j.enzmictec.2010.09.006; Mussatto SI, 2010, BIOTECHNOL ADV, V28, P817, DOI 10.1016/j.biotechadv.2010.07.001; Park JY, 2010, BIORESOURCE TECHNOL, V101, P6805, DOI 10.1016/j.biortech.2010.03.098; Hahn-Hagerdal B, 2006, TRENDS BIOTECHNOL, V24, P549, DOI 10.1016/j.tibtech.2006.10.004; Ike M, 2013, BIOSCI BIOTECH BIOCH, V77, P161, DOI 10.1271/bbb.120696; Sassaki GL, 2005, CARBOHYD RES, V340, P731, DOI 10.1016/j.carres.2005.01.020; Li Y, 2004, APPL MICROBIOL BIOT, V66, P233, DOI 10.1007/s00253-004-1751-y; Nie W, 2005, LETT APPL MICROBIOL, V40, P378, DOI 10.1111/j.1472-765X.2005.01687.x; Saha BC, 2003, J IND MICROBIOL BIOT, V30, P279, DOI 10.1007/s10295-003-0049-x; Appeldoorn MM, 2010, J AGR FOOD CHEM, V58, P11294, DOI 10.1021/jf102849x; ARAUJO A, 1986, BIOTECHNOL BIOENG, V28, P1503, DOI 10.1002/bit.260281008; HOLDER NHM, 1989, BIOL WASTE, V28, P239, DOI 10.1016/0269-7483(89)90107-9; Ike M., 2013, Journal of Applied Glycoscience, V60, P177, DOI 10.5458/jag.jag.JAG-2013_002; Ike M, 2010, APPL MICROBIOL BIOT, V87, P2059, DOI 10.1007/s00253-010-2683-3; Ogawa K., 2007, AU Patent, Patent No. 2007330795; Villas-Boas SG, 2002, WORLD J MICROB BIOT, V18, P541, DOI 10.1023/A:1016350612380; Yanai T, 2001, BIOSCI BIOTECH BIOCH, V65, P527, DOI 10.1271/bbb.65.527	21	1	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0960-8524	1873-2976		BIORESOURCE TECHNOL	Bioresour. Technol.	NOV	2014	172						413	417		10.1016/j.biortech.2014.08.097		5	Agricultural Engineering; Biotechnology & Applied Microbiology; Energy & Fuels	Agriculture; Biotechnology & Applied Microbiology; Energy & Fuels	AS2MG	WOS:000344113800056		
J	Nakano, S; Chang, KH; Shijima, A; Miyamoto, H; Sato, Y; Noto, Y; Ha, JY; Sakamoto, M				Nakano, Sho; Chang, Kwang-Hyeon; Shijima, Atsushi; Miyamoto, Hiroyuki; Sato, Yukio; Noto, Yuji; Ha, Jin-Yong; Sakamoto, Masaki			A usage of CO2 hydrate: Convenient method to increase CO2 concentration in culturing algae	BIORESOURCE TECHNOLOGY			English	Article						CO2 hydrate; Algal culture; Pseudokirchneriella; Population growth	CARBON-DIOXIDE; MICROALGAE; CAPTURE	The addition of CO2 to algal culture systems can increase algal biomass effectively. Generally, gas bubbling is used to increase CO2 levels in culture systems; however, it is difficult to quantitatively operate to control the concentration using this method. In this study, we tested the usability of CO2 hydrate for phytoplankton culture. Specifically, green algae Pseudokirchneriella subcapitata were cultured in COMBO medium that contained dissolved CO2 hydrate, after which its effects were evaluated. The experiment was conducted according to a general bioassay procedure (OECD TG201). CO2 promoted algae growth effectively (about 2-fold relative to the control), and the decrease in pH due to dissolution of the CO2 in water recovered soon because of photosynthesis. Since the CO2 hydrate method can control a CO2 concentration easily and quantitatively, it is expected to be useful in future applications. (C) 2014 Elsevier Ltd. All rights reserved.	[Nakano, Sho; Chang, Kwang-Hyeon] Kyung Hee Univ, Dept Appl Environm Sci, Yongin 446701, Gyeonggi Do, South Korea; [Shijima, Atsushi] Toyama Prefectural Univ, Grad Sch Engn, Imizu, Toyama 9390398, Japan; [Miyamoto, Hiroyuki; Sato, Yukio; Noto, Yuji; Ha, Jin-Yong; Sakamoto, Masaki] Toyama Prefectural Univ, Fac Engn, Imizu, Toyama 9390398, Japan	Sakamoto, M (reprint author), Toyama Prefectural Univ, Fac Engn, 5180 Kurokawa, Imizu, Toyama 9390398, Japan.	masaki@pu-toyama.ac.jp			Department of Applied Environmental Science, Kyung Hee University; Japan Society for the Promotion of Science [23510031]; Toyama Prefectural University	We thank Mr. S. Yoneshima and Mrs. N. Watanabe for their assistance during the laboratory work and insightful suggestions. The first author also acknowledges the scholarship from the Department of Applied Environmental Science, Kyung Hee University. This study was partly supported by Grants-in-Aid to M. Sakamoto (No. 23510031) from Japan Society for the Promotion of Science, and a research fund (Collaborative Research Project for Environmentally Conscious Advanced Technology) from Toyama Prefectural University.	AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705; Linga P, 2007, J HAZARD MATER, V149, P625, DOI 10.1016/j.jhazmat.2007.06.086; Pires JCM, 2012, RENEW SUST ENERG REV, V16, P3043, DOI 10.1016/j.rser.2012.02.055; Verma NM, 2010, AFR J BIOTECHNOL, V9, P1402; Jeong ML, 2003, B KOR CHEM SOC, V24, P1763; Fukumori K, 2008, ESTUAR COAST SHELF S, V79, P45, DOI 10.1016/j.ecss.2008.03.004; Udachin KA, 2001, J PHYS CHEM B, V105, P4200, DOI 10.1021/jp004389o; Devgoswami CR, 2011, AFR J BIOTECHNOL, V10, P13128; Baba M., 2012, ADV PHOTOSYNTHESIS F, P300; Chiu SY, 2009, BIORESOURCE TECHNOL, V100, P833, DOI 10.1016/j.biortech.2008.06.061; Hanawa Y, 2007, PLANT CELL PHYSIOL, V48, P299, DOI 10.1093/pcp/pcl066; Jeffrey G.A., 1984, INCLUSION COMPOUNDS, P135; Kawasaki T, 2012, J JPN SOC FOOD SCI, V59, P611; Kilham S.S., 1998, HYDROBIOLOGIA, V377, P47; Low-Decarie E, 2013, P ROY SOC B-BIOL SCI, V280, DOI 10.1098/rspb.2012.2598; MAKOGON TY, 1994, J CHEM ENG DATA, V39, P351, DOI 10.1021/je00014a035; OECD, 2011, OECD GUID TEST CHEM; R Development Core Team, 2014, R LANG ENV STAT COMP; Sloan E.D., 2008, CLATHRATE HYDRATES N, P54	19	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0960-8524	1873-2976		BIORESOURCE TECHNOL	Bioresour. Technol.	NOV	2014	172						444	448		10.1016/j.biortech.2014.09.019		5	Agricultural Engineering; Biotechnology & Applied Microbiology; Energy & Fuels	Agriculture; Biotechnology & Applied Microbiology; Energy & Fuels	AS2MG	WOS:000344113800062		
J	Poudel-Tandukar, K; Berrone-Johnson, ER; Palmer, PH; Poudel, KC				Poudel-Tandukar, Kalpana; Berrone-Johnson, Elizabeth R.; Palmer, Paula H.; Poudel, Krishna C.			C-reactive protein and depression in persons with Human Immunodeficiency Virus infection: The Positive Living with HIV (POLH) Study	BRAIN BEHAVIOR AND IMMUNITY			English	Article						HIV; C-reactive protein; Depression; Nepal	PRO-INFLAMMATORY CYTOKINES; INDUCED SICKNESS BEHAVIOR; PUBLIC-HEALTH PRACTICE; MAJOR DEPRESSION; CARDIOVASCULAR-DISEASE; PSYCHOLOGICAL STRESS; COGNITIVE DECLINE; PHYSICAL-ACTIVITY; BODY-COMPOSITION; DOUBLE-BLIND	Background: Human Immunodeficiency Virus (HIV) infection has been frequently associated with chronic inflammation as well as depression. C-reactive protein (CRP) is positively associated with depression in people without HIV infection. We tested the hypothesis of an independent relationship between CRP and depression in a cohort of HIV-positive people. Methods: A cross-sectional survey was conducted among 316 HIV-positive people (181 men and 135 women) aged 18-60 years residing in the Kathmandu Valley, Nepal. The latex agglutination turbidimetric method was used to measure serum CRP concentrations and the Beck Depression Inventory (BDI)-I method was used to measure depression, with a cut off of 20 indicating likely depression. The relationship between CRP concentrations and depression symptoms was assessed using both multiple linear regression analysis and multiple logistic regression analysis, with adjustment for potential socio-demographic, cardiovascular, life-style, and HIV-related clinical and treatment confounding factors. Results: Twenty-six percent participants (men: 23%; women: 29%) met criteria for depression. In multiple regression analysis, the authors observed a linear relation between serum CRP concentrations and BDI score (beta for 1 unit change in In(CRP) = 1.13, p = 0.001) in HIV-positive participants. In a logistic regression analysis, participants with serum CRP levels >3 mg/L had a 2.3-fold higher odds of depression symptoms compared to those with serum CRP level <= 3 mg/L (p = 0.005). In analyses stratified by sex, associations were stronger in men than in women. For example, CRP > 3 mg/L was associated with a 3.6-fold higher odds of depression in men (p = 0.002), while in women the odds ratio was 1.7 (p = 0.33). Conclusion: We found a linear relationship between serum CRP concentrations and depression symptoms score in HIV-positive people, and evidence that risk of depression is elevated among HIV-positive men with a high level of inflammation (CRP >3 mg/L). Further prospective study to confirm the role of inflammation in depression among HIV-positive people is warranted. (C) 2014 Elsevier Inc. All rights reserved.	[Poudel-Tandukar, Kalpana] Natl Ctr Global Hlth & Med, AIDS Clin Ctr, Shinjuku Ku, Tokyo 1628655, Japan; [Berrone-Johnson, Elizabeth R.] Univ Massachusetts, Sch Publ Hlth & Hlth Sci, Div Biostat & Epidemiol, Amherst, MA 01003 USA; [Palmer, Paula H.] Claremont Grad Univ, Sch Community & Global Hlth, Claremont, CA 91711 USA; [Poudel, Krishna C.] Univ Massachusetts, Sch Publ Hlth & Hlth Sci, Dept Publ Hlth, Amherst, MA 01003 USA	Poudel, KC (reprint author), Univ Massachusetts, Sch Publ Hlth & Hlth Sci, Dept Publ Hlth, 316 Arnold House,715 North Pleasant St, Amherst, MA 01003 USA.	krishna@schoolph.umass.edu			Japan Society for the Promotion of Science [22790581]; Ministry of Education, Culture, Sports, Science and Technology, Japan; Grant for Research on Global Health and Medicine from the National Center for Global Health and Medicine, Japan [21A-2]	This study is supported by the Grant-in-Aid for Young Scientists (B) (22790581), Japan Society for the Promotion of Science, The Ministry of Education, Culture, Sports, Science and Technology, Japan and by the Grant for Research on Global Health and Medicine (No. 21A-2) from the National Center for Global Health and Medicine, Japan. The funding agency had no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.	American Psychiatric Association APA, 1994, DIAGN STAT MAN MENT; Amiya RM, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-677; Tiemeier H, 2003, EPIDEMIOLOGY, V14, P103, DOI 10.1097/00001648-200301000-00025; Wichers M, 2002, INT J NEUROPSYCHOPH, V5, P375, DOI 10.1017/S1461145702003103; Kiecolt-Glaser JK, 2003, P NATL ACAD SCI USA, V100, P9090, DOI 10.1073/pnas.1531903100; Lau B, 2006, ARCH INTERN MED, V166, P64, DOI 10.1001/archinte.166.1.64; Sherr L, 2011, PSYCHOL HEALTH MED, V16, P493, DOI 10.1080/13548506.2011.579990; Pearson TA, 2003, CIRCULATION, V107, P499, DOI 10.1161/01.CIR.0000052939.59093.45; Ciesla JA, 2001, AM J PSYCHIAT, V158, P725, DOI 10.1176/appi.ajp.158.5.725; Liukkonen T, 2006, BIOL PSYCHIAT, V60, P825, DOI 10.1016/j.biopsych.2006.02.016; Poudel KC, 2003, TROP MED INT HEALTH, V8, P933, DOI 10.1046/j.1365-3156.2003.01110.x; Abramson JL, 2002, ARCH INTERN MED, V162, P1286, DOI 10.1001/archinte.162.11.1286; Francisci D, 2009, AIDS, V23, P589, DOI 10.1097/QAD.0b013e328325a87c; Endeshaw M, 2014, AIDS CARE, V26, P935, DOI 10.1080/09540121.2013.869537; Gonzalez JS, 2011, JAIDS-J ACQ IMM DEF, V58, P181, DOI [10.1097/QAI.0b013e31822d490a, 10.1097/QAI.0B013E31822D490A]; Ford DE, 2004, ARCH INTERN MED, V164, P1010, DOI 10.1001/archinte.164.9.1010; Dantzer R, 2007, BRAIN BEHAV IMMUN, V21, P153, DOI 10.1016/j.bbi.2006.09.006; Raison CL, 2006, TRENDS IMMUNOL, V27, P24, DOI 10.1016/j.it.2005.11.006; Ranjit N, 2007, ARCH INTERN MED, V167, P174, DOI 10.1001/archinte.167.2.174; Poudel-Tandukar K, 2013, AIDS RES HUM RETROV, V29, P528, DOI [10.1089/AID.2012.0120, 10.1089/aid.2012.0120]; Ickovics JR, 2001, JAMA-J AM MED ASSOC, V285, P1466, DOI 10.1001/jama.285.11.1466; Howren MB, 2009, PSYCHOSOM MED, V71, P171, DOI 10.1097/PSY.0b013e3181907c1b; Stewart JC, 2009, BRAIN BEHAV IMMUN, V23, P936, DOI 10.1016/j.bbi.2009.04.011; Myers GL, 2004, CIRCULATION, V110, pE545, DOI 10.1161/01.CIR.0000148980.87579.5E; van den Biggelaar AHJ, 2007, EXP GERONTOL, V42, P693, DOI 10.1016/j.exger.2007.01.011; Muller N, 2006, MOL PSYCHIATR, V11, P680, DOI 10.1038/sj.mp.4001805; Wada N, 2013, AM J EPIDEMIOL, V177, P116, DOI 10.1093/aje/kws321; Miller AH, 2009, BIOL PSYCHIAT, V65, P732, DOI 10.1016/j.biopsych.2008.11.029; Steptoe A, 2007, BRAIN BEHAV IMMUN, V21, P901, DOI 10.1016/j.bbi.2007.03.011; Dantzer R, 2004, EUR J PHARMACOL, V500, P399, DOI 10.1016/j.ejphar.2004.07.040; Chi D, 2000, ENDOTHELIUM-NEW YORK, V7, P223; Penninx BWJH, 2003, BIOL PSYCHIAT, V54, P566, DOI 10.1016/S0006-3223(03)01811-5; Zietz C, 1996, AM J PATHOL, V149, P1887; Tyring S, 2006, LANCET, V367, P29, DOI 10.1016/S0140-6736(05)67763-X; Amiya RM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090959; Yaffe K, 2004, JAMA-J AM MED ASSOC, V292, P2237, DOI 10.1001/jama.292.18.2237; Dantzer R, 2008, NAT REV NEUROSCI, V9, P46, DOI 10.1038/nrn2297; Maes M, 1998, CYTOKINE, V10, P313, DOI 10.1006/cyto.1997.0290; Gimeno D, 2009, PSYCHOL MED, V39, P413, DOI 10.1017/S0033291708003723; Maes M, 1995, J AFFECT DISORDERS, V36, P29, DOI 10.1016/0165-0327(95)00049-6; Spath-Schwalbe E, 1998, J CLIN ENDOCR METAB, V83, P1573, DOI 10.1210/jc.83.5.1573; Matthews KA, 2010, BRAIN BEHAV IMMUN, V24, P96, DOI 10.1016/j.bbi.2009.08.005; Valkanova V, 2013, J AFFECT DISORDERS, V150, P736, DOI 10.1016/j.jad.2013.06.004; Doyle TA, 2013, J PSYCHOSOM RES, V75, P419, DOI 10.1016/j.jpsychores.2013.08.006; Geffken DF, 2001, AM J EPIDEMIOL, V153, P242, DOI 10.1093/aje/153.3.242; MAES M, 1991, NEUROPSYCHOBIOLOGY, V24, P115; Waraich P, 2004, CAN J PSYCHIAT, V49, P124; Bremmer MA, 2008, J AFFECT DISORDERS, V106, P249, DOI 10.1016/j.jad.2007.07.002; Morris AA, 2011, PSYCHOSOM MED, V73, P462, DOI 10.1097/PSY.0b013e318222379c; Khairova RA, 2009, INT J NEUROPSYCHOPH, V12, P561, DOI 10.1017/S1461145709009924; Kohrt BA, 2009, ANN HUM BIOL, V36, P261, DOI 10.1080/03014460902839194; Beck A. T., 1996, MANUAL BECK DEPRESSI; Charles B, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-463; Cyranowski JM, 2007, BRAIN BEHAV IMMUN, V21, P229, DOI 10.1016/j.bbi.2006.07.005; Dekker R.L., 2013, EURO J CARDIOVASC NU; Do AN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092842; Feldman JG, 2003, JAIDS-J ACQ IMM DEF, V32, P210; Jahoor F, 1999, AM J PHYSIOL-ENDOC M, V276, pE1092; Kinyanda E, 2011, BMC PSYCHIATRY, V11, DOI 10.1186/1471-244X-11-205; Kohrt B.A., 2002, NEPALESE J PSYCHIAT, V2, P123; MAES M, 1995, J AFFECT DISORDERS, V34, P301, DOI 10.1016/0165-0327(95)00028-L; MAES M, 1993, PSYCHIAT RES, V49, P11, DOI 10.1016/0165-1781(93)90027-E; NCASC, 2012, NEP COUNTR PROGR REP; NCASC, 2007, NAT EST HIV INF NEP; Poudel Krishna C, 2014, J Int Assoc Provid AIDS Care, V13, P277, DOI 10.1177/2325957413500989; Rabkin Judith G, 2008, Curr HIV/AIDS Rep, V5, P163, DOI 10.1007/s11904-008-0025-1; Ross R, 1999, NEW ENGL J MED, V340, P115; Salama C, 2013, AIDS CARE, V25, P160, DOI 10.1080/09540121.2012.687815; Arseniou S, 2014, PSYCHIAT CLIN NEUROS, V68, P96, DOI 10.1111/pcn.12097; Shrestha Sadhana, 2014, J Int Assoc Provid AIDS Care, V13, P214, DOI 10.1177/1545109712456741; SMITH RS, 1991, MED HYPOTHESES, V35, P298, DOI 10.1016/0306-9877(91)90272-Z; Vetter ML, 2013, INT J OBESITY, V37, pS38, DOI 10.1038/ijo.2013.95	72	5	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	NOV	2014	42						89	95		10.1016/j.bbi.2014.06.004		7	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	AS7IK	WOS:000344429900013		
J	Koyano, S; Yagishita, S; Kuroiwa, Y; Tanaka, F; Uchihara, T				Koyano, Shigeru; Yagishita, Saburo; Kuroiwa, Yoshiyuki; Tanaka, Fumiaki; Uchihara, Toshiki			Neuropathological Staging of Spinocerebellar Ataxia Type 2 by Semiquantitative 1C2-Positive Neuron Typing. Nuclear Translocation of Cytoplasmic 1C2 Underlies Disease Progression of Spinocerebellar Ataxia Type 2	BRAIN PATHOLOGY			English	Article						1C2-immunoreactive typing; cytoplasmic and nuclear; granular cytoplasmic; nuclear with inclusions; spinocerebellar ataxia type 2	INCLUSION-BODY FORMATION; INTRANUCLEAR INCLUSIONS; SCA2; INVOLVEMENT; PATHOGENESIS; EXPANSION; ATROPHY; MOUSE	Spinocerebellar ataxia type 2 (SCA2) is a hereditary neurodegenerative disorder caused by the expansion of the trinucleotide CAG repeats encoding elongated polyglutamine tract in ataxin-2, the SCA2 gene product. Polyglutamine diseases comprise nine genetic entities, including seven different forms of spinocerebellar ataxias, Huntington's disease, and spinal and bulbar muscular atrophy. These are pathologically characterized by neuronal loss and intranuclear aggregates or inclusions of mutant proteins including expanded polyglutamine in selected neuronal groups. Previously, we examined immunolocalization of ubiquitin, expanded polyglutamine (probed by 1C2 antibody), and ataxin-2 in genetically confirmed SCA2 patients. In the present study, we expanded this approach by distinguishing different patterns of subcellular 1C2 immunoreactivity (granular cytoplasmic, cytoplasmic and nuclear and nuclear with inclusions.) and by quantifying their regional frequencies in three autopsied SCA2 brains at different stage of the disease. Comparison with neuronal loss and gliosis revealed that overall 1C2 immunoreactivity was paralleled with their severity. Furthermore, appearance of granular cytoplasmic pattern corresponded to early stage, cytoplasmic and nuclear pattern to active stage, and nuclear with inclusions pattern to final stage. We conclude that this 1C2-immunoreactive typing may be useful for evaluating the overall severity and extent of affected regions and estimating the neuropathological stage of SCA2.	[Koyano, Shigeru; Tanaka, Fumiaki] Yokohama City Univ, Grad Sch Med, Dept Neurol & Stroke Med, Yokohama, Kanagawa 2360004, Japan; [Yagishita, Saburo] Kanagawa Rehabil Ctr, Dept Pathol, Atsugi, Kanagawa, Japan; [Kuroiwa, Yoshiyuki] Teikyo Univ, Sch Med, Univ Hosp Mizonokuchi, Dept Neurol, Kawasaki, Kanagawa, Japan; [Koyano, Shigeru; Uchihara, Toshiki] Tokyo Metropolitan Inst Med Sci, Lab Struct Neuropathol, Tokyo 113, Japan	Koyano, S (reprint author), Yokohama City Univ, Grad Sch Med, Dept Neurol & Stroke Med, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan.	koya77@med.yokohama-cu.ac.jp			Japan Society for Promotion of the Sciences [23591279]	This work was supported by a grant-in Aid for Scientific Research (C) (23591279) from the Japan Society for Promotion of the Sciences. We would like to thank Ms. K. Yamaoka, who provided technical support for pathological examinations.	Lastres-Becker I, 2008, CEREBELLUM, V7, P115, DOI 10.1007/s12311-008-0019-y; OROZCO G, 1989, J NEUROL SCI, V93, P37, DOI 10.1016/0022-510X(89)90159-7; Koyano S, 1999, NEUROSCI LETT, V273, P117, DOI 10.1016/S0304-3940(99)00656-4; Durr A, 1995, BRAIN, V118, P1573, DOI 10.1093/brain/118.6.1573; Fujigasaki H, 2000, EXP NEUROL, V165, P248, DOI 10.1006/exnr.2000.7479; Iwabuchi K, 1999, REV NEUROL, V155, P255; Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Rub U, 2003, BRAIN, V126, P2257, DOI 10.1093/brain/awg234; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; He XH, 2010, NEUROSCI BULL, V26, P247, DOI 10.1007/s12264-010-0113-2; Armstrong J, 2005, NEUROSCI LETT, V381, P247, DOI 10.1016/j.neulet.2005.02.063; Gierga K, 2005, ACTA NEUROPATHOL, V109, P617, DOI 10.1007/s00401-005-1014-8; Hansen ST, 2013, HUM MOL GENET, V22, P271, DOI 10.1093/hmg/dds427; Huynh DP, 2000, NAT GENET, V26, P44; Ishida C, 2011, NEUROPATHOLOGY, V31, P510, DOI 10.1111/j.1440-1789.2010.01176.x; Koyano S, 2002, J NEUROL NEUROSUR PS, V73, P450, DOI 10.1136/jnnp.73.4.450; Malandrini A, 1998, EUR NEUROL, V40, P164, DOI 10.1159/000007974; Pang JT, 2002, BRAIN, V125, P656, DOI 10.1093/brain/awf060; Pril Remko de, 2004, Human Molecular Genetics, V13, P1803; Tarlac V, 2007, INT J NEUROSCI, V117, P1289, DOI 10.1080/00207450600936668; Velazquez-Perez L, 2011, CEREBELLUM, V10, P184, DOI 10.1007/s12311-011-0265-2; Ying SH, 2005, ANN NY ACAD SCI, V1039, P430, DOI 10.1196/annals.1325.040	22	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1015-6305	1750-3639		BRAIN PATHOL	Brain Pathol.	NOV	2014	24	6					599	606		10.1111/bpa.12146		8	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	AS6AI	WOS:000344347000006		
J	Shimizu, C				Shimizu, Chikako			Breast cancer in young women: its biological and clinical uniqueness and needs of comprehensive care	BREAST CANCER			English	Editorial Material							FEATURES; METASTASIS; DIAGNOSIS; PROGNOSIS; TUMOR		Natl Canc Ctr, Breast & Med Oncol Div, Chuo Ku, Tokyo, Japan	Shimizu, C (reprint author), Natl Canc Ctr, Breast & Med Oncol Div, Chuo Ku, Tokyo, Japan.	cshimizu@ncc.go.jp					NIXON AJ, 1994, J CLIN ONCOL, V12, P888; Callihan EB, 2013, BREAST CANCER RES TR, V138, P549, DOI 10.1007/s10549-013-2437-x; Howard-Anderson J, 2012, JNCI-J NATL CANCER I, V104, P386, DOI 10.1093/jnci/djr541; Colleoni M, 2002, ANN ONCOL, V13, P273, DOI 10.1093/annonc/mdf039; Davies C, 2013, LANCET, V381, P805, DOI 10.1016/S0140-6736(12)61963-1; Azim HA, 2012, CLIN CANCER RES, V18, P1341, DOI 10.1158/1078-0432.CCR-11-2599; Schedin P, 2006, NAT REV CANCER, V6, P281, DOI 10.1038/nrc1839; Bando H, 2014, BREAST CANCER-TOKYO, V21, P656, DOI 10.1007/s12282-013-0477-z; Gadizicki D, 2011, J COMMUN GENET, V2, P53; Gray R, 2013, J CLIN ONCOL S, V31, P5; International Agency for Research on Cancer/World Health Organization, GLOBOCAN2012 EST CAN; Kataoka A, 2014, BREAST CANCER-TOKYO, V21, P643, DOI 10.1007/s12282-013-0466-2; Nagatsuma AK, 2013, BREAST CANCER RES TR, V138, P941, DOI 10.1007/s10549-013-2507-0; Shien T, 2014, BREAST CANCER-TOKYO, V21, P651, DOI 10.1007/s12282-013-0463-5; Takahashi M, 2014, BREAST CANCER-TOKYO, V21, P664, DOI 10.1007/s12282-013-0508-9; Veatch RM, 2013, BASICS BIOETHICS	16	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1340-6868	1880-4233		BREAST CANCER-TOKYO	Beast Cancer	NOV	2014	21	6					641	642		10.1007/s12282-014-0567-6		2	Oncology; Obstetrics & Gynecology	Oncology; Obstetrics & Gynecology	AS6AP	WOS:000344347700001		
J	Kataoka, A; Tokunaga, E; Masuda, N; Shien, T; Kawabata, K; Miyashita, M				Kataoka, Akemi; Tokunaga, Eriko; Masuda, Norikazu; Shien, Tadahiko; Kawabata, Kimiko; Miyashita, Mika			Clinicopathological features of young patients (< 35 years of age) with breast cancer in a Japanese Breast Cancer Society supported study	BREAST CANCER			English	Article						Breast cancer in young females; Surveillance data	THERAPY; WOMEN; CHEMOTHERAPY; DISEASE; PROGNOSIS; TRIAL	To clarify the clinicopathological features of breast cancer in young females, surveillance data of the Registration Committee of the Japanese Breast Cancer Society were analyzed. The clinicopathological characteristics were compared between young (< 35) patients and non-young (a parts per thousand yen35) patients among 109,617 records registered between 2004 and 2009. The numbers of young and non-young patients were 2,982 (2.7 %) and 106,295 (97.0 %), respectively. The young patients had more cases of a familial history of breast cancer, more subjective symptoms, fewer bilateral tumors, lower BMIs, larger tumors, more positive lymph nodes, fewer instances of an ER-positive status, more instances of an HER2-positive status, more triple-negative tumors and more advanced TNM stages. The young patients more frequently received neoadjuvant chemotherapy and breast-conserving therapy (BCT) compared with the non-young patients. Eighty percent of all patients received adjuvant therapy. The young patients were more frequently treated with chemotherapy, molecular targeted therapy and radiation therapy than the non-young patients. In this study, young patients with breast cancer were diagnosed at more advanced stages and had more endocrine-unresponsive tumors than non-young patients. Further prognostic analyses should be conducted in this cohort.	[Kataoka, Akemi] Breast Surg Clin, Minato Ku, Tokyo 1080074, Japan; [Tokunaga, Eriko] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka 812, Japan; [Masuda, Norikazu] Natl Hosp Org Osaka Natl Hosp, Dept Surg, Osaka, Japan; [Shien, Tadahiko] Okayama Univ Hosp, Dept Breast & Endocrine Surg, Okayama, Japan; [Kawabata, Kimiko] Saitama Prefectural Univ, Dept Nursing, Sch Hlth & Social Serv, Koshigaya, Saitama, Japan; [Miyashita, Mika] Hiroshima Univ, Grad Sch Biomed & Hlth Sci, Div Nursing Sci, Hiroshima, Japan	Kataoka, A (reprint author), Breast Surg Clin, Minato Ku, 2nd Floor YCC Takanawa Bldg,2-21-43 Takanawa, Tokyo 1080074, Japan.	tkataoka@sol.dti.ne.jp			Japanese Breast Cancer Society	We wish to thank Mr. Naohito Fukui, the NPO Japan Clinical Research Support Unit staff and the Japanese Breast Cancer Society for their collaboration on this study and their ongoing development, maintenance and improvement of this registry. This work was supported by a research fund from the Japanese Breast Cancer Society.	Leong SPL, 2010, WORLD J SURG, V34, P2308, DOI 10.1007/s00268-010-0683-1; Gonzalez-Angulo AM, 2005, CANCER, V103, P2466, DOI 10.1002/cncr.21070; Matsuda T, 2012, JPN J CLIN ONCOL, V42, P139, DOI 10.1093/jjco/hyr184; Gianni L, 2011, LANCET ONCOL, V12, P236, DOI 10.1016/S1470-2045(11)70033-X; Anders CK, 2008, J CLIN ONCOL, V26, P3324, DOI 10.1200/JCO.2007.14.2471; Wong M, 2013, ANN ONCOL, V24, P133, DOI 10.1093/annonc/mds250; Saeki T, 2008, INT J CLIN ONCOL, V13, P8, DOI 10.1007/s10147-007-0728-0; Sugano K, 2008, CANCER SCI, V99, P1967, DOI 10.1111/j.1349-7006.2008.00944.x; Aebi S, 2000, LANCET, V355, P1869, DOI 10.1016/S0140-6736(00)02292-3; Harvey JM, 1999, J CLIN ONCOL, V17, P1474; Pagani O, 1998, EUR J CANCER, V34, P632, DOI 10.1016/S0959-8049(97)10036-3; Colleoni M, 2002, ANN ONCOL, V13, P273, DOI 10.1093/annonc/mdf039; Iwase H, 2010, BREAST CANCER-TOKYO, V17, P118, DOI 10.1007/s12282-009-0113-0; Buzdar AU, 2005, J CLIN ONCOL, V23, P3676, DOI 10.1200/JCO.2005.07.032; Ahn SH, 2007, J CLIN ONCOL, V25, P2360, DOI 10.1200/JCO.2006.10.3754; Anders CK, 2011, J CLIN ONCOL, V29, pE18, DOI 10.1200/JCO.2010.28.9199; Freedman RA, 2012, BREAST CANCER RES TR, V135, P893, DOI 10.1007/s10549-012-2156-8; Howlader N, 2012, SEER CANC STAT REV 1; Pronzato P, 2011, INT J BREAST CANC, DOI [10.4061/2011/534256, DOI 10.4061/2011/534256.C0MPREHENSIVE]; Saji S, 2012, BREAST CANCER-TOKYO, V19, P1, DOI 10.1007/s12282-011-0308-z; Shi YX, 2012, J CANCER RES CLIN, V138, P705, DOI 10.1007/s00432-011-1141-7; The Japanese breast cancer society, 2008, GEN ROL CLIN PATH RE, P18; The World Organization, 1982, AM J CLIN PATHOL, V78, P806; Umemura Shinobu, 2006, Breast Cancer, V13, P232, DOI 10.2325/jbcs.13.232; Yoshimoto M, 2004, JPN J CLIN ONCOL, V34, P457, DOI 10.1093/jjcolhyh076	25	2	2	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1340-6868	1880-4233		BREAST CANCER-TOKYO	Beast Cancer	NOV	2014	21	6					643	650		10.1007/s12282-013-0466-2		8	Oncology; Obstetrics & Gynecology	Oncology; Obstetrics & Gynecology	AS6AP	WOS:000344347700002		
J	Shien, T; Nakatsuka, M; Doihara, H				Shien, Tadahiko; Nakatsuka, Mikiya; Doihara, Hiroyoshi			Fertility preservation in breast cancer patients	BREAST CANCER			English	Article						Breast cancer; Fertility preservation; Systemic therapy	CRYOPRESERVED OVARIAN TISSUE; PROLIFERATION IN-VITRO; YOUNG-WOMEN; ADJUVANT CHEMOTHERAPY; PROGNOSTIC IMPACT; HORMONE; DRUGS; AMENORRHEA; PREGNANCY	Systemic therapies have been shown to effectively improve prognosis in patients with breast cancer. However, such therapies also become increasingly harmful as their duration increases, and they have adverse effects on fertility and ovarian function. Fertility preservation (FP) is important in young adult cancer survivors who may wish to have children. In Japan, some cancer societies recommend that the potentially serious effects of systemic therapy on ovarian function should be explained to women with cancer, and they should be encouraged to undergo FP prior to commencing treatment. Still, as there are no official guidelines, many oncologists lack the required knowledge and mind-set to advise young breast cancer patients on fertility issues. Counseling of patients and their families might improve their understanding about the influence of such treatment on fertility and ensure effective FP. There are several FP methods that can be selected before beginning treatment, and these methods have both advantages and disadvantages. Young adults with breast cancer who want to bear children in the future must be provided with FP counseling, in addition to advice about breast cancer treatment and prognosis.	[Shien, Tadahiko; Doihara, Hiroyoshi] Okayama Univ Hosp, Breast Canc Treatment & Reconstruct Ctr, Kita Ku, Okayama 7008558, Japan; [Nakatsuka, Mikiya] Okayama Univ Hosp, Dept Obstet & Gynecol, Okayama 7008558, Japan	Shien, T (reprint author), Okayama Univ Hosp, Breast Canc Treatment & Reconstruct Ctr, Kita Ku, 2-5-1 Shikata Cho, Okayama 7008558, Japan.	tshien@md.okayama-u.ac.jp					Dolmans MM, 2010, BLOOD, V116, P2908, DOI 10.1182/blood-2010-01-265751; Azim HA, 2013, J CLIN ONCOL, V31, P73, DOI 10.1200/JCO.2012.44.2285; Bines J, 1996, J CLIN ONCOL, V14, P1718; Zreik TG, 2010, BREAST CANCER RES TR, V124, P13, DOI 10.1007/s10549-010-1140-4; Cooley A, 2012, HUM REPROD, V27, P146, DOI 10.1093/humrep/der378; Noyes N, 2009, REPROD BIOMED ONLINE, V18, P769; Peate M, 2011, J CLIN ONCOL, V29, P1670, DOI 10.1200/JCO.2010.31.2462; Boukaidi SA, 2012, FERTIL STERIL, V97, P440, DOI 10.1016/j.fertnstert.2011.11.020; Okanami Y, 2011, BREAST CANCER-TOKYO, V18, P182, DOI 10.1007/s12282-011-0256-7; Pagani O, 1998, EUR J CANCER, V34, P632, DOI 10.1016/S0959-8049(97)10036-3; Kim SS, 2011, FERTIL STERIL, V95, P1535, DOI 10.1016/j.fertnstert.2011.01.003; Fei CY, 2012, J NATL CANCER I, V104, P1021, DOI 10.1093/jnci/djs255; Donnez J, 2004, LANCET, V364, P1405, DOI 10.1016/S0140-6736(04)17222-X; Gerber B, 2011, J CLIN ONCOL, V29, P2334, DOI 10.1200/JCO.2010.32.5704; Lee SJ, 2006, J CLIN ONCOL, V24, P2917, DOI 10.1200/JCO.2006.06.5888; Ayhan A, 2004, ACTA OBSTET GYN SCAN, V83, P1104, DOI 10.1111/j.0001-6349.2004.00669.x; Blumenfeld Z, 1999, J SOC GYNECOL INVEST, V6, P229, DOI 10.1016/S1071-5576(99)00028-3; Institute of Medicine and National Research Council, 2006, CANC PAT CANC SURV; Japan Breast Cancer Society, 2010, CLIN PRACT GUID BREA; Kubo Akiko, 2012, Gan To Kagaku Ryoho, V39, P399; Singh KL, 2007, BRIT J CANCER, V96, P1808, DOI 10.1038/sj.bjc.6603814; Shien T, 2012, JPN J BREAST CANC, V27, P313; Shimizu C, 2012, BREAST CANC; Su HI, 2010, CANCER-AM CANCER SOC, V116, P592, DOI 10.1002/cncr.24746; Tham YL, 2007, AM J CLIN ONCOL-CANC, V30, P126, DOI 10.1097/01.coc.0000251398.57630.4f; Van der Elst J, 2003, HUM REPROD UPDATE, V9, P463, DOI 10.1093/humupd/dmg032; Zevine J, 2010, J CLIN ONCOL, V28, P4831	27	2	2	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1340-6868	1880-4233		BREAST CANCER-TOKYO	Beast Cancer	NOV	2014	21	6					651	655		10.1007/s12282-013-0463-5		5	Oncology; Obstetrics & Gynecology	Oncology; Obstetrics & Gynecology	AS6AP	WOS:000344347700003		
J	Bando, H				Bando, Hiroko			Issues of concern in risk assessment, genetic counseling, and genetic testing of younger breast cancer patients in Japan	BREAST CANCER			English	Article						Hereditary breast cancer; Early onset; Cancer genetic service; Genetic testing	CONTRALATERAL PROPHYLACTIC MASTECTOMY; BRCA2 MUTATION CARRIERS; FAMILY-HISTORY; OVARIAN-CANCER; HEREDITARY BREAST; FUTURE-DIRECTIONS; WOMEN; IMPACT; DIAGNOSIS; PERCEPTION	About 5-10 % of breast cancer cases are considered to be hereditary, and germ line mutations in the BRCA1 and BRCA2 genes have been proven to contribute to the development of hereditary breast and/or ovarian cancer syndrome (HBOC). Breast cancer diagnosed at a young age is an indication of a higher likelihood of HBOC. Risk assessment, genetic counseling, and BRCA1/BRCA2 mutation testing, especially for younger women with breast cancer, have started to be an integral element of practice due to advances in gene sequencing technologies and accumulating evidence for the clinical implications of BRCA mutation status for not only early breast cancer management, but also for the patient's own and their family's next cancer risk, and proactive steps toward a risk-reducing approach. As yet, the cancer genetic service system is immature in Japan. There are several problems to be solved to improve cancer genetic services in clinical practice for breast cancer.	Univ Tsukuba, Dept Breast & Endocrine Surg, Fac Med, Tsukuba, Ibaraki 3058575, Japan	Bando, H (reprint author), Univ Tsukuba, Dept Breast & Endocrine Surg, Fac Med, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	bando@md.tsukuba.ac.jp					Anderson B., 2012, J CANC EPIDEMIOL, V2012, DOI [10.1155/2012/298745, DOI 10.1155/2012/298745]; Ando N, 2011, FAM CANCER, V10, P681, DOI 10.1007/s10689-011-9464-8; Fostira F, 2012, BREAST CANCER RES TR, V134, P353, DOI 10.1007/s10549-012-2021-9; [Anonymous], CANC STAT JAP; James KM, 2011, MAYO CLIN PROC, V86, P933, DOI 10.4065/mcp.2011.0190; Weitzel JN, 2011, CA-CANCER J CLIN, V61, P327, DOI 10.3322/caac.20128; Domchek SM, 2010, JAMA-J AM MED ASSOC, V304, P967, DOI 10.1001/jama.2010.1237; [Anonymous], 2012, CLIN PRACT GUID ONC; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Lerman C, 2002, J CONSULT CLIN PSYCH, V70, P784, DOI 10.1037//0022-006X.70.3.784; Metcalfe K, 2011, BRIT J CANCER, V104, P1384, DOI 10.1038/bjc.2011.120; Armstrong K, 2005, JAMA-J AM MED ASSOC, V293, P1729, DOI 10.1001/jama.293.14.1729; Riley BD, 2012, J GENET COUNS, V21, P151, DOI 10.1007/s10897-011-9462-x; Antoniou AC, 2008, J MED GENET, V45, P425, DOI 10.1136/jmg.2007.056556; Sugano K, 2008, CANCER SCI, V99, P1967, DOI 10.1111/j.1349-7006.2008.00944.x; Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6; Rolnick SJ, 2011, J GENET COUNS, V20, P314, DOI 10.1007/s10897-011-9351-3; McGuire AL, 2009, AM J BIOETHICS, V9, P3, DOI 10.1080/15265160902928209; Fackenthal JD, 2007, NAT REV CANCER, V7, P937, DOI 10.1038/nrc2054; Evans DGR, 2010, BRIT J CANCER, V102, P1091, DOI 10.1038/sj.bjc.6605606; Armes JE, 1999, CANCER RES, V59, P2011; Tercyak KP, 2007, J CLIN ONCOL, V25, P285, DOI 10.1200/JCO.2006.07.3890; Livasy CA, 2006, MODERN PATHOL, V19, P264, DOI 10.1038/modpathol.3800528; Kauff ND, 2008, J CLIN ONCOL, V26, P1331, DOI 10.1200/JCO.2007.13.9626; Kwon JS, 2010, J CLIN ONCOL, V28, P4214, DOI 10.1200/JCO.2010.28.0719; Chen SN, 2007, J CLIN ONCOL, V25, P1329, DOI 10.1200/JCO.2006.09.1066; Tuttle TM, 2007, J CLIN ONCOL, V25, P5203, DOI 10.1200/JCO.2007.12.3141; Ropka ME, 2006, CANCER EPIDEM BIOMAR, V15, P840, DOI 10.1158/1055-9965.EPI-05-0002; Brain K, 2000, J MED GENET, V37, P197, DOI 10.1136/jmg.37.3.197; Mavaddat N, 2012, CANCER EPIDEM BIOMAR, V21, P134, DOI 10.1158/1055-9965.EPI-11-0775; McAllister M, 2007, AM J MED GENET A, V143A, P2651, DOI 10.1002/ajmg.a.32013; Metcalfe KA, 2008, J CLIN ONCOL, V26, P1093, DOI 10.1200/JCO.2007.12.6078; Sweet KM, 2002, J CLIN ONCOL, V20, P528, DOI 10.1200/JCO.20.2.528; McDonnell SK, 2001, J CLIN ONCOL, V19, P3938; Pal T, 2011, GENET TEST MOL BIOMA, V15, P69, DOI 10.1089/gtmb.2010.0098; Herrinton LJ, 2005, J CLIN ONCOL, V23, P4275, DOI 10.1200/JCO.2005.10.080; Pierce LJ, 2010, BREAST CANCER RES TR, V121, P389, DOI 10.1007/s10549-010-0894-z; Pasacreta JV, 2003, CANCER INVEST, V21, P588, DOI 10.1081/CNV-120022380; Ardern-Jones A, 2005, EUR J CANCER CARE, V14, P272, DOI 10.1111/j.1365-2354.2005.00574.x; Bando H, 2011, J JAPAN SOC CLIN ONC, V452, pMS1; Bellcross CA, 2011, AM J PREV MED, V40, P61, DOI 10.1016/j.amepre.2010.09.027; Berliner JL, 2013, J GENET COUNS, V22, P155, DOI 10.1007/s10897-012-9547-1; Bowen D, 1999, CANCER EPIDEM BIOMAR, V8, P581; Chin TM, 2005, CANCER DETECT PREV, V29, P412, DOI 10.1016/j.cdp.2005.06.009; Chionh F, 2011, ASIA-PAC J CLIN ONCO, V7, P197, DOI 10.1111/j.1743-7563.2011.01430.x; Fraser L, 2003, Fam Cancer, V2, P159; Gil F, 2003, PSYCHO-ONCOL, V12, P821, DOI 10.1002/pon.704; Heemskerk-Gerritsen B, 2010, EUR J CANCER, V8, ps206; Katapodi MC, 2011, ONCOL NURS FORUM, V38, P572, DOI 10.1188/11.ONF.572-581; Klee EW, 2011, EXPERT REV MOL DIAGN, V11, P703, DOI [10.1586/erm.11.58, 10.1586/ERM.11.58]; Matloff ET, 2006, J WOMENS HEALTH, V15, P843, DOI 10.1089/jwh.2006.15.843; Meiser Bettina, 2012, Oncol Nurs Forum, V39, pE101, DOI 10.1188/12.ONF.E101-E111; Morgan D, 2009, FAM CANCER, V8, P277, DOI 10.1007/s10689-009-9242-z; Ritvo P, 2012, BMC PUBLIC HEALTH, V12, DOI 10.1186/1471-2458-12-518; Ruddy KJ, 2009, ANN ONCOL, V21, P741; Ryan E L, 1999, J Cancer Educ, V14, P99; Schlich-Bakker KJ, 2006, PATIENT EDUC COUNS, V62, P13, DOI 10.1016/j.pec.2005.08.012; Schlich-Bakker KJ, 2006, EUR J CANCER, V42, P2722, DOI 10.1016/j.ejca.2006.05.032; Schwartz MD, 2004, J CLIN ONCOL, V22, P1823, DOI 10.1200/JCO.2004.04.086; Schwartz MD, 2005, CANCER EPIDEM BIOMAR, V14, P1003, DOI 10.1158/1055-9965.EPI-03-0545; Susswein LR, 2008, J CLIN ONCOL, V26, P32, DOI 10.1200/JCO.2007.10.6377; The Japanese Association of Medical Sciences, GUID GEN TESTS DIAGN; Trivers KF, 2011, CANCER-AM CANCER SOC, V117, P5334, DOI 10.1002/cncr.26166; Tung N, 2011, JAMA-J AM MED ASSOC, V305, P2211, DOI 10.1001/jama.2011.678; Berg AO, 2005, ANN INTERN MED, V143, P355; Wakefield CE, 2011, GENET TEST MOL BIOMA, V15, P379, DOI 10.1089/gtmb.2010.0158; Wevers MR, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-6; Yoon SY, 2011, FAM CANCER, V10, P199, DOI 10.1007/s10689-011-9420-7; Zilliacus E, 2012, SUPPORT CARE CANCER, V20, P2949, DOI 10.1007/s00520-012-1427-6	69	2	2	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1340-6868	1880-4233		BREAST CANCER-TOKYO	Beast Cancer	NOV	2014	21	6					656	663		10.1007/s12282-013-0477-z		8	Oncology; Obstetrics & Gynecology	Oncology; Obstetrics & Gynecology	AS6AP	WOS:000344347700004		
J	Takahashi, M				Takahashi, Miyako			Psychosocial distress among young breast cancer survivors: implications for healthcare providers	BREAST CANCER			English	Article						Young survivor; Interpersonal relationships; Sexuality; Fertility; Employment	QUALITY-OF-LIFE; NATIONWIDE SURVEY; WOMEN; IMPACT; RISK; REHABILITATION; DEPRESSION; DIAGNOSIS; SEXUALITY; SUPPORT	Breast cancer (BC) experiences foster serious psychosocial problems among young survivors. Previous studies have repeatedly discussed younger age as a factor that puts women with BC at higher risk of psychosocial distress. Although most BC survivors receive the necessary information from healthcare providers on treatment options and procedures at diagnosis, they often fail to receive support and guidance after acute treatment has completed in dealing with the possible physical, emotional, social, and psychological effects of cancer. This article discusses common psychosocial problems experienced by young BC survivors, such as issues related to interpersonal relationships, sexuality, fertility, and employment. In particular, it examines influences of the Japanese sociocultural background on young survivors' distress and considers the clinical implications for Japanese healthcare. The importance of integrating psychosocial care with routine oncology care cannot be overemphasized.	Natl Canc Ctr, Canc Survivorship Res Div, Ctr Canc Control & Informat Serv, Chuo Ku, Tokyo 1040045, Japan	Takahashi, M (reprint author), Natl Canc Ctr, Canc Survivorship Res Div, Ctr Canc Control & Informat Serv, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	miyataka@ncc.go.jp					Bloom JR, 2001, SOC SCI MED, V53, P1513, DOI 10.1016/S0277-9536(00)00440-8; Park JH, 2008, J CLIN ONCOL, V26, P1302, DOI 10.1200/JCO.2007.14.2984; Gorman JR, 2010, BREAST CANCER RES TR, V123, P477, DOI 10.1007/s10549-010-0768-4; Visser A, 2004, CANCER TREAT REV, V30, P683, DOI 10.1016/.j.ctrv.2004.06.001; Easley J, 2012, REHABIL NURS, V37, P163, DOI 10.1002/rnj.21; Avis NE, 2005, J CLIN ONCOL, V23, P3322, DOI 10.1200/JCO.2005.05.130; Takahashi M, 2005, SOC SCI MED, V61, P1278, DOI 10.1016/j.socscimed.2005.01.013; Wong-Kim EC, 2005, PSYCHO-ONCOL, V14, P564, DOI 10.1002/pon.873; Dunn J, 2000, PSYCHO-ONCOL, V9, P137, DOI 10.1002/(SICI)1099-1611(200003/04)9:2<137::AID-PON442>3.0.CO;2-0; Shimozuma K, 1999, BREAST CANCER RES TR, V56, P45, DOI 10.1023/A:1006214830854; de Boer AGEM, 2009, JAMA-J AM MED ASSOC, V301, P753, DOI 10.1001/jama.2009.187; MAUNSELL E, 1992, CANCER, V70, P120, DOI 10.1002/1097-0142(19920701)70:1<120::AID-CNCR2820700120>3.0.CO;2-U; Dorval M, 1999, J NATL CANCER I, V91, P54, DOI 10.1093/jnci/91.1.54; Howard-Anderson J, 2012, JNCI-J NATL CANCER I, V104, P386, DOI 10.1093/jnci/djr541; Shimizu C, 2013, BREAST CANCER-TOKYO, V20, P230, DOI 10.1007/s12282-011-0328-8; Ahn E, 2009, BREAST CANCER RES TR, V116, P609, DOI 10.1007/s10549-008-0209-9; Mehnert A, 2011, CRIT REV ONCOL HEMAT, V77, P109, DOI 10.1016/j.critrevonc.2010.01.004; Burgess C, 2005, BRIT MED J, V330, P702, DOI 10.1136/bmj.38343.670868.D3; BAIDER L, 1988, ISRAEL J MED SCI, V24, P631; Bloom JR, 1994, J NATL CANC I MONOGR, V16, P199; Cancer incidence by age and site, CANC INC AG SIT; Dorval M, 2005, J CLIN ONCOL, V23, P3588, DOI 10.1200/JCO.2005.01.628; GANZ PA, 1993, MED CARE, V31, P419, DOI 10.1097/00005650-199305000-00004; Ganz PA, 2008, ONCOLOGY-NY, V22, P642; GANZ PA, 1992, J CLIN EPIDEMIOL, V45, P473, DOI 10.1016/0895-4356(92)90096-6; Hoving JL, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-117; Kobayashi M, 2013, GAN KANGO, V18, P57; MAUNSELL E, 1995, CANCER, V76, P631, DOI 10.1002/1097-0142(19950815)76:4<631::AID-CNCR2820760414>3.0.CO;2-9; Ministry of International Affairs and Communications, LAB FORC SURV; Northouse L L, 1993, Semin Oncol Nurs, V9, P74, DOI 10.1016/S0749-2081(05)80102-0; OBERST MT, 1988, RES NURS HEALTH, V11, P223, DOI 10.1002/nur.4770110404; Ozawa M, 2013, SHONI HOKEN KENKYU, V72, P217; Peuckmann V, 2009, EUR J CANCER, V45, P625, DOI 10.1016/j.ejca.2008.09.027; Saeki T, 2003, RINSHO KANGO, V9, P1051; Saito N, 2013, J OCCUP HLT IN PRESS; SCHAG CAC, 1993, J CLIN ONCOL, V11, P783; Schover L., 1997, SEXUALITY FERTILITY; Schover LR, 1994, J NATL CANC I MONOGR, V16, P177; Takahashi M, 2008, 16 ANN M JAP BREAST; Takahashi M, 2006, J CLIN ONCOL, V24, P5763, DOI 10.1200/JCO.2006.06.9146; Takahashi M, 2012, PSYCHOSOCIAL ADJUSTM, P89; Takahashi M, 2008, PSYCHO-ONCOL, V17, P901, DOI 10.1002/pon.1297; Takahashi M, 2009, MOTHERS BREAST CANC, P24; WELLISCH DK, 1978, AM J PSYCHIAT, V135, P543	44	2	2	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1340-6868	1880-4233		BREAST CANCER-TOKYO	Beast Cancer	NOV	2014	21	6					664	669		10.1007/s12282-013-0508-9		6	Oncology; Obstetrics & Gynecology	Oncology; Obstetrics & Gynecology	AS6AP	WOS:000344347700005		
J	Uematsu, T; Kasami, M; Watanabe, J				Uematsu, Takayoshi; Kasami, Masako; Watanabe, Junichiro			Is evaluation of the presence of prepectoral edema on T2-weighted with fat-suppression 3 T breast MRI a simple and readily available noninvasive technique for estimation of prognosis in patients with breast cancer?	BREAST CANCER			English	Article						3-T; Breast; MRI; T2-weighted image; Prepectoral edema	NEOADJUVANT CHEMOTHERAPY; SYSTEMATIC-APPROACH; LYMPH-NODES; DYNAMIC MRI; CARCINOMA; LESIONS; MAMMOGRAPHY; PREDICTION; ENHANCEMENT; VARIABILITY	The specificity of breast MRI is only moderate. The unsatisfactory specificity of breast MRI has prompted evaluation of high signal intensity (SI) on T2-weighted imaging (T2WI). The purpose of the study was to investigate the prevalence of prepectoral edema determined using high SI on T2WI with fat-suppression 3 T MRI and to correlate its presence with prognostic factors of breast cancer. The retrospective study comprised 589 consecutive histopathologically confirmed lesions, 460 malignant and 129 benign, identified by 3 T MRI. Presence of prepectoral edema was evaluated on T2WI with fat suppression, and its diagnostic value for malignancies and correlation with clinicopathological findings in histopathologically confirmed breast cancer were assessed. Prepectoral edema was present in 54 of the 460 breast cancers (9 % of the total 589) and none of the 129 benign lesions. Its sensitivity and specificity were 12 and 100 %, respectively. The positive predictive value was 100 %. Young age (p = 0.01), large tumor size (p < 0.0001), high histological grade (p < 0.0001), invasive ductal carcinoma (p < 0.0001), high lymphovascular invasion degree (p < 0.0001), high axillary lymph node positivity (p < 0.0001), high inflammatory breast cancer rate (p < 0.0001), high neoadjuvant chemotherapy rate (p < 0.0001), and chemoresistant breast cancers (p < 0.0001) were significantly associated with prepectoral edema. There was no association of the morphological lesion type on MRI and dynamic enhancement imaging pattern with the presence of prepectoral edema. Prepectoral edema has low prevalence but is specific for breast cancer and correlated with prognostic factors.	[Uematsu, Takayoshi] Shizuoka Canc Ctr Hosp, Breast Imaging & Breast Intervent Sect, Shizuoka 4118777, Japan; [Kasami, Masako] Shizuoka Canc Ctr Hosp, Dept Pathol, Shizuoka 4118777, Japan; [Watanabe, Junichiro] Shizuoka Canc Ctr Hosp, Div Med Oncol, Shizuoka 4118777, Japan	Uematsu, T (reprint author), Shizuoka Canc Ctr Hosp, Breast Imaging & Breast Intervent Sect, Shizuoka 4118777, Japan.	t.uematsu@scchr.jp					American College of Radiology, 2003, BREAST IM REP DAT SY; Elsamaloty H, 2009, AM J ROENTGENOL, V192, P1142, DOI 10.2214/AJR.08.1226; Abe H, 2009, RADIOLOGY, V250, P41, DOI 10.1148/radiol.2493071483; Uematsu T, 2009, RADIOLOGY, V250, P638, DOI 10.1148/radiol.2503081054; Pinker K, 2009, INVEST RADIOL, V44, P553, DOI 10.1097/RLI.0b013e3181b4c127; Uematsu T, 2012, AM J ROENTGENOL, V198, pW611, DOI 10.2214/AJR.11.7463; Estourgie SH, 2004, ANN SURG, V239, P232, DOI 10.1097/01.sla.0000109156.26378.90; Xiong QH, 2001, CANCER, V92, P2523, DOI 10.1002/1097-0142(20011115)92:10<2523::AID-CNCR1603>3.0.CO;2-6; Weinstein S, 2010, RADIOL CLIN N AM, V48, P1013, DOI 10.1016/j.rcl.2010.06.011; Kinkel K, 2000, AM J ROENTGENOL, V175, P35; Schmitz AC, 2008, EUR RADIOL, V18, P355, DOI 10.1007/s00330-007-0766-z; Yildirim E, 2000, J SURG ONCOL, V74, P267; Kurosumi M, 2008, BREAST CANCER-TOKYO, V15, P5, DOI 10.1007/s12282-007-0016-x; Uematsu T, 2012, AM J ROENTGENOL, V198, P1223, DOI 10.2214/AJR.11.7350; Pinker-Domenig K, 2012, EUR RADIOL, V22, P322, DOI 10.1007/s00330-011-2256-6; Bevilacqua JLB, 2007, J CLIN ONCOL, V25, P3670, DOI 10.1200/JCO.2006.08.8013; Baltzer PAT, 2009, ACAD RADIOL, V16, P1070, DOI 10.1016/j.acra.2009.03.017; Baltzer PAT, 2010, BREAST J, V16, P233, DOI 10.1111/j.1524-4741.2010.00915.x; Baltzer PAT, 2011, J COMPUT ASSIST TOMO, V35, P361, DOI 10.1097/RCT.0b013e31821065c3; Dietzel M, 2010, ACTA RADIOL, V51, P885, DOI 10.3109/02841851.2010.504232; Hasebe T, 2008, HUM PATHOL, V39, P427, DOI 10.1016/j.humpath.2007.07.016; Kawashima H, 2010, J MAGN RESON IMAGING, V32, P1117, DOI 10.1002/jmri.22279; Malich A, 2005, AM J ROENTGENOL, V185, P964, DOI 10.2214/AJR.04.1073; Mussurakis S, 1997, J COMPUT ASSIST TOMO, V21, P431, DOI 10.1097/00004728-199705000-00017; Mussurakis S, 1996, BRIT J RADIOL, V69, P1009; Renz DM, 2008, EUR RADIOL, V18, P2370, DOI 10.1007/s00330-008-1029-3; Renz DM, 2008, ACAD RADIOL, V15, P209, DOI 10.1016/j.acra.2007.09.011; Tamura N, 2009, CANCER SCI, V100, P1823, DOI 10.1111/j.1349-7006.2009.01264.x; Uematsu T, 2011, BREAST CANCER-TOKYO, V18, P309, DOI 10.1007/s12282-010-0211-z; Uematsu T, 2010, EUR RADIOL, V20, P2315, DOI 10.1007/s00330-010-1813-8; Uematsu T, 2012, BREAST CANC; Uematsu T, 2012, BREAST CANCER-TOKYO, V19, P289, DOI 10.1007/s12282-012-0346-1; Vag T, 2011, EUR RADIOL, V21, P893, DOI 10.1007/s00330-010-2001-6; Vandorpe T, 2011, BREAST CANCER RES TR, V128, P429, DOI 10.1007/s10549-011-1565-4; Warwick J, 2004, CANCER, V100, P1331, DOI 10.1002/cncr.20140; Yasumura K, 1997, BREAST CANC, V4, P161, DOI 10.1007/BF02967070; Yuen S, 2007, J MAGN RESON IMAGING, V25, P502, DOI 10.1002/jmri.20845	37	2	2	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1340-6868	1880-4233		BREAST CANCER-TOKYO	Beast Cancer	NOV	2014	21	6					684	692		10.1007/s12282-013-0440-z		9	Oncology; Obstetrics & Gynecology	Oncology; Obstetrics & Gynecology	AS6AP	WOS:000344347700008		
J	Nogami, T; Shien, T; Tanaka, T; Doihara, H; Taira, N; Takabatake, D; Nishimura, R; Nishiyama, K; Mizoo, T; Ohsumi, S				Nogami, Tomohiro; Shien, Tadahiko; Tanaka, Takehiro; Doihara, Hiroyoshi; Taira, Naruto; Takabatake, Daisuke; Nishimura, Rieko; Nishiyama, Keiko; Mizoo, Taeko; Ohsumi, Shozo			The discordance between primary breast cancer lesions and pulmonary metastatic lesions in expression of aldehyde dehydrogenase 1-positive cancer cells	BREAST CANCER			English	Article						Breast cancer; Pulmonary metastases; ALDH1	LUNG METASTASES; STEM-CELLS; CARCINOMA; RESECTION; SURVIVAL; SURGERY; THERAPY; BENEFIT; DISEASE	We evaluated the expression of aldehyde dehydrogenase 1 (ALDH1) between primary breast lesions and pulmonary metastatic (PM) lesions in breast cancer patients. We retrospectively analyzed the clinicopathological features and the expression statuses of ER, PR, HER2, Ki-67 and ALDH-1 in both primary and metastatic breast cancer lesions and evaluated the discordance rates in the expressions of these markers between the primary and metastatic lesions, and also the prognostic value of these factors. None of the PM patients had metastases at any other sites, and all had undergone curative breast cancer surgery. The pulmonary operation was partial resection in 15 (88 %) patients and lobectomy in 2 (12 %) patients. The median overall survival (OS) after resection of the PNs (OS) was 48 months. The discordance rates in the expressions of ER, PR, HER2, Ki67 and ALDH-1 between the primary and metastatic lesions were 0, 29, 21, 43 and 50 %, respectively. There was significant discordance in the biomarkers between the primary tumors and the metastatic lesions.	[Nogami, Tomohiro; Shien, Tadahiko; Doihara, Hiroyoshi; Taira, Naruto; Nishiyama, Keiko; Mizoo, Taeko] Okayama Univ Hosp, Dept Breast & Endocrine Surg, Okayama, Japan; [Tanaka, Takehiro] Okayama Univ Hosp, Dept Pathol, Okayama, Japan; [Takabatake, Daisuke; Ohsumi, Shozo] Shikoku Canc Ctr, Dept Breast Oncol, Matsuyama, Ehime, Japan; [Nishimura, Rieko] Shikoku Canc Ctr, Dept Pathol, Matsuyama, Ehime, Japan	Nogami, T (reprint author), Okayama Univ Hosp, Dept Breast & Endocrine Surg, Okayama, Japan.	imagon12000@yahoo.co.jp		Shien, Tadahiko/0000-0003-3202-5512			Simmons C, 2009, ANN ONCOL, V20, P1499, DOI 10.1093/annonc/mdp028; Goldhirsch A, 2009, ANN ONCOL, V20, P1319, DOI 10.1093/annonc/mdp322; CASEY JJ, 1984, SURGERY, V96, P801; Friedel G, 2002, EUR J CARDIO-THORAC, V22, P335, DOI 10.1016/S1010-7940(02)00331-7; Zidan J, 2005, BRIT J CANCER, V93, P552, DOI 10.1038/sj.bjc.6602738; Chute JP, 2006, P NATL ACAD SCI USA, V103, P11707, DOI 10.1073/pnas.0603806103; Tanei T, 2009, CLIN CANCER RES, V15, P4234, DOI 10.1158/1078-0432.CCR-08-1479; Ludwig C, 2003, EUR J SURG ONCOL, V29, P532, DOI 10.1016/S0748-7983(03)00074-X; Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014; Tanaka F, 2005, ANN THORAC SURG, V79, P1711, DOI 10.1016/j.athoracsur.2004.10.033; Planchard D, 2004, CANCER, V100, P28, DOI 10.1002/cncr.11881; Bathe OF, 1999, SURG ONCOL, V8, P35, DOI 10.1016/S0960-7404(99)00023-7; Gong Y, 2005, CANCER-AM CANCER SOC, V103, P1763, DOI 10.1002/cncr.20987; Higaki K, 2011, BREAST, V20, pS77; Khasraw M, 2011, CURR ONCOL REP, V13, P17, DOI 10.1007/s11912-010-0137-9; Nogami N, 2012, BREAST CANC; Tanaka F, 2005, ANN THORAC SURG, V79, P1714	17	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1340-6868	1880-4233		BREAST CANCER-TOKYO	Beast Cancer	NOV	2014	21	6					698	702		10.1007/s12282-013-0445-7		5	Oncology; Obstetrics & Gynecology	Oncology; Obstetrics & Gynecology	AS6AP	WOS:000344347700010		
J	Noguchi, S; Masuda, N; Iwata, H; Mukai, H; Horiguchi, J; Puttawibul, P; Srimuninnimit, V; Tokuda, Y; Kuroi, K; Iwase, H; Inaji, H; Ohsumi, S; Noh, WC; Nakayama, T; Ohno, S; Rai, Y; Park, BW; Panneerselvam, A; El-Hashimy, M; Taran, T; Sahmoud, T; Ito, Y				Noguchi, Shinzaburo; Masuda, Norikazu; Iwata, Hiroji; Mukai, Hirofumi; Horiguchi, Jun; Puttawibul, Puttisak; Srimuninnimit, Vichien; Tokuda, Yutaka; Kuroi, Katsumasa; Iwase, Hirotaka; Inaji, Hideo; Ohsumi, Shozo; Noh, Woo-Chul; Nakayama, Takahiro; Ohno, Shinji; Rai, Yoshiaki; Park, Byeong-Woo; Panneerselvam, Ashok; El-Hashimy, Mona; Taran, Tetiana; Sahmoud, Tarek; Ito, Yoshinori			Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2	BREAST CANCER			English	Article						Advanced breast cancer; Endocrine resistance; Everolimus; Exemestane; Progression-free survival	RENAL-CELL CARCINOMA; ENDOCRINE THERAPY RESISTANCE; ETHNIC-DIFFERENCES; JAPANESE PATIENTS; SOLID TUMORS; INHIBITION; MTOR; TAMOXIFEN; PHASE-3; TRIAL	The addition of mTOR inhibitor everolimus (EVE) to exemestane (EXE) was evaluated in an international, phase 3 study (BOLERO-2) in patients with hormone-receptor-positive (HR+) breast cancer refractory to letrozole or anastrozole. The safety and efficacy of anticancer treatments may be influenced by ethnicity (Sekine et al. in Br J Cancer 99:1757-62, 2008). Safety and efficacy results from Asian versus non-Asian patients in BOLERO-2 are reported. Patients were randomized (2:1) to 10 mg/day EVE + EXE or placebo (PBO) + EXE. Primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival, response rate, clinical benefit rate, and safety. Of 143 Asian patients, 98 received EVE + EXE and 45 received PBO + EXE. Treatment with EVE + EXE significantly improved median PFS versus PBO + EXE among Asian patients by 38 % (HR = 0.62; 95 % CI, 0.41-0.94). Median PFS was also improved among non-Asian patients by 59 % (HR = 0.41; 95 % CI, 0.33-0.50). Median PFS duration among EVE-treated Asian patients was 8.48 versus 4.14 months for PBO + EXE, and 7.33 versus 2.83 months, respectively, in non-Asian patients. The most common grade 3/4 adverse events (stomatitis, anemia, elevated liver enzymes, hyperglycemia, and dyspnea) occurred at similar frequencies in Asian and non-Asian patients. Grade 1/2 interstitial lung disease occurred more frequently in Asian patients. Quality of life was similar between treatment arms in Asian patients. Adding EVE to EXE provided substantial clinical benefit in both Asian and non-Asian patients with similar safety profiles. This combination represents an improvement in the management of postmenopausal women with HR+/HER2(-) advanced breast cancer progressing on nonsteroidal aromatase inhibitors, regardless of ethnicity.	[Noguchi, Shinzaburo; Nakayama, Takahiro] Osaka Univ, Dept Breast & Endocrine Surg, Osaka, Japan; [Masuda, Norikazu] Osaka Natl Hosp, Natl Hosp Org, Dept Surg, Osaka, Japan; [Iwata, Hiroji] Aichi Canc Ctr Hosp, Dept Breast Oncol, Nagoya, Aichi 464, Japan; [Mukai, Hirofumi] Natl Canc Ctr Hosp East, Dept Breast Oncol, Kashiwa, Chiba, Japan; [Horiguchi, Jun] Gunma Univ Hosp, Maebashi, Gumma, Japan; [Puttawibul, Puttisak] Prince Songkla Univ, Songklanagarind Hosp, Fac Med, Hat Yai, Thailand; [Srimuninnimit, Vichien] Mahidol Univ, Siriraj Hosp, Bangkok 10700, Thailand; [Tokuda, Yutaka] Tokai Univ Hosp, Dept Breast & Endocrine Surg, Isehara, Kanagawa, Japan; [Kuroi, Katsumasa] Komagome Hosp, Dept Surg, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan; [Iwase, Hirotaka] Kumamoto Univ, Dept Breast & Endocrine Surg, Kumamoto, Japan; [Inaji, Hideo] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Breast & Endocrine Surg, Osaka, Japan; [Ohsumi, Shozo] NHO Shikoku Canc Ctr, Dept Breast Oncol, Matsuyama, Ehime, Japan; [Noh, Woo-Chul] Korea Canc Ctr Hosp, Dept Surg, Seoul, South Korea; [Ohno, Shinji] Kyushu Natl Canc Ctr, Dept Breast Oncol, Fukuoka, Japan; [Rai, Yoshiaki] Hakuaikai Sagara Hosp, Dept Breast Surg, Kagoshima, Japan; [Park, Byeong-Woo] Yonsei Univ, Coll Med, Dept Surg, Seoul, South Korea; [Panneerselvam, Ashok; El-Hashimy, Mona; Taran, Tetiana; Sahmoud, Tarek] Novartis Pharmaceut, Dept Global Oncol Dev, E Hanover, NJ USA; [Ito, Yoshinori] Japanese Fdn Canc Res, Canc Inst Hosp, Breast Oncol Ctr, Dept Med Oncol, Tokyo, Japan	Noguchi, S (reprint author), Osaka Univ, Dept Breast & Endocrine Surg, Osaka, Japan.	noguchi@onsurg.med.osaka-u.ac.jp			Novartis Pharmaceuticals; Novartis	The BOLERO-2 trial was supported by Novartis Pharmaceuticals: ClinicalTrials.gov identifier NCT00863655. Funding for medical editorial support was also provided by Novartis. Financial support for medical editorial assistance was provided by Novartis Pharmaceuticals. We thank Kristin E. Larsen, PhD, ProEd Communications, Inc., for medical editorial assistance with this manuscript. The BOLERO-2 trial was conducted in the USA, Japan, Canada, Brazil, Austria, Belgium, Czech Republic, France, Germany, Hungary, Italy, the Netherlands, Norway, Poland, Spain, Sweden, Turkey, UK, Egypt, Australia, China (Hong Kong), New Zealand, South Korea, and Thailand. We thank the patients, study site personnel, and the study team for their participation in the trial.	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; American Cancer Society, 2011, GLOB CANC FACTS FIG; Boulay A, 2005, CLIN CANCER RES, V11, P5319, DOI 10.1158/1078-0432.CCR-04-2402; Dodwell D, 2006, BREAST, V15, P584, DOI 10.1016/j.breast.2006.01.007; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Doi T, 2010, J CLIN ONCOL, V28, P1904, DOI 10.1200/JCO.2009.26.2923; Beeram M, 2007, ANN ONCOL, V18, P1323, DOI 10.1093/annonc/mdm170; White DA, 2010, AM J RESP CRIT CARE, V182, P396, DOI 10.1164/rccm.200911-1720OC; Miller TW, 2010, J CLIN INVEST, V120, P2406, DOI 10.1172/JCI41680; DeGraffenried LA, 2004, CLIN CANCER RES, V10, P8059, DOI 10.1158/1078-0432.CCR-04-0035; Porta C, 2011, EUR J CANCER, V47, P1287, DOI 10.1016/j.ejca.2011.02.014; Xie HG, 2001, ANNU REV PHARMACOL, V41, P815, DOI 10.1146/annurev.pharmtox.41.1.815; Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653; Ling WHY, 2011, ANN ACAD MED SINGAP, V40, P356; Althuis MD, 2005, INT J EPIDEMIOL, V34, P405, DOI 10.1093/ije/dyh414; Tsukamoto T, 2011, JPN J CLIN ONCOL, V41, P17, DOI 10.1093/jjco/hyq166; Motzer RJ, 2010, CANCER-AM CANCER SOC, V116, P4256, DOI 10.1002/cncr.25219; Okamoto I, 2010, JPN J CLIN ONCOL, V40, P17, DOI 10.1093/jjco/hyp120; Chow LWC, 2006, BREAST CANCER RES TR, V100, pS286; Fayers PM, 2001, EORTC QLQ C30 SCORIN; Ghayad SE, 2008, CANCER SCI, V99, P1992, DOI 10.1111/j.1349-7006.2008.00955.x; Hortobagyi GN, 2011, 34 ANN CTRC AACR SAN; Meric-Bernstam F, 2012, AM ASS CANC RES ANN; Mizuno R, 2012, JPN J CLIN ONCOL, V42, P442, DOI 10.1093/jjco/hys033; National Cancer Institute, COMM TERM CRIT ADV E; National Comprehensive Cancer Network Inc, NCCN CLIN PRACT GUID; Novartis Pharmaceuticals Corporation, 2012, AF EV PRESCR INF; Oberstein Paul E, 2012, Clin Med Insights Oncol, V6, P41, DOI 10.4137/CMO.S7319; Sekine I, 2008, BRIT J CANCER, V99, P1757, DOI 10.1038/sj.bjc.6604721	29	9	10	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1340-6868	1880-4233		BREAST CANCER-TOKYO	Beast Cancer	NOV	2014	21	6					703	714		10.1007/s12282-013-0444-8		12	Oncology; Obstetrics & Gynecology	Oncology; Obstetrics & Gynecology	AS6AP	WOS:000344347700011		
J	Shimada, K; Ishikawa, T; Nakamura, F; Shimizu, D; Chishima, T; Ichikawa, Y; Sasaki, T; Endo, I; Nagashima, Y; Goshima, Y				Shimada, Kazuhiro; Ishikawa, Takashi; Nakamura, Fumio; Shimizu, Daisuke; Chishima, Takashi; Ichikawa, Yasushi; Sasaki, Takeshi; Endo, Itaru; Nagashima, Yoji; Goshima, Yoshio			Collapsin response mediator protein 2 is involved in regulating breast cancer progression	BREAST CANCER			English	Article						Breast cancer; Collapsin response mediator protein 2; Nuclear localization; Microtubule; Triple-negative breast cancer	GROWTH-CONE COLLAPSE; ALZHEIMERS-DISEASE; PACLITAXEL SENSITIVITY; CRMP-2; PHOSPHORYLATION; EXPRESSION; TUBULIN; CDK5; CHEMOTHERAPY; CELLS	Altered expression of collapsin response mediator proteins (CRMPs) has been reported in several malignant tumors, including downregulation of CRMP1 in lung cancer and upregulation of CRMP2 in colorectal cancer. This study aimed to investigate the relationship between CRMP expression and clinicopathological characteristics in patients with breast cancer. Twenty-two breast cancer and four normal breast tissues were used to assess CRMP mRNA expression. The average expression level of each CRMP (CRMP1-5) mRNA was analyzed in a subset of breast cancer specimens and compared with that in normal breast tissue by real-time quantitative reverse-transcription polymerase chain reaction. Furthermore, 173 breast cancer specimens and matching normal breast controls were used for immunohistochemistry based on the tissue microarray technique. Levels of CRMP2 and phosphorylated CRMP2 protein were assessed, and possible correlations between the clinicopathological characteristics were evaluated. The expression of CRMP2 mRNA was significantly decreased in breast cancer tissues, while that of the other CRMPs was similar between normal and breast cancer tissues. Immunohistochemistry revealed that CRMP2 protein expression was also decreased in breast cancer tissues (P < 0.001). Phosphorylated CRMP2 was observed in the nuclei of breast cancer cells but not in normal mammary cells (P < 0.001). Furthermore, nuclear phosphorylated CRMP2 expression was increased in proportion to the histological grade and triple-negative subtype. Reduced CRMP2 expression and elevated expression of nuclear phosphorylated CRMP2 may be associated with breast cancer progression.	[Shimada, Kazuhiro; Chishima, Takashi; Ichikawa, Yasushi; Endo, Itaru] Yokohama City Univ, Grad Sch Med, Dept Surg Gastroenterol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; [Shimada, Kazuhiro; Ishikawa, Takashi; Shimizu, Daisuke] Yokohama City Univ, Med Ctr, Dept Breast & Thyroid Surg, Minami Ku, Yokohama, Kanagawa 2320024, Japan; [Nakamura, Fumio; Goshima, Yoshio] Yokohama City Univ, Grad Sch Med, Dept Mol Pharmacol & Neurobiol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; [Chishima, Takashi; Ichikawa, Yasushi; Endo, Itaru] Yokohama City Univ, Grad Sch Med, Dept Clin Oncol, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan; [Sasaki, Takeshi] Yokohama City Univ, Div Surg Pathol, Med Ctr, Minami Ku, Yokohama, Kanagawa 2320024, Japan; [Nagashima, Yoji] Yokohama City Univ, Dept Mol Pathol, Grad Sch Med, Kanazawa Ku, Yokohama, Kanagawa 2360004, Japan	Shimada, K (reprint author), Yokohama City Univ, Med Ctr, Dept Breast & Thyroid Surg, Minami Ku, 4-57 Urafunecho, Yokohama, Kanagawa 2320024, Japan.	kazu90052003@yahoo.co.jp			Japan Society for the Promotion of Science under the Ministry of Education, Culture, Sports, Science and Technology [23591899, 80275049]	We thank Msato Kodera, Harumi Sakurada, Yuka Honjoh, Makiko Fujimura and Yumi Inada for their technical and secretarial assistance. We also thank the staff of the Human Cancer Tissue Center of Kanagawa Cancer Research and Information Association for preparation of tissue samples and clinicopathological information. This study was supported by Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science under the Ministry of Education, Culture, Sports, Science and Technology (Fundamental Research: C, 23591899) (to Takashi Ishikawa, no. 80275049).	Arimura N, 2000, J BIOL CHEM, V275, P23973, DOI 10.1074/jbc.M001032200; Soutar MPM, 2009, CURR ALZHEIMER RES, V6, P269; Wagner P, 2005, CELL CYCLE, V4, P1149; Yoshimura T, 2005, CELL, V120, P137, DOI 10.1016/j.cell.2004.11.012; Kimura T, 2005, J NEUROCHEM, V93, P1371, DOI 10.1111/j.1471-4159.2005.03063.x; Kojima Y, 2008, HUM PATHOL, V39, P824, DOI 10.1016/j.humpath.2007.11.001; Upadhyay AK, 2008, CURR CANCER DRUG TAR, V8, P741, DOI 10.2174/156800908786733405; Nishimura T, 2003, NAT CELL BIOL, V5, P819, DOI 10.1038/ncb1039; Cole AR, 2007, J NEUROCHEM, V103, P1132, DOI 10.1111/j.1471-4159.2007.04829.x; Amos LA, 1999, CHEM BIOL, V6, pR65, DOI 10.1016/S1074-5521(99)89002-4; Wu CC, 2008, PROTEOMICS, V8, P316, DOI 10.1002/pmic.200700819; Uchida Y, 2005, GENES CELLS, V10, P165, DOI 10.1111/j.1365-2443.2005.00827.x; Tommasi S, 2007, INT J CANCER, V120, P2078, DOI 10.1002/ijc.22557; Yoshida H, 1998, J BIOL CHEM, V273, P9761, DOI 10.1074/jbc.273.16.9761; Paik S, 2006, J CLIN ONCOL, V24, P3726, DOI 10.1200/JCO.2005.04.7985; Fukada M, 2000, J BIOL CHEM, V275, P37957, DOI 10.1074/jbc.M003277200; Brown M, 2004, J NEUROSCI, V24, P8994, DOI 10.1523/JNEUROSCI.3184-04.2004; Cole AR, 2004, J BIOL CHEM, V279, P50176, DOI 10.1074/jbc.C400412200; Lin PC, 2011, J BIOL CHEM, V286, P41466, DOI 10.1074/jbc.M111.283580; Cleator S, 2007, LANCET ONCOL, V8, P235, DOI 10.1016/S1470-2045(07)70074-8; Inagaki N, 2001, NAT NEUROSCI, V4, P781, DOI 10.1038/90476; Gu YJ, 2000, BIOCHEMISTRY-US, V39, P4267, DOI 10.1021/bi992323h; DeSantis C, 2011, CA-CANCER J CLIN, V61, P409, DOI 10.3322/caac.20134; Sasaki Y, 2002, NEURON, V35, P907, DOI 10.1016/S0896-6273(02)00857-7; Goodyear S, 2007, EXP MOL PATHOL, V82, P25, DOI 10.1016/j.yexmp.2006.09.002; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Shih JY, 2001, J NATL CANCER I, V93, P1392, DOI 10.1093/jnci/93.18.1392; Nowak AK, 2004, LANCET ONCOL, V5, P372, DOI 10.1016/S1470-2045(04)01494-9; Gao X, 2010, ONCOGENE, V29, P4555, DOI 10.1038/onc.2010.213; Burkhart CA, 2001, BBA-REV CANCER, V1471, pO1, DOI 10.1016/S0304-419X(00)00022-6; Schmidt EF, 2007, ADV EXP MED BIOL, V600, P1; Smoter M, 2011, CANCER CHEMOTH PHARM, V68, P553, DOI 10.1007/s00280-011-1696-7; Fukata Y, 2002, NAT CELL BIOL, V4, P583, DOI 10.1038/ncb825; GOSHIMA Y, 1995, NATURE, V376, P509, DOI 10.1038/376509a0; Rouzier R, 2005, P NATL ACAD SCI USA, V102, P8315, DOI 10.1073/pnas.0408974102; ELSTON CW, 1991, HISTOPATHOLOGY, V19, P403, DOI 10.1111/j.1365-2559.1991.tb00229.x; Gaetano C, 1997, J BIOL CHEM, V272, P12195, DOI 10.1074/jbc.272.18.12195; Hasegawa S, 2003, CLIN CANCER RES, V9, P2992; Lakhani SR, 2012, WHO CLASSIFICATION T; MINTURN JE, 1995, J NEUROSCI, V15, P6757; Miyoshi Y, 2008, J CANCER RES CLIN, V134, P561, DOI 10.1007/s00432-007-0319-5; Paradiso A, 2005, ANN ONCOL, V16, P14, DOI 10.1093/annonc/mdi902; Prasad CP, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-325; Takagawa R, 2010, ANN SURG ONCOL, V17, P81, DOI 10.1245/s10434-009-0708-x; Trudeau M, 2005, LANCET ONCOL, V6, P886, DOI 10.1016/S1470-2045(05)70424-1; Wang LH, 1997, J NEUROCHEM, V69, P2261	46	2	2	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1340-6868	1880-4233		BREAST CANCER-TOKYO	Beast Cancer	NOV	2014	21	6					715	723		10.1007/s12282-013-0447-5		9	Oncology; Obstetrics & Gynecology	Oncology; Obstetrics & Gynecology	AS6AP	WOS:000344347700012		
J	Fujimoto, H; Kazama, T; Nagashima, T; Sakakibara, M; Suzuki, TH; Okubo, Y; Shiina, N; Fujisaki, K; Ota, S; Miyazaki, M				Fujimoto, Hiroshi; Kazama, Toshiki; Nagashima, Takeshi; Sakakibara, Masahiro; Suzuki, Tiberiu Hiroshi; Okubo, Yoshiyuki; Shiina, Nobumitsu; Fujisaki, Kaoru; Ota, Satoshi; Miyazaki, Masaru			Diffusion-weighted imaging reflects pathological therapeutic response and relapse in breast cancer	BREAST CANCER			English	Article						Diffusion-weighted magnetic resonance imaging; Breast cancer; Neoadjuvant therapy; Response; Prognosis	INTERNATIONAL EXPERT CONSENSUS; NEOADJUVANT CHEMOTHERAPY; PRETREATMENT PREDICTION; PROGNOSTIC-FACTORS; DUCTAL CARCINOMA; BRAIN-TUMORS; MRI; HIGHLIGHTS; RECURRENCE; REDUCTION	Conventional imaging does not always accurately depict the pathological response to neoadjuvant chemotherapy (NAC). Diffusion-weighted imaging (DWI) may provide additional insight into the chemotherapeutic effect. This study assessed whether the apparent diffusion coefficient (ADC) correlated with pathological outcome and prognosis in breast cancer patients receiving NAC. Fifty-six patients with locally advanced breast cancer received surgery after NAC. Dynamic contrast-enhanced (DCE) and DWI were performed before and after NAC. The pathological response was classified into five categories from no response to complete response according to amount of residual cancer. The correlation between ADC and postoperative pathologic and prognostic outcome was assessed. The distribution of the pathological response classification was as follows: no response, 3 cases; mild response, 22 cases; moderate response, 12 cases; marked response, 11 cases; complete response, 8 cases. ADC after NAC correlated with pathological response, but ADC before NAC did not. The change in ADC after chemotherapy had better correlation coefficient (r = 0.67) than change in size (r = 0.58) and ADC after NAC (r = 0.64). Although the group with larger change of tumor size showed only marginal significance compared with the smaller change group (p = 0.089), the group with higher change of ADC showed significantly better prognosis than the lower one (p = 0.038). Change in ADC after chemotherapy better correlated with pathological outcome and prognosis than change in tumor size. DWI has potential in evaluating the pathological outcome of NAC in breast cancer patients.	[Fujimoto, Hiroshi; Nagashima, Takeshi; Sakakibara, Masahiro; Suzuki, Tiberiu Hiroshi; Okubo, Yoshiyuki; Shiina, Nobumitsu; Fujisaki, Kaoru; Miyazaki, Masaru] Chiba Univ, Grad Sch Med, Dept Gen Surg, Chuo Ku, Chiba 2600856, Japan; [Kazama, Toshiki] Chiba Univ, Grad Sch Med, Dept Radiol, Chuo Ku, Chiba 2600856, Japan; [Ota, Satoshi] Chiba Univ, Grad Sch Med, Dept Diagnost Pathol, Chuo Ku, Chiba 2600856, Japan	Fujimoto, H (reprint author), Chiba Univ, Grad Sch Med, Dept Gen Surg, Chuo Ku, 1-8-1 Inohana, Chiba 2600856, Japan.	hifujimonty@chiba-u.jp					Goldhirsch A, 2007, ANN ONCOL, V18, P1133, DOI 10.1093/annonc/mdm271; Bear HD, 2006, J CLIN ONCOL, V24, P2019, DOI 10.1200/JCO.2005.04.1665; Chenevert TL, 1997, CLIN CANCER RES, V3, P1457; Guo Y, 2002, J MAGN RESON IMAGING, V16, P172, DOI 10.1002/jmri.10140; Rahbar H, 2012, RADIOLOGY, V263, P374, DOI 10.1148/radiol.12111368; Esserman L, 1999, J CLIN ONCOL, V17, P110; Rubesova E, 2006, J MAGN RESON IMAGING, V24, P319, DOI 10.1002/jmri.20643; Symmans WF, 2007, J CLIN ONCOL, V25, P4414, DOI 10.1200/JCO.2007.10.6823; Nilsen L, 2010, ACTA ONCOL, V49, P354, DOI 10.3109/02841861003610184; Woodhams R, 2010, RADIOLOGY, V254, P357, DOI 10.1148/radiol.2542090405; Jeh SK, 2011, J MAGN RESON IMAGING, V33, P102, DOI 10.1002/jmri.22400; von Minckwitz G, 2012, J CLIN ONCOL, V30, P1796, DOI 10.1200/JCO.2011.38.8595; Tsushima Y, 2009, J MAGN RESON IMAGING, V30, P249, DOI 10.1002/jmri.21854; Lee KC, 2007, CLIN CANCER RES, V13, P443, DOI 10.1158/1078-0432.CCR-06-1888; Fangberget A, 2011, EUR RADIOL, V21, P1188, DOI 10.1007/s00330-010-2020-3; Ross BD, 2003, MOL CANCER THER, V2, P581; Rajan R, 2004, CANCER, V100, P1365, DOI 10.1002/cncr.20134; Park SH, 2010, RADIOLOGY, V257, P56, DOI 10.1148/radiol.10092021; Chagpar AB, 2006, ANN SURG, V243, P257, DOI 10.1097/01.sla.0000197714.14318.6f; Fisher B, 1998, J CLIN ONCOL, V16, P2672; Iacconi C, 2010, EUR RADIOL, V20, P303, DOI 10.1007/s00330-009-1550-z; Padhani AR, 2006, RADIOLOGY, V239, P361, DOI 10.1148/radiol.2392021099; Chenevert TL, 2000, J NATL CANCER I, V92, P2029, DOI 10.1093/jnci/92.24.2029; Sharma U, 2009, NMR BIOMED, V22, P104, DOI 10.1002/nbm.1245; Thoeny HC, 2010, J MAGN RESON IMAGING, V32, P2, DOI 10.1002/jmri.22167; Goldhirsch A, 2005, ANN ONCOL, V16, P1569, DOI 10.1093/annonc/mdi326; Kurosumi M, 2008, BREAST CANCER-TOKYO, V15, P5, DOI 10.1007/s12282-007-0016-x; Choi SY, 2012, BRIT J RADIOL, V85, pE474, DOI 10.1259/bjr/79381464; Dzik-Jurasz A, 2002, LANCET, V360, P307, DOI 10.1016/S0140-6736(02)09520-X; Koh DM, 2007, AM J ROENTGENOL, V188, P1001, DOI 10.2214/AJR.06.0601; Pickles MD, 2006, MAGN RESON IMAGING, V24, P843, DOI 10.1016/j.mri.2005.11.005; Abe O, 2005, LANCET, V365, P1687; Nagashima T, 2010, BREAST CANCER-TOKYO, V17, P125, DOI 10.1007/s12282-009-0117-9; Parsian S, 2012, RADIOLOGY, V265, P696, DOI 10.1148/radiol.12112672; Wolmark N, 2001, J NATL CANC I MONOGR, V30, P96; Woodhams Reiko, 2005, Magn Reson Med Sci, V4, P35, DOI 10.2463/mrms.4.35; Wu LM, 2012, BREAST CANCER RES TR, V135, P17, DOI 10.1007/s10549-012-2033-5	37	3	3	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1340-6868	1880-4233		BREAST CANCER-TOKYO	Beast Cancer	NOV	2014	21	6					724	731		10.1007/s12282-013-0449-3		8	Oncology; Obstetrics & Gynecology	Oncology; Obstetrics & Gynecology	AS6AP	WOS:000344347700013		
J	Ogura, K; Horii, R; Oosako, T; Iwase, T; Akiyama, F				Ogura, Kaoru; Horii, Rie; Oosako, Tomo; Iwase, Takuji; Akiyama, Futoshi			A clinico-pathological study on cancer in sclerosing adenosis	BREAST CANCER			English	Article						Cancer in sclerosing adenosis; Bilateral breast cancer; Non-comedo type; HER2	CARCINOMA IN-SITU; BREAST-CANCER; INTRADUCTAL CARCINOMA; FIBROADENOMA; PAPILLOMAS; PARAMETERS; ESTROGEN; RECEPTOR; INSITU	Cancer in sclerosing adenosis includes the following 2 types: cancer genuinely arising from sclerosing adenosis and cancer arising near a sclerosing adenosis lesion and infiltrating into it. This study aimed to elucidate the features of the former by comparing both types. This study included 28 lesions in 27 cases of cancer in sclerosing adenosis for which surgery was performed during a 2-year period from January 2006 at the Cancer Institute Hospital of the Japanese Foundation for Cancer Research. We determined the proportions of cancer in sclerosing adenosis relative to the overall lesion of ductal carcinoma in situ. They were compared for 13 clinico-pathological factors by dividing the lesions into 2 groups: those involving cancer in 50 % or more (cancer in sclerosing adenosis predominant type-inner type) and those involving cancer in less than 50 % (cancer out of sclerosing adenosis predominant type-outer type). There were 20 lesions (71 %) of the inner type and 8 lesions (29 %) of the outer type. The comparison between the 2 types revealed significant differences in the following 3 factors. Bilateral breast cancer was observed in 5 cases (26 %) of the inner type and in none (0 %) of the outer type, indicating that there were significantly more cases of bilateral breast cancer for the inner type (p = 0.04). Regarding the subtypes of ductal carcinoma in situ, there were significantly more cases of the non-comedo type for the inner type (p = 0.002). Significantly fewer cases were positive for human epidermal growth factor receptor type 2 (HER2) for the inner type (p = 0.007). The results of this study suggest that cancer genuinely arising in sclerosing adenosis may often have biological features of bilateral breast cancer, non-comedo type in subtype, and being negative for HER2.	[Ogura, Kaoru; Akiyama, Futoshi] Japanese Fdn Canc Res, Inst Canc, Div Pathol, Tokyo 170, Japan; [Ogura, Kaoru] Tokyo Womens Med Univ, Med Ctr East, Dept Breast Surg, Arakawa Ku, Tokyo 1168567, Japan; [Horii, Rie; Oosako, Tomo] Japanese Fdn Canc Res, Canc Inst Hosp, Div Pathol, Tokyo, Japan; [Horii, Rie; Iwase, Takuji; Akiyama, Futoshi] Japanese Fdn Canc Res, Canc Inst Hosp, Div Breast, Tokyo, Japan	Ogura, K (reprint author), Tokyo Womens Med Univ, Med Ctr East, Dept Breast Surg, Arakawa Ku, 2-1-10 Nishiogu, Tokyo 1168567, Japan.	kdomoto@hotmail.com					Beckmann MW, 1997, J MOL MED-JMM, V75, P429, DOI 10.1007/s001090050128; Shahedi K, 2006, CANCER, V106, P1237, DOI 10.1002/cncr.21753; Regan MM, 2006, J NATL CANCER I, V98, P1571, DOI 10.1093/jnci/djj415; Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775; Viale G, 2007, J CLIN ONCOL, V25, P3846, DOI 10.1200/JCO.2007.11.9453; Shoker BS, 2000, J CLIN PATHOL, V53, P778, DOI 10.1136/jcp.53.10.778; CHAN JKC, 1987, PATHOLOGY, V19, P425, DOI 10.3109/00313028709103896; EUSEBI V, 1989, SEMIN DIAGN PATHOL, V6, P146; FECHNER RE, 1981, AM J SURG PATHOL, V5, P233, DOI 10.1097/00000478-198104000-00003; HARADA Y, 1994, CANCER, V74, P2281, DOI 10.1002/1097-0142(19941015)74:8<2281::AID-CNCR2820740812>3.0.CO;2-I; Huo DZ, 2011, CANCER-AM CANCER SOC, V117, P907, DOI 10.1002/cncr.25587; ICHIHARA S, 1994, PATHOL INT, V44, P722; Jung WH, 2000, YONSEI MED J, V41, P293; Kato F, 2011, MAGN RESON MED SCI, V10, P129; MacGrogan G, 2003, VIRCHOWS ARCH, V443, P609, DOI 10.1007/s00428-003-0888-x; Moritani S, 2011, HISTOPATHOLOGY, V58, P835, DOI 10.1111/j.1365-2559.2011.03792.x; Neilsen BB, 1987, HISTOPATHOLOGY, V11, P1259; OBERMAN HA, 1991, MODERN PATHOL, V4, P31; OHUCHI N, 1984, CANCER, V54, P605, DOI 10.1002/1097-0142(1984)54:4<605::AID-CNCR2820540402>3.0.CO;2-6; RASBRIDGE SA, 1995, HISTOPATHOLOGY, V27, P269, DOI 10.1111/j.1365-2559.1995.tb00220.x; Rosen PP, 2009, ROSENS BREAST PATHOL, P285; Umemura S, 1994, BREAST CANC, V30, P131; Visscher DW, 2009, ARCH PATHOL LAB MED, V133, P1817, DOI 10.1043/1543-2165-133.11.1817; Yamaguchi R, 2009, PATHOL INT, V59, P185, DOI 10.1111/j.1440-1827.2009.02348.x; YOSHIDA Y, 1985, J SURG ONCOL, V29, P132, DOI 10.1002/jso.2930290213	25	1	1	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1340-6868	1880-4233		BREAST CANCER-TOKYO	Beast Cancer	NOV	2014	21	6					732	737		10.1007/s12282-013-0450-x		6	Oncology; Obstetrics & Gynecology	Oncology; Obstetrics & Gynecology	AS6AP	WOS:000344347700014		
J	Fujita, T; Mizukami, T; Okawara, T; Inoue, K; Fujimori, M				Fujita, Tomoyuki; Mizukami, Tamio; Okawara, Tadashi; Inoue, Kengo; Fujimori, Minoru			Identification of a novel inhibitor of triple-negative breast cancer cell growth by screening of a small-molecule library	BREAST CANCER			English	Article						Small-molecule library; Triple-negative breast cancer; Drug development; cDNA microarray	PHASE-II; CHEMOSENSITIVITY; CARCINOMA; SUBTYPES	Triple-negative breast cancers (TNBC) are defined as not having amplification of the estrogen receptor, progesterone receptor, or epidermal growth factor receptor 2. Recovery of patients is, currently, severely limited after diagnosis of metastatic TNBC, with fewer than 30 % of patients surviving more than 5 years. The most effective therapy to date is chemotherapy, which has been unsuccessful because of lack of therapeutic targets for these aggressive cancers. To identify new molecular targets for TNBC, we have developed a novel method for drug discovery using active compounds for identification of pharmacodynamic biomarkers. We used chemical informatics to design a small-molecule library with structural diversity. This library was used to screen for compounds that selectively inhibit proliferation of TNBC cell lines. Different gene-expression profiles in cell lines before and after the addition of selected compounds were analyzed and compared with those of control cells. We identified (E)-3-(3,4-dihydroxybenzylidene)benzofuran-2(3H)-one (DBBF) which specifically inhibited proliferation of a TNBC cell line, MDA-MB-468, with an IC50 of 2.4 mu M. Microarray analysis identified several signaling pathways, including the irinotecan pathway, which changed specifically in the TNBC cell lines on addition of DBBF. We have developed a novel research strategy that involves screening of selective inhibitors of TNBC cell line proliferation that can be used for identification of pharmacodynamic biomarkers for TNBC. The discovery of new pathways by this technique should lead to the identification of new therapeutic targets for this aggressive cancer.	[Fujita, Tomoyuki; Fujimori, Minoru] Tokyo Med Univ, Ibaraki Med Ctr, Dept Breast Surg, Ami Inashiki, Ibaraki 3000395, Japan; [Mizukami, Tamio] Nagahama Inst Biosci & Technol, Nagahama, Shiga, Japan; [Okawara, Tadashi] Kumamoto Hlth Sci Univ, Kumamoto, Japan; [Inoue, Kengo] Shizuoka Ind Fdn, Pharma Valley Ctr, Shizuoka, Japan	Fujimori, M (reprint author), Tokyo Med Univ, Ibaraki Med Ctr, Dept Breast Surg, 3-20-1 Chuo, Ami Inashiki, Ibaraki 3000395, Japan.	minoruf@tokyo-med.ac.jp					Carey LA, 2007, CLIN CANCER RES, V13, P2329, DOI 10.1158/1078-0432.CCR-06-1109; Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445; Suzuki K, 2005, BIOORG MED CHEM LETT, V15, P2065, DOI 10.1016/j.bmcl.2005.02.052; Ellard SL, 2009, J CLIN ONCOL, V27, P4536, DOI 10.1200/JCO.2008.21.3033; Finn RS, 2007, BREAST CANCER RES TR, V105, P319, DOI 10.1007/s10549-006-9463-x; Morris GJ, 2007, CANCER, V110, P876, DOI 10.1002/cncr.22836; Nielsen TO, 2004, CLIN CANCER RES, V10, P5367, DOI 10.1158/1078-0432.CCR-04-0220; Rahman M, 2009, BREAST CANCER RES TR, V113, P217, DOI 10.1007/s10549-008-9924-5; Tutt A, 2010, LANCET, V376, P235, DOI 10.1016/S0140-6736(10)60892-6; Lehmann BD, 2011, J CLIN INVEST, V121, P2750, DOI 10.1172/JCI45014; WANI MC, 1980, J MED CHEM, V23, P554, DOI 10.1021/jm00179a016; Desbordes SC, 2008, CELL STEM CELL, V2, P602, DOI 10.1016/j.stem.2008.05.010; Haffty BG, 2006, J CLIN ONCOL, V24, P5652, DOI 10.1200/JCO.2006.06.5664; Pegram MD, 1998, J CLIN ONCOL, V16, P2659; Vazquez M, 2010, NUCLEIC ACIDS RES, V38, pW228, DOI 10.1093/nar/gkq476; Iljin K, 2009, CLIN CANCER RES, V15, P6070, DOI 10.1158/1078-0432.CCR-09-1035; Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045; O'Shaughnessy J, 2011, NEW ENGL J MED, V364, P205, DOI 10.1056/NEJMoa1011418; Burstein HJ, 2008, J CLIN ONCOL, V26, P1810, DOI 10.1200/JCO.2007.14.5375; Kim SY, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-144; Lim SK, 2007, BIOCHEM J, V403, P119, DOI 10.1042/BJ20061272; O'Shaughnessy J, 2011, ANN M AM SOC CLIN ON; Stegmaier K, 2007, PLOS MED, V4, P702, DOI 10.1371/journal.pmed.0040122; Tabuchi Y, 2006, FEBS LETT, V580, P3035, DOI 10.1016/j.febslet.2006.04.048; WIGGANS RG, 1979, CANCER CHEMOTH PHARM, V3, P45	25	1	1	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1340-6868	1880-4233		BREAST CANCER-TOKYO	Beast Cancer	NOV	2014	21	6					738	747		10.1007/s12282-013-0452-8		10	Oncology; Obstetrics & Gynecology	Oncology; Obstetrics & Gynecology	AS6AP	WOS:000344347700015		
J	Uehiro, N; Horii, R; Iwase, T; Tanabe, M; Sakai, T; Morizono, H; Kimura, K; Iijima, K; Miyagi, Y; Nishimura, S; Makita, M; Ito, Y; Akiyama, F				Uehiro, Natsue; Horii, Rie; Iwase, Takuji; Tanabe, Masahiko; Sakai, Takehiko; Morizono, Hidetomo; Kimura, Kiyomi; Iijima, Kotaro; Miyagi, Yumi; Nishimura, Seiichiro; Makita, Masujiro; Ito, Yoshinori; Akiyama, Futoshi			Validation study of the UICC TNM classification of malignant tumors, seventh edition, in breast cancer	BREAST CANCER			English	Article						Breast cancer; TNM classification; Micrometastasis; Staging	LYMPH-NODE METASTASES; MICROMETASTASES; IMMUNOHISTOCHEMISTRY; BIOPSY; CELLS	The TNM classification of the Unio Internationalis Contra Cancrum was revised for the seventh edition. The major change concerning breast cancer is a change in the stages for patients with T0 or T1N1miM0. In the present study, the seventh edition of the TNM classification was validated in breast cancer. The stages of 416 breast cancer patients, treated at our hospital in 1996, were classified according to the TNM classification, sixth and seventh editions, and their prognoses were compared. Case distribution using the sixth edition was stage 0, 56 cases (13.5 %); stage I, 158 cases (38.0 %); stage II, 130 [A, 102; B, 28] cases (31.2 [A, 24.5; B, 6.7] %); and stage III, 72 [A, 31; B, 8; C, 33] cases (17.3 [A, 7.5; B, 1.9; C, 7.9] %). According to the seventh edition, the stages for 20 patients, accounting for 19.6 % of IIA cases according to the sixth edition, decreased from IIA to IB. The 10-year overall survivals were stage 0, 91.1 %; stage I, 88.6 %; stage II, 80.8 %; and stage III, 63.9 % according to the sixth edition; and stage 0, 91.1 %; stage I, 88.8 %; stage II, 79.1 %; and stage III, 63.9 % according to the seventh edition. Although no significant differences were seen among the survival rates for stages 0 to II according to the sixth edition, there was a significant difference between stage I and II according to the seventh edition (p = 0.026). The latest revision of the TNM classification is appropriate for breast cancer from the perspective of prognosis.	[Uehiro, Natsue; Iwase, Takuji; Tanabe, Masahiko; Sakai, Takehiko; Morizono, Hidetomo; Kimura, Kiyomi; Iijima, Kotaro; Miyagi, Yumi; Nishimura, Seiichiro; Makita, Masujiro; Ito, Yoshinori] Japanese Fdn Canc Res, Canc Inst Hosp, Breast Oncol Ctr, Tokyo 1358550, Japan; [Uehiro, Natsue; Akiyama, Futoshi] Japanese Fdn Canc Res, Inst Canc, Div Pathol, Tokyo 1358550, Japan; [Horii, Rie] Japanese Fdn Canc Res, Canc Inst Hosp, Div Pathol, Koto Ku, Tokyo 1358550, Japan	Horii, R (reprint author), Japanese Fdn Canc Res, Canc Inst Hosp, Div Pathol, Koto Ku, 3-8-31 Ariake, Tokyo 1358550, Japan.	rie.horii@jfcr.or.jp					Tsujimoto M, 2007, CLIN CANCER RES, V13, P4807, DOI 10.1158/1078-0432.CCR-06-2512; Tan LK, 2008, J CLIN ONCOL, V26, P1803, DOI 10.1200/JCO.2007.12.6425; Weaver DL, 2011, NEW ENGL J MED, V364, P412, DOI 10.1056/NEJMoa1008108; GIULIANO AE, 1995, ANN SURG, V222, P394, DOI 10.1097/00000658-199509000-00016; Chen SL, 2007, ANN SURG ONCOL, V14, P3378, DOI 10.1245/s10434-007-9513-6; de Boer M, 2010, J NATL CANCER I, V102, P410, DOI 10.1093/jnci/djq008; Reed J, 2009, J AM COLL SURGEONS, V208, P333, DOI 10.1016/j.jamcollsurg.2008.10.036; Cote RJ, 1999, LANCET, V354, P896, DOI 10.1016/S0140-6736(98)11104-2; Patani N, 2011, BREAST CANCER RES TR, V127, P325, DOI 10.1007/s10549-011-1476-4; Ryden L, 2007, EJSO-EUR J SURG ONC, V33, P33, DOI 10.1016/j.ejso.2006.11.007; Salhab M, 2011, SURG ONCOL, V20, pE195, DOI 10.1016/j.suronc.2011.06.006; Grabau D, 2011, HISTOPATHOLOGY, V59, P129, DOI 10.1111/j.1365-2559.2011.03881.x; Greene FL, 2009, TNM CLASSIFICATION M, P181; Greene FL., 2002, TNM CLASSIFICATION M, P131; Park D, 2009, BREAST CANCER RES TR, V118, P57, DOI 10.1007/s10549-009-0340-2; Pugliese MS, 2009, ANN SURG ONCOL, V16, P113, DOI 10.1245/s10434-008-0121-x	16	2	2	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1340-6868	1880-4233		BREAST CANCER-TOKYO	Beast Cancer	NOV	2014	21	6					748	753		10.1007/s12282-013-0453-7		6	Oncology; Obstetrics & Gynecology	Oncology; Obstetrics & Gynecology	AS6AP	WOS:000344347700016		
J	Ishitobi, M; Okumura, Y; Nishimura, R; Nakatsukasa, K; Tanabe, M; Yoshida, A; Masuda, N; Shien, T; Tanaka, S; Komoike, Y; Arima, N; Taguchi, T; Inaji, H				Ishitobi, Makoto; Okumura, Yasuhiro; Nishimura, Reiki; Nakatsukasa, Katsuhiko; Tanabe, Masahiko; Yoshida, Atsushi; Masuda, Norikazu; Shien, Tadahiko; Tanaka, Satoru; Komoike, Yoshifumi; Arima, Nobuyuki; Taguchi, Tetsuya; Inaji, Hideo		Japanese Breast Canc Soc	Repeat lumpectomy for ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery: the impact of radiotherapy on second IBTR	BREAST CANCER			English	Article						Breast cancer; Breast-conserving surgery; Ipsilateral breast tumor recurrence; Repeat lumpectomy	CONSERVATION THERAPY; LOCAL RECURRENCE; DISTANT RECURRENCE; CANCER SUBTYPE; CARCINOMA; PROGNOSIS	There are limited data on the outcomes of patients treated with repeat lumpectomy at the time of ipsilateral breast tumor recurrence (IBTR). Especially, the impact of radiotherapy (RT) on a second IBTR is unknown. We retrospectively analyzed 143 patients from 8 institutions in Japan who underwent repeat lumpectomy after IBTR. The risk factors of a second IBTR were assessed. The median follow-up period was 4.8 years. The 5-year second IBTR-free survival rate was 80.7 %. There was a significant difference in the second IBTR-free survival rate according to RT (p = 0.0003, log-rank test). The 5-year second IBTR-free survival rates for patients who received RT after initial surgery, RT after salvage surgery, and no RT were 78.0, 93.5, and 52.7 %, respectively. Multivariate analysis revealed that RT was a significantly independent predictive factor of second IBTR-free survival. Repeat lumpectomy plus RT is a reasonable option in patients who did not undergo RT at the initial surgery. In contrast, caution is needed when RT is omitted in patients who have undergone repeat lumpectomy.	[Ishitobi, Makoto; Komoike, Yoshifumi; Inaji, Hideo] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Breast Surg, Higashinari Ku, Osaka 5378511, Japan; [Ishitobi, Makoto; Komoike, Yoshifumi; Inaji, Hideo] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Endocrine Surg, Higashinari Ku, Osaka 5378511, Japan; [Okumura, Yasuhiro; Nishimura, Reiki] Kumamoto City Hosp, Dept Breast & Endocrine Surg, Kumamoto, Japan; [Nakatsukasa, Katsuhiko; Taguchi, Tetsuya] Kyoto Prefectural Univ Med, Dept Endocrine & Breast Surg, Kyoto, Japan; [Tanabe, Masahiko] Japanese Fdn Canc Res, Canc Inst Hosp, Div Breast Oncol, Tokyo, Japan; [Yoshida, Atsushi] St Lukes Int Hosp, Dept Breast Surg, Tokyo, Japan; [Masuda, Norikazu] Osaka Natl Hosp, Natl Hosp Org, Dept Surg, Osaka, Japan; [Shien, Tadahiko] Okayama Univ Hosp, Dept Breast & Endocrine Surg, Okayama, Japan; [Tanaka, Satoru] Osaka Med Coll, Dept Gen & Gastroenterol Surg, Sect Breast & Endocrine Surg, Osaka, Japan; [Arima, Nobuyuki] Kumamoto City Hosp, Dept Pathol, Kumamoto, Japan	Ishitobi, M (reprint author), Osaka Med Ctr Canc & Cardiovasc Dis, Dept Breast Surg, Higashinari Ku, 1-3-3 Nakamichi, Osaka 5378511, Japan.	isitobi-ma@mc.pref.osaka.jp			Japanese Breast Cancer Society; Takeda; Chugai	We thank Dr. Takuji Iwase and Dr. Takehiro Tanaka for critical reading of the manuscript. This study was supported in part by Grants-in-Aid for Scientific Research from the Japanese Breast Cancer Society. Dr. Tetsuya Taguchi received a research grant from Takeda and Chugai. Other authors declare that they have no conflict of interest.	Alpert TE, 2005, INT J RADIAT ONCOL, V63, P845, DOI 10.1016/jijrobp.2005.02.035; Cheang MCU, 2009, J NATL CANCER I, V101, P736, DOI 10.1093/jnci/djp082; Mamounas EP, 2010, J CLIN ONCOL, V28, P1677, DOI 10.1200/JCO.2009.23.7610; Ishitobi M, 2013, ANN SURG ONCOL, V20, P1886, DOI 10.1245/s10434-012-2825-1; van der Sangen MJC, 2006, EJSO, V32, P34, DOI 10.1016/j.ejso.2005.10.005; Millar EKA, 2009, J CLIN ONCOL, V27, P4701, DOI 10.1200/JCO.2008.21.7075; Voogd AC, 1999, CANCER, V85, P437, DOI 10.1002/(SICI)1097-0142(19990115)85:2<437::AID-CNCR23>3.0.CO;2-1; Goldhirsch A, 2011, ANN ONCOL, V22, P1736, DOI 10.1093/annonc/mdr304; Nguyen PL, 2008, J CLIN ONCOL, V26, P2373, DOI 10.1200/JCO.2007.14.4287; Ishitobi M, 2011, ONCOLOGY-BASEL, V81, P381, DOI 10.1159/000335265; Nishimura R, 2010, EXP THER MED, V1, P747, DOI 10.3892/etm.2010.133; Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492; Clemons M, 2003, BREAST, V12, P328, DOI 10.1016/S0960-9776(03)00107-3; Darby S, 2011, LANCET, V378, P1707, DOI DOI 10.1016/S0140-6736(11)61629-2; Gentilini O, 2012, ANN SURG ONCOL; KURTZ JM, 1991, EUR J CANCER, V27, P240, DOI 10.1016/0277-5379(91)90505-8; Tuttle TM, 2012, CANCER-AM CANCER SOC, V118, P2004, DOI 10.1002/cncr.26505	17	1	1	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1340-6868	1880-4233		BREAST CANCER-TOKYO	Beast Cancer	NOV	2014	21	6					754	760		10.1007/s12282-013-0454-6		7	Oncology; Obstetrics & Gynecology	Oncology; Obstetrics & Gynecology	AS6AP	WOS:000344347700017		
J	Kagara, N; Nakano, Y; Watanabe, A; Inatome, J; Nakamura, H; Kim, C; Danno, K; Taniguchi, H; Kanoh, T; Kimura, Y; Ohnishi, T; Tono, T; Monden, T; Imaoka, S; Kagawa, K				Kagara, Naofumi; Nakano, Yoshiaki; Watanabe, Ami; Inatome, Junichi; Nakamura, Hidetoshi; Kim, Chiwan; Danno, Katsuki; Taniguchi, Hirokazu; Kanoh, Toshiyuki; Kimura, Yutaka; Ohnishi, Tadashi; Tono, Takeshi; Monden, Takushi; Imaoka, Shingi; Kagawa, Kazufumi			Curative-intent stereotactic body radiation therapy for residual breast cancer liver metastasis after systemic chemotherapy	BREAST CANCER			English	Article						Liver metastasis of breast cancer; Curative-intent SBRT; Oligometastases	PERCUTANEOUS RADIOFREQUENCY ABLATION; PHASE-I/II TRIAL; HEPATIC METASTASES; TUMORS; SBRT; RADIOTHERAPY; EXPERIENCE; DISEASE	Liver metastases from breast cancer are generally treated with systemic therapy such as chemotherapy or hormonotherapy. However, local treatment options such as resection, radiofrequency ablation (RFA), and radiotherapy can also be considered to treat oligometastases. We report the case of a 45-year-old female treated with stereotactic body radiotherapy (SBRT) after chemotherapy against a solitary liver metastasis from primary breast cancer. A liver metastasis with diameter of 35 mm developed 3.5 years after surgery for primary breast cancer in 2004. Fourteen courses of triweekly docetaxel treatments considerably decreased the metastatic lesion, but there still remained a tiny lesion radiographically. Chemotherapy was stopped because of the side-effects of docetaxel, and then SBRT was selected for additional treatment, aiming at complete cure of metastasis. X-ray irradiation (52.8 Gy/4 fractions) was applied to the remaining metastatic lesion, and magnetic resonance imaging (MRI) showed no evidence of residual tumor 4 months after irradiation. Neither regrowth nor recurrences have been found until now, 24 months after SBRT. SBRT for oligometastases of breast cancer may be one of the possible curative-intent options, being less invasive than surgical resection or RFA.	[Kagara, Naofumi; Nakano, Yoshiaki; Watanabe, Ami; Inatome, Junichi] NTT West Osaka Hosp, Div Breast & Endocrine Surg, Tennoji Ku, Osaka 5438922, Japan; [Nakamura, Hidetoshi; Kim, Chiwan; Danno, Katsuki; Taniguchi, Hirokazu; Kanoh, Toshiyuki; Kimura, Yutaka; Ohnishi, Tadashi; Tono, Takeshi; Monden, Takushi; Imaoka, Shingi] NTT West Osaka Hosp, Dept Surg, Tennoji Ku, Osaka 5438922, Japan; [Kagawa, Kazufumi] NTT West Osaka Hosp, Dept Radiat Oncol, Tennoji Ku, Osaka 5438922, Japan	Nakano, Y (reprint author), NTT West Osaka Hosp, Div Breast & Endocrine Surg, Tennoji Ku, 2-6-40 Karasugatsuji, Osaka 5438922, Japan.	nakano-y@mhc.west.ntt.co.jp					Lermite E, 2010, SURG ONCOL, V19, pE79, DOI 10.1016/j.suronc.2009.06.005; Machi J, 2001, J GASTROINTEST SURG, V5, P477, DOI 10.1016/S1091-255X(01)80085-8; Rusthoven KE, 2009, J CLIN ONCOL, V27, P1572, DOI 10.1200/JCO.2008.19.6329; Milano MT, 2009, BREAST CANCER RES TR, V115, P601, DOI 10.1007/s10549-008-0157-4; Livraghi T, 2003, RADIOLOGY, V226, P441, DOI 10.1148/radiol.2262012198; Sutherland LM, 2006, ARCH SURG-CHICAGO, V141, P181, DOI 10.1001/archsurg.141.2.181; Livraghi T, 2001, RADIOLOGY, V220, P145; Kavanagh BD, 2006, ACTA ONCOL, V45, P848, DOI 10.1080/02841860600904870; Illing R, 2010, CLIN ONCOL-UK, V22, P781, DOI 10.1016/j.clon.2010.08.004; Katz AW, 2007, INT J RADIAT ONCOL, V67, P793, DOI 10.1016/j.ijrobp.2006.10.025; Dawson LA, 2006, ACTA ONCOL, V45, P856, DOI 10.1080/02841860600936369; Wulf J, 2006, ACTA ONCOL, V45, P838, DOI 10.1080/02841860600904821; HELLMAN S, 1995, J CLIN ONCOL, V13, P8; Milano MT, 2008, CANCER, V112, P650, DOI 10.1002/cncr.23209; Dawson LA, 2002, INT J RADIAT ONCOL, V53, P810, DOI 10.1016/S0360-3016(02)02846-8; Romero AM, 2009, INT J RADIAT ONCOL, V75, P1201, DOI 10.1016/j.ijrobp.2008.12.020; BLOMGREN H, 1995, ACTA ONCOL, V34, P861; Dawson LA, 2004, CANCER J, V10, P139, DOI 10.1097/00130404-200403000-00009; Goodman KA, 2009, INT J RADIAT ONCOL, V78, P486; Harrison LE, 2003, J AM COLL SURGEONS, V197, P759, DOI 10.1016/S1072-7515(03)00750-6; Pivot X, 2000, ONCOLOGY-BASEL, V58, P185, DOI 10.1159/000012098; Tampellini M, 1997, BRIT J CANCER, V75, P698, DOI 10.1038/bjc.1997.124	22	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1340-6868	1880-4233		BREAST CANCER-TOKYO	Beast Cancer	NOV	2014	21	6					761	764		10.1007/s12282-011-0290-5		4	Oncology; Obstetrics & Gynecology	Oncology; Obstetrics & Gynecology	AS6AP	WOS:000344347700018		
J	Taira, F; Shimizu, H; Kosaka, T; Saito, M; Kasumi, F				Taira, Fumi; Shimizu, Hideo; Kosaka, Taijiro; Saito, Mitsue; Kasumi, Fujio			An osteogenesis imperfecta case with breast cancer	BREAST CANCER			English	Article						Osteogenesis imperfecta; Breast cancer; DPD activity; 5-FU toxicity	DIHYDROPYRIMIDINE DEHYDROGENASE-DEFICIENCY; PATIENT; CARCINOMA; TOXICITY	Osteogenesis imperfecta (OI) is a rare connective tissue disease characterized by abnormalities of type 1 collagen and an increased risk of bone fractures. Several OI cases with malignancies have been reported. Herein, we describe an OI case with breast cancer. A 36-year-old premenopausal woman with OI was admitted to our hospital for evaluation of a right breast lump. We diagnosed right breast cancer with axillary and parasternal lymph node metastasis (T2N3M0 stage IIIC). The tumor had increased in size and tumor markers were elevated after 10 months of hormone therapy. We performed a right mastectomy and axillary dissection. She subsequently received adjuvant chemotherapy and radiotherapy. She is currently taking trastuzumab and tamoxifen. Anesthesia is challenging in OI patients because of difficulty with airway control and intubation. We performed the mastectomy in this case without difficulty by working in cooperation with experienced anesthesiologists, orthopedists, and other medical personnel. Some OI patients reportedly have severe 5-fluorouracil (5-FU) toxicity related to dihydropyrimidine dehydrogenase (DPD) deficiency. DPD is the main enzyme involved in the catabolism of 5-FU. Our present case also had low DPD activity and we thus chose epirubicin and cyclophosphamide for chemotherapy. Our search of the literature yielded only two OI cases with breast cancer as of April 2011. To our knowledge, this is the first case reported in Japan.	[Taira, Fumi; Shimizu, Hideo; Kosaka, Taijiro; Saito, Mitsue; Kasumi, Fujio] Juntendo Univ Hosp, Dept Breast Oncol, Bunkyo Ku, Tokyo 1138421, Japan	Taira, F (reprint author), Juntendo Univ Hosp, Dept Breast Oncol, Bunkyo Ku, 3-1-3 Hongo, Tokyo 1138421, Japan.	fmuraka@juntendo.ac.jp					ALLANSON JE, 1986, OBSTET GYNECOL, V67, P74; LU ZH, 1993, CANCER RES, V53, P5433; TUCHMAN M, 1985, NEW ENGL J MED, V313, P245, DOI 10.1056/NEJM198507253130407; Augustin G, 2007, J INHERIT METAB DIS, V30, P109, DOI 10.1007/s10545-006-0438-1; Beuzeboc P, 1996, EUR J CANCER, V32A, P369, DOI 10.1016/0959-8049(95)00573-0; Böhler F K, 1994, Strahlenther Onkol, V170, P665; Fukushima S, 2001, JPN J GASTROENTEROL, V34, P1466; Garg Munish, 2009, Indian J Anaesth, V53, P68; Karabiyik L, 2002, ACTA ANAESTH SCAND, V46, P618, DOI 10.1034/j.1399-6576.2002.460525.x; Kidouchi K, 1996, IGAKU NO AYUMI, V179, P901; Mattison LK, 2004, CLIN CANCER RES, V10, P2652, DOI 10.1158/1078-0432.CCR-03-0374; NISHIDA T, 1993, ARCH GYNECOL OBSTET, V253, P153, DOI 10.1007/BF02767334; Ogura K, 2006, JPN J CANC CHEMOTHER, V33, P1041; RAMPTON AJ, 1984, BRIT J ANAESTH, V56, P1443, DOI 10.1093/bja/56.12.1443; Rosenstock H A, 1970, Tex Med, V66, P44; Shono A, 2007, ANESTHESIA, V56, P692	16	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1340-6868	1880-4233		BREAST CANCER-TOKYO	Beast Cancer	NOV	2014	21	6					769	773		10.1007/s12282-011-0303-4		5	Oncology; Obstetrics & Gynecology	Oncology; Obstetrics & Gynecology	AS6AP	WOS:000344347700020		
J	Ueda, S; Saeki, T				Ueda, Shigeto; Saeki, Toshiaki			Near-infrared optical imaging of cancer vascular remodeling after antiangiogenic therapy	BREAST CANCER			English	Article						Breast cancer; Bevacizumab; Optical imaging; Hemoglobin; Angiogenesis	BREAST-CANCER; NEOADJUVANT CHEMOTHERAPY; DCE-MRI; NORMALIZATION; PET/CT	Near-infrared diffuse optical imaging (DOSI) has been recently accepted as a method to assess tumor vascularity and oxygenation by measuring tissue hemoglobin (Hb) concentration. It is expected that DOSI could be used to monitor changes in vascularity after antiangiogenic therapy. A patient with advanced breast cancer was treated with single-agent bevacizumab followed by addition of weekly paclitaxel to it. DOSI was performed in the tumor-bearing breast and contralateral normal breast at baseline, 3, 6, 12, 24 h, and then daily for 1 week. Images of a tumor-to-normal ratio of tHb (rtHb) were constructed for identifying a tumor lesion. Serial images of rtHb showed a tumor lesion which corresponded to a hot spot. The level of rtHb rapidly decreased within several hours after administration of single-agent bevacizumab and then persisted at low levels during treatment. From day 2, the value of rtHb gradually increased and peaked on day 5. This trend may be explained considering sequential images of rtHb indicating the inhibition of angiogenesis due to antiangiogenic therapy. We conducted a clinical study using single-agent bevacizumab followed by neoadjuvant chemotherapy in primary breast cancer patients to understand vascular remodeling after antiangiogenic agent at very early time points using DOSI.	[Ueda, Shigeto; Saeki, Toshiaki] Saitama Med Univ, Dept Breast Oncol, Int Med Ctr, Hidaka, Saitama 3501298, Japan	Ueda, S (reprint author), Saitama Med Univ, Dept Breast Oncol, Int Med Ctr, 1397-1 Yamane, Hidaka, Saitama 3501298, Japan.	syueda2000@yahoo.co.jp			JSPS KAKENHI [25830105]; Hidaka Research Grant	The authors thank Noriko Wakui for her excellent technical assistance and Motoki Oda, Yukio Ueda, PhD and Yutaka Yamashita, Central Research Laboratory, Hamamatsu Photonics K. K. for their sincere cooperation of this research. This work was supported by JSPS KAKENHI Grant Number 25830105 and Hidaka Research Grant.	Zwick S, 2009, J MAGN RESON IMAGING, V29, P1125, DOI 10.1002/jmri.21710; Tromberg BJ, 2005, BREAST CANCER RES, V7, P279, DOI 10.1186/bcr1358; Zhu Q, 2013, RADIOLOGY, V266, P433, DOI 10.1148/radiol.12112415; Roblyer D, 2011, P NATL ACAD SCI USA, V108, P14626, DOI 10.1073/pnas.1013103108; Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819; Cheng JY, 2013, J NUCL MED, V54, P333, DOI 10.2967/jnumed.112.111963; Goel S, 2011, PHYSIOL REV, V91, P1071, DOI 10.1152/physrev.00038.2010; Bartlett RM, 2012, J NUCL MED, V53, P1608, DOI 10.2967/jnumed.112.103523; Cerussi A, 2006, J BIOMED OPT, V11, DOI 10.1117/1.2337546; De Bruyne S, 2012, BRIT J CANCER, V106, P1926, DOI 10.1038/bjc.2012.184; Ueda S, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-514; Ueda Y, 2011, TECHNOL CANCER RES T, V10, P393	12	0	0	SPRINGER JAPAN KK	TOKYO	CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065, JAPAN	1340-6868	1880-4233		BREAST CANCER-TOKYO	Beast Cancer	NOV	2014	21	6					776	779		10.1007/s12282-014-0534-2		4	Oncology; Obstetrics & Gynecology	Oncology; Obstetrics & Gynecology	AS6AP	WOS:000344347700022		
J	Broeyer, FJF; Osanto, S; Suzuki, J; de Jongh, F; van Slooten, H; Tanis, BC; Bruning, T; Bax, JJ; van Eck, HJR; de Kam, ML; Cohen, AF; Mituzhima, Y; Burggraaf, J				Broeyer, Frederik J. F.; Osanto, Susanne; Suzuki, Jun; de Jongh, Felix; van Slooten, Henk; Tanis, Bea C.; Bruning, Tobias; Bax, Jeroen J.; van Eck, Henk J. Ritsema; de Kam, Marieke L.; Cohen, Adam F.; Mituzhima, Yutaka; Burggraaf, Jacobus			Evaluation of lecithinized human recombinant super oxide dismutase as cardioprotectant in anthracycline-treated breast cancer patients	BRITISH JOURNAL OF CLINICAL PHARMACOLOGY			English	Article						anthracyclines; biological markers; breast neoplasms; electrocardiography; heart failure; oxidative stress	CONGESTIVE-HEART-FAILURE; HIGH-DOSE CHEMOTHERAPY; SPINAL-CORD INJURY; NATRIURETIC PEPTIDES; TROPONIN-I; PC-SOD; CARDIOTOXICITY; TOXICITY; DOXORUBICIN; ISCHEMIA	AimAnthracycline-induced cardiotoxicity is (partly) mediated by free radical overload. A randomized study was performed in breast cancer patients to investigate whether free radical scavenger super oxide dismutase (SOD) protects against anthracycline-induced cardiotoxicity as measured by changes in echo, electrocardiography and an array of biomarkers. Method and ResultsEighty female, chemotherapy-naive breast cancer patients (median age 49, range 24-67 years) scheduled for four or five courses of adjuvant 3 weekly doxorubicin plus cyclophosphamide (AC) chemotherapy, were randomly assigned to receive 80mg PC-SOD (human recombinant SOD bound to lecithin) or placebo, administered intravenously (i.v.) immediately prior to each AC course. The primary end point was protection against cardiac damage evaluated using echocardiography, QT assessments and a set of biochemical markers for myocardial function, oxidative stress and inflammation. Assessments were performed before and during each course of chemotherapy, and at 1, 4 and 9 months after completion of the chemotherapy regimen. In all patients cardiac effects such as increases in NT-proBNP concentration and prolongation of the QT(c) interval were noticed. There were no differences between the PC-SOD and placebo-treated patients in systolic or diastolic cardiac function or for any other of the biomarkers used to assess the cardiac effects of anthracyclines. ConclusionPC-SOD at a dose of 80mg i.v. is not cardioprotective in patients with breast carcinoma treated with anthracyclines.	[Broeyer, Frederik J. F.; de Kam, Marieke L.; Cohen, Adam F.; Burggraaf, Jacobus] Ctr Human Drug Res, NL-2333 CL Leiden, Netherlands; [Osanto, Susanne; Bax, Jeroen J.] Leiden Univ, Med Ctr, Leiden, Netherlands; [Suzuki, Jun; Mituzhima, Yutaka] LLT Biopharma, Tokyo, Japan; [de Jongh, Felix] Ikazia Ziekenhuis, Rotterdam, Netherlands; [van Slooten, Henk] Diaconessenziekenhuis, Leiden, Netherlands; [Tanis, Bea C.] Groene Hart Ziekenhuis, Gouda, Netherlands; [Bruning, Tobias] Maasstad Ziekenhuis, Rotterdam, Netherlands; [van Eck, Henk J. Ritsema] Adv Med Syst, Maasdam, Netherlands	Burggraaf, J (reprint author), Ctr Human Drug Res, Zernikedreef 10, NL-2333 CL Leiden, Netherlands.	kb@chdr.nl			LTT Bio-Pharma	All authors have completed the Unified Competing Interest form at http://www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare FB, AC, MK and JB are employees of the CHDR, that was financially supported by LTT Bio-Pharma for the submitted work. JS and YM were employees of LTT Bio-Pharma during the study.	Cardinale D, 2000, J AM COLL CARDIOL, V36, P517, DOI 10.1016/S0735-1097(00)00748-8; Suzuki T, 1998, AM HEART J, V136, P362, DOI 10.1053/hj.1998.v136.89908; Broeyer FJF, 2008, BRIT J CLIN PHARMACO, V65, P22, DOI 10.1111/j.1365-2125.2007.02965.x; Cardinale D, 2004, CIRCULATION, V109, P2749, DOI 10.1161/01.CIR.0000130926.51766.CC; IGARASHI R, 1994, J PHARMACOL EXP THER, V271, P1672; Ishihara T, 2009, J PHARMACOL EXP THER, V328, P152, DOI 10.1124/jpet.108.144451; MAO GD, 1993, J BIOL CHEM, V268, P416; Broeyer FJF, 2008, J CANCER RES CLIN, V134, P961, DOI 10.1007/s00432-008-0372-8; Ryberg M, 2008, J NATL CANCER I, V100, P1058, DOI 10.1093/jnci/djn206; SAHN DJ, 1978, CIRCULATION, V58, P1072; Simunek T, 2008, BRIT J PHARMACOL, V155, P138, DOI 10.1038/bjp.2008.236; Minotti G, 2004, PHARMACOL REV, V56, P185, DOI 10.1124/pr.56.2.6; Nakamae H, 2005, CANCER, V104, P2492, DOI 10.1002/cncr.21478; Tsubokawa T, 2007, STROKE, V38, P1057, DOI 10.1161/01.STR.0000257978.70312.1d; Kilickap S, 2005, ANN ONCOL, V16, P798, DOI 10.1093/annonc/mdi152; Lipshultz SE, 1997, CIRCULATION, V96, P2641; IGARASHI R, 1992, J PHARMACOL EXP THER, V262, P1214; Levey AS, 1999, ANN INTERN MED, V130, P461; Gianni L, 2008, J CLIN ONCOL, V26, P3777, DOI 10.1200/JCO.2007.14.9401; Swain SM, 2003, CANCER, V97, P2869, DOI 10.1002/cncr.11407; VONHOFF DD, 1979, ANN INTERN MED, V91, P710; BERNIER M, 1989, AM J PHYSIOL, V256, pH1344; Bryant J, 2007, EUR J CANCER, V43, P1959, DOI 10.1016/j.ejca.2007.06.012; Chikawa T, 2001, J NEUROTRAUM, V18, P93, DOI 10.1089/089771501750055802; densHartog GJ, 2004, TOXICOL APPL PHARM, V194, P180; DOWNEY JM, 1991, FREE RADICAL RES COM, V12-3, P703; Fayers P, 2002, EUR J CANCER, V38, pS125; Germanakis I, 2008, PEDIATR BLOOD CANCER, V51, P327, DOI 10.1002/pbc.21633; Hangaishi M, 2001, BIOCHEM BIOPH RES CO, V285, P1220, DOI 10.1006/bbrc.2001.5319; ISHII T, 1991, FREE RADICAL RES COM, V14, P187, DOI 10.3109/10715769109088948; Meinardi MT, 2001, J CLIN ONCOL, V19, P2746; MUINDI JRF, 1984, FEBS LETT, V172, P226, DOI 10.1016/0014-5793(84)81130-8; Nakagawa K, 2002, KIDNEY INT, V61, P1160, DOI 10.1046/j.1523-1755.2002.00217.x; Nakajima H, 2001, LIFE SCI, V69, P935, DOI 10.1016/S0024-3205(01)01188-2; Nakajima H, 2000, FREE RADICAL BIO MED, V29, P34, DOI 10.1016/S0891-5849(00)00290-2; Nakauchi K, 1996, J NEUROTRAUM, V13, P573; NOHL H, 1983, BIOCHEM BIOPH RES CO, V114, P197, DOI 10.1016/0006-291X(83)91613-3; Nousiainen T, 2002, J INTERN MED, V251, P228, DOI 10.1046/j.1365-2796.2002.00951.x; OMAR BA, 1990, FREE RADICAL BIO MED, V9, P465, DOI 10.1016/0891-5849(90)90123-Z; SCOTT MD, 1987, J BIOL CHEM, V262, P3640; Shimmura S, 2003, AM J OPHTHALMOL, V135, P613, DOI 10.1016/S0002-9394(02)02151-7; Suzuki J, 2008, J CLIN PHARMACOL, V48, P184, DOI 10.1177/0091270007309705; vansDalen EC, 2008, COCHRANE DB SYST REV; Yunoki M, 2003, SURG NEUROL, V59, P156, DOI 10.1016/S0090-3019(02)01040-6	44	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0306-5251	1365-2125		BRIT J CLIN PHARMACO	Br. J. Clin. Pharmacol.	NOV	2014	78	5					950	960		10.1111/bcp.12429		11	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AS4CY	WOS:000344222100003		
J	Nakayama, S; Yokote, T; Tsuji, M; Akioka, T; Miyoshi, T; Hirata, Y; Hiraoka, N; Iwaki, K; Takayama, A; Nishiwaki, U; Masuda, Y; Hanafusa, T				Nakayama, Shoko; Yokote, Taiji; Tsuji, Motomu; Akioka, Toshikazu; Miyoshi, Takuji; Hirata, Yuji; Hiraoka, Nobuya; Iwaki, Kazuki; Takayama, Ayami; Nishiwaki, Uta; Masuda, Yuki; Hanafusa, Toshiaki			Expression of tumour necrosis factor-alpha and its receptors in Hodgkin lymphoma	BRITISH JOURNAL OF HAEMATOLOGY			English	Letter						tumour necrosis factor-; tumour necrosis factor- receptor 1; tumour necrosis factor- receptor 2; immunohistochemistry; Hodgkin lymphoma	REED-STERNBERG CELLS; B-CELL; TRANSCRIPTION FACTORS; CIRCULATING LEVELS; TNF-ALPHA; MALIGNANCIES; PROGNOSIS; MARKERS; DISEASE; CD30		[Nakayama, Shoko; Yokote, Taiji; Akioka, Toshikazu; Miyoshi, Takuji; Hirata, Yuji; Hiraoka, Nobuya; Iwaki, Kazuki; Takayama, Ayami; Nishiwaki, Uta; Masuda, Yuki; Hanafusa, Toshiaki] Osaka Med Coll, Dept Internal Med 1, Osaka, Japan; [Tsuji, Motomu] Osaka Med Coll, Osaka, Japan	Nakayama, S (reprint author), Osaka Med Coll, Dept Internal Med 1, Osaka, Japan.	in1304@poh.osaka-med.ac.jp					Valsami S, 2007, HAEMATOL-HEMATOL J, V92, P1343, DOI 10.3324/haematol.11523; Marafioti T, 2000, BLOOD, V95, P1443; Deutsch YE, 2011, LEUKEMIA LYMPHOMA, V52, P1641, DOI 10.3109/10428194.2011.574761; Li YJ, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-84; Hu SM, 2013, BLOOD, V121, P2715, DOI 10.1182/blood-2012-10-461848; STEIN H, 1985, BLOOD, V66, P848; Salles G, 1996, BRIT J HAEMATOL, V93, P352, DOI 10.1046/j.1365-2141.1996.5181059.x; Herbeck R, 2011, ROM J MORPHOL EMBRYO, V52, P69; GRUSS HJ, 1993, LEUKEMIA, V7, P1339; Metkar SS, 2000, AM J HEMATOL, V65, P105, DOI 10.1002/1096-8652(200010)65:2<105::AID-AJH3>3.0.CO;2-R	10	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-1048	1365-2141		BRIT J HAEMATOL	Br. J. Haematol.	NOV	2014	167	4					574	577		10.1111/bjh.13015		4	Hematology	Hematology	AS6CA	WOS:000344351200020		
J	Ishikawa, S; Taguchi, M; Muraoka, T; Sakurai, Y; Kanda, T; Takeuchi, M				Ishikawa, Sho; Taguchi, Manzo; Muraoka, Tadashi; Sakurai, Yutaka; Kanda, Takayuki; Takeuchi, Masaru			Changes in subfoveal choroidal thickness associated with uveitis activity in patients with Behcet's disease	BRITISH JOURNAL OF OPHTHALMOLOGY			English	Article							OPTICAL COHERENCE TOMOGRAPHY; INDOCYANINE GREEN ANGIOGRAPHY; KOYANAGI-HARADA-DISEASE; POSTERIOR UVEITIS; INVOLVEMENT	Aims To evaluate the efficacy of measuring subfoveal choroidal thickness in monitoring uveitis activity before and after treatment with infliximab in patients with Behcet's disease (BD)-associated uveitis. Methods Thirteen patients with BD (23 eyes) were selected for this retrospective observational case study. Subfoveal choroidal thickness was measured during active and remission phases of uveitis by enhanced depth imaging-spectral domain optical coherence tomography (EDI-OCT). In five patients (10 eyes), choroidal thickness was assessed at weeks 0, 2, 6 and 14 after the initiation of infliximab treatment. Results Accompanied by excessive dye leakage from choroidal vessels on indocyanine green angiography, dilation of choroidal vessels was observed in the active phase of uveitis by EDI-OCT and the choroidal thickness was significantly greater than that in the remission phase. Treatment with infliximab significantly reduced the choroidal thickness from week 2 after the first infusion, and the reduced choroidal thickness was maintained thereafter. No correlation was found between choroidal thickness and best corrected visual acuity converted to logarithm of the minimum angle of resolution, but choroidal thickness correlated significantly with anterior and posterior ocular inflammation scores. Conclusions This study indicates that measurement of subfoveal choroidal thickness by EDI-OCT is useful for evaluating the activity of uveitis and the therapeutic efficacy in patients with BD.	[Ishikawa, Sho; Taguchi, Manzo; Muraoka, Tadashi; Sakurai, Yutaka; Kanda, Takayuki; Takeuchi, Masaru] Natl Def Med Coll, Dept Ophthalmol, Tokorozawa, Saitama 3598513, Japan	Takeuchi, M (reprint author), Natl Def Med Coll, Dept Ophthalmol, 3-2 Namiki, Tokorozawa, Saitama 3598513, Japan.	masatake@ndmc.ac.jp			Japan Society for the Promotion of Science [24592689]	The authors thank Mahsa Takahashi for assistance with analysis of OCT data. This work was supported in part by Grant-in-Aid 24592689 for Scientific Research from the Japan Society for the Promotion of Science.	Sakane T, 1999, NEW ENGL J MED, V341, P1284, DOI 10.1056/NEJM199910213411707; Aoyagi R, 2012, CLIN EXP OPTOM, V95, P212, DOI 10.1111/j.1444-0938.2011.00668.x; Hassenstein A, 2009, CLIN EXP OPHTHALMOL, V37, P130, DOI 10.1111/j.1442-9071.2009.02017.x; Spaide RF, 2008, AM J OPHTHALMOL, V146, P496, DOI 10.1016/j.ajo.2008.05.032; Rao Narsing A., 2007, International Ophthalmology, V27, P81, DOI 10.1007/s10792-006-9029-2; Margolis R, 2009, AM J OPHTHALMOL, V147, P811, DOI 10.1016/j.ajo.2008.12.008; Maruko I, 2011, AM J OPHTHALMOL, V151, P594, DOI 10.1016/j.ajo.2010.10.030; Agawa T, 2011, GRAEF ARCH CLIN EXP, V249, P1485, DOI 10.1007/s00417-011-1708-7; NUSSENBLATT RB, 1985, OPHTHALMOLOGY, V92, P467; Atmaca LS, 2003, BRIT J OPHTHALMOL, V87, P1466, DOI 10.1136/bjo.87.12.1466; Evereklioglu C, 2005, SURV OPHTHALMOL, V50, P297, DOI 10.1016/j.surcophthal.2005.02.009; Maruko I, 2011, RETINA-J RET VIT DIS, V31, P510, DOI 10.1097/IAE.0b013e3181eef053; Fong AHC, 2011, RETINA-J RET VIT DIS, V31, P502, DOI 10.1097/IAE.0b013e3182083beb; Kim M, 2013, INVEST OPHTH VIS SCI, V54, P6033, DOI 10.1167/iovs.13-12231; ATMACA LS, 1989, GRAEF ARCH CLIN EXP, V227, P340, DOI 10.1007/BF02169409; Bouchenaki N, 2002, KLIN MONATSBL AUGENH, V219, P243, DOI 10.1055/s-2002-30661; CHAJEK T, 1975, MEDICINE, V54, P179, DOI 10.1097/00005792-197505000-00001; CHARTERIS DG, 1992, AUTOIMMUNITY, V12, P201, DOI 10.3109/08916939209148460; George RK, 1997, SURV OPHTHALMOL, V42, P157; Iaccarino G, 2009, OPHTHALMOLOGICA, V223, P250, DOI 10.1159/000209274; Ozdal PC, 2002, EUR J OPHTHALMOL, V12, P424; WONG RC, 1984, INT J DERMATOL, V23, P25, DOI 10.1111/j.1365-4362.1984.tb05658.x	22	4	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0007-1161	1468-2079		BRIT J OPHTHALMOL	Br. J. Ophthalmol.	NOV	2014	98	11					1508	1513		10.1136/bjophthalmol-2014-305333		6	Ophthalmology	Ophthalmology	AS3FR	WOS:000344163200009		
J	Lee, H; Takahashi, Y; Ichinose, A; Kakizaki, H				Lee, Hwa; Takahashi, Yasuhiro; Ichinose, Akihiro; Kakizaki, Hirohiko			Comparison of surgical outcomes between simple posterior layer advancement of lower eyelid retractors and combination with a lateral tarsal strip procedure for involutional entropion in a Japanese population	BRITISH JOURNAL OF OPHTHALMOLOGY			English	Article							REPAIR; SUTURES	Aims To compare the effectiveness of simple posterior layer advancement of the lower eyelid retractor (LER) and combination surgery of posterior layer advancement of the LER with a lateral tarsal strip procedure for involutional lower eyelid entropion in a Japanese population. Methods 46 eyelids of 37 patients with horizontal laxity (Group A) and 47 eyelids of 42 patients without horizontal laxity (Group B) that underwent simple posterior layer advancement of the LER, and 47 eyelids of 37 patients with horizontal laxity that had the combination surgery (Group C) were retrospectively reviewed. Results All eyelids were judged as successfully corrected without recurrence in Groups B and C. On the other hand, although 42 eyelids (91.3%) were successfully altered in Group A, four eyelids (8.7%) showed recurrence at a mean period of 7.6 months postoperatively. Surgical success rates in Groups B and C tended to be higher than in Group A (p=0.056). Conclusions The combination surgery in Group C and simple posterior layer advancement of the LER in Group B provided complete surgical success. The present study suggests the importance of preoperative evaluation of horizontal laxity, allowing surgeons to perform the least amount of surgery to achieve success.	[Lee, Hwa; Takahashi, Yasuhiro; Kakizaki, Hirohiko] Aichi Med Univ, Dept Ophthalmol, Nagakute, Aichi 4801195, Japan; [Lee, Hwa] Korea Univ, Coll Med, Dept Ophthalmol, Gyeonggi, South Korea; [Ichinose, Akihiro] Kobe Univ, Sch Med, Dept Plast Surg, Kobe, Hyogo, Japan	Kakizaki, H (reprint author), Aichi Med Univ, Dept Ophthalmol, Nagakute, Aichi 4801195, Japan.	cosme@d1.dion.ne.jp					Scheepers MA, 2010, OPHTHALMOLOGY, V117, P352, DOI 10.1016/j.ophtha.2009.06.056; JORDAN DR, 1989, ARCH OPHTHALMOL-CHIC, V107, P604; ANDERSON RL, 1979, ARCH OPHTHALMOL-CHIC, V97, P2192; Rougraff PM, 2001, OPHTHALMIC PLAST REC, V17, P281, DOI 10.1097/00002341-200107000-00008; Danks JJ, 1998, OPHTHALMOLOGY, V105, P2065, DOI 10.1016/S0161-6420(98)91126-5; Ho SF, 2005, OPHTHAL PLAST RECONS, V21, P345, DOI 10.1097/01.iop.0000179370.96976.ee; Quist LH, 2002, CAN J OPHTHALMOL, V37, P238; Barnes JA, 2006, OPHTHALMOLOGY, V113, P92, DOI 10.1016/j.ophtha.2005.06.039; Beigi B, 2008, OPHTHALMOLOGY, V115, P1608, DOI 10.1016/j.ophtha.2008.02.014; Ben Simon GJ, 2005, AM J OPHTHALMOL, V139, P482, DOI 10.1016/j.ajo.2004.10.003; Boboridis KG, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002221.pub2; Cook T, 2001, OPHTHALMOLOGY, V108, P989, DOI 10.1016/S0161-6420(01)00552-8; Erb MH, 2006, OPHTHALMOLOGY, V113, P2351, DOI 10.1016/j.ophtha.2006.07.034; Kakizaki H, 2007, OPHTHAL PLAST RECONS, V23, P292, DOI 10.1097/IOP.0b013e3180986778; Kakizaki H, 2009, OPHTHALMOLOGY, V116, P1402, DOI 10.1016/j.ophtha.2009.01.031; Kakizaki H, 2006, OPHTHALMOLOGY, V113, P2346, DOI 10.1016/j.ophtha.2006.06.017; Kakizaki H, 2011, PAPERS, V51, P94; Kang Hyera, 2012, Orbit, V31, P279, DOI 10.3109/01676830.2012.694957; Khan SJ, 2002, OPHTHALMOLOGY, V109, P2112, DOI 10.1016/S0161-6420(02)01259-9; Kreis Andreas J, 2013, Orbit, V32, P271, DOI 10.3109/01676830.2013.815230; Olver J, 2001, COLOUR ATLAS LACRIMA, P44; Pereira MGB, 2010, SEMIN OPHTHALMOL, V25, P52, DOI 10.3109/08820538.2010.488573; Roberts MA, 2012, OPHTHAL PLAST RECONS, V28, P44, DOI 10.1097/IOP.0b013e3182364a8e	23	1	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0007-1161	1468-2079		BRIT J OPHTHALMOL	Br. J. Ophthalmol.	NOV	2014	98	11					1579	1582		10.1136/bjophthalmol-2013-304830		4	Ophthalmology	Ophthalmology	AS3FR	WOS:000344163200023		
J	Omori, K; Kida, T; Hori, M; Ozaki, H; Murata, T				Omori, K.; Kida, T.; Hori, M.; Ozaki, H.; Murata, T.			Multiple roles of the PGE(2)-EP receptor signal in vascular permeability	BRITISH JOURNAL OF PHARMACOLOGY			English	Article							NITRIC-OXIDE; VE-CADHERIN; IN-VIVO; PROSTANOID RECEPTORS; ARRIVE GUIDELINES; BETA-CATENIN; CELL; PHOSPHORYLATION; PROSTAGLANDINS; PHARMACOLOGY	Background and PurposePGE(2) is a major prostanoid that regulates inflammation by stimulating EP1-4 receptors. However, how PGE(2) induces an initial inflammatory response to vascular hyper-permeability remains unknown. Here we investigated the role of the PGE(2)-EP receptor signal in modulating vascular permeability both in vivo and in vitro. Experimental ApproachWe used a modified Miles assay and intravital microscopy to examine vascular permeability in vivo. Endothelial barrier property was assessed by measuring transendothelial electrical resistance (TER) in vitro. Key ResultsLocal administration of PGE(2), an EP2 or EP4 receptor agonist into FVB/NJcl mouse ear skin caused vascular leakage, indicated by dye extravasation. Intravital microscopy and laser Doppler blood-flow imaging revealed that these treatments dilated peripheral vessels and increased local blood flow. Pretreatment with the vasoconstrictor phenylephrine inhibited the PGE(2)-induced blood flow increase and vascular leakage. In contrast to the EP2 and EP4 receptor agonists, administration of an EP3 receptor agonist suppressed vascular leakage without altering vascular diameter or blood flow. In isolated HUVECs, the EP3 receptor agonist elevated TER and blocked thrombin-induced dextran passage. Inhibiting PKA restored the hypo-permeability induced by the EP3 receptor agonist. Conclusions and ImplicationsActivation of the PGE(2)-EP2 or -EP4 receptor signal induces vasodilatation in mural cells, resulting in increased local blood flow and hyper-permeability. In contrast, activation of the PGE(2)-EP3 receptor signal induces a cAMP-dependent enhancement of the endothelial barrier, leading to hypo-permeability. We provide the first evidence that endothelial cells and mural cells cooperate to modulate vascular permeability.	[Omori, K.; Murata, T.] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Anim Radiol, Tokyo 1138657, Japan; [Kida, T.; Hori, M.; Ozaki, H.] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Vet Pharmacol, Tokyo 1138657, Japan	Murata, T (reprint author), Univ Tokyo, Grad Sch Agr, Dept Anim Radiol, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1138657, Japan.	amurata@mail.ecc.u-tokyo.ac.jp			Program for Promotion of Basic and Applied Researches for Innovations in Bio-oriented Industry (BRAIN); Science and Technology Research Promotion Program for Agriculture, Forestry, Fisheries and Food Industry; Japan Society for the Promotion of Science; Mochida Memorial Foundation; Towa Foundation; Takeda Science Foundation	We acknowledge the Ono Pharmaceutical Company, Japan for donating ONO-DI-004, ONO-AE1-259-01, ONO-AE-248, and ONO-AE1-329. This work was supported by a Grant-in-Aid for JSPS Fellows (Taiki Kida), the Program for Promotion of Basic and Applied Researches for Innovations in Bio-oriented Industry (BRAIN), the Science and Technology Research Promotion Program for Agriculture, Forestry, Fisheries and Food Industry, a Grant-in-Aid from the Japan Society for the Promotion of Science, the Mochida Memorial Foundation, the Towa Foundation and the Takeda Science Foundation (Takahisa Murata).	Alexander SPH, 2013, BRIT J PHARMACOL, V170, P1459, DOI 10.1111/bph.12445; Nathan RA, 2008, CLIN THER, V30, P573, DOI 10.1016/j.clinthera.2008.04.011; Morales-Ruiz M, 2001, J BIOL CHEM, V276, P19672, DOI 10.1074/jbc.M009993200; Kobayashi K, 2011, EUR J PHARMACOL, V660, P375, DOI 10.1016/j.ejphar.2011.03.032; Thurston G, 1999, SCIENCE, V286, P2511, DOI 10.1126/science.286.5449.2511; Weis SM, 2008, CURR OPIN HEMATOL, V15, P243, DOI 10.1097/MOH.0b013e3282f97d86; Hatae N, 2002, J BIOCHEM, V131, P781; Dejana E, 2008, J CELL SCI, V121, P2115, DOI 10.1242/jcs.017897; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Kilkenny C, 2010, BRIT J PHARMACOL, V160, P1577, DOI 10.1111/j.1476-5381.2010.00872.x; Curry FRE, 2010, CARDIOVASC RES, V87, P218, DOI 10.1093/cvr/cvq115; Mehta D, 2006, PHYSIOL REV, V86, P279, DOI 10.1152/physrev.00012.2005; Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156; Wang Z, 2010, J BIOL CHEM, V285, P21303, DOI 10.1074/jbc.M110.120790; MAJNO G, 1961, J BIOPHYS BIOCHEM CY, V11, P571, DOI 10.1083/jcb.11.3.571; Potter MD, 2005, J BIOL CHEM, V280, P31906, DOI 10.1074/jbc.M505568200; Bos CL, 2004, INT J BIOCHEM CELL B, V36, P1187, DOI 10.1016/j.biocel.2003.08.006; Thibeault S, 2010, MOL CELL, V39, P468, DOI 10.1016/j.molcel.2010.07.013; Lee MJ, 1999, CELL, V99, P301, DOI 10.1016/S0092-8674(00)81661-X; Hahn C, 2009, NAT REV MOL CELL BIO, V10, P53, DOI 10.1038/nrm2596; Breyer RM, 2001, ANNU REV PHARMACOL, V41, P661, DOI 10.1146/annurev.pharmtox.41.1.661; Levick JR, 2010, CARDIOVASC RES, V87, P198, DOI 10.1093/cvr/cvq062; Pawson AJ, 2014, NUCLEIC ACIDS RES, V42, pD1098, DOI 10.1093/nar/gkt1143; Armulik A, 2011, DEV CELL, V21, P193, DOI 10.1016/j.devcel.2011.07.001; Bates DO, 2010, CARDIOVASC RES, V87, P262, DOI 10.1093/cvr/cvq105; McGrath JC, 2010, BRIT J PHARMACOL, V160, P1573, DOI 10.1111/j.1476-5381.2010.00873.x; ARMSTEAD WM, 1995, AM J PHYSIOL-HEART C, V268, pH1436; Birukova AA, 2007, EXP CELL RES, V313, P2504, DOI 10.1016/j.yexcr.2007.03.036; Curry FRE, 2005, MICROCIRCULATION, V12, P17, DOI 10.1080/10739680590894993; Feletou M, 1996, BRIT J PHARMACOL, V118, P1371; Hirase T, 2011, AM J PHYSIOL-HEART C, V302, pH499, DOI DOI 10.1152/AJPHEART.00325.2011; Kida T, 2014, HEART VESSELS, V29, P390, DOI 10.1007/s00380-013-0374-6; Kobayashi K, 2013, ARTERIOSCL THROM VAS, V33, P565, DOI 10.1161/ATVBAHA.112.300993; Murata T, 2008, P NATL ACAD SCI USA, V105, P20009, DOI 10.1073/pnas.0805171105; Orsenigo F, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2199; Szekanecz Z, 2008, ARTHRITIS RES THER, V10, DOI 10.1186/ar2515; Ware LB, 2000, NEW ENGL J MED, V342, P1334, DOI 10.1056/NEJM200005043421806; Zhou G, 2012, AM J PHYSIOL-REG I, V302, pR409, DOI 10.1152/ajpregu.00153.2011	38	3	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-1188	1476-5381		BRIT J PHARMACOL	Br. J. Pharmacol.	NOV	2014	171	21					4879	4889		10.1111/bph.12815		11	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AS5UZ	WOS:000344336100007		
J	Yoshiki, H; Uwada, J; Anisuzzaman, ASM; Umada, H; Hayashi, R; Kainoh, M; Masuoka, T; Nishio, M; Muramatsu, I				Yoshiki, Hatsumi; Uwada, Junsuke; Anisuzzaman, Abu Syed Md; Umada, Hidenori; Hayashi, Ryoji; Kainoh, Mie; Masuoka, Takayoshi; Nishio, Matomo; Muramatsu, Ikunobu			Pharmacologically distinct phenotypes of alpha(1B)-adrenoceptors: variation in binding and functional affinities for antagonists	BRITISH JOURNAL OF PHARMACOLOGY			English	Article							URINARY-TRACT ALPHA(1)-ADRENOCEPTORS; PROTEIN-COUPLED RECEPTORS; TISSUE SEGMENT BINDING; AGONIST PHARMACOLOGY; ARRIVE GUIDELINES; DRUG DISCOVERY; HUMAN PROSTATE; IDENTIFICATION; CLASSIFICATION; ADRENOCEPTOR	Background and PurposeThe pharmacological properties of particular receptors have recently been suggested to vary under different conditions. We compared the pharmacological properties of the (1B)-adrenoceptor subtype in various tissue preparations and under various conditions. Experimental Approach[H-3]-prazosin binding to (1B)-adrenoceptors in rat liver (segments, dispersed hepatocytes and homogenates) was assessed and the pharmacological profiles were compared with the functional and binding profiles in rat carotid artery and recombinant (1B)-adrenoceptors. Key ResultsIn association and saturation-binding experiments with rat liver, binding affinity for [H-3]-prazosin varied significantly between preparations (K-D value approximately ten times higher in segments than in homogenates). The binding profile for various drugs in liver segments also deviated from the representative (1B)-adrenoceptor profile observed in liver homogenates and recombinant receptors. L-765,314 and ALS-77, selective antagonists of (1B)-adrenoceptors, showed high binding and antagonist affinities in liver homogenates and recombinant (1B)-adrenoceptors. However, binding affinities for both ligands in the segments of rat liver and carotid artery were 10 times lower, and the antagonist potencies in (1B)-adrenoceptor-mediated contractions of carotid artery were more than 100 times lower than the representative (1B)-adrenoceptor profile. Conclusions and ImplicationsIn contrast to the consistent profile of recombinant (1B)-adrenoceptors, the pharmacological profile of native (1B)-adrenoceptors of rat liver and carotid artery varied markedly under various receptor environments, showing significantly different binding properties between intact tissues and homogenates, and dissociation between functional and binding affinities. In addition to conventional subtype' characterization, phenotype' pharmacology must be considered in native receptor evaluations in vivo and in future pharmacotherapy.	[Yoshiki, Hatsumi; Uwada, Junsuke; Anisuzzaman, Abu Syed Md; Umada, Hidenori; Muramatsu, Ikunobu] Univ Fukui, Sch Med, Dept Biochem & Bioinformat Sci, Div Pharmacol, Fukui 9101193, Japan; [Uwada, Junsuke; Muramatsu, Ikunobu] Univ Fukui, Org Life Sci Adv Programs, Fukui 9101193, Japan; [Hayashi, Ryoji; Kainoh, Mie] Toray Industries Ltd, Pharmaceut Res Labs, Kamakura, Kanagawa, Japan; [Masuoka, Takayoshi; Nishio, Matomo; Muramatsu, Ikunobu] Kanazawa Med Univ, Sch Med, Dept Pharmacol, Uchinada, Ishikawa 92002, Japan; [Muramatsu, Ikunobu] Kimura Hosp, Fukui, Japan	Muramatsu, I (reprint author), Univ Fukui, Org Life Sci Adv Programs, Fukui 9101193, Japan.	muramatu@u-fukui.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan; Smoking Research Foundation of Japan; Organization for Life Science Advancement Programs (Research and Education Program for Life Science, Translational Research Program); Life Science Research Laboratory, University of Fukui	This work was supported in part by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan, by a grant from the Smoking Research Foundation of Japan, by the Organization for Life Science Advancement Programs (Research and Education Program for Life Science, Translational Research Program) and by the Life Science Research Laboratory, University of Fukui.	Anisuzzaman ASM, 2013, J NEUROCHEM, V118, P958; Alexander SPH, 2013, BRIT J PHARMACOL, V170, P1459, DOI 10.1111/bph.12445; Mohr K, 2010, BRIT J PHARMACOL, V159, P997, DOI 10.1111/j.1476-5381.2009.00601.x; Muramatsu I, 2005, J PHARMACOL SCI, V98, P331, DOI 10.1254/jphs.CPJ05001X; Michelotti GA, 2000, PHARMACOL THERAPEUT, V88, P281, DOI 10.1016/S0163-7258(00)00092-9; Kenakin T, 2003, NAT REV DRUG DISCOV, V2, P429, DOI 10.1038/nrd1110; Kilkenny C, 2010, BRIT J PHARMACOL, V160, P1577, DOI 10.1111/j.1476-5381.2010.00872.x; Graham RM, 1996, CIRC RES, V78, P737; Anisuzzaman AM, 2011, J PHARMACOL EXP THER, V339, P186, DOI 10.1124/jpet.111.182857; Cavalli A, 1997, P NATL ACAD SCI USA, V94, P11589, DOI 10.1073/pnas.94.21.11589; Eltze M, 1996, EUR J PHARMACOL, V295, P69, DOI 10.1016/0014-2999(95)00685-0; Kenakin T, 2010, PHARMACOL REV, V62, P265, DOI 10.1124/pr.108.000992; Lane JR, 2013, TRENDS PHARMACOL SCI, V34, P59, DOI 10.1016/j.tips.2012.10.003; HIEBLE JP, 1995, PHARMACOL REV, V47, P267; ARUNLAKSHANA O, 1959, BRIT J PHARM CHEMOTH, V14, P48; Nishimune A, 2012, BRIT J PHARMACOL, V165, P1226, DOI 10.1111/j.1476-5381.2011.01591.x; Baker JG, 2007, TRENDS PHARMACOL SCI, V28, P374, DOI 10.1016/j.tips.2007.06.011; Nelson CP, 2007, BIOCHEM PHARMACOL, V73, P737, DOI 10.1016/j.bcp.2006.09.005; BERRY MN, 1992, LIFE SCI, V51, P1, DOI 10.1016/0024-3205(92)90212-8; Pawson AJ, 2014, NUCLEIC ACIDS RES, V42, pD1098, DOI 10.1093/nar/gkt1143; Arch JRS, 2002, EUR J PHARMACOL, V440, P99, DOI 10.1016/S0014-2999(02)01421-8; McGrath JC, 2010, BRIT J PHARMACOL, V160, P1573, DOI 10.1111/j.1476-5381.2010.00873.x; BURT RP, 1995, BRIT J PHARMACOL, V115, P467; Cotecchia S, 2010, J RECEPT SIG TRANSD, V30, P410, DOI 10.3109/10799893.2010.518152; Ford APDW, 1996, MOL PHARMACOL, V49, P209; Furchgott RF, 1972, HDB EXPT PHARM, V33, P283; Hayashi R, 2000, 3-(4-(1H-indol-3-yl)piperidin-1-yl)-N,N-dimethylpropan-1-amine dihydrochloride (ALS-77): alpha1b-adrenergic receptor antagonists, Patent No. [EP 00940789 A, 00940789]; JACOBS S, 1976, BIOCHEM BIOPH RES CO, V70, P885, DOI 10.1016/0006-291X(76)90674-4; KENAKIN T, 1995, BIOCHEM PHARMACOL, V50, P17, DOI 10.1016/0006-2952(95)00137-O; LOMASNEY JW, 1991, BIOCHIM BIOPHYS ACTA, V1095, P127, DOI 10.1016/0167-4889(91)90075-9; MICHEL AD, 1989, BRIT J PHARMACOL, V98, P883; MICHEL MC, 1995, N-S ARCH PHARMACOL, V352, P1; MINNEMAN KP, 1988, PHARMACOL REV, V40, P87; Morishima S, 2007, J UROLOGY, V177, P377, DOI 10.1016/j.juro.2006.08.080; Morishima S, 2008, BRIT J PHARMACOL, V153, P1485, DOI 10.1038/sj.bjp.0707679; Muramatsu I, 2008, BRIT J PHARMACOL, V155, P1224, DOI 10.1038/bjp.2008.360; Murata S, 1999, BRIT J PHARMACOL, V127, P19, DOI 10.1038/sj.bjp.0702489; Patane MA, 1998, J MED CHEM, V41, P1205, DOI 10.1021/jm980053f; Sathi ZS, 2008, EUR J PHARMACOL, V584, P222, DOI 10.1016/j.ejphar.2008.02.003; Stam WB, 1998, EUR J PHARMACOL, V361, P79, DOI 10.1016/S0014-2999(98)00735-3; Testa R, 1997, J PHARMACOL EXP THER, V281, P1284; TUONG MDT, 1980, NATURE, V287, P548, DOI 10.1038/287548a0; Yoshiki H, 2013, BRIT J PHARMACOL, V170, P1242, DOI 10.1111/bph.12403	43	2	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-1188	1476-5381		BRIT J PHARMACOL	Br. J. Pharmacol.	NOV	2014	171	21					4890	4901		10.1111/bph.12813		12	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AS5UZ	WOS:000344336100008		
J	Kasutani, K; Fujii, E; Ohyama, S; Adachi, H; Hasegawa, M; Kitamura, H; Yamashita, N				Kasutani, K.; Fujii, E.; Ohyama, S.; Adachi, H.; Hasegawa, M.; Kitamura, H.; Yamashita, N.			Anti-IL-31 receptor antibody is shown to be a potential therapeutic option for treating itch and dermatitis in mice	BRITISH JOURNAL OF PHARMACOLOGY			English	Article							ATOPIC-DERMATITIS; SCRATCHING BEHAVIOR; NC/NGA MICE; MAST-CELLS; T-CELLS; CONTACT HYPERSENSITIVITY; INTERLEUKIN-31 IL-31; MULTIPLE APPLICATION; DIAGNOSTIC-CRITERIA; CYTOKINE PRODUCTION	Background and PurposeIL-31, which is described as a pruritogenic cytokine, is linked to the itching that is associated with allergic and non-allergic eczema, but the precise pruritogenic mechanism of IL-31 and its potential as a therapeutic target for atopic dermatitis (AD) have not been determined. Experimental ApproachWe investigated the effects of existing drugs on the scratching behaviour induced by an i.v. injection of IL-31 to clarify whether IL-31 induced pruritus indirectly. In addition, we studied the effects of an anti-IL-31 receptor subunit (anti-IL-31 receptor ) neutralizing antibody on chronic pruritus-inducing dermatitis in an AD-like model to determine whether IL-31 not only induces scratching behaviour, but is also the causative factor in an AD phenotype. Key ResultsThe scratching behaviour induced by an i.v. injection of IL-31 was inhibited by pretreatment with an anti-IL-31 receptor -neutralizing antibody. In contrast, it was not inhibited significantly by a non-sedative antihistamine (terfenadine), immunosuppressants (dexamethasone and tacrolimus), or a -opioid receptor antagonist (naloxone). The anti-IL-31 receptor -neutralizing antibody reduced the ear swelling and dermatitis score in a chronic pruritus-inducing AD-like model. Moreover, treatment with the anti-IL-31 receptor -neutralizing antibody showed therapeutic effects on the dermatitis even if it was injected after the disease had developed. Conclusions and ImplicationsAnti-IL-31 receptor is a potential novel therapeutic approach for escaping from the itch-scratch cycle and also a treatment for dermatitis in AD.	[Kasutani, K.; Yamashita, N.] Musashino Univ, Pharmaceut Sci Res Inst, Dept Pharmacotherapy, Tokyo, Japan; [Kasutani, K.; Fujii, E.; Ohyama, S.; Adachi, H.; Hasegawa, M.; Kitamura, H.] Chugai Pharmaceut Co Ltd, Res Div, Shizuoka 4128513, Japan	Kasutani, K (reprint author), Chugai Pharmaceut Co Ltd, Fuji Gotemba Res Labs, 1-135 Komakado, Shizuoka 4128513, Japan.	kasutanikik@chugai-pharm.co.jp					Arai I, 2013, EXP DERMATOL, V22, P669, DOI 10.1111/exd.12222; Alexander SPH, 2013, BRIT J PHARMACOL, V170, P1459, DOI 10.1111/bph.12445; Hanifin JM, 1999, ARCH DERMATOL, V135, P1551, DOI 10.1001/archderm.135.12.1551; Zhang Q, 2008, CYTOKINE GROWTH F R, V19, P347, DOI [10.1016/j.cytogfr.2008.08.003, 10.1016/j.cytogfr.200S.08.003]; Steinhoff M, 2006, J INVEST DERMATOL, V126, P1705, DOI 10.1038/sj.jid.5700231; Ezzat MHM, 2011, J EUR ACAD DERMATOL, V25, P334, DOI 10.1111/j.1468-3083.2010.03794.x; Niyonsaba F, 2010, J IMMUNOL, V184, P3526, DOI 10.4049/jimmunol.0900712; Bilsborough J, 2006, J ALLERGY CLIN IMMUN, V117, P418, DOI 10.1016/j.jaci.2005.10.046; Kilkenny C, 2010, BRIT J PHARMACOL, V160, P1577, DOI 10.1111/j.1476-5381.2010.00872.x; Kasraie S, 2010, ALLERGY, V65, P712, DOI 10.1111/j.1398-9995.2009.02255.x; Paus R, 2006, J CLIN INVEST, V116, P1174, DOI 10.1172/JCI28553; Alexander SPH, 2013, BRIT J PHARMACOL, V170, P1676, DOI 10.1111/bph.12449; Xu H, 1996, J EXP MED, V183, P1001, DOI 10.1084/jem.183.3.1001; Cheung PFY, 2010, INT IMMUNOL, V22, P453, DOI 10.1093/intimm/dxq027; Stander S, 2002, EXP DERMATOL, V11, P12, DOI 10.1034/j.1600-0625.2002.110102.x; Kitagaki H, 1997, J IMMUNOL, V159, P2484; Koblenzer CS, 1999, J ALLERGY CLIN IMMUN, V104, pS109, DOI 10.1016/S0091-6749(99)70052-7; OKAYAMA Y, 1994, ALLERGY, V49, P246, DOI 10.1111/j.1398-9995.1994.tb02657.x; Grimstad O, 2009, EXP DERMATOL, V18, P35, DOI 10.1111/j.1600-0625.2008.00766.x; Neis MM, 2006, J ALLERGY CLIN IMMUN, V118, P930, DOI 10.1016/j.jaci.2006.07.015; Raap U, 2008, J ALLERGY CLIN IMMUN, V122, P421, DOI 10.1016/j.jaci.2008.05.047; Konishi H, 2002, P NATL ACAD SCI USA, V99, P11340, DOI 10.1073/pnas.152337799; Dillon SR, 2004, NAT IMMUNOL, V5, P752, DOI 10.1038/ni1084; Pawson AJ, 2014, NUCLEIC ACIDS RES, V42, pD1098, DOI 10.1093/nar/gkt1143; MONROE EW, 1989, J AM ACAD DERMATOL, V21, P135, DOI 10.1016/S0190-9622(89)80353-6; McGrath JC, 2010, BRIT J PHARMACOL, V160, P1573, DOI 10.1111/j.1476-5381.2010.00873.x; Bando T, 2006, NEUROSCIENCE, V142, P1263, DOI 10.1016/j.neuroscience.2006.07.009; Assmann T, 2001, Expert Opin Pharmacother, V2, P1167, DOI 10.1517/14656566.2.7.1167; Baron R, 2001, NEUROREPORT, V12, P3475, DOI 10.1097/00001756-200111160-00020; BERNSTEIN JE, 1982, J INVEST DERMATOL, V78, P82, DOI 10.1111/1523-1747.ep12497974; Cornelissen C, 2012, J ALLERGY CLIN IMMUN, V129, P426, DOI 10.1016/j.jaci.2011.10.042; Fei MJ, 2005, J ALLERGY CLIN IMMUN, V116, P1350, DOI 10.1016/j.jaci.2005.08.032; Finlay AY, 2001, J AM ACAD DERMATOL, V45, pS64, DOI 10.1067/mjd.2001.117010; Gonzales AJ, 2013, VET DERMATOL, V24, P48, DOI 10.1111/j.1365-3164.2012.01098.x; Greaves MW, 2004, INT ARCH ALLERGY IMM, V135, P166, DOI 10.1159/000080898; HANDWERKER HO, 1991, J NEUROPHYSIOL, V66, P307; Hanifin JM, 1999, J ALLERGY CLIN IMMUN, V104, pS123, DOI 10.1016/S0091-6749(99)70054-0; Hawro T, 2014, ALLERGY, V69, P113, DOI 10.1111/all.12316; Inagaki N, 2002, EUR J PHARMACOL, V448, P175, DOI 10.1016/S0014-2999(02)01933-7; Inagaki N, 2003, SKIN PHARMACOL APPL, V16, P165, DOI 10.1159/000069755; Inoue Y, 2002, BRIT J DERMATOL, V147, P675, DOI 10.1046/j.1365-2133.2002.04917.x; Kido M, 2010, J DERMATOL SCI, V58, P130, DOI 10.1016/j.jdermsci.2010.03.007; Kim HO, 2009, INT J DERMATOL, V48, P431, DOI 10.1111/j.1365-4632.2009.03968.x; KITAGAKI H, 1995, J INVEST DERMATOL, V105, P749, DOI 10.1111/1523-1747.ep12325538; Klein PA, 1999, ARCH DERMATOL, V135, P1522, DOI 10.1001/archderm.135.12.1522; Metz M, 2011, VET DERMATOL, V22, P121, DOI 10.1111/j.1365-3164.2010.00945.x; Novak Natalija, 2003, Journal of Allergy and Clinical Immunology, V112, pS128, DOI 10.1016/j.jaci.2003.09.032; Sengoku T, 2000, INT J IMMUNOPHARMACO, V22, P189, DOI 10.1016/S0192-0561(99)00076-4; Sonkoly E, 2006, J ALLERGY CLIN IMMUN, V117, P411, DOI 10.1016/j.jaci.2005.10.033; Takano N, 2003, EUR J PHARMACOL, V471, P223, DOI 10.1016/S0014-2999(03)01828-4; Takano N, 2004, EUR J PHARMACOL, V495, P159, DOI 10.1016/j.ejphar.2004.05.038; Takaoka A, 2005, EUR J PHARMACOL, V516, P180, DOI 10.1016/j.ejphar.2005.04.040; Takaoka A, 2006, EXP DERMATOL, V15, P161, DOI 10.1111/j.1600-0625.2006.00405.x; Wahlgren C F, 1991, Acta Derm Venereol Suppl (Stockh), V165, P1; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P406, DOI 10.1111/j.1365-2133.1994.tb08532.x; Yamaoka K, 2009, INT ARCH ALLERGY IMM, V149, P73, DOI 10.1159/000211376; Yamashita H, 2005, EXP DERMATOL, V14, P438, DOI 10.1111/j.0906-6705.2005.00304.x; Yamashita H, 2007, EUR J PHARMACOL, V563, P233, DOI 10.1016/j.ejphar.2007.01.078	58	4	4	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0007-1188	1476-5381		BRIT J PHARMACOL	Br. J. Pharmacol.	NOV	2014	171	22					5049	5058		10.1111/bph.12823		10	Pharmacology & Pharmacy	Pharmacology & Pharmacy	AS6PN	WOS:000344385200004		
J	Jiang, Q; Cui, J; Feng, XT; Jiang, YJ				Jiang, Quan; Cui, Jie; Feng, Xiating; Jiang, Yujing			Application of computerized tomographic scanning to the study of water-induced weakening of mudstone	BULLETIN OF ENGINEERING GEOLOGY AND THE ENVIRONMENT			English	Article						Computerized tomography scanning; Water-induced deterioration; Mudrock; Interactive mechanism; Rock disintegration	SWELLING BEHAVIOR; DEBRIS FLOWS; ROCKS; DURABILITY; MUDROCKS; FRACTURE; TAIWAN; CT	Water generally plays a harmful role in the stability of mudstone and has induced many geological disasters in mudrock strata. To visually examine water-induced deterioration of mudstone, X-ray computerized tomographic scanning was used to detect the real-time interaction between mudstone and water. This facilitated real-time visual observations of the evolving characteristics of water-induced cracks within the samples. According to these experimental findings, assisted with scanning electron microscopy and X-ray diffraction, the water-weakening mechanisms of mudstone can be divided into the following steps: (1) micro-sized discontinuities provide an initial path for water to invade the rock; (2) the incursive water induces volumetric swelling of clay minerals and dissolution of carbonate; and (3) these effects drive the propagation and connection of cracks. This understanding of the processes of degradation provides a visual evidence for the assessment of mudrock performance with respect to the stability of landslides, debris flows, and susceptibility of subsidence in mudstone strata.	[Jiang, Quan; Cui, Jie; Feng, Xiating] Chinese Acad Sci, Inst Rock & Soil Mech, State Key Lab Geomech & Geotech Engn, Wuhan 430071, Peoples R China; [Jiang, Yujing] Nagasaki Univ, Dept Civil Engn, Fac Engn, Nagasaki 852852, Japan	Jiang, Q (reprint author), Chinese Acad Sci, Inst Rock & Soil Mech, State Key Lab Geomech & Geotech Engn, Wuhan 430071, Peoples R China.	qjiang@whrsm.ac.cn			National Basic Research Program of China [2013CB036405]; National Natural Science Foundation of China [41172284, 51379202]	The authors gratefully acknowledge the financial support from the National Basic Research Program of China (Grant No. 2013CB036405) and the National Natural Science Foundation of China (Grant Nos. 41172284 and 51379202).	Al-homoud AS, 1996, B INT ASS ENG GEOL, V54, P13, DOI 10.1007/BF02600694; Nakashima Y, 2000, ENG GEOL, V56, P11, DOI 10.1016/S0013-7952(99)00130-1; Pejon OJ, 2002, ENG GEOL, V67, P97, DOI 10.1016/S0013-7952(02)00147-3; TAYLOR RK, 1970, INT J ROCK MECH MIN, V7, P481, DOI 10.1016/0148-9062(70)90002-1; Czerewko MA, 2001, Q J ENG GEOL HYDROGE, V34, P153; Dhakal G, 2002, ENG GEOL, V65, P31, DOI 10.1016/S0013-7952(01)00101-6; Raynaud S, 2008, INT J ROCK MECH MIN, V45, P653, DOI 10.1016/j.ijrmms.2007.08.007; DICK JC, 1992, Q J ENG GEOL, V25, P31, DOI 10.1144/GSL.QJEG.1992.025.01.03; Lin GW, 2011, ENG GEOL, V117, P97, DOI 10.1016/j.enggeo.2010.10.009; Arnould M, 2006, B ENG GEOL ENVIRON, V65, P413, DOI 10.1007/s10064-006-0060-3; Chen HG, 2006, QUATERN INT, V147, P3, DOI 10.1016/j.quaint.2005.09.002; Chen YK, 2010, J CENT SOUTH UNIV T, V17, P628, DOI 10.1007/s11771-010-0532-2; Dick J. C., 1994, CAN GEOTECH J, V34, P17; Doostmohammadi R, 2009, ENVIRON GEOL, V58, P999, DOI 10.1007/s00254-008-1579-3; Einstein HH, 1996, ROCK MECH ROCK ENG, V29, P113, DOI 10.1007/BF01032649; Erguler ZA, 2008, INT J ROCK MECH MIN, V46, P355, DOI [10.1016/j.ijrmms.07.002, DOI 10.1016/J.IJRMMS.07.002]; Francoise P, 2012, HDB PARTICLE DETECTI, P883; Hawlader BC, 2003, CAN GEOTECH J, V40, P501, DOI 10.1139/T03-006; HOUNDFIELD GN, 1973, BRIT J RADIOL, V46, P1016; Hu KH, 2010, J MT SCI-ENGL, V7, P207, DOI 10.1007/s11629-010-2022-2; Imumorin P, 2011, B ENG GEOL ENVIRON, V70, P223, DOI 10.1007/s10064-010-0300-4; Kawakatal H, 1997, INT J ROCK MECH MIN, V34; Lashkaripour GR, 2002, B ENG GEOL ENVIRON, V61, P73, DOI [10.1007/s10064100116, DOI 10.1007/S10064100116]; Li DJ, 2011, MIN SCI TECHNOL CHIN, V21, P287, DOI 10.1016/j.mstc.2011.02.002; Lin TT, 1998, J HAZARD MATER, V58, P261, DOI 10.1016/S0304-3894(97)00137-4; Liu CW, 2000, ROCK SOIL MECH, V21, P28, DOI 10.3969/j.issn.1000-7598.2000.01.007; Molinda G. M., 2006, P 25 INT C GROUND CO, P57; Ojo O, 1990, MIN SCI TECHNOL, V10, P145, DOI [10.1016/0167-9031(90)90158-O, DOI 10.1016/0167-9031(90)90158-O]; Okano K, 2012, GEOMORPHOLOGY, V136, P88, DOI 10.1016/j.geomorph.2011.04.006; Ren JX, 2001, CHIN J ROCK MECH ENG, V20, P425; Tang CA, 2011, J MT SCI-ENGL, V8, P131, DOI 10.1007/s11629-011-2098-3; Walters DA, 1998, GEOTECH TEST J, V21, P328; Wang TT, 2002, TUNN UNDERGR SP TECH, V17, P425, DOI 10.1016/S0886-7798(02)00068-8; Weerakone WMSB, 2012, GEOTECH TEST J, V35, P460; WELLINGTON SL, 1987, J PETROL TECHNOL, V39, P885, DOI 10.2118/16983-PA; Wen BP, 2005, ACTA GEOL SIN-ENGL, V79, P139; Wong RCK, 2000, GEOTECH TEST J, V23, P413; [杨春和 YANG Chunhe], 2006, [岩土力学, Rock and Soil Mechanics], V27, P2090; Yoshida N, 1997, INT J ROCK MECH MIN, V34; Zhang CF, 2010, J INORG MATER, V25, P1209, DOI 10.3724/SP.J.1077.2010.01209; Zhao YL, 2009, J CENT SOUTH UNIV T, V16, P488, DOI 10.1007/s11771-009-0082-7	41	1	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1435-9529	1435-9537		B ENG GEOL ENVIRON	Bull. Eng. Geol. Environ.	NOV	2014	73	4					1293	1301		10.1007/s10064-014-0597-5		9	Engineering, Environmental; Engineering, Geological; Geosciences, Multidisciplinary	Engineering; Geology	AS5QA	WOS:000344323700030		
J	Kanekawa, T; Nagai, H; Kanayama, M; Sumino, Y				Kanekawa, Takenori; Nagai, Hidenari; Kanayama, Masahiro; Sumino, Yasukiyo			Importance of branched-chain amino acids in patients with liver cirrhosis and advanced hepatocellular carcinoma receiving hepatic arterial infusion chemotherapy	CANCER CHEMOTHERAPY AND PHARMACOLOGY			English	Article						BCAA; HCC; Liver cirrhosis; Hepatic arterial infusion chemotherapy	LATE EVENING SNACK; FREE SURVIVAL; MTOR SIGNAL; 5-FLUOROURACIL; CISPLATIN; ENERGY; METABOLISM; SORAFENIB; SUPPLEMENTATION; LEUCOVORIN	The aim of this retrospective cohort study was to clarify the effect of a branched-chain amino acids (BCAA) on the liver function and the prognosis of Child-Pugh class (C-P) A and B liver cirrhosis (LC) patients with advanced hepatocellular carcinoma (aHCC) undergoing hepatic arterial infusion chemotherapy (HAIC). Ninety-two adult Japanese patients with LC and aHCC underwent HAIC. They were in C-P A or B, and they showed multiple partial responses or stable disease. We excluded 11 patients classified as C-P C and 47 patients who showed no response. The patients were divided into an HAIC group receiving HAIC alone (n = 43) and a BCAA group treated with HAIC plus BCAA (n = 49). HAIC was delivered via the proper hepatic artery. The BCAA group also received oral administration of BCAA. In the BCAA group, serum albumin increased significantly after HAIC, while there were no significant changes in serum total bilirubin, serum aminotransferases, prothrombin time, ascites, and hepatic encephalopathy. The C-P score decreased significantly after HAIC compared with before HAIC in C-P B patients, although there was no significant change in C-P A patients. Survival of the BCAA group was significantly longer than that of the HAIC group, with the median survival time being 426 versus 272 days for C-P B patients, although there was no significant difference for C-P A patients. Branched-chain amino acids might improve the survival and C-P score by increasing serum albumin in C-P B patients with aHCC receiving HAIC.	[Kanekawa, Takenori; Nagai, Hidenari; Kanayama, Masahiro; Sumino, Yasukiyo] Toho Univ, Div Gastroenterol & Hepatol, Dept Internal Med Omori, Fac Med,Sch Med,Ota Ku, Tokyo 1438541, Japan	Nagai, H (reprint author), Toho Univ, Div Gastroenterol & Hepatol, Dept Internal Med Omori, Fac Med,Sch Med,Ota Ku, 6-11-1 Omorinishi, Tokyo 1438541, Japan.	hidenari@aol.com					Tsuchiya M, 2005, HEPATOL RES, V31, P95, DOI 10.1016/j.hepres.2004.11.009; Pinter M, 2009, ONCOLOGIST, V14, P70, DOI 10.1634/theoncologist.2008-0191; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Moreno-Aspitia A, 2009, J CLIN ONCOL, V27, P11, DOI 10.1200/JCO.2007.15.5242; Kondrup J, 1997, J HEPATOL, V27, P239, DOI 10.1016/S0168-8278(97)80308-X; Poon RTP, 2004, ALIMENT PHARM THERAP, V19, P779, DOI 10.1111/j.1365-2036.2004.01920.x; Hayaishi S, 2011, DIGEST DIS, V29, P326, DOI 10.1159/000327571; Moriwaki H, 2004, BIOCHEM BIOPH RES CO, V313, P405, DOI 10.1016/j.bbrc.2003.07.016; ZILLIKENS MC, 1993, J HEPATOL, V17, P377, DOI 10.1016/S0168-8278(05)80221-1; Muto Y, 2005, CLIN GASTROENTEROL H, V3, P705, DOI 10.1053/S1542-3565(05)00017-0; Abou-Alfa GK, 2006, J CLIN ONCOL, V24, P4293, DOI 10.1200/JCO.2005.01.3441; Miwa Y, 2000, HEPATOL RES, V18, P184, DOI 10.1016/S1386-6346(99)00100-X; SWART GR, 1989, BRIT MED J, V299, P1202; Charlton M, 2006, J NUTR, V136, p295S; Harima Y, 2010, HEPATOL RES, V40, P574, DOI 10.1111/j.1872-034X.2010.00665.x; Ijichi C, 2003, BIOCHEM BIOPH RES CO, V303, P59, DOI 10.1016/S0006-291X(03)00295-X; IWAMIYA T, 1994, CANCER CHEMOTH PHARM, V33, pS134, DOI 10.1007/BF00686685; Kudo M, 2010, DIG DIS, V29, P339; Lam VW, 2008, HEPATOL RES S1, V38, P107; Marchesini G, 2003, GASTROENTEROLOGY, V124, P1729; Matsumura T, 2005, HEPATOL RES, V33, P27, DOI 10.1016/j.hepres.2005.07.001; Murata K, 2003, ANTICANCER RES, V23, P1719; Nagai H, 2008, RECENT PAT ANTI-CANC, V3, P220, DOI 10.2174/157489208786242296; Nagai H, 2007, WORLD J GASTROENTERO, V13, P280; Nakaya Y, 2007, NUTRITION, V23, P113, DOI 10.1016/j.nut.2006.10.008; CAPOCACCIA L, 1994, J HEPATOL, V21, P317; Okamoto M, 2003, HEPATOL RES, V27, P45, DOI 10.1016/S1386-6346(03)00190-6; Okuda K, 1999, ONCOL REP, V6, P587; TOYODA H, 1995, ONCOLOGY, V52, P295; Yamasaki T, 2002, HEPATOL RES, V23, P7, DOI 10.1016/S1386-6346(01)00163-2; YOSHIDA T, 1989, Gastroenterologia Japonica, V24, P692	31	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0344-5704	1432-0843		CANCER CHEMOTH PHARM	Cancer Chemother. Pharmacol.	NOV	2014	74	5					899	909		10.1007/s00280-014-2564-z		11	Oncology; Pharmacology & Pharmacy	Oncology; Pharmacology & Pharmacy	AS5QF	WOS:000344324200002		
J	Nakai, Y; Isayama, H; Saito, K; Sasaki, T; Takahara, N; Hamada, T; Mizuno, S; Miyabayashi, K; Yamamoto, K; Mohri, D; Kogure, H; Yamamoto, N; Hirano, K; Ijichi, H; Tateishi, K; Tada, M; Koike, K				Nakai, Yousuke; Isayama, Hiroyuki; Saito, Kei; Sasaki, Takashi; Takahara, Naminatsu; Hamada, Tsuyoshi; Mizuno, Suguru; Miyabayashi, Koji; Yamamoto, Keisuke; Mohri, Dai; Kogure, Hirofumi; Yamamoto, Natsuyo; Hirano, Kenji; Ijichi, Hideaki; Tateishi, Keisuke; Tada, Minoru; Koike, Kazuhiko			A phase I trial of gemcitabine, S-1 and LV combination (GSL) therapy in advanced pancreatic cancer	CANCER CHEMOTHERAPY AND PHARMACOLOGY			English	Article						Pancreatic cancer; Chemotherapy; Gemcitabine; S-1; Leucovorin	PLUS S-1; LEUCOVORIN; 5-FLUOROURACIL; SURVIVAL; IMPACT; JAPAN	In our previous randomized controlled trial, the addition of S-1 to gemcitabine for advanced pancreatic cancer did not prolong overall survival (OS) significantly, despite its higher response rate and longer progression-free survival (PFS). Leucovorin is known to enhance efficacy of S-1, and we conducted this phase I trial of combination therapy of gemcitabine, S-1 and leucovorin (GSL). Patients with advanced pancreatic cancer who had received no prior chemotherapy were eligible for this study. Gemcitabine was administered at an escalating dose of 600, 800 and 1,000 mg/m(2) over 30 min on day 1, and oral S-1 at a dose of 40 mg/m(2) twice daily and oral leucovorin at a dose of 25 mg twice daily on days 1-7, every 2 weeks. A standard "3 + 3" phase I dose escalation design was utilized. Fifteen patients were enrolled across three dose levels. Three patients developed DLTs: two patients in level 1 (grade 3 anorexia in 1 and grade 3 anorexia, stomatitis and diarrhea in 1) and one patient in level 2 (grade 3 deep vein thrombosis). No DLT was observed in level 3. Response rate and the disease control rate were 33 and 93 %, respectively. The median PFS and OS were 5.4 and 16.6 months. Ten of 12 patients (83 %) with elevated CA19-9 at baseline had a a parts per thousand yen50 % decline. RD of gemcitabine in GSL was determined as 1,000 mg/m(2). GSL was well tolerable and showed promising results in advanced pancreatic cancer.	[Nakai, Yousuke; Isayama, Hiroyuki; Saito, Kei; Sasaki, Takashi; Takahara, Naminatsu; Hamada, Tsuyoshi; Mizuno, Suguru; Miyabayashi, Koji; Yamamoto, Keisuke; Mohri, Dai; Kogure, Hirofumi; Yamamoto, Natsuyo; Hirano, Kenji; Ijichi, Hideaki; Tateishi, Keisuke; Tada, Minoru; Koike, Kazuhiko] Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Bunkyo Ku, Tokyo 1138655, Japan	Isayama, H (reprint author), Univ Tokyo, Grad Sch Med, Dept Gastroenterol, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	isayama-tky@umin.ac.jp					Ueno H, 2013, J CLIN ONCOL, V31, P1640, DOI 10.1200/JCO.2012.43.3680; Ozaka M, 2012, CANCER CHEMOTH PHARM, V69, P1197, DOI 10.1007/s00280-012-1822-1; Conroy T, 2011, NEW ENGL J MED, V364, P1817, DOI 10.1056/NEJMoa1011923; Nakai Y, 2012, BRIT J CANCER, V106, P1934, DOI 10.1038/bjc.2012.183; Von Hoff DD, 2013, NEW ENGL J MED, V369, P1691, DOI 10.1056/NEJMoa1304369; Ueno H, 2005, ONCOLOGY-BASEL, V69, P421, DOI 10.1159/000089997; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Berlin Jordan D., 1998, Investigational New Drugs, V16, P325, DOI 10.1023/A:1006242005837; Denda T, 2012, ASCO M S, V30, P598; Nakai Y, 2010, PANCREAS, V39, P989, DOI 10.1097/MPA.0b013e3181d91936; Nakai Y, 2010, JPN J CLIN ONCOL, V40, P774, DOI 10.1093/jjco/hyq059; Okusaka T, 2013, EUR J CANCER, V49, pS611; Okusaka T, 2013, EUR J CANCER, V49, pS618; Oztop I, 2010, J BUON, V15, P462; Pelzer U, 2011, CANCER CHEMOTH PHARM, V68, P1173, DOI 10.1007/s00280-011-1602-3; Poplin E, 1999, INVEST NEW DRUG, V17, P57, DOI 10.1023/A:1006239200772; Shiah HS, 2006, J GASTROEN HEPATOL, V21, P531, DOI 10.1111/j.1440-1746.2005.03957.x; Ueno H, 2011, JPN J CLIN ONCOL, V41, P953, DOI 10.1093/jjco/hyr090; Uesaka K, 2013, ASCO M S, V31, P145; Yoshino T, 2007, ASCO M S, V25, P4093	20	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0344-5704	1432-0843		CANCER CHEMOTH PHARM	Cancer Chemother. Pharmacol.	NOV	2014	74	5					911	915		10.1007/s00280-014-2563-0		5	Oncology; Pharmacology & Pharmacy	Oncology; Pharmacology & Pharmacy	AS5QF	WOS:000344324200003		
J	Igawa, S; Kasajima, M; Ishihara, M; Kimura, M; Hiyoshi, Y; Niwa, H; Kusuhara, S; Harada, S; Asakuma, M; Otani, S; Katono, K; Sasaki, J; Masuda, N				Igawa, Satoshi; Kasajima, Masashi; Ishihara, Mikiko; Kimura, Michiko; Hiyoshi, Yasuhiro; Niwa, Hideyuki; Kusuhara, Seiichiro; Harada, Shinya; Asakuma, Maiko; Otani, Sakiko; Katono, Ken; Sasaki, Jiichiro; Masuda, Noriyuki			Evaluation of gefitinib efficacy according to body surface area in patients with non-small cell lung cancer harboring an EGFR mutation	CANCER CHEMOTHERAPY AND PHARMACOLOGY			English	Article						Non-small cell lung cancer; Gefitinib; EGFR mutation; Efficacy; Body surface area	GROWTH-FACTOR RECEPTOR; TYROSINE KINASE INHIBITORS; 1ST-LINE TREATMENT; NEVER-SMOKERS; OPEN-LABEL; CHEMOTHERAPY; TRIAL; ERLOTINIB; SURVIVAL; GENE	Exon 19 deletions and L858R point mutation are the most commonly encountered active epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC), and they predict greater efficacy of gefitinib therapy. The objective of this study was to evaluate whether body surface area (BSA) affects the efficacy of gefitinib in patients with NSCLC harboring an active EGFR mutation. We reviewed the medical records of consecutive patients with advanced NSCLC harboring an active EGFR mutation who received gefitinib monotherapy. The median BSA value was used as the cutoff value to evaluate the impact of BSA on the efficacy of gefitinib. The median BSA of the 103 NSCLC patients harboring an active EGFR mutation was 1.45 m(2). The overall response rate, progression-free survival (PFS), and median survival time (MST) were 65.0 %, 11.3 months, and 26.2 months, respectively. There were no significant differences in clinical outcomes between the high-BSA group (BSA a parts per thousand yen 1.45 m(2)) and low-BSA group (BSA < 1.45 m(2)), i.e., the response rates was 60.0 % and 69.8 %, respectively (P = 0.20), and their MST was 24.7 and 26.2 months, respectively (P = 0.78). Although BSA was predictive of PFS between high-BSA group and low-BSA group in the univariate analysis (9.0 and 12.2 months, P = 0.04), the multivariate analysis identified only performance status and smoking status as independent predictors of PFS. The efficacy of gefitinib in patients with NSCLC harboring an EGFR mutation does not differ according to their BSA.	[Igawa, Satoshi; Kasajima, Masashi; Ishihara, Mikiko; Kimura, Michiko; Hiyoshi, Yasuhiro; Niwa, Hideyuki; Kusuhara, Seiichiro; Harada, Shinya; Asakuma, Maiko; Otani, Sakiko; Katono, Ken; Masuda, Noriyuki] Kitasato Univ, Sch Med, Dept Resp Med, Minami Ku, Sagamihara, Kanagawa 2520374, Japan; [Sasaki, Jiichiro] Kitasato Univ, Res & Dev Ctr New Med Frontiers, Sch Med, Minami Ku, Sagamihara, Kanagawa 2520374, Japan	Igawa, S (reprint author), Kitasato Univ, Sch Med, Dept Resp Med, Minami Ku, 1-15-1 Kitasato, Sagamihara, Kanagawa 2520374, Japan.	igawa@kitasato-u.ac.jp					Yang CH, 2006, CANCER, V107, P1873, DOI 10.1002/cncr.22220; Nagai Y, 2005, CANCER RES, V65, P7276, DOI 10.1158/0008-5472.CAN-05-0331; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; McKillop D, 2005, MOL CANCER THER, V4, P641, DOI 10.1158/1535-7163.MCT-04-0329; Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X; Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149; Bria E, 2011, ANN ONCOL, V22, P2277, DOI 10.1093/annonc/mdq742; Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530; Petrelli F, 2012, CLIN LUNG CANCER, V13, P107, DOI 10.1016/j.cllc.2011.08.005; Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038; Pollack VA, 1999, J PHARMACOL EXP THER, V291, P739; Han JY, 2012, J CLIN ONCOL, V30, P1122, DOI 10.1200/JCO.2011.36.8456; Mitsudomi T, 2005, J CLIN ONCOL, V23, P2513, DOI 10.1200/JCO.2005.00.992; Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699; Zhou CC, 2011, LANCET ONCOL, V12, P735, DOI 10.1016/S1470-2045(11)70184-X; Siegel R, 2012, CA-CANCER J CLIN, V62, P220, DOI 10.3322/caac.21149; Ando M, 2006, J CLIN ONCOL, V24, P2549, DOI 10.1200/JCO.2005.04.9866; Mitsudomi T, 2010, LANCET ONCOL, V11, P121, DOI 10.1016/S1470-2045(09)70364-X; Mitsudomi T, 2007, CANCER SCI, V98, P1817, DOI 10.1111/j.1349-7006.2007.00607.x; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Tanaka T, 2010, INT J CANCER, V126, P651, DOI 10.1002/ijc.24746; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Du BOIS, 1916, ARCH INT MED 2, V17, P863; Gao G, 2012, INT J CANCER, V131, P822; Haura E, 2007, J CLIN ONCOL, V25, P7603; Ichihara E, 2013, LUNG CANCER, V81, P435, DOI 10.1016/j.lungcan.2013.05.021; McKillop D, 2004, XENOBIOTICA, V34, P917, DOI 10.1080/00498250400009171	28	2	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0344-5704	1432-0843		CANCER CHEMOTH PHARM	Cancer Chemother. Pharmacol.	NOV	2014	74	5					939	946		10.1007/s00280-014-2570-1		8	Oncology; Pharmacology & Pharmacy	Oncology; Pharmacology & Pharmacy	AS5QF	WOS:000344324200006		
J	Kodama, T; Hasegawa, M; Takanashi, K; Sakurai, Y; Kondoh, O; Sakamoto, H				Kodama, Tatsushi; Hasegawa, Masami; Takanashi, Kenji; Sakurai, Yuji; Kondoh, Osamu; Sakamoto, Hiroshi			Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases	CANCER CHEMOTHERAPY AND PHARMACOLOGY			English	Article						NSCLC; ALK; ALK inhibitor; Brain metastases; Alectinib	CELL LUNG-CANCER; KINASE INHIBITOR; RESISTANCE; CRIZOTINIB; MUTATIONS; CH5424802; BRAIN; EGFR	The clinical efficacy of the anaplastic lymphoma kinase (ALK) inhibitor crizotinib has been demonstrated in ALK fusion-positive non-small cell lung cancer (NSCLC); however, brain metastases are frequent sites of initial failure in patients due to poor penetration of the central nervous system by crizotinib. Here, we examined the efficacy of a selective ALK inhibitor alectinib/CH5424802 in preclinical models of intracranial tumors. We established intracranial tumor implantation mouse models of EML4-ALK-positive NSCLC NCI-H2228 and examined the antitumor activity of alectinib in this model. Plasma distribution and brain distribution of alectinib were examined by quantitative whole-body autoradiography administrating a single oral dose of C-14-labeled alectinib to rats. The drug permeability of alectinib was evaluated in Caco-2 cell. Alectinib resulted in regression of NCI-H2228 tumor in mouse brain and provided a survival benefit. In a pharmacokinetic study using rats, alectinib showed a high brain-to-plasma ratio, and in an in vitro drug permeability study using Caco-2 cells, alectinib was not transported by P-glycoprotein efflux transporter that is a key factor in blood-brain barrier penetration. We established intracranial tumor implantation models of EML4-ALK-positive NSCLC. Alectinib showed potent efficacy against intracranial EML4-ALK-positive tumor. These results demonstrated that alectinib might provide therapeutic opportunities for crizotinib-treated patients with brain metastases.	[Kodama, Tatsushi; Hasegawa, Masami; Takanashi, Kenji; Sakurai, Yuji; Kondoh, Osamu; Sakamoto, Hiroshi] Chugai Pharmaceut Co Ltd, Div Res, Kamakura, Kanagawa 2478530, Japan	Sakamoto, H (reprint author), Chugai Pharmaceut Co Ltd, Div Res, 200 Kajiwara, Kamakura, Kanagawa 2478530, Japan.	sakamotohrs@chugai-pharm.co.jp					Sasaki T, 2011, CANCER RES, V71, P6051, DOI 10.1158/0008-5472.CAN-11-1340; Camidge DR, 2012, NAT REV CLIN ONCOL, V9, P268, DOI 10.1038/nrclinonc.2012.43; Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945; Kodama T, 2014, CANCER LETT, V351, P215, DOI 10.1016/j.canlet.2014.05.020; Gainor JF, 2013, CLIN CANCER RES, V19, P4273, DOI 10.1158/1078-0432.CCR-13-0318; Seto T, 2013, LANCET ONCOL, V14, P590, DOI 10.1016/S1470-2045(13)70142-6; Doebele RC, 2012, CLIN CANCER RES, V18, P1472, DOI 10.1158/1078-0432.CCR-11-2906; Sasaki T, 2010, CANCER RES, V70, P10038, DOI 10.1158/0008-5472.CAN-10-2956; Bartels AL, 2009, NEUROBIOL AGING, V30, P1818, DOI 10.1016/j.neurobiolaging.2008.02.002; Choi YL, 2010, NEW ENGL J MED, V363, P1734, DOI 10.1056/NEJMoa1007478; Mealey KL, 2008, DRUG METAB DISPOS, V36, P1073, DOI 10.1124/dmd.107.018978; Sakamoto H, 2011, CANCER CELL, V19, P679, DOI 10.1016/j.ccr.2011.04.004; Shaw AT, 2013, NEW ENGL J MED, V368, P2385, DOI 10.1056/NEJMoa1214886; Costa DB, 2011, J CLIN ONCOL, V29, pE443, DOI 10.1200/JCO.2010.34.1313; ZIMM S, 1981, CANCER, V48, P384, DOI 10.1002/1097-0142(19810715)48:2<384::AID-CNCR2820480227>3.0.CO;2-8; Mujoomdar A, 2007, RADIOLOGY, V242, P882, DOI 10.1148/radiol.2423051707; Fushiki H, 2013, CANC RES S, V73; Katayama R, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003316; Kuromitsu S, 2011, CANC RES S, V71; Mori M, 2014, MOL CANCER THER, V13, P329, DOI 10.1158/1535-7163.MCT-13-0395; Pfizer Inc, 2011, XALKORI CRIZ CPAS OR; SH Ou, 2013, ANN ONCOL, V44; Tan W, 2010, J CLIN ONCOL S, V28; U.S. Food and Drug Administration, 2012, GUID IND DRUG INT ST; Weickhardt AJ, 2012, J CLIN ONCOL S, V30	25	15	16	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0344-5704	1432-0843		CANCER CHEMOTH PHARM	Cancer Chemother. Pharmacol.	NOV	2014	74	5					1023	1028		10.1007/s00280-014-2578-6		6	Oncology; Pharmacology & Pharmacy	Oncology; Pharmacology & Pharmacy	AS5QF	WOS:000344324200014		
J	Sato, I; Higuchi, A; Yanagisawa, T; Murayama, S; Kumabe, T; Sugiyama, K; Mukasa, A; Saito, N; Sawamura, Y; Terasaki, M; Shibui, S; Takahashi, J; Nishikawa, R; Ishida, Y; Kamibeppu, K				Sato, Iori; Higuchi, Akiko; Yanagisawa, Takaaki; Murayama, Shiho; Kumabe, Toshihiro; Sugiyama, Kazuhiko; Mukasa, Akitake; Saito, Nobuhito; Sawamura, Yutaka; Terasaki, Mizuhiko; Shibui, Soichiro; Takahashi, Jun; Nishikawa, Ryo; Ishida, Yasushi; Kamibeppu, Kiyoko			Impact of Late Effects on Health-Related Quality of Life in Survivors of Pediatric Brain Tumors Motility Disturbance of Limb(s), Seizure, Ocular/Visual Impairment, Endocrine Abnormality, and Higher Brain Dysfunction	CANCER NURSING			English	Article						Adolescent; Brain neoplasms; Child; Multicenter study; Propensity score; Quality of life; Questionnaires; Survivors	CHILDHOOD-CANCER SURVIVOR; LONG-TERM SURVIVORS; ADULT SURVIVORS; JAPANESE VERSION; EORTC QLQ-C30; EUROPEAN-ORGANIZATION; RADIATION-THERAPY; LUNG-CANCER; CHILDREN; MODULE	Background: Survivors of pediatric brain tumors are often affected by late effects, such as motility disturbance of limb(s), seizure, ocular/visual impairment, endocrine abnormality, and higher brain dysfunction, resulting from the disease and its treatment. Appropriate provision of supportive care will require understanding the effects of these experiences on survivors' health-related quality of life (HRQOL). Objective: The aim of this study was to identify the relationships between late effects and specific aspects of the HRQOL of pediatric brain tumor survivors. Methods: We distributed questionnaires for measuring HRQOL to 138 survivors and their parents at 8 hospitals and 1 clinic in Japan and simultaneously surveyed late effects using information provided by the survivors' attending physicians. We compared the HRQOL of survivors with and survivors without specific late effects. Results: A total of 106 survivors and their parents returned the questionnaires to the researchers. The HRQOL of survivors 18 years or older was negatively affected by all 5 late effects, indicating that their higher impairment was associated with diminished HRQOL. The HRQOL of survivors aged 12 to 17 years was negatively affected by 2 late effects (ocular/visual impairment and motility disturbance of the limbs). A part of the HRQOL subdomain (motor and cognitive functioning) of survivors aged 12 to 17 years was positively related to ocular/visual impairment. Conclusions: Five late effects influenced the HRQOL of pediatric brain tumor survivors. Implications for Practice: Nurses and other health professionals should provide specific care designed to support aspects of HRQOL affected by late effects. For example, survivors with ocular/visual impairment may be expected to require additional emotional support, and those with seizures or endocrine abnormalities may be expected to require additional support for sleep disorders.	[Sato, Iori; Higuchi, Akiko; Murayama, Shiho; Kamibeppu, Kiyoko] Univ Tokyo, Fac Med, Dept Family Nursing, Grad Sch Hlth Sci & Nursing, Tokyo 1130033, Japan; [Higuchi, Akiko] Childrens Canc Assoc Japan, Tokyo, Japan; [Yanagisawa, Takaaki] Saitama Med Univ, Int Med Ctr, Dept Neurooncol Neurosurg, Div Pediat Neurooncol,Comprehens Canc Ctr, Saitama, Japan; [Kumabe, Toshihiro] Tohoku Univ, Grad Sch Med, Dept Neurosurg, Sendai, Miyagi 980, Japan; [Sugiyama, Kazuhiko] Hiroshima Univ Hosp, Dept Clin Oncol, Canc Treatment Ctr, Hiroshima, Japan; [Sugiyama, Kazuhiko] Hiroshima Univ Hosp, Neurooncol Program, Canc Treatment Ctr, Hiroshima, Japan; [Mukasa, Akitake; Saito, Nobuhito] Univ Tokyo, Dept Neurosurg, Fac Med, Tokyo 1130033, Japan; [Sawamura, Yutaka] Sawamura Neurosurg Clin, Sapporo, Hokkaido, Japan; [Terasaki, Mizuhiko] Kurume Univ, Sch Med, Dept Neurosurg, Fukuoka, Japan; [Shibui, Soichiro] Natl Canc Ctr, Neurosurg & Neurooncol Div, Tokyo, Japan; [Takahashi, Jun] Tazuke Kofukai Med Res Inst, Dept Neurosurg, Osaka, Japan; [Takahashi, Jun] Kitano Hosp, Osaka, Japan; [Nishikawa, Ryo] Saitama Med Univ, Int Med Ctr, Ctr Comprehens Canc, Dept Neurooncol Neurosurg, Moroyama, Saitama, Japan; [Ishida, Yasushi] Prefectural Cent Hosp, Ctr Child Hlth, Matsuyama, Ehime, Japan	Kamibeppu, K (reprint author), Univ Tokyo, Fac Med, Dept Family Nursing,Grad Sch Hlth Sci & Nursing, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.	kkamibeppu-tky@umin.ac.jp			Society for the Promotion of Science (Kakenhi) [21659516]; Yamaji Fumiko Nursing Education and Research Foundation; Children's Cancer Association of Japan	This work was supported by grants from the Society for the Promotion of Science (Kakenhi grant number 21659516) 2009-2011, the Yamaji Fumiko Nursing Education and Research Foundation 2010-2011, and the Children's Cancer Association of Japan 2009.	AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365; Anderson NE, 2003, CURR OPIN NEUROL, V16, P677, DOI 10.1097/01.wco.0000102623.38669.e5; Meeske KA, 2007, PEDIATR BLOOD CANCER, V49, P298, DOI 10.1002/pbc.20923; Aarsen FK, 2009, J CLIN ONCOL, V27, P3526, DOI 10.1200/JCO.2008.19.6303; Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006; Matsutani M, 2001, J NEURO-ONCOL, V54, P311, DOI 10.1023/A:1012743707883; Ullrich NJ, 2012, SEMIN PEDIATR NEUROL, V19, P35, DOI 10.1016/j.spen.2012.02.014; ROSENBAUM PR, 1983, BIOMETRIKA, V70, P41, DOI 10.1093/biomet/70.1.41; Aarsen FK, 2006, CANCER, V106, P396, DOI 10.1002/cncr.21612; Gerber NU, 2008, ARCH DIS CHILD, V93, P582, DOI 10.1136/adc.2007.116202; Varni JW, 2003, AMBUL PEDIATR, V3, P329, DOI 10.1367/1539-4409(2003)003<0329:TPAAPP>2.0.CO;2; Gajjar A, 2006, LANCET ONCOL, V7, P813, DOI 10.1016/S1470-2045(06)70867-1; Osoba D, 1996, QUAL LIFE RES, V5, P139, DOI 10.1007/BF00435979; Packer RJ, 2006, J CLIN ONCOL, V24, P4202, DOI 10.1200/JCO.2006.06.4980; Stam H, 2006, J ADOLESCENT HEALTH, V39, P4, DOI 10.1016/j.jadohealth.2005.03.011; Zebrack BJ, 2004, J CLIN ONCOL, V22, P999, DOI 10.1200/JCO.2004.06.148; Pietila S, 2012, J NEURO-ONCOL, V108, P153, DOI 10.1007/s11060-012-0816-5; Bhat SR, 2005, J CLIN ONCOL, V23, P5493, DOI 10.1200/JCO.2005.10.190; Oeffinger KC, 2006, NEW ENGL J MED, V355, P1572, DOI 10.1056/NEJMsa060185; Mulhern RK, 2005, J CLIN ONCOL, V23, P5511, DOI 10.1200/JCO.2005.00.703; Zeltzer LK, 2009, J CLIN ONCOL, V27, P2396, DOI 10.1200/JCO.2008.21.1433; Merchant TE, 2009, LANCET ONCOL, V10, P258, DOI 10.1016/S1470-2045(08)70342-5; Palmer SN, 2007, PEDIATR BLOOD CANCER, V49, P287, DOI 10.1002/pbc.21026; Armstrong GT, 2009, J CLIN ONCOL, V27, P2328, DOI 10.1200/JCO.2008.21.1425; Tsuji N, 2011, HEALTH QUAL LIFE OUT, V9, DOI 10.1186/1477-7525-9-22; Taphoorn MJB, 2010, EUR J CANCER, V46, P1033, DOI 10.1016/j.ejca.2010.01.012; Owsley C, 2007, OPHTHAL EPIDEMIOL, V14, P188, DOI 10.1080/09286580701410315; Maringwa JT, 2011, SUPPORT CARE CANCER, V19, P1753, DOI 10.1007/s00520-010-1016-5; Maringwa J, 2011, ANN ONCOL, V22, P2107, DOI 10.1093/annonc/mdq726; Varni JW, 2002, CANCER, V94, P2090, DOI 10.1002/cncr.10427; Kobayashi K, 1998, EUR J CANCER, V34, P810, DOI 10.1016/S0959-8049(97)00395-X; Bazil CW, 2003, CNS DRUGS, V17, P719, DOI 10.2165/00023210-200317100-00003; Packer RJ, 2003, J CLIN ONCOL, V21, P3255, DOI 10.1200/JCO.2003.01.202; Gurney JG, 2003, CANCER, V97, P663, DOI 10.1002/cncr.11094; Benesch M, 2009, CHILD NERV SYST, V25, P173, DOI 10.1007/s00381-008-0742-1; Blaauwbroek R, 2007, EUR J CANCER, V43, P122, DOI 10.1016/j.ejca.2006.08.003; DEKKER R, 1992, DEV MED CHILD NEUROL, V34, P123; Kennedy C, 2004, BRAIN SPINAL TUMORS, P493; Kobayashi K, 2010, PEDIATR INT, V52, P80, DOI 10.1111/j.1442-200X.2009.02889.x; LANNERING B, 1990, MED PEDIATR ONCOL, V18, P304, DOI 10.1002/mpo.2950180410; Gurney JG, 2009, J CLIN ONCOL, V27, P2390, DOI 10.1200/JCO.2008.21.1458; Reimers TS, 2009, PEDIATR BLOOD CANCER, V53, P1086, DOI 10.1002/pbc.22122; Rubin D. B., 1985, BAYESIAN STATISTICS, V2, P463; Sato I, 2010, HEALTH QUAL LIFE OUT, V8, DOI 10.1186/1477-7525-8-38; Sutton LN, 1999, NEUROSURGERY, V45, P1292, DOI 10.1097/00006123-199912000-00002; Suzuki K, 2010, NIPPON RINSHO S10, V68, P653; Testa MA, 1996, NEW ENGL J MED, V334, P835, DOI 10.1056/NEJM199603283341306; The Committee of Brain Tumor Registry of Japan, 2009, NEUR MED CHIR S, V49, P35; Zeltzer LK, 2008, CANCER EPIDEM BIOMAR, V17, P435, DOI 10.1158/1055-9965.EPI-07-2541	49	2	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0162-220X	1538-9804		CANCER NURS	Cancer Nurs.	NOV-DEC	2014	37	6					E1	E14		10.1097/NCC.0000000000000110		14	Oncology; Nursing	Oncology; Nursing	AS4UO	WOS:000344272400001		
J	Yoshimura, T; Tanaka, A; Mori, N; Nakamura, D; Taniike, M; Makino, N; Egami, Y; Shutta, R; Tanouchi, J; Nishino, M				Yoshimura, Takahiro; Tanaka, Akihiro; Mori, Naoki; Nakamura, Daisuke; Taniike, Masayuki; Makino, Nobuhiko; Egami, Yasuyuki; Shutta, Ryu; Tanouchi, Jun; Nishino, Masami			Difference of Neointimal Growth Patterns in Bifurcation Lesions among Four Kinds of Drug-Eluting Stents: An Optical Coherence Tomographic Study	CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS			English	Article						bifurcation; drug-eluting stent; optical coherence tomography	HUMAN CORONARY-ARTERIES; SHEAR-STRESS; FOLLOW-UP; INTRAVASCULAR ULTRASOUND; COMERS TRIAL; IMPLANTATION; EVEROLIMUS; ZOTAROLIMUS; THROMBOSIS; REVASCULARIZATION	Aim: Neointimal proliferation of bifurcation lesions after implantation of drug-eluting stents (DES) has not been well evaluated. Thus, we compared neointimal proliferation of bifurcation lesions among four DES using optical coherence tomography (OCT). Methods: 8-month follow-up OCT was performed in 68 bifurcation lesions treated by 15 sirolimus-eluting stents (SES) and 17 paclitaxel-eluting stents (PES) as first-generation DES, and by 17 zotarolimus-eluting stents (ZES) and 19 everolimus-eluting stents (EES) as second-generation DES. Cross-sectional images of the bifurcation lesion using OCT were analyzed every 450 mu m. All images were divided into three areas: inner wall of the bifurcation (IB), outer wall of the bifurcation (OB), and ostium of the side branch (SB). We compared the incidence of uncovered struts (IUS) among three areas and the averaged neointimal thickness (NIH) between IB and OB in each stent and also compared these OCT parameters among all DES. Results: There were no significant differences of IUS between IB and OB in second-generation DES, while in first-generation DES, IUS of IB and OB showed significant differences. The IUS of SES in both areas was significantly higher than in the other DES (all P<0.001). PES had a significantly higher IUS in SB than the others (all P<0.001). NIH of OB was significantly higher than that of IB in PES, ZES, and EES, but in SES the NIH was similar in the two areas. Conclusions: OCT revealed different neointimal growth patterns among SES, PES, ZES, and EES in bifurcation lesions. (c) 2014 Wiley Periodicals, Inc.	[Yoshimura, Takahiro; Tanaka, Akihiro; Mori, Naoki; Nakamura, Daisuke; Taniike, Masayuki; Makino, Nobuhiko; Egami, Yasuyuki; Shutta, Ryu; Tanouchi, Jun; Nishino, Masami] Osaka Rosai Hosp, Div Cardiol, Sakai, Osaka 5918025, Japan	Nishino, M (reprint author), Osaka Rosai Hosp, Div Cardiol, 1179-3 Nagasone Cho, Sakai, Osaka 5918025, Japan.	mnishino@orh.go.jp					Medina A, 2006, REV ESP CARDIOL, V59, P183, DOI 10.1157/13084649; Kyono H, 2010, EUROINTERVENTION, V6, P69, DOI 10.4244/; Carter AJ, 2004, CARDIOVASC RES, V63, P617, DOI 10.1016/j.cardiores.2004.04.029; Gutierrez-Chico JL, 2011, EUR HEART J, V32, P2454, DOI 10.1093/eurheartj/ehr182; Wentzel JJ, 2001, CIRCULATION, V103, P1740; Smits PC, 2011, J AM COLL CARDIOL, V58, P11, DOI 10.1016/j.jacc.2011.02.023; Garg S, 2010, J AM COLL CARDIOL, V56, pS43, DOI 10.1016/j.jacc.2010.06.008; Iakovou I, 2005, JAMA-J AM MED ASSOC, V293, P2126, DOI 10.1001/jama.293.17.2126; Nakazawa G, 2010, J AM COLL CARDIOL, V55, P1679, DOI 10.1016/j.jacc.2010.01.021; Morice M, 2002, NEW ENGL J MED, V346, P1773, DOI 10.1056/NEJMoa012843; Miki K, 2013, CIRC J, V77, P1543, DOI 10.1253/circj.CJ-12-1182; Finn AV, 2007, CIRCULATION, V115, P2435, DOI 10.1161/CIRCULATIONAHA.107.693739; Her AY, 2010, AM J CARDIOL, V105, P1565, DOI 10.1016/j.amjcard.2010.01.013; Inoue T, 2011, JACC-CARDIOVASC INTE, V4, P1057, DOI 10.1016/j.jcin.2011.05.025; Raber L, 2011, J AM COLL CARDIOL, V57, P2143, DOI 10.1016/j.jacc.2011.01.023; Diletti R, 2013, HEART, V99, P1267, DOI 10.1136/heartjnl-2013-303778; ASAKURA T, 1990, CIRC RES, V66, P1045; Stone GW, 2011, J AM COLL CARDIOL, V58, P19, DOI 10.1016/j.jacc.2011.02.022; Carlier SG, 2003, CIRCULATION, V107, P2741, DOI 10.1161/01.CIR.0000066914.95878.6D; Malek AM, 1999, JAMA-J AM MED ASSOC, V282, P2035, DOI 10.1001/jama.282.21.2035; Papafaklis MI, 2010, JACC-CARDIOVASC INTE, V3, P1181, DOI 10.1016/j.jcin.2010.08.018; Cheneau E, 2003, CIRCULATION, V108, P43, DOI 10.1161/01.CIR.0000078636.71728.40; Burzotta F, 2011, JACC-CARDIOVASC INTE, V4, P327, DOI 10.1016/j.jcin.2010.12.005; Finn AV, 2010, JACC-CARDIOVASC IMAG, V3, P806, DOI 10.1016/j.jcmg.2010.03.011; Inoue T, 2011, HEART, V97, P1379, DOI 10.1136/hrt.2010.204339; Kim JS, 2009, HEART, V95, P1907, DOI 10.1136/hrt.2009.167759; Leon MB, 2010, JACC-CARDIOVASC INTE, V3, P1043, DOI 10.1016/j.jcin.2010.07.008; Nakazawa G, 2007, AM J CARDIOL, V100, p36M, DOI 10.1016/j.amjcard.2007.08.020; Tyczynski P, 2009, EUROINTERVENTION, V5, P544, DOI 10.4244/EIJV5I5A89	29	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1522-1946	1522-726X		CATHETER CARDIO INTE	Catheter. Cardiovasc. Interv.	NOV 1	2014	84	5					742	749		10.1002/ccd.25422		8	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	AS0MS	WOS:000343971700011		
J	Sakamoto, S; Taniguchi, N; Mizuguchi, Y; Yamada, T; Nakajima, S; Hata, T; Takahashi, A				Sakamoto, Shingo; Taniguchi, Norimasa; Mizuguchi, Yukio; Yamada, Takeshi; Nakajima, Shunsuke; Hata, Tetsuya; Takahashi, Akihiko			Clinical and Angiographic Outcomes of Patients Undergoing Entrapped Guidewire Retrieval in Stent-Jailed Side Branch Using a Balloon Catheter	CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS			English	Article						complications; percutaneous coronary intervention; quantitative coronary angiography	OPTICAL COHERENCE TOMOGRAPHY; DRUG-ELUTING STENTS; CORONARY; IMPLANTATION; DEFORMATION; WIRE; APPOSITION; ULTRASOUND; INSIGHTS; REMOVAL	ObjectiveThe purpose of this study was to examine the efficacy and safety of method for retrieval of entrapped guidewire in stent-jailed side branch using a balloon catheter. BackgroundGuidewire entrapment in the side branch after main vessel stenting is an infrequent but potentially serious complication of bifurcation lesion treatment. Entrapped wire retrieval with device advancement over the wire is a previously reported bail-out method, but its efficacy and impact on the proximal edge of the stent are unknown. MethodsWe conducted a single-center, prospective study to evaluate the outcome of 28 consecutive patients who developed guidewire entrapment in a stent-jailed side branch after drug-eluting stent implantation, and underwent retrieval of entrapped wire using a balloon catheter. The primary objective was cumulative 12-month major adverse cardiac events including death, non-fatal myocardial infarction, target lesion revascularization, and stent thrombosis. Secondary objectives included binary restenosis and late lumen loss, evaluated in-stent, 5-mm proximal edge, and 5-mm distal edge sites at 9-month angiographic follow-up. ResultsEntrapped guidewire retrieval was successfully achieved in all patients. Cumulative 12-month major adverse cardiac events were not observed in any patient. At angiographic follow-up, no significant differences were observed in late lumen loss between in-stent, 5-mm proximal edge, and 5-mm distal edge sites (0.120.38 mm vs. 0.09 +/- 0.27 mm vs. 0.03 +/- 0.3 mm, P=0.57). None of the patients had binary in-stent or in-segment restenosis. ConclusionAlthough the decision to apply the present method for entrapped guidewire retrieval should be made with careful consideration, it appears effective for bail-out. (c) 2013 Wiley Periodicals, Inc.	[Sakamoto, Shingo; Taniguchi, Norimasa; Mizuguchi, Yukio; Yamada, Takeshi; Hata, Tetsuya; Takahashi, Akihiko] Sakurakai Takahashi Hosp, Dept Cardiovasc Med, Kobe, Hyogo 6540026, Japan; [Nakajima, Shunsuke] Sakurakai Takahashi Hosp, Dept Cardiac Surg, Kobe, Hyogo 6540026, Japan	Sakamoto, S (reprint author), Sakurakai Takahashi Hosp, Suma Ku, 5-18-1 Oikecho, Kobe, Hyogo 6540026, Japan.	gsakamo@gmail.com					Agostoni P, 2010, J INVASIVE CARDIOL, V22, P453; Joner M, 2006, J AM COLL CARDIOL, V48, P193, DOI 10.1016/j.jacc.2006.03.042; Owens CG, 2011, EUROINTERVENTION, V7, P520, DOI 10.4244/EIJV7I4A83; Ormiston JA, 2011, JACC-CARDIOVASC INTE, V4, P1310, DOI 10.1016/j.jcin.2011.11.002; Cutlip DE, 2007, CIRCULATION, V115, P2344, DOI 10.1161/CIRCULATIONAHA.106.685313; Mamas MA, 2012, EUROINTERVENTION, V8, P196, DOI 10.4244/EIJV8I2A33; Rigattieri S, 2013, J INVASIVE CARDIOL, V25, pE101; Cook S, 2007, CIRCULATION, V115, P2426, DOI 10.1161/CIRCULATIONAHA.106.658237; Natsuaki M, 2013, J AM COLL CARDIOL, V62, P181, DOI 10.1016/j.jacc.2013.04.045; Gogas BD, 2013, JACC-CARDIOVASC INTE, V6, P211, DOI 10.1016/j.jcin.2013.01.132; Burns AT, 2010, CATHETER CARDIO INTE, V75, P351, DOI 10.1002/ccd.22269; Kume T, 2012, CIRC J, V76, P698, DOI 10.1253/circj.CJ-11-0845; Popma JJ, 2004, CIRCULATION, V110, P3773, DOI 10.1161/01.CIR.0000150331.14687.4B; Kereiakes DJ, 2012, EUROINTERVENTION, V8, P187, DOI 10.4244/EIJV8I2A32; Cho YH, 2007, CIRC J, V71, P1326, DOI 10.1253/circj.71.1326; Collins Nicholas, 2007, J Invasive Cardiol, V19, pE230; Leibundgut G, 2013, CATHETER CARDIO INTE, V81, pE206, DOI 10.1002/ccd.24472; Pitney M, 2011, EUROINTERVENTION, V7, P256, DOI 10.4244/EIJV7I2A41; Prasan A, 2002, CATHETER CARDIO INTE, V56, P212, DOI 10.1002/ccd.10193; Wakabayashi K, 2012, CIRC-CARDIOVASC INTE, V5, P305, DOI 10.1161/CIRCINTERVENTIONS.111.966259	20	4	4	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1522-1946	1522-726X		CATHETER CARDIO INTE	Catheter. Cardiovasc. Interv.	NOV 1	2014	84	5					750	756		10.1002/ccd.25358		7	Cardiac & Cardiovascular Systems	Cardiovascular System & Cardiology	AS0MS	WOS:000343971700012		
J	Horiguchi, K; Higuchi, M; Yoshida, S; Nakakura, T; Tateno, K; Hasegawa, R; Takigami, S; Ohsako, S; Kato, T; Kato, Y				Horiguchi, Kotaro; Higuchi, Masashi; Yoshida, Saishu; Nakakura, Takashi; Tateno, Kozue; Hasegawa, Rumi; Takigami, Shu; Ohsako, Shunji; Kato, Takako; Kato, Yukio			Proton receptor GPR68 expression in dendritic-cell-like S100 beta-positive cells of rat anterior pituitary gland: GPR68 induces interleukin-6 gene expression in extracellular acidification	CELL AND TISSUE RESEARCH			English	Article						Anterior pituitary gland; GPR68; Interleukin-6; POMC; S100 beta-positive cells; Folliculo-stellate cells	FOLLICULO-STELLATE CELLS; PROTEIN-COUPLED RECEPTORS; GROWTH-FACTOR; LYSOPHOSPHATIDYLCHOLINE; SECRETION; ADENOMAS; SPHINGOSYLPHOSPHORYLCHOLINE; RELEASE; SYSTEM; GP130	S100 beta-positive cells, which do not express the classical pituitary hormones, appear to possess multifunctional properties and are assumed to be heterogeneous in the anterior pituitary gland. The presence of several protein markers has shown that S100 beta-positive cells are composed of populations such as stem/progenitor cells, epithelial cells, astrocytes and dendritic cells. Recently, we succeeded in separating S100 beta-positive cells into round-cell (dendritic-cell-like) and process-cell types. We also found the characteristic expression of anti-inflammatory factors (interleukin-6, Il-6) and membrane receptors (integrin beta-6) in the round type. Here, we further investigate the function of the subpopulation of S100 beta-positive cells. Since IL-6 is also a paracrine factor that regulates hormone producing-cells, we examine whether a correlation exists among extracellular acid stress, IL-6 and hormone production by using primary cultures of anterior pituitary cells. Dendritic-cell-like S100 beta-positive cells notably expressed Gpr68 (proton receptor) and Il-6. Furthermore, the expression of Il-6 and proopiomelanocortin (Pomc) was up-regulated by extracellular acidification. The functional role of IL-6 and GPR68 in the gene expression of Pomc during extracellular acidification was also examined. Small interfering RNA for Il-6 up-regulated Pomc expression and that for Gpr68 reversed the down-regulation of Il-6 and up-regulated Pomc expression by extracellular acidification. Thus, S100 beta-positive dendritic-like cells can sense an increase in extracellular protons via GPR68 and respond by the production of IL-6 in order to suppress the up-regulation of Pomc expression.	[Horiguchi, Kotaro; Tateno, Kozue; Hasegawa, Rumi; Takigami, Shu; Ohsako, Shunji] Kyorin Univ, Dept Hlth Sci, Lab Anat & Cell Biol, Hachioji, Tokyo 1928508, Japan; [Horiguchi, Kotaro; Higuchi, Masashi; Kato, Takako; Kato, Yukio] Meiji Univ, Inst Reprod & Endocrinol, Tama Ku, Kawasaki, Kanagawa 2148571, Japan; [Nakakura, Takashi] Teikyo Univ, Grad Sch Med, Dept Anat, Tokyo 173, Japan; [Yoshida, Saishu; Kato, Yukio] Meiji Univ, Sch Agr, Dept Life Sci, Tama Ku, Kawasaki, Kanagawa 2148571, Japan	Horiguchi, K (reprint author), Kyorin Univ, Dept Hlth Sci, Lab Anat & Cell Biol, 476 Miyashita Cho, Hachioji, Tokyo 1928508, Japan.	kota@ks.kyorin-u.ac.jp; yukato@isc.meiji.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [25860148]; JSPS KAKENHI [21380184, 24580435]; Meiji University International Institute for BioResource Research (MUIIR)	This work was supported by a Grant-in-Aid for Young Scientists (B) (25860148) from the Ministry of Education, Culture, Sports, Science and Technology of Japan. It was also partially supported by JSPS KAKENHI Grants (nos. 21380184 to Y. K. and 24580435 to T. K.) and by the Meiji University International Institute for BioResource Research (MUIIR).	Allaerts W, 2005, EUR J ENDOCRINOL, V153, P1, DOI 10.1530/eje.1.01949; Ludwig MG, 2003, NATURE, V425, P93, DOI 10.1038/nature01905; Itakura E, 2007, ENDOCRINOLOGY, V148, P1518, DOI 10.1210/en.2006-1390; Mogi C, 2005, J PHARMACOL SCI, V99, P160, DOI 10.1254/jphs.FP0050599; FERRARA N, 1987, P NATL ACAD SCI USA, V84, P5773, DOI 10.1073/pnas.84.16.5773; Radu CG, 2005, P NATL ACAD SCI USA, V102, P1632, DOI 10.1073/pnas.0409415102; Lohrer P, 2000, ENDOCRINOLOGY, V141, P4457, DOI 10.1210/en.141.12.4457; VANKELECOM H, 1989, NEUROENDOCRINOLOGY, V49, P102, DOI 10.1159/000125097; Pereda MP, 2000, EXP CLIN ENDOCR DIAB, V108, P202; Ichimonji I, 2010, AM J PHYSIOL-LUNG C, V299, pL567, DOI 10.1152/ajplung.00415.2009; Tomura H, 2005, CELL SIGNAL, V17, P1466, DOI 10.1016/j.cellsig.2005.06.002; Inoue K, 1999, ARCH HISTOL CYTOL, V62, P205, DOI 10.1679/aohc.62.205; GOSPODAROWICZ D, 1989, BIOCHEM BIOPH RES CO, V165, P292, DOI 10.1016/0006-291X(89)91068-1; Arzt E, 2001, J CLIN INVEST, V108, P1729; CECCATELLI S, 1993, P NATL ACAD SCI USA, V90, P11292, DOI 10.1073/pnas.90.23.11292; Chen M, 2013, CELL TISSUE RES, V354, P823, DOI 10.1007/s00441-013-1713-8; Fujiwara K, 2007, CELL TISSUE RES, V329, P321, DOI 10.1007/s00441-007-0423-5; Fujiwara K, 2007, CELL TISSUE RES, V328, P129, DOI 10.1007/s00441-006-0345-7; HOFLER H, 1984, ACTA NEUROPATHOL, V65, P35; Horiguchi K, 2012, ENDOCRINOLOGY, V153, P1717, DOI 10.1210/en.2011-1937; Horiguchi K, 2014, CELL TISSUE RES, V357, P301, DOI 10.1007/s00441-014-1817-9; Horiguchi K, 2010, J ENDOCRINOL, V204, P115, DOI 10.1677/JOE-09-0333; Horiguchi K, 2011, J ENDOCRINOL, V208, P225, DOI 10.1677/JOE-10-0297; Horvath E, 2002, ULTRASTRUCT PATHOL, V26, P219, DOI 10.1080/01913120290104476; Kurotani R, 2001, MODERN PATHOL, V14, P791, DOI 10.1038/modpathol.3880392; Lardner A, 2001, J LEUKOCYTE BIOL, V69, P522; Martinez D, 2007, J IMMUNOL, V179, P1950; Mogi C, 2013, ENDOCR J, V61, P101; Murakami N, 2004, J BIOL CHEM, V279, P42484, DOI 10.1074/jbc.M406561200; Nakakura T, 2012, ENDOCRINOLOGY, V153, P4171, DOI 10.1210/en.2012-1164; SPANGELO BL, 1989, ENDOCRINOLOGY, V125, P575; Spangelo BL, 1996, ENDOCRINOLOGY, V137, P4419, DOI 10.1210/en.137.10.4419; TACHIBANA O, 1988, ACTA NEUROPATHOL, V76, P458; TATSUNO I, 1991, ENDOCRINOLOGY, V129, P1797; VILAPORC.E, 1972, Z ZELLFORSCH MIK ANA, V129, P328, DOI 10.1007/BF00307293; Xu Y, 2002, BBA-MOL CELL BIOL L, V1582, P81, DOI 10.1016/S1388-1981(02)00140-3; Yoshida S, 2013, J NEUROENDOCRINOL, V25, P779, DOI 10.1111/jne.12077; Yoshida S, 2011, J NEUROENDOCRINOL, V23, P933, DOI 10.1111/j.1365-2826.2011.02198.x; Yoshida S, 2009, BIOCHEM BIOPH RES CO, V385, P11, DOI 10.1016/j.bbrc.2009.05.027; YOSHIMURA F, 1977, ENDOCRINOL JAPON, V24, P435	40	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0302-766X	1432-0878		CELL TISSUE RES	Cell Tissue Res.	NOV	2014	358	2					515	525		10.1007/s00441-014-1958-x		11	Cell Biology	Cell Biology	AS6AY	WOS:000344348500020		
J	Shibutani, ST; Yoshimori, T				Shibutani, Shusaku T.; Yoshimori, Tamotsu			Autophagosome formation in response to intracellular bacterial invasion	CELLULAR MICROBIOLOGY			English	Review							LISTERIA-MONOCYTOGENES; ENDOPLASMIC-RETICULUM; NONCANONICAL AUTOPHAGY; SALMONELLA INFECTION; ISOLATION MEMBRANE; LC3 RECRUITMENT; ATG PROTEINS; CELLS; UBIQUITIN; HOST	Autophagy is an intracellular bulk degradation system in which double-membrane vesicles, called autophagosomes, engulf cytoplasmic components and later fuse with lysosomes to degrade the autophagosome content. Although autophagy was initially thought a non-selective process, recent studies have clarified that it can selectively target intracellular bacteria and function as an intracellular innate immune system that suppresses bacterial survival. A key mechanism for the recognition of cytosol-invading bacteria is ubiquitination, and the recognition of the ubiquitinated target by the autophagy machinery can be accomplished multiple ways. In this review, we discuss recent findings regarding the induction of autophagosome formation in response to intracellular bacterial invasion.	[Shibutani, Shusaku T.; Yoshimori, Tamotsu] Osaka Univ, Grad Sch Frontier Biosci, Lab Intracellular Membrane Dynam, Osaka, Japan; [Shibutani, Shusaku T.; Yoshimori, Tamotsu] Osaka Univ, Grad Sch Med, Dept Genet, Osaka, Japan	Yoshimori, T (reprint author), Osaka Univ, Grad Sch Frontier Biosci, Lab Intracellular Membrane Dynam, Osaka, Japan.	tamyoshi@fbs.osaka-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan; Japan Science and Technology Agency CREST	We apologize to all researchers whose relevant work could not be introduced in this manuscript due to space limitations. We thank P. Karagiannis for proofreading the manuscript. Work in the authors' lab is supported by the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan and by Japan Science and Technology Agency CREST.	Axe EL, 2008, J CELL BIOL, V182, P685, DOI 10.1083/jcb.200803137; Birmingham CL, 2007, AUTOPHAGY, V3, P442; Gutierrez MG, 2004, CELL, V119, P753, DOI 10.1016/j.cell.2004.11.038; Fujita N, 2008, MOL BIOL CELL, V19, P4651, DOI 10.1091/mbc.E08-03-0312; Maejima I, 2013, EMBO J, V32, P2336, DOI 10.1038/emboj.2013.171; Huang J, 2014, NAT REV MICROBIOL, V12, P101, DOI 10.1038/nrmicro3160; Conway KL, 2013, GASTROENTEROLOGY, V145, P1347, DOI 10.1053/j.gastro.2013.08.035; Martinez J, 2011, P NATL ACAD SCI USA, V108, P17396, DOI 10.1073/pnas.1113421108; Wild P, 2011, SCIENCE, V333, P228, DOI 10.1126/science.1205405; Kim JY, 2013, CELL, V154, P365, DOI 10.1016/j.cell.2013.06.012; Henault J, 2012, IMMUNITY, V37, P986, DOI 10.1016/j.immuni.2012.09.014; Hayashi-Nishino M, 2009, NAT CELL BIOL, V11, P1433, DOI 10.1038/ncb1991; Castillo EF, 2012, P NATL ACAD SCI USA, V109, pE3168, DOI 10.1073/pnas.1210500109; Thurston TLM, 2012, NATURE, V482, P414, DOI 10.1038/nature10744; Mizushima N, 2003, J CELL SCI, V116, P1679, DOI 10.1242/jcs.00381; Gammoh N, 2013, NAT STRUCT MOL BIOL, V20, P144, DOI 10.1038/nsmb.2475; Itakura E, 2010, AUTOPHAGY, V6, P764; Travassos LH, 2010, NAT IMMUNOL, V11, P55, DOI 10.1038/ni.1823; Shahnazari S, 2010, CELL HOST MICROBE, V8, P137, DOI 10.1016/j.chom.2010.07.002; Lam GY, 2013, AUTOPHAGY, V9, P985, DOI 10.4161/auto.24406; Hamasaki M, 2013, NATURE, V495, P389, DOI 10.1038/nature11910; Birmingham CL, 2006, J BIOL CHEM, V281, P11374, DOI 10.1074/jbc.M509157200; Fujita N, 2013, J CELL BIOL, V203, P115, DOI 10.1083/jcb.201304188; Thurston TLM, 2009, NAT IMMUNOL, V10, P1215, DOI 10.1038/ni.1800; Ma J, 2012, J BIOL CHEM, V287, P34149, DOI 10.1074/jbc.M112.382812; Perrin AJ, 2004, CURR BIOL, V14, P806, DOI 10.1016/j.cub.2004.04.033; Welchman RL, 2005, NAT REV MOL CELL BIO, V6, P599, DOI 10.1038/nrm1700; Kageyama S, 2011, MOL BIOL CELL, V22, P2290, DOI 10.1091/mbc.E10-11-0893; Romao S, 2013, J CELL BIOL, V203, P757, DOI 10.1083/jcb.201308173; Kirkin V, 2009, MOL CELL, V34, P259, DOI 10.1016/j.molcel.2009.04.026; Sanjuan MA, 2007, NATURE, V450, P1253, DOI 10.1038/nature06421; Flannagan RS, 2009, NAT REV MICROBIOL, V7, P355, DOI 10.1038/nrmicro2128; Zheng YT, 2009, J IMMUNOL, V183, P5909, DOI 10.4049/jimmunol.0900441; Yoshikawa Y, 2009, NAT CELL BIOL, V11, P1233, DOI 10.1038/ncb1967; Manzanillo PS, 2013, NATURE, V501, P512, DOI 10.1038/nature12566; Klionsky DJ, 2003, DEV CELL, V5, P539, DOI 10.1016/S1534-5807(03)00296-X; Choy A, 2012, SCIENCE, V338, P1072, DOI 10.1126/science.1227026; Ng ACY, 2011, P NATL ACAD SCI USA, V108, P4631, DOI 10.1073/pnas.1000093107; Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Ogawa M, 2005, SCIENCE, V307, P727, DOI 10.1126/science.1106036; Huett A, 2012, CELL HOST MICROBE, V12, P778, DOI 10.1016/j.chom.2012.10.019; Narendra D, 2008, J CELL BIOL, V183, P795, DOI 10.1083/jcb.200809125; Nishimura T, 2013, EMBO REP, V14, P284, DOI 10.1038/embor.2013.6; Watson RO, 2012, CELL, V150, P803, DOI 10.1016/j.cell.2012.06.040; Yla-Anttila P, 2009, AUTOPHAGY, V5, P1180; Benjamin JL, 2013, CELL HOST MICROBE, V13, P723, DOI 10.1016/j.chom.2013.05.004; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kabeya Y, 2004, J CELL SCI, V117, P2805, DOI 10.1242/jcs.01131; Py BF, 2007, AUTOPHAGY, V3, P117; Huang J, 2009, P NATL ACAD SCI USA, V106, P6226, DOI 10.1073/pnas.0811045106; Kobayashi S, 2010, AUTOPHAGY, V6, P36; Nakagawa I, 2004, SCIENCE, V306, P1037, DOI 10.1126/science.1103966; Zhao ZJ, 2008, CELL HOST MICROBE, V4, P458, DOI 10.1016/j.chom.2008.10.003; Cossart P, 2004, SCIENCE, V304, P242, DOI 10.1126/science.1090124; Dupont N, 2009, CELL HOST MICROBE, V6, P137, DOI 10.1016/j.chom.2009.07.005; Collins CA, 2009, PLOS PATHOG, V5, DOI 10.1371/journal.ppat.1000430; Dortet L, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002168; Gong L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017852; Hung YH, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3111	60	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1462-5814	1462-5822		CELL MICROBIOL	Cell Microbiol.	NOV	2014	16	11					1619	1626		10.1111/cmi.12357		8	Cell Biology; Microbiology	Cell Biology; Microbiology	AS0TC	WOS:000343990400002		
J	Motokura, K				Motokura, Ken			Multifunctional Solid Surfaces for Enhanced Catalysis	CHEMCATCHEM			English	Editorial Material						core-shell catalysts; heterogeneous catalysis; nanoparticles; oxidation; surface chemistry	TSUJI-TROST REACTION; ONE-POT OXIDATION; CORE-SHELL CATALYST; PALLADIUM COMPLEX; METHYL ALPHA; NANOPARTICLES; ACID; SELECTIVITY; GENERATION; DESIGN		Tokyo Inst Technol, Dept Environm Chem & Engn, Midori Ku, Yokohama, Kanagawa 2268502, Japan	Motokura, K (reprint author), Tokyo Inst Technol, Dept Environm Chem & Engn, Midori Ku, 4259 Nagatsuta Cho, Yokohama, Kanagawa 2268502, Japan.	motokura@chemenv.titech.ac.jp	Motokura, Ken/C-3894-2015	Motokura, Ken/0000-0002-0066-5139			Nakatsuka K, 2014, CHEM-EUR J, V20, P8348, DOI 10.1002/chem.201402586; Mori K, 2009, LANGMUIR, V25, P11180, DOI 10.1021/la9015367; Climent MJ, 2014, ACS CATAL, V4, P870, DOI 10.1021/cs401052k; Diaz U, 2013, CHEM SOC REV, V42, P4083, DOI 10.1039/c2cs35385g; Okada S, 2011, CHEM-EUR J, V17, P9047, DOI 10.1002/chem.201101241; Yu CG, 2012, CHEM COMMUN, V48, P4933, DOI 10.1039/c2cc31585h; [Anonymous], 2012, ANGEW CHEM, V124, P8141; Mitsudome T, 2013, GREEN CHEM, V15, P2636, DOI 10.1039/c3gc41360h; Peng HG, 2012, J MATER CHEM, V22, P14219, DOI 10.1039/c2jm31788e; Ikurumi S, 2014, J PHYS CHEM C, V118, P575, DOI 10.1021/jp411153p; Brunelli NA, 2013, J CATAL, V308, P60, DOI 10.1016/j.jcat.2013.05.022; Dickschat AT, 2013, CHEM COMMUN, V49, P2195, DOI 10.1039/c3cc00235g; EASTY DB, 1962, J ORG CHEM, V27, P2102, DOI 10.1021/jo01053a048; Liu J, 2014, CHEM-EUR J, V20, P11549, DOI 10.1002/chem.201402545; MEHLTRETTER CL, 1951, J AM CHEM SOC, V73, P2424, DOI 10.1021/ja01150a005; Noda H, 2012, ANGEW CHEM INT EDIT, V51, P8017, DOI 10.1002/anie.201203066; Noda H, 2013, ADV SYNTH CATAL, V355, P973, DOI 10.1002/adsc.201300063; Okada S, 2012, J PHYS CHEM C, V116, P14360, DOI 10.1021/jp3025073; OKUDA S, 1990, CARBOHYD RES, V198, P133, DOI 10.1016/0008-6215(90)84283-Z; PERLIN AS, 1972, CARBOHYD RES, V21, P123, DOI 10.1016/S0008-6215(00)81737-1; Song HY, 2009, MICROPOR MESOPOR MAT, V120, P346, DOI 10.1016/j.micromeso.2008.11.023; Waki M, 2013, CHEM COMMUN, V49, P7283, DOI 10.1039/c3cc43482f; Yalfani MS, 2010, PHYS CHEM CHEM PHYS, V12, P14673, DOI 10.1039/c0cp01157f	23	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1867-3880	1867-3899		CHEMCATCHEM	ChemCatChem	NOV	2014	6	11					3067	3068		10.1002/cctc.201402585		2	Chemistry, Physical	Chemistry	AS5SW	WOS:000344330800005		
J	Metzner, R; Okazaki, S; Asano, Y; Groger, H				Metzner, Richard; Okazaki, Seiji; Asano, Yasuhisa; Groeger, Harald			Cyanide-free Enantioselective Synthesis of Nitriles: Synthetic Proof of a Biocatalytic Concept and Mechanistic Insights	CHEMCATCHEM			English	Article						biocatalysis; diastereoselectivity; enantioselectivity; nitriles; reaction mechanisms	ALDOXIME DEHYDRATASE; CONJUGATE ADDITION; STRAIN OXB-1; HYDRATASE; EFFICIENT; AMIDASE; GENE	The first ("by definition") cyanide-free enantioselective synthetic approach towards chiral alpha- and beta-branched nitriles is reported. This process is based on a biocatalytic dehydration of racemic aldoximes by using an aldoxime dehydratase and proceeds with high conversion and excellent enantioselectivity (up to 98% ee) with water as the only side-product when starting from a racemic substrate with a high E/Z ratio. Thus, in combination with the facile generation of aldoximes through condensation of readily accessible aldehydes with hydroxylamine, this methodology offers an attractive and efficient path to chiral nitriles with excellent atom economy in aqueous solution. Furthermore, this study shows a surprising enzymatic dependency of the enantiopreference on the E or Z configuration of the aldoxime moiety. Notably, the whole stereochemical course of this enzymatic reaction has been rationalized by means of a computational study.	[Metzner, Richard; Okazaki, Seiji; Asano, Yasuhisa] Toyama Prefectural Univ, Biotechnol Res Ctr, Imizu, Toyama, Japan; [Metzner, Richard; Okazaki, Seiji; Asano, Yasuhisa] Toyama Prefectural Univ, Dept Biotechnol, Imizu, Toyama, Japan; [Metzner, Richard; Groeger, Harald] Univ Bielefeld, Fac Chem, D-33615 Bielefeld, Germany; [Okazaki, Seiji; Asano, Yasuhisa] JST, ERATO, Asano Act Enzyme Mol Project, Imizu, Toyama, Japan	Asano, Y (reprint author), Toyama Prefectural Univ, Biotechnol Res Ctr, 5180 Kurokawa, Imizu, Toyama, Japan.				German Academic Exchange Service (DAAD); Japan Society for the Promotion of Science (JSPS); JSPS [23248015]; Exploratory Research for Advanced Technology (ERATO) of the Japan Science and Technology Agency (JST)	R.M. thanks the German Academic Exchange Service (DAAD) and the Japan Society for the Promotion of Science (JSPS) for a student exchange scholarship. This work was supported in part by a Grant-in-Aid for Scientific Research (A) (23248015) from JSPS (Y.A.) and Exploratory Research for Advanced Technology (ERATO) of the Japan Science and Technology Agency (JST) (Y.A.).	Fleming FF, 2010, J MED CHEM, V53, P7902, DOI 10.1021/jm100762r; Tanaka Y, 2010, J AM CHEM SOC, V132, P8862, DOI 10.1021/ja1035286; Li T, 2012, J AM CHEM SOC, V134, P6467, DOI 10.1021/ja3010495; Groger H, 2003, CHEM REV, V103, P2795, DOI 10.1021/cr020038p; Mazet C, 2008, ANGEW CHEM INT EDIT, V47, P1762, DOI 10.1002/anie.200704461; Kosjek B, 2008, TETRAHEDRON-ASYMMETR, V19, P1403, DOI 10.1016/j.tetasy.2008.05.023; Savage SA, 2009, ORG PROCESS RES DEV, V13, P1169, DOI 10.1021/op900226j; Kato Y, 2000, BIOCHEMISTRY-US, V39, P800, DOI 10.1021/bi991598u; Mita T, 2005, J AM CHEM SOC, V127, P514, DOI 10.1021/ja043424s; Guin J, 2013, J AM CHEM SOC, V135, P2100, DOI 10.1021/ja312141b; McNicholas S, 2011, ACTA CRYSTALLOGR D, V67, P386, DOI 10.1107/S0907444911007281; Choi JW, 2012, J AM CHEM SOC, V134, P9102, DOI 10.1021/ja303442q; Fleming FF, 1999, NAT PROD REP, V16, P597, DOI 10.1039/a804370a; DeSantis G, 2002, J AM CHEM SOC, V124, P9024, DOI 10.1021/ja0259842; Asano Y, 1998, FEMS MICROBIOL LETT, V158, P185, DOI 10.1111/j.1574-6968.1998.tb12818.x; Brenna E, 2013, CATAL SCI TECHNOL, V3, P1136, DOI 10.1039/c3cy20804d; Kato Y, 2004, J BIOSCI BIOENG, V97, P250, DOI 10.1016/S1389-1723(04)70200-5; Liao RZ, 2012, J PHYS CHEM B, V116, P9396, DOI 10.1021/jp305510c; Martinez CA, 2004, TETRAHEDRON, V60, P759, DOI 10.1016/j.tet.2003.10.001; Mazet C., 2008, ANGEW CHEM, V120, P1786, DOI 10.1002/ange.200704461; Murahashi S.-I., 2004, SCI SYNTHESIS, V19; RajanBabu T. V., 1999, COMPREHENSIVE ASYMME, V1, P267; Thakur VV, 2005, INDIAN J CHEM B, V44, P557; Wieser M., 2000, STEREOSELECTIVE BIOC, P461; Xie SX, 2003, BIOCHEMISTRY-US, V42, P12056, DOI 10.1021/bi035092u	25	1	1	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1867-3880	1867-3899		CHEMCATCHEM	ChemCatChem	NOV	2014	6	11					3105	3109		10.1002/cctc.201402612		5	Chemistry, Physical	Chemistry	AS5SW	WOS:000344330800013		
J	Fujigaya, T; Morita, J; Nakashima, N				Fujigaya, Tsuyohiko; Morita, Junichi; Nakashima, Naotoshi			Grooves of Bundled Single-Walled Carbon Nanotubes Dramatically Enhance the Activity of the Oxygen Reduction Reaction	CHEMCATCHEM			English	Article						bundles; N ligands; nanotubes; oxygen; reduction	FUEL-CELL ELECTROCATALYST; SURFACE-AREA; POLYBENZIMIDAZOLE; ADSORPTION; CATALYSTS; NANOPARTICLES; SIMULATION; DESIGN; IRON; NH3	Nitrogen-doped graphitic structures (N-GSs) are promising and cheap catalyst candidates for the oxygen reduction reaction (ORR). In this paper, we describe, first, the synthesis of single-walled carbon nanotubes (SWNTs) coated by a N-GS (SWNT/N-GS) and, second, the dramatic enhancement in the activity of the ORR by using this catalyst relative to that observed for the analogue composite composed of multiwalled carbon nanotubes (MWNTs) coated by a N-GS (i.e., MWNT/N-GS). Scanning electron microscopy and gas-adsorption experiments revealed that the SWNT/N-GS formed a bundled structure and that superior gas adsorption behavior originated from this groove structure. It is assumed that the grooves of the bundled SWNT/N-GS dramatically enhance the activity of the ORR owing to superior O-2 adsorption on the grooves.	[Fujigaya, Tsuyohiko; Morita, Junichi; Nakashima, Naotoshi] Kyushu Univ, Grad Sch Engn, Dept Appl Chem, Nishi Ku, Fukuoka 819039, Japan; [Fujigaya, Tsuyohiko; Nakashima, Naotoshi] Kyushu Univ, Int Inst Carbon Neutral Energy Res WPI I2CNER, Fukuoka 8190395, Japan; [Nakashima, Naotoshi] Japan Sci & Technol Agcy JST, CREST, Chiyoda Ku, Tokyo 1020075, Japan	Fujigaya, T (reprint author), Kyushu Univ, Grad Sch Engn, Dept Appl Chem, Nishi Ku, 744 Motooka, Fukuoka 819039, Japan.	fujigaya-tcm@mail.cstm.kyushu-u.ac.jp; nakashima-tcm@mail.cstm.kyushu-u.ac.jp	Nakashima, Naotoshi/C-8791-2009		Low-Carbon Research Network (LCnet); Nanotechnology Platform Project (Molecules and Materials Synthesis); Japan Science and Technology Agency (JST) through its Center of Innovation Science and Technology based Radical Innovation and Entrepreneurship Program (COI Program) of the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan; Adaptable and Seamless Technology Transfer Program through Target-Driven RD, JST [AS242Z00200L]; Advanced Low Carbon Technology Research and Development Program (ALCA)	This work was supported in part by the Low-Carbon Research Network (LCnet), the Nanotechnology Platform Project (Molecules and Materials Synthesis), and the Japan Science and Technology Agency (JST) through its Center of Innovation Science and Technology based Radical Innovation and Entrepreneurship Program (COI Program) of the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan as well as by the Adaptable and Seamless Technology Transfer Program through Target-Driven R&D, JST (AS242Z00200L) and the Advanced Low Carbon Technology Research and Development Program (ALCA).	Williams KA, 2000, CHEM PHYS LETT, V320, P352, DOI 10.1016/S0009-2614(00)00225-6; Fujigaya T, 2011, CHEM COMMUN, V47, P6843, DOI 10.1039/c1cc11303h; Fujigaya T, 2009, CARBON, V47, P3227, DOI 10.1016/j.carbon.2009.07.038; Jaouen F, 2011, ENERG ENVIRON SCI, V4, P114, DOI 10.1039/c0ee00011f; Kumbharkar SC, 2006, J MEMBRANE SCI, V286, P161, DOI 10.1016/j.memsci.2006.09.030; Okamoto M, 2009, SMALL, V5, P735, DOI 10.1002/smll.200801742; Agnihotri S, 2006, CARBON, V44, P2376, DOI 10.1016/j.carbon.2006.05.038; Fujigaya T, 2014, J MATER CHEM A, V2, P3888, DOI 10.1039/c3ta14469k; Varcoe JR, 2005, FUEL CELLS, V5, P187, DOI 10.1002/fuce.200400045; Zheng Y, 2012, SMALL, V8, P3550, DOI 10.1002/smll.201200861; HORVATH G, 1983, J CHEM ENG JPN, V16, P470, DOI 10.1252/jcej.16.470; Huang YY, 2012, POLYMERS-BASEL, V4, P275, DOI 10.3390/polym4010275; Okamoto M, 2008, ADV FUNCT MATER, V18, P1776, DOI 10.1002/adfm.200701257; Lefevre M, 2009, SCIENCE, V324, P71, DOI 10.1126/science.1170051; Zhang LP, 2011, J PHYS CHEM C, V115, P11170, DOI 10.1021/jp201991j; Agnihotri S, 2006, J PHYS CHEM B, V110, P7640, DOI 10.1021/jp060040a; Cannon JJ, 2012, J PHYS CHEM B, V116, P9812, DOI 10.1021/jp3039225; Wu G, 2011, SCIENCE, V332, P443, DOI 10.1126/science.1200832; Jaouen F, 2007, J PHYS CHEM C, V111, P5963, DOI 10.1021/jp068273p; Ozaki J, 2010, ELECTROCHIM ACTA, V55, P1864, DOI 10.1016/j.electacta.2009.10.037; Hou PX, 2008, CARBON, V46, P2003, DOI 10.1016/j.carbon.2008.09.009; Chen S, 2012, ADV MATER, V24, P5593, DOI 10.1002/adma.201202424; Heller DA, 2004, J PHYS CHEM B, V108, P6905, DOI 10.1021/jp037690o; Agnihotri S, 2005, LANGMUIR, V21, P896, DOI 10.1021/la047662c; Paulus UA, 2001, J ELECTROANAL CHEM, V495, P134, DOI 10.1016/S0022-0728(00)00407-1; Jaouen F, 2006, J PHYS CHEM B, V110, P5553, DOI 10.1021/jp057135h; Chen ZW, 2011, ENERG ENVIRON SCI, V4, P3167, DOI 10.1039/c0ee00558d; Fujigaya T, 2013, ADV MATER, V25, P1666, DOI 10.1002/adma.201204461; Bezerra CWB, 2008, ELECTROCHIM ACTA, V53, P4937, DOI 10.1016/j.electacta.2008.02.012; Ellison MD, 2004, J PHYS CHEM B, V108, P7938, DOI 10.1021/jp049356d; Jiang JW, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.245412; Jijun Zhao, 2002, Nanotechnology, V13, DOI 10.1088/0957-4484/13/2/312; Ulbricht H, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.075404; Yoo J, 2013, NANOSCALE, V5, P7419, DOI 10.1039/c3nr01828h	34	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1867-3880	1867-3899		CHEMCATCHEM	ChemCatChem	NOV	2014	6	11					3169	3173		10.1002/cctc.201402565		5	Chemistry, Physical	Chemistry	AS5SW	WOS:000344330800022		
J	Hatakeyama, S				Hatakeyama, Susumi			Total Synthesis of Biologically Active Natural Products Based on Highly Selective Synthetic Methodologies	CHEMICAL & PHARMACEUTICAL BULLETIN			English	Review						total synthesis; natural product; asymmetric synthesis; heterocycle synthesis	BAYLIS-HILLMAN REACTION; CONIA-ENE REACTION; STEREOCONTROLLED TOTAL-SYNTHESIS; ALPHA-AMINO ALDEHYDES; ISOCUPREIDINE BETA-ICD; C-H AMINATION; SALINOSPORAMIDE-A; LEUSTRODUCSIN-B; ASYMMETRIC-SYNTHESIS; ENANTIOCOMPLEMENTARY CATALYST	Total syntheses of structurally and biologically intriguing natural products relying on new synthetic methodologies are described. This article features cinchona alkaloid-catalyzed asymmetric Morita-Baylis-Hillman reactions, heterocycle syntheses based on rhodium-catalyzed C-H amination and indium-catalyzed Conia-ene reactions, and their utilization for the syntheses of the phoslactomycin family of antibiotics, glutamate receptor agonists and antagonists, and alkaloids with characteristic highly substituted pyrrolidinone core structures.	Nagasaki Univ, Grad Sch Biomed Sci, Nagasaki 8528521, Japan	Hatakeyama, S (reprint author), Nagasaki Univ, Grad Sch Biomed Sci, 1-14 Bunkyo Machi, Nagasaki 8528521, Japan.	susumi@nagasaki-u.ac.jp			Japan Society for the Promotion of Sciences; Ministry of Education, Culture, Sports, Science and Technology of Japan	I would like to express my sincere gratitude to all co-workers for their great contributions to the achievements described here. Their names are acknowledged in our publications cited in this review. This work was supported by a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Sciences and a Grant-in-Aid for Scientific Research on Priority Areas "Creation of Biologically Functional Molecules" and Innovative Areas "Reaction Integration" and "Advanced Molecular Transformations by Organocatalysis" from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Endo A, 2005, J AM CHEM SOC, V127, P8298, DOI 10.1021/ja0522783; Raheem IT, 2004, J AM CHEM SOC, V126, P706, DOI 10.1021/ja039550y; Shimada K, 2003, J AM CHEM SOC, V125, P4048, DOI 10.1021/ja0340679; Donohoe TJ, 2007, ORG LETT, V9, P1725, DOI 10.1021/ol070430v; Donohoe TJ, 2012, ORG LETT, V14, P5460, DOI 10.1021/ol302541j; Robiette R, 2007, J AM CHEM SOC, V129, P15513, DOI 10.1021/ja0717865; Urabe F, 2013, J ORG CHEM, V78, P3847, DOI 10.1021/jo400263w; Feling RH, 2003, ANGEW CHEM INT EDIT, V42, P355, DOI 10.1002/anie.200390115; Wei Y, 2013, CHEM REV, V113, P6659, DOI 10.1021/cr300192h; Basavaiah D, 2012, CHEM SOC REV, V41, P68, DOI 10.1039/c1cs15174f; Nakano A, 2006, TETRAHEDRON, V62, P381, DOI 10.1016/j.tet.2005.09.072; Hatakeyama S, 2009, PURE APPL CHEM, V81, P217, DOI 10.1351/PAC-CON-08-07-14; Onyango EO, 2007, ANGEW CHEM INT EDIT, V46, P6703, DOI 10.1002/anie.200702229; Lee W, 2013, CHEM COMMUN, V49, P5231, DOI 10.1039/c3cc42365d; Rios R, 2012, CATAL SCI TECHNOL, V2, P267, DOI 10.1039/c1cy00387a; Miyashita K, 2007, TETRAHEDRON LETT, V48, P3829, DOI 10.1016/j.tetlet.2007.03.152; Nakamoto Y, 2013, CHEM-EUR J, V19, P12653, DOI 10.1002/chem.201302665; Cavalheiro EA, 2001, P NATL ACAD SCI USA, V98, P5947, DOI 10.1073/pnas.121179198; Konig CM, 2009, ORG LETT, V11, P2728, DOI 10.1021/ol900757k; Abermil N, 2010, ADV SYNTH CATAL, V352, P656, DOI 10.1002/adsc.200900900; Nakano A, 2006, ORG LETT, V8, P5357, DOI 10.1021/ol0622561; Yu SY, 2011, TETRAHEDRON, V67, P1673, DOI 10.1016/j.tet.2010.12.068; Shibahara S, 2008, ORG LETT, V10, P2139, DOI 10.1021/ol8004672; Wei Y, 2010, ACCOUNTS CHEM RES, V43, P1005, DOI 10.1021/ar900271g; Gao Q, 2005, ORG LETT, V7, P2185, DOI 10.1021/ol050532q; Fukumoto H, 2006, ANGEW CHEM INT EDIT, V45, P2731, DOI 10.1002/anie.200600210; Wang YG, 2006, ANGEW CHEM INT EDIT, V45, P3320, DOI 10.1002/anie.200600458; Takahashi K, 2012, J ORG CHEM, V77, P7364, DOI 10.1021/jo301145r; Abermil N, 2008, J AM CHEM SOC, V130, P12596, DOI 10.1021/ja805122j; Takahashi K, 2012, ORG LETT, V14, P1644, DOI 10.1021/ol300431n; Endo K, 2007, J AM CHEM SOC, V129, P5264, DOI 10.1021/ja0702014; Reddy LR, 2004, J AM CHEM SOC, V126, P6230, DOI 10.1021/ja048613p; Hamada M, 2009, ORG LETT, V11, P4664, DOI 10.1021/ol9019343; Marshall JA, 2007, J ORG CHEM, V72, P8153, DOI 10.1021/jo070787c; Kawahara S, 2003, ORG LETT, V5, P3103, DOI 10.1021/ol035102j; Vaswani RG, 2008, J ORG CHEM, V73, P1661, DOI 10.1021/jo702329z; Ooi H, 2001, ORG LETT, V3, P953, DOI 10.1021/ol015655z; Garner P, 2014, CHEM COMMUN, V50, P4908, DOI 10.1039/c4cc01692k; Abermil N, 2009, ORG LETT, V11, P4648, DOI 10.1021/ol901920s; Matsubara T, 2014, ANGEW CHEM INT EDIT, V53, P757, DOI 10.1002/anie.201307835; Kawasaki M, 2005, ORG LETT, V7, P4165, DOI 10.1021/ol0515154; Watanabe H, 2002, TETRAHEDRON LETT, V43, P861, DOI 10.1016/S0040-4039(01)02255-9; Zhu C, 2004, J AM CHEM SOC, V126, P5352, DOI 10.1021/ja0492900; ShinYa K, 1997, TETRAHEDRON LETT, V38, P7079, DOI 10.1016/S0040-4039(97)01653-5; Druais V, 2009, ORG LETT, V11, P935, DOI 10.1021/ol8029142; Morokuma K, 2008, TETRAHEDRON LETT, V49, P6043, DOI 10.1016/j.tetlet.2008.07.004; Zalatan DN, 2010, TOP CURR CHEM, V292, P347, DOI 10.1007/128_2009_19; Brauner-Osborne H, 2000, J MED CHEM, V43, P2609, DOI 10.1021/jm000007r; Du Bois J, 2011, ORG PROCESS RES DEV, V15, P758, DOI 10.1021/op200046v; Potts BC, 2010, MAR DRUGS, V8, P835, DOI 10.3390/md8040835; Ooi H, 2004, J ORG CHEM, V69, P7765, DOI 10.1021/jo048817o; Igarashi J, 2004, TETRAHEDRON LETT, V45, P3783, DOI 10.1016/j.tetlet.2004.03.085; Kennedy-Smith JJ, 2004, J AM CHEM SOC, V126, P4526, DOI 10.1021/ja049487s; Tsuji H, 2007, ANGEW CHEM INT EDIT, V46, P8060, DOI 10.1002/anie.200702928; Iwabuchi Y, 1999, J AM CHEM SOC, V121, P10219, DOI 10.1021/ja992655+; Basavaiah D, 2010, CHEM REV, V110, P5447, DOI 10.1021/cr900291g; Gulder TAM, 2010, ANGEW CHEM INT EDIT, V49, P9346, DOI 10.1002/anie.201000728; Miyashita K, 2008, J ORG CHEM, V73, P5360, DOI 10.1021/jo8005599; Balazsik K, 2007, J MOL CATAL A-CHEM, V272, P265, DOI 10.1016/j.molcata.2007.03.042; Bastin R, 2011, TETRAHEDRON, V67, P10026, DOI 10.1016/j.tet.2011.09.037; Cachet X, 2013, RSC ADV, V3, P12466, DOI 10.1039/c3ra41005f; Choudhuri Suparna Das, 2005, J Antibiot (Tokyo), V58, P573; Ciaccio JA, 2004, TETRAHEDRON LETT, V45, P7201, DOI 10.1016/j.tetlet.2004.08.039; Coelho F, 2006, SYNLETT, P435, DOI 10.1055/s-2006-926239; CONIA JM, 1975, SYNTHESIS-STUTTGART, P1; Debarge S, 2005, TETRAHEDRON, V61, P2065, DOI 10.1016/j.tet.2004.12.045; Esumi T, 2002, CHEM COMMUN, P3042, DOI 10.1039/b209742g; Eto K, 2011, ORG LETT, V13, P5398, DOI 10.1021/ol202306d; Hatakeyama S., 2012, SCI SYNTHESIS ASYMME, P673; HATAKEYAMA S, 1988, J AM CHEM SOC, V110, P5201, DOI 10.1021/ja00223a055; HATAKEYAMA S, 1985, J CHEM SOC CHEM COMM, P1759, DOI 10.1039/c39850001759; Hatakeyama S, 2006, J SYN ORG CHEM JPN, V64, P1132; Hayashi Y, 2008, ORG LETT, V10, P1405, DOI 10.1021/ol800195g; Igarashi J, 2005, TETRAHEDRON LETT, V46, P6381, DOI 10.1016/j.tetlet.2005.06.171; Iwabuchi Y, 2001, TETRAHEDRON LETT, V42, P7867, DOI 10.1016/S0040-4039(01)01676-8; Iwabuchi Y, 2001, CHEM COMMUN, P2030, DOI 10.1039/b106471c; Kaiya Y, 2011, CHEM-ASIAN J, V6, P209, DOI 10.1002/asia.201000602; KENDE AS, 1990, J AM CHEM SOC, V112, P4070, DOI 10.1021/ja00166a072; MANICKUM T, 1994, S AFR J CHEM-S-AFR T, V47, P1; Masaki H, 2000, J AM CHEM SOC, V122, P5216, DOI 10.1021/ja000817s; Miyashita K, 2007, J SYN ORG CHEM JPN, V65, P874; Mizuhara N, 2007, J ANTIBIOT, V60, P762, DOI 10.1038/ja.2007.101; Moise J, 2008, SYNLETT, P2617, DOI 10.1055/s-0028-1083511; Moloney Mark G, 2004, Curr Drug Discov Technol, V1, P181, DOI 10.2174/1570163043334974; MORI T, 1985, TETRAHEDRON LETT, V26, P1073, DOI 10.1016/S0040-4039(00)98515-0; Morokuma K, 2005, CHEM COMMUN, P2265, DOI 10.1039/b500660k; Nakano A, 2005, ADV SYNTH CATAL, V347, P1790, DOI 10.1002/adsc.200505138; Nakano A, 2005, HETEROCYCLES, V66, P371; Nguyen H, 2011, J ORG CHEM, V76, P2, DOI 10.1021/jo101638r; Nishimaru T, 2014, ANGEW CHEM INT EDIT, V53, P8459, DOI 10.1002/anie.201404408; Nonaka H, 2007, TETRAHEDRON LETT, V48, P5601, DOI 10.1016/j.tetlet.2007.06.058; Panek JS, 2000, J AM CHEM SOC, V122, P11090, DOI 10.1021/ja002377a; Reddy BVS, 2005, TETRAHEDRON LETT, V46, P4589, DOI 10.1016/j.tetlet.2005.05.003; Rilatt I, 2005, SYNLETT, P2701, DOI 10.1055/s-2005-918950; Sakai R, 1997, J AM CHEM SOC, V119, P4112, DOI 10.1021/ja963953z; Sarkar S. M., 2009, CHEM COMMUN, V2009, P5907; Sarkar SM, 2011, TETRAHEDRON LETT, V52, P923, DOI 10.1016/j.tetlet.2010.12.066; Sato Y, 2010, HETEROCYCLES, V81, P2239, DOI 10.3987/COM-10-12042; Satoh N, 2011, ORG LETT, V13, P3028, DOI 10.1021/ol200886j; Sawada D, 2001, TETRAHEDRON LETT, V42, P2501, DOI 10.1016/S0040-4039(01)00212-X; Sekiyama Y, 2003, TETRAHEDRON, V59, P7465, DOI 10.1016/S0040-4020(03)01205-5; Shibahara S, 2009, SYNTHESIS-STUTTGART, P2935, DOI 10.1055/s-0029-1216930; Shibahara S, 2011, ORG LETT, V13, P4700, DOI 10.1021/ol201912w; Shibasaki M, 2007, CHEM-ASIAN J, V2, P20, DOI 10.1002/asia.200600310; Shibasaki M, 2005, HETEROCYCLES, V66, P727; Takahashi K, 2010, J SYN ORG CHEM JPN, V68, P951; Takahashi K, 2007, CHEM COMMUN, P4158, DOI 10.1039/b709627e; Takahashi K, 2014, SYNLETT, V25, P133, DOI 10.1055/s-0033-1340159; Takahashi K, 2008, ANGEW CHEM INT EDIT, V47, P6244, DOI 10.1002/anie.200801967; TAKAHASHI K, 1985, TETRAHEDRON LETT, V26, P1077, DOI 10.1016/S0040-4039(00)98516-2; Takahashi K, 2006, J ORG CHEM, V71, P4227, DOI 10.1021/jo060410r; Takahashi K, 2008, SYNLETT, P671, DOI 10.1055/s-2008-104280; Takeuchi T, 2006, ORG LETT, V8, P5307, DOI 10.1021/ol062111u; Teruya T, 2005, FEBS LETT, V579, P2463, DOI 10.1016/j.febslet.2005.03.049; Thibaudeau S, 2002, TETRAHEDRON LETT, V43, P8773, DOI 10.1016/S0040-4039(02)02068-3; Webb MR, 2008, TETRAHEDRON, V64, P4778, DOI 10.1016/j.tet.2008.01.116; Yanagisawa A, 1999, ANGEW CHEM INT EDIT, V38, P3701, DOI 10.1002/(SICI)1521-3773(19991216)38:24<3701::AID-ANIE3701>3.0.CO;2-D; Yoshimura H, 2012, CHEM PHARM BULL, V60, P1334; Yoshino M, 2012, ORG BIOMOL CHEM, V10, P8164, DOI 10.1039/c2ob26084k	119	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0009-2363			CHEM PHARM BULL	Chem. Pharm. Bull.	NOV	2014	62	11					1045	1061				17	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	AS0JX	WOS:000343964600001		
J	Hayashi, Y; Otoguro, S; Miura, T; Onuki, Y; Obata, Y; Takayama, K				Hayashi, Yoshihiro; Otoguro, Saori; Miura, Takahiro; Onuki, Yoshinori; Obata, Yasuko; Takayama, Kozo			Effect of Process Variables on the Drucker-Prager Cap Model and Residual Stress Distribution of Tablets Estimated by the Finite Element Method	CHEMICAL & PHARMACEUTICAL BULLETIN			English	Article						tablet; simulation; mathematical model; residual stress; processing; Bayesian network	PHARMACEUTICAL POWDERS; DENSITY DISTRIBUTIONS; DIE COMPACTION; MECHANICAL-BEHAVIOR; SIMULATION; FRICTION	A multivariate statistical technique was applied to clarify the causal correlation between variables in the manufacturing process and the residual stress distribution of tablets. Theophylline tablets were prepared according to a Box Behnken design using the wet granulation method. Water amounts (X-1), kneading time (X-2), lubricant-mixing time (X-3), and compression force (X-4) were selected as design variables. The Drucker-Prager cap (DPC) model was selected as the method for modeling the mechanical behavior of pharmaceutical powders. Simulation parameters, such as Young's modulus, Poisson rate, internal friction angle, plastic deformation parameters, and initial density of the powder, were measured. Multiple regression analysis demonstrated that the simulation parameters were significantly affected by process variables. The constructed DPC models were fed into the analysis using the finite element method (FEM), and the mechanical behavior of pharmaceutical powders during the tableting process was analyzed using the FEM. The results of this analysis revealed that the residual stress distribution of tablets increased with increasing X-4. Moreover, an interaction between X-2 and X-3 also had an effect on shear and the x-axial residual stress of tablets. Bayesian network analysis revealed causal relationships between the process variables, simulation parameters, residual stress distribution, and pharmaceutical responses of tablets. These results demonstrated the potential of the FEM as a tool to help improve our understanding of the residual stress of tablets and to optimize process variables, which not only affect tablet characteristics, but also are risks of causing tableting problems.	[Hayashi, Yoshihiro; Otoguro, Saori; Onuki, Yoshinori; Obata, Yasuko; Takayama, Kozo] Hoshi Univ, Dept Pharmaceut, Shinagawa Ku, Tokyo 1428501, Japan; [Miura, Takahiro] Cybernet Syst Co Ltd, Mech CAE Div, Chiyoda Ku, Tokyo 1010022, Japan	Takayama, K (reprint author), Hoshi Univ, Dept Pharmaceut, Shinagawa Ku, 2-4-41 Ebara, Tokyo 1428501, Japan.	takayama@hoshi.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan	This study was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan. The authors thank Mr. Yuuki Ishida, Department of Pharmaceutics, Hoshi University, for performing the dissolution test.	Sinka IC, 2007, KONA, V25, P4; Eiliazadeh B, 2003, PARTICUL SCI TECHNOL, V21, P303, DOI 10.1080/02726350390240124; Laity PR, 2009, POWDER TECHNOL, V192, P287, DOI 10.1016/j.powtec.2009.01.010; Sinka IC, 2004, J PHARM SCI-US, V93, P2040, DOI 10.1002/jps.20111; HAGGBLAD HA, 1991, POWDER TECHNOL, V67, P127, DOI 10.1016/0032-5910(91)80149-D; Kadiri MS, 2013, POWDER TECHNOL, V239, P467, DOI 10.1016/j.powtec.2013.02.022; Djemai A, 2006, INT J PHARM, V319, P55, DOI 10.1016/j.ijpharm.2006.03.049; Diarra H, 2013, INT J PHARMACEUT, V453, P389, DOI 10.1016/j.ijpharm.2013.05.038; Sinka IC, 2003, POWDER TECHNOL, V133, P33, DOI 10.1016/S0032-5910(03)00094-9; Michrafy A, 2002, POWDER TECHNOL, V127, P257, DOI 10.1016/S0032-5910(02)00119-5; Hayashi Y, 2013, J PHARM SCI-US, V102, P3678, DOI 10.1002/jps.23675; Wu CY, 2005, POWDER TECHNOL, V152, P107, DOI 10.1016/j.powtec.2005.01.010; Wu CY, 2008, POWDER TECHNOL, V181, P121, DOI 10.1016/j.powtec.2006.12.017; Cunningham JC, 2004, J PHARM SCI-US, V93, P2022, DOI 10.1002/jps.20110; Michrafy A, 2011, POWDER TECHNOL, V208, P417, DOI 10.1016/j.powtec.2010.08.037; Diarra H, 2012, POWDER TECHNOL, V224, P233, DOI 10.1016/j.powtec.2012.02.058; Aydin I, 1996, POWDER TECHNOL, V89, P239, DOI 10.1016/S0032-5910(96)03188-9; Coube O, 2000, POWDER METALL, V43, P123, DOI 10.1179/003258900665871; Aydin I, 1997, MRS BULL, V22, P45; Bothtner Ulrich, 2002, J Clin Monit Comput, V17, P31, DOI 10.1023/A:1015492919566; Cooper EG, 1992, MACH LEARN, V9, P309; DiMaggio F. L., 1971, ASCE, V97, P935; Hayashi Y, 2012, CHEM PHARM BULL, V60, P1419; Motomura Yoichi, 2009, Synthesiology (English Edition), V2; Ohno I, 2007, INT J PHARM, V338, P79, DOI 10.1016/j.ijpharm.2007.01.030	25	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0009-2363			CHEM PHARM BULL	Chem. Pharm. Bull.	NOV	2014	62	11					1062	1072				11	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	AS0JX	WOS:000343964600002		
J	Komasaka, T; Fujimura, H; Tagawa, T; Sugiyama, A; Kitano, Y				Komasaka, Takao; Fujimura, Hisako; Tagawa, Toshiaki; Sugiyama, Akio; Kitano, Yasunori			Practical Method for Preparing Nanosuspension Formulations for Toxicology Studies in the Discovery Stage: Formulation Optimization and in Vitro/in Vivo Evaluation of Nanosized Poorly Water-Soluble Compounds	CHEMICAL & PHARMACEUTICAL BULLETIN			English	Article						nanosuspension; toxicology study; wet media milling; mixer mill; rotation revolution mixer; oral absorption	MEDIA MILLING TECHNOLOGY; DRUG NANOCRYSTALS; PARTICLE-SIZE; ORAL ABSORPTION; RATS; STABILIZATION; PERMEABILITY; BIOAVAILABILITY; PERSPECTIVE; PERFORMANCE	The present study aimed to develop a practical method for preparing nanosuspension formulations of poorly water-soluble compounds for enhancing oral absorption in toxicology studies in the discovery stage. To obtain a suitable nanosuspension formulation for the intended purpose, formulations were optimized with a focus on the following characteristics: i) containing a high drug concentration, ii) consisting of commonly used excipient types in proper quantities for toxicology studies, iii) having long-term stability, and iv) having versatility for use with diverse compounds. Test compounds were milled with various excipients by wet media milling methods using a mixer mill (10 mg/batch) and a rotation/revolution mixer (0.5g/batch). As a result, 100 mg/mL nanosuspensions of all 11 test compounds could be prepared with an optimized dispersing agent, 0.5% hydroxypropyl methylcellulose (HPMC) (3 cP)-0.5% Tween 80. Notably, it was found that the molecular weight of HPMC influenced not only particle size but also the stability of nanosuspensions and they were stable for 4 weeks at 5 degrees C. The nanosuspensions increased in vitro dissolution rates and provided 3.9 and 3.0 times higher C-max and 4.4 and 1.6 times higher area under the concentration time curve from 0-24h (AUC(0-24h)) in rats (oral dose of 300 mg/kg) for cilostazol and danazol, respectively. In conclusion, applying a wet media milling method with the combination of HPMC of a small molecular weight and Tween 80 as a dispersing agent, nanosuspensions can be practically prepared and conveniently utilized for enhancing the oral absorption of poorly water-soluble compounds in toxicology studies in the discovery stage.	[Komasaka, Takao; Kitano, Yasunori] Mitsubishi Tanabe Pharma Corp, Med Chem Res Labs 1, Aoba Ku, Yokohama, Kanagawa 2270033, Japan; [Tagawa, Toshiaki] Mitsubishi Tanabe Pharma Corp, Med Chem Res Labs, Aoba Ku, Yokohama, Kanagawa 2270033, Japan; [Fujimura, Hisako; Sugiyama, Akio] Mitsubishi Tanabe Pharma Corp, Safety Res Labs, Kisarazu, Chiba 2920818, Japan	Komasaka, T (reprint author), Mitsubishi Tanabe Pharma Corp, Med Chem Res Labs 1, Aoba Ku, 1000 Kamoshida Cho, Yokohama, Kanagawa 2270033, Japan.	Komasaka.Takao@mu.mt-pharma.co.jp					Enright BP, 2010, BIRTH DEFECTS RES B, V89, P504, DOI 10.1002/bdrb.20273; Toyobuku H, 2003, J PHARM SCI-US, V92, P2249, DOI 10.1002/jps.10490; Vasconcelos T, 2007, DRUG DISCOV TODAY, V12, P1068, DOI 10.1016/j.drudis.2007.09.005; Verma S, 2009, LANGMUIR, V25, P12481, DOI 10.1021/la9016432; Ain-Ai A, 2008, INT J PHARM, V351, P282, DOI 10.1016/j.ijpharm.2007.09.029; Van Eerdenbrugh B, 2009, J PHARM SCI-US, V98, P2091, DOI 10.1002/jps.21563; Takano R, 2006, PHARM RES, V23, P1144, DOI 10.1007/s11095-006-0162-4; Wu LB, 2011, ADV DRUG DELIVER REV, V63, P456, DOI 10.1016/j.addr.2011.02.001; Merisko-Liversidge E, 2011, ADV DRUG DELIVER REV, V63, P427, DOI 10.1016/j.addr.2010.12.007; Peltonen L, 2010, J PHARM PHARMACOL, V62, P1569, DOI 10.1111/j.2042-7158.2010.01022.x; Hagio M, 2009, J LIPID RES, V50, P173, DOI 10.1194/jlr.D800041-JLR200; AMIDON GE, 1982, J PHARM SCI, V71, P77, DOI 10.1002/jps.2600710120; Kesisoglou F, 2012, AAPS J, V14, P677, DOI 10.1208/s12248-012-9383-0; Tanaka Y, 2012, J PHARM PHARM SCI, V15, P510; Sugano K, 2010, INT J PHARMACEUT, V387, P103, DOI 10.1016/j.ijpharm.2009.12.014; Lee J, 2005, EUR J PHARM SCI, V24, P441, DOI 10.1016/j.ejps.2004.12.010; Van Eerdenbrugh B, 2009, AAPS PHARMSCITECH, V10, P44, DOI 10.1208/s12249-008-9170-5; Butler JM, 2010, J PHARM SCI-US, V99, P4940, DOI 10.1002/jps.22217; Takatsuka T, 2009, CHEM PHARM BULL, V57, P1061; Van Eerdenbrugh B, 2007, INT J PHARM, V338, P198, DOI 10.1016/j.ijpharm.2007.02.005; Strickley RG, 2004, PHARM RES, V21, P201, DOI 10.1023/B:PHAM.0000016235.32639.23; Kesisoglou F, 2007, ADV DRUG DELIVER REV, V59, P631, DOI 10.1016/j.addr.2007.05.003; Li P, 2007, INT J PHARM, V341, P1, DOI 10.1016/j.ijpharm.2007.05.049; Niwa T, 2011, PHARM RES-DORDR, V28, P2339, DOI 10.1007/s11095-011-0465-y; Van Eerdenbrugh B, 2008, INT J PHARMACEUT, V364, P64, DOI 10.1016/j.ijpharm.2008.07.023; Sigfridsson K, 2011, DRUG DEV IND PHARM, V37, P185, DOI 10.3109/03639045.2010.504209; Pestel Sabine, 2006, Journal of Pharmacological and Toxicological Methods, V54, P200, DOI 10.1016/j.vascn.2006.02.006; Duro R, 1999, DRUG DEV IND PHARM, V25, P817, DOI 10.1081/DDC-100102244; Junghanns JUAH, 2008, INT J NANOMED, V3, P295; Sugano K, 2009, INT J PHARM, V368, P116, DOI 10.1016/j.ijpharm.2008.10.001; Juenemann D, 2011, EUR J PHARM BIOPHARM, V77, P257, DOI 10.1016/j.ejpb.2010.10.012; Lee J, 2008, INT J PHARM, V355, P328, DOI 10.1016/j.ijpharm.2007.12.032; Higgins J, 2012, DRUG DISCOV TODAY, V17, P828, DOI 10.1016/j.drudis.2012.03.016; Niwa T, 2011, INT J PHARMACEUT, V405, P218, DOI 10.1016/j.ijpharm.2010.12.013; Verma S, 2011, INT J PHARMACEUT, V406, P145, DOI 10.1016/j.ijpharm.2010.12.027; Lipinski CA, 2000, J PHARMACOL TOXICOL, V44, P235, DOI 10.1016/S1056-8719(00)00107-6; Pardeike J, 2010, INT J PHARMACEUT, V391, P322, DOI 10.1016/j.ijpharm.2010.03.002; Moschwitzer JP, 2013, INT J PHARMACEUT, V453, P142, DOI 10.1016/j.ijpharm.2012.09.034; Gad S. C., 2006, INT J TOXICOL, V25, P494; Galia E, 1998, PHARMACEUT RES, V15, P698, DOI 10.1023/A:1011910801212; George M, 2013, EUR J PHARM SCI, V48, P142, DOI 10.1016/j.ejps.2012.10.004; Jacobs C, 2000, INT J PHARM, V196, P161, DOI 10.1016/S0378-5173(99)00412-3; Kumar MP, 2007, CURR NANOSCI, V3, P191; Lipinski CA, 2002, AM PHARM REV, V5, P82; NAKAMURA J, 1985, CHEM PHARM BULL, V33, P3527; Neervannan S, 2006, EXPERT OPIN DRUG MET, V2, P715, DOI 10.1517/17425255.2.5.715; NISSIM JA, 1960, NATURE, V187, P305, DOI 10.1038/187305a0; Sigfridsson K, 2011, DRUG DEV IND PHARM, V37, P243, DOI 10.3109/03639045.2010.505927; Sun W, 2011, J PHARM SCI-US, V100, P3365, DOI 10.1002/jps.22587; Van den Mooter G., 2012, DRUG DISCOV TODAY, V9, pe79, DOI DOI 10.1016/J.DDTEC.2011.10.002	50	1	1	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0009-2363			CHEM PHARM BULL	Chem. Pharm. Bull.	NOV	2014	62	11					1073	1082				10	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	AS0JX	WOS:000343964600003		
J	Saito, Y; Mukai, T; Iwamoto, Y; Baba, M; Takiguchi, K; Okamoto, Y; Gong, X; Kawahara, T; Kuroda, C; Tori, M				Saito, Yoshinori; Mukai, Tomomi; Iwamoto, Yuko; Baba, Makiko; Takiguchi, Koji; Okamoto, Yasuko; Gong, Xun; Kawahara, Takayuki; Kuroda, Chiaki; Tori, Motoo			Germacranolides and Their Diversity of Eupatorium heterophyllum Collected in PR China	CHEMICAL & PHARMACEUTICAL BULLETIN			English	Article						Asteraceae; hydroperoxide; sesquiterpenoid; Eupatorium heterophyllum; germacrane type	SESQUITERPENE LACTONES; GENETIC DIVERSITY; CHEMICAL-CONSTITUENTS; HENGDUAN MOUNTAINS; DISYNAPHIA-MULTICRENULATA; LIGULARIA-KANAITZENSIS; SACHALINENSE MAKINO; PLANT CONSTITUENTS; HIYODORILACTONE-B; ANTHEMIS-NOBILIS	Eight new hydroperoxides and a new enone of germacrane-type sesquiterpenoids were isolated from the aerial parts of eight different samples of Eupatorium heterophyllum DC. (Asteraceae) collected in P.R. China. The structures were determined based on spectroscopic analyses. Seven of the eight samples produced hiyodorilactone A as a major constituent, while one afforded neither hiyodorilactone nor hydroperoxide. The results indicated the presence of diversity within this species.	[Saito, Yoshinori; Mukai, Tomomi; Iwamoto, Yuko; Baba, Makiko; Takiguchi, Koji; Okamoto, Yasuko; Tori, Motoo] Tokushima Bunri Univ, Fac Pharmaceut Sci, Tokushima 7708514, Japan; [Gong, Xun] Chinese Acad Sci, Kunming Inst Bot, Kunming 650204, Peoples R China; [Kawahara, Takayuki] Forestry & Forest Prod Res Inst, Tsukuba, Ibaraki 3058687, Japan; [Kuroda, Chiaki] Rikkyo Univ, Dept Chem, Toshima Ku, Tokyo 1718501, Japan	Tori, M (reprint author), Tokushima Bunri Univ, Fac Pharmaceut Sci, Yamashiro Cho, Tokushima 7708514, Japan.	tori@ph.bunri-u.ac.jp					Saito Y, 2011, NAT PROD COMMUN, V6, P361; Saito Y, 2012, TETRAHEDRON, V68, P10011, DOI 10.1016/j.tet.2012.09.042; Tori M, 2002, CHEM PHARM BULL, V50, P1250, DOI 10.1248/cpb.50.1250; Saito Y, 2013, PHYTOCHEMISTRY, V96, P184, DOI 10.1016/j.phytochem.2013.08.009; Saito Y, 2013, TETRAHEDRON, V69, P8505, DOI 10.1016/j.tet.2013.06.104; Saito Y, 2013, NAT PROD COMMUN, V8, P631; Tori M, 2008, CHEM PHARM BULL, V56, P677, DOI 10.1248/cpb.56.677; Siedle B, 2004, J MED CHEM, V47, P6042, DOI 10.1021/jm049937r; Tori M, 2006, TETRAHEDRON, V62, P4988, DOI 10.1016/j.tet.2006.02.078; Schmidt GJ, 2000, AM J BOT, V87, P716, DOI 10.2307/2656858; KUPCHAN SM, 1973, J ORG CHEM, V38, P1260, DOI 10.1021/jo00947a002; Tori M, 2008, HETEROCYCLES, V75, P2029; Zhang ML, 2008, CHEM BIODIVERS, V5, P40, DOI 10.1002/cbdv.200890014; Saito Y, 2012, NAT PROD COMMUN, V7, P447; Nagano H, 2009, HELV CHIM ACTA, V92, P2071, DOI 10.1002/hlca.200900270; Kuroda C, 2012, NAT PROD COMMUN, V7, P539; BOEKER R, 1986, PHYTOCHEMISTRY, V25, P1669, DOI 10.1016/S0031-9422(00)81232-7; BOHLMANN F, 1984, PHYTOCHEMISTRY, V23, P1435, DOI 10.1016/S0031-9422(00)80481-1; BOHLMANN F, 1978, CHEM BER-RECL, V111, P408, DOI 10.1002/cber.19781110139; CALZADA J, 1980, PHYTOCHEMISTRY, V19, P967, DOI 10.1016/0031-9422(80)85151-X; de Gutierrez AN, 2001, BIOCHEM SYST ECOL, V29, P633, DOI 10.1016/S0305-1978(00)00092-2; DOLEJS L, 1962, COLLECT CZECH CHEM C, V27, P2654; GOREN N, 1994, PHYTOCHEMISTRY, V36, P389, DOI 10.1016/S0031-9422(00)97081-X; Hanai R, 2005, B CHEM SOC JPN, V78, P1302, DOI 10.1246/bcsj.78.1302; Ito M, 2000, J PLANT RES, V113, P79, DOI 10.1007/PL00013913; JAKUPOVIC J, 1992, PHYTOCHEMISTRY, V31, P863; LEE KH, 1977, PHYTOCHEMISTRY, V16, P1068, DOI 10.1016/S0031-9422(00)86734-5; MAYER R, 1987, ARCH PHARM, V320, P318, DOI 10.1002/ardp.19873200408; Nagano H, 2012, CHEM BIODIVERS, V9, P789, DOI 10.1002/cbdv.201100240; PEREZ AL, 1986, PHYTOCHEMISTRY, V25, P745, DOI 10.1016/0031-9422(86)88038-4; RUCKER G, 1991, PLANTA MED, V57, P295, DOI 10.1055/s-2006-960099; RUCKER G, 1989, ARCH PHARM, V322, P821, DOI 10.1002/ardp.19893221109; Saito Y, 2014, TETRAHEDRON, V70, P2621, DOI 10.1016/j.tet.2014.02.080; Saito Y, 2011, MOLECULES, V16, P10645, DOI 10.3390/molecules161210645; Saito Y, 2012, HETEROCYCLES, V86, P497, DOI 10.3987/COM-12-S(N)47; Saito Y, 2011, TETRAHEDRON, V67, P2220, DOI 10.1016/j.tet.2011.01.082; Saito Y, 2012, NAT PROD COMMUN, V7, P423; Shimizu A, 2014, PHYTOCHEMISTRY, V102, P137, DOI 10.1016/j.phytochem.2014.03.019; Shimizu A, 2012, NAT PROD COMMUN, V7, P431; TAKAHASHI T, 1979, CHEM PHARM BULL, V27, P2539; TAKAHASHI T, 1978, CHEM LETT, P1345, DOI 10.1246/cl.1978.1345; Tori M, 2008, PHYTOCHEMISTRY, V69, P1158, DOI 10.1016/j.phytochem.2007.12.001; Tori M, 2008, TETRAHEDRON, V64, P4486, DOI 10.1016/j.tet.2008.02.036; Tori M, 2007, NAT PROD COMMUN, V2, P357; Tori M, 2000, HETEROCYCLES, V52, P1075; Tori M, 2008, TETRAHEDRON, V64, P9136, DOI 10.1016/j.tet.2008.06.077; Triana J, 2013, PHYTOCHEMISTRY, V92, P87, DOI 10.1016/j.phytochem.2013.04.015	47	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0009-2363			CHEM PHARM BULL	Chem. Pharm. Bull.	NOV	2014	62	11					1092	1099				8	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	AS0JX	WOS:000343964600005		
J	Inoue, Y; Sato, S; Yamamoto, C; Yamasaki, M; Kanamoto, I				Inoue, Yutaka; Sato, Sayuri; Yamamoto, Chisa; Yamasaki, Mikio; Kanamoto, Ikuo			Study of Complex Formation of Carbamazepine with Thiourea	CHEMICAL & PHARMACEUTICAL BULLETIN			English	Article						thiourea; carbamazepine; complex; X-ray crystallography; hydrogen bond	INCLUSION-COMPOUNDS; PHARMACEUTICAL COCRYSTALS; CRYSTAL-STRUCTURE; SOLUBILITY; ACID; UREA; BIOAVAILABILITY	The aim of this study, we evaluated a complex between thiourea (TU) and carbamazepine (CBZ) of a poorly soluble drug by using powder X-ray diffraction (PXRD), Fourier transform infrared (FT-IR) spectroscopy, X-ray crystallography and the solubility test. PXRD of TU/CBZ=2/1, 1/1, and 1/2 prepared by solvent evaporation (EVP) revealed characteristic diffraction peaks at 2 theta=6.7 degrees, 8.8 degrees, 13.5 degrees, and 20.4 degrees, therefore molecular interaction between TU and CBZ presumably occurred. Results of the FT-IR spectroscopy, asymmetric and symmetric NH stretching vibration of TU were shifted to high region by TU/CBZ=2/1, 1/1, and 1/2 EVP. TU/CBZ=2/1 and 1/1 EVP had absorption derived from TU. It was considered that complex were formed by TU/CBZ=1/2. X-Ray crystallography of TU and CBZ revealed a crystal structure with one TU molecule arranged near two CBZ molecules. Molecules of the same type overlap in this layer. When doing a solubility test by using CBZ and samples of EVP, physical mixture and crystals in TU/CBZ=1/2 to confirm the solubility in water of TU/CBZ complex, there is no difference with the CBZ. It considered that the structure of a complex differs from the tunnel structure of inclusion complexes that has been previously reported contribute to result it.	[Inoue, Yutaka; Sato, Sayuri; Yamamoto, Chisa; Kanamoto, Ikuo] Josai Univ, Fac Pharmaceut Sci, Dept Drug Safety Management, Sakado, Saitama 3500295, Japan; [Yamasaki, Mikio] Rigaku Corp, Akishima, Tokyo 1968666, Japan	Inoue, Y (reprint author), Josai Univ, Fac Pharmaceut Sci, Dept Drug Safety Management, 1-1 Keyakidai, Sakado, Saitama 3500295, Japan.	yinoue@josai.ac.jp					Trask AV, 2006, INT J PHARM, V320, P114, DOI 10.1016/j.ijpharm.2006.04.018; Bethune SJ, 2009, CRYST GROWTH DES, V9, P3976, DOI 10.1021/cg9001187; Good DJ, 2009, CRYST GROWTH DES, V9, P2252, DOI 10.1021/cg801039j; Grzesiak AL, 2003, J PHARM SCI-US, V92, P2260, DOI 10.1002/jps.10455; McNamara DP, 2006, PHARM RES, V23, P1888, DOI 10.1007/s11095-006-9032-3; Trask AV, 2005, CRYST GROWTH DES, V5, P2233, DOI 10.1021/cg0501682; Trask AV, 2005, TOP CURR CHEM, V254, P41, DOI 10.1007/b100995; Vishweshwar P, 2006, J PHARM SCI-US, V95, P499, DOI 10.1002/jps.20578; Weyna DR, 2009, CRYST GROWTH DES, V9, P1106, DOI 10.1021/cg800936d; Jayasankar A, 2007, MOL PHARM, V4, P360, DOI 10.1021/mp0700099; BREWSTER ME, 1991, J PHARM SCI, V80, P380, DOI 10.1002/jps.2600800420; Cabeza AJC, 2006, J AM CHEM SOC, V128, P14466, DOI 10.1021/ja065845a; Cui Y., 2013, J PHARM, V2013, P1; Harris KDM, 1997, CHEM SOC REV, V26, P279, DOI 10.1039/cs9972600279; Koester LS, 2004, EUR J PHARM SCI, V22, P201, DOI 10.1016/j.ejps.2004.03.010; LENNE HU, 1954, ACTA CRYSTALLOGR, V7, P1, DOI 10.1107/S0365110X54000011; Maris T, 2001, CHEM MATER, V13, P2483, DOI 10.1021/cm991173u; MIMA H, 1964, J PHARM SCI, V53, P931, DOI 10.1002/jps.2600530819; Moribe K, 2004, CHEM PHARM BULL, V52, P524, DOI 10.1248/cpb.52.524; SHINDO T, 1993, B CHEM SOC JPN, V66, P1914, DOI 10.1246/bcsj.66.1914; TAYLOR JC, 1981, POSTGRAD MED J, V57, P16; Thakral S, 2008, J PHARM PHARMACOL, V60, P823, DOI 10.1211/jpp.60.7.0003	22	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0009-2363			CHEM PHARM BULL	Chem. Pharm. Bull.	NOV	2014	62	11					1125	1130				6	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	AS0JX	WOS:000343964600009		
J	Sakai, M; Kaneko, S; Nakamura, M; Murakami, Y; Hikawa, H; Azumaya, I; Nakakoshi, M; Yokoyama, Y				Sakai, Masahiro; Kaneko, Satoshi; Nakamura, Mikio; Murakami, Yasuoki; Hikawa, Hidemasa; Azumaya, Isao; Nakakoshi, Masamichi; Yokoyama, Yuusaku			Spectroscopic Investigation for the Interaction of Mycophenolate Mofetil with Ferrous Ions	CHEMICAL & PHARMACEUTICAL BULLETIN			English	Article						mycophenolate mofetile; ferrous ion; complex formation; C-13-NMR; UV-visible (Vis) spectra; IR spectra	RENAL-TRANSPLANT RECIPIENTS; ACID PHARMACOKINETICS; ABSORPTION; IRON; PHARMACODYNAMICS; GLUCURONIDE; IMPAIRMENT; SULFATE	The interaction of mycophenolate mofetil (MMF) with ferrous ions (Fe2+) in the solid state, in water, and in polar organic solvents was investigated using H-1-NMR, C-13-NMR, IR, and UV-visible (Vis) spectroscopies. A red-purple colored substance was formed after grinding solid MMF and FeSO4 center dot 7H(2)O in a mortar. The IR spectrum of taken as a KBr tablet of the colored substance showed a new absorption band at 1651 cm(-1). Although the color disappeared when the sample was dissolved in water, it persisted in organic solvents such as MeOH or dimethyl sulfoxide (HMSO). The UV-Vis spectrum of a 0.25 mm MeOH solution of MMF showed a new absorption maximum at 507nm in the presence of Fe2+ ions, while an aqueous solution of the same mixture showed no significant change from the MMF solution. All the signals in the C-13-NMR spectrum in DMSO-d(6) solution were unambiguously assigned. Upon the addition of 0.5 eq. of Fe2+ ions, all the carbon signals except those of the 2-morpholinoethyl group almost disappeared, which clearly indicated that the Fe2+ ions were located far away from the 2-morpholinoethyl groups in the MMF molecules. On the basis of these results, we have concluded that the MMF-Fe2+ complex is actually formed in the solid state as well as in polar organic solvents such as MeOH or DMSO.	[Sakai, Masahiro] Toho Univ, Omori Hosp, Dept Pharm, Ota Ku, Tokyo 1438540, Japan; [Kaneko, Satoshi; Murakami, Yasuoki; Hikawa, Hidemasa; Azumaya, Isao; Nakakoshi, Masamichi; Yokoyama, Yuusaku] Toho Univ, Dept Pharmaceut Sci, Chiba 2748510, Japan; [Nakamura, Mikio] Toho Univ, Fac Sci, Dept Chem, Chiba 2748510, Japan	Yokoyama, Y (reprint author), Toho Univ, Dept Pharmaceut Sci, 2-2-1 Miyama, Chiba 2748510, Japan.	yokoyama@phar.toho-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan [17590016]; MEXT; Uehara Memorial Foundation	This work was supported by a Grant-in-Aid for Scientific Research (No. 17590016) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan, by an "Open Research Center" project for private university matching fund subsidy from MEXT, and by the Uehara Memorial Foundation.	Lidgate D, 2002, DRUG DEV IND PHARM, V28, P1275, DOI 10.1081/DDC-120015361; Staatz CE, 2007, CLIN PHARMACOKINET, V46, P13, DOI 10.2165/00003088-200746010-00002; Mino Y, 2011, BIOL PHARM BULL, V34, P755; Naito T, 2008, BIOL PHARM BULL, V31, P1292, DOI 10.1248/bpb.31.1292; Badrick AC, 2007, TRANSPLANTATION, V84, P799, DOI 10.1097/01.tp.0000282871.78905.35; Bertini I., 1996, NMR PARAMAGNETIC SUB, V150, P77; Ducray PS, 2006, BRIT J CLIN PHARMACO, V62, P492, DOI 10.1111/j.1365-2125.2005.02541.x; Gelone DK, 2007, PHARMACOTHERAPY, V27, P1272, DOI 10.1592/phco.27.9.1272; Jones CE, 2006, J AM CHEM SOC, V128, P9378, DOI 10.1021/ja057651l; Kato R, 2002, J CLIN PHARMACOL, V42, P1275, DOI 10.1177/0091270002238771; Lorenz M, 2004, AM J KIDNEY DIS, V43, P1098, DOI 10.1053/j.ajkd.2004.03.021; Lu XH, 2009, J ANTIBIOT, V62, P527, DOI 10.1038/ja.2009.54; Morii M, 2000, CLIN PHARMACOL THER, V68, P613, DOI 10.1067/mcp.2000.111480; Mudge DW, 2004, TRANSPLANTATION, V77, P206, DOI 10.1097/01.TP.0000100446.44001.00; Naito T., 2011, IRVOYAKUGAKU, V37, P277; Naito T, 2010, YAKUGAKU ZASSHI, V130, P1695, DOI 10.1248/yakushi.130.1695; Newbold N., 2009, CLIN MED THERAPEUTIC, P927	17	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0009-2363			CHEM PHARM BULL	Chem. Pharm. Bull.	NOV	2014	62	11					1131	1135				5	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	AS0JX	WOS:000343964600010		
J	Nohara, T; Fujiwara, Y; Kudo, R; Yamaguchi, K; Ikeda, T; Murakami, K; Ono, M; Kajimoto, T; Takeya, M				Nohara, Toshihiro; Fujiwara, Yukio; Kudo, Rino; Yamaguchi, Koki; Ikeda, Tsuyoshi; Murakami, Kotaro; Ono, Masateru; Kajimoto, Tetsuya; Takeya, Motohiro			Isolation and Characterization of New Onionins A(2) and A(3) from Allium cepa, and of Onionins A(1), A(2), and A(3) from Allium fistulosum	CHEMICAL & PHARMACEUTICAL BULLETIN			English	Article						Allium cepa; onion; tetrahydrothiophene; onionin; macrophage activation; anticancer agent	REGULATING MACROPHAGE ACTIVATION; TUMOR-ASSOCIATED MACROPHAGES; SATIVUM; PROGRESSION; SULFOXIDE	In this study, the new stable sulfur-containing compounds onionins A(2) (1) and A(3) (2) were isolated from the acetone extracts of the bulbs of Allium cepa L. and identified as the stereoisomers of onionin A(1) discovered in our previous study. Their chemical structures, 3,4-dimethy1-5-(1E-propenyl)-tetrahydrothiophene-2-sulfenic acid-S-oxides, were characterized using various spectroscopic techniques. In addition, 1 and 2 together with onionin A1 were successfully isolated from the leaves of the Welsh onion, Allium fistulosum L. The onion-extracted fractions showed good potential to inhibit the polarization of M2 activated macrophages, indicating their possible ability to inhibit tumor cell proliferation.	[Nohara, Toshihiro; Yamaguchi, Koki; Ikeda, Tsuyoshi; Murakami, Kotaro] Sojo Univ, Fac Pharmaceut Sci, Nishi Ku, Kumamoto 8600082, Japan; [Fujiwara, Yukio; Kudo, Rino; Takeya, Motohiro] Kumamoto Univ, Fac Life Sci, Grad Sch Med Sci, Chuo Ku, Kumamoto 8608556, Japan; [Ono, Masateru] Tokai Univ, Sch Agr, Kumamoto 8691404, Japan; [Kajimoto, Tetsuya] Ritsumeikan Univ, Inst Gen Sci Technol, Kusatsu, Shiga 5258577, Japan	Nohara, T (reprint author), Sojo Univ, Fac Pharmaceut Sci, Nishi Ku, 4-22-2 Ikeda, Kumamoto 8600082, Japan.	none@ph.sojo-u.ac.jp					Amagase H, 2006, J NUTR, V136, p716S; El-Aasr M, 2010, J NAT PROD, V73, P1306, DOI 10.1021/np100105u; Hagemann T, 2009, BLOOD, V113, P3139, DOI 10.1182/blood-2008-12-172825; Sica A, 2006, EUR J CANCER, V42, P717, DOI 10.1016/j.ejca.2006.01.003; Mantovani A, 2003, TUMORI, V89, P459; Gordon S, 2003, NAT REV IMMUNOL, V3, P23, DOI 10.1038/nri978; Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005; Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618; Rose P, 2005, NAT PROD REP, V22, P351, DOI 10.1039/b417639c; Komohara Y, 2006, J HISTOCHEM CYTOCHEM, V54, P763, DOI 10.1369/jhc.5A6871.2006; El-Aasr M, 2011, CHEM PHARM BULL, V59, P1340, DOI 10.1248/cpb.59.1340; Sica A, 2008, SEMIN CANCER BIOL, V18, P349, DOI 10.1016/j.semcancer.2008.03.004; BAYER T, 1989, J AM CHEM SOC, V111, P3085, DOI 10.1021/ja00190a064; Block E, 2010, GARLIC AND OTHER ALLIUMS: THE LORE AND THE SCIENCE, P1; Dewick P. M., 2002, MED NATURAL PRODUCTS; JOHNSON CR, 1964, J AM CHEM SOC, V86, P2935, DOI 10.1021/ja01068a035; JUARISTI E, 1988, TETRAHEDRON, V44, P5653, DOI 10.1016/S0040-4020(01)81426-5; LAMBERT JB, 1966, J ORG CHEM, V31, P3429, DOI 10.1021/jo01348a522; MARTIN JC, 1964, J AM CHEM SOC, V86, P2936, DOI 10.1021/ja01068a036; Nohara T, 2013, CHEM PHARM BULL, V61, P695; Nohara T, 2014, CHEM PHARM BULL, V62, P477, DOI 10.1248/cpb.c14-00003; Nohara T, 2012, CHEM PHARM BULL, V60, P747, DOI 10.1248/cpb.60.747; Ronayne J., 1967, J CHEM SOC B, V1967, P540; Theisen C, 2001, J NATL CANCER I, V93, P1049, DOI 10.1093/jnci/93.14.1049	24	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0009-2363			CHEM PHARM BULL	Chem. Pharm. Bull.	NOV	2014	62	11					1141	1145				5	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	AS0JX	WOS:000343964600012		
J	Kunishima, M; Kato, D; Nakanishi, S; Kitamura, M; Yamada, K; Terao, K; Asano, T				Kunishima, Munetaka; Kato, Daiki; Nakanishi, Shuichi; Kitamura, Masanori; Yamada, Kohei; Terao, Keiji; Asano, Tomoya			Specific Labeling of Streptavidin for Better Understanding of Ligand Modification in Modular Method for Affinity Labeling (MoAL)	CHEMICAL & PHARMACEUTICAL BULLETIN			English	Article						protein labeling; streptavidin; amide; dehydrocondensation; catalytic reaction	AMIDE-FORMING REACTIONS; AVIDIN; BIOTIN; DERIVATIVES	We studied the specific labeling of streptavidin using the modular method for affinity labeling (MoAL) that we developed based on a catalytic amide-forming reaction using 2-chloro-4,6-dimethoxy-1,3,5-triazine (CDMT) and a tertiary amine catalyst. The primary structures of avidin and streptavidin are significantly different from each other, and streptavidin does not possess an acidic amino acid equivalent to Asp108 of avidin, which is the target acidic amino acid that was labeled using MoAL. However, using biotinylated modular ligand catalysts (MLC) originally designed for labeling avidin, the labeling of streptavidin was found to successfully proceed at Glu51, which is located in a different region. The present study indicates that MoAL is readily applicable to protein labeling without a precise design for MLC. The most important factor for the design of MLC is to ensure that the linker is of sufficient length to connect the ligands to a catalytic site.	[Kunishima, Munetaka; Kato, Daiki; Nakanishi, Shuichi; Kitamura, Masanori; Yamada, Kohei] Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Fac Pharmaceut Sci, Kanazawa, Ishikawa 9201192, Japan; [Terao, Keiji] CycloChem, Chuo Ku, Kobe, Hyogo 6500047, Japan; [Asano, Tomoya] Kanazawa Univ, Adv Sci Res Ctr, Div Funct Genom, Kanazawa, Ishikawa 9200934, Japan	Kunishima, M (reprint author), Kanazawa Univ, Inst Med Pharmaceut & Hlth Sci, Fac Pharmaceut Sci, Kakuma Machi, Kanazawa, Ishikawa 9201192, Japan.	kunisima@p.kanazawa-u.ac.jp	Kitamura, Masanori/C-3840-2015; YAMADA, Kohei/D-8418-2015		Ministry of Education, Culture, Sports, Science and Technology of Japan [20390007]	This work was supported partially by a Grant-in-Aid for Science Research (No. 20390007) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	CHAIET L, 1964, ARCH BIOCHEM BIOPHYS, V106, P1, DOI 10.1016/0003-9861(64)90150-X; Kunishima M, 1999, TETRAHEDRON, V55, P13159, DOI 10.1016/S0040-4020(99)00809-1; Hashimoto M, 2008, EUR J ORG CHEM, P2513, DOI 10.1002/ejoc.200701069; Leslie BJ, 2008, CHEM SOC REV, V37, P1347, DOI 10.1039/b702942j; Freitag S, 1997, PROTEIN SCI, V6, P1157; WHITAKER JE, 1991, ANAL BIOCHEM, V198, P119, DOI 10.1016/0003-2697(91)90515-U; Pazy Y, 2002, J BIOL CHEM, V277, P30892, DOI 10.1074/jbc.M202874200; Laitinen OH, 2006, CELL MOL LIFE SCI, V63, P2992, DOI 10.1007/s00018-006-6288-z; Laitinen OH, 1999, FEBS LETT, V461, P52, DOI 10.1016/S0014-5793(99)01423-4; Zhang L, 2007, ANGEW CHEM INT EDIT, V46, P1798, DOI 10.1002/anie.200604222; Fasman G. D., 1989, PREDICTION PROTEIN S; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; Jakoby W. B., 1977, METHOD ENZYMOL, V46, P3; Kitamura M, 2014, J ORG CHEM, V79, P3709, DOI 10.1021/jo500376m; Kunishima M, 2001, J AM CHEM SOC, V123, P10760, DOI 10.1021/ja011660m; Kunishima M, 2013, CHEM PHARM BULL, V61, P882; Kunishima M., 2009, CHEM COMMUN, V2009, P5597; Nakanishi S, 2010, BIOORG MED CHEM LETT, V20, P7050, DOI 10.1016/j.bmcl.2010.09.109; WILCHEK M, 1989, TRENDS BIOCHEM SCI, V14, P408, DOI 10.1016/0968-0004(89)90289-2	19	0	0	PHARMACEUTICAL SOC JAPAN	TOKYO	2-12-15 SHIBUYA, SHIBUYA-KU, TOKYO, 150-0002, JAPAN	0009-2363			CHEM PHARM BULL	Chem. Pharm. Bull.	NOV	2014	62	11					1146	1150				5	Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology & Pharmacy	Pharmacology & Pharmacy; Chemistry	AS0JX	WOS:000343964600013		
J	Ikuma, N; Doi, Y; Fujioka, K; Mikie, T; Kokubo, K; Oshima, T				Ikuma, Naohiko; Doi, Yuta; Fujioka, Koichi; Mikie, Tsubasa; Kokubo, Ken; Oshima, Takumi			Dramatic Mechanistic Change in Acid-Catalyzed Arylation of Azafulleroids Depending on their Ambident N/C Basicity: Formation of Cyclopentene Centered Pentakisadduct	CHEMISTRY-AN ASIAN JOURNAL			English	Article						arylation; homogeneous catalysis; fullerenes; nucleophilic substitution; protonation	FULLERENE APEX; ELECTROPHILIC ADDITION; CONICAL MOLECULES; LIQUID-CRYSTALS; GAS-PHASE; FUNCTIONALIZATION; AZIRIDINOFULLERENES; PROTONATION; STACKING; ENAMINES	Azafulleroid, amino-bridged [5,6]-open fullerene, has the ambident N/C basicity of the incorporated enamine moiety. Acid-catalyzed arylation of N-substituted azafulleroids proceeded via two types of initial N/C protonation to perform monoarylation or 1,4-bisarylation for the N-alkyl substituents and shuttlecock-type pentakisarylation for the N-phenyl substituent. The dramatic product change was explained by considering the possible mechanism as well as the DFT computational results.	[Ikuma, Naohiko; Doi, Yuta; Fujioka, Koichi; Mikie, Tsubasa; Kokubo, Ken; Oshima, Takumi] Osaka Univ, Grad Sch Engn, Div Appl Chem, Suita, Osaka 5650871, Japan	Ikuma, N (reprint author), Osaka Univ, Grad Sch Engn, Div Appl Chem, 2-1 Yamadaoka, Suita, Osaka 5650871, Japan.	ikuma@chem.eng.osaka-u.ac.jp	Ikuma, Naohiko/O-1157-2015	Ikuma, Naohiko/0000-0002-8282-9407	Japan Society for the Promotion of Science (JSPS) [24750039]; Ministry of Health, Labour and Welfare of Japan (MHLW)	We thank Dr. Nobuko Kanehisa for X-ray crystallography. This work was supported by Grant-in-Aid for Young Scientist (B) (No. 24750039) from Japan Society for the Promotion of Science (JSPS), and partly by Health Labour Sciences Research Grants from the Ministry of Health, Labour and Welfare of Japan (MHLW).	Ikuma N, 2012, ORG LETT, V14, P6040, DOI 10.1021/ol302928d; Yang HT, 2014, J ORG CHEM, V79, P1487, DOI 10.1021/jo4025573; Spek AL, 2009, ACTA CRYSTALLOGR D, V65, P148, DOI 10.1107/S090744490804362X; PRATO M, 1993, J AM CHEM SOC, V115, P1148, DOI 10.1021/ja00056a049; Matsuo Y, 2004, J AM CHEM SOC, V126, P432, DOI 10.1021/ja038816y; Tajima Y, 2006, ORG LETT, V8, P3203, DOI 10.1021/ol0610183; Wang GW, 2009, ORG LETT, V11, P1507, DOI 10.1021/ol900110g; Ikuma N, 2010, ORG BIOMOL CHEM, V8, P1394, DOI 10.1039/b918005b; Sawamura M, 2002, NATURE, V419, P702, DOI 10.1038/nature01110; Tsuruoka R, 2009, J ORG CHEM, V74, P1691, DOI 10.1021/jo8025737; Zhong YW, 2007, J AM CHEM SOC, V129, P3052, DOI 10.1021/ja068780k; Nambo M, 2011, J AM CHEM SOC, V133, P2402, DOI 10.1021/ja111213k; Kitagawa T, 1999, J AM CHEM SOC, V121, P4298, DOI 10.1021/ja9900048; Averdung J, 1996, TETRAHEDRON, V52, P5407, DOI 10.1016/0040-4020(96)00171-8; Bayat M, 2010, J MOL STRUC-THEOCHEM, V957, P120, DOI 10.1016/j.theochem.2010.07.015; CHIANG Y, 1990, J ORG CHEM, V55, P1309, DOI 10.1021/jo00291a040; ELLENBERGER MR, 1981, J AM CHEM SOC, V103, P5377, DOI 10.1021/ja00408a017; Hachiya H, 2009, CHEM LETT, V38, P372, DOI 10.1246/cl.2009.372; HAWKER CJ, 1994, J ORG CHEM, V59, P3503, DOI 10.1021/jo00091a051; Heinemann F. W., 2012, ANGEW CHEM, V124, P11892; Huang H, 2013, ANGEW CHEM INT EDIT, V52, P5037, DOI 10.1002/anie.201300973; Huang H., 2013, ANGEW CHEM, V125, P5141; HUMMELEN JC, 1995, J AM CHEM SOC, V117, P7003, DOI 10.1021/ja00131a024; Ikuma N, 2012, TETRAHEDRON LETT, V53, P3581, DOI 10.1016/j.tetlet.2012.05.007; Ikuma N, 2011, EUR J ORG CHEM, P6452, DOI 10.1002/ejoc.201100827; Ivashkevich OA, 2008, CHEM HETEROCYC COMPD, V44, P1472, DOI 10.1007/s10593-009-0210-1; Iwashita A., 2007, ANGEW CHEM, V119, P3583, DOI 10.1002/ange.200700062; Iwashita A, 2007, ANGEW CHEM INT EDIT, V46, P3513, DOI 10.1002/anie.200700062; Kennedy RD, 2012, CHEM-EUR J, V18, P7418, DOI 10.1002/chem.201103400; Kondrashov EV, 2012, J PHYS ORG CHEM, V25, P162, DOI 10.1002/poc.1897; Matsuo Y, 2008, CHEM-ASIAN J, V3, P1350, DOI 10.1002/asia.200800122; Miao CB, 2013, J ORG CHEM, V78, P12257, DOI 10.1021/jo402079m; MULLER K, 1978, HELV CHIM ACTA, V61, P1407, DOI 10.1002/hlca.19780610425; Nagamachi T, 2012, CHEM-EUR J, V18, P12035, DOI 10.1002/chem.201201680; Neubauer R, 2012, ANGEW CHEM INT EDIT, V51, P11722, DOI 10.1002/anie.201206878; Ouchi A, 2002, J AM CHEM SOC, V124, P13364, DOI 10.1021/ja0287728; Sheldrick G. M., 1997, SHELXL 97 PROGRAM CR; Zhang G., 2010, ANGEW CHEM, V122, P5421; Zhang G, 2010, ANGEW CHEM INT EDIT, V49, P5293, DOI 10.1002/anie.201001280	39	2	2	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1861-4728	1861-471X		CHEM-ASIAN J	Chem.-Asian J.	NOV	2014	9	11					3084	3088		10.1002/asia.201402728		5	Chemistry, Multidisciplinary	Chemistry	AS5TK	WOS:000344332200004		
J	Agou, T; Nagata, K; Sasamori, T; Tokitoh, N				Agou, Tomohiro; Nagata, Koichi; Sasamori, Takahiro; Tokitoh, Norihiro			Reaction of a Dialumene-Benzene Adduct with Diphenylacetylene: Formation of 3,4-Dialuminacyclobutene and 5,6-Dialuminabicyclo[2.1.1]hex-2-ene Derivatives	CHEMISTRY-AN ASIAN JOURNAL			English	Article						alkynes; aluminum; alumylene; cycloaddition; dialumene	TERPHENYL; ALUMINUM; BONDS; ALUMINACYCLOPROPENE; SUBSTITUENT; COMPLEXES; ELEMENTS; LIGANDS; AR	Reaction of a dialumene-benzene adduct bearing bulky aryl substituents with diphenylacetylene was found to give a novel 5,6-dialuminabicyclo[2.1.1]hex-2-ene derivative in addition to the 3,4-dialuminacyclobutene derivative, the formal [2+2] cycloadduct of an intermediary dialumene with diphenylacetylene. The molecular structure of the newly obtained 5,6-dialuminabicyclo[2.1.1]hex-2-ene has been elucidated by X-ray crystallographic analysis.	[Agou, Tomohiro; Nagata, Koichi; Sasamori, Takahiro; Tokitoh, Norihiro] Kyoto Univ, Inst Chem Res, Kyoto 6110011, Japan	Tokitoh, N (reprint author), Kyoto Univ, Inst Chem Res, Kyoto 6110011, Japan.	tokitoh@boc.kuicr.kyoto-u.ac.jp	Sasamori, Takahiro/C-4963-2009	Sasamori, Takahiro/0000-0001-5410-8488	JSPS KAKENHI [24550048, 24109013, 26620028]; MEXT Project of Integrated Research on Chemical Synthesis from Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan; "Molecular Systems Research" project of RIKEN Advanced Science Institute; Ube Industries Award in Synthetic Organic Chemistry, Japan; Kyoto Technoscience Center; Research Institute for Production Development;  [252926]	This work was supported by JSPS KAKENHI (Nos. 24550048, 24109013, and 26620028), MEXT Project of Integrated Research on Chemical Synthesis from Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan, the "Molecular Systems Research" project of RIKEN Advanced Science Institute, and the Ube Industries Award in Synthetic Organic Chemistry, Japan. T. A. is thankful to the Kyoto Technoscience Center and the Research Institute for Production Development for their financial support. K.N. acknowledges the financial support by a Grant-in-Aid for JSPS Fellows (No. 252926).	Agou T., 2013, ANGEW CHEM, V125, P11018; Agou T., 2013, ANGEW CHEM, V125, P10215; Agou T, 2012, ORGANOMETALLICS, V31, P3806, DOI 10.1021/om300237q; Agou T, 2013, ANGEW CHEM INT EDIT, V52, P10031, DOI 10.1002/anie.201304143; Zhu HP, 2006, J AM CHEM SOC, V128, P5100, DOI 10.1021/ja057731p; Fischer RC, 2010, CHEM REV, V110, P3877, DOI 10.1021/cr100133q; Hardman NJ, 2003, J AM CHEM SOC, V125, P2667, DOI 10.1021/ja028579j; Agou T, 2013, ANGEW CHEM INT EDIT, V52, P10818, DOI 10.1002/anie.201305228; Fan C, 2010, ORGANOMETALLICS, V29, P5132, DOI 10.1021/om100334r; Mizuhata Y, 2009, CHEM REV, V109, P3479, DOI 10.1021/cr900093s; HOBERG H, 1977, ANGEW CHEM INT EDIT, V16, P539, DOI 10.1002/anie.197705391; Wright RJ, 2003, J AM CHEM SOC, V125, P10784, DOI 10.1021/ja034478p; Wasano T, 2014, CHEM COMMUN, V50, P8148, DOI 10.1039/c4cc03470h; Iwamoto T, 2014, CHEM LETT, V43, P164, DOI 10.1246/cl.130856; Nagata K, 2014, ANGEW CHEM INT EDIT, V53, P3881, DOI 10.1002/anie.201310559; Wright RJ, 2005, J AM CHEM SOC, V127, P4794, DOI 10.1021/ja0432259; KRUGER C, 1977, J ORGANOMET CHEM, V141, P141, DOI 10.1016/S0022-328X(00)92267-8; Cui CM, 2006, ANGEW CHEM INT EDIT, V45, P2245, DOI 10.1002/anie.200504329; Sasamori T, 2013, B CHEM SOC JPN, V86, P1005, DOI 10.1246/bcsj.20130134; Berndt A., 2004, MOL CLUSTERS MAIN GR, P267; CHEY J, 1990, ORGANOMETALLICS, V9, P2430, DOI 10.1021/om00159a009; Cui C., 2006, ANGEW CHEM, V118, P2303, DOI 10.1002/ange.200504329; Frisch M J, 2010, GAUSSIAN 09 REVISION; Grimes RN, 2011, CARBORANES, 2ND EDITION, P1; HOBERG H, 1977, J ORGANOMET CHEM, V127, pC29, DOI 10.1016/S0022-328X(00)89718-1; Hoberg H., 1977, ANGEW CHEM, V89, P563, DOI 10.1002/ange.19770890821; HOBERG H, 1979, J ORGANOMET CHEM, V164, pC13, DOI 10.1016/S0022-328X(00)83130-7; Lee VY, 2010, CHEM LETT, V39, P312, DOI 10.1246/cl.2010.312; Matthew A., 2012, B CHEM SOC JPN, V85, P1245; Nagata K., 2014, ANGEW CHEM, V126, P3962; Schnockel H., 1986, ANGEW CHEM, V98, P929, DOI 10.1002/ange.19860981027; SCHNOCKEL H, 1986, ANGEW CHEM INT EDIT, V25, P921, DOI 10.1002/anie.198609211; Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930; Uffing A. Ecker, 1998, CHEM-EUR J, V4, P2142; Wright RJ, 2002, J AM CHEM SOC, V124, P8538, DOI 10.1021/ja026285s; XIE YM, 1990, J AM CHEM SOC, V112, P5393, DOI 10.1021/ja00170a001; Zhu H., 2005, ANGEW CHEM, V117, P5220, DOI 10.1002/ange.200500899; Zhu HP, 2005, ANGEW CHEM INT EDIT, V44, P5090, DOI 10.1002/anie.200500899; Zhu Z., 2009, ANGEW CHEM, V121, P2061; Zhu ZL, 2009, ANGEW CHEM INT EDIT, V48, P2027, DOI 10.1002/anie.200805718	40	1	1	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1861-4728	1861-471X		CHEM-ASIAN J	Chem.-Asian J.	NOV	2014	9	11					3099	3101		10.1002/asia.201402798		3	Chemistry, Multidisciplinary	Chemistry	AS5TK	WOS:000344332200007		
J	Nakamae, K; Kure, B; Nakajima, T; Ura, Y; Tanase, T				Nakamae, Kanako; Kure, Bunsho; Nakajima, Takayuki; Ura, Yasuyuki; Tanase, Tomoaki			Facile Insertion of Carbon Dioxide into Cu-2(mu-H) Dinuclear Units Supported by Tetraphosphine Ligands	CHEMISTRY-AN ASIAN JOURNAL			English	Article						CO2 insertion; copper hydride complex; dinuclear complex; formate complex; tetraphosphine ligand	IRON PINCER COMPLEX; CRYSTAL-STRUCTURE; HYDRIDE; HYDROGENATION; REACTIVITY; REDUCTION; CATALYSTS; GEOMETRY; CO2	Reactions of meso-bis[(diphenylphosphinomethyl) phenylphosphino] methane (dpmppm) with Cu-I species in the presence of NaBH4 afforded di- and tetranuclear copper hydride complexes, [Cu-2(mu-H)(mu-dpmppm)(2)]X (1) and [Cu-4(mu-H)(2)(mu(4)-H)(mu-dpmppm)(2)]X (2) (X = BF4, PF6). Complex 1 undergoes facile insertion of CO2 (1 atm) at room temperature, leading to a formate-bridged dicopper complex [Cu-2(mu-HCOO)(dpmppm)(2)]X (3). The experimental and DFT theoretical studies clearly demonstrate that CO2 insertion into the Cu-2(mu-H) unit occurred with the flexible dicopper platform. Complex 2 also undergoes CO2 insertion to give a formate-bridged complex, [Cu-4(mu-HCOO)(3)(dpmppm)(2)]X, during which the square Cu-4 framework opened up to a linear tetranuclear chain.	[Nakamae, Kanako; Kure, Bunsho; Nakajima, Takayuki; Ura, Yasuyuki; Tanase, Tomoaki] Nara Womens Univ, Fac Sci, Dept Chem, Nara 6308506, Japan	Tanase, T (reprint author), Nara Womens Univ, Fac Sci, Dept Chem, Kitauoya Nishi Machi, Nara 6308506, Japan.	tanase@cc.nara-wu.ac.jp			Ministry of Education, Science, Sports, and Culture of Japan [22108521, 24108727]	This work was partly supported by Grants-in-Aid for Scientific Research and that on Priority Area 2107 (no. 22108521, 24108727) from the Ministry of Education, Science, Sports, and Culture of Japan. KN is grateful to JSPS fellowship.	Mao Z, 2005, J AM CHEM SOC, V127, P4562, DOI 10.1021/ja042335c; Wang W, 2011, CHEM SOC REV, V40, P3703, DOI 10.1039/c1cs15008a; Takemura Y, 2011, CHEM-EUR J, V17, P10528, DOI 10.1002/chem.201101232; Zell T, 2013, CHEM-EUR J, V19, P8068, DOI 10.1002/chem.201301383; LEMMEN TH, 1985, J AM CHEM SOC, V107, P7774, DOI 10.1021/ja00311a098; STEVENS RC, 1989, J AM CHEM SOC, V111, P3472, DOI 10.1021/ja00191a077; Yoshii A, 2012, ORGANOMETALLICS, V31, P133, DOI 10.1021/om2006744; Federsel C, 2010, ANGEW CHEM INT EDIT, V49, P6254, DOI 10.1002/anie.201000533; SAKAKI S, 1989, INORG CHEM, V28, P2583, DOI 10.1021/ic00312a016; Motokura K, 2013, CHEM-EUR J, V19, P10030, DOI 10.1002/chem.201300935; Eberhart MS, 2013, J AM CHEM SOC, V135, P17262, DOI 10.1021/ja408925m; Wyss CM, 2013, ANGEW CHEM INT EDIT, V52, P12920, DOI 10.1002/anie.201306736; Takemura Y, 2009, ANGEW CHEM INT EDIT, V48, P2157, DOI 10.1002/anie.200806012; ALBERT CF, 1989, INORG CHEM, V28, P1300, DOI 10.1021/ic00306a019; Appel AM, 2013, CHEM REV, V113, P6621, DOI 10.1021/cr300463y; Mankad NP, 2004, ORGANOMETALLICS, V23, P3369, DOI 10.1021/om0496380; Edwards AJ, 2014, ANGEW CHEM INT EDIT, V53, P7214, DOI 10.1002/anie.201403324; Langer R, 2011, ANGEW CHEM INT EDIT, V50, P9948, DOI 10.1002/anie.201104542; MAHONEY WS, 1988, J AM CHEM SOC, V110, P291, DOI 10.1021/ja00209a048; Yang XZ, 2011, ACS CATAL, V1, P849, DOI 10.1021/cs2000329; Shintani R, 2013, ORGANOMETALLICS, V32, P2459, DOI 10.1021/om400175h; Tanase T, 2013, DALTON T, V42, P15941, DOI 10.1039/c3dt51433a; Benson EE, 2009, CHEM SOC REV, V38, P89, DOI 10.1039/b804323j; Deutsch C, 2008, CHEM REV, V108, P2916, DOI 10.1021/cr0684321; Fujihara T, 2010, ANGEW CHEM INT EDIT, V49, P1472, DOI 10.1002/anie.200906348; Frey GD, 2011, CHEM-ASIAN J, V6, P402, DOI 10.1002/asia.201000576; CHURCHIL.MR, 1972, INORG CHEM, V11, P1818, DOI 10.1021/ic50114a015; Edwards A. J., 2014, ANGEW CHEM, V126, P7342; Federsel C., 2010, ANGEW CHEM, V722, P6392, DOI 10.1002/ange.201000533; Fujihara T., 2010, ANGEW CHEM, V122, P1514; Goeden G. V., 1986, INORG CHEM, V25, P2484, DOI 10.1021/ic00235a002; Langer R., 2011, ANGEW CHEM, V123, P10122; Riant O., 2009, CHEM ORGANOCOPPER CO, P731; Takemura Y, 2009, DALTON T, P10231, DOI 10.1039/b909252h; Takemura Y., 2009, ANGEW CHEM, V121, P2191; Takemura Y, 2009, EUR J INORG CHEM, P4820, DOI 10.1002/ejic.200900652; Wyss C. M., 2013, ANGEW CHEM, V125, P13158; Zhang L., 2013, CHEM COMMUN, V49, P2782	38	6	6	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1861-4728	1861-471X		CHEM-ASIAN J	Chem.-Asian J.	NOV	2014	9	11					3106	3110		10.1002/asia.201402900		5	Chemistry, Multidisciplinary	Chemistry	AS5TK	WOS:000344332200009		
J	Kabe, R; Feng, XL; Adachi, C; Mullen, K				Kabe, Ryota; Feng, Xinliang; Adachi, Chihaya; Muellen, Klaus			Exfoliation of Graphite into Graphene in Polar Solvents Mediated by Amphiphilic Hexa-peri-hexabenzocoronene	CHEMISTRY-AN ASIAN JOURNAL			English	Article						graphene; nanostructures; polycyclic aromatic hydrocarbons; self-assembly; surfactants	LIQUID-PHASE EXFOLIATION; ORGANIC-SOLVENTS; AQUEOUS-MEDIA; HIGH-QUALITY; FUNCTIONALIZATION; FILMS; DISPERSIONS; CARBON; WATER	A water-soluble surfactant consisting of hexa-peri-hexabenzocoronene (HBC) as hydrophobic aromatic core and hydrophilic carboxy substituents was synthesized. It exhibited a self-assembled nanofiber structure in the solid state. Profiting from the pi interactions between the large aromatic core of HBC and graphene, the surfactant mediated the exfoliation of graphite into graphene in polar solvents, which was further stabilized by the bulky hydrophilic carboxylic groups. A graphene dispersion with a concentration as high as 1.1 mgL(-1) containing 2-6 multilayer nanosheets was obtained. The lateral size of the graphene sheets was in the range of 100-500 nm based on atomic force microscope (AFM) and transmission electron microscope (TEM) measurements.	[Kabe, Ryota; Adachi, Chihaya] Kyushu Univ, Ctr Organ Photon & Elect Res OPERA, Nishi Ku, Fukuoka 8190395, Japan; [Feng, Xinliang; Muellen, Klaus] Max Planck Inst Polymer Res, D-55128 Mainz, Germany; [Adachi, Chihaya] Kyushu Univ, Int Inst Carbon Neutral Energy Res WPI I2CNER, Nishi Ku, Fukuoka 8190395, Japan	Feng, XL (reprint author), Max Planck Inst Polymer Res, Ackermannweg 10, D-55128 Mainz, Germany.	feng@mpip-mainz.mpg.de; adachi@opera.kyushu-u.ac.jp; muellen@mpip-mainz.mpg.de			ERC; Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST); International Institute for Carbon Neutral Energy Research (WPI-I2CNER) - Ministry of Education, Culture, Sports, Science and Technology (MEXT)	This work was supported by ERC grants on NANOGRAPH and 2D MATER, the Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST), the International Institute for Carbon Neutral Energy Research (WPI-I2CNER), sponsored by the Ministry of Education, Culture, Sports, Science and Technology (MEXT), and a Grant-in-Aid for Japan Society for the Promotion of Science (JSPS) Fellows.	Yang H, 2013, CARBON, V53, P357, DOI 10.1016/j.carbon.2012.11.022; Ghosh A, 2010, CHEM-EUR J, V16, P2700, DOI 10.1002/chem.200902828; Geim AK, 2007, NAT MATER, V6, P183, DOI 10.1038/nmat1849; Pisula W, 2010, ADV MATER, V22, P3634, DOI 10.1002/adma.201000585; Skaltsas T, 2012, J MATER CHEM, V22, P21507, DOI 10.1039/c2jm33245k; Li XS, 2009, SCIENCE, V324, P1312, DOI 10.1126/science.1171245; Englert JM, 2009, ADV MATER, V21, P4265, DOI 10.1002/adma.200901578; Hernandez Y, 2008, NAT NANOTECHNOL, V3, P563, DOI 10.1038/nnano.2008.215; Bourlinos AB, 2009, SMALL, V5, P1841, DOI 10.1002/smll.200900242; Schlierf A, 2013, NANOSCALE, V5, P4205, DOI 10.1039/c3nr00258f; Avouris P, 2012, MATER TODAY, V15, P86, DOI 10.1016/S1369-7021(12)70044-5; Novoselov KS, 2004, SCIENCE, V306, P666, DOI 10.1126/science.1102896; Khan U, 2010, SMALL, V6, P864, DOI 10.1002/smll.200902066; Gupta A, 2006, NANO LETT, V6, P2667, DOI 10.1021/nl061420a; Lotya M, 2010, ACS NANO, V4, P3155, DOI 10.1021/nn1005304; Sampath S, 2013, ADV MATER, V25, P2740, DOI 10.1002/adma.201205157; An XH, 2010, NANO LETT, V10, P4295, DOI 10.1021/nl903557p; Malig J, 2012, CHEM COMMUN, V48, P8745, DOI 10.1039/c2cc32888g; Hughes JM, 2012, J AM CHEM SOC, V134, P12168, DOI 10.1021/ja303683v; Geim AK, 2009, SCIENCE, V324, P1530, DOI 10.1126/science.1158877; Elias DC, 2011, NAT PHYS, V7, P701, DOI [10.1038/nphys2049, 10.1038/NPHYS2049]; Geng J, 2010, CHEM COMMUN, V46, P5091, DOI 10.1039/c001609h; Lee C, 2008, SCIENCE, V321, P385, DOI 10.1126/science.1157996; Wan XJ, 2012, ACCOUNTS CHEM RES, V45, P598, DOI 10.1021/ar200229q; Park S, 2009, NAT NANOTECHNOL, V4, P217, DOI [10.1038/nnano.2009.58, 10.1038/NNANO.2009.58]; Georgakilas V, 2012, CHEM REV, V112, P6156, DOI 10.1021/cr3000412; Coleman JN, 2009, ADV FUNCT MATER, V19, P3680, DOI 10.1002/adfm.200901640; Allen MJ, 2010, CHEM REV, V110, P132, DOI 10.1021/cr900070d; Hamilton CE, 2009, NANO LETT, V9, P3460, DOI 10.1021/nl9016623; Casiraghi C, 2009, NANO LETT, V9, P1433, DOI 10.1021/nl8032697; Hill JP, 2004, SCIENCE, V304, P1481, DOI 10.1126/science.1097789; Lee DW, 2011, CHEM COMMUN, V47, P8259, DOI 10.1039/c1cc12868j; Cardona CM, 2002, J ORG CHEM, V67, P1411, DOI 10.1021/jo0161678; Morozov SV, 2008, PHYS REV LETT, V100, DOI 10.1103/PhysRevLett.100.016602; Oyer AJ, 2012, J AM CHEM SOC, V134, P5018, DOI 10.1021/ja211225p; Safavi A, 2012, J MATER CHEM, V22, P3825, DOI 10.1039/c2jm13929d	36	2	2	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1861-4728	1861-471X		CHEM-ASIAN J	Chem.-Asian J.	NOV	2014	9	11					3125	3129		10.1002/asia.201402535		5	Chemistry, Multidisciplinary	Chemistry	AS5TK	WOS:000344332200013		
J	Oh, SY; Imagawa, H; Itahara, H				Oh, Song-Yul; Imagawa, Haruo; Itahara, Hiroshi			Facile and Scalable Synthesis of Silicon-Based Nanocomposites with Slitlike Nanopores: A Solid-State Exfoliation Reaction Using Layered CaSi2	CHEMISTRY-AN ASIAN JOURNAL			English	Article						batteries; lithium; nanostructures; silicon; solid-state reactions	BATTERY ANODES; LITHIUM; REDUCTION; PERFORMANCE; PARTICLES; NANOTUBES; STORAGE; CARBONS; CELLS	Silicon-based nanocomposites with slitlike nanopores were prepared by heating a mixture of layered CaSi2 and NiCl2. The formation mechanism is based on a solid-state exfoliation reaction wherein the formation of CaCl2 promotes the extraction of Ca from CaSi2, thereby exfoliating the layered structure. The nanocomposites showed anode capacity for lithium ion batteries up to 804 mAhg(-1).	[Oh, Song-Yul; Imagawa, Haruo; Itahara, Hiroshi] Toyota Cent Res & Dev Labs Inc, Nagakute, Aichi 4801192, Japan	Itahara, H (reprint author), Toyota Cent Res & Dev Labs Inc, Nagakute, Aichi 4801192, Japan.	h-itahara@mosk.tytlabs.co.jp					Acker J, 2001, SOLID STATE IONICS, V141, P583, DOI 10.1016/S0167-2738(01)00768-8; Bao ZH, 2007, NATURE, V446, P172, DOI 10.1038/nature05570; Chen DY, 2012, ANGEW CHEM INT EDIT, V51, P2409, DOI 10.1002/anie.201107885; Hwang YJ, 2009, NANO LETT, V9, P410, DOI 10.1021/nl8032763; Rao CNR, 2013, ANGEW CHEM INT EDIT, V52, P13162, DOI 10.1002/anie.201301548; Lou XW, 2008, ADV MATER, V20, P3987, DOI 10.1002/adma.200800854; FONG R, 1990, J ELECTROCHEM SOC, V137, P2009, DOI 10.1149/1.2086855; Yoo JK, 2012, ADV MATER, V24, P5452, DOI 10.1002/adma.201201601; Wolfenstine J, 2003, J POWER SOURCES, V124, P241, DOI 10.1016/S0378-7753(03)00731-6; Kasavajjula U, 2007, J POWER SOURCES, V163, P1003, DOI 10.1016/j.jpowsour.2006.09.084; Richman EK, 2008, NANO LETT, V8, P3075, DOI 10.1021/nl801759x; Gor GY, 2012, CARBON, V50, P1583, DOI 10.1016/j.carbon.2011.11.037; Sha J, 2002, ADV MATER, V14, P1219, DOI 10.1002/1521-4095(20020903)14:17<1219::AID-ADMA1219>3.0.CO;2-T; Kim H, 2008, ANGEW CHEM INT EDIT, V47, P10151, DOI 10.1002/anie.200804355; Yao Y, 2011, NANO LETT, V11, P2949, DOI 10.1021/nl201470j; Fleischauer MD, 2005, ELECTROCHEM SOLID ST, V8, pA137, DOI 10.1149/1.1850395; Bux SK, 2010, CHEM MATER, V22, P2534, DOI 10.1021/cm903410s; Chen D., 2012, ANGEW CHEM, V124, P2459; Dai F, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4605; Itahara H., 2012, IEEE NAN IEEE NAN 20, P1; Kim H., 2008, ANGEW CHEM, V120, P10305, DOI DOI 10.1002/ANGE.200804355; Oh SY, 2014, J MATER CHEM A, V2, P12501, DOI 10.1039/c4ta01318b; Rao C. N., 2013, ANGEW CHEM, V125, P13400; Rouquerol J, 1998, ADSORPTION POWDERS P; Wang JF, 2013, CHEM COMMUN, V49, P5007, DOI 10.1039/c3cc41967c; WILEY JB, 1992, SCIENCE, V255, P1093, DOI 10.1126/science.255.5048.1093; Wu H, 2012, NAT NANOTECHNOL, V7, P309, DOI [10.1038/nnano.2012.35, 10.1038/NNANO.2012.35]; YAMANAKA S, 1981, PHYSICA B & C, V105, P230, DOI 10.1016/0378-4363(81)90250-3	28	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1861-4728	1861-471X		CHEM-ASIAN J	Chem.-Asian J.	NOV	2014	9	11					3130	3135		10.1002/asia.201402544		6	Chemistry, Multidisciplinary	Chemistry	AS5TK	WOS:000344332200014		
J	Chaolumen; Enno, H; Murata, M; Wakamiya, A; Murata, Y				Chaolumen; Enno, Hiroki; Murata, Michihisa; Wakamiya, Atsushi; Murata, Yasujiro			Dibenzo[a,f]perylene Bisimide: Effects of Introducing Two Fused Rings	CHEMISTRY-AN ASIAN JOURNAL			English	Article						benzannulation; dyes; perylene bisimide; tetracene; X-ray analysis	PERYLENE BISIMIDES; N-TYPE; DYES; SEMICONDUCTORS; DIIMIDES; IMIDES; PHOTOVOLTAICS; SPECTROSCOPY; CRYSTALLINE; ELECTRONICS	Perylene bisimides (PBIs) are fascinating dyes with various potential applications. To study the effects of introducing a dibenzo-fused structure to the perylene moiety, pi-extended PBI derivatives with a dibenzo-fused structure at both of the a and f bonds were synthesized. The twisted structure was characterized by X-ray crystal structure analysis. In the cyclic voltammograms, the dibenzo[a,f]-fused PBI showed a reversible oxidation wave at much less positive potential, relative to a dibenzo[a,o]-fused PBI derivative. These data indicated that two ring fusions at both sides of a naphthalene moiety, which construct a tetracene core, effectively raise the HOMO level compared to fusion of one ring at each naphthalene moiety (two anthracene cores). The dibenzo[a,f]-fused PBI derivative showed an absorption band at 735 nm with a shoulder band reaching 900 nm.	[Chaolumen; Enno, Hiroki; Murata, Michihisa; Wakamiya, Atsushi; Murata, Yasujiro] Kyoto Univ, Inst Chem Res, Kyoto 6110011, Japan	Murata, M (reprint author), Kyoto Univ, Inst Chem Res, Kyoto 6110011, Japan.	mmurata@scl.kyoto-u.ac.jp; yasujiro@scl.kyoto-u.ac.jp	Murata, Michihisa/N-8564-2014; Wakamiya, Atsushi/E-6773-2014		JSPS KAKENHI [24350024]	Financial support was provided by JSPS KAKENHI Grant Number 24350024. We thank Dr. Masayuki Wakioka and Prof. Fumiyuki Ozawa at the Institute for Chemical Research, Kyoto University for support of the X-ray measurements.	Andrew TL, 2010, SYNLETT, P3045, DOI 10.1055/s-0030-1259060; Langhals H, 2005, HELV CHIM ACTA, V88, P1309, DOI 10.1002/hlca.200590107; Zhao Y, 2013, ADV MATER, V25, P5372, DOI 10.1002/adma.201302315; Chang NH, 2013, ORG LETT, V15, P3558, DOI 10.1021/ol401375n; Yao JH, 2009, CHEM-EUR J, V15, P9299, DOI 10.1002/chem.200901398; You CC, 2005, TOP CURR CHEM, V258, P39, DOI 10.1007/b136668; LANGHALS H, 1995, HETEROCYCLES, V40, P477; Teraoka T, 2011, ORG LETT, V13, P2532, DOI 10.1021/ol2004534; Yue W, 2012, J AM CHEM SOC, V134, P5770, DOI 10.1021/ja301184r; O'Brien CJ, 2006, CHEM-EUR J, V12, P4743, DOI 10.1002/chem.200600251; Lin MJ, 2011, ANGEW CHEM INT EDIT, V50, P10847, DOI 10.1002/anie.201105129; Bendikov M, 2004, CHEM REV, V104, P4891, DOI 10.1021/cr030666m; Zhan XW, 2011, ADV MATER, V23, P268, DOI 10.1002/adma.201001402; Li C, 2012, ADV MATER, V24, P613, DOI 10.1002/adma.201104447; Okamoto T, 2012, CHEM-ASIAN J, V7, P105, DOI 10.1002/asia.201100590; Jiang W, 2010, ORG LETT, V12, P228, DOI 10.1021/ol902526t; Roy B, 2012, CHEM-EUR J, V18, P14560, DOI 10.1002/chem.201200483; Wurthner F, 2011, ANGEW CHEM INT EDIT, V50, P3376, DOI 10.1002/anie.201002307; Valente C, 2012, ANGEW CHEM INT EDIT, V51, P3314, DOI 10.1002/anie.201106131; Zhong Y, 2014, J AM CHEM SOC, V136, P8122, DOI 10.1021/ja503533y; Kozma E, 2013, DYES PIGMENTS, V98, P160, DOI 10.1016/j.dyepig.2013.01.020; Jones BA, 2007, J AM CHEM SOC, V129, P15259, DOI 10.1021/ja075242e; Muth MA, 2014, J PHYS CHEM C, V118, P92, DOI 10.1021/jp4086602; Lee JE, 2013, ACS NANO, V7, P5064, DOI 10.1021/nn400616u; Nolde F, 2005, CHEM-EUR J, V11, P3959, DOI 10.1002/chem.200401177; Lee SK, 1999, J AM CHEM SOC, V121, P3513, DOI 10.1021/ja984188m; Jung BJ, 2011, CHEM MATER, V23, P568, DOI 10.1021/cm102296d; Pschirer NG, 2006, ANGEW CHEM INT EDIT, V45, P1401, DOI 10.1002/anie.200502998; Burtman V, 2011, INT J MOL SCI, V12, P173, DOI 10.3390/ijms12010173; Buurma AJC, 2007, J PHYS CHEM C, V111, P3486, DOI 10.1021/jp065944a; Eversloh CL, 2011, ORG LETT, V13, P4148, DOI 10.1021/ol201623f; Frisch M J, 2010, GAUSSIAN 09 REVISION; Frischmann PD, 2013, ORG LETT, V15, P4674, DOI 10.1021/ol401946g; Ito S, 2013, ORG LETT, V15, P3110, DOI 10.1021/ol401316q; Kim HN, 2013, CHEM-EUR J, V19, P9160, DOI 10.1002/chem.201300439; Lin M., 2011, ANGEW CHEM, V123, P11039; Muller S, 2005, CHEM COMMUN, P4045, DOI 10.1039/b509220e; Pschirer N. G., 2006, ANGEW CHEM, V118, P1429, DOI 10.1002/ange.200502998; Qian HL, 2008, J AM CHEM SOC, V130, P17970, DOI 10.1021/ja807803j; Rohr U., 1998, ANGEW CHEM, V110, P1463, DOI 10.1002/(SICI)1521-3757(19980518)110:10<1463::AID-ANGE1463>3.0.CO;2-Z; Rohr U, 1998, ANGEW CHEM INT EDIT, V37, P1434; Valente C., 2012, ANGEW CHEM, V124, P3370, DOI DOI 10.1002/ANGE.201106131; Wasielewski MR, 2009, ACCOUNTS CHEM RES, V42, P1910, DOI 10.1021/ar9001735; Wurthner F., 2011, ANGEW CHEM, V723, P3436; Wurthner F, 2004, CHEM COMMUN, P1564, DOI 10.1039/b401630k	45	1	1	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1861-4728	1861-471X		CHEM-ASIAN J	Chem.-Asian J.	NOV	2014	9	11					3136	3140		10.1002/asia.201402688		5	Chemistry, Multidisciplinary	Chemistry	AS5TK	WOS:000344332200015		
J	Katoono, R; Kusaka, K; Fujiwara, K; Suzuki, T				Katoono, Ryo; Kusaka, Keiichi; Fujiwara, Kenshu; Suzuki, Takanori			Controlled Dynamic Helicity of a Folded Macrocycle Based on a Bisterephthalamide with a Twofold Z-Shaped Structure	CHEMISTRY-AN ASIAN JOURNAL			English	Article						chirality; helical structures; host-guest systems; hydrogen bonds; macrocycles	CHIROPTICAL PROPERTIES; POINT CHIRALITY; MEMORY; COMPLEXATION; OLIGOMERS; POLYMERS; AMPLIFICATION; CONFORMATION; TRANSMISSION; RECOGNITION	Dynamic helicity in a folded macrocycle and control of the helical preference are described. We designed macrocycle 1 with a dual mode of folding through the integration of two flexible units that are arranged twice to form a cyclic structure. As a folding unit, we used a terephthalamide skeleton and a Z-shaped hydrocarbon: the former acted as a control unit to induce a preference of a particular sense of dynamic helicity and the latter was just a spacer. A terephthalamide unit provided a binding site for capturing a ditopic hydrogen-bonding guest when it adopted helically folded syn forms (M/P). Thus, only the terephthalamide unit controlled the helical sense of dynamic helicity in a folded macrocycle through the supramolecular transmission of chirality upon complexation with a chiral ditopic guest. In addition, chirality on a host could also contribute to the control of the helical preference in a folded macrocycle, which led to exceptionally enhanced chiroptical signals.	[Katoono, Ryo; Kusaka, Keiichi; Fujiwara, Kenshu; Suzuki, Takanori] Hokkaido Univ, Fac Sci, Dept Chem, Sapporo, Hokkaido 060, Japan	Katoono, R (reprint author), Hokkaido Univ, Fac Sci, Dept Chem, Sapporo, Hokkaido 060, Japan.	katoono@sci.hokudai.ac.jp; tak@sci.hokudai.ac.jp		Suzuki, Takanori/0000-0002-1230-2044			Setnicka V, 2006, CHEM-EUR J, V12, P8735, DOI 10.1002/chem.200500973; Fuentes N, 2012, ANGEW CHEM INT EDIT, V51, P13036, DOI 10.1002/anie.201206259; Watanabe K, 2013, J MATER CHEM C, V1, P2797, DOI 10.1039/c3tc00045a; Pandeeswar M, 2012, CHEM-EUR J, V18, P4818, DOI 10.1002/chem.201200197; Song FY, 2013, CHEM COMMUN, V49, P5772, DOI 10.1039/c3cc42323a; Katoono R, 2014, CHEM COMMUN, V50, P5438, DOI 10.1039/c4cc00323c; Goto H, 2006, J AM CHEM SOC, V128, P7176, DOI 10.1021/ja062171v; Ruan Y, 2013, ORG BIOMOL CHEM, V11, P7667, DOI 10.1039/c3ob41511b; George SJ, 2007, ANGEW CHEM INT EDIT, V46, P8206, DOI 10.1002/anie.200702730; Katoono R, 2009, J AM CHEM SOC, V131, P16896, DOI 10.1021/ja906810b; Takashima S, 2013, TETRAHEDRON-ASYMMETR, V24, P527, DOI 10.1016/j.tetasy.2013.03.019; Alabugin IV, 2008, J AM CHEM SOC, V130, P11535, DOI 10.1021/ja8038213; Pijper D, 2008, SOFT MATTER, V4, P1349, DOI 10.1039/b801886c; Furusho Y, 2011, MACROMOL RAPID COMM, V32, P136, DOI 10.1002/marc.201000533; Dong ZZ, 2011, CHEM COMMUN, V47, P3781, DOI 10.1039/c0cc04794e; Jung SH, 2014, J AM CHEM SOC, V136, P6446, DOI 10.1021/ja5018199; Song C, 2013, MACROMOL RAPID COMM, V34, P1426, DOI 10.1002/marc.201300498; Shimomura K, 2014, NAT CHEM, V6, P429, DOI [10.1038/nchem.1916, 10.1038/NCHEM.1916]; Katoono R, 2006, TETRAHEDRON LETT, V47, P1513, DOI 10.1016/j.tetlet.2006.01.022; Katoono R, 2013, CHEM COMMUN, V49, P10352, DOI 10.1039/c3cc43571g; Sobczuk AA, 2012, CHEM-EUR J, V18, P2832, DOI 10.1002/chem.201103249; Miyake H, 2012, CHEM SOC REV, V41, P6977, DOI 10.1039/c2cs35192g; Hiraoka S, 2010, ANGEW CHEM INT EDIT, V49, P1669, DOI 10.1002/anie.200905947; Lin RG, 2006, INORG CHEM, V45, P4423, DOI 10.1021/ic060140v; Prince RB, 2000, ANGEW CHEM INT EDIT, V39, P228, DOI 10.1002/(SICI)1521-3773(20000103)39:1<228::AID-ANIE228>3.0.CO;2-B; Yamada H, 2012, J AM CHEM SOC, V134, P9506, DOI 10.1021/ja303701d; Eisenberg D, 2008, J ORG CHEM, V73, P6073, DOI 10.1021/jo800359z; Yang Y, 2013, ADV MATER, V25, P6039, DOI 10.1002/adma.201302448; Bergueiro J, 2014, CHEM SCI, V5, P2170, DOI 10.1039/c3sc53330a; Bonnot C, 2004, J AM CHEM SOC, V126, P11412, DOI 10.1021/ja048441w; Chiang YW, 2011, SOFT MATTER, V7, P9797, DOI 10.1039/c1sm05921a; Comba P, 1999, EUR J INORG CHEM, P509; de Bruin AG, 2014, POLYM INT, V63, P165, DOI 10.1002/pi.4639; Fuentes N., 2012, ANGEW CHEM, V124, P13213; George S. J., 2007, ANGEW CHEM, V119, P8354, DOI 10.1002/ange.200702730; Greenwald M, 1999, NEW J CHEM, V23, P337, DOI 10.1039/a808673g; GRUBBS RH, 1993, CHEM BER-RECL, V126, P149, DOI 10.1002/cber.19931260123; Hiraoka S., 2010, ANGEW CHEM, V122, P1713; Hou JL, 2012, MACROMOLECULES, V45, P7835, DOI 10.1021/ma301553y; Howson SE, 2013, DALTON T, V42, P14967, DOI 10.1039/c3dt51725j; Hutin M, 2007, J AM CHEM SOC, V129, P8774, DOI 10.1021/ja070320j; Karageorgaki C, 2014, CHEM COMMUN, V50, P1814, DOI 10.1039/c3cc48797k; Katoono R, 2008, CHEM COMMUN, P4906, DOI 10.1039/b808936a; Mizutani T, 1999, J AM CHEM SOC, V121, P754, DOI 10.1021/ja9830849; Prince R. B., 2000, ANGEW CHEM, V112, P234, DOI 10.1002/(SICI)1521-3757(20000103)112:1<234::AID-ANGE234>3.0.CO;2-6; Qing GY, 2012, NPG ASIA MATER, V4, DOI 10.1038/am.2012.6; Sakai R, 2006, MACROMOLECULES, V39, P4032, DOI 10.1021/ma060376i; Talele HR, 2012, ORG BIOMOL CHEM, V10, P8579, DOI 10.1039/c2ob26669e; Toyota S, 2010, ORG BIOMOL CHEM, V8, P4997, DOI 10.1039/c0ob00290a; Vignon SA, 2004, ORG LETT, V6, P1095, DOI 10.1021/ol0364881; WHITLOCK BJ, 1972, J ORG CHEM, V37, P3559, DOI 10.1021/jo00795a047; Whitnall MR, 1997, J ORGANOMET CHEM, V529, P35, DOI 10.1016/S0022-328X(96)06860-X; WONG MS, 1994, TETRAHEDRON LETT, V35, P6113	53	2	2	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1861-4728	1861-471X		CHEM-ASIAN J	Chem.-Asian J.	NOV	2014	9	11					3182	3187		10.1002/asia.201402658		6	Chemistry, Multidisciplinary	Chemistry	AS5TK	WOS:000344332200020		
J	Kondo, M; Miura, S; Okumoto, K; Hashimoto, M; Kawatsuki, N				Kondo, Mizuho; Miura, Seiya; Okumoto, Kentaro; Hashimoto, Mayuko; Kawatsuki, Nobuhiro			Mechanochromic Luminescence Characteristics of Pyridine-Terminated Chromophores in the Solid State and in a Poly(vinyl alcohol) Matrix	CHEMISTRY-AN ASIAN JOURNAL			English	Article						mechanochromic luminescence; sensors; solid-state photoemission; solvatochromism	AGGREGATION-INDUCED EMISSION; LIQUID-CRYSTALLINE POLYMER; PIEZOCHROMIC LUMINESCENCE; FLUORENE DERIVATIVES; FLUORESCENCE; PROTONATION; ASSEMBLIES; DESIGN; WAVELENGTH; MOIETY	Mechanoresponsive luminophores containing different substituted pyridine rings at the molecular terminus are synthesized and their photoluminescence properties are investigated. The solid chromophore with a 4-substituted pyridine ring exhibits a reversible photoluminescent color change, while the 2-substituted chromophore shows only a small change in luminescence, and the 3-substituted chromophore displays an irreversible photoluminescent color change with mechanical grinding. A change of the sample color in response to mechanical grinding is also achieved for a dye-dispersed poly(vinyl alcohol) film. Furthermore, a simultaneous acid and mechanoresponsive photoemission color change is achieved in the dye-dispersed film.	[Kondo, Mizuho; Miura, Seiya; Okumoto, Kentaro; Hashimoto, Mayuko; Kawatsuki, Nobuhiro] Univ Hyogo, Dept Mat Sci & Chem, Himeji, Hyogo 6712280, Japan	Kondo, M (reprint author), Univ Hyogo, Dept Mat Sci & Chem, 2167 Shosha, Himeji, Hyogo 6712280, Japan.	mizuho-k@eng.u-hyogo.ac.jp			Japan Society for the Promotion of Science [25810079]; University of Hyogo	This work was supported in part by a Grant-in-Aid for Young Scientists B (No. 25810079) from the Japan Society for the Promotion of Science nd a research grant from the University of Hyogo.	Kato T, 2006, ANGEW CHEM INT EDIT, V45, P38, DOI 10.1002/anie.200501384; Rao MR, 2013, J MATER CHEM C, V1, P6386, DOI 10.1039/c3tc31504e; Dou CD, 2011, J PHYS CHEM LETT, V2, P666, DOI 10.1021/jz200140c; Wang S, 2013, DYES PIGMENTS, V99, P543, DOI 10.1016/j.dyepig.2013.06.017; Wei RR, 2013, J PHYS CHEM C, V117, P3467, DOI 10.1021/jp311020w; Nagura K, 2013, J AM CHEM SOC, V135, P10322, DOI 10.1021/ja4055228; Mizoshita N, 2012, ADV MATER, V24, P3350, DOI 10.1002/adma.201201064; Sagara Y, 2011, ANGEW CHEM INT EDIT, V50, P9128, DOI 10.1002/anie.201100914; Davis DA, 2009, NATURE, V459, P68, DOI 10.1038/nature07970; Gong YY, 2013, CHEM COMMUN, V49, P4009, DOI 10.1039/c3cc39243k; Tsukuda T, 2010, CHEM COMMUN, V46, P1905, DOI 10.1039/b921111j; Sagara Y, 2009, NAT CHEM, V1, P605, DOI [10.1038/nchem.411, 10.1038/NCHEM.411]; Dou CD, 2011, LANGMUIR, V27, P6323, DOI 10.1021/la200382b; Qi QK, 2013, RSC ADV, V3, P7996, DOI 10.1039/c3ra40734a; Qi QK, 2013, J PHYS CHEM C, V117, P24997, DOI 10.1021/jp407965a; Ooyama Y, 2011, J MATER CHEM, V21, P8372, DOI 10.1039/c0jm03601c; Yang MD, 2013, J ORG CHEM, V78, P10344, DOI 10.1021/jo401719c; Sagara Y, 2013, ADV FUNCT MATER, V23, P5277, DOI 10.1002/adfm.201300180; Zhang YJ, 2014, J MATER CHEM C, V2, P195, DOI 10.1039/c3tc31416b; Kato T, 1996, J POLYM SCI POL CHEM, V34, P57; Yamane S, 2013, J MATER CHEM C, V1, P2648, DOI 10.1039/c3tc00861d; Zhang YJ, 2012, PHOTOCH PHOTOBIO SCI, V11, P1414, DOI 10.1039/c2pp05404c; Shiotsuki M, 2014, J POLYM SCI POL CHEM, V52, P1392, DOI 10.1002/pola.27133; Shen XY, 2012, J PHYS CHEM C, V116, P10541, DOI 10.1021/jp303100a; Dong YJ, 2013, J MATER CHEM C, V1, P7554, DOI 10.1039/c3tc31553c; Sagara Y, 2007, J AM CHEM SOC, V129, P1520, DOI 10.1021/ja0677362; Pucci A, 2011, J MATER CHEM, V21, P8282, DOI 10.1039/c0jm03653f; Fang XL, 2013, MACROMOLECULES, V46, P6566, DOI 10.1021/ma4014862; Yuan WZ, 2013, ADV MATER, V25, P2837, DOI 10.1002/adma.201205043; Dong YJ, 2012, ANGEW CHEM INT EDIT, V51, P10782, DOI 10.1002/anie.201204660; Xue PC, 2014, CHEM COMMUN, V50, P2569, DOI 10.1039/c3cc49208g; Deng SL, 2014, J MATER CHEM C, V2, P651, DOI 10.1039/c3tc31592d; Dong Y., 2012, ANGEW CHEM, V124, P10940; Frisch M J, 2010, GAUSSIAN 09 REVISION; Kato T., 2006, ANGEW CHEM, V118, P44, DOI DOI 10.1002/ANGE.200501384; Kawatsuki N, 2009, CHEM LETT, V38, P298, DOI 10.1246/cl.2009.298; Kawatsuki N, 2010, MACROMOL CHEM PHYS, V211, P1741, DOI 10.1002/macp.201000183; Kondo M, 2013, CHEM LETT, V42, P891, DOI 10.1246/cl.130365; Mizuguchi J, 2003, J PHYS CHEM B, V107, P12635, DOI 10.1021/jp030692o; Rao R. M, 2013, J MATER CHEM C, V1, P6386; Sagara Y., 2011, ANGEW CHEM, V123, P9294; Yagai S, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5013	42	2	2	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1861-4728	1861-471X		CHEM-ASIAN J	Chem.-Asian J.	NOV	2014	9	11					3188	3195		10.1002/asia.201402739		8	Chemistry, Multidisciplinary	Chemistry	AS5TK	WOS:000344332200021		
J	Tang, J; Torad, NL; Salunkhe, RR; Yoon, JH; Al Hossain, MS; Dou, SX; Kim, JH; Kimura, T; Yamauchi, Y				Tang, Jing; Torad, Nagy L.; Salunkhe, Rahul R.; Yoon, Jang-Hee; Al Hossain, Md Shahriar; Dou, Shi Xue; Kim, Jung Ho; Kimura, Tatsuo; Yamauchi, Yusuke			Towards Vaporized Molecular Discrimination: A Quartz Crystal Microbalance (QCM) Sensor System Using Cobalt-Containing Mesoporous Graphitic Carbon	CHEMISTRY-AN ASIAN JOURNAL			English	Article						carbon; mesoporous materials; molecular discrimination; quartz crystal microbalance; sensors	POROUS COORDINATION POLYMER; METAL-ORGANIC FRAMEWORK; BY-LAYER FILMS; NANOPOROUS CARBON; CATALYTIC GRAPHITIZATION; DIRECT CARBONIZATION; TEMPLATE; SILICA; SUPERCAPACITORS; IMMOBILIZATION	A recent study on nanoporous carbon based materials (J. Am. Chem. Soc. 2012, 134, 2864) showed that the presence of abundant graphitized sp(2) carbon species in the frameworks led to higher affinity for aromatic hydrocarbons than their aliphatic analogues. Herein, improved understanding of the sensitive and selective detection of aromatic substances by using mesoporous carbon (MPC)-based materials, combined with a quartz crystal microbalance (QCM) sensor system, was obtained. MPCs were synthesized by direct carbonization of mesoporous polymers prepared from resol through a soft templating approach with Pluronic F127. The carbon-based frameworks can be graphitized through the addition of a cobalt source to the precursor solution, according to the catalytic activity of the cobalt nanoparticles formed during the carbonization process. From the Raman data, the degree of the graphitization was clearly increased by increasing the cobalt content and elevating the carbonization temperature. From a QCM study, it was proved that the highly graphitized MPCs exhibited a higher affinity for aromatic hydrocarbons than their aliphatic analogues. By increasing the degree of graphitization in the carbon-based pore walls, the MPCs showed both larger adsorption uptake and faster sensor response towards toxic benzene and toluene vapors.	[Tang, Jing; Torad, Nagy L.; Salunkhe, Rahul R.; Yamauchi, Yusuke] NIMS, World Premier Int WPI Res Ctr, Mat Nanoarchitecton MANA, Tsukuba, Ibaraki 3050044, Japan; [Tang, Jing; Yamauchi, Yusuke] Waseda Univ, Fac Sci & Engn, Shinjuku Ku, Tokyo 1698555, Japan; [Torad, Nagy L.] Tanta Univ, Dept Chem, Fac Sci, Tanta 31527, Egypt; [Yoon, Jang-Hee; Al Hossain, Md Shahriar; Dou, Shi Xue] Univ Wollongong, Inst Superconducting & Elect Mat, AIIM, North Wollongong, NSW 2500, Australia; [Yoon, Jang-Hee] Korea Basic Sci Inst, Busan Ctr, Pusan 618230, South Korea; [Kimura, Tatsuo] Natl Inst Adv Ind Sci & Technol, Adv Mfg Res Inst, Nagoya, Aichi 4638560, Japan	Yamauchi, Y (reprint author), NIMS, World Premier Int WPI Res Ctr, Mat Nanoarchitecton MANA, 1-1 Namiki, Tsukuba, Ibaraki 3050044, Japan.	Yamauchi.Yusuke@nims.go.jp	Dou, Shi Xue/D-5179-2012; Yamauchi, Yusuke/D-2780-2015; Kim, Jung Ho/D-4097-2014; Kimura, Tatsuo/F-9382-2014; 	Dou, Shi Xue/0000-0003-3824-7693; Yoon, Jang Hee/0000-0002-8494-9373			Tang J, 2014, NANO TODAY, V9, P305, DOI 10.1016/j.nantod.2014.05.003; Ji QM, 2010, ANGEW CHEM INT EDIT, V49, P9737, DOI 10.1002/anie.201004929; Lei ZB, 2007, CHEM MATER, V19, P477, DOI 10.1021/cm061806m; Srivastava A, 2004, ATMOS ENVIRON, V38, P6829, DOI 10.1016/j.atmosenv.2004.09.009; Kimura T, 2013, J MATER CHEM A, V1, P15135, DOI 10.1039/c3ta13026f; Brun N, 2012, J PHYS CHEM C, V116, P1408, DOI 10.1021/jp206487w; Ayad MM, 2009, J HAZARD MATER, V168, P85, DOI 10.1016/j.jhazmat.2009.02.003; Liu B, 2008, J AM CHEM SOC, V130, P5390, DOI 10.1021/ja7106146; Melde BJ, 2010, ANAL BIOANAL CHEM, V398, P1565, DOI 10.1007/s00216-010-3688-6; Hu M, 2011, CHEM COMMUN, V47, P8124, DOI 10.1039/c1cc12378e; Liu NN, 2010, CARBON, V48, P3579, DOI 10.1016/j.carbon.2010.06.001; Sevilla M, 2013, CARBON, V56, P155, DOI 10.1016/j.carbon.2012.12.090; Lee J, 2006, ADV MATER, V18, P2073, DOI 10.1002/adma.200501576; Fu RW, 2005, LANGMUIR, V21, P2647, DOI 10.1021/la047344d; Bastakoti BP, 2013, EUR J INORG CHEM, P1109, DOI 10.1002/ejic.201201311; Jia Y, 2009, J PHYS CHEM C, V113, P9581, DOI 10.1021/jp9001719; Maldonado-Hodar FJ, 2000, LANGMUIR, V16, P4367, DOI 10.1021/la991080r; Song YF, 2013, NEW J CHEM, V37, P1768, DOI 10.1039/c3nj00261f; Hu M, 2012, J AM CHEM SOC, V134, P2864, DOI 10.1021/ja208940u; Meng Y, 2005, ANGEW CHEM INT EDIT, V44, P7053, DOI 10.1002/anie.200501561; Im JS, 2010, CARBON, V48, P2573, DOI 10.1016/j.carbon.2010.03.045; Lee EZ, 2010, ANGEW CHEM INT EDIT, V49, P9706, DOI 10.1002/anie.201004975; Tang J, 2013, MICROPOR MESOPOR MAT, V177, P105, DOI 10.1016/j.micromeso.2013.04.027; Deng YH, 2010, ADV FUNCT MATER, V20, P3658, DOI 10.1002/adfm.201001202; Meilikhov M, 2013, ANGEW CHEM INT EDIT, V52, P341, DOI 10.1002/anie.201207320; Ji QM, 2009, J AM CHEM SOC, V131, P4220, DOI 10.1021/ja9010354; Kimura T, 2014, J MATER CHEM A, V2, P8196, DOI 10.1039/c4ta00775a; Jiang HL, 2011, J AM CHEM SOC, V133, P11854, DOI 10.1021/ja203184k; Zhou M, 2008, ELECTROCHIM ACTA, V53, P4176, DOI 10.1016/j.electacta.2007.12.077; Ayad MM, 2009, TALANTA, V78, P1280, DOI 10.1016/j.talanta.2009.01.053; Torad NL, 2012, J MATER CHEM, V22, P18261, DOI 10.1039/c2jm32805d; Ariga K, 2014, APL MATER, V2, DOI 10.1063/1.4868177; Torad NL, 2014, SMALL, V10, P2096, DOI 10.1002/smll.201302910; Thorn C, 2013, MICROPOR MESOPOR MAT, V176, P71, DOI 10.1016/j.micromeso.2013.04.001; Kosaki Y, 2013, ACS APPL MATER INTER, V5, P2930, DOI 10.1021/am400940q; Torad NL, 2013, CHEM COMMUN, V49, P2521, DOI 10.1039/c3cc38955c; Chaikittisilp W, 2013, J MATER CHEM A, V1, P14, DOI 10.1039/c2ta00278g; Palaniappan A, 2006, SENSOR ACTUAT B-CHEM, V119, P220, DOI 10.1016/j.snb.2005.12.015; Gooding JJ, 2005, ELECTROCHIM ACTA, V50, P3049, DOI 10.1016/j.electacta.2004.08.052; Bastakoti BP, 2014, ACS APPL MATER INTER, V6, P854, DOI 10.1021/am4039954; Ayad MM, 2008, SENSOR ACTUAT B-CHEM, V134, P887, DOI 10.1016/j.snb.2008.06.058; Claesson M, 2012, SENSOR ACTUAT B-CHEM, V166, P526, DOI 10.1016/j.snb.2012.03.002; Crank J, 1975, MATH DIFFUSION, P414; Ji Q., 2010, ANGEW CHEM, V122, P9931, DOI 10.1002/ange.201004929; Lee E. Z., 2010, ANGEW CHEM, V122, P9900, DOI 10.1002/ange.201004975; Li JR, 2003, CARBON, V41, P2353, DOI 10.1016/S0008-6223(03)00273-2; Meilikhov M., 2013, ANGEW CHEM, V125, P359; Meng Y., 2005, ANGEW CHEM, V117, P7215, DOI DOI 10.1002/ANGE.200501561; Skov H, 2001, ATMOS ENVIRON, V35, P2463, DOI 10.1016/S1352-2310(00)00460-X; Wang B, 2012, MICROPOR MESOPOR MAT, V158, P99, DOI 10.1016/j.micromeso.2012.03.020	50	9	9	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1861-4728	1861-471X		CHEM-ASIAN J	Chem.-Asian J.	NOV	2014	9	11					3238	3244		10.1002/asia.201402629		7	Chemistry, Multidisciplinary	Chemistry	AS5TK	WOS:000344332200027		
J	Zaitseva, EV; Shernyukov, AV; Amitina, SA; Tamura, R; Grigor'ev, IA; Mazhukin, DG				Zaitseva, E. V.; Shernyukov, A. V.; Amitina, S. A.; Tamura, R.; Grigor'ev, I. A.; Mazhukin, D. G.			Synthesis of Diastereomeric Spirocyclic Nitroxyl Radicals of 3-Imidazoline Series with Two Mesogenic Groups	CHEMISTRY OF HETEROCYCLIC COMPOUNDS			English	Article						4-hydroxycyclohexanone; 3-imidazolines; spirocyclic nitroxyl radicals; condensation; Mitsunobu acylation	CHIRAL 2,2'-SPIROBIINDAN-1,1'-DIONE CORES; FERROELECTRIC LIQUID-CRYSTALS; PHYSICAL-PROPERTIES; MAGNETIC-PROPERTIES; BUILDING-BLOCKS; CYCLOHEXANES; DERIVATIVES; MOLECULES; UNIT	Alkylaromatic alpha-hydroxylamino ketones with a p-hydroxy(alkoxy)aryl substituent were used for the preparation of stable diastereomeric spirocyclic nitroxyl radicals of 3-imidazoline series, having two different or identical mesogenic groups in the molecule. The molecular structure of these compounds was determined by NMR study of their diamagnetic reduced derivatives.	[Zaitseva, E. V.; Shernyukov, A. V.; Amitina, S. A.; Grigor'ev, I. A.; Mazhukin, D. G.] Russian Acad Sci, Siberian Branch, NN Vorozhtsov Novosibirsk Inst Organ Chem, Novosibirsk 630090, Russia; [Tamura, R.] Kyoto Univ, Grad Sch Human & Environm Studies, Sakyo Ku, Yoshida Nihonmatsu, Kyoto 6068501, Japan; [Mazhukin, D. G.] Novosibirsk State Univ, Novosibirsk 630090, Russia	Zaitseva, EV (reprint author), Russian Acad Sci, Siberian Branch, NN Vorozhtsov Novosibirsk Inst Organ Chem, 9 Akad Lavrentieva Ave, Novosibirsk 630090, Russia.	elena@nioch.nsc.ru; tamura.rui.8c@kyoto-u.ac.jp; d-mazhukin@yandex.ru	Mazhukin, Dmitrii/A-9160-2010	Mazhukin, Dmitrii/0000-0002-6915-6287	Russian Foundation for Basic Research - JSPS (Japanese Society for the Promotion of Science) [11-03-92107-YaF-a]; Siberian Branch, Russian Academy of Sciences [1]; Ministry of Education and Science of the Russian Federation [8456]	This work was done owing financial support from the Russian Foundation for Basic Research - JSPS (Japanese Society for the Promotion of Science) (project No. 11-03-92107-YaF-a), Integration program of the Siberian Branch, Russian Academy of Sciences (Cooperative Basic Research, project No. 1), and the Ministry of Education and Science of the Russian Federation (contract 8456).	Ikuma N, 2004, ANGEW CHEM INT EDIT, V43, P3677, DOI 10.1002/anie.200460007; Swamy KCK, 2009, CHEM REV, V109, P2551, DOI 10.1021/cr800278z; Perdew JP, 1996, PHYS REV LETT, V77, P3865, DOI 10.1103/PhysRevLett.77.3865; Laikov DN, 2005, CHEM PHYS LETT, V416, P116, DOI 10.1016/j.cplett.2005.09.046; [Anonymous], 1975, [No title captured], Patent No. 19755245; Cui Q, 2013, LIQ CRYST, V40, P1609, DOI 10.1080/02678292.2012.747705; [Anonymous], 1979, [No title captured], Patent No. 657016; JENSEN FR, 1969, J AM CHEM SOC, V91, P344, DOI 10.1021/ja01030a023; Chang CE, 2003, J COMPUT CHEM, V24, P1987, DOI 10.1002/jcc.10325; BOETTCHER J, 1992, CHEM BER-RECL, V125, P1865, DOI 10.1002/cber.19921250813; CALAMINUS W, 1986, Z NATURFORSCH B, V41, P1011; Cui Q, 2013, J MATER CHEM C, V1, P1011, DOI 10.1039/c2tc00440b; Feuerbacher N, 1999, SYNTHESIS-STUTTGART, P117; Haslanger M., 1974, SYNTHETIC COMMUN, V4, P155, DOI 10.1080/00397917408062065; Hintermaier F, 1995, LIEBIGS ANN-RECL, P2189; Impre G., 2006, 1 EUR CHEM C; Itoh T, 2009, J FLUORINE CHEM, V130, P1157, DOI 10.1016/j.jfluchem.2009.06.007; Kogo R, 2010, APPL PHYS EXPRESS, V3, DOI 10.1143/APEX.3.041701; Lahti P. M., 1999, MOL MAGNETISM ORGANI, P728; Miyazawa K, 2000, EUR J ORG CHEM, P4109; Miyazawa K, 2001, MOL CRYST LIQ CRYST, V364, P253, DOI 10.1080/10587250108024994; Reznikov V. A., 1990, CHEM HETEROCYCL COMP, P643; Reznikov VA, 1997, RUSS CHEM B+, V46, P1577, DOI 10.1007/BF02502943; SCHMIDT W, 1995, LIEBIGS ANN, P1319; SCHNEIDER HJ, 1978, J ORG CHEM, V43, P3866, DOI 10.1021/jo00414a017; Sevastjanova T. K., 1972, B ACAD SCI USSR CH, V21, P2276, DOI 10.1007/BF00855320; Suzuki K, 2013, SOFT MATTER, V9, P4687, DOI 10.1039/c3sm27295h; Suzuki K, 2009, HETEROCYCLES, V78, P3091, DOI 10.3987/COM-09-11821; Tamura R., 2012, NITROXIDES THEORY EX, P191; Tamura R, 2008, J MATER CHEM, V18, P2872, DOI 10.1039/b802407c; Tamura R., 2014, HDB LIQUID CRYSTALS, V8, P837; Tamura R., 2012, LIQUID CRYSTALS DISP, P83; Tamura R, 2013, ELECTRON PARAMAG RES, V23, P1, DOI 10.1039/9781849734837-00001; Uchida Y, 2008, J MATER CHEM, V18, P2950, DOI 10.1039/b801704b; Uchida Y, 2010, J AM CHEM SOC, V132, P9746, DOI 10.1021/ja101930d; Uchida Y, 2007, HETEROCYCLES, V74, P607; Vasconcelos UB, 2005, ORG LETT, V7, P1027, DOI 10.1021/ol047524e; Volodarsky L. B., 1988, IMIDAZOLINE NITROXID, V1, P232; Zaitseva E. V., 2014, RUSS J ORG CHEM+, V50, p[78, 72]	39	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0009-3122	1573-8353		CHEM HETEROCYCL COM+	Chem. Heterocycl. Compds.	NOV	2014	50	8					1113	1125		10.1007/s10593-014-1571-7		13	Chemistry, Organic	Chemistry	AS2EU	WOS:000344093400006		
J	Wada, I; Igarashi, A				Wada, Ichiro; Igarashi, Ataru			The social costs of child abuse in Japan	CHILDREN AND YOUTH SERVICES REVIEW			English	Article						Social costs; Child abuse; Japan; Direct costs; Indirect costs	MALTREATMENT	The present study calculates the social costs of child abuse in Japan. The items calculated included the direct costs of dealing with abuse and the indirect costs related to long-term damage from abuse during the fiscal year 2012 (April 1, 2012, to March 31, 2013). Based on previous studies on the social costs of child abuse and peripheral matters conducted in other countries, the present study created items for the estimable direct costs and indirect costs of child abuse, and calculated the cost of each item. Among indirect costs, future losses owing to child abuse were calculated using extra costs with a discount rate of 3%. The social cost of child abuse in Japan in the fiscal year 2012 was at least (sic)1.6 trillion ($16 billion). The direct costs totaled (sic)99 billion ($1 billion), and the indirect costs totaled (sic)1.5 trillion ($15 billion). This sum of (sic)1.6 trillion for only the year 2012 is almost equal to the total amount of damages of (sic)1.9 trillion caused by the 2011 Tohoku Earthquake and Tsunami in Fukushima Prefecture. Moreover, abuse is a serious problem that occurs every year and has recurring costs, unlike a natural calamity. However, Japan has no system for calculating the long-term effects of abuse. Therefore, owing to the scarcity of data, the calculations in the present study may underestimate the true costs. (C) 2014 The Authors. Published by Elsevier Ltd.	[Wada, Ichiro] Child & Family Res Inst, Child & Family Welf Res Dept, Tokyo 1068580, Japan; [Igarashi, Ataru] Univ Tokyo, Grad Sch Pharmaceut Sci, DPM, Tokyo 1138654, Japan	Wada, I (reprint author), Child & Family Res Inst, Child & Family Welf Res Dept, Minato Ku, 5-6-8 Minamiazabu, Tokyo 1068580, Japan.	wada@aiiku.or.jp					Ae R., 2012, JAPANESE J PUBLIC HL, V59, P665; Perou R, 2013, MMWR-MORBID MORTAL W, V62, P1; Fang XM, 2012, CHILD ABUSE NEGLECT, V36, P156, DOI 10.1016/j.chiabu.2011.10.006; [Anonymous], 2010, STAT SMOK CESS MEAS; Libby AM, 2012, MED CARE, V50, P928, DOI 10.1097/MLR.0b013e31826c8613; Florence C, 2013, PEDIATRICS, V132, P312, DOI 10.1542/peds.2012-2212; Bowlus A., 2003, EC COSTS CONSEQUENCE; Cabinet Office Government of Japan, 2013, GEN STAT SUIC FISC 2; City of Osaka, 2012, SURV SUPP IND WHO HA; Fromm S, 2001, TOTAL ESTIMATED COST; Fujino K., 2007, EFFECT CHILD ABUSE A, P1; Fukuda T., 2012, CHANGING SOCIAL COST; Gelles R. J., 2012, ESTIMATED ANN COST C; Ikegami N., 2003, FISCAL 2001 MHLW GRA; Japan Ministry of Health Labour and Welfare, 2013, 2012 BAS SURV WAG ST; Japan Ministry of Health labour and Welfare, 2013, ISS SOC WELF SERV ST; Japan Ministry of Health Labour and Welfare, 2013, CURR STAT FUT COURS; Japan Ministry of Health Labour and Welfare, 2013, SUMM FISC 2012 REP S; Japan Ministry of Health Labour and Welfare, 2013, RES INV CHILD AB DEA; Japan Ministry of Health Labour and Welfare, 2013, REF FISC 2013 NAT C; Japan Ministry of Health Labour and Welfare, 2010, FISC 2009 DIV STAT; Japan Ministry of Health Labour and Welfare Social Welfare and War Victims' Relief Bureau, 2013, NAT SURV PUBL ASS RE; Japan Ministry of Internal Affairs and Communications, 2013, FISC 2012 EMPL STAT; Japan Ministry of Internal Affairs and Communications, 2012, EXP SOC SEC PUBL ASS; Japan Ministry of Internal Affairs and Communications, 2012, FIR FIGHT STAT BRIEF; Japan Ministry of Internal Affairs and Communications, 2012, EV POL REL CHILD AB; Japan Ministry of Justice, 2013, 2012 CRIM WHIT PAP; Japan National Police Agency, 2014, NUMB SUIC MONTH 2013; Kawakami N, 2007, FREQUENCY RISK FACTO; Kyusharen Association of Foster Home Kyusharen Association of Foster Home Survey Study Committee, 2013, FISC 2011 2012 SURV; Machino S., 2014, COMPREHENSIVE EXAMIN; Meier-Grawe U., 2011, EXPERTISE KOSTEN NUT; Miller T. R., 1996, VICTIM COSTS CONSEQU; National Institute for Land and Infrastructure Management, 2009, 26 NILIM; National Institute of Informatics, GRANTS IN AID DAT; National Institute of Public Health, MHLW GRANTS SYST; Saitama Prefectural Government Social Welfare Division Department of Child Safety, 2013, SURV IND WHO HAV LEF; Shizuoka Association of Foster Home, 2012, SURV IND WHO HAV LEF; Takahashi Y., 2007, STUDY EC EFFECTS SMO; Tanaka S., 2010, 20 CONV JAP SOC FAM; Taylor P., 2008, COST CHILD ABUSE AUS; Terasaki T., 2011, ESTIMATED CAPITAL ST; Tokyo Metropolitan Government Bureau of Social Welfare and Public Health, 2011, SURV IND WHO HAV LEF; Ueda K., 2013, FISCAL 2012 REPORT C; Wang C., 2007, TOTAL ESTIMATED COST	45	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0190-7409	1873-7765		CHILD YOUTH SERV REV	Child. Youth Serv. Rev.	NOV	2014	46						72	77		10.1016/j.childyouth.2014.013.002		6	Family Studies; Social Work	Family Studies; Social Work	AS3WH	WOS:000344205500009		
J	Feng, SQ; Terasaki, H; Komizo, Y; Hu, SS; Chen, DG; Ma, ZH				Feng Shengqiang; Terasaki Hidenri; Komizo Yuichi; Hu Shengsun; Chen Donggao; Ma Zhihua			Development of Evaluation Technique of GMAW Welding Quality Based on Statistical Analysis	CHINESE JOURNAL OF MECHANICAL ENGINEERING			English	Article						evaluation technique; Mahalanobis distance; normal distribution; welding fault; gas metal arc welding	TAGUCHI METHOD	Nondestructive techniques for appraising gas metal arc welding(GMAW) faults plays a very important role in on-line quality controllability and prediction of the GMAW process. On-line welding quality controllability and prediction have several disadvantages such as high cost, low efficiency, complication and greatly being affected by the environment. An enhanced, efficient evaluation technique for evaluating welding faults based on Mahalanobis distance(MD) and normal distribution is presented. In addition, a new piece of equipment, designated the weld quality tester(WQT), is developed based on the proposed evaluation technique. MD is superior to other multidimensional distances such as Euclidean distance because the covariance matrix used for calculating MD takes into account correlations in the data and scaling. The values of MD obtained from welding current and arc voltage are assumed to follow a normal distribution. The normal distribution has two parameters: the mean mu and standard deviation sigma of the data. In the proposed evaluation technique used by the WQT, values of MD located in the range from zero to mu+3 sigma are regarded as "good". Two experiments which involve changing the flow of shielding gas and smearing paint on the surface of the substrate are conducted in order to verify the sensitivity of the proposed evaluation technique and the feasibility of using WQT. The experimental results demonstrate the usefulness of the WQT for evaluating welding quality. The proposed technique can be applied to implement the on-line welding quality controllability and prediction, which is of great importance to design some novel equipment for weld quality detection.	[Feng Shengqiang; Chen Donggao; Ma Zhihua] China Acad Ordnance Sci, Ningbo Branch, Ningbo 315103, Peoples R China; [Terasaki Hidenri; Komizo Yuichi] Osaka Univ, Joining & Welding Res Inst, Osaka 5670047, Japan; [Hu Shengsun] Tianjin Univ, Tianjin Key Lab Adv Joining Technol, Tianjin 300072, Peoples R China	Feng, SQ (reprint author), China Acad Ordnance Sci, Ningbo Branch, Ningbo 315103, Peoples R China.	fsq7980@hotmail.com; hidenori@jwri.osaka-u.ac.jp; yuichikomizo@gmail.com; huss@tju.edu.cn; chendg2580@sina.com; mzhbky2012@163.com			Ningbo Municipal Natural Science Foundation of China [2014A610063]	Supported by Ningbo Municipal Natural Science Foundation of China (Grant No. 2014A610063)	Tarng YS, 2000, INT J ADV MANUF TECH, V16, P688, DOI 10.1007/s001700070040; Juang SC, 2002, J MATER PROCESS TECH, V122, P33, DOI 10.1016/S0924-0136(02)00021-3; ARATA Y., 1979, 21245179 IIW SG; ARATA Y., 1981, T JWRI, V10, P39; GRAD L, 1996, P 13 C BIAM 96 ZAGR, pI17; JOHANNES R, 2007, INT J ADV MANUF TECH, V33, P952; JOLLY WD, 1969, WELD J, V48, P21; Kamal P., 2010, J MATER PROCESS TECH, V210, P1397; KRAILJ V, 1968, 21214068 IIWIIS; LADISLAV G, 2004, INT J MACH TOOL MANU, V44, P555; Lee HT, 2003, INT J ADV MANUF TECH, V22, P727, DOI 10.1007/s00170-003-1599-9; Li ZY, 2009, J MATER PROCESS TECH, V209, P4867, DOI 10.1016/j.jmatprotec.2009.01.010; LIN J, 2000, CHINESE J MECH ENG, V36, P4867; LU X Q, 2003, CHINESE J MECH ENG, V39, P4867; MAYER J L, 1987, 32987 IIW VWG; MI M, 2002, MECHATRONICS, V12, P1259; Pan LK, 2007, J MATER PROCESS TECH, V182, P107, DOI 10.1016/j.jmatprotec.2006.07.015; PATRIZIA S, 2002, NDT&E INT, V35, P37; ROSTEK W, 1990, SCHWEIBEN SCHNEIDEN, V42, P96; Wang YW, 2001, INT J PRES VES PIP, V78, P43, DOI 10.1016/S0308-0161(00)00085-5; WATANABE Y, 2006, PRACTICE TAGUCHI MET	21	0	0	EDITORIAL OFFICE CHINESE JOURNAL MECHANICAL ENGINEERING	BEIJING	22 BAIWANZHUANG DAJIE, BEIJING, 100037, PEOPLES R CHINA	1000-9345	2192-8258		CHIN J MECH ENG-EN	Chin. J. Mech. Eng.	NOV	2014	27	6					1257	1263		10.3901/CJME.2014.0718.120		7	Engineering, Mechanical	Engineering	AS7PZ	WOS:000344448800018		
J	Yatagai, Y; Sakamoto, T; Yamada, H; Masuko, H; Kaneko, Y; Iijima, H; Naito, T; Noguchi, E; Hirota, T; Tamari, M; Konno, S; Nishimura, M; Hizawa, N				Yatagai, Y.; Sakamoto, T.; Yamada, H.; Masuko, H.; Kaneko, Y.; Iijima, H.; Naito, T.; Noguchi, E.; Hirota, T.; Tamari, M.; Konno, S.; Nishimura, M.; Hizawa, N.			Genomewide association study identifies HAS2 as a novel susceptibility gene for adult asthma in a Japanese population	CLINICAL AND EXPERIMENTAL ALLERGY			English	Article						asthma; genomewide association study; hyaluronan; hyaluronan synthase 2	MOLECULAR-WEIGHT HYALURONAN; AIRWAY EPITHELIAL-CELLS; ONSET ASTHMA; FUNCTIONAL POLYMORPHISM; WIDE ASSOCIATION; SMOOTH-MUSCLE; SMOKING; INFLAMMATION; EXPRESSION; COPD	BackgroundIt is increasingly clear that asthma is not a single disease, but a disorder with vast heterogeneity in pathogenesis, severity, and treatment response. To date, 30 genomewide association studies (GWASs) of asthma have been performed, including by our group. However, most gene variants identified so far confer relatively small increments in risk and explain only a small proportion of familial clustering. ObjectiveTo identify additional genetic determinants of susceptibility to asthma using a selected Japanese population with reduced tobacco smoking exposure. MethodsWe performed a GWAS by genotyping a total of 480098 single-nucleotide polymorphisms (SNPs) for a Japanese cohort consisting of 734 healthy controls and 240 patients with asthma who had smoked for no more than 10 pack-years. The SNP with the strongest association was genotyped in two other independent Japanese cohorts consisting of a total of 531 healthy controls and 418 patients with asthma who had smoked for no more than 10 pack-years. For the hyaluronan synthase 2 (HAS2) gene, we investigated SNP-gene associations using an expression quantitative trait loci (eQTL) database and also analysed its gene expression profiles in 13 different normal tissues. ResultsIn the discovery GWAS, a SNP located upstream of HAS2, rs7846389, showed the strongest statistical significance (P=1.43x10(-7)). In the two independent replication cohorts, rs7846389 was consistently associated with asthma (nominal P=0.0152 and 0.0478 in the first and second replication cohorts, respectively). In the meta-analysis, association of rs7846389 with susceptibility to asthma reached the level of genomewide significance (P=7.92x10(-9)). This variant was strongly correlated with HAS2 mRNA expression. The strongest expression of the gene was detected in the lung. ConclusionsOur study identified HAS2 as a novel candidate gene for susceptibility to adult asthma.	[Yatagai, Y.; Sakamoto, T.; Yamada, H.; Masuko, H.; Kaneko, Y.; Hizawa, N.] Univ Tsukuba, Fac Med, Dept Pulm Med, Tsukuba, Ibaraki 3058575, Japan; [Iijima, H.; Naito, T.] Tsukuba Med Ctr, Ibaraki, Japan; [Noguchi, E.] Univ Tsukuba, Fac Med, Dept Med Genet, Tsukuba, Ibaraki 3058575, Japan; [Konno, S.; Nishimura, M.] Hokkaido Univ, Sch Med, Dept Med 1, Sapporo, Hokkaido 060, Japan	Yatagai, Y (reprint author), Univ Tsukuba, Fac Med, Dept Pulm Med, Tennodai 1-1-1, Tsukuba, Ibaraki 3058575, Japan.	s1130465@u.tsukuba.ac.jp	Tamari, Mayumi/N-5378-2015; Nishimura, Masaharu/A-4062-2012		Japan Society for the Promotion of Science [24390206]	This study was partly supported by a Grant-in-Aid for Scientific Research (B) (No. 24390206) from the Japan Society for the Promotion of Science. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.	Noble PW, 2002, MATRIX BIOL, V21, P25, DOI 10.1016/S0945-053X(01)00184-6; Bonnelykke K, 2014, NAT GENET, V46, P51, DOI 10.1038/ng.2830; Kim TB, 2013, EUR RESPIR J, V41, P1308, DOI 10.1183/09031936.00100811; McKee CM, 1996, J CLIN INVEST, V98, P2403, DOI 10.1172/JCI119054; Manolio TA, 2008, J CLIN INVEST, V118, P1590, DOI 10.1172/JCI34772; Harada M, 2009, AM J RESP CRIT CARE, V180, P1048, DOI 10.1164/rccm.200905-0652OC; PHILIPSON LH, 1984, J BIOL CHEM, V259, P5017; Kaneko Y, 2013, ALLERGOL INT, V62, P113, DOI 10.2332/allergolint.12-OA-0467; Bollyky PL, 2007, J IMMUNOL, V179, P744; Hirota T, 2011, NAT GENET, V43, P893, DOI 10.1038/ng.887; Itano N, 1999, J BIOL CHEM, V274, P25085, DOI 10.1074/jbc.274.35.25085; Bouzigon E, 2008, NEW ENGL J MED, V359, P1985, DOI 10.1056/NEJMoa0806604; Kaneko Y, 2013, INT J CHRONIC OBSTR, V8, P65, DOI 10.2147/COPD.S39617; Scheibner KA, 2006, J IMMUNOL, V177, P1272; Boodoo S, 2006, AM J PHYSIOL-LUNG C, V291, pL479, DOI 10.1152/ajplung.00518.2005; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Meyers DA, 2005, J ALLERGY CLIN IMMUN, V115, P1169, DOI 10.1016/j.jaci.2005.01.070; Monzon ME, 2008, AM J RESP CELL MOL, V39, P289, DOI 10.1165/rcmb.2007-0361OC; Masuko H, 2011, INT J CHRONIC OBSTR, V6, P181, DOI 10.2147/COPD.S16383; Pruim RJ, 2010, BIOINFORMATICS, V26, P2336, DOI 10.1093/bioinformatics/btq419; Deed R, 1997, INT J CANCER, V71, P251, DOI 10.1002/(SICI)1097-0215(19970410)71:2<251::AID-IJC21>3.0.CO;2-J; Yang TP, 2010, BIOINFORMATICS, V26, P2474, DOI 10.1093/bioinformatics/btq452; Day AJ, 2005, TRENDS IMMUNOL, V26, P637, DOI 10.1016/j.it.2005.09.009; Pietinalho A, 2009, ALLERGY, V64, P1722, DOI 10.1111/j.1398-9995.2009.02208.x; Campo GM, 2011, BBA-MOL BASIS DIS, V1812, P1170, DOI 10.1016/j.bbadis.2011.06.006; Hizawa N, 2002, AM J RESP CRIT CARE, V166, P686, DOI 10.1164/rccm.2002020090OC; Ierodiakonou D, 2013, J ALLERGY CLIN IMMUN, V131, P582, DOI 10.1016/j.jaci.2012.08.013; Isada A, 2010, J HUM GENET, V55, P167, DOI 10.1038/jhg.2010.4; Kanabar V, 2005, BRIT J PHARMACOL, V146, P370, DOI 10.1038/sj.bjp.0706333; Klagas I, 2009, EUR RESPIR J, V34, P616, DOI 10.1183/09031936.00070808; Liu ML, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025099; MILLER SP, 1984, CLIN CHEM, V30, P1467; Osawa R, 2010, J INVEST DERMATOL, V130, P2834, DOI 10.1038/jid.2010.218; Stranger BE, 2012, PLOS GENET, V8, P272, DOI 10.1371/journal.pgen.1002639; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Wang M, 2013, BIOMACROMOLECULES, V14, P4198, DOI 10.1021/bm400947v; Yatagai Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080941; Zhang G, 2007, EUR RESPIR J, V30, P48, DOI 10.1183/09031936.00123206	38	3	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0954-7894	1365-2222		CLIN EXP ALLERGY	Clin. Exp. Allergy	NOV	2014	44	11					1327	1334		10.1111/cea.12415		8	Allergy; Immunology	Allergy; Immunology	AS6KA	WOS:000344371300005		
J	Kita, Y; Kita, R; Takeyama, A; Tomita, G; Goldberg, I				Kita, Yoshiyuki; Kita, Ritsuko; Takeyama, Asuka; Tomita, Goji; Goldberg, Ivan			Effect of high myopia on glaucoma diagnostic parameters measured with optical coherence tomography	CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY			English	Article						axial length; ganglion cell complex; high myopia; optical coherence tomography; ratio	FIBER LAYER MEASUREMENTS; GANGLION-CELL COMPLEX; DOMAIN; NERVE; THICKNESS; EYES; OCT	BackgroundWe examined the influence of high myopia on conventional spectral-domain optical coherence tomographic parameters and assessed the macular ganglion cell complex thickness to macular outer retinal thickness ratio as a new optical coherence tomography parameter. DesignProspective cross-sectional study. ParticipantsSixty normal and 30 highly myopic eyes (refractive error more than -6 D). MethodsWe used the RTVue-100 to measure macular ganglion cell complex and circumpapillary retinal nerve fibre layer thickness, global loss volume, and focal loss volume and then calculated the ganglion cell complex thickness to macular outer retinal thickness ratio. Main Outcome MeasuresEach parameter was compared between the two groups. Using the area under receiver operating characteristics curve, the classification abilities of optical coherence tomography parameters were examined in highly myopic eyes. ResultsBetween normal and highly myopic eyes, we found significant differences in ganglion cell complex and retinal nerve fibre layer thickness, global loss volume and focal loss volume. The new ratio parameter was not significantly different between groups (55.74% vs. 54.50%). The area under receiver operating characteristics curve was 0.775 (P<0.01) for retinal nerve fibre layer thickness, 0.721 (P<0.01) for ganglion cell complex thickness and 0.588 (P>0.05) for the new ratio parameter. ConclusionsAlthough refractive status significantly affected conventional optical coherence tomography parameters, the new ratio parameter may not be influenced by refractive error. Therefore, a normative database for healthy highly myopic eyes may not be necessary if ratio parameter is used.	[Kita, Yoshiyuki; Kita, Ritsuko; Takeyama, Asuka; Tomita, Goji] Toho Univ, Ohashi Med Ctr, Dept Ophthalmol, Tokyo 1538515, Japan; [Goldberg, Ivan] Univ Sydney, Eye Associates, Sydney, NSW 2006, Australia; [Goldberg, Ivan] Univ Sydney, Sydney Eye Hosp, Glaucoma Unit, Sydney, NSW 2006, Australia; [Goldberg, Ivan] Univ Sydney, Discipline Ophthalmol, Sydney, NSW 2006, Australia	Kita, Y (reprint author), Toho Univ, Ohashi Med Ctr, Dept Ophthalmol, Meguro Ku, 2-17-6 Ohashi, Tokyo 1538515, Japan.	kitakita220@gmail.com			Ministry of Education, Culture, Sports, and Technology of the Japanese Government [24592656]	This study was supported, in part, by a Grant-in-Aid for Scientific Research (C) 24592656 from the Ministry of Education, Culture, Sports, and Technology of the Japanese Government.	Fukuoka S, 2008, ACTA OPHTHALMOL, V86, P434, DOI 10.1111/j.1600-0420.2007.01068.x; Kita Y, 2013, CLIN EXP OPHTHALMOL, V41, P674, DOI 10.1111/ceo.12089; Kim NR, 2011, OPHTHALMOLOGY, V118, P1774, DOI 10.1016/j.ophtha.2011.01.058; Kotera Y, 2011, INVEST OPHTH VIS SCI, V52, P1412, DOI 10.1167/iovs.10-5572; Budenz DL, 2007, OPHTHALMOLOGY, V114, P1046, DOI 10.1016/j.ophtha.2006.08.046; Kita Y, 2013, J GLAUCOMA, V22, P757, DOI 10.1097/IJG.0b013e31825af58a; Tan Ou, 2009, Ophthalmology, V116, P2305, DOI 10.1016/j.ophtha.2009.05.025; Garas A, 2010, OPHTHALMOLOGY, V117, P738, DOI 10.1016/j.ophtha.2009.08.039; Kim NR, 2011, INVEST OPHTH VIS SCI, V52, P3413, DOI 10.1167/iovs.10-6648; Mitchell P, 1999, OPHTHALMOLOGY, V106, P2010, DOI 10.1016/S0161-6420(99)90416-5; Leung CKS, 2006, INVEST OPHTH VIS SCI, V47, P5171, DOI 10.1167/iovs.06-0545; Girkin CA, 2011, OPHTHALMOLOGY, V118, P2403, DOI 10.1016/j.ophtha.2011.06.013; Kim NR, 2011, BRIT J OPHTHALMOL, V95, P1115, DOI 10.1136/bjo.2010.182493; Seong M, 2010, INVEST OPHTH VIS SCI, V51, P1446, DOI 10.1167/iovs.09-4258; Shoji T, 2011, INVEST OPHTH VIS SCI, V52, P1098, DOI 10.1167/iovs.10-5922; Aref AA, 2012, J GLAUCOMA, DOI 1097/IJG.0b013e31827b155b; Hirashima T, 2013, GRAEF ARCH CLIN EXP, V251, P129, DOI 10.1007/s00417-012-2076-7; Kita Y, 2013, JPN J OPHTHALMOL, V57, P540, DOI 10.1007/s10384-013-0273-5; Qiu KL, 2011, AM J OPHTHALMOL, V152, P646, DOI 10.1016/j.ajo.2011.04.002; Sinai MJ, 2009, INVEST OPHTHALMOL  S, V50, pP4785; Takeyama A, 2014, JPN J OPHTHALMOL, V58, P86, DOI 10.1007/s10384-013-0292-2; Vernon S A, 2008, Br J Ophthalmol, V92, P1076, DOI 10.1136/bjo.2007.127571; Wang G, 2011, BRIT J OPHTHALMOL, V95, P255, DOI 10.1136/bjo.2009.176768; Zhao ZN, 2013, CLIN EXP OPHTHALMOL, V41, P561, DOI 10.1111/ceo.12045	24	2	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1442-6404	1442-9071		CLIN EXP OPHTHALMOL	Clin. Exp. Ophthalmol.	NOV	2014	42	8					722	728		10.1111/ceo.12318		7	Ophthalmology	Ophthalmology	AS6MB	WOS:000344376500004		
J	Tanase-Nakao, K; Naruse, M; Nanba, K; Tsuiki, M; Tagami, T; Usui, T; Okuno, H; Shimatsu, A; Hashimoto, S; Katabami, T; Ogo, A; Okumura, A; Umakoshi, H; Suzuki, T				Tanase-Nakao, Kanako; Naruse, Mitsuhide; Nanba, Kazutaka; Tsuiki, Mika; Tagami, Tetsuya; Usui, Takeshi; Okuno, Hiroshi; Shimatsu, Akira; Hashimoto, Shigeatsu; Katabami, Takuyuki; Ogo, Atsushi; Okumura, Ataru; Umakoshi, Hironobu; Suzuki, Tomoko			Chronic kidney disease score for predicting postoperative masked renal insufficiency in patients with primary aldosteronism	CLINICAL ENDOCRINOLOGY			English	Article							CARDIOVASCULAR EVENTS; ADRENALECTOMY; HYPERTENSION; GUIDELINES; SOCIETY; PREVALENCE; DIAGNOSIS; DAMAGE	ContextChronic kidney disease (CKD) is sometimes unmasked after unilateral adrenalectomy in patients with primary aldosteronism (PA) without expectation. ObjectiveOur study aim was to elucidate factors responsible for developing postoperative CKD and to provide a simple scoring system to predict postoperative CKD in PA. Design and PatientsForty-five patients with PA treated with unilateral adrenalectomy and followed for at least 1month postsurgery were studied. Thirty-one patients with non-PA adrenal disease who underwent unilateral adrenalectomy were also studied as control. Patients with pre-operative estimated glomerular filtration rate (eGFR)<60ml/min/173 m(2) were excluded from both groups. ResultsA statistically significant (P<0001) decrease in eGFR was observed in PA group within 1month of surgery, then stabilized. Of the 45 patients with PA, 17 (378%) developed CKD after surgery. None of the non-PA group developed CKD after surgery. Of the pre-operative variables, logistic regression analysis showed that lower eGFR and higher aldosterone-to-renin ratios (ARR) were the independent predictors for postoperative CKD in PA. Optimal cut-off values of the two variables analysed with ROC curves were as follows: eGFR769ml/min/173m(2) and ARR305. Using these data, we created a CKD score as a tool for predicting postoperative CKD, with an AUC for the score of 08866. ConclusionThe pre-operative eGFR and ARR were the significant contributing factors for postoperative CKD in PA. By combining these independent factors, we created a CKD score which provides useful information before surgery about the risk for development of postoperative CKD.	[Tanase-Nakao, Kanako; Tsuiki, Mika; Tagami, Tetsuya] Natl Hosp Org Kyoto Med Ctr, Div Endocrinol & Metab, Kyoto, Japan; [Naruse, Mitsuhide; Nanba, Kazutaka; Usui, Takeshi; Shimatsu, Akira] Natl Hosp Org Kyoto Med Ctr, Clin Res Inst, Kyoto, Japan; [Okuno, Hiroshi] Natl Hosp Org Kyoto Med Ctr, Div Urol, Kyoto, Japan; [Hashimoto, Shigeatsu] Fukushima Med Univ Hosp, Dept Diabet Endocrinol & Hypertens, Fukushima, Japan; [Katabami, Takuyuki] St Marianna Univ, Sch Med, Yokohama City Seibu Hosp, Div Endocrinol & Metab, Yokohama, Kanagawa, Japan; [Ogo, Atsushi] Natl Hosp Org Kyushu Med Ctr, Dept Endocrinol & Metab, Fukuoka, Japan; [Okumura, Ataru] Okazaki City Hosp, Dept Endocrinol & Diabet, Okazaki, Aichi, Japan; [Umakoshi, Hironobu] Matsuyama Red Cross Hosp, Div Endocrinol & Metab, Matsuyama, Ehime, Japan; [Suzuki, Tomoko] Natl Ctr Global Hlth & Med, Dept Clin Study & Informat, Ctr Clin Sci, Tokyo, Japan	Naruse, M (reprint author), Natl Hosp Org Kyoto Med Ctr, Clin Res Inst, Div Endocrinol Metab & Hypertens, Fushimi Ku, 1-1 Mukaihata Cho, Kyoto 6128555, Japan.	mnaruse@kyotolan.hosp.go.jp					Rossi GP, 2008, HYPERTENSION, V51, P1366, DOI 10.1161/HYPERTENSIONAHA.108.111369; Matsuo S, 2009, AM J KIDNEY DIS, V53, P982, DOI 10.1053/j.ajkd.2008.12.034; Rossi GP, 2006, J AM COLL CARDIOL, V48, P2293, DOI 10.1016/j.jacc.2006.07.059; Catena C, 2007, CLIN J AM SOC NEPHRO, V2, P722, DOI 10.2215/CJN.00050107; Rossi GP, 2006, HYPERTENSION, V48, P232, DOI 10.1161/01.HYP.0000230444.01215.6a; Zarnegar R, 2008, ANN SURG, V247, P511, DOI 10.1097/SLA.0b013e318165c075; Sechi LA, 2006, JAMA-J AM MED ASSOC, V295, P2638, DOI 10.1001/jama.295.22.2638; Utsumi T, 2013, INT J UROL, V20, P685, DOI 10.1111/iju.12029; Sechi LA, 2009, J CLIN ENDOCR METAB, V94, P1191, DOI 10.1210/jc.2008-2245; Ribstein J, 2005, J AM SOC NEPHROL, V16, P1320, DOI 10.1681/ASN.2004100878; Funder JW, 2008, J CLIN ENDOCR METAB, V93, P3266, DOI 10.1210/jc.2008-0104; Milliez P, 2005, J AM COLL CARDIOL, V45, P1243, DOI 10.1016/j.jacc.2005.01.015; Levey AS, 2003, ANN INTERN MED, V139, P137; Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031; Ogihara T, 2009, HYPERTENS RES, V32, P3, DOI 10.1038/hr.2008.15; Nishikawa T, 2011, ENDOCR J, V58, P711; FAVIA G, 1992, WORLD J SURG, V16, P680; Hollenberg NK, 2004, KIDNEY INT, V66, P1, DOI 10.1111/j.1523-1755.2004.00701.x; Iwakura Y, 2014, J CLIN ENDOCR METAB, V99, P1593, DOI 10.1210/jc.2013-2180; National Kidney Foundation, 2002, AM J KIDNEY DIS S, V39, pS1, DOI DOI 10.1053/AJKD.2002.30571.PUBMED:11904577; Nishikawa T., 2012, INT J UROL, V20, P693	21	2	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-0664	1365-2265		CLIN ENDOCRINOL	Clin. Endocrinol.	NOV	2014	81	5					665	670		10.1111/cen.12497		6	Endocrinology & Metabolism	Endocrinology & Metabolism	AS3KR	WOS:000344176900005		
J	Xi, B; Takeuchi, F; Meirhaeghe, A; Kato, N; Chambers, JC; Morris, AP; Cho, YS; Zhang, WH; Mohlke, KL; Kooner, JS; Shu, XO; Pan, HW; Tai, ES; Pan, HY; Wu, JY; Zhou, DH; Chandak, GR				Xi, Bo; Takeuchi, Fumihiko; Meirhaeghe, Aline; Kato, Norihiro; Chambers, John C.; Morris, Andrew P.; Cho, Yoon Shin; Zhang, Weihua; Mohlke, Karen L.; Kooner, Jaspal S.; Shu, Xiao Ou; Pan, Hongwei; Tai, E. Shyong; Pan, Haiyan; Wu, Jer-Yuarn; Zhou, Donghao; Chandak, Giriraj R.		DIAGRAM Consortium; AGEN-T2D Consortium; SAT2D Consortium	Associations of genetic variants in/near body mass index-associated genes with type 2 diabetes: a systematic meta-analysis	CLINICAL ENDOCRINOLOGY			English	Article							GENOME-WIDE ASSOCIATION; OBESITY-RELATED TRAITS; FTO GENE; FAT MASS; CHINESE POPULATION; SUSCEPTIBILITY VARIANTS; JAPANESE POPULATION; INSULIN-RESISTANCE; COMMON VARIATION; RISK LOCI	ObjectiveGenome-wide association studies have identified many obesity/body mass index (BMI)-associated loci in Europeans and East Asians. Since then, a large number of studies have investigated the role of BMI-associated loci in the development of type 2 diabetes (T2D). However, the results have been inconsistent. The objective of this study was to investigate the associations of eleven obesity/BMI loci with T2D risk and explore how BMI influences this risk. MethodsWe retrieved published literature from PubMed and Embase. The pooled odds ratios (OR) with 95% confidence intervals (CI) were calculated using fixed- or random-effect models. ResultsIn the meta-analysis of 42 studies for 11 obesity/BMI-associated loci, we observed a statistically significant association of the FTO rs9939609 polymorphism (66425 T2D cases/239689 normoglycaemic subjects; P=100x10(-41)) and six other variants with T2D risk (17915 T2D cases/27531 normoglycaemic individuals: n=40629-130001; all P<0001 for SH2B1 rs7498665, FAIM2 rs7138803, TMEM18 rs7561317, GNPDA2 rs10938397, BDNF rs925946 and NEGR1 rs2568958). After adjustment for BMI, the association remained statistically significant for four of the seven variants (all P<005 for FTO rs9939609, SH2B1 rs7498665, FAIM2 rs7138803, GNPDA2 rs10938397). Subgroup analysis by ethnicity demonstrated similar results. ConclusionsThis meta-analysis indicates that several BMI-associated variants are significantly associated with T2D risk. Some variants increase the T2D risk independent of obesity, while others mediate this risk through obesity.	[Xi, Bo] Shandong Univ, Sch Publ Hlth, Dept Maternal & Child Hlth Care, Jinan 250100, Peoples R China; [Takeuchi, Fumihiko; Kato, Norihiro] Natl Ctr Global Hlth & Med, Res Inst, Dept Gene Diagnost & Therapeut, Tokyo, Japan; [Meirhaeghe, Aline] INSERM, U744, F-59045 Lille, France; [Meirhaeghe, Aline] Inst Pasteur, F-59019 Lille, France; [Meirhaeghe, Aline] Univ Lille 2, UMR S744, Lille, France; [Chambers, John C.; Zhang, Weihua] Univ London Imperial Coll Sci Technol & Med, Dept Epidemiol & Biostat, London, England; [Chambers, John C.; Zhang, Weihua; Kooner, Jaspal S.] Ealing Hosp Natl Hlth Serv NHS Trust, Southall, Middx, England; [Morris, Andrew P.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England; [Cho, Yoon Shin] Hallym Univ, Dept Biomed Sci, Chunchon, Gangwon Do, South Korea; [Mohlke, Karen L.] Univ N Carolina, Dept Genet, Chapel Hill, NC USA; [Kooner, Jaspal S.] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, NHLI, London, England; [Shu, Xiao Ou] Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Dept Med,Vanderbilt Epidemiol Ctr, Nashville, TN 37212 USA; [Pan, Hongwei] Jinan Univ, Minist Educ, Key Lab Regenerat Med, Guangzhou, Guangdong, Peoples R China; [Pan, Hongwei] Jinan Univ, Coll Med, Dept Ophthalmol, Guangzhou, Guangdong, Peoples R China; [Tai, E. Shyong] Duke Natl Univ Singapore, Grad Sch Med, Saw Swee Hock Sch Publ Hlth, Singapore, Singapore; [Tai, E. Shyong] Duke Natl Univ Singapore, Grad Sch Med, Yong Loo Lin Sch Med, Dept Med, Singapore, Singapore; [Tai, E. Shyong] Duke Natl Univ Singapore, Grad Sch Med, Natl Univ Hlth Syst, Dept Med,Natl Univ Hosp, Singapore, Singapore; [Tai, E. Shyong] Duke Natl Univ Singapore, Grad Sch Med, Singapore, Singapore; [Pan, Hongwei] Guangdong Med Coll, Dept Epidemiol & Biostat, Dongguan, Peoples R China; [Wu, Jer-Yuarn] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan; [Wu, Jer-Yuarn] China Med Univ, Sch Chinese Med, Taichung, Taiwan; [Zhou, Donghao] Linyi Peoples Hosp, Dept Endocrinol, Linyi, Peoples R China; [Chandak, Giriraj R.] CSIR, Ctr Cellular & Mol Biol, Hyderabad, Andhra Pradesh, India	Zhou, DH (reprint author), Linyi Peoples Hosp, Dept Endocrinol, 27 East Part Jiefang Rd, Linyi, Peoples R China.	donghaozhou@163.com; chandakgrc@ccmb.res.in	Meirhaeghe, Aline/E-4663-2015		Council of Scientific and Industrial Research (CSIR); Ministry of Science of Technology, Govt. of India, India through their XII FYP titled 'CARDI-OMED'	This study was partially supported by Council of Scientific and Industrial Research (CSIR), and Ministry of Science of Technology, Govt. of India, India through their XII FYP titled 'CARDI-OMED'. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. We thank Dr Mark I McCarthy (Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK), Dr Michael Boehnke and Dr Heather M. Stringham (Department of Biostatistics and Center for Statistical Genetics, University of Michigan, Ann Arbor, USA) for providing data.	Andreasen CH, 2008, DIABETES, V57, P95, DOI 10.2337/db07-0910; Robiou-du-Pont S, 2013, INT J OBESITY, V37, P980, DOI 10.1038/ijo.2012.175; Speliotes EK, 2010, NAT GENET, V42, P937, DOI 10.1038/ng.686; Timpson NJ, 2009, DIABETES, V58, P505, DOI 10.2337/db08-0906; Yajnik CS, 2009, DIABETOLOGIA, V52, P247, DOI 10.1007/s00125-008-1186-6; Takeuchi F, 2011, DIABETOLOGIA, V54, P1350, DOI 10.1007/s00125-011-2086-8; Ng MCY, 2008, DIABETES, V57, P2226, DOI [10.2337/db07-1583, 10.2337/007-1583]; Takeuchi F, 2009, DIABETES, V58, P1690, DOI 10.2337/db08-1494; Thorleifsson G, 2009, NAT GENET, V41, P18, DOI 10.1038/ng.274; Chambers JC, 2008, NAT GENET, V40, P716, DOI 10.1038/ng.156; Willer CJ, 2009, NAT GENET, V41, P25, DOI 10.1038/ng.287; Zeggini E, 2007, SCIENCE, V316, P1336, DOI 10.1126/science.1142364; Hertel JK, 2011, DIABETES, V60, P1637, DOI 10.2337/db10-1340; Renstrom F, 2009, HUM MOL GENET, V18, P1489, DOI 10.1093/hmg/ddp041; Bravard A, 2011, DIABETES, V60, P258, DOI 10.2337/db10-0281; Li H, 2012, DIABETOLOGIA, V55, P981, DOI 10.1007/s00125-011-2370-7; Tan JT, 2008, DIABETES, V57, P2851, DOI 10.2337/db08-0214; Cauchi S, 2009, J MOL MED, V87, P537, DOI 10.1007/s00109-009-0451-6; Morris DL, 2009, DIABETES, V58, P2039, DOI 10.2337/db08-1388; Frayling TM, 2007, SCIENCE, V316, P889, DOI 10.1126/science.1141634; Liu Y, 2010, OBESITY, V18, P1619, DOI 10.1038/oby.2009.469; Scott LJ, 2007, SCIENCE, V316, P1341, DOI 10.1126/science.1142382; Chang YC, 2008, DIABETES, V57, P2245, DOI 10.2337/db08-0377; Krabbe KS, 2007, DIABETOLOGIA, V50, P431, DOI 10.1007/s00125-006-0537-4; Li HX, 2008, DIABETES, V57, P264; Freathy RM, 2008, DIABETES, V57, P1419, DOI 10.2337/db07-1466; Razquin C, 2011, MOL NUTR FOOD RES, V55, P136, DOI 10.1002/mnfr.201000445; Legry V, 2009, METABOLISM, V58, P971, DOI 10.1016/j.metabol.2009.02.019; Xi B, 2012, DIABETOLOGIA, V55, P2660, DOI 10.1007/s00125-012-2655-5; Song YQ, 2008, OBESITY, V16, P2472, DOI 10.1038/oby.2008.408; Hertel JK, 2008, DIABETOLOGIA, V51, P971, DOI 10.1007/s00125-008-0982-3; Lyssenko V, 2008, NEW ENGL J MED, V359, P2220, DOI 10.1056/NEJMoa0801869; Pettersen E, 2010, DIABETES, V59, P302, DOI 10.2337/db09-0923; Bressler J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010521; Herder C, 2008, HORM METAB RES, V40, P722, DOI 10.1055/s-2008-1078730; Hu C, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007643; Jacobsson JA, 2008, INT J OBESITY, V32, P1730, DOI 10.1038/ijo.2008.168; Karasawa S, 2010, ENDOCR J, V57, P293, DOI 10.1507/endocrj.K09E-305; Li S, 2011, DIABETOLOGIA, V54, P776, DOI 10.1007/s00125-011-2044-5; Li XY, 2010, DIABETES-METAB RES, V26, P128, DOI 10.1002/dmrr.1066; Marvelle AF, 2008, DIABETES, V57, P1987, DOI 10.2337/db07-1700; Ng MCY, 2010, J CLIN ENDOCR METAB, V95, P2418, DOI 10.1210/jc.2009-2077; Omori Shintaro, 2008, Diabetes, V57, P791, DOI 10.2337/db07-0979; Sandholt CH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023531; Sanghera DK, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-59; Schafer M, 2005, MOL CELL NEUROSCI, V29, P580, DOI 10.1016/j.mcn.2005.04.010; Scuteri A, 2007, PLOS GENET, V3, P1200, DOI 10.1371/journal.pgen.0030115; Shu XO, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001127; Thomsen M, 2012, J CLIN ENDOCR METAB, V97, pE1074, DOI 10.1210/jc.2011-3282; vansHoek M., 2008, DIABETES, V57, P3122; Webster RJ, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-140; Wen J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009153; Xi B, 2013, BIOMED ENVIRON SCI, V26, P787, DOI 10.3967/bes2013.001	53	4	5	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0300-0664	1365-2265		CLIN ENDOCRINOL	Clin. Endocrinol.	NOV	2014	81	5					702	710		10.1111/cen.12428		9	Endocrinology & Metabolism	Endocrinology & Metabolism	AS3KR	WOS:000344176900010		
J	Kajimoto, K; Sato, N; Keida, T; Sakata, Y; Takano, T				Kajimoto, Katsuya; Sato, Naoki; Keida, Takehiko; Sakata, Yasushi; Takano, Teruo		Acute Decompensated Heart Failure	Associations of Anemia and Renal Dysfunction with Outcomes among Patients Hospitalized for Acute Decompensated Heart Failure with Preserved or Reduced Ejection Fraction	CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY			English	Article							CHRONIC KIDNEY-DISEASE; RISK-FACTORS; MORTALITY; HEMOGLOBIN; METAANALYSIS; POPULATION; IMPAIRMENT; MORBIDITY; SURVIVAL; DEATH	Background and objectives The relationship among anemia, renal dysfunction, left ventricular ejection fraction, and outcomes of patients hospitalized for acute decompensated heart failure is unclear. The aim of this study was to evaluate the association between cardiorenal anemia syndrome and postdischarge outcomes in patients hospitalized for heart failure with a preserved or reduced ejection fraction. Design, setting, participants, & measurements Of 4842 patients enrolled in the Acute Decompensated Heart Failure Syndromes Registry between April 1, 2007 and December 31, 2011, 4393 patients were evaluated to investigate the association among anemia, renal dysfunction, preserved or reduced ejection fraction, and the primary end point (mortality and readmission for heart failure since discharge). The patients were divided into four groups on the basis of eGFR and hemoglobin at discharge. The median follow-up period after discharge was 432 (range=253-659) days. Results The primary end point was reached in 37.6% and 34.8% of the preserved and reduced ejection fraction groups, respectively. After adjustment for multiple comorbidities, there was no significant association of either renal dysfunction or anemia alone with the primary end point in patients with preserved ejection fraction, but the combination of renal dysfunction and anemia was associated with a significantly higher risk than that without either condition (hazard ratio, 1.54; 95% confidence interval, 1.12 to 2.12; P<0.01). In patients with reduced ejection fraction, adjusted analysis showed that a significantly higher risk of the primary end point was associated with renal dysfunction alone (hazard ratio, 1.65; 95% confidence interval, 1.21 to 2.25; P=0.002) and also, renal dysfunction plus anemia relative to the risk without either condition (hazard ratio, 2.19; 95% confidence interval, 1.62 to 2.96; P<0.001). Conclusions The findings show that renal dysfunction combined with anemia is associated with an increased risk of adverse postdischarge outcomes in patients with preserved ejection fraction, whereas renal dysfunction is an independent predictor of the risk of adverse outcomes in patients with reduced ejection fraction, regardless of anemia.	[Kajimoto, Katsuya] Sensoji Hosp, Div Cardiol, Tokyo 1110032, Japan; [Sato, Naoki] Musashi Kosugi Hosp, Internal Med Cardiol & Intens Care Unit, Nippon Med Sch, Kawasaki, Kanagawa, Japan; [Keida, Takehiko] Edogawa Hosp, Dept Cardiovasc Med, Tokyo, Japan; [Sakata, Yasushi] Osaka Univ, Grad Sch Med, Dept Cardiol, Osaka, Japan; [Takano, Teruo] Nippon Med Sch, Dept Internal Med, Tokyo 113, Japan	Kajimoto, K (reprint author), Sensoji Hosp, Div Cardiol, Taito Ku, 2-30-17 Asakusa, Tokyo 1110032, Japan.	kkajimoto@gmail.com			Japan Heart Foundation	The study was supported by the Japan Heart Foundation on the basis of a statement issued by the International Committee of Medical Journal Editors in September of 2004, which had no role in the conduct of the study. The funding for statistical support and administration in the study was accepted.	Sarraf M, 2009, CLIN J AM SOC NEPHRO, V4, P2013, DOI 10.2215/CJN.03150509; Smith GL, 2006, J AM COLL CARDIOL, V47, P1987, DOI 10.1016/j.jacc.2005.11.084; Matsuo S, 2009, AM J KIDNEY DIS, V53, P982, DOI 10.1053/j.ajkd.2008.12.034; Groenveld HF, 2008, J AM COLL CARDIOL, V52, P818, DOI 10.1016/j.jacc.2008.04.061; Go AS, 2006, CIRCULATION, V113, P2713, DOI 10.1161/CIRCULATIONHA.105.577577; Hillege HL, 2006, CIRCULATION, V113, P671, DOI 10.1161/CIRCULATIONAHA.105.580506; Horwich TB, 2002, J AM COLL CARDIOL, V39, P1780, DOI 10.1016/S0735-1097(02)01854-5; Androne AS, 2003, CIRCULATION, V107, P226, DOI 10.1161/01.CIR.0000052623.16194.80; Kleijn L, 2013, EUR J HEART FAIL, V15, P479, DOI 10.1093/eurjhf/hft058; Schrier RW, 2006, J AM COLL CARDIOL, V47, P1, DOI 10.1016/j.jacc.2005.07.067; Sato N, 2010, AM HEART J, V159, P949, DOI 10.1016/j.ahj.2010.03.019; Al-Ahmad A, 2001, J AM COLL CARDIOL, V38, P955, DOI 10.1016/S0735-1097(01)01470-X; MCKEE PA, 1971, NEW ENGL J MED, V285, P1441, DOI 10.1056/NEJM197112232852601; Young JB, 2008, AM J CARDIOL, V101, P223, DOI 10.1016/j.amjcard.2007.07.067; Logeart D, 2004, J AM COLL CARDIOL, V43, P635, DOI 10.1016/j.jacc.2003.09.044; Kazory A, 2009, J AM COLL CARDIOL, V53, P639, DOI 10.1016/j.jacc.2008.10.046; Anand IS, 2008, J AM COLL CARDIOL, V52, P501, DOI 10.1016/j.jacc.2008.04.044; Felker GM, 2004, J AM COLL CARDIOL, V44, P959, DOI 10.1016/j.jacc.2004.05.070; Anand IS, 2005, CIRCULATION, V112, P1121, DOI 10.1161/CIRCULATIONAHA.104.512988; Swedberg K, 2013, NEW ENGL J MED, V368, P1210, DOI 10.1056/NEJMoa1214865; McClellan WM, 2002, J AM SOC NEPHROL, V13, P1928, DOI 10.1097/01.ASN.0000018409.45834.FA; Ronco C, 2008, J AM COLL CARDIOL, V52, P1527, DOI 10.1016/j.jacc.2008.07.051; Stevenson LW, 2005, JAMA-J AM MED ASSOC, V294, P1625; Daliman PR, 1996, IRON NUTR HLTH DIS; Herzog CA, 2004, J CARD FAIL, V10, P467, DOI 10.1016/j.cardfail.2004.03.003; Scrutinio D, 2011, EUR J HEART FAIL, V13, P61, DOI 10.1093/eurjhf/hfq167; Silverberg DS, 2008, EUR J HEART FAIL, V10, P819, DOI 10.1016/j.ejheart.2008.06.015; Silverberg DS, 2002, EUR J HEART FAIL, V4, P681, DOI 10.1016/S1388-9842(02)00115-0	28	2	3	AMER SOC NEPHROLOGY	WASHINGTON	1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA	1555-9041	1555-905X		CLIN J AM SOC NEPHRO	Clin. J. Am. Soc. Nephrol.	NOV	2014	9	11					1912	1921		10.2215/CJN.04400514		10	Urology & Nephrology	Urology & Nephrology	AS7OY	WOS:000344446200015		
J	Nozu, K; Vorechoysky, I; Kaito, H; Fu, XJ; Nakanishi, K; Hashimura, Y; Hashimoto, F; Kamei, K; Ito, S; Kaku, Y; Imasawa, T; Ushijima, K; Shimizu, J; Makita, Y; Konomoto, T; Yoshikawa, N; Iijima, K				Nozu, Kandai; Vorechoysky, Igor; Kaito, Hiroshi; Fu, Xue Jun; Nakanishi, Koichi; Hashimura, Yuya; Hashimoto, Fusako; Kamei, Koichi; Ito, Shuichi; Kaku, Yoshitsugu; Imasawa, Toshiyuki; Ushijima, Katsumi; Shimizu, Junya; Makita, Yoshio; Konomoto, Takao; Yoshikawa, Norishige; Iijima, Kazumoto			X-Linked Alport Syndrome Caused by Splicing Mutations in COL4A5	CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY			English	Article							GLOMERULAR-FILTRATION RATE; IV COLLAGEN; GENE; DISEASE; PCR; MOSAICISM; CHAIN; SSCP	Background and objectives X-linked Alport syndrome is caused by mutations in the COL4A5 gene. Although many COL4A5 mutations have been detected, the mutation detection rate has been unsatisfactory. Some men with X-linked Alport syndrome show a relatively mild phenotype, but molecular basis investigations have rarely been conducted to clarify the underlying mechanism. Design, setting, participants, & measurements In total, 152 patients with X-linked Alport syndrome who were suspected of having Alport syndrome through clinical and pathologic investigations and referred to the hospital for mutational analysis between January of 2006 and January of 2013 were genetically diagnosed. Among those patients, 22 patients had suspected splice site mutations. Transcripts are routinely examined when suspected splice site mutations for abnormal transcripts are detected; 11 of them showed expected exon skipping, but others showed aberrant splicing patterns. The mutation detection strategy had two steps: (1) genomic DNA analysis using PCR and direct sequencing and (2) mRNA analysis using RT-PCR to detect RNA processing abnormalities. Results Six splicing consensus site mutations resulting in aberrant splicing patterns, one exonic mutation leading to exon skipping, and four deep intronic mutations producing cryptic splice site activation were identified. Interestingly, one case produced a cryptic splice site with a single nucleotide substitution in the deep intron that led to intronic exonization containing a stop codon; however, the patient showed a clearly milder phenotype for X-linked Alport syndrome in men with a truncating mutation. mRNA extracted from the kidney showed both normal and abnormal transcripts, with the normal transcript resulting in the milder phenotype. This novel mechanism leads to mild clinical characteristics. Conclusions This report highlights the importance of analyzing transcripts to enhance the mutation detection rate and provides insight into genotype-phenotype correlations. This approach can clarify the cause of atypically mild phenotypes in X-linked Alport syndrome.	[Nozu, Kandai; Kaito, Hiroshi; Fu, Xue Jun; Hashimura, Yuya; Hashimoto, Fusako; Iijima, Kazumoto] Kobe Univ, Grad Sch Med, Dept Pediat, Kobe, Hyogo 6500017, Japan; [Vorechoysky, Igor] Univ Southampton, Fac Med, Southampton SO9 5NH, Hants, England; [Nakanishi, Koichi; Yoshikawa, Norishige] Wakayama Med Univ, Dept Pediat, Wakayama, Japan; [Kamei, Koichi; Ito, Shuichi] Natl Ctr Child Hlth & Dev, Div Nephrol & Rheumatol, Tokyo, Japan; [Kaku, Yoshitsugu] Fukuoka Childrens Hosp, Dept Nephrol, Fukuoka, Japan; [Imasawa, Toshiyuki] Chiba East Hosp, Natl Hosp Org, Kidney Ctr, Chiba, Japan; [Ushijima, Katsumi] Yokkaichi Municipal Hosp, Dept Pediat, Yokaichi, Mie, Japan; [Shimizu, Junya] Natl Hosp Org, Dept Pediat, Okayama Med Ctr, Okayama, Japan; [Makita, Yoshio] Asahikawa Med Univ, Educ Ctr, Asahikawa, Hokkaido, Japan; [Konomoto, Takao] Miyazaki Univ, Dept Pediat, Fac Med, Miyazaki, Japan	Nozu, K (reprint author), Kobe Univ, Grad Sch Med, Dept Pediat, Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	nozu@med.kobe-u.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [25893131]; Mother and Child Health Foundation [25-7]; Ministry of Health, Labour and Welfare, Japan [H24-nanchitou (nan)-ippan-041]	This study was supported by Ministry of Education, Culture, Sports, Science and Technology of Japan Grant-in-Aid for Scientific Research (KAKENHI) 25893131 (to K.N.), Mother and Child Health Foundation Grant 25-7 (to K.N.), and Ministry of Health, Labour and Welfare, Japan, for Research on Rare Intractable Diseases in Kidney and Urinary Tract Grant H24-nanchitou (nan)-ippan-041 (to K.I.) in the "Research on Measures for Intractable Diseases" Project.	Matsuo S, 2009, AM J KIDNEY DIS, V53, P982, DOI 10.1053/j.ajkd.2008.12.034; Beicht S, 2013, GENE, V526, P474, DOI 10.1016/j.gene.2013.05.045; Jais JP, 2000, J AM SOC NEPHROL, V11, P649; SADO Y, 1995, HISTOCHEM CELL BIOL, V104, P267, DOI 10.1007/BF01464322; Cartegni L, 2002, NAT REV GENET, V3, P285, DOI 10.1038/nrg775; Bekheirnia MR, 2010, J AM SOC NEPHROL, V21, P876, DOI 10.1681/ASN.2009070784; Gross O, 2002, NEPHROL DIAL TRANSPL, V17, P1218, DOI 10.1093/ndt/17.7.1218; Mercuri E, 2013, CURR OPIN PEDIATR, V25, P701, DOI 10.1097/MOP.0b013e328365ace5; SCHWARTZ GJ, 1985, J PEDIATR-US, V106, P522, DOI 10.1016/S0022-3476(85)80697-1; Martin P, 1998, J AM SOC NEPHROL, V9, P2291; SCHWARTZ GJ, 1976, PEDIATRICS, V58, P259; King K, 2002, HUM GENET, V111, P548, DOI 10.1007/s00439-002-0830-3; Barker DF, 2001, AM J MED GENET, V98, P148, DOI 10.1002/1096-8628(20010115)98:2<148::AID-AJMG1024>3.0.CO;2-W; Buratti E, 2007, NUCLEIC ACIDS RES, V35, P4250, DOI 10.1093/nar/gkm402; Cheong HI, 2000, PEDIATR NEPHROL, V14, P117; Hashimura Y, 2014, KIDNEY INT, V85, P1208, DOI 10.1038/ki.2013.479; Hertz JM, 2001, HUM MUTAT, V18, P141, DOI 10.1002/humu.1163; Inoue YJ, 1999, AM J KIDNEY DIS, V34, P854, DOI 10.1016/S0272-6386(99)70042-9; Kashtan CE, 1998, J AM SOC NEPHROL, V9, P1736; Krol RP, 2008, NEPHROL DIAL TRANSPL, V23, P2525, DOI 10.1093/ndt/gfn005; Lo YF, 2011, CLIN J AM SOC NEPHRO, V6, P630, DOI 10.2215/CJN.06730810; Nagel Mato, 2005, Hum Mutat, V26, P60, DOI 10.1002/humu.9349; Naito I, 1996, KIDNEY INT, V50, P304, DOI 10.1038/ki.1996.316; Nakanishi K, 1998, J AM SOC NEPHROL, V9, P1433; Nozu K, 2009, PEDIATR RES, V66, P590, DOI 10.1203/PDR.0b013e3181b9b4d3	25	1	1	AMER SOC NEPHROLOGY	WASHINGTON	1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA	1555-9041	1555-905X		CLIN J AM SOC NEPHRO	Clin. J. Am. Soc. Nephrol.	NOV	2014	9	11					1958	1964		10.2215/CJN.04140414		7	Urology & Nephrology	Urology & Nephrology	AS7OY	WOS:000344446200020		
J	Kishimoto, N; Momota, Y; Hashimoto, Y; Tatsumi, S; Ando, K; Omasa, T; Kotani, J				Kishimoto, Naotaka; Momota, Yoshihiro; Hashimoto, Yoshiya; Tatsumi, Shinichi; Ando, Kayoko; Omasa, Takeshi; Kotani, Junichiro			The osteoblastic differentiation ability of human dedifferentiated fat cells is higher than that of adipose stem cells from the buccal fat pad	CLINICAL ORAL INVESTIGATIONS			English	Article						Dedifferentiated fat cells; Adipose stem cells; Ceiling culture; Buccal fat pad; Osteoblastic differentiation; Bone tissue engineering	BONE REGENERATION; STROMAL CELLS; TISSUE; ADIPOCYTES; THERAPIES; DEFECT; BMP-2	The purpose of this study was to evaluate and compare the osteoblastic differentiation ability of dedifferentiated fat (DFAT) cells and adipose stem cells (ASCs) from the buccal fat pad (BFP). We isolated human DFAT cells and ASCs from the BFP of a patient who underwent oral and maxillofacial surgery and then analyzed their cell surface antigens by flow cytometry. Then, the cells were cultured in osteogenic medium for 14 days. Measurement of bone-specific alkaline phosphatase (BAP), osteocalcin (OCN), and calcium deposition and alizarin red staining were performed to evaluate the osteoblastic differentiation ability of both cell types. ASCs and DFAT cells were positive for CD90 and CD105 and negative for CD11b, CD34, and CD45. BAP (days 3 and 7), OCN (day 14), and calcium deposition (days 7 and 14) within DFAT cell cultures were significantly higher than those in ASC cultures. The alizarin red-stained area in DFAT cell cultures, which indicates mineralized matrix deposition, was stained more strongly than that in ASC cultures. The cell surface antigens of ASCs and DFAT cells tend to be similar. Furthermore, the osteoblastic differentiation ability of human DFAT cells is higher than that of ASCs from the BFP. Isolation of DFAT cells from the BFP has an esthetic advantage because the BFP can be obtained via the oral cavity without injury to the external body surface. Therefore, we consider that DFAT cells from the BFP are an ideal cell source for bone tissue engineering.	[Kishimoto, Naotaka; Momota, Yoshihiro; Ando, Kayoko; Kotani, Junichiro] Osaka Dent Univ, Dept Anesthesiol, Chuo Ku, Osaka 5400008, Japan; [Hashimoto, Yoshiya] Osaka Dent Univ, Dept Biomat, Hirakata, Osaka 5731121, Japan; [Kishimoto, Naotaka; Momota, Yoshihiro; Omasa, Takeshi] Univ Tokushima, Inst Sci & Technol, Tokushima 7708506, Japan; [Tatsumi, Shinichi] Merck Ltd, Merck Millipore, Meguro Ku, Tokyo 1538927, Japan	Kishimoto, N (reprint author), Osaka Dent Univ, Dept Anesthesiol, Chuo Ku, 1-5-17 Otemae, Osaka 5400008, Japan.	kisimoto@cc.osaka-dent.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [23792397, 24792263]	We thank Dr. Masahiro Nakajima and Dr. Yuichi Shoju (Second Department of Oral and Maxillofacial Surgery, Osaka Dental University) for their cooperation with collecting the BFP. This study was supported by Grants-in-Aid for Scientific Research (B) (nos. 23792397 and 24792263) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.	Abuabara A, 2006, INT J ORAL MAX SURG, V35, P155, DOI 10.1016/j.ijom.2005.04.024; Hattori H, 2006, J BIOMED MATER RES B, V76B, P230, DOI 10.1002/jbm.b.30357; Schaffler A, 2007, STEM CELLS, V25, P818, DOI 10.1634/stemcells.2006-0589; GOMEZ B, 1995, CLIN CHEM, V41, P1560; Li HW, 2007, BIOCHEM BIOPH RES CO, V356, P836, DOI 10.1016/j.bbrc.2007.02.165; LIAN JB, 1992, CRIT REV ORAL BIOL M, V3, P269; Poloni A, 2012, STEM CELLS, V30, P965, DOI 10.1002/stem.1067; Mizuno H, 2012, STEM CELLS, V30, P804, DOI 10.1002/stem.1076; Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859; Yoon E, 2007, TISSUE ENG, V13, P619, DOI 10.1089/ten.2006.0102; Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02-02-0105; Kishimoto N, 2013, CYTOTECHNOLOGY, V65, P15, DOI 10.1007/s10616-012-9456-z; Matsumoto T, 2008, J CELL PHYSIOL, V215, P210, DOI 10.1002/jcp.21304; El Haddad SA, 2008, J PERIODONTOL, V79, P1271, DOI 10.1902/jop.2008.070176 ; Farre-Guasch E, 2010, TISSUE ENG PART C-ME, V16, P1083, DOI 10.1089/ten.TEC.2009.0487; Gao Q, 2012, MOL BIOL REP, V39, P5791, DOI 10.1007/s11033-011-1371-4; Kishimoto N, 2008, J ORAL TISSUE ENG, V6, P127; Kishimoto N, 2011, J ORAL TISSUE ENG, V8, P151; Lin YF, 2008, HISTOCHEM CELL BIOL, V129, P203, DOI 10.1007/s00418-007-0351-1; MartinGranizo R, 1997, BRIT J ORAL MAX SURG, V35, P81, DOI 10.1016/S0266-4356(97)90680-X; Ogawa R, 2004, BIOCHEM BIOPH RES CO, V313, P871, DOI 10.1016/j.bbrc.2003.12.017; Sakamoto F, 2015, CYTOTECHNOLOGY, V67, P75, DOI 10.1007/s10616-013-9659-y; Shiraishi T, 2012, J DENT RES, V91, P592, DOI 10.1177/0022034512445633; Yagi K, 2004, BIOCHEM BIOPH RES CO, V321, P967, DOI 10.1016/j.bbrc.2004.07.055; Zhao JY, 2009, J BIOSCI BIOENG, V107, P318, DOI 10.1016/j.jbiosc.2008.10.007	25	2	2	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1432-6981	1436-3771		CLIN ORAL INVEST	Clin. Oral Investig.	NOV	2014	18	8					1893	1901		10.1007/s00784-013-1166-1		9	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	AS6QH	WOS:000344387100002		
J	Tosaka, Y; Nakakura-Ohshima, K; Murakami, N; Ishii, R; Saitoh, I; Iwase, Y; Yoshihara, A; Ohuchi, A; Hayasaki, H				Tosaka, Yuki; Nakakura-Ohshima, Kuniko; Murakami, Nozomi; Ishii, Rikako; Saitoh, Issei; Iwase, Yoko; Yoshihara, Akihiro; Ohuchi, Akitsugu; Hayasaki, Haruaki			Analysis of tooth brushing cycles	CLINICAL ORAL INVESTIGATIONS			English	Article						Toothbrush; Motion; Cycle; Duration; Acceleration; Force	PLAQUE REMOVAL; TOOTHBRUSHING FORCE; MANUAL TOOTHBRUSH; ADOLESCENTS; PERFORMANCE; KINEMATICS; ACCURACY; CHILDREN; EFFICACY; BEHAVIOR	The aim of this study was to demonstrate the effectiveness of an analysis of tooth brushing cycles using a system that measures tooth brushing motion and brushing force with an accelerometer and strain tension gage attached to a toothbrush. Mechanical plaque removal with a manual toothbrush remains the primary method of maintaining good oral hygiene for the majority of the population. Because toothbrush motion has not been fully understood, it should be clarified by analysis of tooth brushing cycles. Twenty healthy female dental hygienists participated in this study. Their tooth brushing motions were measured and analyzed using an American Dental Association-approved manual toothbrush to which a three-dimensional (3-D) accelerometer and strain tension gage were attached. 3-D motion and brushing force on the labial surface of the mandibular right central incisor and the lingual surface of the mandibular left first molar were measured, analyzed, and compared. Multilevel linear model analysis was applied to estimate variables and compare motion and forces related to the two tooth surfaces. The analysis of tooth brushing cycles was feasible, and significant differences were detected for durations and 3-D ranges of toothbrush motion as well as brushing force between the two tooth surfaces. The analysis used in this study demonstrated an ability to detect characteristics of tooth brushing motion, showing tooth brushing motion to change depending on the brushed location. These results also suggest that more detailed instructions might be required according to patient's oral condition.	[Tosaka, Yuki; Yoshihara, Akihiro; Ohuchi, Akitsugu] Niigata Univ, Grad Sch Med & Dent Sci, Dept Oral Hlth & Welf, Chuo Ku, Niigata 9518514, Japan; [Nakakura-Ohshima, Kuniko; Murakami, Nozomi; Saitoh, Issei; Iwase, Yoko; Hayasaki, Haruaki] Niigata Univ, Grad Sch Med & Dent Sci, Dept Pediat Dent, Chuo Ku, Niigata 9518514, Japan; [Ishii, Rikako] Tokyo Metropolitan Ctr Oral Hlth Persons Disabil, Shinjyuku Ku, Tokyo 1620823, Japan	Nakakura-Ohshima, K (reprint author), Niigata Univ, Grad Sch Med & Dent Sci, Dept Pediat Dent, Chuo Ku, 2-5274 Gakkocho Dori, Niigata 9518514, Japan.	n11f752g@mail.cc.niigata-u.ac.jp; ohshima@dent.niigata-u.ac.jp; nozomi@dent.niigata-u.ac.jp; ishii@tokyo-ohc.org; isaito@dent.niigata-u.ac.jp; iwase@dent.niigata-u.ac.jp; akihiro@dent.niigata-u.ac.jp; ohuchi@dent.niigata-u.ac.jp; hayasaki@dent.niigata-u.ac.jp					Schlueter N, 2010, CLIN ORAL INVEST, V14, P99, DOI 10.1007/s00784-009-0269-1; Sim M, 2010, HUM MOVEMENT SCI, V29, P932, DOI 10.1016/j.humov.2010.07.014; Wells GD, 2009, J STRENGTH COND RES, V23, P741, DOI 10.1519/JSC.0b013e3181a07970; STRENIO JF, 1983, BIOMETRICS, V39, P71, DOI 10.2307/2530808; Kim KS, 2009, COMPUT METH PROG BIO, V96, P125, DOI 10.1016/j.cmpb.2009.04.006; Pakpour AH, 2012, J CLIN PERIODONTOL, V39, P132, DOI 10.1111/j.1600-051X.2011.01826.x; van der Weijden GA, 1998, J CLIN PERIODONTOL, V25, P413; van der Weijden GA, 2005, J CLIN PERIODONTOL, V32, P214, DOI 10.1111/j.1600-051X.2005.00795.x; Wiegand A, 2013, CLIN ORAL INVEST, V17, P815, DOI 10.1007/s00784-012-0788-z; WEINSTEIN P, 1989, J PUBLIC HEALTH DENT, V49, P32, DOI 10.1111/j.1752-7325.1989.tb02017.x; Kuitunen S, 2002, MED SCI SPORT EXER, V34, P166, DOI 10.1097/00005768-200201000-00025; Graetz C, 2013, J PERIODONTOL, V84, P186, DOI 10.1902/jop.2012.110675; Ganss C, 2009, EUR J ORAL SCI, V117, P255, DOI 10.1111/j.1600-0722.2009.00617.x; Marteau TM, 2012, SCIENCE, V337, P1492, DOI 10.1126/science.1226918; Atassi Farhad, 2010, J Contemp Dent Pract, V11, pE025; Berlin-Broner Y, 2012, EUR J PAEDIATR DENT, V13, P187; Boyd RL, 1997, J CLIN DENT, V8, P72; Buschang PH, 2000, ARCH ORAL BIOL, V45, P461, DOI 10.1016/S0003-9969(00)00015-7; Creeth Jonathan E, 2009, J Dent Hyg, V83, P111; Dorri M, 2010, INT J PAEDIATR DENT, V20, P261, DOI 10.1111/j.1365-263X.2010.01048.x; Gorniak SL, 2008, MOTOR CONTROL, V12, P151; Hayasaki H, 2002, J ORAL REHABIL, V29, P1120, DOI 10.1046/j.1365-2842.2002.00949.x; Hotta M, 1997, J CLIN DENT, V8, P156; Lee YC, 2012, PERCEPT MOTOR SKILL, V115, P187, DOI 10.2466/25.15.PMS.115.4.187-196; Lesser LI, 2012, JAMA-J AM MED ASSOC, V308, P983, DOI 10.1001/2012.jama.10427; MACGREGOR IDM, 1985, COMMUNITY DENT ORAL, V13, P121, DOI 10.1111/j.1600-0528.1985.tb00423.x; Okamoto T, 2007, J JPN SOC DISABIL OR, V22, P83; Poyato-Ferrera M, 2003, Int J Dent Hyg, V1, P110, DOI 10.1034/j.1601-5037.2003.00018.x; Saitoh I, 2010, J ORAL REHABIL, V37, P26, DOI 10.1111/j.1365-2842.2009.02006.x; Saxer UP, 1997, I QUINTESSENCE INT, V28, P513; Smith M, 2009, INT J LANG COMM DIS, V44, P864, DOI [10.1080/13682820802389873, 10.3109/13682820802389873]; vanderWeijden GA, 1996, J CLIN PERIODONTOL, V23, P724; Volpenhein D. W., 1996, Journal of Clinical Dentistry, V7, P21; Wintergerst AM, 2004, ARCH ORAL BIOL, V49, P991, DOI 10.1016/j.archoralbio.2004.07.010; Yankell S L, 2003, J Clin Dent, V14, P19; Yankell S. L., 1994, Journal of Clinical Dentistry, V4, P128; Yeung C Albert, 2010, Evid Based Dent, V11, P14, DOI 10.1038/sj.ebd.6400703	37	1	1	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1432-6981	1436-3771		CLIN ORAL INVEST	Clin. Oral Investig.	NOV	2014	18	8					2045	2053		10.1007/s00784-013-1172-3		9	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	AS6QH	WOS:000344387100018		
J	Kishikawa, H; Sato, K; Yamauchi, T; Katakura, A; Shibahara, T; Takano, N; Nishida, J				Kishikawa, H.; Sato, K.; Yamauchi, T.; Katakura, A.; Shibahara, T.; Takano, N.; Nishida, J.			Incidence and risk factors for colorectal neoplasia in patients with oral squamous cell carcinoma	COLORECTAL DISEASE			English	Article						Oral cancer; advanced adenoma; colorectal cancer; colonoscopy; second primary tumours	PRIMARY TUMORS; POSITRON-EMISSION; CANCER INCIDENCE; NECK-CANCER; COLON; TOMOGRAPHY; POPULATION; MORTALITY; SMOKING; HEAD	AimColorectal adenoma and cancer are not regarded as being associated with primary oral cancer. The aim of this study was to determine whether screening colonoscopy should be performed for patients with oral cancer in addition to the upper gastrointestinal endoscopic screening that is now routinely performed. MethodBetween 2007 and 2013, 162 patients with oral squamous cell carcinoma were enrolled at Tokyo Dental College, Ichikawa General Hospital, and 136 individuals were assigned to colonoscopic surveillance. Advanced neoplasia was defined as an adenoma 10mm, adenoma with villous histology or high-grade dysplasia regardless of size and invasive cancer. Associations between advanced neoplasia and clinical factors, including age, sex, body mass index, physical activity, smoking, alcohol consumption and oral cancer site and staging were determined. ResultsAdvanced neoplasia, including five invasive cancers, was identified in 32 (23.5%) patients. An age- and sex-adjusted multivariate analysis revealed that smoking (Brinkmann index>400; OR=3.24, 95% CI=1.28-8.18), alcohol consumption (lifetime pure ethanol consumption >600l; OR=2.84, 95% CI=1.18-6.79) and a diagnosis of cancer of the floor of the mouth (OR=7.97, 95% CI=2.49-25.46) were independent risk factors for advanced colorectal neoplasia. ConclusionThe prevalence of advanced colorectal neoplasia is unexpectedly high in patients with oral cancer. It should be recognized as a second primary tumour of oral cancer. Screening of oral cancer patients by colonoscopy should be routine practice, particularly among smokers and patients with a high intake of alcohol and cancer of the floor of the mouth.	[Kishikawa, H.; Nishida, J.] Ichikawa Gen Hosp, Tokyo Dent Coll, Dept Gastroenterol, Ichikawa, Chiba 2728513, Japan; [Sato, K.; Yamauchi, T.; Katakura, A.; Shibahara, T.; Takano, N.] Ichikawa Gen Hosp, Tokyo Dent Coll, Oral Canc Ctr, Ichikawa, Chiba 2728513, Japan	Kishikawa, H (reprint author), Ichikawa Gen Hosp, Tokyo Dent Coll, Dept Gastroenterol, 5-11-13 Sugano, Ichikawa, Chiba 2728513, Japan.	kisikawa@tdc.ac.jp					Parkin DM, 2005, CA-CANCER J CLIN, V55, P74; Matsuda T, 2012, JPN J CLIN ONCOL, V42, P139, DOI 10.1093/jjco/hyr184; SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q; Cho EY, 2004, ANN INTERN MED, V140, P603; FerroLuzzi A, 1995, WHO TECH REP SER, V854, P1; Brenner H, 2007, GUT, V56, P1585, DOI 10.1136/gut.2007.122739; Zauber AG, 2012, NEW ENGL J MED, V366, P687, DOI 10.1056/NEJMoa1100370; Stokkel MPM, 1999, CANCER, V86, P2370, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2370::AID-CNCR27>3.0.CO;2-B; MUTO T, 1975, CANCER, V36, P2251, DOI 10.1002/cncr.2820360944; Lieberman DA, 2007, GASTROENTEROLOGY, V133, P1077, DOI 10.1053/j.gastro.2007.07.006; Liang PS, 2009, INT J CANCER, V124, P2406, DOI 10.1002/ijc.24191; Duell EJ, 2012, MOL CARCINOGEN, V51, P40, DOI 10.1002/mc.20786; Weston BR, 2010, CANCER-AM CANCER SOC, V116, P1454, DOI 10.1002/cncr.24885; Center MM, 2009, CA-CANCER J CLIN, V59, P366, DOI 10.3322/caac.20038; Chiang JM, 2004, HEPATO-GASTROENTEROL, V51, P1341; Crosher R, 1998, BRIT J ORAL MAX SURG, V36, P58, DOI 10.1016/S0266-4356(98)90751-3; DAY GL, 1992, CANCER, V70, P14, DOI 10.1002/1097-0142(19920701)70:1<14::AID-CNCR2820700103>3.0.CO;2-S; Garrote LF, 2001, BRIT J CANCER, V85, P46, DOI 10.1054/bjoc.2000.1825; Hashibe M, 2005, CANCER LETT, V220, P185, DOI 10.1016/j.canlet.2004.10.023; Kolligs FT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020076; Kramer Franz-Josef, 2004, Clin Oral Investig, V8, P56; Sanchez Nelson F, 2012, BMC Res Notes, V5, P312, DOI 10.1186/1756-0500-5-312; Sankaranarayanan R, 2005, LANCET, V365, P1927, DOI 10.1016/S0140-6736(05)66658-5; Sobin LH, 2010, TNM CLASSIFICATION M, P1; Tamamoto S, 2006, DIS COLON RECTUM, V49, pS30; Warnakulasuriya KAAS, 2003, J ORAL PATHOL MED, V32, P443, DOI 10.1034/j.1600-0714.2003.00179.x	26	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1462-8910	1463-1318		COLORECTAL DIS	Colorectal Dis.	NOV	2014	16	11					888	895		10.1111/codi.12717		8	Gastroenterology & Hepatology; Surgery	Gastroenterology & Hepatology; Surgery	AS6KZ	WOS:000344373800014		
J	Urakami, J				Urakami, Jacqueline			Cross-cultural comparison of hand gestures of Japanese and Germans for tabletop systems	COMPUTERS IN HUMAN BEHAVIOR			English	Article						Cultural differences; User study; Surface gestures; Hand gestures; Japanese; German	INTERFACE DESIGN; SELF-CONCEPT; INDIVIDUALISM; COLLECTIVISM; COGNITION	Goal was to study cultural differences between Japanese and Germans gesture use when interacting with a map and a video walkthrough application for a table top system. Japanese and Germans' choice of gestures was compared in a quasi-experimental design. Gestures had to be generated for two different scenarios, an electronic map and a video walkthrough. Data revealed that physical aspects of hand gestures such as hand shape, focus on motion pattern, and preference of simple, one-hand gestures are similar between Japanese and Germans. However, Japanese and Germans differed in the choice of symbolic and metaphorical gestures and in the frame of reference and perspective taken for performing gestures. Furthermore, differences between Germans and Japanese were larger for the map application than for the video walkthrough. Culture partly affects the choice of hand gestures for table top systems. Designers of gesture vocabularies for tabletop systems have to carefully consider which referents are carried out by hand gestures alone. Gesture input appears to be appropriate for the direct manipulation of objects or real world applications. However, abstract functions or artificial realities should not be handled by gestures alone. Also, designers should consider the development of culture-centered interfaces. (C) 2014 Elsevier Ltd. All rights reserved.	[Urakami, Jacqueline] Keio Univ, Tokyo 108, Japan	Urakami, J (reprint author), 3-10-43 Kikunodai, Chofu, Tokyo 1820007, Japan.	jacqueline.waniek@gmail.com					MARKUS HR, 1991, PSYCHOL REV, V98, P224, DOI 10.1037/0033-295X.98.2.224; RHEE E, 1995, J PERS SOC PSYCHOL, V69, P142, DOI 10.1037/0022-3514.69.1.142; Nisbett RE, 2001, PSYCHOL REV, V108, P291, DOI 10.1037//0033-295X.108.2.291; Nisbett RE, 2005, TRENDS COGN SCI, V9, P467, DOI 10.1016/j.tics.2005.08.004; Kuhn MH, 1954, AM SOCIOL REV, V19, P68, DOI 10.2307/2088175; Ji LJ, 2004, J PERS SOC PSYCHOL, V87, P57, DOI 10.1037/0022-3514.87.1.57; Wobbrock JO, 2009, CHI2009: PROCEEDINGS OF THE 27TH ANNUAL CHI CONFERENCE ON HUMAN FACTORS IN COMPUTING SYSTEMS, VOLS 1-4, P1083; Urakami J, 2012, HUM FACTORS, V54, P636, DOI 10.1177/0018720811433052; Derboven J, 2012, INT J HUM-COMPUT ST, V70, P714, DOI 10.1016/j.ijhcs.2012.05.005; Norenzayan A, 2002, COGNITIVE SCI, V26, P653, DOI 10.1207/s15516709cog2605_4; Barber W., 1998, P 4 HUM FACT WEB C; BOCHNER S, 1994, J CROSS CULT PSYCHOL, V25, P273, DOI 10.1177/0022022194252007; BOND MH, 1983, J CROSS CULT PSYCHOL, V14, P153, DOI 10.1177/0022002183014002002; Buchinger Shelley, 2010, P 10 INT C MULT, P699, DOI 10.1145/1873951.1874055; Choi B, 2006, INT J HUM-COMPUT INT, V20, P171, DOI 10.1207/s15327590ijhc2003_2; Epps J., 2006, P CHI 06 ACM DL, P748; Evers V., 1997, P 13 INT C HUM COMP; Fikkert W, 2009, LECT NOTES ARTIF INT, V5085, P199; Freeman Dustin, 2009, P ACM INT C INT TABL, P165, DOI 10.1145/1731903.1731935; Hall Edward T., 1976, CULTURE; Heine S. J., 2012, CULTURAL PSYCHOL; Inkster I., 2000, CULTURE TECHNOLOGY M; Ishii K, 2003, PSYCHOL SCI, V14, P39, DOI 10.1111/1467-9280.01416; Kendon A., 2004, GESTURE VISIBLE ACTI; Koike H, 2009, CHI2009: PROCEEDINGS OF THE 27TH ANNUAL CHI CONFERENCE ON HUMAN FACTORS IN COMPUTING SYSTEMS, VOLS 1-4, P163; Kuhnel C, 2011, INT J HUM-COMPUT ST, V69, P693, DOI 10.1016/j.ijhcs.2011.04.005; Ma V, 1997, BASIC APPL SOC PSYCH, V19, P261, DOI 10.1207/s15324834basp1902_7; Mauney D, 2010, P 28 INT C HUM FACT, P4015, DOI DOI 10.1145/1753846.1754095; Miyamoto Y, 2006, J EXP SOC PSYCHOL, V42, P540, DOI 10.1016/j.jesp.2005.09.001; Nielsen M., 2004, P 5 INT GEST WORKSH, P409; Nisbett Richard E., 2003, GEOGRAPHY THOUGHT AS; Nojima H., 1994, P C NEW VIS POST SOC; Pappachan P, 2008, BEHAV INFORM TECHNOL, V27, P331, DOI 10.1080/01449290802228399; Schraefel M. C., 2005, ECSTRIAM05009 U SOUT; Shen S.-T., 2009, INT J INTERCULTURAL, V33, P11; Stern H. I., 2008, INT J SEMANTIC COMPU, V2, P137, DOI DOI 10.1142/S1793351X08000385; Streeck Jurgen, 2009, GESTURECRAFT MANUFAC; van der Sluis I, 2012, INT J HUM-COMPUT ST, V70, P611, DOI 10.1016/j.ijhcs.2012.05.002; Wigdor D, 2011, BRAVE NUI WORLD: DESIGNING NATURAL USER INTERFACES FOR TOUCH AND GESTURE, P1; Xie AP, 2009, INT J INTERCULT REL, V33, P11, DOI 10.1016/j.ijintrel.2008.09.002	40	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0747-5632	1873-7692		COMPUT HUM BEHAV	Comput. Hum. Behav.	NOV	2014	40						180	189		10.1016/j.chb.2014.08.010		10	Psychology, Multidisciplinary; Psychology, Experimental	Psychology	AS7IM	WOS:000344430100019		
J	Ogawa, T; Shibato, J; Rakwal, R; Saito, T; Tamura, G; Kuwagata, M; Shioda, S				Ogawa, Tetsuo; Shibato, Junko; Rakwal, Randeep; Saito, Tomomi; Tamura, Gaku; Kuwagata, Makiko; Shioda, Seiji			Seeking genes responsible for developmental origins of health and disease from the fetal mouse liver following maternal food restriction	CONGENITAL ANOMALIES			English	Article						developmental origins of health and disease; lepr; maternal undernutrition; promoter methylation microarray; trib1	TERM CALORIE RESTRICTION; EARLY POSTNATAL-GROWTH; CATCH-UP GROWTH; NF-KAPPA-B; LIFE-SPAN; GLUCOCORTICOID EXPOSURE; PPAR-GAMMA; TRANSCRIPTIONAL COACTIVATOR; CARDIOVASCULAR-DISEASE; GLUCOSE-INTOLERANCE	Low birthweight resulting from a nonoptimal fetal environment is correlated epidemiologically to a higher risk of adult diseases, and which has also been demonstrated using animal models for maternal undernutrition. In this study, we subjected pregnant mice to 50% food restriction (FR), and profiled gene expression and promoter DNA methylation genome-wide using the fetal livers. The fact that effect of food restriction is opposite between before and after birth encouraged us to hunt for genes that are expressed oppositely to adult calorie restriction (CR) using the maternal livers. Among oppositely regulated genes, we identified trib1 (tribbles homolog 1). Using genetically modified mice, trib1 has been shown to have a demonstrable contribution to a risk of hypertriglyceridaemia and insulin resistance. Our data showed that the trib1 expression and its promoter DNA methylation could be affected physiologically (by maternal nutrition), and therefore might be a strong candidate gene for developmental origins of adult diseases. Furthermore, lepr (leptin receptor) gene was downregulated by maternal FR, indicating its potential role in induction of obesity and diabetes. Gene expression as well as promoter DNA methylation profiling revealed that glucocorticoid receptor target genes were regulated by maternal FR. This supports previous studies that suggest an important role of fetal glucocorticoid exposure in the mechanism of developmental origins of diseases. Our transcriptomics profiling data also suggested that maternal FR impaired development of the immune system. An inventory of candidate genes responsible for developmental origins of health and disease is presented and discussed in this study.	[Ogawa, Tetsuo; Shibato, Junko; Rakwal, Randeep; Saito, Tomomi; Tamura, Gaku; Kuwagata, Makiko; Shioda, Seiji] Showa Univ, Sch Med, Dept Anat, Shinagawa, Tokyo 1428555, Japan; [Rakwal, Randeep] Univ Tsukuba, Fac Life & Environm Sci, Ibaraki, Japan; [Rakwal, Randeep] Univ Tsukuba, Org Educ Initiat, Ibaraki, Japan	Ogawa, T (reprint author), Showa Univ, Sch Med, Dept Anat, 1-5-8 Hatanodai, Shinagawa, Tokyo 1428555, Japan.	ogawatetsuo@hotmail.co.jp			Center for Innovative Dentistry by Ministry of Education, Culture, Sports, Science, and Technology; Fordays Inc. (Chuo-ku, Tokyo, Japan)	This study was supported in part by the Project to Establish Strategic Research from the Center for Innovative Dentistry by Ministry of Education, Culture, Sports, Science, and Technology, and a private grant from Fordays Inc. (Chuo-ku, Tokyo, Japan). RR acknowledges the great support from Professors Yoshihiro Shiraiwa (Provost, Faculty of Life and Environmental Sciences, University of Tsukuba) and Koji Nomura (Organization for Educational Initiatives, University of Tsukuba) in promoting interdisciplinary research and unselfish encouragement.	Teslovich TM, 2010, NATURE, V466, P707, DOI 10.1038/nature09270; Hales CN, 2001, BRIT MED BULL, V60, P5, DOI 10.1093/bmb/60.1.5; Redman LM, 2011, ANTIOXID REDOX SIGN, V14, P275, DOI 10.1089/ars.2010.3253; Hayden MS, 2011, CELL RES, V21, P223, DOI 10.1038/cr.2011.13; Barker DJP, 2002, INT J EPIDEMIOL, V31, P1235, DOI 10.1093/ije/31.6.1235; Weaver ICG, 2004, ANN NY ACAD SCI, V1024, P182, DOI 10.1196/annals.1321.001; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Lindsay RS, 1996, DIABETOLOGIA, V39, P1299, DOI 10.1007/s001250050573; Margetic S, 2002, INT J OBESITY, V26, P1407, DOI 10.1038/sj.ijo.0802142; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Godfrey KM, 2011, DIABETES, V60, P1528, DOI 10.2337/db10-0979; Xydakis AM, 2004, J CLIN ENDOCR METAB, V89, P2697, DOI 10.1210/jc.2003-031826; Ozanne SE, 2004, NATURE, V427, P411, DOI 10.1038/427411b; Conley ME, 2012, J EXP MED, V209, P463, DOI 10.1084/jem.20112533; Burkhardt R, 2010, J CLIN INVEST, V120, P4410, DOI [10.1172/JCI44213, 10.1172/JC144213]; Selman C, 2009, SCIENCE, V326, P140, DOI 10.1126/science.1177221; BENEDIKTSSON R, 1993, LANCET, V341, P339, DOI 10.1016/0140-6736(93)90138-7; Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276; Vickers MH, 2000, AM J PHYSIOL-ENDOC M, V279, pE83; Omodei D, 2011, FEBS LETT, V585, P1537, DOI 10.1016/j.febslet.2011.03.015; Berrebi D, 2003, BLOOD, V101, P729, DOI 10.1182/blood-2002-02-0538; Eriksson JG, 1999, BRIT MED J, V318, P427; Yajnik C, 2000, P NUTR SOC, V59, P257, DOI 10.1017/S0029665100000288; Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Hayden MS, 2012, GENE DEV, V26, P203, DOI 10.1101/gad.183434.111; Mair W, 2008, ANNU REV BIOCHEM, V77, P727, DOI 10.1146/annurev.biochem.77.061206.171059; Hori M, 2012, DIS MODEL MECH, V5, P270, DOI 10.1242/dmm.008276; BRAY GA, 1979, PHYSIOL REV, V59, P719; Pei H, 2011, CELL DEATH DIFFER, V18, P315, DOI 10.1038/cdd.2010.100; Nyirenda MJ, 1998, J CLIN INVEST, V101, P2174, DOI 10.1172/JCI1567; Ogawa T, 2011, CONGENIT ANOM, V51, P70, DOI 10.1111/j.1741-4520.2010.00304.x; Vickers MH, 2005, ENDOCRINOLOGY, V146, P4211, DOI 10.1210/en.2005-0581; Lillycrop KA, 2008, BRIT J NUTR, V100, P278, DOI 10.1017/S0007114507894438; Briana DD, 2009, EUR J ENDOCRINOL, V160, P337, DOI 10.1530/EJE-08-0621; D'Adamio F, 1997, IMMUNITY, V7, P803, DOI 10.1016/S1074-7613(00)80398-2; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; Vuillermin PJ, 2009, ALLERGY, V64, P348, DOI 10.1111/j.1398-9995.2009.01970.x; LangleyEvans SC, 1996, PLACENTA, V17, P169, DOI 10.1016/S0143-4004(96)80010-5; Cheung YB, 2000, HYPERTENSION, V36, P795; Yura S, 2005, CELL METAB, V1, P371, DOI 10.1016/j.cmet.2005.05.005; van Straten EME, 2010, AM J PHYSIOL-REG I, V298, pR275, DOI 10.1152/ajpregu.00413.2009; Forsen T, 2000, ANN INTERN MED, V133, P176; Nusken KD, 2011, ENDOCRINOLOGY, V152, P1327, DOI 10.1210/en.2010-1116; Rothwarf DM, 1998, NATURE, V395, P297; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; Ayroldi E, 2001, BLOOD, V98, P743, DOI 10.1182/blood.V98.3.743; Woods LL, 2001, PEDIATR RES, V49, P460, DOI 10.1203/00006450-200104000-00005; Lillycrop KA, 2007, BRIT J NUTR, V97, P1064, DOI 10.1017/S000711450769196X; Masoro EJ, 2005, MECH AGEING DEV, V126, P913, DOI 10.1016/j.mad.2005.03.012; Guan HY, 2005, AM J PHYSIOL-ENDOC M, V288, pE663, DOI 10.1152/ajpendo.00461.2004; Varbo A, 2011, ARTERIOSCL THROM VAS, V31, P451, DOI 10.1161/ATVBAHA.110.216333; Ogawa T, 2011, CONGENIT ANOM, V51, P110, DOI 10.1111/j.1741-4520.2011.00315.x; Okada Y, 2012, NAT GENET, V44, P302, DOI 10.1038/ng.1086; Singhal A, 2007, CIRCULATION, V115, P213, DOI 10.1161/CIRCULATIONAHA.106.617811; Barker DJP, 2002, J HYPERTENS, V20, P1951, DOI 10.1097/00004872-200210000-00013; Crowther NJ, 1998, DIABETOLOGIA, V41, P1163, DOI 10.1007/s001250051046; Fontana L, 2004, P NATL ACAD SCI USA, V101, P6659, DOI 10.1073/pnas.0308291101; Wilkinson JE, 2012, AGING CELL, V11, P675, DOI 10.1111/j.1474-9726.2012.00832.x; Satoh T, 2013, NATURE, V495, P524, DOI 10.1038/nature11930; Barroso I, 1999, NATURE, V402, P880; Gluckman PD, 2007, P NATL ACAD SCI USA, V104, P12796, DOI 10.1073/pnas.0705667104; Barker DJP, 2007, J INTERN MED, V261, P412, DOI 10.1111/j.1365-2796.2007.01809.x; Baranowski M, 2010, J LIPID RES, V51, P74, DOI 10.1194/jlr.M900002-JLR200; BARKER DJP, 1986, LANCET, V1, P1077; Cefalu WT, 1999, TOXICOL SCI, V52, P49, DOI 10.1093/toxsci/52.suppl_1.49; CHANDRA RK, 1980, AM J CLIN NUTR, V33, P13; Cox LA, 2006, J PHYSIOL-LONDON, V572, P67, DOI 10.1113/jphysiol.2006.106872; Estep PW, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005242; Floyd ZE, 2012, BBA-MOL BASIS DIS, V1822, P1090, DOI 10.1016/j.bbadis.2012.03.014; Hori M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-256; Jimenez-Chillaron JC, 2006, DIABETOLOGIA, V49, P1974, DOI 10.1007/s00125-006-0311-7; Khorram NM, 2011, REPROD SCI, V18, P931, DOI 10.1177/1933719111404613; Kudo Makiko, 2004, Clin Exp Pharmacol Physiol, V31 Suppl 2, pS57, DOI 10.1111/j.1440-1681.2004.04107.x; Lane MA, 1999, TOXICOL SCI, V52, P41, DOI 10.1093/toxsci/52.suppl_1.41; Marshall Stephen, 2006, Sci STKE, V2006, pre7, DOI 10.1126/stke.3462006re7; Nijland MJ, 2007, J PHYSIOL-LONDON, V579, P643, DOI 10.1113/jphysiol.2006.122101; VONFREEDENJEFFRY U, 1995, J EXP MED, V181, P1519, DOI 10.1084/jem.181.4.1519; Wójcicka Grazyna, 2007, Postepy Hig Med Dosw (Online), V61, P736; Yamashita C, 2000, J BIOCHEM-TOKYO, V128, P93	81	2	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0914-3505	1741-4520		CONGENIT ANOM	Congenit. Anom.	NOV	2014	54	4					195	219		10.1111/cga.12089		25	Pediatrics	Pediatrics	AS6DX	WOS:000344355900002		
J	Inoue, A; Arima, A; Kato, H; Ebihara, S				Inoue, Ayumi; Arima, Akihiro; Kato, Hirohito; Ebihara, Shizufumi			Utility of finger maze test for learning and memory abilities in infants of cynomolgus monkeys exposed to thiamazole	CONGENITAL ANOMALIES			English	Article						cynomolgus monkey; finger maze; infant; learning and memory test; thiamazole	SPATIAL MEMORY; PRIMATE HIPPOCAMPUS; FORAGING STRATEGIES; TASK; RATS; ANTAGONISTS; RECEPTOR; MICE; CA3	A new type of learning and memory test using a finger maze was conducted in infant cynomolgus monkeys that were exposed to thiamazole (2 and 3.5 mg/kg per day to pregnant animals orally) during the fetal period (gestational days 120 to 150). We modified Tsuchida's original finger maze test method by reducing the number of trials per day and simplifying the criteria for achievement of training, and we added a long-term memory test. In the memory test, thiamazole-exposed infants required greater time to complete the finger maze test than the control infants although no effect was noted in the training or learning test. The results suggest that an impaired long-term memory could be detected by our modified finger maze test.	[Inoue, Ayumi; Arima, Akihiro; Kato, Hirohito] Shin Nippon Biomed Labs SNBL Ltd, Drug Safety Res Labs, Kagoshima 8911394, Japan; [Inoue, Ayumi; Ebihara, Shizufumi] Nagoya Univ, Grad Sch Bioagr Sci, Div Biomodeling, Nagoya, Aichi 4648601, Japan	Inoue, A (reprint author), Shin Nippon Biomed Labs SNBL Ltd, Drug Safety Res Labs, 2438 Miyanoura, Kagoshima 8911394, Japan.	inoue-ayumi@snbl.co.jp					Dellu F, 2000, NEUROBIOL LEARN MEM, V73, P31, DOI 10.1006/nlme.1999.3919; SAWAGUCHI T, 1994, J NEUROPHYSIOL, V71, P515; OLTON DS, 1976, J EXP PSYCHOL ANIM B, V2, P97, DOI 10.1037/0097-7403.2.2.97; Teng E, 1999, NATURE, V400, P675; Negishi T, 2006, TOXICOL LETT, V160, P233, DOI 10.1016/j.toxlet.2005.07.008; Hosseini M, 2012, NAT PROD RES, V26, P1544, DOI 10.1080/14786419.2011.566223; Winocur G, 2005, NAT NEUROSCI, V8, P273, DOI 10.1038/nn1401; HOSOI E, 1995, APPL ANIM BEHAV SCI, V43, P189, DOI 10.1016/0168-1591(95)00565-A; HARLOW HARRY F., 1959, AMER SCIENTIST, V47, P459; ICH, 2011, PRECL SAF EV BIOT DE; Inoue A, 2013, CONGENIT ANOM, V53, P149, DOI 10.1111/cga.12024; KATZ JL, 1993, PSYCHOPHARMACOLOGY, V113, P19, DOI 10.1007/BF02244328; Laughlin K, 2000, ANIM BEHAV, V60, P403, DOI 10.1006/anbe.2000.1468; Mandel JS, 2001, J CLIN ENDOCR METAB, V86, P2354; MHLW (The Ministry of Health Labour and Welfare), 2012, GUID NONCL SAF STUD; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Parker A, 1995, BEHAV NEUROSCI, V109, P1045; Ridley RM, 1997, EXP BRAIN RES, V115, P83, DOI 10.1007/PL00005688; Takuma Kazuhiro, 2007, Folia Pharmacologica Japonica, V130, P112, DOI 10.1254/fpj.130.112; Tsuchida J, 2003, INT J PRIMATOL, V24, P261, DOI 10.1023/A:1023040931101; Urban NN, 1996, LEARN MEMORY, V3, P86, DOI 10.1101/lm.3.2-3.86; Williams SH, 1996, J NEUROSCI, V16, P3652; Yoshida T, 2006, TPRC HDB CARE MANAGE, P206; Zhang B, 2008, J NEUROSCI METH, V170, P111, DOI 10.1016/j.jneumeth.2007.12.017	24	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0914-3505	1741-4520		CONGENIT ANOM	Congenit. Anom.	NOV	2014	54	4					220	224		10.1111/cga.12090		5	Pediatrics	Pediatrics	AS6DX	WOS:000344355900003		
J	Yagihashi, T; Torii, C; Takahashi, R; Omori, M; Kosaki, R; Yoshihashi, H; Ihara, M; Minagawa-Kawai, Y; Yamamoto, J; Takahashi, T; Kosaki, K				Yagihashi, Tatsuhiko; Torii, Chiharu; Takahashi, Reiko; Omori, Mikimasa; Kosaki, Rika; Yoshihashi, Hiroshi; Ihara, Masahiro; Minagawa-Kawai, Yasuyo; Yamamoto, Junichi; Takahashi, Takao; Kosaki, Kenjiro			Clinical utility of an array comparative genomic hybridization analysis for Williams syndrome	CONGENITAL ANOMALIES			English	Article						developmental origins of health and disease; lepr; maternal undernutrition; promoter methylation microarray; trib1	PROTEIN-RESTRICTED DIET; EARLY POSTNATAL-GROWTH; CATCH-UP GROWTH; NF-KAPPA-B; CALORIC RESTRICTION; LIFE-SPAN; GLUCOCORTICOID EXPOSURE; GENE-EXPRESSION; PPAR-GAMMA; TRANSCRIPTIONAL COACTIVATOR	Low birthweight resulting from a non-optimal fetal environment is correlated epidemiologically to a higher risk of adult diseases, and which has also been demonstrated using animal models for maternal undernutrition. In this study, we subjected pregnant mice to 50% food restriction (FR), and profiled gene expression and promoter DNA methylation genome-wide using the fetal livers. The fact that effect of food restriction is opposite between before and after birth encouraged us to hunt for genes that are expressed oppositely to adult calorie restriction (CR) using the maternal livers. Among oppositely regulated genes, we identified trib1 (tribbles homolog 1). Using genetically modified mice, trib1 has been shown to have a demonstrable contribution to a risk of hypertriglyceridaemia and insulin resistance. Our data showed that the trib1 expression and its promoter DNA methylation could be affected physiologically (by maternal nutrition), and therefore might be a strong candidate gene for developmental origins of adult diseases. Furthermore, lepr (leptin receptor) gene was downregulated by maternal FR, indicating its potential role in induction of obesity and diabetes. Gene expression as well as promoter DNA methylation profiling revealed that glucocorticoid receptor target genes were regulated by maternal FR. This supports previous studies that suggest an important role of fetal glucocorticoid exposure in the mechanism of developmental origins of diseases. Our transcriptomics profiling data also suggested that maternal FR impaired development of the immune system. An inventory of candidate genes responsible for developmental origins of health and disease is presented and discussed in this study.	[Yagihashi, Tatsuhiko] Keio Univ, Dept Child Psychiat, Komagino Hosp, Sch Med, Tokyo, Japan; [Yagihashi, Tatsuhiko; Torii, Chiharu; Kosaki, Kenjiro] Keio Univ, Sch Med, Ctr Med Genet, Tokyo 1608582, Japan; [Kosaki, Rika; Yoshihashi, Hiroshi; Ihara, Masahiro; Takahashi, Takao] Keio Univ, Sch Med, Dept Pediat, Tokyo 1608582, Japan; [Takahashi, Reiko; Omori, Mikimasa; Yamamoto, Junichi] Keio Univ, Grad Sch Human Relat, Dept Psychol, Tokyo 1608582, Japan; [Takahashi, Reiko] Keio Univ, Japan Portage Assoc, Tokyo 1608582, Japan; [Kosaki, Rika] Keio Univ, Natl Ctr Child Hlth & Dev, Div Clin Genet & Mol Med, Tokyo 1608582, Japan; [Yoshihashi, Hiroshi] Keio Univ, Tokyo Metropolitan Childrens Med Ctr, Div Med Genet, Tokyo 1608582, Japan; [Ihara, Masahiro] Keio Univ, Fac Letters, Dept Psychol, Tokyo 1608582, Japan; [Minagawa-Kawai, Yasuyo] Saiseikai Utsunomiya Hosp, Dept Pediat, Utsunomiya, Tochigi, Japan	Kosaki, K (reprint author), Keio Univ, Sch Med, Ctr Med Genet, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.	kkosaki@z3.keio.jp			Ministry of Education, Culture, Sports, Science and Technology, Tokyo, Japan	This work was supported by Grants-in-Aid for Young Scientists (B) from The Ministry of Education, Culture, Sports, Science and Technology, Tokyo, Japan.	Teslovich TM, 2010, NATURE, V466, P707, DOI 10.1038/nature09270; Hales CN, 2001, BRIT MED BULL, V60, P5, DOI 10.1093/bmb/60.1.5; Redman LM, 2011, ANTIOXID REDOX SIGN, V14, P275, DOI 10.1089/ars.2010.3253; Hayden MS, 2011, CELL RES, V21, P223, DOI 10.1038/cr.2011.13; Barker DJP, 2002, INT J EPIDEMIOL, V31, P1235, DOI 10.1093/ije/31.6.1235; Weaver ICG, 2004, ANN NY ACAD SCI, V1024, P182, DOI 10.1196/annals.1321.001; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Lindsay RS, 1996, DIABETOLOGIA, V39, P1299, DOI 10.1007/s001250050573; Margetic S, 2002, INT J OBESITY, V26, P1407, DOI 10.1038/sj.ijo.0802142; Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Godfrey KM, 2011, DIABETES, V60, P1528, DOI 10.2337/db10-0979; Xydakis AM, 2004, J CLIN ENDOCR METAB, V89, P2697, DOI 10.1210/jc.2003-031826; Ozanne SE, 2004, NATURE, V427, P411, DOI 10.1038/427411b; Conley ME, 2012, J EXP MED, V209, P463, DOI 10.1084/jem.20112533; Burkhardt R, 2010, J CLIN INVEST, V120, P4410, DOI [10.1172/JCI44213, 10.1172/JC144213]; Selman C, 2009, SCIENCE, V326, P140, DOI 10.1126/science.1177221; BENEDIKTSSON R, 1993, LANCET, V341, P339, DOI 10.1016/0140-6736(93)90138-7; Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276; Vickers MH, 2000, AM J PHYSIOL-ENDOC M, V279, pE83; Omodei D, 2011, FEBS LETT, V585, P1537, DOI 10.1016/j.febslet.2011.03.015; Berrebi D, 2003, BLOOD, V101, P729, DOI 10.1182/blood-2002-02-0538; Eriksson JG, 1999, BRIT MED J, V318, P427; Yajnik C, 2000, P NUTR SOC, V59, P257, DOI 10.1017/S0029665100000288; Harrison DE, 2009, NATURE, V460, P392, DOI 10.1038/nature08221; Jacobs MD, 1998, CELL, V95, P749, DOI 10.1016/S0092-8674(00)81698-0; Hayden MS, 2012, GENE DEV, V26, P203, DOI 10.1101/gad.183434.111; Mair W, 2008, ANNU REV BIOCHEM, V77, P727, DOI 10.1146/annurev.biochem.77.061206.171059; Hori M, 2012, DIS MODEL MECH, V5, P270, DOI 10.1242/dmm.008276; BRAY GA, 1979, PHYSIOL REV, V59, P719; Pei H, 2011, CELL DEATH DIFFER, V18, P315, DOI 10.1038/cdd.2010.100; Nyirenda MJ, 1998, J CLIN INVEST, V101, P2174, DOI 10.1172/JCI1567; Ogawa T, 2011, CONGENIT ANOM, V51, P70, DOI 10.1111/j.1741-4520.2010.00304.x; Vickers MH, 2005, ENDOCRINOLOGY, V146, P4211, DOI 10.1210/en.2005-0581; Lillycrop KA, 2008, BRIT J NUTR, V100, P278, DOI 10.1017/S0007114507894438; Briana DD, 2009, EUR J ENDOCRINOL, V160, P337, DOI 10.1530/EJE-08-0621; D'Adamio F, 1997, IMMUNITY, V7, P803, DOI 10.1016/S1074-7613(00)80398-2; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; Vuillermin PJ, 2009, ALLERGY, V64, P348, DOI 10.1111/j.1398-9995.2009.01970.x; LangleyEvans SC, 1996, PLACENTA, V17, P169, DOI 10.1016/S0143-4004(96)80010-5; Cheung YB, 2000, HYPERTENSION, V36, P795; Yura S, 2005, CELL METAB, V1, P371, DOI 10.1016/j.cmet.2005.05.005; van Straten EME, 2010, AM J PHYSIOL-REG I, V298, pR275, DOI 10.1152/ajpregu.00413.2009; Forsen T, 2000, ANN INTERN MED, V133, P176; Nusken KD, 2011, ENDOCRINOLOGY, V152, P1327, DOI 10.1210/en.2010-1116; Rothwarf DM, 1998, NATURE, V395, P297; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; Ayroldi E, 2001, BLOOD, V98, P743, DOI 10.1182/blood.V98.3.743; Woods LL, 2001, PEDIATR RES, V49, P460, DOI 10.1203/00006450-200104000-00005; Lillycrop KA, 2007, BRIT J NUTR, V97, P1064, DOI 10.1017/S000711450769196X; Masoro EJ, 2005, MECH AGEING DEV, V126, P913, DOI 10.1016/j.mad.2005.03.012; Guan HY, 2005, AM J PHYSIOL-ENDOC M, V288, pE663, DOI 10.1152/ajpendo.00461.2004; Varbo A, 2011, ARTERIOSCL THROM VAS, V31, P451, DOI 10.1161/ATVBAHA.110.216333; Ogawa T, 2011, CONGENIT ANOM, V51, P110, DOI 10.1111/j.1741-4520.2011.00315.x; Okada Y, 2012, NAT GENET, V44, P302, DOI 10.1038/ng.1086; Singhal A, 2007, CIRCULATION, V115, P213, DOI 10.1161/CIRCULATIONAHA.106.617811; Barker DJP, 2002, J HYPERTENS, V20, P1951, DOI 10.1097/00004872-200210000-00013; Crowther NJ, 1998, DIABETOLOGIA, V41, P1163, DOI 10.1007/s001250051046; Fontana L, 2004, P NATL ACAD SCI USA, V101, P6659, DOI 10.1073/pnas.0308291101; Wilkinson JE, 2012, AGING CELL, V11, P675, DOI 10.1111/j.1474-9726.2012.00832.x; Satoh T, 2013, NATURE, V495, P524, DOI 10.1038/nature11930; Barroso I, 1999, NATURE, V402, P880; Gluckman PD, 2007, P NATL ACAD SCI USA, V104, P12796, DOI 10.1073/pnas.0705667104; Barker DJP, 2007, J INTERN MED, V261, P412, DOI 10.1111/j.1365-2796.2007.01809.x; Baranowski M, 2010, J LIPID RES, V51, P74, DOI 10.1194/jlr.M900002-JLR200; BARKER DJP, 1986, LANCET, V1, P1077; Cefalu WT, 1999, TOXICOL SCI, V52, P49, DOI 10.1093/toxsci/52.suppl_1.49; CHANDRA RK, 1980, AM J CLIN NUTR, V33, P13; Cox LA, 2006, J PHYSIOL-LONDON, V572, P67, DOI 10.1113/jphysiol.2006.106872; Estep 3rd PW, 2009, PLOS ONE, V4, pe5242; Floyd ZE, 2012, BBA-MOL BASIS DIS, V1822, P1090, DOI 10.1016/j.bbadis.2012.03.014; Hori M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-256; Jimenez-Chillaron JC, 2006, DIABETOLOGIA, V49, P1974, DOI 10.1007/s00125-006-0311-7; Khorram NM, 2011, REPROD SCI, V18, P931, DOI 10.1177/1933719111404613; Kudo Makiko, 2004, Clin Exp Pharmacol Physiol, V31 Suppl 2, pS57, DOI 10.1111/j.1440-1681.2004.04107.x; Lane MA, 1999, TOXICOL SCI, V52, P41, DOI 10.1093/toxsci/52.suppl_1.41; Marshall Stephen, 2006, Sci STKE, V2006, pre7, DOI 10.1126/stke.3462006re7; Nijland MJ, 2007, J PHYSIOL-LONDON, V579, P643, DOI 10.1113/jphysiol.2006.122101; vonsFreeden-Jeffry U, 1995, J EXP MED, V181, P1519; Wójcicka Grazyna, 2007, Postepy Hig Med Dosw (Online), V61, P736; Yamashita C, 2000, J BIOCHEM-TOKYO, V128, P93	81	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0914-3505	1741-4520		CONGENIT ANOM	Congenit. Anom.	NOV	2014	54	4					225	227		10.1111/cga.12062		3	Pediatrics	Pediatrics	AS6DX	WOS:000344355900004		
J	Serikawa, T; Nishiyama, K; Tohyama, J; Tazawa, R; Goto, K; Kuriyama, Y; Haino, K; Kanemura, Y; Yamasaki, M; Nakata, K; Takakuwa, K; Enomoto, T				Serikawa, Takehiro; Nishiyama, Kenichi; Tohyama, Jun; Tazawa, Ryushi; Goto, Kiyoe; Kuriyama, Yoko; Haino, Kazufumi; Kanemura, Yonehiro; Yamasaki, Mami; Nakata, Koh; Takakuwa, Koichi; Enomoto, Takayuki			Prenatal molecular diagnosis of X-linked hydrocephalus via a silent C924T mutation in the L1CAM gene	CONGENITAL ANOMALIES			English	Article						lethal skeletal dysplasia; Majewski syndrome; postmortem examination; prenatal ultrasound diagnosis; short-rib polydactyly syndrome	RIB-POLYDACTYLY-SYNDROME; CEPHALIC PRIMORDIAL DWARFISM; SYNDROME TYPE-II; MAJEWSKI TYPE; SPINDLE ORGANIZATION; SECKEL-SYNDROME; PRIMARY CILIA; PERICENTRIN; CHONDROCYTES; ANOMALIES	The Majewski syndrome or short rib-polydactyly syndrome (SRPS) type II is a lethal skeletal dysplasia characterized by severe IUGR (intrauterine growth restriction) and dysmorphic face, polydactyly, relatively proportionate head size at birth with later progression to microcephaly. A case of second trimester ultrasound diagnosis of SRPS type II is reported with review of the medical record of previous observed cases. Postmortem examination and radiogram confirmed the clinical diagnosis. Histological examination of the femoral epypheseal chondral plate showed an expanded and irregular hypertrophic zone. Moreover, characteristic cortico-medullary cysts of both kidneys and portal fibrosis were also demonstrated; findings consistent with the broad phenotypic spectrum of this rare skeletal disease.	[Serikawa, Takehiro; Enomoto, Takayuki] Niigata Univ, Med & Dent Hosp, Dept Obstet & Gynecol, Niigata, Japan; [Nishiyama, Kenichi] Niigata Univ, Med & Dent Hosp, Dept Neurosurg, Niigata, Japan; [Tohyama, Jun; Tazawa, Ryushi; Goto, Kiyoe; Kuriyama, Yoko; Nakata, Koh] Niigata Univ, Med & Dent Hosp, Biosci Med Res Ctr, Niigata, Japan; [Haino, Kazufumi; Takakuwa, Koichi] Niigata Univ, Med & Dent Hosp, Perinatal Intens Care Ctr, Niigata, Japan; [Kanemura, Yonehiro] Natl Hosp Org, Inst Clin Res, Div Regenerat Med, Osaka, Japan; [Kanemura, Yonehiro] Natl Hosp Org, Osaka Natl Hosp, Dept Neurosurg, Osaka, Japan; [Yamasaki, Mami] Takatsuki Gen Hosp, Dept Pediat Neurosurg, Takatsuki, Osaka, Japan	Serikawa, T (reprint author), 1-757 Asahimachi Dori,Chuo Ku, Niigata 9518510, Japan.	takehiro-s@med.niigata-u.ac.jp					Aideen M, 2013, AM J HUM GENET, V93, P515; Ascenzi MG, 2011, J THEOR BIOL, V285, P147, DOI 10.1016/j.jtbi.2011.06.016; Mill P, 2011, AM J HUM GENET, V88, P508, DOI 10.1016/j.ajhg.2011.03.015; Purohit A, 1999, J CELL BIOL, V147, P481, DOI 10.1083/jcb.147.3.481; Giansanti MG, 2001, DEVELOPMENT, V128, P1137; Chang CF, 2012, OSTEOARTHR CARTILAGE, V20, P152, DOI 10.1016/j.joca.2011.11.009; Haycraft CJ, 2007, DEVELOPMENT, V134, P307, DOI 10.1242/dev.02732; Huber C, 2012, AM J MED GENET C, V160C, P165, DOI 10.1002/ajmg.c.31336; MAJEWSKI F, 1982, AM J MED GENET, V12, P23, DOI 10.1002/ajmg.1320120104; Piane M, 2009, AM J MED GENET A, V149A, P2452, DOI 10.1002/ajmg.a.33035; Chen CM, 2012, J ELECTRON MATER, V41, P1, DOI 10.1007/s11664-011-1777-8; Isidor B, 2010, AM J HUM GENET, V87, P95, DOI 10.1016/j.ajhg.2010.05.012; Rauch A, 2008, SCIENCE, V319, P816, DOI 10.1126/science.1151174; El Hokayem J, 2012, J MED GENET, V49, P227, DOI 10.1136/jmedgenet-2011-100717; Thiel C, 2011, AM J HUM GENET, V88, P106, DOI 10.1016/j.ajhg.2010.12.004; Gunay-Aygun M, 2009, AM J MED GENET C, V151C, P296, DOI 10.1002/ajmg.c.30225; Brancati F, 2005, AM J MED GENET A, V139A, P212, DOI 10.1002/ajmg.a.31009; Zimmerman WC, 2004, MOL BIOL CELL, V15, P3642, DOI 10.1091/mbc.E03-11-0796; Griffith E, 2008, NAT GENET, V40, P232, DOI 10.1038/ng.2007.80; Bagul Yiiter A, 2012, GENET COUNSEL, V23, P231; BEEMER FA, 1983, AM J MED GENET, V14, P115, DOI 10.1002/ajmg.1320140116; BENACERRAF BR, 1993, J ULTRAS MED, V12, P552; BERNSTEIN R, 1985, J MED GENET, V22, P46, DOI 10.1136/jmg.22.1.46; Bianchi DW, 2000, FETOLOGY DIAGNOSIS M, P748; Chen CP, 2003, PRENATAL DIAG, V23, P353, DOI 10.1002/pd.574; CHEN H, 1980, AM J MED GENET, V7, P215, DOI 10.1002/ajmg.1320070214; Delaval B, 2008, SCIENCE, V319, P732, DOI 10.1126/science.1154513; Jutur Pramod Setty, 2010, Indian J Radiol Imaging, V20, P138, DOI 10.4103/0971-3026.63044; Lachman RS, 2007, TAYBI LACHMANS RADIO, P1054; Li Qingqin, 2001, Journal of Cell Science, V114, P797; MAJEWSKI F, 1971, Z KINDERHEILKD, V111, P118, DOI 10.1007/BF00446428; MAJEWSKI F, 1982, AM J MED GENET, V12, P37, DOI 10.1002/ajmg.1320120105; MAJEWSKI F, 1982, AM J MED GENET, V12, P7, DOI 10.1002/ajmg.1320120103; Reed GB, 1989, DIS FETUS NEWBORN PA; Steichen-Gersdorf E, 2008, CLIN GENET, V74, P560, DOI 10.1111/j.1399-0004.2008.01050.x; THOMSON GSM, 1982, CLIN RADIOL, V33, P509, DOI 10.1016/S0009-9260(82)80160-8; Toftager Larsen K, 1984, CLIN GENET, V26, P56; Viora E, 2002, ULTRASOUND OBST GYN, V19, P889; Wann AKT, 2012, FASEB J, V26, P1663, DOI 10.1096/fj.11-193649; Willems M, 2008, 58 ANN M AM SOC HUM, P91	40	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0914-3505	1741-4520		CONGENIT ANOM	Congenit. Anom.	NOV	2014	54	4					243	245		10.1111/cga.12066		3	Pediatrics	Pediatrics	AS6DX	WOS:000344355900008		
J	Nonaka, A; Hidaka, N; Kido, S; Fukushima, K; Kato, K				Nonaka, Ayasa; Hidaka, Nobuhiro; Kido, Saki; Fukushima, Kotaro; Kato, Kiyoko			Prenatal imaging of a fetus with the rare combination of a right congenital diaphragmatic hernia and a giant omphalocele	CONGENITAL ANOMALIES			English	Article						Gerbode-type defect; hybrid; Poland syndrome; surgery	SEPTAL-DEFECTS; DEVICE CLOSURE	Poland syndrome and Gerbode-type defect are both very rare congenital malformations. A combination of them is extremely uncommon and no literature has reported this before. We herein present a case of this combination in a 9-year-old boy. Besides the reconstruction of the chest wall, a device closure of the Gerbode-type defect was also planned due to the risk of infective endocarditis. In order to minimize the injury, an innovative hybrid therapeutic strategy was chosen to treat two anomalies simultaneously in one incision.	[Nonaka, Ayasa; Hidaka, Nobuhiro; Kido, Saki; Fukushima, Kotaro; Kato, Kiyoko] Kyushu Univ, Grad Sch Med Sci, Dept Obstet & Gynecol, Fukuoka 8128582, Japan	Hidaka, N (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Obstet & Gynecol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	hidaka.nobuhiro.484@m.kyushu-u.ac.jp					Gan CP, 2008, ANN THORAC SURG, V86, P142, DOI 10.1016/j.athoracsur.2008.03.058; GERBODE F, 1958, ANN SURG, V148, P433, DOI 10.1097/00000658-195809000-00012; Fokin AA, 2002, ANN THORAC SURG, V74, P2218, DOI 10.1016/S0003-4975(02)04161-9; Li WY, 2011, ANN THORAC SURG, V92, P2250, DOI 10.1016/j.athoracsur.2011.04.088; Collaborative of Echocardiography of Beijing Area, 2011, J CLIN ULTRASOUND ME, V13, P573; Gociniak P, 2012, KARDIOL POL, V70, P1191; Lacorte D, 2010, ITAL J PEDIATR, V36, DOI 10.1186/1824-7288-36-21; Zhu D, 2012, EUR J CARDIO-THORAC, V41, P266, DOI 10.1016/j.ejcts.2011.05.045	8	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0914-3505	1741-4520		CONGENIT ANOM	Congenit. Anom.	NOV	2014	54	4					246	249		10.1111/cga.12067		4	Pediatrics	Pediatrics	AS6DX	WOS:000344355900009		
J	Tsuchiya, M; Yamada, S				Tsuchiya, Maiko; Yamada, Shigehito			High-resolution histological 3D-imaging: Episcopic fluorescence image capture is widely applied for experimental animals	CONGENITAL ANOMALIES			English	Letter						L1CAM gene; prenatal diagnosis; silent mutation; X-linked hydrocephalus	X-LINKED HYDROCEPHALUS; L1 SYNDROME; L1CAM GENE; MUTATION	We present a case of a patient whose L1CAM gene in X-chromosome has a C924T transition. Her first son's ventriculomegaly was prenatally detected. A mature infant was born, his head circumference was large, and thumbs were bilaterally adducted. X-linked hydrocephalus (XLH) was suspected. The DNA examination revealed that both her and boy's LICAM gene had a C924T transition. She became pregnant 5 years later and amniocentesis was performed. The results of cytogenetic analysis revealed that the fetus was female. She continued her pregnancy and delivered a healthy girl. She again became pregnant 3 years later. The chromosomal analysis revealed that the fetus was male. Fetal DNA analysis determined that the fetus had the inherited mutation. She chose to terminate the pregnancy. A C924T mutation can be disease causing for XLH, and the detection of this mutation would aid in genetic counseling for the prenatal diagnosis of XLH.	[Tsuchiya, Maiko; Yamada, Shigehito] Kyoto Univ, Grad Sch Med, Congenital Anomaly Res Ctr, Kyoto 6068507, Japan; [Yamada, Shigehito] Kyoto Univ, Grad Sch Med, Kyoto 6068507, Japan	Yamada, S (reprint author), Kyoto Univ, Grad Sch Med, Kyoto 6068507, Japan.	shyamada@cac.med.kyoto-u.ac.jp					Adle-Biassette H, 2013, ACTA NEUROPATHOL, V126, P427, DOI 10.1007/s00401-013-1146-1; ROSENTHAL A, 1992, NAT GENET, V2, P107, DOI 10.1038/ng1092-107; Kanemura Y, 2006, J NEUROSURG, V105, P403, DOI 10.3171/ped.2006.105.5.403; Du YZ, 1998, J MED GENET, V35, P456, DOI 10.1136/jmg.35.6.456; Fernandez RM, 2012, AM J MED GENET A, V158A, P816, DOI 10.1002/ajmg.a.35244; Schrander-Stumpel C, 1998, EUR J PEDIATR, V157, P355, DOI 10.1007/s004310050830; Vos JY, 2010, HUM MUTAT, V31, pE1102; Yamasaki M, 2011, J NEUROSURG-PEDIATR, V8, P411, DOI 10.3171/2011.7.PEDS10531; YAMASAKI M, 1995, J NEUROSURG, V83, P50, DOI 10.3171/jns.1995.83.1.0050	9	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0914-3505	1741-4520		CONGENIT ANOM	Congenit. Anom.	NOV	2014	54	4					250	251		10.1111/cga.12069		2	Pediatrics	Pediatrics	AS6DX	WOS:000344355900010		
J	Honda, M; Mogi, M				Honda, Masashi; Mogi, Mizue			Necessity of sign language at medical support for people with a hearing disability: Providing safe and reassuring health care	CONGENITAL ANOMALIES			English	Letter						congenital diaphragmatic hernia; lung hypoplasia; omphalocele; prenatal diagnosis	CONGENITAL DIAPHRAGMATIC-HERNIA; ABDOMINAL-WALL DEFECTS; TRANSVERSE AREA RATIO; CHROMOSOMAL-ANOMALIES; PROGNOSTIC VALUE; LIVER POSITION; MALFORMATIONS; OMPHALOCELE; SURVIVAL; HYPOPLASIA	A co-existing right congenital diaphragmatic hernia and omphalocele is rare. We present images of a fetus diagnosed with this rare combination of anomalies. Early neonatal death occurred immediately after full-term birth due to severe respiratory insufficiency. In this case, disturbance of chest wall development due to the omphalocele rather than the diaphragmatic hernia was considered as the main cause of lung hypoplasia. Our experience suggests that caution should be exercised for severe respiratory insufficiency in a neonate with an omphalocele and diaphragmatic hernia, even in the absence of an intra-thoracic liver, one of the indicators of poor outcome for congenital diaphragmatic hernia.	[Honda, Masashi] Shiseikai Daini Hosp, Med Support Hearing Disabil, Tokyo, Japan; [Mogi, Mizue] Shiseikai Daini Hosp, Diabet Dept, Tokyo, Japan	Honda, M (reprint author), Med Support Hearing Disabil, Setagaya Ku, 6-16-12-202 Seijo, Tokyo 1570066, Japan.	mashonda@chime.ocn.ne.jp					Albanese CT, 1998, PRENATAL DIAG, V18, P1138, DOI 10.1002/(SICI)1097-0223(199811)18:11<1138::AID-PD416>3.0.CO;2-A; Cohen MS, 2002, J PEDIATR-US, V141, P25, DOI 10.1067/mpd.2002.125004; Witters I, 2001, AM J MED GENET, V103, P278; Yang W, 2006, BIRTH DEFECTS RES A, V76, P170, DOI 10.1002/bdra.20230; Laudy JAM, 2003, PRENATAL DIAG, V23, P634, DOI 10.1002/pd.654; Hedrick HL, 2004, J PEDIATR SURG, V39, P319, DOI 10.1016/j.jpedsurg.2003.11.006; Bedoyan JK, 2004, PEDIATR SURG INT, V20, P170, DOI 10.1007/s00383-004-1138-2; Borys D, 2004, PEDIATR DEVEL PATHOL, V7, P35, DOI 10.1007/s10024-003-2133-7; CHITKARA U, 1987, AM J OBSTET GYNECOL, V156, P1069; Danzer E, 2012, J PEDIATR SURG, V47, P1811, DOI 10.1016/j.jpedsurg.2012.06.006; Danzer E, 2012, FETAL DIAGN THER, V31, P248, DOI 10.1159/000334284; Flake A W, 1996, Semin Pediatr Surg, V5, P266; Graziano JN, 2005, J PEDIATR SURG, V40, P1045, DOI 10.1016/j.jpedsurg.2005.03.025; Harmath A, 2006, AM J MED GENET A, V140A, P2298, DOI 10.1002/ajmg.a.31470; HASEGAWA T, 1990, J CLIN ULTRASOUND, V18, P705; HERSHENSON MB, 1985, J PEDIATR SURG, V20, P348, DOI 10.1016/S0022-3468(85)80217-7; Hidaka N, 2009, J PERINAT MED, V37, P66, DOI 10.1515/JPM.2009.019; Kitano Y, 2005, J PEDIATR SURG, V40, P1827, DOI 10.1016/j.jpedsurg.2005.08.020; Menon SC, 2013, J PEDIATR-US, V162, P114, DOI 10.1016/j.jpeds.2012.06.048; Nakata M, 2003, EARLY HUM DEV, V72, P75, DOI 10.1016/S0378-3782(03)00026-4; NISHIMURA M, 1992, CHEST, V101, P263, DOI 10.1378/chest.101.1.263; Scahill MD, 2013, AM J MED GENET A, V161A, P585, DOI 10.1002/ajmg.a.35703; Skari H, 2000, J PEDIATR SURG, V35, P1187, DOI 10.1053/jpsu.2000.8725; SWEED Y, 1993, ARCH DIS CHILD, V69, P68; THOMPSON PJ, 1993, J PEDIATR SURG, V28, P664, DOI 10.1016/0022-3468(93)90026-H; Tonks A, 2004, PRENATAL DIAG, V24, P596, DOI 10.1002/pd.908; Tsukimori K, 2008, J ULTRAS MED, V27, P707; Usui N, 2011, PEDIATR SURG INT, V27, P39, DOI 10.1007/s00383-010-2725-z	28	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0914-3505	1741-4520		CONGENIT ANOM	Congenit. Anom.	NOV	2014	54	4					252	252		10.1111/cga.12075		1	Pediatrics	Pediatrics	AS6DX	WOS:000344355900011		
J	Amagai, M				Amagai, Masayuki			The Three Musketeers of the Epidermal Barrier and Atopic Diseases	CORNEA			English	Article						skin barrier; atopic dermatitis; stratum corneum; tight junction; dendritic cells			Keio Univ, Sch Med, Dept Dermatol, Tokyo, Japan	Amagai, M (reprint author), Keio Univ, Sch Med, Dept Dermatol, Tokyo, Japan.		Amagai, Masayuki/K-5325-2013		Health and Labour Sciences Research Grant for Research on Allergic Disease and Immunology from the Ministry of Health, Labour and Welfare, Japan; Ministry of Education, Culture, Sports, Science and Technology, Japan	Supported by a Health and Labour Sciences Research Grant for Research on Allergic Disease and Immunology from the Ministry of Health, Labour and Welfare, Japan, and Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology, Japan.		0	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0277-3740	1536-4798		CORNEA	Cornea	NOV	2014	33			1			S9	S9		10.1097/ICO.0000000000000231		1	Ophthalmology	Ophthalmology	AS5ZD	WOS:000344344000003		
J	Ibrahim, OMA; Dogru, M; Kaido, M; Kojima, T; Fujishima, H; Tsubota, K				Ibrahim, Osama M. A.; Dogru, Murat; Kaido, Minako; Kojima, Takashi; Fujishima, Hiroshi; Tsubota, Kazuo			Functional Visual Acuity Assessment of Severe Atopic Keratoconjunctivitis	CORNEA			English	Article						atopic keratoconjunctivitis; visual acuity; eye drop treatment	TOPICAL CYCLOSPORINE-A; STEVENS-JOHNSON-SYNDROME; ALLERGIC CONJUNCTIVITIS; DRY EYE; OCULAR COMPLICATIONS; CONTROLLED-TRIAL; DERMATITIS; EFFICACY	Purpose:To evaluate changes in functional visual acuity (FVA) measurements before and after treatment with 0.1% cyclosporine ophthalmic solution for 3 months in patients with severe atopic keratoconjunctivitis (AKC).Methods:Pairs of eyes were analyzed from 3 boys (mean age 9 3.6 years) who complained of having severe AKC and were recruited for the study. Conventional Landolt visual acuity, FVA, and visual maintenance ratio (VMR) measurements were conducted before and after 3 months of 0.1% cyclosporine eye drop treatment. Tear film lipid layer interferometry, tear film break-up time, fluorescein and rose bengal vital stainings, and the Schirmer test were also performed before and after treatment.Results:Eye drop treatment was associated not only with improvement of tear function and ocular surface status but also with better quality of visual function. The mean logarithm of the minimum angle of resolution FVA and Landolt visual acuity values improved from 0.45 +/- 0.26 and 0.13 +/- 0.17 before treatment to 0.16 +/- 0.03 and -0.06 +/- 0.05 after treatment, respectively. Similarly, the mean VMR values were markedly improved from 0.88 +/- 0.06 to 0.95 +/- 0.03 after treatment.Conclusions:FVA and VMR are promising parameters in the assessment of dynamic visual acuity changes in AKC-affected patients and evaluation of treatment outcome.	[Ibrahim, Osama M. A.; Dogru, Murat; Kaido, Minako; Kojima, Takashi; Tsubota, Kazuo] Keio Univ, Sch Med, Dept Ophthalmol, Tokyo 1608582, Japan; [Dogru, Murat] Tokyo Dent Coll, Dept Ophthalmol, Ichikawa, Japan; [Fujishima, Hiroshi] Tsurumi Univ, Dept Ophthalmol, Sch Dent Med, Yokohama, Kanagawa, Japan	Dogru, M (reprint author), Keio Univ, Sch Med, Shinjuku Ku, Shinanomachi 35, Tokyo 1608582, Japan.	muratodooru2012@yahoo.com			Johnson and Johnson (J&J) Vision Care Company	Supported by a grant from Johnson and Johnson (J&J) Vision Care Company for conducting research. J&J was not involved with the scientific content of this research project and did not pay any fees to the authors, nor did it employ them.	Hingorani M, 1999, INVEST OPHTH VIS SCI, V40, P392; Kaido M, 2007, CORNEA, V26, pS29, DOI 10.1097/ICO.0b013e31812f6913; FOSTER CS, 1990, OPHTHALMOLOGY, V97, P992; RICH LF, 1985, INT OPHTHALMOL CLIN, V25, P61, DOI 10.1097/00004397-198502510-00005; Yokoi N, 1996, AM J OPHTHALMOL, V122, P818; Hingorani M, 1998, OPHTHALMOLOGY, V105, P1715, DOI 10.1016/S0161-6420(98)99043-1; COHEN DJ, 1984, ANN INTERN MED, V101, P667; Goto E, 2002, AM J OPHTHALMOL, V133, P181, DOI 10.1016/S0002-9394(01)01365-4; Kaido M, 2006, AM J OPHTHALMOL, V142, P917, DOI 10.1016/j.ajo.2006.07.055; Cetinkaya A, 2004, CORNEA, V23, P194; Liu ZG, 1999, OPHTHALMOLOGY, V106, P939, DOI 10.1016/S0161-6420(99)00513-8; BRAUDE L S, 1984, International Ophthalmology Clinics, V24, P145, DOI 10.1097/00004397-198402420-00013; Daniell M, 2006, BRIT J OPHTHALMOL, V90, P461, DOI 10.1136/bjo.2005.082461; EASTY D, 1975, T OPHTHAL SOC UK, V95, P267; Ebihara N, 2009, J OCUL PHARMACOL TH, V25, P365, DOI 10.1089/jop.2008.0103; Fujishima H, 1996, OPHTHALMOLOGICA, V210, P115; GARRITY JA, 1984, CAN J OPHTHALMOL, V19, P21; HOGAN MJ, 1953, AM J OPHTHALMOL, V36, P937; Ishida R, 2005, AM J OPHTHALMOL, V139, P253, DOI 10.1016/j.ajo.2004.08.075; Kaido M, 2011, JPN J OPHTHALMOL, V55, P451, DOI 10.1007/s10384-011-0049-8; Kaido M, 2012, AM J OPHTHALMOL, V154, P499, DOI 10.1016/j.ajo.2012.03.044; Kaido M, 2008, OPTOMETRY VISION SCI, V85, P758, DOI 10.1097/OPX.0b013e3181819f0a; Spadavecchia L, 2006, PEDIATR ALLERGY IMMU, V17, P527, DOI 10.1111/j.1399-3038.2006.00427.x; Stumpf T, 2006, CORNEA, V25, P1147, DOI 10.1097/01.ico.0000240091.11854.14; Suzuki S, 2006, CORNEA, V25, P277, DOI 10.1097/01.ico.0000178277.29010.bc; TODA I, 1993, CORNEA, V12, P366, DOI 10.1097/00003226-199307000-00015; Yamaguchi T, 2011, CURR OPIN OPHTHALMOL, V22, P31, DOI 10.1097/ICU.0b013e3283414f36	27	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0277-3740	1536-4798		CORNEA	Cornea	NOV	2014	33			1			S13	S18		10.1097/ICO.0000000000000245		6	Ophthalmology	Ophthalmology	AS5ZD	WOS:000344344000007		
J	Inoue, Y				Inoue, Yoshitsugu			Review of Clinical and Basic Approaches to Corneal Endotheliitis	CORNEA			English	Article						corneal endotheliitis; herpes simplex virus; cytomegalovirus; immortalized human corneal endothelial cells; toll-like receptor 9	HERPES-SIMPLEX-VIRUS; CYTOMEGALOVIRUS ANTERIOR UVEITIS; LASER CONFOCAL MICROSCOPY; IMMUNOCOMPETENT PATIENTS; KERATITIS; EYE; ENDOTHELIOPATHY; INFECTION; FEATURES; CELLS	Corneal endotheliitis was first reported as an autoimmune disease by Khodadoust in 1982. Thereafter, herpes simplex virus (HSV) was detected as a causative agent, and corneal endotheliitis was classified as an infectious disease. However, most primary corneal endotheliitis had been idiopathic. In 2006, cytomegalovirus (CMV) DNA was detected in a case of corneal endotheliitis, and other reports on CMV endotheliitis from Asian countries established it as a new clinical entity. Limited studies have reported clinical findings, and the pathogenesis of HSV and CMV corneal endotheliitis is unknown. Therefore, this review describes what is currently known about the pathogenesis of HSV and CMV endotheliitis by way of previously reported case studies and basic research. In addition, we review work by our own group regarding the role of Toll-like receptor 9 and the results of transcriptome analysis after HSV infection in an in vitro model using immortalized human corneal endothelial cells. It is critical to diagnose corneal endotheliitis early to provide effective treatment with ganciclovir or valganciclovir and prevent the loss of corneal endothelial cells. Therefore, we hope that these in vitro results may provide further information to help elucidate the in vivo pathogenesis of HSV and CMV endotheliitis.	Tottori Univ, Div Ophthalmol & Visual Sci, Fac Med, Yonago, Tottori 6838504, Japan	Inoue, Y (reprint author), Tottori Univ, Div Ophthalmol & Visual Sci, Fac Med, 36-1 Nishi Cho, Yonago, Tottori 6838504, Japan.	yoinoue@grape.med.tottori-u.ac.jp			Japanese Ministry of Education, Culture, Sports, Science and Technology [25462755]	Supported by Grant-in-Aid 25462755 for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology.	Amano S, 1999, AM J OPHTHALMOL, V127, P721, DOI 10.1016/S0002-9394(99)00018-5; OHASHI Y, 1991, AM J OPHTHALMOL, V112, P419; Kandori M, 2013, JPN J OPHTHALMOL, V57, P497, DOI 10.1007/s10384-013-0268-2; Chee SP, 2008, AM J OPHTHALMOL, V145, P834, DOI 10.1016/j.ajo.2007.12.015; Miyazaki D, 2011, INVEST OPHTH VIS SCI, V52, P4282, DOI 10.1167/iovs.10-6911; Kobayashi A, 2012, AM J OPHTHALMOL, V153, P445, DOI 10.1016/j.ajo.2011.07.026; van Boxtel LAA, 2007, OPHTHALMOLOGY, V114, P1358, DOI 10.1016/j.ophtha.2006.09.035; Koizumi N, 2008, OPHTHALMOLOGY, V115, P292, DOI 10.1016/j.ophtha.2007.04.053; Takeda S, 2011, INVEST OPHTH VIS SCI, V52, P6729, DOI 10.1167/iovs.11-7805; HOLBACH LM, 1990, OPHTHALMOLOGY, V97, P722; VANNAS A, 1983, ARCH OPHTHALMOL-CHIC, V101, P913; Holland EJ, 1999, CORNEA, V18, P144, DOI 10.1097/00003226-199903000-00002; Liesegang TJ, 1999, CORNEA, V18, P127, DOI 10.1097/00003226-199903000-00001; Yokogawa H, 2013, JPN J OPHTHALMOL, V57, P80, DOI 10.1007/s10384-012-0189-5; Koizumi N, 2006, AM J OPHTHALMOL, V141, P564, DOI 10.1016/j.ajo.2005.09.021; Chen X, 2006, IMMUNOL LETT, V107, P140, DOI 10.1016/j.imlet.2006.08.006; Markomichelakis NN, 2002, OPHTHALMOLOGY, V109, P879, DOI 10.1016/S0161-6420(02)00961-2; Miyanaga M, 2010, BRIT J OPHTHALMOL, V94, P336, DOI 10.1136/bjo.2008.156422; Chee SP, 2007, OPHTHALMOLOGY, V114, P798, DOI 10.1016/j.ophtha.2006.07.057; de Schryver I, 2006, BRIT J OPHTHALMOL, V90, P852, DOI 10.1136/bjo.2005.086546; Holbach LM, 1998, AM J OPHTHALMOL, V126, P592, DOI 10.1016/S0002-9394(98)00121-4; Kandori M, 2010, OPHTHALMOLOGY, V117, P216, DOI 10.1016/j.ophtha.2009.06.059; KHODADOUST AA, 1982, AM J OPHTHALMOL, V93, P718; Mimura T, 2002, AM J OPHTHALMOL, V133, P699, DOI 10.1016/S0002-9394(02)01410-1; OHASHI Y, 1985, ARCH OPHTHALMOL-CHIC, V103, P1666; ROBIN JB, 1985, AM J OPHTHALMOL, V100, P336; Shiraishi A, 2007, AM J OPHTHALMOL, V143, P715, DOI 10.1016/j.ajo.2006.11.026; Streilein JW, 1996, INVEST OPHTH VIS SCI, V37, P1940; SUNDMACHER R, 1979, KLIN MONATSBL AUGENH, V175, P488; Suzuki T, 2007, CORNEA, V26, P370, DOI 10.1097/ICO.0b013e31802d82fa; Zheng Xiaodong, 2002, International Ophthalmology Clinics, V42, P151; Zheng XD, 2000, INVEST OPHTH VIS SCI, V41, P377	32	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0277-3740	1536-4798		CORNEA	Cornea	NOV	2014	33			1			S3	S8		10.1097/ICO.0000000000000228		6	Ophthalmology	Ophthalmology	AS5ZD	WOS:000344344000002		
J	Ishida, W; Fukuda, K; Harada, Y; Yagita, H; Fukushima, A				Ishida, Waka; Fukuda, Ken; Harada, Yosuke; Yagita, Hideo; Fukushima, Atsuki			Oral Immunotherapy for Allergic Conjunctivitis	CORNEA			English	Article						allergic conjunctivitis; oral tolerance; transgenic rice	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MYELIN BASIC-PROTEIN; GROWTH-FACTOR-BETA; T-CELLS; UP-REGULATION; MURINE MODEL; TOLERANCE; INDUCTION; SUPPRESSION; DISEASES	Antigen-specific immunotherapy is expected to be a desirable treatment for allergic diseases. Currently, antigen-specific immunotherapy is performed by administering disease-causing antigens subcutaneously or sublingually. These approaches induce long-term remission in patients with allergic rhinitis or asthma. The oral route is an alternative to subcutaneous and sublingual routes, and can also induce long-term remission, a phenomenon known as oral tolerance. The effectiveness of oral tolerance has been reported in the context of autoimmune diseases, food allergies, asthma, atopic dermatitis, and allergic rhinitis in both human patients and animal models. However, few studies have examined its efficacy in animal models of allergic conjunctivitis. Previously, we showed that ovalbumin feeding suppressed ovalbumin-induced experimental allergic conjunctivitis, indicating the induction of oral tolerance is effective in treating experimental allergic conjunctivitis. In recent years, transgenic rice has been developed that can induce oral tolerance and reduce the severity of anaphylaxis. The major Japanese cedar pollen antigens in transgenic rice, Cryptomeria japonica 1 and C. japonica 2, were deconstructed by molecular shuffling, fragmentation, and changes in the oligomeric structure. Thus, transgenic rice may be an effective treatment for allergic conjunctivitis.	[Ishida, Waka; Fukuda, Ken; Harada, Yosuke; Fukushima, Atsuki] Kochi Med Sch, Dept Ophthalmol, Nankoku, Kochi 7838505, Japan; [Yagita, Hideo] Juntendo Univ, Sch Med, Dept Immunol, Tokyo 113, Japan	Fukushima, A (reprint author), Kochi Med Sch, Dept Ophthalmol, Oko Cho, Nankoku, Kochi 7838505, Japan.	fukusima@kochi-u.ac.jp			Kyoto Cornea Club	A. Fukushima has received payment as a board member for Kyoto Cornea Club. The other authors have no funding or conflicts of interest to disclose.	Galli SJ, 2008, NATURE, V454, P445, DOI 10.1038/nature07204; Calderon MA, 2012, ALLERGY, V67, P302, DOI 10.1111/j.1398-9995.2011.02761.x; Wakasa Y, 2013, PLANT BIOTECHNOL J, V11, P66, DOI 10.1111/pbi.12007; CHEN YH, 1995, NATURE, V376, P177, DOI 10.1038/376177a0; Valenta R, 2012, J INTERN MED, V272, P144, DOI 10.1111/j.1365-2796.2012.02556.x; Faria AMC, 2003, J AUTOIMMUN, V20, P135, DOI 10.1016/S0896-8411(02)00112-9; HIGGINS PJ, 1988, J IMMUNOL, V140, P440; Vickery BP, 2009, CURR OPIN ALLERGY CL, V9, P364, DOI 10.1097/ACI.0b013e32832d9add; Nakamura K, 2001, J EXP MED, V194, P629, DOI 10.1084/jem.194.5.629; Mayer L, 2004, NAT REV IMMUNOL, V4, P407, DOI 10.1038/nri1370; Brozek JL, 2012, CLIN EXP ALLERGY, V42, P363, DOI 10.1111/j.1365-2222.2011.03948.x; Ishida W, 2013, BRIT J OPHTHALMOL, V97, P492, DOI 10.1136/bjophthalmol-2012-302639; Fukaura H, 1996, J CLIN INVEST, V98, P70, DOI 10.1172/JCI118779; Russo M, 2001, AM J RESP CELL MOL, V24, P518; Chung Y, 2002, IMMUNOBIOLOGY, V206, P408, DOI 10.1078/0171-2985-00190; Jacobsen L, 2007, ALLERGY, V62, P943, DOI 10.1111/j.1398-9995.2007.01451.x; Faria AMC, 2005, IMMUNOL REV, V206, P232, DOI 10.1111/j.0105-2896.2005.00280.x; Bielory Leonard, 2002, Expert Opin Pharmacother, V3, P541, DOI 10.1517/14656566.3.5.541; FRIEDLAENDER MH, 1992, JAMA-J AM MED ASSOC, V268, P2869, DOI 10.1001/jama.268.20.2869; JAVED NH, 1995, J IMMUNOL, V155, P1599; KHOURY SJ, 1992, J EXP MED, V176, P1355, DOI 10.1084/jem.176.5.1355; Kim SJ, 2013, AM J RHINOL ALLERGY, V27, pE11, DOI 10.2500/ajra.2013.27.3853; Koizumi Toshiki, 1995, Nippon Ganka Gakkai Zasshi, V99, P515; Min SY, 2004, ARTHRITIS RES THER, V6, pR213, DOI 10.1186/ar1169; Nelson HS, 2006, J ALLERGY CLIN IMMUN, V117, P1047, DOI 10.1016/j.jaci.2005.12.1306; Noon L, 1911, LANCET, V1, P1572; Nussenblatt RB, 1997, AM J OPHTHALMOL, V123, P583; NUSSENBLATT RB, 1990, J IMMUNOL, V144, P1689; Pajno GB, 2011, ANN ALLERG ASTHMA IM, V107, P395, DOI 10.1016/j.anai.2011.04.011; Torseth JW, 1998, CLIN IMMUNOL IMMUNOP, V88, P297, DOI 10.1006/clin.1998.4592; WEINER HL, 1994, P NATL ACAD SCI USA, V91, P10762, DOI 10.1073/pnas.91.23.10762; WHITACRE CC, 1991, J IMMUNOL, V147, P2155; Zemann B, 2003, J ALLERGY CLIN IMMUN, V111, P1069, DOI 10.1067/mai.2003.1411	33	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0277-3740	1536-4798		CORNEA	Cornea	NOV	2014	33			1			S32	S36		10.1097/ICO.0000000000000241		5	Ophthalmology	Ophthalmology	AS5ZD	WOS:000344344000010		
J	Koizumi, N; Okumura, N; Ueno, M; Kinoshita, S				Koizumi, Noriko; Okumura, Naoki; Ueno, Morio; Kinoshita, Shigeru			New Therapeutic Modality for Corneal Endothelial Disease Using Rho-Associated Kinase Inhibitor Eye Drops	CORNEA			English	Article						corneal endothelial cells; proliferation; Rho kinase (ROCK) inhibitor; corneal endothelial dysfunction; Fuchs corneal dystrophy	ROCK INHIBITOR; CELLS; KERATOPLASTY; PRIMATE; GTPASES; TRANSPLANTATION; PROLIFERATION; ENHANCEMENT; SURVIVAL; DONORS	Corneal endothelial dysfunction accompanied by visual disturbance is a primary indication for corneal endothelial transplantation. However, despite the value and potential of endothelial graft surgery, a strictly pharmacological approach for treating corneal endothelial dysfunction remains an attractive proposition. Previously, we reported that the selective Rho-associated kinase (ROCK) inhibitor Y-27632 promotes cell adhesion and proliferation, and inhibits the apoptosis of primate corneal endothelial cells in culture. These findings have led us to develop a novel medical treatment for the early phase of corneal endothelial disease using ROCK inhibitor eye drops. In rabbit and monkey models of partial endothelial dysfunction, we showed that corneal endothelial wound healing was accelerated via the topical application of ROCK inhibitor to the ocular surface, resulting in the regeneration of a corneal endothelial monolayer with a high endothelial cell density. Based on these animal studies, we are now attempting to advance the clinical application of ROCK inhibitor eye drops for patients with corneal endothelial dysfunction. A pilot clinical study was performed at the Kyoto Prefectural University of Medicine, and the effects of Y-27632 eye drops after transcorneal freezing were evaluated in 8 patients with corneal endothelial dysfunction. We observed a positive effect of ROCK inhibitor eye drops in treating patients with central edema caused by Fuchs corneal endothelial dystrophy. We believe that our new findings will contribute to the establishment of a new approach for the treatment of corneal endothelial dysfunction.	[Koizumi, Noriko; Okumura, Naoki] Doshisha Univ, Dept Biomed Engn, Fac Life & Med Sci, Kyotanabe 6100321, Japan; [Koizumi, Noriko; Okumura, Naoki; Ueno, Morio; Kinoshita, Shigeru] Kyoto Prefectural Univ Med, Dept Ophthalmol, Kyoto, Japan	Koizumi, N (reprint author), Doshisha Univ, Dept Biomed Engn, Fac Life & Med Sci, Kyotanabe 6100321, Japan.	nkoizumi@mail.doshisha.ac.jp			Adaptable and Seamless Technology Transfer Program through Target-Driven R&D from the Japan Science and Technology Agency [AS2314212G]; Funding Program for Next Generation World-Leading Researchers from the Cabinet Office in Japan [LS117]	Supported in part by the Adaptable and Seamless Technology Transfer Program through Target-Driven R&D (S. Kinoshita, N. Okumura, M. Ueno, and N. Koizumi: AS2314212G) from the Japan Science and Technology Agency, and the Funding Program for Next Generation World-Leading Researchers from the Cabinet Office in Japan (N. Koizumi: LS117).	Coleman ML, 2004, NAT REV MOL CELL BIO, V5, P355, DOI 10.1038/nrm1365; Okumura N, 2013, INVEST OPHTH VIS SCI, V54, P2493, DOI 10.1167/iovs.12-11320; Okumura N, 2014, INVEST OPHTH VIS SCI, V55, P318, DOI 10.1167/iovs.13-12225; Watanabe K, 2007, NAT BIOTECHNOL, V25, P681, DOI 10.1038/nbt1310; Miyata K, 2001, CORNEA, V20, P59, DOI 10.1097/00003226-200101000-00012; Koizumi N, 2007, INVEST OPHTH VIS SCI, V48, P4519, DOI 10.1167/iovs.07-0567; Riento K, 2003, NAT REV MOL CELL BIO, V4, P446, DOI 10.1038/nrm1128; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Terry MA, 2008, OPHTHALMOLOGY, V115, P488, DOI 10.1016/j.ophtha.2007.10.035; Okumura N, 2009, INVEST OPHTH VIS SCI, V50, P3680, DOI 10.1167/iovs.08-2634; Okumura N, 2012, AM J PATHOL, V181, P268, DOI 10.1016/j.ajpath.2012.03.033; Senoo T, 2000, INVEST OPHTH VIS SCI, V41, P660; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Melles GRJ, 2006, CORNEA, V25, P987; Gorovoy MS, 2006, CORNEA, V25, P886, DOI 10.1097/01.ico.0000214224.90743.01; Joyce NC, 2003, PROG RETIN EYE RES, V22, P359, DOI 10.1016/S1350-9462(02)00065-4; Okumura N, 2011, BRIT J OPHTHALMOL, V95, P1006, DOI 10.1136/bjo.2010.194571; Koizumi N, 2012, EXP EYE RES, V95, P60, DOI 10.1016/j.exer.2011.10.014; Hirata-Tominaga K, 2013, STEM CELLS, V31, P1396, DOI 10.1002/stem.1390; Mimura T, 2006, INVEST OPHTH VIS SCI, V47, P1387, DOI 10.1167/iovs.05-1199; Koizumi N, 2013, CORNEA, V32, P1167, DOI 10.1097/ICO.0b013e318285475d; Price MO, 2011, OPHTHALMOLOGY, V118, P725, DOI 10.1016/j.ophtha.2010.08.012; Price FW, 2005, J REFRACT SURG, V21, P339; ENGELMANN K, 1988, INVEST OPHTH VIS SCI, V29, P1656; Koizumi N, 2013, INVEST OPHTH VIS SCI, V54, P5594, DOI 10.1167/iovs.13-12813; Koizumi N, 2008, CORNEA, V27, pS48, DOI 10.1097/ICO.0b013e31817f2298; Nakahara M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069009; Okumura N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058000; Pipparelli A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062095; Zhu C, 2004, INVEST OPHTH VIS SCI, V45, P1743, DOI 10.1167/iovs-030814	30	4	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0277-3740	1536-4798		CORNEA	Cornea	NOV	2014	33			1			S25	S31		10.1097/ICO.0000000000000240		7	Ophthalmology	Ophthalmology	AS5ZD	WOS:000344344000009		
J	Oie, Y; Nishida, K				Oie, Yoshinori; Nishida, Kohji			Translational Research on Ocular Surface Reconstruction Using Oral Mucosal Epithelial Cell Sheets	CORNEA			English	Article						ocular surface reconstruction; oral mucosal epithelial cell sheets; translational research	HUMAN CORNEAL EPITHELIUM; LIMBAL STEM-CELLS; CONJUNCTIVAL EPITHELIUM; STEM/PROGENITOR CELLS; CULTURED LIMBAL; EX-VIVO; TRANSPLANTATION; EXPRESSION; DISORDERS; IDENTIFICATION	Ocular surface reconstruction using autologous oral mucosal epithelial cell sheets has drastically changed the treatment of limbal stem-cell deficiency. The morphological and functional characteristics of oral mucosal epithelial cell sheets are similar to those of normal corneal epithelium. Ocular surface reconstruction can prevent potential problems associated with limbal transplantation, including immune rejection and donor tissue shortages. Thus far, ocular reconstruction using epithelial cell sheets has been limited to clinical research. Although the effectiveness and safety of this surgical approach have been confirmed to some extent, efforts to make its use more widespread are required. Translational research refers to the process of developing a new treatment based on basic research findings with useful practical applications in the field of health care. Medical centers for translational research are required to promote translational research in academic institutes. The Pharmaceutical Affairs Law was revised to promote technologies in the field of regenerative medicine in Japan. This article reviews translational research of ocular surface reconstruction using oral mucosal epithelial cell sheets.	[Oie, Yoshinori; Nishida, Kohji] Osaka Univ, Grad Sch Med, Dept Ophthalmol, Suita, Osaka 5650871, Japan	Oie, Y (reprint author), Osaka Univ, Grad Sch Med, Dept Ophthalmol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	yoie@ophthal.med.osaka-u.ac.jp			Translational Research Network Program from the Ministry of Education, Culture, Sports, Science and Technology, Japan; Otsuka Pharmaceutical Co; Santen Pharmaceutical Co; Alcon; Ministry of Health, Labour, and Welfare, Japan; Japanese Society for the Promotion of Science; New Energy and Industrial Technology Development Organization; Ministry of Education, Culture, Sports, Science and Technology, Japan; Hoya Corporation; Wakamoto Pharmaceutical Co; MSD; Novartis; Menicon; Kowa Company; Abbot Medical Optics; Johnson Johnson; Senju Pharmaceutical Co; Pfizer; Takeda Pharmaceutical Company	Supported by the Translational Research Network Program from the Ministry of Education, Culture, Sports, Science and Technology, Japan.; Y. Oie has received payment for lecturing from Otsuka Pharmaceutical Co, Santen Pharmaceutical Co, and Alcon. K. Nishida has received grants from the Ministry of Health, Labour, and Welfare, Japan, the Japanese Society for the Promotion of Science, the New Energy and Industrial Technology Development Organization, the Ministry of Education, Culture, Sports, Science and Technology, Japan, Hoya Corporation, Wakamoto Pharmaceutical Co, Otsuka Pharmaceutical Co, MSD, Novartis, Santen Pharmaceutical Co, Alcon, Menicon, and Kowa Company; and payment for lectures including service on speakers bureaus and travel/accommodations/meeting expenses from Hoya Corporation, Abbot Medical Optics, Otsuka Pharmaceutical Co, Santen Pharmaceutical Co, Johnson & Johnson, Senju Pharmaceutical Co, Pfizer, Alcon, Takeda Pharmaceutical Company, Wakamoto Pharmaceutical Co, and Novartis.	Hayashi R, 2008, BIOCHEM BIOPH RES CO, V367, P256, DOI 10.1016/j.bbrc.2007.12.077; Shimazaki J, 2000, OPHTHALMOLOGY, V107, P1518, DOI 10.1016/S0161-6420(00)00214-1; Tsai RJ, 2000, NEW ENGL J MED, V343, P86, DOI 10.1056/NEJM200007133430202; Gipson IK, 2004, EXP EYE RES, V78, P379, DOI 10.1016/S0014-4835(03)00204-5; Nishida K, 2004, TRANSPLANTATION, V77, P379, DOI 10.1097/01.TP.0000110320.45678.30; Nishida K, 2004, NEW ENGL J MED, V351, P1187, DOI 10.1056/NEJMoa040455; SCHERMER A, 1986, J CELL BIOL, V103, P49, DOI 10.1083/jcb.103.1.49; OKANO T, 1993, J BIOMED MATER RES, V27, P1243, DOI 10.1002/jbm.820271005; Tsubota K, 1999, NEW ENGL J MED, V340, P1697, DOI 10.1056/NEJM199906033402201; Koizumi N, 2001, OPHTHALMOLOGY, V108, P1569, DOI 10.1016/S0161-6420(01)00694-7; Nakamura T, 2004, BRIT J OPHTHALMOL, V88, P1280, DOI 10.1136/bjo.2003.038497; Pellegrini G, 1997, LANCET, V349, P990, DOI 10.1016/S0140-6736(96)11188-0; LINDBERG K, 1993, INVEST OPHTH VIS SCI, V34, P2672; Watanabe K, 2004, FEBS LETT, V565, P6, DOI 10.1016/j.febslet.2004.03.064; Schwab IR, 2000, CORNEA, V19, P421, DOI 10.1097/00003226-200007000-00003; Nishida K, 2003, CORNEA, V22, pS28, DOI 10.1097/00003226-200310001-00005; Rama P, 2001, TRANSPLANTATION, V72, P1478, DOI 10.1097/00007890-200111150-00002; Ban Y, 2003, EXP EYE RES, V76, P663, DOI 10.1016/S0014-4835(03)00054-X; Satake Y, 2011, OPHTHALMOLOGY, V118, P1524, DOI 10.1016/j.ophtha.2011.01.039; Shiraishi A, 1998, INVEST OPHTH VIS SCI, V39, P2554; Nakamura T, 2011, BRIT J OPHTHALMOL, V95, P942, DOI 10.1136/bjo.2010.188714; Pellegrini G, 2009, J PATHOL, V217, P217, DOI 10.1002/path.2441; KENYON KR, 1989, OPHTHALMOLOGY, V96, P709; Hayashi R, 2007, STEM CELLS, V25, P289, DOI 10.1634/stemcells.2006-0167; Sangwan VS, 2003, CORNEA, V22, P478, DOI 10.1097/00003226-200307000-00016; Rama P, 2010, NEW ENGL J MED, V363, P147, DOI 10.1056/NEJMoa0905955; Hayashida Y, 2005, INVEST OPHTH VIS SCI, V46, P1632, DOI 10.1167/iovs.04-0813; Tan DTH, 2012, LANCET, V379, P1749, DOI 10.1016/S0140-6736(12)60437-1; COTSARELIS G, 1989, CELL, V57, P201, DOI 10.1016/0092-8674(89)90958-6; EBATO B, 1988, INVEST OPHTH VIS SCI, V29, P1533; Kenyon K.R., 1989, OPHTHALMOLOGY, V96, P722; Oie Y, 2014, TISSUE ENG PART C-ME, V20, P373, DOI [10.1089/ten.TEC.2013.0266, 10.1089/ten.tec.2013.0266]; Oie Y, 2013, BIOMED RES INT, V2013; Ryan Stephen J, 2005, Retina, V25, pS82, DOI 10.1097/00006982-200512001-00039; Schlotzer-Schrehardt U, 2005, EXP EYE RES, V81, P247, DOI 10.1016/j.exer.2005.02.016; Wagner RT, 2010, TRANSL RES, V156, P169, DOI 10.1016/j.trsl.2010.06.005; Yoshida Y, 2009, INVEST OPHTH VIS SCI, V50, P2103, DOI 10.1167/iovs.08-3046	37	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0277-3740	1536-4798		CORNEA	Cornea	NOV	2014	33			1			S47	S52		10.1097/ICO.0000000000000232		6	Ophthalmology	Ophthalmology	AS5ZD	WOS:000344344000013		
J	Okumura, N; Kinoshita, S; Koizumi, N				Okumura, Naoki; Kinoshita, Shigeru; Koizumi, Noriko			Cell-Based Approach for Treatment of Corneal Endothelial Dysfunction	CORNEA			English	Article						corneal transplantation; corneal endothelial cells; Rho-kinase inhibitor; corneal endothelial dysfunction	ROCK INHIBITOR; TRANSPLANTATION; PROLIFERATION; MODEL; MEMBRANE; SHEET	Decompensation of the corneal endothelium causes severe visual impairments that lead to blindness. Although corneal transplantation is a well-known effective therapy for corneal endothelial dysfunction, many patients are not afforded that therapeutic opportunity owing to the worldwide shortage of donor corneas. Thus, a tissue engineering-based therapy for treating corneal endothelial dysfunction is highly anticipated. Obstacles associated with the development of tissue engineering therapy include in vitro culture of corneal endothelial cells (CECs) and the techniques used to transplant those cells. Limited proliferation ability, cellular senescence, and fibroblastic transformation during culture are all problems associated with the cultivation of CECs. In addition, transplantation of cultured CECs is technically difficult because the corneal endothelium is composed of a fragile monolayer sheet of cells located at the posterior cornea. In this review article, we present our recent findings using a novel cell culture protocol and show that modulation of CEC adhesion properties through a Rho-kinase inhibitor enables transplantation of CECs in the form of a cell suspension without the use of a carrier. Finally, we provide an update on the clinical application status of a cell-based therapy for treating corneal endothelial dysfunction.	[Okumura, Naoki; Koizumi, Noriko] Doshisha Univ, Dept Biomed Engn, Fac Life & Med Sci, Kyotanabe 6100321, Japan; [Okumura, Naoki; Kinoshita, Shigeru] Kyoto Prefectural Univ Med, Dept Ophthalmol, Kyoto, Japan	Koizumi, N (reprint author), Doshisha Univ, Dept Biomed Engn, Fac Life & Med Sci, Kyotanabe 6100321, Japan.	nkoizumi@mail.doshisha.ac.jp			Highway Program for Realization of Regenerative Medicine; Funding Program for Next Generation World-Leading Researchers from the Cabinet Office in Japan [LS117]	Supported in part by the Highway Program for Realization of Regenerative Medicine (S. K. and N.O.) and the Funding Program for Next Generation World-Leading Researchers from the Cabinet Office in Japan (N.K.: LS117).	Mimura T, 2004, INVEST OPHTH VIS SCI, V45, P2992, DOI 10.1167/iovs.03-1174; Joyce NC, 2012, EXP EYE RES, V95, P16, DOI 10.1016/j.exer.2011.08.014; Okumura N, 2014, INVEST OPHTH VIS SCI, V55, P318, DOI 10.1167/iovs.13-12225; Shima N, 2011, INVEST OPHTH VIS SCI, V52, P8711, DOI 10.1167/iovs.11-7592; Miyata K, 2001, CORNEA, V20, P59, DOI 10.1097/00003226-200101000-00012; Koizumi N, 2007, INVEST OPHTH VIS SCI, V48, P4519, DOI 10.1167/iovs.07-0567; Sumide T, 2006, FASEB J, V20, P392, DOI 10.1096/fj.04-3035fje; Okumura N, 2009, INVEST OPHTH VIS SCI, V50, P3680, DOI 10.1167/iovs.08-2634; Ishino Y, 2004, INVEST OPHTH VIS SCI, V45, P800, DOI 10.1167/iovs.03-0016; Okumura N, 2012, AM J PATHOL, V181, P268, DOI 10.1016/j.ajpath.2012.03.033; Peh GSL, 2011, TRANSPLANTATION, V91, P811, DOI 10.1097/TP.0b013e3182111f01; Yamaguchi M, 2011, INVEST OPHTH VIS SCI, V52, P679, DOI 10.1167/iovs.10-5555; Tan DTH, 2012, LANCET, V379, P1749, DOI 10.1016/S0140-6736(12)60437-1; Bourne WM, 1998, T AM OPHTHAL SOC, V96, P239; Bourne W M, 1998, Trans Am Ophthalmol Soc, V96, P229; Liao James K, 2007, J Cardiovasc Pharmacol, V50, P17, DOI 10.1097/FJC.0b013e318070d1bd; Mimura T, 2003, EXP EYE RES, V76, P745, DOI 10.1016/S0014-4835(03)00057-5; Nakahara M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069009; Numata R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088169; Okumura N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058000; Patel SV, 2009, INVEST OPHTH VIS SCI, V50, P2123, DOI 10.1167/iovs.08-2653; Peh GSL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028310; Yamagami S, 2004, INVEST OPHTH VIS SCI, V45, P515, DOI 10.1167/iovs.03-0912; Yoshizaki H, 2004, J BIOL CHEM, V279, P44756, DOI 10.1074/jbc.M402292200	24	4	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0277-3740	1536-4798		CORNEA	Cornea	NOV	2014	33			1			S37	S41		10.1097/ICO.0000000000000229		5	Ophthalmology	Ophthalmology	AS5ZD	WOS:000344344000011		
J	Satake, Y; Yamaguchi, T; Hirayama, M; Higa, K; Shimazaki-Den, S; Dogru, M; Kawakita, T; Kawashima, M; Shimmura, S; Tsubota, K; Shimazaki, J				Satake, Yoshiyuki; Yamaguchi, Takefumi; Hirayama, Masatoshi; Higa, Kazunari; Shimazaki-Den, Seika; Dogru, Murat; Kawakita, Tetsuya; Kawashima, Motoko; Shimmura, Shigeto; Tsubota, Kazuo; Shimazaki, Jun			Ocular Surface Reconstruction by Cultivated Epithelial Sheet Transplantation	CORNEA			English	Article						ocular surface reconstruction; limbal stem cells; epithelial sheet transplantation; keratoplasty	STEVENS-JOHNSON-SYNDROME; ORAL MUCOSAL EPITHELIUM; STEM-CELL DEFICIENCY; AMNIOTIC MEMBRANE; AUTOLOGOUS TRANSPLANTATION; CORNEAL EPITHELIUM; HUMAN LIMBAL; DISORDERS; KERATOPROSTHESIS; CULTURE	Recent advances in ocular surface reconstruction for patients with severe ocular surface diseases have significantly improved the prognosis of patients with vision-impairing corneal abnormalities. The history of cultivated epithelial sheet transplantation is short, and debate on the current approaches for these procedures is continuing. Limbal stem cell transplantation, including conjunctivolimbal autograft and keratolimbal allograft, has brought opportunities for vision improvement. In addition, the use of cultivated limbal epithelial transplantation from both allogeneic and autologous sources has provided further options for immediate postoperative epithelialization of the corneal surface. Finally, cultivated oral mucosal epithelial transplantation, which allows autologous transplantation for patients with bilateral limbal stem cell deficiency, has provided the best overall midterm and long-term results. Its biggest advantages are the absence of rejection reactions and the reduction of postoperative complications associated with steroid therapy. However, a solitary surgical approach is not sufficient for obtaining a good clinical outcome. To maximize the possibility of success using these procedures, it is important to preoperatively enhance aggressive treatment of the ocular surface, especially with factors that facilitate moisture retention. In this review article, we also discuss our clinical experience in relation to these surgical procedures.	[Satake, Yoshiyuki; Yamaguchi, Takefumi; Higa, Kazunari; Shimazaki-Den, Seika; Dogru, Murat; Shimazaki, Jun] Tokyo Dent Coll, Dept Ophthalmol, Ichikawa, Chiba 2728513, Japan; [Hirayama, Masatoshi; Kawakita, Tetsuya; Kawashima, Motoko; Shimmura, Shigeto; Tsubota, Kazuo] Keio Univ, Sch Med, Dept Ophthalmol, Tokyo, Japan	Satake, Y (reprint author), Tokyo Dent Coll, Dept Ophthalmol, Sugano 5-11-13, Ichikawa, Chiba 2728513, Japan.	satake@eyebank.or.jp			Otsuka Pharmaceutical Co; Santen Pharmaceutical Co; Alcon Japan; Japan Society for the Promotion of Science (JSPS) [17791259]; Advanced and Innovational Research Program in Life Sciences of the Ministry of Education, Culture, Sports, Science, and Technology, Japan; Japan Society for the Promotion of Science (KAKENHI) [22591951]; Oral Health Science Center from Tokyo Dental College [hrc8]; Ministry of Education, Culture, Sports, Science, and Technology, Japan; Keio University Research Grants for Life Science and Medicine, Keio University Medical Science Fund	J. Shimazaki is a consultant to Otsuka Pharmaceutical Co, and has received payment for lecturing from Otsuka Pharmaceutical Co, Santen Pharmaceutical Co, and Alcon Japan. Y. Satake received a Grant-in-Aid for Young Scientists (B) from the Japan Society for the Promotion of Science (JSPS) (KAKENHI: 17791259); a grant from the Advanced and Innovational Research Program in Life Sciences of the Ministry of Education, Culture, Sports, Science, and Technology, Japan; a Grant-in-Aid for scientific research (C) from the Japan Society for the Promotion of Science (KAKENHI: 22591951); an Oral Health Science Center Grant hrc8 from Tokyo Dental College; and a grant from the Project for Private Universities: matching fund subsidy from the Ministry of Education, Culture, Sports, Science, and Technology, Japan, 2010 to 2012. M. Hirayama received funding from Keio University Research Grants for Life Science and Medicine, Keio University Medical Science Fund. J. Shimazaki received a grant from the Ministry of Education, Culture, Sports, Science, and Technology, Japan. The other authors have no funding or conflicts of interest to disclose.	Koizumi N, 2000, CORNEA, V19, P65, DOI 10.1097/00003226-200001000-00013; Tsubota K, 1996, AM J OPHTHALMOL, V122, P38; Shimazaki J, 2000, OPHTHALMOLOGY, V107, P1518, DOI 10.1016/S0161-6420(00)00214-1; Kolli S, 2014, STEM CELLS, V32, P2135, DOI 10.1002/stem.1694; KIM JC, 1995, CORNEA, V14, P473; DOHLMAN CH, 1974, AM J OPHTHALMOL, V77, P694; TSAI RJF, 1994, CORNEA, V13, P389, DOI 10.1097/00003226-199409000-00003; Tsai RJ, 2000, NEW ENGL J MED, V343, P86, DOI 10.1056/NEJM200007133430202; Nishida K, 2004, NEW ENGL J MED, V351, P1187, DOI 10.1056/NEJMoa040455; SCHERMER A, 1986, J CELL BIOL, V103, P49, DOI 10.1083/jcb.103.1.49; Tsubota K, 1999, NEW ENGL J MED, V340, P1697, DOI 10.1056/NEJM199906033402201; Sayegh RR, 2008, AM J OPHTHALMOL, V145, P438, DOI 10.1016/j.ajo.2007.11.002; Nakamura T, 2004, BRIT J OPHTHALMOL, V88, P1280, DOI 10.1136/bjo.2003.038497; Pellegrini G, 1997, LANCET, V349, P990, DOI 10.1016/S0140-6736(96)11188-0; TSUBOTA K, 1995, OPHTHALMOLOGY, V102, P1486; Shimazaki J, 2004, OPHTHALMOLOGY, V111, P38, DOI 10.1016/j.ophtha.2003.02.003; Falcinelli G, 2005, ARCH OPHTHALMOL-CHIC, V123, P1319, DOI 10.1001/archopht.123.10.1319; Nakamura T, 2003, INVEST OPHTH VIS SCI, V44, P106, DOI 10.1167/iovs.02-0195; Inatomi T, 2006, AM J OPHTHALMOL, V141, P267, DOI 10.1016/j.ajo.2005.09.003; Satake Y, 2011, OPHTHALMOLOGY, V118, P1524, DOI 10.1016/j.ophtha.2011.01.039; Nakamura T, 2011, BRIT J OPHTHALMOL, V95, P942, DOI 10.1136/bjo.2010.188714; KENYON KR, 1989, OPHTHALMOLOGY, V96, P709; Hirayama M, 2012, INVEST OPHTH VIS SCI, V53, P1602, DOI 10.1167/iovs.11-7847; Yaghouti F, 2001, CORNEA, V20, P19, DOI 10.1097/00003226-200101000-00003; Buxton JN, 1993, CORNEAL SURG THEORY, P77; COTSARELIS G, 1989, CELL, V57, P201, DOI 10.1016/0092-8674(89)90958-6; He YG, 1999, CORNEA, V18, P570, DOI 10.1097/00003226-199909000-00010; Higa K, 2007, INVEST OPHTH VIS SCI, V48, P597, DOI 10.1167/iovs.06-0664; Hiscott P, 1996, EXP CELL RES, V226, P140, DOI 10.1006/excr.1996.0212; Kanayama S, 2007, EXP EYE RES, V85, P772, DOI 10.1016/j.exer.2007.08.011; Kenyon K.R., 1989, OPHTHALMOLOGY, V96, P722; Satake Y, 2013, JAMA OPHTHALMOL, V131, P920, DOI 10.1001/jamaophthalmol.2013.15; Schwab I R, 1999, Trans Am Ophthalmol Soc, V97, P891; Sekiyama E, 2006, EXP EYE RES, V83, P741, DOI 10.1016/j.exer.2006.02.015; Shimazaki J, 2002, OPHTHALMOLOGY, V109, P1285, DOI 10.1016/S0161-6420(02)01089-8; STRAMPELLI B, 1963, Ann Ottalmol Clin Ocul, V89, P1039; Tsubota K, 1996, LANCET, V348, P123, DOI 10.1016/S0140-6736(96)24028-0	37	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0277-3740	1536-4798		CORNEA	Cornea	NOV	2014	33			1			S42	S46		10.1097/ICO.0000000000000242		5	Ophthalmology	Ophthalmology	AS5ZD	WOS:000344344000012		
J	Sumioka, T; Miyamoto, T; Takatsuki, R; Okada, Y; Yamanaka, O; Saika, S				Sumioka, Takayoshi; Miyamoto, Takeshi; Takatsuki, Reiko; Okada, Yuka; Yamanaka, Osamu; Saika, Shizuya			Histological Analysis of a Cornea Following Experimental Femtosecond Laser Ablation	CORNEA			English	Article						femtosecond laser; corneal photorefractive surgery; histological analysis	IN-SITU KERATOMILEUSIS; REFRACTIVE LENTICULE EXTRACTION; FLAP ADHESION STRENGTH; PHOTOREFRACTIVE KERATECTOMY; MECHANICAL MICROKERATOME; SURFACE QUALITY; ENERGY-LEVEL; STROMAL BED; LASIK; TRANSPARENCY	Corneal photorefractive surgery is currently performed by ablation of corneal stroma under the stromal flap. A stromal flap is created using a femtosecond (FS) laser or mechanical microkeratome, although the FS laser procedure is considered safer and more accurate. This review assesses and compares the use of FS laser versus mechanical microkeratome ablation for corneal stromal characteristics mainly examined by histology and cellular biological responses. Supporting data from our studies, using corneas of enucleated porcine eye globes, are included in this review. Histological analysis and experimental studies of cellular/tissue responses to FS laser irradiation should be further investigated, and the equipment used to perform these techniques should be improved.	[Sumioka, Takayoshi; Miyamoto, Takeshi; Okada, Yuka; Yamanaka, Osamu; Saika, Shizuya] Wakayama Med Univ, Sch Med, Dept Ophthalmol, Wakayama 6410012, Japan; [Takatsuki, Reiko] Takatsuki Eye Clin, Osaka, Japan	Sumioka, T (reprint author), Wakayama Med Univ, Sch Med, Dept Ophthalmol, 811-1 Kimiidera, Wakayama 6410012, Japan.	sumioka@wakayama-med.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan [C24791869, C24592638, C25462759, C25462729]	Supported by grants from the Ministry of Education, Culture, Sports, Science and Technology of Japan (C24791869 to T. S., C24592638 to Y.O., C25462759 to O.Y., C25462729 to S.S.).	Ang M, 2012, INVEST OPHTH VIS SCI, V53, P1414, DOI 10.1167/iovs.11-8808; Angunawela RI, 2011, MOL VIS, V17, P3005; Lombardo M, 2012, CORNEA, V31, P1369, DOI 10.1097/ICO.0b013e31823f774c; Fini ME, 1999, PROG RETIN EYE RES, V18, P529, DOI 10.1016/S1350-9462(98)00033-0; Torricelli AAM, 2013, INVEST OPHTH VIS SCI, V54, P6390, DOI 10.1167/iovs.13-12547; Mohan RR, 2003, EXP EYE RES, V76, P71, DOI 10.1016/S0014-4835(02)00251-8; Kunert KS, 2011, GRAEF ARCH CLIN EXP, V249, P1417, DOI 10.1007/s00417-010-1578-4; Saika S, 2008, PROG RETIN EYE RES, V27, P177, DOI 10.1016/j.preteyeres.2007.12.002; Morishige N, 2007, INVEST OPHTH VIS SCI, V48, P1087, DOI 10.1167/iovs.06-1177; Baldwin HC, 2002, ACTA OPHTHALMOL SCAN, V80, P238, DOI 10.1034/j.1600-0420.2002.800303.x; PALLIKARIS IG, 1990, LASER SURG MED, V10, P463; Salomao MQ, 2010, J CATARACT REFR SURG, V36, P1024, DOI 10.1016/j.jcrs.2010.03.025; Kymionis GD, 2014, BRIT J OPHTHALMOL, V98, P133, DOI 10.1136/bjophthalmol-2013-304023; Kao WWY, 2002, GLYCOCONJUGATE J, V19, P275, DOI 10.1023/A:1025396316169; Sutton G, 2008, J REFRACT SURG, V24, P802; de Medeiros FW, 2009, J REFRACT SURG, V25, P869, DOI 10.3928/1081597X-20090917-08; Dong ZX, 2014, BRIT J OPHTHALMOL, V98, P263, DOI 10.1136/bjophthalmol-2013-303415; Heichel J, 2011, OPHTHALMIC RES, V46, P107, DOI 10.1159/000323814; Hosny Mohamed, 2013, Clin Ophthalmol, V7, P1919, DOI 10.2147/OPTH.S51774; Hutcheon AEK, 2005, INVEST OPHTH VIS SCI, V46, P2362, DOI 10.1167/iovs.04-0759; Knorz MC, 2008, J REFRACT SURG, V24, P875; Marian A, 2013, J CATARACT REFR SURG, V39, P118, DOI 10.1016/j.jcrs.2012.08.050; Mayer WJ, 2013, J CATARACT REFR SURG, V39, P1088, DOI 10.1016/j.jcrs.2013.01.047; Miyamoto T, 2003, J CATARACT REFR SURG, V29, P153, DOI 10.1016/S0886-3350(02)01450-5; Moller-Pedersen T, 2000, OPHTHALMOLOGY, V107, P1235, DOI 10.1016/S0161-6420(00)00142-1; Nakano K, 2004, J REFRACT SURG, V20, pS723; Netto MV, 2007, J REFRACT SURG, V23, P667; Riau AK, 2014, INVEST OPHTH VIS SCI, V55, P3186, DOI 10.1167/iovs.14-14434; Riau AK, 2012, J CATARACT REFR SURG, V38, P1467, DOI 10.1016/j.jcrs.2012.03.037; Saika S, 2010, EYE CONTACT LENS, V36, P286, DOI 10.1097/ICL.0b013e3181eef01c; Santhiago MR, 2012, CORNEA, V31, P198, DOI 10.1097/ICO.0b013e3182068c42; Vestergaard AH, 2014, ACTA OPHTHALMOL, V92, P492, DOI 10.1111/aos.12450	32	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0277-3740	1536-4798		CORNEA	Cornea	NOV	2014	33			1			S19	S24		10.1097/ICO.0000000000000251		6	Ophthalmology	Ophthalmology	AS5ZD	WOS:000344344000008		
J	Tanaka, Y; Tsuda, M; Yasumoto, K; Terachi, T; Yamagishi, H				Tanaka, Yoshiyuki; Tsuda, Mizue; Yasumoto, Keita; Terachi, Toru; Yamagishi, Hiroshi			The complete mitochondrial genome sequence of Brassica oleracea and analysis of coexisting mitotypes	CURRENT GENETICS			English	Article						Brassica oleracea; Complete mitochondrial genome; Heteroplasmy; Mitotype; Substoichiometric shifting	CYTOPLASMIC MALE-STERILITY; INTRASPECIFIC VARIATION; RECOMBINATION; ARABIDOPSIS; EVOLUTION; GENES; ANGIOSPERM; VULGARIS; MAIZE; DNA	The complete mitochondrial genome sequences of Brassica species have provided insight into inter-and intraspecific variation of plant mitochondrial genomes. However, the size of mitochondrial genome sequenced for Brassica oleracea hitherto does not match to its physical mapping data. This fact led us to investigate B. oleracea mitochondrial genome in detail. Here we report novel B. oleracea mitochondrial genome, derived from var. capitata, a cabbage cultivar "Fujiwase". The genome was assembled into a 219,952-bp circular sequence that is comparable to the mitochondrial genomes of other Brassica species (ca. 220-232 kb). This genome contained 34 protein-coding genes, 3 rRNA genes and 17 tRNA genes. Due to absence of a large repeat (140 kb), the mitochondrial genome of "Fujiwase" is clearly smaller than the previously reported mitochondrial genome of B. oleracea accession "08C717" (360 kb). In both mitotypes, all genes were identical, except cox2-2, which was present only in the Fujiwase type. At least two rearrangement events via large and small repeat sequences have contributed to the structural differences between the two mitotypes. PCR-based marker analysis revealed that the Fujiwase type is predominant, whereas the 08C717 type coexists at low frequency in all B. oleracea cultivars examined. Intraspecific variations in the mitochondrial genome in B. oleracea may occur because of heteroplasmy, coexistence of different mitotypes within an individual, and substoichiometric shifting. Our data indicate that the Fujiwase-type genome should be used as the representative genome of B. oleracea.	[Tanaka, Yoshiyuki; Tsuda, Mizue; Yasumoto, Keita; Terachi, Toru; Yamagishi, Hiroshi] Kyoto Sangyo Univ, Fac Life Sci, Kita Ku, Kyoto 6038555, Japan	Yamagishi, H (reprint author), Kyoto Sangyo Univ, Fac Life Sci, Kita Ku, Kyoto 6038555, Japan.	yoshi-tanaka@cc.okayama-u.ac.jp; hiyamagi@cc.kyoto-su.ac.jp			Private University Strategic Research Foundation Support Program [22380008]; Program for Promotion of Basic and Applied Researches for Innovations in Bio-oriented Industry (BRAIN), Japan	This study was supported in part by the Private University Strategic Research Foundation Support Program, Grants-in-Aid for Scientific Research, Scientific Research (B) (No. 22380008), and the Program for Promotion of Basic and Applied Researches for Innovations in Bio-oriented Industry (BRAIN), Japan.	Alverson AJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016404; Bergthorsson U, 2003, NATURE, V424, P197, DOI 10.1038/nature01743; PALMER JD, 1988, GENETICS, V118, P341; SMALL I, 1989, CELL, V58, P69, DOI 10.1016/0092-8674(89)90403-0; Janska H, 1998, PLANT CELL, V10, P1163; Woloszynska M, 2009, PLANT MOL BIOL, V70, P511, DOI 10.1007/s11103-009-9488-8; Zaegel V, 2006, PLANT CELL, V18, P3548, DOI 10.1105/tpc.106.042028; Stothard P, 2005, BIOINFORMATICS, V21, P537, DOI 10.1093/bioinformatics/bti054; Marechal A, 2010, NEW PHYTOL, V186, P299, DOI 10.1111/j.1469-8137.2010.03195.x; Feng X, 2009, THEOR APPL GENET, V118, P1361, DOI 10.1007/s00122-009-0986-5; Kubo T, 2008, MITOCHONDRION, V8, P5, DOI 10.1016/j.mito.2007.10.006; Sloan DB, 2012, NEW PHYTOL, V196, P1228, DOI 10.1111/j.1469-8137.2012.04340.x; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; Shedge V, 2007, PLANT CELL, V19, P1251, DOI 10.1105/tpc.106.048355; Allen JO, 2007, GENETICS, V177, P1173, DOI 10.1534/genetics.107.073312; Handa H, 2003, NUCLEIC ACIDS RES, V31, P5907, DOI 10.1093/nar/gkg795; PALMER JD, 1987, CURR GENET, V11, P565, DOI 10.1007/BF00384620; Woloszynska M, 2010, J EXP BOT, V61, P657, DOI 10.1093/jxb/erp361; Chang SX, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-497; Chen JM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017662; CHETRIT P, 1984, CURR GENET, V8, P413, DOI 10.1007/BF00433907; Darracq A, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-233; Davila JI, 2011, BMC BIOL, V9, DOI 10.1186/1741-7007-9-64; Fujii S, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-209; Sloan DB, 2012, PLOS BIOL, V10; Tanaka Y, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-352; U N, 1935, JPN J BOT, V7, P389	27	2	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8083	1432-0983		CURR GENET	Curr. Genet.	NOV	2014	60	4					277	284		10.1007/s00294-014-0433-2		8	Genetics & Heredity	Genetics & Heredity	AS1SK	WOS:000344061200005		
J	Kusaba, M; Mochida, T; Naridomi, T; Fujita, Y; Chuma, I; Tosa, Y				Kusaba, Motoaki; Mochida, Taiga; Naridomi, Takeshi; Fujita, Yoshikatsu; Chuma, Izumi; Tosa, Yukio			Loss of a 1.6 Mb chromosome in Pyricularia oryzae harboring two alleles of AvrPik leads to acquisition of virulence to rice cultivars containing resistance alleles at the Pik locus	CURRENT GENETICS			English	Article						Pyricularia oryzae; AvrPik; AvrPik-m; AvrPik-p; Supernumerary chromosome	CONDITIONALLY DISPENSABLE CHROMOSOME; MAGNAPORTHE-ORYZAE; AVIRULENCE GENE; BLAST RESISTANCE; B-CHROMOSOME; ALTERNARIA-ALTERNATA; ISOLATE 84R-62B; GRISEA; PATHOGENICITY; FUNGUS	A small and extra chromosome of 1.6 Mb was previously identified in a Pyricularia oryzae strain, 84R-62B. To understand a role of the 1.6 Mb chromosome in the pathogenic changeability of P. oryzae, we performed experiments designed to characterize the 1.6 Mb chromosome in the present study. A gene family encoding secreted protein Pex31s in P. oryzae consists of five homologs, Pex31-A to -E. Among them, Pex31-A and -D are known to be recognized by Pik-m and Pik/Pik-m/Pik-p, respectively. In the present study, we identified Pex31-A and -D in the genome of 84R-62B. Segregation analyses using an F-1 population between 84R-62B and another rice blast strain, Y93-245c-2, revealed a strong linkage between the two homologs and the 1.6 Mb chromosome of 84R-62B. A CHEF-Southern analysis revealed an association between the 1.6 Mb chromosome and the homologs, indicating that both homologs are located on the 1.6 Mb chromosome of 84R-62B. The loss of the 1.6 Mb chromosome was observed in subcultures of a F-1 progeny, F1-327. These subcultures concomitantly acquired virulence on Pik, Pik-m, and Pik-p. The present study is the first report showing that loss of a small and extra chromosome leads to pathogenic mutation of P. oryzae and may provide a new insight into the mechanisms generating pathogenic variation of this fungus.	[Kusaba, Motoaki; Mochida, Taiga; Naridomi, Takeshi] Saga Univ, Fac Agr, Plant Pathol Lab, Saga 8408502, Japan; [Fujita, Yoshikatsu] Nihon Univ, Coll Bioresource Sci, Fujisawa, Kanagawa 2520880, Japan; [Chuma, Izumi; Tosa, Yukio] Kobe Univ, Grad Sch Agr Sci, Kobe, Hyogo 6578501, Japan	Kusaba, M (reprint author), Saga Univ, Fac Agr, Plant Pathol Lab, Saga 8408502, Japan.	mkusaba@cc.saga-u.ac.jp			JSPS KAKENHI Grant [20248005]	This study was supported by JSPS KAKENHI Grant Number 20248005.	Ma LJ, 2010, NATURE, V464, P367, DOI 10.1038/nature08850; Orbach MJ, 1996, MOL PLANT MICROBE IN, V9, P261, DOI 10.1094/MPMI-9-0261; Jia Y, 2000, EMBO J, V19, P4004, DOI 10.1093/emboj/19.15.4004; Orbach MJ, 2000, PLANT CELL, V12, P2019, DOI 10.1105/tpc.12.11.2019; Couch BC, 2002, MYCOLOGIA, V94, P683, DOI 10.2307/3761719; Johnson LJ, 2001, CURR GENET, V40, P65, DOI 10.1007/s002940100233; Luo CX, 2004, PLANT DIS, V88, P265, DOI 10.1094/PDIS.2004.88.3.265; Li W, 2009, MOL PLANT MICROBE IN, V22, P411, DOI 10.1094/MPMI-22-4-0411; Farman ML, 2007, FEMS MICROBIOL LETT, V273, P125, DOI 10.1111/j.1574-6968.2007.00812.x; Yamagashira A, 2008, J GEN PLANT PATHOL, V74, P230, DOI 10.1007/s10327-008-0087-3; Mehrabi R, 2011, FEMS MICROBIOL REV, V35, P542, DOI 10.1111/j.1574-6976.2010.00263.x; Kanzaki H, 2012, PLANT J, V72, P894, DOI 10.1111/j.1365-313X.2012.05110.x; Yoshida K, 2009, PLANT CELL, V21, P1573, DOI 10.1105/tpc.109.066324; Jones RN, 1995, NEW PHYTOL, V131, P411, DOI 10.1111/j.1469-8137.1995.tb03079.x; Covert SF, 1998, CURR GENET, V33, P311, DOI 10.1007/s002940050342; [Anonymous], 1984, RICE GENET NEWSL; Bohnert HU, 2004, PLANT CELL, V16, P2499, DOI 10.1105/tpc.104.022715; Tosa Y, 2004, PHYTOPATHOLOGY, V94, P454, DOI 10.1094/PHYTO.2004.94.5.454; MIAO VP, 1991, SCIENCE, V254, P1773, DOI 10.1126/science.1763326; Hatta R, 2002, GENETICS, V161, P59; Chuma I, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1002147; FARMAN ML, 1995, GENETICS, V140, P479; ITOI S, 1983, PHYTOPATHOLOGY, V73, P155, DOI 10.1094/Phyto-73-155; Kiyosawa S, 1974, MISC PUBL NATL I A D, V1, P1; KIYOSAWA S, 1969, Japanese Journal of Breeding, V19, P61; Kiyosawa S, 1978, JPN J BREED, V28, P289; Kusaba M, 2008, J GEN PLANT PATHOL, V74, P250, DOI 10.1007/s10327-008-0094-4; Leong SA, 2008, GENOMICS DIS, P119; Luo CX, 2007, MYCOL RES, V111, P232, DOI 10.1016/j.mycres.2006.10.008; Luo Chao-Xi, 2002, Journal of General Plant Pathology, V68, P300, DOI 10.1007/PL00013095; Luo CX, 2005, PHYTOPATHOLOGY, V95, P640, DOI 10.1094/PHYTO-95-0640; POHLER W, 1990, HEREDITAS, V112, P217, DOI 10.1111/j.1601-5223.1990.tb00060.x; SCHLEGEL R, 1994, BREEDING SCI, V44, P279; SILUE D, 1992, PHYTOPATHOLOGY, V82, P577; TSUGE T, 1986, Annals of the Phytopathological Society of Japan, V52, P488; YAMASAKI Y., 1966, Bull. natn. Inst. agric. Sci., Tokyo, V14, P39	36	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0172-8083	1432-0983		CURR GENET	Curr. Genet.	NOV	2014	60	4					315	325		10.1007/s00294-014-0437-y		11	Genetics & Heredity	Genetics & Heredity	AS1SK	WOS:000344061200009		
J	Takahashi, T				Takahashi, Toshiyuki			Direct Evaluation of Endosymbiotic Status in Paramecium bursaria Using a Capillary Flow Cytometer	CYTOMETRY PART A			English	Letter							GREEN PARAMECIUM; ALGAE; CILIATE		Miyakonojo Coll, Natl Inst Technol, Dept Chem Sci & Engn, Miyazaki 8858567, Japan	Takahashi, T (reprint author), Miyakonojo Coll, Natl Inst Technol, Dept Chem Sci & Engn, Miyazaki 8858567, Japan.	mttaka@cc.miyakonojo-nct.ac.jp					Kadono T, 2004, PROTOPLASMA, V223, P133, DOI 10.1007/s00709-004-0046-6; Richier S, 2006, FEBS J, V273, P4186, DOI 10.1111/j.1742-4658.2006.05414.x; Rowan R, 2004, NATURE, V430, P742, DOI 10.1038/430742a; Gerashchenko BI, 2000, CYTOMETRY, V41, P209, DOI 10.1002/1097-0320(20001101)41:3<209::AID-CYTO8>3.0.CO;2-U; Hosoya H, 1995, ZOOL SCI, V12, P807, DOI 10.2108/zsj.12.807; Kodama Y, 2011, PROTIST, V162, P288, DOI 10.1016/j.protis.2010.06.005; Millipore Corporation, 2013, MUS CELL AN US GUID, P1; MUSCATIN.L, 1967, COMP BIOCHEM PHYSIOL, V20, P1; Nishihara N, 1998, PROTOPLASMA, V203, P91, DOI 10.1007/BF01280591; Takahashi T, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001352	10	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1552-4922	1552-4930		CYTOM PART A	Cytom. Part A	NOV	2014	85A	11					911	914		10.1002/cyto.a.22562		4	Biochemical Research Methods; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	AS3GT	WOS:000344166300002		
J	Dozawa, M; Kono, H; Sato, Y; Ito, Y; Tanaka, H; Ohshima, T				Dozawa, Miki; Kono, Hiromitsu; Sato, Yuki; Ito, Yoko; Tanaka, Hideomi; Ohshima, Toshio			Valproic Acid, a Histone Deacetylase Inhibitor, Regulates Cell Proliferation in the Adult Zebrafish Optic Tectum	DEVELOPMENTAL DYNAMICS			English	Article						VPA; HDAC; adult neurogenesis; zebrafish; optic tectum	NEURAL STEM-CELLS; TRANSGENIC ZEBRAFISH; SPINAL-CORD; IN-VIVO; NEUROGENESIS; EXPRESSION; MAINTENANCE; NEURONS; DIFFERENTIATION; BRAIN	Background: Valproic acid (VPA) has been used to treat epilepsy and bipolar disorder. Several reports have demonstrated that VPA functions as a histone deacetylase (HDAC) inhibitor. While VPA is known to cause teratogenic changes in the embryonic zebrafish brain, its effects on neural stem cells (NSCs) in both the embryonic and adult zebrafish are not well understood. Results: In this study, we observed a proliferative effect of VPA on NSCs in the embryonic hindbrain. In contrast, VPA reduced cell proliferation in the adult zebrafish optic tectum. Treatment with HDAC inhibitors showed a similar inhibitory effect on cell proliferation in the adult zebrafish optic tectum, suggesting that VPA reduces cell proliferation through HDAC inhibition. Cell cycle progression was also suppressed in the optic tectum of the adult zebrafish brain because of HDAC inhibition. Recent studies have demonstrated that HDAC inhibits the Notch signaling pathway; hence, adult zebrafish were treated with a Notch inhibitor. This increased the number of proliferating cells in the adult zebrafish optic tectum with down-regulated expression of her4, a target of Notch signaling. Conclusions: These results suggest that VPA inhibits HDAC activity and upregulates Notch signaling to reduce cell proliferation in the optic tectum of adult zebrafish. Developmental Dynamics 243:1401-1415, 2014. (c) 2014 Wiley Periodicals, Inc.	[Dozawa, Miki; Kono, Hiromitsu; Sato, Yuki; Ito, Yoko; Tanaka, Hideomi; Ohshima, Toshio] Waseda Univ, Sch Adv Sci & Engn, Dept Life Sci & Med Biosci, Tokyo 1628480, Japan; [Tanaka, Hideomi] Inst Phys & Chem Res RIKEN, Brain Sci Inst, Lab Dev Gene Regulat, Saitama, Japan	Ohshima, T (reprint author), Waseda Univ, Sch Adv Sci & Engn, Dept Life Sci & Med Biosci, Shinjuku Ku, 2-2 Wakamatsu Cho, Tokyo 1628480, Japan.	ohshima@waseda.jp					Androutsellis-Theotokis A, 2006, NATURE, V442, P823, DOI 10.1038/nature04940; Marks PA, 2003, CURR OPIN PHARMACOL, V3, P344, DOI 10.1016/S1471-4892(03)00084-5; Lunyak VV, 2002, SCIENCE, V298, P1747, DOI 10.1126/science.1076469; Gurvich N, 2005, FASEB J, V19, P1166, DOI 10.1096/fj.04-3425fje; Kim HJ, 2009, J NEUROCHEM, V110, P1226, DOI 10.1111/j.1471-4159.2009.06212.x; Leslie JD, 2007, DEVELOPMENT, V134, P839, DOI 10.1242/dev.003244; Kizil C, 2012, DEV NEUROBIOL, V72, P429, DOI 10.1002/dneu.20918; Strahl BD, 2000, NATURE, V403, P41; Lagace DC, 2004, J BIOL CHEM, V279, P18851, DOI 10.1074/jbc.M312795200; Selderslaghs IWT, 2009, REPROD TOXICOL, V28, P308, DOI 10.1016/j.reprotox.2009.05.004; Imayoshi I, 2010, J NEUROSCI, V30, P3489, DOI 10.1523/JNEUROSCI.4987-09.2010; Phiel CJ, 2001, J BIOL CHEM, V276, P36734, DOI 10.1074/jbc.M101287200; Park HC, 2000, DEV BIOL, V227, P279, DOI 10.1006/dbio.2000.9898; Zupanc GKH, 2008, J PHYSIOL-PARIS, V102, P357, DOI 10.1016/j.jphysparis.2008.10.007; Yu IT, 2009, NEUROPHARMACOLOGY, V56, P473, DOI 10.1016/j.neuropharm.2008.09.019; Rothenaigner I, 2011, DEVELOPMENT, V138, P1459, DOI 10.1242/dev.058156; Chapouton P, 2010, J NEUROSCI, V30, P7961, DOI 10.1523/JNEUROSCI.6170-09.2010; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Yamaguchi M, 2005, DEVELOPMENT, V132, P3027, DOI 10.1242/dev.01881; Ito Y, 2010, DEV BIOL, V342, P26, DOI 10.1016/j.ydbio.2010.03.008; Shimojo H, 2008, NEURON, V58, P52, DOI 10.1016/j.neuron.2008.02.014; Bernardos RL, 2006, GENE EXPR PATTERNS, V6, P1007, DOI 10.1016/j.modgep.2006.04.006; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033; Glaser KB, 2007, BIOCHEM PHARMACOL, V74, P659, DOI 10.1016/j.bcp.2007.04.007; Ables JL, 2010, J NEUROSCI, V30, P10484, DOI 10.1523/JNEUROSCI.4721-09.2010; Hsieh J, 2004, P NATL ACAD SCI USA, V101, P16659, DOI 10.1073/pnas.0407643101; Ehm O, 2010, J NEUROSCI, V30, P13794, DOI 10.1523/JNEUROSCI.1567-10.2010; Korzh V, 1998, DEV DYNAM, V213, P92, DOI 10.1002/(SICI)1097-0177(199809)213:1<92::AID-AJA9>3.0.CO;2-T; Montgomery RL, 2009, P NATL ACAD SCI USA, V106, P7876, DOI 10.1073/pnas.0902750106; Cunliffe VT, 2004, DEVELOPMENT, V131, P2983, DOI 10.1242/dev.01166; Chapouton P, 2007, BIOESSAYS, V29, P745, DOI 10.1002/bies.20615; Appel B, 1998, DEVELOPMENT, V125, P371; Chapouton P, 2011, J COMP NEUROL, V519, P1748, DOI 10.1002/cne.22599; DESOLIVEIRACARL.V, 2013, PLOS ONE, V8; DORAK MT, 2006, REAL TIME PCR ADV ME; FAUQ LM, 2007, BIOORG MED CHEM LETT, V17, P6392; Harrison MRM, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-24; HERRMANN K, 1993, TOXICOL IN VITRO, V7, P41, DOI 10.1016/0887-2333(93)90111-H; Jacob J, 2014, DIS MODEL MECH, V7, P107, DOI 10.1242/dmm.013219; KIMMEL CB, 1995, DEV DYNAM, V203, P253; Lightman EG, 2011, INT J DEV BIOL, V55, P597, DOI 10.1387/ijdb.113315el; Mahler J, 2007, BMC DEV BIOL, V7, DOI 10.1186/1471-213X-7-89; Morimura R, 2013, DEV NEUROBIOL, V73, P911, DOI 10.1002/dneu.22117; Schmidt R, 2013, NEURAL DEV, V8, DOI 10.1186/1749-8104-8-3; Takahata T, 2006, CEREB CORTEX, V16, P929, DOI 10.1093/cercor/bhj034; Tanaka H, 2011, DEV DYNAM, V240, P9, DOI 10.1002/dvdy.22499; Wegener D, 2003, MOL GENET METAB, V80, P138, DOI 10.1016/j.ymgme.2003.08.008; Westerfield M., 2007, ZEBRAFISH BOOK	48	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1058-8388	1097-0177		DEV DYNAM	Dev. Dyn.	NOV	2014	243	11					1401	1415		10.1002/dvdy.24173		15	Anatomy & Morphology; Developmental Biology	Anatomy & Morphology; Developmental Biology	AS6UU	WOS:000344398400003		
J	Saito, K; Sakai, C; Kawasaki, T; Sakai, N				Saito, Kenji; Sakai, Chiharu; Kawasaki, Toshihiroa; Sakai, Noriyoshi			Telomere Distribution Pattern and Synapsis Initiation During Spermatogenesis in Zebrafish	DEVELOPMENTAL DYNAMICS			English	Article						telomere bouquet; meiosis; Sycp3; meiotic mutant	FISSION YEAST; MEIOTIC PROPHASE; BOUQUET; CHROMOSOME; MEIOSIS; PROTEIN; MOUSE; REDISTRIBUTION; ARCHITECTURE; ATTACHMENT	Background: Telomeres are located at ends of eukaryotic chromosomes and can affect proper chromosomal positioning. During spermatogenesis, the appropriate dynamics and behavior of chromosomes is crucial to generate haploid cells through meiosis. Here, we describe telomere distribution patterns during spermatogenesis in zebrafish, especially during meiotic prophase I, using fluorescence in situ hybridization. This was combined with synaptonemal complex protein 3 immunostaining, which allows the staging of spermatocytes. Results: During spermatogonial proliferation and the preleptotene stage, telomeres were dispersed throughout the nucleus. During the leptotene stage, telomeres temporarily moved to one pole of the nucleus at which -tubulin was located, forming the telomere bouquet. The cluster lasted until the onset of zygotene where it coincided with terminal synapsis initiation. They then spread around the periphery of the nucleus during the zygotene to pachytene stages. During postmeiotic stages, telomeres in spermatids and sperm were again dispersed throughout the nuclei. Application of this procedure in meiotic mutants confirmed that meiotic telomere clustering is independent of axial element formation of the synaptonemal complex. Conclusions: These data clearly showed the clustering and distributions of telomeres throughout spermatogenesis in zebrafish. This procedure could be used to screen for mutants that have primary defects in telomere clustering. Developmental Dynamics 243:1448-1456, 2014. (c) 2014 Wiley Periodicals, Inc.	[Saito, Kenji; Sakai, Chiharu; Kawasaki, Toshihiroa; Sakai, Noriyoshi] Natl Inst Genet, Genet Strains Res Ctr, Mishima, Shizuoka 4118540, Japan; [Sakai, Noriyoshi] Grad Univ Adv Studies SOKENDAI, Dept Genet, Mishima, Shizuoka, Japan	Sakai, N (reprint author), Natl Inst Genet, Genet Strains Res Ctr, 1111 Yata, Mishima, Shizuoka 4118540, Japan.	nosakai@lab.nig.ac.jp			Ministry of Education, Culture, Sport, Science, and Technology, Japan [23013023, 25251034]	Grant sponsor: Grant-in-Aid from the Ministry of Education, Culture, Sport, Science, and Technology, Japan; Grant numbers: 23013023; 25251034	Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; Scherthan H, 1996, J CELL BIOL, V134, P1109, DOI 10.1083/jcb.134.5.1109; Ding X, 2007, DEV CELL, V12, P863, DOI 10.1016/j.devcel.2007.03.018; Shimanuki M, 1997, MOL GEN GENET, V254, P238; Krovel AV, 2002, MECH DEVELOP, V116, P141, DOI 10.1016/S0925-4773(02)00154-5; Yamamoto A, 2001, BIOESSAYS, V23, P526, DOI 10.1002/bies.1072; Scherthan H, 2001, NAT REV MOL CELL BIO, V2, P621, DOI 10.1038/35085086; Meyer-Ficca M, 1998, J CELL SCI, V111, P1363; Kanoh J, 2001, CURR BIOL, V11, P1624, DOI 10.1016/S0960-9822(01)00503-6; Chikashige Y, 2006, CELL, V125, P59, DOI 10.1016/j.cell.2006.01.048; Tanemura K, 2005, DEV BIOL, V281, P196, DOI 10.1016/j.ydbio.2005.02.025; Liebe B, 2004, MOL BIOL CELL, V15, P827, DOI 10.1091/mbc.E03-07-0524; Ducray C, 1999, ONCOGENE, V18, P4211, DOI 10.1038/sj.onc.1202797; STEARNS T, 1991, CELL, V65, P825, DOI 10.1016/0092-8674(91)90390-K; Shibuya H, 2014, NAT CELL BIOL, V16, P145, DOI 10.1038/ncb2896; Feldser DM, 2003, NAT REV CANCER, V3, P623, DOI 10.1038/nrc1142; Ding DQ, 2004, DEV CELL, V6, P329, DOI 10.1016/S1534-5807(04)00059-0; Cooper JP, 1998, NATURE, V392, P828, DOI 10.1038/33947; Harper L, 2004, J CELL SCI, V117, P4025, DOI 10.1242/jcs.01363; Ozaki Y, 2011, GENE EXPR PATTERNS, V11, P309, DOI 10.1016/j.gep.2011.03.002; Pfeifer C, 2001, CYTOGENET CELL GENET, V93, P304, DOI 10.1159/000057002; Zalenskaya IA, 2002, INT REV CYTOL, V218, P37; Scherthan H, 2007, CELL MOL LIFE SCI, V64, P117, DOI 10.1007/s00018-006-6463-2; Trelles-Sticken E, 2000, J CELL BIOL, V151, P95, DOI 10.1083/jcb.151.1.95; Chikashige Y, 2001, CURR BIOL, V11, P1618, DOI 10.1016/S0960-9822(01)00457-2; Ashley T, 2004, CYTOGENET GENOME RES, V105, P166, DOI 10.1159/000078186; Cooper JP, 2000, CURR OPIN GENET DEV, V10, P169; desLange T., 2009, SCIENCE, V326, P948; Hashiguchi M, 2008, DEV BIOL, V321, P387, DOI 10.1016/j.ydbio.2008.06.035; Iwai T, 2006, EXP CELL RES, V312, P2528, DOI 10.1016/j.jexcr.2006.04.015; KIMMEL CB, 1995, DEV DYNAM, V203, P253; Luderus ME, 1996, J CELL BIOL, V135, P867, DOI 10.1083/jcb.135.4.867; Pfeifer C, 2003, DEV BIOL, V255, P206, DOI 10.1016/S0012-1606(02)00093-3; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; Saito K, 2011, DEV DYNAM, V240, P1779, DOI 10.1002/dvdy.22661; Scherthan H, 2011, CHROMOSOMA, V120, P151, DOI 10.1007/s00412-010-0295-4; Tomita K, 2006, CELL, V125, P19, DOI 10.1016/j.cell.2006.03.020; VOURCH C, 1993, EXP CELL RES, V205, P142, DOI 10.1006/excr.1993.1068; Westerfield M., 1995, ZEBRAFISH BOOK GUIDE	39	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1058-8388	1097-0177		DEV DYNAM	Dev. Dyn.	NOV	2014	243	11					1448	1456		10.1002/dvdy.24166		9	Anatomy & Morphology; Developmental Biology	Anatomy & Morphology; Developmental Biology	AS6UU	WOS:000344398400007		
J	Kaku, K; Kiyosue, A; Inoue, S; Ueda, N; Tokudome, T; Yang, J; Langkilde, AM				Kaku, K.; Kiyosue, A.; Inoue, S.; Ueda, N.; Tokudome, T.; Yang, J.; Langkilde, A. M.			Efficacy and safety of dapaglflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise	DIABETES OBESITY & METABOLISM			English	Article						clinical trial; dapagliflozin; phase Ill study; randomized trial; 5GL12 inhibitor; type 2 diabetes mellitus	RANDOMIZED CLINICAL-TRIALS; PLACEBO-CONTROLLED TRIAL; DOUBLE-BLIND; GLYCEMIC CONTROL; BODY-WEIGHT; ADD-ON; DAPAGLIFLOZIN; METFORMIN; MELLITUS; INHIBITOR	Aims: To evaluate the efficacy and safety of the selective sodium glucose co-transporter 2 inhibitor dapagliflozin in Japanese patients with type 2 diabetes mellitus (T2DM) inadequately controlled by diet and exercise. Methods: Patients received placebo or dapagliflozin (5 or 10 mg) once daily for 24 weeks. The primary outcome measure was change from baseline in glycated haemoglobin (HbAlc). Results: Patients (N = 261) had modestly elevated baseline HbAl c (mean 7.59/o) and most had mild or moderate renal impairment (estimated glomerular filtration rate range 43-103 mlimin11.73 m2). Greater reductions in mean HbAl c level were observed with dapagliflozin (5 mg, -0.419/o; 10 mg, -0.450(o) than with placebo (-0.060/o) at week 24 and these were greater in patients with higher baseline HbAl c levels. Fasting plasma glucose (HG) was also significantly reduced with dapagliflozin (5 mg, -8.6 mgidl; 10 mg, -13.7 mg/c11) compared with placebo (+5.8 mg/d1). Dapagliflozin significantly reduced body weight (5 mg, -2.13 kg; 10 mg, -2.22 kg) compared with placebo (-0.84 kg). Overall, 47.7 and 64.8% of patients with dapagliflozin 5 and 10 mg, respectively, and 51.70/0 with placebo experienced >1 adverse event, mostly mild or moderate, and unrelated to study treatment. Two patients on dapagliflozin 10 mg reported hypoglycaemia. Four patients across all groups reported events suggestive of genital infection and four of urinary tract infection. No events of pyelonephritis were reported. Conclusion: Dapagliflozin (5 and 10 mg) was well tolerated and effective in reducing HbAl c, ERG and body weight over 24 weeks in Japanese patients with 12DM inadequately controlled by diet and exercise.	[Kaku, K.] Kawasaki Med Univ, Dept Internal Med, Okayama, Japan; [Kiyosue, A.] Tokyo Eki Ctr Bldg Clin, Tokyo, Japan; [Inoue, S.] Med Corp Heishinkai OCROM Clin, Osaka, Japan; [Ueda, N.] AMC Nishi Umeda Clin, Osaka, Japan; [Tokudome, T.] Bristol Myers KK, Tokyo, Japan; [Yang, J.] AstraZeneca KK, Osaka, Japan; [Langkilde, A. M.] AstraZeneca R&D, Molndal, Sweden	Kaku, K (reprint author), Kawasaki Med Univ, Dept Internal Med, Okayama, Japan.	kka@med.kawasaki-m.ac.jp			AstraZeneca; Bristol-Myers Squibb	Medical writing assistance was provided by Karen Pemberton, PhD, of PPSI (a PAREXEL company) and funded by AstraZeneca and Bristol-Myers Squibb.	Abdul-Ghani Muhammad A, 2008, Endocr Pract, V14, P782; Inagaki N, 2013, DIABETES OBES METAB, V15, P1136, DOI 10.1111/dom.12149; Kasichayanula S, 2011, DIABETES OBES METAB, V13, P357, DOI 10.1111/j.1463-1326.2011.01359.x; Vallon V, 2011, J AM SOC NEPHROL, V22, P104, DOI 10.1681/ASN.2010030246; Henry RR, 2012, INT J CLIN PRACT, V66, P446, DOI 10.1111/j.1742-1241.2012.02911.x; Bailey CJ, 2010, LANCET, V375, P2223, DOI 10.1016/S0140-6736(10)60407-2; Neville SE, 2009, DIABETES-METAB RES, V25, P705, DOI 10.1002/dmrr.1012; Rosenstock J, 2012, DIABETES CARE, V35, P1473, DOI 10.2337/dc11-1693; Wilding JPH, 2009, DIABETES CARE, V32, P1656, DOI 10.2337/dc09-0517; Kasichayanula S, 2013, BRIT J CLIN PHARMACO, V76, P432, DOI 10.1111/bcp.12056; Strojek K, 2011, DIABETES OBES METAB, V13, P928, DOI 10.1111/j.1463-1326.2011.01434.x; Ferrannini E, 2010, DIABETES CARE, V33, P2217, DOI 10.2337/dc10-0612; List JF, 2009, DIABETES CARE, V32, P650, DOI 10.2337/dc08-1863; Tsiatis AA, 2008, STAT MED, V27, P4658, DOI 10.1002/sim.3113; Bailey CJ, 2011, TRENDS PHARMACOL SCI, V32, P63, DOI 10.1016/j.tips.2010.11.011; Wilding JPH, 2012, ANN INTERN MED, V156, P405, DOI [10.7326/0003-4819-156-6-201203200-00003, 10.1059/0003-4819-156-6-201203200-00003]; Bolinder J, 2012, J CLIN ENDOCR METAB, V97, P1020, DOI 10.1210/jc.2011-2260; Zhang M, 2008, BIOMETRICS, V64, P707, DOI 10.1111/j.1541-0420.2007.00976.x; Nauck MA, 2011, DIABETES CARE, V34, P2015, DOI [10.2337/dc11-0606, 10.2337/de11-0606]; AstraZeneca, FORXIGA DAP NOW APPR; Bailey CJ, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-43; Bailey CJ, 2012, DIABETOLOGIA, V55, pS295; Food and Drug Administration, FDA APPR FARX TREAT; Ghosh RK, 2012, J CLIN PHARMACOL, V52, P457, DOI 10.1177/0091270011400604; Kaku K, 2012, DIABETES OBES METAB, V15, P432; Wright EM, 2007, J INTERN MED, V261, P32, DOI 10.1111/j.1365-2796.2006.01746.x	26	7	8	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1462-8902	1463-1326		DIABETES OBES METAB	Diabetes Obes. Metab.	NOV	2014	16	11					1102	1110		10.1111/dom.12325		9	Endocrinology & Metabolism	Endocrinology & Metabolism	AT3ZK	WOS:000344875200009		
J	Dibaba, DT; Xun, P; Fly, AD; Yokota, K; He, K				Dibaba, D. T.; Xun, P.; Fly, A. D.; Yokota, K.; He, K.			Dietary magnesium intake and risk of metabolic syndrome: a meta-analysis	DIABETIC MEDICINE			English	Review							DEPENDENT DIABETES-MELLITUS; CORONARY-HEART-DISEASE; LIFE-STYLE FACTORS; DOUBLE-BLIND; NONDIABETIC SUBJECTS; INSULIN SENSITIVITY; RANDOMIZED-TRIAL; SMOOTH-MUSCLE; YOUNG-ADULTS; FATTY-ACIDS	AimsTo estimate quantitatively the association between dietary magnesium intake and risk of metabolic syndrome by combining the relevant published articles using meta-analysis. MethodsWe reviewed the relevant literature in PubMed and EMBASE published up until August 2013 and obtained additional information through Google or a hand search of the references in relevant articles. A random-effects or fixed-effects model, as appropriate, was used to pool the effect sizes on metabolic syndrome comparing individuals with the highest dietary magnesium intake with those having the lowest intake. The dose-response relationship was assessed for every 100-mg/day increment in magnesium intake and risk of metabolic syndrome. ResultSix cross-sectional studies, including a total of 24 473 individuals and 6311 cases of metabolic syndrome, were identified as eligible for the meta-analysis. A weighted inverse association was found between dietary magnesium intake and the risk of metabolic syndrome (odds ratio 0.69, 95% CI 0.59, 0.81) comparing the highest with the lowest group. For every 100-mg/day increment in magnesium intake, the overall risk of having metabolic syndrome was lowered by 17% (odds ratio 0.83, 95% CI 0. 77, 0.89). ConclusionFindings from the present meta-analysis suggest that dietary magnesium intake is inversely associated with the prevalence of metabolic syndrome. Further studies, in particular well-designed longitudinal cohort studies and randomized placebo-controlled clinical trials, are warranted to provide solid evidence and to establish causal inference.	[Dibaba, D. T.; Xun, P.; He, K.] Indiana Univ, Dept Epidemiol & Biostat, Sch Publ Hlth Bloomington, Bloomington, IN 47405 USA; [Fly, A. D.] Indiana Univ, Dept Appl Hlth Sci, Sch Publ Hlth Bloomington, Bloomington, IN 47405 USA; [Yokota, K.] Jikei Univ, Sch Med, Dept Internal Med, Tokyo, Japan	He, K (reprint author), Indiana Univ, Dept Epidemiol & Biostat, Sch Publ Hlth Bloomington, Bloomington, IN 47405 USA.	kahe@indiana.edu			National Institutes of Health [R01HL081572, R01ES021735]	This study was partially supported by National Institutes of Health grants (R01HL081572 and R01ES021735).	ALTURA BM, 1982, CAN J PHYSIOL PHARM, V60, P459; Deshmukh-Taskar PR, 2009, PUBLIC HEALTH NUTR, V12, P2493, DOI 10.1017/S1368980009991261; Yu YH, 2012, NUTR RES, V32, P71, DOI 10.1016/j.nutres.2011.12.004; Guerrero-Romero F, 2004, DIABETES METAB, V30, P253, DOI 10.1016/S1262-3636(07)70116-7; Riccardi G, 2000, BRIT J NUTR, V83, pS143; Riccardi G, 2004, CLIN NUTR, V23, P447, DOI 10.1016/j.clnu.2004.02.006; PAOLISSO G, 1992, AM J CLIN NUTR, V55, P1161; SUAREZ A, 1995, DIABETOLOGIA, V38, P1262; Li XT, 2012, ASIA PAC J CLIN NUTR, V21, P296; He K, 2006, CIRCULATION, V113, P1675, DOI 10.1161/CIRCULATIONAHA.105.588327; Gillingham LG, 2011, LIPIDS, V46, P209, DOI 10.1007/s11745-010-3524-y; Montague CT, 1997, NATURE, V387, P903; Zhu SK, 2004, METABOLISM, V53, P1503, DOI 10.1016/j.metabol.2004.04.017; Guerrero-Romero F, 2006, DIABETES-METAB RES, V22, P471, DOI 10.1002/dmrr.644; Volek JS, 2009, LIPIDS, V44, P297, DOI 10.1007/s11745-008-3274-2; Mirmiran P, 2012, PUBLIC HEALTH NUTR, V15, P693, DOI 10.1017/S1368980011002941; McKeown NM, 2008, EUR J NUTR, V47, P210, DOI 10.1007/s00394-008-0715-x; Song YQ, 2005, DIABETES CARE, V28, P1438, DOI 10.2337/diacare.28.6.1438; Beydoun MA, 2008, AM J CLIN NUTR, V87, P1914; Feldeisen SE, 2007, APPL PHYSIOL NUTR ME, V32, P46, DOI 10.1139/H06-101; Andersen CJ, 2013, REV ENDOCR METAB DIS, V14, P241, DOI 10.1007/s11154-013-9251-y; Guerrero-Romero F, 2002, ACTA DIABETOL, V39, P209; GREENLAND S, 1992, AM J EPIDEMIOL, V135, P1301; Ninomiya JK, 2004, CIRCULATION, V109, P42, DOI 10.1161/01.CIR.0000108926.04022.0C; Noori N, 2010, J RENAL NUTR, V20, P101, DOI 10.1053/j.jrn.2009.06.001; Hata A, 2013, DIABETIC MED, V30, P1487, DOI 10.1111/dme.12250; Mooren FC, 2011, DIABETES OBES METAB, V13, P281, DOI 10.1111/j.1463-1326.2010.01332.x; Bo S, 2006, AM J CLIN NUTR, V84, P1062; Boucher Barbara J, 2012, Dermatoendocrinol, V4, P212, DOI 10.4161/derm.20012; Cahill F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058278; Chien KL, 2007, ATHEROSCLEROSIS, V194, P214, DOI 10.1016/j.atherosclerosis.2006.07.033; DANGELO EKG, 1992, J CLIN INVEST, V89, P1988, DOI 10.1172/JCI115807; desOliveira EP, 2012, NUTR J, V11, P13; ECKEL J, 1984, DIABETES, V33, P214, DOI 10.2337/diabetes.33.3.214; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Ford ES, 2007, OBESITY, V15, P1139, DOI 10.1038/oby.2007.628; Guerrero-Romero F, 2009, J HUM HYPERTENS, V23, P245, DOI 10.1038/jhh.2008.129; Huang JH, 2012, NUTR J, V11, DOI 10.1186/1475-2891-11-41; Joung Hyojee, 2012, Korean J Pediatr, V55, P128, DOI 10.3345/kjp.2012.55.4.128; Kandeel FR, 1996, METABOLISM, V45, P838, DOI 10.1016/S0026-0495(96)90156-0; Kishimoto Y, 2010, BRIT J NUTR, V103, P469, DOI 10.1017/S0007114509992716; Laakso M, 1996, ANN MED, V28, P341, DOI 10.3109/07853899608999091; Leite MLC, 2009, PUBLIC HEALTH NUTR, V12, P1494, DOI 10.1017/S1368980008004539; Liu S, 2013, MAGNESIUM HUMAN HLTH, P35; NOGUERA MA, 1993, J PHARM PHARMACOL, V45, P697; Steemburgo T, 2007, ARQ BRAS ENDOCRINOL, V51, P1425, DOI 10.1590/S0004-27302007000900004; Syvanne M, 1997, LANCET, V350, pSI20; Volek Jeff S, 2005, Nutr Metab (Lond), V2, P31, DOI 10.1186/1743-7075-2-31; Wannamethee SG, 2006, J AM GERIATR SOC, V54, P1909, DOI 10.1111/j.1532-5415.2006.00974.x	49	3	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0742-3071	1464-5491		DIABETIC MED	Diabetic Med.	NOV	2014	31	11					1301	1309		10.1111/dme.12537		9	Endocrinology & Metabolism	Endocrinology & Metabolism	AS1BB	WOS:000344010200005		
J	Kawakita, R; Hosokawa, Y; Fujimaru, R; Tamagawa, N; Urakami, T; Takasawa, K; Moriya, K; Mizuno, H; Maruo, Y; Takuwa, M; Nagasaka, H; Nishi, Y; Yamamoto, Y; Aizu, K; Yorifuji, T				Kawakita, R.; Hosokawa, Y.; Fujimaru, R.; Tamagawa, N.; Urakami, T.; Takasawa, K.; Moriya, K.; Mizuno, H.; Maruo, Y.; Takuwa, M.; Nagasaka, H.; Nishi, Y.; Yamamoto, Y.; Aizu, K.; Yorifuji, T.			Molecular and clinical characterization of glucokinase maturity-onset diabetes of the young (GCK-MODY) in Japanese patients	DIABETIC MEDICINE			English	Article							MUTATIONS; MELLITUS; IDENTIFICATION; FAMILIES; GLUCOSE; GENES	AimsTo investigate the molecular and clinical characteristics of the largest series of Japanese patients with glucokinase maturity-onset diabetes of the young (GCK-MODY), and to find any features specific to Asian people. MethodsWe enrolled 78 Japanese patients with GCK-MODY from 41 families (55 probands diagnosed at the age of 0-14years and their 23 adult family members). Mutations were identified by direct sequencing or multiplex ligation-dependent probe amplification of all exons of the GCK gene. Detailed clinical and laboratory data were collected on the probands using questionnaires, which were sent to the treating physicians.Data on current clinical status and HbA(1c) levels were also collected from adult patients. ResultsA total of 35 different mutations were identified, of which seven were novel. Fasting blood glucose and HbA(1c) levels of the probands were 9.3mmol/l and 56mmol/mol (7.3%), respectively, and there was considerable variation in their BMI percentiles (0.4-96.2). In total, 25% of the probands had elevated homeostatic assessment of insulin resistance values, and 58.3% of these had evidence of concomitant Type 2 diabetes in their family. The HbA(1c) levels for adults were slightly higher, up to 61mmol/mol (7.8%). The incidence of microvascular complications was low. Out of these 78 people with GCK-MODY and 40 additional family members with hyperglycaemia whose genetic status was unknown, only one had diabetic nephropathy. ConclusionsThe molecular and clinical features of GCK-MODY in Japanese people are similar to those of other ethnic populations; however, making a diagnosis of GCK-MODY was more challenging in patients with signs of insulin resistance.	[Kawakita, R.; Hosokawa, Y.; Fujimaru, R.; Yorifuji, T.] Childrens Med Ctr, Dept Pediat Endocrinol & Metab, Osaka, Japan; [Tamagawa, N.; Yorifuji, T.] Osaka City Gen Hosp, Clin Res Ctr, Osaka, Japan; [Urakami, T.] Nihon Univ, Sch Med, Dept Paediat, Tokyo, Japan; [Takasawa, K.] Tokyo Med & Dent Univ, Dept Paediat, Tokyo, Japan; [Moriya, K.] Tohoku Univ, Sch Med, Dept Paediat, Sendai, Miyagi 980, Japan; [Mizuno, H.] Nagoya City Univ, Grad Sch Med Sci, Dept Paediat & Neonatol, Nagoya, Aichi, Japan; [Maruo, Y.] Shiga Univ Med Sci, Dept Paediat, Otsu, Shiga, Japan; [Takuwa, M.; Nagasaka, H.] Takarazuka City Hosp, Dept Paediat, Takarazuka, Hyogo, Japan; [Nishi, Y.] Hiroshima Red Cross Hosp, Dept Paediat, Hiroshima, Japan; [Yamamoto, Y.] Univ Occupat & Environm Hlth, Sch Med, Dept Paediat, Kitakyushu, Fukuoka 807, Japan; [Aizu, K.] Saitama Childrens Med Ctr, Div Endocrinol & Metab, Saitama, Japan	Kawakita, R (reprint author), Childrens Med Ctr, Dept Pediat Endocrinol & Metab, Osaka, Japan.	r-kawakita@hospital.city.osaka.jp			Grant for National Center for Child Health and Development [25-10]	This work was supported in part by a Grant for National Center for Child Health and Development (25-10).	MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Xu JY, 2005, EUR J HUM GENET, V13, P422, DOI 10.1038/sj.ejhg.5201347; Ma RCW, 2013, ANN NY ACAD SCI, V1281, P64, DOI 10.1111/nyas.12098; Ellard S, 2008, DIABETOLOGIA, V51, P546, DOI 10.1007/s00125-008-0942-y; Velho G, 1997, DIABETOLOGIA, V40, P217, DOI 10.1007/s001250050666; Hwang JS, 2006, DIABETES RES CLIN PR, V74, P75, DOI 10.1016/j.diabres.2006.03.002; Yorifuji T, 2012, PEDIATR DIABETES, V13, P26, DOI 10.1111/j.1399-5448.2011.00827.x; Ng MCY, 1999, DIABETIC MED, V16, P956, DOI 10.1046/j.1464-5491.1999.00188.x; Sone H, 2003, LANCET, V361, P85, DOI 10.1016/S0140-6736(03)12151-4; Steele AM, 2014, JAMA-J AM MED ASSOC, V311, P279, DOI 10.1001/jama.2013.283980; Murphy R, 2008, NAT CLIN PRACT ENDOC, V4, P200, DOI 10.1038/ncpendmet0778; Inokuchi M, 2006, ANN HUM BIOL, V33, P444, DOI 10.1080/03014460600802353; IWASAKI N, 1995, ACTA DIABETOL, V32, P17; Pruhova S, 2013, INT J ENDOCRINOL, DOI 10.1155/2013/718254; Steele AM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065326; Stride A, 2002, DIABETOLOGIA, V45, P427, DOI 10.1007/s00125-001-0770-9; World Health Organization, 2006, DEF DIAGN DIAB MELL, P1; Yamane S, 2012, HIMAN KENKYU, V18, P33	18	2	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0742-3071	1464-5491		DIABETIC MED	Diabetic Med.	NOV	2014	31	11					1357	1362		10.1111/dme.12487		6	Endocrinology & Metabolism	Endocrinology & Metabolism	AS1BB	WOS:000344010200012		
J	Heianza, Y; Kato, K; Fujihara, K; Tanaka, S; Kodama, S; Hanyu, O; Sato, K; Sone, H				Heianza, Y.; Kato, K.; Fujihara, K.; Tanaka, S.; Kodama, S.; Hanyu, O.; Sato, K.; Sone, H.			Role of sleep duration as a risk factor for Type 2 diabetes among adults of different ages in Japan: the Niigata Wellness Study	DIABETIC MEDICINE			English	Article							POPULATION; QUALITY; METAANALYSIS; HYPERTENSION; QUANTITY; OBESITY; WORKERS; COHORT; HEALTH; FAMILY	AimTo compare the role of short sleep duration as a risk factor for diabetes among adults of different ages. MethodsThe study enrolled 38987 Japanese individuals without diabetes, and the 8-year risk of developing diabetes attributable to different sleep durations (<5.5h, 5.5 to <6.5h, 6.5 to <7.0h, 7.0-7.5h, >7.5-8.0h, or >8.0h) was assessed among individuals aged 45, 46-59 or 60years. ResultsDuring the 8-year follow-up period, 2085 individuals developed diabetes. Overall, individuals with a short sleep duration of <5.5h or 5.5 to <6.5h had, respectively, a 1.53-fold (95% CI 1.19, 1.97) or 1.25-fold (95% CI 1.10, 1.42) increased risk of diabetes as compared with those who had 7.0-7.5h of sleep. A sleep duration of <5.5h or 5.5 to <6.5h was predictive of the development of diabetes among individuals aged 45years, but not among those aged 60years. With increasing age, the effect of short sleep duration on the risk of diabetes was attenuated. ConclusionsShort sleep duration was predictive of diabetes among young or middle-aged Japanese adults but not among elderly individuals after age was considered. Managing habitual short sleep and the possible reasons for having such short sleep duration could be particularly important for young or middle-aged adults in the development of future diabetes.	[Heianza, Y.; Kato, K.; Fujihara, K.; Kodama, S.; Hanyu, O.; Sone, H.] Niigata Univ, Fac Med, Dept Internal Med, Niigata, Japan; [Kato, K.; Kodama, S.] Niigata Univ, Grad Sch Med & Dent Sci, Dept Lab Med & Clin Epidemiol Prevent Noncommun, Niigata, Japan; [Tanaka, S.] Kyoto Univ, Grad Sch Med & Publ Hlth, Dept Pharmacoepidemiol, Kyoto, Japan; [Sato, K.; Sone, H.] Niigata Assoc Occupat Hlth, Niigata, Japan	Sone, H (reprint author), Niigata Univ, Fac Med, Dept Internal Med, Niigata, Japan.	sone@med.niigata-u.ac.jp			Ministry of Health, Labour and Welfare, Japan; Japan Society for the Promotion of Science	This work was financially supported in part by the Ministry of Health, Labour and Welfare, Japan. H.S. and Y.H. are recipients of a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science. The sponsors had no role in the design and conduct of the study.	American Diabetes Association, 2010, DIABETES CARE S1, V33, pS62, DOI DOI 10.2337/DC10-S062; Gangwisch JE, 2006, HYPERTENSION, V47, P833, DOI 10.1161/01.HYP.0000217362.34748.e0; Kita T, 2012, DIABETES CARE, V35, P313, DOI 10.2337/dc11-1455; Ayas NT, 2003, DIABETES CARE, V26, P380, DOI 10.2337/diacare.26.2.380; Zimberg IZ, 2012, CELL BIOCHEM FUNCT, V30, P524, DOI 10.1002/cbf.2832; Gangwisch JE, 2007, SLEEP, V30, P1667; Kim J, 2010, AM J HYPERTENS, V23, P1286, DOI 10.1038/ajh.2010.166; Cappuccio FP, 2010, DIABETES CARE, V33, P414, DOI 10.2337/dc09-1124; Xu Q, 2010, DIABETES CARE, V33, P78, DOI 10.2337/dc09-1143; Ohayon MM, 2004, SLEEP, V27, P1255; Spiegel K, 2005, J APPL PHYSIOL, V99, P2008, DOI 10.1152/japplphysiol.00660.2005; Hairston KG, 2010, SLEEP, V33, P289; Yaggi HK, 2006, DIABETES CARE, V29, P657, DOI 10.2337/diacare.29.03.06.dc05-0879; Gangwisch JE, 2005, SLEEP, V28, P1289; Boyko EJ, 2013, DIABETES CARE, V36, P3154, DOI 10.2337/DC13-0042; Krueger PM, 2009, AM J EPIDEMIOL, V169, P1052, DOI 10.1093/aje/kwp023; Hayashino Y, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-129; Holliday EG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082305; von Ruesten A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030972; yStatistics Bureau Ministry of Internal Affairs and Communications, SURV TIM US LEIS ACT	20	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0742-3071	1464-5491		DIABETIC MED	Diabetic Med.	NOV	2014	31	11					1363	1367		10.1111/dme.12555		5	Endocrinology & Metabolism	Endocrinology & Metabolism	AS1BB	WOS:000344010200013		
J	Yoshizawa, S; Heianza, Y; Arase, Y; Saito, K; Hsieh, SD; Tsuji, H; Hanyu, O; Suzuki, A; Tanaka, S; Kodama, S; Shimano, H; Hara, S; Sone, H				Yoshizawa, S.; Heianza, Y.; Arase, Y.; Saito, K.; Hsieh, S. D.; Tsuji, H.; Hanyu, O.; Suzuki, A.; Tanaka, S.; Kodama, S.; Shimano, H.; Hara, S.; Sone, H.			Comparison of different aspects of BMI history to identify undiagnosed diabetes in Japanese men and women: Toranomon Hospital Health Management Center Study 12 (TOPICS 12)	DIABETIC MEDICINE			English	Article							BODY-WEIGHT; FAT DISTRIBUTION; RISK-FACTORS; MELLITUS; AGE; ASSOCIATION; ADULTHOOD; PATTERNS; OBESITY; DISEASE	AimsTo examine current BMI and various aspects of BMI history as pre-screening tools for undiagnosed diabetes in Japanese individuals. MethodsThis cross-sectional study included 16 226 men and 7026 women aged 30-75 years without a self-reported history of clinician-diagnosed diabetes. We estimated the probability of having undiagnosed diabetes (fasting glucose 7.0 mmol/l and/or HbA(1c) 48 mmol/mol ( 6.5%) for the following variables: current BMI, BMI in the early 20s (BMI20y), lifetime maximum BMI (BMImax), change between BMI in the early 20s and current BMI (BMI20y-cur), change between BMI in the early 20s and maximum BMI (BMI20y-max), and change between lifetime maximum and current BMI (BMImax-cur). ResultsThe prevalence of undiagnosed diabetes was 3.3% (771/23252) among participants. BMImax, BMI20y-max and current BMI (1-sd increments) were more strongly associated with diabetes than the other factors (multivariate odds ratio 1.58 [95% CI 1.47-1.70] in men and 1.65 [95% CI 1.43-1.90] in women for BMImax; multivariate odds ratio 1.47 [95% CI 1.37-1.58] in men and 1.61 [95% CI 1.41-1.84] in women for BMI20y-max; multivariate odds ratio 1.47 [95% CI 1.36-1.58] in men and 1.63 [95% CI 1.40-1.89] in women for current BMI). The probability of having diabetes was markedly higher in those with both the highest tertile of BMImax and greatest BMI20y-max; however, a substantially lower likelihood of diabetes was observed among individuals with the lowest and middle tertiles of current BMI (< 24.62 kg/m(2) in men and < 22.54 kg/m(2) in women). ConclusionsLifetime maximum BMI and BMI changes from early adulthood were strongly associated with undiagnosed diabetes. Adding BMI history to people's current BMI would improve the identification of individuals with a markedly higher probability of having undiagnosed diabetes.	[Yoshizawa, S.; Heianza, Y.; Saito, K.; Hanyu, O.; Suzuki, A.; Kodama, S.; Sone, H.] Niigata Univ, Fac Med, Dept Internal Med, Niigata, Japan; [Heianza, Y.; Arase, Y.; Saito, K.; Hsieh, S. D.; Tsuji, H.; Kodama, S.; Hara, S.; Sone, H.] Toranomon Gen Hosp, Hlth Management Ctr, Tokyo, Japan; [Arase, Y.; Hsieh, S. D.; Tsuji, H.; Hara, S.] Okinaka Mem Inst Med Res, Tokyo, Japan; [Saito, K.] Ibaraki Prefectural Univ Hlth Sci, Ctr Med Sci, Ibaraki, Japan; [Tanaka, S.] Kyoto Univ, Grad Sch Med & Publ Hlth, Dept Pharmacoepidemiol, Kyoto, Japan; [Shimano, H.] Univ Tsukuba, Dept Internal Med, Inst Clin Med, Ibaraki, Japan	Sone, H (reprint author), Niigata Univ, Fac Med, Dept Internal Med, Niigata, Japan.	sone@med.niigata-u.ac.jp			Ministry of Health, Labour and Welfare, Japan; Japan Society for the Promotion of Science	This work was financially supported in part by the Ministry of Health, Labour and Welfare, Japan. H. S. and Y.H. are recipients of a Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science. The sponsor had no role in the design and conduct of the study.	FORBES GB, 1970, METABOLIS, V19, P653, DOI 10.1016/0026-0495(70)90062-4; Schmidt MI, 2005, DIABETES CARE, V28, P2013, DOI 10.2337/diacare.28.8.2013; Simmons RK, 2010, DIABETES OBES METAB, V12, P838, DOI 10.1111/j.1463-1326.2010.01244.x; [Anonymous], 2011, DIABETES CARE S1, V34, pS11; CASEY VA, 1991, AM J CLIN NUTR, V53, P1493; CHAN JM, 1994, DIABETES CARE, V17, P961, DOI 10.2337/diacare.17.9.961; Tamakoshi K, 2003, INT J OBESITY, V27, P247, DOI 10.1038/sj.ijo.802195; Schienkiewitz A, 2006, AM J CLIN NUTR, V84, P427; Yang WY, 2010, NEW ENGL J MED, V362, P1090, DOI 10.1056/NEJMoa0908292; HOLBROOK TL, 1989, INT J OBESITY, V13, P723; Tirosh A, 2011, NEW ENGL J MED, V364, P1315, DOI 10.1056/NEJMoa1006992; Oguma Y, 2005, OBES RES, V13, P945, DOI 10.1038/oby.2005.109; Ma J, 2013, JAMA INTERN MED, V173, P113, DOI 10.1001/2013.jamainternmed.987; Narayan KMV, 2007, DIABETES CARE, V30, P1562, DOI 10.2337/dc06-2544; Schellenberg ES, 2013, ANN INTERN MED, V159, P543, DOI 10.7326/0003-4819-159-8-201310150-00007; Kashiwagi A, 2012, J DIABETES INVEST, V3, P39, DOI 10.1111/j.2040-1124.2012.00207.x; Nanri A, 2011, J EPIDEMIOL COMMUN H, V65, P1104, DOI 10.1136/jech.2009.097964; Nakamura K, 1999, J BIOSOC SCI, V31, P555, DOI 10.1017/S0021932099005556; Attard SM, 2013, OBESITY, V21, P2180, DOI 10.1002/oby.20569; Brancati FL, 1999, ARCH INTERN MED, V159, P957, DOI 10.1001/archinte.159.9.957; Cohen SS, 2009, PREV MED, V49, P476, DOI 10.1016/j.ypmed.2009.10.010; COLDITZ GA, 1995, ANN INTERN MED, V122, P481; Kaneto C, 2013, DIABETES RES CLIN PR, V102, P138, DOI 10.1016/j.diabres.2013.08.011; Koh-Banerjee P, 2004, AM J EPIDEMIOL, V159, P1150, DOI 10.1093/aje/kwh167; Kowall B, 2011, INT J OBESITY, V36, P826; Lim S, 2013, PLOS ONE, V8; Noble D, 2011, BRIT MED J, V343, DOI 10.1136/bmj.d7163; Sakurai Y, 1997, DIABETES CARE, V20, P978, DOI 10.2337/diacare.20.6.978; Wakabayashi I, 2012, DIABETES CARE, V35, P175, DOI 10.2337/dc11-1775; Wei W, 2010, PUBLIC HEALTH, V124, P593, DOI 10.1016/j.puhe.2010.05.014	30	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0742-3071	1464-5491		DIABETIC MED	Diabetic Med.	NOV	2014	31	11					1378	1386		10.1111/dme.12471		9	Endocrinology & Metabolism	Endocrinology & Metabolism	AS1BB	WOS:000344010200015		
J	Tokuhara, D; Nochi, T; Matsumura, A; Mejima, M; Takahashi, Y; Kurokawa, S; Kiyono, H; Yuki, Y				Tokuhara, Daisuke; Nochi, Tomonori; Matsumura, Akiko; Mejima, Mio; Takahashi, Yuko; Kurokawa, Shiho; Kiyono, Hiroshi; Yuki, Yoshikazu			Specific Expression of Apolipoprotein A-IV in the Follicle-Associated Epithelium of the Small Intestine	DIGESTIVE DISEASES AND SCIENCES			English	Article						Apolipoprotein A-IV; Mucosal immunology; Epithelial cell; Peyer's patch	GENE-EXPRESSION; INDUCTION; CELLS; RAT; PLASMA; IMMUNITY; AIV	Peyer's patches (PPs), which are covered by specialized follicle-associated epithelium (FAE) including M cells, play a central role in immune induction in the gastrointestinal tract. This study is to investigate a new molecule to characterize PPs. We generated a monoclonal antibody (mAb 10-15-3-3) that specifically reacts to the epithelium of PPs and isolated lymphoid follicles. Target antigen was analyzed by immunoprecipitation and mass spectrometry. Localization and expression of target antigen were evaluated by immunofluorescence, in situ hybridization and real-time PCR. Immunoprecipitation and mass spectrometry revealed that mAb 10-15-3-3 recognized apolipoprotein A-IV (ApoA-IV), a well-known lipid transporter; this finding was confirmed by the specific reactivity of mAb 10-15-3-3 to cells transfected with the murine ApoA-IV gene. Immunofluorescence using mAb 10-15-3-3 showed intestinal localization of ApoA-IV, in which strong expression of the ApoA-IV protein occurred throughout the entire intestinal epithelium during developing period before weaning but was restricted to the FAE in adult mice. In support of these findings, in situ hybridization showed strong expression of the ApoA-IV gene throughout the entire intestinal epithelium during developing period before weaning, but this expression was restricted to the FAE predominantly and the tips of villi to a lesser extent in adult mice. Deficiency of ApoA-IV had no effect on the organogenesis of PP in mice. Our current results reveal ApoA-IV as a novel FAE-specific marker especially in the upper small intestine of adult mice.	[Tokuhara, Daisuke; Nochi, Tomonori; Matsumura, Akiko; Mejima, Mio; Takahashi, Yuko; Kurokawa, Shiho; Kiyono, Hiroshi; Yuki, Yoshikazu] Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Div Mucosal Immunol, Tokyo 1088639, Japan; [Tokuhara, Daisuke] Osaka City Univ, Dept Pediat, Grad Sch Med, Osaka 558, Japan	Yuki, Y (reprint author), Univ Tokyo, Inst Med Sci, Dept Microbiol & Immunol, Div Mucosal Immunol, Tokyo 1088639, Japan.	yukiy@ims.u-tokyo.ac.jp			Ministry of Education, Culture, Sports, Science and Technology of Japan; Young Researcher Overseas Visits Program for Vitalizing Brain Circulation of the Japan Society for the Promotion of Science (JSPS); Japan Foundation for Pediatric Research; Department of Pediatrics at Osaka City University Graduate School of Medicine; Association for Preventive Medicine of Japan	This work was supported by grants from the Grant-in-Aid for Research Activity Start-up of the Ministry of Education, Culture, Sports, Science and Technology of Japan; Young Researcher Overseas Visits Program for Vitalizing Brain Circulation of the Japan Society for the Promotion of Science (JSPS); the Japan Foundation for Pediatric Research; Houjinkai fellowship award of the Department of Pediatrics at Osaka City University Graduate School of Medicine; and the Association for Preventive Medicine of Japan.	WU AL, 1979, J BIOL CHEM, V254, P7316; Kunisawa J, 2008, TRENDS IMMUNOL, V29, P505, DOI 10.1016/j.it.2008.07.008; Yuki Y, 2003, REV MED VIROL, V13, P293, DOI 10.1002/rmv.398; Finke D, 2002, IMMUNITY, V17, P363, DOI 10.1016/S1074-7613(02)00395-3; Nochi T, 2007, J EXP MED, V204, P2789, DOI 10.1084/jem.20070607; Stan S, 2003, BBA-MOL CELL BIOL L, V1631, P177, DOI 10.1016/S1388-1981(03)00004-0; KALOGERIS TJ, 1994, J LIPID RES, V35, P1141; Nochi T, 2004, CLIN IMMUNOL, V113, P326, DOI 10.1016/j.clim.2004.08.013; GREEN PHR, 1980, J CLIN INVEST, V65, P911, DOI 10.1172/JCI109745; Kronenberg F, 2000, J AM COLL CARDIOL, V36, P751, DOI 10.1016/S0735-1097(00)00775-0; Black DD, 2007, AM J PHYSIOL-GASTR L, V293, pG519, DOI 10.1152/ajpgi.00189.2007; BLACK DD, 1990, J LIPID RES, V31, P497; Carriere V, 2005, J BIOL CHEM, V280, P5406; Doi T, 2001, AM J PHYSIOL-REG I, V281, pR753; ELSHOURBAGY NA, 1985, P NATL ACAD SCI USA, V82, P8242, DOI 10.1073/pnas.82.23.8242; Haiman M, 2005, KIDNEY INT, V68, P1130, DOI 10.1111/j.1523-1755.2005.00519.x; Kalogeris TJ, 1996, AM J PHYSIOL-GASTR L, V270, pG277; Liu M, 2003, BRAIN RES, V971, P232, DOI 10.1016/S0006-8993(03)02402-8; Okumura T, 1996, AM J PHYSIOL-GASTR L, V270, pG49; Peignon G, 2006, J BIOL CHEM, V281, P3560, DOI 10.1074/jbc/M506360200; Vowinkel T, 2004, J CLIN INVEST, V114, P260, DOI 10.1172/JCI200421233; WILLIAMS SC, 1986, MOL CELL BIOL, V6, P3807	22	1	1	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0163-2116	1573-2568		DIGEST DIS SCI	Dig. Dis. Sci.	NOV	2014	59	11					2682	2692		10.1007/s10620-014-3203-6		11	Gastroenterology & Hepatology	Gastroenterology & Hepatology	AS6BA	WOS:000344348700014		
J	Moriwaki, T; Kajiwara, T; Matsumoto, T; Suzuki, H; Hiroshima, Y; Matsuda, K; Hirai, S; Yamamoto, Y; Yamada, T; Sugaya, A; Kobayashi, M; Endo, S; Ishige, K; Nishina, T; Hyodo, I				Moriwaki, T.; Kajiwara, T.; Matsumoto, T.; Suzuki, H.; Hiroshima, Y.; Matsuda, K.; Hirai, S.; Yamamoto, Y.; Yamada, T.; Sugaya, A.; Kobayashi, M.; Endo, S.; Ishige, K.; Nishina, T.; Hyodo, I.			Survival analysis of platinum-refractory patients with advanced esophageal cancer treated with docetaxel or best supportive care alone: a retrospective study	DISEASES OF THE ESOPHAGUS			English	Article						best supportive care; docetaxel; esophageal cancer; Glasgow prognostic score; platinum-refractory	PHASE-II TRIAL; SQUAMOUS-CELL CARCINOMA; ARBEITSGEMEINSCHAFT INTERNISTISCHE ONKOLOGIE; 2ND-LINE CHEMOTHERAPY; PROGNOSTIC SCORE; PLUS DOCETAXEL; CISPLATIN; ADENOCARCINOMA; PACLITAXEL; 5-FLUOROURACIL	The survival benefit of second-line chemotherapy with docetaxel in platinum-refractory patients with advanced esophageal cancer (AEC) remains unclear. A retrospective analysis of AEC patients with Eastern Cooperative Oncology Group performance status (PS) 2 was performed, and major organ functions were preserved, who determined to receive docetaxel or best supportive care (BSC) alone after failure of platinum-based chemotherapy. The post-progression survival (PPS), defined as survival time after disease progression following platinum-based chemotherapy, was analyzed by multivariate Cox regression analysis using factors identified as significant in univariate analysis of various 20 characteristics (age, sex, PS, primary tumor location, etc) including Glasgow prognostic score (GPS), which is a well-known prognostic factor in many malignant tumors. Sixty-six and 45 patients were determined to receive docetaxel and BSC between January 2007 and December 2011, respectively. The median PPS was 5.4 months (95% confidence interval [CI] 4.8-6.0) in the docetaxel group and 3.3 months (95% CI 2.5-4.0) in the BSC group (hazard ratio [HR] 0.56, 95% CI 0.38-0.84, P = 0.005). Univariate analysis revealed six significant factors: treatment, PS, GPS, number of metastatic organs, liver metastasis, and bone metastasis. Multivariate analysis including these significant factors revealed three independent prognostic factors: docetaxel treatment (HR 0.62, 95% CI 0.39-0.99, P = 0.043), better GPS (HR 0.61, 95% CI 0.46-0.81, P = 0.001), and no bone metastasis (HR 0.31, 95% CI 0.15-0.68, P = 0.003). There was a trend for PPS in favor of the docetaxel group compared with patients who refused docetaxel treatment in the BSC group (adjusted HR 0.61, 95% CI 0.29-1.29, P = 0.20). Docetaxel treatment may have prolonged survival in platinum-refractory patients with AEC.	[Moriwaki, T.; Suzuki, H.; Hiroshima, Y.; Matsuda, K.; Hirai, S.; Yamamoto, Y.; Yamada, T.; Sugaya, A.; Kobayashi, M.; Endo, S.; Ishige, K.; Hyodo, I.] Univ Tsukuba, Div Gastroenterol, Tsukuba, Ibaraki 3050006, Japan; [Kajiwara, T.; Matsumoto, T.; Nishina, T.] Natl Hosp Org, Shikoku Canc Ctr, Dept Gastrointestinal Med Oncol, Matsuyama, Ehime, Japan	Moriwaki, T (reprint author), Univ Tsukuba, Div Gastroenterol, Tennodai 1-1-1, Tsukuba, Ibaraki 3050006, Japan.	tmoriwak@gmail.com					Anderson SE, 2003, CANCER INVEST, V21, P512, DOI 10.1081/CNV-120022360; Lorenzen S, 2009, ANN ONCOL, V20, P1667, DOI 10.1093/annonc/mdp069; Al-Batran SE, 2008, J CLIN ONCOL, V26, P1435, DOI 10.1200/JCO.2007.13.9378; McMillan DC, 2013, CANCER TREAT REV, V39, P534, DOI 10.1016/j.ctrv.2012.08.003; Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516; IIZUKA T, 1992, JPN J CLIN ONCOL, V22, P172; Tebbutt NC, 2013, BRIT J CANCER, V108, P771, DOI 10.1038/bjc.2013.41; Thallinger CMR, 2011, J CLIN ONCOL, V29, P4709, DOI 10.1200/JCO.2011.36.7599; Muro K, 2004, ANN ONCOL, V15, P955, DOI 10.1093/annonc/mdh231; Jin JH, 2009, J THORAC ONCOL, V4, P1017, DOI 10.1097/JTO.0b013e3181add9c7; Mao WM, 2011, ASIAN PAC J CANCER P, V12, P2461; Lorenzen S, 2005, BRIT J CANCER, V92, P2129, DOI 10.1038/sj.bjc.6602645; Vashist YK, 2011, ANN SURG ONCOL, V18, P1130, DOI 10.1245/s10434-010-1383-7; Ford HER, 2014, LANCET ONCOL, V15, P78, DOI 10.1016/S1470-2045(13)70549-7; Kang JH, 2012, J CLIN ONCOL, V30, P1513, DOI 10.1200/JCO.2011.39.4585; Crumley ABC, 2008, J GASTROEN HEPATOL, V23, pE325, DOI 10.1111/j.1440-1746.2007.05105.x; Burtness B, 2009, ANN ONCOL, V20, P1242, DOI 10.1093/annonc/mdn787; Heath EI, 2002, INVEST NEW DRUG, V20, P95, DOI 10.1023/A:1014476602804; Kato K, 2011, CANCER CHEMOTH PHARM, V67, P1265, DOI 10.1007/s00280-010-1422-x; Li XY, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0746-x; Lordick F, 2003, BRIT J CANCER, V89, P630, DOI 10.1038/sj.bjc.6601168; Mizota A, 2011, ONCOLOGY-BASEL, V81, P237, DOI 10.1159/000334057; Rigas JR, 2005, SEMIN ONCOL, V32, pS39, DOI 10.1053/j.seminoncol.2005.04.005; Shim HJ, 2010, AM J CLIN ONCOL-CANC, V33, P624, DOI 10.1097/COC.0b013e3181bead92; Yamazaki K, 2008, INT J CLIN ONCOL, V13, P150, DOI 10.1007/s10147-007-0738-y	25	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1120-8694	1442-2050		DIS ESOPHAGUS	Dis. Esophagus	NOV-DEC	2014	27	8					737	743		10.1111/dote.12246		7	Gastroenterology & Hepatology	Gastroenterology & Hepatology	AS4DU	WOS:000344224300007		
J	Matui, H; Sato, Y				Matui, Hiroki; Sato, Yasuhiko			DECOMPOSITION RANK OF UHF-ABSORBING C*-ALGEBRAS	DUKE MATHEMATICAL JOURNAL			English	Article							CROSSED-PRODUCTS; STAR-ALGEBRAS; HYPERFINITENESS; AUTOMORPHISMS; EQUIVALENCE; INJECTIVITY; DIMENSION; PROOF	Let A be a unital separable simple C*-algebra with a unique tracial state. We prove that if A is nuclear and quasidiagonal, then A tensored with the universal uniformly hyperfinite (UHF) algebra has decomposition rank at most one. We then prove that A is nuclear, quasidiagonal, and has strict comparison if and only if A has finite decomposition rank. For such A, we also give a direct proof that A tensored with a UHF algebra has tracial rank zero. Using this result, we obtain a counterexample to the Powers-Sakai conjecture.	[Matui, Hiroki] Chiba Univ, Grad Sch Sci, Inage Ku, Chiba 2638522, Japan; [Sato, Yasuhiko] Kyoto Univ, Grad Sch Sci, Sakyo Ku, Kyoto 6068502, Japan	Matui, H (reprint author), Chiba Univ, Grad Sch Sci, Inage Ku, Chiba 2638522, Japan.	matui@math.s.chiba-u.ac.jp; ysato@math.kyoto-u.ac.jp			Japan Society for the Promotion of Science [22740099, 25887031]; Japan Society for the Promotion of Science, Global Centers of Excellence (COE) Program	Matui's work partially supported by Japan Society for the Promotion of Science Grant-in-Aid for Young Scientist (B) No. 22740099.; Sato's work partially supported by Japan Society for the Promotion of Science Grant-in-Aid for Research Activity Start-up No. 25887031 and by its Global Centers of Excellence (COE) Program.	AKEMANN CA, 1986, CAN J MATH, V38, P1239, DOI 10.4153/CJM-1986-063-7; Winter W, 2010, ADV MATH, V224, P461, DOI 10.1016/j.aim.2009.12.005; Lin HX, 2011, J FUNCT ANAL, V260, P1, DOI 10.1016/j.jfa.2010.08.019; Sato Y, 2010, J FUNCT ANAL, V259, P453, DOI 10.1016/j.jfa.2010.04.006; [Anonymous], 1988, LONDON MATH SOC LECT; Lin HX, 2008, ADV MATH, V219, P1729, DOI 10.1016/j.aim.2008.07.011; CONNES A, 1975, ANN SCI ECOLE NORM S, V8, P383; HAAGERUP U, 1985, J FUNCT ANAL, V62, P160, DOI 10.1016/0022-1236(85)90002-3; Matui H, 2012, COMMUN MATH PHYS, V314, P193, DOI 10.1007/s00220-011-1392-9; Matui H, 2012, ACTA MATH-DJURSHOLM, V209, P179, DOI 10.1007/s11511-012-0084-4; Lin HX, 2001, P LOND MATH SOC, V83, P199, DOI 10.1112/plms/83.1.199; Kirchberg E, 2002, ADV MATH, V167, P195, DOI 10.1006/aima.2001.2041; Kirchberg E, 2004, INT J MATH, V15, P63, DOI 10.1142/S0129167X04002119; RORDAM M, 1991, J FUNCT ANAL, V100, P1, DOI 10.1016/0022-1236(91)90098-P; Jiang XH, 1999, AM J MATH, V121, P359; Brown NP, 1998, J FUNCT ANAL, V160, P150, DOI 10.1006/jfan.1998.3339; BRATTELI O, 1980, COMMUN MATH PHYS, V74, P281, DOI 10.1007/BF01952891; Brown N. P., 2008, GRAD STUD MATH, V88; Kirchberg E., 1994, PREPRINT; KIRCHBERG E., J REINE ANG IN PRESS; Kishimoto A, 2003, J FUNCT ANAL, V200, P281, DOI 10.1016/S0022-1236(03)00024-7; Lin H., 2008, INT MATH RES PAP IMR; Lin Huaxin, 2001, T AM MATH SOC, V353, P693, DOI 10.1090/S0002-9947-00-02680-5; Loring Terry A., 1997, FIELDS I MONOGRAPHS, V8; Matui H., AM J MATH IN PRESS; POPA S, 1986, J OPERAT THEOR, V16, P261; Popa S, 1997, PAC J MATH, V181, P141; Powers R. T., 1974, Communications in Mathematical Physics, V39; Winter W, 2007, J FUNCT ANAL, V243, P394, DOI 10.1016/j.jfa.2006.11.001	31	8	8	DUKE UNIV PRESS	DURHAM	905 W MAIN ST, STE 18-B, DURHAM, NC 27701 USA	0012-7094	1547-7398		DUKE MATH J	Duke Math. J.	NOV 1	2014	163	14					2687	2708		10.1215/00127094-2826908		22	Mathematics	Mathematics	AS4AZ	WOS:000344217200005		
J	Dhaiveegan, P; Elangovan, N; Nishimura, T; Rajendran, N				Dhaiveegan, P.; Elangovan, N.; Nishimura, T.; Rajendran, N.			Electrochemical Characterization of Carbon and Weathering Steels Corrosion Products to Determine the Protective Ability Using Carbon Paste Electrode (CPE)	ELECTROANALYSIS			English	Article						Rust; Carbon paste electrode; SWV; Electrochemical impedance spectroscopy (EIS)	ATMOSPHERIC CORROSION; SOLID-STATE; HYDROXY-OXIDES; RUST PHASES; IRON-OXIDES; VOLTAMMETRY; IDENTIFICATION; BEHAVIOR; MICROPARTICLES; DISSOLUTION	The electrochemistry of the corrosion products formed from carbon and weathering steel during four years of atmospheric exposure were investigated using a carbon paste electrode (CPE) by cyclic and square wave voltammetry. The iron rust products with crystalline nature were identified from their standard formal potential. The corrosion protection ability of the rust layers were determined by polarization and electrochemical impedance spectroscopy studies using CPE. ATR-FTIR, SEM and XRD studies were employed to identify the composition and morphology of the corrosion products which supports SWV results. Results showed that the weathering steel has higher corrosion resistance than the carbon steel.	[Dhaiveegan, P.; Rajendran, N.] Anna Univ, Dept Chem, Madras 25, Tamil Nadu, India; [Elangovan, N.] AM Jain Coll, Dept Chem, Madras 114, Tamil Nadu, India; [Nishimura, T.] Natl Inst Mat Sci, Res Ctr Strateg Mat, Tsukuba, Ibaraki, Japan	Rajendran, N (reprint author), Anna Univ, Dept Chem, Madras 25, Tamil Nadu, India.	nrajendran@annauniv.edu					Almeida E, 2000, MATER CORROS, V51, P865, DOI 10.1002/1521-4176(200012)51:12<865::AID-MACO865>3.3.CO;2-J; Domenech-Carbo A, 2012, J SOLID STATE ELECTR, V16, P2349, DOI 10.1007/s10008-012-1668-9; Nishimura T, 2000, CORROS SCI, V42, P1611, DOI 10.1016/S0010-938X(00)00018-4; MISAWA T, 1974, CORROS SCI, V14, P279, DOI 10.1016/S0010-938X(74)80037-5; KUWANA T, 1964, ANAL CHEM, V36, P241, DOI 10.1021/ac60207a006; Lowinsohn D, 2013, ELECTROANAL, V25, P2435, DOI 10.1002/elan.201300364; Cook DC, 1999, HYPERFINE INTERACT, V122, P59, DOI 10.1023/A:1012685320582; Kong D, 2012, MATER CORROS, V63, P475, DOI 10.1002/maco.201006035; RAMAN A, 1989, METALLOGRAPHY, V22, P79, DOI 10.1016/0026-0800(89)90024-4; [Anonymous], 1997, G91 ASTM; Wang J, 2010, MATER CHEM PHYS, V124, P952, DOI 10.1016/j.matchemphys.2010.07.069; Zou Y, 2011, CORROS SCI, V53, P208, DOI 10.1016/j.corsci.2010.09.011; [Anonymous], 1997, G50 ASTM; [Anonymous], 1996, G140 ASTM; ADAMS RN, 1958, ANAL CHEM, V30, P1576, DOI 10.1021/ac60141a600; Mirceski V, 2013, ELECTROANAL, V25, P2411, DOI 10.1002/elan.201300369; Li QX, 2008, CORROS SCI, V50, P365, DOI 10.1016/j.corsci.2007.06.020; RAMAN A, 1991, CORROS SCI, V32, P1295, DOI 10.1016/0010-938X(91)90049-U; England AH, 2014, ELECTROANAL, V26, P1059, DOI 10.1002/elan.201300653; Nishimura T, 2000, CORROSION, V56, P935; Svancara I, 2009, ELECTROANAL, V21, P7, DOI 10.1002/elan.200804340; Nishimura T, 2003, CORROS SCI, V45, P1073, DOI 10.1016/S0010-938X(02)00186-5; Singh DDN, 2008, CORROS SCI, V50, P93, DOI 10.1016/j.corsci.2007.06.026; Zhao YX, 2011, CORROS SCI, V53, P1646, DOI 10.1016/j.corsci.2011.01.007; BACHILLER PE, 1994, J ELECTROANAL CHEM, V367, P99; Cepria G, 2003, ANAL CHIM ACTA, V477, P157, DOI 10.1016/S0003-2670(02)01371-5; Cepria G, 2004, MICROCHIM ACTA, V144, P139, DOI 10.1007/s00604-003-0096-z; Cornell R., 1991, IRON OXIDES LAB PREP; Domenech A, 2007, ELECTROANAL, V19, P1890, DOI 10.1002/elan.200703948; Domenech A, 2013, MICROCHEM J, V106, P41, DOI 10.1016/j.microc.2012.05.002; Domnech-Carbo A., 2011, ELECTROANAL, V23, P139; Hao L, 2012, CORROS SCI, V54, P244, DOI 10.1016/j.corsci.2011.09.023; ENCINAS P, 1994, J ELECTROANAL CHEM, V371, P161, DOI 10.1016/0022-0728(93)03246-L; GRYGAR T, 1995, COLLECT CZECH CHEM C, V60, P950, DOI 10.1135/cccc19950950; Grygar T, 2002, ELECTROANAL, V14, P339, DOI 10.1002/1521-4109(200203)14:5<339::AID-ELAN339>3.0.CO;2-Q; GRYGAR T, 1995, COLLECT CZECH CHEM C, V60, P1261, DOI 10.1135/cccc19951261; Guo J., 2008, CORROS SCI, V51, P242; Hana D., 2013, ELECTROCHIM ACTA, V114, P403; MOUHANDESS MT, 1982, J ELECTROANAL CHEM, V131, P367, DOI 10.1016/0022-0728(82)87088-5; Nishimura T, 2010, CORROS SCI, V52, P3609, DOI 10.1016/j.corsci.2010.07.006; Santana-Rodriguez J. J., 2006, MATER CORROS, V57, P350; Scholz F, 2005, ELECTROCHEMISTRY IMM	42	1	1	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1040-0397	1521-4109		ELECTROANAL	Electroanalysis	NOV	2014	26	11			SI		2419	2428		10.1002/elan.201400240		10	Chemistry, Analytical; Electrochemistry	Chemistry; Electrochemistry	AS6KK	WOS:000344372400016		
J	Kato, T; Kumazawa, S; Honda, N; Koaizawa, M; Nishino, S; Suzuoki, Y				Kato, Takeyoshi; Kumazawa, Shinsuke; Honda, Nobuyuki; Koaizawa, Masakazu; Nishino, Shinichi; Suzuoki, Yasuo			Development of Estimation Method of Spatial Average Irradiance Fluctuation Characteristics Considering Smoothing Effect around Observation Point	ELECTRONICS AND COMMUNICATIONS IN JAPAN			English	Article						photovoltaic power generation system; irradiance; smoothing effect; spectrum analysis; low-pass filter		In order to estimate the total power output fluctuation of a high-penetration photovoltaic power generation system by using data from a limited number of points, the smoothing effect around individual observation points should be taken into account. Based on the transfer hypothesis, this study proposes a low-pass filter (LPF) to estimate the spatial average irradiance fluctuation characteristics taking the smoothing effect around the observation point into account. First, by using the irradiance data observed at 18 points in the Nobi plain, we confirmed that the fluctuation characteristics of the spatial average irradiance can be estimated by using the characteristics of the single point irradiance when the radius of the equivalent circular area is smaller than 30km. Then, by formulating the relation between the area size and the fluctuation cycle from which the random fluctuation factor begins to increase, we developed a LPF to take the smoothing effect around the observation point into account. Finally, we demonstrated that the spatial average fluctuation characteristics can be estimated successfully for various area sizes within a radius of 20km by applying a dedicated LPF according to the area size.	[Kato, Takeyoshi; Kumazawa, Shinsuke] Nagoya Univ, Grad Sch Engn, Dept Elect Engn & Comp Sci, Nagoya, Aichi 4648601, Japan; [Honda, Nobuyuki; Koaizawa, Masakazu; Nishino, Shinichi; Suzuoki, Yasuo] Chubu Elect Power Co Inc, Elect Power R&D Ctr, Nagoya, Aichi, Japan	Kato, T (reprint author), Nagoya Univ, Grad Sch Engn, Dept Elect Engn & Comp Sci, Nagoya, Aichi 4648601, Japan.				MEXT [21360127]	This study was supported in part by a MEXT Grant-in-Aid for Scientific Research (FY 2009-2012, B No. 21360127).	Akatsuka M, 2011, JOINT TECHN M FRONT; Inoue T, 2011, IEEJ T PE, V131, P44, DOI 10.1541/ieejpes.131.44; Kato T, 2012, IEEJ T PE, V132, P213; Kato T, 2011, IEEJ T PE, V131, P29, DOI 10.1541/ieejpes.131.29; Kato T, 2011, IEEJ T PE, V131, P37, DOI 10.1541/ieejpes.131.37; Kumazawa S, 2012, IEEJ T PE, V132, P452; Nagoya H, 2011, IEEJ T EIS, V131, P1688	7	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1942-9533	1942-9541		ELECTR COMMUN JPN	Electr. Commun. Jpn.	NOV	2014	97	11					1	9		10.1002/ecj.11595		9	Engineering, Electrical & Electronic	Engineering	AS0ZU	WOS:000344006300001		
J	Ohsaki, H; Iwase, M; Hatakeyama, S				Ohsaki, Hiroshi; Iwase, Masami; Hatakeyama, Shoshiro			Discretization and Control of Rotating Pendulum under Lebesgue Sampling	ELECTRONICS AND COMMUNICATIONS IN JAPAN			English	Article						Lebesgue sampling control; event-based control; cart-pendulum	SYSTEMS	This study addresses a discretization method with Lebesgue sampling for a type of nonlinear system, and proposes a control method based on the discrete system model. A cart-pendulum system is used as an example. Applying this control method to some real system, a crucial problem is how to implement the controller. To overcome the problem, an impulsive Luenberger observer is introduced with numerical forward mapping from the current system state to the one-step-ahead state by the well-known Runge-Kutta method. As a result, a cart-pendulum system with a rotary encoder, whose quantization interval is relatively large, can be controlled effectively. Numerical simulations are performed to verify the effectiveness of the proposed method.	[Ohsaki, Hiroshi; Iwase, Masami; Hatakeyama, Shoshiro] Tokyo Denki Univ, Sch Sci & Engn Future Life, Dept Robot & Mechatron, Tokyo, Japan; [Iwase, Masami; Hatakeyama, Shoshiro] Tokyo Denki Univ, Sch Sci & Technol, Dept Informat Syst, Tokyo, Japan; [Hatakeyama, Shoshiro] Tokyo Denki Univ, Sch Sci & Engn, Tokyo, Japan	Ohsaki, H (reprint author), Tokyo Denki Univ, Sch Sci & Engn Future Life, Dept Robot & Mechatron, Tokyo, Japan.						Montestruque LA, 2003, AUTOMATICA, V39, P1837, DOI 10.1016/S0005-1098(03)00186-9; Astrom KJ, 2002, IEEE DECIS CONTR P, P2011; Arzen KE, 1999, P IFAC WORLD C BEIJ; Astrom K. J., 1997, COMPUTER CONTROLLED; Iwase M, 2009, IEEE INTL CONF CONTR, P1105, DOI 10.1109/CCA.2009.5280930; Marchand N, 2008, P 17 IFAC WORLD C SE, P10265; MITA T, 1985, IEEE T AUTOMAT CONTR, V30, P542, DOI 10.1109/TAC.1985.1104007; Sur J, 1997, P AMER CONTR CONF, P3012, DOI 10.1109/ACC.1997.612010; Xu YK, 2007, P 46 IEEE C DEC CONT, P5904	9	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1942-9533	1942-9541		ELECTR COMMUN JPN	Electr. Commun. Jpn.	NOV	2014	97	11					10	18		10.1002/ecj.11596		9	Engineering, Electrical & Electronic	Engineering	AS0ZU	WOS:000344006300002		
J	Fujii, A; Nakamoto, M; Muneyasu, M; Ohno, S				Fujii, Atsuhiro; Nakamoto, Masayoshi; Muneyasu, Mitsuji; Ohno, Shuichi			Improved Data Embedding Method for Digital Image with Human Visual Systems	ELECTRONICS AND COMMUNICATIONS IN JAPAN			English	Article						data embedding; human visual system (HVS); bit pattern	WATERMARKING	In this paper, we consider a data-embedding method in the discrete wavelet transform (DWT) domain of digital images. A bit pattern embedding method with the human visual system (HVS) and correlation-based detection have been proposed by Kino and Wada based on the watermarking scheme, which is referred to as the conventional method. In the conventional method, the capacity of embedding data depends on the potential correlation between the DWT coefficients of the host image and the watermark signal. We propose a new embedding and detection algorithm not affected by the potential correlation in order to increase the capacity of embedding data. The data-embedding and detection in the proposed method are performed by considering the absolute value of the correlation between the watermarked DWT coefficients and the watermark signal. In simulations, we show that the capacity of the embedding data in the proposed method is increased compared with the conventional method at the same PSNR value (image quality).	[Fujii, Atsuhiro] Hiroshima Univ, Grad Sch Engn, Hiroshima 730, Japan; [Nakamoto, Masayoshi; Ohno, Shuichi] Hiroshima Univ, Hiroshima 730, Japan; [Muneyasu, Mitsuji] Kansai Univ, Fac Engn Sci, Suita, Osaka, Japan	Fujii, A (reprint author), Hiroshima Univ, Grad Sch Engn, Hiroshima 730, Japan.				 [23070268]	This study was supported by Grant-in-Aid No 23070268.	Lewis AS, 1992, IEEE T IMAGE PROCESS, V1, P244, DOI 10.1109/83.136601; Barni M, 2001, IEEE T IMAGE PROCESS, V10, P783, DOI 10.1109/83.918570; Choi Y, 2000, IEICE T D, VJ83-D-II, P1620; Cox IJ, 1997, IEEE T IMAGE PROCESS, V6, P1673, DOI 10.1109/83.650120; Ito S, 2002, IEICE T D2, VJ85-D-II, P1664; Kino M, 2003, IEICE T FUNDAMENTAL, VJ86-A, P160; Kuribayashi M, 2002, IEICE T FUNDAMEN J A, VJ85-A, P322; Matsui K., 1998, FUNDAMENTALS DIGITAL; Matsui K, 1996, IEICE T JD, VJ79-D-II, P1017; Minami N, 2004, IEICE T A, VJ87-A, P967; Minami N, 1998, IEICE T D2, VJ81-D-II, P2535; Miyazaki A, 2002, IEICE T FUND ELECTR, VJ85-A, P103; Mizumoto T, 2002, IEICE T A, VJ85-A, P451; Nakamoto M, 2011, IEICE T FUND ELECTR, VE94A, P661, DOI 10.1587/transfun.E94.A.661; Ohta M, 2005, IEEJ T C, V125-C, P1652, DOI 10.1541/ieejeiss.125.1652; Ohta M, 2004, IEICE T A, VJ87-A, P797; Ooe K, 2005, IEICE T A, VJ88-A, P1137; Piva A, 1997, INTERNATIONAL CONFERENCE ON IMAGE PROCESSING - PROCEEDINGS, VOL I, P520, DOI 10.1109/ICIP.1997.647964	18	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1942-9533	1942-9541		ELECTR COMMUN JPN	Electr. Commun. Jpn.	NOV	2014	97	11					19	27		10.1002/ecj.11597		9	Engineering, Electrical & Electronic	Engineering	AS0ZU	WOS:000344006300003		
J	Matsuo, Y; Takauji, H; Kaneko, S				Matsuo, Yoshikazu; Takauji, Hidenori; Kaneko, Shun'Ichi			Efficient Learning for Test Feature Classifier by Overlap Index List	ELECTRONICS AND COMMUNICATIONS IN JAPAN			English	Article						test feature classifier; overlap index list; fast learning; adding dimension; curse of dimensionality	ALGORITHM	This paper presents a novel low cost learning algorithm for a test feature classifier by use of an overlap index list (OIL). In general, classifiers need a large amount of training data to achieve the high performance, which results in long computation times. The proposed algorithm using OIL can maintain search and check elemental combinatorial features from lower dimensions up to higher ones. Classification problems in real industrial inspection lines have been solved by the proposed algorithm, and large reductions in computation time have been obtained.	[Matsuo, Yoshikazu; Kaneko, Shun'Ichi] Hokkaido Univ, Grad Sch Informat Sci & Technol, Sapporo, Hokkaido 060, Japan; [Takauji, Hidenori] Muroran Inst Technol, Muroran, Hokkaido 050, Japan	Matsuo, Y (reprint author), Hokkaido Univ, Grad Sch Informat Sci & Technol, Sapporo, Hokkaido 060, Japan.				JSPS Global COE Program	We express our gratitude to Mr. T. Kobayashi of Nippon Steel Corporation for providing us with data, and to Prof. T. Tanaka of Hokkaido University for valuable discussions. This study was supported in part by the JSPS Global COE Program.	Dong JX, 2005, IEEE T PATTERN ANAL, V27, P603; Lanckriet GRG, 2004, J MACH LEARN RES, V5, P27; BROWN M, 1995, PROCEEDINGS OF 1995 IEEE INTERNATIONAL CONFERENCE ON FUZZY SYSTEMS, VOLS I-IV, P2139, DOI 10.1109/FUZZY.1995.409976; Bellman R.E., 1961, ADAPTIVE CONTROL PRO; Bhattacharya U, 2004, NINTH INTERNATIONAL WORKSHOP ON FRONTIERS IN HANDWRITING RECOGNITION, PROCEEDINGS, P419, DOI 10.1109/IWFHR.2004.77; Do TN, 2008, LECT NOTES ARTIF INT, V5139, P147; Itgon Kaneko S, 2000, IEEJ J C, V120-C, P1762; Kasai Wataru, 2009, IEICE Transactions on Information and Systems, VJ92-D; Lashkia V, 2000, IEICE T INF SYST, VE83D, P904; Okatani K, 2009, 23 ANN C JSAI; Sakata Y, 2005, PATTERN RECOGN, V38, P1847, DOI 10.1016/j.patcog.2005.04.013; Sakata Y, 2008, IEICE T D, VJ91-D, P89; Wang JG, 2005, LECT NOTES COMPUT SC, V3610, P554	13	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1942-9533	1942-9541		ELECTR COMMUN JPN	Electr. Commun. Jpn.	NOV	2014	97	11					28	36		10.1002/ecj.11599		9	Engineering, Electrical & Electronic	Engineering	AS0ZU	WOS:000344006300004		
J	Ishikawa, T; Lee, J; Miyake, R				Ishikawa, Tomohiro; Lee, Jaesung; Miyake, Ryo			On-Chip Manipulation of Magnetic Beads for Integrated Immunosensor	ELECTRONICS AND COMMUNICATIONS IN JAPAN			English	Article						magnetic beads; immunoassay		The purpose of this work is in-plane manipulation of dispersed magnetic beads on a chip. This makes an immunoassay chip that completes all its procedures on itself and eliminates any off-chip components. A test chip was drawn in a 180 nm standard complementary metal oxide semiconductor process and tested. Beads with a diameter of 2.8 m were diluted and applied to the chip. The chip successfully manipulated them with an affordable current down to 5 mA.	[Ishikawa, Tomohiro; Miyake, Ryo] Hiroshima Univ, JST Crest, Res Inst Nanodevices, Hiroshima 730, Japan; [Lee, Jaesung] Hiroshima Univ, Res Inst Nanodevices, Hiroshima 730, Japan	Ishikawa, T (reprint author), Hiroshima Univ, JST Crest, Res Inst Nanodevices, Hiroshima 730, Japan.						Alberts B., 2008, MOL BIOL CELL, P588; Baselt DR, 1998, BIOSENS BIOELECTRON, V13, P731, DOI 10.1016/S0956-5663(98)00037-2; Gijs MAM, 2004, MICROFLUID NANOFLUID, V1, P22, DOI 10.1007/s10404-004-0010-y; ENGVALL E, 1971, IMMUNOCHEMISTRY, V8, P871, DOI 10.1016/0019-2791(71)90454-X; Aytur T.-S., 2004, P S VLSI CIRC, P314; Ishikawa T, 2012, JPN J APPL PHYS, V51, DOI 10.1143/JJAP.51.04DE01; VANWEEME.BK, 1971, FEBS LETT, V15, P232, DOI 10.1016/0014-5793(71)80319-8; Ishikawa T, 2010, JPN J APPL PHYS, V49, DOI 10.1143/JJAP.49.04DL08	8	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1942-9533	1942-9541		ELECTR COMMUN JPN	Electr. Commun. Jpn.	NOV	2014	97	11					37	41		10.1002/ecj.11600		5	Engineering, Electrical & Electronic	Engineering	AS0ZU	WOS:000344006300005		
J	Nomoto, Y; Ohmuta, T; Ohya, T; Sawai, K; Koyama, H; Kawasumi, M				Nomoto, Yohei; Ohmuta, Takao; Ohya, Tetsuya; Sawai, Kei; Koyama, Hironori; Kawasumi, Masashi			Fundamental Study of Physiological Evaluation by Paired Comparison Test and Heart Rate Variability: The Effect of Chromatic Lights on Living Organisms	ELECTRONICS AND COMMUNICATIONS IN JAPAN			English	Article						chromatic light; paired comparison test; heart rate variability		The popularization of LEDs and the development of light control technology have provided chromatic lights such as red, blue, and green. Chromatic lights are attracting attention in connection with the psychology and physiological effects of color. It is predicted that chromatic lights will result in favorable innovations in life spaces. This investigation studied chromatic lights as related to heart rate variability (HRV), using a psychological methodology, that is, the paired comparison test. The subjects of the paired comparison test were 14 healthy participants (age 21.9 +/- 3.7 years). The HRV subjects were seven healthy participants (age 24.0 +/- 3.9 years). We examined the experimental results from two viewpoints. (1) In the results of the paired comparison test, the scores for white-ice, yellow, and green were higher than those for the other colors, and the scores for blue, red, and pink were lower than those for the other colors. (2) In the results for HRV, the mean high-frequency (HF) values for white-ice, yellow, and green were higher than those for the other colors, and the mean HF values for blue, red, and pink were lower than those for the other colors. It is concluded that by using physiological parameters and a questionnaire it is possible to analyze the effect of chromatic lights on living organisms.	[Nomoto, Yohei] Univ Niigata Prefecture, Dept Int Studies & Reg Dev, Fac Int Studies & Reg Dev, Niigata, Niigata, Japan; [Ohmuta, Takao; Koyama, Hironori; Kawasumi, Masashi] Tokyo Denki Univ, Fac Engn, Tokyo, Japan; [Ohya, Tetsuya; Sawai, Kei] Tokyo Denki Univ, Sch Adv Sci & Technol, Tokyo, Japan	Nomoto, Y (reprint author), Univ Niigata Prefecture, Dept Int Studies & Reg Dev, Fac Int Studies & Reg Dev, Niigata, Niigata, Japan.				Education and Research Promotion project of the University of Niigata Prefecture; Uchida Energy Science Promotion Foundation	We express our gratitude to students of the University of Niigata Prefecture and Tokyo Denki University for their cooperation in the measurements underlying this study. In addition, this study was supported in part by the Education and Research Promotion project of the University of Niigata Prefecture and the Uchida Energy Science Promotion Foundation.	[Anonymous], 1985, EXPT TESTS FUNDAMENT, P73; HOPF HB, 1995, ANESTHESIOLOGY, V82, P609; JACOBS KW, 1974, PERCEPT MOTOR SKILL, V38, P763; Sloan RP, 1996, PSYCHOSOM MED, V58, P25; Hayano J., 1993, BME, V7; Houle M. S., 1999, AM J PHYSIOL, V276, P215; Inoue H., 1996, CARDIOVASCULAR DIS A, P91; Inoue Y., 2010, IEIJ J, V94, P630; Katsuura T., 2008, JES J, V44, P18; Kubo H, 2008, IEIJ J, V92, P645; Nakamura H, 1997, IEIJ J, V81, P69; National Police Agency, 2005, CRIM STAT; Takahashi K, 2006, J MED WELFARE, V2; Thurstone LL., 1959, MEASUREMENT VALUES; Thurstone LL., 1927, PSYCHO REV, V34	15	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1942-9533	1942-9541		ELECTR COMMUN JPN	Electr. Commun. Jpn.	NOV	2014	97	11					42	48		10.1002/ecj.11611		7	Engineering, Electrical & Electronic	Engineering	AS0ZU	WOS:000344006300006		
J	Goto, M; Yoshida, L; Saito, A; Saito, A; Takayama, Y; Moriguchi, H; Kotani, K; Jimbo, Y				Goto, Miho; Yoshida, Lui; Saito, Atsushi; Saito, Aki; Takayama, Yuzo; Moriguchi, Hiroyuki; Kotani, Kiyoshi; Jimbo, Yasuhiko			Analysis of Avalanche Phenomena in Developing Neuronal Circuits Cultured on Microelectrode Array	ELECTRONICS AND COMMUNICATIONS IN JAPAN			English	Article						neuronal avalanche; cortical neuronal network; microelectrode array (MEA)	CRITICALITY; NETWORKS	To analyze network dynamics, neuronal avalanche is a quite interesting phenomenon. Recently, it was reported that neuronal avalanches were power-law distributed in a slice cortex of a rat, which attracted attention because power-law behavior in neuronal avalanches is an important index representing network criticality and its efficiency of information transition. In this study, we focused on the early stage of network growth and observed avalanche phenomena during their development. Power-law behavior in neuronal avalanches was observed at a matured stage, as reported in previous research. However, in the early stage, the size distribution of avalanches did not follow a power law, indicating that there was a transient period moving on to the critical point.	[Goto, Miho; Yoshida, Lui; Saito, Atsushi; Moriguchi, Hiroyuki; Kotani, Kiyoshi; Jimbo, Yasuhiko] Univ Tokyo, Grad Sch Frontier Sci, Tokyo 1138654, Japan; [Saito, Aki] Univ Tokyo, Grad Sch Frontier Sci, Doctoral Program, Tokyo 1138654, Japan; [Takayama, Yuzo] Univ Tokyo, Grad Sch Informat Sci, Tokyo 1138654, Japan	Goto, M (reprint author), Univ Tokyo, Grad Sch Frontier Sci, Tokyo 1138654, Japan.						ALSTROM P, 1988, PHYS REV A, V38, P4905, DOI 10.1103/PhysRevA.38.4905; Haldeman C, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.058101; Beggs JM, 2008, PHILOS T R SOC A, V366, P329, DOI 10.1098/rsta.2007.2092; Pasquale V, 2008, NEUROSCIENCE, V153, P1354, DOI 10.1016/j.neuroscience.2008.03.050; Stewart CV, 2006, J NEUROSCI, V26, P8148, DOI 10.1523/JNEUROSCI.0723-06.2006; Beggs JM, 2003, J NEUROSCI, V23, P11167; BAK P, 1987, PHYS REV LETT, V59, P381, DOI 10.1103/PhysRevLett.59.381; Beggs JM, 2008, PHIL R SOC A; Harris T.E., 1963, THEORY BRANCHING PRO	9	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1942-9533	1942-9541		ELECTR COMMUN JPN	Electr. Commun. Jpn.	NOV	2014	97	11					49	55		10.1002/ecj.11612		7	Engineering, Electrical & Electronic	Engineering	AS0ZU	WOS:000344006300007		
J	Honma, S; Takagi, Y; Wakamatsu, H				Honma, Satoru; Takagi, Yutaka; Wakamatsu, Hidetoshi			3D-Visualised Model of Temperature Distribution in the Brain for Investigation of Brain Cooling Effect	ELECTRONICS AND COMMUNICATIONS IN JAPAN			English	Article						hypothermia; temperature distribution; virtual reality; mathematical model	HYPOTHERMIA	Brain hypothermia requires control of its temperature within an appropriate range, considering the change of body temperature over a long period. Various mathematical models have been used for the study of control and cooling capability of brain temperature in hypothermia. In previous models, a lumped-parameter hemisphere of uniform temperature has been assumed as a simplified brain model without considering the temperature distribution. In the present study, however, a new model is proposed to visualize the temperature distribution in the brain. The model has the approximate shape of the organs in the head based on MRI data, and may well reflect properties such as heat transfer coefficients, metabolic heat production, and heat capacity of human organs. The model has a pseudo-blood-flow component in which any temperature can be set as the initial value at the starting place of blood flow. Simulations using this model were performed with the temperature controlled by the introduction of Ringer's solution into any of the four arteries leading to the brain. The simulation results suggest that the various cooling effects are manifested in every region of brain, and that the temperature distribution can be known for applications to controlling brain temperature in a part of interest.	[Honma, Satoru; Takagi, Yutaka; Wakamatsu, Hidetoshi] Tokyo Med & Dent Univ, Grad Sch Hlth Care Sci, Tokyo, Japan	Honma, S (reprint author), Tokyo Med & Dent Univ, Grad Sch Hlth Care Sci, Tokyo, Japan.						Xu XJ, 1999, J APPL PHYSIOL, V86, P265; Editorial, 2008, SCI NEWS, V442, P164; Herman IP, 2007, PHYS HUMAN BODY BIOL; Honma S, 2010, P HAPTIC DISPLAY COP, V001, P11; Honma S, 2011, P 16 VIRT REL SOC JA, V70, P340; Honma S, 2011, T JSMBE S, V49, P172; Honma S, 2011, 2011 ANN M REC IEE J, V3; Kuroda K., 2003, Medical Imaging Technology, V21; Takagi Y, 2011, CLIN PATHOL S, V59; Takagi Y, 2011, P IEEH  EL INF SYST; Utsuki T, 2012, IEEJ T EIS C, V132-C, P615; Wakamatsu H, 2010, TECHNOL HEALTH CARE, V18, P181, DOI 10.3233/THC-2010-0581; Wakamatsu H., 2004, Artificial Life and Robotics, V8, DOI 10.1007/s10015-004-0310-z; Wakamatsu H, 2004, BRAIN DEATH RESUSCIT, V16, P62; Wakamatsu H, 2011, FORCE REPRESENTATION; Wakamatsu H, 2003, IEEJ T EIS C, V123-C, P1537, DOI 10.1541/ieejeiss.123.1537; Zhu L, 2001, MED BIOL ENG COMPUT, V39, P681, DOI 10.1007/BF02345442	17	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1942-9533	1942-9541		ELECTR COMMUN JPN	Electr. Commun. Jpn.	NOV	2014	97	11					56	64		10.1002/ecj.11613		9	Engineering, Electrical & Electronic	Engineering	AS0ZU	WOS:000344006300008		
J	Takamura, N; Wang, DY; Satoh, T; Namihira, T; Saitoh, H; Akiyama, H				Takamura, Norimitsu; Wang, Douyan; Satoh, Takao; Namihira, Takao; Saitoh, Hisato; Akiyama, Hidenori			Effect of Atmospheric-Pressure Helium Plasma Jet on Cell Culture Medium	ELECTRONICS AND COMMUNICATIONS IN JAPAN			English	Article						atmospheric-pressure plasma jet; cell culture medium; HPLC; pH; electric conductivity; ultraviolet transmission		Atmospheric-pressure, nonthermal plasma jets produced by using helium gas have been studied for various applications. In particular, plasma applications for biological treatment have attracted attention and investigation all over the world. In this paper, various kinds of cell culture media were irradiated with a plasma jet, and its components were analyzed. The results showed that irradiating a cell culture medium with a plasma jet could cause changes in its pH, electrical conductivity, and so on. These results suggest that irradiating with a plasma jet might cause changes in the form of cells and produce cell death. Plasma jets also generate UV light, which may kill cells. It was found that the plasma jet irradiation time is a very important factor in the treatment of cells.	[Takamura, Norimitsu] Kumamoto Univ, Global COE Program, Kumamoto 860, Japan; [Wang, Douyan; Akiyama, Hidenori] Kumamoto Univ, Kumamoto 860, Japan; [Namihira, Takao; Saitoh, Hisato] Kumamoto Univ, Grad Sch Sci & Technol, Kumamoto 860, Japan; [Satoh, Takao] Kumamoto Ind Res Inst, Microbiol Technol Div, Kyoto, Japan	Takamura, N (reprint author), Kumamoto Univ, Global COE Program, Kumamoto 860, Japan.						Witte MB, 2002, AM J SURG, V183, P406, DOI 10.1016/S0002-9610(02)00815-2; EAGLE H, 1973, J CELL PHYSIOL, V82, P1, DOI 10.1002/jcp.1040820102; Hamaguchi S., 2011, JPFR JPN, V87, P696; Kitano Katsuhisa, 2008, Oyo Buturi, V77; Kogoma M., 2003, J PLASMA FUSION RES, V79, P1000, DOI 10.1585/jspf.79.1000; Liu DX, 2010, PLASMA SOURCES SCI T, V19, DOI 10.1088/0963-0252/19/2/025018; Matsumori M, 2011, PANASONIC TECH J, V57, P19; Matsushita M, 2009, RYUKYU MED J, V28, P1; Murakami I, 2012, JPFR JPN, V88, P35; Nagatsu M, 2011, JPFR JPN, V87, P715; Oda T, 2003, OYO BUTSURI, V72, P415; Takamura N, 2012, INT J PLASMA ENV SCI, V6, P59; Tannock IF, 1998, BASIC SCI ONCOLOGY, P299; Tochikubo F, 2006, IEEJ J, V126, P781; Yamazaki H, 2011, JPN J DENT MAT, V29, P3	15	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1942-9533	1942-9541		ELECTR COMMUN JPN	Electr. Commun. Jpn.	NOV	2014	97	11					65	73		10.1002/ecj.11636		9	Engineering, Electrical & Electronic	Engineering	AS0ZU	WOS:000344006300009		
J	Kakuta, R; Yano, H; Kanamori, H; Shimizu, T; Gu, Y; Hatta, M; Aoyagi, T; Endo, S; Inomata, S; Oe, C; Tokuda, K; Ozawa, D; Goto, H; Katori, Y; Kaku, M				Kakuta, Risako; Yano, Hisakazu; Kanamori, Hajime; Shimizu, Takuya; Gu, Yoshiaki; Hatta, Masumitsu; Aoyagi, Tetsuji; Endo, Shiro; Inomata, Shinya; Oe, Chihiro; Tokuda, Koichi; Ozawa, Daiki; Goto, Hitoshi; Katori, Yukio; Kaku, Mitsuo			Helicobacter cinaedi Infection of Abdominal Aortic Aneurysm, Japan	EMERGING INFECTIOUS DISEASES			English	Letter							IDENTIFICATION; BACTEREMIA; STRAINS; TIME		[Kakuta, Risako] Tohoku Univ Hosp, Sendai, Miyagi, Japan	Kakuta, R (reprint author), Tohoku Univ, Grad Sch Med, Dept Infect Control & Lab Diagnost, Aoba Ku, 1-1 Seiryomachi, Sendai, Miyagi 9808574, Japan.	kakuta-r@med.tohoku.ac.jp					Oyama K, 2012, J CLIN MICROBIOL, V50, P3893, DOI 10.1128/JCM.01622-12; Lasry S, 2000, CLIN INFECT DIS, V31, P201, DOI 10.1086/313930; Tomida J, 2013, MICROBIOL IMMUNOL, V57, P353, DOI 10.1111/1348-0421.12044; Araoka H, 2014, J CLIN MICROBIOL, V52, P1519, DOI 10.1128/JCM.00265-14; Minauchi K, 2010, INTERNAL MED, V49, P1733, DOI 10.2169/internalmedicine.49.3649; Miller DV, 2004, HUM PATHOL, V35, P1112, DOI 10.1016/j.humpath.2004.05.013; Zhang JW, 2011, DIAGN MICR INFEC DIS, V70, P307, DOI 10.1016/j.diagmicrobio.2011.02.012; Rimbara E, 2012, J CLIN MICROBIOL, V50, P2553, DOI 10.1128/JCM.06810-11; Laohapensang Kamphol, 2012, Ann Vasc Dis, V5, P334, DOI 10.3400/avd.oa.12.00014; Taniguchi T, 2014, J CLIN MICROBIOL, V52, P95, DOI 10.1128/JCM.01798-13	10	1	1	CENTERS  DISEASE CONTROL	ATLANTA	1600 CLIFTON RD, ATLANTA, GA 30333 USA	1080-6040	1080-6059		EMERG INFECT DIS	Emerg. Infect. Dis	NOV	2014	20	11					1942	1945		10.3201/eid2011.140440		4	Immunology; Infectious Diseases	Immunology; Infectious Diseases	AS0KO	WOS:000343966300034		
J	Uchida, T; Goto, H; Kasai, T; Komiya, K; Takeno, K; Abe, H; Shigihara, N; Sato, J; Honda, A; Mita, T; Kanazawa, A; Fujitani, Y; Watada, H				Uchida, Toyoyoshi; Goto, Hiromasa; Kasai, Takatoshi; Komiya, Koji; Takeno, Kageumi; Abe, Hiroko; Shigihara, Nayumi; Sato, Junko; Honda, Akira; Mita, Tomoya; Kanazawa, Akio; Fujitani, Yoshio; Watada, Hirotaka			Therapeutic effectiveness of potassium iodine in drug-naive patients with Graves' disease: a single-center experience	ENDOCRINE			English	Article						Organic iodine; Methimazole; Graves' disease; Thyrotoxicosis; Retrospective study	SODIUM IPODATE; ANTITHYROID DRUGS; HYPERTHYROIDISM; THYROTOXICOSIS; THYROXINE; METHIMAZOLE; CELLS	Iodine is beneficial against Graves' thyrotoxicosis, though its effects are short-lived. However, its long-term effectiveness as an initial therapy has not been fully elucidated. Here, we compared the effects of potassium iodine (KI) and methimazole (MMI) in Graves' thyrotoxicosis and on thyrotropin receptor antibody (TRAb) levels. Between 2008 and 2011, 293 patients with untreated Graves' disease visited the outpatient clinic of Juntendo University. Of these, 227 patients were treated with MMI and 30 treated with KI as the initial therapy. To compare the effects of KI and MMI, we identified patients with similar probabilities of receiving MMI or KI using propensity score (PS) analysis based on the observed clinical features. PS matching created 20 matched pairs of patients with Graves' disease treated with MMI and KI. The baseline characteristics of post-matched patients treated with MMI were comparable to those treated with KI (FT3; 7.16 +/- 2.30, 6.56 +/- 1.85 pg/ml, FT4; 2.57 +/- 0.79, 2.49 +/- 0.70 ng/dl, respectively). The initial dose of MMI was 14.0 +/- 8.2 mg/day and that of KI was 53.6 +/- 11.7 mg/day. Three patients of the KI group did not respond to the monotherapy, requiring the inclusion of antithyroid drugs. One patient on MMI developed moderate skin eruption, but continued the treatment. Patients who continued the initial treatment showed significant and comparable reductions in FT4, FT3 and TRAb by MMI as well as by KI at the end of 12-month treatment. Although patients were limited to mild untreated Graves' disease thyrotoxicosis, KI offers a possible alternative initial treatment for this condition.	[Uchida, Toyoyoshi; Goto, Hiromasa; Komiya, Koji; Takeno, Kageumi; Abe, Hiroko; Shigihara, Nayumi; Sato, Junko; Honda, Akira; Mita, Tomoya; Kanazawa, Akio; Fujitani, Yoshio; Watada, Hirotaka] Juntendo Univ, Grad Sch Med, Dept Med Metab & Endocrinol, Bunkyo Ku, Tokyo 1138421, Japan; [Kasai, Takatoshi] Juntendo Univ, Grad Sch, Dept Cardiol, Bunkyo Ku, Tokyo 1138421, Japan	Uchida, T (reprint author), Juntendo Univ, Grad Sch Med, Dept Med Metab & Endocrinol, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.	uchitoyo@juntendo.ac.jp			Philips-Respironics; Teijin Home Healthcare; Fukuda Denshi; Eli Lilly; Takeda Pharmaceutical Co.; MSD; Sanofi-Aventis; Novartis Pharmaceuticals; Boehringer Ingelheim; Ono Pharmaceutical Co.; Novo Nordisk Pharma; Sanwakagaku Kenkyusho; Daiichi Sankyo Inc.; Dainippon Sumitomo Pharm; Kowa Co.; Pfizer; Mochida Pharmaceutical Co.; Terumo Corp.; Mitsubishi Tanabe Pharma; Shionogi; Pharma; Dainippon Sumitomo Pharma; Kissei Pharma; Astrazeneca	TK has research funds from Philips-Respironics, Teijin Home Healthcare, Fukuda Denshi. TM has research funds from Eli Lilly, Takeda Pharmaceutical Co., MSD. AK has received lecture fees from Takeda Pharmaceutical Co., Sanofi-Aventis. YF has lecture fees from Novartis Pharmaceuticals, Eli Lilly and research funds from Eli Lilly, Takeda Pharmaceutical Co., MSD. HW has received lecture fees from Boehringer Ingelheim, Sanofi-Aventis, Ono Pharmaceutical Co., Novo Nordisk Pharma, Novartis Pharmaceuticals, Eli Lilly, Sanwakagaku Kenkyusho, Daiichi Sankyo Inc., Takeda Pharmaceutical Co., MSD, Dainippon Sumitomo Pharm., Kowa Co. and research funds from Boehringer Ingelheim, Pfizer, Mochida Pharmaceutical Co. Sanofi-Aventis, Novo Nordisk Pharma, Novartis Pharmaceuticals, Sanwakagaku Kenkyusho, Terumo Corp. Eli Lilly, Mitsubishi Tanabe Pharma, Daiichi Sankyo Inc., Takeda Pharmaceutical Co., MSD, Shionogi, Pharma, Dainippon Sumitomo Pharma, Kissei Pharma, and Astrazeneca.	WOLFF J, 1948, J BIOL CHEM, V174, P555; LIAW YF, 1993, ANN INTERN MED, V118, P424; Eng PHK, 1999, ENDOCRINOLOGY, V140, P3404, DOI 10.1210/en.140.8.3404; ROTI E, 1988, CLIN ENDOCRINOL, V28, P305, DOI 10.1111/j.1365-2265.1988.tb01217.x; Kasai T, 2012, ATHEROSCLEROSIS, V220, P463, DOI 10.1016/j.atherosclerosis.2011.09.051; Uchida T, 2010, ENDOCR J, V57, P439, DOI 10.1507/endocrj.K09E-263; EMERSON CH, 1975, J CLIN ENDOCR METAB, V40, P33; McLachlan SM, 2005, ENDOCR REV, V26, P800, DOI 10.1210/er.2004-0023; Austin PC, 2009, STAT MED, V28, P3083, DOI 10.1002/sim.3697; Shah BR, 2005, J CLIN EPIDEMIOL, V58, P550, DOI 10.1016/j.jclinepi.2004.10.016; Cooper DS, 2005, NEW ENGL J MED, V352, P905, DOI 10.1056/NEJMra042972; GREER MA, 1956, METABOLISM, V5, P682; FEEK CM, 1980, NEW ENGL J MED, V302, P883, DOI 10.1056/NEJM198004173021602; MEYERGESSNER M, 1989, DEUT MED WOCHENSCHR, V114, P166, DOI 10.1055/s-2008-1066570; Mitsiades N, 2000, THYROID, V10, P527, DOI 10.1089/thy.2000.10.527; NAGATAKI S, 1970, J CLIN ENDOCR METAB, V30, P469; PHILIPPOU G, 1992, CLIN ENDOCRINOL, V36, P573, DOI 10.1111/j.1365-2265.1992.tb02267.x; PHILIPPOU G, 1991, EXP CLIN ENDOCRINOL, V97, P308; ROBUSCHI G, 1986, J ENDOCRINOL INVEST, V9, P287; ROTI E, 1985, CLIN ENDOCRINOL, V22, P489, DOI 10.1111/j.1365-2265.1985.tb00148.x; ROTI E, 1993, J CLIN ENDOCR METAB, V76, P928, DOI 10.1210/jc.76.4.928; Takata K, 2010, CLIN ENDOCRINOL, V72, P845, DOI 10.1111/j.1365-2265.2009.03745.x; TAN TT, 1989, CLIN ENDOCRINOL, V30, P645, DOI 10.1111/j.1365-2265.1989.tb00270.x; TOTTERMAN TH, 1987, NEW ENGL J MED, V316, P15, DOI 10.1056/NEJM198701013160104; WARTOFSK.L, 1970, J CLIN INVEST, V49, P78, DOI 10.1172/JCI106225; Zava Theodore T, 2011, Thyroid Res, V4, P14, DOI 10.1186/1756-6614-4-14	26	2	2	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1355-008X	1559-0100		ENDOCRINE	Endocrine	NOV	2014	47	2					506	511		10.1007/s12020-014-0171-8		6	Endocrinology & Metabolism	Endocrinology & Metabolism	AS2DF	WOS:000344088900024		
J	Hattori, Y; Takeda, T; Fujii, M; Taura, J; Ishii, Y; Yamada, H				Hattori, Yukiko; Takeda, Tomoki; Fujii, Misaki; Taura, Junki; Ishii, Yuji; Yamada, Hideyuki			Dioxin-induced fetal growth retardation: the role of a preceding attenuation in the circulating level of glucocorticoid	ENDOCRINE			English	Article						2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD); Growth hormone; Corticosterone; Growth retardation; Rat; Fetus	2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN TCDD; LACTATIONAL EXPOSURE; MATERNAL EXPOSURE; THYROID-HORMONE; PITUITARY-GLAND; IN-UTERO; REPRODUCTIVE TOXICITY; HALF-LIFE; MALE-RATS; EXPRESSION	Exposure of pregnant rats to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) at a low dose causes developmental disorders such as growth retardation and sexual immaturity in their pups. Our previous studies have demonstrated that TCDD attenuates the expression of pituitary luteinizing hormone in fetuses, resulting in the impairment of sexual behavior after they reach maturity. In this study, we focused on growth disturbance and investigated whether TCDD affects the expression of growth hormone (GH), another pituitary hormone which is essential for normal development in perinatal pups. The result showed that maternal exposure to TCDD (1 mu g/kg) at gestational day (GD) 15 reduced the fetal expression of GH from the onset at GD18. In accordance with this, TCDD attenuated the pup weight during the perinatal period. We then examined the effect of TCDD on the serum concentration of corticosterone, which plays a key role in the proliferation of GH-producing cells, and found that TCDD reduces the circulating level of corticosterone in the mothers at GD18 and the male fetuses at GD19. The reduction in fetuses seems to be due to increased inactivation rather than reduced synthesis, because TCDD induces the fetal expression of hepatic enzymes participating in the metabolism of glucocorticoids without changing the expression of steroidogenic proteins in the pituitary-adrenal axis. Supplying corticosterone to TCDD-exposed mothers restored or tended to restore a TCDD-induced reduction in pup weight as well as the levels of pituitary GH mRNA and serum GH. These results suggest that TCDD lowers GH expression and growth retardation owing, at least partially, to a reduction in the circulating level of glucocorticoid in pregnant mothers and their fetuses.	[Hattori, Yukiko; Takeda, Tomoki; Fujii, Misaki; Taura, Junki; Ishii, Yuji; Yamada, Hideyuki] Kyushu Univ, Grad Sch Pharmaceut Sci, Higashi Ku, Fukuoka 8128582, Japan	Yamada, H (reprint author), Kyushu Univ, Grad Sch Pharmaceut Sci, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	hyamada@phar.kyushu-u.ac.jp			Japan Society for the Promotion of Science [24221004]; Ministry of Health, Labour and Welfare, Japan [Research on Food Safety] [H24-Designated Research-014]	This work was supported by Grants from the Japan Society for the Promotion of Science [Scientific Research (S) 24221004] and the Ministry of Health, Labour and Welfare, Japan [Research on Food Safety (H24-Designated Research-014)].	Tanida T, 2009, TOXICOL LETT, V189, P40, DOI 10.1016/j.toxlet.2009.04.005; Mazziotti G, 2013, NAT REV ENDOCRINOL, V9, P265, DOI 10.1038/nrendo.2013.5; Takeda T, 2014, MOL PHARMACOL, V85, P74, DOI 10.1124/mol.113.088575; Ahmed RG, 2011, FOOD CHEM TOXICOL, V49, P1276, DOI 10.1016/j.fct.2011.03.008; Weinstock M, 2001, PROG NEUROBIOL, V65, P427, DOI 10.1016/S0301-0082(01)00018-1; Blake MJ, 2005, SEMIN FETAL NEONAT M, V10, P123, DOI 10.1016/j.siny.2004.11.001; Hurst CH, 2000, TOXICOL SCI, V53, P411, DOI 10.1093/toxsci/53.2.411; Waxman DJ, 2006, MOL ENDOCRINOL, V20, P2613, DOI 10.1210/me.2006-0007; Nishijo M, 2007, TOXICOL LETT, V173, P41, DOI 10.1016/j.toxlet.2007.06.007; Geusau A, 2002, ARCH TOXICOL, V76, P316, DOI 10.1007/s00204-002-0345-7; Itaaho K, 2008, DRUG METAB DISPOS, V36, P2307, DOI 10.1124/dmd.108.022731; Vaughan OR, 2012, J PHYSIOL-LONDON, V590, P5529, DOI 10.1113/jphysiol.2012.239426; SEO BW, 1995, TOXICOL LETT, V78, P253, DOI 10.1016/0378-4274(95)03329-J; Mutoh J, 2006, ENDOCRINOLOGY, V147, P927, DOI 10.1210/en.2005-1125; Bingham BC, 2013, PSYCHONEUROENDOCRINO, V38, P2746, DOI 10.1016/j.psyneuen.2013.07.003; Nyirenda MJ, 1998, J CLIN INVEST, V101, P2174, DOI 10.1172/JCI1567; PIRKLE JL, 1989, J TOXICOL ENV HEALTH, V27, P165; Takeda T, 2012, J BIOL CHEM, V287, P18440, DOI 10.1074/jbc.M111.335158; PETERSON RE, 1993, CRIT REV TOXICOL, V23, P283, DOI 10.3109/10408449309105013; Takeda T, 2009, J PHARMACOL EXP THER, V329, P1091, DOI 10.1124/jpet.109.151282; MABLY TA, 1992, TOXICOL APPL PHARM, V114, P97, DOI 10.1016/0041-008X(92)90101-W; Lepine J, 2004, J CLIN ENDOCR METAB, V89, P5222, DOI 10.1210/jc.2004-0331; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; Matsumoto Y, 2010, J TOXICOL SCI, V35, P365; Krozowski Z, 1999, J STEROID BIOCHEM, V69, P391, DOI 10.1016/S0960-0760(99)00074-6; Kerger BD, 2006, ENVIRON HEALTH PERSP, V114, P1596, DOI 10.1289/ehp.8884; Auyeung DJ, 2003, MOL PHARMACOL, V63, P119, DOI 10.1124/mol.63.1.119; BJERKE DL, 1994, TOXICOL APPL PHARM, V127, P241, DOI 10.1006/taap.1994.1158; CABELLO G, 1989, REPROD NUTR DEV, V29, P387, DOI 10.1051/rnd:19890401; De Jesus K, 2009, GROWTH FACTORS, V27, P438, DOI 10.3109/08977190903299270; Ejiri N, 2003, EXP TOXICOL PATHOL, V54, P273, DOI 10.1078/0940-2993-00263; Gasiewicz TA., 1991, HDB PESTICIDE TOXICO, V3, P1217; GIUSTINA A, 1992, TRENDS ENDOCRIN MET, V3, P306, DOI 10.1016/1043-2760(92)90142-N; GRAY LE, 1995, TOXICOL APPL PHARM, V133, P285, DOI 10.1006/taap.1995.1153; KORNEL L, 1975, J CLIN ENDOCR METAB, V40, P949; Lee C, 2012, CAN J PHYSIOL PHARM, V90, P1354, DOI [10.1139/y2012-099, 10.1139/Y2012-099]; Li E, 2011, ENDOCR J, V58, P257, DOI 10.1507/endocrj.K11E-006; Li L, 2012, ACTA PHARMACOL SIN, V33, P127, DOI 10.1038/aps.2011.161; Lu SK, 2003, J PHARMACOL EXP THER, V305, P331, DOI 10.1124/jpet.102.044776; Nishimura N, 2005, ARCH TOXICOL, V79, P260, DOI 10.1007/s00204-004-0626-4; Nishimura N, 2005, TOXICOL SCI, V85, P607, DOI 10.1093/toxsci/kfi122; Nishimura N, 2003, ENDOCRINOLOGY, V144, P2075, DOI 10.1210/en.2002-220737; Nogami H, 1997, ENDOCRINOLOGY, V138, P1810, DOI 10.1210/en.138.5.1810; NOGAMI H, 1993, ENDOCRINOLOGY, V132, P517, DOI 10.1210/en.132.2.517; Nogami H, 2008, GROWTH HORM IGF RES, V18, P379, DOI 10.1016/j.ghir.2008.01.007; OLSON JR, 1986, TOXICOL APPL PHARM, V85, P263, DOI 10.1016/0041-008X(86)90121-3; Porter TE, 2005, DOMEST ANIM ENDOCRIN, V29, P52, DOI 10.1016/j.domaniend.2005.04.004; Schimmer B, 2011, GOODMAN GILMANS PHAR, V12th, P1209; Seo BW, 2000, NEUROTOXICOL TERATOL, V22, P511, DOI 10.1016/S0892-0362(00)00070-2; Sjogren K, 2000, BIOCHEM BIOPH RES CO, V267, P603, DOI 10.1006/bbrc.1999.1986; Takeda Tomoki, 2013, Fukuoka Acta Medica, V104, P143; Taketoh J, 2007, LIFE SCI, V80, P1259, DOI 10.1016/j.lfs.2006.12.029; Vakili Hana, 2011, Mol Cell Endocrinol, V345, P48, DOI 10.1016/j.mce.2011.07.010; VANDENBERG M, 1994, CRIT REV TOXICOL, V24, P1; WEHRENBERG WB, 1990, ENDOCRINOLOGY, V127, P2705; WILSON JT, 1973, P SOC EXP BIOL MED, V143, P978; YAMAZOE Y, 1986, J BIOCHEM-TOKYO, V100, P1095	57	5	7	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1355-008X	1559-0100		ENDOCRINE	Endocrine	NOV	2014	47	2					572	580		10.1007/s12020-014-0257-3		9	Endocrinology & Metabolism	Endocrinology & Metabolism	AS2DF	WOS:000344088900033		
J	Ikeoka, T; Ito, T; Ando, T				Ikeoka, Toshiyuki; Ito, Tatsuhiro; Ando, Takao			Left ventricular infiltration from thyroid papillary carcinoma mimicking the electrocardiographic changes of acute myocardial infarction	ENDOCRINE			English	Editorial Material									[Ikeoka, Toshiyuki; Ito, Tatsuhiro; Ando, Takao] Nagasaki Univ, Dept Endocrinol & Metab, Grad Sch Biomed Sci, Nagasaki 8528501, Japan	Ando, T (reprint author), Nagasaki Univ, Dept Endocrinol & Metab, Grad Sch Biomed Sci, 1-7-1 Sakamoto, Nagasaki 8528501, Japan.	takaoando@gmail.com		Ando, Takao/0000-0001-6371-1908			Catford S.R., 2011, THYROID, V21, P1; LESTUZZI C, 1989, CHEST, V95, P980, DOI 10.1378/chest.95.5.980; Sugimoto S, 2006, ACTA MED OKAYAMA, V60, P135	3	0	0	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1355-008X	1559-0100		ENDOCRINE	Endocrine	NOV	2014	47	2					652	653		10.1007/s12020-014-0188-z		2	Endocrinology & Metabolism	Endocrinology & Metabolism	AS2DF	WOS:000344088900043		
J	Druce, J; Tellez, H; Burriel, M; Sharp, MD; Fawcett, LJ; Cook, SN; McPhail, DS; Ishihara, T; Brongersma, HH; Kilner, JA				Druce, J.; Tellez, H.; Burriel, M.; Sharp, M. D.; Fawcett, L. J.; Cook, S. N.; McPhail, D. S.; Ishihara, T.; Brongersma, H. H.; Kilner, J. A.			Surface termination and subsurface restructuring of perovskite-based solid oxide electrode materials	ENERGY & ENVIRONMENTAL SCIENCE			English	Article							ENERGY ION-SCATTERING; OXYGEN REDUCTION KINETICS; ELEVATED-TEMPERATURES; SR SEGREGATION; DOPED LA2NIO4; FUEL-CELLS; SRTIO3; REGION; CONDUCTIVITY; MANGANITES	We study the outer atomic surfaces of a series of perovskite-based ceramics using low energy ion scattering spectroscopy. After high temperature treatment, segregated A-site (or acceptor substituent) cations dominate the outer surfaces with no B-site cations detected. We also find evidence of an associated B-cation enriched region below the surface.	[Druce, J.; Ishihara, T.; Kilner, J. A.] Kyushu Univ, Int Inst Carbon Neutral Energy Res Wpi I2CNER, Nishi Ku, Fukuoka 8190395, Japan; [Tellez, H.; Burriel, M.; Sharp, M. D.; Fawcett, L. J.; Cook, S. N.; McPhail, D. S.; Kilner, J. A.] Univ London Imperial Coll Sci Technol & Med, Dept Mat, London SW7 2AZ, England; [Brongersma, H. H.] Eindhoven Univ Technol, Dept Appl Phys, NL-5600 MB Eindhoven, Netherlands	Druce, J (reprint author), Kyushu Univ, Int Inst Carbon Neutral Energy Res Wpi I2CNER, Nishi Ku, Fukuoka 8190395, Japan.	john.druce@i2cner.kyushu-u.ac.jp; htellez@i2cner.kyushu-u.ac.jp; j.kilner@imperial.ac.uk	Cook, Stuart/N-1417-2015; 	Cook, Stuart/0000-0001-9813-5808; Tellez Lozano, Helena/0000-0001-7516-4227	International Institute for Carbon Neutral Energy Research (wpi-I2CNER); World Premier International Research Center Initiative (WPI), MEXT, Japan; Marie Curie Intra European Fellowships within the 7th European Community Framework Programme of the European Union [PIEF-GA-2010-274999, PIEF-GA-2009252711];  [24226016]	JD, JK and TI gratefully acknowledge the support of the International Institute for Carbon Neutral Energy Research (wpi-I2CNER), sponsored by the World Premier International Research Center Initiative (WPI), MEXT, Japan. HT and MB are funded by Marie Curie Intra European Fellowships within the 7th European Community Framework Programme of the European Union (PIEF-GA-2010-274999 and PIEF-GA-2009252711, respectively). JD and HT contributed equally to this work. This work was partially supported by Grant-in-Aid for Scientific Research (S) No. 24226016.	Ohtomo A, 2002, NATURE, V419, P378, DOI 10.1038/nature00977; Mastrikov YA, 2010, J PHYS CHEM C, V114, P3017, DOI 10.1021/jp909401g; Crumlin EJ, 2012, ENERG ENVIRON SCI, V5, P6081, DOI 10.1039/c2ee03397f; Burriel M, 2014, ENERG ENVIRON SCI, V7, P311, DOI 10.1039/c3ee41622d; Read MSD, 2001, J MATER CHEM, V11, P2597, DOI 10.1039/b102678j; Viitanen MM, 2002, SOLID STATE IONICS, V150, P223, DOI 10.1016/S0167-2738(02)00455-1; Choi JW, 1999, PHYS REV B, V59, P13453, DOI 10.1103/PhysRevB.59.13453; Chen Y, 2012, ENERG ENVIRON SCI, V5, P7979, DOI 10.1039/c2ee21463f; Gauquelin N, 2009, MONATSH CHEM, V140, P1095, DOI 10.1007/s00706-009-0146-2; Ponce S, 2000, APPL CATAL B-ENVIRON, V24, P193, DOI 10.1016/S0926-3373(99)00111-3; Druce J, 2014, SOLID STATE IONICS, V262, P893, DOI 10.1016/j.ssi.2013.09.010; Brongersma HH, 2007, SURF SCI REP, V62, P63, DOI 10.1016/j.surfrep.2006.12.002; Aguadero A, 2012, J MATER SCI, V47, P3925, DOI 10.1007/s10853-011-6213-1; Harrison WA, 2010, PHYS REV B, V81, DOI 10.1103/PhysRevB.81.045433; Lee W, 2013, J AM CHEM SOC, V135, P7909, DOI 10.1021/ja3125349; Cai ZH, 2012, CHEM MATER, V24, P1116, DOI 10.1021/cm203501u; Szot K, 1999, PHYS REV B, V60, P5909, DOI 10.1103/PhysRevB.60.5909; Jung W, 2012, ENERG ENVIRON SCI, V5, P5370, DOI 10.1039/c1ee02762j; Setter N, 2000, ACTA MATER, V48, P151, DOI 10.1016/S1359-6454(99)00293-1; Han JW, 2012, ENERG ENVIRON SCI, V5, P8598, DOI 10.1039/c2ee03592h; Tarancon A, 2010, J MATER CHEM, V20, P3799, DOI 10.1039/b922430k; Kubicek M, 2011, J ELECTROCHEM SOC, V158, pB727, DOI 10.1149/1.3581114; Kotomin EA, 2008, PHYS CHEM CHEM PHYS, V10, P4644, DOI 10.1039/b804378g; Fister TT, 2008, APPL PHYS LETT, V93, DOI 10.1063/1.2987731; Cai ZH, 2011, J AM CHEM SOC, V133, P17696, DOI 10.1021/ja2059445; Ding HP, 2013, PHYS CHEM CHEM PHYS, V15, P489, DOI 10.1039/c2cp43148c; Jiang SP, 2001, SOLID STATE IONICS, V138, P183, DOI 10.1016/S0167-2738(00)00806-7; Egger A, 2010, J ELECTROCHEM SOC, V157, pB1537, DOI 10.1149/1.3481420; Zhou J, 2013, J PHYS CHEM C, V117, P12991, DOI 10.1021/jp403094x; TASKER PW, 1979, J PHYS C SOLID STATE, V12, P4977, DOI 10.1088/0022-3719/12/22/036; Bertacco R, 2002, SURF SCI, V511, P366, DOI 10.1016/S0039-6028(02)01546-7; Borca CN, 2002, SURF SCI, V512, pL346, DOI 10.1016/S0039-6028(02)01494-2; Brongersma HH, 2012, CHARACTERIZATION MAT, P2024; Dulli H, 2000, PHYS REV B, V62, P14629; Fullarton IC, 1995, IONICS, V1, P51, DOI 10.1007/BF02426008; Garcia-Barriocanal J, 2008, SCIENCE, V321, P676, DOI 10.1126/science.1156393; Gunhold A, 2002, SURF SCI, V507, P447, DOI 10.1016/S0039-6028(02)01284-0; Herger R, 2008, PHYS REV B, V77, DOI 10.1103/PhysRevB.77.085401; Lee YL, 2009, PHYS REV B, V80, DOI 10.1103/PhysRevB.80.224101; Rosink JJWM, 1996, AIP CONF PROC, P44; Szot K, 2000, J PHYS-CONDENS MAT, V12, P4687, DOI 10.1088/0953-8984/12/22/302; Szot K, 1996, APPL PHYS A-MATER, V62, P335; Szot K, 1997, APPL PHYS A-MATER, V64, P55; SZOT K, 1991, APPL PHYS A-MATER, V53, P563, DOI 10.1007/BF00331547; Teraoka Y., 1988, J SURF SCI SOC JPN, V9, P153; Vickerman j.C., 2009, SURFACE ANAL PRINCIP; Wei H, 2001, J EUR CERAM SOC, V21, P1677, DOI 10.1016/S0955-2219(01)00091-7; Ziegler J. F., 1985, STOPPING RANGE IONS, V1	48	17	17	ROYAL SOC CHEMISTRY	CAMBRIDGE	THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND	1754-5692	1754-5706		ENERG ENVIRON SCI	Energy Environ. Sci.	NOV	2014	7	11					3593	3599		10.1039/c4ee01497a		7	Chemistry, Multidisciplinary; Energy & Fuels; Engineering, Chemical; Environmental Sciences	Chemistry; Energy & Fuels; Engineering; Environmental Sciences & Ecology	AS0NR	WOS:000343974700007		
J	Hou, JG; Yang, C; Cheng, HJ; Jiao, SQ; Takeda, O; Zhu, HM				Hou, Jungang; Yang, Chao; Cheng, Huijie; Jiao, Shuqiang; Takeda, Osamu; Zhu, Hongmin			High-performance p-Cu2O/n-TaON heterojunction nanorod photoanodes passivated with an ultrathin carbon sheath for photoelectrochemical water splitting	ENERGY & ENVIRONMENTAL SCIENCE			English	Article							VISIBLE-LIGHT IRRADIATION; OXYNITRIDE TAON PHOTOANODE; TA3N5 NANOTUBE ARRAYS; HYDROGEN-PRODUCTION; GRAPHENE OXIDE; QUANTUM DOTS; OXIDATION; CONVERSION; TIO2; PHOTOCATALYSTS	Considerable efforts have been made to design and discover photoactive nanostructured (oxy) nitride materials that can be used as photoanodes for photoelectrochemical (PEC) water splitting. However, the high recombination rate of photoexcited electron-hole pairs and the poor photostability have greatly limited their practical applications. Herein, a p-type Cu2O/n-type TaON heterojunction nanorod array passivated with an ultrathin carbon sheath (carbon-Cu2O/TaON) as a surface protection layer was produced via a solution-based process. Due to the shape anisotropy and p-n heterojunction structure, the photocurrent density of carbon-Cu2O/TaON heterojunction nanorod arrays as the integrated photoanode, with a maximum IPCE of 59% at a wavelength of 400 nm, reached 3.06 mA cm(-2) under AM 1.5G simulated sunlight at 1.0 V vs. RHE and remained at about 87.3% of the initial activity after 60 min irradiation. Not only is the onset potential negatively shifted but the photocurrent density and photostability are also significantly improved for this photoanode compared to those of TaON and Cu2O/TaON. These improvements are due to a high built-in potential in the p-n heterojunction device that is protected from the electrolyte by being encapsulated in an ultrathin graphitic carbon sheath. Our design introduces material components to provide a dedicated charge-transport pathway, alleviating the reliance on the materials' intrinsic properties, and therefore has the potential to greatly broaden where and how various existing materials can be used in energy-related applications.	[Hou, Jungang; Yang, Chao; Cheng, Huijie; Jiao, Shuqiang; Zhu, Hongmin] Univ Sci & Technol Beijing, Sch Met & Ecol Engn, Beijing 100083, Peoples R China; [Hou, Jungang; Takeda, Osamu; Zhu, Hongmin] Tohoku Univ, Aoba Ku, Sendai, Miyagi 9808579, Japan	Hou, JG (reprint author), Univ Sci & Technol Beijing, Sch Met & Ecol Engn, Beijing 100083, Peoples R China.	hzhu@material.tohoku.ac.jp	Hou, Jungang/E-8177-2012		National Science Foundation of China [51472027, 51102015]; Beijing High School Youth Talent Plan [YETP0351]; National Basic Research Program of China (973 Program) [2013CB632404]; Japan Society for the Promotion of Science (JSPS); Tohoku University, Sendai, Japan	This work was supported by National Science Foundation of China (no. 51472027 and 51102015), Beijing High School Youth Talent Plan (YETP0351) and National Basic Research Program of China (973 Program, no. 2013CB632404). J. G. Hou thanks the Japan Society for the Promotion of Science (JSPS) for a support in the form of a fellowship tenable at Tohoku University, Sendai, Japan.	Liu GJ, 2014, ANGEW CHEM INT EDIT, V53, P7295, DOI 10.1002/anie.201404697; Maeda K, 2007, J PHYS CHEM C, V111, P7851, DOI 10.1021/jp070911w; Su JZ, 2011, NANO LETT, V11, P1928, DOI 10.1021/nl2000743; Cao JY, 2013, LANGMUIR, V29, P3116, DOI 10.1021/la304377z; Marsen B, 2007, INT J HYDROGEN ENERG, V32, P3110, DOI 10.1016/j.ijhydene.2006.01.022; Wang Z, 2014, CHEM COMMUN, V50, P1731, DOI 10.1039/c3cc48752k; Abe R, 2010, J AM CHEM SOC, V132, P11828, DOI 10.1021/ja1016552; Chen ZB, 2010, J MATER RES, V25, P3, DOI 10.1557/JMR.2010.0020; Kim ES, 2013, J AM CHEM SOC, V135, P5375, DOI 10.1021/ja308723w; Hou JG, 2013, ENERG ENVIRON SCI, V6, P3322, DOI 10.1039/c3ee41854e; Zhen C, 2013, CHEM COMMUN, V49, P3019, DOI 10.1039/c3cc40760h; Cong YQ, 2012, CHEM MATER, V24, P579, DOI 10.1021/cm203269n; Walter MG, 2010, CHEM REV, V110, P6446, DOI 10.1021/cr1002326; Paracchino A, 2011, NAT MATER, V10, P456, DOI [10.1038/nmat3017, 10.1038/NMAT3017]; Hara M, 2003, J PHYS CHEM B, V107, P13441, DOI 10.1021/jp036189t; Tang LB, 2012, ACS NANO, V6, P5102, DOI 10.1021/nn300760g; Higashi M, 2011, ENERG ENVIRON SCI, V4, P4138, DOI 10.1039/c1ee01878g; Feng XJ, 2010, NANO LETT, V10, P948, DOI 10.1021/nl903886e; Nozik AJ, 2010, CHEM REV, V110, P6443, DOI 10.1021/cr1003419; McDonald KJ, 2011, CHEM MATER, V23, P4863, DOI 10.1021/cm202399g; SMOTKIN ES, 1987, J PHYS CHEM-US, V91, P6, DOI 10.1021/j100285a003; Ye MD, 2012, J AM CHEM SOC, V134, P15720, DOI 10.1021/ja307449z; Kasahara A, 2002, J PHYS CHEM A, V106, P6750, DOI 10.1021/jp025961+; Hong SJ, 2011, ENERG ENVIRON SCI, V4, P1781, DOI 10.1039/c0ee00743a; Qiu XQ, 2012, ACS NANO, V6, P1609, DOI 10.1021/nn2045888; Alper JP, 2014, NANO LETT, V14, P1843, DOI 10.1021/nl404609a; Li ZS, 2013, ENERG ENVIRON SCI, V6, P347, DOI 10.1039/c2ee22618a; Cong YQ, 2012, J PHYS CHEM C, V116, P14541, DOI 10.1021/jp304340a; Zhang ZH, 2013, ACS NANO, V7, P1709, DOI 10.1021/nn3057092; Hou JG, 2011, DALTON T, V40, P4038, DOI 10.1039/c0dt01847c; Hong SJ, 2009, INT J HYDROGEN ENERG, V34, P3234, DOI 10.1016/j.ijhydene.2009.02.006; Iwase A, 2010, J MATER CHEM, V20, P7536, DOI 10.1039/c0jm00961j; Liao MJ, 2012, ADV FUNCT MATER, V22, P3066, DOI 10.1002/adfm.201102966; Sivula K, 2011, CHEMSUSCHEM, V4, P432, DOI 10.1002/cssc.201000416; Higashi M, 2012, J AM CHEM SOC, V134, P6968, DOI 10.1021/ja302059g; Hou JG, 2013, APPL CATAL B-ENVIRON, V142, P579, DOI 10.1016/j.apcatb.2013.05.078; Suzuki A, 2014, CHEM MATER, V26, P976, DOI 10.1021/cm402720d; An XQ, 2014, CHEMSUSCHEM, V7, P1086, DOI 10.1002/cssc.201301194; Choi HJ, 2007, INT J HYDROGEN ENERG, V32, P3841, DOI 10.1016/j.ijhydene.2007.05.011; Zhou M, 2012, CHEMSUSCHEM, V5, P1420, DOI 10.1002/cssc.201200287; Ng YH, 2010, J PHYS CHEM LETT, V1, P2607, DOI 10.1021/jz100978u; Zhang LW, 2008, ADV FUNCT MATER, V18, P2180, DOI 10.1002/adfm.200701478; Li MX, 2013, ANGEW CHEM INT EDIT, V52, P11016, DOI 10.1002/anie.201305350; Chen HM, 2011, J PHYS CHEM C, V115, P21971, DOI 10.1021/jp204291b; Li YB, 2013, ADV MATER, V25, P125, DOI 10.1002/adma.201202582; Wang Y, 2010, ACS NANO, V4, P4753, DOI 10.1021/nn1004183; Wang XN, 2010, ACS NANO, V4, P3302, DOI 10.1021/nn1001547; Xu M, 2012, NANO LETT, V12, P1503, DOI 10.1021/nl2042968; Banerjee S, 2009, CHEM COMMUN, P7137, DOI 10.1039/b912549c; Hitoki G, 2002, CHEM COMMUN, P1698, DOI 10.1039/b202393h; Hitoki G, 2002, CHEM LETT, P736, DOI 10.1246/cl.2002.736; Hou J. G., 2012, J MATER CHEM, V22, P7291; Jun H, 2012, ENERG ENVIRON SCI, V5, P6375, DOI 10.1039/c1ee02526k; Li YB, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3566; Shao Z., 2011, J PHYS CHEM C, V116, P2438	55	16	17	ROYAL SOC CHEMISTRY	CAMBRIDGE	THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND	1754-5692	1754-5706		ENERG ENVIRON SCI	Energy Environ. Sci.	NOV	2014	7	11					3758	3768		10.1039/c4ee02403f		11	Chemistry, Multidisciplinary; Energy & Fuels; Engineering, Chemical; Environmental Sciences	Chemistry; Energy & Fuels; Engineering; Environmental Sciences & Ecology	AS0NR	WOS:000343974700026		
J	Shinkawa, S				Shinkawa, Seiji			Inorganic -e and double n in the Caligula Brut: implications for case marking	ENGLISH LANGUAGE & LINGUISTICS			English	Article								This article investigates variant forms of the demonstrative 'that' and the adjective in the Caligula Manuscript of La.amon's Brut and concludes that they to a large extent maintain the traditional category distinction between the accusative and the dative by the use of the suffixes -ne and -Vn (where V stands for any vowel) respectively. There are, however, factors that potentially compromise the status of these terminations as case markers: phonetic reduction (which has often been invoked), capricious addition or deletion of final e, occasional doubling or simplification of nasals, and simply unexpected choices of forms in the paradigm. These seem to be consistent with the sort of mistakes that scribes might occasionally make when faced with an original that has a different orthographical and morphological system from their own, and they are not as disruptive of the case-marking system as at first sight they might appear. For one thing, they occur rather rarely and are generally outnumbered by historically expected forms; for another, the resultant unexpected case forms, usually with the stem vowel preferred by the historical forms in the case of the demonstrative, are predominantly accompanied by a historically motivated case form of their head noun. The status of accusative -ne and dative -Vn, in fact, appears to be stable enough to lead to the development of a system or subsystem of indicating case regardless of gender considerations in their respective case contexts. These suffixes can therefore be treated validly as independent case markers, although in concrete cases the possibility always exists that there is an optional final e, an unhistorical double or single n, or an unexpected choice of inflectional forms.	Hakuoh Univ, Fac Business Adm, Oyama, Tochigi 3238585, Japan	Shinkawa, S (reprint author), Hakuoh Univ, Fac Business Adm, 1117 Daigyoji, Oyama, Tochigi 3238585, Japan.	shinkawa@fc.hakuoh.ac.jp					Allen Cynthia, 1995, CASE MARKING REANALY; [Anonymous], 2011, MIDDLE ENGLISH DICT; Bennett Jack A. W., 1982, EARLY MIDDLE ENGLISH; Bosworth J., 1898, ANGLO SAXON DICT BAS; Brook George L., 1978, LA AMON BRUT, V250, P277; Campbell Alistair, 1959, OLD ENGLISH GRAMMAR; Jones Charles, 1988, GRAMMATICAL GENDER E; Laing Meg, 2003, ENGL LANG LINGUIST, V7, P257, DOI 10.1017/S1360674303001102; Leslie Roy F., 1963, LA AMON BRUT, V250, P277; Madden Frederic, 1847, LA AMONS BRUT CHRONI; McSparran Frances, 2005, RETHINKING MIDDLE EN, P42; MILLAR RM, 1995, NEUPHILOL MITT, V96, P145; Mitchell Bruce, 1985, OLD ENGLISH SYNTAX; Shinkawa Seiji, 2012, UNHISTORICAL GENDER, V156; Stanley E. G., 1969, MEDIUM AEVUM, V38, P23; Stanley Eric G., 1968, NOTES QUERIES, V213, P85; Toller T. Northcote, 1921, ANGLO SAXON DICT BAS	17	0	0	CAMBRIDGE UNIV PRESS	CAMBRIDGE	EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND	1360-6743	1469-4379		ENGL LANG LINGUIST	Engl. Lang. Linguist.	NOV	2014	18	3					387	405		10.1017/S1360674314000094		19	Linguistics; Language & Linguistics	Linguistics	AS6GW	WOS:000344363300002		
J	Wakahara, T; Onda, Y; Kato, H; Sakaguchi, A; Yoshimura, K				Wakahara, Taeko; Onda, Yuich; Kato, Hiroaki; Sakaguchi, Aya; Yoshimura, Kazuya			Radiocesium discharge from paddy fields with different initial scrapings for decontamination after the Fukushima Dai-ichi Nuclear Power Plant accident	ENVIRONMENTAL SCIENCE-PROCESSES & IMPACTS			English	Article							FLUVIAL SUSPENDED SEDIMENT; PARTICLE-SIZE; CS-137; SOILS; PB-210; I-131	To explore the behavior of radionuclides released after the Fukushima Dai-ichi Nuclear Power Plant (FDNPP) accident in March 2011, and the distribution of radiocesium in paddy fields, we monitored radiocesium (Cs) and suspended sediment (SS) discharge from paddy fields. We proposed a rating scale for measuring the effectiveness of surface soil removal. Our experimental plots in paddy fields were located similar to 40 km from the FDNPP. Two plots were established: one in a paddy field where surface soil was not removed (the "normally cultivated paddy field") and the second in a paddy field where the top 5-10 cm of soil was removed before cultivation (the "surface-removed paddy field"). The amounts of Cs and SS discharge from the paddy fields were continuously measured from June to August 2011. The Cs soil inventory measured 3 months after the FDNPP accident was approximately 200 kBq m(-2). However, after removing the surface soil, the concentration of Cs-137 decreased to 5 kBq m(-2). SS discharged from the normally cultivated and surface-removed paddy fields after puddling (mixing of soil and water before planting rice) was 11.0 kg and 3.1 kg, respectively, and Cs-137 discharge was 630 000 Bq (1240 Bq m(-2)) and 24 800 Bq (47.8 Bq m(-2)), respectively. The total amount of SS discharge after irrigation (natural rainfall-runoff) was 5.5 kg for the normally cultivated field and 70 kg for the surface-removed field, and the total amounts of Cs-137 discharge were 51 900 Bq (102 Bq m(-2)) and 165 000 Bq (317 Bq m(-2)), respectively. During the irrigation period, discharge from the surface-removed plot showed a twofold greater inflow than that from the normally cultivated plot. Thus, Cs inflow may originate from the upper canal. The topsoil removal process eliminated at least approximately 95% of the Cs-137, but upstream water contaminated with Cs-137 flowed into the paddy field. Therefore, to accurately determine the Cs discharge, it is important to examine Cs inflow from the upper channel. Furthermore, puddling and irrigation processes inhibit the discharge of radiocesium downstream. This indicates that water control in paddy fields is an important process in the prevention of river pollution and radionuclide transfer.	[Wakahara, Taeko] Tokyo Univ Agr & Technol, Inst Symbiot Sci & Technol, Fuchu, Tokyo, Japan; [Onda, Yuich; Kato, Hiroaki; Yoshimura, Kazuya] Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki, Japan; [Sakaguchi, Aya] Univ Tsukuba, Ctr Res Isotopes & Environm Dynam, Tsukuba, Ibaraki, Japan	Wakahara, T (reprint author), Tokyo Univ Agr & Technol, Inst Symbiot Sci & Technol, 3-5-8 Saiwai Cho, Fuchu, Tokyo, Japan.	amusel@cc.tuat.ac.jp	Onda, Yuichi/N-6527-2014; Kato, Hiroaki/E-7695-2015; Sakaguchi, Aya/E-8134-2015; Yoshimura, Kazuya/N-9508-2015	Onda, Yuichi/0000-0001-8753-0378; Kato, Hiroaki/0000-0003-0194-3775; Yoshimura, Kazuya/0000-0001-5256-2679	MEXT (Ministry of Education, Culture, Sports, Science & Technology in Japan); MEXT [24110006]	This work was carried out in the FMWSE project (Fukushima Radiation Monitoring of Water, Soil and Entrainment) supported by MEXT (Ministry of Education, Culture, Sports, Science & Technology in Japan). This work was also partially supported by Grant-in-Aid for Scientific Research on Innovative Areas Grant Number 24110006 of the MEXT. The authors would like to thank Mr Shuhei Kanno and Mr Hiroshi Kanno for maintaining the paddy fields. Mr Yoshio Hirono kindly permitted us to use his land. Mr Hiroki Yoda of the University of Tsukuba and the other student members helped us with field work. Finally, we thank two anonymous referees for their helpful comments and suggestions.	He Q, 1997, APPL RADIAT ISOTOPES, V48, P677, DOI 10.1016/S0969-8043(96)00302-8; Phillips JM, 2000, HYDROL PROCESS, V14, P2589, DOI 10.1002/1099-1085(20001015)14:14<2589::AID-HYP94>3.3.CO;2-4; LIVENS FR, 1988, SCI TOTAL ENVIRON, V70, P1, DOI 10.1016/0048-9697(88)90248-3; Sakaguchi A, 2015, J ENVIRON RADIOACTIV, V139, P379, DOI 10.1016/j.jenvrad.2014.05.011; Shozugawa K, 2012, ENVIRON POLLUT, V163, P243, DOI 10.1016/j.envpol.2012.01.001; Mizugaki S, 2008, HYDROL PROCESS, V22, P4519, DOI 10.1002/hyp.7053; Onda Y, 2010, HYDROL PROCESS, V24, P527, DOI 10.1002/hyp.7548; He Q, 1996, J ENVIRON RADIOACTIV, V30, P117, DOI 10.1016/0265-931X(96)89275-7; Chino M, 2011, J NUCL SCI TECHNOL, V48, P1129, DOI 10.3327/jnst.48.1129; Endo S, 2013, ARCH BIOCHEM BIOPHYS, V529, P131, DOI 10.1016/j.abb.2012.11.013; GOLOSOV VN, 2002, APPL GEOMORPHOLOGY T, P165; Harada H., 2008, Japanese Journal of Soil Science and Plant Nutrition, V79, P53; HARADA H, 2005, TOHOKU J AGR RES, V58, P43; HASUKAWA H, 2009, B SHIGA PREF AGR TEC, V48, P1; *IAEA, 2007, REPORT ON THE IAEA C; Kato H, 2012, J ENVIRON RADIOACTIV, V111, P59, DOI 10.1016/j.jenvrad.2011.10.003; KINOUCHI T, 2007, J JAPAN SOC CIVIL EN, V51, P1177; KONDOH T, 1993, T JAPANESE SOC IRRIG, V164, P147; *MEXT, 2012, REP RES REL RAD CO 3, P17; MEXT (Ministry of Education Culture Sports Science and Technology Japan), 2011, PREP DISTR MAP RAD D; MIZUTANI M, 1995, STUDY GROUP PROMOTIO, P80; Murayama S., 2001, Japanese Journal of Soil Science and Plant Nutrition, V72, P409; ONDA Y, 2012, STUDY CONDITION COMP; ONDA Y, 2011, METHOD SOIL SAMPLING, P4; Sakai M, 2014, ENVIRON POLLUT, V187, P112, DOI 10.1016/j.envpol.2014.01.002; *SBJ, 2012, JAP STAT YB 2012, pCH7; Steinhauser G, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057760; Takeda I., 1991, T JSIDRE, V153, P63; Tanaka K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080794; TANIYAMA I, 2002, PREDICT ENV LOAD MON, P127; UDO A, 2000, J JAPAN SOC WATER EN, V23, P298, DOI 10.2965/jswe.23.298; WALLING DE, 1989, HYDROBIOLOGIA, V176, P125, DOI 10.1007/BF00026549; Yamada Yoshihiro, 2006, Japanese Journal of Limnology, V67, P105, DOI 10.3739/rikusui.67.105; Yamaguchi N, 2012, SCI TOTAL ENVIRON, V425, P128, DOI 10.1016/j.scitotenv.2012.02.037; YAMAMOTO M, 1983, J RADIAT RES, V24, P237, DOI 10.1269/jrr.24.237; YAMASHIKI Y, 2013, ANN DISASTER PREVE A, V56, P25; YAMASHIKI Y, 2014, SCI REP-UK, V4, DOI DOI 10.1038/SREP03714	37	1	1	ROYAL SOC CHEMISTRY	CAMBRIDGE	THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND	2050-7887	2050-7895		ENVIRON SCI-PROC IMP	Environ. Sci.-Process Impacts	NOV	2014	16	11					2580	2591		10.1039/c4em00262h		12	Chemistry, Analytical; Environmental Sciences	Chemistry; Environmental Sciences & Ecology	AS2TB	WOS:000344131200013		
J	Chen, JY; Zhu, AP; Tang, CY; Luo, YL; Zhang, YZ				Chen, Jianyao; Zhu, Aiping; Tang, Changyuan; Luo, Yinglin; Zhang, Yizhang			Nitrogen aspects of hydrological processes: a case study in Likeng landfill, Guangzhou, China	ENVIRONMENTAL SCIENCE-PROCESSES & IMPACTS			English	Article							BIOGEOCHEMICAL PROCESSES; NATURAL DENITRIFICATION; GROUNDWATER QUALITY; NITRATE SOURCES; ISOTOPE RATIOS; WATER; LEACHATE; CONTAMINATION; POLLUTION; SYSTEM	The nitrogen aspects of hydrological processes must be determined to identify nitrogen sources and relevant mechanisms. Landfills are the dominant disposal approach to deal with solid waste in urban areas in China. Landfills require adequate land and pose a potential threat to aquifer contamination, particularly in the humid zone, such as Guangzhou. The unlined Likeng landfill in Guangzhou was investigated in three campaigns during the period 2001-2007: water was sampled and analyzed for major ions, heavy metals, and stable isotopes of O-18 and H-2 in water, and O-18 and N-15 in nitrate. Contamination sources, water components, and groundwater flow were examined, revealing a mixture of various sources from landfill effluent, septic tank leakage, fertilizer, and manure following complex processes of recharge, mixing, and denitrification. The effluent from the landfill was rich in Na+, Ca2+, K+, HCO3-, and Cl- ions. A similar process of high NH4+ in effluent resulting in episodic increases in NO3- because of NH4+ oxidation was found in Likeng landfill when compared with landfills in Denmark and the USA. Twenty-five percent of the precipitation was lost to evaporation before recharging the aquifer, indicating a possible maximum recharge rate of 75% and the potential for a large amount of water penetration to the landfill if not well constructed. Apparent groundwater flow velocity of 3.7 x 10(-7) m s(-1) (11.67 m/a) was found for the front of the effluent under the landfill by considering the vertical and horizontal flow. These findings provide background to delineate the plume from Likeng landfill and to conceptualize the natural attenuation processes of other toxic compounds, which are imperative for any remediation strategy.	[Chen, Jianyao; Zhu, Aiping; Luo, Yinglin] Sun Yat Sen Univ, Sch Geog & Planning, Guangzhou 510275, Guangdong, Peoples R China; [Tang, Changyuan] Chiba Univ, Fac Hort, Dept Environm Sci & Landscape Architecture, Matsudo, Chiba 2718510, Japan; [Zhang, Yizhang] Chinese Res Inst Environm Sci, Lab Riverine Ecol Conservat & Technol, State Key Lab Environm Criteria & Risk Assessment, Beijing 100012, Peoples R China	Chen, JY (reprint author), Sun Yat Sen Univ, Sch Geog & Planning, Guangzhou 510275, Guangdong, Peoples R China.	chenjyao@mail.sysu.edu.cn			National Natural Sciences Foundation of China [41371055]; Innovation and Application Research Fund of the Water Sciences Department of Guangdong Province; Fundamental Research Funds for the Central Universities (Sun Yatsen University) [13lgjc08]	This research was supported financially by the following projects: the National Natural Sciences Foundation of China (no. 41371055), the Innovation and Application Research Fund of the Water Sciences Department of Guangdong Province (2009-2011, 2014-2016), and the Fundamental Research Funds for the Central Universities (13lgjc08, Sun Yatsen University). The authors thank Dr Fajin Chen for his help in analyzing <SUP>15</SUP>N and <SUP>18</SUP>O-NO<INF>3</INF><SUP>-</SUP>, and Kate Bentsen (Chinese Research Academy of Environmental Science) for editing the manuscript for grammar. The authors also thank two anonymous reviewers for helpful comments.	Carlson MA, 2011, J HYDROL, V409, P196, DOI 10.1016/j.jhydrol.2011.08.020; Mayer B, 2001, GEOCHIM COSMOCHIM AC, V65, P2743, DOI 10.1016/S0016-7037(01)00612-3; Cozzarelli IM, 2011, GROUND WATER, V49, P663, DOI 10.1111/j.1745-6584.2010.00792.x; Kjeldsen P, 2001, WASTE MANAGE RES, V19, P249; Scanlon BR, 2007, WATER RESOUR RES, V43, DOI 10.1029/2006WR005486; Lu Y, 2008, HYDROL PROCESS, V22, P443, DOI 10.1002/hyp.6617; KOROM SF, 1992, WATER RESOUR RES, V28, P1657, DOI 10.1029/92WR00252; Milosevic N, 2012, J HYDROL, V446, P13, DOI 10.1016/j.jhydrol.2012.04.012; Robertson WD, 2013, J HYDROL, V477, P43, DOI 10.1016/j.jhydrol.2012.10.048; Chen FJ, 2009, BIOGEOCHEMISTRY, V94, P163, DOI 10.1007/s10533-009-9316-x; Othman F, 2012, J ENVIRON MONITOR, V14, P3164, DOI 10.1039/c2em30676j; Chen J, 2005, HYDROGEOL J, V13, P481, DOI 10.1007/s10040-004-0321-9; Liu H, 2010, WASTE MANAGE, V30, P1569, DOI 10.1016/j.wasman.2010.01.040; MARIOTTI A, 1988, GEOCHIM COSMOCHIM AC, V52, P1869, DOI 10.1016/0016-7037(88)90010-5; Carey RO, 2013, ENVIRON POLLUT, V173, P138, DOI 10.1016/j.envpol.2012.10.004; Brun A, 2002, J HYDROL, V256, P228, DOI 10.1016/S0022-1694(01)00549-2; Silva SR, 2000, J HYDROL, V228, P22, DOI 10.1016/S0022-1694(99)00205-X; Yang K, 2008, WASTE MANAGE, V28, P2750, DOI 10.1016/j.wasman.2008.01.021; Katz BG, 2011, J HYDROL, V397, P151, DOI 10.1016/j.jhydrol.2010.11.017; Wang GQ, 2009, J ENVIRON MANAGE, V90, P2414, DOI 10.1016/j.jenvman.2008.12.008; Lin L, 2007, WASTE MANAGE, V27, P1376, DOI 10.1016/j.wasman.2006.09.001; Slomp CP, 2004, J HYDROL, V295, P64, DOI 10.1016/j.jhydrol.2004.02.018; Silva SR, 2002, ENVIRON FORENSICS, V3, P125, DOI 10.1006/enfo.2002.0086; Arora B, 2013, WATER RESOUR RES, V49, P6909, DOI 10.1002/wrcr.20484; BENGTSSON L, 1994, J HYDROL, V158, P203, DOI 10.1016/0022-1694(94)90054-X; Bjerg PL, 2011, GROUND WATER, V49, P688, DOI 10.1111/j.1745-6584.2009.00613.x; Burns D.A., 2002, WATER RESOUR RES, V38; Chen JY, 2006, J HYDROL, V326, P367, DOI 10.1016/j.jhydrol.2005.11.007; Clark I. D., 1997, ENV ISOTOPES HYDROGE, p[148, 172]; Gonfiantini R., 1986, HDB ENV ISOTOPE GEOC, P113; Hai L., 2009, GEOL CHEM MINER, V31, P105; HEATON THE, 1986, CHEM GEOL, V59, P87, DOI 10.1016/0168-9622(86)90059-X; Hosono T, 2011, J HYDROL, V397, P23, DOI 10.1016/j.jhydrol.2010.11.025; Howard K. W. F., 1996, HYDROGEOL J, V4, P64, DOI 10.1007/s100400050092; Huang Q., 2006, J MATER CYCLES WASTE, V8, P63, DOI 10.1007/s10163-005-0137-2; International Atomic Energy Agency (IAEA), 2003, GNIP GLOB NETW IS PR; Kendall C., 1998, ISOTOPE TRACERS CATC, P839; Lunau M, 2013, ENVIRON MICROBIOL, V15, P1492, DOI 10.1111/j.1462-2920.2012.02773.x; Luo Dinggui, 2009, Acta Scientiarum Naturalium Universitatis Pekinensis, V45; Mendoza-Sanchez I, 2013, J HYDROL, V498, P237, DOI 10.1016/j.jhydrol.2013.06.022; Mikac N, 1998, WATER SCI TECHNOL, V37, P37, DOI 10.1016/S0273-1223(98)00233-9; North JC, 2004, ENVIRON INT, V30, P631, DOI 10.1016/j.envint.2003.12.006; Ogata A, 1970, 411I US GEOL SURV; Pierobon E, 2013, CLEAN-SOIL AIR WATER, V41, P24, DOI 10.1002/clen.201100106; Rahim BEEA, 2010, HYDROGEOL J, V18, P997, DOI 10.1007/s10040-009-0567-3; Sadeq M, 2008, INT J HYG ENVIR HEAL, V211, P546, DOI 10.1016/j.ijheh.2007.09.009; Sanjay S. K., 2010, ENVIRON MONIT ASSESS, V162, P327; Scholl M. A., 2004, 20045238 US GEOL SUR, P60; Scholl M. A., 2005, RECJARGE PROCESSES A, P998; Smolders AJP, 2010, BIOGEOCHEMISTRY, V98, P1, DOI 10.1007/s10533-009-9387-8; Tian Yang-Jie, 2005, J Zhejiang Univ Sci B, V6, P165, DOI 10.1631/jzus.2005.B0165; [杨文澜 Yang Wenlan], 2010, [地球与环境, Earth and Environment], V38, P157; Zeng S. Q., 2010, J HYDROL, V30, P20; Zhao X. F., 2008, THESIS SUN TS U; Zheng Z, 2007, WATER RES, V41, P4696, DOI 10.1016/j.watres.2007.06.040; Zhu L, 2005, J SHANDONG U ARCHITE, V20, P46	56	0	0	ROYAL SOC CHEMISTRY	CAMBRIDGE	THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND	2050-7887	2050-7895		ENVIRON SCI-PROC IMP	Environ. Sci.-Process Impacts	NOV	2014	16	11					2604	2616		10.1039/c4em00194j		13	Chemistry, Analytical; Environmental Sciences	Chemistry; Environmental Sciences & Ecology	AS2TB	WOS:000344131200015		
J	Shinkai, Y; Nakajima, S; Eiguren-Fernandez, A; Di Stefano, E; Schmitz, DA; Froines, JR; Cho, AK; Kumagai, Y				Shinkai, Yasuhiro; Nakajima, Syun; Eiguren-Fernandez, Arantza; Di Stefano, Emma; Schmitz, Debra A.; Froines, John R.; Cho, Arthur K.; Kumagai, Yoshito			Ambient Vapor Samples Activate the Nrf2-ARE Pathway in Human Bronchial Epithelial BEAS-2B Cells	ENVIRONMENTAL TOXICOLOGY			English	Article						ambient air sample; vapor phase; electrophile; microarray; Nrf2	DIESEL EXHAUST PARTICLES; CARDIOVASCULAR-DISEASE; GENE-EXPRESSION; AIR-POLLUTION; PARTICULATE MATTER; AIRBORNE PARTICLES; HEME OXYGENASE-1; INFLAMMATION; ASSOCIATION; MECHANISMS	Ambient air pollutants have been reported to induce oxidative stress based inflammatory responses in humans and experimental animals. However, most of these reports describe the actions of the particulate phase of ambient and exhaust samples. We describe here results of studies investigating the actions of the vapor phase of ambient air samples collected in the midtown area of Los Angeles on human bronchial epithelial BEAS-2B cells using DNA microarray analysis. Among 26 genes whose expression increased fourfold or more, four genes were associated with detoxifying genes regulated by the transcription factor Nrf2. Consistent with these results, the vapor samples activate the Nrf2-ARE pathway, resulting in up-regulation of heme oxygenase-1 (HO-1), glutamate cysteine ligase modifier subunit, and cystine transporter (xCT) mRNA and proteins. No appreciable increases in pro-inflammatory genes were observed. These results suggest that ambient vapor samples activate the Nrf2-ARE pathway but not an inflammatory response. Also, treatment of the vapor samples with glutathione resulted in reduction in the Nrf2 activation and HO-1 induction, suggesting that electrophiles in vapor samples contribute to this Nrf2-dependent antioxidant or adaptive response. (C) 2013 Wiley Periodicals, Inc.	[Shinkai, Yasuhiro; Kumagai, Yoshito] Univ Tsukuba, Environm Biol Sect, Fac Med, Tsukuba, Ibaraki 3058575, Japan; [Shinkai, Yasuhiro; Nakajima, Syun; Kumagai, Yoshito] Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058575, Japan; [Eiguren-Fernandez, Arantza; Di Stefano, Emma; Schmitz, Debra A.; Froines, John R.; Cho, Arthur K.] Univ Calif Los Angeles, Southern Calif Particle Ctr, Los Angeles, CA 90095 USA	Kumagai, Y (reprint author), Univ Tsukuba, Environm Biol Sect, Fac Med, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.	yk-em-tu@md.tsukuba.ac.jp			The Ministry of Education, Culture, Sports, Science, and Technology of Japan [22406004]; U.S. Environmental Protection Agency [RD-83241301]; South Coast Air Quality Management District [12865]	Contract grant sponsor: The Ministry of Education, Culture, Sports, Science, and Technology of Japan (Grant-in-Aid for Scientific Research on Innovative Areas).; Contract grant number: 22406004.; Contract grant sponsor: U.S. Environmental Protection Agency-funded Southern California Particle Center.; Contract grant number: RD-83241301.; Contract grant sponsor: South Coast Air Quality Management District.; Contract grant number: 12865.	Halatek T, 2011, J ENVIRON SCI HEAL A, V46, P1469, DOI 10.1080/10978526.2011.609064; Van Eeden S, 2012, AM J RESP CRIT CARE, V186, P11, DOI 10.1164/rccm.201203-0455PP; Gozzelino R, 2010, ANNU REV PHARMACOL, V50, P323, DOI 10.1146/annurev.pharmtox.010909.105600; Brook RD, 2010, CIRCULATION, V121, P2331, DOI 10.1161/CIR.0b013e3181dbece1; Taguchi K, 2011, GENES CELLS, V16, P123, DOI 10.1111/j.1365-2443.2010.01473.x; Franchini M, 2012, THROMB RES, V129, P230, DOI 10.1016/j.thromres.2011.10.030; Kumagai Y, 2002, CHEM RES TOXICOL, V15, P483, DOI 10.1021/tx0100993; Paine A, 2010, BIOCHEM PHARMACOL, V80, P1895, DOI 10.1016/j.bcp.2010.07.014; Cho AK, 2005, ENVIRON RES, V99, P40, DOI 10.1016/j.envres.2005.01.003; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Shinyashiki M, 2009, ENVIRON RES, V109, P239, DOI 10.1016/j.envres.2008.12.008; Jacobs AT, 2010, ACCOUNTS CHEM RES, V43, P673, DOI 10.1021/ar900286y; Shinkai Y, 2009, TOXICOL APPL PHARM, V237, P232, DOI 10.1016/j.taap.2009.03.014; Delfino RJ, 2010, ENVIRON HEALTH PERSP, V118, P756, DOI 10.1289/ehp.0901407; Takizawa H, 2003, AM J PHYSIOL-LUNG C, V284, pL1055, DOI 10.1152/ajplung.00358.2002; Becker Susanne, 2005, Toxicol Appl Pharmacol, V207, P269, DOI 10.1016/j.taap.2005.01.023; Ebtekar Massoumeh, 2006, Iran J Allergy Asthma Immunol, V5, P47; Eiguren-Fernandez A, 2010, ENVIRON RES, V110, P207, DOI 10.1016/j.envres.2010.01.009; Eiguren-Fernandez A, 2008, AEROSOL SCI TECH, V42, P854, DOI 10.1080/02786820802339546; Hasegawa G, 2011, INHAL TOXICOL, V23, P897, DOI 10.3109/08958378.2011.625058; Iwamoto N, 2010, ATMOS ENVIRON, V44, P1483, DOI 10.1016/j.atmosenv.2010.01.045; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; Li N, 2003, ENVIRON HEALTH PERSP, V111, P455, DOI 10.1289/ehp.6000; Murdoch JR, 2010, MUTAT RES-FUND MOL M, V690, P24, DOI [10.1016/j.mrfmmm.2009.09.005, 10.1016/j.mrfmmm.2010.09.005]; Netto LES, 1996, ARCH BIOCHEM BIOPHYS, V333, P233, DOI 10.1006/abbi.1996.0386; Quay JL, 1998, AM J RESP CELL MOL, V19, P98; Rudolph TK, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.290re7; Salonen RO, 2004, SCAND J WORK ENV HEA, V30, P80; Shinyashiki M, 2008, ATMOS ENVIRON, V42, P517, DOI 10.1016/j.atmosenv.2007.09.047; Toyama T, 2011, J TOXICOL SCI, V36, P843	30	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1520-4081	1522-7278		ENVIRON TOXICOL	Environ. Toxicol.	NOV	2014	29	11					1292	1300		10.1002/tox.21860		9	Environmental Sciences; Toxicology; Water Resources	Environmental Sciences & Ecology; Toxicology; Water Resources	AS6NP	WOS:000344380400007		
J	Kawai, K; Moriya, A; Uemura, S; Abe, F				Kawai, Ken; Moriya, Atsuto; Uemura, Satoshi; Abe, Fumiyoshi			Functional Implications and Ubiquitin-Dependent Degradation of the Peptide Transporter Ptr2 in Saccharomyces cerevisiae	EUKARYOTIC CELL			English	Article							AMINO-ACID PERMEASE; MAJOR FACILITATOR SUPERFAMILY; BETA-LACTAM ANTIBIOTICS; END RULE PATHWAY; TRYPTOPHAN PERMEASE; POT FAMILY; TRANSCRIPTIONAL REPRESSOR; OLIGOPEPTIDE TRANSPORTERS; DIFFERENTIAL REGULATION; STRUCTURAL BASIS	The peptide transporter Ptr2 plays a central role in di- or tripeptide import in Saccharomyces cerevisiae. Although PTR2 transcription has been extensively analyzed in terms of upregulation by the Ubr1-Cup9 circuit, the structural and functional information for this transporter is limited. Here we identified 14 amino acid residues required for peptide import through Ptr2 based on the crystallographic information of Streptococcus thermophilus peptide transporter PepT(st) and based on the conservation of primary sequences among the proton-dependent oligopeptide transporters (POTs). Expression of Ptr2 carrying one of the 14 mutations of which the corresponding residues of PepT(st) are involved in peptide recognition, salt bridge interaction, or peptide translocation failed to enable ptr2 Delta trp1 cell growth in alanyl-tryptophan (Ala-Trp) medium. We observed that Ptr2 underwent rapid degradation after cycloheximide treatment (half-life, approximately 1 h), and this degradation depended on Rsp5 ubiquitin ligase. The ubiquitination of Ptr2 most likely occurs at the N-terminal lysines 16, 27, and 34. Simultaneous substitution of arginine for the three lysines fully prevented Ptr2 degradation. Ptr2 mutants of the presumed peptide-binding site (E92Q, R93K, K205R, W362L, and E480D) exhibited severe defects in peptide import and were subjected to Rsp5-dependent degradation when cells were moved to Ala-Trp medium, whereas, similar to what occurs in the wild-type Ptr2, mutant proteins of the intracellular gate were upregulated. These results suggest that Ptr2 undergoes quality control and the defects in peptide binding and the concomitant conformational change render Ptr2 subject to efficient ubiquitination and subsequent degradation.	[Kawai, Ken; Moriya, Atsuto; Uemura, Satoshi; Abe, Fumiyoshi] Aoyama Gakuin Univ, Coll Sci & Engn, Dept Chem & Biol Sci, Sagamihara, Kanagawa, Japan	Abe, F (reprint author), Aoyama Gakuin Univ, Coll Sci & Engn, Dept Chem & Biol Sci, Sagamihara, Kanagawa, Japan.	abef@chem.aoyama.ac.jp			Japan Society for the Promotion of Science [24580122]; Ministry of Education, Culture, Sports, Science, and Technology [2013-2017]	This work was supported by grants from the Japan Society for the Promotion of Science (No. 24580122 to F. Abe) and the Program for the Strategic Research Foundation at Private Universities by the Ministry of Education, Culture, Sports, Science, and Technology (No. 2013-2017).	Lambert C, 2002, BIOINFORMATICS, V18, P1250, DOI 10.1093/bioinformatics/18.9.1250; Marzluf GA, 1997, MICROBIOL MOL BIOL R, V61, P17; Kanda N, 2013, BIOCHEMISTRY-US, V52, P4296, DOI 10.1021/bi4004638; Doki S, 2013, P NATL ACAD SCI USA, V110, P11343, DOI 10.1073/pnas.1301079110; Abe F, 2003, MOL CELL BIOL, V23, P7566, DOI 10.1128/MCB.23.21.7566-7584.2003; Bolger MB, 1998, J PHARM SCI, V87, P1286, DOI 10.1021/js980090u; PERRY JR, 1994, MOL CELL BIOL, V14, P104; Newstead S, 2011, EMBO J, V30, P417, DOI 10.1038/emboj.2010.309; STEINER HY, 1995, MOL MICROBIOL, V16, P825, DOI 10.1111/j.1365-2958.1995.tb02310.x; Ganapathy ME, 1998, BIOCHEM BIOPH RES CO, V246, P470, DOI 10.1006/bbrc.1998.8628; Newstead S, 2011, BIOCHEM SOC T, V39, P1353, DOI 10.1042/BST0391353; Cai HJ, 2007, EUKARYOT CELL, V6, P1805, DOI 10.1128/EC.00257-06; Hori G, 2001, BIOSCI BIOTECH BIOCH, V65, P72, DOI 10.1271/bbb.65.72; Turner GC, 2000, NATURE, V405, P579; Keener JM, 2013, TRAFFIC, V14, P412, DOI 10.1111/tra.12039; Byrd C, 1998, EMBO J, V17, P269, DOI 10.1093/emboj/17.1.269; Forsberg H, 2001, MOL CELL BIOL, V21, P814, DOI 10.1128/MCB.21.3.814-826.2001; Soetens O, 2001, J BIOL CHEM, V276, P43949, DOI 10.1074/jbc.M102945200; Tsuruki T, 2003, FEBS LETT, V540, P206, DOI 10.1016/S0014-5793(03)00265-5; Ikeda K, 2011, APPL MICROBIOL BIOT, V89, P1971, DOI 10.1007/s00253-010-3001-9; Tamai I, 1997, J PHARM PHARMACOL, V49, P796; Nielsen CU, 2003, CURR DRUG TARGETS, V4, P373, DOI 10.2174/1389450033491028; Daniel H, 2006, PHYSIOLOGY, V21, P93, DOI 10.1152/physiol.00054.2005; Solcan N, 2012, EMBO J, V31, P3411, DOI 10.1038/emboj.2012.157; Forsberg H, 2001, MOL MICROBIOL, V42, P215, DOI 10.1046/j.1365-2958.2001.02627.x; Forsberg H, 2001, GENETICS, V158, P973; Xia ZX, 2008, J BIOL CHEM, V283, P28958, DOI 10.1074/jbc.M803980200; Lyons JA, 2014, EMBO REP, V15, P886, DOI 10.15252/embr.201338403; Yan N, 2013, TRENDS BIOCHEM SCI, V38, P151, DOI 10.1016/j.tibs.2013.01.003; Smith DE, 2013, MOL ASPECTS MED, V34, P323, DOI 10.1016/j.mam.2012.11.003; WENZEL U, 1995, BRIT J PHARMACOL, V116, P3021; Hauser M, 2001, MOL MEMBR BIOL, V18, P105, DOI 10.1080/713816114; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; Kitamura K, 2012, EUKARYOT CELL, V11, P302, DOI 10.1128/EC.05253-11; Barnes D, 1998, MOL MICROBIOL, V29, P297, DOI 10.1046/j.1365-2958.1998.00931.x; Beck T, 1999, J CELL BIOL, V146, P1227, DOI 10.1083/jcb.146.6.1227; Cain NE, 2011, MOL BIOL CELL, V22, P1919, DOI 10.1091/mbc.E10-10-0800; Delano WL., 2002, THE PYMOL MOLECULAR; Faria TN, 2004, MOL PHARMACEUT, V1, P67, DOI 10.1021/mp034001k; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; Hauser M, 2005, MOL MEMBR BIOL, V22, P215, DOI 10.1080/09687860500093248; Hwang CS, 2008, P NATL ACAD SCI USA, V105, P19188, DOI 10.1073/pnas.0808891105; ISLAND MD, 1991, CURR GENET, V20, P457, DOI 10.1007/BF00334772; Ito K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3502; Izawa S, 2007, APPL MICROBIOL BIOT, V75, P533, DOI 10.1007/s00253-007-0855-6; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; Kitagawa S, 2008, J BIOSCI BIOENG, V105, P360, DOI 10.1263/jbb.105.360; Omura F, 2001, BIOCHEM BIOPH RES CO, V287, P1045, DOI 10.1006/bbrc.2001.5697; Risinger AL, 2006, MOL BIOL CELL, V17, P4411, DOI 10.1091/mbc.E06-06-0506; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Simossis VA, 2005, NUCLEIC ACIDS RES, V33, pW289, DOI 10.1093/nar/gki390; Suzuki A, 2013, EUKARYOT CELL, V12, P990, DOI 10.1128/EC.00049-13; Takenaka A, 2003, BIOSCI BIOTECH BIOCH, V67, P278, DOI 10.1271/bbb.67.278; Wiles AM, 2006, MICROBIOL-SGM, V152, P3133, DOI 10.1099/mic.0.29055-0	54	0	0	AMER SOC MICROBIOLOGY	WASHINGTON	1752 N ST NW, WASHINGTON, DC 20036-2904 USA	1535-9778	1535-9786		EUKARYOT CELL	Eukaryot. Cell	NOV	2014	13	11					1380	1392		10.1128/EC.00094-14		13	Microbiology; Mycology	Microbiology; Mycology	AT0TB	WOS:000344646600004		
J	Kawabata, M; Shima, N; Nishizono, H				Kawabata, Masashi; Shima, Norihiro; Nishizono, Hidetsugu			Regular change in spontaneous preparative behaviour on intra-abdominal pressure and breathing during dynamic lifting	EUROPEAN JOURNAL OF APPLIED PHYSIOLOGY			English	Article						Abdominal; Diaphragm; Preparative action; Respiratory mechanics	INTRA-ABDOMINAL PRESSURE; TRUNK MUSCLE-ACTIVITY; LUMBAR SPINE; ACTIVATION; DIAPHRAGM; FORCE; RESISTANCE; STABILITY; STIFFNESS; BELT	Intra-abdominal pressure (IAP) and breathing behaviour are important preparative pre-lifting actions for functional stability during lifting. This study aimed to examine spontaneous changes in the peak rate of IAP development (Rate-IAP), peak IAP (Peak-IAP), the time of Rate- and Peak-IAP occurrence and respiratory volume in response to dynamic load lifting. Eleven healthy men performed quick dynamic deadlifting using 30, 45, 60 and 75 % of the isometric maximal lifting effort (iMLE). IAP was measured using an intrarectal pressure transducer. The spontaneous respiratory volume was calculated from air flow data using pneumotachography. The lifting motion onset was determined from the hip joint motion using an electrogoniometer. From 30 to 75 % of the iMLE, Rate-IAP occurred early from 2 +/- A 28 to -179 +/- A 16 ms (P < 0.01), whereas Peak-IAP occurred late from 165 +/- A 31 to 82 +/- A 23 ms (P = 0.12) relative to the lifting motion onset. Rate-IAP increased from 224 +/- A 47 to 507 +/- A 69 mmHg/s (P < 0.01), whereas Peak-IAP increased from 37 +/- A 8 to 90 +/- A 11 mmHg (P < 0.01) at 30-75 % of the iMLE. Rate-IAP strongly correlated with Peak-IAP at each lifting load (r = 0.94-0.97). Relative to the resting tidal volume, the inspiratory volume during pre-lifting significantly increased above 60 % of the iMLE, whereas expiratory volume significantly decreased at all lifting loads. Preparative pre-lifting behaviours alter IAP and breathing and are co-ordinated by the lifting load magnitude. These behaviours appear to be functionally important for dynamic lifting.	[Kawabata, Masashi] Sagamihara Kyodo Hosp, Rehabil Ctr, Sagamihara, Kanagawa, Japan; [Shima, Norihiro] Tokai Gakuen Univ, Sch Sport & Hlth Sci, Miyoshi, Aichi 4700207, Japan; [Nishizono, Hidetsugu] Natl Inst Fitness & Sports Kanoya, Kanoya, Kagoshima, Japan	Shima, N (reprint author), Tokai Gakuen Univ, Sch Sport & Hlth Sci, 21-233 Nishinohora, Miyoshi, Aichi 4700207, Japan.	shima@tokaigakuen-u.ac.jp					Al-Bilbeisi F, 2000, AM J RESP CRIT CARE, V162, P456; Hodges P, 1999, EXP BRAIN RES, V124, P69, DOI 10.1007/s002210050601; Hodges PW, 2000, J APPL PHYSIOL, V89, P967; DePalo VA, 2004, J APPL PHYSIOL, V96, P731, DOI 10.1152/japplphysiol.00511.2003; Cholewicki J, 1999, J BIOMECH, V32, P13, DOI 10.1016/S0021-9290(98)00129-8; Hagins M, 2006, CLIN BIOMECH, V21, P775, DOI 10.1016/j.clinbiomech.2006.04.003; Kawabata M, 2010, EUR J APPL PHYSIOL, V109, P279, DOI 10.1007/s00421-009-1344-7; CRESSWELL AG, 1994, EUR J APPL PHYSIOL O, V68, P315, DOI 10.1007/BF00571450; Aagaard P, 2002, J APPL PHYSIOL, V93, P1318, DOI 10.1152/japplphysiol.00283.2002; LIANG MH, 1990, MED CARE, V28, P632, DOI 10.1097/00005650-199007000-00008; Cholewicki J, 1999, EUR SPINE J, V8, P388, DOI 10.1007/s005860050192; CRESSWELL AG, 1994, SCAND J REHABIL MED, V26, P79; GOLDISH GD, 1994, ARCH PHYS MED REHAB, V75, P324, DOI 10.1016/0003-9993(94)90037-X; Hagins M, 2004, SPINE, V29, P464, DOI 10.1097/01.BRS.0000092368.90019.D8; HARMAN EA, 1988, MED SCI SPORT EXER, V20, P195; HARMAN EA, 1989, MED SCI SPORT EXER, V21, P186; HEMBORG B, 1985, SCAND J REHABIL MED, V17, P25; Hodges P, 2003, SPINE, V28, P2594, DOI 10.1097/01.BRS.0000096676.14323.25; Hodges PW, 2005, J BIOMECH, V38, P1873, DOI 10.1016/j.jbiomech.2004.08.016; Kawabata M, 2008, JPN J PHYS FIT SPORT, V57, P225; Mateika JH, 2000, BRAIN RES, V864, P327, DOI 10.1016/S0006-8993(00)02221-6; Stevens VK, 2008, J ELECTROMYOGR KINES, V18, P434, DOI 10.1016/j.jelekin.2006.10.009; Stokes IAF, 2011, CLIN BIOMECH, V26, P797, DOI 10.1016/j.clinbiomech.2011.04.006	23	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	1439-6319	1439-6327		EUR J APPL PHYSIOL	Eur. J. Appl. Physiol.	NOV	2014	114	11					2233	2239		10.1007/s00421-014-2944-4		7	Physiology; Sport Sciences	Physiology; Sport Sciences	AR9SD	WOS:000343915300001		
J	Yoshida, T; Ogawa, T; Taguchi, N; Maeda, J; Abe, K; Rodis, OM; Nakai, Y; Shirai, H; Torii, Y; Konoo, T; Suzuki, K				Yoshida, T.; Ogawa, T.; Taguchi, N.; Maeda, J.; Abe, K.; Rodis, O. M.; Nakai, Y.; Shirai, H.; Torii, Y.; Konoo, T.; Suzuki, K.			Effectiveness of a simulated patient training programme based on trainee response accuracy and appropriateness of feedback	EUROPEAN JOURNAL OF DENTAL EDUCATION			English	Article						accuracy; feedback; simulated patient; standardised patient; training programme	OF-THE-LITERATURE; STANDARDIZED PATIENTS; MEDICAL-EDUCATION; PERFORMANCE; COMMUNICATION; EXPERIENCE; STUDENTS; SKILLS	IntroductionSimulated patients (SPs) need education and training in required skills to be effective resources in education. This study was conducted to examine the effectiveness of an SP training programme based on the accuracy of trainee responses and the appropriateness of their feedback. MethodsThirty-two applicants to the training programme and 35 experienced SPs were included in this study. The experienced SPs served as a reference group. The rate of accurate responses and the rate of appropriate feedback were assessed with pre- and post-training tests, and these two outcome measures were compared with those of the experienced SPs. ResultsNo significant differences were found in trainee response accuracy or appropriateness of feedback between pre- and post-training tests. The response accuracy rate of the trainees on the pre-training test was significantly lower than that of SPs with 1-2years of experience, whilst there was no significant difference between these SPs and the trainees on the post-training test. ConclusionsAlthough our study suggests that more training is needed to improve the skills of SPs, the training programme may contribute to helping trainees reach a novice level in the skill of providing accurate responses. SP training should be encouraged to contribute to the effectiveness of such teaching and to establish the validity of the assessment.	[Yoshida, T.] Okayama Univ, Ctr Dev Med & Healthcare Educ Dent Educ, Okayama 7008558, Japan; [Ogawa, T.] Hiroshima Univ Hosp, Hiroshima, Japan; [Taguchi, N.] Kagoshima Univ Grad Sch Med & Dent Sci, Dept Dent Educ, Kagoshima, Japan; [Maeda, J.] Okayama Working Grp Simulated Patients, Okayama, Japan; [Abe, K.] Nagoya Univ Grad Sch Med, Dept Educ Community Oriented Med, Nagoya, Aichi, Japan; [Rodis, O. M.] Univ Tokushima Grad Sch, Int Exchange & Collaborat Inst Hlth Biosci, Support Off Frontier Oral Sci, Tokushima, Japan; [Nakai, Y.] Okayama Univ Grad Sch Med Dent & Pharmaceut Sci, Dept Pediat Dent, Okayama, Japan; [Shirai, H.; Torii, Y.] Okayama Univ Hosp, Comprehens Dent Clin, Okayama, Japan; [Konoo, T.] Kyushu Dent Univ, Div Comprehens Dent, Kitakyushu, Fukuoka, Japan; [Suzuki, K.] Aichi Gakuin Univ, Sch Dent, Dept Endodont, Nagoya, Aichi 464, Japan	Yoshida, T (reprint author), Okayama Univ, Ctr Dev Med & Healthcare Educ Dent Educ, Kita Ku, 2-5-1 Shikata Cho, Okayama 7008558, Japan.	toshiko@md.okayama-u.ac.jp			KAKENHI from Japan Society for the Promotion of Science [19592404]	This study was supported by a KAKENHI, Grant-in-Aid for Scientific Research (C) 19592404 from Japan Society for the Promotion of Science.	Abe K, 2011, PATIENT EDUC COUNS, V84, P261, DOI 10.1016/j.pec.2010.07.017; Wind LA, 2004, MED EDUC, V38, P39, DOI 10.1046/j.1365-2923.2004.01686.x; May W, 2009, MED TEACH, V31, P487, DOI 10.1080/01421590802530898; Bokken L, 2009, MED EDUC, V43, P202, DOI 10.1111/j.1365-2923.2008.03268.x; Cannick GF, 2007, J DENT EDUC, V71, P1203; TAMBLYN RM, 1991, MED EDUC, V25, P100; Howley L, 2008, MED EDUC, V42, P350, DOI 10.1111/j.1365-2923.2007.02999.x; Beaulieu MD, 2003, INT J QUAL HEALTH C, V15, P251, DOI 10.1093/intqhc/mzg037; Hattie J, 2007, REV EDUC RES, V77, P81, DOI 10.3102/003465430298487; McGraw RC, 1999, MED EDUC, V33, P572, DOI 10.1046/j.1365-2923.1999.00381.x; BARROWS HS, 1964, J MED EDUC, V39, P802; Cleland JA, 2009, MED TEACH, V31, P477, DOI 10.1080/01421590903002821; van de Ridder JMM, 2008, MED EDUC, V42, P189, DOI 10.1111/j.1365-2923.2007.02973.x; [Anonymous], 2006, INT J PHARM PRACT, DOI 10.1211/ijpp.14.2.0002; Bandura A, 1986, SOCIAL FDN THOUGHT A, P47; Eyler AE, 1997, AM J PREV MED, V13, P153; Johnson J A, 1990, J Dent Educ, V54, P331; Manogue M, 1998, Eur J Dent Educ, V2, P51, DOI 10.1111/j.1600-0579.1998.tb00039.x; Olive KE, 1997, ADV HEALTH SCI EDUC, V2, P49, DOI 10.1023/A:1009704030279; Perera J, 2009, BMC MED EDUC, V9, DOI 10.1186/1472-6920-9-37; Schoonheim-Klein M E, 2006, Eur J Dent Educ, V10, P226, DOI 10.1111/j.1600-0579.2006.00421.x; Stilwell N A, 1992, J Dent Educ, V56, P118; Taguchi N, 2010, EUR J DENT EDUC, V14, P203, DOI 10.1111/j.1600-0579.2009.00610.x; Tamblyn RM, 1997, TEACH LEARN MED, V9, P25; Wallace P, 2007, COACHING STANDARDIZE; WHITEHOUSE C, 1984, MED EDUC, V18, P262	26	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1396-5883	1600-0579		EUR J DENT EDUC	Eur. J. Dent. Educ.	NOV	2014	18	4					241	251		10.1111/eje.12093		11	Dentistry, Oral Surgery & Medicine; Education, Scientific Disciplines	Dentistry, Oral Surgery & Medicine; Education & Educational Research	AR9XN	WOS:000343930500008		
J	Abe, T; Mino, T; Watanabe, K; Sakamoto, M				Abe, Taichi; Mino, Takashi; Watanabe, Kohei; Sakamoto, Masami			Suzuki-Miyaura Coupling of Aryl Chlorides with Arylboronic Acids Using the Morpholine-NiCl2 Catalyst System	EUROPEAN JOURNAL OF ORGANIC CHEMISTRY			English	Article						Synthetic methods; C-C coupling; Cross coupling; Nickel; N ligands	NICKEL-COMPLEXES; ALKYL-HALIDES; CHLOROARENES; BIARYLS; MESYLATES; ARENESULFONATES; PALLADIUM; CHARCOAL; LIGANDS	We report a new catalyst system, morpholine-NiCl2, for the Suzuki-Miyaura coupling of aryl chlorides with aryl-or alkenylboronic acids to give biaryl compounds. This catalyst system is easy to apply on a large scale because of its easy preparation and the use of inexpensive reagents. In addition, analysis of the residual nickel shows only 9.7 ppm remaining after normal work-up. This catalyst system has been applied to 26 compounds to give a variety of biaryl products, including hetero-biaryl compounds.	[Abe, Taichi; Mino, Takashi; Watanabe, Kohei; Sakamoto, Masami] Chiba Univ, Dept Appl Chem & Biotechnol, Grad Sch Engn, Inage Ku, Chiba 2638522, Japan	Abe, T (reprint author), Chiba Univ, Dept Appl Chem & Biotechnol, Grad Sch Engn, Inage Ku, 1-33 Yayoi Cho, Chiba 2638522, Japan.	t2-abe@hhc.eisai.co.jp; tmino@faculty.chiba-u.jp	Mino, Takashi/F-8350-2010				Abe T, 2014, EUR J ORG CHEM, V2014, P3909, DOI 10.1002/ejoc.201402120; Ackermann L, 2011, CHEM-EUR J, V17, P2965, DOI 10.1002/chem.201002386; Moncomble A, 2012, J ORG CHEM, V77, P5056, DOI 10.1021/jo3005149; Zim D, 2002, TETRAHEDRON LETT, V43, P4009, DOI 10.1016/S0040-4039(02)00716-5; Lipshutz BH, 2008, ORG LETT, V10, P697, DOI 10.1021/ol702453q; Kobayashi O, 2009, ORG LETT, V11, P2679, DOI 10.1021/ol900778m; Tang ZY, 2006, J ORG CHEM, V71, P2167, DOI 10.1021/jo052369i; Bhayana B, 2009, ORG LETT, V11, P3954, DOI 10.1021/ol9015892; Gurung SK, 2013, ORG LETT, V15, P5378, DOI 10.1021/ol402701x; Indolese AF, 1997, TETRAHEDRON LETT, V38, P3513, DOI 10.1016/S0040-4039(97)00707-7; Wang SH, 2011, TETRAHEDRON, V67, P4800, DOI 10.1016/j.tet.2011.05.031; Wu L, 2011, ADV SYNTH CATAL, V353, P1452, DOI 10.1002/adsc.201100134; Han FS, 2013, CHEM SOC REV, V42, P5270, DOI 10.1039/c3cs35521g; Yang CT, 2011, ANGEW CHEM INT EDIT, V50, P3904, DOI 10.1002/anie.201008007; Inada K, 2000, TETRAHEDRON, V56, P8657, DOI 10.1016/S0040-4020(00)00814-0; Percec V, 2004, J ORG CHEM, V69, P3447, DOI 10.1021/jo049940i; Brun S, 2012, ORGANOMETALLICS, V31, P1983, DOI 10.1021/om201271y; Molander GA, 2009, J ORG CHEM, V74, P973, DOI 10.1021/jo802590b; Saito S, 1996, TETRAHEDRON LETT, V37, P2993, DOI 10.1016/0040-4039(96)00482-0; Guo Y, 2008, TETRAHEDRON LETT, V49, P5620, DOI 10.1016/j.tetlet.2008.07.060; Galland JC, 1999, TETRAHEDRON LETT, V40, P2323, DOI 10.1016/S0040-4039(99)00239-7; Lipshutz BH, 2000, TETRAHEDRON, V56, P2139, DOI 10.1016/S0040-4020(99)01096-0; Hatakeyama T, 2010, J AM CHEM SOC, V132, P10674, DOI 10.1021/ja103973a; Wilson DA, 2008, ORG LETT, V10, P4879, DOI 10.1021/ol801972f; Magano J, 2011, CHEM REV, V111, P2177, DOI 10.1021/cr100346g; Shen T, 2013, ANGEW CHEM INT EDIT, V52, P6677, DOI 10.1002/anie.201300193; Zhou L, 2007, TETRAHEDRON LETT, V48, P7899, DOI 10.1016/j.tetlet.2007.08.089; Zhao YL, 2011, ADV SYNTH CATAL, V353, P1543, DOI 10.1002/adsc.201100101; Saito S, 1997, J ORG CHEM, V62, P8024, DOI 10.1021/jo9707848; Tang ZY, 2006, TETRAHEDRON LETT, V47, P2427, DOI 10.1016/j.tetlet.2006.01.145; Asaumi T., 2009, WO Pat, Patent No. 2009136646; Dobele M., 2011, ANGEW CHEM, V123, P11737; Dobele M, 2011, ANGEW CHEM INT EDIT, V50, P11533, DOI 10.1002/anie.201105446; Eguchi H., 2012, J SYNTH ORG CHEM, V170, P937; Fan XH, 2011, EUR J ORG CHEM, P1467, DOI 10.1002/ejoc.201001519; Gavryushin A, 2005, ORG LETT, V7, P4871, DOI 10.1021/ol051615+; Ishikawa S., 2006, European Patent, Patent No. [EP 1707263, 1707263]; Itabashi T., 2005, Japanese Patent, Patent No. [JP 2005008578, 2005008578]; Kuroda JI, 2009, EUR J ORG CHEM, P2251, DOI 10.1002/ejoc.200900067; Leadbeater NE, 1999, TETRAHEDRON, V55, P11889, DOI 10.1016/S0040-4020(99)00676-6; Lipshutz BH, 2001, ADV SYNTH CATAL, V343, P313; PALAZON J, 1985, POLYHEDRON, V4, P1985, DOI 10.1016/S0277-5387(00)86723-6; Pawaret L., 2012, J ORG CHEM, V77, P1018; Santosh K. G., 2014, ORG LETT, V16, P1264; Shen T., 2013, ANGEW CHEM, V125, P6809; Wang ZX, 2012, EUR J INORG CHEM, P901, DOI 10.1002/ejic.201101036; Yang C.-T., 2011, ANGEW CHEM, V123, P3990; You EL, 2006, SYNTHESIS-STUTTGART, P1465, DOI 10.1055/s-2006-926424	48	0	0	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1434-193X	1099-0690		EUR J ORG CHEM	Eur. J. Org. Chem.	NOV	2014		31					6983	6991		10.1002/ejoc.201402881		9	Chemistry, Organic	Chemistry	AS5SC	WOS:000344328900021		
J	Yamazaki, S; Ueda, K; Fukushima, Y; Ogawa, A; Kakiuchi, K				Yamazaki, Shoko; Ueda, Kohta; Fukushima, Yugo; Ogawa, Akiya; Kakiuchi, Kiyomi			Six-Membered Ring Formation from Lewis Acid Promoted Reactions of 2-Substituted 2-Alkenyl Amides and Esters of Ethenetricarboxylate	EUROPEAN JOURNAL OF ORGANIC CHEMISTRY			English	Article						Heterocycles; Cyclization; Lewis acids; Reaction mechanisms	INTRAMOLECULAR ENE REACTIONS; DYOTROPIC REARRANGEMENTS; STEREOSELECTIVE-SYNTHESIS; ORGANIC-SYNTHESIS; PIPERIDINE; ALKALOIDS; ALLENES; CYCLIZATION; HETEROCYCLES; PYRROLIDINE	The Lewis acid promoted reactions of 2-substituted 2-propenyl amides and the 2-methylbuta-2,3-dienyl ester of ethene-tricarboxylate have been examined. The reactions of 2-substituted 2-propenyl amides with AlCl3 gave 2-oxo-5,6-dehydropiperidines as the major products. The reaction of 2-methylbuta-2,3-dienyl ester with Lewis acids such as AlCl3 and SnCl4 gave 2-oxo-3,6-dihydropyran as the major product. The preference for six-over five-membered-ring formation was observed.	[Yamazaki, Shoko; Ueda, Kohta] Nara Univ Educ, Dept Chem, Takabatake, Nara 6308528, Japan; [Fukushima, Yugo; Ogawa, Akiya] Osaka Prefecture Univ, Grad Sch Engn, Dept Appl Chem, Naka Ku, Sakai, Osaka 5998531, Japan; [Kakiuchi, Kiyomi] Nara Inst Sci & Technol NAIST, Grad Sch Mat Sci, Nara 6300192, Japan	Yamazaki, S (reprint author), Nara Univ Educ, Dept Chem, Takabatake, Nara 6308528, Japan.	yamazaks@nara-edu.ac.jp	Ogawa, Akiya/B-2039-2010		Ministry of Education, Culture, Sports, Science, and Technology of the Japanese Government	This work was supported by the Ministry of Education, Culture, Sports, Science, and Technology of the Japanese Government. The authors thank the Nara Institute of Science and Technology (NAIST) for mass spectra.	Adams D. R., 1977, SYNTHESIS, P661; Yamazaki S, 2005, ORG LETT, V7, P759, DOI 10.1021/ol047693z; Fukushima Y, 2014, ORG BIOMOL CHEM, V12, P3964, DOI 10.1039/c4ob00233d; GONZALEZ C, 1989, J CHEM PHYS, V90, P2154, DOI 10.1063/1.456010; Wu HP, 2001, ORGANOMETALLICS, V20, P2183, DOI 10.1021/om010045o; Sydnes LK, 2003, CHEM REV, V103, P1133, DOI 10.1021/cr010025w; BECKE AD, 1993, J CHEM PHYS, V98, P5648, DOI 10.1063/1.464913; [Anonymous], 1977, ADV ORGANOMET CHEM; Kesting JR, 2009, J NAT PROD, V72, P312, DOI 10.1021/np800743w; Yamazaki S, 2013, J ORG CHEM, V78, P8405, DOI 10.1021/jo401106m; [Anonymous], 2006, EUR J ORG CHEM; Mitome H, 2001, J NAT PROD, V64, P1506, DOI 10.1021/np010299e; Mennucci B, 1997, J CHEM PHYS, V106, P5151, DOI 10.1063/1.473558; Tsupova S, 2013, ORG LETT, V15, P3381, DOI 10.1021/ol4014798; Ma SM, 2005, CHEM REV, V105, P2829, DOI 10.1021/cr020024j; Cances E, 1997, J CHEM PHYS, V107, P3032, DOI 10.1063/1.474659; Hassan HHAM, 2007, CURR ORG SYNTH, V4, P413, DOI 10.2174/157017907782408798; Cook SP, 2006, ORG LETT, V8, P5693, DOI 10.1021/ol062067i; Corma A, 2003, CHEM REV, V103, P4307, DOI 10.1021/cr030680z; REETZ MT, 1972, ANGEW CHEM INT EDIT, V11, P129, DOI 10.1002/anie.197201291; Greco SJ, 2013, ALDRICHIM ACTA, V46, P59; OPPOLZER W, 1981, PURE APPL CHEM, V53, P1181, DOI 10.1351/pac198153061181; SNIDER BB, 1979, J ORG CHEM, V44, P4229, DOI 10.1021/jo01338a003; Larrosa I, 2008, TETRAHEDRON, V64, P2683, DOI 10.1016/j.tet.2007.11.092; BALIAH V, 1983, CHEM REV, V83, P379, DOI 10.1021/cr00056a002; ARUNDALE E, 1952, CHEM REV, V51, P505, DOI 10.1021/cr60160a004; Ouedraogo M, 2007, J NAT PROD, V70, P2006, DOI 10.1021/np070355x; Dragutan I, 2012, RSC ADV, V2, P719, DOI 10.1039/c1ra00910a; Buffat MGP, 2004, TETRAHEDRON, V60, P1701, DOI 10.1016/j.tet.2003.11.043; Fernandez I, 2009, CHEM REV, V109, P6687, DOI 10.1021/cr900209c; Olier C, 2010, TETRAHEDRON, V66, P413, DOI 10.1016/j.tet.2009.10.069; TIETZE LF, 1988, ANGEW CHEM INT EDIT, V27, P1186, DOI 10.1002/anie.198811861; Kallstrom S, 2008, BIOORGAN MED CHEM, V16, P601, DOI 10.1016/j.bmc.2007.10.018; O'Hagan D, 2000, NAT PROD REP, V17, P435, DOI 10.1039/a707613d; LEE CT, 1988, PHYS REV B, V37, P785, DOI 10.1103/PhysRevB.37.785; Davis RL, 2011, J ORG CHEM, V76, P7167, DOI 10.1021/jo2012175; Bailey P. D., 1998, CHEM COMMUN, P633; Brandsma L., 2004, SYNTHESIS ACETYLENES; Cheng JJ, 2013, ACS CATAL, V3, P663, DOI 10.1021/cs300838k; Cossi M, 1998, CHEM PHYS LETT, V286, P253, DOI 10.1016/S0009-2614(98)00106-7; Frisch M. J., 2004, GAUSSIAN 03 REVISION; FUKUI K, 1970, J PHYS CHEM-US, V74, P4161, DOI 10.1021/j100717a029; HATCH LF, 1954, J AM CHEM SOC, V76, P2705, DOI 10.1021/ja01639a032; ISAAC MB, 1995, J CHEM SOC CHEM COMM, P1003, DOI 10.1039/c39950001003; Katavic PL, 2006, J NAT PROD, V69, P1295, DOI 10.1021/np060179c; Krause N., 2004, TETRAHEDRON, V60, P11671; Laschat S., 2000, SYNTHESIS, P1781; Felpin FX, 2003, EUR J ORG CHEM, P3693, DOI 10.1002/ejoc.200300193; Ma SM, 2009, ACCOUNTS CHEM RES, V42, P1679, DOI 10.1021/ar900153r; Maxwell A, 1998, J NAT PROD, V61, P815, DOI 10.1021/np970520g; Mondol MAM, 2011, J NAT PROD, V74, P2582, DOI 10.1021/np200487k; Oppolzer W., 1978, ANGEW CHEM, V90, P506, DOI 10.1002/ange.19780900705; OPPOLZER W, 1978, ANGEW CHEM INT EDIT, V17, P476, DOI 10.1002/anie.197804761; Overman E., 1995, ALDRICHIM ACTA, V28, P107; Ragoussis V, 2007, J AGR FOOD CHEM, V55, P5050, DOI 10.1021/jf0704662; Reategui RF, 2005, J NAT PROD, V68, P701, DOI 10.1021/np050035i; REED SF, 1965, J ORG CHEM, V30, P3258, DOI 10.1021/jo01020a539; Reetz M. T., 1972, ANGEW CHEM INT EDIT, V11, P131; Reetz M. T., 1972, ANGEW CHEM, V84, P113; Reetz M. T., 1972, ANGEW CHEM, V84, P161, DOI 10.1002/ange.19720840410; REETZ MT, 1973, TETRAHEDRON, V29, P2189, DOI 10.1016/0040-4020(73)80163-2; Rocha DFO, 2011, J NAT PROD, V74, P658, DOI 10.1021/np100719f; Schuster H. F., 1984, ALLENES ORGANIC SYNT; SNIDER BB, 1980, ACCOUNTS CHEM RES, V13, P426, DOI 10.1021/ar50155a007; Snider B. B., 1991, COMPREHENSIVE ORGANI, V2, P527, DOI DOI 10.1016/B978-0-08-052349-1.00040-8; Tietze L.F., 1988, ANGEW CHEM, V100, P1200, DOI 10.1002/ange.19881000911; TIETZE LF, 1988, SYNTHESIS-STUTTGART, P359; Yamamoto H., 2000, LEWIS ACIDS ORGANIC, P1, DOI 10.1002/9783527618309.ch1; Yamazaki S, 2010, J ORG CHEM, V75, P5216, DOI 10.1021/jo1009855; Yamazaki S, 2012, SYNTHESIS-STUTTGART, V44, P2155, DOI 10.1055/s-0031-1290776; Yua S., 2011, CHEM COMMUN, V47, P5384	71	1	1	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1434-193X	1099-0690		EUR J ORG CHEM	Eur. J. Org. Chem.	NOV	2014		31					7023	7033		10.1002/ejoc.201402637		11	Chemistry, Organic	Chemistry	AS5SC	WOS:000344328900026		
J	Katoh, T; Monma, H; Wakasugi, J; Narita, K; Katoh, T				Katoh, Takeru; Monma, Hiromitsu; Wakasugi, Jun; Narita, Koichi; Katoh, Tadashi			Synthesis of beta-Lapachone, a Potential Anticancer Agent from the Lapacho Tree	EUROPEAN JOURNAL OF ORGANIC CHEMISTRY			English	Article						Natural products; Drug discovery; Antitumor agents; Domino reactions; Synthetic methods; Cyclization; Quinones	IN-VITRO; DERIVATIVES; (+)-AUREOL; NQO1; NAPHTHOQUINONES; (-)-NEOAVARONE; IDENTIFICATION; REARRANGEMENT; CONSTITUENTS; METABOLISM	A pharmaceutically important natural product, beta-lapachone, was efficiently synthesized in four steps in 70% overall yield starting from commercially available 1,4-naphthoquinone. The key step of the synthesis was the direct conversion of 2-prenyl-1,4-naphthoquinone into beta-lapachone through an advantageous cyclization/hydration/oxidation cascade process.	[Katoh, Takeru; Monma, Hiromitsu; Wakasugi, Jun; Narita, Koichi; Katoh, Tadashi] Tohoku Pharmaceut Univ, Fac Pharmaceut Sci, Lab Synthet & Med Chem, Aoba Ku, Sendai, Miyagi 9818558, Japan	Katoh, T (reprint author), Tohoku Pharmaceut Univ, Fac Pharmaceut Sci, Lab Synthet & Med Chem, Aoba Ku, 4-4-1 Komatsushima, Sendai, Miyagi 9818558, Japan.	katoh@tohoku-pharm.ac.jp			Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT) through a Grant-in-Aid for the Strategic Research Foundation Program at Private Universities [2010-2014]; Grant-in-Aid for Scientific Research [24590017]	This study was supported by the Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT) through a Grant-in-Aid for the Strategic Research Foundation Program at Private Universities (grant number 2010-2014) and a Grant-in-Aid for Scientific Research (C) (grant number 24590017).	Alves GBC, 1999, SYNTHESIS-STUTTGART, P1875; AMARAL ACF, 1992, J HETEROCYCLIC CHEM, V29, P1457; Bian JL, 2014, TETRAHEDRON LETT, V55, P1475, DOI 10.1016/j.tetlet.2014.01.059; Macedo L, 2013, PHYTOMEDICINE, V21, P25, DOI 10.1016/j.phymed.2013.08.010; JOSHI KC, 1979, PLANTA MED, V37, P60; Huang XM, 2012, CANCER RES, V72, P3038, DOI 10.1158/0008-5472.CAN-11-3135; Terai K, 2009, ANTI-CANCER DRUG, V20, P901, DOI 10.1097/CAD.0b013e328330098d; Bentle MS, 2007, CANCER RES, V67, P6936, DOI 10.1158/0008-5472.CAN-07-0935; Parkinson EI, 2013, ACS CHEM BIOL, V8, P2173, DOI 10.1021/cb4005832; Salas C, 2008, BIOORGAN MED CHEM, V16, P668, DOI 10.1016/j.bmc.2007.10.038; Kotha S, 2006, CHEM-EUR J, V12, P4446, DOI 10.1002/chem.200501366; Pardee AB, 2002, CURR CANCER DRUG TAR, V2, P227, DOI 10.2174/1568009023333854; Moon DO, 2007, INT IMMUNOPHARMACOL, V7, P506, DOI 10.1016/j.intimp.2006.12.006; GUIRAUD P, 1994, PLANTA MED, V60, P373, DOI 10.1055/s-2006-959504; Li CJ, 1999, P NATL ACAD SCI USA, V96, P13369, DOI 10.1073/pnas.96.23.13369; Perez-Sacau E, 2005, CHEM BIODIVERS, V2, P264, DOI 10.1002/cbdv.200590009; Fukui Y, 2014, CHEM-EUR J, V20, P2436, DOI 10.1002/chem.201304809; BRANDAO MAF, 1993, TETRAHEDRON LETT, V34, P2437, DOI 10.1016/S0040-4039(00)60435-5; BURNETT AR, 1967, J CHEM SOC C, P2100, DOI 10.1039/j39670002100; Cheng XF, 2012, MOL PHARMACEUT, V9, P3476, DOI 10.1021/mp300296m; Claessens S, 2010, ORG BIOMOL CHEM, V8, P3790, DOI 10.1039/c004580b; Claessens S, 2006, TETRAHEDRON, V62, P8419, DOI 10.1016/j.tet.2006.06.014; D'Anneo A., 2009, J CELL PHYSL, V222, P433; Hamamura K., 1994, [No title captured], Patent No. [EP 0 613 877 A1, 0613877]; Katoh T, 2001, ORG LETT, V3, P2701, DOI 10.1021/ol016285h; Kim IS, 2013, CANCER CHEMOTH PHARM, V72, P699, DOI 10.1007/s00280-013-2230-x; Kumi-Diaka J, 2004, CANCER CELL INT, V4, DOI 10.1186/1475-2867-4-5; Kung HN, 2007, J CELL PHYSIOL, V211, P522, DOI 10.1002/jcp.20963; Larsson DE, 2006, ANTICANCER RES, V26, P4125; Nakamura M, 2002, TETRAHEDRON LETT, V43, P6929, DOI 10.1016/S0040-4039(02)01627-1; Narita K, 2011, EUR J ORG CHEM, P4985, DOI 10.1002/ejoc.201100845; Sacau EP, 2003, BIOORGAN MED CHEM, V11, P483, DOI 10.1016/S0968-0896(02)00542-4; Sakurai J, 2008, CHEM-EUR J, V14, P829, DOI 10.1002/chem.200701386; Sandermann H. W., 1968, NATURWISSENSCHAFTEN, V54, P118; Savage RE, 2008, DRUG METAB DISPOS, V36, P753, DOI 10.1124/dmd.107.018655; Suzuki A, 2003, SYNLETT, P329; Tseng CH, 2013, BIOORGAN MED CHEM, V21, P523, DOI 10.1016/j.bmc.2012.10.047; Watanabe K, 2012, HETEROCYCLES, V86, P985, DOI 10.3987/COM-12-S(N)104; Xu JH, 2013, J NEUROIMMUNOL, V254, P46, DOI 10.1016/j.jneuroim.2012.09.004; Yang R.- Y., 2008, BIOORGAN MED CHEM, V16, P5653	40	1	1	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1434-193X	1099-0690		EUR J ORG CHEM	Eur. J. Org. Chem.	NOV	2014		32					7099	7103		10.1002/ejoc.201403064		5	Chemistry, Organic	Chemistry	AT0KB	WOS:000344624000005		
J	Galangau, O; Kimura, Y; Kanazawa, R; Nakashima, T; Kawai, T				Galangau, Olivier; Kimura, Yuka; Kanazawa, Rui; Nakashima, Takuya; Kawai, Tsuyoshi			Enhanced Photochemical Sensitivity in Photochromic Diarylethenes Based on a Benzothiophene/Thiophene Nonsymmetrical Structure	EUROPEAN JOURNAL OF ORGANIC CHEMISTRY			English	Article						Photochromism; Noncovalent interactions; Density functional calculations; Diarylethenes	SINGLE-CRYSTALLINE PHOTOCHROMISM; AMORPHOUS MOLECULAR MATERIALS; QUANTUM YIELDS; OPTICAL-PROPERTIES; DITHIENYLETHENE; DERIVATIVES; PERFORMANCE; PHASE; UNITS; 1,2-BIS(2-METHYL-5-PHENYL-3-THIENYL)PERFLUOROCYCLOPENTENE	Photosensitivity of molecules is one of the central subjects of organic photochemistry. In this article, we present how and why a benzothiophene moiety impacts the photochromic quantum yield for the photochemical pericyclic ring closing of the hexatriene moiety. Two compounds were prepared: a symmetrical one incorporating two fluorenylthiophene units, and its corresponding nonsymmetrical partner, where one of the thiophene units was replaced by a benzothiophene group. Interestingly, the latter presents relatively high cyclization quantum yield (0.74), a value close to the largest one so far reported. Based on crystal structures, VT-NMR data and DFT calculations, we demonstrate that introducing a benzothiophene in the molecular scaffold induces skeleton stiffening by means of CH-pi interactions and steric repulsions, and leads to increased population of the reactive conformer in the ambient conditions.	[Galangau, Olivier; Kimura, Yuka; Kanazawa, Rui; Nakashima, Takuya; Kawai, Tsuyoshi] NAIST, Nara Inst Sci & Technol, Grad Sch Mat Sci, Nara 6300192, Japan	Kawai, T (reprint author), NAIST, Nara Inst Sci & Technol, Grad Sch Mat Sci, 8916-5 Takayama Cho, Nara 6300192, Japan.	tkawai@ms.naist.jp			Japan Society for the Promotion of Science; Centre National pour la Recherche Scientifique (CNRS); Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan (Japan Advanced Institute of Science and Technology, JAIST)	O. G. thanks the Japan Society for the Promotion of Science and the Centre National pour la Recherche Scientifique (CNRS) for financial support. This work was also partly supported by the Ministry of Education, Culture, Sports, Science and Technology (MEXT), Japan (Grant-in-Aid for Scientific Research on Innovative Area, "Application of Cooperative Excitation into Innovative Molecular Systems with High-Order Photofunctions" by the Nanotechnology Platform Program running in Japan Advanced Institute of Science and Technology, JAIST). The authors are grateful to Mr. M. Asanoma and Mr. M. Katao, technical staff members at NAIST, for their help with VT-NMR experiments and X-ray characterizations, respectively. Finally, the authors show their gratitude to Prof. Delbaere, Prof. Maurel, Dr. Sliwa, Dr. Aloise and Dr. Perrier for fruitful discussions.	Aloise S, 2013, PHYS CHEM CHEM PHYS, V15, P6226, DOI 10.1039/c3cp43806f; Gostl R, 2012, CHEM-EUR J, V18, P14282, DOI 10.1002/chem.201203111; Liu G, 2012, DYES PIGMENTS, V95, P553, DOI 10.1016/j.dyepig.2012.05.016; Morinaka K, 2009, ORG LETT, V11, P3890, DOI 10.1021/ol901497t; IRIE M, 1992, J PHYS CHEM-US, V96, P7671, DOI 10.1021/j100198a035; IRIE M, 1988, J ORG CHEM, V53, P803, DOI 10.1021/jo00239a022; Baggioli A, 2013, INT J QUANTUM CHEM, V113, P2154, DOI 10.1002/qua.24472; Kamiya H, 2011, ORG LETT, V13, P6394, DOI 10.1021/ol2026069; Morimoto M, 2005, CHEM COMMUN, P3895, DOI 10.1039/b505256d; Feringa BL, 2000, CHEM REV, V100, P1789, DOI 10.1021/cr9900228; Utsumi H, 2000, J MATER CHEM, V10, P2436, DOI 10.1039/b005067i; Delaire JA, 2000, CHEM REV, V100, P1817, DOI 10.1021/cr980078m; Fukumoto S, 2011, ANGEW CHEM INT EDIT, V50, P1565, DOI 10.1002/anie.201006844; Delbaere S, 2012, J ORG CHEM, V77, P1853, DOI 10.1021/jo202466g; Li WL, 2014, ANGEW CHEM INT EDIT, V53, P4603, DOI 10.1002/anie.201310438; Zhu WH, 2011, ANGEW CHEM INT EDIT, V50, P10986, DOI 10.1002/anie.201105136; Irie M, 2000, J AM CHEM SOC, V122, P4871, DOI 10.1021/ja993181h; Massaad J, 2012, CHEM-EUR J, V18, P6568, DOI 10.1002/chem.201103896; Pu SZ, 2013, CHEM COMMUN, V49, P8036, DOI 10.1039/c3cc44348e; Shibata K, 2002, J PHYS CHEM A, V106, P209, DOI 10.1021/jp0115648; Balzani V., 2003, MOL DEVICES MACHINES; Brown G.H., 1971, PHOTOCHROMISM TECHNI, VIII; Castellanos S, 2013, J PHYS CHEM C, V117, P23529, DOI 10.1021/jp407858s; Durr H., 1990, PHOTOCHROMISM MOL SY; Fihey A, 2012, J PHOTOCH PHOTOBIO A, V247, P30, DOI 10.1016/j.jphotochem.2012.08.004; Fukumoto S, 2011, EUR J ORG CHEM, P5047, DOI 10.1002/ejoc.201100676; Hasegawa Y, 2010, COORDIN CHEM REV, V254, P2643, DOI 10.1016/j.ccr.2009.12.036; Irie M, 2010, P JPN ACAD B-PHYS, V86, P472, DOI 10.2183/pjab.86.472; Irie M, 1997, TETRAHEDRON, V53, P12263, DOI 10.1016/S0040-4020(97)00558-9; Irie M., 2000, CHEM REV, V100, P1684; Kawai S, 2009, J MATER CHEM, V19, P3606, DOI 10.1039/b823354c; Kobatake S, 2002, CHEM COMMUN, P2804, DOI 10.1039/b208419h; Matsuda K, 2001, CHEM COMMUN, P363, DOI 10.1039/b009352l; Micheau JC, 2014, DYES PIGMENTS, V106, P32, DOI 10.1016/j.dyepig.2014.02.013; Miyasaka H, 2002, J PHYS CHEM A, V106, P8096, DOI 10.1021/jp0206626; Nakamura S, 2007, J PHYS ORG CHEM, V20, P821, DOI 10.1002/poc.1245; Nakashima T, 2013, CHEM-EUR J, V19, P16972, DOI 10.1002/chem.201302564; Nishi H, 2011, J MATER CHEM, V21, P17249, DOI 10.1039/c1jm12707a; SAUTER F, 1989, SYNTHESIS-STUTTGART, P771; Shirota Y, 2003, OPT MATER, V21, P249, DOI 10.1016/S0925-3467(02)00145-3; Stellacci F, 1999, ADV MATER, V11, P292, DOI 10.1002/(SICI)1521-4095(199903)11:4<292::AID-ADMA292>3.0.CO;2-V; Suezawa H, 2002, EUR J INORG CHEM, P3148; Bens AT, 1998, EUR J ORG CHEM, P2333; Utsumi H, 2002, J MATER CHEM, V12, P2612, DOI 10.1039/b205201f; Wang HK, 2013, CHEM-EUR J, V19, P3366, DOI 10.1002/chem.201202520; Yamada T, 2001, J ORG CHEM, V66, P6164, DOI 10.1021/jo0101171; Yamaguchi T, 2011, CHEM LETT, V40, P635, DOI 10.1246/cl.2011.635; Zhu W. H., 2011, ANGEW CHEM, V123, P11178	48	3	3	WILEY-V C H VERLAG GMBH	WEINHEIM	BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY	1434-193X	1099-0690		EUR J ORG CHEM	Eur. J. Org. Chem.	NOV	2014		32					7165	7173		10.1002/ejoc.201402774		9	Chemistry, Organic	Chemistry	AT0KB	WOS:000344624000013		
J	Sano, F; Kanemura, H; Tando, T; Goto, Y; Hosaka, H; Sugita, K; Aihara, M				Sano, Fumikazu; Kanemura, Hideaki; Tando, Tomoko; Goto, Yusuke; Hosaka, Hiromi; Sugita, Kanji; Aihara, Masao			Depressive symptoms contribute to quality of life in children with epilepsy	EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY			English	Article						Epilepsy; Quality of life (QOL); Depression; Questionnaire for measuring health-related quality of life in children (KINDL-R); Depression self-rating scale for children (DsRs-c); Children	PEDIATRIC EPILEPSY; CHILDHOOD EPILEPSY; ADOLESCENTS; PEOPLE; DISORDER; ANXIETY; IMPACT; POPULATION	Background: Improvement of the quality of life (QOL) for children with epilepsy is one of the most important therapeutic goals. It is widely acknowledged that in adults with epilepsy one of the best QOL predictors is psychiatric comorbidity. In children with epilepsy, however, it is not clear whether psychiatric comorbidity impairs QOL. Aims: The aim of this study was to evaluate QOL in children with epilepsy and to identify the strongest predictors of the same. Methods: A total of 28 enrolled patients completed the Questionnaire for Measuring Health-Related Quality of Life in Children (KINDL-R) and 3 assessments of clinical status: the Depression Self-Rating Scale for Children (DSRS-C), the Children Manifest Anxiety Scale (CMAS), and the Side Effects and Life Satisfaction (SEALS). Various demographic and clinical factors were analyzed as possible predictors of KINDL-R scores. Results: The strongest predictor of QOL was the total DSRS-C score (r = -0.69, p < 0.01), which also predicted physical (r = -0.58, p < 0.01) and emotional wellbeing (r = -0.53, p < 0.05) subscale scores. Conclusions: Symptoms of depression were more predictive of QOL than were seizure type, seizure duration, number and adverse effects of AEDs, or anxiety. Number of AEDs did have an effect, just not as prominent as symptoms of depression. (C) 2014 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.	[Sano, Fumikazu; Kanemura, Hideaki; Tando, Tomoko; Goto, Yusuke; Hosaka, Hiromi; Sugita, Kanji] Univ Yamanashi, Fac Med, Dept Pediat, Yamanashi 4093898, Japan; [Aihara, Masao] Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Yamanashi 4093898, Japan	Kanemura, H (reprint author), Univ Yamanashi, Fac Med, Dept Pediat, Chuo Ku, Yamanashi 4093898, Japan.	ykimu@yamanashi.ac.jp			 [22591124];  [22591123]	This work was supported by Grants-in-Aid for Scientific Research (C) (22591124 and 22591123).	Albrecht GL, 1999, SOC SCI MED, V48, P977, DOI 10.1016/S0277-9536(98)00411-0; Ravens-Sieberer U, 1998, QUAL LIFE RES, V7, P399, DOI 10.1023/A:1008853819715; Kanner AM, 2009, EPILEPSY BEHAV, V15, P83, DOI 10.1016/j.yebeh.2009.02.034; Turky A, 2008, EPILEPSY BEHAV, V12, P136, DOI 10.1016/j.yebeh.2007.08.003; Jacoby A, 2009, NEUROL CLIN, V27, P843, DOI 10.1016/j.ncl.2009.06.003; Stevanovic D, 2007, EPILEPSY BEHAV, V10, P571, DOI 10.1016/j.yebeh.2007.02.015; Kessler RC, 2003, JAMA-J AM MED ASSOC, V289, P3095, DOI 10.1001/jama.289.23.3095; Reilly C, 2011, SEIZURE-EUR J EPILEP, V20, P589, DOI 10.1016/j.seizure.2011.06.004; Modi AC, 2011, J PEDIATR PSYCHOL, V36, P466, DOI 10.1093/jpepsy/jsq114; Roeder R, 2009, EPILEPSIA, V50, P1943, DOI 10.1111/j.1528-1167.2009.02046.x; Johnson EK, 2004, EPILEPSIA, V45, P544, DOI 10.1111/j.0013-9580.2004.47003.x; Gillham R, 2000, SEIZURE-EUR J EPILEP, V9, P458, DOI 10.1053/seiz.2000.0446; Stevanovic D, 2011, EPILEPSIA, V52, pE75, DOI 10.1111/j.1528-1167.2011.03133.x; Miller V, 2003, EPILEPSY BEHAV, V4, P36, DOI 10.1016/S1525-5050(02)00601-7; Devinsky O, 1999, EPILEPSIA, V40, P1715, DOI 10.1111/j.1528-1157.1999.tb01588.x; Taylor J, 2011, EPILEPSIA, V52, P1489, DOI 10.1111/j.1528-1167.2011.03094.x; BIRLESON P, 1987, J CHILD PSYCHOL PSYC, V28, P43, DOI 10.1111/j.1469-7610.1987.tb00651.x; Cross JH, 2013, EUR J PAEDIATR NEURO, V17, P334, DOI 10.1016/j.ejpn.2013.02.003; Baker GA, 2001, EPILEPSIA, V42, P66, DOI 10.1046/j.1528-1157.2001.042suppl.3066.x; Benavente-Aguilar I, 2004, J PAEDIATR CHILD H, V40, P110, DOI 10.1111/j.1440-1754.2004.00308.x; Brown SW, 1982, BR J CLIN PRACT S, V18, P147; Canuet L, 2009, EPILEPSY RES, V83, P58, DOI 10.1016/j.eplepsyres.2008.09.001; Castaneda A, 1956, CHILD DEV, V27, P285; Cushner-Weinstein S, 2008, EPILEPSY BEHAV, V13, P109, DOI 10.1016/j.yebeh.2008.03.010; Eddy CM, 2010, EPILEPSY BEHAV, V19, P623, DOI 10.1016/j.yebeh.2010.09.017; Gillham R, 1996, EPILEPSY RES, V24, P47, DOI 10.1016/0920-1211(95)00102-6; Kugoh T, 1998, J JPN EPIL SOC, V16, P1; Matsuzaki K, 2007, J JPN PEDIAT SOC, V111, P1404; Montanaro M, 2004, NEUROL SCI, V25, P264, DOI 10.1007/s10072-004-0353-x; Murata T, 1996, JPN J PSYCHIAT, V1, P131; Sakamoto T., 1966, RES REP KOCHI U, V14, P161; Shibata R, 2003, J JPN PEDIAT SOC, V107, P1514; Stavem K, 2000, EPILEPSIA, V41, P85, DOI 10.1111/j.1528-1157.2000.tb01510.x; Wang J, 2012, EPILEPSY RES, V101, P157, DOI 10.1016/j.eplepsyres.2012.03.017	34	2	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1090-3798	1532-2130		EUR J PAEDIATR NEURO	Eur. J. Paediatr. Neurol.	NOV	2014	18	6					774	779		10.1016/j.ejpn.2014.08.002		6	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	AS7LO	WOS:000344437800018		
J	Igarashi, A; Okumura, A; Komatsu, M; Tomita, O; Abe, S; Ikeno, M; Saito, M; Nakazawa, T; Shimizu, T				Igarashi, Ayuko; Okumura, Akihisa; Komatsu, Mitsutaka; Tomita, Osamu; Abe, Shinpei; Ikeno, Mitsuru; Saito, Masako; Nakazawa, Tomoyuki; Shimizu, Toshiaki			Amplitude-integrated EEG revealed nonconvulsive status epilepticus in children with non-accidental head injury	EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY			English	Article						Amplitude-integrated EEG; Nonconvulsive status epilepticus; Saw-tooth pattern; Subclinical seizure; Non-accidental head injury; Encephalopathic children	SEIZURES; ELECTROENCEPHALOGRAPHY	Objective: We describe the clinical course and amplitude-integrated EEG findings in three children with non-accidental head injury and discuss on the importance of continuous aEEG monitoring in infants. Methods: NCSE was defined as a continuous 30-min seizure or briefer seizures occurring consecutively comprising at least 30 min of any 1-h period. Non-accidental head injury was diagnosed on the basis of neuroimaging findings such as subdural hemorrhage. Antiepileptic treatment was performed with continuous amplitude-integrated EEG monitoring. Results: The age of the patients ranged from 48 days to nine months. All of them had loss of consciousness and seizures on presentation. Nonconvulsive status epilepticus without clinical symptoms were recognized in all patients. Vigorous antiepileptic treatment against nonconvulsive status epilepticus was made in two patients, whereas nonconvulsive status epilepticus disappeared within one hour without additional treatment in one. Conclusions: Our experience indicates that nonconvulsive status epilepticus were not uncommon in children with non-accidental head injury. Continuous amplitude-integrated EEG monitoring will be one of the useful methods in encephalopathic children in order to estimate seizure burden objectively and to treat seizures appropriately. (C) 2014 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.	[Igarashi, Ayuko; Okumura, Akihisa; Komatsu, Mitsutaka; Tomita, Osamu; Abe, Shinpei; Ikeno, Mitsuru; Saito, Masako; Shimizu, Toshiaki] Juntendo Univ, Fac Med, Dept Pediat, Bunkyo Ku, Tokyo 1138421, Japan; [Nakazawa, Tomoyuki] Juntendo Urayasu Hosp, Dept Pediat, Kanazawa, Ishikawa, Japan	Igarashi, A (reprint author), Juntendo Univ, Fac Med, Dept Pediat, Bunkyo Ku, Hongo 2-1-1, Tokyo 1138421, Japan.	aigara@juntendo.ac.jp					McCoy B, 2011, EPILEPSIA, V52, P1973, DOI 10.1111/j.1528-1167.2011.03291.x; Walker M, 2005, EPILEPTIC DISORD, V7, P253; Williams K, 2011, EPILEPSIA, V52, P1130, DOI 10.1111/j.1528-1167.2011.03070.x; Shellhaas RA, 2007, PEDIATRICS, V120, P770, DOI 10.1542/peds.2007-0514; Hasbani DM, 2013, PEDIATR CRIT CARE ME, V14, P709, DOI 10.1097/PCC.0b013e3182917b83; Sutter R, 2012, EPILEPSIA, V53, P1, DOI 10.1111/j.1528-1167.2012.03593.x; Abend NS, 2011, NEUROLOGY, V76, P1071, DOI 10.1212/WNL.0b013e318211c19e; Hellstrom-Westas L, 2006, SEMIN FETAL NEONAT M, V11, P503, DOI 10.1016/j.siny.2006.07.011; Topjian AA, 2013, CRIT CARE MED, V41, P215, DOI 10.1097/CCM.0b013e3182668035; Komatsu M, 2010, BRAIN DEV-JPN, V32, P472, DOI 10.1016/j.braindev.2009.09.012; Greiner HM, 2012, PEDIATRICS, V129, P748; Hyllienmark L, 2007, EUR J PAEDIATR NEURO, V11, P70, DOI 10.1016/j.ejpn.2006.11.005; Kidokoro H, 2013, ARCH DIS CHILD-FETAL, V98, P359; Korff CM, 2007, NAT CLIN PRACT NEURO, V3, P505, DOI 10.1038/ncpneuro0605; Okumura A, 2009, BRAIN DEV-JPN, V31, P766, DOI 10.1016/j.braindev.2008.11.009; Okumura A, 2011, BRAIN DEV-JPN, V33, P77, DOI 10.1016/j.braindev.2009.12.009	16	0	0	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1090-3798	1532-2130		EUR J PAEDIATR NEURO	Eur. J. Paediatr. Neurol.	NOV	2014	18	6					806	810		10.1016/j.ejpn.2014.07.003		5	Clinical Neurology; Pediatrics	Neurosciences & Neurology; Pediatrics	AS7LO	WOS:000344437800024		
J	Shima, H				Shima, Hiroyuki			Analytic expression for the pull-or-jerk experiment	EUROPEAN JOURNAL OF PHYSICS			English	Article						inertia ball demonstration; harmonic oscillator; breaking string	INERTIA DEMONSTRATION	This work focuses on a theoretical analysis of a well-known inertia demonstration, which uses a weight suspended by a string with an extra string that hangs below the weight. The point in question is which string, the upper or lower, will break when pulling down on the bottom edge of the lower string at a constant pulling speed. An analytic solution for the equation of motion allows us to identify the critical value of the pulling speed, beyond which the string breaking varies from one to the other. The analysis also provides us with a phase diagram that illustrates the interplay between the pulling speed and the string's elasticity in the pull-or-jerk experiment.	Univ Yamanashi, Dept Environm Sci, Kofu, Yamanashi 4008510, Japan	Shima, H (reprint author), Univ Yamanashi, Dept Environm Sci, 4-4-37 Takeda, Kofu, Yamanashi 4008510, Japan.	hshima@yamanashi.ac.jp			JSPS (the Japan Society for the Promotion of Science) KAKENHI [25390147]	The author gratefully acknowledges financial support from JSPS (the Japan Society for the Promotion of Science) KAKENHI Grant-in-Aid for Scientific Research (C), No. 25390147.	Caplan GM, 2004, AM J PHYS, V72, P860, DOI 10.1119/1.1677337; Heald M A, 1996, PHYS TEACH, V34, P504, DOI 10.1119/1.2344545; KARIORIS FG, 1978, AM J PHYS, V46, P710, DOI 10.1119/1.11273; LECORBEILLER P, 1945, AM J PHYS, V13, P156, DOI 10.1119/1.1990691	4	0	0	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0143-0807	1361-6404		EUR J PHYS	Eur. J. Phys.	NOV	2014	35	6								10.1088/0143-0807/35/6/065016		11	Education, Scientific Disciplines; Physics, Multidisciplinary	Education & Educational Research; Physics	AS3LY	WOS:000344180400020		
J	Sonoda, A; Nitta, N; Tsuchiya, K; Otani, H; Watanabe, S; Mukaisho, K; Tomozawa, Y; Nagatani, Y; Ohta, S; Takahashi, M; Murata, K				Sonoda, Akinaga; Nitta, Norihisa; Tsuchiya, Keiko; Otani, Hideji; Watanabe, Shobu; Mukaisho, Kenichi; Tomozawa, Yuki; Nagatani, Yukihiro; Ohta, Shinichi; Takahashi, Masashi; Murata, Kiyoshi			Asialoerythropoietin ameliorates bleomycin-induced acute lung injury in rabbits by reducing inflammation	EXPERIMENTAL AND THERAPEUTIC MEDICINE			English	Article						asialoerythropoietin; acute lung injury; rabbit; bleomycin; score	RESPIRATORY-DISTRESS-SYNDROME; ERYTHROPOIETIN; MANAGEMENT; CARE	Acute lung injury, a critical illness characterized by acute respiratory failure with bilateral pulmonary infiltrates, remains unresponsive to current treatments. The condition involves injury to the alveolar capillary barrier, neutrophil accumulation and the induction of proinflammatory cytokines followed by lung fibrosis. In the present study, a rabbit model of bleomycin-induced acute lung injury was established to examine the effects of asialoerythropoietin (AEP), an agent with tissue-protective activities, on pulmonary inflammation. Six Japanese white rabbits were randomly divided into two equal groups. Acute lung injury was induced in all rabbits by intratracheally injecting bleomycin. The control group was injected with bleomycin only; the experimental (AEP) group was injected intravenously with AEP (80 mu g/kg) prior to the bleomycin injection. Computed tomography (CT) studies were performed seven days later. The CT inflammatory scores of areas exhibiting abnormal density and the pathological inflammatory scores were recorded as a ratio on a 7x7 mm grid. The CT and pathological inflammatory scores were significantly different between the control and AEP groups [122 +/- 10 and 163 +/- 1.5 (controls) vs. 71 +/- 8.5 and 9.7 +/- 1.4'(AEP), respectively; P<0.01]. Thus, the present study revealed that AEP prevents bleomycin-induced acute lung injury in rabbits.	[Sonoda, Akinaga; Nitta, Norihisa; Tsuchiya, Keiko; Otani, Hideji; Watanabe, Shobu; Tomozawa, Yuki; Nagatani, Yukihiro; Ohta, Shinichi; Takahashi, Masashi; Murata, Kiyoshi] Shiga Univ Med Sci, Dept Radiol, Otsu, Shiga 5202192, Japan; [Mukaisho, Kenichi] Shiga Univ Med Sci, Dept Pathol, Otsu, Shiga 5202192, Japan	Sonoda, A (reprint author), Shiga Univ Med Sci, Dept Radiol, Seta Tsukinowa Cho, Otsu, Shiga 5202192, Japan.	akinaga@belle.shiga-med.ac.jp					Abraham E, 2003, CRIT CARE MED, V31, pS195, DOI 10.1097/01.CCM.0000057843.47705.E8; Nakazawa J, 2010, NEPHROLOGY, V15, P93, DOI 10.1111/j.1440-1797.2009.01170.x; Yokomaku Y, 2008, J AM SOC NEPHROL, V19, P321, DOI 10.1681/ASN.2007040481; Cortes I, 2012, MINERVA ANESTESIOL, V78, P343; Kakavas S, 2011, EUR J CLIN PHARMACOL, V67, P1, DOI 10.1007/s00228-010-0938-7; Watanabe D, 2005, NEW ENGL J MED, V353, P782, DOI 10.1056/NEJMoa041773; Wang WJ, 2008, BIOTECHNOL BIOENG, V99, P1261, DOI 10.1002/bit.21677; Brun-Buisson C, 2004, INTENS CARE MED, V30, P51, DOI 10.1007/s00134-003-2022-6; HASLETT C, 1989, AM REV RESPIR DIS, V140, P756; IMAI Y, 1990, MOL IMMUNOL, V27, P335, DOI 10.1016/0161-5890(90)90046-3; Lamy M L, 1975, Acta Anaesthesiol Belg, V23 Suppl, P64; Mofidi A, 2011, MINI-REV MED CHEM, V11, P763; Rjiba-Touati K, 2012, DRUG CHEM TOXICOL, V35, P134, DOI 10.3109/01480545.2011.589445; Saguil A, 2012, AM FAM PHYSICIAN, V85, P352; Shang Y, 2007, APOPTOSIS, V12, P2187, DOI 10.1007/s10495-007-0141-1; Srisawat N, 2008, INT J UROL, V15, P1011, DOI 10.1111/j.1442-2042.2008.02149.x; Ware Lorraine B, 2008, Proc Am Thorac Soc, V5, P755, DOI 10.1513/pats.200806-049TT	17	0	0	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1792-0981	1792-1015		EXP THER MED	Exp. Ther. Med.	NOV	2014	8	5					1443	1446		10.3892/etm.2014.1960		4	Medicine, Research & Experimental	Research & Experimental Medicine	AS7GF	WOS:000344424400016		
J	Shima, H; Kutomi, G; Satomi, F; Maeda, H; Takamaru, T; Kameshima, H; Omura, T; Mori, M; Hatakenaka, M; Hasegawa, T; Hirata, K				Shima, Hiroaki; Kutomi, Goro; Satomi, Fukino; Maeda, Hideki; Takamaru, Tomoko; Kameshima, Hidekazu; Omura, Tosei; Mori, Mitsuru; Hatakenaka, Masamitsu; Hasegawa, Tadashi; Hirata, Koichi			Risk of node metastasis of sentinel lymph nodes detected in level II/III of the axilla by single-photon emission computed tomography/computed tomography	EXPERIMENTAL AND THERAPEUTIC MEDICINE			English	Article						breast cancer; sentinel node biopsy; single-photon emission computed tomography/computed tomography; atypical lymphatic drainage; level II; level III	STAGE BREAST-CANCER; SPECT-CT; BIOPSY; DRAINAGE; LYMPHOSCINTIGRAPHY; DISSECTION; ANATOMY	In breast cancer, single-photon emission computed tomography/computed tomography (SPECT/CT) shows the exact anatomical location of sentinel nodes (SN). SPECT/CT mainly exposes axilla and partly exposes atypical sites of extra-axillary lymphatic drainage. The mechanism of how the atypical hot nodes are involved in lymphatic metastasis was retrospectively investigated in the present study, particularly at the level II/III region. SPECT/CT was performed in 92 clinical stage 0-IIA breast cancer patients. Sentinel lymph nodes are depicted as hot nodes in SPECT/CT: Patients were divided into two groups: With or without hot node in level II/III on SPEC/CT. The existence of metastasis in level II/III was investigated and the risk factors were identified. A total of 12 patients were sentinel lymph node biopsy metastasis positive and axillary lymph node dissection (ALND) was performed. These patients were divided into two groups: With and without SN in level and nodes in level II/III were pathologically proven. In 11 of the 92 patients, hot nodes were detected in level There was a significant difference in node metastasis depending on whether there were hot nodes in level II/III (P=0.0319). Multivariate analysis indicated that the hot nodes in level II/III and lymphatic invasion were independent factors associated with node metastasis. There were 12 SN-positive patients followed by ALND. In four of the 12 patients, hot nodes were observed in level Two of the four patients with hot nodes depicted by SPECT/CT and metastatic nodes were pathologically evident in the same lesion. Therefore, the present study indicated that the hot node in level II/III as depicted by SPECT/CT may be a risk of SN metastasis, including deeper nodes.	[Shima, Hiroaki; Kutomi, Goro; Satomi, Fukino; Maeda, Hideki; Hirata, Koichi] Sapporo Med Univ, Dept Surg Surg Oncol & Sci, Sapporo, Hokkaido 0608543, Japan; [Takamaru, Tomoko] Showa Univ, Sch Med, Dept Breast Surg Oncol, Tokyo 1428666, Japan; [Kameshima, Hidekazu; Omura, Tosei] Higashi Sapporo Hosp, Dept Surg, Sapporo, Hokkaido 0038585, Japan; [Mori, Mitsuru] Sapporo Med Univ, Dept Publ Hlth, Sapporo, Hokkaido 0608556, Japan; [Hatakenaka, Masamitsu] Sapporo Med Univ, Dept Diagnost Radiol, Sapporo, Hokkaido 0608543, Japan; [Hasegawa, Tadashi] Sapporo Med Univ, Dept Surg Pathol, Sapporo, Hokkaido 0608543, Japan	Shima, H (reprint author), Sapporo Med Univ, Dept Surg Surg Oncol & Sci, Chuo Ku, S 1,W 16, Sapporo, Hokkaido 0608543, Japan.	simahiro@sapmed.ac.jp					Anan K, 2006, SURGERY, V139, P624, DOI 10.1016/j.surg.2005.11.007; Tanis PJ, 2001, J AM COLL SURGEONS, V192, P399, DOI 10.1016/S1072-7515(00)00776-6; Giuliano AE, 2010, ANN SURG, V252, P426, DOI 10.1097/SLA.0b013e3181f08f32; Pepels MJ, 2011, BREAST CANCER RES TR, V125, P301, DOI 10.1007/s10549-010-1210-7; Goyal A, 2005, EUR J CANCER, V41, P238, DOI 10.1016/j.ejca.2004.05.008; Suami H, 2008, ANN SURG ONCOL, V15, P863, DOI 10.1245/s10434-007-9709-9; Lyman GH, 2005, J CLIN ONCOL, V23, P7703, DOI 10.1200/JCO.2005.08.001; Uren RF, 2012, BREAST, V21, P480, DOI 10.1016/j.breast.2011.11.007; Tanis PJ, 2002, BRIT J CANCER, V87, P705, DOI 10.1038/sj.bjc.6600359; Vermeeren L, 2010, J SURG ONCOL, V101, P184, DOI 10.1002/jso.21439; Noguchi M, 2002, ONCOL REP, V9, P461; Brouwer OR, 2012, EUR J NUCL MED MOL I, V39, P1137, DOI 10.1007/s00259-012-2131-y; De Gournay E, 2013, BRIT J CANCER, P1; Fregnani JHTG, 2009, INT J MORPHOL, V27, P873, DOI 10.4067/S0717-95022009000300038; Haagensen C. D., 1972, LYMPHATICS CANC, P300; Harbeck Nadia, 2013, Breast Care (Basel), V8, P102, DOI 10.1159/000351193; Lerman H, 2006, EUR J NUCL MED MOL I, V33, P329, DOI 10.1007/s00259-005-1927-4; National Comprehensive Cancer Network, 2014, NCCN GUID TREATM CAN; Noguchi M, 2013, BREAST CANCER-TOKYO, V20, P41, DOI 10.1007/s12282-012-0416-4; Pecking AP, 2007, CANC TREAT, P79; Stavros AT, 2004, BREAST ULTRASOUND, P834; van der Ploeg Iris M C, 2008, World J Surg, V32, P1930, DOI 10.1007/s00268-008-9618-5; van der Ploeg IMC, 2009, EUR J NUCL MED MOL I, V36, P903, DOI 10.1007/s00259-008-1050-4; VERONESI U, 1981, CANCER, V47, P170, DOI 10.1002/1097-0142(19810101)47:1<170::AID-CNCR2820470128>3.0.CO;2-C	24	1	1	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1792-0981	1792-1015		EXP THER MED	Exp. Ther. Med.	NOV	2014	8	5					1447	1452		10.3892/etm.2014.1968		6	Medicine, Research & Experimental	Research & Experimental Medicine	AS7GF	WOS:000344424400017		
J	Soonthornsit, J; Yamaguchi, Y; Tamura, D; Ishida, R; Nakakoji, Y; Osako, S; Yamamoto, A; Nakamura, N				Soonthornsit, Jeerawat; Yamaguchi, Yoko; Tamura, Daisuke; Ishida, Ryuichi; Nakakoji, Yoko; Osako, Shiho; Yamamoto, Akitsugu; Nakamura, Nobuhiro			Low cytoplasmic pH reduces ER-Golgi trafficking and induces disassembly of the Golgi apparatus	EXPERIMENTAL CELL RESEARCH			English	Article						Acidosis; Live-cell imaging; Brefeldin A; Cis-Golgi; Tubular extension	PHOSPHOLIPASE A(2) ANTAGONISTS; MATRIX PROTEIN GM130; ENDOPLASMIC-RETICULUM; BREFELDIN-A; SECRETORY PROTEINS; RAB GTPASES; INTRACELLULAR-TRANSPORT; RETROGRADE TRANSPORT; LIVING CELLS; COMPLEX	The Golgi apparatus was dramatically disassembled when cells were incubated in a low pH medium. The cis-Golgi disassembled quickly, extended tubules and spread to the periphery of cells within 30 mm. In contrast, medial- and trans-Golgi were fragmented in significantly larger structures of smaller numbers at a slower rate and remained largely in structures distinct from the cis-Golgi. Electron microscopy revealed the complete disassembly of the Golgi stack in low pH treated cells. The effect of low pH was reversible; the Golgi apparatus reassembled to form a normal ribbon-like structure within 1-2 h after the addition of a control medium. The anterograde ER to Golgi transport and retrograde Golgi to ER transport were both reduced under low pH. Phospholipase A(2) inhibitors (ONO, BEL) effectively suppressed the Golgi disassembly, suggesting that the phospholipase A(2) was involved in the Golgi disassembly. Over-expression of Rab1, 2, 30, 33 and 41 also suppressed the Golgi disassembly under low pH, suggesting that they have protective role against Golgi disassembly. Low pH treatment reduced cytoplasmic pH, but not the luminal pH of the Golgi apparatus, strongly suggesting that reduction of the cytoplasmic pH triggered the Golgi disassembly. Because a lower cytoplasmic pH is induced in physiological or pathological conditions, disassembly of the Golgi apparatus and reduction of vesicular transport through the Golgi apparatus may play important roles in cell physiology and pathology. Furthermore, our findings indicated that low pH treatment can serve as an important tool to analyze the molecular mechanisms that support the structure and function of the Golgi apparatus. (C) 2014 Elsevier Inc. All rights reserved.	[Soonthornsit, Jeerawat; Ishida, Ryuichi; Nakakoji, Yoko; Osako, Shiho; Nakamura, Nobuhiro] Kyoto Sangyo Univ, Fac Life Sci, Dept Mol Biosci, Lab Cell & Dev Biol,Kita Ku, Kyoto 6038555, Japan; [Yamaguchi, Yoko; Tamura, Daisuke; Nakamura, Nobuhiro] Kanazawa Univ, Grad Sch Nat Sci & Technol, Div Life Sci, Kanazawa, Ishikawa 9201192, Japan; [Yamamoto, Akitsugu] Nagahama Inst Biosci & Technol, Dept Anim Biosci, Nagahama, Shiga 5260829, Japan	Nakamura, N (reprint author), Kyoto Sangyo Univ, Fac Life Sci, Dept Mol Biosci, Lab Cell & Dev Biol,Kita Ku, Kyoto 6038555, Japan.	osaru3@cc.kyoto-su.ac.jp	Nakamura, Nobuhiro/F-7811-2011	Nakamura, Nobuhiro/0000-0002-8836-6714	JSPS, MEXT of Japan [16044218, 17028016, 18570173, 24112525, 25440092]; KSU	We would like to thank Drs. Shin-ichiro Yoshimura (Osaka Univ.) and Francis Bar (Univ. Oxford) for providing the Rab-GFP plasmids, Drs. Yoshio Misumi (Fukuoka Univ.) and Miwa Sohda (Nigata Univ.) for providing the anti-GM130 and anti-giantin antibodies, Drs. Gero Miesenbock and James Rothman (Memorial Sloan-Kettering Cancer Center, USA) for providing the pHluorin cDNA, Dr. Masako Tanabe for assistance, Drs. Kazuhisa Nakayama (Kyoto Univ.) YukioYoneda (Kanazawa Univ.) and late Shoji Ohkuma (Kanazawa Univ.) for their support and finally all the past and present members of the Nakamura Lab for their comments, discussions and encouragement. This work was supported by a Grant-in-Aid for Scientific Research (16044218, 17028016, 18570173, 24112525, and 25440092) from JSPS, MEXT of Japan and research grants from KSU.	ROOS A, 1981, PHYSIOL REV, V61, P296; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Bechler ME, 2010, J CELL BIOL, V190, P45, DOI 10.1083/jcb.200908105; Lowe M, 2000, J CELL BIOL, V149, P341, DOI 10.1083/jcb.149.2.341; Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478; de Figueiredo P, 2000, TRAFFIC, V1, P504, DOI 10.1034/j.1600-0854.2000.010608.x; Yoshimura S, 2007, J CELL BIOL, V178, P363, DOI 10.1083/jcb.200703047; Scales SJ, 1997, CELL, V90, P1137, DOI 10.1016/S0092-8674(00)80379-7; de Figueiredo P, 1998, P NATL ACAD SCI USA, V95, P8642, DOI 10.1073/pnas.95.15.8642; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Gladden LB, 2004, J PHYSIOL-LONDON, V558, P5, DOI 10.1113/jphysiol.2003.058701; Trucco A, 2004, NAT CELL BIOL, V6, P1071, DOI 10.1038/ncb1180; Short B, 2005, BBA-MOL CELL RES, V1744, P383, DOI 10.1016/j.bbamcr.2005.02.001; Schwartz SL, 2007, J CELL SCI, V120, P3905, DOI 10.1242/jcs.015909; Lee TH, 1999, MOL BIOL CELL, V10, P1445; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; Lowe M, 1998, CELL, V94, P783, DOI 10.1016/S0092-8674(00)81737-7; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; RAMBOURG A, 1990, EUR J CELL BIOL, V51, P189; Marra P, 2007, MOL BIOL CELL, V18, P1595, DOI 10.1091/mbc.E06-10-0886; Horton AC, 2005, NEURON, V48, P757, DOI 10.1016/j.neuron.2005.11.005; Dippold HC, 2009, CELL, V139, P337, DOI 10.1016/j.cell.2009.07.052; Drecktrah D, 1999, MOL BIOL CELL, V10, P4021; Cole NB, 1996, MOL BIOL CELL, V7, P631; Shima DT, 1997, J CELL BIOL, V137, P1211, DOI 10.1083/jcb.137.6.1211; Dinter A, 1998, HISTOCHEM CELL BIOL, V109, P571, DOI 10.1007/s004180050256; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; Storrie B, 1998, J CELL BIOL, V143, P1505, DOI 10.1083/jcb.143.6.1505; ROGALSKI AA, 1984, J CELL BIOL, V99, P1101, DOI 10.1083/jcb.99.3.1101; COSSON P, 1989, J CELL BIOL, V108, P377, DOI 10.1083/jcb.108.2.377; Presley JF, 1997, NATURE, V389, P81; Dupree P, 1998, BBA-MOL CELL RES, V1404, P259, DOI 10.1016/S0167-4889(98)00061-5; Yoshimura S, 2004, J BIOCHEM, V135, P201, DOI 10.1093/jb/mvh024; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; de Figueiredo P, 1999, MOL BIOL CELL, V10, P1763; Ward TH, 2001, J CELL BIOL, V155, P557, DOI 10.1083/jcb.200107045; Shorter J, 1999, J CELL BIOL, V146, P57; Nishimura N, 1997, SCIENCE, V277, P556, DOI 10.1126/science.277.5325.556; Puthenveedu MA, 2006, NAT CELL BIOL, V8, P238, DOI 10.1038/ncb1366; Horgan CP, 2011, BIOCHEM SOC T, V39, P1202, DOI 10.1042/BST0391202; Harada A, 1998, J CELL BIOL, V141, P51, DOI 10.1083/jcb.141.1.51; Antonny B, 2001, CURR OPIN CELL BIOL, V13, P438, DOI 10.1016/S0955-0674(00)00234-9; Appenzeller-Herzog C, 2006, J CELL SCI, V119, P2173, DOI 10.1242/jcs.03019; BARR EA, 2009, SEMIN CELL DEV BIOL, V20, P780; BECHLER ME, 2011, TRENDS CELL BIOL, V22, P116; FRANZUSOFF A, 1991, J CELL BIOL, V112, P27, DOI 10.1083/jcb.112.1.27; Fullekrug J, 1997, FEBS LETT, V404, P75, DOI 10.1016/S0014-5793(97)00097-5; Gillingham AK, 2003, BBA-MOL CELL RES, V1641, P71, DOI 10.1016/S0167-4889(03)00088-0; Griffiths G, 2000, TRAFFIC, V1, P738, DOI 10.1034/j.1600-0854.2000.010906.x; HEUSER J, 1989, J CELL BIOL, V108, P855, DOI 10.1083/jcb.108.3.855; JUDAH JD, 1989, J CELL SCI, V92, P173; KELLY EE, 2011, BIOL CELL, V104, P84; KREIS TE, 1990, CELL MOTIL CYTOSKEL, V15, P67, DOI 10.1002/cm.970150202; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; MISUMI Y, 1986, J BIOL CHEM, V261, P1398; MOLLENHAUER HH, 1994, PROTOPLASMA, V180, P14, DOI 10.1007/BF01379220; Morel-Huaux VM, 2002, EUR J CELL BIOL, V81, P87, DOI 10.1078/0171-9335-00224; Morin-Ganet MN, 2000, TRAFFIC, V1, P56, DOI 10.1034/j.1600-0854.2000.010109.x; Munro S, 2002, NAT CELL BIOL, V4, pE223, DOI 10.1038/ncb1002-e223; NAKAMURA N, 1997, CELL, V89; NAKAMURA N, 1992, EUR J BIOCHEM, V205, P947, DOI 10.1111/j.1432-1033.1992.tb16861.x; Ohta E, 2003, J BIOL CHEM, V278, P51957, DOI 10.1074/jbc.M310014200; PARTON RG, 1991, J CELL BIOL, V113, P261, DOI 10.1083/jcb.113.2.261; Pelham HRB, 2000, CELL, V102, P713, DOI 10.1016/S0092-8674(00)00060-X; Pelham HRB, 2001, J CELL BIOL, V155, P1099, DOI 10.1083/jcb.200110160; Shorter J, 2002, ANNU REV CELL DEV BI, V18, P379, DOI 10.1146/annurev.cellbio.18.030602.133733; Vasile E, 2003, TRAFFIC, V4, P254; Warren G, 1998, CURR OPIN CELL BIOL, V10, P493, DOI 10.1016/S0955-0674(98)80064-1; WARREN G, 1995, TRENDS CELL BIOL, V5, P413, DOI 10.1016/S0962-8924(00)89094-7; Yoshida T, 1999, INT J EXP PATHOL, V80, P51, DOI 10.1046/j.1365-2613.1999.00097.x; Yoshida Y, 2008, EXP CELL RES, V314, P3427, DOI 10.1016/j.yexcr.2008.07.023	75	1	2	ELSEVIER INC	SAN DIEGO	525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4827	1090-2422		EXP CELL RES	Exp. Cell Res.	NOV 1	2014	328	2					325	339		10.1016/j.yexcr.2014.09.009		15	Oncology; Cell Biology	Oncology; Cell Biology	AS0FL	WOS:000343953500011		
J	Gallenberger, M; Kroeber, M; Marz, L; Koch, M; Fuchshofer, R; Braunger, BM; Iwata, T; Tamm, ER				Gallenberger, Martin; Kroeber, Markus; Maerz, Loreen; Koch, Marcus; Fuchshofer, Rudolf; Braunger, Barbara M.; Iwata, Takeshi; Tamm, Ernst R.			Heterozygote Wdr36-deficient mice do not develop glaucoma	EXPERIMENTAL EYE RESEARCH			English	Article						Primary open-angle glaucoma; Animal model; Genetics	OPEN-ANGLE GLAUCOMA; NORMAL-TENSION GLAUCOMA; OCULAR HYPERTENSION TREATMENT; DNA-SEQUENCE VARIANTS; WDR36 GENE; INTRAOCULAR-PRESSURE; RIBOSOME BIOGENESIS; MEDICATION DELAYS; GERMAN PATIENTS; MOUSE	There is an ongoing controversy regarding the role of WDR36 sequence variants in the pathogenesis of primary open-angle glaucoma (POAG). WDR36 is a nucleolar protein involved in the maturation of 18S rRNA. The function of WDR36 is essential as homozygous Wdr36-deficient mouse embryos die before reaching the blastocyst stage. Here we provide a detailed analysis of the phenotype of heterozygous Wdr36-deficient mice. Loss of one Wdr36 allele causes a substantial reduction in the expression of Wdr36 mRNA. In the eyes of Wdr36(+/-) animals, the structure of the tissues involved in aqueous humor circulation and of the optic nerve head are not different from that of control littermates. In addition, one-year-old Wdr36(+/-) animals do not differ from wild-type animals with regards to intraocular pressure and number of optic nerve axons. The susceptibility of retinal ganglion cells to excitotoxic damage induced by NMDA is similar in Wdr36(+/-) and wild-type animals. Moreover, the amount of optic nerve axonal damage induced by high IOP is not different between Wdr36(+/-) and wild-type mice. Transgenic overexpression of mutated DeI605-607 Wdr36 in Wdr36(+/-) animals does not cause changes in the number of optic nerve axons or susceptibility to excitotoxic damage. In addition, analysis of 18S rRNA maturation in Del605-607 Wdr36(+/-) or Wdr36(+/-) mice does not show obvious differences in rRNA processing or in the amounts of precursor forms when compared to wild-type animals. Our data obtained in Wdr36(+/-) mice do not support the assumption of a causative role for WDR36 in the pathogenesis of POAG. (C) 2014 Elsevier Ltd. All rights reserved.	[Gallenberger, Martin; Kroeber, Markus; Maerz, Loreen; Koch, Marcus; Fuchshofer, Rudolf; Braunger, Barbara M.; Tamm, Ernst R.] Univ Regensburg, Inst Human Anat & Embryol, D-93053 Regensburg, Germany; [Iwata, Takeshi] Natl Hosp Org Tokyo Med Ctr, Natl Inst Sensory Organs, Mol & Cellular Biol Div, Meguro Ku, Tokyo 1528902, Japan	Tamm, ER (reprint author), Univ Regensburg, Inst Human Anat & Embryol, Univ Str 31, D-93053 Regensburg, Germany.	ernst.tamm@vkl.uni-regensburg.de	Fuchshofer, Rudolf/E-8221-2010; Braunger, Barbara/K-4272-2015; 	Fuchshofer, Rudolf/0000-0002-0474-6980; Braunger, Barbara/0000-0002-3926-6725; Tamm, Ernst/0000-0002-6679-8743	Deutsche Forschungsgemeinschaft [FOR 1075, TP5]	This work was supported by the Deutsche Forschungsgemeinschaft (FOR 1075, TP5 to E.R.T.). We greatly appreciate the expert technical assistance of Silvia Babl, Angelika Pach and Margit Schimmel.	Monemi S, 2005, HUM MOL GENET, V14, P725, DOI 10.1093/hmg/ddi068; Fumagalli S, 2011, SEMIN HEMATOL, V48, P97, DOI 10.1053/j.seminhematol.2011.02.004; Chi ZL, 2010, HUM MOL GENET, V19, P3806, DOI 10.1093/hmg/ddq299; Kass MA, 2002, ARCH OPHTHALMOL-CHIC, V120, P701; RICHARDSON KC, 1960, STAIN TECHNOL, V35, P313; Johnson M, 2006, EXP EYE RES, V82, P545, DOI 10.1016/j.exer.2005.10.011; Barlow JL, 2010, NAT MED, V16, P59, DOI 10.1038/nm.2063; Rezaie T, 2002, SCIENCE, V295, P1077, DOI 10.1126/science.1066901; Pasutto F, 2009, AM J HUM GENET, V85, P447, DOI 10.1016/j.ajhg.2009.08.016; Stone EM, 1997, SCIENCE, V275, P668, DOI 10.1126/science.275.5300.668; Matsson H, 2004, MOL CELL BIOL, V24, P4032, DOI 10.1128/MCB.24.9.4032-4037.2004; Quigley HA, 2011, LANCET, V377, P1367, DOI 10.1016/S0140-6736(10)61423-7; Liu YT, 2011, EXP EYE RES, V93, P331, DOI 10.1016/j.exer.2011.08.007; Fingert JH, 2011, HUM MOL GENET, V20, P2482, DOI 10.1093/hmg/ddr123; Narla A, 2010, BLOOD, V115, P3196, DOI 10.1182/blood-2009-10-178129; Fingert JH, 2011, EYE, V25, P587, DOI 10.1038/eye.2011.97; Alward WL, 1998, AM J OPHTHALMOL, V126, P498; Kressler D, 2010, BBA-MOL CELL RES, V1803, P673, DOI 10.1016/j.bbamcr.2009.10.009; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Gallenberger M, 2011, HUM MOL GENET, V20, P422, DOI 10.1093/hmg/ddq478; McGowan KA, 2011, SEMIN HEMATOL, V48, P106, DOI 10.1053/j.seminhematol.2011.02.001; Chakraborty A, 2011, WIRES RNA, V2, P507, DOI 10.1002/wrna.73; Leske MC, 2003, ARCH OPHTHALMOL-CHIC, V121, P48; Bernstein KA, 2004, EUKARYOT CELL, V3, P1619, DOI 10.1128/EC.3.6.1619-1626.2004; Freed EF, 2010, MOL BIOSYST, V6, P481, DOI 10.1039/b919670f; Higginbotham EJ, 2004, ARCH OPHTHALMOL-CHIC, V122, P813, DOI 10.1001/archopht.122.6.813; Kroeber M, 2010, HUM MOL GENET, V19, P3332, DOI 10.1093/hmg/ddq237; Morrison RS, 2003, NEUROCHEM RES, V28, P15, DOI 10.1023/A:1021687810103; Junglas B, 2012, AM J PATHOL, V180, P2386, DOI 10.1016/j.ajpath.2012.02.030; Newton K, 2003, MOL CELL BIOL, V23, P8519, DOI 10.1128/MCB.23.23.8519-8527.2003; Hauser MA, 2006, INVEST OPHTH VIS SCI, V47, P2542, DOI 10.1167/iovs.05-1476; Blanco-Marchite C, 2011, INVEST OPHTH VIS SCI, V52, P8467, DOI 10.1167/iovs.11-7489; Chen H, 2008, BIOCHEM BIOPH RES CO, V365, P636, DOI 10.1016/j.bbrc.2007.11.019; Schulzer M, 1998, AM J OPHTHALMOL, V126, P487; Fan BJ, 2009, MOL VIS, V15, P646; Fan B.J., 2011, J CLIN INVEST, V120, P3064; Fingert JH, 2007, ARCH OPHTHALMOL-CHIC, V125, P434, DOI 10.1001/archopht.125.3.434-b; Footz TK, 2009, HUM MOL GENET, V18, P1276, DOI 10.1093/hmg/ddp027; Hewitt AW, 2006, AM J OPHTHALMOL, V142, P324, DOI 10.1016/j.ajo.2006.02.041; Karnovsky M. J., 1965, J CELL BIOL, V27, P137; Kramer PL, 2006, ARCH OPHTHALMOL-CHIC, V124, P1328, DOI 10.1001/archopht.124.9.1328; Kwon YH, 2009, NEW ENGL J MED, V360, P1113, DOI 10.1056/NEJMra0804630; Lerch-Gaggl A, 2002, J BIOL CHEM, V277, P45347, DOI 10.1074/jbc.M208338200; Miyazawa A, 2007, MOL VIS, V13, P1912; Pang CP, 2006, MOL VIS, V12, P85; Pasutto F, 2008, INVEST OPHTH VIS SCI, V49, P270, DOI 10.1167/iovs.07-0500; Romanova LG, 2006, BIOL REPROD, V75, P690, DOI 10.1095/biolreprod.106.054072; Schultze W.H., 1972, ZENTRALBL PATHOL, V36, P639; Seitz Roswitha, 2013, Methods Mol Biol, V935, P99, DOI 10.1007/978-1-62703-080-9_7; Skarie JM, 2008, HUM MOL GENET, V17, P2474, DOI 10.1093/hmg/ddn147; Tamm E.R., 2007, INTRAOCULAR PRESSURE, P1; Van Veldhuisen PC, 2000, AM J OPHTHALMOL, V130, P429; Weisschuh N, 2007, MOL VIS, V13, P724; Zhang J, 2008, BMC DEV BIOL, V8, DOI 10.1186/1471-213X-8-115	54	1	1	ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD	LONDON	24-28 OVAL RD, LONDON NW1 7DX, ENGLAND	0014-4835	1096-0007		EXP EYE RES	Exp. Eye Res.	NOV	2014	128						83	91		10.1016/j.exer.2014.09.008		9	Ophthalmology	Ophthalmology	AS5LL	WOS:000344312300011		
J	Fujikawa, M; Maeda, N; Yamabe, J; Kodama, Y; Koishi, M				Fujikawa, M.; Maeda, N.; Yamabe, J.; Kodama, Y.; Koishi, M.			Determining Stress-Strain in Rubber with In-Plane Biaxial Tensile Tester	EXPERIMENTAL MECHANICS			English	Article						Biaxial tensile test; Industrial rubber; Hyperelasticity; Finite element method	BUBBLE INFLATION TECHNIQUE	The nominal stress-strain relationships of industrial rubber materials under multiaxial deformation are essential for precisely determining the constitutive laws of those materials. This paper proposes a new method for precisely estimating the nominal stress-stretch relationships of carbon-black-filled styrene butadiene rubbers (SBRs) under uniaxial tension, pure shear, and equibiaxial tension by using an in-plane biaxial tensile tester. The proposed method employs sheet-shaped rubber samples with notches for the pure-shear and equibiaxial tension tests to mitigate the influence of non-uniform deformation around the clamps. Finite element analysis and biaxial tensile tests were performed to verify the effectiveness of the proposed method. Performance evaluations based on both numerical calculations and experiments revealed that the proposed method enabled the precise calculation of the nominal stress-stretch relationship for uniform deformation from a tensile load and deformation of the reference area defined at the center of the samples.	[Fujikawa, M.] Univ Ryukyus, Dept Mech Syst Engn, Nishihara, Okinawa 9030213, Japan; [Maeda, N.] Univ Ryukyus, Grad Sch Sci & Technol, Nishihara, Okinawa 9030213, Japan; [Yamabe, J.] Kyushu Univ, Int Res Ctr Hydrogen Energy, Nishi Ku, Fukuoka 8190395, Japan; [Kodama, Y.; Koishi, M.] Yokohama Rubber Co Ltd, KOISHI Lab, Hiratsuka, Kanagawa 2548601, Japan	Fujikawa, M (reprint author), Univ Ryukyus, Dept Mech Syst Engn, 1 Senbaru, Nishihara, Okinawa 9030213, Japan.	fujikawa@tec.u-ryukyu.ac.jp					Sasso M, 2008, POLYM TEST, V27, P995, DOI 10.1016/j.polymertesting.2008.09.001; Tada T, 2010, J POLYM SCI POL PHYS, V48, P1380, DOI 10.1002/polb.22017; Steinmann P, 2012, ARCH APPL MECH, V82, P1183, DOI 10.1007/s00419-012-0610-z; Reuge N, 2001, POLYM ENG SCI, V41, P522, DOI 10.1002/pen.10749; Batra RC, 2005, MATH MECH SOLIDS, V10, P705, DOI 10.1177/1081286505043032; Blatz P, 1962, J RHEOL, V6, P223, DOI 10.1122/1.548937; Fujikawa M, 2010, JAP SOC EXP MECH, V10, P104; Higuchi T, 2001, J JAPANESE SOC ARTIF, V16, P147; Holzapfel G. A., 2000, NONLINEAR SOLID MECH; Hossain Mokarram, 2013, Journal of the Mechanical Behaviour of Materials, V22, DOI 10.1515/jmbm-2012-0007; KAWABATA S, 1981, MACROMOLECULES, V14, P154, DOI 10.1021/ma50002a032; Ogden R.W., 1997, NONLINEAR ELASTIC DE; Rachik M, 2001, POLYM ENG SCI, V41, P532, DOI 10.1002/pen.10750; Sasso M, 2014, EXP MECH, V54, P315, DOI 10.1007/s11340-013-9807-5; Treloar LRG, 1944, RUBBER CHEM TECHNOL, V17, P957, DOI 10.5254/1.3546716; Woo CS, 2011, P 7 EUR C CONST MOD, P439; Zhao X, 2014, EXP MECH, V54, P343, DOI 10.1007/s11340-013-9808-4	17	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0014-4851	1741-2765		EXP MECH	Exp. Mech.	NOV	2014	54	9					1639	1649		10.1007/s11340-014-9942-7		11	Materials Science, Multidisciplinary; Mechanics; Materials Science, Characterization & Testing	Materials Science; Mechanics	AS3BC	WOS:000344149800012		
J	Nakazawa, T; Matsubara, M; Mita, S; Saitou, K				Nakazawa, T.; Matsubara, M.; Mita, S.; Saitou, K.			Teaching Materials and Lesson Plans for Hands-On Mechanics Education	EXPERIMENTAL TECHNIQUES			English	Article						Engineering Education; Hands-On Approach; Mechanics Education		In this study, we developed teaching materials and lesson plans to expand students' understanding of fundamental engineering principles through experimentation with and manufacturing of real products. The products used for this study were a model car and a walking model. With the development of these products as a specific objective and not using special equipment, we aimed to enable students to learn and utilize one of fundamental discipline in engineering, mechanics. The products were introduced in a lecture format class and the effectiveness of the lesson plan was evaluated. Results of the evaluations administered at the beginning and the end of the class showed that the students obtained a greater understanding of mechanics by engaging in the design and production of the two products. Concept maps created by the students showed that through the lesson, they improved their ability to apply scientific knowledge to experimental investigation and manufacturing processes. Moreover, results of a survey questionnaire suggested an improvement in students' aptitude for and confidence in applying scientific knowledge to real problems, including experiments and product manufacturing.	[Nakazawa, T.] Gunma Univ, Grad Sch Engn, Kiryu, Gunma 376, Japan; [Matsubara, M.; Saitou, K.] Gunma Univ, Grad Sch Engn, Dept Mech Syst Engn, Kiryu, Gumma 376, Japan; [Mita, S.] Gunma Univ, Fac Educ, Maebashi, Gunma, Japan	Nakazawa, T (reprint author), Gunma Univ, Grad Sch Engn, 1-5-1 Tenjincho, Kiryu, Gunma 376, Japan.	nakaza-t@gunma-u.ac.jp					American Association for the Advancement of Science (AAAS), 1991, SCI ALL AM, P197; Jeffrey D.H., P 2007 SOC EXP MECH; Joseph D.N., 1984, LEARNING LEARN, p[15, 32]; Kind K., 2007, INT J SCI ED, V29, P871; Kolb D.A., 1984, EXPT LEARNING EXPERI, P30; Nakazawa T., 2007, J JAPANESE SOC ENG E, V55, P230; OECD Programme on Institutional Management in Higher Education (IMHE), TEST STUD U PERF GLO	7	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0732-8818	1747-1567		EXP TECHNIQUES	Exp. Tech.	NOV-DEC	2014	38	6					72	80		10.1111/j.1747-1567.2012.00835.x		9	Engineering, Mechanical; Mechanics; Materials Science, Characterization & Testing	Engineering; Mechanics; Materials Science	AS5ZU	WOS:000344345700009		
J	Erkan, N; Okamoto, K				Erkan, Nejdet; Okamoto, Koji			Full-field spreading velocity measurement inside droplets impinging on a dry solid surface	EXPERIMENTS IN FLUIDS			English	Article							LIQUID-DROP; IMPACT; DEFORMATION; VELOCIMETRY; MODEL	Liquid droplet impacts onto solid surfaces have attracted enormous amount of attention from wide range of research fields including experimental and numerical investigations. Unlike experimental efforts, numerical and analytical studies generated various sets of data. In this study, we investigated the spreading velocities inside the water droplets impinging onto a dry glass substrate using time-resolved PIV. The method, together with the high spatiotemporal resolution and the additional treatments improving the robustness, allowed us to resolve the radial velocity profiles efficiently in the spreading phase. Several impact velocity cases ranging from 0.40 to 0.96 m/s were studied. They correspond to low and moderate level Weber numbers (4.9-27.6). We observed that instantaneous radial velocity distributions exhibit linear and nonlinear modes. The nonlinearity is caused by the vortical flows formed at outer regions of the spreading liquid lamella. We demonstrated that even at low impact velocities the linear parts of the profiles obey a quasi-one-dimensional theory proposed in the literature. The comparison of obtained results with a literature-based numerical study, performed for high range of Weber numbers, confirmed the simultaneous existence of linear and nonlinear parts in the radial velocity profiles. In spite of the scale differences in terms of Weber number, the agreements in the tendencies of the profiles imply the validity of the mechanism considered in the numerical study even at low and moderate level range of Weber numbers.	[Erkan, Nejdet; Okamoto, Koji] Univ Tokyo, Nucl Profess Sch, Tokai, Ibaraki 3191188, Japan	Erkan, N (reprint author), Univ Tokyo, Nucl Profess Sch, 2-22 Shirakata, Tokai, Ibaraki 3191188, Japan.	erkan@vis.t.u-tokyo.ac.jp					ADRIAN RJ, 1986, APPL OPTICS, V25, P3855; Kamnis S, 2005, J PHYS D APPL PHYS, V38, P3664, DOI 10.1088/0022-3727/38/19/015; Pasandideh-Fard M, 2002, INT J HEAT MASS TRAN, V45, P2229, DOI 10.1016/S0017-9310(01)00336-2; Mao T, 1997, AICHE J, V43, P2169, DOI 10.1002/aic.690430903; FUKAI J, 1995, PHYS FLUIDS, V7, P236, DOI 10.1063/1.868622; Rioboo R, 2002, EXP FLUIDS, V33, P112, DOI [10.1007/s00348-002-0431-x, 10.1007/s00348-002-0431-X]; Adrian RJ, 2005, EXP FLUIDS, V39, P159, DOI 10.1007/s00348-005-0991-7; Clanet C, 2004, J FLUID MECH, V517, P199, DOI 10.1017/S0022112004000904; Biance AL, 2004, PHYS REV E, V69, DOI 10.1103/PhysRevE.69.016301; Roisman IV, 2002, P ROY SOC A-MATH PHY, V458, P1411, DOI 10.1098/rspa.2001.0923; Stanton DW, 1998, INT J HEAT MASS TRAN, V41, P3037, DOI 10.1016/S0017-9310(98)00054-4; STOW CD, 1981, P ROY SOC LOND A MAT, V373, P419, DOI 10.1098/rspa.1981.0002; YARIN AL, 1995, J FLUID MECH, V283, P141, DOI 10.1017/S0022112095002266; Buchmuller I, 2012, ICLASS 2012 HEID; Erkan N, 2008, MEAS SCI TECHNOL, V19; Hao PF, 2010, EPL-EUROPHYS LETT, V90, DOI 10.1209/0295-5075/90/66003; Harvie DJE, 2001, INT J HEAT MASS TRAN, V44, P2643, DOI 10.1016/S0017-9310(00)00304-5; Kang KH, 2013, PHYS FLUIDS, V25, DOI 10.1063/1.4797497; Lecordier B, 2004, PARTICLE IMAGE VELOCIMETRY: RECENT IMPROVEMENTS, P115; Raffel M, 2007, EXP FLUID MECH, P1, DOI 10.1007/978-3-540-72308-0; Roisman VI, 2009, PHYS FLUIDS, V21; Saha A, 2012, PHYS LETT A, V376, P3185, DOI 10.1016/j.physleta.2012.08.013; Sakai M, 2007, REV SCI INSTRUM, V78, P103; Scarano F, 2002, MEAS SCI TECHNOL, V13, pR1, DOI 10.1088/0957-0233/13/1/201; Sen S, 2014, EXP THERM FLUID SCI, V54, P38, DOI 10.1016/j.expthermflusci.2014.01.014; Smith MI, 2011, EXP FLUIDS, V50, P1385, DOI 10.1007/s00348-010-0998-6; Worthington A. M., 1876, P ROY SOC LONDON, V25, P261, DOI DOI 10.1098/RSPL.1876.0048; Xu L, 2005, PHYS REV LETT, V94, P184	28	1	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0723-4864	1432-1114		EXP FLUIDS	Exp. Fluids	NOV	2014	55	11							1845	10.1007/s00348-014-1845-y		9	Engineering, Mechanical; Mechanics	Engineering; Mechanics	AS3IQ	WOS:000344171200012		
J	Liu, CJ; Hayashi, K				Liu, Chuanjun; Hayashi, Kenshi			Visualization of controlled fragrance release from cyclodextrin inclusion complexes by fluorescence imaging	FLAVOUR AND FRAGRANCE JOURNAL			English	Article						fragrance release; cyclodextrin inclusion complex; visualization sensor; fluorescence imaging	COLORIMETRIC SENSOR ARRAY; L-MENTHOL; VANILLIN RELEASE; ELECTRONIC NOSES; VOLATILE RELEASE; ENCAPSULATION; DISCRIMINATION; RETENTION; MACROCAPSULES; SORPTION	Evaluation of odour release is important for the development of encapsulated fragrances. However, the use of existing instrumental analysis or gas-sensor technologies for odour-release evaluation is time- and labour-consuming. This paper introduces a fluorescence imaging system that can be used as a simple but effective tool to visualize the moisture-activated release of fragrance from cyclodextrin inclusion complexes. The visualization is based on the fluorescence changes of samples caused by the release of fragrance molecules from the cavity of cyclodextrin. Fluorescence spectroscopy investigations proved that different strategies could be used in the visualization depending on the molecular characters of the encapsulated fragrances. In the case of fragrance molecules with fluorescence (typically methyl anthranilate: MA), the change of fluorescence intensity was derived from the changed microenvironment of MA - from the encapsulated state to the released state. For the fragrance molecules without fluorescence (typically menthol), an appropriate fluorescent probe (7-amino-4-methylcoumarin: AMC) was used, and the fluorescence change was observed due to the interactions between AMC and the released menthol molecules. The real-time releases were visualized by two-dimensional/three-dimensional surface plots of the fluorescence images using image-processing software. Both the burst release occurring on the short time scale and the slow, natural release in ambient conditions can be demonstrated by the proposed visualization technique. Copyright (c) 2014 John Wiley & Sons, Ltd.	[Liu, Chuanjun; Hayashi, Kenshi] Kyushu Univ, Grad Sch Informat Sci & Elect Engn, Dept Elect, Nishi Ku, Fukuoka 8190395, Japan	Liu, CJ (reprint author), Kyushu Univ, Grad Sch Informat Sci & Elect Engn, Dept Elect, Nishi Ku, 744 Motooka, Fukuoka 8190395, Japan.	liu@o.ed.kyushu-u.ac.jp		Liu, Chuanjun/0000-0002-7232-2573	Strategic Information and Communications R&D Promotion Program, Ministry of Internal Affairs and Communications, Japan	This work is partly supported by the Strategic Information and Communications R&D Promotion Program, Ministry of Internal Affairs and Communications, Japan.	Aernecke MJ, 2009, ANAL CHEM, V81, P5762, DOI 10.1021/ac900589b; Albert KJ, 2001, ANAL CHEM, V73, P2501, DOI 10.1021/ac001137a; Madene A, 2006, INT J FOOD SCI TECH, V41, P1, DOI 10.1111/j.1365-2621.2005.00980.x; Rodrigues SN, 2009, CHEM ENG J, V149, P463, DOI 10.1016/j.cej.2009.02.021; Na N, 2006, J AM CHEM SOC, V128, P14420, DOI 10.1021/ja063632f; Kayaci F, 2012, FOOD CHEM, V133, P641, DOI 10.1016/j.foodchem.2012.01.040; Marques HMC, 2010, FLAVOUR FRAG J, V25, P313, DOI 10.1002/ffj.2019; Dickinson TA, 1999, ANAL CHEM, V71, P2192, DOI 10.1021/ac981457i; Suslick BA, 2010, ANAL CHEM, V82, P2067, DOI 10.1021/ac902823w; Ciobanu A, 2013, FOOD RES INT, V53, P110, DOI 10.1016/j.foodres.2013.03.048; Wu YY, 2009, ANAL CHEM, V81, P961, DOI 10.1021/ac801733k; Astray G, 2009, FOOD HYDROCOLLOID, V23, P1631, DOI 10.1016/j.foodhyd.2009.01.001; Ciobanu A, 2013, FOOD CHEM, V138, P291, DOI 10.1016/j.foodchem.2012.10.106; Del Valle EMM, 2004, PROCESS BIOCHEM, V39, P1033, DOI 10.1016/S0032-9592(03)00258-9; Arias-Estevez M, 2007, B ENVIRON CONTAM TOX, V79, P251, DOI 10.1007/s00128-007-9022-0; Astray G, 2010, FOOD RES INT, V43, P1212, DOI 10.1016/j.foodres.2010.02.017; Zhang C, 2005, J AM CHEM SOC, V127, P11548, DOI 10.1021/ja052606z; Rakow NA, 2005, ANGEW CHEM INT EDIT, V44, P4528, DOI 10.1002/anie.200500939; Liu CJ, 2013, SENSOR ACTUAT B-CHEM, V183, P117, DOI 10.1016/j.snb.2013.03.111; Bencic-Nagale S, 2006, J AM CHEM SOC, V128, P5041, DOI 10.1021/ja057057b; Pena B, 2009, IND ENG CHEM RES, V48, P1562, DOI 10.1021/ie801133f; Janzen MC, 2006, ANAL CHEM, V78, P3591, DOI 10.1021/ac052111s; LI S, 1992, CHEM REV, V92, P1457, DOI 10.1021/cr00014a009; Lim SH, 2009, NAT CHEM, V1, P562, DOI [10.1038/nchem.360, 10.1038/NCHEM.360]; Vaughn J, 2013, CHEM COMMUN, V49, P5724, DOI 10.1039/c3cc41236a; Albert KJ, 2000, ANAL CHEM, V72, P1947, DOI 10.1021/ac991397w; Wang P, 2008, FLAVOUR FRAG J, V23, P29, DOI 10.1002/ffj.1851; Arias M, 2007, J FOOD ENG, V78, P69, DOI 10.1016/j.jfoodeng.2005.09.016; Bencic-Nagale S, 2005, ANAL CHEM, V77, P6155, DOI 10.1021/ac0505021; Bhatia SP, 2008, FOOD CHEM TOXICOL, V46, pS209, DOI 10.1016/j.fct.2008.06.059; Blee N, 2011, FLAVOUR FRAG J, V26, P186, DOI 10.1002/ffj.2051; Bohn DM, 2005, J AGR FOOD CHEM, V53, P3149, DOI 10.1021/jf0487598; Camerlo A, 2013, EUR POLYM J, V49, P3806, DOI 10.1016/j.eurpolymj.2013.08.028; Gambetta C, 2013, J PHOTOCH PHOTOBIO A, V269, P27, DOI 10.1016/j.jphotochem.2013.06.013; Rouseff R, 2011, PRACTICAL ANALYSIS OF FLAVOR AND FRAGRANCE MATERIALS, P45; Gumi T, 2009, DESALINATION, V245, P769, DOI 10.1016/j.desal.2009.02.050; Linforth RST, 1999, FOOD CHEM, V65, P77, DOI 10.1016/S0308-8146(98)00173-3; Liu C., 2013, IEEE SENS P, DOI [10.1109/ICSEN.2013.6688508, DOI 10.1109/ICSEN.2013.6688508]; Liu XD, 2000, BIOSCI BIOTECH BIOCH, V64, P1608, DOI 10.1271/bbb.64.1608; Matsuo H., 2012, J ROBOT MECHATRON, V24, P47; Monge ME, 2004, SENSOR ACTUAT B-CHEM, V101, P28, DOI 10.1016/j.snb.2004.02.019; Mortenson MA, 2008, FLAVOUR FRAG J, V23, P392, DOI 10.1002/ffj.1885; Mortenson MA, 2008, FLAVOUR FRAG J, V23, P407, DOI 10.1002/ffj.1892; Numanoglu U., 2007, AAPS PHARMSCITECH, V8, pE1; Pena B, 2012, CHEM ENG J, V179, P394, DOI 10.1016/j.cej.2011.10.090; Reineccius TA, 2002, J FOOD SCI, V67, P3271, DOI 10.1111/j.1365-2621.2002.tb09577.x; Rodriguez SD, 2010, FOOD RES INT, V43, P797, DOI 10.1016/j.foodres.2009.11.022; Sansukcharearnpon A, 2010, INT J PHARMACEUT, V391, P267, DOI 10.1016/j.ijpharm.2010.02.020; Schofield WCE, 2011, ACS APPL MATER INTER, V3, P2051, DOI 10.1021/am200281x; Shefer A., 2004, US Patent, Patent No. [US 0175404 A1, 0175404]; Sousa Filipa L, 2012, Results Pharma Sci, V2, P52, DOI 10.1016/j.rinphs.2012.07.001; Tiwari Gaurav, 2010, J Pharm Bioallied Sci, V2, P72, DOI 10.4103/0975-7406.67003; Tzhayik O, 2012, ULTRASON SONOCHEM, V19, P858, DOI 10.1016/j.ultsonch.2011.12.023; Zhang J, 2011, J INCL PHENOM MACRO, V71, P593, DOI 10.1007/s10847-011-9996-4	54	2	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0882-5734	1099-1026		FLAVOUR FRAG J	Flavour Frag. J.	NOV	2014	29	6					356	363		10.1002/ffj.3213		8	Chemistry, Applied; Food Science & Technology	Chemistry; Food Science & Technology	AS4DT	WOS:000344224200005		
J	Yamasaki, M; Nishimura, M; Sakakibara, Y; Suiko, M; Morishita, K; Nishiyama, K				Yamasaki, Masao; Nishimura, Misato; Sakakibara, Yoichi; Suiko, Masahito; Morishita, Kazuhiro; Nishiyama, Kazuo			Delta-tocotrienol induces apoptotic cell death via depletion of intracellular squalene in ED40515 cells	FOOD & FUNCTION			English	Article							NF-KAPPA-B; VIVO ANTITUMOR-ACTIVITY; BREAST-CANCER CELLS; C-FLIP EXPRESSION; LEUKEMIA-CELLS; VITAMIN-E; IN-VIVO; TRANSCRIPTIONAL REGULATION; CONSTITUTIVE ACTIVATION; SEQUENCE ELEMENTS	Here, we examined the effect of tocotrienols (T3) on the growth of adult T-cell leukemia (ATL) cells. All three forms (beta-, gamma-, and delta-T3) inhibited cell proliferation in a dose-dependent manner; delta-T3 showed the strongest growth-inhibitory effect. delta-T3 increased the G1, G2/M, and subG1 populations and induced internucleosomal DNA fragmentation. delta-T3 treatment also increased the levels of cleaved caspase-3, -6, -7, -9, and poly-ADP ribose polymerase (PARP), and this was accompanied by downregulation of Bcl-2, Bcl-xL, and XIAP. Moreover, delta-T3 decreased nuclear p65 NF-kappa B levels, indicating downregulation of NF-kappa B activity. This cytotoxic effect of delta-T3 was abrogated by squalene (SQL) but not mevalonate (MVL), farnesyl diphosphate (FPP), geranylgeranyl diphosphate (GGPP), or cholesterol (CL). delta-T3 decreased intracellular SQL levels, and inhibition of de novo cholesterol synthesis did not affect the action of SQL. Furthermore, delta-T3 significantly decreased farnesyl-diphosphate farnesyltransferase 1 (FDFT1) expression. Taken together, it is evident that delta-T3, due to its ability to potently induce apoptosis via the depletion of intracellular SQL, shows the potential to be considered a therapeutic agent in patients with ATL	[Yamasaki, Masao; Nishimura, Misato; Sakakibara, Yoichi; Suiko, Masahito; Nishiyama, Kazuo] Miyazaki Univ, Fac Agr, Dept Biochem & Appl Biosci, Miyazaki 8892192, Japan; [Morishita, Kazuhiro] Miyazaki Univ, Fac Agr, Dept Biochem, Miyazaki 8892192, Japan	Yamasaki, M (reprint author), Miyazaki Univ, Fac Agr, Dept Biochem & Appl Biosci, 1-1 Gakuenkibanadai Nishi, Miyazaki 8892192, Japan.	myamasaki@cc.miyazaki-u.ac.jp; nishiyam@cc.miyazaki-u.ac.jp			Tojuro Iijima Foundation for Food Science and Technology	This work was supported by the Tojuro Iijima Foundation for Food Science and Technology in 2012.	Katuru R, 2011, EXP BIOL MED, V236, P604, DOI 10.1258/ebm.2011.010379; Tsuduki T, 2013, J OLEO SCI, V62, P825, DOI 10.5650/jos.62.825; Kannappan R, 2010, MOL CANCER THER, V9, P2196, DOI 10.1158/1535-7163.MCT-10-0277; Haneji K, 2005, NUTR CANCER, V52, P189, DOI 10.1207/s15327914nc5202_9; Bleumink M, 2011, CELL DEATH DIFFER, V18, P362, DOI 10.1038/cdd.2010.99; Tomita M, 2006, INT J CANCER, V118, P765, DOI 10.1002/ijc.21389; Mori N, 1999, BLOOD, V93, P2360; Wu SJ, 2008, MOL NUTR FOOD RES, V52, P921, DOI 10.1002/mnfr.200700418; Tomita M, 2006, LEUKEMIA RES, V30, P313, DOI 10.1016/j.leukres.2005.08.004; Park SK, 2010, BREAST CANCER RES TR, V124, P361, DOI 10.1007/s10549-010-0786-2; Taylor JM, 2008, APOPTOSIS, V13, P733, DOI 10.1007/s10495-008-0208-7; Krueger A, 2006, BLOOD, V107, P3933, DOI 10.1182/blood-2005-06-2567; Brusselmans K, 2007, J BIOL CHEM, V282, P18777, DOI 10.1074/jbc.M611763200; Husain K, 2011, MOL CANCER THER, V10, P2363, DOI 10.1158/1535-7163.MCT-11-0424; Nonaka M, 2009, EXP CELL RES, V315, P141, DOI 10.1016/j.yexcr.2008.10.010; Mori N, 2002, BLOOD, V100, P1828, DOI 10.1182/blood-2002-01-0151; Nesaretnam K, 1998, LIPIDS, V33, P461, DOI 10.1007/s11745-998-0229-3; Tiwari RV, 2014, EXP BIOL MED, V239, P33, DOI 10.1177/1535370213511022; Comitato R, 2009, AM J PHYSIOL-ENDOC M, V297, pE427, DOI 10.1152/ajpendo.00187.2009; Sylvester PW, 2005, ASIA PAC J CLIN NUTR, V14, P366; Constantinou C, 2012, NUTR CANCER, V64, P136, DOI 10.1080/01635581.2012.630167; Constantinou C, 2009, NUTR CANCER, V61, P864, DOI 10.1080/01635580903285130; Edwards DC, 2011, VIRUSES-BASEL, V3, P1815, DOI 10.3390/v3101815; Fernandes NV, 2010, ANTICANCER RES, V30, P4937; FOLCH J, 1957, J BIOL CHEM, V226, P497; Guan GM, 1997, J BIOL CHEM, V272, P10295; Guan GM, 1998, J BIOL CHEM, V273, P12526, DOI 10.1074/jbc.273.20.12526; HANCHARD B, 1990, HUMAN RETROVIROLOGY : HTLV, P173; Maccarrone M, 1998, EUR J BIOCHEM, V253, P107, DOI 10.1046/j.1432-1327.1998.2530107.x; Mohapatra S, 2003, CANCER RES, V63, P8523; Mori N, 2001, BIOCHEM BIOPH RES CO, V282, P1110, DOI 10.1006/bbrc.2001.4708; Ohsugi T, 2006, LEUKEMIA RES, V30, P90, DOI 10.1016/j.leukres.2005.06.001; Ohsugi T, 2005, CARCINOGENESIS, V26, P1382, DOI 10.1093/carcin/bgi095; Saggioro D, 2009, FRONT BIOSCI, V14, P3338, DOI 10.2741/4056; Sakai M, 2004, ANTICANCER RES, V24, P1683; Sanda T, 2006, LEUKEMIA, V20, P590, DOI 10.1038/sj.leu.2404129; Shah S, 2004, EXP BIOL MED, V229, P745; Takahashi K, 2004, BIOCHEM PHARMACOL, V67, P315, DOI 10.1016/j.bcp.2003.07.015; Vajente N, 2009, APOPTOSIS, V14, P153, DOI 10.1007/s10495-008-0289-3; Wali VB, 2009, APOPTOSIS, V14, P1366, DOI 10.1007/s10495-009-0406-y; Wang WM, 2014, J VIROL, V88, P2786, DOI 10.1128/JVI.03025-13; Wilankar C, 2011, CURR PHARM DESIGN, V17, P2176, DOI 10.2174/138161211796957463; Wong RSY, 2012, MICROSC MICROANAL, V18, P462, DOI 10.1017/S1431927612000177; YAMAGUCHI K, 1990, HUMAN RETROVIROLOGY : HTLV, P163; Yamasaki M, 2007, CANCER SCI, V98, P1740, DOI 10.1111/j.1349-7006.2007.00595.x; Yamasaki M, 2013, CELL BIOL INT, V37, P742, DOI 10.1002/cbin.10101; Yamasaki M, 2010, BIOSCI BIOTECH BIOCH, V74, P2113, DOI 10.1271/bbb.100359; Zhang J, 2003, LEUKEMIA RES, V27, P275, DOI 10.1016/S0145-2126(02)00164-9	48	0	0	ROYAL SOC CHEMISTRY	CAMBRIDGE	THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND	2042-6496	2042-650X		FOOD FUNCT	Food Funct.	NOV	2014	5	11					2842	2849		10.1039/c4fo00635f		8	Biochemistry & Molecular Biology; Food Science & Technology	Biochemistry & Molecular Biology; Food Science & Technology	AS5OT	WOS:000344320600015		
J	Suzuki, H; Vuong, TV; Gong, YC; Chan, K; Ho, CY; Master, ER; Kondo, A				Suzuki, Hitoshi; Vuong, Thu V.; Gong, Yunchen; Chan, Kin; Ho, Chi-Yip; Master, Emma R.; Kondo, Akihiko			Sequence diversity and gene expression analyses of expansin-related proteins in the white-rot basidiomycete, Phanerochaete carnosa	FUNGAL GENETICS AND BIOLOGY			English	Article						Expansin; Loosenin; Cell wall loosening; Phanerochaete carnosa; Sequence homology; Gene expression	CELL-WALL; BACTERIAL EXPANSIN; ENZYMATIC-HYDROLYSIS; ROOT COLONIZATION; BACILLUS-SUBTILIS; BARLEY SEED; CELLULOSE; WOOD; SACCHARIFICATION; ENDOGLUCANASE	Expansin and expansin-related proteins loosen plant cell wall architectures and are widely distributed in several types of organisms, including plants, fungi and bacteria. Here we describe sequence diversity and unique gene expression profiles of multiple expansin-related proteins identified in the basidiomycete, Phanerochaete carnosa. The protein sequences were homologous to loosenin, an expansin-related protein reported in the basidiomycete, Bjerkandera adusta. We identified homologous sequences of each of those P. carnosa proteins in many basidiomycete species. Twelve P. carnosa loosenin-like proteins (LOOLs) were classified into two subgroups according to sequence homology. Conservation of polysaccharide-binding amino acid residues was stricter in subgroup A. Subgroup A sequences included a conserved 8-9 amino acid insertion in a polysaccharide-binding groove whereas subgroup B contained a 12-18 amino acid insertion next to the binding groove. The P. carnosa genome also encodes the expansin-related protein, DREX1, which adopts a loosenin-like structure but has lower sequence homology to other LOOLs. The gene expression analysis of those proteins showed distinct patterns that were not significantly related to subgroupings. The variation in the protein sequences and gene expression patterns, and wide distribution among the basidiomycota, suggest that the diverse cell wall loosening proteins contribute to effective plant cell wall association and utilization by basidiomycetes. (C) 2014 Elsevier Inc. All rights reserved.	[Suzuki, Hitoshi; Kondo, Akihiko] RIKEN, Biomass Engn Program, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; [Suzuki, Hitoshi; Vuong, Thu V.; Master, Emma R.] Univ Toronto, Dept Chem Engn & Appl Chem, Toronto, ON M5S 3E5, Canada; [Gong, Yunchen] Univ Toronto, Ctr Anal Genome Evolut & Funct, Toronto, ON M5S 3B3, Canada; [Chan, Kin; Ho, Chi-Yip] Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X5, Canada; [Kondo, Akihiko] Kobe Univ, Grad Sch Engn, Dept Chem Sci & Engn, Nada Ku, Kobe, Hyogo 6578501, Japan	Kondo, A (reprint author), RIKEN, Biomass Engn Program, Tsurumi Ku, 1-7-22 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.	hitoshi.suzuki.gc@riken.jp; thu.vuong@utoronto.ca; yunchen.gong@utoronto.ca; kin@lunenfeld.ca; cyho@lunenfeld.ca; emma.master@utoronto.ca; akondo@kobe-u.ac.jp	Kondo, Akihiko/A-2130-2015; Master, Emma/O-3554-2014		Government of Ontario [ORF-RE-05-005]; Natural Sciences and Engineering Research Council of Canada	Funding for contributions from H.S., T.V.V. and E.R.M. was provided by the Government of Ontario for the project "FFABnet: Functionalized Fibre and Biochemicals" (ORF-RE-05-005), and the Natural Sciences and Engineering Research Council of Canada.	Martinez D, 2009, P NATL ACAD SCI USA, V106, P1954, DOI 10.1073/pnas.0809575106; Kim ES, 2009, BIOTECHNOL BIOENG, V102, P1342, DOI 10.1002/bit.22193; Igarashi K, 2008, APPL ENVIRON MICROB, V74, P5628, DOI 10.1128/AEM.00812-08; Cosgrove DJ, 2000, NATURE, V407, P321, DOI 10.1038/35030000; MacDonald J, 2012, APPL MICROBIOL BIOT, V94, P339, DOI 10.1007/s00253-012-3937-z; Saloheimo M, 2002, EUR J BIOCHEM, V269, P4202, DOI 10.1046/j.1432-1033.2002.03095.x; Bouzarelou D, 2008, FUNGAL GENET BIOL, V45, P839, DOI 10.1016/j.fgb.2008.03.001; MCQUEENMASON S, 1994, P NATL ACAD SCI USA, V91, P6574, DOI 10.1073/pnas.91.14.6574; Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616; Benkert P, 2011, BIOINFORMATICS, V27, P343, DOI 10.1093/bioinformatics/btq662; MCQUEENMASON S, 1992, PLANT CELL, V4, P1425; MacDonald J, 2011, APPL ENVIRON MICROB, V77, P3211, DOI 10.1128/AEM.02490-10; Cosgrove DJ, 1997, P NATL ACAD SCI USA, V94, P6559, DOI 10.1073/pnas.94.12.6559; Merino ST, 2007, ADV BIOCHEM ENG BIOT, V108, P95, DOI 10.1007/10_2007_066; Bordoli L, 2009, NAT PROTOC, V4, P1, DOI 10.1038/nprot.2008.197; Kerff F, 2008, P NATL ACAD SCI USA, V105, P16876, DOI 10.1073/pnas.0809382105; Brotman Y, 2008, PLANT PHYSIOL, V147, P779, DOI 10.1104/pp.108.116293; Arantes V, 2010, BIOTECHNOL BIOFUELS, V3, DOI 10.1186/1754-6834-3-4; Baker JO, 2000, APPL BIOCHEM BIOTECH, V84-6, P217, DOI 10.1385/ABAB:84-86:1-9:217; Chen XA, 2010, APPL ENVIRON MICROB, V76, P2556, DOI 10.1128/AEM.02499-09; COSGROVE DJ, 1993, PLANT PHYSIOL, V103, P1321; Eriksson K., 1990, MICROBIAL ENZYMATIC; Georgelis N, 2011, J BIOL CHEM, V286, P16814, DOI 10.1074/jbc.M111.225037; LUDVIGSEN S, 1992, BIOCHEMISTRY-US, V31, P8783, DOI 10.1021/bi00152a014; Nikolaidis N., 2013, MOL BIOL EVOL; Nordberg H., 2013, NUCL ACIDS RES; Quiroz-Castañeda Rosa E, 2011, Biotecnol Apl, V28, P205; Quiroz-Castaneda RE, 2011, MICROB CELL FACT, V10, DOI 10.1186/1475-2859-10-8; Suzuki H, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-444; SVENSSON B, 1992, BIOCHEMISTRY-US, V31, P8767, DOI 10.1021/bi00152a012	30	3	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1087-1845	1096-0937		FUNGAL GENET BIOL	Fungal Genet. Biol.	NOV	2014	72				SI		115	123		10.1016/j.fgb.2014.05.008		9	Genetics & Heredity; Mycology	Genetics & Heredity; Mycology	AS3WU	WOS:000344206800013		
J	Sabau, AS; Ohriner, EK; Kiggans, J; Schaich, CR; Ueda, Y; Harper, DC; Katoh, Y; Snead, LL				Sabau, Adrian S.; Ohriner, Evan K.; Kiggans, Jim; Schaich, Charles R.; Ueda, Yoshio; Harper, David C.; Katoh, Yutai; Snead, Lance L.			HIGH-HEAT-FLUX TESTING OF IRRADIATED TUNGSTEN-BASED MATERIALS FOR FUSION APPLICATIONS USING INFRARED PLASMA ARC LAMPS	FUSION SCIENCE AND TECHNOLOGY			English	Article						high-heat-flux testing; infrared plasma arc lamp; plasma-facing material	NEUTRON-IRRADIATION; TEMPERATURE; METALS; TRANSIENT; BEHAVIOR; DIVERTOR; ALLOYS; NICKEL	Testing of advanced materials and component mockups under prototypical fusion high-heat-flux conditions, while historically a mainstay of fusion research, has proved challenging, especially for irradiated materials. A new high-heat-flux-testing (HHFT) facility based on water-wall plasma arc lamps (PALs) is now introduced for materials and small-component testing. Two PAL systems, utilizing a 12 000 degrees C plasma arc contained in a quartz tube cooled by a spiral water flow over the inside tube surface, provide maximum incident heat fluxes of 4.2 and 27 MW/m(2) over areas of 9 X 12 and 1 x 10 cm(2), respectively. This paper will present the overall design and implementation of a PAL-based irradiated material target station (IMTS). The IMTS is primarily designed for testing the effects of heat flux or thermal cycling on material coupons of interest, such as those for plasma-facing components. Temperature results are shown for thermal cycling under HHFT of tungsten coupon specimens that were neutron irradiated in HFIR. Radiological surveys indicated minimal contamination of the 36- x 36- x 18-cm test section, demonstrating the capability of the new facility to handle irradiated specimens at high temperature.	[Sabau, Adrian S.; Ohriner, Evan K.; Kiggans, Jim; Harper, David C.; Katoh, Yutai; Snead, Lance L.] Oak Ridge Natl Lab, Mat Sci & Technol Div, Oak Ridge, TN 37831 USA; [Schaich, Charles R.] Oak Ridge Natl Lab, Energy & Transportat Sci Div, Oak Ridge, TN 37831 USA; [Ueda, Yoshio] Osaka Univ, Grad Sch Engn, Suita, Osaka 5650871, Japan	Sabau, AS (reprint author), Oak Ridge Natl Lab, Mat Sci & Technol Div, Oak Ridge, TN 37831 USA.	sabaua@ornl.gov	Sabau, Adrian/B-9571-2008	Sabau, Adrian/0000-0003-3088-6474	Office of Fusion Energy Sciences, U.S. Department of Energy under UT-Battelle, LLC [DE-AC05-00OR22725]; "Technological Assessment of Plasma Facing Components for DEMO Reactors" Japan/United States Fusion Research joint project	This work was supported by the Office of Fusion Energy Sciences, U.S. Department of Energy under contract DE-AC05-00OR22725 with UT-Battelle, LLC, and the "Technological Assessment of Plasma Facing Components for DEMO Reactors" Japan/United States Fusion Research joint project. The authors would like to thank M. Rieth and J. Reiser of Karlsruhe Institute of Technology, Germany, for providing the tungsten specimens and M. A. Williams of ORNL for safety considerations related to the neutron-irradiated materials and S. Curlin of ORNL for taking the micrographs.	Byun TS, 2004, J NUCL MATER, V326, P86, DOI 10.1016/j.jnucmat.2003.12.012; GORYNIN IV, 1992, J NUCL MATER, V191, P421; Zhang TQ, 2006, J MATER SCI, V41, P7506, DOI 10.1007/s10853-006-0834-9; Hirai T, 2005, MATER TRANS, V46, P412, DOI 10.2320/matertrans.46.412; Rieth M, 2010, INT J REFRACT MET H, V28, P679, DOI 10.1016/j.ijrmhm.2010.04.010; Hasegawa A, 2011, J NUCL MATER, V417, P491, DOI 10.1016/j.jnucmat.2010.12.114; Matsumoto T, 1999, INT J THERMOPHYS, V20, P943, DOI 10.1023/A:1022699622719; Barabash V, 2000, J NUCL MATER, V283, P138, DOI 10.1016/S0022-3115(00)00203-8; STEICHEN JM, 1976, J NUCL MATER, V60, P13, DOI 10.1016/0022-3115(76)90112-4; Byun TS, 2004, J NUCL MATER, V329, P998, DOI 10.1016/j.jnucmat.2004.04.071; CAMM D. M., 1987, U.S. Patent, Patent No. [4,700,102, 4700102]; CAMM D. M., 2000, 197 M EL SOC TOR ONT; CAMM D. M., 1987, U.S. Patent, Patent No. [4,683,525, 4683525]; Faleschini M, 2007, J NUCL MATER, V367, P800, DOI 10.1016/j.jnucmat.2007.03.079; Grabowski S, 2002, PHASE TRANSIT, V75, P265, DOI 10.1080/01411590290023157; HAGER JM, 1993, J THERMOPHYS HEAT TR, V7, P531, DOI 10.2514/3.452; Hinoki T, 2005, J NUCL MATER, V347, P207, DOI 10.1016/j.jnucmat.2005.08.020; Hirai T, 2007, FUSION ENG DES, V82, P1839, DOI 10.1016/j.fusengdes.2007.02.024; LEFRANCOIS M., 2000, 8 INT C ADV THERM PR; NODWELL R. A., 1977, U.S. Patent, Patent No. [4,027,185, 4027185]; RAU RC, 1967, J NUCL MATER, V24, P164, DOI 10.1016/0022-3115(67)90005-0; Reiser J, 2012, J NUCL MATER, V424, P197, DOI 10.1016/j.jnucmat.2012.02.030; RIETH M., 2008, P 18 TOPL M TECHN FU; Rivard JDK, 2003, METALL MATER TRANS A, V34A, P3043, DOI 10.1007/s11661-003-0202-1; ROBERTS S, 1959, PHYS REV, V114, P104, DOI 10.1103/PhysRev.114.104; ROMANOSKI G., 2005, P HIGH AV POW LAS WO; SABAU A. S., 2003, P INT THERM COND C K, P511; SABAU A. S., 2006, J MATER PROCESS TECH, V182, P312; Sabau AS, 2009, J APPL PHYS, V105, DOI 10.1063/1.3097356; SABAU A. S., 2014, PHYS SCR, V2014; SUZUKI S., 1997, P 17 IEEE NPSS S FUS, V1, P385; THRUM T., 2004, P IEEE IND APPL C 39, P1019	32	0	0	AMER NUCLEAR SOC	LA GRANGE PK	555 N KENSINGTON AVE, LA GRANGE PK, IL 60526 USA	1536-1055	1943-7641		FUSION SCI TECHNOL	Fusion Sci. Technol.	NOV	2014	66	3					394	404				11	Nuclear Science & Technology	Nuclear Science & Technology	AS0FW	WOS:000343954500003		
J	Matsumoto, K; Imasato, M; Yamazaki, Y; Tanaka, H; Watanabe, M; Eguchi, H; Nagano, H; Hikita, H; Tatsumi, T; Takehara, T; Tamura, A; Tsukita, S				Matsumoto, Kengo; Imasato, Mitsunobu; Yamazaki, Yuji; Tanaka, Hiroo; Watanabe, Mitsuhiro; Eguchi, Hidetoshi; Nagano, Hiroaki; Hikita, Hayato; Tatsumi, Tomohide; Takehara, Tetsuo; Tamura, Atsushi; Tsukita, Sachiko			Claudin 2 Deficiency Reduces Bile Flow and Increases Susceptibility to Cholesterol Gallstone Disease in Mice	GASTROENTEROLOGY			English	Article						Mouse Model; Claudin 2; Hepatic Microcirculation; TJ	TIGHT JUNCTION; WATER TRANSPORT; LIVER-DISEASE; NULL MICE; PHYSIOLOGY; SECRETION; CHANNELS; PERMEABILITY; AQUAPORIN-8; SATURATION	BACKGROUND & AIMS: Bile formation and secretion are essential functions of the hepatobiliary system. Bile flow is generated by transepithelial transport of water and ionic/nonionic solutes via transcellular and paracellular pathways that is mainly driven by osmotic pressure. We examined the role of tight junction-based paracellular transport in bile secretion. Claudins are cell-cell adhesion molecules in tight junctions that create the paracellular barrier. The claudin family has 27 reported members, some of which have paracellular ion- and/or water-channel-like functions. Claudin 2 is a paracellular channel-forming protein that is highly expressed in hepatocytes and cholangiocytes; we examined the hepatobiliary system of claudin 2 knockout (Cldn2(-/-)) mice. METHODS: We collected liver and biliary tissues from Cldn2(-/-) and Cldn2(+/+) mice and performed histologic, biochemical, and electrophysiologic analyses. We measured osmotic movement of water and/or ions in Cldn2(-/-) and Cldn2(+/+) hepatocytes and bile ducts. Mice were placed on lithogenic diets for 4 weeks and development of gallstone disease was assessed. RESULTS: The rate of bile flow in Cldn2(-/-) mice was half that of Cldn2(+/+) mice, resulting in significantly more concentrated bile in livers of Cldn2(-/-) mice. Consistent with these findings, osmotic gradient-driven water flow was significantly reduced in hepatocyte bile canaliculi and bile ducts isolated from Cldn2(-/-) mice, compared with Cldn2(+/+) mice. After 4 weeks on lithogenic diets, all Cldn2(-/-) mice developed macroscopically visible gallstones; the main component of the gallstones was cholesterol (>98%). In contrast, none of the Cldn2(+/+) mice placed on lithogenic diets developed gallstones. CONCLUSIONS: Based on studies of Cldn2(-/-) mice, claudin 2 regulates paracellular ion and water flow required for proper regulation of bile composition and flow. Dysregulation of this process increases susceptibility to cholesterol gallstone disease in mice.	[Matsumoto, Kengo; Imasato, Mitsunobu; Yamazaki, Yuji; Tanaka, Hiroo; Tamura, Atsushi; Tsukita, Sachiko] Osaka Univ, Grad Sch Frontier Biosci, Biol Sci Lab, Suita, Osaka 5650871, Japan; [Matsumoto, Kengo; Imasato, Mitsunobu; Yamazaki, Yuji; Tanaka, Hiroo; Tamura, Atsushi; Tsukita, Sachiko] Osaka Univ, Grad Sch Med, Suita, Osaka 5650871, Japan; [Matsumoto, Kengo; Hikita, Hayato; Tatsumi, Tomohide; Takehara, Tetsuo] Osaka Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Suita, Osaka 5650871, Japan; [Watanabe, Mitsuhiro] Keio Univ, Sch Med, Dept Internal Med, Tokyo, Japan; [Watanabe, Mitsuhiro] Keio Univ, Fac Environm & Informat Studies, Grad Sch Media & Governance, Fujisawa, Kanagawa, Japan; [Eguchi, Hidetoshi; Nagano, Hiroaki] Osaka Univ, Grad Sch Med, Dept Surg, Suita, Osaka 5650871, Japan	Tamura, A (reprint author), Osaka Univ, Grad Sch Frontier Biosci, Biol Sci Lab, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	atamura@biosci.med.osaka-u.ac.jp; atsukita@biosci.med.osaka-u.ac.jp			CREST (Core Research for Evolutional Science and Technology) of Japan Science and Technology Agency; Ministry of Education, Culture, and Sports, Science and Technology of Japan	This work was supported in part by Grants-in-Aid for Scientific Research (A) and Creative Scientific Research, and by CREST (Core Research for Evolutional Science and Technology) of Japan Science and Technology Agency to Sachiko Tsukita, and by Grant-in-Aid for Exploratory Research to Yuji Yamazaki, and by Scientific Research (C) to Atsushi Tamura from the Ministry of Education, Culture, and Sports, Science and Technology of Japan.	Esteller A, 2008, WORLD J GASTROENTERO, V14, P5641, DOI 10.3748/wjg.14.5641; Hirschfield GM, 2010, GASTROENTEROLOGY, V139, P1481, DOI 10.1053/j.gastro.2010.09.004; CAREY MC, 1978, J LIPID RES, V19, P945; Huebert RC, 2002, J BIOL CHEM, V277, P22710, DOI 10.1074/jbc.M202394200; Mineta K, 2011, FEBS LETT, V585, P606, DOI 10.1016/j.febslet.2011.01.028; Yu ASL, 2009, J GEN PHYSIOL, V133, P111, DOI 10.1085/jgp.200810154; Tamura A, 2011, GASTROENTEROLOGY, V140, P913, DOI 10.1053/j.gastro.2010.08.006; Tabibian JH, 2013, COMPR PHYSIOL, V3, P541, DOI 10.1002/cphy.c120019; Gunzel D, 2013, PHYSIOL REV, V93, P525, DOI 10.1152/physrev.00019.2012; Mitaka T, 1998, INT J EXP PATHOL, V79, P393, DOI 10.1046/j.1365-2613.1998.00083.x; Rosenthal R, 2010, J CELL SCI, V123, P1913, DOI 10.1242/jcs.060665; Portincasa P, 2012, MOL ASPECTS MED, V33, P651, DOI 10.1016/j.mam.2012.03.010; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Yang BX, 2005, AM J PHYSIOL-CELL PH, V288, pC1161, DOI 10.1152/ajpcell.00564.2004; Shen L, 2011, ANNU REV PHYSIOL, V73, P283, DOI 10.1146/annurev-physiol-012110-142150; Mennone A, 2002, AM J PHYSIOL-GASTR L, V283, pG739, DOI 10.1152/ajpgi.00540.2001; Masyuk AI, 2002, GASTROENTEROLOGY, V122, P545, DOI 10.1053/gast.2002.31035; Nicolaou M, 2012, J PATHOL, V226, P300, DOI 10.1002/path.3019; Amasheh S, 2002, J CELL SCI, V115, P4969, DOI 10.1242/jcs.00165; Furuse M, 2001, J CELL BIOL, V153, P263, DOI 10.1083/jcb.153.2.263; BALLATORI N, 1992, AM J PHYSIOL, V263, pG617; Steed E, 2010, TRENDS CELL BIOL, V20, P142, DOI 10.1016/j.tcb.2009.12.002; Stokes CS, 2011, DIGEST DIS, V29, P191, DOI 10.1159/000323885; van Erpecum KJ, 2005, BIOL CELL, V97, P815, DOI 10.1042/BC20040088; Maurer KJ, 2009, GASTROENTEROLOGY, V136, P425, DOI 10.1053/j.gastro.2008.12.031; Tamura A, 2008, GASTROENTEROLOGY, V134, P523, DOI 10.1053/j.gastro.2007.11.040; BEYENBACH KW, 1985, AM J PHYSIOL, V248, pF282; Boyer JL, 1996, AM J PHYSIOL-GASTR L, V270, pG1; Cova E, 2001, HEPATOLOGY, V34, P456, DOI 10.1053/jhep.2001.27092; Hadj-Rabia S, 2004, GASTROENTEROLOGY, V127, P1386, DOI 10.1053/j.gast.2004.07.022; Jessner Wolfgang, 2008, Wien Med Wochenschr, V158, P565, DOI 10.1007/s10354-008-0597-9; Krug SM, 2012, ANN NY ACAD SCI, V1257, P20, DOI 10.1111/j.1749-6632.2012.06555.x; Larocca MC, 2009, AM J PHYSIOL-GASTR L, V296, pG93, DOI 10.1152/ajpgi.90410.2008; Matsuo M, 2010, BIOSCI BIOTECH BIOCH, V74, P899, DOI 10.1271/bbb.90921; Matsuzaki Toshiyuki, 2004, Medical Electron Microscopy, V37, P71; Muto S, 2010, P NATL ACAD SCI USA, V107, P801; Paumgartner G, 2010, HEPATOLOGY, V51, P1095, DOI 10.1002/hep.23472; Schnermann J, 2013, AM J PHYSIOL-RENAL, V305, pF1352, DOI 10.1152/ajprenal.00342.2013; Son S, 2009, HISTOCHEM CELL BIOL, V131, P411, DOI 10.1007/s00418-008-0546-0; VANERPECUM KJ, 1990, HEPATOLOGY, V11, P1, DOI 10.1002/hep.1840110102; Wada M, 2013, GASTROENTEROLOGY, V144, P369, DOI 10.1053/j.gastro.2012.10.035; Yeh TH, 2010, HEPATOLOGY, V52, P1410, DOI 10.1002/hep.23801	42	5	5	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0016-5085	1528-0012		GASTROENTEROLOGY	Gastroenterology	NOV	2014	147	5					1134	+		10.1053/j.gastro.2014.07.033		22	Gastroenterology & Hepatology	Gastroenterology & Hepatology	AS4HJ	WOS:000344234200034		
J	Slupecka, M; Pierzynowski, SG; Kuwahara, A; Kato, I; Wolinski, J				Slupecka, M.; Pierzynowski, S. G.; Kuwahara, A.; Kato, I.; Wolinski, J.			Age-dependent effect of obestatin on intestinal contractility in Wistar rats	GENERAL AND COMPARATIVE ENDOCRINOLOGY			English	Article						Obestatin; Intestine; Contractility; Neonates	GASTROINTESTINAL-TRACT; POSTNATAL LIFE; GHRELIN; NEURONS; DIFFERENTIATION; MOTILITY; RODENTS; CELLS; GUT	Obestatin is a 23-amino acid peptide encoded by the ghrelin gene. We have investigated the effect of obestatin on intestinal contractility in rats ranging from the suckling period till adolescence. Duodenal and middle jejunum whole-thickness preparations from neonatal and adult rats were studied in an organ bath, for isometric recording under treatment with obestatin (1 mu mol L-1) in the presence of acetylocholine (ACh), atropine and tetradotoxin (TTX). Both the EFS and ACh-stimulated contractile response, as well as spontaneous contractile activity is age-dependent and specific for the segment of jejunum. Except for the middle jejunum of 7 day old rats, treatment with obestatin caused a significant TTX-sensitive increase in the amplitude of EFS-stimulated off-contraction of both intestinal segments studied. Following injection of obestatin, the amplitude of spontaneous contraction in the duodenum increased in 7 day old rats. In the middle jejunum, treatment with obestatin significantly increased both the amplitude and frequency of spontaneous contraction in rats till the 28th day of life, whereas in adult rats the observed effect of obestatin was the opposite (P < 0.001 and P < 0.0001, respectively). The effects of treatment with obestatin on stimulation with increasing doses of ACh were only observed in the preparations from suckling rats. ACh-stimulated contractility in the duodenum was decreased while in the middle jejunum the observed effect was opposite. These results indicate the importance of peripheral obestatin in the cholinergic control of intestinal contractility in both neonatal and adult rats. (C) 2014 Elsevier Inc. All rights reserved.	[Slupecka, M.; Wolinski, J.] PAS, Kielanowski Inst Anim Physiol & Nutr, Dept Endocrinol, PL-05110 Jablonna, Poland; [Pierzynowski, S. G.] Lund Univ, Dept Biol, Lund, Sweden; [Pierzynowski, S. G.] Inst Agr Med, Dept Med Biol, Lublin, Poland; [Kuwahara, A.] Univ Shizuoka, Inst Environm Sci, Physiol Lab, Shizuoka 4228526, Japan; [Kuwahara, A.] Univ Shizuoka, Grad Sch Nutr & Environm Sci, Shizuoka 4228526, Japan; [Kato, I.] Hokuriku Univ, Fac Pharmaceut Sci, Dept Bioorgan Chem, Kanazawa, Ishikawa 92011, Japan	Slupecka, M (reprint author), PAS, Kielanowski Inst Anim Physiol & Nutr, Dept Endocrinol, Instytucka 3, PL-05110 Jablonna, Poland.	m.slupecka@ifzz.pan.pl					Holst B, 2007, ENDOCRINOLOGY, V148, P13, DOI 10.1210/en.2006-0933; Lauwers E, 2006, BIOCHEM BIOPH RES CO, V351, P21, DOI 10.1016/j.bbrc.2006.09.141; Zhang JV, 2005, SCIENCE, V310, P996, DOI 10.1126/science.1117255; Furness JB, 2004, PROG NEUROBIOL, V72, P143, DOI 10.1016/j.pneurobio.2003.12.004; De Smet B, 2007, NEUROGASTROENT MOTIL, V19, P211, DOI 10.1111/j.1365-2982.2006.00883.x; Ataka K, 2008, AM J PHYSIOL-GASTR L, V294, pG1210, DOI 10.1152/ajpgi.00549.2007; Bassil AK, 2007, BRIT J PHARMACOL, V150, P58, DOI 10.1038/sj.bjp.0706969; Chartrel N, 2007, Science, V315, P766; Dun SL, 2006, J ENDOCRINOL, V191, P481, DOI 10.1677/joe.1.06944; FaussonePellegrini MS, 1996, ACTA ANAT, V155, P113; Gourcerol G, 2006, PEPTIDES, V27, P2811, DOI 10.1016/j.peptides.2006.07.012; KIRCHGESSNER AL, 1992, J NEUROSCI, V12, P235; Korczynski W, 2006, J PHYSIOL PHARMACOL, V57, P43; Matini P, 1997, CELL TISSUE RES, V288, P11, DOI 10.1007/s004410050788; Mondal A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060365; Wurner L, 2013, NEUROGASTROENT MOTIL, V25, pE581, DOI 10.1111/nmo.12165; Zhao CM, 2008, CELL TISSUE RES, V331, P575, DOI 10.1007/s00441-007-0514-3	17	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0016-6480	1095-6840		GEN COMP ENDOCR	Gen. Comp. Endocrinol.	NOV 1	2014	208						109	115		10.1016/j.ygcen.2014.08.015		7	Endocrinology & Metabolism	Endocrinology & Metabolism	AS3XR	WOS:000344209000013		
J	Chanyshev, AD; Litasov, KD; Shatskiy, AF; Furukawa, Y; Ohtani, E				Chanyshev, A. D.; Litasov, K. D.; Shatskiy, A. F.; Furukawa, Y.; Ohtani, E.			Stability Conditions of Polycyclic Aromatic Hydrocarbons at High Pressures and Temperatures (vol 52, pg 767, 2014)	GEOCHEMISTRY INTERNATIONAL			English	Correction									[Chanyshev, A. D.; Litasov, K. D.; Shatskiy, A. F.] Novosibirsk State Univ, Novosibirsk 630090, Russia; [Chanyshev, A. D.; Litasov, K. D.; Shatskiy, A. F.] Russian Acad Sci, VS Sobolev Inst Geol & Mineral, Siberian Branch, Novosibirsk 630090, Russia; [Furukawa, Y.; Ohtani, E.] Tohoku Univ, Sendai, Miyagi 9808578, Japan	Chanyshev, AD (reprint author), Novosibirsk State Univ, Ul Pirogova 2, Novosibirsk 630090, Russia.	chanyshev_90@mail.ru	Chanyshev, Artem/A-7885-2014; Shatskiy, Anton/F-8731-2010; Litasov, Konstantin/A-5366-2014	Shatskiy, Anton/0000-0003-4554-9550; 			Chanyshev AD, 2014, GEOCHEM INT+, V52, P767, DOI 10.1134/S001670291409002X	1	0	0	MAIK NAUKA/INTERPERIODICA/SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013-1578 USA	0016-7029	1556-1968		GEOCHEM INT+	Geochem. Int.	NOV	2014	52	11					1011	1011		10.1134/S001670291424001X		1	Geochemistry & Geophysics	Geochemistry & Geophysics	AS3BF	WOS:000344150200008		
J	Tanikawa, W; Tadai, O; Mukoyoshi, H				Tanikawa, W.; Tadai, O.; Mukoyoshi, H.			Permeability changes in simulated granite faults during and after frictional sliding	GEOFLUIDS			English	Article						fracture aperture; fracture transmissivity; frictional heating; permeability	NEAR-THE-SURFACE; DRIFT SCALE TEST; ROCK PERMEABILITY; THERMAL-EXPANSION; SLIP; EVOLUTION; TRANSPORT; PRESSURE; FRACTURE; JAPAN	Thermal-hydrological-mechanical coupling processes suggest that fault permeability should undergo dynamic change as a result of seismic slip. In igneous rocks, a fault's slip surface may have much higher permeability than the surrounding rock matrix and therefore operate as a conduit for fluids. We conducted laboratory experiments to investigate changes in fracture permeability (or transmissivity) of a fault in granite due to shear slip and cyclic heating and cooling. Our experiments showed that high initial fracture transmissivity (>10(-18)m(3)) was associated with a high friction coefficient and that transmissivity decreased during slip. We propose that this reduction in transmissivity reflects the presence of gouge in fracture voids, increasing the area of contact in the fault plane and reducing the hydraulic aperture. In contrast, when initial fracture transmissivity was low (<10(-18)m(3)), we observed that friction was lower and transmissivity increased during slip. The high transmissivity and high friction may be explained by large areas of bare rock being in contact on the slip surface. Slip velocity had little influence on the evolution of permeability, probably because gouge produced at different slip velocities had similar grain size distributions, or because gouge leaked from the slip surface. Transmissivity decreased with increasing temperature in heating tests, probably due to thermal expansion increasing normal stress on the fracture. Frictional heating did not influence transmissivity during the shearing tests.	[Tanikawa, W.] Japan Agcy Marine Earth Sci & Technol, Kochi Inst Core Sample Res, Nankoku, Kochi 7838502, Japan; [Tadai, O.; Mukoyoshi, H.] Marine Works Japan Ltd, Nankoku, Kochi, Japan; [Mukoyoshi, H.] Waseda Univ, Fac Educ & Integrated Arts & Sci, Shinjuku Ku, Tokyo, Japan	Tanikawa, W (reprint author), Japan Agcy Marine Earth Sci & Technol, Kochi Inst Core Sample Res, Nankoku, Kochi 7838502, Japan.	tanikawa@jamstec.go.jp			Japan Society for the Promotion of Science JSPS) [25800284, 21107004]	We thank anonymous reviewers for improving the clarity of our paper. The valuable comments and suggestions of Dr. W. Lin and T. Hirose Japan Agency for Marine-Earth Science and Technology) are gratefully acknowledged. This study was supported by the Japan Society for the Promotion of Science JSPS) Grant-in-Aid for Science Research Nos. 25800284 and 21107004.	Jiang Y, 2006, INT J ROCK MECH MIN, V43, P837, DOI 10.1016/j.ijrmms.2005.11.013; Koyama T, 2006, INT J ROCK MECH MIN, V43, P89, DOI 10.1016/j.ijrmms.2005.04.006; RICHTER D, 1974, INT J ROCK MECH MIN, V11, P403, DOI 10.1016/0148-9062(74)91111-5; Wibberley CAJ, 2003, J STRUCT GEOL, V25, P59, DOI 10.1016/S0191-8141(02)00014-7; Han R, 2010, J GEOPHYS RES-SOL EA, V115, DOI 10.1029/2008JB006136; Brodsky EE, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB002321; Fisher AT, 1998, REV GEOPHYS, V36, P143, DOI 10.1029/97RG02916; Dwivedi RD, 2008, INT J ROCK MECH MIN, V45, P303, DOI 10.1016/j.ijrmms.2007.05.008; Reches Z, 2010, NATURE, V467, P452, DOI 10.1038/nature09348; Noda H, 2010, J GEOPHYS RES-SOL EA, V115, DOI 10.1029/2010JB007780; Wang CY, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2009GL037330; Lin WR, 2002, J GEOPHYS RES-SOL EA, V107, DOI 10.1029/2001JB000648; Rutqvist J, 2005, INT J ROCK MECH MIN, V42, P680, DOI 10.1016/j.ijrmms.2005.03.008; DisToro G, 2011, NATURE, V471, P494; Eberl D. D., 2003, 200378 US GEOL SURV; Elkhoury JE, 2006, NATURE, V441, P1135, DOI 10.1038/nature04798; Elkhoury JE, 2011, J GEOPHYS RES-SOL EA, V116, DOI 10.1029/2010JB007759; Gale JE, 1982, P 23 US S ROCK MECH, P290; GANGI AF, 1978, INT J ROCK MECH MIN, V15, P249, DOI 10.1016/0148-9062(78)90957-9; Hirose T, 2012, J STRUCT GEOL, V38, P102, DOI 10.1016/j.jsg.2011.12.007; Kabeya KK, 1997, INT J ROCK MECH MIN, V34; Kounikova A, 2011, GEOTECHNIQUE, V61, P1081; Koyama T, 2008, INT J ROCK MECH MIN, V45, P1403, DOI 10.1016/j.ijrmms.2008.01.018; Liu WQ, 2009, GEOPHYS RES LETT, V36, DOI 10.1029/2009GL039852; Matsuki K, 2010, INT J ROCK MECH MIN, V47, P436, DOI 10.1016/j.ijrmms.2009.10.002; Min KB, 2009, INT J ROCK MECH MIN, V46, P80, DOI 10.1016/j.ijrmms.2008.04.002; Mitsui Y, 2012, EARTH PLANET SC LETT, V325, P21, DOI 10.1016/j.epsl.2012.01.026; Mizoguchi K, 2007, GEOPHYS RES LETT, V34, DOI 10.1029/2006GL027931; O'Hara K, 2005, J STRUCT GEOL, V27, P1892, DOI 10.1016/j.jsg.2005.04.013; Renard F, 2012, J STRUCT GEOL, V45, P99, DOI 10.1016/j.jsg.2012.03.009; Rice J., 1992, INT GEOPHYS, V51, P475, DOI DOI 10.1016/S0074-6142(08)62835-1; Rice JR, 2006, J GEOPHYS RES-SOL EA, V111, DOI 10.1029/2005JB004006; Rutqvist J, 2008, INT J ROCK MECH MIN, V45, P1373, DOI 10.1016/j.ijrmms.2008.01.016; Suzuki T, 2008, J GEOPHYS RES-SOL EA, V113, DOI 10.1029/2008JB005581; Tanikawa W, 2012, J STRUCT GEOL, V38, P90, DOI 10.1016/j.jsg.2011.08.013; Tanikawa W, 2010, J GEOPHYS RES-SOL EA, V115, DOI 10.1029/2009JB007013; Tanikawa W, 2013, EARTH PLANET SC LETT, V382, P150, DOI 10.1016/j.epsl.2013.08.052; Tokunaga T, 1999, J HYDROL, V223, P221, DOI 10.1016/S0022-1694(99)00124-9; Wang C., 2009, EARTHQUAKES WATER, P225; Yamashita F, 2011, 2011 FALL M AGU SAN; Yasuhara H, 2004, J GEOPHYS RES-SOL EA, V109, DOI 10.1029/2003JB002663; Yuhara M, 2003, J MINERALOGICAL PETR, V98, P19, DOI 10.2465/jmps.98.19	42	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1468-8115	1468-8123		GEOFLUIDS	Geofluids	NOV	2014	14	4					481	494		10.1111/gfl.12091		14	Geochemistry & Geophysics; Geology	Geochemistry & Geophysics; Geology	AS5UJ	WOS:000344334600007		
J	Ishikawa, H; Mutoh, M; Suzuki, S; Tokudome, S; Saida, Y; Abe, T; Okamura, S; Tajika, M; Joh, T; Tanaka, S; Kudo, S; Matsuda, T; Iimuro, M; Yukawa, T; Takayama, T; Sato, Y; Lee, K; Kitamura, S; Mizuno, M; Sano, Y; Gondo, N; Sugimoto, K; Kusunoki, M; Goto, C; Matsuura, N; Sakai, T; Wakabayashi, K				Ishikawa, Hideki; Mutoh, Michihiro; Suzuki, Sadao; Tokudome, Shinkan; Saida, Yoshihisa; Abe, Takashi; Okamura, Shozo; Tajika, Masahiro; Joh, Takashi; Tanaka, Shinji; Kudo, Shin-ei; Matsuda, Takahisa; Iimuro, Masaki; Yukawa, Tomomi; Takayama, Tetsuji; Sato, Yasushi; Lee, Kyowon; Kitamura, Shinji; Mizuno, Motowo; Sano, Yasushi; Gondo, Nobuhisa; Sugimoto, Kenji; Kusunoki, Masato; Goto, Chiho; Matsuura, Nariaki; Sakai, Toshiyuki; Wakabayashi, Keiji			The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial	GUT			English	Article							ANTIINFLAMMATORY DRUGS; ADENOMA RECURRENCE; CANCER INCIDENCE; COLON-CANCER; RISK; CHEMOPREVENTION; METAANALYSIS; ACTIVATION; APOPTOSIS; PATHWAY	Objective To evaluate the influence of low-dose, enteric-coated aspirin tablets (100 mg/day for 2 years) on colorectal tumour recurrence in Asian patients with single/multiple colorectal tumours excised by endoscopy. Design A double-blinded, randomised, placebo-controlled multicentre clinical trial was conducted. Participants 311 subjects with single/multiple colorectal adenomas and adenocarcinomas excised by endoscopy were enrolled in the study (152 patients in the aspirin group and 159 patients in the placebo group). Enrolment began at the hospitals (n=19) in 2007 and was completed in 2009. Results The subjects treated with aspirin displayed reduced colorectal tumourigenesis and primary endpoints with an adjusted OR of 0.60 (95% CI 0.36 to 0.98) compared with the subjects in the placebo group. Subgroup analysis revealed that subjects who were nonsmokers, defined as those who had smoked in the past or who had never smoked, had a marked reduction in the number of recurrent tumours in the aspirin-treated group. The adjusted OR for aspirin treatment in nonsmokers was 0.37 (CI 0.21 to 0.68, p<0.05). Interestingly, the use of aspirin in smokers resulted in an increased risk, with an OR of 3.44. In addition, no severe adverse effects were observed in either group. Conclusions Low-dose, enteric-coated aspirin tablets reduced colorectal tumour recurrence in an Asian population. The results are consistent with those obtained from other randomised controlled trials in Western countries.	[Ishikawa, Hideki; Sakai, Toshiyuki] Kyoto Prefectural Univ Med, Dept Mol Targeting Canc Prevent, Kyoto, Japan; [Mutoh, Michihiro] Natl Canc Ctr, Res Inst, Div Canc Prevent Res, Tokyo 1040045, Japan; [Suzuki, Sadao; Tokudome, Shinkan] Nagoya City Univ, Dept Publ Hlth, Grad Sch Med Sci, Nagoya, Aichi, Japan; [Tokudome, Shinkan] Natl Inst Hlth & Nutr, Tokyo 162, Japan; [Saida, Yoshihisa] Toho Univ, Ohashi Med Ctr, Tokyo, Japan; [Abe, Takashi] Takarazuka Municipal Hosp, Dept Gastroenterol, Takarazuka, Hyogo, Japan; [Okamura, Shozo] Toyohashi Municipal Hosp, Dept Internal Med, Toyohashi, Aichi, Japan; [Tajika, Masahiro] Aichi Canc Ctr Hosp, Dept Endoscopy, Nagoya, Aichi, Japan; [Joh, Takashi] Nagoya City Univ, Dept Gastroenterol & Metab, Grad Sch Med Sci, Aichi, Japan; [Tanaka, Shinji] Hiroshima Univ Hosp, Dept Endoscopy, Hiroshima, Japan; [Kudo, Shin-ei] Showa Univ, Northern Yokohama Hosp, Digest Dis Ctr, Sch Med, Shinagawa, Kanagawa, Japan; [Matsuda, Takahisa] Natl Canc Ctr, Endoscopy Div, Tokyo, Japan; [Iimuro, Masaki; Yukawa, Tomomi] Higashisumiyoshi Morimoto Hosp, Osaka, Japan; [Iimuro, Masaki] Hyogo Coll Med, Dept Lower Gastroenterol, Nishinomiya, Hyogo, Japan; [Takayama, Tetsuji] Univ Tokushima, Dept Gastroenterol & Oncol, Inst Hlth Biosci, Grad Sch, Tokushima 770, Japan; [Sato, Yasushi] Sapporo Med Univ, Dept Internal Med 4, Sch Med, Sapporo, Hokkaido, Japan; [Lee, Kyowon] Moriguchi Keijinkai Hosp, Osaka, Japan; [Kitamura, Shinji] Sakai City Hosp, Dept Gastroenterol, Osaka, Japan; [Mizuno, Motowo] Hiroshima City Hosp, Dept Internal Med, Hiroshima, Japan; [Sano, Yasushi] Natl Canc Ctr Hosp East, Div Digest Endoscopy & Gastrointestinal Oncol, Chiba, Japan; [Gondo, Nobuhisa] Kimura Hosp, Fukuoka, Hyogo, Japan; [Sugimoto, Kenji] Sugimoto Kenji Clin, Osaka, Japan; [Kusunoki, Masato] Mie Univ, Grad Sch Med, Inst Life Sci, Dept Gastrointestinal & Pediat Surg,Div Reparat M, Tsu, Mie, Japan; [Goto, Chiho] Nagoya Bunri Univ, Dept Hlth & Nutr, Inazawa, Aichi, Japan; [Matsuura, Nariaki] Osaka Univ, Dept Funct Diagnost Sci, Grad Sch Med, Osaka, Japan; [Wakabayashi, Keiji] Univ Shizuoka, Grad Div Nutr & Environm Sci, Shizuoka 4228526, Japan	Mutoh, M (reprint author), Natl Canc Ctr, Res Inst, Div Canc Prevent Res, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	mimutoh@ncc.go.jp			Ministry of Health, Labour and Welfare of Japan [H22-3jigann-ippan-014]	This work was supported by Grants-in-Aid for the Third-Term Comprehensive 10-Year Strategy for Cancer Control from the Ministry of Health, Labour and Welfare of Japan (H22-3jigann-ippan-014).	Chan AT, 2012, CANCER PREV RES, V5, P164, DOI 10.1158/1940-6207.CAPR-11-0391; Gu Q, 2005, CARCINOGENESIS, V26, P541, DOI 10.1093/carcin/bgh345; Cole BF, 2009, J NATL CANCER I, V101, P256, DOI 10.1093/jnci/djn485; Uemura N, 2014, J GASTROENTEROL, V49, P814, DOI 10.1007/s00535-013-0839-5; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; LANZA FL, 1980, NEW ENGL J MED, V303, P136, DOI 10.1056/NEJM198007173030305; Benamouzig R, 2003, GASTROENTEROLOGY, V125, P328, DOI 10.1016/S0016-5085(03)00887-4; Jacobs EJ, 2007, J NATL CANCER I, V99, P608, DOI 10.1093/jnci/djk132; Greving JP, 2008, CIRCULATION, V117, P2875, DOI 10.1161/CIRCULATIONAHA.107.735340; Burn J, 2011, CANCER PREV RES, V4, P655, DOI 10.1158/1940-6207.CAPR-11-0106; Pan MR, 2008, CELL SIGNAL, V20, P1134, DOI 10.1016/j.cellsig.2008.02.004; Martinez ME, 2003, P NATL ACAD SCI USA, V100, P7859, DOI 10.1073/pnas.1332465100; Hawley SA, 2012, SCIENCE, V336, P918, DOI 10.1126/science.1215327; Zimmermann KC, 2000, NEOPLASIA, V2, P505, DOI 10.1038/sj.neo.7900120; Mirkhel A, 2006, AM J CARDIOL, V98, P577, DOI 10.1016/j.amjcard.2006.03.029; Ishikawa H, 2013, CANCER MED-US, V2, P50, DOI 10.1002/cam4.46; Bos CL, 2006, ONCOGENE, V25, P6447, DOI 10.1038/sj.onc.1209658; Ruffin MT, 1997, J NATL CANCER I, V89, P1152, DOI 10.1093/jnci/89.15.1152; Li WJ, 2011, CHINESE MED J-PEKING, V124, P1569, DOI 10.3760/cma.j.issn.0366-6999.2011.10.024; Lanas A, 2011, CLIN GASTROENTEROL H, V9, P762, DOI 10.1016/j.cgh.2011.05.020; Baron JA, 2003, NEW ENGL J MED, V348, P891, DOI 10.1056/NEJMoa021735; Babbar N, 2006, BIOCHEM J, V394, P317, DOI 10.1042/BJ20051298; FARRELL B, 1991, J NEUROL NEUROSUR PS, V54, P1044, DOI 10.1136/jnnp.54.12.1044; Leung FW, 2008, DIGEST DIS SCI, V53, P2604, DOI 10.1007/s10620-007-0178-6; Patrono C, 2001, CLIN EXP RHEUMATOL, V19, pS45; Pilotto A, 2004, ALIMENT PHARM THERAP, V20, P1091, DOI 10.1111/j.1365-2036.2004.02246.x; Rothwell PM, 2010, LANCET, V376, P1741, DOI 10.1016/S0140-6736(10)61543-7; Tokudome Shinkan, 2004, Asian Pac J Cancer Prev, V5, P40	28	17	17	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0017-5749	1468-3288		GUT	Gut	NOV	2014	63	11					1755	1759		10.1136/gutjnl-2013-305827		5	Gastroenterology & Hepatology	Gastroenterology & Hepatology	AR9YI	WOS:000343933000018		
J	Yanase, T; Tsuneki, I; Tamura, M; Kurabayashi, T				Yanase, Toru; Tsuneki, Ikunosuke; Tamura, Masaki; Kurabayashi, Takumi			Relief of uterine bleeding by cyclic administration of dienogest for endometriosis	GYNECOLOGICAL ENDOCRINOLOGY			English	Article						Cyclic administration; dienogest; drug adherence; endometriosis; lessen uterine bleeding	AGONIST TREATMENT; STROMAL CELLS	Objective: This study assessed the relief of uterine bleeding and clinical symptoms during cyclic administration of dienogest for the treatment of endometriosis. Methods: In total, 25 patients undergoing ovarian cyst enucleation and given dienogest participated in this study. Dienogest 2 mg/day was administered for 3 weeks, and the drug was then withdrawn for 1 week (cyclic administration of dienogest). This 4-week cycle was repeated six times. Patients' records were prospectively analyzed for the number of days on which any uterine bleeding occurred, as well as menstrual pain before and after the start of dienogest administration were evaluated with a view to using the data obtained herein as the basis. Results: During the period of cyclic administration of dienogest, uterine bleeding occurred on 5.8 to 7.7 days per 4-week period on an average through cycles. Of uterine bleeding episodes, menstruation-like uterine bleeding was present in about 80% of patients. The visual analog scale (VAS) value for menstrual pain significantly decreased from 3.8 before dienogest administration after surgery to 1.5 at the completion of cycle 1, VAS remained low thereafter. Conclusion: These results raise the possibility that cyclic administration of dienogest may relieve lessen uterine bleeding, a major adverse event and menstrual pain.	[Yanase, Toru; Tsuneki, Ikunosuke; Tamura, Masaki; Kurabayashi, Takumi] Niigata City Gen Hosp, Dept Obstet & Gynecol, Niigata 9501197, Japan	Yanase, T (reprint author), Niigata City Gen Hosp, Dept Obstet & Gynecol, Chuo Ku, 463-7 Shumoku, Niigata 9501197, Japan.	toyanase@gmail.com					Strowitzki T, 2010, HUM REPROD, V25, P633, DOI 10.1093/humrep/dep469; Fu L, 2008, FERTIL STERIL, V89, P1344, DOI 10.1016/j.fertnstert.2007.03.042; Yamanaka K, 2012, FERTIL STERIL, V97, P477, DOI 10.1016/j.fertnstert.2011.11.005; Sasagawa S, 2008, STEROIDS, V73, P222, DOI 10.1016/j.steroids.2007.10.003; Momoeda M, 2009, J OBSTET GYNAECOL RE, V35, P1069, DOI 10.1111/j.1447-0756.2009.01076.x; Kohler G, 2010, INT J GYNECOL OBSTET, V108, P21, DOI 10.1016/j.ijgo.2009.08.020; Irahara Minoru, 2007, Reproductive Medicine and Biology, V6, P223, DOI 10.1111/j.1447-0578.2007.00189.x; Barbieri RL, 1992, AM J OBSTET GYNECOL, V166, P645; Barbieri RL, 1998, J REPROD MED, V43, P287; Harada T, 2008, FERTIL STERIL, V91, P675; Jee BC, 2009, FERTIL STERIL, V91, P40, DOI 10.1016/j.fertnstert.2007.11.027; Kitawaki J, 2011, EUR J OBSTET GYN R B, V157, P212, DOI 10.1016/j.ejogrb.2011.03.012; Momoeda M, 2007, JPN PHARMACOL THER, V35, P768; Moore C, 1999, CLIN DRUG INVEST, V18, P271, DOI 10.2165/00044011-199918040-00003; Petraglia F, 2011, ARCH GYNECOL OBSTET, V17, P1941; Sasagawa S, 2008, J ENDOCRINOL INVEST, V31, P636; Vercellini P, 2008, AM J OBSTET GYNECOL, V198	17	0	0	INFORMA HEALTHCARE	NEW YORK	52 VANDERBILT AVE, NEW YORK, NY 10017 USA	0951-3590	1473-0766		GYNECOL ENDOCRINOL	Gynecol. Endocrinol.	NOV	2014	30	11					804	807		10.3109/09513590.2014.943717		4	Endocrinology & Metabolism; Obstetrics & Gynecology	Endocrinology & Metabolism; Obstetrics & Gynecology	AS5WC	WOS:000344336400011		
J	Hah, JH; Zhao, M; Pickering, CR; Frederick, MJ; Andrews, GA; Jasser, SA; Fooshee, DR; Milas, ZL; Galer, C; Sano, D; William, WN; Kim, E; Heymach, J; Byers, LA; Papadimitrakopoulou, V; Myers, JN				Hah, J. Hun; Zhao, Mei; Pickering, Curtis R.; Frederick, Mitchell J.; Andrews, Genevieve A.; Jasser, Samar A.; Fooshee, David R.; Milas, Zvonimir L.; Galer, Chad; Sano, Daisuke; William, William N., Jr.; Kim, Edward; Heymach, John; Byers, Lauren A.; Papadimitrakopoulou, Vali; Myers, Jeffrey N.			HRAS mutations and resistance to the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in head and neck squamous cell carcinoma cells	HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK			English	Article						epidermal growth factor receptor; erlotinib; HRAS; resistance; head and neck squamous cell carcinoma	RAS ONCOGENE MUTATION; TARGETED THERAPY; KRAS MUTATIONS; CANCER CELLS; GEFITINIB; PATHWAYS; CETUXIMAB; ACTIVATION; LINES; AKT	BackgroundThe purpose of this study was to identify mechanisms of innate resistance to an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, erlotinib, in a panel of head and neck squamous cell carcinoma (HNSCC) cell lines. Specifically, we analyzed the role of HRAS mutations in erlotinib resistance. MethodsErlotinib sensitivity was determined by methyl thiazolyl-tetrazolium (MTT) assays. Molecular signaling pathways and somatic mutations were examined. Changes in sensitivity after modulation of HRAS expression were evaluated. ResultsAll 7 cell lines were wild-type for EGFR and KRAS regardless of erlotinib sensitivity; however, 1 erlotinib-resistant cell line (HN31) harbored an HRAS G12D mutation. Downregulation of HRAS expression by small interfering RNA (siRNA) or short hairpin RNA (shRNA) in HN31 led to increased erlotinib sensitivity in vitro and in vivo. Transfection of activating HRAS-mutant (G12D and G12V) constructs into erlotinib-sensitive cell lines made them more resistant to erlotinib. ConclusionActivating HRAS mutations can confer erlotinib resistance in an HRAS mutant HNSCC cell line. (c) 2014 Wiley Periodicals, Inc. Head Neck 36: 1547-1554, 2014	[Hah, J. Hun; Zhao, Mei; Pickering, Curtis R.; Frederick, Mitchell J.; Andrews, Genevieve A.; Jasser, Samar A.; Fooshee, David R.; Milas, Zvonimir L.; Galer, Chad; Sano, Daisuke; Myers, Jeffrey N.] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA; [William, William N., Jr.; Kim, Edward; Heymach, John; Byers, Lauren A.; Papadimitrakopoulou, Vali] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; [Hah, J. Hun] Seoul Natl Univ, Coll Med, Seoul Natl Univ Hosp, Dept Otolaryngol Head & Neck Surg, Seoul, South Korea; [Hah, J. Hun] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea; [Andrews, Genevieve A.] Penn State Milton S Hershey Med Ctr, Div Otolaryngol Head & Neck Surg, Hershey, PA USA; [Fooshee, David R.] Univ Calif Irvine, Dept Informat & Comp Sci, Inst Genom & Bioinformat, Irvine, CA 92717 USA; [Milas, Zvonimir L.] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg Oncol, Orlando, FL USA; [Galer, Chad] Indiana Univ, Richard L Roudebush VAMC Dept Otolaryngol Head &, Indianapolis, IN 46204 USA; [Sano, Daisuke] Yokohama City Univ, Grad Sch Med, Dept Biol & Funct Head & Neck, Yokohama, Kanagawa 232, Japan	Myers, JN (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Unit 1445, 1515 Holcombe Blvd, Houston, TX 77030 USA.	jmyers@mdanderson.org	Hah, Jeong Hun/A-6084-2015; 	Hah, Jeong Hun/0000-0002-5110-012X; Sano, Daisuke/0000-0002-7686-4724	National Institutes of Health (NIH) [P50CA097007]; NIH [CA016672]; University of Texas MD Anderson Cancer Center PANTHEON program; TRIUMPH Fellowship; GSK Translational Research Fellowship; NIH via National Research Science Award Research Training Grant [T32CA060374]	Contract grant sponsor: This work was supported by National Institutes of Health (NIH) Specialized Program of Research Excellence Grant P50CA097007, NIH Cancer Center Support Grant CA016672, The University of Texas MD Anderson Cancer Center PANTHEON program, a TRIUMPH Fellowship, a GSK Translational Research Fellowship, and the NIH via National Research Science Award Research Training Grant T32CA060374 (National Cancer Institute).	Lievre A, 2008, J CLIN ONCOL, V26, P374, DOI 10.1200/JCO.2007.12.5906; Normanno N, 2006, J CELL PHYSIOL, V207, P420, DOI 10.1002/jcp.20588; Zhao M, 2011, CLIN CANCER RES, V17, P7248, DOI 10.1158/1078-0432.CCR-11-0690; Yamatodani T, 2009, J CANCER RES CLIN, V135, P395, DOI 10.1007/s00432-008-0475-2; Scaltriti M, 2006, CLIN CANCER RES, V12, P5268, DOI 10.1158/1078-0432.CCR-06-1554; Cohen EEW, 2009, ORAL ONCOL, V45, pE155, DOI 10.1016/j.oraloncology.2009.05.637; ANDERSON JA, 1992, J OTOLARYNGOL, V21, P321; ANDERSON JA, 1994, ARCH OTOLARYNGOL, V120, P755; Stewart JSW, 2009, J CLIN ONCOL, V27, P1864, DOI 10.1200/JCO.2008.17.0530; Sheu JJC, 2009, CANCER RES, V69, P2568, DOI 10.1158/0008-5472.CAN-08-3199; Agrawal N, 2011, SCIENCE, V333, P1154, DOI 10.1126/science.1206923; Janmaat ML, 2003, CLIN CANCER RES, V9, P2316; DesLuca A, 2012, EXPERT OPIN THER S2, V16, pS17; Forbes S. A., 2008, CURR PROTOC HUM GENE, DOI DOI 10.1002/0471142905.HG1011S57; Frederick MJ, 2011, AM J PATHOL, V178, P548, DOI 10.1016/j.ajpath.2010.10.044; Lea IA, 2007, CARCINOGENESIS, V28, P1851, DOI 10.1093/carcin/bgm176; Luwor RB, 2011, CANCER LETT, V306, P85, DOI 10.1016/j.canlet.2011.02.035; Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sano D, 2011, HEAD NECK-J SCI SPEC, V33, P349, DOI 10.1002/hed.21455; William Jr WN, 2011, J CLIN ONCOL S, V29	21	2	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1043-3074	1097-0347		HEAD NECK-J SCI SPEC	Head Neck-J. Sci. Spec. Head Neck	NOV	2014	36	11					1547	1554		10.1002/hed.23499		8	Otorhinolaryngology; Surgery	Otorhinolaryngology; Surgery	AR9XB	WOS:000343929000008		
J	Kano, S; Hayashi, R; Homma, A; Matsuura, K; Kato, K; Kawabata, K; Monden, N; Hasegawa, Y; Onitsuka, T; Fujimoto, Y; Iwae, S; Okami, K; Matsuzuka, T; Yoshino, K; Fujii, M				Kano, Satoshi; Hayashi, Ryuichi; Homma, Akihiro; Matsuura, Kazuto; Kato, Kengo; Kawabata, Kazuyoshi; Monden, Nobuya; Hasegawa, Yasuhisa; Onitsuka, Tetsuro; Fujimoto, Yasushi; Iwae, Shigemichi; Okami, Kenji; Matsuzuka, Takashi; Yoshino, Kunitoshi; Fujii, Masato			Effect of local extension sites on survival in locally advanced maxillary sinus cancer	HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK			English	Article						maxillary sinus cancer; total maxillectomy; radiation and intra-arterial cisplatin (RADPLAT); local extension site; hard palate	SQUAMOUS-CELL CARCINOMA; HIGH-DOSE CISPLATIN; PARANASAL SINUSES; PROGNOSTIC-FACTORS; NASAL CAVITY; CHEMOTHERAPY; RADIOTHERAPY; NECK; HEAD; INFUSION	BackgroundWe analyzed the effects of local extension sites on survival in patients with locally advanced maxillary sinus cancer. MethodsThe criteria for inclusion in this study were as follows: (1) previously untreated maxillary sinus cancer; (2) squamous cell carcinoma; (3) T4 disease; and (4) curative-intent treatment. The data for 118 patients were obtained from 28 institutions across Japan and analyzed for overall survival and local control rates by local extension site. ResultsSites with a poor prognosis included the cribriform plate, dura, nasopharynx, middle cranial fossa, and cranial nerves other than V2. There was a significant correlation among these sites, except for the cranial nerves. Additionally, the hard palate was the only site that correlated with nodal involvement and showed a poor treatment outcome. ConclusionEven in cases presenting with similar T4 maxillary sinus cancer, treatment should be performed in consideration of the local extension site. (c) 2013 Wiley Periodicals, Inc. Head Neck 36: 1567-1572, 2014	[Kano, Satoshi; Homma, Akihiro] Hokkaido Univ, Grad Sch Med, Dept Otolaryngol Head & Neck Surg, Sapporo, Hokkaido 0608638, Japan; [Hayashi, Ryuichi] Natl Canc Ctr Hosp East, Div Head & Neck Surg, Kashiwa, Chiba, Japan; [Matsuura, Kazuto] Miyagi Canc Ctr, Div Head & Neck Surg, Sendai, Miyagi, Japan; [Kato, Kengo] Tohoku Univ, Sch Med, Dept Otolaryngol Head & Neck Surg, Sendai, Miyagi 980, Japan; [Kawabata, Kazuyoshi] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Head & Neck Oncol, Tokyo, Japan; [Monden, Nobuya] Natl Shikoku Canc Ctr, Dept Otorhinolaryngol Head & Neck Surg, Matsuyama, Ehime, Japan; [Hasegawa, Yasuhisa] Aichi Canc Ctr, Dept Head & Neck Surg, Nagoya, Aichi 464, Japan; [Onitsuka, Tetsuro] Shizuoka Canc Ctr, Dept Head & Neck Surg, Shizuoka, Japan; [Fujimoto, Yasushi] Nagoya Univ, Grad Sch Med, Dept Otolaryngol, Nagoya, Aichi 4648601, Japan; [Iwae, Shigemichi] Hyogo Canc Ctr, Dept Head & Neck Surg, Akashi, Hyogo, Japan; [Okami, Kenji] Tokai Univ, Dept Otolaryngol, Isehara, Kanagawa, Japan; [Matsuzuka, Takashi] Fukushima Med Univ, Dept Otolaryngol, Fukushima, Japan; [Yoshino, Kunitoshi] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Otolaryngol Head & Neck Surg, Osaka, Japan; [Fujii, Masato] Natl Tokyo Med Ctr, Dept Otorhinolaryngol, Tokyo, Japan	Homma, A (reprint author), Hokkaido Univ, Grad Sch Med, Dept Otolaryngol Head & Neck Surg, Kita Ku, Kita 15,Nishi 7, Sapporo, Hokkaido 0608638, Japan.	ak-homma@med.hokudai.ac.jp			Foundation for Promotion of Cancer Research	Contract grant sponsor: The Foundation for Promotion of Cancer Research	Homma A, 2009, CANCER, V115, P4705, DOI 10.1002/cncr.24515; PACCAGNELLA A, 1994, J NATL CANCER I, V86, P265, DOI 10.1093/jnci/86.4.265; Airoldi M, 2009, ONCOLOGY-BASEL, V76, P262, DOI 10.1159/000206140; Morris LGT, 2011, HEAD NECK-J SCI SPEC, V33, P824, DOI 10.1002/hed.21547; Bhattacharyya N, 2003, J ORAL MAXIL SURG, V61, P1016, DOI 10.1016/S0278-2391(03)00313-6; Dulguerov P, 2001, CANCER, V92, P3012, DOI 10.1002/1097-0142(20011215)92:12<3012::AID-CNCR10131>3.0.CO;2-E; Cantu G, 2008, ARCH OTOLARYNGOL, V134, P170, DOI 10.1001/archoto.2007.30; ALSARRAF M, 1987, CANCER, V59, P259, DOI 10.1002/1097-0142(19870115)59:2<259::AID-CNCR2820590214>3.0.CO;2-1; Carrillo JF, 2005, EJSO, V31, P1206, DOI 10.1016/j.ejso.2005.04.001; Merlano M, 1996, J NATL CANCER I, V88, P583, DOI 10.1093/jnci/88.9.583; Japan Society for Head and Neck Cancer, 2007, JPN J HEAD NECK CA S, V33, P90; Kanoto M, 2010, AM J NEURORADIOL, V31, P1390, DOI 10.3174/ajnr.A2082; McMahon JD, 2013, BRIT J ORAL MAX SURG, V51, P389, DOI 10.1016/j.bjoms.2012.09.018; Nishino H, 2003, LARYNGOSCOPE, V113, P1064, DOI 10.1097/00005537-200306000-00028; Robbins KT, 2000, ARCH OTOLARYNGOL, V126, P265; SATO Y, 1970, CANCER, V25, P571, DOI 10.1002/1097-0142(197003)25:3<571::AID-CNCR2820250312>3.0.CO;2-N	16	2	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1043-3074	1097-0347		HEAD NECK-J SCI SPEC	Head Neck-J. Sci. Spec. Head Neck	NOV	2014	36	11					1567	1572		10.1002/hed.23483		6	Otorhinolaryngology; Surgery	Otorhinolaryngology; Surgery	AR9XB	WOS:000343929000011		
J	Tsutsumi, N; Kojima, Y; Nishida, K; Maeno, K; Kakutani, K; Kawakami, F; Kanzawa, M; Itoh, T; Otsuki, N; Nibu, KI				Tsutsumi, Nao; Kojima, Yasutaka; Nishida, Kotaro; Maeno, Koichiro; Kakutani, Kenichiro; Kawakami, Fumi; Kanzawa, Maki; Itoh, Tomoo; Otsuki, Naoki; Nibu, Ken-ichi			Surgical treatment for recurrent solitary fibrous tumor invading atlas	HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK			English	Article						solitary fibrous tumor; atlas; surgical treatment; recurrent; combined approach	PARAPHARYNGEAL SPACE; ANTERIOR APPROACH; DIAGNOSIS; HEAD; NECK	BackgroundSolitary fibrous tumor (SFT), a rare neoplasm, usually originates in the pleura. Extrapleural SFTs occasionally occur in the head and neck. MethodsIn this study, the extirpation of a rare case of recurrent SFT invading the atlas is discussed. ResultsTen years after surgical resection of an SFT in the right parapharyngeal space, the patient returned with a complaint of swelling sensation in the right neck. MRI and CT showed an enhanced lobulated mass invading the right lateral C1 vertebral body and canal and encasing the right vertebral artery. Extirpation of the recurrent tumor with a combined transcervical and midline posterior approach was successful. The surgical margin was negative for cancer and the postoperative course was uneventful. ConclusionAlthough an SFT is generally benign, recurrence can occur even after several years, therefore, careful long-term follow-up is essential for early detection. A combined transcervical and midline posterior approach proved useful for resection of the atlas body. (c) 2014 Wiley Periodicals, Inc. Head Neck 36: E121-E124, 2014	[Tsutsumi, Nao; Kojima, Yasutaka; Otsuki, Naoki; Nibu, Ken-ichi] Kobe Univ Hosp, Dept Otolaryngol Head & Neck Surg, Kobe, Hyogo, Japan; [Nishida, Kotaro; Maeno, Koichiro; Kakutani, Kenichiro] Kobe Univ Hosp, Dept Orthoped Surg, Kobe, Hyogo, Japan; [Kawakami, Fumi; Kanzawa, Maki; Itoh, Tomoo] Kobe Univ Hosp, Dept Diagnost Pathol, Kobe, Hyogo, Japan	Tsutsumi, N (reprint author), Kobe Univ, Nishikobe Med Ctr, Dept Otolaryngol Head & Neck Surg, Nishi Ku, 5-7-1 Kojidai, Kobe, Hyogo 6512273, Japan.	n223@nmc-kobe.org					Abe T, 2005, AURIS NASUS LARYNX, V32, P285, DOI 10.1016/j.anl.2005.01.003; Abdullah KG, 2012, NEUROSURGERY, V70, P202, DOI 10.1227/NEU.0b013e31824042e6; Zhu Q, 2012, ONCOL LETT, V3, P721, DOI 10.3892/ol.2012.550; Ayoub B, 2011, TURK NEUROSURG, V21, P494, DOI [10.5137/1019-5149.JTN .4277-11.2, 10.5137/1019-5149.JTN.4277-11.2]; Bowe SN, 2012, LARYNGOSCOPE, V122, P1748, DOI 10.1002/lary.23350; Daigeler Adrien, 2006, BMC Surg, V6, P10, DOI 10.1186/1471-2482-6-10; HABAL MB, 1972, J NEUROSURG, V37, P113, DOI 10.3171/jns.1972.37.1.0113; Hashimoto D, 2006, OTOLARYNG HEAD NECK, V134, P535, DOI 10.1016/j.otohns.2005.03.072; Iwasaki Y, 1999, NEUROSURGERY, V44, P655, DOI 10.1097/00006123-199903000-00123; Janjua A, 2011, SKULL BASE-INTERD AP, V21, P129, DOI 10.1055/s-0031-1275259; Jungehuelsing M, 2010, LARYNGOSCOPE, V120, P1557, DOI 10.1002/lary.20872; Pipolo C, 2010, ACTA OTORHINOLARYNGO, V30, P160; Ridder GJ, 2007, ANN OTO RHINOL LARYN, V116, P265; Sbrocca M, 2009, ACTA OTORHINOLARYNGO, V29, P41; Wakisaka N, 2009, AURIS NASUS LARYNX, V36, P367, DOI 10.1016/j.anl.2008.05.010	15	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1043-3074	1097-0347		HEAD NECK-J SCI SPEC	Head Neck-J. Sci. Spec. Head Neck	NOV	2014	36	11					E121	E124		10.1002/hed.23628		4	Otorhinolaryngology; Surgery	Otorhinolaryngology; Surgery	AR9XB	WOS:000343929000004		
J	Kurth, MJ; Yokoi, T; Gershwin, ME				Kurth, Mark J.; Yokoi, Tsuyoshi; Gershwin, M. Eric			Halothane-Induced Hepatitis: Paradigm or Paradox for Drug-Induced Liver Injury	HEPATOLOGY			English	Editorial Material							THYMIC STROMAL LYMPHOPOIETIN; LIPID-PEROXIDATION; CELLS; METABOLISM; MICE		[Kurth, Mark J.] Univ Calif Davis, Dept Chem, Davis, CA 95616 USA; [Yokoi, Tsuyoshi] Nagoya Univ, Grad Sch Med, Dept Drug Safety Sci, Nagoya, Aichi 4648601, Japan; [Gershwin, M. Eric] Univ Calif Davis, Sch Med, Div Rheumatol Allergy & Clin Immunol, Davis, CA 95616 USA	Gershwin, ME (reprint author), Univ Calif Davis, Sch Med, Div Rheumatol Allergy & Clin Immunol, 451 Hlth Sci Dr,Suite 6510, Davis, CA 95616 USA.	megershwin@ucdavis.edu					Siracusa MC, 2013, J ALLERGY CLIN IMMUN, V132, P789, DOI 10.1016/j.jaci.2013.07.046; Moon PD, 2011, EUR J PHARMACOL, V671, P128, DOI 10.1016/j.ejphar.2011.09.163; Kobayashi E, 2009, TOXICOL SCI, V111, P302, DOI 10.1093/toxsci/kfp165; Kashyap M, 2011, J IMMUNOL, V187, P1207, DOI 10.4049/jimmunol.1100355; Bogdanos DP, 2012, J AUTOIMMUN, V38, pJ156, DOI 10.1016/j.jaut.2011.11.003; Endo S, 2014, TOXICOLOGY, V319, P75, DOI 10.1016/j.tox.2014.02.011; Lin J, 2013, CELL PHYSIOL BIOCHEM, V31, P305, DOI 10.1159/000343369; Ziegler SF, 2013, ADV PHARMACOL, V66, P129, DOI 10.1016/B978-0-12-404717-4.00004-4; Proctor WR, 2013, HEPATOLOGY, V57, P2026, DOI 10.1002/hep.26196; Bogiatzi SI, 2012, J ALLERGY CLIN IMMUN, V130, P233, DOI 10.1016/j.jaci.2012.04.038; Bourdi M, 1996, CHEM RES TOXICOL, V9, P1159, DOI 10.1021/tx960083q; Cheng LL, 2010, BIOCHEM PHARMACOL, V80, P255, DOI 10.1016/j.bcp.2010.03.025; Feng DC, 2009, BIOCHEM PHARMACOL, V77, P277, DOI 10.1016/j.bcp.2008.09.028; Furst SM, 1997, INT ARCH ALLERGY IMM, V114, P46; JENNER MA, 1990, ANAESTH INTENS CARE, V18, P395; Kharasch ED, 2000, EUR J CLIN PHARMACOL, V55, P853, DOI 10.1007/s002280050707; Lee HC, 2013, HEPATOLOGY, V57, P1314, DOI 10.1002/hep.26128; Minoda Y, 2001, ANESTHESIOLOGY, V95, P509, DOI 10.1097/00000542-200108000-00037; Proctor WR, 2014, HEPATOLOGY, V60, P1741, DOI 10.1002/hep.27169; RAY DC, 1991, BRIT J ANAESTH, V67, P84, DOI 10.1093/bja/67.1.84; You Q, 2006, HEPATOLOGY, V44, P1421, DOI 10.1002/hep.21425	21	3	3	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0270-9139	1527-3350		HEPATOLOGY	Hepatology	NOV	2014	60	5					1473	1475		10.1002/hep.27253		3	Gastroenterology & Hepatology	Gastroenterology & Hepatology	AS6CM	WOS:000344352400006		
J	Shirasaki, T; Honda, M; Shimakami, T; Murai, K; Shiomoto, T; Okada, H; Takabatake, R; Tokumaru, A; Sakai, Y; Yamashita, T; Lemon, SM; Murakami, S; Kaneko, S				Shirasaki, Takayoshi; Honda, Masao; Shimakami, Tetsuro; Murai, Kazuhisa; Shiomoto, Takayuki; Okada, Hikari; Takabatake, Riuta; Tokumaru, Akihiro; Sakai, Yoshio; Yamashita, Taro; Lemon, Stanley M.; Murakami, Seishi; Kaneko, Shuichi			Impaired Interferon Signaling in Chronic Hepatitis C Patients With Advanced Fibrosis via the Transforming Growth Factor Beta Signaling Pathway	HEPATOLOGY			English	Article							HEPATOCELLULAR-CARCINOMA; THERAPY; LIVER; EXPRESSION; RIBAVIRIN; PROGRAM; CELLS; MTOR	Malnutrition in the advanced fibrosis stage of chronic hepatitis C (CH-C) impairs interferon (IFN) signaling by inhibiting mammalian target of rapamycin complex 1 (mTORC1) signaling. However, the effect of profibrotic signaling on IFN signaling is not known. Here, the effect of transforming growth factor (TGF)-beta signaling on IFN signaling and hepatitis C virus (HCV) replication was examined in Huh-7.5 cells by evaluating the expression of forkhead box O3A (Foxo3a), suppressor of cytokine signaling 3 (Socs3), c-Jun, activating transcription factor 2, ras homolog enriched in brain, and mTORC1. The findings were confirmed in liver tissue samples obtained from 91 patients who received pegylated-IFN and ribavirin combination therapy. TGF-beta signaling was significantly up-regulated in the advanced fibrosis stage of CH-C. A significant positive correlation was observed between the expression of TGF-beta 2 and mothers against decapentaplegic homolog 2 (Smad2), Smad2 and Foxo3a, and Foxo3a and Socs3 in the liver of CH-C patients. In Huh-7.5 cells, TGF-beta 1 activated the Foxo3a promoter through an AP1 binding site; the transcription factor c-Jun was involved in this activation. Foxo3a activated the Socs3 promoter and increased HCV replication. TGF-beta 1 also inhibited mTORC1 and IFN signaling. Interestingly, c-Jun and TGF-beta signaling was up-regulated in treatment-resistant IL28B minor genotype patients (TG/GG at rs8099917), especially in the early fibrosis stage. Branched chain amino acids or a TGF-beta receptor inhibitor canceled these effects and showed an additive effect on the anti-HCV activity of direct-acting antiviral drugs (DAAs). Conclusion: Blocking TGF-beta signaling could potentiate the antiviral efficacy of IFN- and/ or DAA-based treatment regimens and would be useful for the treatment of difficult-to-cure CH-C patients.	[Shirasaki, Takayoshi; Honda, Masao; Shimakami, Tetsuro; Murai, Kazuhisa; Shiomoto, Takayuki; Okada, Hikari; Takabatake, Riuta; Tokumaru, Akihiro; Sakai, Yoshio; Yamashita, Taro; Murakami, Seishi; Kaneko, Shuichi] Kanazawa Univ, Grad Sch Med, Dept Gastroenterol, Kanazawa, Ishikawa 9208641, Japan; [Shirasaki, Takayoshi; Honda, Masao; Murai, Kazuhisa; Shiomoto, Takayuki] Kanazawa Univ, Grad Sch Hlth Med, Dept Adv Med Technol, Kanazawa, Ishikawa 9208641, Japan; [Lemon, Stanley M.] Univ N Carolina, Sch Med, Div Infect Dis, Chapel Hill, NC USA	Honda, M (reprint author), Kanazawa Univ, Grad Sch Med, Dept Gastroenterol, Takara Machi 13-1, Kanazawa, Ishikawa 9208641, Japan.	mhonda@m-kanazawa.jp					Tanaka Y, 2009, NAT GENET, V41, P1105, DOI 10.1038/ng.449; Mu YB, 2012, CELL TISSUE RES, V347, P11, DOI 10.1007/s00441-011-1201-y; Okitsu T, 2004, DIABETES, V53, P105; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Fu LC, 2011, J BIOL CHEM, V286, P36724, DOI 10.1074/jbc.M111.277673; Yamagata K, 2012, J BIOL CHEM, V287, P1588, DOI 10.1074/jbc.M111.315127; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Yamanaka H, 2002, EMBO REP, V3, P69, DOI 10.1093/embo-reports/kvf008; Honda M, 2014, HEPATOLOGY, V59, P828, DOI 10.1002/hep.26788; Yi MK, 2007, J VIROL, V81, P629; Leask A, 2004, FASEB J, V18, P816, DOI 10.1096/fj.03-1273rev; Hezode C, 2013, J HEPATOL, V59, P434, DOI 10.1016/j.jhep.2013.04.035; Lee JC, 2013, CELL, V155, P57, DOI 10.1016/j.cell.2013.08.034; Trembling PM, 2013, NAT REV GASTRO HEPAT, V10, P713, DOI 10.1038/nrgastro.2013.163; Honda M, 2011, GASTROENTEROLOGY, V141, P128, DOI 10.1053/j.gastro.2011.03.051; Bai XC, 2007, SCIENCE, V318, P977, DOI 10.1126/science.1147379; Yoshida H, 1999, ANN INTERN MED, V131, P174; Bruno S, 2013, J HEPATOL, V58, P479, DOI 10.1016/j.jhep.2012.11.020; Carayol N, 2008, J BIOL CHEM, V283, P8601, DOI 10.1074/jbc.M707934200; Chaveroux C, 2009, MOL CELL BIOL, V29, P6515, DOI 10.1128/MCB.00489-09; Honda M, 2010, J HEPATOL, V53, P817, DOI 10.1016/j.jhep.2010.04.036; Sakata K, 2013, SCI REP-UK, V3, DOI 10.1038/srep03243	22	4	4	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0270-9139	1527-3350		HEPATOLOGY	Hepatology	NOV	2014	60	5					1519	1530		10.1002/hep.27277		12	Gastroenterology & Hepatology	Gastroenterology & Hepatology	AS6CM	WOS:000344352400012		
J	Yamasaki, K; Tateyama, M; Abiru, S; Komori, A; Nagaoka, S; Saeki, A; Hashimoto, S; Sasaki, R; Bekki, S; Kugiyama, Y; Miyazoe, Y; Kuno, A; Korenaga, M; Togayachi, A; Ocho, M; Mizokami, M; Narimatsu, H; Yatsuhashi, H				Yamasaki, Kazumi; Tateyama, Masakuni; Abiru, Seigo; Komori, Atsumasa; Nagaoka, Shinya; Saeki, Akira; Hashimoto, Satoru; Sasaki, Ryu; Bekki, Shigemune; Kugiyama, Yuki; Miyazoe, Yuri; Kuno, Atsushi; Korenaga, Masaaki; Togayachi, Akira; Ocho, Makoto; Mizokami, Masashi; Narimatsu, Hisashi; Yatsuhashi, Hiroshi			Elevated Serum Levels of Wisteria floribunda Agglutinin-Positive Human Mac-2 Binding Protein Predict the Development of Hepatocellular Carcinoma in Hepatitis C Patients	HEPATOLOGY			English	Article							VIRUS-RELATED CIRRHOSIS; ALANINE AMINOTRANSFERASE LEVELS; CHRONIC VIRAL-HEPATITIS; CHRONIC LIVER-DISEASE; ALPHA-FETOPROTEIN; TRANSIENT ELASTOGRAPHY; SURVEILLANCE PROGRAM; INTERFERON THERAPY; RISK-FACTOR; FIBROSIS	The Wisteria floribunda agglutinin-positive human Mac-2-binding protein (WFA(+) -M2BP) was recently shown to be a liver fibrosis glycobiomarker with a unique fibrosis-related glycoalteration. We evaluated the ability of WFA(+) -M2BP to predict the development of hepatocellular carcinoma (HCC) in patients who were infected with the hepatitis C virus (HCV). A total of 707 patients who had been admitted to our hospital with chronic HCV infection without other potential risk factors were evaluated to determine the ability of WFA(+) -M2BP to predict the development of HCC; factors evaluated included age, sex, viral load, genotypes, fibrosis stage, aspartate and alanine aminotransferase levels, bilirubin, albumin, platelet count, alpha-fetoprotein (AFP), WFA(+) -M2BP, and the response to interferon (IFN) therapy. Serum WFA(+) -M2BP levels were significantly increased according to the progression of liver fibrosis stage (P < 0.001). In each distinctive stage of fibrosis (F0-F1, F2, F3, and F4), the risk of development of HCC was increased according to the elevation of WFA(+) -M2BP. Multivariate analysis identified age >57 years, F4, AFP >20 ng/mL, WFA(+) -M2BP >= 4, and WFA(+) -M2BP 1-4 as well as the response to IFN (no therapy vs. sustained virological response) as independent risk factors for the development of HCC. The time-dependent areas under the receiver operating characteristic curve demonstrated that the WFA(+) -M2BP assay predicted the development of HCC with higher diagnostic accuracy than AFP. Conclusion: WFA(+) -M2BP can be applied as a useful surrogate marker for the risk of HCC development, in addition to liver biopsy.	[Yamasaki, Kazumi; Abiru, Seigo; Komori, Atsumasa; Nagaoka, Shinya; Saeki, Akira; Hashimoto, Satoru; Sasaki, Ryu; Bekki, Shigemune; Kugiyama, Yuki; Miyazoe, Yuri; Yatsuhashi, Hiroshi] Natl Hosp Org, Nagasaki Med Ctr, Clin Res Ctr, Omura, Nagasaki 8568562, Japan; [Kuno, Atsushi; Togayachi, Akira; Ocho, Makoto; Narimatsu, Hisashi] Natl Inst Adv Ind Sci & Technol, Res Ctr Med Glycosci, Tsukuba, Ibaraki, Japan; [Korenaga, Masaaki; Mizokami, Masashi] Natl Ctr Global Hlth & Med, Res Ctr Hepatitis & Immunol, Ichikawa, Japan; [Tateyama, Masakuni] Kumamoto Univ Med, Dept Gastroenterol & Hepatol, Kumamoto, Japan	Yatsuhashi, H (reprint author), Natl Hosp Org, Nagasaki Med Ctr, Clin Res Ctr, 2-1001-1 Kubara, Omura, Nagasaki 8568562, Japan.	yatsuhashi@nagasaki-mc.com			Health and Labor Sciences Research Grants for Research on Hepatitis from the Ministry of Health, Labor and Welfare of Japan	This study was supported, in part, by Health and Labor Sciences Research Grants for Research on Hepatitis from the Ministry of Health, Labor and Welfare of Japan.	Cadranel JF, 2000, HEPATOLOGY, V32, P477, DOI 10.1053/jhep.2000.16602; Degos F, 2000, GUT, V47, P131, DOI 10.1136/gut.47.1.131; Yano M, 1996, HEPATOLOGY, V23, P1334, DOI 10.1002/hep.510230607; GanneCarrie N, 1996, HEPATOLOGY, V23, P1112; Castera L, 2005, GASTROENTEROLOGY, V128, P343, DOI 10.1053/j.gastro.2004.11.018; Sandrin L, 2003, ULTRASOUND MED BIOL, V29, P1705, DOI 10.1016/j.ultrasmedbio.2003.07.001; Bruix J, 2005, HEPATOLOGY, V42, P1208, DOI 10.1002/hep20933; OKA H, 1994, HEPATOLOGY, V19, P61, DOI 10.1016/0270-9139(94)90053-1; Crespo G, 2012, J HEPATOL, V57, P281, DOI 10.1016/j.jhep.2012.03.016; Degos F, 2010, J HEPATOL, V53, P1013, DOI 10.1016/j.jhep.2010.05.035; Tarao K, 1999, CANCER, V86, P589, DOI 10.1002/(SICI)1097-0142(19990815)86:4<589::AID-CNCR7>3.0.CO;2-K; Artini M, 1996, J HEPATOL, V25, P212, DOI 10.1016/S0168-8278(96)80076-6; Bolondi L, 2001, GUT, V48, P251, DOI 10.1136/gut.48.2.251; Sasaki T, 1998, EMBO J, V17, P1606, DOI 10.1093/emboj/17.6.1606; Tanaka E, 2000, HEPATOLOGY, V32, P388, DOI 10.1053/jhep.2000.9112; Cheung KJ, 2009, J VIRAL HEPATITIS, V16, P418, DOI 10.1111/j.1365-2893.2009.01083.x; Liang TJ, 2004, GASTROENTEROLOGY, V127, pS62, DOI 10.1053/j.gastro.2004.09.017; Kuno A, 2013, PROTEOM CLIN APPL, V7, P642, DOI 10.1002/prca.201300010; Tateyama M, 2011, J GASTROENTEROL, V46, P92, DOI 10.1007/s00535-010-0293-6; Heagerty PJ, 2000, BIOMETRICS, V56, P337, DOI 10.1111/j.0006-341X.2000.00337.x; Yoshida H, 1999, ANN INTERN MED, V131, P174; Ikeda K, 1998, J HEPATOL, V28, P930, DOI 10.1016/S0168-8278(98)80339-5; Tarao K, 2002, CANCER, V94, P1787, DOI 10.1002/cncr.10390; Dienstag JL, 2002, HEPATOLOGY, V36, pS152, DOI 10.1053/jhep.2002.36381; Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8; Bedossa P, 2003, HEPATOLOGY, V38, P1449, DOI 10.1016/j.hep.2003.09.022; TAKANO S, 1995, HEPATOLOGY, V21, P650; Bravo AA, 2001, NEW ENGL J MED, V344, P495, DOI 10.1056/NEJM200102153440706; Bruce MG, 2008, J VIRAL HEPATITIS, V15, P179, DOI 10.1111/j.1365-2893.2007.00928.x; COLOMBO M, 1991, NEW ENGL J MED, V325, P675, DOI 10.1056/NEJM199109053251002; DESMET VJ, 1994, HEPATOLOGY, V19, P1513, DOI 10.1016/0270-9139(94)90250-X; Gebo KA, 2002, HEPATOLOGY, V36, pS161, DOI 10.1053/jhep.2002.36989; Iacovazzi PA, 2005, CLIN CHEM LAB MED, V39, P961; Ikeda K, 2006, J HEPATOL, V44, P1089, DOI 10.1016/j.jhep.2006.02.008; Inoue A, 2000, J Epidemiol, V10, P234; Kuno A, 2013, SCI REP-UK, V3, DOI 10.1038/srep01065; Matsumura H, 2000, J VIRAL HEPATITIS, V7, P268; Narimatsu Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091079; Ohki T, 2008, CLIN GASTROENTEROL H, V6, P459, DOI [10.1016/j.cgh.2008.02.012, 10.1016/j.cgh.2008.02.0.12]; Ohno O, 1997, J Clin Microbiol, V35, P201; Rodriguez-Diaz JL, 2007, CLIN ONCOL-UK, V19, P197, DOI 10.1016/j.clon.2006.12.005; Saadeh S, 2001, HEPATOLOGY, V33, P196, DOI 10.1053/jhep.2001.20534; Sangiovanni A, 2001, AM J GASTROENTEROL, V96, P1575; TSUKUMA H, 1993, NEW ENGL J MED, V328, P1797, DOI 10.1056/NEJM199306243282501	44	8	8	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0270-9139	1527-3350		HEPATOLOGY	Hepatology	NOV	2014	60	5					1563	1570		10.1002/hep.27305		8	Gastroenterology & Hepatology	Gastroenterology & Hepatology	AS6CM	WOS:000344352400016		
J	Yamashita, T; Kitao, A; Matsui, O; Hayashi, T; Nio, K; Kondo, M; Ohno, N; Miyati, T; Okada, H; Yamashita, T; Mizukoshi, E; Honda, M; Nakanuma, Y; Takamura, H; Ohta, T; Nakamoto, Y; Yamamoto, M; Takayama, T; Arii, S; Wang, XW; Kaneko, S				Yamashita, Taro; Kitao, Azusa; Matsui, Osamu; Hayashi, Takehiro; Nio, Kouki; Kondo, Mitsumasa; Ohno, Naoki; Miyati, Tosiaki; Okada, Hikari; Yamashita, Tatsuya; Mizukoshi, Eishiro; Honda, Masao; Nakanuma, Yasuni; Takamura, Hiroyuki; Ohta, Tetsuo; Nakamoto, Yasunari; Yamamoto, Masakazu; Takayama, Tadatoshi; Arii, Shigeki; Wang, XinWei; Kaneko, Shuichi			Gd-EOB-DTPA-Enhanced Magnetic Resonance Imaging and Alpha-Fetoprotein Predict Prognosis of Early-Stage Hepatocellular Carcinoma	HEPATOLOGY			English	Article							NUCLEAR FACTOR 4-ALPHA; CANCER STEM-CELLS; FORKHEAD BOX M1B; TRANSCRIPTION FACTOR; LIVER-CANCER; SIGNAL INTENSITY; EXPRESSION; FOXM1; FEATURES; THERAPY	The survival of patients with hepatocellular carcinoma (HCC) is often individually different even after surgery for early-stage tumors. Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance imaging (MRI) has been introduced recently to evaluate hepatic lesions with regard to vascularity and the activity of the organic anion transporter OATP1B3. Here we report that Gd-EOB-DTPA-enhanced MRI (EOB-MRI) in combination with serum alpha-fetoprotein (AFP) status reflects the stem/maturational status of HCC with distinct biology and prognostic information. Gd-EOB-DTPA uptake in the hepatobiliary phase was observed in similar to 15% of HCCs. This uptake correlated with low serum AFP levels, maintenance of hepatocyte function with the upregulation of OATP1B3 and HNF4A expression, and good prognosis. By contrast, HCC showing reduced Gd-EOB-DTPA uptake with high serum AFP levels was associated with poor prognosis and the activation of the oncogene FOXM1. Knockdown of HNF4A in HCC cells showing Gd-EOB-DTPA uptake resulted in the increased expression of AFP and FOXM1 and the loss of OATP1B3 expression accompanied by morphological changes, enhanced tumorigenesis, and loss of Gd-EOB-DTPA uptake in vivo. HCC classification based on EOB-MRI and serum AFP levels predicted overall survival in a single-institution cohort (n = 70), and its prognostic utility was validated independently in a multi-institution cohort of early-stage HCCs (n = 109). Conclusion: This noninvasive classification system is molecularly based on the stem/maturation status of HCCs and can be incorporated into current staging practices to improve management algorithms, especially in the early stage of disease.	[Yamashita, Taro] Kanazawa Univ, Grad Sch Med Sci, Dept Gen Med, Kanazawa, Ishikawa 9208641, Japan; [Yamashita, Taro; Hayashi, Takehiro; Nio, Kouki; Kondo, Mitsumasa; Okada, Hikari; Yamashita, Tatsuya; Mizukoshi, Eishiro; Honda, Masao; Kaneko, Shuichi] Kanazawa Univ, Grad Sch Med Sci, Dept Gastroenterol, Kanazawa, Ishikawa 9208641, Japan; [Kitao, Azusa; Matsui, Osamu] Kanazawa Univ, Grad Sch Med Sci, Dept Radiol, Kanazawa, Ishikawa 9208641, Japan; [Ohno, Naoki; Miyati, Tosiaki] Kanazawa Univ, Fac Hlth Sci, Inst Med Pharmaceut & Hlth Sci, Kanazawa, Ishikawa 9208641, Japan; [Nakanuma, Yasuni] Kanazawa Univ, Grad Sch Med Sci, Dept Pathol, Kanazawa, Ishikawa 9208641, Japan; [Takamura, Hiroyuki; Ohta, Tetsuo] Kanazawa Univ, Grad Sch Med Sci, Dept Surg Gastroenterol, Kanazawa, Ishikawa 9208641, Japan; [Nakamoto, Yasunari] Univ Fukui, Sch Med, Dept Internal Med 2, Fukui 910, Japan; [Yamamoto, Masakazu] Tokyo Womens Med Univ, Inst Gastroenterol, Dept Surg, Tokyo, Japan; [Takayama, Tadatoshi] Nihon Univ, Sch Med, Dept Digest Surg, Tokyo, Japan; [Arii, Shigeki] Tokyo Med & Dent Univ, Dept Hepatobiliary Pancreat Surg, Tokyo, Japan; [Wang, XinWei] NCI, Human Carcinogenesis Lab, Ctr Canc Res, Bethesda, MD 20892 USA	Yamashita, T (reprint author), Kanazawa Univ, Grad Sch Med Sci, Dept Gastroenterol Gen Med, 13-1 Takara Machi, Kanazawa, Ishikawa 9208641, Japan.	taroy@m-kanazawa.jp	Wang, Xin/B-6162-2009		Health and Labor Sciences Research Grants for "Development of novel molecular markers and imaging modalities for earlier diagnosis of hepatocellular carcinoma"; Ministry of Education, Culture, Sports, Science, and Technology of Japan; National Cancer Center Research and Development Fund [23-B-5]; Center for Cancer Research, US National Cancer Institute [Z01 BC 010313]	Supported by Health and Labor Sciences Research Grants for "Development of novel molecular markers and imaging modalities for earlier diagnosis of hepatocellular carcinoma," Grants from the Ministry of Education, Culture, Sports, Science, and Technology of Japan, the National Cancer Center Research and Development Fund (23-B-5), and the Intramural Research Program Grant (Z01 BC 010313) of the Center for Cancer Research, US National Cancer Institute.	Kitao A, 2011, EUR RADIOL, V21, P2056, DOI 10.1007/s00330-011-2165-8; Sala M, 2005, SEMIN LIVER DIS, V25, P171, DOI 10.1055/s-2005-871197; Yamashita T, 2013, J CLIN INVEST, V123, P1911, DOI 10.1172/JCI66024; Kalinichenko VV, 2004, GENE DEV, V18, P830, DOI 10.1101/gad.1200704; Jemal A, 2011, CA-CANCER J CLIN, V61, P69, DOI 10.3322/caac.20107; Di Tommaso L, 2009, J HEPATOL, V50, P746, DOI 10.1016/j.jhep.2008.11.014; Hatziapostolou M, 2011, CELL, V147, P1233, DOI 10.1016/j.cell.2011.10.043; Yamashita T, 2013, HEPATOLOGY, V57, P1484, DOI 10.1002/hep.26168; Llovet JM, 2006, GASTROENTEROLOGY, V131, P1758, DOI 10.1053/j.gastro.2006.09.014; Kalin TV, 2011, CELL CYCLE, V10, P396, DOI 10.4161/cc.10.3.14709; Kitao A, 2012, RADIOLOGY, V265, P780, DOI 10.1148/radiol.12120226; Villanueva A, 2010, CLIN CANCER RES, V16, P4688, DOI 10.1158/1078-0432.CCR-09-1811; Trauner M, 2011, GASTROENTEROLOGY, V140, P1120, DOI 10.1053/j.gastro.2011.02.044; Yamashita T, 2010, CANCER RES, V70, P4687, DOI 10.1158/0008-5472.CAN-09-4210; Yin C, 2008, HEPATOLOGY, V48, P1528, DOI 10.1002/hep.22510; Raychaudhuri P, 2011, CANCER RES, V71, P4329, DOI 10.1158/0008-5472.CAN-11-0640; Sherman M, 2011, CLIN LIVER DIS, V15, P323, DOI 10.1016/j.cld.2011.03.003; Cairo S, 2010, P NATL ACAD SCI USA, V107, P20471, DOI 10.1073/pnas.1009009107; de Lope CR, 2012, J HEPATOL, V56, pS75, DOI 10.1016/S0168-8278(12)60009-9; Marquardt JU, 2011, HEPATOLOGY, V54, P1031, DOI 10.1002/hep.24454; Crestani M, 2004, BIOCHEM SOC T, V32, P92, DOI 10.1042/BST0320092; Ji JF, 2009, NEW ENGL J MED, V361, P1437, DOI 10.1056/NEJMoa0901282; Yamashita T, 2008, CANCER RES, V68, P1451, DOI 10.1158/0008-5472.CAN-07-6013; Lee JS, 2006, NAT MED, V12, P410, DOI 10.1038/nm1377; Ning BF, 2010, CANCER RES, V70, P7640, DOI 10.1158/0008-5472.CAN-10-0824; Yamashita T, 2009, GASTROENTEROLOGY, V136, P1012, DOI 10.1053/j.gastro.2008.12.004; Koo CY, 2012, BBA-GENE REGUL MECH, V1819, P28, DOI 10.1016/j.bbagrm.2011.09.004; Bonzo JA, 2012, J BIOL CHEM, V287, P7345, DOI 10.1074/jbc.M111.334599; Reimer P, 2004, EUR RADIOL, V14, P559, DOI 10.1007/s00330-004-2236-1; Hoshida Y, 2008, NEW ENGL J MED, V359, P1995, DOI 10.1056/NEJMoa0804525; Wang XH, 2002, P NATL ACAD SCI USA, V99, P16881, DOI 10.1073/pnas.252570299; Kitao A, 2010, RADIOLOGY, V256, P817, DOI 10.1148/radiol.10092214; Lade AG, 2011, DEV DYNAM, V240, P486, DOI 10.1002/dvdy.22522; Sun HC, 2011, CANCER LETT, V306, P214, DOI 10.1016/j.canlet.2011.03.009; Calvisi DF, 2009, GUT, V58, P679, DOI 10.1136/gut.2008.152652; Kanki A, 2012, MAGN RESON IMAGING, V20, P356, DOI 10.1016/j.mri.2011.11.002; Zhong JH, 2012, EJSO-EUR J SURG ONC, V38, P286, DOI 10.1016/j.ejso.2012.01.006	37	9	9	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0270-9139	1527-3350		HEPATOLOGY	Hepatology	NOV	2014	60	5					1674	1685		10.1002/hep.27093		12	Gastroenterology & Hepatology	Gastroenterology & Hepatology	AS6CM	WOS:000344352400025		
J	Kudo, M; Han, GH; Finn, RS; Poon, RTP; Blanc, JF; Yan, LN; Yang, JJ; Lu, LG; Tak, WY; Yu, XP; Lee, JH; Lin, SM; Wu, CP; Tanwandee, T; Shao, GL; Walters, IB; Dela Cruz, C; Poulart, V; Wang, JH				Kudo, Masatoshi; Han, Guohong; Finn, Richard S.; Poon, Ronnie T. P.; Blanc, Jean-Frederic; Yan, Lunan; Yang, Jijin; Lu, Ligong; Tak, Won-Young; Yu, Xiaoping; Lee, Joon-Hyeok; Lin, Shi-Ming; Wu, Changping; Tanwandee, Tawesak; Shao, Guoliang; Walters, Ian B.; Dela Cruz, Christine; Poulart, Valerie; Wang, Jian-Hua			Brivanib as Adjuvant Therapy to Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma: A Randomized Phase III Trial	HEPATOLOGY			English	Article							ENDOTHELIAL GROWTH-FACTOR; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; FACTOR RECEPTOR-2; DUAL INHIBITOR; SORAFENIB; ANGIOGENESIS; EXPRESSION; CONFIDENCE; ALANINATE; KINASES	Transarterial chemoembolization (TACE) is the current standard of treatment for unresectable intermediate-stage hepatocellular carcinoma (HCC). Brivanib, a selective dual inhibitor of vascular endothelial growth factor and fibroblast growth factor signaling, may improve the effectiveness of TACE when given as an adjuvant to TACE. In this multinational, randomized, double-blind, placebo-controlled, phase III study, 870 patients with TACE-eligible HCC were planned to be randomly assigned (1: 1) after the first TACE to receive either brivanib 800 mg or placebo orally once-daily. The primary endpoint was overall survival (OS). Secondary endpoints included time to disease progression (TTDP; a composite endpoint based on development of extrahepatic spread or vascular invasion, deterioration of liver function or performance status, or death), time to extrahepatic spread or vascular invasion (TTES/VI), rate of TACE, and safety. Time to radiographic progression (TTP) and objective response rate were exploratory endpoints. The trial was terminated after randomization of 502 patients (brivanib, 249; placebo, 253) when two other phase III studies of brivanib in advanced HCC patients failed to meet OS objectives. At termination, median follow-up was approximately 16 months. Intention-to-treat analysis showed no improvement in OS with brivanib versus placebo (median, 26.4 [95% confidence interval {CI}: 19.1 to not reached] vs. 26.1 months [19.0-30.9]; hazard ratio [HR]: 0.90 [95% CI: 0.66-1.23]; log-rank P50.5280). Brivanib improved TTES/VI (HR, 0.64 [95% CI: 0.45-0.90]), TTP (0.61 [0.48-0.77]), and rate of TACE (0.72 [0.61-0.86]), but not TTDP (0.94 [0.72-1.22]) versus placebo. Most frequent grade 3-4 adverse events included hyponatremia (brivanib, 18% vs. placebo, 5%) and hypertension (13% vs. 3%). Conclusions: In this study, brivanib as adjuvant therapy to TACE did not improve OS.	[Kudo, Masatoshi] Kinki Univ, Sch Med, Dept Gastroenterol & Hepatol, Osaka 5898511, Japan; [Han, Guohong] Fourth Mil Med Univ, Xijing Hosp, Xian 710032, Shaanxi, Peoples R China; [Finn, Richard S.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA; [Poon, Ronnie T. P.] Univ Hong Kong, Dept Hepatobiliary & Pancreat Surg, Hong Kong, Hong Kong, Peoples R China; [Blanc, Jean-Frederic] Hosp St Andre, Dept Hepatogastroenterol, Bordeaux, France; [Blanc, Jean-Frederic] Univ Hosp Bordeaux, Bordeaux, France; [Yan, Lunan] Sichuan Univ, West China Hosp, Liver Transplantat Dept, Chengdu 610064, Peoples R China; [Yang, Jijin] Changhai Hosp, Shanghai, Peoples R China; [Lu, Ligong] Guangdong Prov Peoples Hosp, Guangzhou, Guangdong, Peoples R China; [Tak, Won-Young] Kyungpook Natl Univ Hosp, Dept Internal Med, Taegu, South Korea; [Yu, Xiaoping] Hunan Prov Tumor Hosp, Changsha, Hunan, Peoples R China; [Lee, Joon-Hyeok] Sungkyunkwan Univ, Sch Med, Div Gastroenterol, Seoul, South Korea; [Lee, Joon-Hyeok] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea; [Lin, Shi-Ming] Chang Gung Mem Hosp, Linkou Branch, Taoyuan, Taiwan; [Wu, Changping] First Peoples Hosp Changzhou, Changzhou, Peoples R China; [Tanwandee, Tawesak] Mahidol Univ, Fac Med, Siriraj Hosp, Bangkok 10700, Thailand; [Shao, Guoliang] Zhejiang Canc Hosp, Hangzhou, Peoples R China; [Walters, Ian B.] Bristol Myers Squibb Co, Wallingford, CT 06492 USA; [Dela Cruz, Christine] Bristol Myers Squibb, Singapore, Singapore; [Poulart, Valerie] Bristol Myers Squibb, Braine Lalleud, Belgium; [Wang, Jian-Hua] Zhongshan Hosp, Shanghai, Peoples R China	Kudo, M (reprint author), Kinki Univ, Sch Med, Dept Gastroenterol & Hepatol, 377-2 Ohno Higashi, Osaka 5898511, Japan.	m-kudo@med.kindai.ac.jp			Bristol-Myers Squibb Company (Princeton, NJ)	The study was sponsored by Bristol-Myers Squibb Company (Princeton, NJ).	Allen E, 2011, CLIN CANCER RES, V17, P5299, DOI 10.1158/1078-0432.CCR-10-2847; Kudo M, 2011, EUR J CANCER, V47, P2117, DOI 10.1016/j.ejca.2011.05.007; Poon RTP, 2001, AM J SURG, V182, P298, DOI 10.1016/S0002-9610(01)00708-5; Park JW, 2011, CLIN CANCER RES, V17, P1973, DOI 10.1158/1078-0432.CCR-10-2011; Llovet JM, 2002, LANCET, V359, P1734, DOI 10.1016/S0140-6736(02)08649-X; Shim JH, 2008, CANCER SCI, V99, P2037, DOI 10.1111/j.1349-7006.2008.00909.x; Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857; Finn RS, 2012, CLIN CANCER RES, V18, P2090, DOI 10.1158/1078-0432.CCR-11-1991; Lencioni R, 2012, SEMIN ONCOL, V39, P503, DOI 10.1053/j.seminoncol.2012.05.004; Schoenleber SJ, 2009, BRIT J CANCER, V100, P1385, DOI 10.1038/sj.bjc.6605017; Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7; Lencioni R, 2010, SEMIN LIVER DIS, V30, P52, DOI 10.1055/s-0030-1247132; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Sergio A, 2008, AM J GASTROENTEROL, V103, P914, DOI 10.1111/j.1572-0241.2007.01712.x; Johnson PJ, 2013, J CLIN ONCOL, V31, P3517, DOI 10.1200/JCO.2012.48.4410; Huynh H, 2008, CLIN CANCER RES, V14, P6146, DOI 10.1158/1078-0432.CCR-08-0509; Clopper CJ, 1934, BIOMETRIKA, V26, P404, DOI 10.2307/2331986; Lo CM, 2002, HEPATOLOGY, V35, P1164, DOI 10.1053/jhep.2002.33156; Llovet JM, 2013, J CLIN ONCOL, V31, P3509, DOI 10.1200/JCO.2012.47.3009; Rosmorduc O, 2010, SEMIN LIVER DIS, V30, P258, DOI 10.1055/s-0030-1255355; Bhide RS, 2010, MOL CANCER THER, V9, P369, DOI 10.1158/1535-7163.MCT-09-0472; BROOKMEYER R, 1982, BIOMETRICS, V38, P29, DOI 10.2307/2530286; Cai ZW, 2008, J MED CHEM, V51, P1976, DOI 10.1021/jm7013309; Lencioni M, 2012, J CLIN ONCOL S, V30; Li X, 2003, WORLD J GASTROENTERO, V9, P2445; Li X, 2004, WORLD J GASTROENTERO, V10, P2878; Strebel BM, 2008, EXPERT REV ANTICANC, V8, P1743, DOI [10.1586/14737140.8.11.1743, 10.1586/14737140.8-11.1743]	27	8	8	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0270-9139	1527-3350		HEPATOLOGY	Hepatology	NOV	2014	60	5					1697	1707		10.1002/hep.27290		11	Gastroenterology & Hepatology	Gastroenterology & Hepatology	AS6CM	WOS:000344352400027		
J	Tsuchiya, A; Lu, WY; Weinhold, B; Boulter, L; Stutchfield, BM; Williams, MJ; Guest, RV; Minnis-Lyons, SE; MacKinnon, AC; Schwarzer, D; Ichida, T; Nomoto, M; Aoyagi, Y; Gerardy-Schahn, R; Forbes, SJ				Tsuchiya, Atsunori; Lu, Wei-Yu; Weinhold, Birgit; Boulter, Luke; Stutchfield, Benjamin M.; Williams, Michael J.; Guest, Rachel V.; Minnis-Lyons, Sarah E.; MacKinnon, Alison C.; Schwarzer, David; Ichida, Takafumi; Nomoto, Minoru; Aoyagi, Yutaka; Gerardy-Schahn, Rita; Forbes, Stuart J.			Polysialic Acid/Neural Cell Adhesion Molecule Modulates the Formation of Ductular Reactions in Liver Injury	HEPATOLOGY			English	Article							HEPATIC STEM/PROGENITOR CELLS; POSTNATAL MOUSE-BRAIN; STEM-CELLS; RAT-LIVER; SYNCAM 1; N-CAM; ACID; NCAM; POLYSIALYLATION; EXPRESSION	In severe liver injury, ductular reactions (DRs) containing bipotential hepatic progenitor cells (HPCs) branch from the portal tract. Neural cell adhesion molecule (NCAM) marks bile ducts and DRs, but not mature hepatocytes. NCAM mediates interactions between cells and surrounding matrix; however, its role in liver development and regeneration is undefined. Polysialic acid (polySia), a unique posttranslational modifier of NCAM, is produced by the enzymes, ST8SiaII and ST8SiaIV, and weakens NCAM interactions. The role of polySia with NCAM synthesizing enzymes ST8SiaII and ST8SiaIV were examined in HPCs in vivo using the choline-deficient ethionine-supplemented and 3,5-diethoxycarbonyl-1,4-dihydrocollidine diet models of liver injury and regeneration, in vitro using models of proliferation, differentiation, and migration, and by use of mouse models with gene defects in the polysialyltransferases (St8sia2(+/-) 4(+/-), and St8sia2(-/-) 4(-/-)). We show that, during liver development, polySia is required for the correct formation of bile ducts because gene defects in both the polysialyltransferases (St8sia2(+/-) 4(+/-) and St8sia2(-/-) 4(-/-) mice) caused abnormal bile duct development. In normal liver, there is minimal polySia production and few ductular NCAM 1 cells. Subsequent to injury, NCAM 1 cells expand and polySia is produced by DRs/HPCs through ST8SiaIV. PolySia weakens cell-cell and cell-matrix interactions, facilitating HGF-induced migration. Differentiation of HPCs to hepatocytes in vitro results in both transcriptional down-regulation of polySia and cleavage of polySia-NCAM. Cleavage of polySia by endosialidase (endoN) during liver regeneration reduces migration of DRs into parenchyma. Conclusion: PolySia modification of NCAM 1 ductules weakens cell-cell and cell-matrix interactions, allowing DRs/HPCs to migrate for normal development and regeneration. Modulation of polySia levels may provide a therapeutic option in liver regeneration.	[Tsuchiya, Atsunori; Lu, Wei-Yu; Boulter, Luke; Stutchfield, Benjamin M.; Williams, Michael J.; Guest, Rachel V.; Minnis-Lyons, Sarah E.; MacKinnon, Alison C.; Forbes, Stuart J.] Univ Edinburgh, Edinburgh BioQuarter, Med Res Council Ctr Regenerat Med, Edinburgh EH16 4UU, Midlothian, Scotland; [Tsuchiya, Atsunori; Nomoto, Minoru; Aoyagi, Yutaka] Niigata Univ, Grad Sch Med & Dent Sci, Div Gastroenterol & Hepatol, Niigata, Japan; [Weinhold, Birgit; Schwarzer, David; Gerardy-Schahn, Rita] Hannover Med Sch, Inst Cellular Chem, Hannover, Germany; [Ichida, Takafumi] Juntendo Shizuoka Hosp, Dept Gastroenterol & Hepatol, Izunokuni City, Japan	Forbes, SJ (reprint author), Univ Edinburgh, Edinburgh BioQuarter, SCRM Bldg,5 Little France Dr, Edinburgh EH16 4UU, Midlothian, Scotland.	stuart.forbes@ed.ac.uk			NICHD	The authors thank Prof. Frederic A. Troy II (University of California School of Medicine) and Prof. Ken Kitajima (Nagoya University) for providing critical comments on the study. The TROMA-III Ab developed by Rolf Kemler was obtained from the Developmental Studies Hybridoma Bank, developed under the auspices of the NICHD, and maintained by The University of Iowa, Department of Biology (Iowa City, IA).	Tsuchiya A, 2009, HEPATOL RES, V39, P1080, DOI 10.1111/j.1872-034X.2009.00559.x; Tirnitz-Parker JEE, 2007, INT J BIOCHEM CELL B, V39, P2226, DOI 10.1016/j.biocel.2007.06.008; ACHESON A, 1991, J CELL BIOL, V114, P143, DOI 10.1083/jcb.114.1.143; Lorenzini S, 2010, GUT, V59, P645, DOI 10.1136/gut.2009.182345; Bird TG, 2008, CELL TISSUE RES, V331, P283, DOI 10.1007/s00441-007-0542-z; Oltmann-Norden I, 2008, J BIOL CHEM, V283, P1463, DOI 10.1074/jbc.M708463200; Nakatani K, 2006, ARCH HISTOL CYTOL, V69, P61, DOI 10.1679/aohc.69.61; Boulter L, 2012, NAT MED, V18, P572, DOI 10.1038/nm.2667; Hildebrandt H, 2010, ADV EXP MED BIOL, V663, P95, DOI 10.1007/978-1-4419-1170-4_6; Espanol-Suner R, 2012, GASTROENTEROLOGY, V143, P1564, DOI 10.1053/j.gastro.2012.08.024; Fabris L, 2000, AM J PATHOL, V156, P1599, DOI 10.1016/S0002-9440(10)65032-8; Ono S, 2012, J BIOL CHEM, V287, P3710, DOI 10.1074/jbc.M111.276618; Rutishauser U, 2008, NAT REV NEUROSCI, V9, P26, DOI 10.1038/nrn2285; Bird TG, 2013, P NATL ACAD SCI USA, V110, P6542, DOI 10.1073/pnas.1302168110; Curreli S, 2007, J BIOL CHEM, V282, P30346, DOI 10.1074/jbc.M702965200; Sackett SD, 2009, HEPATOLOGY, V49, P920, DOI 10.1002/hep.22705; Muhlenhoff M, 2013, NEUROCHEM RES, V38, P1134, DOI 10.1007/s11064-013-0979-2; Theis T, 2013, J BIOL CHEM, V288, P6726, DOI 10.1074/jbc.M112.444034; Zhou HC, 2007, HEPATOLOGY, V45, P716, DOI 10.1002/hep.21557; Galuska SP, 2010, P NATL ACAD SCI USA, V107, P10250, DOI 10.1073/pnas.0912103107; Kleene R, 2004, NAT REV NEUROSCI, V5, P195, DOI 10.1038/nrn1349; Stummeyer K, 2005, NAT STRUCT MOL BIOL, V12, P90, DOI 10.1038/nsmb874; Hildebrandt H, 2009, BRAIN, V132, P2831, DOI 10.1093/brain/awp117; Hildebrandt H, 2013, TOP CURR CHEM, DOI [10.1007/128_2013_446, DOI 10.1007/128_2013_446]; HOFFMAN S, 1982, J BIOL CHEM, V257, P7720; Johnson CP, 2005, J BIOL CHEM, V280, P137, DOI 10.1074/jbc.M410216200; Knittel T, 1996, AM J PATHOL, V149, P449; Nakatani K, 1996, CELL TISSUE RES, V283, P159; Sonzogni A, 2004, J HEPATOL, V40, P592, DOI 10.1016/j.jhep.2003.12.019; Tsuchiya A, 2005, GASTROENTEROLOGY, V128, P2089, DOI 10.1053/j.gastro.2005.03.030; Weinhold B, 2005, J BIOL CHEM, V280, P42971, DOI 10.1074/jbc.M511097200	31	7	7	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0270-9139	1527-3350		HEPATOLOGY	Hepatology	NOV	2014	60	5					1727	1740		10.1002/hep.27099		14	Gastroenterology & Hepatology	Gastroenterology & Hepatology	AS6CM	WOS:000344352400030		
J	Yoneda, M; Thomas, E; Sumida, Y; Eguchi, Y; Schiff, ER				Yoneda, Masato; Thomas, Emmanuel; Sumida, Yoshio; Eguchi, Yuichiro; Schiff, Eugene R.			The Influence of Menopause on the Development of Hepatic Fibrosis in Nonobese Women With Nonalcoholic Fatty Liver Disease	HEPATOLOGY			English	Letter									[Yoneda, Masato; Thomas, Emmanuel; Schiff, Eugene R.] Univ Miami, Miller Sch Med, Schiff Ctr Liver Dis, Miami, FL 33136 USA; [Sumida, Yoshio] Kyoto Prefectural Univ Med, Dept Gastroenterol & Hepatol, Kyoto, Japan; [Eguchi, Yuichiro] Saga Med Sch, Ctr Liver, Saga, Japan	Yoneda, M (reprint author), Univ Miami, Miller Sch Med, Schiff Ctr Liver Dis, Miami, FL 33136 USA.						Freeman EW, 2010, MENOPAUSE, V17, P718, DOI 10.1097/gme.0b013e3181cec85d; Yang JD, 2014, HEPATOLOGY, V59, P1406, DOI 10.1002/hep.26761; Yoneda M, 2011, J GASTROENTEROL, V46, P1300, DOI 10.1007/s00535-011-0436-4	3	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0270-9139	1527-3350		HEPATOLOGY	Hepatology	NOV	2014	60	5					1792	1792		10.1002/hep.27097		1	Gastroenterology & Hepatology	Gastroenterology & Hepatology	AS6CM	WOS:000344352400038		
J	Gardner, JC; Liew, G; Quan, YH; Ermetal, B; Ueyama, H; Davidson, AE; Schwarz, N; Kanuga, N; Chana, R; Maher, ER; Webster, AR; Holder, GE; Robson, AG; Cheetham, ME; Liebelt, J; Ruddle, JB; Moore, AT; Michaelides, M; Hardcastle, AJ				Gardner, Jessica C.; Liew, Gerald; Quan, Ying-Hua; Ermetal, Burcu; Ueyama, Hisao; Davidson, Alice E.; Schwarz, Nele; Kanuga, Naheed; Chana, Ravinder; Maher, Eamonn R.; Webster, Andrew R.; Holder, Graham E.; Robson, Anthony G.; Cheetham, Michael E.; Liebelt, Jan; Ruddle, Jonathan B.; Moore, Anthony T.; Michaelides, Michel; Hardcastle, Alison J.			Three Different Cone Opsin Gene Array Mutational Mechanisms with Genotype-Phenotype Correlation and Functional Investigation of Cone Opsin Variants	HUMAN MUTATION			English	Article						opsin; blue cone monochromacy; splicing; cone dystrophy; OPN1LW; OPN1MW	VISUAL PIGMENT GENES; LOCUS-CONTROL REGION; HUMAN COLOR-VISION; LINKED INCOMPLETE ACHROMATOPSIA; MUTUALLY EXCLUSIVE EXPRESSION; EXONIC SPLICING ENHANCERS; HUMAN RED; MOLECULAR-GENETICS; ISCEV STANDARD; GREEN	Mutations in the OPN1LW (L-) and OPN1MW (M-)cone opsin genes underlie a spectrum of cone photoreceptor defects from stationary loss of color vision to progressive retinal degeneration. Genotypes of 22 families with a range of cone disorders were grouped into three classes: deletions of the locus control region (LCR); missense mutation (p.Cys203Arg) in an L-/M-hybrid gene; and exon 3 single-nucleotide polymorphism (SNP) interchange haplotypes in an otherwise normal gene array. Moderate-to-high myopia was observed in all mutation categories. Individuals with LCR deletions or p.Cys203Arg mutations were more likely to have nystagmus and poor vision, with disease progression in some p.Cys203Arg patients. Three disease-associated exon 3 SNP haplotypes encoding LIAVA, LVAVA, or MIAVA were identified in our cohort. These patients were less likely to have nystagmus but more likely to show progression, with all patients over the age of 40 years having marked macular abnormalities. Previously, the haplotype LIAVA has been shown to result in exon 3 skipping. Here, we show that haplotypes LVAVA and MIAVA also result in aberrant splicing, with a residual low level of correctly spliced cone opsin. The OPN1LW/OPN1MW: c.532A>G SNP, common to all three disease-associated haplotypes, appears to be principally responsible for this mutational mechanism. Published 2014 Wiley Periodicals, Inc.**	[Gardner, Jessica C.; Quan, Ying-Hua; Ermetal, Burcu; Davidson, Alice E.; Schwarz, Nele; Kanuga, Naheed; Webster, Andrew R.; Holder, Graham E.; Robson, Anthony G.; Cheetham, Michael E.; Moore, Anthony T.; Michaelides, Michel; Hardcastle, Alison J.] UCL Inst Ophthalmol, London EC1V 9EL, England; [Liew, Gerald; Chana, Ravinder; Webster, Andrew R.; Holder, Graham E.; Robson, Anthony G.; Moore, Anthony T.; Michaelides, Michel] Moorfields Eye Hosp NHS Fdn Trust, London EC1V 2PD, England; [Ueyama, Hisao] Shiga Univ Med Sci, Dept Biochem & Mol Biol, Otsu, Shiga 5202192, Japan; [Maher, Eamonn R.] Univ Birmingham, Sch Med, Ctr Rare Dis & Personalised Med Clin & Expt Med, Birmingham B15 2TT, W Midlands, England; [Maher, Eamonn R.] Univ Cambridge, Dept Med Genet, Cambridge CB2 0QQ, England; [Liebelt, Jan] Womens & Childrens Hosp, Adelaide, SA 5006, Australia; [Ruddle, Jonathan B.] Univ Melbourne, Ctr Eye Res Australia, East Melbourne, Vic 3002, Australia; [Ruddle, Jonathan B.] Royal Victorian Eye & Ear Hosp, East Melbourne, Vic 3002, Australia	Michaelides, M (reprint author), UCL Inst Ophthalmol, 11-43 Bath St, London EC1V 9EL, England.	michel.michaelides@ucl.ac.uk; a.hardcastle@ucl.ac.uk		Cheetham, Michael/0000-0001-6429-654X	National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust; UCL Institute of Ophthalmology; Fight for Sight (UK); Retinitis Pigmentosa Fighting Blindness (UK); Moorfields Eye Hospital Special Trustees; Foundation Fighting Blindness (USA)	Contract grant sponsors: National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology; Fight for Sight (UK); Retinitis Pigmentosa Fighting Blindness (UK); Moorfields Eye Hospital Special Trustees; Foundation Fighting Blindness (USA).	Carroll J, 2012, INVEST OPHTH VIS SCI, V53, P8006, DOI 10.1167/iovs.12-11087; NATHANS J, 1993, AM J HUM GENET, V53, P987; Jagla WM, 2002, HUM MOL GENET, V11, P23, DOI 10.1093/hmg/11.1.23; Gardner JC, 2010, AM J HUM GENET, V87, P26, DOI 10.1016/j.ajhg.2010.05.019; Neitz M, 2004, VISUAL NEUROSCI, V21, P205, DOI 10.1017/S0952523804213293; Young TL, 2004, ARCH OPHTHALMOL-CHIC, V122, P897, DOI 10.1001/archopht.122.6.897; Carroll J, 2009, P NATL ACAD SCI USA, V106, P20948, DOI 10.1073/pnas.0910128106; Bach M, 2013, DOC OPHTHALMOL, V126, P1, DOI 10.1007/s10633-012-9353-y; Smallwood PM, 2002, P NATL ACAD SCI USA, V99, P1008, DOI 10.1073/pnas.022629799; Michaelides M, 2005, EYE, V19, P2, DOI 10.1038/sj.eye.6701391; Ueyama H, 2012, BIOCHEM BIOPH RES CO, V424, P152, DOI 10.1016/j.bbrc.2012.06.094; Fairbrother WG, 2002, SCIENCE, V297, P1007, DOI 10.1126/science.1073774; WINDERICKX J, 1992, NAT GENET, V1, P251, DOI 10.1038/ng0792-251; Marmor MF, 2009, DOC OPHTHALMOL, V118, P69, DOI 10.1007/s10633-008-9155-4; Nathans J, 1999, NEURON, V24, P299, DOI 10.1016/S0896-6273(00)80845-4; Gardner JC, 2009, MOL VIS, V15, P876; Ayyagari R, 2000, HUM GENET, V107, P75; DEEB SS, 1992, AM J HUM GENET, V51, P687; VOLLRATH D, 1988, SCIENCE, V240, P1669, DOI 10.1126/science.2837827; Neitz J, 2011, VISION RES, V51, P633, DOI 10.1016/j.visres.2010.12.002; Crognale MA, 2004, VISUAL NEUROSCI, V21, P197, DOI 10.1017/S0952523804213384; Carroll J, 2004, P NATL ACAD SCI USA, V101, P8461, DOI 10.1073/pnas.0401440101; NATHANS J, 1986, SCIENCE, V232, P203, DOI 10.1126/science.3485310; WANG YS, 1992, NEURON, V9, P429, DOI 10.1016/0896-6273(92)90181-C; REYNIERS E, 1995, GENOMICS, V29, P323; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; Holder GE, 2007, DOC OPHTHALMOL, V114, P111, DOI 10.1007/s10633-007-9053-1; Cideciyan AV, 2013, HUM GENE THER, V24, P993, DOI 10.1089/hum.2013.153; Wang ZF, 2004, CELL, V119, P831, DOI 10.1016/j.cell.2004.11.010; NATHANS J, 1989, SCIENCE, V245, P831, DOI 10.1126/science.2788922; Michaelides M, 2005, OPHTHALMOLOGY, V112, P1448, DOI 10.1016/j.ophtha.2005.02.021; Holder GE, 2006, ESSENT OPHTHALMOL, P133; Carroll J, 2010, VISION RES, V50, P1989, DOI 10.1016/j.visres.2010.07.009; Arden G, 1999, VISION RES, V39, P641, DOI 10.1016/S0042-6989(98)00182-5; Ayyagari R, 1999, Mol Vis, V5, P13; Deeb SS, 2011, GENEREVIEW; Fairbrother WG, 2004, NUCLEIC ACIDS RES, V32, pW187, DOI 10.1093/nar/gkh393; FLEISCHMAN JA, 1981, ARCH OPHTHALMOL-CHIC, V99, P468; Hayashi T, 1999, NAT GENET, V22, P90; Kazmi MA, 1997, INVEST OPHTH VIS SCI, V38, P1074; Kellner U, 2004, GRAEF ARCH CLIN EXP, V242, P729, DOI 10.1007/s00417-004-0921-z; LadekjaerMikkelsen AS, 1996, HUM GENET, V98, P403, DOI 10.1007/s004390050229; Mizrahi-Meissonnier L, 2010, INVEST OPHTH VIS SCI, V51, P3884, DOI 10.1167/iovs.09-4592; Wang Y, 1999, P NATL ACAD SCI USA, V96, P5251, DOI 10.1073/pnas.96.9.5251	44	5	5	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1059-7794	1098-1004		HUM MUTAT	Hum. Mutat.	NOV	2014	35	11					1354	1362		10.1002/humu.22679		9	Genetics & Heredity	Genetics & Heredity	AS6JM	WOS:000344369900011		
J	Asano, N; Yoshida, A; Kobayashi, E; Yamaguchi, T; Kawai, A				Asano, Naofumi; Yoshida, Akihiko; Kobayashi, Eisuke; Yamaguchi, Takehiko; Kawai, Akira			Multiple metastases from histologically benign intraarticular diffuse-type tenosynovial giant cell tumor: a case report	HUMAN PATHOLOGY			English	Article						Diffuse-type tenosynovial giant cell tumor; Intraarticular D-TGCT; PVNS; Metastasis; Implantation phenomenon	PIGMENTED VILLONODULAR SYNOVITIS; BONE	Diffuse-type tenosynovial giant cell tumor (D-TGCT) is a relatively rare mesenchymal tumor. It is a locally aggressive but virtually nonmetastasizing neoplasm and thus regarded as benign. Only a few D-TGCTs with benign histology have been reported to metastasize. We report an extremely rare case of benign D-TGCT in which multiple metastases developed 9 years after surgery for the primary tumor. The present case suggests that conventional D-TGCT has the potential to form distant metastases, albeit exceptionally rarely, and that this probable implantation phenomenon can be managed conservatively. (C) 2014 Elsevier Inc. All rights reserved.	[Asano, Naofumi; Kobayashi, Eisuke; Kawai, Akira] Natl Canc Ctr, Dept Musculoskeletal Oncol, Tokyo 1040045, Japan; [Asano, Naofumi] Natl Canc Ctr, Dept Pathol & Clin Labs, Tokyo 1040045, Japan; [Yoshida, Akihiko] Jichi Med Univ, Dept Pathol, Shimotsuke, Tochigi 3290498, Japan; [Yamaguchi, Takehiko] Keio Univ, Dept Orthoped Surg, Tokyo 1608582, Japan	Asano, N (reprint author), Natl Canc Ctr, Dept Musculoskeletal Oncol, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.	asanonaofumi@yahoo.co.jp					Jaffe HL, 1941, ARCH PATHOL, V31, P731; Boland JM, 2009, AM J SURG PATHOL, V33, P1225, DOI 10.1097/PAS.0b013e3181a6d86f; Somerhausen ND, 2000, AM J SURG PATHOL, V24, P479; West RB, 2006, P NATL ACAD SCI USA, V103, P690, DOI 10.1073/pnas.0507321103; Bertoni F, 1997, AM J SURG PATHOL, V21, P153, DOI 10.1097/00000478-199702000-00004; Awonuga AO, 2010, OBSTET GYNECOL SURV, V65, P189, DOI 10.1097/OGX.0b013e3181d60f93; CABALLES RL, 1981, HUM PATHOL, V12, P762, DOI 10.1016/S0046-8177(81)80182-7; CHOONG PFM, 1995, ACTA ORTHOP SCAND, V66, P64, DOI 10.3109/17453679508994643; Enzinger FM, 2008, SOFT TISSUE TUMORS, P777; Li CF, 2008, AM J SURG PATHOL, V32, P587, DOI 10.1097/PAS.0b013e318158428f; Somerhausen N, 2013, WHO CLASSIFICATION T, P102; Viswanathan S, 2010, CLIN ORTHOP RELAT R, V468, P827, DOI 10.1007/s11999-009-0966-8	12	0	0	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0046-8177	1532-8392		HUM PATHOL	Hum. Pathol.	NOV	2014	45	11					2355	2358		10.1016/j.humpath.2014.06.025		4	Pathology	Pathology	AS0KZ	WOS:000343967300022		
J	Kuroda, T; Medvedev, AS; Hartogh, P				Kuroda, Takeshi; Medvedev, Alexander S.; Hartogh, Paul			Parameterization of radiative heating and cooling rates in the stratosphere of Jupiter	ICARUS			English	Article						Jupiter, atmosphere; Solar radiation; Radiative transfer	GENERAL-CIRCULATION MODEL; K-DISTRIBUTION METHOD; ABSORPTION-COEFFICIENTS; MARTIAN ATMOSPHERE; JOVIAN ATMOSPHERE; THERMAL STRUCTURE; POLAR WARMINGS; CASSINI CIRS; ZONAL JETS; SPECTRA	We present a newly developed parameterization of radiative heating and cooling for Jupiter's upper troposphere and stratosphere (10(3) to 10(-3) hPa) suitable for general circulation models. The scheme is based on the correlated k-distribution approach, and accounts for all the major radiative mechanisms in the jovian atmosphere: heating due to absorption of solar radiation by methane, cooling in the infrared by methane, acetylene, ethane, and collisionally-induced molecular hydrogen-hydrogen, and molecular hydrogen-helium transitions. The results with the scheme are compared with line-by-line calculations to demonstrate that the accuracy of the scheme is within 10%. The parameterization was applied to study the sensitivity of the heating/cooling rates due to variations of mixing ratios of hydrocarbon molecules. It was also used for calculating the radiative-convective equilibrium temperature, which is in agreement with observations in the equatorial region. In midlatitudes, the equilibrium temperature is approximately 10 K colder. Our results suggest that the radiative forcing in the upper stratosphere is much stronger than it was thought before. In particular, the characteristic radiative relaxation time decreases exponentially with height from 10(8) s near the tropopause to 10(5) s in the upper stratosphere. (C) 2014 Elsevier Inc. All rights reserved.	[Kuroda, Takeshi] Tohoku Univ, Dept Geophys, Sendai, Miyagi 980, Japan; [Medvedev, Alexander S.; Hartogh, Paul] Max Planck Inst Solar Syst Res, Gottingen, Germany; [Medvedev, Alexander S.] Univ Gottingen, Inst Astrophys, D-37073 Gottingen, Germany	Kuroda, T (reprint author), Tohoku Univ, Dept Geophys, Sendai, Miyagi 980, Japan.	tkuroda@pat.gp.tohoku.ac.jp; medvedev@mps.mpg.de; hartogh@mps.mpg.de		Medvedev, Alexander/0000-0003-2713-8977			Niemann HB, 1998, J GEOPHYS RES-PLANET, V103, P22831, DOI 10.1029/98JE01050; Seiff A, 1998, J GEOPHYS RES-PLANET, V103, P22857, DOI 10.1029/98JE01766; Sromovsky LA, 2012, ICARUS, V218, P1, DOI 10.1016/j.icarus.2011.12.008; Sayanagi KM, 2008, J ATMOS SCI, V65, P3947, DOI 10.1175/2008JAS2558.1; Zhang H, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD003358; CONRATH BJ, 1990, ICARUS, V83, P255, DOI 10.1016/0019-1035(90)90068-K; Hartogh P, 2005, J GEOPHYS RES-PLANET, V110, DOI 10.1029/2005JE002498; Sekiguchi M, 2008, J QUANT SPECTROSC RA, V109, P2779, DOI 10.1016/j.jqsrt.2008.07.013; von Zahn U, 1998, J GEOPHYS RES-PLANET, V103, P22815, DOI 10.1029/98JE00695; KYLLING A, 1995, J ATMOS CHEM, V21, P115, DOI 10.1007/BF00696577; Zhang X, 2013, ICARUS, V226, P159, DOI 10.1016/j.icarus.2013.05.020; FU Q, 1992, J ATMOS SCI, V49, P2139, DOI 10.1175/1520-0469(1992)049<2139:OTCDMF>2.0.CO;2; Hartmann JM, 2002, J QUANT SPECTROSC RA, V72, P117, DOI 10.1016/S0022-4073(01)00058-9; Karkoschka E, 2010, ICARUS, V205, P674, DOI 10.1016/j.icarus.2009.07.044; Rothman LS, 2009, J QUANT SPECTROSC RA, V110, P533, DOI 10.1016/j.jqsrt.2009.02.013; PINE AS, 1992, J CHEM PHYS, V97, P773, DOI 10.1063/1.463943; Nakajima T, 2000, APPL OPTICS, V39, P4869, DOI 10.1364/AO.39.004869; LACIS AA, 1991, J GEOPHYS RES-ATMOS, V96, P9027, DOI 10.1029/90JD01945; O'Brien JJ, 2002, J QUANT SPECTROSC RA, V75, P323, DOI 10.1016/S0022-4073(02)00015-8; NAKAJIMA T, 1986, J QUANT SPECTROSC RA, V35, P13, DOI 10.1016/0022-4073(86)90088-9; Kuroda T, 2005, J METEOROL SOC JPN, V83, P1, DOI 10.2151/jmsj.83.1; Borysow A., 1988, ASTROPHYS J, V326, P509; Borysow A, 2002, ASTRON ASTROPHYS, V390, P779, DOI 10.1051/0004-6361:20020555; CESS RD, 1975, ICARUS, V26, P444, DOI 10.1016/0019-1035(75)90113-X; Encrenaz T, 1999, PLANET SPACE SCI, V47, P1225, DOI 10.1016/S0032-0633(99)00046-X; Eymet V, 2009, J GEOPHYS RES-PLANET, V114, DOI 10.1029/2008JE003276; FINK U, 1977, J QUANT SPECTROSC RA, V18, P447, DOI 10.1016/0022-4073(77)90077-2; FOX K, 1988, J QUANT SPECTROSC RA, V39, P473, DOI 10.1016/0022-4073(88)90092-1; Hartogh P, 2007, PLANET SPACE SCI, V55, P1103, DOI 10.1016/j.pss.2006.11.018; Irwin PGJ, 2006, ICARUS, V181, P309, DOI [10.1016/j.icarus.2005.11.003, 10.1016/j.icartis.2005.11.003]; Irwin PGJ, 1996, J GEOPHYS RES-PLANET, V101, P26137, DOI 10.1029/96JE02707; LINDAL GF, 1981, J GEOPHYS RES-SPACE, V86, P8721, DOI 10.1029/JA086iA10p08721; Liou K.N., 1992, RAD CLOUD PROCESSES, P504; Medvedev AS, 2007, ICARUS, V186, P97, DOI 10.1016/j.icarus.2006.08.020; Medvedev AS, 2013, ICARUS, V225, P228, DOI 10.1016/j.icarus.2013.03.028; Mischna MA, 2012, J GEOPHYS RES-PLANET, V117, DOI 10.1029/2012JE004110; Moses JI, 2005, J GEOPHYS RES-PLANET, V110, DOI 10.1029/2005JE002411; Moses JI, 2004, CAMB PLANET, P129; Nixon CA, 2010, PLANET SPACE SCI, V58, P1667, DOI [10.1016/j.pss.2010.05.008, 10.1016/j.pss.010.05.008]; Nixon CA, 2007, ICARUS, V188, P47, DOI 10.1016/j.icarus.2006.11.016; Showman AP, 2007, J ATMOS SCI, V64, P3132, DOI 10.1175/JAS4007.1; Simon-Miller AA, 2006, ICARUS, V180, P98, DOI 10.1016/j.icarus.2005.07.019; WEST RA, 1992, ICARUS, V100, P245, DOI 10.1016/0019-1035(92)90033-4; Wong AS, 2000, ASTROPHYS J, V534, pL215, DOI 10.1086/312675; Yamazaki YH, 2004, PLANET SPACE SCI, V52, P423, DOI 10.1016/j.pss.2003.06.006; Yelle RV, 2001, ICARUS, V152, P331, DOI 10.1006/icar.2001.6640; Young RE, 1998, J GEOPHYS RES-PLANET, V103, P22775, DOI 10.1029/98JE01051; Zhang X, 2013, PLANET SPACE SCI, V88, P3, DOI 10.1016/j.pss.2013.07.005; Zhang X., 2013, THESIS CALTECH PASAD	49	0	0	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0019-1035	1090-2643		ICARUS	Icarus	NOV 1	2014	242						149	157		10.1016/j.icarus.2014.08.001		9	Astronomy & Astrophysics	Astronomy & Astrophysics	AS0KX	WOS:000343967100016		
J	Rodriguez, JAP; Gulick, VC; Baker, VR; Platz, T; Fairen, AG; Miyamoto, H; Kargel, JS; Rice, JW; Glines, N				Rodriguez, J. Alexis P.; Gulick, Virginia C.; Baker, Victor R.; Platz, Thomas; Fairen, Alberto G.; Miyamoto, Hideaki; Kargel, Jeffrey S.; Rice, James W.; Glines, Natalie			Evidence for Middle Amazonian catastrophic flooding and glaciation on Mars	ICARUS			English	Article						Mars; Surface; Geological processes	OUTFLOW CHANNELS; VALLES-MARINERIS; GRAVEL DUNES; ICE; FLOWS; EVOLUTION; SURFACE; ORIGIN; CHAOS; WATER	Early geologic investigations of Mars revealed some of the largest channels in the Solar System (outflow channels), which appear to have mostly developed similar to 3 byr ago. These channels have been the subject of much scientific inquiry since the 1970s and proposed formative processes included surface erosion by catastrophic floods, glaciers, debris flows and lava flows. Based on the analysis of newly acquired Mars Reconnaissance Orbiter (MRO) Context (CTX, 5.15-5.91 m/pixel) and High Resolution Imaging Science Experiment (HiRISE, 25-50 cm/pixel) image data, we have identified a few locations contained within relatively narrow canyons of the southern circum-Chryse outflow channels that retain well-preserved decameter/hectometer-scale landform assemblages. These terrains include landforms consistent in shape, dimension and overall assemblage to those produced by catastrophic floods, and at one location, to glacial morphologies. Impact crater statistics for four of these surfaces, located within upstream, midstream and downstream outflow channel surfaces, yield an age estimate of similar to 600 myr. This suggests that the southern circum-Chryse outflow channels were locally resurfaced by some of the most recent catastrophic floods on the planet, and that these floods coexisted within regional glacier environments as recently as during the Middle Amazonian. (C) 2014 Published by Elsevier Inc.	[Rodriguez, J. Alexis P.; Gulick, Virginia C.; Glines, Natalie] NASA, Ames Res Ctr, Moffett Field, CA 94035 USA; [Rodriguez, J. Alexis P.; Platz, Thomas; Rice, James W.] Planetary Sci Inst, Tucson, AZ 85719 USA; [Gulick, Virginia C.] SETI Inst, Mountain View, CA 94043 USA; [Baker, Victor R.; Kargel, Jeffrey S.] Univ Arizona, Dept Hydrol & Water Resources, Tucson, AZ 85721 USA; [Platz, Thomas] Free Univ Berlin, Inst Geol Sci, D-12249 Berlin, Germany; [Fairen, Alberto G.] Cornell Univ, Dept Astron, Ithaca, NY 14853 USA; [Miyamoto, Hideaki] Univ Tokyo, Univ Museum, Tokyo 1130033, Japan	Rodriguez, JAP (reprint author), NASA, Ames Res Ctr, Mail Stop 239-20, Moffett Field, CA 94035 USA.	Alexis.Rodriguez@NASA.gov	Platz, Thomas/F-7539-2013; Ahirwal, Ashish/B-8886-2015	Platz, Thomas/0000-0002-1253-2034; Ahirwal, Ashish/0000-0002-8247-9793	NASA's NPP program; MRO HiRISE Co-Investigator funds; DFG [PL61312-1]; KAKENHI [23340126]	Funding provided by NASA's NPP program to J. Alexis P. Rodriguez and by MRO HiRISE Co-Investigator funds to V.C. Gulick. T. Platz was supported by a DFG grant (PL61312-1) and the Helmholtz association through the research alliance "Planetary Evolution and Life". HiRISE images were analyzed using HiView developed by the Lunar and Planetary Laboratory at the University of Arizona.The participation of Hideaki Miyamoto was supported by grant KAKENHI 23340126.	Komatsu G, 2009, GEOMORPHOLOGY, V104, P143, DOI 10.1016/j.geomorph.2008.08.009; Platz T, 2013, ICARUS, V225, P806, DOI 10.1016/j.icarus.2013.04.021; Meresse S, 2008, ICARUS, V194, P487, DOI 10.1016/j.icarus.2007.10.023; Kneissl T, 2011, PLANET SPACE SCI, V59, P1243, DOI 10.1016/j.pss.2010.03.015; Carling PA, 1996, SEDIMENTOLOGY, V43, P647; Warner NH, 2013, GEOLOGY, V41, P675, DOI 10.1130/G34172.1; Head JW, 2005, NATURE, V434, P346, DOI 10.1038/nature03359; BAKER VR, 1991, NATURE, V352, P589, DOI 10.1038/352589a0; Montgomery DR, 2004, QUATERNARY RES, V62, P201, DOI 10.1016/j.yres.2004.06.008; LUCCHITTA BK, 1982, J GEOPHYS RES, V87, P9951, DOI 10.1029/JB087iB12p09951; Hartmann WK, 2001, SPACE SCI REV, V96, P165, DOI 10.1023/A:1011945222010; Michael GG, 2010, EARTH PLANET SC LETT, V294, P223, DOI 10.1016/j.epsl.2009.12.041; BAKER VR, 1974, ICARUS, V23, P27, DOI 10.1016/0019-1035(74)90101-8; Burr DM, 2002, ICARUS, V159, P53, DOI 10.1006/icar.2002.6921; Skinner JA, 2012, GEOLOGY, V40, P1127, DOI 10.1130/G33513.1; Ivanov BA, 2001, SPACE SCI REV, V96, P87, DOI 10.1023/A:1011941121102; Christensen PR, 2003, SCIENCE, V300, P2056, DOI 10.1126/science.1080885; Lewis AR, 2006, GEOLOGY, V34, P513, DOI 10.1130/G22145.1; Alexander J, 1997, SEDIMENTOLOGY, V44, P327, DOI 10.1111/j.1365-3091.1997.tb01527.x; [Anonymous], 2004, DEV QUA SCI, DOI DOI 10.1016/S1571-0866(03)01003-0; CARR MH, 1979, J GEOPHYS RES, V84, P2995, DOI 10.1029/JB084iB06p02995; Michael GG, 2012, ICARUS, V218, P169, DOI 10.1016/j.icarus.2011.11.033; Hoffman N, 2000, ICARUS, V146, P326, DOI 10.1006/icar.2000.6398; Baker V. R., 1982, CHANNELS MARS; Baker V. R., 1992, MARS, P493; Baker V.R, 2009, CHANNELED SCAB LAND; Baker V.R., 2009, ANN REV EARTH PLANET, V37; Baker V.R., 2012, PLANET SPACE SCI; BAKER VR, 1979, J GEOPHYS RES, V84, P7985, DOI 10.1029/JB084iB14p07985; Bennett M., 2009, GLACIAL GEOLOGY ICE; Carling P., 2009, MEGAFLOODING EARTH M, P33, DOI 10.1017/CBO9780511635632.003; Carling PA, 2002, SEDIMENTOLOGY, V49, P1269, DOI 10.1046/j.1365-3091.2002.00496.x; Carling P.A., 2009, CONT SHELF RES, P1913; Carling PA, 1999, J SEDIMENT RES, V69, P534; Gourronc M, 2014, GEOMORPHOLOGY, V204, P235, DOI 10.1016/j.geomorph.2013.08.009; Grosswald M.G., 1999, CATACLYSMIC MEGAFLOO; Gulick VC, 1997, ICARUS, V130, P68, DOI 10.1006/icar.1997.5802; Hopper JP, 2014, GEOMORPHOLOGY, V207, P96, DOI 10.1016/j.geomorph.2013.10.029; Johnsen TF, 2004, CAN J EARTH SCI, V41, P1367, DOI 10.1139/E04-074; Koster E., 1978, CANADIAN SOC PETROLE, V5, P161; Leverington DW, 2011, GEOMORPHOLOGY, V132, P51, DOI 10.1016/j.geomorph.2011.05.022; Lucchitta BK, 2001, GEOPHYS RES LETT, V28, P403, DOI 10.1029/2000GL011924; LUCCHITTA BK, 1994, J GEOPHYS RES-PLANET, V99, P3783, DOI 10.1029/93JE03095; NUMMEDAL D, 1981, ICARUS, V45, P77, DOI 10.1016/0019-1035(81)90007-5; Pacifici A, 2009, ICARUS, V202, P60, DOI 10.1016/j.icarus.2009.02.029; Rice J.W., 2000, LUNAR PLANET SCI, VXXXI; Rice J.W., 2002, EXTREME EXTREMES EXT; Rodriguez JAP, 2005, ICARUS, V175, P36, DOI 10.1016/j.icarus.2004.10.025; Rodriguez JAP, 2006, GEOPHYS RES LETT, V33, DOI 10.1029/2005GL024320; SCHONFELD E, 1976, EOS T AM GEOPHYS UN, V57, P948; Warner N.H., 2013, GEOLOGY, V38, P791; Williams RME, 2004, J GEOPHYS RES-PLANET, V109, DOI 10.1029/2003JE002178; Wilson L., 2004, J GEOPHYS RES, V109	53	3	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0019-1035	1090-2643		ICARUS	Icarus	NOV 1	2014	242						202	210		10.1016/j.icarus.2014.06.008		9	Astronomy & Astrophysics	Astronomy & Astrophysics	AS0KX	WOS:000343967100020		
J	Melskens, J; Schouten, M; Mannheim, A; Vullers, AS; Mohammadian, Y; Eijt, SWH; Schut, H; Matsui, T; Zeman, M; Smets, AHM				Melskens, Jimmy; Schouten, Marc; Mannheim, Awital; Vullers, Albert S.; Mohammadian, Yalda; Eijt, Stephan W. H.; Schut, Henk; Matsui, Takuya; Zeman, Miro; Smets, Arno H. M.			The Nature and the Kinetics of Light-Induced Defect Creation in Hydrogenated Amorphous Silicon Films and Solar Cells	IEEE JOURNAL OF PHOTOVOLTAICS			English	Article						Dangling bonds; defects; hydrogenated amorphous silicon (a-Si:H); light-induced degradation; metastability; nanostructure; vacancies	TRANSFORM PHOTOCURRENT SPECTROSCOPY; METASTABLE DEFECTS; THIN-FILMS; A-SIH; EFFICIENCY; STATES; DEGRADATION; GROWTH; MODEL; VOIDS	The nature and the kinetics of light-induced defect creation in hydrogenated amorphous silicon (a-Si:H) films and solar cells are investigated by means of Doppler broadening positron annihilation spectroscopy, Fourier transform photocurrent spectroscopy, and J-V characterization. There is a strong correlation between the open volume deficiencies in a-Si:H and the Staebler-Wronski effect (SWE). The carrier generation and recombination profiles in the absorber layer are spatially correlated, and the recombination due to defects in the top and bottom parts of the absorber layer is different. Furthermore, the various defect distributions in the bandgap have different defect creation kinetics. It is demonstrated that the SWE defect formation kinetics in a solar cell are very complex and can impossibly be described by one time scaling similar to t(beta) as is often claimed.	[Melskens, Jimmy; Schouten, Marc; Vullers, Albert S.; Mohammadian, Yalda; Zeman, Miro; Smets, Arno H. M.] Delft Univ Technol, Fac Elect Engn Math & Comp Sci, NL-2628 CD Delft, Netherlands; [Mannheim, Awital; Eijt, Stephan W. H.; Schut, Henk] Delft Univ Technol, Fac Sci Appl, NL-2629 JB Delft, Netherlands; [Matsui, Takuya] Natl Inst Adv Ind Sci & Technol, Res Ctr Photovolta Technol, Tsukuba, Ibaraki 3058568, Japan; [Matsui, Takuya] Photovolta Power Generat Technol Res Assoc, Thin Film Silicon Lab, Tsukuba, Ibaraki 3058568, Japan	Melskens, J (reprint author), Delft Univ Technol, Fac Elect Engn Math & Comp Sci, NL-2628 CD Delft, Netherlands.	j.melskens@tudelft.nl; marcschouten@gmail.com; a.mannheim1@gmail.com; a.s.vullers@student.tudelft.nl; mohammadian@student.tudelft.nl; s.w.h.eijt@tudelft.nl; h.schut@tudelft.nl; t-matsui@aist.go.jp; m.zeman@tudelft.nl; a.h.m.smets@tudelft.nl			ADEM, A Green Deal in Energy Materials of the Ministry of Economic Affairs of The Netherlands; STW Vidi Project from Delft University of Technology; New Energy and Industrial Technology Development Organization, Japan	This work was supported by ADEM, A Green Deal in Energy Materials of the Ministry of Economic Affairs of The Netherlands, the STW Vidi Project of A.H.M. Smets from Delft University of Technology, and the New Energy and Industrial Technology Development Organization, Japan.	Shimizu T, 2004, JPN J APPL PHYS 1, V43, P3257, DOI 10.1143/JJAP.43.3257; Fritzsche H, 2001, ANNU REV MATER RES, V31, P47, DOI 10.1146/annurev.matsci.31.1.47; Branz HM, 1999, PHYS REV B, V59, P5498, DOI 10.1103/PhysRevB.59.5498; Zeman M, 2013, SOL ENERG MAT SOL C, V119, P94, DOI 10.1016/j.solmat.2013.05.037; VANVEEN A, 1990, AIP CONF PROC, V218, P171; Guha S, 2013, SOL ENERG MAT SOL C, V119, P1, DOI 10.1016/j.solmat.2013.03.036; Smets AHM, 2007, PHYS REV B, V76, DOI 10.1103/PhysRevB.76.073202; Fehr M, 2014, PHYS REV LETT, V112, DOI 10.1103/PhysRevLett.112.066403; Powell MJ, 1996, PHYS REV B, V53, P10121, DOI 10.1103/PhysRevB.53.10121; Matsui T, 2013, PROG PHOTOVOLTAICS, V21, P1363, DOI 10.1002/pip.2300; Kim S, 2013, SOL ENERG MAT SOL C, V119, P26, DOI 10.1016/j.solmat.2013.04.016; Smets AHM, 2003, APPL PHYS LETT, V82, P1547, DOI 10.1063/1.1559657; Nishimoto T, 2002, J NON-CRYST SOLIDS, V299, P1116, DOI 10.1016/S0022-3093(02)00942-0; STAEBLER DL, 1977, APPL PHYS LETT, V31, P292, DOI 10.1063/1.89674; Melskens J, 2013, IEEE J PHOTOVOLT, V3, P65, DOI 10.1109/JPHOTOV.2012.2226870; Melskens J, 2008, THIN SOLID FILMS, V516, P6877, DOI 10.1016/j.tsf.2007.12.049; STUTZMANN M, 1985, PHYS REV B, V32, P23, DOI 10.1103/PhysRevB.32.23; Schuttauf JW, 2014, IEEE J PHOTOVOLT, V4, P757, DOI 10.1109/JPHOTOV.2014.2307162; BHATTACHARYA E, 1988, APPL PHYS LETT, V52, P1587, DOI 10.1063/1.99089; Carlson D. E., 1987, DISORDERED SEMICONDU; CARLSON DE, 1986, APPL PHYS A-MATER, V41, P305, DOI 10.1007/BF00616053; Fehr M., 2010, PHYS REV B, V84; Gunes M, 1997, J APPL PHYS, V81, P3526, DOI 10.1063/1.365000; Holovsky J., 2011, FOURIER TRANSFORMS N; Isabella O, 2014, SOL ENERG MAT SOL C, V129, P82, DOI 10.1016/j.solmat.2014.03.021; Melskens J, 2014, SOL ENERG MAT SOL C, V129, P70, DOI 10.1016/j.solmat.2014.03.022; Melskens J, 2012, J NON-CRYST SOLIDS, V358, P2015, DOI 10.1016/j.jnoncrysol.2012.01.037; Niu X., 2006, THESIS PENNSYLVANIA; Pearce JM, 2002, P 17 EUR PHOT SOL EN, P2842; Polk D. E., 1971, Journal of Non-Crystalline Solids, V5, DOI 10.1016/0022-3093(71)90038-X; Smets AHM, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1853508; Smets A. H. M., 2010, P MAT RES SOC S, V1245; Street R. A., 1991, HYDROGENATED AMORPHO; Stuckelberger M., 2013, J APPL PHYS, V114; Vanecek M., 2002, APPL PHYS LETT, V80, P719; Wronski CR, 2014, IEEE J PHOTOVOLT, V4, P778, DOI 10.1109/JPHOTOV.2014.2311498; Yan B.J., 2011, APPL PHYS LETT, V99; YANG L, 1993, APPL PHYS LETT, V63, P400, DOI 10.1063/1.110031; Yue G., 2012, P MAT RES SOC S, V1426, P33	39	4	4	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	2156-3381			IEEE J PHOTOVOLT	IEEE J. Photovolt.	NOV	2014	4	6					1331	1336		10.1109/JPHOTOV.2014.2349655		6	Energy & Fuels; Materials Science, Multidisciplinary; Physics, Applied	Energy & Fuels; Materials Science; Physics	AS9DH	WOS:000344542900003		
J	Fukuda, M; Lee, KT; Lee, JY; Guo, LJ				Fukuda, Masanori; Lee, Kyu-Tae; Lee, Jae Yong; Guo, L. Jay			Optical Simulation of Periodic Surface Texturing on Ultrathin Amorphous Silicon Solar Cells	IEEE JOURNAL OF PHOTOVOLTAICS			English	Article						Light trapping; optical modeling; surface texturing; thin-film silicon solar cells	NONCONFORMAL LAYERS; GRATINGS	In this paper, we study the effect of sinusoidal textures on light absorption properties in an ultrathin amorphous silicon (a-Si) solar cell with conductive transparent layer composed of dielectric/metal/dielectric layers by using 2-D optical simulation. We found that the absorption at visible region can be enhanced at an optimized period (P) and height (H) combination, despite the weakening of a cavity resonance at the a-Si layer. The short-circuit current density for the structure with P=300 nm and H=180 nm showed a 52% higher value than that of the reference. A random texture was also simulated, and the absorption spectrum of the a-Si layer was reproduced by superposition of those with sinusoidal textures weighted by power spectrum density of the random texture, which implies the superiority of sinusoidal texture over random texture.	[Fukuda, Masanori; Lee, Kyu-Tae; Lee, Jae Yong; Guo, L. Jay] Univ Michigan, Dept Elect Engn & Comp Sci, Ann Arbor, MI 48109 USA; [Fukuda, Masanori] Kaneka Corp, Solar Energy Div, Osaka 5300005, Japan	Fukuda, M (reprint author), Univ Michigan, Dept Elect Engn & Comp Sci, Ann Arbor, MI 48109 USA.	mfukuda@umich.edu; ktlee@umich.edu; jyonglee@umich.edu; guo@umich.edu			National Science Foundation [ECCS 1202046]	This work was supported in part by the National Science Foundation under Grant ECCS 1202046.	Kats MA, 2013, NAT MATER, V12, P20, DOI [10.1038/nmat3443, 10.1038/NMAT3443]; Ameri T, 2010, ADV FUNCT MATER, V20, P1592, DOI 10.1002/adfm.201000176; Lee KT, 2014, ADV MATER, V26, P6324, DOI 10.1002/adma.201402117; Ferry VE, 2010, OPT EXPRESS, V18, pA237, DOI 10.1364/OE.18.00A237; [Anonymous], 2013, COMSOL OFFICIAL WEBS; Sever M, 2013, SOL ENERG MAT SOL C, V119, P59, DOI 10.1016/j.solmat.2013.05.016; Muller J, 2004, SOL ENERGY, V77, P917, DOI 10.1016/j.solener.2004.03.015; Lin A, 2008, SOL ENERG MAT SOL C, V92, P1689, DOI 10.1016/j.solmat.2008.07.021; Campa A, 2010, PROG PHOTOVOLTAICS, V18, P160, DOI 10.1002/pip.940; Chen YH, 2014, ADV MATER, V26, P1129, DOI 10.1002/adma.201304658; Illy BN, 2011, J MATER CHEM, V21, P12949, DOI 10.1039/c1jm11225b; Solntsev S, 2013, IEEE J PHOTOVOLT, V3, P46, DOI 10.1109/JPHOTOV.2012.2220123; Berginski M., 2007, J APPL PHYS, V101; Campa A., 2009, J APPL PHYS, V105; Kim S., 2012, J PHOTON ENERGY, V2; Lee J. Y., 2014, SCI REP, V4; Lee K. - T., LIGHT SCI A IN PRESS; Lee K.-T., 2014, APPL PHYS LETT, V104; Lipovsek B., 2010, Proceedings of the 25th European Photovoltaic Solar Energy Conference and Exhibition and the 5th World Conference on Photovoltaic Energy Conversion; Solntsev S, 2011, ENRGY PROCED, V10, DOI 10.1016/j.egypro.2011.10.196	20	3	3	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	2156-3381			IEEE J PHOTOVOLT	IEEE J. Photovolt.	NOV	2014	4	6					1337	1342		10.1109/JPHOTOV.2014.2350693		6	Energy & Fuels; Materials Science, Multidisciplinary; Physics, Applied	Energy & Fuels; Materials Science; Physics	AS9DH	WOS:000344542900004		
J	Sai, H; Matsui, T; Matsubara, K; Kondo, M; Yoshida, I				Sai, Hitoshi; Matsui, Takuya; Matsubara, Koji; Kondo, Michio; Yoshida, Isao			11.0%-Efficient Thin-Film Microcrystalline Silicon Solar Cells With Honeycomb Textured Substrates	IEEE JOURNAL OF PHOTOVOLTAICS			English	Article						Light trapping; periodic structures; photovoltaic cells; silicon; thin-film devices		In this paper, we present our latest results toward high-efficiency thin-film silicon solar cells. Owing to the superior light trapping capability of periodic textures combined with other technologies, a new world record was achieved for the efficiency of single-junction microcrystalline silicon solar cells, with a conversion efficiency of 11.0%, independently confirmed by the Advanced Industrial Science and Technology (AIST) Characterization, Standards, and Measurement (CSM) team.	[Sai, Hitoshi; Matsui, Takuya; Matsubara, Koji] Natl Inst Adv Ind Sci & Technol, Res Ctr Photovolta Technol, Tsukuba, Ibaraki 3058568, Japan; [Kondo, Michio] Fukushima Renewable Energy Inst, Koriyama, Fukushima 9630298, Japan; [Yoshida, Isao] Photovolta Power Generat Technol Res Assoc, Tsukuba, Ibaraki 3058568, Japan	Sai, H (reprint author), Natl Inst Adv Ind Sci & Technol, Res Ctr Photovolta Technol, Tsukuba, Ibaraki 3058568, Japan.	hitoshi-sai@aist.go.jp; t-matsui@aist.go.jp; koji.matsubara@aist.go.jp; michio.kondo@aist.go.jp; i.yoshida@pvtec.or.jp			New Energy and Industrial Technology Development Organization, Japan; "Nanotechnology Network Japan" of the Ministry of Education, Culture, Sports, Science, and Technology, Japan	This work was supported by New Energy and Industrial Technology Development Organization, Japan. The photolithography process was conducted at the AIST Nano-Processing Facility, supported by the "Nanotechnology Network Japan" of the Ministry of Education, Culture, Sports, Science, and Technology, Japan.	Python M, 2009, SOL ENERG MAT SOL C, V93, P1714, DOI 10.1016/j.solmat.2009.05.025; Battaglia C, 2012, ACS NANO, V6, P2790, DOI 10.1021/nn300287j; Yamamoto K, 1997, JPN J APPL PHYS 2, V36, pL569, DOI 10.1143/JJAP.36.L569; Green MA, 2014, PROG PHOTOVOLTAICS, V22, P701, DOI 10.1002/pip.2525; Berginski M, 2008, THIN SOLID FILMS, V516, P5836, DOI 10.1016/j.tsf.2007.10.029; Taguchi M, 2014, IEEE J PHOTOVOLT, V4, P96, DOI 10.1109/JPHOTOV.2013.2282737; Kim S, 2013, SOL ENERG MAT SOL C, V119, P26, DOI 10.1016/j.solmat.2013.04.016; Yang J, 2005, THIN SOLID FILMS, V487, P162, DOI 10.1016/j.tsf.2005.01.058; Li HBT, 2009, SOL ENERG MAT SOL C, V93, P338, DOI 10.1016/j.solmat.2008.11.013; Meier J, 1997, SOL ENERG MAT SOL C, V49, P35, DOI 10.1016/S0927-0248(97)00173-6; Han SE, 2010, NANO LETT, V10, P4692, DOI 10.1021/nl1029804; Chong T. K., 2012, J OPT, V14; Escarre J., 2012, J OPT, V14; Hanni S, 2013, PROG PHOTOVOLTAICS, V21, P821, DOI 10.1002/pip.2398; Kawamoto Y., 2014, IEEE PHOTONICS J, V1, P10; Koida T, 2007, JPN J APPL PHYS 2, V46, pL685, DOI 10.1143/JJAP.46.L685; Lin J., 2014, 40 IEEE PHOT SPEC C; Meier M, 2014, IEEE J PHOTOVOLT, V4, P772, DOI 10.1109/JPHOTOV.2014.2311233; Sai H., 2013, APPL PHYS EXP, V6; Sai H., 2009, J APPL PHYS, V105; Sai H., 2012, APPL PHYS LETT, V101; Sal H., 2013, APPL PHYS LETT, V102; Tan H., 2013, APPL PHYS LETT, V103; Toyama N., 2004, P 3 WORLD C PHOT EN, P1601; van den Donker M. N., 2007, APPL PHYS LETT, V90; Yue G., 2009, APPL PHYS LETT, V95	26	17	17	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	2156-3381			IEEE J PHOTOVOLT	IEEE J. Photovolt.	NOV	2014	4	6					1349	1353		10.1109/JPHOTOV.2014.2355037		5	Energy & Fuels; Materials Science, Multidisciplinary; Physics, Applied	Energy & Fuels; Materials Science; Physics	AS9DH	WOS:000344542900006		
J	Abe, Y; Kagei, T; Sichanugrist, P; Konagai, M				Abe, Yusuke; Kagei, Taijiro; Sichanugrist, Porponth; Konagai, Makoto			Development of Double-Textured ZnO:B Substrates for Improving Microcrystalline Silicon Solar Cell Performance	IEEE JOURNAL OF PHOTOVOLTAICS			English	Article						Conductive films; light trapping; photovoltaic cells; silicon; thin-film devices	A-SI-H; SURFACE-MORPHOLOGY; FILMS; ROUGHNESS; TCO	Zinc oxide (ZnO) films are widely used as front transparent conductive oxide films in thin-film silicon solar cells. Double-textured B-doped zinc oxide(W-textured ZnO: B) substrates, which are formed by reactive ion etching (RIE) and metal-organic chemical vapor deposition, have a high haze ratio over a wide wavelength range. In this study, we have investigated the RIE conditions necessary to modify the surface morphology and the optical properties of a glass substrate. By increasing the pressure during the RIE process, the surface morphology of etched glass was changed from circular to ellipsoidal shapes, and its texture size increased. A newly developed W-textured ZnO: B substrate fabricated using the modified glass exhibited a higher haze ratio than a conventional W-textured ZnO: B substrate and achieved a higher short-circuit current in microcrystalline silicon solar cells without significant deterioration of open-circuit voltage and fill factor.	[Abe, Yusuke; Kagei, Taijiro; Sichanugrist, Porponth; Konagai, Makoto] Tokyo Inst Technol, Dept Phys Elect, Tokyo 1528552, Japan; [Konagai, Makoto] Tokyo Inst Technol, Photovolta Res Ctr, Tokyo 1528552, Japan	Abe, Y (reprint author), Tokyo Inst Technol, Dept Phys Elect, Tokyo 1528552, Japan.	abe.y.ar@m.titech.ac.jp; kagei.t.aa@m.titech.ac.jp; konagai.m.aa@m.titech.ac.jp	Sichanugrist, Porponth/D-6102-2015		New Energy and Industrial Technology Development Organization under Ministry of Economy, Trade, and Industry, Japan	This work was supported by the New Energy and Industrial Technology Development Organization under the Ministry of Economy, Trade, and Industry, Japan.	Python M, 2009, SOL ENERG MAT SOL C, V93, P1714, DOI 10.1016/j.solmat.2009.05.025; Krc J, 2010, THIN SOLID FILMS, V518, P3054, DOI 10.1016/j.tsf.2009.09.164; Tamang A, 2014, IEEE J PHOTOVOLT, V4, P16, DOI 10.1109/JPHOTOV.2013.2280020; Nasuno Y, 2001, JPN J APPL PHYS 2, V40, pL303, DOI 10.1143/JJAP.40.L303; Lambertz A, 2012, J NON-CRYST SOLIDS, V358, P1962, DOI 10.1016/j.jnoncrysol.2011.12.047; WENAS WW, 1991, JPN J APPL PHYS 2, V30, pL441, DOI 10.1143/JJAP.30.L441; Muller J, 2004, SOL ENERGY, V77, P917, DOI 10.1016/j.solener.2004.03.015; Yan BJ, 2012, SOL ENERG MAT SOL C, V104, P13, DOI 10.1016/j.solmat.2012.04.036; Zeman M, 2000, J APPL PHYS, V88, P6436, DOI 10.1063/1.1324690; Krc J, 2003, THIN SOLID FILMS, V426, P296, DOI 10.1016/S0040-6090(03)00006-3; Hongsingthong A, 2011, SOL ENERG MAT SOL C, V95, P171, DOI 10.1016/j.solmat.2010.04.025; Python M, 2008, J NON-CRYST SOLIDS, V354, P2258, DOI 10.1016/j.jnoncrysol.2007.09.084; Shah AV, 2004, J NON-CRYST SOLIDS, V338, P639, DOI [10.1016/j.jnoncrysol.2004.03.074, 10.1016/j.jnonerysol.2004.03.074]; Boccard M., 2010, Proceedings of the 25th European Photovoltaic Solar Energy Conference and Exhibition and the 5th World Conference on Photovoltaic Energy Conversion; Cuony P, 2010, APPL PHYS LETT, V97; Haase C., 2007, APPL PHYS LETT, V91; Hongsingthong A., 2010, APPL PHYS EXP, V3; Kim DY, 2014, IEEE J PHOTOVOLT, V4, P22, DOI 10.1109/JPHOTOV.2013.2287770; Kuo Y., 1989, P SOC PHOTO-OPT INS, V1037, P103; Lin J., 2014, 40 IEEE PHOT SPEC C; MIZUHASHI M, 1988, JPN J APPL PHYS 1, V27, P2053, DOI 10.1143/JJAP.27.2053; Sai H., 2010, J APPL PHYS, V108; Sai H., 2009, J APPL PHYS, V105; Sal H., 2013, APPL PHYS LETT, V102; Smets A. H. M., 2008, J APPL PHYS, V104; Tan H., 2013, APPL PHYS LETT, V103; ZAROWIN CB, 1983, J ELECTROCHEM SOC, V130, P1144, DOI 10.1149/1.2119905	27	1	1	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	2156-3381			IEEE J PHOTOVOLT	IEEE J. Photovolt.	NOV	2014	4	6					1374	1379		10.1109/JPHOTOV.2014.2358085		6	Energy & Fuels; Materials Science, Multidisciplinary; Physics, Applied	Energy & Fuels; Materials Science; Physics	AS9DH	WOS:000344542900010		
J	Masuko, K; Shigematsu, M; Hashiguchi, T; Fujishima, D; Kai, M; Yoshimura, N; Yamaguchi, T; Ichihashi, Y; Mishima, T; Matsubara, N; Yamanishi, T; Takahama, T; Taguchi, M; Maruyama, E; Okamoto, S				Masuko, Keiichiro; Shigematsu, Masato; Hashiguchi, Taiki; Fujishima, Daisuke; Kai, Motohide; Yoshimura, Naoki; Yamaguchi, Tsutomu; Ichihashi, Yoshinari; Mishima, Takahiro; Matsubara, Naoteru; Yamanishi, Tsutomu; Takahama, Tsuyoshi; Taguchi, Mikio; Maruyama, Eiji; Okamoto, Shingo			Achievement of More Than 25% Conversion Efficiency With Crystalline Silicon Heterojunction Solar Cell	IEEE JOURNAL OF PHOTOVOLTAICS			English	Article						Amorphous materials; photovoltaic cells; silicon heterojunction; surface passivation	CONTACT	The crystalline silicon heterojunction structure adopted in photovoltaic modules commercialized as Panasonic's HIT has significantly reduced recombination loss, resulting in greater conversion efficiency. The structure of an interdigitated back contact was adopted with our crystalline silicon heterojunction solar cells to reduce optical loss from a front grid electrode, a transparent conducting oxide (TCO) layer, and a-Si: H layers as an approach for exceeding the conversion efficiency of 25%. As a result of the improved short-circuit current (J(sc)), we achieved the world's highest efficiency of 25.6% for crystalline silicon-based solar cells under 1-sun illumination (designated area: 143.7 cm(2)).	[Masuko, Keiichiro; Shigematsu, Masato; Hashiguchi, Taiki; Fujishima, Daisuke; Kai, Motohide; Yoshimura, Naoki; Yamaguchi, Tsutomu; Ichihashi, Yoshinari; Mishima, Takahiro; Matsubara, Naoteru; Yamanishi, Tsutomu; Takahama, Tsuyoshi; Taguchi, Mikio; Maruyama, Eiji; Okamoto, Shingo] Panasonic Corp, Eco Solut Co, Solar Business Unit, Kaizuka City, Osaka 5970094, Japan	Masuko, K (reprint author), Panasonic Corp, Eco Solut Co, Solar Business Unit, Kaizuka City, Osaka 5970094, Japan.	masuko.keiichiro@jp.panasonic.com; shigematsu.masato@jp.panasonic.com; hashiguchi.taiki@jp.panasonic.com; fujishima.daisuke006@jp.panasonic.com; kai.motohide@jp.panasonic.com; yoshimura.naoki3@jp.panasonic.com; yamaguchi.ttm@jp.panasonic.com; ichihashi.yoshinari@jp.panasonic.com; mishima.takahiro@jp.panasonic.com; matsubara.naoteru@jp.panasonic.com; yamanishi.tsutomu@jp.panasonic.com; takahama.tsuyoshi@jp.panasonic.com; taguchi.mikio@jp.panasonic.com; maruyama.eiji@jp.panasonic.com; okamoto.shingo1@jp.panasonic.com					Fujiwara H, 2007, J APPL PHYS, V101, DOI 10.1063/1.2559975; Mingirulli N, 2011, PHYS STATUS SOLIDI-R, V5, P159, DOI 10.1002/pssr.201105056; Bivour M, 2012, SOL ENERG MAT SOL C, V106, P11, DOI 10.1016/j.solmat.2012.06.036; Tomasi A, 2014, IEEE J PHOTOVOLT, V4, P1046, DOI 10.1109/JPHOTOV.2014.2320586; Lee SY, 2014, SOL ENERG MAT SOL C, V120, P412, DOI 10.1016/j.solmat.2013.06.026; LAMMERT MD, 1977, IEEE T ELECTRON DEV, V24, P337, DOI 10.1109/T-ED.1977.18738; Green MA, 2014, PROG PHOTOVOLTAICS, V22, P1, DOI 10.1002/pip.2452; Bivour M, 2014, SOL ENERG MAT SOL C, V122, P120, DOI 10.1016/j.solmat.2013.11.029; De Wolf Stefaan, 2012, Green, V2, DOI 10.1515/green-2011-0018; Kinoshita T., 2011, Proceedings of the 26th European International Conference on Photovoltaic Solar Energy; Lu M., 2007, APPL PHYS LETT, V91, DOI [10. 1063/ 1. 2768635, DOI 10.1063/1.2768635]; Smith D. D., 2014, P 40 IEEE PHOT SPEC, P129; Swanson RM, 1985, P 18 IEEE PHOT SPEC, P604; Taguchi M., 2013, P 39 IEEE PHOT SPEC, V4, P96; Taguchi M., 1990, P 5 PHOT SOL EN C PV, P689; Tohoda S., 2013, P 23 PHOT SCI ENG C, P1405; Yano A., 2013, P 28 EUR PHOT SOL EN, p748 	17	60	62	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	2156-3381			IEEE J PHOTOVOLT	IEEE J. Photovolt.	NOV	2014	4	6					1433	1435		10.1109/JPHOTOV.2014.2352151		3	Energy & Fuels; Materials Science, Multidisciplinary; Physics, Applied	Energy & Fuels; Materials Science; Physics	AS9DH	WOS:000344542900018		
J	Tajima, M				Tajima, Michio			Spectroscopy and Topography of Deep-Level Luminescence in Photovoltaic Silicon	IEEE JOURNAL OF PHOTOVOLTAICS			English	Article						Deep level; dislocations; imaging; mapping; oxygen precipitates; photoluminescence (PL); photovoltaic cells; Si; spectroscopy	DISLOCATION-RELATED PHOTOLUMINESCENCE; MULTICRYSTALLINE SILICON; ROOM-TEMPERATURE; THERMAL DONORS; SI CRYSTALS; OXYGEN; WAFERS; CARBON; RECOMBINATION; DEFECTS	The aim of this paper is to identify the origin of a deep-level emission band with a peak at about 0.8 eV observed in photoluminescence from defective areas in multicrystalline Si crystals at room temperature. We compare the band with that in a plastically deformed float-zone and annealed Czochralski-grown Si crystals investigated in detail previously for microelectronic applications and point out the similarities in spectroscopic characteristics and in spatial distributions around dislocations. This prompted us to suggest that the 0.8-eV band consists of two dislocation-related components termed D-a1 and D-a2 at about 0.79 and 0.94 eV, respectively, and an oxygen-precipitation-related component D-b at approximately 0.87 eV. Spatial variations of the three components around dislocation clusters forming small-angle grain boundaries reflect secondary defects or impurities trapped by the strain field around the dislocations, the intrinsic nature of the dislocations, and preferential oxygen precipitation on the dislocations, respectively. The presence of oxygen precipitates in a region emitting the strong Db component was confirmed by highly spatially resolved and highly sensitive secondary ion mass spectroscopy and by mapping of oxygen by luminescence activation using electron irradiation. Anisotropic properties expected for the dislocation-related D-a1 component were detected by polarized luminescence imaging.	[Tajima, Michio] Japan Aerosp Explorat Agcy, Inst Space & Astronaut Sci, Sagamihara, Kanagawa 2525210, Japan; [Tajima, Michio] Meiji Univ, Kawasaki, Kanagawa 2148571, Japan	Tajima, M (reprint author), Japan Aerosp Explorat Agcy, Inst Space & Astronaut Sci, Sagamihara, Kanagawa 2525210, Japan.	tajima@isas.jaxa.jp			New Energy and Industrial Technology Development Organization under Ministry of Economy, Trade and Industry	This work was partly supported by the New Energy and Industrial Technology Development Organization under the Ministry of Economy, Trade and Industry.	DROZDOV NA, 1976, JETP LETT+, V23, P597; Pizzini S, 2000, J PHYS-CONDENS MAT, V12, P10131, DOI 10.1088/0953-8984/12/49/312; Kittler M, 2002, SOL ENERG MAT SOL C, V72, P465, DOI 10.1016/S0927-0248(01)00194-5; Schmid RP, 2011, PHYS STATUS SOLIDI A, V208, P888, DOI 10.1002/pssa.201026269; MINAEV NS, 1981, PHYS STATUS SOLIDI A, V68, P561, DOI 10.1002/pssa.2210680227; Moller HJ, 1999, PHYS STATUS SOLIDI A, V171, P175, DOI 10.1002/(SICI)1521-396X(199901)171:1<175::AID-PSSA175>3.0.CO;2-Q; Johnston S, 2014, IEEE J PHOTOVOLT, V4, P348, DOI 10.1109/JPHOTOV.2013.2283575; Trupke T, 2006, APPL PHYS LETT, V89, DOI 10.1063/1.2234747; Binetti S, 2002, J APPL PHYS, V92, P2437, DOI 10.1063/1.1497450; Bothe K., 2012, APPL PHYS LETT, V101; DAVIES G, 1983, J PHYS C SOLID STATE, V16, P5503, DOI 10.1088/0022-3719/16/28/017; HIGGS V, 1992, APPL PHYS LETT, V61, P1087, DOI 10.1063/1.107676; Inoue M, 2008, J MATER SCI-MATER EL, V19, pS132, DOI 10.1007/s10854-008-9605-5; Kato G, 2014, ACTA PHYS POL A, V125, P1010; Kato G, 2014, JPN J APPL PHYS, V53, DOI 10.7567/JJAP.53.080303; KITAGAWARA Y, 1992, J ELECTROCHEM SOC, V139, P2277, DOI 10.1149/1.2221215; Koshka Y, 1999, APPL PHYS LETT, V74, P1555, DOI 10.1063/1.123614; KVEDER VV, 1995, PHYS REV B, V51, P10520, DOI 10.1103/PhysRevB.51.10520; Mchedlidze T., 2012, J APPL PHYS, V111; Nakagawa S, 2009, JPN J APPL PHYS, V48, DOI 10.1143/JJAP.48.04C093; NAKAMURA M, 1994, J ELECTROCHEM SOC, V141, P3576, DOI 10.1149/1.2059372; Ostapenko S, 2000, SEMICOND SCI TECH, V15, P840, DOI 10.1088/0268-1242/15/8/310; Peloso M. P., 2011, APPL PHYS LETT, V98; SAUER R, 1985, APPL PHYS A-MATER, V36, P1, DOI 10.1007/BF00616453; Schubert M. C., 2008, P 23 EUR PHOT SOL EN, P17; SUEZAWA M, 1981, JPN J APPL PHYS, V20, pL537, DOI 10.1143/JJAP.20.L537; TAJIMA M, 1983, APPL PHYS LETT, V43, P270, DOI 10.1063/1.94323; TAJIMA M, 1983, JPN J APPL PHYS 2, V22, pL589, DOI 10.1143/JJAP.22.L589; TAJIMA M, 1979, JPN J APPL PHYS, V18, P1401, DOI 10.1143/JJAP.18.1401; Tajima M, 1996, INST PHYS CONF SER, V149, P243; Tajima M., 2012, J APPL PHYS, V111; TAJIMA M, 1992, MATER SCI FORUM, V83, P1327; Tajima M, 2002, JPN J APPL PHYS 2, V41, pL1505, DOI 10.1143/JJAP.41.L1505; Tajima M, 2009, ECS TRANSACTIONS, V25, P3, DOI 10.1149/1.3204389; Tajima M., 1990, SEMICONDUCTOR SILICO, V90-7, P994; Tajima M., 2011, 21 INT PHOT SCI ENG; Tajima M, 1995, MATER SCI FORUM, V196-, P1749; Trupke T., 2007, P 22 EUR PHOT SOL EN, P22; Weber J., 1983, MATER RES SOC S P, V14, P165	39	3	3	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	2156-3381			IEEE J PHOTOVOLT	IEEE J. Photovolt.	NOV	2014	4	6					1452	1458		10.1109/JPHOTOV.2014.2350082		7	Energy & Fuels; Materials Science, Multidisciplinary; Physics, Applied	Energy & Fuels; Materials Science; Physics	AS9DH	WOS:000344542900021		
J	Nakamura, J; Asano, N; Hieda, T; Okamoto, C; Katayama, H; Nakamura, K				Nakamura, Junichi; Asano, Naoki; Hieda, Takeshi; Okamoto, Chikao; Katayama, Hiroyuki; Nakamura, Kyotaro			Development of Heterojunction Back Contact Si Solar Cells	IEEE JOURNAL OF PHOTOVOLTAICS			English	Article						Back contact (BC); cell efficiency; heterojunction; patterning process; solar cell		An energy conversion efficiency of 25.1% was achieved in heterojunction back contact (HBC) structure Si solar cell utilizing back contact technology and an amorphous silicon thin-film technology. A new patterning process was established, and it was applied to the fabrication process of HBC cells. In addition, the unique technology of the surface mount technology concept contributed to the superior performance of HBC cell. A short-circuit current density (J(sc)) and an open-circuit voltage (V-oc) were 41.7 mA/cm(2) and 736 mV, respectively. The high J(sc) as well as the high V-oc indicates the strength of HBC structure cell. Besides, a high fill factor of 0.82 was obtained, which shows that HBC structure cell does not have any fundamental critical losses caused from series resistance or shunt resistance. Such high values of I-V parameter means that the patterning process was properly performed.	[Nakamura, Junichi; Asano, Naoki; Hieda, Takeshi; Okamoto, Chikao; Katayama, Hiroyuki] Sharp Co Ltd, Nara 6392198, Japan; [Nakamura, Kyotaro] Meiji Univ, Kawasaki, Kanagawa 2148571, Japan	Nakamura, J (reprint author), Sharp Co Ltd, Nara 6392198, Japan.	nakamura.junichi@sharp.co.jp; asano.naoki@sharp.co.jp; hieda.takeshi@sharp.co.jp; okamoto.chikao@sharp.co.jp; katayama.hiroyuki@sharp.co.jp; kyotaro@toyota-ti.ac.jp			NEDO project named as "R&D on Ultimate Wafer-based Si Solar Cells"	This work was supported in part by the NEDO project named as "R&D on Ultimate Wafer-based Si Solar Cells" accelerated and elevated by consortium framework centered on Toyota Technological Institute.	Taguchi M, 2014, IEEE J PHOTOVOLT, V4, P96, DOI 10.1109/JPHOTOV.2013.2282737; Desrues T., 2010, Proceedings of the 25th European Photovoltaic Solar Energy Conference and Exhibition and the 5th World Conference on Photovoltaic Energy Conversion; Desrues T., 2008, P 23 EPVSEC VAL SPAI, P1673; Haschke J, 2012, ENRGY PROCED, V27, P116, DOI 10.1016/j.egypro.2012.07.038; Haschke J., 2008, P 23 EUR PHOT SOL EN, P1652; Hertanto A., 2009, P 34 IEEE PHOT SPEC; Ji KS, 2012, JPN J APPL PHYS, V51, DOI 10.1143/JJAP.51.10NA05; Lu M.-S., 2008, P 8 S AGR BIOCH MOL, P1; Masuko K., 2014, 40 IEEE PHOT SPEC C; Nakamura K., 2008, P 23 EUR PHOT SOL EN, P1006; Nakamura K., 2007, P 19 PHOT SCI ENG C, P1006; O'Sullivan BJ, 2010, IEEE PHOT SPEC CONF, P3549; Smith DD, 2013, IEEE PHOT SPEC CONF, P908, DOI 10.1109/PVSC.2013.6744291; Tucci M., 2007, P 22 EUR PHOT SOL EN, P1600	14	11	11	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	2156-3381			IEEE J PHOTOVOLT	IEEE J. Photovolt.	NOV	2014	4	6					1491	1495		10.1109/JPHOTOV.2014.2358377		5	Energy & Fuels; Materials Science, Multidisciplinary; Physics, Applied	Energy & Fuels; Materials Science; Physics	AS9DH	WOS:000344542900027		
J	Toprasertpong, K; Kasamatsu, N; Fujii, H; Kada, T; Asahi, S; Wang, YP; Watanabe, K; Sugiyama, M; Kita, T; Nakano, Y				Toprasertpong, Kasidit; Kasamatsu, Naofumi; Fujii, Hiromasa; Kada, Tomoyuki; Asahi, Shigeo; Wang, Yunpeng; Watanabe, Kentaroh; Sugiyama, Masakazu; Kita, Takashi; Nakano, Yoshiaki			Carrier Time-of-Flight Measurement Using a Probe Structure for Direct Evaluation of Carrier Transport in Multiple Quantum Well Solar Cells	IEEE JOURNAL OF PHOTOVOLTAICS			English	Article						Carrier transport; measurement techniques; photoluminescence; photovoltaic cells; probes; quantum well devices; thermionic emission; time-of-flight; tunneling	EFFICIENCY ENHANCEMENT; COLLECTION EFFICIENCY; RECOMBINATION; PHOTOVOLTAICS; DEVICES	Carrier transport across multiple quantum well (MQW) structures inserted in the i-region of a p-i-n diode is an important mechanism that determines the performance of MQW solar cells. We have employed a carrier time-of-flight measurement technique using a quantum-well probe to investigate the electron transport time across MQW structures. Delay of the carrier arrival time, defined as time-of-flight, caused by MQWs shows almost linear increment to the number of wells. Tunneling transport in InGaAs/GaAsP MQW structures is studied by varying the GaAsP barrier thickness. Barrier thickness of 2 nm results in extremely small electron time-of-flight, less than a hundred picoseconds per well, whereas MQW with 8-nm-thick barriers results in approximately 20 times slower transport. Furthermore, the fast time-of-flight in thin barriers shows no degradation after the insertion of GaAs interlayers that form the multistep potential. This suggests that the fast thermally assisted tunneling transport dominates the electron escape dynamics in thin-barrier InGaAs/GaAsP MQWs. The rapid carrier transport results in the significant suppression of current drop at the cell maximum power point of MQW solar cells.	[Toprasertpong, Kasidit; Fujii, Hiromasa; Sugiyama, Masakazu; Nakano, Yoshiaki] Univ Tokyo, Sch Engn, Dept Elect Engn & Informat Syst, Tokyo 1138654, Japan; [Wang, Yunpeng; Watanabe, Kentaroh] Univ Tokyo, Res Ctr Adv Sci & Technol, Tokyo 1538904, Japan; [Kasamatsu, Naofumi; Kada, Tomoyuki; Asahi, Shigeo; Kita, Takashi] Kobe Univ, Dept Elect & Elect Engn, Grad Sch Engn, Kobe, Hyogo 6578501, Japan	Toprasertpong, K (reprint author), Univ Tokyo, Sch Engn, Dept Elect Engn & Informat Syst, Tokyo 1138654, Japan.	toprasertpong@hotaka.t.u-tokyo.ac.jp; 118t803t@stu.kobe-u.ac.jp; fujii@hotaka.t.u-tokyo.ac.jp; 131t216t@stu.kobe-u.ac.jp; 134t214t@stu.kobe-u.ac.jp; wangyunpeng@hotaka.t.u-tokyo.ac.jp; kentaroh@hotaka.t.u-tokyo.ac.jp; sugiyama@ee.t.u-tokyo.ac.jp; kita@eedept.kobe-u.ac.jp; nakano@ee.t.u-tokyo.ac.jp	Kita, Takashi/H-6884-2013; Sugiyama, Masakazu/P-9616-2015	Sugiyama, Masakazu/0000-0002-4303-4038	Research and Development of Innovative Solar Cell Program, New Energy and Industrial Technology Development Organization, Japan	This work was supported in part by the Research and Development of Innovative Solar Cell Program, New Energy and Industrial Technology Development Organization, Japan.	Akram MN, 2006, IEEE J QUANTUM ELECT, V42, P713, DOI 10.1109/JQE.2006.876710; Alemu A, 2009, Proceedings of the 2009 34th IEEE Photovoltaic Specialists Conference (PVSC 2009), DOI 10.1109/PVSC.2009.5411285; Wen Y, 2013, IEEE J PHOTOVOLT, V3, P289, DOI 10.1109/JPHOTOV.2012.2212698; Fujii H, 2014, PROG PHOTOVOLTAICS, V22, P784, DOI 10.1002/pip.2454; Alemu A, 2006, J APPL PHYS, V99, DOI 10.1063/1.2191433; Fujii H, 2012, J CRYST GROWTH, V352, P239, DOI 10.1016/j.jcrysgro.2011.11.036; Toprasertpong K, 2014, IEEE J PHOTOVOLT, V4, P607, DOI 10.1109/JPHOTOV.2013.2293877; Nozik AJ, 2002, PHYSICA E, V14, P115, DOI 10.1016/S1386-9477(02)00374-0; Green MA, 2000, MAT SCI ENG B-SOLID, V74, P118, DOI 10.1016/S0921-5107(99)00546-2; BARNHAM KWJ, 1991, APPL PHYS LETT, V59, P135, DOI 10.1063/1.105553; Zhu HM, 2010, J AM CHEM SOC, V132, P15038, DOI 10.1021/ja106710m; Walker AW, 2013, IEEE J PHOTOVOLT, V3, P1118, DOI 10.1109/JPHOTOV.2013.2257920; Fujii H, 2014, IEEE J PHOTOVOLT, V4, P237, DOI 10.1109/JPHOTOV.2013.2287994; Adams JGJ, 2011, PROG PHOTOVOLTAICS, V19, P865, DOI 10.1002/pip.1069; BARNHAM KWJ, 1990, J APPL PHYS, V67, P3490, DOI 10.1063/1.345339; Barnham K, 1997, APPL SURF SCI, V113, P722, DOI 10.1016/S0169-4332(96)00876-8; Ekins-Daukes NJ, 2001, SOL ENERG MAT SOL C, V68, P71, DOI 10.1016/S0927-0248(00)00346-9; Green MA, 2001, PROG PHOTOVOLTAICS, V9, P123, DOI 10.1002/pip.360; Tessler N, 1997, IEEE J SEL TOP QUANT, V3, P315, DOI 10.1109/2944.605673; Hirst LC, 2014, IEEE J PHOTOVOLT, V4, P244, DOI 10.1109/JPHOTOV.2013.2289321; Aroutiounian VM, 2001, P SOC PHOTO-OPT INS, V4458, P38, DOI 10.1117/12.448264; Conibeer G., 2012, PHOT SPEC C PVSC 201, P32; Corkish R., 1993, P 23 IEEE PHOT SPEC, P675; DEVEAUD B, 1987, PHYS REV LETT, V58, P2582, DOI 10.1103/PhysRevLett.58.2582; Fujii H., 2013, J APPL PHYS, V114; Gorji NE, 2010, PHYSICA E, V42, P2353, DOI 10.1016/j.physe.2010.05.014; HILLMER H, 1986, APPL PHYS LETT, V49, P948, DOI 10.1063/1.97492; Jolley G., 2010, APPL PHYS LETT, V97; Kasamatsu N., 2014, J APPL PHYS, V115; Okada Y, 2002, J CRYST GROWTH, V237, P1515, DOI 10.1016/S0022-0248(01)02373-9; Raisky OY, 2001, APPL PHYS LETT, V79, P430, DOI 10.1063/1.1386402; Raisky OY, 1999, APPL PHYS LETT, V74, P129, DOI 10.1063/1.122972; Toprasertpong K., MICROSCOPIC OBSERVAT	33	1	1	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	2156-3381			IEEE J PHOTOVOLT	IEEE J. Photovolt.	NOV	2014	4	6					1518	1525		10.1109/JPHOTOV.2014.2354256		8	Energy & Fuels; Materials Science, Multidisciplinary; Physics, Applied	Energy & Fuels; Materials Science; Physics	AS9DH	WOS:000344542900031		
J	Tachi, S; Inami, M; Uema, Y				Tachi, Susumu; Inami, Masahiko; Uema, Yuji			THE TRANSPARENT COCKPIT	IEEE SPECTRUM			English	Article									[Tachi, Susumu; Inami, Masahiko; Uema, Yuji] Keio Univ, Grad Sch Media Design, Yokohama, Kanagawa 223, Japan; [Tachi, Susumu] Keio Univ, Int Virtual Real Ctr, Yokohama, Kanagawa 223, Japan	Tachi, S (reprint author), Keio Univ, Grad Sch Media Design, Yokohama, Kanagawa 223, Japan.							0	0	0	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0018-9235	1939-9340		IEEE SPECTRUM	IEEE Spectr.	NOV	2014	51	11					52	56				5	Engineering, Electrical & Electronic	Engineering	AS6YX	WOS:000344406100015		
J	Washizawa, Y; Hotta, S				Washizawa, Yoshikazu; Hotta, Seiji			Mahalanobis Distance on Extended Grassmann Manifolds for Variational Pattern Analysis	IEEE TRANSACTIONS ON NEURAL NETWORKS AND LEARNING SYSTEMS			English	Article						Grassmann manifolds; Mahalanobis distance; subspace method; tangent distance (TD)	TANGENT DISTANCE; VECTOR KERNELS; RECOGNITION	In pattern classification problems, pattern variations are often modeled as a linear manifold or a low-dimensional subspace. Conventional methods use such models and define a measure of similarity or dissimilarity. However, these similarity measures are deterministic and do not take into account the distribution of linear manifolds or low-dimensional subspaces. Therefore, if the distribution is not isotopic, the distance measurements are not reliable, as well as vector-based distance measurement in the Euclidean space. We previously systematized the representations of variational patterns using the Grassmann manifold and introduce the Mahalanobis distance to the Grassmann manifold as a natural extension of Euclidean case. In this paper, we present two methods that flexibly extend the Mahalanobis distance on the extended Grassmann manifolds. These methods can be used to measure pattern (dis)similarity on the basis of the pattern structure. Experimental evaluation of the performance of the proposed methods demonstrated that they exhibit a lower error classification rate.	[Washizawa, Yoshikazu] Univ Electrocommun, Dept Commun Engn & Informat, Tokyo 1828585, Japan; [Washizawa, Yoshikazu] RIKEN, Brain Sci Inst, Saitama 3511098, Japan; [Hotta, Seiji] Tokyo Univ Agr & Technol, Dept Comp & Informat Sci, Tokyo 1838538, Japan; [Washizawa, Yoshikazu] Toshiba Co Ltd, Tokyo, Japan; [Washizawa, Yoshikazu] Tokyo Inst Technol, Tokyo, Japan; [Washizawa, Yoshikazu] RIKEN, Brain Sci Inst, Lab Adv Brain Signal Proc, Saitama 3511098, Japan; [Hotta, Seiji] Nagasaki Univ, Nagasaki 852, Japan; [Hotta, Seiji] Tokyo Univ Agr & Technol, Tokyo 1838538, Japan	Washizawa, Y (reprint author), Univ Electrocommun, Dept Commun Engn & Informat, Tokyo 1828585, Japan.	washizawa@uec.ac.jp; s-hotta@cc.tuat.ac.jp			Japan Society for the Promotion of Science [24700163, 23300069]	This work was supported in part by a Grant-in-Aid for Young Scientists (B) under Grant 24700163 and in part by a Grant-in-Aid for Scientific Research (B) under Grant 23300069 through the Japan Society for the Promotion of Science.	HULL JJ, 1994, IEEE T PATTERN ANAL, V16, P550, DOI 10.1109/34.291440; Zhang S, 2007, IEEE T PATTERN ANAL, V29, P1732, DOI 10.1109/TPAMI.2007.1089; Fukui K, 2005, SPR TRA ADV ROBOT, V15, P192; Dalal N, 2005, PROC CVPR IEEE, P886; Demsar J, 2006, J MACH LEARN RES, V7, P1; Baker S, 1998, INT J COMPUT VISION, V27, P27, DOI 10.1023/A:1007901712605; Davis J. V., 2007, P 24 INT C MACH LEAR, P209, DOI DOI 10.1145/1273496.127352; Elad M, 2010, SPARSE AND REDUNDANT REPRESENTATIONS, P3, DOI 10.1007/978-1-4419-7011-4_1; Groetsch C.E., 1993, INVERSE PROBLEMS MAT; Haasdonk B, 2002, INT C PATT RECOG, P864; Hamm J., 2008, P NIPS, P601; Hamm J., 2008, P 25 INT C MACH LEAR, P376, DOI 10.1145/1390156.1390204; Huo XM, 2004, IEEE SIGNAL PROC LET, V11, P123, DOI 10.1109/LSP.2003.821650; Keysers D, 2000, INT C PATT RECOG, P38, DOI 10.1109/ICPR.2000.906014; Leibe B, 2003, PROC CVPR IEEE, P409; Mikat S, 1999, P IEEE NEUR NETW SIG, P41; Oja E., 1983, SUBSPACE METHODS PAT; Pozdnoukhov A, 2004, INT C PATT RECOG, P486, DOI 10.1109/ICPR.2004.1334572; Sakano H., 2000, P 4 INT C KNOWL BAS, V1, P245; Scholkopf B, 1998, ADV NEUR IN, V10, P640; Simard P., 1993, P ADV NEURAL INFORM, V5, P50; Simard PY, 2000, INT J IMAG SYST TECH, V11, P181, DOI 10.1002/1098-1098(2000)11:3<181::AID-IMA1003>3.3.CO;2-5; Washizawa Y., 2012, P IEEE INT WORKSH ML, P1; Washizawa Y., 2009, P 10 INT C DOC AN RE, P471; Washizawa Y, 2010, IEEE T NEURAL NETWOR, V21, P201, DOI 10.1109/TNN.2009.2034852; Xing E. P., 2003, ADV NEURAL INFORMATI, V15, P505; Xu Y., 2011, P INT QUANT EL C C L, P874; Yamaguchi O., 1998, Proceedings Third IEEE International Conference on Automatic Face and Gesture Recognition (Cat. No.98EX107), DOI 10.1109/AFGR.1998.670968	28	1	1	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	2162-237X	2162-2388		IEEE T NEUR NET LEAR	IEEE Trans. Neural Netw. Learn. Syst.	NOV	2014	25	11					1980	1990		10.1109/TNNLS.2014.2301178		11	Computer Science, Artificial Intelligence; Computer Science, Hardware & Architecture; Computer Science, Theory & Methods; Engineering, Electrical & Electronic	Computer Science; Engineering	AS2DJ	WOS:000344089300003		
J	Yang, CG; Li, ZJ; Cui, RX; Xu, BG				Yang, Chenguang; Li, Zhijun; Cui, Rongxin; Xu, Bugong			Neural Network-Based Motion Control of Underactuated Wheeled Inverted Pendulum Models	IEEE TRANSACTIONS ON NEURAL NETWORKS AND LEARNING SYSTEMS			English	Article						Finite time linear quadratic regulation (LQR); neural network (NN); underactuated; wheeled inverted pendulum (WIP)	OUTPUT-FEEDBACK CONTROL; NONLINEAR-SYSTEMS; ADAPTIVE-CONTROL; ROBOTS; MOBILE; DYNAMICS; OBSERVER	In this paper, automatic motion control is investigated for wheeled inverted pendulum (WIP) models, which have been widely applied for modeling of a large range of two wheeled modern vehicles. First, the underactuated WIP model is decomposed into a fully actuated second-order subsystem Sigma(a) consisting of planar movement of vehicle forward motion and yaw angular motions, and a passive (nonactuated) first-order subsystem Sigma(b) of pendulum tilt motion. Due to the unknown dynamics of subsystem Sigma(a) and universal approximation ability of neural network (NN), an adaptive NN scheme has been employed for motion control of subsystem Sigma(a). Model reference approach has been used, whereas the reference model is optimized by finite time linear quadratic regulation technique. Inspired by human control strategy of inverted pendulum, the tilt angular motion in the passive subsystem Sigma(b) has been indirectly controlled using the dynamic coupling with planar forward motion of subsystem Sigma(a), such that the satisfactory tracking of set tilt angle can be guaranteed. Rigorous theoretic analysis has been established, and simulation studies have been performed to demonstrate the developed method.	[Yang, Chenguang] Univ Plymouth, Sch Comp & Math, Plymouth PL4 8AA, Devon, England; [Li, Zhijun; Xu, Bugong] S China Univ Technol, Coll Automat Sci & Engn, Key Lab Autonomous Syst & Network Control, Guangzhou 510081, Guangdong, Peoples R China; [Cui, Rongxin] Northwestern Polytech Univ, Sch Marine Engn, Xian 710072, Peoples R China; [Yang, Chenguang] Univ London Imperial Coll Sci Technol & Med, London, England; [Yang, Chenguang] Univ Plymouth, Plymouth PL4 8AA, Devon, England; [Li, Zhijun] Univ Electrocommun, Dept Mech Engn & Intelligent Syst, Tokyo, Japan; [Li, Zhijun] Shanghai Jiao Tong Univ, Dept Automat, Shanghai 200030, Peoples R China; [Li, Zhijun] Natl Univ Singapore, Dept Elect & Comp Engn, Singapore 117548, Singapore; [Li, Zhijun] Nanyang Technol Univ, Singapore 639798, Singapore; [Li, Zhijun] Microsoft Res Asia, Beijing, Peoples R China; [Cui, Rongxin] Natl Univ Singapore, Ctr Offshore Res & Engn, Singapore 117548, Singapore; [Xu, Bugong] S China Univ Technol, Coll Automat Sci & Engn, Guangzhou 510081, Guangdong, Peoples R China	Yang, CG (reprint author), Univ Plymouth, Sch Comp & Math, Plymouth PL4 8AA, Devon, England.	cyang@ieee.org; zjli@ieee.org; r.cui@nwpu.edu.cn; aubgxu@scut.edu.cn			Foundation of Key Laboratory of Autonomous Systems and Networked Control, Chinese Ministry of Education [2012A04]; Key Laboratory of Robotics and System [SKLRS-2012-MS-04]; National Natural Science Foundation of China [51209174, 61174045, 61111130208]; Fundamental Research Program of Northwestern Polytechnical University [JCY20130113]; Fundamental Research Funds for the Central Universities [2013ZG0035]; Program for New Century Excellent Talents in University [NCET-12-0195]; Ph.D. Programs Foundation of Ministry of Education of China [20130172110026]	This work was supported in part by the Foundation of Key Laboratory of Autonomous Systems and Networked Control, Chinese Ministry of Education, under Grant 2012A04; in part by the State Key Laboratory of Robotics and System under Grant SKLRS-2012-MS-04; in part by the National Natural Science Foundation of China under Grant 51209174, Grant 61174045, and Grant 61111130208; in part by the Fundamental Research Program of Northwestern Polytechnical University under Grant JCY20130113; in part by the Fundamental Research Funds for the Central Universities under Grant 2013ZG0035; in part by the Program for New Century Excellent Talents in University under Grant NCET-12-0195; and in part by the Ph.D. Programs Foundation of Ministry of Education of China under Grant 20130172110026.	Anderson B. D. O, 1990, OPTIMAL CONTROL; Liu YJ, 2011, IEEE T NEURAL NETWOR, V22, P1162, DOI 10.1109/TNN.2011.2146788; Li ZJ, 2010, AUTOMATICA, V46, P1346, DOI 10.1016/j.automatica.2010.05.015; Chen M, 2010, IEEE T NEURAL NETWOR, V21, P796, DOI 10.1109/TNN.2010.2042611; Li Z, 2010, AUTOMATICA, V46, P832, DOI 10.1016/j.automatica.2010.02.019; De Luca A, 2002, INT J ROBOT RES, V21, P575; Hovakimyan N, 2006, AUTOMATICA, V42, P513, DOI 10.1016/j.automatica.2005.11.001; Pathak K, 2005, IEEE T ROBOT, V21, P505, DOI [10.1109/TRO.2004.840905, 10.1109/TRO.840905]; Li ZJ, 2010, NEUROCOMPUTING, V73, P2773, DOI 10.1016/j.neucom.2010.04.009; Ren BB, 2009, IEEE T NEURAL NETWOR, V20, P1148, DOI 10.1109/TNN.2009.2016959; Yang CG, 2013, IEEE T CYBERNETICS, V43, P24, DOI 10.1109/TSMCB.2012.2198813; KURDILA AJ, 1995, SIAM J CONTROL OPTIM, V33, P625, DOI 10.1137/S0363012992232555; Calise AJ, 2001, AUTOMATICA, V37, P1201, DOI 10.1016/S0005-1098(01)00070-X; Yang CG, 2008, IEEE T NEURAL NETWOR, V19, P1873, DOI 10.1109/TNN.2008.2003290; Cui RX, 2012, AUTON ROBOT, V32, P189, DOI 10.1007/s10514-011-9265-9; Liu YJ, 2011, IEEE T NEURAL NETWOR, V22, P1328, DOI 10.1109/TNN.2011.2159865; Li ZJ, 2012, IEEE T CONTR SYST T, V20, P1583, DOI 10.1109/TCST.2011.2168224; Chen WS, 2010, IEEE T NEURAL NETWOR, V21, P345, DOI 10.1109/TNN.2009.2038999; Cui RX, 2012, J INTELL ROBOT SYST, V68, P105, DOI 10.1007/s10846-012-9674-9; [Anonymous], 2004, SEGW HUM TRANSP; Arai H, 1998, IEEE T ROBOTIC AUTOM, V14, P681, DOI 10.1109/70.720345; Campion G, 1996, IEEE T ROBOTIC AUTOM, V12, P47, DOI 10.1109/70.481750; Cao CY, 2007, IEEE T NEURAL NETWOR, V18, P1160, DOI 10.1109/TNN.2007.899197; Christofides PD, 1996, IEEE T AUTOMAT CONTR, V41, P1645, DOI 10.1109/9.544001; Ge S. S., 1998, ADAPTIVE NEURAL NETW; Grasser F, 2002, IEEE T IND ELECTRON, V49, P107, DOI 10.1109/41.982254; Hovakimyan N, 2002, IEEE T AUTOMAT CONTR, V47, P1310, DOI 10.1109/TAC.2002.800766; Isidori A, 2003, ROBUST AUTONOMOUS GU; JIANG ZP, 1994, MATH CONTROL SIGNAL, V7, P95, DOI 10.1007/BF01211469; Kim Y, 2005, J INTELL ROBOT SYST, V44, P25, DOI 10.1007/s10846-005-9022-4; Lewis F. L., 1999, NEURAL NETWORK CONTR; Munkres J. R., 1991, ANAL MANIFOLDS; Park J., 1991, Neural Computation, V3, DOI 10.1162/neco.1991.3.2.246; Petrov P., 2010, P 13 INT IEEE ANN C, P1031; Slotine J.J.E., 1991, APPL NONLINEAR CONTR; Yang C., 2012, P 31 CCC HEF CHIN JU, P4400	36	8	8	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	2162-237X	2162-2388		IEEE T NEUR NET LEAR	IEEE Trans. Neural Netw. Learn. Syst.	NOV	2014	25	11					2004	2016		10.1109/TNNLS.2014.2302475		13	Computer Science, Artificial Intelligence; Computer Science, Hardware & Architecture; Computer Science, Theory & Methods; Engineering, Electrical & Electronic	Computer Science; Engineering	AS2DJ	WOS:000344089300005		
J	Guo, S; Zeng, DZ; Xiang, Y				Guo, Song; Zeng, Deze; Xiang, Yang			Chameleon Hashing for Secure and Privacy-Preserving Vehicular Communications	IEEE TRANSACTIONS ON PARALLEL AND DISTRIBUTED SYSTEMS			English	Article						Security and privacy; ecliptic curve based chameleon hashing; authentication protocol design	AD HOC NETWORKS; MESSAGE AUTHENTICATION SCHEME	Many services and applications in vehicular ad-hoc networks (VANETs) require preserving and secure data communications. To improve driving safety and comfort, the traffic-related status information will be broadcasted regularly and shared among drivers. Without the security and privacy guarantees, attackers could track their interested vehicles by collecting and analyzing their traffic messages. Hence, anonymous message authentication is an essential requirement of VANETs. On the other hand, when a vehicle is involved in a dispute event of warning message, the certificate authority should be able to recover the real identity of this vehicle. To deal with this issue, we propose a new privacy-preserving authentication protocol with authority traceability using elliptic curve based chameleon hashing. Compared with existing schemes, our approach possesses the following features: 1) mutual and anonymous authentication for both vehicle-to-vehicle and vehicle-to-roadside communications, 2) vehicle unlinkability, 3) authority tracking capability, and 4) high computational efficiency. We also demonstrate the merits of our proposed scheme through security analysis and extensive performance evaluation.	[Guo, Song; Zeng, Deze] Univ Aizu, Sch Comp Sci & Engn, Aizu Wakamatsu, Fukushima, Japan; [Xiang, Yang] Deakin Univ, Sch Informat Technol, Geelong, Vic 3217, Australia	Guo, S (reprint author), Univ Aizu, Sch Comp Sci & Engn, Aizu Wakamatsu, Fukushima, Japan.	sguo@u-aizu.ac.jp; yang.xiang@deakin.edu.au					Galbraith SD, 2008, DISCRETE APPL MATH, V156, P3113, DOI 10.1016/j.dam.2007.12.010; Li F, 2007, IEEE VEH TECHNOL MAG, V2, P12, DOI 10.1109/MVT.2007.912927; Huang JL, 2011, IEEE T VEH TECHNOL, V60, P248, DOI 10.1109/TVT.2010.2089544; Peng YL, 2006, IEEE ICC, P3602; Hartenstein H, 2008, IEEE COMMUN MAG, V46, P164, DOI 10.1109/MCOM.2008.4539481; Chen W, 2011, WIREL COMMUN MOB COM, V11, P787, DOI 10.1002/wcm.862; Lin XD, 2007, IEEE T VEH TECHNOL, V56, P3442, DOI 10.1109/TVT.2007.906878; Lu RX, 2009, IEEE INFOCOM SER, P1413, DOI 10.1109/INFCOM.2009.5062057; Zhang CX, 2008, IEEE T VEH TECHNOL, V57, P3357, DOI 10.1109/TVT.2008.928581; Ateniese G, 2004, LECT NOTES COMPUT SC, V3110, P164; Biswas S, 2010, AD HOC SENS WIREL NE, V10, P177; Blake G.S.I., 1999, ELLIPTIC CURVES CRYP; Boneh D., 2001, IDENTITY BASED ENCRY, P213; CHAUM D, 1991, LECT NOTES COMPUT SC, V547, P257; Choi J, 2010, IEEE COMMUN LETT, V14, P54, DOI 10.1109/LCOMM.2010.01.091607; Ciccarese G., 2009, P IEEE WIR COMM NETW, P1; Guo H., 2011, P IEEE ICC, P1; Harri J., 2006, P 3 INT WORKSH VEH A, P96, DOI DOI 10.1145/1161064.1161084; Hsiao H-C., 2011, P ACM MOB 11 SEP, P193; Jeomgoo Kim, 2010, P IEEE CUST INT CIRC, P1; Jiang D., 2008, IEEE VTS VEH TECHNOL, P2036; Jiang SR, 2013, 2013 IEEE WIRELESS COMMUNICATIONS AND NETWORKING CONFERENCE (WCNC), P2375; Krawczyk H., 2000, P NETW DISTR SYST SE, P143; Lu R., 2008, P IEEE INFOCOM, P1229; Muhlethaler P., 2007, P 7 INT C ITS TEL IT, P1; Raya M., 2007, Journal of Computer Security, V15; Scott M, EFFICIENT IMPLEMENTA; Shen A., 2012, P WIR COMM NETW C WC, P2543; Studer A., 2009, P IEEE SECON 09 JUN, P1; Zhang CX, 2008, IEEE ICC, P1451, DOI 10.1109/ICC.2008.281	30	1	1	IEEE COMPUTER SOC	LOS ALAMITOS	10662 LOS VAQUEROS CIRCLE, PO BOX 3014, LOS ALAMITOS, CA 90720-1314 USA	1045-9219	1558-2183		IEEE T PARALL DISTR	IEEE Trans. Parallel Distrib. Syst.	NOV	2014	25	11					2794	2803		10.1109/TPDS.2013.277		10	Computer Science, Theory & Methods; Engineering, Electrical & Electronic	Computer Science; Engineering	AR9OM	WOS:000343904400004		
J	Wang, C; Ye, BL; Wang, XL; Guo, S; Lu, SL				Wang, Chen; Ye, Baoliu; Wang, Xiaoliang; Guo, Song; Lu, Sanglu			Delay and Capacity Analysis in MANETs with Correlated Mobility and f-Cast Relay	IEEE TRANSACTIONS ON PARALLEL AND DISTRIBUTED SYSTEMS			English	Article						Capacity and delay analysis; mobile ad-hoc networks; correlated mobility	AD-HOC NETWORKS; WIRELESS NETWORKS; TRADEOFFS	Many studies have presented the order sense results of information transmission capacity and packet delivery delay in mobile ad hoc networks (MANETs). To achieve the fundamental understanding of MANETs, we focus on deriving the closed-form expressions of the network capacity and end-to-end delay. A MANET with the generalized correlated mobility model is considered in this paper, where the mobility of nodes clustered in one group is confined within a specified area, and multiple groups move uniformly across the network. We also leverage limited packet redundancy to speed up the packet transmission, i.e., each source node is allowed to distribute at most f copies of each packet in its delivery process. Specifically, we first propose an effective multi-hop scheduling-routing scheme under the correlated mobility model, and then develop the closed-form expressions of both per node throughput capacity and expected end-to-end delay. We further explore the tradeoff between throughput capacity and packet delay by using packet redundancy f. The simulation studies validate our theoretical results.	[Wang, Chen; Ye, Baoliu; Wang, Xiaoliang; Lu, Sanglu] Nanjing Univ, Dept Comp Sci & Technol, Nanjing 210046, Jiangsu, Peoples R China; [Guo, Song] Univ Aizu, Sch Comp Sci & Engn, Aizu Wakamatsu, Fukushima, Japan	Wang, C (reprint author), Nanjing Univ, Dept Comp Sci & Technol, 163 Xianlin St, Nanjing 210046, Jiangsu, Peoples R China.	wangchen194910@gmail.com; yebl@nju.edu.cn; waxili@nju.edu.cn; sguo@u-aizu.ac.jp; sanglu@nju.edu.cn			National Natural Science Foundation of China [61170069, 61373014, 61321491, 91218302]	The authors would like to thank Professor Xiaohong Jiang and Dr. Jiajia Liu for many insightful discussions and invaluable comments. This work was partially supported by the National Natural Science Foundation of China under Grant No. 61170069, 61373014, 61321491, and 91218302. B. Ye is the corresponding author.	Spyropoulos T, 2008, IEEE ACM T NETWORK, V16, P77, DOI 10.1109/TNET.2007.897964; Gupta P, 2000, IEEE T INFORM THEORY, V46, P388, DOI 10.1109/18.825799; Lin XJ, 2006, IEEE T INFORM THEORY, V52, P2777, DOI 10.1109/TIT.2006.874544; El Gamal A, 2006, IEEE T INFORM THEORY, V52, P2568, DOI 10.1109/TIT.2006.874379; Andrews J, 2008, IEEE COMMUN MAG, V46, P94, DOI 10.1109/MCOM.2008.4689214; Neely MJ, 2005, IEEE T INFORM THEORY, V51, P1917, DOI 10.1109/TIT.2005.847717; Ciullo D., 2010, P IEEE INFOCOM; De Moraes R., 2004, P 1 ANN IEEE COMM SO; Gamal A. E., 2004, P IEEE INFOCOM; Grossglauser M., 2001, P IEEE INFOCOM; Hanbali A.A., 2007, P 6 INT IFIP TC6 C A; Hong X., 1999, P 2 ACM INT WORKSH M; Jacquet P., 2012, P IEEE INFOCOM; Liu J., 2012, P IEEE WIR COMM NETW; Liu JJ, 2011, IEEE T WIREL COMMUN, V10, P2738, DOI 10.1109/TWC.2011.062111.101976; Liu J., 2012, P IEEE INFOCOM; Sharma G., 2004, P IEEE INT C COMM IC; Sharma G., 2004, P WORKSH MOD OPT MOB; Small T., 2005, P ACM SIGCOMM WORKSH	19	0	0	IEEE COMPUTER SOC	LOS ALAMITOS	10662 LOS VAQUEROS CIRCLE, PO BOX 3014, LOS ALAMITOS, CA 90720-1314 USA	1045-9219	1558-2183		IEEE T PARALL DISTR	IEEE Trans. Parallel Distrib. Syst.	NOV	2014	25	11					2829	2839		10.1109/TPDS.2014.2298014		11	Computer Science, Theory & Methods; Engineering, Electrical & Electronic	Computer Science; Engineering	AR9OM	WOS:000343904400007		
J	Kawabe, K; Tanaka, K				Kawabe, K.; Tanaka, K.			Analytical Method for Short-Term Voltage Stability Using the Stability Boundary in the P-V Plane	IEEE TRANSACTIONS ON POWER SYSTEMS			English	Article						Induction motors; reactive power control; short-term voltage stability; stability analysis	MOTORS	Short-term voltage stability is one of the issues of concern for power system operations. As dispersed power generation is connected tomiddle- and low-voltage transmission networks, the development of analytical methods will become more important. This paper describes a stability boundary line in the P-V plane of the load bus for the analysis of short-term voltage stability. By comparing the operating point of the load with the boundary line, we can visually determine the acceleration or deceleration state of the induction motor, thereby clearly explaining the short-term voltage instability phenomena. In addition, the idea of the stability boundary is applied to voltage stability assessment and emergency controls such as reactive power compensation. Numerical simulations are carried out for a single-load infinite-bus system to explain the basic theory of the proposed method and to provide examples of its application.	[Kawabe, K.; Tanaka, K.] Toyama Univ, Grad Sch Sci & Engn, Gofuku 3190, Japan	Kawabe, K (reprint author), Toyama Univ, Grad Sch Sci & Engn, Gofuku 3190, Japan.				Japan Science and Technology Agency (JST)	This work was supported in part by CREST program, "Creation of Fundamental Theory and Technology to Establish a Cooperative Distributed Energy Management System and Integration of Technologies across Broad Disciplines toward Social Application", of Japan Science and Technology Agency (JST). Paper no. TPWRS-01381-2013.	Kundur P, 2004, IEEE T POWER SYST, V19, P1387, DOI 10.1109/TPWRS.2004.825981; Diaz de Leon II B. J. A., 2002, P 2002 IEEE POW ENG, V2, P745; HAMMAD AE, 1989, IEEE T POWER SYST, V4, P1182, DOI 10.1109/59.32616; Kawabe K., 2013, P IEEE PES POWERTECH; OHTSUKI H, 1990, PROCEEDINGS OF THE TENTH POWER SYSTEMS COMPUTATION CONFERENCE, P1202; Potamianakis EG, 2006, IEEE T POWER SYST, V21, P791, DOI 10.1109/TPWRS.2006.873022; SEKINE Y, 1990, IEEE T POWER SYST, V5, P250, DOI 10.1109/59.49113; Stanley H. C., 1938, AIEE T, V57, P751; Vournas CD, 1998, IEEE T POWER SYST, V13, P775, DOI 10.1109/59.708603; Wang ZJ, 2012, IEEE T POWER DELIVER, V27, P2412, DOI 10.1109/TPWRD.2012.2202204	10	0	0	IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC	PISCATAWAY	445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA	0885-8950	1558-0679		IEEE T POWER SYST	IEEE Trans. Power Syst.	NOV	2014	29	6					3041	3047		10.1109/TPWRS.2014.2313152		7	Engineering, Electrical & Electronic	Engineering	AS6YR	WOS:000344405600048		
J	Ardiyanto, I; Miura, J				Ardiyanto, I.; Miura, J.			Partial least squares-based human upper body orientation estimation with combined detection and tracking	IMAGE AND VISION COMPUTING			English	Article						Human upper body orientation; Partial least squares; Multi-level HOG-LBP; Random Forest classifier; UKF tracker		This paper deals with the problem of estimating the human upper body orientation. We propose a framework which integrates estimation of the human upper body orientation and the human movements. Our human orientation estimator utilizes a novel approach which hierarchically employs partial least squares-based models of the gradient and texture features, coupled with the random forest classifier. The movement predictions are done by projecting detected persons into 3D coordinates and running an Unscented Kalman Filter-based tracker. The body orientation results are then fused with the movement predictions to build a more robust estimation of the human upper body orientation. We carry out comprehensive experiments and provide comparison results to show the advantages of our system over the other existing methods. (C) 2014 Elsevier B.V. All rights reserved.	[Ardiyanto, I.; Miura, J.] Toyohashi Univ Technol, Dept Comp Sci & Engn, Toyohashi, Aichi 4418580, Japan	Ardiyanto, I (reprint author), Toyohashi Univ Technol, Dept Comp Sci & Engn, Toyohashi, Aichi 4418580, Japan.	iardiyanto@aisl.cs.tut.ac.jp; jun.miura@tut.jp					Benbouzid D, 2012, J MACH LEARN RES, V13, P549; Breiman L, 2001, MACH LEARN, V45, P5, DOI 10.1023/A:1010933404324; Andriluka M, 2010, PROC CVPR IEEE, P623, DOI 10.1109/CVPR.2010.5540156; Ess A, 2009, IEEE T PATTERN ANAL, V31, P1831, DOI 10.1109/TPAMI.2009.109; Julier SJ, 2004, P IEEE, V92, P401, DOI 10.1109/JPROC.2003.823141; Schwartz WR, 2009, IEEE I CONF COMP VIS, P24, DOI 10.1109/ICCV.2009.5459205; Archer KJ, 2008, COMPUT STAT DATA AN, V52, P2249, DOI 10.1016/j.csda.2007.08.015; Genuer R, 2010, PATTERN RECOGN LETT, V31, P2225, DOI 10.1016/j.patrec.2010.03.014; Wang LM, 2007, LECT NOTES COMPUT SC, V4843, P189; Weinrich C, 2012, IEEE INT C INT ROBOT, P2147, DOI 10.1109/IROS.2012.6386122; Ojala T, 2002, IEEE T PATTERN ANAL, V24, P971, DOI 10.1109/TPAMI.2002.1017623; Crammer K, 2002, J MACH LEARN RES, V2, P265, DOI 10.1162/15324430260185628; Baltieri D., 2012, P EUR C COMP VIS, V7576, P270; Bosch A., 2007, IEEE INT C COMP VIS, V8, P14; Cheng CK, 2011, ISPD 11: PROCEEDINGS OF THE 2011 ACM/SIGDA INTERNATIONAL SYMPOSIUM ON PHYSICAL DESIGN, P5, DOI 10.1109/icc.2011.5962933; Choi W, 2010, LECT NOTES COMPUT SC, V6314, P553; Dalai N., 2005, INT C COMP VIS PATT, V1, P886, DOI DOI 10.1109/CVPR.2005.177; Ferrari V., 2008, IEEE C COMP VIS PATT, P1; Hoiem D., 2006, IEEE C COMP VIS PATT, V2, P2137; Rosipal R, 2006, LECT NOTES COMPUT SC, V3940, P34; Wold H., 1975, PERSPECTIVES PROBABI, P520; Wold S., 1993, 3D QSAR DRUG DESIGN, P523; Zhu Q., 2006, IEEE COMP SOC C COMP, V2, P1491	23	2	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0262-8856	1872-8138		IMAGE VISION COMPUT	Image Vis. Comput.	NOV	2014	32	11					904	915		10.1016/j.imavis.2014.08.002		12	Computer Science, Artificial Intelligence; Computer Science, Software Engineering; Computer Science, Theory & Methods; Engineering, Electrical & Electronic; Optics	Computer Science; Engineering; Optics	AS7FP	WOS:000344422900008		
J	Baber, J; Dailey, MN; Satoh, S; Afzulpurkar, N; Bakhtyar, M				Baber, Junaid; Dailey, Matthew N.; Satoh, Shin'ichi; Afzulpurkar, Nitin; Bakhtyar, Maheen			BIG-OH: BInarization of gradient orientation histograms	IMAGE AND VISION COMPUTING			English	Article						Gradient orientation histograms; SIFT; Gradient based keypoint descriptors; Keypoint descriptor quantization	LOCAL BINARY PATTERNS; SCALE; SEARCH; DESCRIPTORS; RECOGNITION; FEATURES	Extracting local keypoints and keypoint descriptions from images is a primary step for many computer vision and image retrieval applications. In the literature, many researchers have proposed methods for representing local texture around keypoints with varying levels of robustness to photometric and geometric transformations. Gradient-based descriptors such as the Scale Invariant Feature Transform (SIFT) are among the most consistent and robust descriptors. The SIFT descriptor, a 128-element vector consisting of multiple gradient histograms computed from local image patches around a keypoint, is widely considered as the gold standard keypoint descriptor. However, SIFT descriptors require at least 128 bytes of storage per descriptor. Since images are typically described by thousands of keypoints, it may require more space to store the SIFT descriptors for an image than the original image itself. This may be prohibitive in extremely large-scale applications and applications on memory-constrained devices such as tablets and smartphones. In this paper, with the goal of reducing the memory requirements of keypoint descriptors such as SIFT, without affecting their performance, we propose BIG-OH, a simple yet extremely effective method for binary quantization of any descriptor based on gradient orientation histograms. BIG-OH's memory requirements are very small when it uses SIFT's default parameters for the construction of the gradient orientation histograms, it only requires 16 bytes per descriptor. BIG-OH quantizes gradient orientation histograms by computing a bit vector representing the relative magnitudes of local gradients associated with neighboring orientation bins. In a series of experiments on keypoint matching with different types of keypoint detectors under various photometric and geometric transformations, we find that the quantized descriptor has performance comparable to or better than other descriptors, including BRISK, CARD, BRIEF, D-BRIEF, SQ, and PCA-SIFT. Our experiments also show that BIG-OH is extremely effective for image retrieval, with modestly better performance than SIFT. BIG-OH's drastic reduction in memory requirements, obtained while preserving or improving the image matching and image retrieval performance of SIFT, makes it an excellent descriptor for large image databases and applications running on memory-constrained devices. (C) 2014 Elsevier B.V. All rights reserved.	[Baber, Junaid; Bakhtyar, Maheen] Univ Balochistan, Dept Comp Sci & Informat Technol, Quetta, Pakistan; [Baber, Junaid; Dailey, Matthew N.; Afzulpurkar, Nitin] Asian Inst Technol, Sch Engn & Technol, Pathum Thani 12120, Thailand; [Satoh, Shin'ichi] Natl Inst Informat, Tokyo, Japan	Baber, J (reprint author), Univ Balochistan, Dept Comp Sci & Informat Technol, Quetta, Pakistan.	junaidbaber@ieee.org; mdailey@ait.asia; satoh@nii.ac.jp; nafzulpurkar@aud.edu	Ahirwal, Ashish/B-8886-2015	Ahirwal, Ashish/0000-0002-8247-9793	University of Balochistan; National Institute of Informatics; Asian Institute of Technology	This research was supported by fellowships to Junaid Baber from the University of Balochistan, the National Institute of Informatics, and the Asian Institute of Technology. We are thankful to Wengang Zhou for providing the IR-II dataset.	Adam B., 2000, COMPUTER VISION PATT, P774; Ambai M., 2011, INT C COMP VIS ICCV; Lindeberg T, 1997, IMAGE VISION COMPUT, V15, P415, DOI 10.1016/S0262-8856(97)01144-X; Heikkila M, 2009, PATTERN RECOGN, V42, P425, DOI 10.1016/j.patcog.2008.08.014; Liu XL, 2014, PATTERN RECOGN, V47, P748, DOI 10.1016/j.patcog.2013.08.022; Ling HF, 2012, IEEE MULTIMEDIA, V19, P60; Mikolajczyk K, 2004, INT J COMPUT VISION, V60, P63, DOI 10.1023/B:VISI.0000027790.02288.f2; Bay H, 2008, COMPUT VIS IMAGE UND, V110, P346, DOI 10.1016/j.cviu.2007.09.014; Tola E, 2010, IEEE T PATTERN ANAL, V32, P815, DOI 10.1109/TPAMI.2009.77; Strecha C, 2012, IEEE T PATTERN ANAL, V34, P66, DOI 10.1109/TPAMI.2011.103; Jegou H, 2011, IEEE T PATTERN ANAL, V33, P117, DOI 10.1109/TPAMI.2010.57; Jegou H, 2008, LECT NOTES COMPUT SC, V5302, P304, DOI 10.1007/978-3-540-88682-2_24; Ojala T, 2002, IEEE T PATTERN ANAL, V24, P971, DOI 10.1109/TPAMI.2002.1017623; Mikolajczyk K, 2005, IEEE T PATTERN ANAL, V27, P1615, DOI 10.1109/TPAMI.2005.188; Ahonen T, 2006, IEEE T PATTERN ANAL, V28, P2037, DOI 10.1109/TPAMI.2006.244; Lowe DG, 2004, INT J COMPUT VISION, V60, P91, DOI 10.1023/B:VISI.0000029664.99615.94; Rosten E, 2006, LECT NOTES COMPUT SC, V3951, P430; Everingham M, 2010, INT J COMPUT VISION, V88, P303, DOI 10.1007/s11263-009-0275-4; Wang J, 2012, IEEE T PATTERN ANAL, V34, P2393, DOI 10.1109/TPAMI.2012.48; Liu W, 2012, PROC CVPR IEEE, P2074; Baber J, 2013, INT J PATTERN RECOGN, V27, DOI 10.1142/S0218001413550070; Baber J., 2011, INT C DIG SIGN PROC; Baber Junaid, 2011, INT C DIG SIGN PROC, P1; Boiman O., 2008, COMPUTER VISION PATT; Calonder M, 2010, LECT NOTES COMPUT SC, V6314, P778, DOI 10.1007/978-3-642-15561-1_56; Calonder M., 2010, EUR C COMP VIS ECCV; Douze M, 2010, IEEE T MULTIMEDIA, V12, P257, DOI 10.1109/TMM.2010.2046265; Gionis A., 1999, INT C VER LARG DAT B, P518; Heikkila M, 2006, IEEE T PATTERN ANAL, V28, P657, DOI 10.1109/TPAMI.2006.68; Heinly J., 2012, LECT NOTES COMPUTER, P759; Indyk P., 1998, ACM S THEOR COMP, P604, DOI DOI 10.1145/276698.276876; Ke Y., 2004, CVPR, P511; Leutenegger S., 2011, INT C COMP VIS ICCV; Nister D., 2006, CVPR, P2161, DOI [10.1109/CVPR, DOI 10.1109/CVPR.2006.264]; Philbin J., 2007, COMPUTER VISION PATT; Pietikainen M, 2004, PATTERN RECOGN, V37, P313, DOI [10.1016/S0031-3203(03)00231-0, 10.1016/S0031-3203(03)00321-0]; Rublee E., 2011, INT C COMP VIS ICCV; Sivic J., 2003, INT C COMP VIS ICCV; Snavely N., 2008, COMPUTER VISION PATT; Ta D.-N., 2009, COMPUTER VISION PATT; Trzcinski T., 2012, EUR C COMP VIS ECCV; Weiss Y., 2008, SPECTRAL HASHING; Xiaoyu W., 2009, INT C COMP VIS ICCV, P32; Yamazaki M, 2009, IEICE T INF SYST, VE92D, P1745, DOI 10.1587/transinf.E92.D.1745; Zhou W., 2013, MULTIMEDIA SYST, P1; Zhou W., 2010, INT C MULT; Zhou W., 2012, ACM INT C MUL, P169	47	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0262-8856	1872-8138		IMAGE VISION COMPUT	Image Vis. Comput.	NOV	2014	32	11					940	953		10.1016/j.imavis.2014.08.006		14	Computer Science, Artificial Intelligence; Computer Science, Software Engineering; Computer Science, Theory & Methods; Engineering, Electrical & Electronic; Optics	Computer Science; Engineering; Optics	AS7FP	WOS:000344422900011		
J	Matsui, S; Nagahara, H; Taniguchi, R				Matsui, Shuhei; Nagahara, Hajime; Taniguchi, Rin-ichiro			Half-sweep imaging for depth from defocus	IMAGE AND VISION COMPUTING			English	Article						Computational photography; Depth from defocus; Image deblurring	CAMERA	Depth from defocus (DFD) is a technique that restores scene depth based on the amount of defocus blur in the images. DFD usually captures two differently focused images, one near-focused and the other far-focused, and calculates the size of the defocus blur in these images. However, DFD using a regular circular aperture is not sensitive to depth, since the point spread function (PSF) is symmetric and only the radius changes with the depth. In recent years, the coded aperture technique, which uses a special pattern for the aperture to engineer the PSF, has been used to improve the accuracy of DFD estimation. The technique is often used to restore an all-in-focus image and estimate depth in DFD applications. Use of a coded aperture has a disadvantage in terms of image deblurring, since deblurring requires a higher signal-to-noise ratio (SNR) of the captured images. The aperture attenuates incoming light in controlling the PSF and, as a result decreases the input image SNR. In this paper, we propose a new computational imaging approach for DFD estimation using focus changes during image integration to engineer the PSF. We capture input images with a higher SNR since we can control the PSF with a wide aperture setting unlike with a coded aperture. We confirm the effectiveness of the method through experimental comparisons with conventional DFD and the coded aperture approach. (C) 2014 Elsevier B.V. All rights reserved.	[Matsui, Shuhei; Nagahara, Hajime; Taniguchi, Rin-ichiro] Kyushu Univ, Grad Sch Informat Sci & Elect Engn, Nishi Ku, Fukuoka 8190395, Japan	Matsui, S (reprint author), Kyushu Univ, Grad Sch Informat Sci & Elect Engn, Nishi Ku, 744 Motooka, Fukuoka 8190395, Japan.						Dowski E.R., 1994, APPL OPT, V33; Green P., 2007, ACM T GRAPH, V26; Hasinoff SW, 2009, IEEE I CONF COMP VIS, P333, DOI 10.1109/ICCV.2009.5459269; Hiura S, 1998, PROC CVPR IEEE, P953, DOI 10.1109/CVPR.1998.698719; Kuthirummal S, 2011, IEEE T PATTERN ANAL, V33, P58, DOI 10.1109/TPAMI.2010.66; Levin A., 2007, ACM T GRAPH, V26; Levin A., 2009, ACM T GRAPH, V28; Levin A, 2010, LECT NOTES COMPUT SC, V6311, P214, DOI 10.1007/978-3-642-15549-9_16; Matsui S, 2011, LECT NOTES COMPUT SC, V7087, P335; Nagahara H, 2010, LECT NOTES COMPUT SC, V6316, P337, DOI 10.1007/978-3-642-15567-3_25; Nagahara H., 2008, P EUR C COMP VIS; Pentland A., 1987, IEEE T PATTERN ANAL, V9, P423; Rajagopalan AN, 1997, PROC CVPR IEEE, P219, DOI 10.1109/CVPR.1997.609323; Subbarao M., 1988, Proceedings CVPR '88: The Computer Society Conference on Computer Vision and Pattern Recognition (Cat. No.88CH2605-4), DOI 10.1109/CVPR.1988.196281; Surya G., 1993, Proceedings. 1993 IEEE Computer Society Conference on Computer Vision and Pattern Recognition (Cat. No.93CH3309-2), DOI 10.1109/CVPR.1993.340978; Veeraraghavan A., 2007, ACM T GRAPH, V26; Zhou C., 2009, P IEEE INT C COMP PH; Zhou CY, 2009, IEEE I CONF COMP VIS, P325; Zhou CY, 2011, INT J COMPUT VISION, V93, P53, DOI 10.1007/s11263-010-0409-8	19	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0262-8856	1872-8138		IMAGE VISION COMPUT	Image Vis. Comput.	NOV	2014	32	11					954	964		10.1016/j.imavis.2014.09.001		11	Computer Science, Artificial Intelligence; Computer Science, Software Engineering; Computer Science, Theory & Methods; Engineering, Electrical & Electronic; Optics	Computer Science; Engineering; Optics	AS7FP	WOS:000344422900012		
J	Dogan, B; Suzuki, H; Herlekar, D; Sartor, RB; Campbell, BJ; Roberts, CL; Stewart, K; Scherl, EJ; Araz, Y; Bitar, PP; Lefebure, T; Chandler, B; Schukken, YH; Stanhope, MJ; Simpson, KW				Dogan, Belgin; Suzuki, Haruo; Herlekar, Deepali; Sartor, R. Balfour; Campbell, Barry J.; Roberts, Carol L.; Stewart, Katrina; Scherl, Ellen J.; Araz, Yasemin; Bitar, Paulina P.; Lefebure, Tristan; Chandler, Brendan; Schukken, Ynte H.; Stanhope, Michael J.; Simpson, Kenneth W.			Inflammation-associated Adherent-invasive Escherichia coli Are Enriched in Pathways for Use of Propanediol and Iron and M-cell Translocation	INFLAMMATORY BOWEL DISEASES			English	Article						comparative genomics; inflammatory bowel disease; Crohn's disease; dysbiosis; long polar fimbriae	BACTERIAL VIRULENCE FACTORS; LONG POLAR FIMBRIAE; CROHNS-DISEASE; E. COLI; SALMONELLA-TYPHIMURIUM; BOWEL-DISEASE; ILEAL MUCOSA; PEYERS-PATCHES; MAXIMUM-LIKELIHOOD; POSITIVE SELECTION	Background: Perturbations of the intestinal microbiome, termed dysbiosis, are linked to intestinal inflammation. Isolation of adherent-invasive Escherichia coli (AIEC) from intestines of patients with Crohn's disease (CD), dogs with granulomatous colitis, and mice with acute ileitis suggests these bacteria share pathoadaptive virulence factors that promote inflammation. Methods: To identify genes associated with AIEC, we sequenced the genomes of phylogenetically diverse AIEC strains isolated from people with CD (4), dogs with granulomatous colitis (2), and mice with ileitis (2) and 1 non-AIEC strain from CD ileum and compared them with 38 genome sequences of E. coli and Shigella. We then determined the prevalence of AIEC-associated genes in 49 E. coli strains from patients with CD and controls and correlated genotype with invasion of intestinal epithelial cells, persistence within macrophages, AIEC pathotype, and growth in standardized conditions. Results: Genes encoding propanediol utilization (pdu operon) and iron acquisition (yersiniabactin, chu operon) were overrepresented in AIEC relative to nonpathogenic E. coli. PduC (propanediol dehydratase) was enriched in CD-derived AIEC, correlated with increased cellular invasion, and persistence in vitro and was increasingly expressed in fucose-containing media. Growth of AIEC required iron, and the presence of chuA (heme acquisition) correlated with persistence in macrophages. CD-associated AIEC with lpfA(154) (long polar fimbriae) demonstrated increased invasion of epithelial cells and translocation across M cells. Conclusions: Our findings provide novel insights into the genetic basis of the AIEC pathotype, supporting the concept that AIEC are equipped to exploit and promote intestinal inflammation and reveal potential targets for intervention against AIEC and inflammation-associated dysbiosis.	[Dogan, Belgin; Herlekar, Deepali; Stewart, Katrina; Araz, Yasemin; Chandler, Brendan; Simpson, Kenneth W.] Cornell Univ, Coll Vet Med, Dept Clin Sci, Ithaca, NY 14853 USA; [Suzuki, Haruo; Bitar, Paulina P.; Lefebure, Tristan; Schukken, Ynte H.; Stanhope, Michael J.] Cornell Univ, Coll Vet Med, Dept Populat Med & Diagnost Sci, Ithaca, NY 14853 USA; [Suzuki, Haruo] Yamaguchi Univ, Dept Environm Sci & Engn, Grad Sch Sci & Engn, Yamaguchi, Japan; [Sartor, R. Balfour] Univ N Carolina, Sch Med, Dept Med, Chapel Hill, NC USA; [Sartor, R. Balfour] Univ N Carolina, Sch Med, Dept Microbiol & Immunol, Chapel Hill, NC 27599 USA; [Campbell, Barry J.; Roberts, Carol L.] Univ Liverpool, Dept Gastroenterol, Inst Translat Med, Liverpool L69 3BX, Merseyside, England; [Scherl, Ellen J.] Cornell Univ, Weill Med Coll, Jill Roberts Ctr Inflammatory Bowel Dis, Dept Med, Ithaca, NY 14853 USA	Simpson, KW (reprint author), Cornell Univ, Coll Vet Med, Dept Clin Sci, Ithaca, NY 14853 USA.	kws5@cornell.edu	Lefebure, Tristan/A-6489-2009; Schukken, Ynte/C-3405-2008	Lefebure, Tristan/0000-0003-3923-8166; Schukken, Ynte/0000-0002-8250-4194	Crohn's Colitis Foundation; NIH [R01 DK53347]; Wellcome Trust UK [074949/Z/04/Z]; National Institute of Health Research Specialist Biomedical Research Centre in Microbial Disease [01CD1]; Crohn's & Colitis UK award [M/13/2]	Supported by grants from the Crohn's Colitis Foundation (Senior Research Award to K. W. Simpson), NIH R01 DK53347 (R. B. Sartor and K. W. Simpson), and the Jill Roberts Center for Inflammatory Bowel Disease, Weill Medical College of Cornell University, New York. C. L. Roberts and B. J. Campbell were supported by grants from the Wellcome Trust UK (074949/Z/04/Z) and the National Institute of Health Research Specialist Biomedical Research Centre in Microbial Disease (01CD1). B. J. Campbell is also supported by a Crohn's & Colitis UK award (M/13/2).	Kothary V, 2013, ANTIMICROB AGENTS CH, V57, P811, DOI 10.1128/AAC.02163-12; Bringer MA, 2012, LAB INVEST, V92, P411, DOI 10.1038/labinvest.2011.156; Conner CP, 1998, P NATL ACAD SCI USA, V95, P4641, DOI 10.1073/pnas.95.8.4641; Klumpp J, 2007, MICROBIOL-SGM, V153, P1207, DOI 10.1099/mic.0. 2006/004747-0; Walter D, 1997, J BACTERIOL, V179, P1013; Baumgart M, 2007, ISME J, V1, P403, DOI 10.1038/ismej.2007.52; Carvalho FA, 2012, CELL HOST MICROBE, V12, P139, DOI 10.1016/j.chom.2012.07.004; Adkins JN, 2006, MOL CELL PROTEOMICS, V5, P1450, DOI 10.1074/mcp.M600139-MCP200; Lefebure T, 2009, GENOME RES, V19, P1224, DOI 10.1101/gr.089250.108; Clarke DJ, 2011, J BACTERIOL, V193, P4540, DOI 10.1128/JB.05374-11; Kim SC, 2005, GASTROENTEROLOGY, V128, P891, DOI 10.1053/j.gastro.2005.02.009; Pond SLK, 2006, BIOINFORMATICS, V22, P3096, DOI 10.1093/bioinformatics/btl474; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Guindon S, 2010, SYST BIOL, V59, P307, DOI 10.1093/sysbio/syq010; Arakawa K, 2006, J PESTIC SCI, V31, P282, DOI 10.1584/jpestics.31.282; Germon P, 2005, MICROBIOL-SGM, V151, P1179, DOI 10.1099/mic.0.27809-0; Krause DO, 2011, J BACTERIOL, V193, P583, DOI 10.1128/JB.01290-10; Chassaing B, 2014, GUT, V63, P1069, DOI 10.1136/gutjnl-2013-304909; Simpson KW, 2006, INFECT IMMUN, V74, P4778, DOI 10.1128/IAI.00067-06; Lapaquette P, 2012, CELL MICROBIOL, V14, P791, DOI 10.1111/j.1462-5822.2012.01768.x; Egan CE, 2009, MUCOSAL IMMUNOL, V2, P527, DOI 10.1038/mi.2009.105; Mansfield CS, 2009, J VET INTERN MED, V23, P964, DOI 10.1111/j.1939-1676.2009.0363.x; Lawhon SD, 2003, MOL MICROBIOL, V48, P1633, DOI 10.1046/j.1365-2958.2003.03535.x; Ng KM, 2013, NATURE, V502, P96, DOI 10.1038/nature12503; Roshan U, 2006, BIOINFORMATICS, V22, P2715, DOI 10.1093/bioinformatics/btl472; Roberts CL, 2010, GUT, V59, P1331, DOI 10.1136/gut.2009.195370; LEBOUGUENEC C, 1992, J CLIN MICROBIOL, V30, P1189; Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954; Keita AC, 2008, J PATHOL, V215, P135, DOI 10.1002/path.2337; Horne SM, 2000, AVIAN DIS, V44, P179, DOI 10.2307/1592522; Jordan DM, 2004, INFECT IMMUN, V72, P6168, DOI 10.1128/IAI.72.10.6168-6171.2004; Heithoff DM, 1999, J BACTERIOL, V181, P799; Massey DCO, 2007, AUTOPHAGY, V3, P649; Kotlowski R, 2007, GUT, V56, P669, DOI 10.1136/gut.2006.099796; Van Kruiningen HJ, 2002, INFLAMM BOWEL DIS, V8, P180, DOI 10.1097/00054725-200205000-00004; Parrow NL, 2013, INFECT IMMUN, V81, P3503, DOI 10.1128/IAI.00602-13; Bach S, 2000, FEMS MICROBIOL LETT, V183, P289, DOI 10.1016/S0378-1097(00)00005-7; Sasaki M, 2007, LAB INVEST, V87, P1042, DOI 10.1038/labinvest.3700661; Barnich N, 2007, J CLIN INVEST, V117, P1566, DOI 10.1172/JCI30504; McGovern DPB, 2010, HUM MOL GENET, V19, P3468, DOI 10.1093/hmg/ddq248; Chen LH, 2005, NUCLEIC ACIDS RES, V33, pD325, DOI 10.1093/nar/gki008; Bringer MA, 2007, J BACTERIOL, V189, P4860, DOI 10.1128/JB.00233-07; Nugent SG, 2001, GUT, V48, P571, DOI 10.1136/gut.48.4.571; Arakawa K, 2003, BIOINFORMATICS, V19, P305, DOI 10.1093/bioinformatics/19.2.305; Autieri SM, 2007, INFECT IMMUN, V75, P5465, DOI 10.1128/IAI.00822-07; Martin HM, 2004, GASTROENTEROLOGY, V127, P80, DOI 10.1053/j.gastro.2004.03.054; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Chassaing B, 2011, J CLIN INVEST, V121, P966, DOI 10.1172/JCI44632; Nairz M, 2010, CELL MICROBIOL, V12, P1691, DOI 10.1111/j.1462-5822.2010.01529.x; Martinez-Medina M, 2009, INFLAMM BOWEL DIS, V15, P872, DOI 10.1002/ibd.20860; Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121; Chen LH, 2012, NUCLEIC ACIDS RES, V40, pD641, DOI 10.1093/nar/gkr989; Arakawa K., 2008, GENES GENOMES GENOMI, V2, P1; Baumler AJ, 1996, P NATL ACAD SCI USA, V93, P279, DOI 10.1073/pnas.93.1.279; Bringer MA, 2005, INFECT IMMUN, V73, P712, DOI 10.1128/IAI.73.2.712-721.2005; Craven M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041594; Darfeuille-Michaud A, 2004, GASTROENTEROLOGY, V127, P412, DOI 10.1053/j.gastro.2004.04.061; Darfeuille-Michaud A, 1998, GASTROENTEROLOGY, V115, P1405, DOI 10.1016/S0016-5085(98)70019-8; Davidsen T, 2010, NUCLEIC ACIDS RES, V38, pD340, DOI 10.1093/nar/gkp912; DebRoy Chitrita, 2001, Animal Health Research Reviews, V2, P129; Dogan B, 2012, VET MICROBIOL; Flanagan P, 2011, BIOCHEM SOC T, V39, P1067, DOI 10.1042/BST0391067; Fujimura Y, 1996, GUT, V38, P724, DOI 10.1136/gut.38.5.724; Girardin SE, 2003, TRENDS IMMUNOL, V24, P652, DOI 10.1016/j.it.2003.10.007; Gullberg E, 2006, ANN NY ACAD SCI, V1072, P218, DOI 10.1196/annals.1326.028; Korbel JO, 2005, PLOS BIOL, V3, P815, DOI 10.1371/journal.pbio.0030134; Lefebure T, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-5-r71; Leimbach A, 2013, CURR TOP MICROBIOL, V358, P3, DOI 10.1007/82_2012_303; Lu Z, 1998, J BIOL CHEM, V273, P8308, DOI 10.1074/jbc.273.14.8308; Lymberopoulos MH, 2006, J BACTERIOL, V188, P6449, DOI 10.1128/JB.00453-06; Meconi S, 2007, CELL MICROBIOL, V9, P1252, DOI 10.1111/j.1462-5822.2006.00868.x; Miquel S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012714; Nash JHE, 2010, BMC GENOMICS, V11, DOI 10.1186/1471-2164-11-667; Newton HJ, 2004, INFECT IMMUN, V72, P1230, DOI 10.1108/IAI.72.3.1230-1239.2004; R Development Core Team, 2010, R LANG ENV STAT COMP; RICKERT RR, 1980, J CLIN GASTROENTEROL, V2, P11, DOI 10.1097/00004836-198003000-00003; Schmitz JM, 2011, GASTROENTEROLOGY, V140, pS29; Small CLN, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2957; Snider TA, 2009, VET MICROBIOL, V136, P150, DOI 10.1016/j.vetmic.2008.10.033; Tatusov RL, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-41; Thomson NR, 2006, PLOS GENET, V2, P2039, DOI 10.1371/journal.pgen.0020206	82	5	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1078-0998	1536-4844		INFLAMM BOWEL DIS	Inflamm. Bowel Dis.	NOV	2014	20	11					1919	1932		10.1097/MIB.0000000000000183		14	Gastroenterology & Hepatology	Gastroenterology & Hepatology	AS5YI	WOS:000344342000007		
J	Nakase, H; Yoshino, T; Matsuura, M				Nakase, Hiroshi; Yoshino, Takuya; Matsuura, Minoru			Role in Calcineurin Inhibitors for Inflammatory Bowel Disease in the Biologics Era: When and How to Use	INFLAMMATORY BOWEL DISEASES			English	Review						Cyclosporin A; Tacrolimus; ant-TNF-alpha therapy; inflammatory bowel disease	REFRACTORY ULCERATIVE-COLITIS; TERM-FOLLOW-UP; RANDOMIZED CONTROLLED-TRIAL; ORAL TACROLIMUS FK506; CROHNS-DISEASE; RESCUE THERAPY; INTRAVENOUS CYCLOSPORINE; RETROSPECTIVE ANALYSIS; DOUBLE-BLIND; INFLIXIMAB	Ulcerative colitis and Crohn's disease, which is the 2 major forms of inflammatory bowel disease, are chronic relapsing and remitting inflammatory disorder of the gastrointestinal tract. During the last 30 years, the therapy for patients with refractory inflammatory bowel diseases is still challenging despite the fact that morbidity and mortality rates have been obviously reduced. The conventional management with corticosteroids has been modified by the introduction of calcineurin inhibitors and biologics. In this review, we focus on role in calcineurin inhibitors for patients with inflammatory bowel disease in the currently clinical practice.	[Nakase, Hiroshi; Yoshino, Takuya; Matsuura, Minoru] Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Kyoto 6068507, Japan	Nakase, H (reprint author), Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sakyo Ku, 54 Kawahara Cho, Kyoto 6068507, Japan.	hiropy_n@kuhp.kyoto-u.ac.jp			Japan Society for the Promotion of Science [24590941, 25860532, 26460967]; Health and Labor Sciences Research Grants for Research on Rare and Intractable Diseases from the Ministry of Health, Labor, and Welfare, Japan	Supported by the Japan Society for the Promotion of Science Grants-in-aid for Scientific Research (24590941, 25860532, and 26460967) and Health and Labor Sciences Research Grants for Research on Rare and Intractable Diseases from the Ministry of Health, Labor, and Welfare, Japan.	Ford AC, 2011, AM J GASTROENTEROL, V106, P590, DOI 10.1038/ajg.2011.70; Ogata H, 2006, GUT, V55, P1255, DOI 10.1136/gut.2005.081794; Van Assche G, 2003, GASTROENTEROLOGY, V125, P1025, DOI 10.1053/S0016-5085(03)01214-9; Jarnerot G, 2005, GASTROENTEROLOGY, V128, P1805, DOI 10.1053/j.gasto.2005.03.003; Olsen T, 2009, SCAND J GASTROENTERO, V44, P727, DOI 10.1080/00365520902803507; STANGE EF, 1995, GASTROENTEROLOGY, V109, P774, DOI 10.1016/0016-5085(95)90384-4; Azzi JR, 2013, J IMMUNOL, V191, P5785, DOI 10.4049/jimmunol.1390055; Mocciaro F, 2012, J CROHNS COLITIS, V6, P681, DOI 10.1016/j.crohns.2011.11.021; Fric J, 2012, BLOOD, V120, P1380, DOI 10.1182/blood-2012-02-404475; KINO T, 1987, J ANTIBIOT, V40, P1256; Moss AC, 2008, DRUGS, V68, P1157, DOI 10.2165/00003495-200868090-00001; Gerich ME, 2013, INFLAMM BOWEL DIS, V19, P1107, DOI 10.1097/MIB.0b013e318280b154; Naganuma M, 2011, J GASTROENTEROL, V46, P129, DOI 10.1007/s00535-010-0352-z; LICHTIGER S, 1994, NEW ENGL J MED, V330, P1841, DOI 10.1056/NEJM199406303302601; KNIGHT DM, 1993, MOL IMMUNOL, V30, P1443, DOI 10.1016/0161-5890(93)90106-L; Probert CSJ, 2003, GUT, V52, P998, DOI 10.1136/gut.52.7.998; Benson A, 2008, INFLAMM BOWEL DIS, V14, P7, DOI 10.1002/ibd.20263; D'Haens G, 2001, GASTROENTEROLOGY, V120, P1323, DOI 10.1053/gast.2001.23983; Sternthal MB, 2008, AM J GASTROENTEROL, V103, P937, DOI 10.1111/j.1572-0241.2007.01718.x; Rusnak F, 2000, PHYSIOL REV, V80, P1483; Yoshino T, 2010, INFLAMM BOWEL DIS, V16, P2022, DOI 10.1002/ibd.21318; Laharie D, 2012, LANCET, V380, P1909, DOI 10.1016/S0140-6736(12)61084-8; BOREL JF, 1976, AGENTS ACTIONS, V6, P468, DOI 10.1007/BF01973261; Maser EA, 2008, CLIN GASTROENTEROL H, V6, P1112, DOI 10.1016/j.cgh.2008.04.035; Moskovitz DN, 2006, CLIN GASTROENTEROL H, V4, P760, DOI 10.1016/j.cgh.2006.01.001; Rutgeerts P, 2005, NEW ENGL J MED, V353, P2462, DOI 10.1056/NEJMoa050516; Goodridge HS, 2007, J IMMUNOL, V178, P3107; Chow CW, 1999, MOL CELL BIOL, V19, P2300; Baumgart DC, 2006, AM J GASTROENTEROL, V101, P1048, DOI 10.1111/j.1542-0241.2006.00524.x; Baumgart DC, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007216; BRYNSKOV J, 1989, NEW ENGL J MED, V321, P845, DOI 10.1056/NEJM198909283211301; de Mare-Bredemeijer ELD, 2012, BEST PRACT RES CL GA, V26, P85, DOI 10.1016/j.bpg.2012.01.017; Dean KE, 2012, J GASTROEN HEPATOL, V27, P487, DOI 10.1111/j.1440-1746.2011.06958.x; Fellermann K, 2002, INFLAMM BOWEL DIS, V8, P317, DOI 10.1097/00054725-200209000-00002; Fujisawa Healthcare Inc, 2005, PROGR TACR FULL PRES, P1098; Garcia Cadenas I, 2014, MEDIAT INFLAMM, V2014; Hogenauer C, 2003, ALIMENT PHARM THERAP, V18, P415, DOI 10.1046/j.0269-2813.2003.01662.x; Kohn A, 2007, ALIMENT PHARM THERAP, V26, P747, DOI 10.1111/j.1365-2036.2007.03415.x; Kohn A, 2002, DIGEST LIVER DIS, V34, P626, DOI 10.1016/S1590-8658(02)80204-3; Landy Jonathan, 2013, J Crohns Colitis, V7, pe516, DOI 10.1016/j.crohns.2013.03.008; Leblanc S, 2011, AM J GASTROENTEROL, V106, P771, DOI 10.1038/ajg.2011.62; Lees CW, 2007, ALIMENT PHARM THERAP, V26, P411, DOI 10.1111/j.1365-2036.2007.03383.x; Lichtiger S, 2009, INFLAMM BOWEL DIS, V15, P141, DOI 10.1002/ibd.20363; Löwenberg Mark, 2013, Curr Gastroenterol Rep, V15, P311, DOI 10.1007/s11894-012-0311-3; Manosa M, 2009, DIGESTION, V80, P30, DOI 10.1159/000212075; McSharry K, 2011, ALIMENT PHARM THER, V34, P1282, DOI 10.1111/j.1365-2036.2011.04873.x; Minami N, 2014, GASTROENTEROLOGY, pA707; PARK JC, 1995, J BIOL CHEM, V270, P20653; Schmidt KJ, 2013, ALIMENT PHARM THER, V37, P129, DOI 10.1111/apt.12118; Shibolet O, 2005, COCHRANE DB SYST REV, V1; Sjoberg M, 2012, INFLAMM BOWEL DIS, V18, P212, DOI 10.1002/ibd.21680; Tamaki H, 2008, J GASTROENTEROL, V43, P774, DOI 10.1007/s00535-008-2229-y; Thin LWY, 2013, INFLAMM BOWEL DIS, V19, P1490, DOI 10.1097/MIB.0b013e318281f362; van Hooff JP, 1999, TRANSPLANT P, V31, P3298, DOI 10.1016/S0041-1345(99)00732-0; Vanrenterghem Y, 1998, TRANSPLANT P, V30, P2171, DOI 10.1016/S0041-1345(98)00578-8; Wong SHY, 2001, CLIN CHIM ACTA, V313, P241, DOI 10.1016/S0009-8981(01)00678-7; Yamamoto S, 2011, J CLIN GASTROENTEROL, V45, P526, DOI 10.1097/MCG.0b013e318209cdc4; Yamamoto S, 2008, ALIMENT PHARM THER, V28, P589, DOI 10.1111/j.1365-2036.2008.03764.x	58	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1078-0998	1536-4844		INFLAMM BOWEL DIS	Inflamm. Bowel Dis.	NOV	2014	20	11					2151	2156		10.1097/MIB.0000000000000130		6	Gastroenterology & Hepatology	Gastroenterology & Hepatology	AS5YI	WOS:000344342000031		
J	Yokoyama, K; Sato, M; Haneda, T; Yamazaki, K; Kitano, T; Umetsu, K				Yokoyama, Kazutaka; Sato, Michihiko; Haneda, Toshihiro; Yamazaki, Kentaro; Kitano, Takashi; Umetsu, Kazuo			An N-acetyllactosamine-specific lectin, PFA, isolated from a moth (Phalera flavescens), structurally resembles an invertebrate-type lysozyme	INSECT BIOCHEMISTRY AND MOLECULAR BIOLOGY			English	Article						Lectin; Lobster moth; Lysozyme; Gene; Evolution	CARBOHYDRATE-BINDING-SPECIFICITY; COCKROACH PERIPLANETA-AMERICANA; MAXIMUM-LIKELIHOOD APPROACH; LINKED OLIGOSACCHARIDES; GLYCOSYL HYDROLASES; PROTEIN; PURIFICATION; CHITINASE; HEMOLYMPH; GLYCOPROTEIN	PFA (Phalera flavescens agglutinin) lectin purified from larvae of the lobster moth (P. flavescens) shows a strong binding ability specific to the N-acetyllactosamine (Gal beta 1-4GlcNAc) site. We determined the genomic and cDNA sequences of the PFA gene, which consists of five exons and spans approximately 5 kb of a genomic region. Surprisingly, the amino acid sequence (149 amino acids) was similar to invertebrate-type lysozymes and related proteins. The predicted tertiary structure of the PFA protein was similar to the lysozymes of clams such as the common orient clam (Meretrix lusoria) and Japanese littleneck (Venerupis philippinarum (Tapes japonica)). The PFA, however, lacks a catalytically essential amino acid, an Asp (D), which is one of the two important amino acids (Glu (E) and D) express the function of lysozyme. As a result, lysozyme activity assays indicated that PFA does not have lysozyme activity. Results suggest that the PFA gene evolved from a lysozyme gene through the loss of lysozyme activity sites and the acquisition of lectin activity during evolution of the genus Phalera. (C) 2014 Elsevier Ltd. All rights reserved.	[Yokoyama, Kazutaka; Kitano, Takashi] Ibaraki Univ, Coll Engn, Dept Biomol Funct Engn, Hitachi, Ibaraki 3168511, Japan; [Sato, Michihiko] Yamagata Univ, Sch Med, Tech Support Ctr Educ & Res, Yamagata 9909585, Japan; [Haneda, Toshihiro; Yamazaki, Kentaro; Umetsu, Kazuo] Yamagata Univ, Sch Med, Dept Forens Med, Yamagata 9909585, Japan	Kitano, T (reprint author), Ibaraki Univ, Coll Engn, Dept Biomol Funct Engn, 4-12-1 Nakanarusawa Cho, Hitachi, Ibaraki 3168511, Japan.	tkitano@mx.ibaraki.ac.jp					Ewing B, 1998, GENOME RES, V8, P175; Crooks GE, 2004, GENOME RES, V14, P1188, DOI 10.1101/gr.849004; Salamov AA, 1998, BIOINFORMATICS, V14, P384, DOI 10.1093/bioinformatics/14.5.384; Gordon D, 1998, GENOME RES, V8, P195; UMETSU K, 1993, ARCH BIOCHEM BIOPHYS, V301, P200, DOI 10.1006/abbi.1993.1133; Renkema GH, 1998, EUR J BIOCHEM, V251, P504, DOI 10.1046/j.1432-1327.1998.2510504.x; Whelan S, 2001, MOL BIOL EVOL, V18, P691; KITAGAKI H, 1986, CARBOHYD RES, V151, P271, DOI 10.1016/S0008-6215(00)90347-1; Kelley LA, 2009, NAT PROTOC, V4, P363, DOI 10.1038/nprot.2009.2; YAMASHITA K, 1988, J BIOL CHEM, V263, P17482; GOLDSTEIN IJ, 1980, NATURE, V285, P66, DOI 10.1038/285066b0; Goto T, 2007, J BIOL CHEM, V282, P27459, DOI 10.1074/jbc.M704555200; JOMORI T, 1990, EUR J BIOCHEM, V190, P201, DOI 10.1111/j.1432-1033.1990.tb15565.x; Matsumoto R, 2011, COMP BIOCHEM PHYS B, V158, P266, DOI 10.1016/j.cbpb.2010.12.004; HAPNER KD, 1981, INSECT BIOCHEM, V11, P287, DOI 10.1016/0020-1790(81)90006-8; Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340; Zavalova L, 1996, MOL GEN GENET, V253, P20; Petersen TN, 2011, NAT METHODS, V8, P785, DOI 10.1038/nmeth.1701; Tamura K, 2011, MOL BIOL EVOL, V28, P2731, DOI 10.1093/molbev/msr121; ARUMUGHAM RG, 1986, BIOCHIM BIOPHYS ACTA, V883, P112, DOI 10.1016/0304-4165(86)90142-X; Boratyn GM, 2012, BIOL DIRECT, V7, DOI 10.1186/1745-6150-7-12; Bussink AP, 2007, GENETICS, V177, P959, DOI 10.1534/genetics.107.075846; Capella-Gutierrez S, 2009, BIOINFORMATICS, V25, P1972, DOI 10.1093/bioinformatics/btp348; CROWLEY JF, 1984, ARCH BIOCHEM BIOPHYS, V231, P524, DOI 10.1016/0003-9861(84)90417-X; FELSENSTEIN J, 1981, J MOL EVOL, V17, P368, DOI 10.1007/BF01734359; Houston DR, 2003, J BIOL CHEM, V278, P30206, DOI 10.1074/jbc.M303371200; KNIBBS RN, 1989, BIOCHEMISTRY-US, V28, P6379, DOI 10.1021/bi00441a034; Kobata A., 1993, PRACTICAL APPROACH G, P103; [Anonymous], 1989, METHOD ENZYMOL; KUBO T, 1990, INSECT BIOCHEM, V20, P585, DOI 10.1016/0020-1790(90)90070-B; Kuwano Y, 2013, ACTA CRYSTALLOGR F, V69, P1202, DOI 10.1107/S1744309113028170; LEE N, 1990, J BIOL CHEM, V265, P20476; MERKLE RK, 1987, J BIOL CHEM, V262, P8179; Patil DN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063779; Van Damme EJM, 2007, PLANT PHYSIOL, V144, P662, DOI 10.1104/pp.106.087981	35	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0965-1748	1879-0240		INSECT BIOCHEM MOLEC	Insect Biochem. Mol. Biol.	NOV	2014	54						106	111		10.1016/j.ibmb.2014.09.005		6	Biochemistry & Molecular Biology; Entomology	Biochemistry & Molecular Biology; Entomology	AS7MQ	WOS:000344440500012		
J	Rong, Y; Fujii, T; Katsuma, S; Yamamoto, M; Ando, T; Ishikawa, Y				Rong, Yu; Fujii, Takeshi; Katsuma, Susumu; Yamamoto, Masanobu; Ando, Tetsu; Ishikawa, Yukio			CYP341B14: A cytochrome P450 involved in the specific epoxidation of pheromone precursors in the fall webworm Hyphantria cunea	INSECT BIOCHEMISTRY AND MOLECULAR BIOLOGY			English	Article						Cytochrome P450; Epoxidase; Sex pheromone; Biosynthesis; Hyphantria cunea	LEPIDOPTERAN SEX-PHEROMONES; NAVEL ORANGEWORM; BIOSYNTHESIS; IDENTIFICATION; COMPONENTS; DIVERSITY; MOTHS; HYDROCARBONS; DROSOPHILA; GLANDS	Two of the four sex pheromone components in the fall webworm Hyphantria cunea (Lepidoptera: Arctiidae), cis-9,10-epoxy-(3Z,6Z)-3,6-henicosadiene and cis-9,10-epoxy-(3Z,6Z)-1,3,6-henicosatriene, possess an epoxy ring within their molecules. These compounds have been suggested to be bio-synthesized from dietary linolenic acid via the following enzymatic reactions; chain elongation, terminal desaturation (in the case of the latter component), decarboxylation, and epoxidation. The last step of this biosynthesis, epoxidation, is known to occur specifically in the sex pheromone gland of females. We identified the enzyme involved in the epoxidation of pheromone precursors by focusing on cytochromes P450, which are known to catalyze the oxidation of various compounds. Three P450-like sequences (Hc_epo1, Hc_epo2, and Hc_epo3) were identified in the cDNA library prepared from the sex pheromone gland of H. cunea. Among these clones, only Hc_epo1 was specifically expressed in the pheromone gland. The full-length sequence of Hc_epo1 contained an ORF of 1527 bp, which encoded a protein of 509 amino acids with a predicted molecular weight of 57.9 kDa. The deduced Hc_epo1 amino acid sequence possessed the characteristics of P450. A phylogenetic analysis of the sequence indicated that Hc_epo1 belonged to the CYP341B clade in the CYP341 family. Therefore, it was named CYP341B14. A subsequent functional assay using Sf-9 cells transiently expressing CYP341B14 demonstrated that this P450 protein was able to specifically epoxidize a (Z)-double bond at the 9th position in the pheromone precursor, (3Z,6Z,9Z)-3,6,9-henicosatriene. (C) 2014 Elsevier Ltd. All rights reserved.	[Rong, Yu; Fujii, Takeshi; Katsuma, Susumu; Yamamoto, Masanobu; Ishikawa, Yukio] Univ Tokyo, Grad Sch Agr & Life Sci, Tokyo 1138657, Japan; [Ando, Tetsu] Tokyo Univ Agr & Technol, Grad Sch Bioapplicat & Syst Engn BASE, Tokyo 1848588, Japan	Fujii, T (reprint author), Univ Tokyo, Grad Sch Agr & Life Sci, Tokyo 1138657, Japan.	takeshi.f0405@gmail.com			JSPS KAKENHI Grant [23248008]	We thank Prof. D. Nelson of the University of Tennessee for assigning the name CYP341B14 to Hc_epo1. This work was supported by JSPS KAKENHI Grant Number 23248008 to Y.I.	Ando T, 2014, Internet Database, Patent No. [474486, EP 474486]; Cabrera A, 2001, J CHEM ECOL, V27, P2097, DOI 10.1023/A:1012299021967; Ando T, 2011, TRAC-TREND ANAL CHEM, V30, P990, DOI 10.1016/j.trac.2011.03.010; Qiu Y, 2012, P NATL ACAD SCI USA, V109, P14858, DOI 10.1073/pnas.1208650109; Miyamoto T, 1999, INSECT BIOCHEM MOLEC, V29, P63, DOI 10.1016/S0965-1748(98)00105-2; Feyereisen R, 2012, INSECT MOLECULAR BIOLOGY AND BIOCHEMISTRY, P236, DOI 10.1016/B978-0-12-384747-8.10008-X; Omura T, 2013, BIOTECHNOL APPL BIOC, V60, P4, DOI 10.1002/bab.1099; Lassance JM, 2013, P NATL ACAD SCI USA, V110, P3967, DOI 10.1073/pnas.1208706110; Fujii T, 2010, J INSECT PHYSIOL, V56, P1986, DOI 10.1016/j.jinsphys.2010.08.024; Symonds MRE, 2008, TRENDS ECOL EVOL, V23, P220, DOI 10.1016/j.tree.2007.11.009; Jurenka R, 2004, TOP CURR CHEM, V239, P97, DOI 10.1007/b95450; Millar JG, 2000, ANNU REV ENTOMOL, V45, P575, DOI 10.1146/annurev.ento.45.1.575; Schuler MA, 2013, J CHEM ECOL, V39, P1232, DOI 10.1007/s10886-013-0335-7; Omura T, 2010, J BIOCHEM, V147, P297, DOI 10.1093/jb/mvq001; Daimon T, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002486; Goswami P, 2013, APPL MICROBIOL BIOT, V97, P4259, DOI 10.1007/s00253-013-4842-9; Niwa R, 2004, J BIOL CHEM, V279, P35942, DOI 10.1074/jbc.M404514200; Leal WS, 2005, NATURWISSENSCHAFTEN, V92, P139, DOI 10.1007/s00114-004-0598-5; Daborn PJ, 2007, INSECT BIOCHEM MOLEC, V37, P512, DOI 10.1016/j.ibmb.2007.02.008; Ando T, 2004, TOP CURR CHEM, V239, P51, DOI 10.1007/b95449; Yan Q, 2014, J CHEM ECOL, V40, P590, DOI 10.1007/s10886-014-0446-9; Ando T, 2008, J PESTIC SCI, V33, P17, DOI 10.1584/jpestics.R07-06; Helvig C, 2004, P NATL ACAD SCI USA, V101, P4024, DOI 10.1073/pnas.0306980101; Schuler MA, 2011, BBA-PROTEINS PROTEOM, V1814, P36, DOI 10.1016/j.bbapap.2010.09.012; Millar JG, 2010, INSECT HYDROCARBONS: BIOLOGY, BIOCHEMISTRY, AND CHEMICAL ECOLOGY, P390, DOI 10.1017/CBO9780511711909.019; Wei W, 2003, INSECT BIOCHEM MOLEC, V33, P397, DOI 10.1016/S0965-1748(03)00002-X; El-Sayed A.M., 2014, PHEROBASE DATABASE P; El-Sayed A.M., 2012, CHEMOECOLOGY, V23, P93; Kiyota R, 2011, INSECT BIOCHEM MOLEC, V41, P362, DOI 10.1016/j.ibmb.2011.02.004; Kuenen LPS, 2010, J ECON ENTOMOL, V103, P314, DOI 10.1603/EC09177; Mansuy D, 1998, COMP BIOCHEM PHYS C, V121, P5, DOI 10.1016/S0742-8413(98)10026-9; Niu GD, 2011, INSECT BIOCHEM MOLEC, V41, P244, DOI 10.1016/j.ibmb.2010.12.009; Ono H, 2005, INSECT BIOCHEM MOLEC, V35, P837, DOI 10.1016/j.ibmb.2005.03.013; Yamakawa R, 2012, J CHEM ECOL, V38, P1042, DOI 10.1007/s10886-012-0165-z	34	2	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0965-1748	1879-0240		INSECT BIOCHEM MOLEC	Insect Biochem. Mol. Biol.	NOV	2014	54						122	128		10.1016/j.ibmb.2014.09.009		7	Biochemistry & Molecular Biology; Entomology	Biochemistry & Molecular Biology; Entomology	AS7MQ	WOS:000344440500014		
J	Omori, Y; Tanito, K; Ito, K; Ishiji, T; Saeki, H; Nakagawa, H; Saeki, Y				Omori, Yasutaka; Tanito, Katsumi; Ito, Keigo; Ishiji, Takaoki; Saeki, Hidehisa; Nakagawa, Hidemi; Saeki, Yoko			Bowen's carcinoma of the penis with sebaceous differentiation associated with human papillomavirus type 16	INTERNATIONAL JOURNAL OF DERMATOLOGY			English	Letter							VULVA; SKIN		[Omori, Yasutaka; Tanito, Katsumi; Ito, Keigo; Ishiji, Takaoki; Saeki, Hidehisa; Nakagawa, Hidemi] Jikei Univ, Sch Med, Dept Dermatol, Tokyo, Japan; [Saeki, Yoko] Sanno Hosp, Div Dermatol, Tokyo, Japan	Omori, Y (reprint author), Jikei Univ, Sch Med, Dept Dermatol, Tokyo, Japan.	saeki-der@jikei.ac.jp					Escalonilla P, 1999, AM J DERMATOPATH, V21, P468, DOI 10.1097/00000372-199910000-00012; FULLING KH, 1981, J CUTAN PATHOL, V8, P79, DOI 10.1111/j.1600-0560.1981.tb00990.x; JACOBS DM, 1986, ARCH DERMATOL, V122, P1191, DOI 10.1001/archderm.122.10.1191; Mii S, 2012, INT J DERMATOL, V51, P804, DOI 10.1111/j.1365-4632.2011.05143.x; Ueda M, 2005, J EUR ACAD DERMATOL, V19, P232, DOI 10.1111/j.1468-3083.2005.01063.x	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0011-9059	1365-4632		INT J DERMATOL	Int. J. Dermatol.	NOV	2014	53	11					E531	E532		10.1111/ijd.12475		2	Dermatology	Dermatology	AS3KX	WOS:000344177600009		
J	Chen, YL; Zhao, SH; Wang, YL; Li, YF; Bai, L; Liu, RH; Fan, JL; Liu, EQ				Chen, Yulong; Zhao, Sihai; Wang, Yanli; Li, Yafeng; Bai, Liang; Liu, Ruihan; Fan, Jianglin; Liu, Enqi			Homocysteine reduces protein S-nitrosylation in endothelium	INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE			English	Article						homocysteine; endothelial cells; nitric oxide; S-nitrosylation	NF-KAPPA-B; NITRIC-OXIDE SYNTHASE; OXIDATIVE STRESS; CELL MIGRATION; ACTIVATION; HYPERHOMOCYSTEINEMIA; NO; DYSFUNCTION; INHIBITION; INCREASES	Hyperhomocysteinemia (HHcy) is a risk factor for cardiovascular disease. The S-nitrosylation of proteins is involved in the regulation of cardiovascular functions. However, whether homocysteine (Hcy) impairs vascular functions through the inhibition of protein S-nitrosylation in the endothelium remains to be determined. The experiments were performed in human umbilical vein endothelial cells (HUVECs). Male Sprague-Dawley rats, with or without administration of L-methionine, were used for the in vivo validation of findings. S-nitrosylation was analyzed using immunofluorescence for nitrosocysteine, and further confirmed by the biotin switch method. The levers of reactive oxygen species (ROS) were detected by 2',7'-dichlorofluorescein diacetate (DCFH-DA) staining. The levels of nitric oxide (NO) were determined by the nitrate reduction method. Protein expression was analysed by western blot analysis. The activity of nuclear factor kappa B (NF-kappa B) was evaluated by an electrophoretic mobility shift assay (EMSA). The levels of plasma Hcy were measured by ELISA. The results showed that Hey significantly reduced the levels of protein S-nitrosylation in HUVECs and endothelial S-nitrosylation of aorta. This reduction of protein S-nitrosylation was accompanied by increasing ROS, decreasing phosphorylation levels of A kt and endothelial nitric oxide synthase (eNOS), and reduced levels of nitric oxide in HUVECs. In addition, it was found that Hcy increased the protein expression of vascular cell adhesion molecule-1 by attenuating the cytoplasm S-nitrosylation of NF-kappa B (p65). These data suggested that Hcy impairs endothelial functions by inhibiting endothelial protein S-nitrosylation.	[Chen, Yulong; Zhao, Sihai; Wang, Yanli; Li, Yafeng; Bai, Liang; Liu, Ruihan; Liu, Enqi] Xi An Jiao Tong Univ, Res Inst Atherosclerot Dis, Cardiovasc Res Ctr, Xian 710061, Shaanxi, Peoples R China; [Chen, Yulong; Zhao, Sihai; Wang, Yanli; Li, Yafeng; Bai, Liang; Liu, Ruihan; Liu, Enqi] Xi An Jiao Tong Univ, Lab Anim Ctr, Sch Med, Xian 710061, Shaanxi, Peoples R China; [Fan, Jianglin] Univ Yamanashi, Interdisciplinary Grad Sch Med & Engn, Dept Mol Pathol, Yamanashi 4093898, Japan	Liu, EQ (reprint author), Xi An Jiao Tong Univ, Res Inst Atherosclerot Dis, Cardiovasc Res Ctr, Sch Med, 76 Yanta West Rd, Xian 710061, Shaanxi, Peoples R China.	liuenqi@mail.xjtu.edu.cn			National Natural Science Foundation of China [81070250]; Public Service Platform Grant of Shaanxi Province [2010FWPT-1]	This study was partly supported by the National Natural Science Foundation of China (81070250) and by a Public Service Platform Grant of Shaanxi Province (2010FWPT-1).	Forrester MT, 2009, FREE RADICAL BIO MED, V46, P119, DOI 10.1016/j.freeradbiomed.2008.09.034; Michaud SE, 2006, J MOL CELL CARDIOL, V41, P275, DOI 10.1016/j.yjmcc.2006.05.004; Marshall HE, 2004, P NATL ACAD SCI USA, V101, P8841, DOI 10.1073/pnas.0403034101; McCully KS, 2009, ANN CLIN LAB SCI, V39, P219; Suematsu N, 2007, CIRCULATION, V115, P255, DOI 10.1161/CIRCULATIONHA.106.652693; Dimmeler S, 1999, NATURE, V399, P601; Martinez-Ruiz A, 2007, CARDIOVASC RES, V75, P220, DOI 10.1016/j.cardiores.2007.03.016; Selemidis S, 2007, CARDIOVASC RES, V75, P349, DOI 10.1016/j.cardiores.2007.03.030; Santhanam L, 2010, CIRC RES, V107, P117, DOI 10.1161/CIRCRESAHA.109.215228; Marshall HE, 2001, BIOCHEMISTRY-US, V40, P1688, DOI 10.1021/bi002239y; Reynaert NL, 2004, P NATL ACAD SCI USA, V101, P8945, DOI 10.1073/pnas.0400588101; Thibeault S, 2010, MOL CELL, V39, P468, DOI 10.1016/j.molcel.2010.07.013; Lan TH, 2011, BIOCHEM PHARMACOL, V82, P148, DOI 10.1016/j.bcp.2011.04.001; Chakrabarti S, 2010, CARDIOVASC RES, V85, P796, DOI 10.1093/cvr/cvp368; Wu Y, 2011, ATHEROSCLEROSIS, V215, P170, DOI 10.1016/j.atherosclerosis.2010.12.007; Lima B, 2010, CIRC RES, V106, P633, DOI 10.1161/CIRCRESAHA.109.207381; Sun JH, 2006, CIRC RES, V98, P403, DOI 10.1161/01.RES.0000202707.79018.0a; Kelleher ZT, 2007, J BIOL CHEM, V282, P30667, DOI 10.1074/jbc.M705929200; Kang-Decker N, 2007, J CELL SCI, V120, P492, DOI 10.1242/jcs.03361; Au-Yeung KKW, 2004, CIRC RES, V94, P28, DOI 10.1161/01.RES.0000108264.67601.2C; Carluccio MA, 2007, AM J PHYSIOL-HEART C, V293, pH2344, DOI 10.1152/ajpheart.00432.2007; Chavakis E, 2001, CIRCULATION, V103, P2102; Chen SC, 2008, BIOCHEM BIOPH RES CO, V377, P1274, DOI 10.1016/j.bbrc.2008.10.144; Hankey GJ, 1999, LANCET, V354, P407, DOI 10.1016/S0140-6736(98)11058-9; Hoffmann J, 2003, FEBS LETT, V551, P153, DOI 10.1016/S0014-5793(03)00917-7; Hoffmann J, 2001, J BIOL CHEM, V276, P41383, DOI 10.1074/jbc.M107566200; Martinez-Ruiz A, 2004, ARCH BIOCHEM BIOPHYS, V423, P192, DOI 10.1016/j.abb.2003.12.006; Oliveira CJR, 2008, NITRIC OXIDE-BIOL CH, V18, P241, DOI 10.1016/j.niox.2008.02.001; Ota H, 2008, ARTERIOSCL THROM VAS, V28, P1634, DOI 10.1161/ATVBAHA.108.164368; Pi XC, 2009, P NATL ACAD SCI USA, V106, P5675, DOI 10.1073/pnas.0809568106; Ungvari Z, 2000, ARTERIOSCL THROM VAS, V20, P1203; Wadham C, 2007, DIABETES, V56, P2715, DOI 10.2337/db06-1294	32	1	2	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1107-3756	1791-244X		INT J MOL MED	Int. J. Mol. Med.	NOV	2014	34	5					1277	1285		10.3892/ijmm.2014.1920		9	Medicine, Research & Experimental	Research & Experimental Medicine	AS7FZ	WOS:000344423800011		
J	Yamamoto, N; Tokuda, H; Kuroyanagi, G; Mizutani, J; Matsushima-Nishiwaki, R; Kondo, A; Kozawa, O; Otsuka, T				Yamamoto, Naohiro; Tokuda, Haruhiko; Kuroyanagi, Gen; Mizutani, Jun; Matsushima-Nishiwaki, Rie; Kondo, Akira; Kozawa, Osamu; Otsuka, Takanobu			Regulation by resveratrol of prostaglandin E-2-stimulated osteoprotegerin synthesis in osteoblasts	INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE			English	Article						resveratrol; prostaglandin E-2; osteoprotegerin; osteoblast	ACTIVATED PROTEIN-KINASE; CROSS-TALK REGULATION; CYCLIC-AMP; CELLS; INHIBITOR; STRESS; YEAST	Resveratrol is a natural polyphenol found in red grape skins, berries and red wine. Accumulating evidence suggests that resveratrol has various beneficial effects on the human body. In the present study, we investigated the effects of prostaglandin E-2 (PGE(2)) on osteoprotegerin (OPG) synthesis and the effects of resveratrol on OPG synthesis in osteoblast-like MC3T3-E1 cells. PGE(2) significantly stimulated both the release of OPG and the mRNA expression levels of OPG, as. shown by OPG assay and real-time RT-PCR, respectively. Resveratrol markedly suppressed the release and the mRNA levels of OPG induced by PGE(2). On the contrary, SRT1720, an activator of sirtuin 1 (SIRT1), hardly affected the PGE(2)-induced release of OPG. PD98059 [a specific inhibitor of the upstream kinase that activates p44/p42 mitogen-activated protein (MAP) kinase], SB203580 (a specific inhibitor of p38 MAP kinase) and SP600125 [a specific inhibitor of stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK)], reduced the PGE(2)-induced release of OPG. Resveratrol attenuated the PGE(2)-induced phosphorylation of p44/p42 MAP kinase, p38 MAP kinase and SAPK/JNK. However, SRT1720 failed to affect the phosphorylation of p44/p42 MAP kinase, p38 MAP kinase and SAPK/JNK induced by PGE(2). These results strongly suggest that resveratrol reduces PGE(2)-stimulated OPG synthesis through the inhibition of p44/p42 MAP kinase, p38 MAP kinase and SAPK/JNK in osteoblasts, and that these suppressive effects are independent of the activation of SIRT1.	[Yamamoto, Naohiro; Kuroyanagi, Gen; Mizutani, Jun; Kondo, Akira; Otsuka, Takanobu] Nagoya City Univ, Grad Sch Med Sci, Dept Orthoped Surg, Nagoya, Aichi 4678601, Japan; [Yamamoto, Naohiro; Tokuda, Haruhiko; Kuroyanagi, Gen; Matsushima-Nishiwaki, Rie; Kondo, Akira; Kozawa, Osamu] Gifu Univ, Grad Sch Med, Dept Pharmacol, Gifu 5011194, Japan; [Tokuda, Haruhiko] Natl Ctr Geriatr & Gerontol, Dept Clin Lab, Obu, Aichi 4748511, Japan	Tokuda, H (reprint author), Natl Ctr Geriatr & Gerontol, Dept Clin Lab, 35 Gengo,Morioka Cho, Obu, Aichi 4748511, Japan.	tokuda@ncgg.go.jp			Ministry of Education, Science, Sports and Culture of Japan [19591042]; Foundation for Growth Science; Research Funding for Longevity Sciences [23-9, 25-4]; National Center for Geriatrics and Gerontology (NCGG), Japan	We are very grateful to Yumiko Kurokawa for her skillful technical assistance. This investigation was supported in part by Grants-in-Aid for Scientific Research (19591042) from the Ministry of Education, Science, Sports and Culture of Japan, the Foundation for Growth Science, the Research Funding for Longevity Sciences (23-9, 25-4) and the National Center for Geriatrics and Gerontology (NCGG), Japan.	Kyriakis JM, 2001, PHYSIOL REV, V81, P807; Mader I, 2010, FASEB J, V24, P1997, DOI 10.1096/fj.09-142943; Widmann C, 1999, PHYSIOL REV, V79, P143; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Timmers S, 2012, AGING-US, V4, P146; Wang AP, 2011, J BIOL CHEM, V286, P60, DOI 10.1074/jbc.M110.188144; Parfitt AM, 2002, BONE, V30, P5, DOI 10.1016/S8756-3282(01)00642-1; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; ALESSI DR, 1995, J BIOL CHEM, V270, P27489; Blackwell KA, 2010, TRENDS ENDOCRIN MET, V21, P294, DOI 10.1016/j.tem.2009.12.004; Karsenty G, 2002, DEV CELL, V2, P389, DOI 10.1016/S1534-5807(02)00157-0; SUDO H, 1983, J CELL BIOL, V96, P191, DOI 10.1083/jcb.96.1.191; Baur JA, 2006, NATURE, V444, P337, DOI 10.1038/nature05354; SMITH WL, 1989, BIOCHEM J, V259, P315; Milne JC, 2007, NATURE, V450, P712, DOI 10.1038/nature06261; Fremont L, 2000, LIFE SCI, V66, P663, DOI 10.1016/S0024-3205(99)00410-5; Udagawa N, 2000, ENDOCRINOLOGY, V141, P3478, DOI 10.1210/en.141.9.3478; Kato K, 1996, J NEUROCHEM, V66, P946; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; KOZAWA O, 1992, EXP CELL RES, V198, P130, DOI 10.1016/0014-4827(92)90158-5; Kondo A, 2014, INT J MOL MED, V33, P1013, DOI 10.3892/ijmm.2014.1626; Kozawa O, 1998, BONE, V22, P355, DOI 10.1016/S8756-3282(97)00293-7; Kwan TS, 2004, CYTOKINE GROWTH F R, V15, P49; Nijiweide PJ, 1986, PHYSIOL REV, V66, P855; Tokuda H, 2002, J ENDOCRINOL, V172, P271, DOI 10.1677/joe.0.1720271	26	1	1	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1107-3756	1791-244X		INT J MOL MED	Int. J. Mol. Med.	NOV	2014	34	5					1439	1445		10.3892/ijmm.2014.1934		7	Medicine, Research & Experimental	Research & Experimental Medicine	AS7FZ	WOS:000344423800032		
J	Endo, T; Omura, K; Kudo, M				Endo, Tomomi; Omura, Kazuhiro; Kudo, Mineichi			ANALYSIS OF RELATIONSHIP BETWEEN RENYI ENTROPY AND MARGINAL BAYES ERROR AND ITS APPLICATION TO WEIGHTED NAIVE BAYES CLASSIFIERS	INTERNATIONAL JOURNAL OF PATTERN RECOGNITION AND ARTIFICIAL INTELLIGENCE			English	Article						Naive Bayes classifier; Renyi entropy; marginal Bayes error; tree augmented naive Bayes classifier		A weighted naive Bayes (WNB) classifier using Renyi entropy is discussed with its tree augmented extension. A WNB classifier is one solution for gaining efficiency against large-scale classification problems with an enormous amount of data and a lot of features. Such a WNB classifier has been studied so far, aiming at improving the prediction performance or at reducing the number of features. Among those studies, weighting with Shannon entropy has succeeded in reducing the number of features while keeping the classification performance. However, it has not been fully revealed how different weighting methods affect the performance of classification and feature selection. In this paper, it is analyzed by changing the weights using a parametric cx-Renyi entropy. As the first clue, the relationship between Renyi entropy and the marginal Bayes error is analyzed in detail. It was revealed that the WNB classifiers becomes the regular (without weight) naive Bayes classifier in one end (alpha = 0.0) and naive Bayes classifier weighted by the marginal Bayes error in the other end (alpha = infinity). In addition, an extension of WNB classifiers to incorporate tree-structured correlation between features is discussed.	[Endo, Tomomi; Omura, Kazuhiro; Kudo, Mineichi] Hokkaido Univ, Grad Sch Informat Sci & Technol, Sapporo, Hokkaido 0600814, Japan	Endo, T (reprint author), Fujitsu Co Ltd, Tokyo, Japan.	mine@main.ist.hokudai.ac.jp			JSPS KAKENHI [25280079]	This work was partially supported by JSPS KAKENHI Grant Number 25280079.	Friedman N, 1997, MACH LEARN, V29, P131, DOI 10.1023/A:1007465528199; Yang Y, 2003, LECT NOTES ARTIF INT, V2903, P440; Kudo M, 2000, PATTERN RECOGN, V33, P25, DOI 10.1016/S0031-3203(99)00041-2; FEDER M, 1994, IEEE T INFORM THEORY, V40, P259, DOI 10.1109/18.272494; Omura K, 2012, INT CONF INTELL SYST, P865, DOI 10.1109/ISDA.2012.6416651; Chen L. F., 2012, P ACM INT C INF KNOW, P1243; Endo T., 2013, P 18 IB C PATT REC C, P149; Frank E., 2002, P 19 C UNC ART INT, P249; Friedman J., 2009, ELEMENTS STAT LEARNI; Gartner T., 2001, 18 INT C MACH LEARN, P154; Lee C. H., 2011, IEEE INT C DAT MIN, P1146; Zhang H., 2004, P 4 IEEE INT C DAT M, P567	12	1	1	WORLD SCIENTIFIC PUBL CO PTE LTD	SINGAPORE	5 TOH TUCK LINK, SINGAPORE 596224, SINGAPORE	0218-0014	1793-6381		INT J PATTERN RECOGN	Int. J. Pattern Recognit. Artif. Intell.	NOV	2014	28	7			SI				1460006	10.1142/S0218001414600064		18	Computer Science, Artificial Intelligence	Computer Science	AS0WP	WOS:000343996900006		
J	Wu, CT; Funck, C; Hayashi, Y				Wu, Chuntao; Funck, Carolin; Hayashi, Yoshitsugu			The Impact of Host Community on Destination (re)branding: A Case Study of Hiroshima	INTERNATIONAL JOURNAL OF TOURISM RESEARCH			English	Article						urban tourism; identity; Hiroshima; host community; disaster destination	TOURISM	This paper investigates local groups' opinions on interpreting a dark heritage site for the promotion of tourism and analyzes their roles in tourism activities, through a case study of Hiroshima, Japan. As the first city suffered nuclear bombing, Hiroshima is a primary tourism destination in Japan but faced the challenge of revitalization. Fieldwork investigation methods, including semi-structured interviews, were applied. The results suggest that local people hold favorable attitudes toward tourism development. They conduct an alternative approach to rejuvenating Hiroshima by identifying the essence of the place - a cheerful and peaceful city - and incorporating it into tourism events. Copyright (c) 2013 John Wiley & Sons, Ltd.	[Wu, Chuntao; Hayashi, Yoshitsugu] Nagoya Univ, Grad Sch Enviroment Studies, Nagoya, Aichi 4648603, Japan; [Funck, Carolin] Hiroshima Univ, Grad Sch Integrated Arts & Sci, Higashihiroshima 724, Japan	Wu, CT (reprint author), Nagoya Univ, Grad Sch Enviroment Studies, Chikusa Ku, C1-2 651,Furo Cho, Nagoya, Aichi 4648603, Japan.	chuntao@urban.env.nagoya-u.ac.jp	Funck, Carolin/D-2956-2015				Bramwell B, 1996, ANN TOURISM RES, V23, P201, DOI 10.1016/0160-7383(95)00061-5; Wight AC, 2007, TOURISM MANAGE, V28, P519, DOI 10.1016/j.tourman.2006.03.006; Winter C, 2009, ANN TOURISM RES, V36, P607, DOI 10.1016/j.annals.2009.05.002; Garcia JA, 2012, TOURISM MANAGE, V33, P646, DOI 10.1016/j.tourman.2011.07.006; Yang WQ, 2011, TOURISM MANAGE, V32, P949, DOI 10.1016/j.tourman.2010.07.007; Kavaratzis M, 2005, TIJDSCHR ECON SOC GE, V96, P506, DOI 10.1111/j.1467-9663.2005.00482.x; Ritchie JRB, 2000, TOURISM MANAGE, V21, P1; Dahles H, 1998, ANN TOURISM RES, V25, P55, DOI 10.1016/S0160-7383(97)00061-3; Strange C, 2003, ANN TOURISM RES, V30, P386, DOI 10.1016/S0160-7383(02)00102-0; Biran A, 2011, ANN TOURISM RES, V38, P820, DOI 10.1016/j.annals.2010.12.001; Ashworth G., 2005, HORROR HUMAN TRAGEDY, P1; Cais LA., 2002, ANN TOURISM RES, V29, P720; City of Hiroshima, 2001, HIR PEAC MEM CER; Freire J. R., 2009, J BRAND MANAGEMENT, V16, P420, DOI 10.1057/palgrave.bm.2550097; Gilmore F., 2002, J BRAND MANAGEMENT, V9, P281, DOI DOI 10.1057/PALGRAVE.BM.2540078; Hankinson G., 2007, J BRAND MANAGEMENT, V14, P240, DOI DOI 10.1057/PALGRAVE.BM.2550065; Hiroshima City Hall, 2009, HIR PEAC MEM CIT CON; Hiroshima Peace Culture Foundation, 1998, HIR PEAC MEM; Kavaratzis1 Mihalis, 2005, MARKETING REV, V05, P329, DOI DOI 10.1362/146934705775186854; Lennons JJ, 2000, DARK TOURISM ATTRACT; Miuras H., 2004, NEW URBAN BRANDING H; Morrisons A, 2002, DESTINATION BRANDING; Seaton T, 2009, ASPEC TOUR, P75; Seatons AV, 2001, SLAVERY CONTESTED HE, P107; Sendais S, 2006, J ARCHITECTURE PLANN, V600, P237; Sharpley R, 2009, ASPEC TOUR, P145; Shorts JD, 2005, J INT DEV COOPERATIO, V1, P85; Siegenthaler P, 2002, ANN TOURISM RES, V29, P1111, DOI 10.1016/S0160-7383(02)00027-0; Stone P. R., 2006, Tourism (Zagreb), V54, P145; UNESCO, 1996, ADV BOD EV HIR; Yoneyamas L., 1999, HIROSHIMA TRACES TIM	31	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1099-2340	1522-1970		INT J TOUR RES	Int. J. Tour. Res.	NOV-DEC	2014	16	6					546	555		10.1002/jtr.1946		10	Hospitality, Leisure, Sport & Tourism	Social Sciences - Other Topics	AS6DN	WOS:000344355000003		
J	Sakamoto, S				Sakamoto, Shinichi			Editorial Comment to Retrograde flexible ureteroscopic approach of upper urinary tract pathology: What is the status in 2014?	INTERNATIONAL JOURNAL OF UROLOGY			English	Editorial Material									Chiba Univ, Dept Urol, Grad Sch Med, Chiba, Japan	Sakamoto, S (reprint author), Chiba Univ, Dept Urol, Grad Sch Med, Chiba, Japan.	rbatbat1@yahoo.co.jp					Aboumarzouk OM, 2012, J ENDOUROL, V26, P1257, DOI 10.1089/end.2012.0217; Hamamoto S, 2014, J ENDOUROL, V28, P28, DOI 10.1089/end.2013.0361; Geavlete P, 2014, INT J UROL, V21, P1076, DOI 10.1111/iju.12582; Mmarshall VF, 1964, J UROLOGY, V91, P110; Turk C, 2014, GUIDELINES UROLITHIA	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-8172	1442-2042		INT J UROL	Int. J. Urol.	NOV	2014	21	11					1085	1085		10.1111/iju.12645		1	Urology & Nephrology	Urology & Nephrology	AS6WT	WOS:000344400800003		
J	Hongo, F; Kawauchi, A; Ueda, T; Fujihara, A; Naitoh, Y; Nakamura, T; Naya, Y; Kamoi, K; Okihara, K; Miki, T				Hongo, Fumiya; Kawauchi, Akihiro; Ueda, Takashi; Fujihara, Atsuko; Naitoh, Yasuyuki; Nakamura, Terukazu; Naya, Yoshio; Kamoi, Kazumi; Okihara, Koji; Miki, Tsuneharu			Long-term outcome of hand-assisted laparoscopic radical nephrectomy for T1 renal cell carcinoma	INTERNATIONAL JOURNAL OF UROLOGY			English	Article						hand-assisted method; laparoscopic surgery; long-term outcome; renal cell carcinoma	FOLLOW-UP; EXPERIENCE	ObjectivesTo investigate the long-term outcomes of hand-assisted laparoscopic radical nephrectomy compared with those of open nephrectomy. MethodsHand-assisted laparoscopic radical nephrectomy was carried out in 132 patients with T1 renal cell carcinoma (between November 1999 and November 2008). Their outcomes were compared with those of 61 patients treated with open nephrectomy. The durations of follow up were 6-121 months (median 65 months) and 7-146 months (median 84 months) in the hand-assisted laparoscopic radical nephrectomy and open nephrectomy groups, respectively. ResultsThe 7-year recurrence-free rates were 88.5 and 85.6% in the hand-assisted laparoscopic radical nephrectomy and open nephrectomy groups, respectively, showing no significant difference between the two groups. The 7-year cancer-specific survival rates were 92.3 and 91.4% in the hand-assisted laparoscopic radical nephrectomy and open nephrectomy groups, respectively, showing no significant difference between the two groups. Also, the 10-year recurrence-free rates were 85.4 and 78.1% in the hand-assisted laparoscopic radical nephrectomy and open nephrectomy groups, respectively. When changes in the recurrence-free rate were analyzed using the Kaplan-Meier method, no significant difference was observed between the two groups. The 10-year cancer-specific survival rates were 91.8 and 87.9% for hand-assisted laparoscopic radical nephrectomy and open nephrectomy, respectively, showing no significant difference between the groups. ConclusionsHand-assisted laparoscopic radical nephrectomy might be comparable with open nephrectomy with regard to long-term cancer control.	[Hongo, Fumiya; Ueda, Takashi; Fujihara, Atsuko; Naitoh, Yasuyuki; Nakamura, Terukazu; Naya, Yoshio; Kamoi, Kazumi; Okihara, Koji; Miki, Tsuneharu] Kyoto Prefectural Univ Med, Dept Urol, Kyoto 6028566, Japan; [Kawauchi, Akihiro] Shiga Univ Med Sci, Dept Urol, Otsu, Shiga 52021, Japan	Hongo, F (reprint author), Kyoto Prefectural Univ Med, Dept Urol, Kamigyo Ku, 465 Kajii Cho, Kyoto 6028566, Japan.	fhongo@koto.kpu-m.ac.jp					Dunn MD, 2000, J UROLOGY, V164, P1153, DOI 10.1016/S0022-5347(05)67131-5; Dindo D, 2004, ANN SURG, V240, P205, DOI 10.1097/01.sla.0000133083.54934.ae; Gill IS, 2000, J UROLOGY, V163, P1665, DOI 10.1016/S0022-5347(05)67516-7; Wolf JS, 2001, UROLOGY, V58, P310, DOI 10.1016/S0090-4295(01)01215-8; CLAYMAN RV, 1991, J UROLOGY, V146, P278; Nakada SY, 1997, UROLOGY, V49, P612, DOI 10.1016/S0090-4295(97)80003-9; Borin JF, 2008, CURR OPIN UROL, V18, P139, DOI 10.1097/MOU.0b013e3282f4a851; Chung SD, 2007, UROLOGY, V69, P652, DOI 10.1016/j.urology.2006.12.032; Gill IS, 2001, UROLOGY, V58, P313, DOI 10.1016/S0090-4295(01)01216-X; Harano M, 2005, J ENDOUROL, V19, P803, DOI 10.1089/end.2005.19.803; Hattori R, 2009, J ENDOUROL, V23, P1523, DOI 10.1089/end.2009.0393; Kawauchi A, 2005, INT J UROL, V12, P1, DOI 10.1111/j.1442-2042.2004.00981.x; Kawauchi A, 2003, JPN J ENDOUROL ESWL, V16, P24; Kawauchi A, 2007, UROLOGY, V69, P53, DOI 10.1016/j.urology.2006.09.009; Kawauchi A, 2002, INT J UROL, V9, P480, DOI 10.1046/j.1442-2042.2002.00512.x; Matin SF, 2006, J ENDOUROL, V20, P891, DOI 10.1089/end.2006.20.891; Nelson CP, 2002, J UROLOGY, V167, P1989, DOI 10.1016/S0022-5347(05)65070-7; Okihara K, 2005, JPN J ENDOUROL ESWL, V18, P48; Permpongkosol S, 2005, J UROLOGY, V174, P1222, DOI 10.1097/01.ju.0000173917.37265.41; Portis AJ, 2002, J UROLOGY, V167, P1257, DOI 10.1016/S0022-5347(05)65277-9; Saika T, 2003, UROLOGY, V62, P1018, DOI 10.1016/j.urology.2003.07.009; Tanaka M, 2000, J UROLOGY, V164, P314, DOI 10.1016/S0022-5347(05)67348-X; TIERNEY JP, 1994, MINIMAL INVASIV THER, V3, P303, DOI 10.3109/13645709409153027; Wolf JS, 1998, J UROLOGY, V160, P22, DOI 10.1016/S0022-5347(01)63016-7	24	2	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-8172	1442-2042		INT J UROL	Int. J. Urol.	NOV	2014	21	11					1093	1096		10.1111/iju.12551		4	Urology & Nephrology	Urology & Nephrology	AS6WT	WOS:000344400800005		
J	Ito, K				Ito, Keiichi			Editorial Comment from Dr Ito to Long-term outcome of hand-assisted laparoscopic radical nephrectomy for T1 renal cell carcinoma	INTERNATIONAL JOURNAL OF UROLOGY			English	Editorial Material							EXPERIENCE		Natl Def Med Coll, Dept Urol, Tokorozawa, Saitama 359, Japan	Ito, K (reprint author), Natl Def Med Coll, Dept Urol, Tokorozawa, Saitama 359, Japan.	itok@ndmc.ac.jp					Gill IS, 2000, J UROLOGY, V163, P1665, DOI 10.1016/S0022-5347(05)67516-7; Hongo F, 2014, INT J UROL, V21, P1093, DOI 10.1111/iju.12551; Kawauchi A, 2002, INT J UROL, V9, P480, DOI 10.1046/j.1442-2042.2002.00512.x; Matin SF, 2006, J ENDOUROL, V20, P891, DOI 10.1089/end.2006.20.891; Tanaka M, 2000, J UROLOGY, V164, P314, DOI 10.1016/S0022-5347(05)67348-X; Wolf JS, 1998, J UROLOGY, V160, P22, DOI 10.1016/S0022-5347(01)63016-7	6	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-8172	1442-2042		INT J UROL	Int. J. Urol.	NOV	2014	21	11					1097	1097		10.1111/iju.12593		1	Urology & Nephrology	Urology & Nephrology	AS6WT	WOS:000344400800007		
J	Fukushima, H; Saito, K; Ishioka, J; Matsuoka, Y; Numao, N; Koga, F; Masuda, H; Fujii, Y; Sakai, Y; Arisawa, C; Okuno, T; Yonese, J; Kamata, S; Nagahama, K; Noro, A; Morimoto, S; Tsujii, T; Kitahara, S; Gotoh, S; Higashi, Y; Kihara, K				Fukushima, Hiroshi; Saito, Kazutaka; Ishioka, Junichiro; Matsuoka, Yoh; Numao, Noboru; Koga, Fumitaka; Masuda, Hitoshi; Fujii, Yasuhisa; Sakai, Yasuyuki; Arisawa, Chizuru; Okuno, Tetsuo; Yonese, Junji; Kamata, Shigeyoshi; Nagahama, Katsushi; Noro, Akira; Morimoto, Shinji; Tsujii, Toshihiko; Kitahara, Satoshi; Gotoh, Shuichi; Higashi, Yotsuo; Kihara, Kazunori			Equivalent survival and improved preservation of renal function after distal ureterectomy compared with nephroureterectomy in patients with urothelial carcinoma of the distal ureter: A propensity score-matched multicenter study	INTERNATIONAL JOURNAL OF UROLOGY			English	Article						cancer-specific survival; distal ureteral urothelial carcinoma; distal ureterectomy; nephroureterectomy; renal function	TRANSITIONAL-CELL CARCINOMA; UPPER URINARY-TRACT; RADICAL NEPHROURETERECTOMY; SEGMENTAL URETERECTOMY; ONCOLOGICAL OUTCOMES; SURGICAL-MANAGEMENT; CANCER; PREDICTION	ObjectivesTo investigate the oncological and functional outcome of distal ureterectomy compared with nephroureterectomy in the management of distal ureteral urothelial carcinoma. MethodsUsing a database including upper urinary tract urothelial carcinoma patients (n=1329), 282 patients were identified with urothelial carcinoma localized in the distal ureter on clinical evaluation. To adjust for potential baseline differences between groups, 43 patients undergoing distal ureterectomy were matched with 86 patients undergoing nephroureterectomy using propensity scoring. Cox regression models tested the effect of surgery type on recurrence-free survival and cancer-specific survival. Estimated glomerular filtration rate was measured before and after surgery. ResultsThe median follow-up period was 50months. There were no significant differences in 5-year recurrence-free survival and cancer-specific survival rates between the distal ureterectomy and nephroureterectomy groups (P=0.22 and P=0.70, respectively). Multivariate analysis showed that surgery type was not associated with recurrence-free survival and cancer-specific survival (P=0.90 and P=0.28, respectively). In the subanalysis, recurrence-free survival and cancer-specific survival in the distal ureterectomy group were equivalent to those of the nephroureterectomy group in both pTa-1 and pT2-4 patients. Renal function was better preserved in the distal ureterectomy group than in the nephroureterectomy group (rate of change in estimated glomerular filtration rate 2% vs -20%; P<0.001). ConclusionsThe oncological outcome of distal ureterectomy is comparable with that of nephroureterectomy in distal ureteral urothelial carcinoma patients, and distal ureterectomy provides better preservation of renal function. Distal ureterectomy would be feasible for carefully selected patients with distal ureteral urothelial carcinoma.	[Fukushima, Hiroshi; Saito, Kazutaka; Ishioka, Junichiro; Matsuoka, Yoh; Numao, Noboru; Koga, Fumitaka; Masuda, Hitoshi; Fujii, Yasuhisa; Kihara, Kazunori] Tokyo Med & Dent Univ, Grad Sch, Dept Urol, Tokyo 1138519, Japan; [Sakai, Yasuyuki] Natl Canc Ctr Hosp East, Dept Urol, Chiba, Japan; [Arisawa, Chizuru] Tobu Chiiki Hosp, Dept Urol, Tokyo, Japan; [Okuno, Tetsuo] JA Toride Med Ctr, Dept Urol, Ibaraki, Japan; [Yonese, Junji] Canc Inst Hosp, Dept Urol, Tokyo, Japan; [Kamata, Shigeyoshi] Soka Municipal Hosp, Dept Urol, Saitama, Japan; [Nagahama, Katsushi] Kohnodai Hosp, Natl Ctr Global Hlth & Med, Dept Urol, Chiba, Japan; [Noro, Akira] Saitama Red Cross Hosp, Dept Urol, Saitama, Japan; [Morimoto, Shinji] Tsuchiura Kyodo Gen Hosp, Dept Urol, Ibaraki, Japan; [Tsujii, Toshihiko] Tokyo Metropolitan Otsuka Hosp, Dept Urol, Tokyo, Japan; [Kitahara, Satoshi] Tama Nambu Chiiki Hosp, Dept Urol, Tokyo, Japan; [Gotoh, Shuichi] Hamamatsu Med Ctr, Dept Urol, Shizuoka, Japan; [Higashi, Yotsuo] Saitama Prefectural Canc Ctr, Dept Urol, Saitama, Japan	Saito, K (reprint author), Tokyo Med & Dent Univ, Grad Sch, Dept Urol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.	kz-saito.uro@tmd.ac.jp					Bagrodia A, 2013, UROLOGY, V81, P972, DOI 10.1016/j.urology.2012.12.059; MacLennan S, 2012, EUR UROL, V61, P972, DOI 10.1016/j.eururo.2012.02.039; Colin P, 2012, BJU INT, V110, P1134, DOI 10.1111/j.1464-410X.2012.10960.x; Roupret M, 2013, EUR UROL, V63, P1059, DOI 10.1016/j.eururo.2013.03.032; Rai BP, 2012, BJU INT, V110, P1426, DOI 10.1111/j.1464-410X.2012.11341.x; Jeldres C, 2010, J UROLOGY, V183, P1324, DOI 10.1016/j.juro.2009.12.018; Silberstein JL, 2012, J UROLOGY, V187, P429, DOI 10.1016/j.juro.2011.09.150; Brien JC, 2010, J UROLOGY, V184, P69, DOI 10.1016/j.juro.2010.03.030; Tawfiek ER, 1997, UROLOGY, V50, P321, DOI 10.1016/S0090-4295(97)00230-6; Levey AS, 1999, ANN INTERN MED, V130, P461; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; Lughezzani G, 2009, EUR J CANCER, V45, P3291, DOI 10.1016/j.ejca.2009.06.016; Weight CJ, 2010, J UROLOGY, V183, P1317, DOI 10.1016/j.juro.2009.12.030; Dalpiaz O, 2014, UROL ONCOL, V32; Giannarini G, 2007, BJU INT, V100, P264, DOI 10.1111/j.1464-410X.2007.06993.x; Hung SY, 2014, INT UROL NEPHROL, V46, P921, DOI 10.1007/s11255-013-0514-z; Leitenberger A, 1996, EUR UROL, V29, P272; Mostofi FK, 1973, INT HISTOLOGICAL CLA, V10; National Comprehensive Cancer Network Inc, 2012, NAT COMPR CANC GUID; Pohar KS, 2001, J ENDOUROL, V15, P405, DOI 10.1089/089277901300189439; Simonato A, 2012, BJU INT, V110, pE744, DOI 10.1111/j.1464-410X.2012.11554.x; Sobin LH, 2002, TNM CLASSIFICATION M; Takeshita H, 2012, INT J UROL, V19, P722, DOI 10.1111/j.1442-2042.2012.03015.x; Thompson RH, 2008, BJU INT, V102, P1107, DOI 10.1111/j.1464-410X.2008.07766.x	24	2	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-8172	1442-2042		INT J UROL	Int. J. Urol.	NOV	2014	21	11					1098	1104		10.1111/iju.12554		7	Urology & Nephrology	Urology & Nephrology	AS6WT	WOS:000344400800008		
J	Inamoto, T; Azuma, H				Inamoto, Teruo; Azuma, Haruhito			Editorial Comment from Dr Inamoto and Dr Azuma to Obesity and prognosis in muscle-invasive bladder cancer: The continuing controversy	INTERNATIONAL JOURNAL OF UROLOGY			English	Editorial Material							BODY-MASS INDEX		[Inamoto, Teruo; Azuma, Haruhito] Osaka Med Coll, Dept Urol, Osaka, Japan	Inamoto, T (reprint author), Osaka Med Coll, Dept Urol, Osaka, Japan.	tinamoto@poh.osaka-med.ac.jp					Gonzalez MC, 2014, AM J CLIN NUTR, V99, P999, DOI 10.3945/ajcn.113.071399; Koebnick C, 2008, CANCER EPIDEM BIOMAR, V17, P1214, DOI 10.1158/1055-9965.EPI-08-0026; Hafron J, 2005, J UROLOGY, V173, P1513, DOI 10.1097/01.ju.0000154352.54965.14; Kwon T, 2014, INT J UROL, V21, P1106, DOI 10.1111/iju.12530; Roswall N, 2014, INT J CANCER, V135, P2918, DOI 10.1002/ijc.28936	5	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-8172	1442-2042		INT J UROL	Int. J. Urol.	NOV	2014	21	11					1112	1113		10.1111/iju.12543		2	Urology & Nephrology	Urology & Nephrology	AS6WT	WOS:000344400800011		
J	Mitsuzuka, K; Yamashita, S; Namiki, S; Yamada, S; Sato, K; Saito, H; Kaiho, Y; Ito, A; Nakagawa, H; Arai, Y				Mitsuzuka, Koji; Yamashita, Shinichi; Namiki, Shunichi; Yamada, Shigeyuki; Sato, Ko; Saito, Hideo; Kaiho, Yasuhiro; Ito, Akihiro; Nakagawa, Haruo; Arai, Yoichi			Low-dose maintenance gemcitabine-carboplatin chemotherapy could be an alternative to continuous standard chemotherapy for patients with metastatic urothelial carcinoma	INTERNATIONAL JOURNAL OF UROLOGY			English	Article						adverse event; carboplatin; cisplatin-unfit; low-dose maintenance chemotherapy; urothelial carcinoma	CISPLATIN-BASED CHEMOTHERAPY; TRANSITIONAL-CELL CARCINOMA; PHASE-II TRIAL; PLATINUM-CONTAINING REGIMEN; BLADDER-CANCER; URINARY-TRACT; METHOTREXATE; VINBLASTINE; PACLITAXEL; DOXORUBICIN	ObjectivesTo examine whether low-dose maintenance gemcitabine-carboplatin chemotherapy is beneficial for patients with metastatic urothelial carcinoma. MethodsWe retrospectively reviewed the records of 36 patients with metastatic urothelial carcinoma who received first-line chemotherapy (gemcitabine/cisplatin, gemcitabine/carboplatin, or methotrexate/vinblastine/adriamycin/cisplatin) between 2006 and 2012. Those who had responded, but were unable to tolerate ongoing first-line chemotherapy, had been switched to low-dose maintenance chemotherapy consisting of 1g/m(2) of gemcitabine and area under the curve 2-4 of carboplatin given on day 1 of a 6-week cycle, and were continued unless disease progression was seen. ResultsAfter a median of three cycles of first-line chemotherapy, 17 patients had been switched to low-dose maintenance chemotherapy. The median age was 70 years (range 56-79 years), and 12 patients (70.6%) had renal dysfunction (creatinine clearance <60mL/min). The median number of cycles of low-dose maintenance chemotherapy was six (range 2-22), and the median survival time from initiation of first-line chemotherapy was 12 months (range 4-32 months). Adverse events requiring hospitalization were seen in three patients, but all of them recovered within a few days with conservative treatment. Seven patients discontinued within 9 months, whereas 10 patients continued on low-dose maintenance chemotherapy for 9 months. Patients with only lymph node metastases or who had a good response to previous first-line chemotherapy were likely to be able to continue low-dose maintenance chemotherapy. ConclusionsLow-dose maintenance gemcitabine-carboplatin chemotherapy might represent an alternative for patients with metastatic urothelial carcinoma not tolerating continuous first-line standard chemotherapy regimens.	[Mitsuzuka, Koji; Yamashita, Shinichi; Namiki, Shunichi; Yamada, Shigeyuki; Sato, Ko; Saito, Hideo; Kaiho, Yasuhiro; Ito, Akihiro; Nakagawa, Haruo; Arai, Yoichi] Tohoku Univ, Sch Med, Dept Urol, Sendai, Miyagi 9808574, Japan	Mitsuzuka, K (reprint author), Tohoku Univ, Sch Med, Dept Urol, Aoba Ku, 1-1 Seiryo Machi, Sendai, Miyagi 9808574, Japan.	mitsuzuka@uro.med.tohoku.ac.jp					Sweeney CJ, 2006, J CLIN ONCOL, V24, P3451, DOI 10.1200/JCO.2005.03.6699; Nogue-Aliguer M, 2003, CANCER, V97, P2180, DOI 10.1002/cncr.10990; McCaffrey JA, 1997, J CLIN ONCOL, V15, P1853; De Santis M, 2012, J CLIN ONCOL, V30, P191, DOI 10.1200/JCO.2011.37.3571; Gentzler RD, 2014, THER ADV MED ONCOL, V6, P4, DOI 10.1177/1758834013510589; Witjes JA, 2014, EUR UROL, V65, P778, DOI 10.1016/j.eururo.2013.11.046; Culine S, 2006, BRIT J CANCER, V94, P1395, DOI 10.1038/sj.bjc.6603118; von der Maase H, 2000, J CLIN ONCOL, V18, P3068; Rosenberg JE, 2005, J UROLOGY, V174, P14, DOI 10.1097/01.ju.0000162039.38023.5f; Galsky MD, 2011, J CLIN ONCOL, V29, P2432, DOI 10.1200/JCO.2011.34.8433; Witte RS, 1997, J CLIN ONCOL, V15, P589; Dogliotti L, 2007, EUR UROL, V52, P134, DOI 10.1016/j.eururo.2006.12.029; Vaughn DJ, 2002, J CLIN ONCOL, V20, P937, DOI 10.1200/JCO.20.4.937; Dash A, 2006, CANCER, V107, P506, DOI 10.1002/cncr.22031; De Santis M, 2009, J CLIN ONCOL, V27, P5634, DOI 10.1200/JCO.2008.21.4924; Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026; Bellmunt J, 2009, J CLIN ONCOL, V27, P4454, DOI 10.1200/JCO.2008.20.5534; BELLMUNT J, 1992, CANCER, V70, P1974, DOI 10.1002/1097-0142(19921001)70:7<1974::AID-CNCR2820700727>3.0.CO;2-D; Morales-Barrera R, 2012, EUR J CANCER, V48, P1816, DOI 10.1016/j.ejca.2012.04.002; Papamichael D, 1997, BRIT J CANCER, V75, P606, DOI 10.1038/bjc.1997.106; SCHER HI, 1988, J UROLOGY, V139, P475; Sternberg CN, 2003, CRIT REV ONCOL HEMAT, V46, pS105, DOI 10.1016/S1040-8428(03)00068-4; Witte RS, 1998, INVEST NEW DRUG, V16, P191, DOI 10.1023/A:1006159525793	23	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-8172	1442-2042		INT J UROL	Int. J. Urol.	NOV	2014	21	11					1114	1119		10.1111/iju.12532		6	Urology & Nephrology	Urology & Nephrology	AS6WT	WOS:000344400800013		
J	Kitagawa, Y; Izumi, K; Sawada, K; Mizokami, A; Nakashima, K; Koshida, K; Nakashima, T; Miyazaki, K; Namiki, M				Kitagawa, Yasuhide; Izumi, Kouji; Sawada, Kiyoshi; Mizokami, Atsushi; Nakashima, Kazuyoshi; Koshida, Kiyoshi; Nakashima, Takao; Miyazaki, Kimiomi; Namiki, Mikio			Age-specific reference range of prostate-specific antigen and prostate cancer detection in population-based screening cohort in Japan: Verification of Japanese Urological Association Guideline for prostate cancer	INTERNATIONAL JOURNAL OF UROLOGY			English	Article						age-specific prostate-specific antigen reference range; population screening; prostate cancer	2.1-10.0 NG/ML; PSA RATIO; MEN; MORTALITY; LEVEL	ObjectivesTo investigate the age-specific reference range of prostate-specific antigen and clinical characteristics of screening-detected cancer in prostate-specific antigen-based screening, and to verify the age-specific prostate-specific antigen cut-offs in the Japanese Urological Association Guidelines. MethodsProstate-specific antigen distributions were estimated in a total of 69028 screening tests according to the age of the participants in population screening from 2000 to 2013. The age-specific reference range of prostate-specific antigen for detection of cancer was investigated by analyzing the receiver operating characteristic curves. Furthermore, the clinicopathological features of screening-detected cancer with serum prostate-specific antigen levels below the age-specific prostate-specific antigen cut-off in the Japanese Urological Association Guidelines were also investigated. ResultsOf all 69028 screens, 2053 prostate biopsies (2.97%) were carried out and 549 cases of cancer (0.79%) were diagnosed. The 95th percentiles in all participants aged 54-59, 60-64, 65-69 and 70-75 years old were 2.90, 3.60, 4.10, and 4.70ng/mL, respectively. The optimal prostate-specific antigen cut-offs for cancer detection determined from the receiver operating characteristic curves were 2.3 and 2.6 for the age ranges 54-69 and 70-75 years, respectively. These values were lower than the age-specific cut-offs in the Japanese Urological Association Guidelines. Of all 137 patients with prostate-specific antigen levels below the age-specific cut-offs in the Japanese Urological Association Guidelines, 80 (58.4%) had unfavorable clinicopathological features as active surveillance criteria. ConclusionsThe age-specific reference range of prostate-specific antigen might be lower than that recommended in the Japanese Urological Association Guidelines. An individualized and natural history-adjusted screening system should be established for screening participants with low prostate-specific antigen level.	[Kitagawa, Yasuhide; Izumi, Kouji; Sawada, Kiyoshi; Mizokami, Atsushi; Namiki, Mikio] Kanazawa Univ, Grad Sch Med Sci, Dept Integrat Canc Therapy & Urol, Kanazawa, Ishikawa 9208640, Japan; [Nakashima, Kazuyoshi; Koshida, Kiyoshi; Nakashima, Takao; Miyazaki, Kimiomi] Kanazawa Med Assoc, Kanazawa, Ishikawa, Japan	Kitagawa, Y (reprint author), Kanazawa Univ, Grad Sch Med Sci, Dept Integrat Canc Therapy & Urol, 13-1 Takaramachi, Kanazawa, Ishikawa 9208640, Japan.	yasukita@med.kanazawa-u.ac.jp	IZUMI, KOUJI/C-5973-2015				Thompson IM, 2004, NEW ENGL J MED, V350, P2239, DOI 10.1056/NEJMoa031918; Hugosson J, 2010, LANCET ONCOL, V11, P725, DOI 10.1016/S1470-2045(10)70146-7; ELGALLEY RES, 1995, UROLOGY, V46, P200, DOI 10.1016/S0090-4295(99)80194-0; Klotz L, 2010, J CLIN ONCOL, V28, P126, DOI 10.1200/JCO.2009.24.2180; Schroder FH, 2012, NEW ENGL J MED, V366, P981, DOI 10.1056/NEJMoa1113135; Carter HB, 2013, J UROLOGY, V190, P419, DOI 10.1016/j.juro.2013.04.119; Bouchardy C, 2008, INT J CANCER, V123, P421, DOI 10.1002/ijc.23520; Casey RG, 2012, ISRN ONCOL; Naito S, 2010, INT J UROL, V17, P830, DOI 10.1111/j.1442-2042.2010.02613.x; Ito K, 2000, UROLOGY, V56, P278, DOI 10.1016/S0090-4295(00)00613-0; Kakehi Y, 2008, JPN J CLIN ONCOL, V38, P122, DOI 10.1093/jjco/hym161; Kato T, 2010, AKTUEL UROL, V41, pS53, DOI 10.1055/s-0029-1224653; Kitagawa Y, 2011, INT J UROL, V18, P592, DOI 10.1111/j.1442-2042.2011.02796.x; Kitagawa Y, 2014, J CANCER RES CLIN, V140, P53, DOI 10.1007/s00432-013-1543-9; Kobori Y, 2008, INT J CLIN ONCOL, V13, P229, DOI 10.1007/s10147-007-0742-2; Krumholtz JS, 2002, UROLOGY, V60, P469, DOI 10.1016/S0090-4295(02)01875-7; Kubota Y, 2002, PROSTATE, V50, P262, DOI 10.1002/pros.10057; Liu ZY, 2009, ASIAN J ANDROL, V11, P100, DOI 10.1038/aja.2008.17; Okihara K, 2008, INT J UROL, V15, P156, DOI 10.1111/j.1442-2042.2007.01957.x; Sawada K, 2014, INT J UROL, V21, P560, DOI 10.1111/iju.12380; Wittekind CH, 1997, TNM CLASS MAL TUM, VFifth, P170	21	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-8172	1442-2042		INT J UROL	Int. J. Urol.	NOV	2014	21	11					1120	1125		10.1111/iju.12523		6	Urology & Nephrology	Urology & Nephrology	AS6WT	WOS:000344400800014		
J	Hoshi, A; Nitta, M; Shimizu, Y; Higure, T; Kawakami, M; Nakajima, N; Hanai, K; Nomoto, T; Usui, Y; Terachi, T				Hoshi, Akio; Nitta, Masahiro; Shimizu, Yuuki; Higure, Taro; Kawakami, Masayoshi; Nakajima, Nobuyuki; Hanai, Kazuya; Nomoto, Takeshi; Usui, Yukio; Terachi, Toshiro			Total pelvic floor reconstruction during non-nerve-sparing laparoscopic radical prostatectomy: Impact on early recovery of urinary continence	INTERNATIONAL JOURNAL OF UROLOGY			English	Article						anterior reconstruction; laparoscopic surgery; posterior reconstruction; prostate cancer; urinary incontinence	ROBOTIC PROSTATECTOMY; MEN; PRESERVATION; INCONTINENCE; RESTORATION; OUTCOMES; COMPLEX	ObjectivesTo develop a modified technique of total pelvic floor reconstruction during non-nerve-sparing laparoscopic radical prostatectomy, and to determine its effect on postoperative urinary outcomes. MethodsA total of 128 patients who underwent non-nerve-sparing laparoscopic radical prostatectomy were evaluated, including 81 with total pelvic floor reconstruction and 47 with non-total pelvic floor reconstruction. Nerve-sparing cases were excluded. Urinary outcomes were assessed with self-administrated questionnaires (Expanded Prostate Cancer Index Composite) at 1, 3, 6 and 12 months after laparoscopic radical prostatectomy. The total pelvic floor reconstruction technique included two concepts involving posterior and anterior reconstructions. In posterior reconstruction, Denonvilliers' fascia was approximated to the bladder neck and the median dorsal raphe by slipknot. The anterior surface of the bladder-neck was approximated to the anterior detrusor apron and the puboprostatic ligament collar for anterior reconstruction. ResultsThere were no significant differences between the two groups in the patients' characteristics, and in perioperative and oncological outcomes. In the total pelvic floor reconstruction group, the continence rates at 3, 6 and 12 months after laparoscopic radical prostatectomy were 45.7%, 71.4%, and 84.6%, respectively. In the non-total pelvic floor reconstruction group, the continence rates were 26.1%, 46.8% and 60.9%, respectively. The total pelvic floor reconstruction technique resulted in significantly higher continence rates at 3, 6 and 12 months after laparoscopic radical prostatectomy, respectively (all P<0.05). The mean interval to achieve continence was significantly shorter in the total pelvic floor reconstruction group (mean 7.7 months) than in the non-total pelvic floor reconstruction group (mean 9.8 months; P=0.0003). ConclusionThe total pelvic floor reconstruction technique allows preservation of the blood supply to the urethra and physical reinforcement of the pelvic floor. Therefore, this technique is likely to improve urinary continence outcomes after laparoscopic radical prostatectomy.	[Hoshi, Akio; Nitta, Masahiro; Shimizu, Yuuki; Higure, Taro; Kawakami, Masayoshi; Nakajima, Nobuyuki; Hanai, Kazuya; Nomoto, Takeshi; Terachi, Toshiro] Tokai Univ, Sch Med, Dept Urol, Isehara, Kanagawa 2591193, Japan; [Usui, Yukio] Shizuoka City Shimizu Hosp, Dept Urol, Shimizu, Shizuoka, Japan	Hoshi, A (reprint author), Tokai Univ, Sch Med, Dept Urol, 143 Shimokasuya, Isehara, Kanagawa 2591193, Japan.	a-hoshi@is.icc.u-tokai.ac.jp					Menon M, 2008, J UROLOGY, V180, P1018, DOI 10.1016/j.juro.2008.05.046; Secin FP, 2010, J UROLOGY, V184, P2291, DOI 10.1016/j.juro.2010.08.003; Patel VR, 2009, EUR UROL, V56, P472, DOI 10.1016/j.eururo.2009.06.007; Tewari AK, 2007, UROLOGY, V69, P726, DOI 10.1016/j.urology.2006.12.028; Tewari A, 2008, BJU INT, V101, P871, DOI 10.1111/j.1464-410X.2008.07424.x; Coelho RF, 2011, EUR UROL, V59, P72, DOI 10.1016/j.eururo.2010.08.025; Stolzenburg JU, 2008, EUR UROL, V53, P931, DOI 10.1016/j.eururo.2007.11.047; Kielb SJ, 2005, UROLOGY, V66, P392, DOI 10.1016/j.urology.2005.03.026; Ficarra V, 2009, EUR UROL, V55, P1037, DOI 10.1016/j.eururo.2009.01.036; Rocco F, 2006, J UROLOGY, V175, P2201, DOI 10.1016/S0022-5347(06)00262-X; Nguyen MM, 2008, BJU INT, V101, P1135, DOI 10.1111/j.1464-410X.2007.07425.x; Groutz A, 2000, J UROLOGY, V163, P1767, DOI 10.1016/S0022-5347(05)67538-6; Rocco B, 2007, EUR UROL, V51, P996, DOI 10.1016/j.eururo.2006.10.014; Good DW, 2014, WORLD J UROL, V32, P1225, DOI 10.1007/s00345-013-1198-9; Hoshi A, 2013, INT J UROL, V20, P493, DOI 10.1111/j.1442-2042.2012.03181.x; Joshi Neil, 2010, Eur Urol, V58, P84, DOI 10.1016/j.eururo.2010.03.028; Kakehi Y, 2007, J UROLOGY, V177, P1856, DOI 10.1016/j.juro.2007.01.066; Menon M, 2007, EUR UROL, V51, P648, DOI 10.1016/j.eururo.2006.10.055; Porpiglia F, 2009, EUR UROL, V55, P1377, DOI 10.1016/j.eururo.2009.02.009; Stolzenburg JU, 2006, EUR UROL, V49, P103, DOI 10.1016/j.eururo.2005.10.002; Woo JR, 2009, J ENDOUROL, V23, P1995, DOI 10.1089/end.2009.0117	21	0	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-8172	1442-2042		INT J UROL	Int. J. Urol.	NOV	2014	21	11					1132	1137		10.1111/iju.12539		6	Urology & Nephrology	Urology & Nephrology	AS6WT	WOS:000344400800018		
J	Sugihara, T; Yasunaga, H; Horiguchi, H; Fushimi, K; Dalton, JE; Schold, J; Kattan, MW; Homma, Y				Sugihara, Toru; Yasunaga, Hideo; Horiguchi, Hiromasa; Fushimi, Kiyohide; Dalton, Jarrod E.; Schold, Jesse; Kattan, Michael W.; Homma, Yukio			Performance comparisons in major uro-oncological surgeries between the USA and Japan	INTERNATIONAL JOURNAL OF UROLOGY			English	Article						cross-cultural comparison; nephrectomy; nephroureterectomy; prostatectomy; radical cystectomy	LAPAROSCOPIC RADICAL PROSTATECTOMY; PROCEDURE COMBINATION DATABASE; PERIOPERATIVE OUTCOMES; NEPHROURETERECTOMY; COMPLICATIONS; RISK	ObjectivesTo elucidate the differences in clinical practice between the USA and Japan in major types of uro-oncological surgery by a head-to-head comparison of national databases in the two countries. MethodsWe compared variations in surgical modality, length of stay, total charges, caseload centralization, transfusion incidence, and in-hospital mortality between the two countries for four major types of uro-oncological surgery (radical prostatectomy, radical cystectomy, nephrectomy and nephroureterectomy) in 2011. Additionally, the chronological changes in surgical modalities were investigated for 2009-11. The national estimates were based on data from the Japanese Diagnosis Procedure Combination database and the US National Inpatient Sample. ResultsFor radical prostatectomy, radical cystectomy, nephrectomy and nephroureterectomy, minimally-invasive surgery accounted for 24.2% versus 70.2%, 0% versus 14.0%, 50.7% versus 30.7% and 50.2% versus 30.5%, respectively, in Japan versus the USA in 2011. Although minimally-invasive surgery has become increasingly frequent in both countries, the major procedures were robot-assisted surgery in the USA and laparoscopic surgery in Japan. The USA was generally characterized by a slightly younger age at operation, far higher hospital volume, a shorter length of stay, higher charges and less use of transfusion than Japan. ConclusionsThe findings suggest substantial differences between the USA and Japan regarding clinical practices in uro-oncological surgery. Standing at the beginning of robotic surgery era in Japan, the precise recognition of these differences will aid a proper understanding of clinical practices.	[Sugihara, Toru; Dalton, Jarrod E.; Schold, Jesse; Kattan, Michael W.] Cleveland Clin Fdn, Dept Quantitat Hlth Sci, Cleveland, OH 44195 USA; [Sugihara, Toru; Homma, Yukio] Univ Tokyo, Dept Urol, Tokyo, Japan; [Yasunaga, Hideo] Univ Tokyo, Dept Hlth Econ & Epidemiol Res, Tokyo, Japan; [Horiguchi, Hiromasa] Tokyo Med & Dent Univ, Clin Res Ctr, Dept Clin Data Management & Res, Tokyo, Japan; [Fushimi, Kiyohide] Tokyo Med & Dent Univ, Dept Hlth Care Informat, Tokyo, Japan	Sugihara, T (reprint author), Cleveland Clin, Dept Quantitat Hlth Sci, Main Campus,Mail Code JJN3-01,9500 Euclid Ave, Cleveland, OH 44195 USA.	ezy04707@nifty.com		Yasunaga, Hideo/0000-0002-6017-469X	Ito Genboku and Sagara Chian Memorial Scholarship from Saga Prefecture, Japan; Ministry of Health, Labor and Welfare, Japan [H22-Policy-031]; Ministry of Education, Culture, Sports, Science and Technology [22390131]; Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST program) from the Council for Science and Technology Policy, Japan [0301002001001]	This study was funded by an Ito Genboku and Sagara Chian Memorial Scholarship from Saga Prefecture, Japan, by a Grant-in-Aid for Research on Policy Planning and Evaluation from the Ministry of Health, Labor and Welfare, Japan (grant number: H22-Policy-031), by a Grant-in-Aid for Scientific Research B (No. 22390131) from the Ministry of Education, Culture, Sports, Science and Technology, and by the Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST program) from the Council for Science and Technology Policy, Japan (grant number: 0301002001001).	Agency for Healthcare Research and Quality: HCUP Nationwide Inpatient Sample (NIS), HCUP NAT INP SAMPL N; Guillonneau B, 2002, J UROLOGY, V167, P51, DOI 10.1016/S0022-5347(05)65381-5; Sugihara T, 2012, INT J UROL, V19, P86, DOI 10.1111/j.1442-2042.2011.02883.x; Sugihara T, 2013, INT J UROL, V20, P695, DOI 10.1111/iju.12031; Trinh QD, 2012, EUR UROL, V61, P679, DOI 10.1016/j.eururo.2011.12.027; Sugihara T, 2013, INT J UROL, V20, P1193, DOI 10.1111/iju.12157; Hashimoto H, 2011, LANCET, V378, P1174, DOI 10.1016/S0140-6736(11)60987-2; Glickman SW, 2009, NEW ENGL J MED, V360, P816, DOI 10.1056/NEJMsb0803929; Finks JF, 2011, NEW ENGL J MED, V364, P2128, DOI 10.1056/NEJMsa1010705; Hanna N, 2012, EUR UROL, V61, P715, DOI 10.1016/j.eururo.2011.12.026; Tewari A, 2012, EUR UROL, V62, P1, DOI 10.1016/j.eururo.2012.02.029; Sugihara T, 2013, INT J UROL, V20, P349, DOI 10.1111/iju.12079; Ghani KR, 2013, J UROLOGY, V191, P907; Intuitive Surgical Inc, 2013, INV PRES Q4 2013; Kihara K, 2009, INT J UROL, V16, P791, DOI 10.1111/j.1442-2042.2009.02366.x; Kuwahara K., 2012, SHINIRYO, V39, P162; OECD, 2013, OECD HLTH DAT 2013; Okamura Kikuo, 2007, Nihon Hinyokika Gakkai Zasshi, V98, P595; Sugihara T, 2013, INT J CLIN ONCOL, V18, P1070, DOI 10.1007/s10147-012-0500-y; The DPC Research Group, DIAGN PROC COMB DPC	20	2	2	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-8172	1442-2042		INT J UROL	Int. J. Urol.	NOV	2014	21	11					1145	1150		10.1111/iju.12548		6	Urology & Nephrology	Urology & Nephrology	AS6WT	WOS:000344400800021		
J	Okamura, K; Kimura, K; Mizuno, H; Okamoto, N; Aota, Y				Okamura, Kikuo; Kimura, Kyosuke; Mizuno, Hideki; Okamoto, Noriko; Aota, Yasuhiro			Core lower urinary tract symptom score questionnaire: A psychometric analysis	INTERNATIONAL JOURNAL OF UROLOGY			English	Article						core lower urinary tract symptom score; psychometric analysis; reliability; validity	INTERNATIONAL CONSULTATION; ASSESSMENT-TOOL; SHORT-FORM; INCONTINENCE; JAPANESE; VALIDATION; WOMEN; CLSS	ObjectivesTo analyze the reliability and validity of the Japanese version of the core lower urinary symptom score questionnaire with psychometric methods. MethodThe present study included 140 women and 125 men who filled in a core lower urinary symptom score questionnaire while attending two lectures on lower urinary tract symptoms. Missing response rates to individual questions were 1.5-5.3%. After the descriptive analyses including box plot, Cronbach's coefficients and Spearman's were calculated for reliability and validity assessment, respectively. Factor analysis was also carried out to explore the underlying structure. ResultsOf the scores for 10 core symptoms, the interquartile range for pain in the bladder and urethra was 0 in both sexes, and that for stress incontinence was 0 in men. Cronbach's of the core lower urinary symptom score was 0.733 in women and 0.721 in men. Questions regarding daytime frequency, nocturia, urgency and urgency urinary incontinence, and those on slow stream, straining and feeling of incomplete emptying were significantly correlated with each other in both sexes. Pain in the urethra and bladder showed more extensive associations in women than in men. Factor analysis showed four components in both sexes: the first was storage symptoms, second was voiding symptoms, third was pain and the fourth was urinary incontinence. ConclusionsThe core lower urinary symptom score questionnaire shows good reliability and validity for both sexes, and it could be used as screening tool for lower urinary tract symptoms in any clinical setting or epidemiological investigation.	[Okamura, Kikuo] Natl Hosp Org, Higashi Nagoya Hosp, Dept Urol, Nagoya, Aichi, Japan; [Kimura, Kyosuke; Mizuno, Hideki; Okamoto, Noriko; Aota, Yasuhiro] Natl Hosp Org, Nagoya Med Ctr, Dept Urol, Nagoya, Aichi, Japan	Okamura, K (reprint author), Higashi Nagoya Natl Hosp, Dept Urol, Meitou Ku, 5-101 Umemorizaka, Nagoya, Aichi 4658620, Japan.	kokamura@toumei.hosp.go.jp					Abrams P, 2006, J UROLOGY, V175, P1063, DOI 10.1016/S0022-5347(05)00349-4; Brookes ST, 2004, AM J OBSTET GYNECOL, V191, P73, DOI 10.1016/j.ajog.2003.12.027; Homma Y, 2006, UROLOGY, V68, P318, DOI 10.1016/j.urology.2006.02.042; Donovan JL, 2000, J UROLOGY, V164, P1948, DOI 10.1016/S0022-5347(05)66926-1; Fujimura T, 2011, BJU INT, V109, P1512; Fujimura T, 2011, INT J UROL, V18, P778, DOI 10.1111/j.1442-2042.2011.02848.x; Gotoh M, 2009, INT J UROL, V16, P303, DOI 10.1111/j.1442-2042.2008.02237.x; Homma Y, 2009, INT J UROL, V16, P775, DOI 10.1111/j.1442-2042.2009.02369.x; Homma Yukio, 2003, Nihon Hinyokika Gakkai Zasshi, V94, P560; Homma Y, 2008, INT J UROL, V15, P816, DOI 10.1111/j.1442-2042.2008.02121.x; Ito H, 2014, INT J UROL, V21, P108, DOI 10.1111/iju.12167; Kline P, 2000, HDB PSYCHOL TESTING, P7; Okamura K, 2009, UROLOGY, V73, P1199, DOI 10.1016/j.urology.2009.01.054; Okamura K, 2002, EUR UROL, V42, P498, DOI 10.1016/S0302-2838(02)00438-4; Osuga Y, 2013, GERIATR GERONTOL INT, V13, P1010, DOI 10.1111/ggi.12048	15	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-8172	1442-2042		INT J UROL	Int. J. Urol.	NOV	2014	21	11					1151	1154		10.1111/iju.12522		4	Urology & Nephrology	Urology & Nephrology	AS6WT	WOS:000344400800023		
J	Oh-oka, H; Yamada, T; Noto, H; Umeyama, T; Kadekawa, K; Ashitomi, K; Nishijima, S; Sugaya, K				Oh-oka, Hitoshi; Yamada, Tetsuo; Noto, Hiromitsu; Umeyama, Tomokazu; Kadekawa, Katsumi; Ashitomi, Katsuhiro; Nishijima, Saori; Sugaya, Kimio			Effect of carbazochrome sodium sulfonate on refractory chronic prostatitis	INTERNATIONAL JOURNAL OF UROLOGY			English	Article						capillary permeability; carbazochrome; chronic prostatitis; urine occult blood	PELVIC PAIN SYNDROME; DYSFUNCTION; ETIOLOGY; RATS	ObjectivesTo study the effect of carbazochrome sodium sulfonate, an agent that reduces capillary permeability, on refractory chronic prostatitis. MethodsPatients with prostatitis refractory to at least 8 weeks of routine therapy and with urinalysis positive for microhematuria were considered for the present study. In addition to their prior therapy, the patients received carbazochrome at a dose of 30mg three times a day. The severity of pain (score 0-10), daytime and night-time frequency, international prostate symptom score, global self-assessment, urine occult blood positivity, and adverse events were assessed after 4 and 8 weeks of treatment, and compared with baseline findings. ResultsA total of 50 patients (mean age 68.68.5 years) were evaluable. The pain score decreased significantly from 3.2 +/- 2.1 at baseline to 1.7 +/- 1.4 after 4 weeks of treatment and to 1.1 +/- 1.8 after 8 weeks. Daytime and night-time frequency, storage symptoms, post-micturition symptoms, and urine occult blood positivity also significantly improved. More than 36% of the patients gave a global self-assessment rating of improved or better after both 4 and 8 weeks of treatment. Mild adverse events occurred in three patients; one had nausea and two developed drug rash. ConclusionsCarbazochrome seems to effectively improve pain as well as storage and post-micturition symptoms in patients with refractory chronic prostatitis.	[Oh-oka, Hitoshi] Kobe Med Ctr, Natl Hosp Org, Dept Urol, Kobe, Hyogo, Japan; [Yamada, Tetsuo] Yamada Urol Clin, Sagamihara, Kanagawa, Japan; [Noto, Hiromitsu] Akita Urol Clin, Akita, Japan; [Umeyama, Tomokazu] Umeyama Clin, Takasaki, Gunma, Japan; [Kadekawa, Katsumi; Ashitomi, Katsuhiro; Nishijima, Saori; Sugaya, Kimio] Southern Knights Lab LLP, Okinawa, 9042171, Japan; [Kadekawa, Katsumi] Okinawa Kyodo Hosp, Dept Urol, Naha, Japan; [Ashitomi, Katsuhiro] Okinawa Hokubu Hosp, Dept Urol, Nago, Japan; [Sugaya, Kimio] Kitakami Cent Hosp, Dept Urol, Chatan, Okinawa, Japan	Sugaya, K (reprint author), Southern Knights Lab LLP, 2-7-7-301 Takahara, Okinawa, 9042171, Japan.	sugaya@sklabo.com					Krieger JN, 1999, JAMA-J AM MED ASSOC, V282, P236, DOI 10.1001/jama.282.3.236; Schaeffer AJ, 2004, UROLOGY, V63, P75, DOI 10.1016/j.urology.2003.11.002; Rivero VE, 2007, CRIT REV IMMUNOL, V27, P33; Nickel JC, 2008, BJU INT, V101, P11, DOI 10.1111/j.1464-410X.2008.07496.x; Hayakawa M, 2009, JPN J THROMB HEMOST, V20, P278; McNaughton Collins M, 2001, J Gen Intern Med, V16, P656, DOI 10.1046/j.1525-1497.2001.01223.x; Nickel JC, 2007, REV UROL, V9, P63; Nishijima S, 2013, LIFE SCI, V93, P897, DOI 10.1016/j.lfs.2013.10.010; Nishijima S, 2013, NBS, V24, P255; Nishijima S, 2013, NIHON HINYOKIKA GAKK, V104, P423; Pontari MA, 2008, J UROLOGY, V179, pS61, DOI 10.1016/j.juro.2008.03.139; Sendo T, 2003, N-S ARCH PHARMACOL, V368, P175, DOI 10.1007/s00210-003-0785-5; Sendo T, 2002, EUR J PHARMACOL, V450, P203, DOI 10.1016/S0014-2999(02)02120-9; Sugaya K, 2013, NIHON HINYOKIKA GAKK, V104, P423; Sugaya K, 2011, LUTS, V3, P94, DOI 10.1111/j.1757-5672.2011.00086.x; TERASAKI T, 1995, EUR UROL, V27, P280	16	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-8172	1442-2042		INT J UROL	Int. J. Urol.	NOV	2014	21	11					1162	1166		10.1111/iju.12533		5	Urology & Nephrology	Urology & Nephrology	AS6WT	WOS:000344400800026		
J	Nakane, K; Yasuda, M; Deguchi, T; Takahashi, S; Tanaka, K; Hayami, H; Hamasuna, R; Yamamoto, S; Arakawa, S; Matsumoto, T				Nakane, Keita; Yasuda, Mitsuru; Deguchi, Takashi; Takahashi, Satoshi; Tanaka, Kazushi; Hayami, Hiroshi; Hamasuna, Ryoichi; Yamamoto, Shingo; Arakawa, Soichi; Matsumoto, Tetsuro			Nationwide survey of urogenital tuberculosis in Japan	INTERNATIONAL JOURNAL OF UROLOGY			English	Article						nationwide survey; urinary tract infection; urogenital tuberculosis	GENITOURINARY TUBERCULOSIS; MANAGEMENT; HIV	ObjectivesTo determine current epidemiology and treatment patterns of urogenital tuberculosis in Japan. MethodsA questionnaire was sent to the urological departments of 1203 Japanese hospitals. Clinical data was reviewed retrospectively; no time range was specified. ResultsOf the 1203 hospitals, 399 returned questionnaires with information about 355 urogenital tuberculosis patients. Of the 399, 153 institutions reported at least one patient, and 201 patients were identified between 2000 and 2007. Infections were located in the kidneys (n=242), ureter (n=96), bladder (n=100), epididymis or testes (n=81) and prostate (n=9). ConclusionsUrogenital tuberculosis is rare in Japan, but patients do exist, and we should not ignore them.	[Nakane, Keita; Yasuda, Mitsuru; Deguchi, Takashi] Gifu Univ, Grad Sch Med, Dept Urol, Gifu 5011194, Japan; [Takahashi, Satoshi] Sapporo Med Univ, Sch Med, Dept Urol, Sapporo, Hokkaido, Japan; [Tanaka, Kazushi; Arakawa, Soichi] Kobe Univ, Dept Surg, Div Urol, Related Fac Med,Grad Sch Med, Kobe, Hyogo 657, Japan; [Hayami, Hiroshi] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Urol, Kagoshima 890, Japan; [Hamasuna, Ryoichi] Univ Occupat & Environm Hlth, Dept Urol, Kitakyushu, Fukuoka 807, Japan; [Yamamoto, Shingo; Matsumoto, Tetsuro] Hyogo Coll Med, Dept Urol, Nishinomiya, Hyogo 6638501, Japan; [Nakane, Keita; Yasuda, Mitsuru; Deguchi, Takashi; Takahashi, Satoshi; Tanaka, Kazushi; Hayami, Hiroshi; Hamasuna, Ryoichi; Yamamoto, Shingo; Arakawa, Soichi; Matsumoto, Tetsuro] Japanese Res Grp UTI, Kitakyushu, Fukuoka, Japan	Nakane, K (reprint author), Gifu Univ, Grad Sch Med, Dept Urol, 1-1 Yanagi Do, Gifu 5011194, Japan.	keitaco2009@water.ocn.ne.jp					Aljohaney A, 2012, CLIN DEV IMMUNOL, V2012, P1; Faustini A, 2006, THORAX, V61, P158, DOI 10.1136/thx.2005.045963; [Anonymous], 2009, GUID TUB; ALVAREZ S, 1984, MEDICINE, V63, P25; Beijer U, 2012, LANCET INFECT DIS, V12, P859, DOI 10.1016/S1473-3099(12)70177-9; Carl P, 1997, WORLD J SURG, V21, P505; Cek M, 2005, EUR UROL, V48, P353, DOI 10.1016/j.eururo.2005.03.008; Centers for Disease Control and Prevention, 2012, QUEST ANSW TUB; Figueiredo AA, 2008, INT J UROL, V15, P827, DOI 10.1111/j.1442-2042.2008.02099.x; Ghotbi Nader, 2005, Environmental Health and Preventive Medicine, V10, P213, DOI 10.1007/BF02897713; Glynn JR, 1998, BRIT MED BULL, V54, P579; GOKALP A, 1990, BRIT J CLIN PRACT, V44, P599; Hemal AK, 2000, J UROLOGY, V164, P32, DOI 10.1016/S0022-5347(05)67442-3; Ito K., 2010, NIPPON IJI SHINPO, V4473, P59; McAleer SJJC, 2007, CAMPBELLWALSH UROLOG, P436; Ohmori M, 2005, INT J TUBERC LUNG D, V9, P999; PSIHRAMIS KE, 1986, J UROLOGY, V135, P1033; Ramanathan R, 1998, BRIT J UROL, V81, P199; SCHUBERT GE, 1992, EUR UROL, V21, P216; Stop TB Initiative (World Health Organization), 2010, TREATM TUB GUID; Takahashi Satoshi, 2005, Journal of Infection and Chemotherapy, V11, P300, DOI 10.1007/s10156-005-0414-y; The Tuberculosis Surveillance Center The Research Institute of Tuberculosis/JATA, 2011, NEWL NOT CAS CAS RAT; The Tuberculosis Surveillance Center The Research Institute of Tuberculosis/JATA, 2011, STAT TB; UNAIDS, 2013, GLOB REP UNAIDS REP; World Health Organization, 2010, MULT EXT DRUG RES TB	25	2	4	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-8172	1442-2042		INT J UROL	Int. J. Urol.	NOV	2014	21	11					1171	1177		10.1111/iju.12549		7	Urology & Nephrology	Urology & Nephrology	AS6WT	WOS:000344400800028		
J	Yamashita, S; Kamiyama, Y; Nakagawa, A; Kaiho, Y; Tominaga, T; Arai, Y				Yamashita, Shinichi; Kamiyama, Yoshihiro; Nakagawa, Atsuhiro; Kaiho, Yasuhiro; Tominaga, Teiji; Arai, Yoichi			Novel pulsed water jet system permits off-clamp partial nephrectomy in swine	INTERNATIONAL JOURNAL OF UROLOGY			English	Editorial Material							OUTCOMES; LASER		[Yamashita, Shinichi; Kamiyama, Yoshihiro; Kaiho, Yasuhiro; Arai, Yoichi] Tohoku Univ, Grad Sch Med, Dept Urol, Sendai, Miyagi 980, Japan; [Nakagawa, Atsuhiro; Tominaga, Teiji] Tohoku Univ, Grad Sch Med, Dept Neurosurg, Sendai, Miyagi 980, Japan	Yamashita, S (reprint author), Tohoku Univ, Grad Sch Med, Dept Urol, Sendai, Miyagi 980, Japan.	yamashita@uro.med.tohoku.ac.jp					Hirano T, 2003, ACTA NEUROCHIR, V145, P401, DOI 10.1007/s00701-003-0010-9; Kaczmarek BF, 2013, EUR UROL, V64, P988, DOI 10.1016/j.eururo.2012.10.009; Ota T, 2014, INT J UROL, V21, P244, DOI 10.1111/iju.12276; Seki S, 1998, J TRAUMA, V45, P1079, DOI 10.1097/00005373-199812000-00019; Saito H, 2012, J ENDOUROL, V26, P652, DOI 10.1089/end.2011.0505; Sato C, 2013, DIGEST ENDOSC, V25, P255, DOI 10.1111/j.1443-1661.2012.01375.x	6	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-8172	1442-2042		INT J UROL	Int. J. Urol.	NOV	2014	21	11					1181	1182		10.1111/iju.12538		2	Urology & Nephrology	Urology & Nephrology	AS6WT	WOS:000344400800031		
J	Yamamoto, Y; Nozawa, M; Shimizu, N; Minami, T; Yoshimura, K; Uemura, H				Yamamoto, Yutaka; Nozawa, Masahiro; Shimizu, Nobutaka; Minami, Takafumi; Yoshimura, Kazuhiro; Uemura, Hirotsugu			Pazopanib for recurrent extraosseous Ewing's sarcoma of the retroperitoneum	INTERNATIONAL JOURNAL OF UROLOGY			English	Editorial Material							STANDARD CHEMOTHERAPY		[Yamamoto, Yutaka; Nozawa, Masahiro; Shimizu, Nobutaka; Minami, Takafumi; Yoshimura, Kazuhiro; Uemura, Hirotsugu] Kinki Univ, Fac Med, Dept Urol, Osaka, Japan	Yamamoto, Y (reprint author), Kinki Univ, Fac Med, Dept Urol, Osaka, Japan.	nozawa06@med.kindai.ac.jp					Granowetter L, 2009, J CLIN ONCOL, V27, P2536, DOI 10.1200/JCO.2008.19.1478; ZUCMAN J, 1992, GENE CHROMOSOME CANC, V5, P271, DOI 10.1002/gcc.2870050402; Ahmad R, 1999, CANCER, V85, P725, DOI 10.1002/(SICI)1097-0142(19990201)85:3<725::AID-CNCR23>3.0.CO;2-2; van der Graaf WTA, 2012, LANCET, V379, P1879, DOI 10.1016/S0140-6736(12)60651-5; ANGERVALL L, 1975, CANCER, V36, P240, DOI 10.1002/1097-0142(197507)36:1<240::AID-CNCR2820360127>3.0.CO;2-H; Grier HE, 2003, NEW ENGL J MED, V348, P694, DOI 10.1056/NEJMoa020890; Raney RB, 1997, J CLIN ONCOL, V15, P574	7	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-8172	1442-2042		INT J UROL	Int. J. Urol.	NOV	2014	21	11					1183	1184		10.1111/iju.12546		2	Urology & Nephrology	Urology & Nephrology	AS6WT	WOS:000344400800032		
J	Fujimura, M; Sakamoto, S; Sekita, N; Mikami, K; Ichikawa, T; Akakura, K				Fujimura, Masaaki; Sakamoto, Shinichi; Sekita, Nobuyuki; Mikami, Kazuo; Ichikawa, Tomohiko; Akakura, Koichiro			Visceral fat accumulation is a risk factor for urinary stone	INTERNATIONAL JOURNAL OF UROLOGY			English	Editorial Material							OBESITY		[Fujimura, Masaaki; Sekita, Nobuyuki; Mikami, Kazuo] Chiba Univ, Chiba Ken Saiseikai Narashino Hosp, Dept Urol, Chiba, Japan; [Sakamoto, Shinichi; Ichikawa, Tomohiko] Chiba Univ, Grad Sch Med, Dept Urol, Chiba, Japan; [Akakura, Koichiro] JCHO Tokyo Shinjuku Med Ctr, Dept Urol, Tokyo, Japan	Fujimura, M (reprint author), Chiba Univ, Chiba Ken Saiseikai Narashino Hosp, Dept Urol, Chiba, Japan.	rbatbat1@yahoo.co.jp					FUJIOKA S, 1987, METABOLISM, V36, P54, DOI 10.1016/0026-0495(87)90063-1; [Anonymous], 2002, CIRC J, V66, P987; Eguchi M, 2007, HYPERTENS RES, V30, P317; Yamamoto S, 2004, MEDIX, V41, P15	4	1	1	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-8172	1442-2042		INT J UROL	Int. J. Urol.	NOV	2014	21	11					1184	1185		10.1111/iju.12556		2	Urology & Nephrology	Urology & Nephrology	AS6WT	WOS:000344400800033		
J	Yamamoto, T; Hashimoto, K; Itoh, N				Yamamoto, Takanobu; Hashimoto, Kohei; Itoh, Naoki			Case of pheochromocytoma associated with neurofibromatosis type 1 developing postoperative hypertension	INTERNATIONAL JOURNAL OF UROLOGY			English	Letter									[Yamamoto, Takanobu; Hashimoto, Kohei; Itoh, Naoki] NTT East Corp Sapporo Med Ctr, Dept Urol, Sapporo, Hokkaido, Japan	Yamamoto, T (reprint author), NTT East Corp Sapporo Med Ctr, Dept Urol, Sapporo, Hokkaido, Japan.	kohei@cj9.so-net.ne.jp					Stolk RF, 2013, J CLIN ENDOCR METAB, V98, P1100, DOI 10.1210/jc.2012-3669; Manger William M, 2002, J Clin Hypertens (Greenwich), V4, P62, DOI 10.1111/j.1524-6175.2002.01452.x; NORTON KK, 1995, NEUROBIOL DIS, V2, P13, DOI 10.1006/nbdi.1995.0002; Zinnamosca L, 2011, ARCH DERMATOL RES, V303, P317, DOI 10.1007/s00403-010-1090-z	4	0	0	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0919-8172	1442-2042		INT J UROL	Int. J. Urol.	NOV	2014	21	11					1187	1188		10.1111/iju.12537		2	Urology & Nephrology	Urology & Nephrology	AS6WT	WOS:000344400800035		
J	Hernigou, J; Picard, L; Alves, A; Silvera, J; Homma, Y; Hernigou, P				Hernigou, Jacques; Picard, Laure; Alves, Alexandra; Silvera, Jonathan; Homma, Yasuhiro; Hernigou, Philippe			Understanding bone safety zones during bone marrow aspiration from the iliac crest: the sector rule	INTERNATIONAL ORTHOPAEDICS			English	Article						Bone marrow aspiration; Complications Sector rule for marrow aspiration; Ilium anatomy; Iliac crest anatomy; Iliac artery; Neurologic complication	TRANSPLANTATION; BIOPSY; CELLS	Purpose Should the trocar suddenly lose contact with bone during bone marrow aspiration, it may result in visceral injury. The anatomy of the ilium and the structures adjacent to the iliac bone were studied to determine the danger of breach by a trocar introduced into the iliac crest. Methods The authors followed two series of patients, one series to do measurements of distance and angles of the structures at risk to the iliac bone and the other to evaluate the risk of a trocar being directed outside the iliac wing during bone marrow aspiration. The authors also examined 24 pelvices by computed tomography (CT) scans of mature adults (48 iliac crests). Lines dividing the iliac wing into six equal sectors were used to form sectors (e.g. sector 1 anterior, sector 6 posterior). Vascular or neurological structures were considered at risk if they were accessible to the tip of a 10-cm trocar introduced into the iliac crest with a possible deviation of 20A degrees from the plane of the iliac wing on the three-dimensional reconstruction. The authors tracked bone marrow aspiration of six different surgeons and calculated among 120 patients (480 entry points) the number of times the needle lost contact with bone in each sector of aspiration. Results The sector system reliably predicted safe and unsafe areas for trocar placement. Among the 480 entry points in the 120 patients, 94 breaches were observed and higher risks were observed in the thinner sectors. The risk was also higher in obese patients and the risk decreased with more experienced surgeons. The trocar could reach the external iliac artery on pelvic CT scans in the four most anterior sectors with a higher frequency in women. Posterior sectors were at risk for sciatic nerve and gluteal vessel damage when the trocar was pushed deeper than 6 cm into the posterior iliac crest. In cadavers, the dissection demonstrated nine vascular or neurological lesions. Conclusions Using the sector system, trocars can be directed away from neural and vascular structures and toward zones that are likely to contain larger bone marrow stock.	[Hernigou, Jacques; Picard, Laure; Alves, Alexandra; Hernigou, Philippe] Hop Henri Mondor, Dept Orthoped Surg, F-94010 Creteil, France; [Silvera, Jonathan] Hop Europeen Georges Pompidou, Dept Radiol, Creteil, France; [Homma, Yasuhiro] Juntendo Univ, Dept Orthopaed Surg, Bunkyo Ku, Tokyo, Japan	Hernigou, P (reprint author), Hop Henri Mondor, Dept Orthoped Surg, F-94010 Creteil, France.	philippe.hernigou@wanadoo.fr					Amann B, 2009, CELL TRANSPLANT, V18, P371; Chevallier N, 2010, BIOMATERIALS, V31, P270, DOI 10.1016/j.biomaterials.2009.09.043; Hernigou P, 2005, J BONE JOINT SURG BR, V87B, P896, DOI 10.1302/0301-620X.87B7.16289; Dahabreh Z, 2009, INT ORTHOP, V33, P1407, DOI 10.1007/s00264-008-0709-6; Hernigou P, 2005, J BONE JOINT SURG AM, V87A, P1430, DOI 10.2106/JBJS.D.02215; Hernigou P, 2014, INT ORTHOP, V38, P1855, DOI 10.1007/s00264-014-2318-x; Hernigou P, 2014, INT ORTHOP, V38, P1913, DOI 10.1007/s00264-014-2285-2; Arrington ED, 1996, CLIN ORTHOP RELAT R, P300; Bain BJ, 2005, J CLIN PATHOL, V58, P406, DOI 10.1136/jcp.2004.022178; Ben-Chetrit E, 1984, Arch Intern Med, V144, P2284, DOI 10.1001/archinte.144.11.2284; Cockin J, 1971, J BONE JOINT SURG BR, V53, P153; Hernigou P, 2013, J BONE JOINT SURG AM, V95A, P2215, DOI 10.2106/JBJS.M.00261; Hernigou P, 2002, CLIN ORTHOP RELAT R, P14, DOI 10.1097/01.blo.0000038472.05771.79; Hernigou Ph, 2006, J Bone Joint Surg Am, V88 Suppl 1 Pt 2, P322, DOI 10.2106/JBJS.F.00203; KAHN B, 1979, CLIN ORTHOP RELAT R, P204; PEDERSEN LM, 1993, EUR J HAEMATOL, V51, P52; Schizas C, 2009, INT ORTHOP, V33, P187, DOI 10.1007/s00264-007-0446-2; Tsai HL, 2008, AM J EMERG MED, V26	18	2	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0341-2695	1432-5195		INT ORTHOP	Int. Orthop.	NOV	2014	38	11					2377	2384		10.1007/s00264-014-2343-9		8	Orthopedics	Orthopedics	AS5ZQ	WOS:000344345300022		
